(	O
a	O
)	O
Schematic	O
drawing	O
of	O
the	O
magnetic	O
tweezers	O
.	O
A	O
DNA	O
molecule	O
is	O
attached	O
at	O
one	O
end	O
to	O
the	O
bottom	O
of	O
the	O
flow	O
cell	B-Anatomy
and	O
at	O
the	O
other	O
end	O
to	O
a	O
magnetic	O
bead	O
.	O
This	O
molecule	O
can	O
be	O
pulled	O
and	O
twisted	O
using	O
small	O
magnets	O
placed	O
above	O
the	O
flow	O
cell	B-Anatomy
.	O
The	O
position	O
of	O
the	O
magnetic	O
bead	O
is	O
measured	O
using	O
an	O
inverted	O
microscope	O
placed	O
beneath	O
the	O
flow	O
cell	B-Anatomy
.	O
The	O
bead	O
position	O
and	O
thus	O
the	O
end	O
-	O
to	O
-	O
end	O
distance	O
of	O
the	O
DNA	O
molecule	O
is	O
determined	O
using	O
video	O
microscopy	O
and	O
image	O
analysis	O
.	O
(	O
b	O
)	O
Extension	O
of	O
a	O
DNA	O
molecule	O
versus	O
the	O
number	O
of	O
turns	O
applied	O
by	O
the	O
magnets	O
for	O
various	O
stretching	O
forces	O
.	O
At	O
low	O
force	O
,	O
contraction	O
of	O
the	O
molecule	O
is	O
symmetrical	O
under	O
positive	O
and	O
negative	O
applied	O
turns	O
.	O
At	O
higher	O
force	O
,	O
the	O
molecule	O
'	O
s	O
extension	O
initially	O
remains	O
constant	O
for	O
positive	O
applied	O
turns	O
.	O
The	O
induced	O
torque	O
increases	O
linearly	O
with	O
the	O
number	O
of	O
applied	O
turns	O
,	O
as	O
depicted	O
in	O
the	O
top	O
graph	O
until	O
a	O
buckling	O
transition	O
allows	O
the	O
system	O
to	O
saturate	O
its	O
torsional	O
constraint	O
through	O
the	O
formation	O
of	O
plectonemes	B-Anatomy
.	O
Effect	O
of	O
Trail	O
on	O
the	O
expression	O
of	O
endogenous	O
M2	O
.	O
(	O
A	O
)	O
Effect	O
of	O
Trail	O
on	O
the	O
level	O
of	O
endogenous	O
M2	O
protein	O
.	O
The	O
expression	O
level	O
of	O
endogenous	O
M2	O
protein	O
in	O
HeLa	B-Anatomy
cells	I-Anatomy
was	O
determined	O
using	O
western	O
blot	O
4	O
h	O
following	O
Trail	O
(	O
250	O
mug	O
/	O
ml	O
)	O
treatment	O
.	O
(	O
B	O
)	O
Effect	O
of	O
Trail	O
on	O
the	O
endogenous	O
M2	O
mRNA	O
.	O
The	O
expression	O
level	O
of	O
endogenous	O
M2	O
mRNA	O
in	O
HeLa	B-Anatomy
cells	I-Anatomy
was	O
detected	O
using	O
RNase	O
protection	O
assay	O
4	O
h	O
following	O
Trail	O
(	O
250	O
mug	O
/	O
ml	O
)	O
treatment	O
.	O
(	O
C	O
)	O
Effect	O
of	O
Trail	O
on	O
the	O
synthesis	O
of	O
endogenous	O
M2	O
protein	O
.	O
HeLa	B-Anatomy
cells	I-Anatomy
were	O
first	O
treated	O
with	O
250	O
mug	O
/	O
ml	O
Trail	O
followed	O
by	O
pulse	O
labeling	O
of	O
newly	O
synthesized	O
proteins	O
with	O
[	O
35S	O
]	O
methionine	O
.	O
M2	O
protein	O
was	O
then	O
immunoprecipitated	O
and	O
separated	O
by	O
SDS	O
-	O
PAGE	O
for	O
autoradiography	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O
The	O
most	O
highly	O
represented	O
gene	O
ontology	O
themes	O
in	O
the	O
neurosphere	B-Anatomy
vs	O
.	O
differentiated	O
cells	B-Anatomy
comparison	O
(	O
F	O
-	O
G	O
)	O
.	O
Planning	O
for	O
the	O
Future	O
:	O
Disaster	O
Preparedness	O
and	O
Mitigation	O
It	O
is	O
often	O
believed	O
that	O
casualties	O
from	O
natural	O
disasters	O
are	O
unavoidable	O
,	O
but	O
this	O
belief	O
is	O
false	O
[	O
8	O
]	O
.	O
There	O
are	O
many	O
measures	O
that	O
can	O
reduce	O
morbidity	O
and	O
mortality	O
following	O
large	O
and	O
potentially	O
catastrophic	O
flooding	O
events	O
[	O
19	O
]	O
.	O
Early	O
warning	O
of	O
impending	O
floods	O
and	O
natural	O
events	O
such	O
as	O
hurricanes	O
allows	O
sufficient	O
time	O
for	O
communities	O
to	O
be	O
evacuated	O
to	O
safe	O
areas	O
.	O
Although	O
Florida	O
experienced	O
one	O
of	O
the	O
worst	O
hurricane	O
seasons	O
on	O
record	O
in	O
2004	O
,	O
the	O
number	O
of	O
fatalities	O
was	O
lower	O
than	O
expected	O
because	O
of	O
early	O
warning	O
and	O
evacuation	O
.	O
Early	O
warning	O
also	O
provides	O
sufficient	O
time	O
to	O
prepare	O
when	O
evacuation	O
is	O
not	O
possible	O
.	O
Hurricane	O
George	O
in	O
1998	O
caused	O
widespread	O
damage	O
and	O
several	O
fatalities	O
in	O
the	O
Dominican	O
Republic	O
,	O
where	O
residents	O
were	O
not	O
warned	O
.	O
In	O
contrast	O
,	O
Cuba	O
and	O
Puerto	O
Rico	O
experienced	O
relatively	O
limited	O
damage	O
and	O
loss	O
of	O
life	O
,	O
because	O
preparations	O
were	O
made	O
in	O
the	O
hours	O
before	O
the	O
storm	O
.	O
Disaster	O
preparedness	O
can	O
also	O
be	O
developed	O
for	O
communities	O
that	O
are	O
regularly	O
exposed	O
to	O
flooding	O
disasters	O
.	O
Cyclone	O
shelters	O
built	O
by	O
the	O
Red	O
Cross	O
in	O
Orissa	O
,	O
India	O
,	O
saved	O
many	O
thousands	O
of	O
lives	O
in	O
1999	O
when	O
two	O
cyclones	O
struck	O
.	O
In	O
the	O
region	O
of	O
the	O
Americas	O
,	O
the	O
Pan	O
American	O
Health	O
Organization	O
has	O
spent	O
many	O
years	O
promoting	O
and	O
integrating	O
disaster	O
preparedness	O
into	O
building	O
health	O
facilities	O
to	O
ensure	O
that	O
medical	O
services	O
needed	O
to	O
treat	O
victims	O
and	O
maintain	O
ongoing	O
care	O
for	O
patients	O
with	O
chronic	O
conditions	O
will	O
not	O
be	O
disrupted	O
by	O
disasters	O
.	O
A	O
recent	O
global	O
-	O
scale	O
review	O
of	O
health	O
risks	O
from	O
flooding	O
highlights	O
that	O
in	O
flood	O
-	O
prone	O
areas	O
,	O
disaster	O
preparedness	O
within	O
the	O
health	O
system	O
as	O
a	O
whole	O
is	O
particularly	O
important	O
[	O
20	O
]	O
.	O
In	O
addition	O
to	O
infrastructure	O
and	O
early	O
-	O
warning	O
systems	O
,	O
another	O
key	O
element	O
in	O
disaster	O
preparedness	O
is	O
education	O
and	O
raising	O
awareness	O
about	O
disaster	O
risks	O
and	O
response	O
plans	O
.	O
Had	O
there	O
been	O
greater	O
awareness	O
about	O
the	O
risk	O
of	O
tsunamis	O
,	O
perhaps	O
many	O
lives	O
could	O
have	O
been	O
saved	O
in	O
the	O
South	O
Asian	O
disaster	O
in	O
December	O
2004	O
.	O
Discussion	O
Among	O
adolescent	O
boys	O
in	O
Chapaevsk	O
,	O
Russia	O
,	O
higher	O
serum	B-Anatomy
levels	O
of	O
sum	O
of	O
dioxin	O
-	O
like	O
compounds	O
and	O
sum	O
of	O
dioxin	O
TEQs	O
were	O
positively	O
associated	O
with	O
increased	O
age	O
,	O
consumption	O
of	O
fish	O
,	O
local	O
meats	B-Anatomy
other	O
than	O
chicken	O
,	O
and	O
inversely	O
with	O
weeks	O
of	O
gestation	O
.	O
The	O
age	O
association	O
was	O
found	O
despite	O
a	O
narrow	O
age	O
range	O
of	O
slightly	O
over	O
two	O
years	O
in	O
our	O
study	O
.	O
Although	O
not	O
statistically	O
significant	O
,	O
the	O
distance	O
the	O
boy	O
lived	O
from	O
the	O
Khimprom	O
factory	O
at	O
the	O
time	O
of	O
blood	B-Anatomy
draw	O
was	O
inversely	O
associated	O
with	O
serum	B-Anatomy
levels	O
of	O
sum	O
of	O
dioxin	O
-	O
like	O
compounds	O
and	O
sum	O
of	O
dioxin	O
TEQs	O
.	O
As	O
expected	O
,	O
serum	B-Anatomy
PCBs	O
,	O
specifically	O
PCB	O
118	O
,	O
were	O
strongly	O
associated	O
with	O
both	O
sum	O
of	O
dioxin	O
-	O
like	O
compounds	O
and	O
sum	O
of	O
dioxin	O
TEQs	O
.	O
There	O
was	O
no	O
association	O
between	O
the	O
distance	O
of	O
the	O
residence	O
from	O
the	O
Khimprom	O
plant	O
during	O
the	O
pregnancy	O
and	O
subsequent	O
serum	B-Anatomy
dioxin	O
levels	O
.	O
One	O
potential	O
explanation	O
for	O
the	O
lack	O
of	O
association	O
may	O
include	O
misclassification	O
of	O
distance	O
since	O
the	O
mother	O
was	O
asked	O
to	O
recall	O
a	O
time	O
period	O
more	O
than	O
14	O
years	O
prior	O
to	O
the	O
study	O
.	O
However	O
,	O
we	O
would	O
expect	O
that	O
the	O
mother	O
would	O
be	O
able	O
to	O
recall	O
residential	O
history	O
at	O
the	O
time	O
of	O
the	O
birth	O
of	O
their	O
son	O
.	O
Mother	O
'	O
s	O
self	O
-	O
reported	O
estimates	O
of	O
current	O
residential	O
distance	O
from	O
Khimprom	O
was	O
generally	O
accurate	O
;	O
twenty	O
-	O
one	O
of	O
twenty	O
-	O
nine	O
mothers	O
correctly	O
categorized	O
their	O
current	O
residential	O
distance	O
from	O
the	O
Khimprom	O
plants	O
based	O
on	O
cross	O
-	O
referencing	O
using	O
GIS	O
mapping	O
.	O
Other	O
explanations	O
include	O
that	O
prenatal	O
exposure	O
14	O
or	O
more	O
years	O
prior	O
to	O
the	O
current	O
serum	B-Anatomy
sample	I-Anatomy
is	O
not	O
as	O
strong	O
a	O
predictor	O
as	O
are	O
exposures	O
resulting	O
from	O
present	O
residential	O
location	O
.	O
Although	O
there	O
was	O
no	O
association	O
of	O
case	O
status	O
(	O
cryptorchidism	O
or	O
hypospadias	O
)	O
with	O
dioxin	O
levels	O
,	O
we	O
did	O
not	O
have	O
sufficient	O
power	O
to	O
definitively	O
assess	O
this	O
relationship	O
.	O
Perinatal	O
history	O
(	O
e	O
.	O
g	O
.	O
weeks	O
of	O
breastfeeding	O
)	O
was	O
generally	O
not	O
associated	O
with	O
exposure	O
measures	O
in	O
this	O
population	O
;	O
this	O
may	O
be	O
a	O
function	O
of	O
older	O
age	O
of	O
the	O
children	O
.	O
However	O
,	O
there	O
are	O
limited	O
data	O
on	O
the	O
relationship	O
of	O
perinatal	O
factors	O
with	O
organochlorine	O
exposures	O
in	O
this	O
age	O
group	O
so	O
a	O
finding	O
is	O
of	O
interest	O
given	O
reports	O
that	O
differences	O
in	O
organochlorine	O
levels	O
among	O
breastfed	O
and	O
non	O
-	O
breastfed	O
are	O
generally	O
no	O
longer	O
discernable	O
by	O
early	O
school	O
age	O
[	O
24	O
,	O
25	O
]	O
and	O
,	O
furthermore	O
,	O
that	O
dietary	O
intake	O
after	O
this	O
age	O
contributes	O
significantly	O
to	O
total	O
dioxin	O
intake	O
[	O
26	O
]	O
.	O
In	O
prior	O
studies	O
,	O
substantial	O
emphasis	O
has	O
been	O
placed	O
on	O
pre	O
-	O
and	O
early	O
postnatal	O
(	O
via	O
breastfeeding	O
)	O
exposures	O
because	O
of	O
particular	O
vulnerability	O
during	O
fetal	B-Anatomy
and	O
early	O
infant	O
development	O
.	O
The	O
exposure	O
risk	O
factors	O
during	O
peri	O
-	O
adolescence	O
,	O
another	O
period	O
of	O
potential	O
developmental	O
vulnerability	O
,	O
has	O
not	O
been	O
studied	O
in	O
-	O
detail	O
,	O
therefore	O
,	O
the	O
identification	O
of	O
exposure	O
risk	O
factors	O
specific	O
to	O
this	O
period	O
will	O
enhance	O
our	O
understanding	O
of	O
this	O
critical	O
period	O
.	O
Although	O
data	O
on	O
levels	O
of	O
PCDD	O
/	O
PCDFs	O
in	O
children	O
is	O
limited	O
,	O
our	O
results	O
suggest	O
that	O
the	O
mean	O
total	O
TEQs	O
among	O
Chapaevsk	O
adolescents	O
were	O
higher	O
than	O
most	O
values	O
previously	O
reported	O
in	O
non	O
-	O
occupationally	O
exposed	O
populations	O
of	O
comparable	O
or	O
even	O
older	O
ages	O
.	O
Figure	O
2	O
shows	O
a	O
comparison	O
of	O
the	O
mean	O
PCDD	O
/	O
PCDFs	O
TEQ	O
levels	O
in	O
Chapaevsk	O
boys	O
with	O
other	O
populations	O
(	O
TEQ	O
from	O
dioxin	O
-	O
like	O
PCBs	O
was	O
not	O
included	O
,	O
since	O
some	O
of	O
these	O
studies	O
did	O
not	O
report	O
them	O
)	O
.	O
The	O
mean	O
TEQs	O
of	O
pooled	O
blood	B-Anatomy
samples	I-Anatomy
from	O
10	O
year	O
-	O
old	O
German	O
boys	O
in	O
rural	O
and	O
urban	O
settings	O
was	O
8	O
.	O
2	O
pg	O
TEQ	O
/	O
g	O
lipid	O
for	O
an	O
urban	O
industrial	O
area	O
,	O
9	O
.	O
0	O
pg	O
TEQ	O
/	O
g	O
lipid	O
for	O
an	O
industrial	O
area	O
within	O
a	O
rural	O
setting	O
,	O
and	O
10	O
.	O
1	O
pg	O
TEQ	O
/	O
g	O
lipid	O
for	O
a	O
rural	O
area	O
[	O
27	O
]	O
.	O
In	O
comparison	O
,	O
the	O
mean	O
TEQ	O
in	O
the	O
Chapevsk	O
boys	O
was	O
19	O
.	O
3	O
pg	O
TEQ	O
/	O
g	O
lipid	O
.	O
With	O
the	O
exception	O
of	O
children	O
described	O
by	O
Wuthe	O
et	O
al	O
.	O
[	O
27	O
]	O
,	O
subjects	O
in	O
the	O
other	O
studies	O
in	O
Figure	O
2	O
were	O
significantly	O
older	O
than	O
the	O
Chapaevsk	O
boys	O
.	O
Despite	O
age	O
differences	O
,	O
the	O
mean	O
TEQ	O
in	O
Chapaevsk	O
boys	O
was	O
comparable	O
to	O
or	O
even	O
higher	O
than	O
the	O
mean	O
TEQ	O
in	O
older	O
populations	O
from	O
other	O
countries	O
.	O
For	O
example	O
,	O
they	O
were	O
higher	O
than	O
mean	O
TEQs	O
of	O
18	O
.	O
4	O
pg	O
TEQ	O
/	O
g	O
lipid	O
in	O
adults	O
(	O
40	O
.	O
6	O
years	O
old	O
average	O
)	O
from	O
South	O
Germany	O
[	O
27	O
]	O
or	O
16	O
.	O
4	O
pg	O
TEQ	O
/	O
g	O
lipid	O
from	O
20	O
year	O
old	O
Japanese	O
women	O
[	O
28	O
]	O
or	O
pooled	O
samples	B-Anatomy
from	O
randomly	O
selected	O
males	O
and	O
females	O
18	O
-	O
69	O
years	O
of	O
age	O
from	O
the	O
Spanish	O
city	O
of	O
Mataro	O
[	O
29	O
]	O
,	O
which	O
were	O
12	O
.	O
5	O
and	O
14	O
.	O
7	O
pg	O
TEQ	O
/	O
g	O
lipid	O
respectively	O
.	O
The	O
mean	O
levels	O
in	O
adult	O
female	O
(	O
mean	O
age	O
41	O
years	O
)	O
non	O
-	O
factory	O
workers	O
in	O
the	O
Russian	O
city	O
of	O
Shelekhovo	O
were	O
also	O
lower	O
at	O
14	O
.	O
5	O
pg	O
TEQ	O
/	O
g	O
lipid	O
[	O
30	O
]	O
.	O
Mean	O
TEQs	O
for	O
the	O
general	O
population	O
(	O
mean	O
age	O
44	O
.	O
2	O
years	O
)	O
in	O
Germany	O
,	O
collected	O
in	O
1997	O
-	O
98	O
[	O
31	O
]	O
,	O
and	O
median	O
TEQs	O
for	O
long	O
-	O
term	O
workers	O
of	O
pulp	B-Anatomy
and	O
paper	O
mill	O
and	O
non	O
-	O
workers	O
in	O
the	O
U	O
.	O
S	O
.	O
in	O
1996	O
[	O
32	O
]	O
were	O
similar	O
to	O
levels	O
found	O
in	O
the	O
Chapaevsk	O
boys	O
.	O
The	O
mean	O
levels	O
in	O
the	O
study	O
in	O
Germany	O
were	O
20	O
.	O
71	O
pg	O
TEQ	O
/	O
g	O
lipid	O
and	O
in	O
the	O
U	O
.	O
S	O
.	O
the	O
median	O
levels	O
were	O
19	O
.	O
1	O
pg	O
TEQ	O
/	O
g	O
lipid	O
for	O
community	O
residents	O
and	O
21	O
.	O
2	O
pg	O
TEQ	O
/	O
g	O
lipid	O
for	O
low	O
exposure	O
workers	O
.	O
Figure	O
2	O
Mean	O
PCDD	O
/	O
PCDFs	O
TEQ	O
levels	O
in	O
Chapaevsk	O
boys	O
in	O
comparison	O
with	O
other	O
populations	O
.	O
Although	O
TCDD	O
was	O
largely	O
below	O
the	O
detection	O
limits	O
in	O
this	O
small	O
pilot	O
sample	B-Anatomy
,	O
the	O
two	O
boys	O
with	O
detectable	O
values	O
had	O
high	O
TCDD	O
levels	O
(	O
17	O
.	O
9	O
and	O
21	O
.	O
7	O
pg	O
/	O
g	O
lipid	O
)	O
,	O
suggesting	O
that	O
exposure	O
for	O
at	O
least	O
some	O
portion	O
of	O
this	O
population	O
is	O
substantially	O
higher	O
than	O
typical	O
of	O
this	O
age	O
group	O
.	O
In	O
comparison	O
,	O
in	O
a	O
cohort	O
of	O
adult	O
(	O
mean	O
age	O
of	O
58	O
years	O
)	O
fishermen	O
from	O
a	O
polluted	O
region	O
of	O
Finland	O
,	O
the	O
mean	O
TCDD	O
concentration	O
was	O
19	O
pg	O
/	O
g	O
lipid	O
[	O
33	O
]	O
.	O
In	O
adult	O
(	O
mean	O
age	O
of	O
53	O
years	O
)	O
residents	O
from	O
Calcasieu	O
Parish	O
,	O
Louisiana	O
,	O
which	O
is	O
near	O
a	O
chemical	O
industrial	O
complex	O
,	O
the	O
mean	O
TCDD	O
level	O
was	O
7	O
.	O
6	O
pg	O
/	O
g	O
lipid	O
[	O
34	O
]	O
.	O
Not	O
only	O
were	O
the	O
dioxin	O
levels	O
in	O
these	O
two	O
children	O
higher	O
than	O
those	O
found	O
in	O
these	O
studies	O
,	O
but	O
the	O
adults	O
in	O
the	O
previous	O
studies	O
were	O
several	O
decades	O
older	O
and	O
therefore	O
would	O
be	O
expected	O
to	O
have	O
higher	O
dioxin	O
body	B-Anatomy
burdens	O
than	O
younger	O
children	O
[	O
35	O
]	O
.	O
Potential	O
explanations	O
for	O
the	O
large	O
number	O
of	O
non	O
-	O
detectable	O
samples	B-Anatomy
for	O
TCDD	O
include	O
the	O
small	O
sample	B-Anatomy
volume	O
and	O
young	O
age	O
of	O
the	O
subjects	O
.	O
In	O
our	O
future	O
studies	O
in	O
this	O
population	O
,	O
we	O
will	O
collect	O
larger	O
volumes	O
of	O
serum	B-Anatomy
for	O
dioxin	O
analysis	O
.	O
In	O
one	O
of	O
the	O
few	O
studies	O
on	O
dioxin	O
-	O
like	O
compounds	O
in	O
which	O
children	O
were	O
included	O
,	O
Eskenazi	O
and	O
coworkers	O
[	O
36	O
]	O
evaluated	O
the	O
relationship	O
between	O
serum	B-Anatomy
TCDD	O
concentrations	O
and	O
age	O
at	O
exposure	O
of	O
female	O
residents	O
of	O
Seveso	O
,	O
Italy	O
.	O
Residents	O
near	O
the	O
ICMESA	O
chemical	O
plant	O
in	O
Seveso	O
were	O
exposed	O
to	O
some	O
of	O
the	O
highest	O
known	O
residential	O
levels	O
of	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
TCDD	O
as	O
a	O
result	O
of	O
an	O
explosion	O
at	O
the	O
plant	O
.	O
Archived	O
serum	B-Anatomy
collected	O
near	O
the	O
time	O
of	O
the	O
accident	O
was	O
used	O
to	O
measure	O
exposures	O
.	O
Residents	O
closest	O
to	O
the	O
plant	O
had	O
a	O
median	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
TCDD	O
level	O
of	O
272	O
ppt	O
(	O
IQR	O
92	O
-	O
883	O
ppt	O
)	O
.	O
Residential	O
proximity	O
to	O
the	O
plant	O
and	O
younger	O
age	O
(	O
up	O
to	O
13	O
years	O
old	O
)	O
were	O
the	O
strongest	O
predictors	O
of	O
an	O
individual	O
'	O
s	O
serum	B-Anatomy
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
TCDD	O
level	O
.	O
Other	O
predictors	O
included	O
being	O
outdoors	O
at	O
the	O
time	O
of	O
explosion	O
and	O
consumption	O
of	O
homegrown	O
food	O
.	O
The	O
higher	O
levels	O
found	O
in	O
children	O
were	O
most	O
likely	O
a	O
result	O
of	O
increased	O
exposure	O
as	O
a	O
result	O
of	O
activity	O
patterns	O
and	O
a	O
greater	O
proportionate	O
consumption	O
of	O
food	O
,	O
water	O
and	O
air	O
than	O
adults	O
[	O
37	O
]	O
.	O
Although	O
the	O
exposure	O
scenario	O
(	O
an	O
acute	O
high	O
exposure	O
event	O
)	O
is	O
different	O
than	O
the	O
chronic	O
low	O
/	O
moderate	O
exposure	O
occurring	O
in	O
Chapaevsk	O
,	O
the	O
results	O
from	O
Seveso	O
suggest	O
that	O
children	O
may	O
be	O
at	O
increased	O
risk	O
for	O
high	O
dioxin	O
exposure	O
from	O
environmental	O
contamination	O
.	O
In	O
our	O
study	O
,	O
although	O
distance	O
from	O
the	O
Khimprom	O
plants	O
was	O
a	O
weak	O
predictor	O
of	O
serum	B-Anatomy
dioxin	O
-	O
like	O
compounds	O
,	O
consumption	O
of	O
local	O
foods	O
(	O
specifically	O
meat	B-Anatomy
and	O
fish	O
)	O
,	O
as	O
in	O
the	O
Seveso	O
study	O
,	O
was	O
a	O
strong	O
predictor	O
of	O
sum	O
of	O
dioxin	O
-	O
like	O
compounds	O
and	O
dioxin	O
TEQs	O
.	O
This	O
finding	O
is	O
notable	O
given	O
concerns	O
regarding	O
environmental	O
dioxin	O
contamination	O
in	O
the	O
community	O
and	O
suggests	O
that	O
food	O
may	O
be	O
one	O
of	O
the	O
more	O
,	O
if	O
not	O
most	O
,	O
important	O
routes	O
of	O
environmental	O
contaminant	O
exposure	O
for	O
residents	O
in	O
this	O
setting	O
.	O
In	O
other	O
settings	O
,	O
contaminated	O
food	O
generally	O
contributes	O
much	O
more	O
substantially	O
to	O
human	O
organochlorine	O
burden	O
than	O
air	O
or	O
soil	O
(	O
which	O
may	O
be	O
related	O
to	O
residential	O
proximity	O
to	O
pollutant	O
sources	O
)	O
[	O
6	O
]	O
.	O
We	O
will	O
investigate	O
this	O
issue	O
in	O
more	O
detail	O
in	O
our	O
ongoing	O
study	O
.	O
Figures	O
and	O
Tables	O
Figure	O
1	O
Allergen	O
and	O
particle	O
dose	O
-	O
response	O
experiments	O
in	O
BALB	O
/	O
cA	O
and	O
NIH	O
mice	O
Levels	O
of	O
serum	B-Anatomy
OVA	O
-	O
specific	O
IgE	O
(	O
A	O
,	O
D	O
)	O
,	O
IgG1	O
(	O
B	O
,	O
E	O
)	O
and	O
IgG2a	O
(	O
C	O
,	O
F	O
)	O
on	O
day	O
26	O
after	O
injection	O
into	O
one	O
hind	B-Anatomy
footpad	I-Anatomy
of	O
100	O
(	O
open	O
columns	O
)	O
,	O
50	O
(	O
gray	O
)	O
or	O
10	O
(	O
black	O
)	O
mug	O
OVA	O
combined	O
with	O
100	O
,	O
40	O
,	O
10	O
or	O
0	O
mug	O
PSP	O
,	O
or	O
buffer	O
(	O
HBSS	O
(	O
hatched	O
)	O
)	O
,	O
in	O
BALB	O
/	O
cA	O
(	O
A	O
,	O
B	O
,	O
C	O
)	O
and	O
NIH	O
(	O
D	O
,	O
E	O
,	O
F	O
)	O
mice	O
.	O
On	O
day	O
21	O
the	O
mice	O
were	O
boostered	O
with	O
the	O
same	O
OVA	O
dose	O
in	O
the	O
footpad	B-Anatomy
.	O
The	O
PSP	O
-	O
control	O
(	O
""""	O
PSP	O
ctr	O
""""	O
)	O
group	O
was	O
given	O
100	O
mug	O
PSP	O
on	O
day	O
0	O
,	O
followed	O
by	O
HBSS	O
injection	O
on	O
day	O
21	O
(	O
diamonds	O
)	O
.	O
Values	O
(	O
arbitrary	O
units	O
,	O
AU	O
)	O
for	O
individual	O
mice	O
(	O
circles	O
)	O
and	O
median	O
values	O
(	O
columns	O
)	O
for	O
groups	O
of	O
eight	O
mice	O
are	O
shown	O
.	O
Dotted	O
lines	O
indicate	O
the	O
lower	O
or	O
higher	O
detection	O
limits	O
for	O
the	O
ELISA	O
assays	O
.	O
Note	O
different	O
scales	O
for	O
the	O
two	O
strains	O
of	O
mice	O
.	O
Figure	O
2	O
The	O
adjuvant	O
effect	O
of	O
PSP	O
on	O
OVA	O
-	O
specific	O
IgE	O
and	O
IgG2a	O
responses	O
in	O
different	O
strains	O
of	O
mice	O
Levels	O
of	O
serum	B-Anatomy
OVA	O
-	O
specific	O
IgE	O
(	O
A	O
)	O
and	O
IgG2a	O
(	O
B	O
)	O
on	O
day	O
26	O
after	O
injection	O
into	O
one	O
hind	B-Anatomy
footpad	I-Anatomy
of	O
HBSS	O
(	O
open	O
columns	O
)	O
,	O
10	O
mug	O
OVA	O
(	O
gray	O
)	O
,	O
40	O
mug	O
PSP	O
(	O
hatched	O
)	O
or	O
10	O
mug	O
OVA	O
+	O
40	O
mug	O
PSP	O
(	O
black	O
)	O
in	O
different	O
mouse	O
strains	O
.	O
On	O
day	O
21	O
all	O
mice	O
were	O
boostered	O
with	O
10	O
mug	O
OVA	O
in	O
the	O
footpad	B-Anatomy
.	O
Vertical	O
straight	O
lines	O
indicate	O
separate	O
experiments	O
.	O
Values	O
(	O
arbitrary	O
units	O
,	O
AU	O
)	O
for	O
individual	O
mice	O
(	O
circles	O
)	O
and	O
median	O
values	O
(	O
columns	O
)	O
for	O
groups	O
of	O
mice	O
are	O
shown	O
.	O
Dotted	O
lines	O
indicate	O
the	O
lower	O
detection	O
limits	O
for	O
the	O
ELISA	O
assays	O
.	O
Brackets	O
indicate	O
statistically	O
significant	O
differences	O
between	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
All	O
experiments	O
were	O
performed	O
twice	O
with	O
similar	O
results	O
,	O
with	O
eight	O
mice	O
per	O
group	O
.	O
Figure	O
3	O
The	O
primary	O
cellular	B-Anatomy
response	O
in	O
the	O
draining	O
lymph	B-Anatomy
node	I-Anatomy
The	O
primary	O
cellular	B-Anatomy
response	O
in	O
the	O
draining	O
PLN	B-Anatomy
was	O
determined	O
five	O
days	O
after	O
a	O
single	O
injection	O
of	O
HBSS	O
(	O
open	O
columns	O
)	O
,	O
10	O
mug	O
OVA	O
(	O
gray	O
)	O
,	O
40	O
mug	O
PSP	O
(	O
hatched	O
)	O
or	O
10	O
mug	O
OVA	O
+	O
40	O
mug	O
PSP	O
(	O
black	O
)	O
into	O
both	O
hind	O
footpads	O
of	O
BALB	O
/	O
cA	O
,	O
NIH	O
and	O
C3H	O
/	O
HeN	O
mice	O
.	O
The	O
total	O
lymph	B-Anatomy
node	I-Anatomy
cell	I-Anatomy
numbers	O
(	O
A	O
)	O
and	O
IL	O
-	O
4	O
(	O
B	O
)	O
,	O
IFN	O
-	O
gamma	O
(	O
C	O
)	O
and	O
IL	O
-	O
10	O
(	O
D	O
)	O
secreted	O
from	O
the	O
PLN	B-Anatomy
cells	I-Anatomy
after	O
ex	O
vivo	O
stimulation	O
with	O
Con	O
A	O
were	O
determined	O
.	O
Values	O
for	O
individual	O
samples	B-Anatomy
(	O
circles	O
)	O
and	O
group	O
median	O
values	O
(	O
columns	O
)	O
are	O
shown	O
.	O
Dotted	O
lines	O
indicate	O
the	O
lower	O
detection	O
limits	O
for	O
the	O
cytokine	O
ELISA	O
assays	O
,	O
and	O
brackets	O
indicate	O
statistically	O
significant	O
differences	O
between	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Figures	O
and	O
Tables	O
Stages	O
in	O
the	O
life	O
cycle	O
of	O
Plasmodium	O
falciparum	O
(	O
Illustration	O
:	O
Coatney	O
GR	O
,	O
Collins	O
WE	O
,	O
Warren	O
M	O
,	O
Contacos	O
PG	O
(	O
1971	O
)	O
The	O
primate	O
malarias	O
.	O
(	O
Bethesda	O
)	O
:	O
U	O
.	O
S	O
.	O
Department	O
of	O
Health	O
,	O
Education	O
and	O
Welfare	O
.	O
)	O
Images	O
FIGURE	O
2	O
.	O
A	O
FIGURE	O
2	O
.	O
B	O
FIGURE	O
3	O
.	O
Supporting	O
Information	O
Table	O
S1	O
Supplementary	O
Information	O
on	O
Genes	O
in	O
the	O
Three	O
Gene	O
Sets	O
(	O
219	O
KB	O
PDF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
Table	O
S2	O
UFW	O
Primers	O
for	O
Gene	O
Set	O
I	O
(	O
36	O
KB	O
PDF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
Table	O
S3	O
UFW	O
Primers	O
for	O
Gene	O
Set	O
II	O
(	O
44	O
KB	O
PDF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
Table	O
S4	O
UFW	O
Primers	O
for	O
Gene	O
Set	O
III	O
(	O
31	O
KB	O
PDF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
Table	O
S5	O
Transposable	O
Element	O
-	O
Specific	O
Primers	O
for	O
Additional	O
Screens	O
(	O
80	O
KB	O
PDF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
Table	O
S6	O
Primers	O
for	O
Intergenic	O
Regions	O
(	O
58	O
KB	O
PDF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
Table	O
S7	O
P	O
Element	O
-	O
Specific	O
Primers	O
for	O
Orientation	O
and	O
Length	O
Determination	O
(	O
299	O
KB	O
PDF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
Background	O
HIV	O
-	O
1	O
infectivity	O
depends	O
on	O
free	O
cholesterol	O
incorporated	O
into	O
the	O
viral	O
envelope	B-Anatomy
.	O
Here	O
,	O
we	O
analyze	O
HIV	O
infectivity	O
in	O
the	O
presence	O
of	O
drugs	O
that	O
stimulate	O
cholesterol	O
efflux	O
.	O
Additional	O
File	O
1	O
Appendix	O
1	O
.	O
Indications	O
for	O
liver	B-Anatomy
function	O
tests	O
with	O
no	O
obvious	O
liver	B-Anatomy
disease	O
,	O
and	O
consequent	O
investigations	O
Representative	O
PCR	O
/	O
LDR	O
results	O
for	O
HPTs	O
in	O
fimX	O
,	O
BP0059	O
,	O
BP0880	O
,	O
sphB2	O
,	O
ptxA	O
,	O
and	O
bhuR	O
.	O
Raw	O
capillary	O
electrophoresis	O
data	O
for	O
ligation	O
products	O
(	O
green	O
)	O
and	O
molecular	O
weight	O
standards	O
(	O
red	O
)	O
displayed	O
as	O
if	O
an	O
electrophoretic	O
gel	O
image	O
.	O
Assayed	O
locus	O
is	O
indicated	O
at	O
the	O
top	O
of	O
each	O
panel	O
;	O
strain	O
and	O
length	O
of	O
its	O
HPT	O
allele	O
are	O
noted	O
above	O
each	O
lane	O
.	O
Representative	O
LDR	O
results	O
are	O
depicted	O
here	O
;	O
for	O
complete	O
data	O
from	O
all	O
strains	O
see	O
Additional	O
files	O
8	O
,	O
9	O
,	O
10	O
,	O
11	O
,	O
12	O
,	O
and	O
13	O
.	O
BP0880	O
,	O
BP0059	O
,	O
fimX	O
,	O
and	O
sphB2	O
HPTs	O
were	O
screened	O
by	O
uniplex	O
LDR	O
reactions	O
containing	O
only	O
the	O
discriminating	O
oligonucleotide	O
that	O
targets	O
the	O
Tohama	O
I	O
sequence	O
.	O
The	O
ptxA	O
and	O
bhuR	O
HPTs	O
were	O
screened	O
by	O
multiplex	O
reactions	O
that	O
contain	O
all	O
three	O
discriminating	O
oligonucleotides	O
.	O
Letters	O
in	O
teal	O
indicate	O
molecular	O
weight	O
standards	O
as	O
labeled	O
in	O
the	O
corresponding	O
supplementary	O
figures	O
.	O
Ligation	O
products	O
(	O
arrows	O
)	O
are	O
labeled	O
using	O
the	O
notation	O
described	O
in	O
the	O
legend	O
to	O
Figure	O
1	O
.	O
The	O
open	O
arrowhead	O
indicates	O
a	O
synthesis	O
artifact	O
in	O
the	O
BP0059	O
common	O
oligonucleotide	O
preparation	O
.	O
INTRODUCTION	O
Comparing	O
genomic	O
sequences	O
across	O
related	O
species	O
is	O
a	O
fruitful	O
source	O
of	O
biological	O
insight	O
.	O
Functional	O
elements	O
such	O
as	O
exons	O
tend	O
to	O
exhibit	O
significant	O
sequence	O
similarity	O
due	O
to	O
purifying	O
selection	O
,	O
whereas	O
regions	O
that	O
are	O
not	O
functional	O
tend	O
to	O
be	O
neutrally	O
evolving	O
and	O
thus	O
less	O
conserved	O
.	O
The	O
first	O
step	O
in	O
comparing	O
genomic	O
sequences	O
is	O
to	O
align	O
them	O
-	O
-	O
to	O
map	O
the	O
letters	O
of	O
the	O
sequences	O
to	O
each	O
other	O
.	O
After	O
an	O
alignment	O
is	O
computed	O
,	O
visualization	O
frameworks	O
become	O
essential	O
to	O
enable	O
users	O
to	O
interact	O
with	O
the	O
sequence	O
and	O
conservation	O
data	O
,	O
especially	O
in	O
the	O
context	O
of	O
longer	O
DNA	O
sequences	O
or	O
whole	O
genomes	O
.	O
Visualization	O
frameworks	O
should	O
be	O
easy	O
to	O
understand	O
by	O
a	O
biologist	O
and	O
provide	O
insight	O
into	O
the	O
mutations	O
that	O
a	O
particular	O
genomic	O
locus	O
has	O
undergone	O
.	O
The	O
VISTA	O
portal	O
is	O
a	O
comprehensive	O
comparative	O
genomics	O
resource	O
that	O
provides	O
biomedical	O
scientists	O
with	O
a	O
single	O
unified	O
framework	O
to	O
generate	O
and	O
download	O
multiple	O
sequence	O
alignments	O
,	O
visualize	O
the	O
results	O
in	O
the	O
context	O
of	O
existing	O
annotations	O
and	O
analyze	O
comparative	O
results	O
in	O
search	O
for	O
important	O
sequence	O
signals	O
in	O
alignments	O
.	O
The	O
VISTA	O
suite	O
of	O
programs	O
has	O
been	O
in	O
development	O
and	O
continued	O
use	O
since	O
2000	O
(	O
1	O
-	O
4	O
)	O
.	O
It	O
was	O
originally	O
developed	O
for	O
the	O
alignment	O
and	O
comparative	O
analysis	O
of	O
long	O
genomic	O
sequences	O
and	O
later	O
was	O
expanded	O
to	O
pair	O
-	O
wise	O
and	O
multiple	O
alignment	O
of	O
vertebrate	O
genomes	O
.	O
VISTA	O
has	O
popularized	O
the	O
visualization	O
of	O
the	O
level	O
of	O
conservation	O
in	O
the	O
format	O
of	O
a	O
continuous	O
curve	O
based	O
on	O
the	O
conservation	O
in	O
a	O
sliding	O
window	O
.	O
This	O
concept	O
proved	O
to	O
be	O
extremely	O
successful	O
due	O
to	O
the	O
easy	O
interpretation	O
of	O
the	O
resulting	O
plots	O
.	O
VISTA	O
was	O
built	O
through	O
a	O
close	O
collaboration	O
between	O
computational	O
and	O
biological	O
scientists	O
,	O
resulting	O
in	O
a	O
product	O
that	O
is	O
robust	O
,	O
efficient	O
and	O
powerful	O
,	O
yet	O
simple	O
to	O
use	O
for	O
a	O
person	O
without	O
extensive	O
computer	O
experience	O
,	O
as	O
is	O
illustrated	O
by	O
more	O
than	O
1000	O
citations	O
to	O
the	O
various	O
VISTA	O
-	O
associated	O
tools	O
(	O
according	O
to	O
http	O
:	O
/	O
/	O
scholar	O
.	O
google	O
.	O
com	O
)	O
.	O
In	O
the	O
last	O
2	O
years	O
the	O
VISTA	O
portal	O
has	O
seen	O
many	O
significant	O
improvements	O
.	O
In	O
addition	O
to	O
updating	O
the	O
whole	O
genome	O
alignments	O
,	O
computed	O
using	O
recent	O
assemblies	O
of	O
vertebrate	O
,	O
insect	O
,	O
plant	O
and	O
microbial	O
genomes	O
,	O
we	O
have	O
added	O
significant	O
new	O
functionality	O
and	O
resources	O
to	O
the	O
Genome	O
Browser	O
and	O
other	O
tools	O
,	O
including	O
:	O
A	O
novel	O
multiple	O
whole	O
genome	O
alignment	O
algorithm	O
.	O
A	O
new	O
server	O
for	O
whole	O
-	O
genome	O
alignment	O
of	O
bacterial	O
genomes	O
.	O
Base	O
-	O
pair	O
level	O
visualization	O
ability	O
within	O
the	O
VISTA	O
browser	O
.	O
Visual	O
access	O
to	O
the	O
results	O
of	O
the	O
prediction	O
of	O
potential	O
deleteriousness	O
of	O
non	O
-	O
synonymous	O
Single	O
Nucleotide	O
Polymorphisms	O
(	O
SNPs	O
)	O
by	O
the	O
algorithm	O
PolyPhen	O
(	O
5	O
)	O
.	O
A	O
novel	O
conservation	O
track	O
,	O
Rank	O
-	O
VISTA	O
,	O
to	O
show	O
the	O
statistical	O
significance	O
of	O
conserved	O
regions	O
computed	O
by	O
the	O
Gumby	O
algorithm	O
(	O
6	O
)	O
.	O
Whole	O
-	O
genome	O
rVISTA	O
,	O
that	O
allows	O
for	O
evaluation	O
of	O
which	O
conserved	O
transcription	O
factor	O
binding	O
sites	O
(	O
TFBS	O
)	O
are	O
over	O
-	O
represented	O
in	O
a	O
group	O
of	O
genes	O
.	O
Images	O
Figure	O
5	O
Miscellaneous	O
Proteins	O
Apart	O
from	O
the	O
above	O
-	O
described	O
proteins	O
,	O
several	O
other	O
molecules	O
are	O
also	O
associated	O
with	O
the	O
pathological	B-Anatomy
lesions	I-Anatomy
of	O
AD	O
,	O
and	O
some	O
of	O
these	O
can	O
be	O
regarded	O
as	O
amateur	O
chaperones	O
.	O
Acute	O
phase	O
proteins	O
,	O
such	O
as	O
alpha1	O
-	O
antichymotrypsin	O
(	O
ACT	O
)	O
,	O
alpha2	O
-	O
macroglobulin	O
(	O
alpha2M	O
)	O
,	O
and	O
SAP	O
,	O
are	O
all	O
associated	O
with	O
Abeta	O
deposition	O
[	O
129	O
-	O
132	O
]	O
.	O
ACT	O
is	O
a	O
serine	O
protease	O
inhibitor	O
of	O
the	O
serpin	O
family	O
,	O
and	O
in	O
AD	O
,	O
ACT	O
levels	O
are	O
upregulated	O
,	O
and	O
binding	O
of	O
ACT	O
with	O
Abeta	O
induces	O
Abeta	O
fibrillogenesis	O
[	O
133	O
-	O
135	O
]	O
.	O
Furthermore	O
,	O
when	O
ACT	O
is	O
overexpressed	O
in	O
transgenic	O
mice	O
,	O
an	O
increased	O
plaque	B-Anatomy
load	O
in	O
the	O
brains	B-Anatomy
of	O
these	O
mice	O
and	O
impaired	O
spatial	O
learning	O
is	O
observed	O
[	O
134	O
,	O
135	O
]	O
.	O
alpha2M	O
also	O
binds	O
Abeta	O
,	O
although	O
in	O
contrast	O
to	O
ACT	O
,	O
this	O
binding	O
prevents	O
Abeta	O
fibril	B-Anatomy
formation	O
and	O
fibril	B-Anatomy
-	O
associated	O
neurotoxicity	O
[	O
136	O
,	O
137	O
]	O
.	O
alpha2M	O
promotes	O
the	O
protease	O
-	O
mediated	O
degradation	O
of	O
alpha2M	O
/	O
Abeta	O
complexes	O
and	O
contributes	O
to	O
clearance	O
of	O
Abeta	O
from	O
the	O
brain	B-Anatomy
(	O
discussed	O
in	O
paragraph	O
4	O
)	O
[	O
138	O
,	O
139	O
]	O
.	O
The	O
glycoprotein	O
SAP	O
belongs	O
to	O
the	O
pentraxin	O
family	O
and	O
is	O
a	O
common	O
component	O
of	O
all	O
known	O
types	O
of	O
amyloid	B-Anatomy
fibrils	I-Anatomy
.	O
SAP	O
is	O
upregulated	O
in	O
AD	O
and	O
protects	O
amyloid	B-Anatomy
fibrils	I-Anatomy
from	O
proteolysis	O
in	O
vitro	O
[	O
140	O
,	O
141	O
]	O
.	O
SAP	O
not	O
only	O
colocalizes	O
with	O
SPs	O
and	O
interacts	O
with	O
aggregated	O
Abeta	O
;	O
SAP	O
oligomers	O
also	O
bind	O
and	O
activate	O
C1	O
[	O
142	O
]	O
.	O
Both	O
C1	O
and	O
SAP	O
may	O
bind	O
to	O
fibrillar	B-Anatomy
Abeta	O
deposits	O
in	O
vivo	O
and	O
induce	O
microglial	B-Anatomy
activation	O
,	O
as	O
cultured	O
human	O
microglial	B-Anatomy
cells	I-Anatomy
show	O
an	O
increase	O
in	O
cytokine	O
production	O
after	O
co	O
-	O
stimulation	O
of	O
Abeta	O
with	O
C1q	O
and	O
SAP	O
[	O
104	O
]	O
.	O
These	O
observations	O
further	O
strengthen	O
the	O
above	O
-	O
noted	O
suggestion	O
that	O
not	O
only	O
Abeta	O
,	O
but	O
also	O
several	O
Abeta	O
-	O
binding	O
proteins	O
,	O
are	O
capable	O
of	O
activating	O
the	O
complement	O
system	O
,	O
and	O
thus	O
,	O
contribute	O
to	O
neuroinflammation	O
in	O
AD	O
.	O
In	O
addition	O
,	O
both	O
alpha2M	O
and	O
ACT	O
,	O
in	O
contrast	O
to	O
SAP	O
,	O
can	O
be	O
regarded	O
as	O
amateur	O
chaperones	O
,	O
as	O
they	O
regulate	O
conformational	O
changes	O
of	O
Abeta	O
.	O
Tissue	O
-	O
type	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
regulates	O
activation	O
of	O
plasminogen	O
into	O
plasmin	O
and	O
is	O
expressed	O
in	O
various	O
regions	O
of	O
the	O
brain	B-Anatomy
especially	O
in	O
the	O
hippocampus	B-Anatomy
[	O
143	O
]	O
.	O
Several	O
reports	O
suggested	O
an	O
important	O
role	O
for	O
tPA	O
in	O
AD	O
,	O
as	O
the	O
tPA	O
system	O
is	O
involved	O
in	O
Abeta	O
turnover	O
[	O
144	O
,	O
145	O
]	O
.	O
Fibrillar	B-Anatomy
forms	O
of	O
Abeta	O
stimulate	O
tPA	O
activity	O
in	O
vitro	O
,	O
whereas	O
in	O
AD	O
patients	O
,	O
a	O
reduction	O
of	O
tPA	O
activity	O
is	O
observed	O
in	O
the	O
affected	O
areas	O
[	O
144	O
,	O
146	O
]	O
.	O
Although	O
tPA	O
has	O
no	O
effect	O
on	O
conformational	O
changes	O
of	O
Abeta	O
,	O
it	O
might	O
play	O
a	O
role	O
in	O
the	O
clearance	O
of	O
Abeta	O
from	O
the	O
brain	B-Anatomy
(	O
paragraph	O
4	O
]	O
.	O
The	O
actin	O
-	O
regulatory	O
protein	O
gelsolin	O
is	O
found	O
both	O
intracellularly	B-Anatomy
and	O
in	O
plasma	B-Anatomy
[	O
147	O
,	O
148	O
]	O
.	O
Plasma	B-Anatomy
gelsolin	O
can	O
be	O
considered	O
an	O
amateur	O
chaperone	O
,	O
as	O
it	O
binds	O
Abeta	O
and	O
not	O
only	O
inhibits	O
its	O
Abeta	O
fibrillization	O
but	O
is	O
also	O
capable	O
of	O
degrading	O
preformed	O
Abeta	O
fibrils	B-Anatomy
[	O
149	O
,	O
150	O
]	O
.	O
Furthermore	O
,	O
gelsolin	O
inhibits	O
Abeta	O
-	O
mediated	O
neurotoxicity	O
[	O
151	O
]	O
.	O
One	O
of	O
the	O
major	O
gangliosides	O
in	O
the	O
brain	B-Anatomy
is	O
GM1	O
.	O
Soluble	O
Abeta	O
binds	O
GM1	O
and	O
the	O
formed	O
complexes	O
accelerate	O
Abeta	O
fibrillogenesis	O
by	O
acting	O
as	O
a	O
seed	O
for	O
Abeta	O
[	O
152	O
]	O
.	O
In	O
the	O
presence	O
of	O
GM1	O
,	O
Abeta	O
is	O
more	O
neurotoxic	O
than	O
Abeta	O
alone	O
,	O
and	O
cholesterol	O
-	O
rich	O
membranes	B-Anatomy
demonstrate	O
accelerated	O
Abeta	O
binding	O
due	O
to	O
the	O
formation	O
of	O
GM1	O
clusters	O
[	O
153	O
,	O
154	O
]	O
.	O
As	O
GM1	O
is	O
a	O
major	O
component	O
of	O
lipid	B-Anatomy
rafts	I-Anatomy
and	O
recent	O
studies	O
suggest	O
that	O
Abeta	O
accumulation	O
in	O
these	O
lipid	B-Anatomy
rafts	I-Anatomy
is	O
an	O
early	O
event	O
in	O
AD	O
development	O
,	O
GM1	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
early	O
steps	O
in	O
AD	O
pathogenesis	O
[	O
155	O
,	O
156	O
]	O
.	O
In	O
summary	O
,	O
several	O
proteins	O
are	O
associated	O
with	O
Abeta	O
aggregates	O
in	O
the	O
AD	B-Anatomy
brain	I-Anatomy
and	O
contribute	O
to	O
the	O
aggregation	O
of	O
Abeta	O
and	O
should	O
,	O
therefore	O
,	O
be	O
considered	O
as	O
amateur	O
chaperones	O
.	O
In	O
addition	O
,	O
they	O
might	O
play	O
a	O
role	O
in	O
triggering	O
inflammation	O
.	O
Mineralization	O
(	O
red	O
)	O
of	O
the	O
aorta	B-Anatomy
is	O
prevented	O
by	O
local	O
(	O
left	O
)	O
,	O
but	O
not	O
global	O
(	O
right	O
)	O
,	O
Mgp	O
expression	O
.	O
Basilar	B-Anatomy
papilla	I-Anatomy
The	O
basilar	B-Anatomy
papilla	I-Anatomy
is	O
found	O
in	O
a	O
recess	B-Anatomy
that	O
opens	O
into	O
the	O
saccular	B-Anatomy
space	I-Anatomy
at	O
one	O
end	O
,	O
and	O
is	O
limited	O
by	O
a	O
thin	O
contact	B-Anatomy
membrane	I-Anatomy
at	O
the	O
other	O
.	O
The	O
contact	B-Anatomy
membrane	I-Anatomy
separates	O
the	O
endolymphatic	B-Anatomy
fluid	I-Anatomy
in	O
the	O
papillar	B-Anatomy
recess	I-Anatomy
from	O
the	O
perilymphatic	B-Anatomy
fluid	I-Anatomy
at	O
the	O
round	O
window	O
(	O
Lewis	O
and	O
Narins	O
1999	O
;	O
Wever	O
1985	O
)	O
.	O
The	O
recess	B-Anatomy
perimeter	O
is	O
roughly	O
oval	O
in	O
shape	O
;	O
in	O
the	O
bullfrog	O
,	O
Rana	O
catesbeiana	O
,	O
its	O
major	O
axis	O
is	O
approximately	O
200	O
mum	O
long	O
,	O
while	O
the	O
minor	O
axis	O
measures	O
approximately	O
150	O
mum	O
(	O
Van	O
Bergeijk	O
1957	O
)	O
.	O
In	O
the	O
leopard	O
frog	O
,	O
Rana	O
pipiens	O
pipiens	O
,	O
it	O
is	O
of	O
similar	O
size	O
(	O
personal	O
observation	O
,	O
RLMS	O
&	O
JMS	O
)	O
.	O
The	O
oval	O
perimeter	O
of	O
the	O
lumen	B-Anatomy
is	O
formed	O
from	O
limbic	B-Anatomy
tissue	I-Anatomy
;	O
a	O
substance	O
unique	O
to	O
the	O
inner	B-Anatomy
ear	I-Anatomy
,	O
and	O
similar	O
to	O
cartilage	B-Anatomy
(	O
Wever	O
1985	O
)	O
.	O
The	O
sensory	B-Anatomy
epithelium	I-Anatomy
is	O
approximately	O
100	O
mum	O
long	O
.	O
It	O
occupies	O
a	O
curved	O
area	B-Anatomy
that	O
is	O
symmetrical	O
in	O
the	O
major	O
axis	O
of	O
the	O
elliptical	B-Anatomy
lumen	I-Anatomy
.	O
It	O
contains	O
approximately	O
60	O
hair	B-Anatomy
cells	I-Anatomy
(	O
measured	O
in	O
Rana	O
catesbeiana	O
)	O
,	O
from	O
which	O
the	O
stereovilli	B-Anatomy
protrude	O
into	O
the	O
lumen	B-Anatomy
and	O
connect	O
to	O
the	O
tectorial	B-Anatomy
membrane	I-Anatomy
(	O
Frishkopf	O
and	O
Flock	O
1974	O
)	O
.	O
Typically	O
the	O
orientation	O
of	O
the	O
hair	B-Anatomy
cells	I-Anatomy
,	O
as	O
defined	O
by	O
the	O
direction	O
to	O
which	O
the	O
v	O
-	O
shape	O
of	O
the	O
stereovilli	B-Anatomy
bundle	O
points	O
(	O
Lewis	O
et	O
al	O
.	O
1985	O
)	O
,	O
is	O
away	O
from	O
the	O
sacculus	B-Anatomy
in	O
Ranidae	O
.	O
The	O
tectorial	B-Anatomy
membrane	I-Anatomy
spans	O
the	O
lumen	B-Anatomy
of	O
the	O
papillar	B-Anatomy
recess	I-Anatomy
.	O
It	O
occludes	O
about	O
half	O
the	O
lumen	B-Anatomy
,	O
and	O
consequently	O
takes	O
an	O
approximately	O
semi	O
-	O
circular	O
shape	O
when	O
viewed	O
from	O
the	O
saccular	B-Anatomy
side	O
(	O
Frishkopf	O
and	O
Flock	O
1974	O
;	O
Wever	O
1985	O
)	O
.	O
The	O
membrane	B-Anatomy
has	O
pores	B-Anatomy
at	O
the	O
surface	B-Anatomy
closest	O
to	O
the	O
epithelium	B-Anatomy
,	O
into	O
which	O
the	O
tips	B-Anatomy
of	O
the	O
hair	B-Anatomy
bundles	I-Anatomy
project	O
(	O
Lewis	O
and	O
Narins	O
1999	O
)	O
.	O
4	O
Haplotype	O
block	O
structure	O
from	O
one	O
replicate	O
generated	O
by	O
the	O
block	O
method	O
(	O
ALS	O
)	O
.	O
Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O
Background	O
Previous	O
publications	O
indicate	O
that	O
acupuncture	O
is	O
efficient	O
for	O
the	O
treatment	O
of	O
pelvic	B-Anatomy
girdle	I-Anatomy
pain	O
,	O
PGP	O
,	O
in	O
pregnant	O
women	O
.	O
However	O
,	O
the	O
use	O
of	O
acupuncture	O
for	O
PGP	O
is	O
rare	O
due	O
to	O
insufficient	O
documentation	O
of	O
adverse	O
effects	O
of	O
this	O
treatment	O
in	O
this	O
specific	O
condition	O
.	O
The	O
aim	O
of	O
the	O
present	O
work	O
was	O
to	O
assess	O
adverse	O
effects	O
of	O
acupuncture	O
on	O
the	O
pregnancy	O
,	O
mother	O
,	O
delivery	O
and	O
the	O
fetus	B-Anatomy
/	O
neonate	O
in	O
comparison	O
with	O
women	O
that	O
received	O
stabilising	O
exercises	O
as	O
adjunct	O
to	O
standard	O
treatment	O
or	O
standard	O
treatment	O
alone	O
.	O
Authors	O
'	O
contributions	O
MP	O
prepared	O
the	O
first	O
draft	O
with	O
the	O
assistance	O
of	O
JLdR	O
.	O
Other	O
authors	O
reviewed	O
the	O
manuscript	O
,	O
provided	O
further	O
contributions	O
and	O
suggestions	O
.	O
All	O
of	O
the	O
authors	O
worked	O
collectively	O
to	O
develop	O
the	O
algorithms	O
and	O
methods	O
described	O
in	O
this	O
paper	O
.	O
Study	O
of	O
freeze	O
-	O
thaw	O
effects	O
and	O
CSF	O
pH	O
on	O
tissue	B-Anatomy
RNA	O
integrity	O
We	O
have	O
long	O
suspected	O
,	O
on	O
the	O
basis	O
of	O
our	O
tissue	B-Anatomy
banking	O
experience	O
,	O
that	O
most	O
of	O
the	O
molecular	O
degradation	O
that	O
occurs	O
in	O
banked	O
tissue	B-Anatomy
is	O
due	O
to	O
repeated	O
freeze	O
-	O
thaw	O
cycles	O
,	O
which	O
occur	O
due	O
to	O
improper	O
handling	O
during	O
dissection	O
for	O
tissue	B-Anatomy
retrieval	O
or	O
due	O
to	O
freezer	O
malfunctions	O
.	O
Our	O
freezers	O
are	O
currently	O
protected	O
by	O
temperature	O
-	O
sensitive	O
alarms	O
that	O
automatically	O
telephone	O
maintenance	O
and	O
tissue	B-Anatomy
banking	O
personnel	O
when	O
the	O
temperature	O
reaches	O
a	O
certain	O
level	O
.	O
More	O
protection	O
is	O
preferable	O
,	O
with	O
CO2	O
tanks	O
for	O
backup	O
cooling	O
the	O
optimum	O
(	O
but	O
expensive	O
)	O
approach	O
.	O
We	O
plan	O
to	O
systematically	O
investigate	O
the	O
effects	O
of	O
thawing	O
and	O
refreezing	O
on	O
RNA	O
integrity	O
,	O
by	O
deliberately	O
thawing	O
and	O
freezing	O
small	O
samples	B-Anatomy
of	O
brain	B-Anatomy
tissue	I-Anatomy
over	O
varying	O
time	O
intervals	O
and	O
temperatures	O
.	O
Printing	O
solution	O
Several	O
transfection	O
reagents	O
were	O
tested	O
(	O
data	O
not	O
shown	O
)	O
,	O
and	O
we	O
found	O
that	O
the	O
X	O
-	O
tremeGENE	O
siRNA	O
transfection	O
reagent	O
(	O
Roche	O
)	O
gave	O
good	O
transfection	O
efficiencies	O
both	O
for	O
plasmids	B-Anatomy
and	O
siRNAs	O
,	O
and	O
chose	O
to	O
use	O
this	O
reagent	O
for	O
all	O
transfected	O
cell	B-Anatomy
microarray	O
experiments	O
in	O
the	O
present	O
study	O
.	O
For	O
printing	O
the	O
arrays	O
,	O
one	O
major	O
challenge	O
is	O
to	O
find	O
a	O
good	O
balance	O
between	O
high	O
transfection	O
efficiency	O
and	O
spatially	O
confined	O
spots	O
to	O
avoid	O
cross	O
-	O
contamination	O
between	O
the	O
spots	O
.	O
In	O
order	O
to	O
optimize	O
the	O
reverse	O
transfection	O
protocol	O
for	O
HEK	B-Anatomy
293ind	I-Anatomy
-	I-Anatomy
ICER	I-Anatomy
IIgamma	I-Anatomy
cells	I-Anatomy
(	O
see	O
below	O
)	O
and	O
X	O
-	O
tremeGENE	O
transfection	O
reagent	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
varying	O
the	O
concentrations	O
of	O
gelatine	O
and	O
sucrose	O
in	O
the	O
printing	O
solution	O
.	O
These	O
reagents	O
have	O
been	O
reported	O
to	O
influence	O
both	O
the	O
transfection	O
efficiency	O
and	O
spot	O
integrity	O
(	O
6	O
,	O
27	O
)	O
.	O
Sucrose	O
was	O
observed	O
to	O
be	O
specifically	O
beneficial	O
for	O
obtaining	O
high	O
transfection	O
efficiency	O
when	O
storing	O
the	O
arrays	O
for	O
several	O
weeks	O
before	O
use	O
(	O
data	O
not	O
shown	O
)	O
.	O
Figure	O
1A	O
and	O
B	O
show	O
representative	O
images	O
of	O
the	O
observed	O
effects	O
of	O
varying	O
the	O
concentrations	O
of	O
gelatine	O
and	O
sucrose	O
.	O
We	O
observed	O
that	O
the	O
transfection	O
efficiency	O
increased	O
with	O
increasing	O
gelatine	O
concentration	O
(	O
tested	O
in	O
the	O
range	O
0	O
.	O
01	O
-	O
0	O
.	O
40	O
%	O
)	O
.	O
However	O
,	O
an	O
increased	O
disturbance	O
of	O
the	O
spatial	O
definition	O
of	O
the	O
spots	O
was	O
observed	O
with	O
increasing	O
concentrations	O
of	O
gelatine	O
or	O
sucrose	O
(	O
tested	O
in	O
the	O
range	O
0	O
-	O
100	O
mM	O
)	O
.	O
A	O
combined	O
effect	O
of	O
the	O
concentrations	O
of	O
gelatine	O
and	O
sucrose	O
was	O
also	O
observed	O
,	O
as	O
low	O
concentrations	O
of	O
gelatine	O
allowed	O
us	O
to	O
use	O
higher	O
concentrations	O
of	O
sucrose	O
than	O
with	O
higher	O
concentrations	O
of	O
gelatine	O
before	O
cells	B-Anatomy
spread	O
outside	O
the	O
spots	O
.	O
Based	O
on	O
several	O
optimizing	O
experiments	O
,	O
we	O
found	O
that	O
3	O
microl	O
X	O
-	O
tremeGENE	O
solution	O
per	O
microgram	O
nucleic	O
acid	O
,	O
25	O
mM	O
sucrose	O
and	O
0	O
.	O
1	O
%	O
gelatine	O
in	O
the	O
final	O
printing	O
solution	O
reproducibly	O
gave	O
spatial	O
restricted	O
transfection	O
with	O
high	O
transfection	O
efficiency	O
printing	O
the	O
arrays	O
with	O
both	O
a	O
pipette	O
tip	O
and	O
a	O
hand	B-Anatomy
-	O
held	O
arrayer	O
(	O
see	O
below	O
)	O
.	O
Figure	O
1	O
.	O
Effects	O
of	O
sucrose	O
and	O
gelatine	O
concentrations	O
on	O
spot	O
integrity	O
and	O
transfection	O
efficiency	O
.	O
(	O
A	O
)	O
Array	O
printed	O
with	O
pDsRed	O
(	O
50	O
ng	O
/	O
microl	O
)	O
in	O
a	O
printing	O
solution	O
with	O
different	O
gelatine	O
and	O
sucrose	O
concentrations	O
.	O
Scanning	O
image	O
of	O
the	O
whole	O
array	O
and	O
magnifications	O
of	O
specific	O
spots	O
.	O
(	O
B	O
)	O
Array	O
printed	O
with	O
pEGFP	O
(	O
50	O
ng	O
/	O
microl	O
)	O
in	O
a	O
printing	O
solution	O
with	O
25	O
mM	O
sucrose	O
and	O
four	O
different	O
concentrations	O
of	O
gelatine	O
.	O
Top	O
:	O
Box	O
plot	O
of	O
the	O
fluorescence	O
intensities	O
in	O
each	O
spot	O
(	O
n	O
=	O
32	O
-	O
34	O
)	O
.	O
Bottom	O
:	O
Scanning	O
image	O
showing	O
squares	O
of	O
seven	O
times	O
five	O
spots	O
for	O
the	O
four	O
gelatine	O
concentrations	O
.	O
From	O
left	O
to	O
right	O
:	O
0	O
.	O
01	O
,	O
0	O
.	O
05	O
,	O
0	O
.	O
1	O
and	O
0	O
.	O
2	O
%	O
gelatine	O
.	O
The	O
DNA	O
-	O
lipid	O
-	O
gelatine	O
-	O
sucrose	O
solutions	O
were	O
printed	O
manually	O
with	O
a	O
10	O
microl	O
pipette	O
tip	O
(	O
A	O
)	O
or	O
by	O
MicroCasterTM	O
manual	O
arrayer	O
system	O
(	O
B	O
)	O
.	O
In	O
a	O
1	O
.	O
5	O
ml	O
microcentrifuge	O
tube	O
,	O
plasmid	B-Anatomy
(	O
1	O
microg	O
/	O
microl	O
)	O
and	O
siRNA	O
were	O
mixed	O
with	O
growth	O
medium	O
without	O
fetal	B-Anatomy
calf	I-Anatomy
serum	I-Anatomy
(	O
FCS	B-Anatomy
)	O
,	O
0	O
.	O
5	O
microl	O
1	O
.	O
5	O
M	O
sucrose	O
and	O
3	O
microl	O
X	O
-	O
tremeGENE	O
per	O
microgram	O
nucleic	O
acid	O
to	O
a	O
final	O
volume	O
of	O
22	O
.	O
5	O
microl	O
.	O
After	O
15	O
-	O
20	O
min	O
of	O
incubation	O
,	O
7	O
.	O
5	O
microl	O
0	O
.	O
4	O
%	O
gelatine	O
(	O
Type	O
B	O
,	O
G9391	O
,	O
Sigma	O
)	O
was	O
added	O
to	O
give	O
30	O
microl	O
printing	O
solution	O
.	O
The	O
gelatine	O
solution	O
was	O
prepared	O
as	O
described	O
by	O
Ziauddin	O
and	O
Sabatini	O
(	O
1	O
)	O
.	O
To	O
achieve	O
sufficient	O
level	O
of	O
expression	O
from	O
the	O
transfected	O
plasmids	B-Anatomy
,	O
25	O
-	O
50	O
ng	O
/	O
microl	O
pEGFP	O
-	O
N1	O
or	O
pDsRed	O
-	O
express	O
-	O
N1	O
and	O
50	O
-	O
75	O
ng	O
/	O
microl	O
of	O
CRE	O
or	O
NFkappaB	O
reporter	O
plasmids	B-Anatomy
was	O
used	O
.	O
For	O
siRNA	O
studies	O
,	O
2	O
-	O
30	O
ng	O
/	O
microl	O
siRNA	O
in	O
the	O
final	O
printing	O
solution	O
was	O
used	O
.	O
Candle	O
wicks	O
Candles	O
with	O
a	O
lead	O
metal	O
core	O
contribute	O
to	O
lead	O
in	O
the	O
home	O
(	O
Nriagu	O
and	O
Kim	O
2000	O
;	O
van	O
Alphen	O
1999	O
)	O
.	O
Exposure	O
occurs	O
both	O
from	O
air	O
and	O
from	O
hand	O
-	O
to	O
-	O
mouth	O
activity	O
.	O
However	O
,	O
to	O
date	O
,	O
no	O
children	O
'	O
s	O
EBLs	O
traceable	O
to	O
candles	O
have	O
been	O
reported	O
.	O
In	O
2002	O
,	O
the	O
CPSC	O
banned	O
candlewicks	O
containing	O
>	O
0	O
.	O
06	O
%	O
lead	O
(	O
CPSC	O
2003	O
)	O
.	O
Variables	O
Our	O
study	O
used	O
the	O
following	O
9	O
HRQOL	O
questions	O
from	O
the	O
2004	O
Rhode	O
Island	O
BRFSS	O
:	O
1	O
)	O
self	O
-	O
rated	O
general	O
health	O
status	O
;	O
and	O
self	O
-	O
reported	O
number	O
of	O
healthy	O
and	O
unhealthy	O
days	O
in	O
the	O
previous	O
30	O
days	O
for	O
2	O
)	O
physical	O
health	O
,	O
3	O
)	O
mental	O
health	O
,	O
4	O
)	O
physical	O
or	O
mental	O
health	O
-	O
related	O
activity	O
limitation	O
,	O
5	O
)	O
pain	O
-	O
related	O
activity	O
limitation	O
,	O
6	O
)	O
sad	O
,	O
blue	O
,	O
or	O
depressed	O
,	O
7	O
)	O
worried	O
,	O
tense	O
,	O
or	O
anxious	O
,	O
8	O
)	O
lack	O
of	O
rest	O
or	O
sleep	O
,	O
and	O
9	O
)	O
lack	O
of	O
energy	O
(	O
1	O
,	O
2	O
,	O
15	O
)	O
.	O
We	O
created	O
9	O
dichotomous	O
indicator	O
variables	O
.	O
The	O
responses	O
to	O
the	O
self	O
-	O
rated	O
general	O
health	O
status	O
question	O
were	O
dichotomized	O
into	O
""""	O
poor	O
""""	O
(	O
poor	O
or	O
fair	O
)	O
health	O
or	O
""""	O
good	O
""""	O
(	O
good	O
,	O
very	O
good	O
,	O
or	O
excellent	O
)	O
health	O
.	O
The	O
indicators	O
measured	O
in	O
days	O
were	O
dichotomized	O
at	O
a	O
cutoff	O
value	O
of	O
14	O
or	O
more	O
days	O
of	O
poor	O
health	O
in	O
the	O
previous	O
month	O
compared	O
to	O
less	O
than	O
14	O
days	O
(	O
3	O
)	O
.	O
We	O
selected	O
the	O
14	O
-	O
day	O
minimum	O
period	O
because	O
most	O
of	O
the	O
publications	O
we	O
reviewed	O
that	O
use	O
the	O
BRFSS	O
HRQOL	O
indicators	O
(	O
outcomes	O
)	O
use	O
the	O
cutoff	O
of	O
14	O
or	O
more	O
days	O
compared	O
to	O
13	O
or	O
fewer	O
days	O
(	O
3	O
-	O
5	O
,	O
7	O
-	O
11	O
,	O
16	O
,	O
17	O
)	O
.	O
Adopting	O
this	O
precedent	O
ensured	O
comparability	O
.	O
In	O
addition	O
,	O
clinicians	O
and	O
clinical	O
researchers	O
often	O
use	O
this	O
period	O
as	O
a	O
marker	O
for	O
clinical	O
depression	O
and	O
anxiety	O
disorders	O
,	O
and	O
long	O
symptomatic	O
durations	O
are	O
associated	O
with	O
high	O
levels	O
of	O
activity	O
limitation	O
(	O
2	O
,	O
18	O
)	O
.	O
Detailed	O
definitions	O
of	O
the	O
9	O
indicators	O
are	O
available	O
in	O
our	O
previous	O
article	O
(	O
1	O
)	O
or	O
are	O
accessible	O
through	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
'	O
s	O
HRQOL	O
Web	O
site	O
(	O
2	O
)	O
.	O
We	O
chose	O
12	O
predictors	O
for	O
the	O
analysis	O
:	O
5	O
standard	O
demographic	O
measures	O
(	O
age	O
,	O
sex	O
,	O
race	O
/	O
Hispanic	O
ethnicity	O
,	O
annual	O
income	O
,	O
and	O
employment	O
status	O
)	O
;	O
4	O
health	O
conditions	O
(	O
asthma	O
,	O
diabetes	O
,	O
obesity	O
,	O
and	O
physical	O
disability	O
)	O
;	O
and	O
3	O
health	O
risk	O
behaviors	O
(	O
smoking	O
,	O
chronic	O
alcohol	O
use	O
,	O
and	O
no	O
leisure	O
-	O
time	O
physical	O
activity	O
)	O
.	O
These	O
predictors	O
paralleled	O
the	O
results	O
of	O
other	O
studies	O
that	O
have	O
examined	O
relationships	O
between	O
a	O
specific	O
HRQOL	O
indicator	O
and	O
various	O
predictors	O
(	O
17	O
,	O
19	O
)	O
,	O
or	O
that	O
have	O
examined	O
multiple	O
HRQOL	O
indicators	O
in	O
relation	O
to	O
demographics	O
(	O
4	O
,	O
20	O
)	O
,	O
health	O
risks	O
(	O
5	O
,	O
10	O
,	O
21	O
)	O
,	O
or	O
specific	O
health	O
conditions	O
(	O
6	O
-	O
9	O
,	O
12	O
,	O
22	O
)	O
.	O
We	O
dichotomized	O
some	O
predictors	O
for	O
the	O
analysis	O
(	O
ie	O
,	O
sex	O
,	O
current	O
smoking	O
,	O
alcohol	O
use	O
,	O
physical	O
activity	O
,	O
asthma	O
,	O
diabetes	O
,	O
obesity	O
,	O
and	O
disability	O
)	O
,	O
whereas	O
other	O
predictors	O
had	O
multiple	O
categories	O
(	O
ie	O
,	O
age	O
,	O
race	O
/	O
Hispanic	O
ethnicity	O
,	O
income	O
,	O
and	O
employment	O
status	O
)	O
.	O
The	O
definitions	O
of	O
the	O
12	O
predictors	O
are	O
available	O
in	O
our	O
previous	O
article	O
(	O
1	O
)	O
.	O
Reference	O
groups	O
chosen	O
for	O
the	O
IRT	O
model	O
were	O
those	O
having	O
the	O
lowest	O
risk	O
for	O
poor	O
or	O
fair	O
general	O
health	O
and	O
usually	O
the	O
lowest	O
risk	O
for	O
the	O
other	O
HRQOL	O
variables	O
as	O
well	O
.	O
Results	O
1	O
.	O
Introduction	O
Phase	O
I	O
clinical	O
trials	O
of	O
new	O
anticancer	O
agents	O
have	O
been	O
commonly	O
conducted	O
using	O
the	O
method	O
of	O
modified	O
Fibonacci	O
[	O
1	O
]	O
.	O
In	O
brief	O
,	O
3	O
patients	O
are	O
treated	O
at	O
a	O
starting	O
dose	O
which	O
is	O
typically	O
one	O
tenth	O
of	O
the	O
dose	O
that	O
is	O
lethal	O
to	O
10	O
%	O
of	O
animals	O
defined	O
in	O
preclinical	O
studies	O
.	O
If	O
none	O
of	O
the	O
3	O
patients	O
experiences	O
DLT	O
,	O
then	O
the	O
next	O
3	O
patients	O
will	O
be	O
treated	O
at	O
the	O
next	O
higher	O
dose	O
.	O
If	O
DLT	O
is	O
observed	O
,	O
additional	O
patients	O
will	O
be	O
treated	O
at	O
the	O
same	O
or	O
lower	O
dose	O
level	O
to	O
determine	O
MTD	O
according	O
to	O
a	O
predetermined	O
schema	O
.	O
The	O
MTD	O
is	O
defined	O
as	O
the	O
highest	O
dose	O
reached	O
for	O
which	O
the	O
incidence	O
of	O
DLT	O
occurs	O
in	O
less	O
than	O
33	O
%	O
of	O
the	O
subjects	O
.	O
Typically	O
,	O
intrapatient	O
dose	O
escalation	O
is	O
not	O
allowed	O
.	O
There	O
are	O
several	O
shortcomings	O
associated	O
with	O
the	O
modified	O
-	O
Fibonacci	O
design	O
.	O
It	O
has	O
long	O
been	O
recognized	O
that	O
a	O
substantial	O
number	O
of	O
patients	O
are	O
likely	O
to	O
be	O
treated	O
at	O
subtherapeutic	O
doses	O
[	O
2	O
,	O
3	O
]	O
.	O
This	O
is	O
particularly	O
true	O
for	O
drugs	O
with	O
potential	O
anticancer	O
activity	O
.	O
Since	O
the	O
primary	O
purpose	O
of	O
phase	O
I	O
trials	O
is	O
to	O
determine	O
DLT	O
and	O
MTD	O
,	O
the	O
efficacy	O
of	O
the	O
drug	O
may	O
not	O
be	O
evident	O
for	O
certain	O
tumor	B-Anatomy
types	O
as	O
there	O
are	O
only	O
a	O
small	O
number	O
of	O
patients	O
enrolled	O
into	O
the	O
trial	O
.	O
Furthermore	O
,	O
the	O
modified	O
-	O
Fibonacci	O
design	O
does	O
not	O
take	O
into	O
account	O
individual	O
variations	O
in	O
therapeutic	O
and	O
toxicologic	O
responses	O
due	O
to	O
genomic	O
polymorphisms	O
[	O
4	O
,	O
5	O
]	O
.	O
In	O
addition	O
,	O
since	O
there	O
is	O
a	O
limit	O
of	O
3	O
subjects	O
allowed	O
for	O
each	O
cohort	O
,	O
a	O
waiting	O
period	O
of	O
up	O
to	O
four	O
weeks	O
is	O
commonly	O
required	O
before	O
enrollment	O
of	O
the	O
next	O
cohort	O
of	O
subjects	O
.	O
This	O
latter	O
requirement	O
creates	O
anxiety	O
of	O
waiting	O
for	O
eligible	O
patients	O
.	O
Several	O
alternative	O
phase	O
I	O
designs	O
have	O
been	O
proposed	O
which	O
limit	O
the	O
number	O
of	O
patients	O
accrued	O
at	O
each	O
dose	O
level	O
and	O
accelerate	O
the	O
dose	O
escalation	O
process	O
[	O
1	O
,	O
6	O
]	O
.	O
There	O
has	O
also	O
been	O
an	O
increase	O
in	O
the	O
number	O
of	O
clinical	O
trials	O
that	O
include	O
a	O
component	O
of	O
intrapatient	O
dose	O
escalation	O
although	O
no	O
formal	O
validation	O
with	O
the	O
modified	O
-	O
Fibonacci	O
approach	O
has	O
been	O
reported	O
[	O
7	O
-	O
9	O
]	O
.	O
We	O
have	O
pioneered	O
a	O
population	O
-	O
based	O
design	O
to	O
maximize	O
therapeutic	O
efficacy	O
,	O
to	O
provide	O
preliminary	O
efficacy	O
information	O
and	O
to	O
allow	O
derivation	O
of	O
a	O
pMTD	O
for	O
subsequent	O
phase	O
II	O
trials	O
.	O
Irinotecan	O
and	O
cisplatin	O
have	O
been	O
shown	O
to	O
have	O
promising	O
efficacy	O
in	O
patients	O
with	O
small	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
cancer	I-Anatomy
in	O
phase	O
III	O
trial	O
where	O
irinotecan	O
was	O
given	O
on	O
a	O
weekly	O
schedule	O
[	O
10	O
]	O
.	O
We	O
wished	O
to	O
perform	O
a	O
population	O
-	O
based	O
phase	O
I	O
trial	O
of	O
irinotecan	O
,	O
given	O
every	O
3	O
weeks	O
,	O
and	O
carboplatin	O
,	O
a	O
platinated	O
anticancer	O
drug	O
which	O
is	O
generally	O
better	O
tolerated	O
than	O
its	O
cisplatin	O
analog	O
.	O
2	O
.	O
2	O
.	O
Iris	B-Anatomy
and	O
Ciliary	B-Anatomy
Body	I-Anatomy
Serotonin	O
is	O
present	O
in	O
mammalian	O
iris	B-Anatomy
-	I-Anatomy
ciliary	I-Anatomy
body	I-Anatomy
complex	I-Anatomy
(	O
ICB	B-Anatomy
)	O
at	O
higher	O
concentration	O
that	O
in	O
non	O
-	O
mammalian	O
species	O
[	O
5	O
,	O
45	O
,	O
73	O
,	O
129	O
,	O
137	O
]	O
.	O
Moreover	O
,	O
the	O
presence	O
of	O
serotonergic	O
nerves	B-Anatomy
has	O
been	O
demonstrated	O
in	O
studies	O
conducted	O
on	O
the	O
ICB	B-Anatomy
of	O
various	O
species	O
[	O
102	O
,	O
137	O
,	O
138	O
]	O
.	O
Experimental	O
evidence	O
and	O
radioligand	O
analyses	O
have	O
defined	O
the	O
presence	O
at	O
this	O
level	O
of	O
three	O
different	O
types	O
of	O
serotonin	O
receptors	O
[	O
10	O
,	O
28	O
,	O
85	O
,	O
136	O
,	O
137	O
]	O
,	O
i	O
.	O
e	O
.	O
5	O
-	O
HT1A	O
,	O
5	O
-	O
HT2A	O
/	O
2C	O
and	O
5	O
-	O
HT7	O
[	O
98	O
]	O
,	O
one	O
linked	O
to	O
a	O
stimulation	O
of	O
inositol	O
phosphates	O
(	O
5	O
-	O
HT2	O
subtype	O
)	O
,	O
while	O
the	O
others	O
two	O
are	O
linked	O
to	O
cAMP	O
activity	O
.	O
The	O
plausibility	O
of	O
the	O
existence	O
of	O
more	O
than	O
one	O
5	O
-	O
HT	O
receptor	O
type	O
in	O
the	O
ciliary	B-Anatomy
body	I-Anatomy
is	O
confirmed	O
by	O
intraocular	B-Anatomy
pressure	O
(	O
IOP	O
)	O
experiments	O
.	O
Topical	O
application	O
of	O
serotonin	O
has	O
been	O
reported	O
to	O
both	O
elevate	O
[	O
84	O
]	O
and	O
lower	O
[	O
88	O
]	O
IOP	O
in	O
rabbit	O
.	O
A	O
large	O
number	O
of	O
reports	O
have	O
shown	O
that	O
serotonin	O
agonists	O
and	O
antagonists	O
can	O
produce	O
increases	O
and	O
decreases	O
in	O
IOP	O
when	O
given	O
orally	B-Anatomy
,	O
topically	O
to	O
the	O
eye	B-Anatomy
or	O
when	O
they	O
are	O
directly	O
injected	O
in	O
the	O
anterior	B-Anatomy
chamber	I-Anatomy
[	O
10	O
,	O
26	O
,	O
34	O
,	O
35	O
,	O
64	O
,	O
75	O
,	O
84	O
,	O
87	O
,	O
88	O
,	O
112	O
,	O
113	O
,	O
126	O
,	O
136	O
,	O
137	O
]	O
.	O
A	O
rationale	O
for	O
such	O
apparently	O
contradictory	O
results	O
may	O
be	O
due	O
to	O
the	O
different	O
sites	O
of	O
action	O
,	O
i	O
.	O
e	O
.	O
which	O
class	O
of	O
serotonin	O
receptor	O
is	O
activated	O
.	O
In	O
fact	O
,	O
in	O
rabbit	O
the	O
administration	O
of	O
5	O
-	O
methyl	O
-	O
urapidil	O
(	O
a	O
combined	O
5	O
-	O
HT1A	O
agonist	O
/	O
alpha1	O
adrenoreceptor	O
antagonist	O
)	O
and	O
8	O
-	O
OH	O
-	O
DPAT	O
(	O
8	O
-	O
hydroxydypropylaminotetralin	O
,	O
a	O
5HT1A	O
agonist	O
)	O
reduces	O
IOP	O
,	O
while	O
the	O
administration	O
of	O
5	O
-	O
CT	O
(	O
5	O
-	O
carboxamidotryptamine	O
,	O
a	O
5	O
-	O
HT1A	O
and	O
5	O
-	O
HT7	O
agonist	O
)	O
increases	O
IOP	O
[	O
36	O
,	O
84	O
,	O
99	O
]	O
.	O
Chidlow	O
,	O
Le	O
Corre	O
and	O
Osborne	O
[	O
28	O
]	O
have	O
recently	O
demonstrated	O
that	O
,	O
in	O
section	B-Anatomy
taken	O
through	O
the	O
whole	O
eye	B-Anatomy
and	O
ciliary	B-Anatomy
body	I-Anatomy
,	O
prominent	O
5	O
-	O
HT1A	O
and	O
5	O
-	O
HT7	O
receptor	O
messenger	O
ribonucleic	O
acid	O
signals	O
were	O
obtained	O
.	O
These	O
signals	O
were	O
evident	O
in	O
both	O
the	O
pigmented	O
and	O
non	O
-	O
pigmented	O
epithelial	B-Anatomy
cell	I-Anatomy
layers	O
of	O
the	O
pars	B-Anatomy
plicata	I-Anatomy
region	O
of	O
the	O
ciliary	B-Anatomy
processes	O
,	O
but	O
not	O
in	O
the	O
pars	B-Anatomy
plana	I-Anatomy
or	O
in	O
the	O
ciliary	B-Anatomy
musculature	I-Anatomy
.	O
5	O
-	O
HT1A	O
and	O
5	O
-	O
HT7	O
signals	O
were	O
apparent	O
in	O
the	O
posterior	O
processes	O
but	O
not	O
in	O
the	O
iris	B-Anatomy
processes	O
.	O
The	O
presence	O
of	O
both	O
receptors	O
in	O
the	O
ciliary	B-Anatomy
body	I-Anatomy
would	O
certainly	O
provide	O
an	O
explanation	O
for	O
the	O
shallow	O
displacement	O
curves	O
observed	O
in	O
[	O
3H	O
]	O
5	O
-	O
HT	O
binding	O
studies	O
with	O
the	O
tissue	B-Anatomy
[	O
110	O
]	O
,	O
since	O
this	O
ligand	O
can	O
be	O
used	O
to	O
label	O
both	O
receptors	O
.	O
Because	O
the	O
ciliary	B-Anatomy
epithelium	I-Anatomy
of	O
the	O
pars	B-Anatomy
plicata	I-Anatomy
is	O
responsible	O
for	O
the	O
secretion	O
of	O
aqueous	B-Anatomy
humor	I-Anatomy
,	O
an	O
obvious	O
function	O
for	O
these	O
two	O
receptors	O
would	O
be	O
an	O
involvement	O
in	O
the	O
control	O
of	O
aqueous	O
production	O
and	O
,	O
consequently	O
,	O
of	O
the	O
IOP	O
level	O
.	O
Further	O
,	O
the	O
almost	O
identical	O
distribution	O
of	O
the	O
5	O
-	O
HT1A	O
and	O
5	O
-	O
HT7	O
messengers	O
ribonucleic	O
acid	O
indicate	O
that	O
the	O
receptors	O
may	O
be	O
co	O
-	O
localized	O
in	O
epithelial	B-Anatomy
cells	I-Anatomy
.	O
The	O
presence	O
of	O
two	O
serotonin	O
receptors	O
with	O
opposing	O
effects	O
on	O
cAMP	O
in	O
the	O
same	O
cell	B-Anatomy
layer	O
prompts	O
the	O
suggestion	O
that	O
they	O
could	O
act	O
antagonistically	O
.	O
The	O
agonism	O
of	O
5	O
-	O
HT1A	O
receptors	O
,	O
negatively	O
coupled	O
to	O
cAMP	O
,	O
reduces	O
IOP	O
by	O
decreasing	O
the	O
production	O
of	O
aqueous	B-Anatomy
humor	I-Anatomy
,	O
like	O
beta	O
-	O
receptor	O
antagonists	O
which	O
,	O
diminishing	O
the	O
content	O
of	O
cAMP	O
at	O
the	O
postjunctional	O
site	O
,	O
lowers	O
the	O
aqueous	B-Anatomy
humor	I-Anatomy
secretion	O
with	O
a	O
consequent	O
decrease	O
in	O
IOP	O
[	O
98	O
]	O
.	O
On	O
the	O
contrary	O
,	O
the	O
administration	O
of	O
5	O
-	O
CT	O
induces	O
a	O
rise	O
in	O
IOP	O
,	O
which	O
is	O
partly	O
or	O
entirely	O
caused	O
by	O
an	O
increase	O
in	O
aqueous	B-Anatomy
humor	I-Anatomy
secretion	O
mediated	O
by	O
5	O
-	O
HT7	O
receptors	O
[	O
84	O
]	O
.	O
The	O
other	O
type	O
of	O
serotonin	O
receptor	O
present	O
in	O
the	O
ICB	B-Anatomy
is	O
a	O
5	O
-	O
HT2	O
type	O
.	O
Serotonin	O
stimulates	O
the	O
accumulation	O
of	O
inositol	O
phosphates	O
in	O
the	O
ICB	B-Anatomy
and	O
this	O
effect	O
is	O
partially	O
counteracted	O
by	O
the	O
5	O
-	O
HT2	O
antagonists	O
ketanserin	O
,	O
methysergide	O
and	O
mianserin	O
[	O
98	O
]	O
.	O
Studies	O
with	O
ketanserin	O
have	O
demonstrated	O
that	O
,	O
when	O
orally	B-Anatomy
or	O
topically	O
applied	O
,	O
it	O
lowers	O
IOP	O
in	O
animals	O
,	O
healthy	O
volunteers	O
and	O
in	O
glaucomatous	B-Anatomy
patients	O
[	O
26	O
,	O
34	O
,	O
37	O
,	O
64	O
,	O
75	O
,	O
88	O
,	O
113	O
,	O
126	O
]	O
.	O
It	O
has	O
been	O
emphasized	O
that	O
ketanserin	O
also	O
possesses	O
an	O
affinity	O
for	O
alpha1	O
-	O
adrenoreceptors	O
[	O
27	O
,	O
36	O
,	O
139	O
]	O
,	O
and	O
for	O
this	O
reason	O
the	O
effects	O
of	O
ketanserin	O
on	O
IOP	O
may	O
not	O
be	O
entirely	O
caused	O
by	O
its	O
action	O
on	O
5	O
-	O
HT2	O
receptors	O
.	O
However	O
,	O
data	O
from	O
human	O
studies	O
conducted	O
after	O
oral	B-Anatomy
or	O
topical	O
administration	O
of	O
ketanserin	O
,	O
in	O
which	O
were	O
determined	O
the	O
variations	O
of	O
IOP	O
,	O
total	O
outflow	O
facility	O
and	O
pupil	B-Anatomy
diameter	O
,	O
demonstrated	O
that	O
the	O
alpha1	O
-	O
adrenoreceptor	O
blocking	O
effect	O
exerted	O
by	O
ketanserin	O
should	O
represent	O
a	O
further	O
aspect	O
of	O
its	O
mechanism	O
of	O
action	O
,	O
probably	O
due	O
to	O
a	O
functional	O
sharing	O
of	O
these	O
receptors	O
[	O
64	O
,	O
87	O
]	O
.	O
Lastly	O
,	O
already	O
in	O
1992	O
Martin	O
and	O
co	O
-	O
workers	O
showed	O
the	O
occurrence	O
of	O
a	O
significant	O
correlation	O
between	O
the	O
content	O
of	O
serotonin	O
in	O
the	O
aqueous	B-Anatomy
humor	I-Anatomy
and	O
IOP	O
in	O
the	O
human	O
eye	B-Anatomy
[	O
85	O
]	O
.	O
In	O
1981	O
,	O
Moro	O
and	O
his	O
collaborators	O
found	O
that	O
intravitreal	O
injection	O
of	O
5	O
,	O
6	O
-	O
dihydroxytryptamine	O
,	O
a	O
serotonergic	O
neurotoxin	O
,	O
causes	O
miosis	O
[	O
91	O
]	O
.	O
The	O
identification	O
of	O
5	O
-	O
HT7	O
,	O
but	O
not	O
of	O
5	O
-	O
HT1	O
receptors	O
in	O
the	O
rabbit	O
iris	B-Anatomy
,	O
suggests	O
that	O
this	O
population	O
of	O
serotonergic	O
receptors	O
is	O
involved	O
in	O
the	O
relaxation	O
of	O
the	O
sphincter	B-Anatomy
of	O
the	O
pupil	B-Anatomy
.	O
In	O
fact	O
,	O
one	O
of	O
the	O
function	O
correlate	O
to	O
5	O
-	O
HT7	O
receptor	O
activation	O
includes	O
smooth	B-Anatomy
muscle	I-Anatomy
relaxation	O
observed	O
in	O
a	O
variety	O
of	O
isolated	O
tissue	B-Anatomy
preparations	O
,	O
in	O
which	O
elevation	O
of	O
cAMP	O
concentration	O
was	O
also	O
detected	O
[	O
3	O
,	O
44	O
]	O
.	O
Further	O
evidence	O
for	O
the	O
mediation	O
of	O
the	O
relaxant	O
response	O
via	O
the	O
5	O
-	O
HT7	O
receptor	O
is	O
provided	O
by	O
the	O
localization	O
of	O
messenger	O
ribonucleic	O
acid	O
transcripts	O
encoding	O
the	O
5	O
-	O
HT7	O
receptor	O
in	O
many	O
blood	B-Anatomy
vessels	I-Anatomy
[	O
67	O
]	O
.	O
This	O
hypothesized	O
mechanism	O
of	O
action	O
is	O
also	O
supported	O
by	O
the	O
fact	O
that	O
various	O
other	O
receptor	O
types	O
,	O
also	O
positively	O
coupled	O
to	O
cAMP	O
,	O
in	O
the	O
iris	B-Anatomy
cause	O
relaxation	O
of	O
the	O
sphincter	B-Anatomy
muscle	I-Anatomy
[	O
1	O
,	O
28	O
]	O
.	O
Luciferase	O
Assay	O
For	O
Fig	O
.	O
1	O
,	O
10	O
ng	O
of	O
TORC1	O
,	O
5	O
ng	O
of	O
TORC2	O
,	O
and	O
15	O
ng	O
of	O
PKAalpha	O
expression	O
plasmids	B-Anatomy
were	O
transfected	O
into	O
HEK293	B-Anatomy
cells	I-Anatomy
.	O
For	O
Fig	O
.	O
2	O
,	O
800	O
ng	O
of	O
total	O
DNA	O
consisted	O
of	O
200	O
ng	O
of	O
the	O
pMLHoxb1ARE	O
luciferase	O
reporter	O
and	O
100	O
ng	O
of	O
each	O
expression	O
plasmid	B-Anatomy
.	O
A	O
lacZ	O
reporter	O
was	O
co	O
-	O
transfected	O
to	O
normalize	O
transfection	O
efficiency	O
.	O
For	O
Fig	O
.	O
3A	O
,	O
the	O
amounts	O
of	O
pENTR	O
T2i	O
shRNA	O
(	O
TORC2	O
shRNA	O
)	O
are	O
given	O
within	O
the	O
panel	O
.	O
For	O
Fig	O
.	O
3B	O
,	O
25	O
,	O
000	O
cells	B-Anatomy
per	O
well	O
were	O
plated	O
in	O
48	O
-	O
well	O
plates	O
and	O
transfected	O
using	O
Lipofectamine	O
2000	O
with	O
the	O
following	O
vectors	O
:	O
40	O
ng	O
of	O
pML5xUAS	O
,	O
40	O
ng	O
of	O
pGAL	O
-	O
DBD	O
or	O
pGAL	O
-	O
MEIS1A	O
(	O
335	O
-	O
390	O
)	O
,	O
40	O
ng	O
of	O
pRSV	O
-	O
PBS	O
or	O
pRSV	O
-	O
PKA	O
,	O
40	O
ng	O
of	O
pENTR	O
U6	O
(	O
control	O
shRNA	O
)	O
or	O
pENTR	O
T2i	O
shRNA	O
(	O
TORC2	O
shRNA	O
)	O
,	O
and	O
100	O
ng	O
of	O
pRSV	O
-	O
beta	O
-	O
galactosidase	O
.	O
At	O
48	O
h	O
post	O
-	O
transfection	O
,	O
cell	B-Anatomy
lysates	I-Anatomy
were	O
prepared	O
using	O
100	O
mul	O
per	O
well	O
of	O
lysis	O
buffer	O
(	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
1	O
mm	O
dithiothreitol	O
,	O
92	O
.	O
8	O
mm	O
K2HPO4	O
,	O
pH	O
7	O
.	O
8	O
,	O
9	O
.	O
2	O
mm	O
KH2PO4	O
,	O
pH	O
7	O
.	O
8	O
)	O
and	O
centrifuged	O
for	O
5	O
min	O
at	O
4	O
degreesC	O
.	O
A	O
20	O
-	O
mul	O
aliquot	O
of	O
the	O
supernatant	B-Anatomy
was	O
added	O
to	O
12	O
.	O
5	O
mul	O
of	O
assay	O
buffer	O
(	O
20	O
mm	O
ATP	O
,	O
40	O
mm	O
MgCl2	O
,	O
0	O
.	O
4	O
m	O
Tris	O
-	O
Cl	O
,	O
pH	O
7	O
.	O
8	O
)	O
.	O
The	O
mixture	O
was	O
immediately	O
quantified	O
for	O
luciferase	O
activity	O
using	O
a	O
Lumat	O
LB	O
9507	O
luminometer	O
(	O
EG	O
&	O
G	O
Berthold	O
)	O
that	O
dispensed	O
100	O
mul	O
per	O
reaction	O
of	O
luciferin	O
solution	O
,	O
which	O
contains	O
1	O
mm	O
d	O
-	O
(	O
-	O
)	O
-	O
luciferin	O
(	O
catalogue	O
number	O
11626353001	O
,	O
Roche	O
)	O
and	O
0	O
.	O
1	O
m	O
Tris	O
-	O
Cl	O
,	O
pH	O
7	O
.	O
8	O
.	O
Implications	O
for	O
Psychological	O
Models	O
of	O
Interval	O
Timing	O
Several	O
models	O
have	O
been	O
previously	O
applied	O
to	O
interpret	O
data	O
obtained	O
in	O
interval	O
-	O
timing	O
experiments	O
involving	O
gaps	O
(	O
retention	O
-	O
intervals	O
)	O
.	O
A	O
switch	O
model	O
,	O
assuming	O
that	O
during	O
the	O
gap	O
time	O
fails	O
to	O
accumulate	O
due	O
to	O
the	O
opening	O
of	O
a	O
stimulus	O
-	O
controlled	O
switch	O
,	O
predicts	O
that	O
,	O
irrespective	O
of	O
gap	O
and	O
criterion	O
durations	O
,	O
subjects	O
should	O
use	O
a	O
stop	O
rule	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
,	O
[	O
30	O
]	O
,	O
[	O
31	O
]	O
.	O
In	O
contrast	O
,	O
the	O
present	O
data	O
indicate	O
that	O
rats	O
flexibly	O
change	O
their	O
behavior	O
with	O
both	O
gap	O
and	O
criterion	O
duration	O
.	O
An	O
instructional	O
-	O
ambiguity	O
model	O
proposing	O
that	O
subjects	O
perceive	O
the	O
gap	O
as	O
an	O
ambiguous	O
,	O
ITI	O
-	O
like	O
event	O
,	O
predicts	O
that	O
manipulations	O
that	O
render	O
the	O
gap	O
similar	O
to	O
the	O
ITI	O
should	O
reset	O
the	O
clock	O
,	O
while	O
manipulations	O
that	O
render	O
the	O
gap	O
dissimilar	O
from	O
the	O
ITI	O
should	O
stop	O
the	O
clock	O
[	O
37	O
]	O
.	O
Because	O
in	O
our	O
experiment	O
the	O
gap	O
and	O
ITI	O
were	O
identical	O
(	O
dark	O
)	O
this	O
hypothesis	O
predicts	O
the	O
use	O
of	O
the	O
same	O
rule	O
(	O
reset	O
)	O
at	O
all	O
gap	O
and	O
criteria	O
durations	O
,	O
in	O
contrast	O
to	O
the	O
current	O
data	O
showing	O
the	O
use	O
of	O
different	O
rules	O
for	O
different	O
temporal	O
criteria	O
.	O
To	O
account	O
for	O
the	O
flexible	O
use	O
of	O
the	O
run	O
/	O
stop	O
/	O
reset	O
rules	O
by	O
rats	O
and	O
pigeons	O
,	O
Cabeza	O
de	O
Vaca	O
et	O
al	O
.	O
[	O
38	O
]	O
proposed	O
a	O
passive	O
memory	O
-	O
decay	O
model	O
which	O
assumes	O
that	O
subjective	O
time	O
-	O
-	O
stored	O
in	O
WM	O
-	O
-	O
decays	O
passively	O
during	O
the	O
gap	O
.	O
This	O
model	O
predicts	O
that	O
the	O
effect	O
of	O
a	O
gap	O
should	O
depend	O
solely	O
on	O
absolute	O
gap	O
duration	O
,	O
but	O
not	O
on	O
criterion	O
duration	O
,	O
as	O
found	O
here	O
(	O
Fig	O
.	O
1B	O
-	O
D	O
)	O
.	O
These	O
models	O
can	O
not	O
account	O
for	O
the	O
differential	O
effects	O
of	O
gaps	O
on	O
multiple	O
intervals	O
.	O
In	O
contrast	O
to	O
these	O
alternatives	O
,	O
the	O
present	O
resource	O
allocation	O
model	O
assumes	O
that	O
during	O
the	O
gaps	O
resources	O
are	O
re	O
-	O
allocated	O
(	O
diverted	O
away	O
from	O
timing	O
)	O
,	O
each	O
clock	O
is	O
unable	O
to	O
maintain	O
its	O
current	O
subjective	O
time	O
in	O
WM	O
,	O
and	O
the	O
response	O
is	O
delayed	O
[	O
16	O
]	O
,	O
[	O
17	O
]	O
,	O
[	O
27	O
]	O
in	O
proportion	O
to	O
the	O
perceived	O
salience	O
of	O
the	O
distracter	O
relative	O
to	O
the	O
times	O
signal	O
[	O
34	O
]	O
,	O
[	O
35	O
]	O
.	O
Indeed	O
,	O
the	O
effect	O
of	O
a	O
gap	O
is	O
affected	O
by	O
the	O
contrast	O
in	O
intensity	O
between	O
the	O
gap	O
and	O
the	O
timed	O
signal	O
[	O
27	O
]	O
,	O
[	O
34	O
]	O
,	O
[	O
39	O
]	O
and	O
by	O
the	O
perceptual	O
acuity	O
of	O
the	O
subjects	O
[	O
27	O
]	O
.	O
Importantly	O
,	O
the	O
predictions	O
of	O
this	O
resource	O
re	O
-	O
allocation	O
model	O
are	O
not	O
restricted	O
to	O
retention	O
-	O
intervals	O
(	O
i	O
.	O
e	O
.	O
,	O
gaps	O
)	O
,	O
but	O
extend	O
to	O
distracters	O
presented	O
during	O
the	O
continuous	O
presentation	O
of	O
a	O
timed	O
signal	O
.	O
Previous	O
data	O
were	O
quantitatively	O
accounted	O
for	O
by	O
assuming	O
that	O
during	O
a	O
gap	O
and	O
/	O
or	O
distracter	O
the	O
accumulated	O
time	O
decays	O
at	O
a	O
rate	O
that	O
varies	O
with	O
the	O
relative	O
salience	O
of	O
the	O
distracter	O
to	O
the	O
timed	O
signal	O
[	O
25	O
]	O
,	O
[	O
26	O
]	O
,	O
[	O
35	O
]	O
.	O
Here	O
we	O
found	O
that	O
the	O
comparison	O
between	O
the	O
gap	O
and	O
the	O
(	O
multiple	O
)	O
timed	O
signal	O
(	O
s	O
)	O
extends	O
to	O
the	O
temporal	O
domain	O
.	O
Simulations	O
indicate	O
that	O
both	O
the	O
differential	O
effect	O
of	O
the	O
gap	O
on	O
multiple	O
durations	O
,	O
and	O
the	O
gradual	O
hierarchical	O
reset	O
due	O
to	O
increasing	O
gap	O
duration	O
can	O
be	O
quantitatively	O
accounted	O
for	O
assuming	O
that	O
the	O
three	O
clocks	O
have	O
separate	O
resources	O
re	O
-	O
allocated	O
independently	O
during	O
a	O
gap	O
at	O
a	O
rate	O
proportional	O
to	O
the	O
ratio	O
g	O
/	O
Tk	O
between	O
the	O
duration	O
of	O
the	O
gap	O
and	O
each	O
criterion	O
duration	O
(	O
Fig	O
.	O
2A	O
:	O
D	O
-	O
Model	O
)	O
.	O
SUMMARY	O
This	O
is	O
a	O
prospective	O
study	O
carried	O
out	O
to	O
determine	O
the	O
outcome	O
of	O
patients	O
who	O
refuse	O
cystectomy	O
after	O
receiving	O
neoadjuvant	O
chemotherapy	O
for	O
muscle	B-Anatomy
-	I-Anatomy
invasive	I-Anatomy
bladder	I-Anatomy
cancer	I-Anatomy
.	O
Sixty	O
-	O
three	O
patients	O
were	O
evaluated	O
between	O
1995	O
and	O
2001	O
who	O
declined	O
to	O
undergo	O
a	O
planned	O
cystectomy	O
because	O
they	O
achieved	O
a	O
complete	O
clinical	O
response	O
to	O
neoadjuvant	O
cisplatin	O
-	O
based	O
chemotherapy	O
.	O
Herr	O
assessed	O
patient	O
,	O
tumor	B-Anatomy
and	O
treatment	O
features	O
for	O
a	O
median	O
follow	O
-	O
up	O
of	O
86	O
months	O
,	O
all	O
patients	O
being	O
followed	O
-	O
up	O
for	O
more	O
than	O
5	O
years	O
.	O
Forty	O
patients	O
(	O
64	O
%	O
)	O
survived	O
,	O
with	O
54	O
%	O
of	O
them	O
having	O
an	O
intact	O
functioning	O
bladder	B-Anatomy
.	O
The	O
number	O
and	O
size	O
of	O
invasive	B-Anatomy
tumors	I-Anatomy
were	O
strongly	O
associated	O
with	O
the	O
overall	O
survival	O
.	O
The	O
most	O
significant	O
treatment	O
variable	O
predicting	O
better	O
survival	O
was	O
complete	O
resection	O
of	O
the	O
invasive	B-Anatomy
tumor	I-Anatomy
on	O
restaging	O
transurethral	O
resection	O
(	O
TUR	O
)	O
before	O
starting	O
chemotherapy	O
.	O
Of	O
23	O
patients	O
(	O
36	O
%	O
)	O
who	O
subsequently	O
died	O
of	O
disease	O
,	O
19	O
(	O
30	O
%	O
)	O
relapsed	O
with	O
invasive	B-Anatomy
cancer	I-Anatomy
in	O
the	O
bladder	B-Anatomy
.	O
Over	O
90	O
%	O
of	O
the	O
surviving	O
patients	O
had	O
solitary	O
,	O
small	O
and	O
low	O
-	O
stage	O
invasive	B-Anatomy
tumors	I-Anatomy
completely	O
resected	O
and	O
83	O
%	O
survived	O
without	O
relapses	O
in	O
the	O
bladder	B-Anatomy
.	O
[	O
1	O
]	O
COMMENTS	O
Recurrent	O
anterior	B-Anatomy
vaginal	I-Anatomy
wall	I-Anatomy
prolapse	O
can	O
develop	O
in	O
more	O
than	O
20	O
%	O
of	O
patients	O
undergoing	O
traditional	O
anterior	O
colporrhaphy	O
.	O
In	O
light	O
of	O
this	O
high	O
recurrence	O
rate	O
many	O
surgeons	O
have	O
been	O
incorporating	O
synthetic	O
or	O
allograft	O
mesh	O
to	O
augment	O
the	O
repair	O
.	O
In	O
this	O
study	O
there	O
are	O
some	O
shortcomings	O
,	O
including	O
retrospective	O
design	O
,	O
short	O
follow	O
-	O
up	O
for	O
a	O
study	O
spanning	O
almost	O
six	O
years	O
and	O
a	O
lack	O
of	O
validated	O
questionnaires	O
.	O
Authors	O
report	O
a	O
negative	O
experience	O
with	O
porcine	O
dermis	B-Anatomy
,	O
both	O
in	O
terms	O
of	O
success	O
and	O
extrusion	O
rate	O
.	O
However	O
,	O
others	O
have	O
reported	O
better	O
outcome	O
[	O
1	O
]	O
which	O
may	O
be	O
due	O
to	O
different	O
follow	O
-	O
up	O
times	O
and	O
outcome	O
measures	O
.	O
Apart	O
from	O
this	O
,	O
biological	O
grafts	B-Anatomy
are	O
also	O
associated	O
with	O
allergic	O
reactions	O
and	O
disease	O
transmission	O
.	O
There	O
is	O
paucity	O
of	O
data	O
regarding	O
prospective	O
randomized	O
trials	O
on	O
the	O
use	O
of	O
these	O
biomaterials	O
prior	O
to	O
their	O
widespread	O
human	O
need	O
which	O
might	O
help	O
in	O
reducing	O
such	O
type	O
of	O
experiences	O
.	O
Unless	O
such	O
data	O
are	O
available	O
surgeons	O
should	O
give	O
serious	O
thought	O
prior	O
to	O
embarking	O
on	O
the	O
use	O
of	O
such	O
biological	O
materials	O
.	O
[	O
2	O
]	O
Background	O
Opioid	O
analgesics	O
are	O
generally	O
used	O
to	O
combat	O
the	O
pain	O
associated	O
with	O
cancerous	B-Anatomy
conditions	O
.	O
These	O
agents	O
not	O
only	O
inhibit	O
respiratory	B-Anatomy
function	O
and	O
cause	O
constipation	O
,	O
but	O
also	O
induce	O
other	O
significant	O
side	O
effects	O
such	O
as	O
addiction	O
and	O
tolerance	O
,	O
all	O
of	O
which	O
further	O
contribute	O
to	O
a	O
reduced	O
quality	O
of	O
life	O
for	O
cancer	B-Anatomy
patients	O
.	O
Thus	O
,	O
in	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
electro	O
-	O
acupuncture	O
treatment	O
(	O
EA	O
)	O
on	O
mechanical	O
allodynia	O
were	O
examined	O
in	O
a	O
cancer	B-Anatomy
pain	O
mouse	O
model	O
.	O
2	O
.	O
1	O
.	O
Biological	O
samples	B-Anatomy
Placental	B-Anatomy
tissues	I-Anatomy
from	O
the	O
first	O
trimester	O
legally	O
induced	O
abortions	O
(	O
8	O
-	O
12	O
weeks	O
of	O
gestation	O
)	O
were	O
obtained	O
from	O
the	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
at	O
the	O
Broussais	O
,	O
Saint	O
Vincent	O
de	O
Paul	O
and	O
Cochin	O
Hospitals	O
.	O
Second	O
trimester	O
placental	B-Anatomy
tissues	I-Anatomy
were	O
collected	O
at	O
the	O
time	O
of	O
termination	O
of	O
pregnancy	O
at	O
15	O
and	O
25	O
weeks	O
of	O
gestation	O
(	O
in	O
weeks	O
of	O
amenorrhea	O
)	O
in	O
trisomy	O
21	O
-	O
affected	O
pregnancies	O
.	O
Fetal	B-Anatomy
Down	O
syndrome	O
was	O
diagnosed	O
by	O
karyotyping	O
of	O
amniotic	B-Anatomy
fluid	I-Anatomy
cells	I-Anatomy
.	O
The	O
indication	O
of	O
amniocentesis	O
was	O
the	O
maternal	O
age	O
.	O
Term	O
placentas	B-Anatomy
were	O
obtained	O
after	O
elective	O
cesarean	O
section	O
from	O
healthy	O
mothers	O
near	O
term	O
with	O
uncomplicated	O
pregnancies	O
.	O
With	O
written	O
informed	O
consent	O
of	O
the	O
pregnant	O
woman	O
,	O
the	O
following	O
samples	B-Anatomy
were	O
collected	O
at	O
term	O
:	O
a	O
fragment	B-Anatomy
of	O
the	O
placenta	B-Anatomy
,	O
umbilical	B-Anatomy
cord	I-Anatomy
fetal	I-Anatomy
blood	I-Anatomy
and	O
maternal	O
blood	B-Anatomy
.	O
The	O
placenta	B-Anatomy
biopsy	I-Anatomy
sample	I-Anatomy
was	O
collected	O
at	O
a	O
depth	O
of	O
1	O
cm	O
and	O
at	O
a	O
distance	O
of	O
8	O
cm	O
from	O
the	O
edge	O
of	O
the	O
placenta	B-Anatomy
,	O
with	O
the	O
maternal	O
side	O
facing	O
upward	O
.	O
The	O
use	O
of	O
these	O
biological	O
samples	B-Anatomy
was	O
approved	O
by	O
local	O
ethical	O
committee	O
.	O
Villous	B-Anatomy
cytotrophoblastic	I-Anatomy
cells	I-Anatomy
were	O
isolated	O
by	O
sequential	O
enzymatic	O
digestion	O
of	O
chorionic	B-Anatomy
villi	I-Anatomy
from	O
the	O
first	O
trimester	O
,	O
second	O
trimester	O
and	O
term	O
placenta	B-Anatomy
and	O
purified	O
on	O
a	O
discontinuous	O
percoll	O
gradient	O
,	O
as	O
described	O
previously	O
.	O
47	O
-	O
49	O
These	O
cells	B-Anatomy
were	O
positively	O
stained	O
for	O
cytokeratin	O
7	O
at	O
95	O
%	O
,	O
indicating	O
the	O
cytotrophoblastic	O
origin	O
of	O
the	O
cells	B-Anatomy
.	O
Placental	B-Anatomy
fibroblasts	I-Anatomy
were	O
isolated	O
by	O
prolonged	O
enzymatic	O
digestion	O
from	O
first	O
trimester	O
chorionic	B-Anatomy
villi	I-Anatomy
as	O
in	O
Malassine	O
et	O
al	O
.	O
50	O
Fibroblastic	B-Anatomy
cells	I-Anatomy
(	O
1	O
.	O
25	O
x	O
105	O
cells	O
/	O
mL	O
)	O
were	O
plated	O
on	O
35	O
-	O
mm	O
plastic	O
dishes	O
(	O
TPP	O
,	O
Switzerland	O
)	O
and	O
cultured	O
for	O
48	O
h	O
,	O
and	O
the	O
culture	O
medium	O
was	O
changed	O
daily	O
.	O
These	O
cultured	O
fibroblasts	B-Anatomy
were	O
characterized	O
using	O
immunocytochemistry	O
.	O
It	O
was	O
found	O
that	O
98	O
%	O
of	O
the	O
cells	B-Anatomy
were	O
vimentin	O
positive	O
and	O
also	O
positive	O
for	O
a	O
monoclonal	O
antibody	O
against	O
specific	O
fibroblast	B-Anatomy
antigen	O
(	O
clone	O
ASO2	O
,	O
Dianova	O
,	O
Hamburg	O
,	O
Germany	O
)	O
.	O
Owing	O
to	O
the	O
limited	O
amount	O
of	O
cells	B-Anatomy
,	O
only	O
DNA	O
was	O
extracted	O
.	O
Methods	O
Therefore	O
,	O
we	O
developed	O
a	O
reciprocal	O
system	O
of	O
a	O
full	B-Anatomy
-	I-Anatomy
length	I-Anatomy
HIV	I-Anatomy
packaging	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
and	O
a	O
shortened	O
HI	O
-	O
viral	O
shuttle	O
vector	O
.	O
The	O
Tat	O
-	O
deficient	O
packaging	O
construct	O
is	O
stably	O
integrated	O
in	O
a	O
VSVG	B-Anatomy
-	I-Anatomy
pseudotyped	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
and	O
transactivated	O
by	O
the	O
shuttle	O
vector	O
by	O
expression	O
of	O
TATGFP	O
from	O
a	O
heterologous	O
promoter	O
which	O
also	O
indicates	O
positive	O
cells	B-Anatomy
.	O
Expression	O
of	O
the	O
HI	O
-	O
viral	O
structure	O
proteins	O
is	O
driven	O
by	O
a	O
natural	O
5	O
'	O
LTR	B-Anatomy
promoter	O
and	O
a	O
3	O
'	O
polyadenylation	O
signal	O
,	O
whereas	O
the	O
envelope	B-Anatomy
expression	O
out	O
of	O
the	O
shuttle	O
vector	O
is	O
achieved	O
by	O
an	O
IRES	O
.	O
This	O
system	O
of	O
two	O
vectors	O
is	O
tightly	O
controllable	O
and	O
bypasses	O
the	O
problem	O
of	O
limited	O
packaging	O
capacity	O
into	O
HIV	O
-	O
1	O
virions	O
.	O
Percutaneous	B-Anatomy
coronary	B-Anatomy
intervention	O
for	O
the	O
very	O
late	O
stent	O
thrombosis	O
in	O
right	B-Anatomy
coronary	I-Anatomy
artery	I-Anatomy
.	O
A	O
:	O
a	O
balloon	O
angioplasty	O
was	O
performed	O
to	O
treat	O
total	O
occlusion	O
of	O
the	O
stented	O
right	B-Anatomy
coronary	I-Anatomy
artery	I-Anatomy
.	O
B	O
:	O
final	O
coronary	B-Anatomy
angiogram	O
showed	O
good	O
distal	O
flow	O
without	O
residual	O
stenosis	O
.	O
All	O
-	O
cause	O
mortality	O
in	O
RALES	O
and	O
EPHESUS	O
(	O
adapted	O
from	O
[	O
4	O
]	O
and	O
[	O
5	O
]	O
)	O
.	O
Mean	O
follow	O
-	O
up	O
period	O
is	O
24	O
months	O
in	O
RALES	O
and	O
16	O
months	O
in	O
EPHESUS	O
Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
http	O
:	O
/	O
/	O
www	O
.	O
biomedcentral	O
.	O
com	O
/	O
1471	O
-	O
2377	O
/	O
9	O
/	O
57	O
/	O
prepub	O
Magnetic	O
resonance	O
imaging	O
of	O
axial	O
plan	O
with	O
intravenous	B-Anatomy
contrast	O
gadolinium	O
-	O
BOPTA	O
demonstrating	O
a	O
mass	B-Anatomy
adherent	O
to	O
the	O
right	B-Anatomy
ventricular	I-Anatomy
wall	I-Anatomy
.	O
Additional	O
file	O
3	O
Primers	O
used	O
in	O
this	O
study	O
.	O
All	O
of	O
the	O
primers	O
used	O
for	O
generating	O
PCR	O
products	O
for	O
microinjection	O
and	O
site	O
-	O
direct	O
mutagenesis	O
are	O
listed	O
.	O
2	O
.	O
Methods	O
We	O
conducted	O
a	O
systematic	O
study	O
of	O
patients	O
hospitalized	O
from	O
August	O
2006	O
until	O
September	O
2007	O
at	O
the	O
Yerevan	O
City	O
and	O
the	O
Republican	O
Dispensaries	O
,	O
the	O
two	O
reference	O
TB	O
hospitals	O
in	O
Armenia	O
.	O
Following	O
focus	O
group	O
discussions	O
and	O
pilot	O
testing	O
to	O
refine	O
the	O
survey	O
instrument	O
,	O
patient	O
interviews	O
began	O
in	O
the	O
fall	O
of	O
2006	O
and	O
were	O
conducted	O
by	O
trained	O
students	O
in	O
the	O
public	O
health	O
program	O
of	O
the	O
American	O
University	O
of	O
Armenia	O
.	O
Students	O
received	O
training	O
by	O
the	O
study	O
designer	O
(	O
SO	O
)	O
on	O
principles	O
of	O
interview	O
ethics	O
and	O
interviewing	O
processes	O
.	O
Most	O
patient	O
interviews	O
were	O
conducted	O
at	O
the	O
Republican	O
Dispensary	O
in	O
Abovian	O
Marz	O
,	O
the	O
national	O
TB	O
diagnostic	O
and	O
treatment	O
facility	O
to	O
which	O
all	O
suspected	O
cases	O
throughout	O
the	O
country	O
are	O
referred	O
for	O
diagnostic	O
confirmation	O
.	O
In	O
the	O
past	O
several	O
years	O
,	O
strong	O
financial	O
support	O
has	O
been	O
provided	O
to	O
Armenia	O
by	O
a	O
number	O
of	O
international	O
organizations	O
,	O
such	O
as	O
the	O
German	O
Gesellschaft	O
fur	O
Technische	O
Zusammenarbeit	O
(	O
GTZ	O
)	O
,	O
the	O
Global	O
Fund	O
to	O
Fight	O
AIDS	O
,	O
Tuberculosis	O
and	O
Malaria	O
,	O
and	O
the	O
Red	O
Cross	O
,	O
which	O
has	O
enabled	O
both	O
microscopic	O
and	O
culture	B-Anatomy
examinations	O
for	O
each	O
TB	O
case	O
to	O
be	O
performed	O
at	O
the	O
National	O
Reference	O
Laboratory	O
located	O
at	O
the	O
Republican	O
TB	O
Dispensary	O
.	O
All	O
culture	B-Anatomy
-	O
confirmed	O
TB	O
cases	O
are	O
admitted	O
as	O
in	O
-	O
patients	O
while	O
undergoing	O
the	O
initial	O
phase	O
of	O
therapy	O
.	O
Because	O
all	O
confirmed	O
TB	O
patients	O
in	O
Armenia	O
are	O
referred	O
to	O
one	O
of	O
these	O
dispensaries	O
for	O
treatment	O
,	O
this	O
population	O
represents	O
all	O
known	O
TB	O
cases	O
in	O
the	O
country	O
.	O
Therefore	O
,	O
all	O
culture	B-Anatomy
-	O
confirmed	O
TB	O
in	O
-	O
patients	O
present	O
at	O
the	O
time	O
of	O
the	O
interviewer	O
visits	O
were	O
eligible	O
for	O
inclusion	O
in	O
the	O
study	O
(	O
the	O
study	O
group	O
included	O
both	O
new	O
and	O
relapsed	O
patients	O
)	O
.	O
Our	O
systematic	O
sample	O
of	O
the	O
inpatient	O
TB	O
population	O
-	O
-	O
in	O
which	O
interviewers	O
visited	O
every	O
hospital	O
room	O
to	O
identify	O
patients	O
willing	O
to	O
participate	O
-	O
-	O
yielded	O
a	O
participation	O
rate	O
of	O
approximately	O
80	O
%	O
(	O
a	O
total	O
of	O
240	O
patients	O
)	O
.	O
Interviewers	O
collected	O
demographic	O
information	O
and	O
asked	O
each	O
patient	O
to	O
recall	O
when	O
they	O
first	O
began	O
to	O
feel	O
ill	O
,	O
what	O
symptoms	O
they	O
experienced	O
,	O
how	O
long	O
after	O
symptom	O
onset	O
they	O
waited	O
to	O
see	O
a	O
doctor	O
,	O
their	O
reasons	O
for	O
delaying	O
medical	O
evaluation	O
,	O
the	O
type	O
of	O
facility	O
at	O
which	O
they	O
first	O
sought	O
care	O
,	O
the	O
initial	O
diagnosis	O
,	O
if	O
they	O
had	O
been	O
referred	O
for	O
further	O
evaluation	O
,	O
and	O
their	O
adherence	O
to	O
treatment	O
once	O
diagnosed	O
with	O
TB	O
.	O
In	O
2006	O
,	O
129	O
of	O
the	O
planned	O
250	O
surveys	O
were	O
completed	O
.	O
Data	O
collection	O
resumed	O
in	O
the	O
fall	O
of	O
2007	O
and	O
a	O
total	O
of	O
240	O
interviews	O
were	O
conducted	O
.	O
Summary	O
Kindt	O
et	O
al	O
.	O
1	O
published	O
a	O
report	O
entitled	O
""""	O
Intestinal	B-Anatomy
immune	O
activation	O
in	O
presumed	O
post	O
-	O
infectious	O
functional	O
syspepsia	O
""""	O
in	O
the	O
August	O
issue	O
of	O
Neurogastroenterology	O
and	O
Motility	O
in	O
2009	O
.	O
By	O
comparing	O
the	O
signs	O
of	O
inflammation	O
and	O
the	O
degree	O
of	O
hyperplasia	O
of	O
the	O
enterochromaffin	B-Anatomy
cells	I-Anatomy
(	O
EC	B-Anatomy
)	O
in	O
duodenal	B-Anatomy
biopsies	I-Anatomy
obtained	O
from	O
patients	O
with	O
presumed	O
post	O
-	O
infectious	O
functional	O
dyspepsia	O
(	O
PI	O
-	O
FD	O
)	O
and	O
unspecified	O
-	O
onset	O
functional	O
dyspepsia	O
(	O
U	O
-	O
FD	O
)	O
,	O
they	O
showed	O
that	O
PI	O
-	O
FD	O
is	O
associated	O
with	O
persistence	O
of	O
focal	O
T	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
aggregates	O
,	O
decrease	O
in	O
CD4	B-Anatomy
+	I-Anatomy
cells	I-Anatomy
and	O
increased	O
macrophage	B-Anatomy
counts	O
surrounding	O
the	O
crypts	B-Anatomy
,	O
without	O
any	O
significant	O
differences	O
in	O
the	O
numbers	O
of	O
EC	B-Anatomy
or	O
chromogranin	B-Anatomy
A	I-Anatomy
(	I-Anatomy
CA	I-Anatomy
)	I-Anatomy
-	I-Anatomy
positive	I-Anatomy
cells	I-Anatomy
(	O
mast	B-Anatomy
cells	I-Anatomy
)	O
.	O
This	O
finding	O
may	O
indicate	O
impaired	O
ability	O
of	O
the	O
immune	B-Anatomy
system	I-Anatomy
in	O
these	O
cases	O
to	O
terminate	O
the	O
inflammatory	O
response	O
after	O
an	O
acute	O
insult	O
.	O
Temporary	O
migration	O
module	O
A	O
temporary	O
migration	O
census	O
module	O
was	O
conducted	O
in	O
2002	O
and	O
2007	O
.	O
People	O
who	O
were	O
identified	O
as	O
temporary	O
migrants	O
were	O
entered	O
into	O
the	O
module	O
,	O
and	O
a	O
household	O
respondent	O
answered	O
questions	O
about	O
the	O
migration	O
.	O
Key	O
areas	O
included	O
the	O
duration	O
of	O
migration	O
,	O
destination	O
,	O
reasons	O
for	O
migration	O
,	O
return	O
pattern	O
,	O
communication	O
pattern	O
,	O
remittances	O
,	O
linked	O
moves	O
and	O
child	O
care	O
arrangements	O
.	O
MOR1K	O
expression	O
and	O
binding	O
pattern	O
.	O
(	O
A	O
)	O
The	O
schematic	O
diagram	O
illustrates	O
the	O
exonic	O
composition	O
and	O
relative	O
positions	O
of	O
PCR	O
primers	O
designed	O
to	O
amplify	O
the	O
major	O
MOR1	O
isoform	O
and	O
the	O
newly	O
identified	O
alternative	O
MOR1K	O
isoform	O
.	O
The	O
relative	O
positions	O
of	O
translation	O
initiation	O
start	O
and	O
stop	O
codons	O
are	O
designated	O
by	O
ATG	O
and	O
TGA	O
,	O
respectively	O
.	O
The	O
predicted	O
protein	O
structure	O
of	O
MOR1	O
and	O
MOR1K	O
isoforms	O
is	O
schematically	O
presented	O
.	O
Translation	O
of	O
the	O
MOR1K	O
variant	O
results	O
in	O
a	O
6TM	O
receptor	O
,	O
truncated	O
at	O
the	O
N	O
-	O
terminus	O
.	O
(	O
B	O
)	O
Real	O
-	O
time	O
PCR	O
was	O
performed	O
on	O
total	O
RNA	O
samples	O
from	O
the	O
human	O
brain	B-Anatomy
regions	I-Anatomy
known	O
to	O
express	O
MOR1	O
.	O
Primers	O
specific	O
for	O
exons	O
1	O
and	O
2	O
were	O
used	O
to	O
measure	O
MOR1	O
and	O
primers	O
specific	O
for	O
exons	O
13	O
and	O
exon	O
2	O
were	O
used	O
to	O
measure	O
MOR1K	O
[	O
32	O
]	O
.	O
GAP3DH	O
was	O
used	O
as	O
a	O
control	O
for	O
cDNA	O
loading	O
and	O
PCR	O
efficiency	O
.	O
(	O
C	O
)	O
Confocal	O
images	O
of	O
C	O
-	O
terminally	O
MYC	O
-	O
tagged	O
MOR1	O
or	O
FLAG	O
-	O
tagged	O
MOR1K	O
overexpressed	O
in	O
HEK293	B-Anatomy
cells	I-Anatomy
and	O
stained	O
with	O
either	O
Anti	O
-	O
MYC	O
-	O
Tag	O
Antibody	O
(	O
Alexa	O
Fluor	O
647	O
Conjugate	O
)	O
or	O
Anti	O
-	O
DYKDDDDK	O
Tag	O
Antibody	O
(	O
Alexa	O
Fluor	O
555	O
conjugate	O
)	O
.	O
Cells	B-Anatomy
transfected	O
with	O
MOR1	O
showed	O
membrane	B-Anatomy
expression	O
of	O
receptor	O
,	O
while	O
cell	B-Anatomy
transfected	O
with	O
MOR1K	O
express	O
receptor	O
only	O
intracellular	B-Anatomy
.	O
(	O
D	O
)	O
Confocal	O
images	O
of	O
C	O
-	O
terminally	O
FLAG	O
-	O
tagged	O
MOR1K	O
overexpressed	O
in	O
Be2C	B-Anatomy
cells	I-Anatomy
and	O
stained	O
with	O
either	O
Anti	O
-	O
FLAG	O
M2	O
Antibody	O
Alexa	O
Fluor	O
Conjugate	O
or	O
fluorescent	O
-	O
labeled	O
naloxone	O
(	O
FNAL	O
)	O
.	O
Cells	B-Anatomy
transfected	O
with	O
MOR1K	O
showed	O
intracellular	B-Anatomy
retention	O
of	O
FNAL	O
that	O
co	O
-	O
localized	O
with	O
antibody	O
-	O
labeled	O
receptor	O
.	O
(	O
E	O
)	O
The	O
binding	O
of	O
naloxone	O
to	O
MOR1K	O
was	O
assessed	O
using	O
flow	O
cytometry	O
to	O
measure	O
FNAL	O
retention	O
.	O
Be2C	B-Anatomy
cells	I-Anatomy
transfected	O
with	O
either	O
MOR1	O
or	O
MOR1K	O
isoforms	O
showed	O
increased	O
retention	O
of	O
FNAL	O
at	O
concentrations	O
of	O
0	O
.	O
1	O
and	O
1	O
muM	O
.	O
FNAL	O
retention	O
was	O
abolished	O
in	O
the	O
presence	O
of	O
10	O
muM	O
unlabelled	O
naloxone	O
(	O
Nal	O
)	O
.	O
In	O
panel	O
E	O
,	O
data	O
are	O
presented	O
as	O
mean	O
+	O
SEM	O
.	O
*	O
P	O
<	O
0	O
.	O
05	O
different	O
from	O
controls	O
)	O
.	O
Authors	O
'	O
contributions	O
MBH	O
made	O
the	O
pathological	O
diagnosis	O
and	O
was	O
responsible	O
for	O
conception	O
and	O
final	O
approval	O
of	O
the	O
manuscript	O
.	O
MB	O
carried	O
out	O
the	O
literature	O
search	O
and	O
drafted	O
the	O
manuscript	O
.	O
IC	O
carried	O
out	O
the	O
surgical	O
procedure	O
and	O
reviewed	O
the	O
manuscript	O
.	O
RM	O
carried	O
out	O
the	O
surgical	O
procedure	O
,	O
provided	O
clinical	O
details	O
,	O
followed	O
up	O
our	O
patient	O
and	O
obtained	O
her	O
consent	O
to	O
publish	O
this	O
case	O
report	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
Breast	B-Anatomy
cancer	I-Anatomy
The	O
incidence	O
of	O
breast	B-Anatomy
cancer	I-Anatomy
is	O
no	O
higher	O
than	O
in	O
the	O
rest	O
of	O
the	O
population	O
.	O
Tamoxifen	O
should	O
not	O
be	O
used	O
as	O
it	O
may	O
worsen	O
symptoms	O
[	O
43	O
]	O
.	O
Women	O
need	O
also	O
specific	O
management	O
for	O
treatment	O
of	O
HAE	O
.	O
Short	O
term	O
prophylaxis	O
:	O
three	O
options	O
are	O
available	O
:	O
attenuated	O
androgens	O
,	O
tranexamic	O
acid	O
or	O
C1Inh	O
concentrate	O
.	O
There	O
is	O
no	O
specific	O
problem	O
for	O
the	O
use	O
of	O
theses	O
drugs	O
for	O
short	O
course	O
in	O
female	O
patients	O
.	O
In	O
case	O
of	O
short	O
term	O
prophylaxis	O
with	O
attenuated	O
androgens	O
,	O
no	O
virilisation	O
has	O
been	O
observed	O
[	O
44	O
,	O
45	O
]	O
.	O
Acute	O
attack	O
treatment	O
:	O
there	O
is	O
no	O
specific	O
problem	O
for	O
the	O
use	O
of	O
C1inh	O
concentrate	O
,	O
tranexamic	O
acid	O
,	O
icatibant	O
;	O
or	O
ecallantide	O
in	O
female	O
patients	O
.	O
RNA	O
extraction	O
and	O
reverse	O
transcription	O
Total	O
RNA	O
were	O
extracted	O
from	O
cells	B-Anatomy
using	O
either	O
Trizol	O
reagent	O
(	O
Invitrogen	O
)	O
or	O
RNeasy	O
kit	O
(	O
Qiagen	O
)	O
and	O
treated	O
with	O
DNaseI	O
reagent	O
(	O
Macherey	O
-	O
Nagel	O
)	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O
Reverse	O
transcriptions	O
were	O
performed	O
using	O
1microg	O
total	O
RNA	O
and	O
the	O
High	O
capacity	O
cDNA	O
reverse	O
transcription	O
kit	O
with	O
RNase	O
Inhibitor	O
(	O
Applied	O
Biosystems	O
)	O
.	O
Statistical	O
results	O
showing	O
significant	O
differences	O
between	O
habitats	O
.	O
Definition	O
of	O
pathogens	O
It	O
remains	O
difficult	O
to	O
determine	O
whether	O
the	O
organisms	O
detected	O
by	O
the	O
DNA	O
Detection	O
Kit	O
are	O
true	O
pathogens	O
.	O
This	O
also	O
applies	O
,	O
although	O
to	O
a	O
much	O
lesser	O
degree	O
,	O
to	O
conventional	O
blood	B-Anatomy
culture	O
analysis	O
.	O
However	O
,	O
detected	O
organisms	O
were	O
considered	O
to	O
be	O
pathogens	O
if	O
the	O
results	O
of	O
culture	O
tests	O
from	O
samples	B-Anatomy
of	O
the	O
suspected	O
infectious	O
sites	O
coincided	O
with	O
the	O
results	O
of	O
DNA	O
Detection	O
Kit	O
or	O
blood	B-Anatomy
culture	O
analysis	O
.	O
The	O
culture	O
data	O
of	O
sputum	B-Anatomy
,	O
urine	B-Anatomy
,	O
pus	B-Anatomy
and	O
drainage	O
fluid	B-Anatomy
were	O
used	O
to	O
define	O
the	O
pathogens	O
.	O
A	O
decision	O
as	O
to	O
whether	O
an	O
identified	O
organism	O
was	O
a	O
pathogen	O
was	O
taken	O
based	O
on	O
the	O
decision	O
tree	O
shown	O
in	O
Figure	O
1	O
.	O
Thus	O
,	O
when	O
the	O
same	O
organism	O
was	O
detected	O
by	O
both	O
DNA	O
Detection	O
Kit	O
and	O
blood	B-Anatomy
culture	O
analysis	O
,	O
the	O
detected	O
organism	O
was	O
considered	O
an	O
infectious	O
pathogen	O
.	O
If	O
there	O
was	O
a	O
discrepancy	O
between	O
the	O
organism	O
that	O
was	O
detected	O
by	O
SeptiFast	O
analysis	O
and	O
that	O
detected	O
by	O
blood	B-Anatomy
culture	O
analysis	O
,	O
or	O
if	O
an	O
organism	O
was	O
only	O
detected	O
in	O
one	O
of	O
these	O
tests	O
,	O
then	O
other	O
samples	B-Anatomy
taken	O
from	O
the	O
infection	O
site	O
were	O
analyzed	O
.	O
If	O
this	O
second	O
culture	O
test	O
of	O
the	O
suspected	O
infectious	O
site	O
revealed	O
the	O
presence	O
of	O
the	O
same	O
organism	O
,	O
this	O
organism	O
was	O
considered	O
to	O
be	O
a	O
pathogen	O
.	O
If	O
the	O
microbial	O
strain	B-Anatomy
was	O
only	O
detected	O
once	O
for	O
a	O
sample	B-Anatomy
,	O
we	O
then	O
checked	O
the	O
second	O
culture	O
results	O
in	O
the	O
suspected	O
infectious	O
sites	O
.	O
If	O
this	O
result	O
identified	O
the	O
same	O
strain	B-Anatomy
as	O
that	O
identified	O
by	O
SeptiFast	O
analysis	O
then	O
it	O
was	O
decided	O
that	O
this	O
strain	B-Anatomy
was	O
a	O
pathogen	O
.	O
However	O
,	O
if	O
the	O
strain	B-Anatomy
was	O
still	O
only	O
detected	O
in	O
some	O
of	O
the	O
assays	O
,	O
we	O
next	O
determined	O
if	O
the	O
patient	O
involved	O
suffered	O
from	O
sepsis	O
.	O
Sepsis	O
is	O
defined	O
as	O
SIRS	O
caused	O
by	O
infection	O
.	O
The	O
definition	O
of	O
sepsis	O
that	O
we	O
used	O
was	O
based	O
on	O
the	O
International	O
Sepsis	O
Forum	O
Definition	O
of	O
Infection	O
at	O
the	O
ICU	O
Consensus	O
Conference	O
[	O
7	O
]	O
.	O
However	O
,	O
if	O
the	O
underlying	O
disease	O
is	O
acute	B-Anatomy
lymphoma	I-Anatomy
leukemia	I-Anatomy
(	O
ALL	B-Anatomy
)	O
,	O
malignant	B-Anatomy
lymphoma	I-Anatomy
(	O
ML	B-Anatomy
)	O
,	O
or	O
acute	B-Anatomy
myelogenous	I-Anatomy
leukemia	I-Anatomy
(	O
AML	B-Anatomy
)	O
,	O
the	O
definition	O
of	O
infection	O
is	O
defined	O
as	O
the	O
ability	O
to	O
detect	O
infectious	O
organisms	O
by	O
blood	B-Anatomy
culture	O
analysis	O
.	O
If	O
the	O
patient	O
was	O
not	O
defined	O
as	O
having	O
sepsis	O
when	O
whole	B-Anatomy
blood	I-Anatomy
was	O
administered	O
to	O
the	O
patient	O
,	O
we	O
decided	O
that	O
the	O
strain	B-Anatomy
detected	O
by	O
subsequent	O
DNA	O
Detection	O
Kit	O
or	O
blood	B-Anatomy
culture	O
analysis	O
was	O
not	O
a	O
pathogen	O
.	O
Figure	O
1	O
Flowchart	O
for	O
pathogen	O
decision	O
.	O
Samples	B-Anatomy
were	O
defined	O
as	O
negative	O
for	O
pathogens	O
if	O
a	O
pathogen	O
could	O
not	O
be	O
detected	O
by	O
any	O
method	O
of	O
analysis	O
within	O
seven	O
days	O
,	O
and	O
if	O
another	O
type	O
of	O
culture	O
test	O
did	O
not	O
detect	O
this	O
pathogen	O
but	O
could	O
detect	O
other	O
organisms	O
.	O
CoNS	O
bacteria	O
,	O
which	O
are	O
represented	O
by	O
the	O
Staphylococcus	O
epidermidis	O
(	O
S	O
.	O
epidermidis	O
)	O
and	O
Streptococcus	O
spp	O
.	O
are	O
indigenous	O
bacteria	O
and	O
often	O
cause	O
contamination	O
in	O
assays	O
of	O
pathogens	O
.	O
Therefore	O
,	O
when	O
CoNS	O
or	O
Streptococcus	O
spp	O
.	O
were	O
detected	O
by	O
blood	B-Anatomy
culture	O
and	O
SeptiFast	O
analysis	O
,	O
the	O
following	O
criteria	O
were	O
applied	O
to	O
define	O
whether	O
these	O
strains	B-Anatomy
represented	O
a	O
pathogenic	O
infection	O
:	O
(	O
1	O
)	O
Tests	O
were	O
performed	O
at	O
least	O
twice	O
within	O
48	O
hours	O
before	O
and	O
after	O
CoNS	O
were	O
detected	O
by	O
blood	B-Anatomy
culture	O
or	O
SeptiFast	O
analysis	O
;	O
(	O
2	O
)	O
CoNS	O
or	O
Streptococcus	O
spp	O
.	O
were	O
detected	O
in	O
two	O
different	O
blood	B-Anatomy
culture	O
tests	O
that	O
were	O
separately	O
performed	O
twice	O
within	O
48	O
hours	O
;	O
and	O
,	O
(	O
3	O
)	O
CoNS	O
or	O
Streptococcus	O
spp	O
.	O
were	O
detected	O
twice	O
or	O
more	O
in	O
tests	O
that	O
were	O
performed	O
three	O
times	O
[	O
11	O
-	O
15	O
]	O
.	O
If	O
a	O
sample	B-Anatomy
'	O
s	O
results	O
met	O
any	O
of	O
these	O
three	O
criteria	O
,	O
then	O
the	O
sample	B-Anatomy
was	O
evaluated	O
as	O
a	O
pathogen	O
.	O
The	O
distinction	O
between	O
pathogen	O
and	O
contamination	O
was	O
also	O
determined	O
for	O
CoNS	O
or	O
Streptococcus	O
spp	O
.	O
from	O
the	O
crossing	O
point	O
(	O
Cp	O
)	O
obtained	O
using	O
the	O
LightCycler	O
analysis	O
software	O
v4	O
.	O
05	O
.	O
The	O
Cp	O
represents	O
the	O
point	O
in	O
the	O
amplification	O
cycle	O
where	O
the	O
amplification	O
curve	O
crosses	O
the	O
detection	O
threshold	O
.	O
When	O
CoNS	O
or	O
Streptococcus	O
spp	O
.	O
were	O
detected	O
using	O
the	O
LightCycler	O
analysis	O
software	O
v4	O
.	O
05	O
,	O
a	O
Cp	O
of	O
less	O
than	O
20	O
was	O
defined	O
as	O
indicating	O
a	O
pathogen	O
and	O
a	O
Cp	O
of	O
over	O
20	O
was	O
defined	O
as	O
contamination	O
by	O
checking	O
the	O
amplification	O
curve	O
.	O
Conclusion	O
:	O
This	O
study	O
demonstrates	O
that	O
surgery	O
plus	O
chemotherapy	O
and	O
radiation	O
therapy	O
is	O
helpful	O
for	O
treating	O
patients	O
with	O
pelvic	B-Anatomy
Ewing	I-Anatomy
'	I-Anatomy
s	I-Anatomy
sarcoma	I-Anatomy
,	O
particularly	O
in	O
achieving	O
local	O
control	O
.	O
Fractional	O
atomic	O
coordinates	O
and	O
isotropic	O
or	O
equivalent	O
isotropic	O
displacement	O
parameters	O
(	O
A2	O
)	O
x	O
y	O
z	O
Uiso	O
*	O
/	O
Ueq	O
C1	O
0	O
.	O
3043	O
(	O
3	O
)	O
0	O
.	O
1779	O
(	O
4	O
)	O
0	O
.	O
79280	O
(	O
13	O
)	O
0	O
.	O
0445	O
(	O
6	O
)	O
C2	O
0	O
.	O
4358	O
(	O
4	O
)	O
0	O
.	O
1697	O
(	O
5	O
)	O
0	O
.	O
84058	O
(	O
17	O
)	O
0	O
.	O
0604	O
(	O
8	O
)	O
H2	O
0	O
.	O
4201	O
0	O
.	O
1476	O
0	O
.	O
8809	O
0	O
.	O
072	O
*	O
C3	O
0	O
.	O
5911	O
(	O
4	O
)	O
0	O
.	O
1953	O
(	O
6	O
)	O
0	O
.	O
8269	O
(	O
2	O
)	O
0	O
.	O
0783	O
(	O
12	O
)	O
H3	O
0	O
.	O
6811	O
0	O
.	O
1914	O
0	O
.	O
8584	O
0	O
.	O
094	O
*	O
C4	O
0	O
.	O
6130	O
(	O
4	O
)	O
0	O
.	O
2267	O
(	O
6	O
)	O
0	O
.	O
7670	O
(	O
2	O
)	O
0	O
.	O
0773	O
(	O
11	O
)	O
H4	O
0	O
.	O
7180	O
0	O
.	O
2427	O
0	O
.	O
7582	O
0	O
.	O
093	O
*	O
C5	O
0	O
.	O
4818	O
(	O
5	O
)	O
0	O
.	O
2344	O
(	O
5	O
)	O
0	O
.	O
7202	O
(	O
2	O
)	O
0	O
.	O
0746	O
(	O
10	O
)	O
H5	O
0	O
.	O
4980	O
0	O
.	O
2547	O
0	O
.	O
6798	O
0	O
.	O
090	O
*	O
C6	O
0	O
.	O
3257	O
(	O
4	O
)	O
0	O
.	O
2121	O
(	O
4	O
)	O
0	O
.	O
73293	O
(	O
15	O
)	O
0	O
.	O
0562	O
(	O
7	O
)	O
H6	O
0	O
.	O
2360	O
0	O
.	O
2200	O
0	O
.	O
7015	O
0	O
.	O
067	O
*	O
C7	O
0	O
.	O
1252	O
(	O
3	O
)	O
0	O
.	O
3838	O
(	O
4	O
)	O
0	O
.	O
90059	O
(	O
11	O
)	O
0	O
.	O
0400	O
(	O
6	O
)	O
C8	O
0	O
.	O
2051	O
(	O
4	O
)	O
0	O
.	O
5522	O
(	O
4	O
)	O
0	O
.	O
90920	O
(	O
13	O
)	O
0	O
.	O
0484	O
(	O
6	O
)	O
H8	O
0	O
.	O
2132	O
0	O
.	O
6288	O
0	O
.	O
8758	O
0	O
.	O
058	O
*	O
C9	O
0	O
.	O
2725	O
(	O
4	O
)	O
0	O
.	O
6041	O
(	O
4	O
)	O
0	O
.	O
96827	O
(	O
15	O
)	O
0	O
.	O
0558	O
(	O
7	O
)	O
C10	O
0	O
.	O
2645	O
(	O
4	O
)	O
0	O
.	O
4935	O
(	O
4	O
)	O
1	O
.	O
01861	O
(	O
14	O
)	O
0	O
.	O
0590	O
(	O
8	O
)	O
H10	O
0	O
.	O
3122	O
0	O
.	O
5293	O
1	O
.	O
0582	O
0	O
.	O
071	O
*	O
C11	O
0	O
.	O
1830	O
(	O
4	O
)	O
0	O
.	O
3278	O
(	O
4	O
)	O
1	O
.	O
00819	O
(	O
13	O
)	O
0	O
.	O
0534	O
(	O
7	O
)	O
C12	O
0	O
.	O
1118	O
(	O
3	O
)	O
0	O
.	O
2699	O
(	O
4	O
)	O
0	O
.	O
95062	O
(	O
12	O
)	O
0	O
.	O
0480	O
(	O
6	O
)	O
H12	O
0	O
.	O
0561	O
0	O
.	O
1577	O
0	O
.	O
9451	O
0	O
.	O
058	O
*	O
N1	O
0	O
.	O
0494	O
(	O
3	O
)	O
0	O
.	O
3297	O
(	O
3	O
)	O
0	O
.	O
84009	O
(	O
10	O
)	O
0	O
.	O
0441	O
(	O
5	O
)	O
H1N	O
0	O
.	O
038	O
(	O
4	O
)	O
0	O
.	O
418	O
(	O
3	O
)	O
0	O
.	O
8138	O
(	O
12	O
)	O
0	O
.	O
053	O
*	O
O1	O
-	O
0	O
.	O
0021	O
(	O
3	O
)	O
0	O
.	O
1298	O
(	O
3	O
)	O
0	O
.	O
74998	O
(	O
9	O
)	O
0	O
.	O
0527	O
(	O
5	O
)	O
O2	O
0	O
.	O
1112	O
(	O
3	O
)	O
-	O
0	O
.	O
0066	O
(	O
3	O
)	O
0	O
.	O
85135	O
(	O
10	O
)	O
0	O
.	O
0574	O
(	O
6	O
)	O
Cl1	O
0	O
.	O
37237	O
(	O
16	O
)	O
0	O
.	O
81541	O
(	O
13	O
)	O
0	O
.	O
97944	O
(	O
5	O
)	O
0	O
.	O
0927	O
(	O
4	O
)	O
Cl2	O
0	O
.	O
16462	O
(	O
15	O
)	O
0	O
.	O
18752	O
(	O
15	O
)	O
1	O
.	O
07089	O
(	O
4	O
)	O
0	O
.	O
0834	O
(	O
4	O
)	O
S1	O
0	O
.	O
10584	O
(	O
7	O
)	O
0	O
.	O
14095	O
(	O
9	O
)	O
0	O
.	O
80800	O
(	O
3	O
)	O
0	O
.	O
0412	O
(	O
3	O
)	O
Crystal	O
data	O
C16H20N4	O
M	O
r	O
=	O
268	O
.	O
36	O
Monoclinic	O
,	O
a	O
=	O
12	O
.	O
819	O
(	O
4	O
)	O
A	O
b	O
=	O
8	O
.	O
441	O
(	O
3	O
)	O
A	O
c	O
=	O
13	O
.	O
310	O
(	O
4	O
)	O
A	O
beta	O
=	O
95	O
.	O
462	O
(	O
5	O
)	O
degrees	O
V	O
=	O
1433	O
.	O
7	O
(	O
8	O
)	O
A3	O
Z	O
=	O
4	O
Mo	O
Kalpha	O
radiation	O
mu	O
=	O
0	O
.	O
08	O
mm	O
-	O
1	O
T	O
=	O
298	O
(	O
2	O
)	O
K	O
0	O
.	O
33	O
x	O
0	O
.	O
28	O
x	O
0	O
.	O
21	O
mm	O
Crystal	O
data	O
C15H12ClN3O2S2	O
F	O
(	O
000	O
)	O
=	O
752	O
Mr	O
=	O
365	O
.	O
85	O
Dx	O
=	O
1	O
.	O
507	O
Mg	O
m	O
-	O
3	O
Monoclinic	O
,	O
P21	O
/	O
n	O
Mo	O
Kalpha	O
radiation	O
,	O
lambda	O
=	O
0	O
.	O
71073	O
A	O
Hall	O
symbol	O
:	O
-	O
P	O
2yn	O
Cell	B-Anatomy
parameters	O
from	O
25	O
reflections	O
a	O
=	O
10	O
.	O
175	O
(	O
2	O
)	O
A	O
theta	O
=	O
9	O
-	O
12degrees	O
b	O
=	O
8	O
.	O
4958	O
(	O
17	O
)	O
A	O
micro	O
=	O
0	O
.	O
51	O
mm	O
-	O
1	O
c	O
=	O
19	O
.	O
318	O
(	O
4	O
)	O
A	O
T	O
=	O
293	O
K	O
beta	O
=	O
105	O
.	O
01	O
(	O
3	O
)	O
degrees	O
Block	O
,	O
yellow	O
V	O
=	O
1613	O
.	O
0	O
(	O
6	O
)	O
A3	O
0	O
.	O
25	O
x	O
0	O
.	O
15	O
x	O
0	O
.	O
15	O
mm	O
Z	O
=	O
4	O
Results	O
and	O
Discussion	O
Figure	O
4	O
shows	O
the	O
frequency	O
response	O
of	O
the	O
device	O
before	O
and	O
after	O
plating	O
cells	B-Anatomy
.	O
In	O
the	O
frequency	O
range	O
measured	O
(	O
4	O
-	O
600	O
Hz	O
)	O
,	O
only	O
two	O
clear	O
peaks	O
can	O
be	O
seen	O
in	O
the	O
bare	O
device	O
.	O
After	O
cells	B-Anatomy
had	O
adhered	O
to	O
the	O
surface	O
,	O
there	O
is	O
a	O
shift	O
in	O
both	O
the	O
resonant	O
frequency	O
and	O
the	O
height	O
of	O
these	O
peaks	O
.	O
Table	O
1	O
shows	O
the	O
results	O
for	O
this	O
trial	O
and	O
a	O
second	O
trial	O
where	O
the	O
experiment	O
was	O
repeated	O
to	O
confirm	O
the	O
initial	O
results	O
.	O
At	O
a	O
plating	O
density	O
of	O
1300	O
cells	B-Anatomy
/	O
mm2	O
,	O
there	O
were	O
approximately	O
140	O
cells	B-Anatomy
on	O
the	O
portion	O
of	O
the	O
cantilever	O
free	O
to	O
vibrate	O
(	O
dimensions	O
shown	O
in	O
Figure	O
1	O
)	O
.	O
Table	O
1	O
Cantilever	O
response	O
data	O
from	O
two	O
trials	O
Experiment	O
#	O
1	O
Experiment	O
#	O
2	O
Freq	O
.	O
1	O
(	O
kHz	O
)	O
Amp	O
.	O
1	O
(	O
deg	O
)	O
Freq	O
.	O
2	O
(	O
kHz	O
)	O
Amp	O
.	O
2	O
(	O
deg	O
)	O
Freq	O
.	O
1	O
(	O
kHz	O
)	O
Amp	O
.	O
1	O
(	O
deg	O
)	O
Freq	O
.	O
2	O
(	O
kHz	O
)	O
Amp	O
.	O
2	O
(	O
deg	O
)	O
Initial	O
313	O
.	O
0	O
.	O
086	O
375	O
.	O
5	O
.	O
055	O
313	O
.	O
9	O
.	O
091	O
376	O
.	O
5	O
.	O
071	O
With	O
cells	B-Anatomy
307	O
.	O
5	O
.	O
031	O
371	O
.	O
0	O
.	O
018	O
308	O
.	O
052	O
370	O
.	O
5	O
.	O
043	O
Change	O
5	O
.	O
5	O
.	O
055	O
4	O
.	O
5	O
.	O
037	O
5	O
.	O
9	O
.	O
039	O
6	O
.	O
0	O
.	O
028	O
Figure	O
4	O
Phase	O
angle	O
vs	O
.	O
frequency	O
.	O
(	O
left	O
)	O
Phase	O
angle	O
of	O
impedance	O
with	O
linear	O
regression	O
line	O
.	O
(	O
right	O
)	O
To	O
provide	O
an	O
easier	O
comparison	O
,	O
phase	O
angles	O
have	O
been	O
levelled	O
with	O
respect	O
to	O
the	O
linear	O
regression	O
line	O
that	O
passes	O
through	O
each	O
set	O
of	O
data	O
.	O
The	O
addition	O
of	O
cells	B-Anatomy
causes	O
the	O
peaks	O
to	O
shift	O
to	O
lower	O
frequencies	O
and	O
decrease	O
in	O
amplitude	O
.	O
The	O
two	O
peaks	O
shown	O
were	O
the	O
only	O
detectable	O
resonances	O
despite	O
the	O
relatively	O
wide	O
frequency	O
range	O
measured	O
.	O
The	O
electrical	O
detection	O
of	O
resonances	O
is	O
critically	O
compromised	O
by	O
the	O
strong	O
damping	O
imposed	O
by	O
the	O
cell	B-Anatomy
media	O
,	O
making	O
these	O
measurements	O
more	O
challenging	O
than	O
those	O
carried	O
out	O
in	O
air	O
or	O
in	O
a	O
vacuum	O
where	O
resonance	O
peaks	O
show	O
much	O
larger	O
amplitude	O
[	O
18	O
]	O
.	O
In	O
the	O
desired	O
in	O
vivo	O
application	O
for	O
this	O
work	O
,	O
as	O
a	O
sensor	O
for	O
stent	O
healing	O
,	O
it	O
can	O
be	O
expected	O
that	O
in	O
the	O
course	O
of	O
normal	O
healing	O
the	O
stent	O
will	O
be	O
fully	O
populated	O
with	O
a	O
significantly	O
thicker	O
layer	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
In	O
the	O
case	O
of	O
restenosis	O
,	O
this	O
lining	O
would	O
be	O
even	O
thicker	O
.	O
This	O
may	O
hamper	O
any	O
movement	O
of	O
the	O
cantilever	O
and	O
cause	O
the	O
peaks	O
to	O
eventually	O
become	O
undetectable	O
.	O
Frequent	O
measurements	O
of	O
the	O
resonant	O
frequencies	O
will	O
differentiate	O
this	O
end	O
state	O
with	O
the	O
possibility	O
of	O
device	O
failure	O
.	O
The	O
noninvasive	O
nature	O
of	O
these	O
measurements	O
that	O
can	O
be	O
transmitted	O
wirelessly	O
to	O
an	O
external	O
device	O
make	O
this	O
an	O
attractive	O
and	O
low	O
risk	O
option	O
for	O
monitoring	O
healing	O
.	O
2	O
.	O
1	O
.	O
Genome	O
sequencing	O
,	O
assembly	O
and	O
validation	O
DNA	O
shotgun	O
libraries	O
with	O
average	O
insert	O
sizes	O
of	O
1	O
.	O
6	O
and	O
6	O
.	O
5	O
kb	O
were	O
constructed	O
in	O
pUC118	O
(	O
TaKaRa	O
)	O
,	O
whereas	O
a	O
fosmid	O
library	O
with	O
average	O
insert	O
size	O
of	O
37	O
kb	O
was	O
constructed	O
in	O
pCC1FOS	O
(	O
EPICENTRE	O
)	O
as	O
described	O
previously	O
.	O
18	O
,	O
19	O
A	O
total	O
of	O
50	O
400	O
clones	O
(	O
34	O
560	O
,	O
10	O
752	O
and	O
5088	O
clones	O
from	O
libraries	O
with	O
1	O
.	O
6	O
,	O
6	O
.	O
5	O
and	O
37	O
kb	O
inserts	O
,	O
respectively	O
)	O
were	O
subjected	O
to	O
sequencing	O
from	O
both	O
ends	O
of	O
the	O
inserts	O
on	O
either	O
ABI	O
3730xl	O
DNA	O
Analyzer	O
(	O
Applied	O
Biosystems	O
)	O
or	O
Base	O
Station	O
DNA	O
Fragment	O
Analyzer	O
BST	O
-	O
0100	O
(	O
MJ	O
Research	O
,	O
Inc	O
.	O
)	O
.	O
Sequence	O
reads	O
were	O
trimmed	O
at	O
a	O
threshold	O
quality	O
value	O
of	O
20	O
by	O
Phred	O
and	O
assembled	O
by	O
Phrap	O
and	O
CONSED	O
assembly	O
tools	O
.	O
20	O
,	O
21	O
For	O
alignment	O
and	O
validation	O
of	O
contigs	O
,	O
Optical	O
Mapping	O
(	O
OpGen	O
)	O
was	O
used	O
.	O
Gaps	O
between	O
contigs	O
were	O
closed	O
by	O
sequencing	O
PCR	O
products	O
,	O
which	O
bridge	O
two	O
neighboring	O
contigs	O
.	O
Finally	O
,	O
each	O
base	O
of	O
K	O
.	O
setae	O
NBRC	O
14216T	O
genome	O
was	O
ensured	O
to	O
be	O
sequenced	O
from	O
multiple	O
clones	O
and	O
from	O
both	O
directions	O
with	O
Phrap	O
quality	O
score	O
>	O
=	O
70	O
or	O
from	O
one	O
direction	O
with	O
Phrap	O
quality	O
score	O
>	O
=	O
40	O
.	O
Chromosomal	B-Anatomy
terminus	O
was	O
determined	O
after	O
attaching	O
adenine	O
and	O
thymine	O
homopolymers	O
to	O
the	O
naked	O
3	O
'	O
ends	O
of	O
the	O
chromosome	B-Anatomy
as	O
described	O
previously	O
.	O
5	O
Correlation	O
matrix	O
for	O
ear	B-Anatomy
(	O
E	O
)	O
traits	O
in	O
2006	O
;	O
data	O
from	O
water	O
stress	O
plots	O
(	O
lower	O
left	O
)	O
and	O
well	O
-	O
watered	O
plots	O
(	O
upper	O
right	O
)	O
of	O
350	O
maize	O
inbreds	O
FUNDING	O
National	O
Institutes	O
of	O
Health	O
grants	O
,	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
and	O
the	O
National	O
Library	O
of	O
Medicine	O
(	O
R01	O
ES014065	O
and	O
R01	O
ES014065	O
-	O
04S1	O
to	O
CTD	O
)	O
;	O
INBRE	O
program	O
of	O
the	O
National	O
Center	O
for	O
Research	O
Resources	O
(	O
P20	O
RR016463	O
)	O
.	O
Funding	O
for	O
open	O
access	O
charge	O
:	O
NIEHS	O
grant	O
(	O
R01	O
ES014065	O
)	O
.	O
Conflict	O
of	O
interest	O
statement	O
.	O
None	O
declared	O
.	O
Tarsoconjunctival	B-Anatomy
flap	I-Anatomy
after	O
division	O
MoClo	O
cloning	O
protocol	O
Restriction	O
-	O
ligations	O
were	O
set	O
up	O
by	O
pipetting	O
in	O
one	O
tube	O
approximately	O
40	O
fmol	O
(	O
~	O
100	O
ng	O
of	O
DNA	O
for	O
a	O
4	O
kb	O
plasmid	B-Anatomy
)	O
of	O
each	O
DNA	O
component	O
(	O
PCR	O
product	O
or	O
plasmid	B-Anatomy
)	O
,	O
10	O
U	O
of	O
the	O
required	O
restriction	O
enzyme	O
(	O
BsaI	O
or	O
BpiI	O
)	O
and	O
10	O
U	O
T4	O
DNA	O
ligase	O
(	O
using	O
high	O
concentration	O
ligase	O
,	O
20	O
U	O
/	O
microl	O
)	O
in	O
Promega	O
ligation	O
buffer	O
in	O
a	O
final	O
reaction	O
volume	O
of	O
20	O
microl	O
.	O
The	O
reaction	O
was	O
incubated	O
in	O
a	O
thermocycler	O
for	O
5	O
hours	O
at	O
37degreesC	O
,	O
5	O
min	O
at	O
50degreesC	O
and	O
10	O
min	O
at	O
80degreesC	O
.	O
The	O
reaction	O
mix	O
was	O
then	O
added	O
to	O
100	O
microl	O
chemically	O
competent	O
DH10b	B-Anatomy
cells	I-Anatomy
,	O
incubated	O
for	O
15	O
-	O
30	O
min	O
on	O
ice	O
and	O
transformed	O
by	O
heat	O
shock	O
.	O
800	O
microl	O
of	O
liquid	O
LB	O
was	O
then	O
added	O
to	O
the	O
transformation	O
,	O
and	O
the	O
cells	B-Anatomy
were	O
let	O
to	O
recover	O
45	O
min	O
at	O
37degreesC	O
.	O
Different	O
aliquots	O
of	O
the	O
transformation	O
were	O
plated	O
on	O
LB	O
plates	O
containing	O
the	O
appropriate	O
antibiotic	O
.	O
The	O
number	O
of	O
colonies	B-Anatomy
was	O
counted	O
for	O
one	O
or	O
two	O
selected	O
plates	O
(	O
containing	O
countable	O
number	O
of	O
colonies	B-Anatomy
)	O
,	O
or	O
from	O
a	O
section	O
of	O
the	O
plates	O
when	O
very	O
high	O
number	O
of	O
colonies	B-Anatomy
were	O
obtained	O
even	O
for	O
the	O
lowest	O
volume	O
plated	O
.	O
The	O
number	O
of	O
colonies	B-Anatomy
was	O
then	O
extrapolated	O
for	O
the	O
entire	O
transformation	O
.	O
For	O
level	O
2	O
-	O
2	O
cloning	O
,	O
two	O
type	O
IIS	O
enzymes	O
were	O
required	O
,	O
BpiI	O
and	O
BsaI	O
.	O
The	O
same	O
protocol	O
was	O
used	O
as	O
described	O
above	O
except	O
that	O
10	O
U	O
and	O
2	O
.	O
5	O
U	O
were	O
used	O
for	O
the	O
enzymes	O
BpiI	O
and	O
BsaI	O
,	O
respectively	O
.	O
To	O
optimize	O
efficiency	O
of	O
the	O
restriction	O
-	O
ligation	O
for	O
the	O
final	O
construct	O
containing	O
11	O
transcription	O
units	O
(	O
cL2	O
-	O
13	O
*	O
)	O
,	O
a	O
variation	O
of	O
this	O
protocol	O
was	O
used	O
as	O
follows	O
.	O
The	O
reaction	O
mix	O
was	O
set	O
up	O
containing	O
20	O
U	O
ligase	O
,	O
5	O
U	O
BpiI	O
and	O
5	O
U	O
BsaI	O
,	O
in	O
a	O
total	O
reaction	O
volume	O
of	O
20	O
microl	O
.	O
The	O
mix	O
was	O
incubated	O
in	O
a	O
thermocycler	O
with	O
the	O
following	O
parameters	O
:	O
incubation	O
for	O
2	O
minutes	O
at	O
37degreesC	O
,	O
5	O
minutes	O
at	O
16degreesC	O
,	O
both	O
steps	O
repeated	O
45	O
times	O
,	O
followed	O
by	O
incubation	O
for	O
5	O
minutes	O
at	O
50degreesC	O
and	O
10	O
minutes	O
at	O
80degreesC	O
.	O
The	O
reaction	O
mix	O
was	O
transformed	O
in	O
E	O
.	O
coli	O
chemically	O
competent	B-Anatomy
cells	I-Anatomy
as	O
described	O
above	O
.	O
Observed	O
type	O
I	O
error	O
for	O
datasets	O
simulated	O
under	O
the	O
hypothesis	O
DNA	O
isolation	O
All	O
solutions	O
used	O
for	O
DNA	O
isolation	O
are	O
purged	O
with	O
nitrogen	O
(	O
immediately	O
prior	O
to	O
use	O
)	O
and	O
supplemented	O
with	O
50	O
muM	O
phenyl	O
-	O
tert	O
-	O
butyl	O
nitrone	O
to	O
minimise	O
oxidative	O
damage	O
to	O
DNA	O
[	O
31	O
]	O
.	O
Qiagen	O
DNAeasy	O
Kit	O
(	O
#	O
69506	O
)	O
includes	O
:	O
Proteinase	O
K	O
,	O
AW1	O
,	O
AW2	O
,	O
AE	O
and	O
Spin	O
-	O
columns	O
Dithiothreitol	O
(	O
DTT	O
;	O
Sigma	O
)	O
Ethanol	O
(	O
Ajax	O
Finechem	O
#	O
214	O
-	O
2	O
.	O
5L	O
)	O
Nitrogen	O
(	O
for	O
purging	O
of	O
buffers	O
)	O
Genes	O
related	O
to	O
signal	O
transduction	O
On	O
day	O
7	O
,	O
the	O
up	O
-	O
regulated	O
genes	O
related	O
to	O
signal	O
transduction	O
were	O
PDE1A	O
,	O
MYO10	O
,	O
APOB	O
,	O
and	O
so	O
on	O
,	O
and	O
down	O
-	O
regulated	O
genes	O
were	O
CYTL1	O
and	O
IL6	O
.	O
On	O
day	O
14	O
,	O
the	O
up	O
-	O
regulated	O
genes	O
were	O
ANGPTL4	O
,	O
EPHA3	O
,	O
RASL10B	O
,	O
etc	O
.	O
,	O
and	O
the	O
down	O
-	O
regulated	O
genes	O
were	O
CXCL12	O
,	O
CCL8	O
and	O
VLDLR	O
.	O
The	O
genes	O
up	O
-	O
regulated	O
on	O
both	O
days	O
were	O
LEP	O
,	O
RAC3	O
,	O
and	O
RASL11B	O
,	O
and	O
those	O
down	O
-	O
regulated	O
both	O
days	O
were	O
MX1	O
and	O
WISP2	O
.	O
Notably	O
,	O
up	O
-	O
and	O
down	O
-	O
regulated	O
genes	O
PDE1A	O
,	O
APOB	O
,	O
ALCAM	O
,	O
PSCD4	O
,	O
CYTL1	O
,	O
and	O
IL6	O
were	O
more	O
strongly	O
expressed	O
on	O
day	O
7	O
than	O
on	O
day	O
14	O
,	O
while	O
ANGPTL4	O
,	O
EPHA3	O
,	O
RAB12	O
,	O
CXCL12	O
,	O
CCL8	O
,	O
and	O
VLDLR	O
were	O
more	O
strongly	O
expressed	O
on	O
day	O
14	O
than	O
on	O
day	O
7	O
.	O
SUMMARY	O
Both	O
the	O
innate	O
and	O
adaptive	O
immune	B-Anatomy
subsystems	I-Anatomy
are	O
necessary	O
to	O
provide	O
an	O
effective	O
immune	O
response	O
whether	O
to	O
an	O
actual	O
pathogenic	O
agent	O
or	O
to	O
an	O
immunization	O
.	O
Further	O
,	O
effective	O
immunizations	O
must	O
induce	O
long	O
-	O
term	O
stimulation	O
of	O
both	O
the	O
humoral	O
and	O
cell	B-Anatomy
-	O
mediated	O
arms	O
of	O
the	O
adaptive	O
system	O
by	O
the	O
production	O
of	O
effector	B-Anatomy
cells	I-Anatomy
for	O
the	O
current	O
infection	O
and	O
memory	B-Anatomy
cells	I-Anatomy
for	O
future	O
infections	O
with	O
the	O
pathogenic	O
agent	O
.	O
At	O
least	O
seven	O
different	O
types	O
of	O
vaccines	O
are	O
currently	O
in	O
use	O
or	O
in	O
development	O
that	O
produce	O
this	O
effective	O
immunity	O
and	O
have	O
contributed	O
greatly	O
to	O
the	O
prevention	O
of	O
infectious	O
disease	O
around	O
the	O
world	O
.	O
Encoding	O
methods	O
of	O
SOLiDzipper	O
.	O
Notes	O
:	O
A	O
)	O
The	O
quality	O
value	O
in	O
QV	O
files	O
from	O
ABI	O
SOLiD	O
system	O
ranges	O
from	O
-	O
1	O
to	O
40	O
,	O
which	O
requires	O
6	O
bit	O
space	O
.	O
The	O
remaining	O
2	O
bit	O
space	O
out	O
of	O
1	O
byte	O
can	O
be	O
used	O
for	O
storing	O
another	O
quality	O
value	O
in	O
part	O
.	O
B	O
)	O
Csfasta	O
files	O
contain	O
the	O
sequence	O
information	O
in	O
four	O
digits	O
,	O
'	O
0123	O
'	O
,	O
which	O
require	O
2	O
bit	O
space	O
.	O
Provided	O
that	O
'	O
0	O
'	O
,	O
1	O
byte	O
character	O
in	O
csfasta	O
files	O
,	O
is	O
mapped	O
as	O
binary	O
data	O
'	O
00	O
'	O
,	O
'	O
1	O
'	O
as	O
'	O
01	O
'	O
,	O
'	O
2	O
'	O
as	O
'	O
10	O
'	O
,	O
'	O
3	O
'	O
as	O
'	O
11	O
'	O
,	O
4	O
byte	O
data	O
'	O
0113	O
'	O
can	O
be	O
encoded	O
into	O
1	O
byte	O
character	O
0x17	O
(	O
00010111	O
)	O
through	O
shift	O
operation	O
.	O
C	O
)	O
Sequence	O
IDs	O
are	O
extracted	O
from	O
QV	O
and	O
csfasta	O
files	O
,	O
combined	O
,	O
and	O
compressed	O
using	O
the	O
general	O
purpose	O
compression	O
methods	O
.	O
D	O
)	O
Encoded	O
data	O
are	O
stored	O
as	O
data	O
blocks	O
of	O
fixed	O
size	O
.	O
This	O
allows	O
for	O
selective	O
decoding	O
.	O
CONCLUSION	O
Intra	O
-	O
operative	O
monitoring	O
of	O
partial	O
pressure	O
of	O
tissue	B-Anatomy
oxygen	O
(	O
PtiO2	O
)	O
is	O
a	O
very	O
sensitive	O
method	O
of	O
detecting	O
the	O
decrease	O
of	O
oxygen	O
for	O
cell	B-Anatomy
utilization	O
,	O
due	O
to	O
decreased	O
blood	B-Anatomy
flow	O
,	O
during	O
temporary	O
clipping	O
and	O
after	O
definitive	O
clipping	O
,	O
in	O
middle	B-Anatomy
cerebral	I-Anatomy
artery	I-Anatomy
incidental	O
unruptured	O
aneurysm	B-Anatomy
surgery	O
.	O
""""	O
Basal	O
values	O
""""	O
,	O
obtained	O
without	O
the	O
influence	O
of	O
subarachnoid	B-Anatomy
blood	I-Anatomy
,	O
were	O
lower	O
than	O
expected	O
in	O
""""	O
uninjured	O
""""	O
brain	B-Anatomy
,	O
and	O
this	O
fact	O
,	O
although	O
unexplained	O
,	O
should	O
be	O
kept	O
in	O
mind	O
in	O
future	O
investigation	O
in	O
this	O
field	O
.	O
Although	O
values	O
that	O
could	O
be	O
predictive	O
of	O
brain	B-Anatomy
ischemia	O
could	O
not	O
be	O
established	O
,	O
an	O
incomplete	O
recovery	O
or	O
continuous	O
decrease	O
in	O
PtiO2	O
values	O
after	O
definitive	O
clipping	O
should	O
be	O
considered	O
an	O
indicator	O
of	O
high	O
risk	O
for	O
the	O
development	O
of	O
post	O
-	O
operative	O
brain	B-Anatomy
infarction	O
,	O
and	O
,	O
therefore	O
,	O
an	O
indication	O
for	O
verification	O
of	O
the	O
position	O
of	O
the	O
clip	O
.	O
View	O
of	O
the	O
structure	O
of	O
the	O
title	O
compound	O
along	O
the	O
a	O
axis	O
displaying	O
chains	O
alternating	O
with	O
amine	O
groups	O
.	O
Results	O
(	O
a	O
)	O
Sequence	O
alignment	O
of	O
PY	O
-	O
NLSs	O
.	O
The	O
homologous	O
regions	O
of	O
C	O
-	O
NLS	O
of	O
the	O
EWS	O
protein	O
,	O
NLS	O
of	O
Sam68	O
and	O
FUS	O
/	O
TLS	O
protein	O
and	O
M9	O
NLS	O
of	O
hnRNP	O
A1	O
and	O
hnRNP	O
M	O
,	O
classified	O
as	O
PY	O
-	O
NLS	O
are	O
in	O
yellow	O
boxes	O
.	O
Phosphorylated	O
Y656	O
of	O
the	O
EWS	O
protein	O
and	O
Y440	O
of	O
Sam68	O
are	O
indicated	O
(	O
in	O
red	O
)	O
.	O
Positions	O
of	O
identical	O
residues	O
in	O
SAM68	O
and	O
EWS	O
C	O
-	O
NLS	O
are	O
indicated	O
in	O
bold	O
and	O
residues	O
with	O
identical	O
charges	O
are	O
underlined	O
.	O
Known	O
positions	O
of	O
the	O
FUS	O
/	O
TLS	O
mutations	O
in	O
ALS	O
are	O
in	O
bold	O
.	O
(	O
b	O
)	O
Subcellular	B-Anatomy
localization	O
of	O
YFP	O
,	O
the	O
C	O
-	O
terminally	O
tagged	O
EWS	O
-	O
YFP	O
,	O
EWS	O
(	O
Y656A	O
)	O
-	O
YFP	O
,	O
EWS	O
(	O
Y656F	O
)	O
-	O
YFP	O
,	O
and	O
EWS	O
(	O
Y656D	O
)	O
-	O
YFP	O
(	O
in	O
green	O
)	O
.	O
Nuclei	B-Anatomy
are	O
shown	O
by	O
DAPI	O
staining	O
(	O
in	O
blue	O
)	O
.	O
Bars	O
,	O
15	O
mum	O
.	O
Conclusions	O
Myocardial	B-Anatomy
ischaemia	O
during	O
DCMR	O
is	O
independently	O
predictive	O
of	O
cardiac	B-Anatomy
events	O
among	O
patients	O
with	O
previous	O
myocardial	B-Anatomy
revascularisation	O
.	O
Importing	O
citations	O
in	O
different	O
formats	O
using	O
Google	O
Scholar	O
Subject	O
disposition	O
.	O
Data	O
from	O
110	O
enrolled	O
subjects	O
were	O
eligible	O
for	O
analysis	O
.	O
The	O
demographics	O
of	O
the	O
study	O
subjects	O
,	O
by	O
site	O
,	O
are	O
recorded	O
in	O
Table	O
1	O
.	O
The	O
population	O
studied	O
was	O
predominantly	O
not	O
HIV	O
infected	O
(	O
92	O
%	O
)	O
,	O
and	O
by	O
the	O
study	O
entry	O
criteria	O
,	O
their	O
probability	O
of	O
infection	O
was	O
considered	O
to	O
be	O
low	O
.	O
The	O
risk	O
categories	O
assigned	O
at	O
the	O
time	O
of	O
study	O
entry	O
were	O
combined	O
into	O
groups	O
for	O
analysis	O
,	O
based	O
on	O
the	O
predisposition	O
for	O
PCP	O
.	O
The	O
analysis	O
groups	O
were	O
as	O
follows	O
:	O
(	O
i	O
)	O
HIV	O
/	O
AIDS	O
,	O
(	O
ii	O
)	O
lung	B-Anatomy
transplant	O
(	O
one	O
subject	O
with	O
a	O
dual	O
organ	B-Anatomy
transplant	O
[	O
lung	B-Anatomy
/	O
kidney	B-Anatomy
]	O
was	O
included	O
in	O
this	O
category	O
)	O
,	O
(	O
iii	O
)	O
all	O
other	O
organ	B-Anatomy
transplants	O
and	O
allogeneic	B-Anatomy
hematopoietic	I-Anatomy
stem	I-Anatomy
cell	I-Anatomy
transplants	O
(	O
HSCT	O
)	O
,	O
(	O
iv	O
)	O
leukemia	B-Anatomy
,	O
other	O
hematological	O
disorders	O
,	O
and	O
autologous	O
HSCT	O
,	O
(	O
v	O
)	O
other	O
solid	B-Anatomy
tumors	I-Anatomy
,	O
and	O
(	O
vi	O
)	O
other	O
nonmalignant	O
conditions	O
.	O
Table	O
1	O
.	O
Subject	O
enrollment	O
,	O
disposition	O
,	O
and	O
demographics	O
by	O
sitea	O
Characteristic	O
Valueb	O
Site	O
1	O
Site	O
2	O
Site	O
3	O
Site	O
4	O
Enrollment	O
Unique	O
subjects	O
18	O
29	O
22	O
62	O
Subjects	O
entering	O
into	O
primary	O
analysisc	O
18	O
22	O
22	O
48	O
Subjects	O
with	O
repeat	O
visits	O
0	O
0	O
0	O
16	O
No	O
.	O
of	O
samples	B-Anatomy
assayed	O
18	O
22	O
22	O
70	O
Gender	O
Male	O
7	O
10	O
13	O
29	O
Female	O
11	O
12	O
9	O
19	O
Race	O
Caucasian	O
12	O
4	O
0	O
48	O
Black	O
6	O
13	O
0	O
0	O
Other	O
(	O
nonwhite	O
)	O
0	O
5	O
0	O
0	O
No	O
data	O
0	O
0	O
22	O
0	O
Mean	O
(	O
range	O
)	O
age	O
(	O
yr	O
)	O
57	O
(	O
26	O
-	O
78	O
)	O
54	O
(	O
21	O
-	O
75	O
)	O
52	O
(	O
26	O
-	O
74	O
)	O
56	O
(	O
23	O
-	O
73	O
)	O
Pretest	O
probability	O
of	O
PCP	O
Moderate	O
0	O
3	O
4	O
0	O
Low	O
18	O
19	O
18	O
48	O
Sample	B-Anatomy
type	O
BAL	O
18	O
20	O
20	O
43	O
Sputum	B-Anatomy
0	O
1	O
1	O
0	O
Other	O
LRT	O
0	O
1	O
1	O
5	O
At	O
-	O
risk	O
group	O
HIV	O
/	O
AIDS	O
0	O
3	O
6	O
0	O
Lung	B-Anatomy
transplant	O
8	O
0	O
1	O
31	O
Other	O
transplants	O
1	O
7	O
3	O
0	O
Leukemia	B-Anatomy
1	O
1	O
7	O
0	O
Other	O
solid	B-Anatomy
tumors	I-Anatomy
2	O
1	O
1	O
7	O
Other	O
nonmalignant	O
conditions	O
6	O
10	O
4	O
10	O
a	O
The	O
testing	O
and	O
enrollment	O
sites	O
for	O
the	O
study	O
were	O
Duke	O
University	O
School	O
of	O
Medicine	O
,	O
Durham	O
,	O
NC	O
;	O
Albert	O
Einstein	O
College	O
of	O
Medicine	O
and	O
Montefiore	O
Medical	O
Center	O
,	O
Bronx	O
,	O
NY	O
;	O
Centre	O
Hospitalier	O
Universitaire	O
Vaudois	O
and	O
University	O
of	O
Lausanne	O
,	O
Lausanne	O
,	O
Switzerland	O
;	O
and	O
Medizinische	O
Universitat	O
and	O
Landeskrankenhaus	O
Natters	O
,	O
Innsbruck	O
,	O
Austria	O
.	O
b	O
Except	O
where	O
otherwise	O
indicated	O
,	O
values	O
are	O
numbers	O
of	O
patients	O
.	O
c	O
Subjects	O
were	O
excluded	O
from	O
analysis	O
if	O
they	O
withdrew	O
consent	O
or	O
if	O
there	O
was	O
inadequate	O
sample	B-Anatomy
left	O
for	O
PCR	O
testing	O
.	O
Acknowledgments	O
and	O
Funding	O
The	O
authors	O
thank	O
CRB	O
GADIE	O
(	O
Diane	O
Esquerre	O
)	O
for	O
BAC	O
clones	O
handling	O
and	O
Brian	O
Smith	O
,	O
Renee	O
Fincham	O
and	O
Kristy	O
Shewbridge	O
for	O
microsatellites	O
genotyping	O
.	O
We	O
are	O
grateful	O
to	O
Yann	O
Guiguen	O
for	O
help	O
and	O
precious	O
contribution	O
to	O
fund	O
raising	O
for	O
this	O
study	O
.	O
This	O
work	O
was	O
made	O
possible	O
by	O
financial	O
support	O
of	O
Genoscope	O
.	O
We	O
acknowledge	O
Rene	O
Guyomard	O
for	O
his	O
initial	O
contribution	O
in	O
BAC	O
library	O
procurement	O
.	O
The	O
microsatellites	O
genotyping	O
was	O
supported	O
by	O
NRI	O
Grant	O
No	O
.	O
2007	O
-	O
35616	O
-	O
17875	O
from	O
the	O
USDA	O
National	O
Institute	O
of	O
Food	O
and	O
Agriculture	O
.	O
Confocal	O
and	O
scanning	O
microscopic	O
images	O
of	O
mammoth	O
'	O
s	O
and	O
human	O
hair	B-Anatomy
.	O
Taphonomic	O
changes	O
,	O
indicated	O
by	O
arrow	O
-	O
heads	O
and	O
straight	O
white	O
arrow	O
in	O
the	O
confocal	O
image	O
.	O
Bacterial	O
-	O
fungal	O
colonies	B-Anatomy
are	O
shown	O
by	O
broken	O
arrows	O
.	O
Red	O
arrow	O
indicates	O
space	O
between	O
cuticle	O
and	O
hair	B-Anatomy
shaft	I-Anatomy
due	O
to	O
shrinkage	O
.	O
Extensive	O
taphonomic	O
changes	O
in	O
YUK	O
are	O
evident	O
.	O
Note	O
the	O
preservation	O
of	O
the	O
cuticle	O
in	O
the	O
human	O
hair	B-Anatomy
in	O
contrast	O
to	O
the	O
craters	O
in	O
the	O
cuticles	O
of	O
the	O
mammoth	O
'	O
s	O
hair	B-Anatomy
.	O
Bacterial	O
biofilms	O
are	O
a	O
feature	O
of	O
human	O
hair	B-Anatomy
;	O
mammoth	O
'	O
s	O
hair	B-Anatomy
was	O
protected	O
from	O
bacterial	O
invasion	O
in	O
permafrost	O
.	O
Calculation	O
of	O
male	O
mating	O
success	O
In	O
order	O
to	O
compare	O
whether	O
males	O
'	O
access	O
to	O
receptive	O
females	O
followed	O
the	O
predictions	O
of	O
the	O
PoA	O
model	O
,	O
we	O
calculated	O
mating	O
success	O
as	O
follows	O
.	O
For	O
all	O
the	O
mating	O
partners	O
a	O
female	O
had	O
during	O
the	O
receptive	O
period	O
of	O
her	O
conceptive	O
cycle	O
,	O
mating	O
success	O
of	O
each	O
mating	O
partner	O
was	O
calculated	O
as	O
the	O
number	O
of	O
mating	O
series	O
a	O
male	O
was	O
involved	O
in	O
divided	O
by	O
the	O
total	O
number	O
of	O
mating	O
series	O
the	O
female	O
was	O
involved	O
in	O
.	O
Overall	O
mating	O
success	O
of	O
each	O
male	O
was	O
calculated	O
as	O
the	O
sum	O
of	O
all	O
mating	O
successes	O
calculated	O
for	O
this	O
male	O
as	O
described	O
above	O
.	O
Tail	O
flick	O
test	O
CSLE	O
did	O
not	O
show	O
any	O
difference	O
compared	O
with	O
control	O
,	O
at	O
all	O
the	O
tested	O
doses	O
[	O
Figure	O
4	O
]	O
.	O
Morphine	O
showed	O
a	O
significant	O
increase	O
of	O
latency	O
time	O
at	O
45	O
,	O
60	O
and	O
75	O
min	O
.	O
Figure	O
4	O
Effect	O
of	O
CSLE	O
(	O
100	O
,	O
200	O
and	O
500	O
mg	O
/	O
kg	O
)	O
and	O
morphine	O
on	O
the	O
latency	O
response	O
of	O
mice	O
in	O
the	O
tail	B-Anatomy
flick	O
test	O
.	O
Values	O
are	O
presented	O
as	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
5	O
)	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
significant	O
increase	O
from	O
control	O
Details	O
of	O
treatment	O
programs	O
A	O
and	O
B	O
in	O
respect	O
to	O
visits	O
to	O
different	O
health	O
care	O
professionals	O
and	O
treatment	O
activities	O
Genes	O
associated	O
with	O
nonsegmental	O
vitiligo	O
.	O
a	O
,	O
b	O
Radiographs	O
of	O
the	O
left	B-Anatomy
elbow	I-Anatomy
and	O
forearm	B-Anatomy
5	O
months	O
after	O
the	O
surgery	O
Discussion	O
The	O
two	O
most	O
important	O
factors	O
leading	O
to	O
the	O
development	O
of	O
hypoxia	O
are	O
biological	O
processes	O
that	O
determine	O
the	O
amount	O
of	O
organic	O
matter	O
available	O
to	O
be	O
degraded	O
and	O
physical	O
factors	O
creating	O
stratification	O
.	O
Stratification	O
in	O
most	O
areas	O
of	O
the	O
coastal	O
zone	O
of	O
the	O
Baltic	O
Sea	O
is	O
due	O
to	O
seasonal	O
temperature	O
changes	O
,	O
although	O
stratification	O
by	O
occasional	O
inflowing	O
saltier	O
water	O
does	O
occur	O
in	O
some	O
estuaries	O
.	O
(	O
14	O
)	O
Hypoxia	O
is	O
common	O
in	O
estuaries	O
located	O
in	O
the	O
Danish	O
Straits	O
due	O
to	O
the	O
large	O
load	O
of	O
nutrients	O
sustaining	O
algal	O
production	O
and	O
the	O
strong	O
stratification	O
caused	O
by	O
large	O
differences	O
in	O
surface	O
and	O
bottom	O
water	O
salinity	O
.	O
(	O
5	O
)	O
Hypoxia	O
in	O
the	O
Swedish	O
and	O
Finnish	O
archipelagos	O
are	O
influenced	O
by	O
phytoplankton	O
growth	O
stimulated	O
by	O
nutrient	O
loads	O
from	O
urban	O
and	O
agricultural	O
sources	O
,	O
but	O
also	O
by	O
restricted	O
water	O
circulation	O
.	O
The	O
Finnish	O
Archipelago	O
Sea	O
is	O
impacted	O
by	O
drifting	O
algal	O
mats	O
that	O
consume	O
oxygen	O
during	O
their	O
decomposition	O
when	O
they	O
sink	O
to	O
the	O
bottom	O
.	O
(	O
15	O
)	O
By	O
contrast	O
,	O
hypoxia	O
is	O
rare	O
in	O
the	O
northern	O
Baltic	O
Sea	O
estuaries	O
located	O
in	O
the	O
Bothnian	O
Sea	O
coastal	O
zone	O
where	O
nutrient	O
loads	O
are	O
lower	O
.	O
Hypoxia	O
is	O
uncommon	O
along	O
the	O
eastern	O
shore	O
from	O
Estonia	O
to	O
Poland	O
due	O
to	O
enhanced	O
circulation	O
of	O
water	O
in	O
open	O
areas	O
along	O
the	O
coastline	O
(	O
Figure	O
1	O
)	O
.	O
There	O
are	O
very	O
limited	O
data	O
available	O
to	O
examine	O
how	O
far	O
back	O
in	O
time	O
hypoxia	O
has	O
occurred	O
.	O
A	O
key	O
question	O
in	O
this	O
ecosystem	O
affected	O
daily	O
by	O
over	O
85	O
million	O
people	O
could	O
be	O
""""	O
Is	O
hypoxia	O
a	O
natural	O
phenomenon	O
?	O
""""	O
.	O
(	O
16	O
)	O
The	O
large	O
numbers	O
of	O
enclosed	O
areas	O
,	O
in	O
many	O
cases	O
with	O
shallow	O
sills	O
that	O
restrict	O
the	O
exchange	O
of	O
bottom	O
water	O
and	O
often	O
in	O
combination	O
with	O
large	O
irregular	O
changes	O
in	O
salinity	O
,	O
might	O
mean	O
that	O
hypoxia	O
has	O
always	O
been	O
present	O
in	O
the	O
coastal	O
zone	O
.	O
However	O
,	O
sediment	O
laminations	O
from	O
Stockholm	O
Archipelago	O
,	O
an	O
indicator	O
of	O
past	O
hypoxia	O
,	O
(	O
17	O
)	O
have	O
been	O
shown	O
to	O
be	O
a	O
recent	O
phenomenon	O
with	O
very	O
few	O
areas	O
with	O
laminated	O
sediments	O
prior	O
to	O
1900	O
.	O
17	O
,	O
18	O
The	O
long	O
-	O
term	O
millennial	O
trends	O
in	O
coastal	O
hypoxia	O
remain	O
unknown	O
,	O
although	O
hypoxia	O
has	O
occurred	O
intermittently	O
throughout	O
the	O
last	O
8000	O
years	O
in	O
offshore	O
deep	O
waters	O
of	O
the	O
Baltic	O
Sea	O
.	O
(	O
10	O
)	O
Further	O
sediment	O
studies	O
are	O
necessary	O
,	O
similar	O
to	O
those	O
carried	O
out	O
in	O
the	O
open	O
Baltic	O
Sea	O
,	O
(	O
10	O
)	O
to	O
ascertain	O
how	O
far	O
back	O
in	O
time	O
hypoxia	O
was	O
observed	O
in	O
the	O
coastal	O
zone	O
.	O
Key	O
uncertainties	O
remain	O
including	O
how	O
have	O
the	O
driving	O
forces	O
for	O
hypoxia	O
,	O
e	O
.	O
g	O
.	O
,	O
climate	O
(	O
19	O
)	O
and	O
nutrient	O
loading	O
,	O
changed	O
through	O
time	O
in	O
the	O
Baltic	O
Sea	O
coastal	O
zone	O
,	O
and	O
do	O
they	O
vary	O
during	O
the	O
same	O
time	O
periods	O
that	O
hypoxia	O
varies	O
in	O
the	O
open	O
waters	O
?	O
(	O
16	O
)	O
An	O
important	O
consideration	O
in	O
determining	O
the	O
number	O
of	O
ecosystems	O
experiencing	O
hypoxia	O
is	O
the	O
size	O
of	O
the	O
assessment	O
unit	O
.	O
We	O
combined	O
numerous	O
monitoring	O
points	O
and	O
sites	O
to	O
form	O
a	O
coherent	O
coastal	O
unit	O
when	O
bottom	O
waters	O
were	O
physically	O
connected	O
to	O
each	O
other	O
.	O
This	O
means	O
that	O
assessment	O
units	O
considered	O
hypoxic	O
might	O
occur	O
in	O
the	O
same	O
geographical	O
region	O
and	O
could	O
be	O
in	O
close	O
proximately	O
to	O
each	O
other	O
,	O
if	O
their	O
bottom	O
waters	O
were	O
physically	O
disconnected	O
.	O
The	O
Baltic	O
Sea	O
archipelagos	O
have	O
a	O
complex	O
topography	O
with	O
many	O
basins	O
disjoined	O
by	O
shallow	O
sills	O
resulting	O
in	O
many	O
distinct	O
sites	O
,	O
although	O
they	O
are	O
all	O
affected	O
by	O
similar	O
mechanisms	O
.	O
In	O
fact	O
,	O
the	O
Stockholm	O
and	O
Finnish	O
archipelagos	O
contributed	O
21	O
%	O
of	O
the	O
total	O
assessment	O
units	O
,	O
a	O
relatively	O
large	O
share	O
compared	O
to	O
the	O
total	O
Baltic	O
Sea	O
coastal	O
zone	O
,	O
but	O
>	O
40	O
%	O
of	O
the	O
hypoxic	O
sites	O
.	O
The	O
coastal	O
stretches	O
of	O
the	O
Western	O
Gotland	O
Basin	O
and	O
Gulf	O
of	O
Finland	O
that	O
have	O
a	O
substantial	O
number	O
of	O
hypoxic	O
sites	O
are	O
also	O
archipelagos	O
,	O
which	O
are	O
more	O
prone	O
to	O
hypoxia	O
because	O
of	O
the	O
complex	O
topography	O
,	O
proximity	O
to	O
development	O
,	O
and	O
consequently	O
more	O
sensitive	O
to	O
enhanced	O
nutrient	O
inputs	O
from	O
land	O
.	O
Surprisingly	O
only	O
4	O
.	O
0	O
%	O
of	O
all	O
sites	O
were	O
classified	O
as	O
seasonally	O
hypoxic	O
according	O
to	O
our	O
definition	O
when	O
>	O
50	O
%	O
and	O
<	O
80	O
%	O
of	O
profiles	O
during	O
the	O
stratified	O
period	O
have	O
oxygen	O
concentrations	O
less	O
than	O
2	O
mg	O
L	O
-	O
1	O
.	O
A	O
statistically	O
rigorous	O
definition	O
of	O
what	O
constitutes	O
seasonal	O
hypoxia	O
does	O
not	O
currently	O
exist	O
and	O
in	O
fact	O
should	O
be	O
linked	O
to	O
ecological	O
consequences	O
for	O
it	O
to	O
be	O
ecologically	O
relevant	O
and	O
not	O
just	O
connected	O
to	O
absolute	O
concentrations	O
.	O
(	O
3	O
)	O
Currently	O
coastal	O
marine	O
ecosystems	O
that	O
experience	O
hypoxia	O
for	O
a	O
period	O
of	O
days	O
to	O
months	O
every	O
year	O
are	O
often	O
considered	O
to	O
be	O
seasonally	O
hypoxic	O
,	O
although	O
we	O
have	O
categorized	O
them	O
here	O
as	O
being	O
episodic	O
,	O
because	O
we	O
required	O
the	O
monitoring	O
units	O
to	O
be	O
hypoxic	O
for	O
most	O
of	O
the	O
stratified	O
period	O
.	O
However	O
,	O
in	O
Limfjorden	O
,	O
Denmark	O
,	O
bottom	O
water	O
oxygen	O
concentrations	O
can	O
vary	O
greatly	O
between	O
weekly	O
samplings	O
(	O
SI	O
Figure	O
S6	O
)	O
,	O
although	O
nearly	O
every	O
year	O
hypoxic	O
conditions	O
are	O
observed	O
somewhere	O
in	O
the	O
Limfjorden	O
.	O
Our	O
statistical	O
estimation	O
is	O
that	O
Limfjorden	O
is	O
episodically	O
hypoxic	O
.	O
Diaz	O
and	O
Rosenberg	O
(	O
1	O
)	O
would	O
classify	O
Limfjorden	O
as	O
periodically	O
hypoxic	O
,	O
although	O
we	O
have	O
found	O
it	O
difficult	O
to	O
create	O
a	O
statistically	O
robust	O
indicator	O
that	O
would	O
classify	O
systems	O
as	O
periodically	O
hypoxic	O
.	O
Periodic	O
hypoxia	O
is	O
problematic	O
because	O
it	O
never	O
allows	O
for	O
re	O
-	O
establishment	O
of	O
benthic	O
communities	O
.	O
(	O
20	O
)	O
Currently	O
,	O
there	O
are	O
416	O
areas	O
in	O
the	O
world	O
with	O
reported	O
coastal	O
hypoxia	O
with	O
about	O
30	O
previously	O
reported	O
sites	O
in	O
the	O
Baltic	O
Sea	O
region	O
,	O
which	O
includes	O
both	O
coastal	O
zone	O
hypoxia	O
and	O
deep	O
water	O
sites	O
in	O
the	O
Baltic	O
Sea	O
.	O
(	O
1	O
)	O
We	O
have	O
identified	O
an	O
additional	O
96	O
sites	O
that	O
have	O
experienced	O
hypoxia	O
,	O
increasing	O
the	O
global	O
total	O
to	O
nearly	O
500	O
sites	O
.	O
Of	O
all	O
the	O
known	O
sites	O
around	O
the	O
world	O
,	O
around	O
20	O
%	O
of	O
the	O
sites	O
are	O
found	O
in	O
the	O
Baltic	O
Sea	O
region	O
.	O
Most	O
sites	O
experienced	O
episodic	O
hypoxia	O
,	O
which	O
is	O
a	O
precursor	O
to	O
development	O
of	O
seasonal	O
hypoxia	O
.	O
(	O
20	O
)	O
The	O
large	O
number	O
of	O
sites	O
partially	O
reflects	O
the	O
fact	O
that	O
the	O
Baltic	O
Sea	O
is	O
one	O
of	O
the	O
most	O
data	O
rich	O
regions	O
of	O
the	O
world	O
with	O
no	O
tidal	O
mixing	O
and	O
complex	O
bottom	O
topography	O
creating	O
conditions	O
favorable	O
for	O
hypoxia	O
,	O
although	O
these	O
are	O
only	O
the	O
""""	O
monitored	O
areas	O
""""	O
and	O
many	O
more	O
hypoxic	O
sites	O
probably	O
exist	O
in	O
the	O
Baltic	O
Sea	O
coastal	O
zone	O
.	O
In	O
contrast	O
,	O
there	O
was	O
no	O
evidence	O
of	O
hypoxia	O
at	O
95	O
stations	O
in	O
estuarine	O
and	O
coastal	O
waters	O
around	O
Ireland	O
due	O
to	O
sufficient	O
tidal	O
mixing	O
.	O
(	O
21	O
)	O
If	O
such	O
detailed	O
data	O
existed	O
for	O
other	O
coastal	O
regions	O
around	O
the	O
world	O
,	O
it	O
is	O
likely	O
that	O
the	O
number	O
of	O
areas	O
would	O
increase	O
globally	O
.	O
Oxygen	O
is	O
an	O
important	O
parameter	O
in	O
water	O
quality	O
assessments	O
since	O
sufficient	O
oxygen	O
is	O
essential	O
to	O
aquatic	O
life	O
and	O
is	O
necessary	O
to	O
support	O
healthy	O
biological	O
communities	O
.	O
(	O
3	O
)	O
For	O
example	O
,	O
oxygen	O
concentration	O
is	O
a	O
supporting	O
element	O
to	O
the	O
biological	O
quality	O
elements	O
in	O
the	O
European	O
Water	O
Framework	O
Directive	O
,	O
(	O
21	O
)	O
is	O
one	O
of	O
the	O
ecological	O
objectives	O
in	O
the	O
Helsinki	O
Commission	O
'	O
s	O
(	O
HELCOM	O
)	O
eutrophication	O
assessment	O
of	O
the	O
Baltic	O
Sea	O
,	O
and	O
is	O
included	O
in	O
the	O
European	O
Marine	O
Strategy	O
Framework	O
Directive	O
as	O
an	O
effect	O
parameter	O
of	O
eutrophication	O
.	O
Accurate	O
data	O
for	O
the	O
concentration	O
of	O
dissolved	O
oxygen	O
are	O
essential	O
for	O
documenting	O
environmental	O
changes	O
in	O
water	O
resources	O
resulting	O
from	O
natural	O
phenomena	O
and	O
human	O
activities	O
.	O
Reports	O
of	O
hypoxia	O
globally	O
are	O
increasing1	O
,	O
22	O
both	O
due	O
to	O
the	O
recognition	O
of	O
the	O
seriousness	O
of	O
hypoxia	O
on	O
ecosystem	O
functioning	O
and	O
as	O
decades	O
-	O
long	O
monitoring	O
records	O
become	O
available	O
in	O
databases	O
.	O
How	O
the	O
large	O
number	O
of	O
newly	O
identified	O
hypoxic	O
areas	O
influences	O
nutrient	O
biogeochemical	O
cycles	O
and	O
ecosystem	O
services	O
in	O
the	O
coastal	O
zone	O
in	O
the	O
Baltic	O
Sea	O
is	O
currently	O
unknown	O
,	O
although	O
the	O
functioning	O
of	O
the	O
coastal	O
filter	O
certainly	O
plays	O
an	O
important	O
role	O
in	O
how	O
adjacent	O
marine	O
systems	O
respond	O
to	O
changes	O
in	O
nutrient	O
loading	O
.	O
Presently	O
about	O
40	O
%	O
of	O
the	O
world	O
'	O
s	O
population	O
lives	O
within	O
100	O
km	O
of	O
the	O
coastal	O
zone	O
strongly	O
impacting	O
ocean	O
health	O
,	O
(	O
24	O
)	O
including	O
increasing	O
the	O
occurrence	O
of	O
hypoxic	O
areas	O
.	O
1	O
,	O
2	O
What	O
is	O
currently	O
lacking	O
is	O
the	O
link	O
to	O
the	O
driving	O
factors	O
of	O
hypoxia	O
including	O
nutrient	O
enrichment	O
,	O
organic	O
carbon	O
loading	O
and	O
climate	O
change	O
,	O
(	O
25	O
)	O
and	O
a	O
determination	O
of	O
appropriate	O
nutrient	O
loading	O
targets	O
for	O
guidance	O
to	O
managers	O
to	O
ameliorate	O
the	O
devastating	O
impact	O
of	O
hypoxia	O
.	O
(	O
24	O
)	O
Pharmacokinetic	O
-	O
pharmacodynamic	O
analysis	O
.	O
The	O
mean	O
(	O
90	O
%	O
CI	O
)	O
slope	O
estimate	O
from	O
the	O
linezolid	O
concentration	O
-	O
R	O
-	O
R	O
interval	O
analysis	O
was	O
-	O
0	O
.	O
0017	O
(	O
-	O
0	O
.	O
0022	O
to	O
-	O
0	O
.	O
0011	O
)	O
ms	O
/	O
ng	O
/	O
ml	O
.	O
This	O
translates	O
to	O
mean	O
(	O
90	O
%	O
CI	O
)	O
predicted	O
decreases	O
in	O
heart	B-Anatomy
rate	O
of	O
approximately	O
1	O
.	O
5	O
(	O
1	O
.	O
0	O
to	O
2	O
.	O
0	O
)	O
and	O
3	O
.	O
0	O
(	O
2	O
.	O
1	O
to	O
4	O
.	O
1	O
)	O
beats	O
/	O
min	O
at	O
the	O
mean	O
Cmax	O
following	O
the	O
administration	O
of	O
600	O
-	O
and	O
1	O
,	O
200	O
-	O
mg	O
linezolid	O
doses	O
,	O
respectively	O
.	O
The	O
study	O
-	O
specific	O
mean	O
correction	O
factor	O
estimated	O
from	O
baseline	O
data	O
was	O
0	O
.	O
278	O
,	O
which	O
is	O
slightly	O
less	O
than	O
Fridericia	O
'	O
s	O
correction	O
(	O
0	O
.	O
333	O
)	O
.	O
Evaluation	O
of	O
the	O
various	O
correction	O
factors	O
showed	O
that	O
QTcF	O
most	O
appropriately	O
resolves	O
the	O
relationship	O
between	O
the	O
QT	O
interval	O
and	O
the	O
heart	B-Anatomy
rate	O
in	O
the	O
baseline	O
data	O
from	O
the	O
present	O
study	O
.	O
This	O
is	O
evident	O
upon	O
inspection	O
of	O
Fig	O
.	O
4	O
,	O
since	O
the	O
slope	O
between	O
the	O
QTcF	O
interval	O
and	O
the	O
R	O
-	O
R	O
interval	O
is	O
closest	O
to	O
zero	O
when	O
this	O
correction	O
is	O
applied	O
.	O
Fig	O
.	O
4	O
.	O
Evaluation	O
of	O
various	O
heart	B-Anatomy
rate	O
correction	O
factors	O
for	O
the	O
QT	O
interval	O
versus	O
the	O
R	O
-	O
R	O
interval	O
.	O
The	O
predicted	O
line	O
in	O
each	O
figure	O
represents	O
the	O
fit	O
from	O
a	O
linear	O
mixed	O
-	O
effect	O
model	O
with	O
R	O
-	O
R	O
interval	O
as	O
a	O
fixed	O
effect	O
and	O
subject	O
-	O
specific	O
random	O
effects	O
for	O
intercept	O
and	O
slope	O
.	O
The	O
results	O
from	O
the	O
concentration	O
-	O
QTcF	O
analysis	O
are	O
graphically	O
depicted	O
in	O
Fig	O
.	O
5	O
.	O
The	O
mean	O
(	O
90	O
%	O
CI	O
)	O
slope	O
estimate	O
from	O
the	O
linezolid	O
concentration	O
-	O
QTcF	O
analysis	O
was	O
-	O
0	O
.	O
0145	O
(	O
-	O
0	O
.	O
0768	O
to	O
0	O
.	O
0477	O
)	O
ms	O
/	O
mug	O
/	O
ml	O
.	O
At	O
the	O
geometric	O
mean	O
Cmax	O
following	O
the	O
infusion	O
of	O
linezolid	O
at	O
600	O
mg	O
(	O
14	O
.	O
9	O
mug	O
/	O
ml	O
)	O
and	O
1	O
,	O
200	O
mg	O
(	O
30	O
.	O
5	O
mug	O
/	O
ml	O
)	O
,	O
the	O
mean	O
(	O
90	O
%	O
CI	O
)	O
predicted	O
placebo	O
-	O
adjusted	O
changes	O
from	O
the	O
baseline	O
QTcF	O
were	O
-	O
0	O
.	O
217	O
(	O
-	O
1	O
.	O
14	O
to	O
0	O
.	O
710	O
)	O
and	O
-	O
0	O
.	O
444	O
(	O
-	O
2	O
.	O
34	O
to	O
1	O
.	O
45	O
)	O
ms	O
,	O
respectively	O
,	O
thus	O
confirming	O
a	O
lack	O
of	O
a	O
relationship	O
between	O
linezolid	O
concentrations	O
and	O
QTc	O
interval	O
.	O
Fig	O
.	O
5	O
.	O
QTcF	O
interval	O
versus	O
plasma	B-Anatomy
linezolid	O
concentrations	O
.	O
Results	O
primary	B-Anatomy
pancreatic	I-Anatomy
sarcomas	I-Anatomy
are	O
extremely	O
rare	O
.	O
Pancreatic	B-Anatomy
sarcomas	I-Anatomy
are	O
more	O
aggressive	O
than	O
other	O
pancreatic	B-Anatomy
neoplasms	I-Anatomy
.	O
Introduction	O
Hip	B-Anatomy
fractures	O
in	O
the	O
aged	O
constitute	O
a	O
major	O
health	O
problem	O
with	O
substantial	O
morbidity	O
[	O
1	O
]	O
,	O
mortality	O
[	O
2	O
,	O
3	O
]	O
,	O
and	O
,	O
as	O
the	O
ageing	O
population	O
increases	O
,	O
an	O
increasing	O
burden	O
on	O
the	O
health	O
care	O
system	O
[	O
4	O
]	O
.	O
Fracture	O
risk	O
varies	O
markedly	O
between	O
countries	O
[	O
5	O
]	O
.	O
In	O
a	O
study	O
by	O
Kanis	O
et	O
al	O
.	O
[	O
6	O
]	O
,	O
comparing	O
10	O
-	O
year	O
probability	O
of	O
hip	B-Anatomy
fracture	O
,	O
all	O
countries	O
except	O
Norway	O
had	O
lower	O
risk	O
than	O
Sweden	O
.	O
Other	O
countries	O
categorized	O
at	O
very	O
high	O
risk	O
(	O
>	O
75	O
%	O
of	O
the	O
risk	O
of	O
Sweden	O
)	O
were	O
Iceland	O
,	O
Denmark	O
and	O
the	O
US	O
.	O
At	O
the	O
age	O
of	O
80	O
,	O
the	O
estimated	O
probability	O
of	O
sustaining	O
a	O
hip	B-Anatomy
fracture	O
the	O
next	O
10	O
years	O
is	O
8	O
.	O
6	O
%	O
and	O
17	O
.	O
7	O
%	O
in	O
Norwegian	O
men	O
and	O
women	O
,	O
respectively	O
[	O
7	O
]	O
,	O
and	O
a	O
report	O
from	O
the	O
Norwegian	O
capital	O
Oslo	O
calculated	O
an	O
overall	O
annual	O
fracture	O
rate	O
of	O
118	O
.	O
0	O
in	O
women	O
and	O
44	O
.	O
0	O
in	O
men	O
per	O
10	O
,	O
000	O
[	O
8	O
]	O
.	O
Several	O
recent	O
studies	O
are	O
reporting	O
declining	O
fracture	O
incidence	O
[	O
9	O
-	O
14	O
]	O
.	O
Although	O
the	O
Norwegian	O
hip	B-Anatomy
fracture	O
rates	O
remain	O
the	O
highest	O
reported	O
in	O
the	O
world	O
,	O
data	O
from	O
Oslo	O
in	O
1996	O
-	O
1997	O
indicated	O
no	O
increasing	O
incidence	O
rates	O
compared	O
to	O
the	O
1988	O
-	O
1989	O
[	O
8	O
]	O
.	O
Within	O
Norway	O
,	O
considerable	O
geographic	O
differences	O
have	O
been	O
reported	O
,	O
with	O
substantially	O
lower	O
rates	O
in	O
smaller	O
cities	O
and	O
rural	O
areas	O
compared	O
to	O
Oslo	O
[	O
7	O
,	O
15	O
]	O
.	O
However	O
,	O
these	O
are	O
reports	O
based	O
on	O
sporadic	O
studies	O
in	O
few	O
regions	O
and	O
in	O
limited	O
time	O
periods	O
[	O
16	O
,	O
17	O
]	O
.	O
From	O
1985	O
to	O
2003	O
,	O
the	O
Norwegian	O
Institute	O
of	O
Public	O
Health	O
commissioned	O
four	O
Norwegian	O
hospitals	O
,	O
representing	O
10	O
%	O
of	O
the	O
population	O
,	O
to	O
run	O
a	O
national	O
injury	O
registry	O
[	O
18	O
]	O
.	O
The	O
registry	O
collected	O
a	O
variety	O
of	O
data	O
connected	O
to	O
the	O
actual	O
injury	O
itself	O
and	O
the	O
event	O
leading	O
to	O
the	O
injury	O
.	O
In	O
the	O
city	O
of	O
Harstad	O
in	O
Northern	O
Norway	O
,	O
the	O
registration	O
continued	O
and	O
has	O
been	O
running	O
for	O
more	O
than	O
23	O
years	O
.	O
Throughout	O
the	O
years	O
of	O
the	O
National	O
Injury	O
Registry	O
,	O
the	O
injury	O
rates	O
in	O
Harstad	O
closely	O
resembled	O
the	O
rates	O
of	O
the	O
national	O
registry	O
[	O
18	O
]	O
.	O
With	O
reference	O
to	O
the	O
recent	O
reports	O
suggesting	O
stabilizing	O
hip	B-Anatomy
fracture	O
incidence	O
internationally	O
as	O
well	O
as	O
nationally	O
,	O
and	O
regional	O
differences	O
within	O
Norway	O
,	O
we	O
have	O
used	O
the	O
hip	B-Anatomy
fracture	O
data	O
in	O
the	O
Harstad	O
Injury	O
Registry	O
to	O
:	O
Describe	O
age	O
-	O
and	O
sex	O
-	O
specific	O
incidence	O
of	O
hip	B-Anatomy
fractures	O
in	O
Harstad	O
,	O
Northern	O
Norway	O
and	O
make	O
comparison	O
with	O
rates	O
from	O
the	O
Norwegian	O
capital	O
Oslo	O
Describe	O
time	O
trends	O
in	O
hip	B-Anatomy
fracture	O
incidence	O
in	O
Harstad	O
from	O
1994	O
to	O
2008	O
Describe	O
place	O
of	O
injury	O
and	O
seasonal	O
variations	O
in	O
hip	B-Anatomy
fracture	O
incidence	O
in	O
Harstad	O
Compare	O
3	O
-	O
month	O
,	O
6	O
-	O
month	O
,	O
and	O
1	O
-	O
year	O
mortality	O
after	O
hip	B-Anatomy
fracture	O
between	O
women	O
and	O
men	O
in	O
Harstad	O
(	O
a	O
)	O
The	O
Tn6087	O
target	O
site	O
within	O
S	O
.	O
oralis	O
F	O
.	O
MI	O
.	O
5	O
.	O
(	O
b	O
)	O
The	O
left	O
end	O
and	O
(	O
c	O
)	O
right	O
end	O
of	O
Tn6087	O
are	O
shown	O
in	O
bold	O
.	O
(	O
d	O
)	O
The	O
joint	O
of	O
the	O
circular	O
intermediate	O
of	O
Tn6087	O
is	O
shown	O
.	O
The	O
transposon	O
'	O
s	O
coupling	O
sequences	O
are	O
shown	O
in	O
bold	O
italics	O
.	O
As	O
can	O
be	O
seen	O
in	O
(	O
d	O
)	O
,	O
the	O
coupling	O
sequence	O
at	O
the	O
joint	O
of	O
the	O
circular	O
form	O
is	O
a	O
heteroduplex	O
.	O
Breeding	O
of	O
p53	O
mice	O
with	O
BCCIP	O
conditional	O
knockdown	O
mice	O
The	O
heterozygous	O
p53	O
knockout	O
mice	O
[	O
36	O
]	O
were	O
crossed	O
with	O
LoxPshBCCIP	O
+	O
/	O
+	O
-	O
4	O
mouse	O
and	O
EIIaCre	O
+	O
/	O
+	O
mouse	O
respectively	O
to	O
generate	O
p53	O
+	O
/	O
-	O
;	O
LoxPshBCCIP	O
+	O
/	O
-	O
,	O
and	O
p53	O
+	O
/	O
-	O
;	O
EIIaCre	O
+	O
/	O
-	O
mice	O
.	O
The	O
PCR	O
primers	O
used	O
to	O
genotype	O
p53	O
are	O
:	O
p53ex6F	O
:	O
5	O
'	O
-	O
GTATCCCGAGTATCTGGAAGACAG	O
-	O
3	O
'	O
,	O
p53neoF	O
:	O
5	O
'	O
-	O
GCCTTCTATCGCCTTCTTGACG	O
-	O
3	O
'	O
,	O
p53ex7RN	O
:	O
5	O
'	O
-	O
AAGGATAGGTCGGCGGTTCATGC	O
-	O
3	O
'	O
.	O
The	O
same	O
PCR	O
primer	O
pairs	O
as	O
described	O
earlier	O
in	O
this	O
report	O
were	O
used	O
for	O
BCCIPshRNA	O
and	O
EIIaCre	O
genotyping	O
.	O
The	O
p53	O
+	O
/	O
-	O
;	O
LoxPshBCCIP	O
+	O
/	O
+	O
mice	O
were	O
obtained	O
by	O
crossing	O
p53	O
+	O
/	O
-	O
;	O
LoxPshBCCIP	O
+	O
/	O
-	O
females	O
with	O
p53	O
+	O
/	O
-	O
;	O
LoxPshBCCIP	O
+	O
/	O
-	O
males	O
.	O
The	O
p53	O
+	O
/	O
-	O
;	O
LoxPshBCCIP	O
+	O
/	O
+	O
or	O
p53	O
+	O
/	O
-	O
;	O
LoxPshBCCIP	O
+	O
/	O
-	O
mice	O
were	O
crossed	O
with	O
p53	O
+	O
/	O
-	O
;	O
EIIaCre	O
+	O
/	O
-	O
mice	O
respectively	O
.	O
Biochemical	O
traits	O
ERK	O
signaling	O
is	O
involved	O
in	O
decreasing	O
BDNF	O
-	O
induced	O
gene	O
activity	O
via	O
Eph	O
receptors	O
Data	O
provided	O
so	O
far	O
suggest	O
that	O
ephrin	O
-	O
A5	O
might	O
counteract	O
BDNF	O
-	O
mediated	O
gene	O
expression	O
and	O
growth	B-Anatomy
cone	I-Anatomy
responses	O
via	O
decreasing	O
ERK	O
activity	O
and	O
nuclear	B-Anatomy
localization	O
(	O
Figs	O
.	O
2	O
and	O
3	O
)	O
.	O
To	O
test	O
this	O
hypothesis	O
more	O
directly	O
,	O
we	O
analyzed	O
whether	O
Eph	O
forward	O
signaling	O
can	O
still	O
suppress	O
BDNF	O
-	O
stimulated	O
IEG	O
induction	O
and	O
growth	B-Anatomy
cone	I-Anatomy
collapse	O
when	O
ERK	O
kinase	O
activity	O
was	O
experimentally	O
raised	O
.	O
For	O
this	O
,	O
ERK	O
activity	O
was	O
elevated	O
by	O
expressing	O
constitutively	O
-	O
active	O
MEK1	O
(	O
CA	O
-	O
MEK1	O
)	O
,	O
an	O
ERK	O
upstream	O
activator	O
,	O
in	O
cortical	B-Anatomy
neurons	I-Anatomy
(	O
Fig	O
.	O
S3	O
)	O
.	O
Subsequently	O
,	O
neurons	B-Anatomy
were	O
subjected	O
to	O
either	O
an	O
ephrin	O
-	O
A5	O
mediated	O
growth	B-Anatomy
cone	I-Anatomy
collapse	O
assay	O
(	O
Fig	O
.	O
5	O
)	O
or	O
stimulated	O
with	O
guidance	O
cues	O
for	O
20	O
minutes	O
and	O
IEG	O
mRNA	O
levels	O
were	O
quantified	O
via	O
qRT	O
-	O
PCR	O
(	O
Fig	O
.	O
6	O
)	O
.	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0026089	O
.	O
g005	O
Figure	O
5	O
Constitutively	O
-	O
active	O
MEK1	O
blocks	O
ephrin	O
-	O
A5	O
mediated	O
growth	B-Anatomy
cone	I-Anatomy
collapse	O
.	O
Wild	O
-	O
type	O
neurons	B-Anatomy
were	O
electroporated	O
with	O
vectors	O
expressing	O
GFP	O
(	O
control	O
;	O
A	O
,	O
C	O
,	O
E	O
)	O
or	O
expressing	O
a	O
FLAG	O
-	O
tagged	O
constitutively	O
-	O
active	O
MEK1	O
(	O
CA	O
-	O
MEK1	O
;	O
B	O
,	O
D	O
,	O
F	O
)	O
.	O
Neurons	B-Anatomy
were	O
treated	O
with	O
ephrin	O
-	O
A5	O
-	O
Fc	O
for	O
30	O
min	O
followed	O
by	O
visualization	O
of	O
GFP	O
(	O
A	O
,	O
C	O
,	O
E	O
)	O
or	O
CA	O
-	O
MEK	O
-	O
1	O
(	O
green	O
in	O
B	O
,	O
D	O
,	O
F	O
)	O
,	O
F	O
-	O
actin	O
and	O
betaIII	O
tubulin	O
.	O
(	O
A	O
,	O
B	O
)	O
Overexpression	O
of	O
CA	O
-	O
MEK1	O
(	O
B	O
)	O
reduces	O
mean	O
neurite	B-Anatomy
length	O
compared	O
to	O
a	O
control	O
GFP	O
-	O
expressing	O
neuron	B-Anatomy
(	O
A	O
)	O
.	O
(	O
C	O
-	O
F	O
)	O
A	O
control	O
growth	B-Anatomy
cone	I-Anatomy
without	O
ephrin	O
-	O
A5	O
application	O
(	O
C	O
)	O
typically	O
protrudes	O
multiple	O
filopodia	B-Anatomy
(	O
arrow	O
)	O
.	O
CA	O
-	O
MEK	O
-	O
1	O
expressing	O
growth	B-Anatomy
cones	I-Anatomy
(	O
D	O
)	O
were	O
indistinguishable	O
from	O
a	O
GFP	O
-	O
expressing	O
growth	B-Anatomy
cone	I-Anatomy
.	O
Note	O
that	O
CA	O
-	O
MEK1	O
was	O
expressed	O
in	O
a	O
dot	O
-	O
like	O
pattern	O
in	O
the	O
growth	B-Anatomy
cone	I-Anatomy
(	O
arrowheads	O
in	O
D	O
and	O
F	O
)	O
.	O
Upon	O
ephrin	O
-	O
A5	O
application	O
,	O
a	O
control	O
growth	B-Anatomy
cone	I-Anatomy
(	O
E	O
)	O
collapsed	O
resulting	O
in	O
only	O
few	O
filopodia	B-Anatomy
.	O
In	O
contrast	O
,	O
a	O
CA	O
-	O
MEK1	O
expressing	O
growth	B-Anatomy
cone	I-Anatomy
(	O
F	O
)	O
was	O
only	O
partially	O
collapsed	O
and	O
many	O
filopodia	B-Anatomy
structures	O
were	O
preserved	O
after	O
ephrin	O
-	O
A5	O
induction	O
.	O
(	O
G	O
)	O
Quantification	O
of	O
average	O
neurite	B-Anatomy
length	O
.	O
(	O
H	O
,	O
I	O
)	O
Quantification	O
of	O
growth	B-Anatomy
cone	I-Anatomy
area	O
(	O
H	O
)	O
and	O
filopodia	B-Anatomy
number	O
/	O
growth	B-Anatomy
cone	I-Anatomy
(	O
I	O
)	O
in	O
the	O
four	O
conditions	O
.	O
Ephrin	O
-	O
A5	O
induces	O
a	O
growth	B-Anatomy
cone	I-Anatomy
collapse	O
,	O
resulting	O
in	O
reduced	O
growth	B-Anatomy
cone	I-Anatomy
area	O
and	O
filopodia	B-Anatomy
number	O
in	O
GFP	O
but	O
not	O
CA	O
-	O
MEK1	O
expressing	O
neurons	B-Anatomy
.	O
Scale	O
-	O
bar	O
(	O
A	O
,	O
B	O
)	O
=	O
10	O
microm	O
;	O
(	O
C	O
-	O
F	O
)	O
=	O
2	O
microm	O
.	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0026089	O
.	O
g006	O
Figure	O
6	O
Ephrin	O
-	O
A5	O
suppresses	O
BDNF	O
-	O
induced	O
IEG	O
responses	O
via	O
MAP	O
kinase	O
signaling	O
.	O
Wild	O
-	O
type	O
cortical	B-Anatomy
neurons	I-Anatomy
,	O
mock	O
-	O
electroporated	O
(	O
black	O
bars	O
)	O
or	O
with	O
a	O
vector	O
expressing	O
constitutively	O
-	O
active	O
MEK1	O
(	O
white	O
bars	O
)	O
,	O
were	O
treated	O
with	O
guidance	O
cues	O
for	O
20	O
minutes	O
as	O
depicted	O
,	O
followed	O
by	O
mRNA	O
quantification	O
.	O
In	O
mock	O
-	O
electroporated	O
neurons	B-Anatomy
,	O
BDNF	O
induced	O
an	O
IEG	O
response	O
of	O
c	O
-	O
fos	O
(	O
A	O
)	O
,	O
Egr1	O
(	O
B	O
)	O
,	O
Egr2	O
(	O
C	O
)	O
and	O
Arc	O
(	O
D	O
)	O
.	O
Co	O
-	O
application	O
of	O
ephrin	O
-	O
A5	O
and	O
BDNF	O
reduced	O
mRNA	O
levels	O
of	O
all	O
four	O
IEGs	O
in	O
mock	O
-	O
electroporated	O
neurons	B-Anatomy
(	O
A	O
-	O
D	O
)	O
.	O
In	O
contrast	O
,	O
expression	O
of	O
constitutively	O
-	O
active	O
MEK1	O
prevented	O
Eph	O
forward	O
signaling	O
from	O
suppressing	O
BDNF	O
-	O
evoked	O
IEG	O
responses	O
.	O
This	O
was	O
most	O
evident	O
for	O
the	O
IEGs	O
Egr1	O
(	O
B	O
)	O
and	O
Egr2	O
(	O
C	O
)	O
.	O
First	O
of	O
all	O
,	O
we	O
analyzed	O
the	O
impact	O
of	O
CA	O
-	O
MEK1	O
on	O
neurite	B-Anatomy
outgrowth	O
and	O
ephrin	O
-	O
A5	O
mediated	O
growth	B-Anatomy
cone	I-Anatomy
responses	O
(	O
Fig	O
.	O
5	O
)	O
.	O
The	O
average	O
neurite	B-Anatomy
length	O
of	O
neurons	B-Anatomy
overexpressing	O
CA	O
-	O
MEK1	O
(	O
Fig	O
.	O
5B	O
)	O
was	O
clearly	O
reduced	O
compared	O
to	O
control	O
GFP	O
expressing	O
neurons	B-Anatomy
(	O
Fig	O
.	O
5A	O
;	O
see	O
quantification	O
in	O
(	O
G	O
)	O
)	O
.	O
Growth	B-Anatomy
cones	I-Anatomy
of	O
GFP	O
(	O
C	O
)	O
and	O
CA	O
-	O
MEK1	O
expressing	O
neurons	B-Anatomy
were	O
similar	O
and	O
protruded	O
many	O
filopodia	B-Anatomy
(	O
arrows	O
in	O
Fig	O
.	O
5C	O
-	O
F	O
)	O
.	O
CA	O
-	O
MEK1	O
expression	O
in	O
growth	B-Anatomy
cones	I-Anatomy
was	O
confined	O
to	O
individual	O
dot	O
-	O
like	O
structures	O
(	O
arrowheads	O
in	O
Fig	O
.	O
5D	O
,	O
F	O
)	O
.	O
Ephrin	O
-	O
A5	O
application	O
on	O
a	O
GFP	O
expressing	O
control	O
growth	B-Anatomy
cone	I-Anatomy
(	O
Fig	O
.	O
5E	O
)	O
resulted	O
in	O
a	O
growth	B-Anatomy
cone	I-Anatomy
collapse	O
as	O
revealed	O
by	O
reduced	O
overall	O
growth	B-Anatomy
cone	I-Anatomy
area	O
and	O
filopodia	B-Anatomy
number	O
(	O
quantified	O
in	O
Fig	O
.	O
5H	O
,	O
I	O
)	O
.	O
In	O
contrast	O
,	O
in	O
neurons	B-Anatomy
overexpressing	O
CA	O
-	O
MEK1	O
(	O
Fig	O
.	O
5F	O
)	O
,	O
ephrin	O
-	O
A5	O
induced	O
only	O
a	O
partial	O
growth	B-Anatomy
cone	I-Anatomy
collapse	O
.	O
Thus	O
,	O
growth	B-Anatomy
cone	I-Anatomy
area	O
and	O
filopodia	B-Anatomy
number	O
were	O
not	O
reduced	O
(	O
see	O
Fig	O
.	O
5H	O
,	O
I	O
)	O
.	O
This	O
result	O
suggests	O
that	O
an	O
ephrin	O
-	O
A5	O
induced	O
signaling	O
cascade	O
targets	O
MAP	O
kinase	O
signaling	O
to	O
exert	O
a	O
full	O
growth	B-Anatomy
cone	I-Anatomy
collapse	O
.	O
This	O
result	O
is	O
in	O
contrast	O
to	O
a	O
recent	O
report	O
[	O
46	O
]	O
which	O
excluded	O
ERK	O
signaling	O
downstream	O
of	O
an	O
ephrin	O
-	O
A5	O
mediated	O
growth	B-Anatomy
cone	I-Anatomy
collapse	O
.	O
Next	O
,	O
we	O
tested	O
whether	O
ephrin	O
-	O
A5	O
signaling	O
suppresses	O
ERK	O
kinase	O
signaling	O
also	O
to	O
interfere	O
with	O
BDNF	O
-	O
mediated	O
gene	O
expression	O
(	O
Fig	O
.	O
6	O
)	O
.	O
In	O
agreement	O
with	O
previous	O
results	O
(	O
Fig	O
.	O
4	O
)	O
,	O
in	O
mock	O
-	O
electroporated	O
neurons	B-Anatomy
,	O
ephrin	O
-	O
A5	O
incubation	O
reduced	O
the	O
BDNF	O
-	O
mediated	O
up	O
-	O
regulation	O
of	O
c	O
-	O
fos	O
(	O
Fig	O
.	O
6A	O
)	O
,	O
Egr1	O
(	O
Fig	O
.	O
6B	O
)	O
,	O
Egr2	O
(	O
Fig	O
.	O
6C	O
)	O
and	O
Arc	O
(	O
Fig	O
.	O
6D	O
)	O
mRNA	O
.	O
In	O
contrast	O
,	O
in	O
neurons	B-Anatomy
over	O
-	O
expressing	O
CA	O
-	O
MEK1	O
,	O
ephrin	O
-	O
A5	O
could	O
not	O
suppress	O
BDNF	O
-	O
induced	O
IEG	O
responses	O
to	O
the	O
same	O
degree	O
.	O
Particularly	O
Egr1	O
(	O
Fig	O
.	O
6B	O
)	O
and	O
Egr2	O
(	O
Fig	O
.	O
6C	O
)	O
mRNA	O
levels	O
were	O
almost	O
identical	O
when	O
comparing	O
neurons	B-Anatomy
treated	O
with	O
BDNF	O
alone	O
and	O
neurons	B-Anatomy
with	O
BDNF	O
and	O
ephrin	O
-	O
A5	O
together	O
.	O
Thus	O
,	O
ephrin	O
-	O
A5	O
represses	O
gene	O
activity	O
elicited	O
by	O
BDNF	O
at	O
least	O
in	O
part	O
via	O
MAP	O
kinases	O
.	O
Besides	O
IEGs	O
,	O
we	O
inspected	O
the	O
influence	O
of	O
both	O
guidance	O
cues	O
on	O
cytoskeletal	B-Anatomy
genes	O
,	O
whose	O
gene	O
products	O
might	O
modulate	O
cytoskeletal	B-Anatomy
dynamics	O
evoked	O
by	O
ephrin	O
-	O
As	O
and	O
/	O
or	O
neurotrophins	O
(	O
Fig	O
.	O
S4	O
)	O
.	O
Therefore	O
,	O
the	O
filamentous	B-Anatomy
actin	O
(	O
F	O
-	O
actin	O
)	O
stabilizing	O
tropomyosins	O
(	O
Tpm1	O
and	O
Tpm2	O
)	O
,	O
the	O
F	O
-	O
actin	O
cross	O
-	O
linker	O
alpha	O
-	O
actinin	O
1	O
(	O
Actn1	O
)	O
and	O
the	O
motor	O
protein	O
dynein	O
light	O
chain	O
1	O
(	O
Dnal1	O
)	O
were	O
analyzed	O
.	O
mRNA	O
levels	O
of	O
other	O
cytoskeletal	B-Anatomy
genes	O
were	O
not	O
altered	O
by	O
any	O
of	O
the	O
guidance	O
cues	O
(	O
i	O
.	O
e	O
.	O
cofilin	O
,	O
filamin	O
A	O
,	O
mena	O
,	O
vinculin	O
and	O
smooth	B-Anatomy
muscle	I-Anatomy
actin	O
;	O
data	O
not	O
shown	O
)	O
.	O
Short	O
-	O
term	O
stimulation	O
with	O
guidance	O
cues	O
did	O
not	O
result	O
in	O
major	O
alterations	O
of	O
cytoskeletal	B-Anatomy
mRNA	O
levels	O
except	O
for	O
upregulation	O
of	O
Tpm1	O
by	O
ephrin	O
-	O
A5	O
(	O
Fig	O
.	O
S4A	O
)	O
.	O
At	O
16h	O
of	O
incubation	O
,	O
both	O
tropomyosin	O
genes	O
were	O
induced	O
by	O
BDNF	O
and	O
ephrin	O
-	O
A5	O
alone	O
and	O
both	O
together	O
(	O
Fig	O
.	O
S4B	O
,	O
D	O
)	O
.	O
Actn1	O
levels	O
were	O
induced	O
by	O
individual	O
application	O
of	O
ephrin	O
-	O
A5	O
and	O
BDNF	O
and	O
by	O
co	O
-	O
application	O
of	O
both	O
(	O
Fig	O
.	O
S4F	O
)	O
.	O
A	O
similar	O
profile	O
was	O
observed	O
for	O
the	O
dynein	O
light	O
chain	O
(	O
Fig	O
.	O
S4H	O
)	O
.	O
Taken	O
together	O
,	O
cytoskeletal	B-Anatomy
gene	O
expression	O
was	O
modulated	O
by	O
ephrin	O
-	O
A5	O
and	O
BDNF	O
.	O
In	O
contrast	O
to	O
the	O
antagonistic	O
impact	O
on	O
the	O
IEG	O
gene	O
response	O
(	O
Figs	O
.	O
4	O
and	O
6	O
)	O
,	O
ephrin	O
-	O
A5	O
and	O
BDNF	O
resulted	O
in	O
rather	O
synergistic	O
action	O
on	O
cytoskeletal	B-Anatomy
gene	O
expression	O
.	O
This	O
difference	O
might	O
be	O
due	O
to	O
short	O
-	O
term	O
(	O
i	O
.	O
e	O
.	O
20	O
minutes	O
)	O
vs	O
.	O
long	O
-	O
term	O
(	O
i	O
.	O
e	O
.	O
16h	O
)	O
exposure	O
of	O
both	O
guidance	O
cues	O
in	O
the	O
IEG	O
and	O
cytoskeletal	B-Anatomy
gene	O
response	O
,	O
respectively	O
.	O
Introduction	O
Yeast	O
infections	O
cause	O
significant	O
mortality	O
in	O
critically	O
ill	O
and	O
immunocompromised	O
patients	O
.	O
In	O
particular	O
,	O
Candida	O
species	O
are	O
the	O
4th	O
most	O
common	O
cause	O
of	O
nosocomial	O
bloodstream	B-Anatomy
infections	O
in	O
the	O
United	O
States	O
,	O
and	O
Cryptococcus	O
neoformans	O
,	O
the	O
commonest	O
cause	O
of	O
fungal	O
meningitis	O
worldwide	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O
Whilst	O
Candida	O
albicans	O
remains	O
the	O
leading	O
pathogenic	O
yeast	O
,	O
infections	O
due	O
to	O
non	O
-	O
C	O
.	O
albicans	O
species	O
such	O
as	O
Candida	O
glabrata	O
,	O
as	O
well	O
as	O
previously	O
rare	O
opportunists	O
such	O
as	O
Trichosporon	O
and	O
Geotrichum	O
species	O
,	O
are	O
increasingly	O
reported	O
[	O
1	O
]	O
,	O
[	O
3	O
]	O
-	O
[	O
6	O
]	O
.	O
Novel	O
pathogenic	O
Candida	O
species	O
such	O
as	O
Candida	O
nivariensis	O
and	O
Candida	O
bracarensis	O
have	O
also	O
been	O
described	O
[	O
7	O
]	O
.	O
Since	O
many	O
non	O
-	O
C	O
.	O
albicans	O
Candida	O
and	O
non	O
-	O
Candida	O
yeasts	O
are	O
resistant	O
or	O
less	O
susceptible	O
to	O
antifungal	O
agents	O
,	O
rapid	O
accurate	O
species	O
identification	O
is	O
central	O
to	O
timely	O
,	O
effective	O
antifungal	O
therapy	O
[	O
3	O
]	O
-	O
[	O
6	O
]	O
,	O
[	O
8	O
]	O
,	O
[	O
9	O
]	O
.	O
Conventional	O
phenotypic	O
-	O
based	O
methods	O
for	O
yeast	O
identification	O
,	O
however	O
,	O
are	O
slow	O
(	O
24	O
-	O
72	O
h	O
)	O
,	O
insensitive	O
and	O
often	O
unable	O
to	O
identify	O
more	O
unusual	O
species	O
.	O
Various	O
molecular	O
techniques	O
including	O
real	O
-	O
time	O
PCR	O
,	O
DNA	O
sequence	O
analysis	O
,	O
microarray	O
analysis	O
,	O
and	O
fluorescence	O
in	O
-	O
situ	O
hybridization	O
provide	O
accurate	O
identification	O
[	O
10	O
]	O
,	O
[	O
11	O
]	O
but	O
are	O
expensive	O
,	O
require	O
substantial	O
specimen	B-Anatomy
processing	O
time	O
(	O
hours	O
to	O
a	O
day	O
)	O
and	O
are	O
not	O
easily	O
implemented	O
as	O
routine	O
techniques	O
in	O
the	O
clinical	O
laboratory	O
.	O
Matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
-	O
time	O
of	O
flight	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
TOF	O
MS	O
)	O
has	O
emerged	O
as	O
a	O
powerful	O
and	O
rapid	O
tool	O
for	O
the	O
identification	O
of	O
bacterial	O
and	O
yeast	O
pathogens	O
[	O
12	O
]	O
-	O
[	O
17	O
]	O
.	O
Using	O
MALDI	O
-	O
TOF	O
MS	O
,	O
the	O
protein	O
spectral	O
""""	O
fingerprint	O
""""	O
of	O
an	O
isolate	O
is	O
compared	O
to	O
a	O
reference	O
spectral	O
database	O
for	O
identification	O
[	O
18	O
]	O
.	O
Previous	O
studies	O
have	O
reported	O
species	O
identification	O
rates	O
of	O
92	O
-	O
99	O
%	O
amongst	O
collections	O
of	O
yeasts	O
and	O
yeast	O
-	O
like	O
organisms	O
[	O
14	O
]	O
-	O
[	O
17	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
.	O
However	O
,	O
taken	O
collectively	O
,	O
the	O
results	O
may	O
not	O
be	O
directly	O
comparable	O
since	O
these	O
studies	O
have	O
used	O
different	O
approaches	O
to	O
assign	O
species	O
-	O
from	O
comparing	O
spectra	O
from	O
test	O
organisms	O
to	O
reference	O
spectra	O
in	O
MALDI	O
-	O
TOF	O
MS	O
databases	O
[	O
16	O
]	O
,	O
[	O
20	O
]	O
,	O
to	O
enhancing	O
these	O
databases	O
,	O
and	O
in	O
some	O
instances	O
developing	O
study	O
-	O
specific	O
databases	O
,	O
with	O
""""	O
in	O
-	O
house	O
""""	O
spectral	O
signatures	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
.	O
There	O
also	O
is	O
a	O
continuing	O
need	O
to	O
extend	O
the	O
repository	O
of	O
reference	O
spectra	O
in	O
MALDI	O
-	O
TOF	O
MS	O
databases	O
.	O
We	O
therefore	O
undertook	O
the	O
present	O
study	O
to	O
evaluate	O
the	O
utility	O
of	O
the	O
MALDI	O
Biotyper	O
2	O
.	O
0	O
Microflex	O
LT	O
spectrometer	O
(	O
Bruker	O
Daltonik	O
GmbH	O
;	O
Bremen	O
,	O
Germany	O
)	O
with	O
its	O
current	O
spectral	O
database	O
in	O
comparison	O
with	O
phenotypic	O
-	O
based	O
methods	O
for	O
the	O
identification	O
of	O
a	O
broad	O
range	O
of	O
yeasts	O
in	O
a	O
diagnostic	O
laboratory	O
.	O
The	O
first	O
part	O
of	O
the	O
study	O
comprised	O
testing	O
of	O
reference	O
and	O
clinical	O
strains	B-Anatomy
from	O
our	O
culture	O
collection	O
.	O
The	O
second	O
was	O
a	O
blinded	O
prospective	O
analysis	O
of	O
freshly	O
-	O
collected	O
yeast	O
isolates	O
recovered	O
during	O
routine	O
laboratory	O
work	O
flow	O
;	O
discrepant	O
results	O
between	O
MALDI	O
TOF	O
MS	O
and	O
phenotypic	O
methods	O
were	O
resolved	O
using	O
sequence	O
analysis	O
of	O
the	O
fungal	O
internal	O
transcribed	O
spacer	O
(	O
ITS	O
)	O
regions	O
[	O
21	O
]	O
,	O
[	O
22	O
]	O
.	O
Results	O
obtained	O
by	O
preparation	O
of	O
yeasts	O
by	O
extraction	O
of	O
fungal	O
proteins	O
and	O
by	O
direct	O
application	O
of	O
yeast	O
colonies	B-Anatomy
onto	O
the	O
MALDI	O
TOF	O
MS	O
plate	O
were	O
also	O
compared	O
.	O
Classification	O
result	O
.	O
3	O
.	O
2	O
.	O
Molecular	O
Mechanisms	O
Mediating	O
the	O
Perinatal	O
Beta	B-Anatomy
-	I-Anatomy
Cell	I-Anatomy
Adaptive	O
Response	O
to	O
Early	O
-	O
Life	O
Stressors	O
Molecular	O
mechanisms	O
responsible	O
for	O
impaired	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
mass	O
formation	O
after	O
IUCR	O
or	O
IUPR	O
have	O
come	O
under	O
investigation	O
.	O
First	O
,	O
it	O
has	O
been	O
proposed	O
that	O
IUCR	O
can	O
result	O
in	O
a	O
reduction	O
of	O
the	O
embryonic	B-Anatomy
beta	I-Anatomy
-	I-Anatomy
cell	I-Anatomy
progenitor	I-Anatomy
pool	I-Anatomy
leading	O
to	O
inappropriate	O
postnatal	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
formation	O
.	O
Stanger	O
et	O
al	O
.	O
[	O
108	O
]	O
demonstrated	O
that	O
selective	O
genetic	O
reduction	O
in	O
the	O
size	O
of	O
PDX	O
-	O
1	O
+	O
pancreatic	B-Anatomy
progenitors	I-Anatomy
during	O
the	O
fetal	B-Anatomy
period	O
results	O
in	O
impaired	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
formation	O
during	O
the	O
postnatal	O
period	O
with	O
consequent	O
development	O
of	O
glucose	O
intolerance	O
during	O
adulthood	O
.	O
Consistent	O
with	O
this	O
,	O
maternal	O
food	O
restriction	O
leads	O
to	O
significant	O
reduction	O
in	O
PDX	O
-	O
1	O
+	O
and	O
neurogenin	O
-	O
3	O
+	O
pancreatic	B-Anatomy
precursors	I-Anatomy
during	O
embryonic	B-Anatomy
development	O
in	O
rats	O
,	O
diminished	O
postnatal	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
formation	O
,	O
and	O
inability	O
to	O
expand	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
mass	O
in	O
response	O
to	O
pregnancy	O
[	O
47	O
,	O
94	O
]	O
.	O
The	O
UPI	O
model	O
is	O
also	O
characterized	O
by	O
a	O
permanent	O
decrease	O
in	O
islet	B-Anatomy
PDX	O
-	O
1	O
mRNA	O
expression	O
.	O
This	O
decrease	O
has	O
recently	O
been	O
shown	O
to	O
be	O
due	O
to	O
progressive	O
epigenetic	O
silencing	O
of	O
the	O
Pdx1	O
gene	O
locus	O
secondary	O
to	O
proximal	O
promoter	O
methylation	O
[	O
69	O
,	O
109	O
]	O
,	O
and	O
it	O
may	O
be	O
responsible	O
for	O
the	O
decreased	O
rate	O
of	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
replication	O
and	O
inappropriate	O
postnatal	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
mass	O
development	O
[	O
69	O
,	O
110	O
]	O
.	O
In	O
the	O
same	O
way	O
of	O
thinking	O
,	O
studies	O
have	O
demonstrated	O
that	O
the	O
maintenance	O
of	O
methylated	O
histone	O
H3	O
Lys4	O
by	O
Set7	O
/	O
9	O
,	O
a	O
member	O
of	O
the	O
SET	O
methyltransferase	O
family	O
,	O
is	O
crucial	O
to	O
Pdx1	O
activity	O
in	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
[	O
111	O
-	O
113	O
]	O
.	O
This	O
led	O
to	O
the	O
hypothesis	O
that	O
Set7	O
/	O
9	O
may	O
represent	O
a	O
novel	O
chromatin	O
-	O
modifying	O
protein	O
that	O
functions	O
in	O
part	O
through	O
its	O
recruitment	O
to	O
target	O
genes	O
by	O
cell	B-Anatomy
-	O
specific	O
transcription	O
factors	O
such	O
as	O
Pdx1	O
.	O
Since	O
then	O
,	O
a	O
role	O
of	O
histone	O
methyl	O
transferases	O
,	O
particularly	O
set7	O
,	O
has	O
also	O
been	O
demonstrated	O
in	O
the	O
sustained	O
deleterious	O
effects	O
of	O
chronic	O
hyperglycemia	O
on	O
human	O
microvascular	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
[	O
114	O
]	O
.	O
Such	O
an	O
epigenetic	O
change	O
could	O
potentially	O
be	O
involved	O
in	O
the	O
deleterious	O
effect	O
of	O
high	O
glucose	O
upon	O
the	O
fetal	B-Anatomy
pancreas	I-Anatomy
in	O
the	O
IUED	O
models	O
.	O
Another	O
mechanism	O
proposed	O
to	O
explain	O
reduced	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
formation	O
after	O
IUCR	O
is	O
related	O
to	O
prenatal	O
glucocorticoid	O
exposure	O
.	O
Administration	O
of	O
either	O
dexamethasone	O
or	O
carbenoxolone	O
(	O
to	O
inhibit	O
11	O
beta	O
-	O
hydroxysteroid	O
dehydrogenase	O
type	O
2	O
)	O
to	O
normal	O
pregnant	O
rats	O
also	O
causes	O
fetal	B-Anatomy
growth	O
retardation	O
and	O
the	O
adult	O
offspring	O
are	O
hypertensive	O
and	O
hyperglycemic	O
,	O
with	O
hyperactive	O
hypothalamic	B-Anatomy
-	I-Anatomy
pituitary	I-Anatomy
-	I-Anatomy
adrenal	I-Anatomy
axis	I-Anatomy
[	O
115	O
]	O
.	O
Maternal	O
undernutrition	O
significantly	O
increased	O
both	O
fetal	B-Anatomy
and	O
maternal	O
corticosterone	O
concentrations	O
in	O
rats	O
[	O
116	O
]	O
.	O
Subsequently	O
,	O
maternal	O
and	O
/	O
or	O
fetal	B-Anatomy
overexposure	O
to	O
glucocorticoids	O
(	O
via	O
administration	O
of	O
dexamethasone	O
)	O
impairs	O
both	O
fetal	B-Anatomy
and	O
postnatal	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
formation	O
in	O
rodents	O
and	O
nonhuman	O
primates	O
[	O
94	O
,	O
117	O
-	O
119	O
]	O
.	O
Seckl	O
et	O
al	O
.	O
[	O
115	O
]	O
have	O
shown	O
that	O
fetal	B-Anatomy
corticosterone	O
concentrations	O
are	O
inversely	O
correlated	O
with	O
fetal	B-Anatomy
insulin	O
content	O
and	O
postnatal	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
formation	O
in	O
rats	O
.	O
Evidence	O
suggests	O
that	O
glucocorticoids	O
can	O
exert	O
a	O
direct	O
effect	O
on	O
the	O
developing	O
fetal	B-Anatomy
pancreas	I-Anatomy
via	O
transcriptional	O
modulation	O
of	O
transcription	O
factors	O
involved	O
in	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
formation	O
and	O
differentiation	O
[	O
117	O
]	O
.	O
Glucocorticoid	O
receptors	O
are	O
present	O
in	O
the	O
pancreas	B-Anatomy
during	O
embryonic	B-Anatomy
development	O
of	O
rodents	O
and	O
humans	O
[	O
117	O
]	O
,	O
and	O
glucocorticoids	O
can	O
bind	O
to	O
the	O
Pdx1	O
promoter	O
and	O
thus	O
suppress	O
fetal	B-Anatomy
endocrine	I-Anatomy
cell	I-Anatomy
differentiation	O
[	O
117	O
]	O
.	O
Glucocorticoid	O
treatment	O
has	O
been	O
shown	O
to	O
significantly	O
reduce	O
fetal	B-Anatomy
expression	O
of	O
key	O
endocrine	B-Anatomy
transcription	O
factors	O
such	O
as	O
Pdx1	O
and	O
Pax6	O
but	O
simultaneously	O
increase	O
expression	O
of	O
transcription	O
factors	O
that	O
regulate	O
development	O
of	O
the	O
exocrine	B-Anatomy
pancreas	I-Anatomy
[	O
119	O
]	O
.	O
It	O
has	O
also	O
been	O
demonstrated	O
that	O
the	O
UPI	O
or	O
the	O
low	O
-	O
protein	O
IUPR	O
offspring	O
experience	O
increased	O
oxidative	O
stress	O
and	O
impaired	O
mitochondrial	B-Anatomy
function	O
[	O
96	O
,	O
120	O
]	O
.	O
The	O
mitochondrial	B-Anatomy
dysfunction	O
was	O
not	O
limited	O
to	O
just	O
the	O
beta	B-Anatomy
cell	I-Anatomy
,	O
as	O
mitochondria	B-Anatomy
from	O
both	O
the	O
liver	B-Anatomy
and	O
skeletal	B-Anatomy
muscle	I-Anatomy
exhibit	O
decreased	O
oxidation	O
of	O
pyruvate	O
,	O
subsequently	O
leading	O
to	O
the	O
development	O
of	O
features	O
commonly	O
found	O
in	O
T2D	O
[	O
100	O
,	O
121	O
]	O
.	O
Also	O
exposure	O
to	O
a	O
Western	O
-	O
style	O
diet	O
before	O
and	O
during	O
pregnancy	O
(	O
an	O
IUEO	O
model	O
)	O
alters	O
the	O
redox	O
state	O
as	O
early	O
as	O
preimplantation	O
development	O
,	O
leading	O
to	O
mild	O
oxidative	O
stress	O
associated	O
with	O
inflammation	O
.	O
The	O
finding	O
that	O
administration	O
of	O
antioxidants	O
to	O
the	O
dam	O
reverses	O
oxidative	O
stress	O
and	O
completely	O
prevents	O
the	O
development	O
of	O
glucose	O
intolerance	O
and	O
increased	O
adiposity	O
in	O
the	O
adult	O
offspring	O
suggests	O
that	O
oxidative	O
stress	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
adiposity	O
in	O
this	O
case	O
[	O
122	O
]	O
.	O
Some	O
studies	O
in	O
the	O
low	O
-	O
protein	O
IUPR	O
model	O
have	O
demonstrated	O
that	O
oxidative	O
stress	O
is	O
not	O
limited	O
to	O
just	O
mitochondrial	B-Anatomy
DNA	O
damage	O
,	O
but	O
also	O
to	O
genomic	O
DNA	O
,	O
impacting	O
cell	B-Anatomy
-	O
cycle	O
regulation	O
and	O
gene	O
expression	O
[	O
123	O
]	O
.	O
While	O
DNA	O
is	O
being	O
targeted	O
throughout	O
by	O
ROS	O
,	O
there	O
are	O
particular	O
regions	O
that	O
are	O
known	O
to	O
be	O
more	O
sensitive	O
to	O
ROS	O
-	O
mediated	O
damage	O
,	O
for	O
example	O
,	O
telomeres	B-Anatomy
.	O
Telomeres	B-Anatomy
comprise	O
GC	O
-	O
rich	O
repeats	O
and	O
are	O
found	O
at	O
the	O
ends	O
of	O
each	O
chromosome	B-Anatomy
.	O
They	O
are	O
known	O
to	O
shorten	O
with	O
each	O
cellular	B-Anatomy
division	O
and	O
,	O
hence	O
,	O
can	O
act	O
as	O
a	O
mitotic	O
clock	O
,	O
registering	O
the	O
number	O
of	O
replicative	O
divisions	O
to	O
have	O
taken	O
place	O
within	O
the	O
cell	B-Anatomy
.	O
Investigations	O
using	O
an	O
IUPR	O
model	O
have	O
indeed	O
reported	O
a	O
decrease	O
in	O
longevity	O
in	O
the	O
offspring	O
[	O
123	O
,	O
124	O
]	O
accompanied	O
by	O
reduction	O
in	O
mitochondrial	B-Anatomy
antioxidant	O
defences	O
[	O
96	O
,	O
125	O
]	O
and	O
telomere	B-Anatomy
length	O
in	O
islets	B-Anatomy
[	O
125	O
]	O
.	O
Pancreatic	B-Anatomy
islet	I-Anatomy
development	O
has	O
been	O
shown	O
to	O
be	O
influenced	O
by	O
a	O
number	O
of	O
growth	O
factors	O
including	O
the	O
insulin	O
-	O
like	O
growth	O
factors	O
,	O
IGF	O
-	O
I	O
and	O
IGF	O
-	O
II	O
whose	O
expression	O
in	O
utero	O
is	O
regulated	O
by	O
nutrient	O
and	O
hormone	O
concentrations	O
.	O
IUPR	O
modifies	O
expression	O
of	O
both	O
IGF	O
genes	O
in	O
a	O
variety	O
of	O
fetal	B-Anatomy
tissues	I-Anatomy
.	O
In	O
an	O
IUPR	O
rat	O
model	O
with	O
a	O
decreased	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
mass	O
and	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
replication	O
and	O
an	O
increased	O
rate	O
of	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
apoptosis	O
,	O
gene	O
expression	O
for	O
IGF	O
-	O
II	O
but	O
not	O
IGF	O
-	O
I	O
was	O
found	O
reduced	O
in	O
the	O
fetal	B-Anatomy
pancreas	I-Anatomy
[	O
126	O
]	O
.	O
In	O
a	O
different	O
IUPR	O
model	O
with	O
more	O
severe	O
global	O
food	O
restriction	O
which	O
induced	O
hyperinsulinemia	O
and	O
an	O
increase	O
in	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
mass	O
in	O
their	O
fetuses	B-Anatomy
[	O
90	O
]	O
,	O
the	O
fetal	B-Anatomy
phenotype	O
was	O
unexpectedly	O
associated	O
with	O
an	O
increase	O
in	O
pancreatic	B-Anatomy
IGF	O
-	O
I	O
expression	O
,	O
islet	B-Anatomy
IGF	O
-	O
1R	O
[	O
91	O
]	O
,	O
and	O
IRS	O
-	O
2	O
[	O
92	O
]	O
.	O
In	O
the	O
fetal	B-Anatomy
GK	O
/	O
Par	O
rat	O
exposed	O
to	O
mild	O
hyperglycemia	O
during	O
gestation	O
(	O
a	O
model	O
of	O
IUED	O
)	O
,	O
data	O
from	O
our	O
group	O
suggest	O
that	O
the	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
deficit	O
(	O
reduced	O
by	O
more	O
than	O
50	O
%	O
)	O
starts	O
as	O
early	O
as	O
fetal	B-Anatomy
age	O
E16	O
and	O
reflects	O
decreased	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
proliferation	O
,	O
a	O
limitation	O
of	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
neogenesis	O
from	O
precursors	B-Anatomy
,	O
and	O
increased	O
apoptosis	O
of	O
both	O
beta	B-Anatomy
cells	I-Anatomy
and	O
their	O
precursors	B-Anatomy
[	O
86	O
]	O
.	O
Notably	O
,	O
Pdx1	O
and	O
Neurogenin3	O
expression	O
were	O
decreased	O
on	O
E18	O
but	O
normally	O
expressed	O
on	O
E13	O
[	O
86	O
]	O
.	O
Defective	O
signalling	O
through	O
the	O
Igf2	O
/	O
Igf1	O
-	O
R	O
pathway	O
may	O
represent	O
the	O
primary	O
instrumental	O
anomaly	O
since	O
Igf2	O
and	O
Igf1	O
-	O
R	O
protein	O
expressions	O
are	O
already	O
decreased	O
within	O
the	O
GK	O
/	O
Par	O
pancreatic	B-Anatomy
rudiment	I-Anatomy
at	O
E13	O
,	O
at	O
a	O
time	O
when	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
mass	O
(	O
first	O
wave	O
of	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
expansion	O
)	O
is	O
in	O
fact	O
normal	O
[	O
31	O
]	O
.	O
Low	O
levels	O
of	O
pancreatic	B-Anatomy
Igf2	O
associated	O
with	O
beta	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
mass	O
deficiency	O
are	O
maintained	O
thereafter	O
within	O
the	O
fetal	B-Anatomy
pancreas	I-Anatomy
[	O
87	O
]	O
.	O
Crossbreeding	O
protocols	O
between	O
nondiabetic	O
W	O
and	O
diabetic	O
GK	O
rats	O
showed	O
that	O
,	O
in	O
late	O
gestation	O
(	O
E18	O
)	O
,	O
pancreatic	B-Anatomy
Igf2	O
protein	O
expression	O
was	O
as	O
low	O
in	O
GKmother	O
/	O
GKfather	O
and	O
Wmother	O
/	O
GKfather	O
crosses	O
as	O
in	O
GKmother	O
/	O
GKfather	O
crosses	O
[	O
87	O
]	O
.	O
These	O
findings	O
rather	O
support	O
the	O
hypothesis	O
that	O
the	O
pancreatic	B-Anatomy
Igf2	O
anomaly	O
in	O
the	O
GK	O
diabetic	O
model	O
is	O
linked	O
to	O
a	O
genetic	O
determinism	O
.	O
This	O
view	O
is	O
also	O
consistent	O
with	O
the	O
results	O
of	O
genetic	O
analyses	O
that	O
linked	O
a	O
locus	O
containing	O
the	O
gene	O
encoding	O
Igf2	O
to	O
diabetes	O
in	O
the	O
GK	O
rat	O
[	O
127	O
]	O
.	O
The	O
Igf2	O
gene	O
is	O
subjected	O
to	O
paternal	O
genomic	O
imprinting	O
.	O
However	O
,	O
because	O
the	O
Igf2	O
expression	O
is	O
similarly	O
affected	O
in	O
fetuses	B-Anatomy
,	O
regardless	O
of	O
whether	O
the	O
father	O
is	O
W	O
or	O
GK	O
[	O
87	O
]	O
,	O
we	O
cannot	O
conclude	O
with	O
a	O
simple	O
change	O
of	O
Igf2	O
gene	O
imprinting	O
in	O
the	O
GK	O
rat	O
.	O
Finally	O
,	O
our	O
understanding	O
of	O
the	O
underlying	O
mechanisms	O
for	O
reduced	O
BCM	O
in	O
response	O
to	O
inappropriate	O
perinatal	O
nutrition	O
is	O
growing	O
rapidly	O
.	O
However	O
,	O
the	O
relative	O
contribution	O
of	O
the	O
many	O
intrinsic	O
and	O
extrinsic	O
factors	O
which	O
contribute	O
to	O
the	O
adaptive	O
response	O
of	O
the	O
developing	O
endocrine	B-Anatomy
pancreas	I-Anatomy
is	O
still	O
to	O
be	O
established	O
.	O
Refinement	O
R	O
[	O
F	O
2	O
>	O
2sigma	O
(	O
F	O
2	O
)	O
]	O
=	O
0	O
.	O
052	O
wR	O
(	O
F	O
2	O
)	O
=	O
0	O
.	O
132	O
S	O
=	O
1	O
.	O
02	O
3804	O
reflections	O
229	O
parameters	O
67	O
restraints	O
H	O
-	O
atom	O
parameters	O
constrained	O
Deltarhomax	O
=	O
0	O
.	O
56	O
e	O
A	O
-	O
3	O
Deltarhomin	O
=	O
-	O
0	O
.	O
38	O
e	O
A	O
-	O
3	O
Outcomes	O
The	O
primary	O
outcomes	O
of	O
this	O
study	O
are	O
smoking	O
abstinence	O
rates	O
post	O
release	O
as	O
well	O
as	O
number	O
of	O
days	O
to	O
first	O
cigarette	O
after	O
release	O
.	O
Seven	O
day	O
point	O
-	O
prevalence	O
abstinence	O
will	O
be	O
determined	O
by	O
combining	O
self	O
-	O
reported	O
tobacco	O
use	O
over	O
the	O
prior	O
seven	O
days	O
and	O
urine	B-Anatomy
cotinine	O
assays	O
(	O
below	O
200	O
ng	O
/	O
ml	O
versus	O
200	O
or	O
above	O
)	O
.	O
Participants	O
with	O
self	O
-	O
reported	O
abstinence	O
and	O
cotinine	O
levels	O
below	O
the	O
cut	O
-	O
off	O
will	O
be	O
classified	O
as	O
abstinent	O
.	O
Participants	O
lost	O
to	O
follow	O
-	O
up	O
will	O
be	O
considered	O
non	O
-	O
abstinent	O
.	O
A	O
secondary	O
analysis	O
will	O
examine	O
the	O
effect	O
of	O
length	O
of	O
forced	O
abstinence	O
on	O
quit	O
rates	O
.	O
Abbreviations	O
ARDS	O
:	O
acute	O
respiratory	B-Anatomy
distress	O
syndrome	O
;	O
CMV	O
:	O
conventional	O
mechanical	O
ventilation	O
;	O
HFOV	O
:	O
high	O
-	O
frequency	O
oscillation	O
ventilation	O
;	O
LPS	O
:	O
lipopolysaccharide	O
;	O
PEEP	O
:	O
positive	O
end	O
-	O
expiratory	O
pressure	O
;	O
VILI	O
:	O
ventilator	O
-	O
induced	O
lung	B-Anatomy
injury	O
.	O
TxA2	O
,	O
generated	O
from	O
arachidonic	O
acid	O
by	O
cyclooxygenase	O
1	O
(	O
COX	O
-	O
1	O
)	O
and	O
Tx	O
synthase	O
,	O
further	O
amplifies	O
platelet	B-Anatomy
activation	O
.	O
COX	O
-	O
1	O
converts	O
arachidonic	O
acid	O
into	O
prostaglandin	O
endoperoxides	O
PGG2	O
and	O
PGH2	O
,	O
the	O
latter	O
being	O
,	O
in	O
turn	O
,	O
transformed	O
by	O
Tx	O
synthase	O
into	O
TxA2	O
,	O
a	O
potent	O
amplifier	O
of	O
platelet	B-Anatomy
aggregation	O
with	O
vasoconstrictive	O
properties	O
.	O
At	O
the	O
site	B-Anatomy
of	O
the	O
atheroma	B-Anatomy
rupture	O
,	O
platelet	B-Anatomy
-	O
released	O
TxA2	O
leads	O
to	O
downstream	O
micro	B-Anatomy
-	I-Anatomy
vessel	I-Anatomy
contraction	O
and	O
thrombus	B-Anatomy
propagation	O
(	O
7	O
)	O
.	O
In	O
addition	O
to	O
its	O
role	O
in	O
coagulation	O
,	O
thrombin	O
at	O
extremely	O
low	O
concentrations	O
is	O
one	O
of	O
the	O
major	O
platelet	B-Anatomy
activators	O
(	O
8	O
)	O
.	O
Human	O
platelets	B-Anatomy
express	O
two	O
cell	B-Anatomy
surface	I-Anatomy
G	O
-	O
protein	O
-	O
coupled	O
protease	O
-	O
activated	O
receptors	O
(	O
PARs	O
)	O
for	O
thrombin	O
:	O
PAR	O
-	O
1	O
and	O
PAR	O
-	O
4	O
.	O
By	O
binding	O
the	O
hirudin	O
-	O
like	O
extracellular	B-Anatomy
amino	O
terminal	O
domain	O
(	O
the	O
so	O
-	O
called	O
thrombin	O
receptor	O
)	O
,	O
thrombin	O
activates	O
platelets	B-Anatomy
and	O
smooth	B-Anatomy
muscle	I-Anatomy
cells	I-Anatomy
,	O
thus	O
promoting	O
platelet	B-Anatomy
pro	O
-	O
coagulant	O
activity	O
,	O
shape	O
change	O
,	O
secretion	O
and	O
release	O
of	O
agonists	O
(	O
ADP	O
and	O
TxA2	O
)	O
,	O
expression	O
of	O
P	O
-	O
selectin	O
,	O
activation	O
of	O
the	O
alphaIIbbeta3	O
integrin	O
receptor	O
,	O
and	O
aggregation	O
.	O
Thrombin	O
also	O
binds	O
to	O
GpIbalpha	O
on	O
the	O
surface	B-Anatomy
of	O
platelets	B-Anatomy
,	O
thought	O
to	O
act	O
as	O
a	O
co	O
-	O
factor	O
that	O
localizes	O
the	O
enzyme	O
on	O
the	O
platelet	B-Anatomy
surface	I-Anatomy
and	O
accelerates	O
the	O
hydrolysis	O
of	O
PAR	O
-	O
1	O
(	O
9	O
)	O
.	O
PAR	O
-	O
1	O
and	O
P2Y12	O
cross	O
-	O
react	O
in	O
platelet	B-Anatomy
activation	O
,	O
and	O
Galphaq	O
and	O
Galphai	O
-	O
coupled	O
receptors	O
are	O
involved	O
in	O
this	O
process	O
.	O
Thrombin	O
-	O
dependent	O
platelet	B-Anatomy
aggregation	O
is	O
mediated	O
in	O
part	O
by	O
secreted	O
ADP	O
,	O
acting	O
on	O
the	O
Galphai	O
-	O
linked	O
ADP	O
receptor	O
.	O
By	O
blocking	O
Galphaq	O
via	O
PAR	O
-	O
1	O
and	O
Gbetai	O
via	O
P2Y12	O
,	O
combined	O
inhibition	O
of	O
thrombin	O
and	O
P2Y12	O
receptors	O
leads	O
to	O
a	O
synergistic	O
inhibitory	O
effect	O
on	O
thrombin	O
-	O
induced	O
platelet	B-Anatomy
aggregation	O
(	O
10	O
)	O
.	O
5	O
-	O
HT	O
is	O
a	O
vasoconstrictor	O
agent	O
that	O
binds	O
to	O
5HT	O
-	O
2A	O
receptors	O
and	O
amplifies	O
the	O
platelet	B-Anatomy
response	O
by	O
stimulating	O
shape	O
change	O
and	O
enhancing	O
platelet	B-Anatomy
recruitment	O
at	O
sites	O
of	O
injury	O
(	O
3	O
)	O
.	O
It	O
may	O
also	O
play	O
a	O
pro	O
-	O
coagulant	O
role	O
by	O
promoting	O
the	O
retention	O
of	O
fibrinogen	O
and	O
thrombospondin	O
on	O
the	O
platelet	B-Anatomy
surface	I-Anatomy
.	O
Intraplatelet	B-Anatomy
5	O
-	O
HT	O
stores	O
are	O
implicated	O
in	O
shear	O
-	O
induced	O
platelet	B-Anatomy
aggregation	O
and	O
thrombus	B-Anatomy
propagation	O
(	O
3	O
)	O
.	O
Methods	O
We	O
studied	O
3	O
,	O
574	O
Canadian	O
children	O
,	O
aged	O
7	O
-	O
8	O
yr	O
,	O
enrolled	O
in	O
a	O
population	O
-	O
based	O
birth	O
cohort	O
.	O
Standardized	O
questionnaires	O
were	O
completed	O
by	O
the	O
children	O
'	O
s	O
parents	O
,	O
and	O
data	O
were	O
analyzed	O
by	O
multivariate	O
logistic	O
regression	O
.	O
(	O
iii	O
)	O
HIV	O
testing	O
response	O
rate	O
by	O
educational	O
attainment	O
and	O
gender	O
.	O
Relative	O
phage	O
haplotype	O
frequencies	O
in	O
PAO1	O
samples	O
,	O
(	O
A	O
)	O
planktonic	O
,	O
(	O
B	O
)	O
biofilm	B-Anatomy
4	O
days	O
,	O
(	O
C	O
)	O
biofilm	B-Anatomy
11	O
days	O
.	O
Collaxa	O
BPEL	O
Server	O
Screenshot	O
of	O
Collaxa	O
'	O
s	O
bpelz	O
design	O
tool	O
,	O
building	O
a	O
choreography	O
of	O
GetHAPI	O
and	O
GetUMLS	O
web	O
services	O
Abbreviations	O
Ac	O
-	O
DEVD	O
-	O
AMC	O
=	O
N	O
-	O
acetyl	O
-	O
Asp	O
-	O
Glu	O
-	O
Val	O
-	O
Asp	O
-	O
7	O
-	O
amino	O
-	O
4	O
-	O
methylcoumarin	O
;	O
Ac	O
-	O
DEVD	O
-	O
CHO	O
=	O
N	O
-	O
acetyl	O
-	O
Asp	O
-	O
Glu	O
-	O
Val	O
-	O
Asp	O
-	O
aldehyde	O
;	O
COX	O
=	O
cyclooxygenase	O
;	O
Deltapsim	O
=	O
mitochondrial	B-Anatomy
membrane	I-Anatomy
potential	O
;	O
DAPI	O
=	O
4	O
'	O
,	O
6	O
-	O
diamidino	O
-	O
2	O
-	O
phenylindole	O
;	O
DMEM	O
=	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
;	O
ELISA	O
=	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
;	O
FCS	B-Anatomy
=	O
fetal	B-Anatomy
calf	I-Anatomy
serum	I-Anatomy
;	O
FLS	B-Anatomy
=	O
fibroblast	B-Anatomy
-	I-Anatomy
like	I-Anatomy
synoviocytes	I-Anatomy
;	O
IL	O
=	O
interleukin	O
;	O
JC	O
-	O
1	O
=	O
5	O
,	O
5	O
'	O
,	O
6	O
,	O
6	O
'	O
-	O
tetrachloro	O
-	O
1	O
,	O
1	O
'	O
,	O
3	O
,	O
3	O
'	O
-	O
tetraethylbenzimidazole	O
carbocyanide	O
iodide	O
;	O
MTT	O
=	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
2	O
,	O
5	O
-	O
diphenyltetrazolium	O
bromide	O
;	O
PBS	O
=	O
phosphate	O
-	O
buffered	O
saline	O
;	O
PGE2	O
=	O
prostaglandin	O
E2	O
;	O
RA	O
=	O
rheumatoid	O
arthritis	O
.	O
Authors	O
'	O
contributions	O
FR	O
initiated	O
and	O
designed	O
the	O
research	O
,	O
collected	O
and	O
analyzed	O
the	O
data	O
and	O
wrote	O
the	O
paper	O
.	O
FO	O
was	O
the	O
main	O
supervisor	O
,	O
helped	O
in	O
analysis	O
,	O
and	O
revised	O
and	O
edited	O
the	O
drafts	O
.	O
MN	O
was	O
co	O
-	O
supervisor	O
and	O
revised	O
the	O
drafts	O
.	O
Conclusion	O
Artificial	O
addition	O
of	O
siderophores	O
and	O
HSLs	O
may	O
be	O
a	O
possible	O
method	O
to	O
aid	O
in	O
the	O
identification	O
and	O
isolation	O
of	O
marine	O
bacterial	O
species	O
which	O
are	O
thought	O
to	O
be	O
unknown	O
.	O
Positron	O
emission	O
tomography	O
in	O
a	O
case	O
of	O
intracranial	B-Anatomy
hemangiopericytoma	I-Anatomy
.	O
Due	O
to	O
the	O
low	O
prevalence	O
of	O
hemangiopericytomas	B-Anatomy
(	O
HPCs	B-Anatomy
)	O
,	O
data	O
on	O
the	O
biophysiological	O
characteristics	O
of	O
this	O
tumor	B-Anatomy
are	O
rare	O
.	O
Positron	O
emission	O
tomography	O
(	O
PET	O
)	O
demonstrated	O
a	O
sixfold	O
increased	O
uptake	O
of	O
[	O
11C	O
]	O
methionine	O
and	O
hyperperfusion	O
in	O
the	O
HPC	B-Anatomy
,	O
whereas	O
glucose	O
utilization	O
was	O
decreased	O
in	O
this	O
area	O
.	O
This	O
low	O
glucose	O
utilization	O
is	O
in	O
contrast	O
to	O
the	O
high	O
[	O
11C	O
]	O
methionine	O
uptake	O
and	O
the	O
malignancy	O
of	O
these	O
tumors	B-Anatomy
.	O
The	O
characteristics	O
of	O
HPCs	B-Anatomy
in	O
PET	O
described	O
herein	O
for	O
the	O
first	O
time	O
offer	O
additional	O
diagnostic	O
criteria	O
and	O
may	O
help	O
especially	O
to	O
differentiate	O
these	O
tumors	B-Anatomy
from	O
meningiomas	B-Anatomy
.	O
Thyrotropin	O
receptor	O
:	O
a	O
role	O
for	O
thyroid	B-Anatomy
tumourigenesis	O
?	O
Human	O
thyroid	B-Anatomy
tumours	I-Anatomy
represent	O
an	O
example	O
of	O
the	O
interplay	O
of	O
genetic	O
and	O
non	O
genetic	O
carcinogenesis	O
.	O
Recently	O
,	O
genetic	O
abnormalities	O
in	O
the	O
elements	O
of	O
the	O
Thyrotropin	O
receptor	O
(	O
TSH	O
-	O
R	O
)	O
dependent	O
cAMP	O
regulatory	O
cascade	O
have	O
been	O
found	O
to	O
be	O
involved	O
both	O
in	O
benign	B-Anatomy
and	O
malignant	B-Anatomy
thyroid	I-Anatomy
tumours	I-Anatomy
.	O
The	O
presence	O
of	O
activating	O
mutations	O
has	O
been	O
demonstrated	O
in	O
the	O
TSH	O
-	O
R	O
gene	O
as	O
well	O
as	O
in	O
the	O
Gs	O
alpha	O
protein	O
gene	O
in	O
thyroid	B-Anatomy
toxic	I-Anatomy
adenoma	I-Anatomy
resulting	O
in	O
the	O
constitutive	O
activation	O
of	O
the	O
cAMP	O
pathway	O
and	O
it	O
has	O
been	O
hypothesised	O
that	O
these	O
genetic	O
alterations	O
may	O
play	O
a	O
causative	O
role	O
in	O
the	O
disease	O
.	O
However	O
,	O
recent	O
observations	O
suggest	O
more	O
caution	O
in	O
accepting	O
such	O
a	O
hypothesis	O
.	O
The	O
presence	O
of	O
activating	O
TSH	O
-	O
R	O
mutations	O
has	O
also	O
been	O
demonstrated	O
in	O
differentiated	O
thyroid	B-Anatomy
carcinomas	I-Anatomy
.	O
At	O
present	O
,	O
the	O
percentage	O
of	O
such	O
a	O
modification	O
is	O
low	O
,	O
unless	O
referred	O
to	O
selected	O
series	O
of	O
tumours	B-Anatomy
.	O
Activating	O
mutations	O
of	O
the	O
TSH	O
-	O
R	O
gene	O
have	O
been	O
detected	O
in	O
a	O
group	O
of	O
differentiated	O
carcinomas	B-Anatomy
with	O
high	O
basal	O
adenylyl	O
cyclase	O
activity	O
,	O
and	O
in	O
a	O
few	O
cases	O
of	O
hyperfunctioning	O
thyroid	B-Anatomy
carcinoma	I-Anatomy
.	O
However	O
,	O
the	O
role	O
of	O
the	O
TSH	O
-	O
R	O
-	O
related	O
cAMP	O
pathway	O
alterations	O
in	O
thyroid	B-Anatomy
transformation	O
remains	O
to	O
be	O
elucidated	O
.	O
In	O
this	O
review	O
,	O
the	O
role	O
of	O
TSH	O
-	O
R	O
gene	O
alterations	O
in	O
benign	B-Anatomy
and	O
malignant	B-Anatomy
thyroid	I-Anatomy
neoplasia	I-Anatomy
is	O
examined	O
.	O
[	O
Histopathologic	O
examination	O
of	O
rectal	B-Anatomy
carcinoma	I-Anatomy
]	O
.	O
In	O
patients	O
with	O
rectal	B-Anatomy
carcinoma	I-Anatomy
,	O
the	O
histopathological	O
evaluation	O
of	O
the	O
surgical	B-Anatomy
specimen	I-Anatomy
provides	O
pivotal	O
prognostic	O
and	O
therapeutic	O
information	O
.	O
Important	O
parameters	O
are	O
tumor	B-Anatomy
site	I-Anatomy
,	I-Anatomy
depth	O
of	O
invasion	O
,	O
histological	O
type	O
and	O
grade	O
,	O
pattern	O
of	O
invasion	O
(	O
diffusely	O
infiltrating	O
versus	O
expanding	O
margin	O
)	O
,	O
degree	O
of	O
peritumoral	B-Anatomy
lymphocytic	I-Anatomy
infiltration	O
,	O
and	O
tumor	B-Anatomy
involvement	O
of	O
surgical	B-Anatomy
margins	I-Anatomy
and	O
lymph	B-Anatomy
nodes	I-Anatomy
.	O
Evaluation	O
of	O
the	O
circumferential	B-Anatomy
(	I-Anatomy
deep	I-Anatomy
,	I-Anatomy
lateral	I-Anatomy
)	I-Anatomy
margin	I-Anatomy
is	O
of	O
utmost	O
importance	O
.	O
It	O
should	O
be	O
labeled	O
with	O
ink	O
in	O
the	O
gross	B-Anatomy
specimen	I-Anatomy
and	O
should	O
be	O
examined	O
histologically	O
using	O
several	O
tissue	B-Anatomy
blocks	O
.	O
The	O
number	O
of	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
and	O
the	O
total	O
number	O
of	O
lymph	B-Anatomy
nodes	I-Anatomy
examined	O
should	O
be	O
reported	O
.	O
A	O
histological	O
evaluation	O
of	O
the	O
distal	B-Anatomy
mesorectum	I-Anatomy
in	O
its	O
entirety	O
is	O
recommended	O
to	O
detect	O
discontinuous	O
distal	B-Anatomy
mesorectal	I-Anatomy
tumor	I-Anatomy
spread	O
.	O
The	O
histopathological	O
findings	O
should	O
be	O
summarized	O
using	O
the	O
TNM	O
-	O
classification	O
.	O
Cooccurrence	O
of	O
reduced	O
expression	O
of	O
alpha	O
-	O
catenin	O
and	O
overexpression	O
of	O
p53	O
is	O
a	O
predictor	O
of	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
in	O
early	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Even	O
though	O
the	O
pathological	O
background	O
contributes	O
to	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
,	O
the	O
biological	O
characteristics	O
of	O
tumors	B-Anatomy
have	O
also	O
gained	O
wide	O
attention	O
.	O
In	O
this	O
study	O
,	O
the	O
expression	O
of	O
the	O
cadherin	O
-	O
catenin	O
complex	O
and	O
p53	O
was	O
studied	O
in	O
early	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
Their	O
correlation	O
with	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
and	O
the	O
predictability	O
of	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
,	O
by	O
combining	O
these	O
factors	O
,	O
were	O
also	O
discussed	O
.	O
METHODS	O
:	O
One	O
hundred	O
and	O
one	O
specimens	B-Anatomy
obtained	O
from	O
surgery	O
were	O
studied	O
by	O
immunohistochemistry	O
using	O
monoclonal	O
anti	O
-	O
E	O
-	O
cadherin	O
,	O
anti	O
-	O
alpha	O
-	O
catenin	O
and	O
anti	O
-	O
p53	O
antibodies	O
.	O
RESULTS	O
:	O
Expression	O
of	O
E	O
-	O
cadherin	O
and	O
alpha	O
-	O
catenin	O
was	O
reduced	O
in	O
50	O
.	O
5	O
and	O
64	O
.	O
4	O
%	O
,	O
respectively	O
.	O
p53	O
protein	O
staining	O
was	O
positive	O
in	O
29	O
.	O
7	O
%	O
.	O
There	O
was	O
a	O
significant	O
correlation	O
between	O
E	O
-	O
cadherin	O
and	O
alpha	O
-	O
catenin	O
expression	O
,	O
but	O
no	O
correlation	O
was	O
found	O
between	O
p53	O
expression	O
and	O
E	O
-	O
cadherin	O
or	O
alpha	O
-	O
catenin	O
expression	O
.	O
A	O
reduction	O
in	O
alpha	O
-	O
catenin	O
expression	O
and	O
p53	O
overexpression	O
correlated	O
to	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
,	O
respectively	O
.	O
Multivariate	O
analysis	O
showed	O
that	O
cooccurrence	O
of	O
reduced	O
expression	O
of	O
alpha	O
-	O
catenin	O
and	O
overexpression	O
of	O
p53	O
was	O
an	O
independent	O
factor	O
indicating	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
.	O
CONCLUSION	O
:	O
A	O
study	O
of	O
both	O
alpha	O
-	O
catenin	O
and	O
p53	O
expression	O
may	O
be	O
helpful	O
to	O
predict	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
in	O
early	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
Antisense	O
technologies	O
have	O
a	O
future	O
fighting	O
neurodegenerative	O
diseases	O
.	O
Our	O
growing	O
understanding	O
of	O
the	O
role	O
that	O
unfavorable	O
patterns	O
of	O
gene	O
expression	O
play	O
in	O
the	O
etiology	O
of	O
neurodegenerative	O
disease	O
emphasizes	O
the	O
need	O
for	O
strategies	O
to	O
selectively	O
block	O
the	O
biosynthesis	O
of	O
harmful	O
proteins	O
in	O
the	O
brain	B-Anatomy
.	O
Antisense	O
technologies	O
are	O
ideally	O
suited	O
to	O
this	O
purpose	O
.	O
Tailor	O
-	O
designed	O
to	O
target	O
specific	O
RNA	O
,	O
antisense	O
oligonucleotides	O
and	O
ribozymes	O
offer	O
tools	O
to	O
suppress	O
the	O
production	O
of	O
proteins	O
mediating	O
neurodegeneration	O
.	O
Although	O
technical	O
limitations	O
must	O
still	O
be	O
overcome	O
,	O
the	O
antisense	O
approach	O
represents	O
a	O
novel	O
and	O
exciting	O
strategy	O
for	O
intervention	O
in	O
diseases	O
of	O
the	O
central	B-Anatomy
nervous	I-Anatomy
system	I-Anatomy
.	O
Proto	O
-	O
oncogene	O
N	O
-	O
myc	O
promoter	O
is	O
down	O
regulated	O
by	O
the	O
Wilms	B-Anatomy
'	I-Anatomy
tumor	I-Anatomy
suppressor	O
gene	O
WT1	O
.	O
The	O
Wilms	O
'	O
tumor	O
1	O
(	O
WT1	O
)	O
gene	O
is	O
a	O
tumor	B-Anatomy
suppressor	O
gene	O
that	O
encodes	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
.	O
WT1	O
represses	O
transcription	O
of	O
several	O
growth	O
factors	O
and	O
growth	O
factor	O
receptors	O
.	O
The	O
N	O
-	O
myc	O
proto	O
-	O
oncogene	O
encodes	O
a	O
transcription	O
factor	O
which	O
regulates	O
cell	B-Anatomy
growth	O
and	O
differentiation	O
.	O
N	O
-	O
myc	O
is	O
coexpressed	O
with	O
WT1	O
in	O
the	O
developing	O
kidney	B-Anatomy
and	O
is	O
overexpressed	O
in	O
many	O
Wilms	B-Anatomy
'	I-Anatomy
tumors	I-Anatomy
.	O
Here	O
,	O
we	O
show	O
that	O
the	O
proto	O
-	O
oncogene	O
N	O
-	O
myc	O
promoter	O
was	O
down	O
-	O
regulated	O
by	O
WT1	O
in	O
transient	O
transfection	O
assays	O
.	O
However	O
,	O
mutant	O
WT1	O
(	O
R394W	O
)	O
which	O
has	O
a	O
mutation	O
in	O
the	O
DNA	O
binding	O
domain	O
could	O
not	O
repress	O
the	O
N	O
-	O
myc	O
promoter	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
the	O
oligonucleotides	O
containing	O
the	O
WT1	O
motifs	O
could	O
bind	O
recombinant	O
WT1	O
proteins	O
.	O
This	O
suggests	O
that	O
the	O
repression	O
of	O
the	O
N	O
-	O
myc	O
promoter	O
is	O
mediated	O
through	O
the	O
WT1	O
binding	O
sites	O
.	O
This	O
finding	O
may	O
help	O
to	O
elucidate	O
the	O
relationship	O
of	O
WT1	O
and	O
N	O
-	O
myc	O
in	O
tumorigenesis	O
and	O
renal	B-Anatomy
development	O
.	O
Spacing	O
effects	O
on	O
the	O
memory	O
for	O
faces	B-Anatomy
.	O
25	O
undergraduate	O
women	O
studied	O
12	O
stimulus	O
pictures	O
of	O
female	O
faces	B-Anatomy
successively	O
presented	O
in	O
spaced	O
or	O
massed	O
conditions	O
and	O
made	O
affective	O
judgments	O
for	O
the	O
pictures	O
along	O
a	O
dimension	O
of	O
like	O
to	O
dislike	O
.	O
One	O
week	O
after	O
the	O
exposure	O
(	O
study	O
)	O
period	O
,	O
subjects	O
were	O
given	O
an	O
identification	O
test	O
comprised	O
of	O
photographs	O
of	O
the	O
same	O
female	O
faces	B-Anatomy
with	O
different	O
expressions	O
.	O
Analysis	O
showed	O
that	O
the	O
pictures	O
presented	O
in	O
the	O
spaced	O
condition	O
were	O
more	O
frequently	O
and	O
accurately	O
identified	O
than	O
those	O
presented	O
under	O
the	O
massed	O
condition	O
and	O
that	O
affective	O
judgment	O
was	O
unrelated	O
to	O
conditions	O
of	O
presentation	O
.	O
Tumour	B-Anatomy
-	O
specific	O
distribution	O
of	O
BRCA1	O
promoter	O
region	O
methylation	O
supports	O
a	O
pathogenetic	O
role	O
in	O
breast	B-Anatomy
and	O
ovarian	B-Anatomy
cancer	I-Anatomy
.	O
The	O
role	O
of	O
BRCA1	O
in	O
sporadic	O
breast	B-Anatomy
and	O
ovarian	B-Anatomy
cancers	I-Anatomy
remains	O
elusive	O
.	O
Direct	O
involvement	O
of	O
BRCA1	O
in	O
the	O
development	O
of	O
breast	B-Anatomy
and	O
ovarian	B-Anatomy
cancer	I-Anatomy
is	O
suggested	O
by	O
the	O
finding	O
that	O
the	O
BRCA1	O
promoter	O
region	O
CpG	O
island	O
is	O
methylated	O
in	O
a	O
proportion	O
of	O
breast	B-Anatomy
and	O
ovarian	B-Anatomy
cancers	I-Anatomy
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
incidence	O
of	O
BRCA1	O
promoter	O
region	O
methylation	O
in	O
tumours	B-Anatomy
in	O
which	O
loss	O
of	O
BRCA1	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
pathogenesis	O
(	O
breast	B-Anatomy
and	O
ovarian	B-Anatomy
carcinomas	I-Anatomy
)	O
with	O
the	O
incidence	O
in	O
tumours	B-Anatomy
in	O
which	O
BRCA1	O
is	O
unlikely	O
to	O
play	O
a	O
role	O
in	O
pathogenesis	O
.	O
Promoter	O
region	O
hypermethylation	O
was	O
significantly	O
more	O
common	O
(	O
P	O
<	O
0	O
.	O
008	O
)	O
in	O
breast	B-Anatomy
and	O
ovarian	B-Anatomy
cancer	I-Anatomy
(	O
6	O
/	O
38	O
tumours	B-Anatomy
methylated	O
)	O
than	O
in	O
colon	B-Anatomy
cancer	I-Anatomy
(	O
0	O
/	O
35	O
tumours	B-Anatomy
methylated	O
)	O
or	O
in	O
leukaemias	B-Anatomy
(	O
0	O
/	O
19	O
samples	B-Anatomy
methylated	O
)	O
.	O
The	O
restriction	O
of	O
BRCA1	O
promoter	O
region	O
hypermethylation	O
to	O
breast	B-Anatomy
and	O
ovarian	B-Anatomy
cancer	I-Anatomy
is	O
consistent	O
with	O
a	O
pathogenetic	O
role	O
of	O
BRCA1	O
promoter	O
methylation	O
in	O
these	O
tumours	B-Anatomy
.	O
We	O
suggest	O
that	O
the	O
rarity	O
of	O
observed	O
BRCA1	O
mutations	O
in	O
sporadic	O
breast	B-Anatomy
and	O
ovarian	B-Anatomy
cancer	I-Anatomy
is	O
due	O
to	O
the	O
greater	O
likelihood	O
of	O
BRCA1	O
inactivation	O
by	O
non	O
-	O
mutational	O
mechanisms	O
such	O
as	O
methylation	O
.	O
Regulation	O
of	O
the	O
resident	O
chromosomal	B-Anatomy
copy	O
of	O
c	O
-	O
myc	O
by	O
c	O
-	O
Myb	O
is	O
involved	O
in	O
myeloid	B-Anatomy
leukemogenesis	O
.	O
c	O
-	O
myb	O
is	O
a	O
frequent	O
target	O
of	O
retroviral	O
insertional	O
mutagenesis	O
in	O
murine	O
leukemia	O
virus	O
-	O
induced	O
myeloid	B-Anatomy
leukemia	I-Anatomy
.	O
Induction	O
of	O
the	O
leukemogenic	O
phenotype	O
is	O
generally	O
associated	O
with	O
inappropriate	O
expression	O
of	O
this	O
transcriptional	O
regulator	O
.	O
Despite	O
intensive	O
investigations	O
,	O
the	O
target	O
genes	O
of	O
c	O
-	O
myb	O
that	O
are	O
specifically	O
involved	O
in	O
development	O
of	O
these	O
myeloid	B-Anatomy
lineage	O
neoplasms	B-Anatomy
are	O
still	O
unknown	O
.	O
In	O
vitro	O
assays	O
have	O
indicated	O
that	O
c	O
-	O
myc	O
may	O
be	O
a	O
target	O
gene	O
of	O
c	O
-	O
Myb	O
;	O
however	O
,	O
regulation	O
of	O
the	O
resident	O
chromosomal	B-Anatomy
gene	O
has	O
not	O
yet	O
been	O
demonstrated	O
.	O
To	O
address	O
this	O
question	O
further	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
c	O
-	O
myc	O
in	O
a	O
myeloblastic	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
,	O
M1	B-Anatomy
,	O
expressing	O
a	O
conditionally	O
active	O
c	O
-	O
Myb	O
-	O
estrogen	O
receptor	O
fusion	O
protein	O
(	O
MybER	O
)	O
.	O
Activation	O
of	O
MybER	O
both	O
prevented	O
the	O
growth	O
arrest	O
induced	O
by	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
and	O
rapidly	O
restored	O
c	O
-	O
myc	O
expression	O
in	O
nearly	O
terminal	O
differentiated	O
cells	B-Anatomy
that	O
had	O
been	O
exposed	O
to	O
IL	O
-	O
6	O
for	O
3	O
days	O
.	O
Restoration	O
occurred	O
in	O
the	O
presence	O
of	O
a	O
protein	O
synthesis	O
inhibitor	O
but	O
not	O
after	O
a	O
transcriptional	O
block	O
,	O
indicating	O
that	O
c	O
-	O
myc	O
is	O
a	O
direct	O
,	O
transcriptionally	O
regulated	O
target	O
of	O
c	O
-	O
Myb	O
.	O
c	O
-	O
myc	O
is	O
a	O
major	O
target	O
that	O
transduces	O
Myb	O
'	O
s	O
proliferative	O
signal	O
,	O
as	O
shown	O
by	O
the	O
ability	O
of	O
a	O
c	O
-	O
Myc	O
-	O
estrogen	O
receptor	O
fusion	O
protein	O
alone	O
to	O
also	O
reverse	O
growth	O
arrest	O
in	O
this	O
system	O
.	O
To	O
investigate	O
the	O
possibility	O
that	O
this	O
regulatory	O
connection	O
contributes	O
to	O
Myb	O
'	O
s	O
oncogenicity	O
,	O
we	O
expressed	O
a	O
dominant	O
negative	O
Myb	O
in	O
the	O
myeloid	B-Anatomy
leukemic	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
RI	I-Anatomy
-	I-Anatomy
4	I-Anatomy
-	I-Anatomy
11	I-Anatomy
.	O
In	O
this	O
cell	B-Anatomy
line	I-Anatomy
,	O
c	O
-	O
myb	O
is	O
activated	O
by	O
insertional	O
mutagenesis	O
and	O
cannot	O
be	O
effectively	O
down	O
regulated	O
by	O
cytokine	O
.	O
Myb	O
'	O
s	O
ability	O
to	O
regulate	O
c	O
-	O
myc	O
'	O
s	O
expression	O
was	O
also	O
demonstrated	O
in	O
these	O
cells	B-Anatomy
,	O
showing	O
a	O
mechanism	O
through	O
which	O
the	O
proto	O
-	O
oncogene	O
c	O
-	O
myb	O
can	O
exert	O
its	O
oncogenic	O
potential	O
in	O
myeloid	B-Anatomy
lineage	I-Anatomy
hematopoietic	I-Anatomy
cells	I-Anatomy
.	O
Adenovirus	O
-	O
mediated	O
gene	O
transfer	O
of	O
endostatin	O
in	O
vivo	O
results	O
in	O
high	O
level	O
of	O
transgene	O
expression	O
and	O
inhibition	O
of	O
tumor	B-Anatomy
growth	O
and	O
metastases	O
.	O
Inhibition	O
of	O
angiogenesis	O
has	O
been	O
shown	O
to	O
be	O
an	O
effective	O
strategy	O
in	O
cancer	B-Anatomy
therapy	O
in	O
mice	O
.	O
However	O
,	O
its	O
widespread	O
application	O
has	O
been	O
hampered	O
by	O
difficulties	O
in	O
the	O
large	O
-	O
scale	O
production	O
of	O
the	O
antiangiogenic	O
proteins	O
.	O
This	O
limitation	O
may	O
be	O
resolved	O
by	O
in	O
vivo	O
delivery	O
and	O
expression	O
of	O
the	O
antiangiogenic	O
genes	O
.	O
We	O
have	O
constructed	O
a	O
recombinant	O
adenovirus	O
that	O
expresses	O
murine	O
endostatin	O
that	O
is	O
biologically	O
active	O
both	O
in	O
vitro	O
,	O
as	O
determined	O
in	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
assays	O
,	O
and	O
in	O
vivo	O
,	O
by	O
suppression	O
of	O
angiogenesis	O
induced	O
by	O
vascular	O
endothelial	O
growth	O
factor	O
165	O
.	O
Persistent	O
high	O
serum	B-Anatomy
levels	O
of	O
endostatin	O
(	O
605	O
-	O
1740	O
ng	O
/	O
ml	O
;	O
mean	O
,	O
936	O
ng	O
/	O
ml	O
)	O
were	O
achieved	O
after	O
systemic	O
administration	O
of	O
the	O
vector	O
to	O
nude	O
mice	O
,	O
which	O
resulted	O
in	O
significant	O
reduction	O
of	O
the	O
growth	O
rates	O
and	O
the	O
volumes	O
of	O
JC	B-Anatomy
breast	I-Anatomy
carcinoma	I-Anatomy
and	O
Lewis	B-Anatomy
lung	I-Anatomy
carcinoma	I-Anatomy
(	O
P	O
less	O
than	O
0	O
.	O
001	O
and	O
P	O
less	O
than	O
0	O
.	O
05	O
,	O
respectively	O
)	O
.	O
In	O
addition	O
,	O
the	O
endostatin	O
vector	O
treatment	O
completely	O
prevented	O
the	O
formation	O
of	O
pulmonary	B-Anatomy
micrometastases	I-Anatomy
in	O
Lewis	B-Anatomy
lung	I-Anatomy
carcinoma	I-Anatomy
(	O
P	O
=	O
0	O
.	O
0001	O
)	O
.	O
Immunohistochemical	O
staining	O
of	O
the	O
tumors	B-Anatomy
demonstrated	O
a	O
decreased	O
number	O
of	O
blood	B-Anatomy
vessels	I-Anatomy
in	O
the	O
treatment	O
group	O
versus	O
the	O
controls	O
.	O
In	O
conclusion	O
,	O
the	O
present	O
study	O
clearly	O
demonstrates	O
the	O
potential	O
of	O
vector	O
-	O
mediated	O
antiangiogenic	O
gene	O
therapy	O
as	O
a	O
component	O
in	O
cancer	B-Anatomy
therapy	O
.	O
Abdominal	B-Anatomy
approach	O
for	O
the	O
ligation	O
of	O
bleeding	O
oesophageal	B-Anatomy
varices	I-Anatomy
.	O
The	O
conventional	O
surgical	O
treatment	O
of	O
bleeding	O
oesophageal	B-Anatomy
varices	I-Anatomy
in	O
the	O
emergency	O
situation	O
is	O
based	O
upon	O
the	O
Boerema	O
-	O
Crile	O
operation	O
of	O
transthoracic	B-Anatomy
oesophagotomy	O
and	O
ligation	O
of	O
the	O
varices	B-Anatomy
.	O
This	O
and	O
the	O
other	O
methods	O
of	O
treatment	O
of	O
this	O
condition	O
in	O
current	O
practice	O
are	O
discussed	O
.	O
Two	O
cases	O
are	O
reported	O
in	O
which	O
a	O
transabdominal	B-Anatomy
oesophagogastrotomy	O
was	O
used	O
to	O
approach	O
the	O
site	B-Anatomy
of	O
bleeding	O
.	O
This	O
operation	O
is	O
described	O
and	O
the	O
theoretical	O
and	O
practical	O
advantages	O
it	O
appears	O
to	O
offer	O
over	O
the	O
standard	O
approach	O
are	O
considered	O
.	O
High	O
frequency	O
of	O
hypermethylation	O
at	O
the	O
14	O
-	O
3	O
-	O
3	O
sigma	O
locus	O
leads	O
to	O
gene	O
silencing	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
.	O
Expression	O
of	O
14	O
-	O
3	O
-	O
3	O
final	O
sigma	O
(	O
final	O
sigma	O
)	O
is	O
induced	O
in	O
response	O
to	O
DNA	O
damage	O
,	O
and	O
causes	O
cells	B-Anatomy
to	O
arrest	O
in	O
G	O
(	O
2	O
)	O
.	O
By	O
SAGE	O
(	O
serial	O
analysis	O
of	O
gene	O
expression	O
)	O
analysis	O
,	O
we	O
identified	O
final	O
sigma	O
as	O
a	O
gene	O
whose	O
expression	O
is	O
7	O
-	O
fold	O
lower	O
in	O
breast	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
than	O
in	O
normal	O
breast	B-Anatomy
epithelium	I-Anatomy
.	O
We	O
verified	O
this	O
finding	O
by	O
Northern	O
blot	O
analysis	O
.	O
Remarkably	O
,	O
final	O
sigma	O
mRNA	O
was	O
undetectable	O
in	O
45	O
of	O
48	O
primary	B-Anatomy
breast	I-Anatomy
carcinomas	I-Anatomy
.	O
Genetic	O
alterations	O
at	O
final	O
sigma	O
such	O
as	O
loss	O
of	O
heterozygosity	O
were	O
rare	O
(	O
1	O
/	O
20	O
informative	O
cases	O
)	O
,	O
and	O
no	O
mutations	O
were	O
detected	O
(	O
0	O
/	O
34	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
hypermethylation	O
of	O
CpG	O
islands	O
in	O
the	O
final	O
sigma	O
gene	O
was	O
detected	O
in	O
91	O
%	O
(	O
75	O
/	O
82	O
)	O
of	O
breast	B-Anatomy
tumors	I-Anatomy
and	O
was	O
associated	O
with	O
lack	O
of	O
gene	O
expression	O
.	O
Hypermethylation	O
of	O
final	O
sigma	O
is	O
functionally	O
important	O
,	O
because	O
treatment	O
of	O
final	O
sigma	O
-	O
non	O
-	O
expressing	O
breast	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
with	O
the	O
drug	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
resulted	O
in	O
demethylation	O
of	O
the	O
gene	O
and	O
synthesis	O
of	O
final	O
sigma	O
mRNA	O
.	O
Breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
lacking	O
final	O
sigma	O
expression	O
showed	O
increased	O
number	O
of	O
chromosomal	B-Anatomy
breaks	O
and	O
gaps	O
when	O
exposed	O
to	O
gamma	O
-	O
irradiation	O
.	O
Therefore	O
,	O
it	O
is	O
possible	O
that	O
loss	O
of	O
final	O
sigma	O
expression	O
contributes	O
to	O
malignant	O
transformation	O
by	O
impairing	O
the	O
G	O
(	O
2	O
)	O
cell	B-Anatomy
cycle	O
checkpoint	O
function	O
,	O
thus	O
allowing	O
an	O
accumulation	O
of	O
genetic	O
defects	O
.	O
Hypermethylation	O
and	O
loss	O
of	O
final	O
sigma	O
expression	O
are	O
the	O
most	O
consistent	O
molecular	O
alterations	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
identified	O
so	O
far	O
.	O
Stimulation	O
of	O
the	O
sodium	O
pump	O
by	O
azide	O
and	O
high	O
internal	O
sodium	O
:	O
changes	O
in	O
the	O
number	O
of	O
pumping	O
sites	O
and	O
turnover	O
rate	O
.	O
1	O
.	O
The	O
effects	O
of	O
5	O
mM	O
azide	O
on	O
[	O
3H	O
]	O
ouabain	O
uptake	O
and	O
22Na	O
efflux	O
were	O
determined	O
.	O
Both	O
glycoside	O
uptake	O
and	O
22Na	O
efflux	O
were	O
enhanced	O
by	O
azide	O
.	O
2	O
.	O
Azide	O
stimulated	O
the	O
Na	O
pump	O
in	O
muscles	B-Anatomy
whose	O
pumping	O
sites	O
had	O
been	O
inhibited	O
by	O
ouabain	O
and	O
then	O
transferred	O
to	O
a	O
glycoside	O
-	O
free	O
solution	O
.	O
This	O
stimulation	O
was	O
observed	O
before	O
detecting	O
any	O
recovery	O
of	O
the	O
initial	O
pumping	O
activity	O
.	O
3	O
.	O
When	O
both	O
the	O
resting	O
and	O
the	O
azide	O
-	O
stimulated	O
22Na	O
efflux	O
had	O
been	O
blocked	O
by	O
ouabain	O
,	O
an	O
additional	O
exposure	O
to	O
azide	O
,	O
in	O
a	O
ouabain	O
-	O
free	O
solution	O
,	O
had	O
no	O
further	O
effects	O
on	O
22Na	O
efflux	O
.	O
4	O
.	O
It	O
is	O
concluded	O
that	O
the	O
increase	O
in	O
Na	O
pumping	O
caused	O
by	O
azide	O
is	O
due	O
in	O
part	O
to	O
an	O
increase	O
in	O
the	O
number	O
of	O
pumping	O
sites	O
.	O
5	O
.	O
[	O
3H	O
]	O
ouabain	O
binding	O
was	O
measured	O
in	O
muscles	B-Anatomy
with	O
different	O
intracellular	B-Anatomy
alkali	O
cation	O
concentrations	O
.	O
Variations	O
in	O
[	O
Na	O
]	O
i	O
from	O
15	O
up	O
to	O
50	O
mM	O
did	O
not	O
significantly	O
affect	O
the	O
amount	O
of	O
glycoside	O
bound	O
.	O
A	O
substantial	O
increase	O
in	O
binding	O
occurred	O
when	O
[	O
Na	O
]	O
i	O
reached	O
70	O
mM	O
.	O
6	O
.	O
It	O
is	O
proposed	O
that	O
the	O
increase	O
in	O
Na	O
extrusion	O
that	O
occurs	O
during	O
the	O
recovery	O
of	O
Na	O
loaded	O
muscles	B-Anatomy
mostly	O
results	O
from	O
an	O
increased	O
turnover	O
rate	O
of	O
the	O
pump	O
rather	O
than	O
from	O
an	O
increase	O
in	O
number	O
of	O
pumping	O
sites	O
.	O
Reduced	O
oncogenicity	O
of	O
p190	O
Bcr	O
/	O
Abl	O
F	O
-	O
actin	O
-	O
binding	O
domain	O
mutants	O
.	O
The	O
deregulated	O
Bcr	O
/	O
Abl	O
tyrosine	O
kinase	O
is	O
responsible	O
for	O
the	O
development	O
of	O
Philadelphia	O
(	O
Ph	O
)	O
-	O
positive	O
leukemia	B-Anatomy
in	O
humans	O
.	O
To	O
investigate	O
the	O
significance	O
of	O
the	O
C	O
-	O
terminal	O
Abl	O
actin	O
-	O
binding	O
domain	O
within	O
Bcr	O
/	O
Abl	O
p190	O
in	O
the	O
development	O
of	O
leukemia	B-Anatomy
/	O
lymphoma	B-Anatomy
in	O
vivo	O
,	O
mutant	O
p190	O
DNA	O
constructs	O
were	O
used	O
to	O
generate	O
transgenic	O
mice	O
.	O
Eight	O
founder	O
and	O
progeny	O
mice	O
of	O
5	O
different	O
lines	O
were	O
monitored	O
for	O
leukemogenesis	O
.	O
Latency	O
was	O
markedly	O
increased	O
and	O
occurrence	O
decreased	O
in	O
the	O
p190	O
del	O
C	O
lines	O
as	O
compared	O
with	O
nonmutated	O
p190	O
BCR	O
/	O
ABL	O
transgenics	O
.	O
Western	O
blot	O
analysis	O
of	O
involved	O
hematologic	B-Anatomy
tissues	I-Anatomy
of	O
the	O
p190	O
del	O
C	O
transgenics	O
with	O
end	O
-	O
stage	O
disease	O
showed	O
high	O
-	O
level	O
expression	O
of	O
the	O
transgene	O
and	O
tyrosine	O
phosphorylation	O
of	O
Cbl	O
and	O
Hef1	O
/	O
Cas	O
,	O
proteins	O
previously	O
shown	O
to	O
be	O
affected	O
by	O
Bcr	O
/	O
Abl	O
.	O
These	O
results	O
show	O
that	O
the	O
actin	O
-	O
binding	O
domain	O
of	O
Abl	O
enhances	O
leukemia	B-Anatomy
development	O
but	O
does	O
not	O
appear	O
to	O
be	O
an	O
absolute	O
requirement	O
for	O
leukemogenesis	O
.	O
Building	O
the	O
vertebrate	O
vasculature	B-Anatomy
:	O
research	O
is	O
going	O
swimmingly	O
.	O
The	O
vertebrate	O
vasculature	B-Anatomy
develops	O
in	O
remarkably	O
similar	O
fashion	O
in	O
all	O
vertebrates	O
.	O
A	O
cohort	O
of	O
unspecified	O
mesodermal	B-Anatomy
cells	I-Anatomy
differentiates	O
into	O
primitive	O
endothelial	B-Anatomy
cells	I-Anatomy
,	O
which	O
migrate	O
to	O
and	O
occupy	O
positions	O
within	O
the	O
stereotypical	O
blueprint	O
of	O
the	O
primitive	O
vasculature	B-Anatomy
.	O
Once	O
in	O
position	O
,	O
these	O
cells	B-Anatomy
coalesce	O
and	O
form	O
cords	B-Anatomy
,	O
which	O
lumenize	O
and	O
become	O
ensheathed	O
by	O
supporting	O
pericytes	B-Anatomy
and	O
smooth	B-Anatomy
muscle	I-Anatomy
cells	I-Anatomy
.	O
This	O
primitive	O
vascular	B-Anatomy
network	I-Anatomy
is	O
extensively	O
remodeled	O
in	O
some	O
places	O
,	O
and	O
expanded	O
by	O
sprouting	O
in	O
others	O
.	O
Various	O
studies	O
using	O
the	O
mouse	O
,	O
quail	O
/	O
chick	O
,	O
and	O
frog	O
have	O
uncovered	O
a	O
number	O
of	O
signals	O
that	O
guide	O
these	O
complex	O
processes	O
but	O
many	O
gaps	O
still	O
exist	O
in	O
our	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
the	O
embryonic	B-Anatomy
vasculature	I-Anatomy
is	O
built	O
.	O
Because	O
many	O
questions	O
will	O
require	O
in	O
vivo	O
studies	O
to	O
be	O
properly	O
addressed	O
,	O
the	O
zebrafish	O
,	O
with	O
its	O
unique	O
accessibility	O
to	O
analysis	O
by	O
combined	O
embryological	B-Anatomy
,	O
molecular	O
,	O
and	O
genetic	O
methods	O
,	O
should	O
prove	O
invaluable	O
in	O
identifying	O
new	O
molecules	O
involved	O
in	O
blood	B-Anatomy
vessel	I-Anatomy
development	O
and	O
integrating	O
pathways	O
that	O
influence	O
embryonic	B-Anatomy
blood	I-Anatomy
vessel	I-Anatomy
formation	O
.	O
[	O
Interleukin	O
-	O
18	O
and	O
new	O
drugs	O
.	O
Protective	O
effect	O
against	O
tumor	B-Anatomy
growth	O
and	O
infections	O
]	O
.	O
IL	O
-	O
18	O
,	O
originally	O
identified	O
as	O
interferon	O
-	O
gamma	O
inducing	O
factor	O
(	O
IGIF	O
)	O
,	O
is	O
related	O
to	O
the	O
IL	O
-	O
1	O
family	O
in	O
terms	O
of	O
its	O
structure	O
as	O
well	O
as	O
its	O
processing	O
,	O
receptor	O
,	O
signal	O
transduction	O
pathway	O
and	O
pro	O
-	O
inflammatory	O
properties	O
.	O
IL	O
-	O
18	O
is	O
also	O
functionally	O
related	O
to	O
IL	O
-	O
12	O
,	O
as	O
it	O
induces	O
the	O
production	O
of	O
Th1	O
cytokines	O
and	O
participates	O
in	O
cell	B-Anatomy
-	O
mediated	O
immune	O
cytotoxicity	O
.	O
A	O
summary	O
is	O
made	O
of	O
recent	O
advances	O
in	O
the	O
understanding	O
of	O
IL	O
-	O
18	O
structure	O
,	O
processing	O
,	O
receptor	O
expression	O
and	O
immunoregulatory	O
functions	O
.	O
It	O
focuses	O
on	O
the	O
role	O
of	O
IL	O
-	O
18	O
modulation	O
in	O
tumours	B-Anatomy
,	O
infections	O
and	O
autoimmune	O
and	O
inflammatory	O
diseases	O
.	O
Focal	O
congenital	O
alveolar	B-Anatomy
proteinosis	O
associated	O
with	O
abnormal	O
surfactant	O
protein	O
B	O
messenger	O
RNA	O
.	O
Two	O
siblings	O
presented	O
with	O
typical	O
clinical	O
features	O
of	O
congenital	O
pulmonary	B-Anatomy
alveolar	I-Anatomy
proteinosis	O
(	O
PAP	O
)	O
.	O
Necropsy	O
of	O
one	O
sibling	O
revealed	O
scattered	O
foci	B-Anatomy
of	O
the	O
diagnostic	O
histologic	O
changes	O
in	O
the	O
lung	B-Anatomy
tissue	I-Anatomy
.	O
In	O
contrast	O
to	O
infantile	O
and	O
adult	O
PAP	O
,	O
focal	B-Anatomy
distribution	O
is	O
uncommon	O
in	O
congenital	O
PAP	O
.	O
Defective	O
expression	O
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
receptor	O
was	O
ruled	O
out	O
.	O
The	O
surfactant	O
protein	O
B	O
(	O
SP	O
-	O
B	O
)	O
content	O
in	O
the	O
lung	B-Anatomy
tissue	I-Anatomy
of	O
the	O
autopsied	O
patient	O
was	O
low	O
,	O
and	O
a	O
deletion	O
in	O
the	O
SP	O
-	O
B	O
messenger	O
RNA	O
was	O
detected	O
.	O
We	O
speculate	O
that	O
the	O
PAP	O
in	O
our	O
patients	O
was	O
related	O
to	O
the	O
reduced	O
quantity	O
and	O
/	O
or	O
to	O
the	O
altered	O
quality	O
of	O
SP	O
-	O
B	O
.	O
Tonometry	O
in	O
normal	O
and	O
scarred	O
corneas	B-Anatomy
,	O
and	O
in	O
postkeratoplasty	O
eyes	B-Anatomy
:	O
a	O
comparative	O
study	O
of	O
the	O
Goldmann	O
,	O
the	O
ProTon	O
and	O
the	O
Schiotz	O
tonometers	O
.	O
PURPOSE	O
:	O
Clinical	O
comparison	O
of	O
intraocular	B-Anatomy
pressure	O
(	O
IOP	O
)	O
measured	O
with	O
the	O
Goldmann	O
applanation	O
tonometer	O
(	O
GAT	O
)	O
,	O
the	O
ProTon	O
tonometer	O
(	O
PT	O
)	O
,	O
and	O
the	O
Schiotz	O
tonometer	O
(	O
ST	O
)	O
,	O
in	O
normal	O
eyes	B-Anatomy
,	O
eyes	B-Anatomy
with	O
scarred	O
corneas	B-Anatomy
and	O
postkeratoplasty	O
eyes	B-Anatomy
.	O
MATERIAL	O
AND	O
METHODS	O
:	O
The	O
IOP	O
readings	O
with	O
GAT	O
,	O
PT	O
,	O
and	O
ST	O
were	O
compared	O
in	O
125	O
eyes	B-Anatomy
with	O
normal	O
corneas	B-Anatomy
(	O
Group	O
A	O
)	O
,	O
17	O
eyes	B-Anatomy
with	O
scarred	O
corneas	B-Anatomy
(	O
Group	O
B	O
)	O
,	O
and	O
in	O
21	O
postkeratoplasty	O
eyes	B-Anatomy
(	O
Group	O
C	O
)	O
.	O
The	O
data	O
were	O
statistically	O
analysed	O
at	O
95	O
%	O
confidence	O
interval	O
;	O
linear	O
regression	O
analysis	O
and	O
paired	O
t	O
-	O
test	O
were	O
done	O
.	O
RESULTS	O
:	O
The	O
mean	O
differences	O
and	O
their	O
standard	O
deviation	O
[	O
SD	O
]	O
between	O
GAT	O
and	O
PT	O
readings	O
,	O
and	O
GAT	O
and	O
ST	O
readings	O
respectively	O
were	O
:	O
[	O
1	O
]	O
in	O
Group	O
A	O
:	O
-	O
0	O
.	O
23	O
[	O
SD	O
2	O
.	O
75	O
]	O
mmHg	O
and	O
+	O
0	O
.	O
24	O
[	O
SD	O
3	O
.	O
18	O
]	O
mmHg	O
respectively	O
;	O
[	O
2	O
]	O
in	O
Group	O
B	O
:	O
-	O
1	O
.	O
8	O
[	O
SD	O
12	O
.	O
67	O
]	O
mmHg	O
and	O
-	O
4	O
.	O
5	O
[	O
SD	O
9	O
.	O
95	O
mmHg	O
;	O
and	O
[	O
3	O
]	O
in	O
Group	O
C	O
:	O
+	O
0	O
.	O
24	O
[	O
SD	O
8	O
.	O
72	O
]	O
mmHg	O
and	O
-	O
0	O
.	O
12	O
[	O
SD	O
8	O
.	O
7	O
]	O
mmHg	O
.	O
They	O
were	O
not	O
statistically	O
significant	O
.	O
In	O
Group	O
A	O
the	O
95	O
%	O
confidence	O
interval	O
between	O
GAT	O
and	O
PT	O
readings	O
was	O
-	O
5	O
.	O
27	O
mmHg	O
to	O
5	O
.	O
73	O
mmHg	O
,	O
and	O
between	O
GAT	O
and	O
ST	O
readings	O
,	O
-	O
6	O
.	O
12	O
mmHg	O
to	O
6	O
.	O
59	O
mmHg	O
.	O
Ninety	O
six	O
[	O
77	O
%	O
]	O
eyes	B-Anatomy
with	O
the	O
PT	O
and	O
84	O
[	O
69	O
%	O
]	O
eyes	B-Anatomy
with	O
ST	O
measurements	O
were	O
within	O
3	O
mmHg	O
of	O
GAT	O
pressure	O
.	O
The	O
correlation	O
coefficients	O
[	O
r	O
]	O
for	O
PT	O
and	O
ST	O
were	O
0	O
.	O
93	O
[	O
P	O
=	O
0	O
.	O
0000	O
]	O
and	O
0	O
.	O
88	O
[	O
P	O
=	O
0	O
.	O
0000	O
]	O
respectively	O
.	O
In	O
Group	O
B	O
95	O
%	O
confidence	O
interval	O
between	O
GAT	O
and	O
PT	O
readings	O
was	O
-	O
27	O
.	O
17	O
mmHg	O
to	O
23	O
.	O
51	O
mmHg	O
,	O
and	O
between	O
GAT	O
and	O
ST	O
measurement	O
,	O
-	O
24	O
.	O
37	O
mmHg	O
to	O
15	O
.	O
44	O
mmHg	O
.	O
The	O
correlation	O
coefficients	O
[	O
r	O
]	O
for	O
the	O
PT	O
and	O
ST	O
were	O
0	O
.	O
112	O
[	O
P	O
=	O
0	O
.	O
660	O
]	O
and	O
0	O
.	O
630	O
[	O
P	O
=	O
0	O
.	O
006	O
]	O
respectively	O
.	O
In	O
group	O
C	O
,	O
the	O
95	O
%	O
confidence	O
interval	O
between	O
GAT	O
and	O
PT	O
measurements	O
was	O
-	O
17	O
.	O
20	O
mmHg	O
to	O
17	O
.	O
67	O
mmHg	O
,	O
and	O
between	O
GAT	O
and	O
ST	O
measurements	O
,	O
-	O
17	O
.	O
51	O
mmHg	O
to	O
17	O
.	O
27	O
mmHg	O
.	O
The	O
correlation	O
coefficients	O
[	O
r	O
]	O
for	O
the	O
PT	O
and	O
the	O
ST	O
were	O
0	O
.	O
780	O
[	O
P	O
=	O
0	O
.	O
0000	O
]	O
and	O
0	O
.	O
740	O
[	O
P	O
=	O
0	O
.	O
0001	O
]	O
respectively	O
.	O
CONCLUSIONS	O
:	O
In	O
clinical	O
practice	O
PT	O
appears	O
to	O
have	O
a	O
higher	O
level	O
of	O
accuracy	O
than	O
ST	O
in	O
normal	O
corneas	B-Anatomy
.	O
In	O
scarred	O
corneas	B-Anatomy
and	O
post	O
-	O
penetrating	O
keratoplasty	O
eyes	B-Anatomy
,	O
because	O
of	O
high	O
SD	O
for	O
mean	O
differences	O
and	O
wide	O
confidence	O
interval	O
of	O
95	O
%	O
,	O
both	O
PT	O
and	O
ST	O
are	O
inaccurate	O
in	O
measuring	O
IOP	O
as	O
compared	O
to	O
GAT	O
in	O
such	O
eyes	B-Anatomy
.	O
A	O
small	O
peptide	O
derived	O
from	O
Flt	O
-	O
1	O
(	O
VEGFR	O
-	O
1	O
)	O
functions	O
as	O
an	O
angiogenic	O
inhibitor	O
.	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
an	O
angiogenic	O
stimulator	O
which	O
functions	O
through	O
two	O
endothelial	B-Anatomy
specific	O
tyrosine	O
kinase	O
receptors	O
,	O
Flt	O
-	O
1	O
and	O
Flk	O
-	O
1	O
.	O
In	O
this	O
work	O
,	O
we	O
show	O
that	O
an	O
11	O
-	O
amino	O
acid	O
peptide	O
derived	O
from	O
the	O
second	O
immunoglobulin	O
-	O
like	O
domain	O
of	O
Flt	O
-	O
1	O
functions	O
as	O
an	O
angiogenic	O
inhibitor	O
in	O
chick	O
chorioallantoic	B-Anatomy
membrane	I-Anatomy
and	O
inhibited	O
VEGF	O
-	O
induced	O
vascular	B-Anatomy
permeability	O
in	O
Miles	O
'	O
assay	O
without	O
binding	O
to	O
VEGF	O
directly	O
.	O
Circular	O
dichroism	O
and	O
nuclear	O
magnetic	O
resonance	O
analyses	O
indicate	O
that	O
this	O
peptide	O
forms	O
a	O
stable	O
extended	O
structure	O
in	O
solution	O
,	O
presumably	O
beta	O
-	O
sheet	O
structure	O
and	O
is	O
most	O
likely	O
existing	O
as	O
a	O
dimer	O
.	O
Our	O
results	O
suggest	O
that	O
this	O
small	O
peptide	O
functions	O
as	O
an	O
angiogenic	O
inhibitor	O
by	O
inhibiting	O
VEGF	O
function	O
through	O
a	O
non	O
-	O
VEGF	O
binding	O
mechanism	O
.	O
[	O
H	O
.	O
pylori	O
infection	O
.	O
Our	O
experience	O
with	O
the	O
quadruple	O
and	O
triple	O
therapy	O
as	O
first	O
pharmacologic	O
approach	O
]	O
.	O
For	O
now	O
the	O
most	O
used	O
pharmacological	O
treatment	O
of	O
first	O
instance	O
to	O
eradication	O
of	O
Hp	O
foresees	O
utilization	O
of	O
triple	O
therapy	O
(	O
PPI	O
+	O
two	O
antibiotics	O
)	O
.	O
In	O
our	O
study	O
we	O
have	O
compared	O
this	O
kind	O
of	O
treatment	O
with	O
the	O
quadruple	O
therapy	O
(	O
PPI	O
+	O
three	O
antibiotics	O
)	O
,	O
that	O
have	O
showed	O
a	O
taller	O
percentage	O
of	O
eradication	O
at	O
the	O
end	O
of	O
first	O
therapeutical	O
cycle	O
with	O
a	O
shorter	O
time	O
and	O
lower	O
price	O
of	O
treatment	O
.	O
Coexpression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
p53	O
protein	O
in	O
squamous	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
of	O
the	O
esophagus	B-Anatomy
.	O
OBJECTIVE	O
:	O
p53	O
plays	O
a	O
role	O
in	O
tumor	B-Anatomy
angiogenesis	O
,	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
plays	O
a	O
key	O
role	O
in	O
tumor	B-Anatomy
angiogenesis	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
clarify	O
how	O
expression	O
of	O
p53	O
protein	O
participates	O
in	O
angiogenesis	O
,	O
and	O
whether	O
the	O
coexpression	O
of	O
VEGF	O
and	O
p53	O
protein	O
has	O
a	O
significance	O
for	O
angiogenesis	O
and	O
the	O
clinicopathological	O
features	O
in	O
esophageal	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
(	O
SCC	B-Anatomy
)	O
.	O
METHODS	O
:	O
Tissues	B-Anatomy
samples	I-Anatomy
were	O
taken	O
from	O
60	O
patients	O
with	O
esophageal	B-Anatomy
SCC	I-Anatomy
after	O
surgery	O
.	O
The	O
expression	O
of	O
VEGF	O
and	O
p53	O
protein	O
in	O
these	O
SCC	B-Anatomy
was	O
examined	O
immunohistochemically	O
.	O
Microvessel	B-Anatomy
density	O
(	O
MVD	O
)	O
was	O
determined	O
by	O
counting	O
microvessels	B-Anatomy
in	O
tumor	B-Anatomy
sections	I-Anatomy
stained	O
for	O
Factor	O
VIII	O
-	O
related	O
antigen	O
.	O
Ki	O
-	O
67	O
labeling	O
index	O
(	O
LI	O
)	O
was	O
calculated	O
,	O
based	O
on	O
Ki	O
-	O
67	O
antigen	O
immunostaining	O
,	O
as	O
a	O
proliferative	O
marker	O
.	O
Apoptotic	O
index	O
(	O
AI	O
)	O
was	O
calculated	O
,	O
based	O
on	O
the	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
deoxyuridine	O
triphosphate	O
biotin	O
nick	O
end	O
labeling	O
,	O
to	O
evaluate	O
apoptosis	O
.	O
RESULTS	O
:	O
VEGF	O
expression	O
was	O
observed	O
in	O
58	O
.	O
3	O
%	O
,	O
and	O
p53	O
protein	O
expression	O
was	O
observed	O
in	O
61	O
.	O
7	O
%	O
of	O
the	O
60	O
patients	O
.	O
VEGF	O
and	O
p53	O
protein	O
were	O
significantly	O
coexpressed	O
in	O
26	O
(	O
43	O
.	O
4	O
%	O
)	O
.	O
Histological	O
venous	B-Anatomy
invasion	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
distant	O
metastasis	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
were	O
significantly	O
correlated	O
with	O
p53	O
protein	O
expression	O
.	O
The	O
two	O
parameters	O
were	O
more	O
frequently	O
observed	O
in	O
the	O
SCC	B-Anatomy
with	O
VEGF	O
/	O
p53	O
coexpression	O
than	O
in	O
those	O
without	O
the	O
coexpression	O
.	O
The	O
MVD	O
and	O
Ki	O
-	O
67	O
LI	O
were	O
significantly	O
higher	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
and	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
the	O
AI	O
was	O
significantly	O
lower	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
in	O
the	O
SCC	B-Anatomy
with	O
p53	O
protein	O
expression	O
than	O
in	O
the	O
SCC	B-Anatomy
without	O
it	O
.	O
The	O
MVD	O
and	O
Ki	O
-	O
67	O
LI	O
were	O
higher	O
,	O
and	O
the	O
AI	O
was	O
lower	O
in	O
the	O
SCC	B-Anatomy
with	O
VEGF	O
/	O
p53	O
coexpression	O
than	O
in	O
those	O
without	O
the	O
coexpression	O
.	O
The	O
5	O
-	O
yr	O
survival	O
rate	O
in	O
patients	O
with	O
the	O
coexpression	O
was	O
poorer	O
than	O
in	O
the	O
other	O
patients	O
.	O
CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
mutant	O
p53	O
expression	O
is	O
associated	O
with	O
angiogenesis	O
and	O
distant	O
metastasis	O
in	O
esophageal	B-Anatomy
SCC	I-Anatomy
,	O
and	O
that	O
the	O
coexpression	O
of	O
p53	O
and	O
VEGF	O
may	O
play	O
an	O
important	O
role	O
in	O
angiogenesis	O
,	O
and	O
have	O
important	O
clinical	O
significance	O
.	O
[	O
mRNA	O
expression	O
of	O
metastasis	O
-	O
suppressor	O
gene	O
nm23	O
in	O
carcinoma	B-Anatomy
of	O
buccal	B-Anatomy
mucosa	I-Anatomy
.	O
II	O
.	O
Quantitative	O
reverse	O
transcription	O
PCR	O
amplification	O
]	O
.	O
The	O
nm23	O
gene	O
is	O
a	O
conspicuous	O
metastasis	O
-	O
suppressor	O
gene	O
.	O
The	O
authors	O
detected	O
both	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
mRNA	O
levels	O
in	O
47	O
tissues	B-Anatomy
samples	I-Anatomy
of	O
patients	O
with	O
carcinoma	B-Anatomy
of	O
buccal	B-Anatomy
mucosa	I-Anatomy
(	O
CBM	B-Anatomy
)	O
by	O
quantitative	O
reverse	O
transcription	O
PCR	O
amplification	O
.	O
The	O
results	O
showed	O
that	O
expression	O
levels	O
of	O
both	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
mRNA	O
varied	O
in	O
normal	O
buccal	B-Anatomy
mucosa	I-Anatomy
,	O
leukoplakia	B-Anatomy
,	O
adjacent	O
nontumorous	B-Anatomy
mucosa	I-Anatomy
,	O
submandibular	B-Anatomy
gland	I-Anatomy
,	O
CBM	B-Anatomy
and	O
lymph	B-Anatomy
nodes	I-Anatomy
with	O
or	O
without	O
metastasis	O
.	O
The	O
nm23	O
-	O
H1	O
mRNA	O
expression	O
levels	O
in	O
CBM	B-Anatomy
with	O
lymph	B-Anatomy
nodes	I-Anatomy
metastases	I-Anatomy
were	O
lower	O
than	O
those	O
in	O
CBM	B-Anatomy
without	O
metastases	B-Anatomy
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
while	O
no	O
significance	O
of	O
nm23	O
-	O
H2	O
mRNA	O
expression	O
levels	O
was	O
found	O
between	O
CBM	B-Anatomy
with	O
and	O
CBM	B-Anatomy
without	O
metastasis	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O
The	O
results	O
were	O
comparative	O
to	O
those	O
of	O
Northern	O
blotting	O
of	O
the	O
same	O
cases	O
.	O
The	O
authors	O
concluded	O
that	O
,	O
as	O
also	O
in	O
the	O
study	O
of	O
Northern	O
blotting	O
,	O
the	O
expression	O
of	O
nm23	O
-	O
H1	O
mRNA	O
significantly	O
correlated	O
inversely	O
with	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
in	O
CBM	B-Anatomy
,	O
while	O
the	O
expression	O
of	O
nm23	O
-	O
H2	O
mRNA	O
not	O
.	O
Q	O
-	O
RT	O
-	O
PCR	O
was	O
a	O
useful	O
method	O
to	O
detect	O
the	O
mRNA	O
levels	O
of	O
nm23	O
gene	O
in	O
buccal	B-Anatomy
carcinoma	I-Anatomy
.	O
Neoplastic	B-Anatomy
transformation	O
and	O
tumorigenesis	O
associated	O
with	O
overexpression	O
of	O
phospholipase	O
D	O
isozymes	O
in	O
cultured	O
murine	O
fibroblasts	B-Anatomy
.	O
Phospholipase	O
D	O
(	O
PLD	O
)	O
has	O
been	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
a	O
variety	O
of	O
cellular	B-Anatomy
functions	O
.	O
PLD	O
activity	O
has	O
been	O
shown	O
to	O
be	O
significantly	O
elevated	O
in	O
many	O
tumours	B-Anatomy
and	O
transformed	O
cells	B-Anatomy
,	O
suggesting	O
the	O
possibility	O
that	O
PLD	O
might	O
be	O
involved	O
in	O
tumorigenesis	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
established	O
stable	O
cell	B-Anatomy
lines	I-Anatomy
overexpressing	O
PLD1	O
and	O
PLD2	O
from	O
fibroblast	B-Anatomy
cells	I-Anatomy
.	O
These	O
cells	B-Anatomy
,	O
but	O
not	O
control	O
cells	B-Anatomy
,	O
showed	O
altered	O
growth	O
properties	O
and	O
anchorage	O
-	O
independent	O
growth	O
in	O
soft	O
agar	O
.	O
Both	O
PLD1	O
and	O
PLD2	O
also	O
induced	O
an	O
up	O
-	O
regulation	O
of	O
the	O
activity	O
of	O
matrix	O
metalloprotease	O
-	O
9	O
as	O
detected	O
by	O
zymograms	O
.	O
Furthermore	O
,	O
both	O
PLD1	B-Anatomy
and	O
PLD2	B-Anatomy
transformants	I-Anatomy
,	O
but	O
not	O
vector	B-Anatomy
-	I-Anatomy
transfectants	I-Anatomy
,	O
induced	O
undifferentiated	O
sarcoma	B-Anatomy
when	O
transplanted	O
into	O
nude	O
mice	O
.	O
Both	O
PLD1	O
-	O
and	O
PLD2	O
-	O
mediated	O
cell	B-Anatomy
cycle	O
distributions	O
in	O
stable	O
cell	B-Anatomy
lines	I-Anatomy
revealed	O
an	O
increased	O
fraction	O
of	O
cells	B-Anatomy
in	O
the	O
S	O
phase	O
compared	O
with	O
control	O
cells	B-Anatomy
.	O
Interestingly	O
,	O
the	O
level	O
of	O
cyclin	O
D3	O
protein	O
,	O
known	O
as	O
an	O
activator	O
of	O
G	O
(	O
1	O
)	O
to	O
S	O
phase	O
transition	O
in	O
the	O
cell	B-Anatomy
cycle	O
,	O
was	O
aberrantly	O
high	O
in	O
cells	B-Anatomy
overexpressing	O
PLD1	O
and	O
PLD2	O
compared	O
with	O
control	O
cells	B-Anatomy
.	O
These	O
results	O
suggest	O
that	O
overexpression	O
of	O
PLD	O
isozymes	O
may	O
play	O
an	O
important	O
role	O
in	O
neoplastic	B-Anatomy
transformation	O
.	O
Renormalization	O
group	O
analysis	O
of	O
autoregressive	O
processes	O
and	O
fractional	O
noise	O
.	O
A	O
renormalization	O
group	O
analysis	O
is	O
applied	O
to	O
autoregressive	O
processes	O
with	O
an	O
infinite	O
series	O
of	O
coefficients	O
.	O
A	O
simple	O
fixed	O
point	O
is	O
given	O
by	O
a	O
random	O
walk	O
,	O
and	O
a	O
second	O
class	O
is	O
found	O
that	O
is	O
proportional	O
to	O
the	O
high	O
order	O
coefficients	O
of	O
fractional	O
autoregressive	O
integrated	O
moving	O
average	O
(	O
ARIMA	O
)	O
processes	O
.	O
The	O
approach	O
might	O
be	O
useful	O
to	O
detect	O
nonstationarity	O
in	O
autoregressive	O
processes	O
.	O
Troponin	O
I	O
inhibits	O
capillary	B-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
proliferation	O
by	O
interaction	O
with	O
the	O
cell	B-Anatomy
'	O
s	O
bFGF	O
receptor	O
.	O
Troponin	O
I	O
(	O
TnI	O
)	O
is	O
a	O
novel	O
cartilage	O
-	O
derived	O
angiogenesis	O
inhibitor	O
,	O
first	O
demonstrated	O
by	O
Moses	O
et	O
al	O
.	O
(	O
1999	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
2645	O
-	O
2650	O
)	O
to	O
inhibit	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
and	O
angiogenesis	O
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
and	O
to	O
inhibit	O
metastasis	O
of	O
a	O
wide	O
variety	O
of	O
tumors	B-Anatomy
in	O
vivo	O
.	O
Despite	O
convincing	O
evidence	O
of	O
its	O
efficacy	O
,	O
little	O
is	O
known	O
about	O
the	O
mechanism	O
of	O
action	O
of	O
TnI	O
as	O
an	O
anti	O
-	O
proliferative	O
and	O
anti	O
-	O
angiogenic	O
agent	O
.	O
In	O
the	O
current	O
article	O
we	O
demonstrate	O
that	O
TnI	O
inhibits	O
both	O
bFGF	O
-	O
stimulated	O
and	O
basal	O
levels	O
of	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
,	O
and	O
we	O
hypothesize	O
that	O
this	O
inhibition	O
is	O
occurring	O
,	O
at	O
least	O
in	O
part	O
,	O
via	O
an	O
interaction	O
of	O
TnI	O
with	O
the	O
cell	B-Anatomy
-	I-Anatomy
surface	I-Anatomy
bFGF	O
receptor	O
on	O
capillary	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
We	O
further	O
support	O
this	O
hypothesis	O
by	O
providing	O
the	O
first	O
evidence	O
that	O
TnI	O
can	O
act	O
on	O
nonendothelial	B-Anatomy
as	O
well	O
as	O
endothelial	B-Anatomy
cells	I-Anatomy
and	O
by	O
demonstrating	O
that	O
this	O
inhibitory	O
action	O
is	O
specific	O
for	O
the	O
bFGF	O
receptor	O
on	O
the	O
target	O
cells	B-Anatomy
.	O
Preliminary	O
data	O
suggest	O
that	O
TnI	O
may	O
be	O
competing	O
with	O
bFGF	O
for	O
interaction	O
with	O
the	O
bFGF	O
receptor	O
on	O
responsive	O
cells	B-Anatomy
.	O
RhoA	O
activation	O
promotes	O
transformation	O
and	O
loss	O
of	O
thyroid	B-Anatomy
cell	I-Anatomy
differentiation	O
interfering	O
with	O
thyroid	O
transcription	O
factor	O
-	O
1	O
activity	O
.	O
Highly	O
specialized	O
cells	B-Anatomy
,	O
the	O
thyrocytes	B-Anatomy
,	O
express	O
a	O
thyroid	B-Anatomy
-	O
specific	O
set	O
of	O
genes	O
for	O
thyroglobulin	O
(	O
Tg	O
)	O
,	O
thyroperoxidase	O
,	O
and	O
the	O
transcription	O
factors	O
TTF	O
-	O
1	O
,	O
TTF	O
-	O
2	O
,	O
and	O
Pax	O
-	O
8	O
.	O
The	O
implication	O
of	O
the	O
small	O
GTPase	O
RhoA	O
in	O
TSH	O
-	O
mediated	O
proliferation	O
of	O
FRTL	B-Anatomy
-	I-Anatomy
5	I-Anatomy
rat	I-Anatomy
thyroid	I-Anatomy
cells	I-Anatomy
has	O
been	O
previously	O
demonstrated	O
.	O
To	O
further	O
analyze	O
RhoA	O
function	O
in	O
thyroid	B-Anatomy
cell	I-Anatomy
proliferation	O
and	O
differentiation	O
patterns	O
,	O
we	O
combined	O
transient	O
and	O
stable	O
transfection	O
assays	O
to	O
express	O
different	O
mutant	O
RhoA	O
forms	O
in	O
FRTL	B-Anatomy
-	I-Anatomy
5	I-Anatomy
cells	I-Anatomy
.	O
Constitutively	O
active	O
RhoA	O
(	O
FRTL	B-Anatomy
-	I-Anatomy
5	I-Anatomy
-	I-Anatomy
RhoA	I-Anatomy
QL	I-Anatomy
cells	I-Anatomy
)	O
exhibited	O
a	O
fibroblast	B-Anatomy
-	O
like	O
phenotype	O
with	O
organized	O
actin	B-Anatomy
fibers	I-Anatomy
,	O
whereas	O
cells	B-Anatomy
expressing	O
the	O
RhoA	O
negative	O
dominant	O
phenotype	O
(	O
FRTL	B-Anatomy
-	I-Anatomy
5	I-Anatomy
-	I-Anatomy
RhoA	I-Anatomy
N19	I-Anatomy
cells	I-Anatomy
)	O
present	O
a	O
rounded	O
morphology	O
and	O
lose	O
normal	O
cytoskeletal	B-Anatomy
architecture	O
.	O
In	O
addition	O
,	O
expression	O
of	O
the	O
constitutively	O
active	O
form	O
of	O
RhoA	O
results	O
in	O
TSH	O
-	O
independent	O
proliferation	O
and	O
anchorage	O
-	O
independent	O
growth	O
and	O
induces	O
tumors	B-Anatomy
when	O
inoculated	O
in	O
nude	O
mice	O
.	O
Interestingly	O
,	O
FRTL	B-Anatomy
-	I-Anatomy
5	I-Anatomy
-	I-Anatomy
RhoA	I-Anatomy
QL	I-Anatomy
cells	I-Anatomy
express	O
less	O
Tg	O
and	O
TTF	O
-	O
1	O
than	O
wild	O
-	O
type	O
FRTL	B-Anatomy
-	I-Anatomy
5	I-Anatomy
(	O
FRTL	B-Anatomy
-	I-Anatomy
5	I-Anatomy
-	O
vector	O
)	O
or	O
FRTL	B-Anatomy
-	I-Anatomy
5	I-Anatomy
-	I-Anatomy
RhoA	I-Anatomy
N19	I-Anatomy
,	O
suggesting	O
a	O
loss	O
at	O
the	O
differentiation	O
stage	O
.	O
This	O
effect	O
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
decrease	O
in	O
TTF	O
-	O
1	O
activity	O
,	O
since	O
transient	O
or	O
stable	O
expression	O
of	O
RhoA	B-Anatomy
QL	I-Anatomy
results	O
in	O
a	O
reduction	O
in	O
the	O
activity	O
of	O
the	O
wild	O
-	O
type	O
Tg	O
promoter	O
as	O
well	O
as	O
an	O
artificial	O
promoter	O
the	O
activation	O
of	O
which	O
depends	O
exclusively	O
on	O
TTF	O
-	O
1	O
.	O
The	O
similarity	O
between	O
RhoA	O
effects	O
and	O
thyroid	B-Anatomy
transformation	O
by	O
Ras	O
suggests	O
that	O
RhoA	O
may	O
act	O
as	O
a	O
downstream	O
effector	O
of	O
Ras	O
;	O
in	O
fact	O
,	O
the	O
dominant	O
negative	O
RhoA	O
N19	O
abolished	O
the	O
down	O
-	O
regulatory	O
effect	O
of	O
Ras	O
V12	O
over	O
the	O
Tg	O
promoter	O
.	O
Taken	O
together	O
,	O
these	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
active	O
RhoA	O
is	O
able	O
to	O
transform	O
FRTL	B-Anatomy
-	I-Anatomy
5	I-Anatomy
cells	I-Anatomy
and	O
that	O
this	O
effect	O
is	O
coupled	O
to	O
a	O
loss	O
of	O
thyroid	B-Anatomy
differentiation	O
due	O
to	O
impaired	O
TTF	O
-	O
1	O
activity	O
.	O
Clinical	O
significance	O
of	O
plasma	B-Anatomy
endostatin	O
in	O
acute	B-Anatomy
myeloid	I-Anatomy
leukemia	I-Anatomy
/	O
myelodysplastic	O
syndrome	O
.	O
BACKGROUND	O
:	O
Endostatin	O
,	O
a	O
C	O
-	O
terminal	O
fragment	O
of	O
collagen	O
XVIII	O
,	O
is	O
an	O
endogenous	O
angiogenesis	O
inhibitor	O
.	O
While	O
endostatin	O
is	O
being	O
investigated	O
for	O
its	O
usefulness	O
in	O
treating	O
solid	B-Anatomy
tumors	I-Anatomy
,	O
its	O
significance	O
in	O
hematologic	B-Anatomy
malignancies	I-Anatomy
is	O
unknown	O
.	O
METHODS	O
:	O
The	O
authors	O
evaluated	O
plasma	B-Anatomy
endostatin	O
(	O
PE	O
)	O
levels	O
using	O
an	O
enzyme	O
linked	O
immunoassay	O
in	O
71	O
patients	O
with	O
acute	B-Anatomy
myeloid	I-Anatomy
leukemia	I-Anatomy
(	O
AML	B-Anatomy
)	O
and	O
43	O
patients	O
with	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
,	O
and	O
correlated	O
PE	O
with	O
various	O
clinical	O
parameters	O
.	O
RESULTS	O
:	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
median	O
PE	O
level	O
between	O
AML	B-Anatomy
/	O
MDS	O
patients	O
and	O
the	O
normal	O
controls	O
.	O
Nevertheless	O
,	O
patients	O
who	O
achieved	O
complete	O
remission	O
(	O
CR	O
)	O
had	O
a	O
significantly	O
lower	O
median	O
PE	O
level	O
compared	O
to	O
those	O
who	O
did	O
not	O
.	O
In	O
multivariate	O
analysis	O
,	O
PE	O
was	O
found	O
to	O
be	O
a	O
significant	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
predictor	O
of	O
overall	O
survival	O
(	O
OS	O
)	O
with	O
adjustment	O
of	O
the	O
other	O
baseline	O
covariates	O
,	O
including	O
patient	O
age	O
,	O
history	O
of	O
antecedent	O
hematologic	B-Anatomy
disorders	O
,	O
and	O
the	O
use	O
of	O
protective	O
environments	O
.	O
The	O
prognostic	O
value	O
of	O
PE	O
was	O
also	O
evaluated	O
by	O
dividing	O
MDS	O
/	O
AML	B-Anatomy
patients	O
into	O
high	O
and	O
low	O
PE	O
groups	O
using	O
the	O
median	O
PE	O
level	O
of	O
normal	O
controls	O
as	O
the	O
cut	O
-	O
off	O
.	O
The	O
authors	O
found	O
that	O
patients	O
in	O
the	O
high	O
PE	O
group	O
survived	O
for	O
a	O
significantly	O
shorter	O
time	O
than	O
those	O
patients	O
in	O
the	O
low	O
PE	O
group	O
.	O
CONCLUSIONS	O
:	O
PE	O
is	O
a	O
useful	O
prognostic	O
predictor	O
of	O
CR	O
and	O
OS	O
for	O
AML	B-Anatomy
/	O
MDS	O
patients	O
.	O
The	O
mechanism	O
underlying	O
the	O
association	O
between	O
high	O
PE	O
and	O
poor	O
clinical	O
outcome	O
is	O
unclear	O
,	O
although	O
it	O
may	O
be	O
related	O
to	O
the	O
possible	O
PE	O
reflection	O
of	O
tumor	B-Anatomy
burden	O
.	O
Modulation	O
of	O
angiogenesis	O
and	O
progelatinase	O
a	O
by	O
thrombin	O
receptor	O
mimetics	O
and	O
antagonists	O
.	O
The	O
angiogenic	O
action	O
of	O
thrombin	O
has	O
been	O
shown	O
to	O
be	O
mediated	O
by	O
activation	O
of	O
the	O
thrombin	O
receptor	O
.	O
In	O
this	O
report	O
we	O
studied	O
the	O
effects	O
of	O
SFLLR	O
,	O
an	O
agonist	O
of	O
the	O
activated	O
thrombin	O
receptor	O
and	O
thrombin	O
receptor	O
peptide	O
and	O
non	O
peptide	O
antagonists	O
on	O
angiogenesis	O
in	O
the	O
chick	O
chorioallantoic	B-Anatomy
membrane	I-Anatomy
(	O
CAM	B-Anatomy
)	O
system	O
.	O
As	O
antagonists	O
were	O
used	O
the	O
tripeptide	O
FPR	O
and	O
non	O
-	O
peptide	O
1	O
,	O
4	O
-	O
disubstituted	O
piperazine	O
derivatives	O
.	O
The	O
pentapeptide	O
SFLLR	O
,	O
like	O
thrombin	O
,	O
caused	O
a	O
marked	O
stimulation	O
of	O
angiogenesis	O
in	O
the	O
CAM	B-Anatomy
.	O
FPR	O
and	O
the	O
piperazine	O
derivatives	O
caused	O
suppression	O
of	O
angiogenesis	O
and	O
in	O
combination	O
with	O
thrombin	O
antagonized	O
its	O
angiogenic	O
effect	O
.	O
Thrombin	O
and	O
SFLLR	O
activated	O
progelatinase	O
A	O
(	O
MMP	O
-	O
2	O
)	O
in	O
the	O
culture	O
medium	O
of	O
human	B-Anatomy
umbilical	I-Anatomy
cord	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
(	O
HUVECs	B-Anatomy
)	O
.	O
MMP	O
-	O
2	O
is	O
involved	O
in	O
the	O
early	O
steps	O
of	O
angiogenesis	O
leading	O
to	O
local	O
dissolution	O
of	O
basement	B-Anatomy
membrane	I-Anatomy
collagen	O
and	O
migration	O
of	O
the	O
activated	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
FPR	O
and	O
the	O
piperazine	O
derivatives	O
inhibited	O
the	O
activation	O
of	O
this	O
enzyme	O
.	O
They	O
also	O
antagonised	O
the	O
effects	O
of	O
both	O
thrombin	O
and	O
SFLLR	O
on	O
MMP	O
-	O
2	O
activation	O
.	O
These	O
results	O
suggest	O
that	O
non	O
-	O
thrombogenic	O
agonists	O
or	O
antagonists	O
of	O
the	O
activated	O
thrombin	O
receptor	O
can	O
be	O
used	O
as	O
modulators	O
of	O
angiogenesis	O
.	O
Abnormal	O
expression	O
of	O
E	O
-	O
cadherin	O
and	O
beta	O
-	O
catenin	O
may	O
be	O
a	O
molecular	O
marker	O
of	O
submucosal	B-Anatomy
invasion	O
and	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
in	O
early	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
BACKGROUND	O
:	O
Impaired	O
expression	O
of	O
E	O
-	O
cadherin	O
and	O
alpha	O
-	O
and	O
beta	O
-	O
catenin	O
is	O
frequently	O
observed	O
in	O
several	O
human	O
cancers	B-Anatomy
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
immunohistochemical	O
expression	O
of	O
these	O
adhesion	O
molecules	O
,	O
focusing	O
on	O
early	O
gastric	B-Anatomy
carcinomas	I-Anatomy
,	O
and	O
to	O
investigate	O
differences	O
between	O
differentiated	O
and	O
undifferentiated	O
gastric	B-Anatomy
cancer	I-Anatomy
at	O
the	O
early	O
phase	O
of	O
carcinogenesis	O
.	O
METHODS	O
:	O
Immunohistochemical	O
staining	O
of	O
E	O
-	O
cadherin	O
and	O
alpha	O
-	O
and	O
beta	O
-	O
catenin	O
was	O
performed	O
using	O
specimens	B-Anatomy
from	O
143	O
patients	O
with	O
early	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
RESULTS	O
:	O
Abnormal	O
E	O
-	O
cadherin	O
and	O
beta	O
-	O
catenin	O
staining	O
correlated	O
with	O
depth	O
of	O
tumour	B-Anatomy
invasion	O
in	O
differentiated	O
-	O
type	O
tumours	B-Anatomy
.	O
In	O
contrast	O
,	O
abnormal	O
staining	O
was	O
frequently	O
found	O
even	O
in	O
intramucosal	B-Anatomy
carcinoma	I-Anatomy
of	O
undifferentiated	O
-	O
type	O
tumours	B-Anatomy
,	O
suggesting	O
an	O
apparent	O
difference	O
in	O
the	O
onset	O
of	O
E	O
-	O
cadherin	O
-	O
catenin	O
complex	O
abnormality	O
between	O
the	O
two	O
cancer	B-Anatomy
types	O
.	O
Absent	O
staining	O
of	O
beta	O
-	O
catenin	O
was	O
associated	O
with	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
.	O
Multivariate	O
analysis	O
revealed	O
abnormal	O
E	O
-	O
cadherin	O
expression	O
as	O
an	O
independent	O
factor	O
that	O
correlated	O
with	O
submucosal	B-Anatomy
invasion	O
in	O
early	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
CONCLUSION	O
:	O
Abnormal	O
E	O
-	O
cadherin	O
expression	O
is	O
a	O
possible	O
marker	O
of	O
submucosal	B-Anatomy
invasion	O
in	O
differentiated	O
-	O
type	O
early	O
gastric	B-Anatomy
cancer	I-Anatomy
and	O
absent	O
beta	O
-	O
catenin	O
staining	O
could	O
be	O
used	O
as	O
a	O
predictor	O
of	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
in	O
both	O
types	O
.	O
Dominant	O
negative	O
interference	O
of	O
transcription	O
factor	O
AP	O
-	O
2	O
causes	O
inhibition	O
of	O
ErbB	O
-	O
3	O
expression	O
and	O
suppresses	O
malignant	B-Anatomy
cell	I-Anatomy
growth	O
.	O
ErbB	O
-	O
3	O
(	O
HER3	O
)	O
is	O
a	O
member	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
family	O
.	O
Increasing	O
evidence	O
suggests	O
that	O
elevated	O
expression	O
of	O
ErbB	O
-	O
3	O
is	O
important	O
for	O
malignancy	O
.	O
In	O
this	O
study	O
,	O
we	O
found	O
that	O
elevated	O
levels	O
of	O
ErbB	O
-	O
3	O
expression	O
did	O
not	O
occur	O
in	O
the	O
absence	O
of	O
AP	O
-	O
2gamma	O
in	O
a	O
panel	O
of	O
human	O
mammary	B-Anatomy
epithelial	I-Anatomy
and	O
fibroblasts	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
In	O
contrast	O
,	O
there	O
was	O
no	O
association	O
between	O
the	O
expression	O
of	O
AP	O
-	O
2alpha	O
or	O
AP	O
-	O
2beta	O
and	O
the	O
level	O
of	O
ErbB	O
-	O
3	O
,	O
or	O
between	O
AP	O
-	O
2alpha	O
and	O
AP	O
-	O
2gamma	O
double	O
positivity	O
and	O
ErbB	O
-	O
3	O
expression	O
.	O
In	O
co	O
-	O
transfection	O
experiments	O
,	O
exogenous	O
expression	O
of	O
AP	O
-	O
2gamma	O
robustly	O
activated	O
ErbB	O
-	O
3	O
promoter	O
activity	O
.	O
Moreover	O
,	O
expression	O
of	O
a	O
dominant	O
negative	O
AP	O
-	O
2	O
protein	O
,	O
AP	O
-	O
2delta	O
(	O
deleted	O
residues	O
31	O
-	O
117	O
)	O
,	O
not	O
only	O
repressed	O
the	O
ErbB	O
-	O
3	O
promoter	O
activity	O
but	O
also	O
suppressed	O
endogenous	O
ErbB	O
-	O
3	O
transcription	O
in	O
the	O
ErbB	O
-	O
3	O
overexpressing	O
cell	B-Anatomy
line	I-Anatomy
MRC	I-Anatomy
-	I-Anatomy
5VA	I-Anatomy
.	O
Overexpression	O
of	O
AP	O
-	O
2A	O
resulted	O
in	O
a	O
decreased	O
proliferation	O
rate	O
and	O
inhibitin	O
of	O
colony	B-Anatomy
formation	O
.	O
Taken	O
together	O
,	O
these	O
data	O
strongly	O
support	O
a	O
role	O
for	O
the	O
AP	O
-	O
2	O
gene	O
family	O
,	O
in	O
particular	O
,	O
AP	O
-	O
2gamma	O
,	O
in	O
the	O
control	O
of	O
ErbB	O
-	O
3	O
expression	O
.	O
Interference	O
with	O
the	O
function	O
of	O
transcription	O
factor	O
AP	O
-	O
2	O
might	O
provide	O
a	O
potential	O
strategy	O
for	O
modulation	O
of	O
the	O
malignant	O
phenotype	O
.	O
VEGF165	O
mediates	O
formation	O
of	O
complexes	O
containing	O
VEGFR	O
-	O
2	O
and	O
neuropilin	O
-	O
1	O
that	O
enhance	O
VEGF165	O
-	O
receptor	O
binding	O
.	O
Co	O
-	O
expression	O
of	O
NRP1	O
and	O
(	O
VEGFR	O
-	O
2	O
)	O
KDR	O
on	O
the	O
surface	B-Anatomy
of	O
endothelial	B-Anatomy
cells	I-Anatomy
(	O
EC	B-Anatomy
)	O
enhances	O
VEGF165	O
binding	O
to	O
KDR	O
and	O
EC	B-Anatomy
chemotaxis	O
in	O
response	O
to	O
VEGF165	O
.	O
Overexpression	O
of	O
NRP1	O
by	O
prostate	B-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
in	O
vivo	O
results	O
in	O
increased	O
tumor	B-Anatomy
angiogenesis	O
and	O
growth	O
.	O
We	O
investigated	O
the	O
molecular	O
mechanisms	O
underlying	O
NRP1	O
-	O
mediated	O
angiogenesis	O
by	O
analyzing	O
the	O
association	O
of	O
NRP1	O
and	O
KDR	O
.	O
An	O
intracellular	B-Anatomy
complex	O
containing	O
NRP1	O
and	O
KDR	O
was	O
immunoprecipitated	O
from	O
EC	B-Anatomy
by	O
anti	O
-	O
NRP1	O
antibodies	O
only	O
in	O
the	O
presence	O
of	O
VEGF165	O
.	O
In	O
contrast	O
,	O
VEGF121	O
,	O
which	O
does	O
not	O
bind	O
to	O
NRP1	O
,	O
did	O
not	O
support	O
complex	O
formation	O
.	O
Complexes	O
containing	O
VEGF165	O
,	O
NRP1	O
,	O
and	O
KDR	O
were	O
also	O
formed	O
in	O
an	O
intercellular	B-Anatomy
fashion	O
by	O
co	O
-	O
culture	O
of	O
EC	B-Anatomy
expressing	O
KDR	O
only	O
,	O
with	O
cells	B-Anatomy
expressing	O
NRP1	O
only	O
,	O
for	O
example	O
,	O
breast	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
.	O
VEGF165	O
also	O
mediated	O
the	O
binding	O
of	O
a	O
soluble	O
NRP1	O
dimer	O
to	O
cells	B-Anatomy
expressing	O
KDR	O
only	O
,	O
confirming	O
the	O
formation	O
of	O
such	O
complexes	O
.	O
Furthermore	O
,	O
the	O
formation	O
of	O
complexes	O
containing	O
KDR	O
and	O
NRP1	O
markedly	O
increased	O
125I	O
-	O
VEGF165	O
binding	O
to	O
KDR	O
.	O
Our	O
results	O
suggest	O
that	O
formation	O
of	O
a	O
ternary	O
complex	O
of	O
VEGF165	O
,	O
KDR	O
,	O
and	O
NRP1	O
potentiates	O
VEGF165	O
binding	O
to	O
KDR	O
.	O
These	O
complexes	O
are	O
formed	O
on	O
the	O
surface	B-Anatomy
of	O
EC	B-Anatomy
and	O
in	O
a	O
juxtacrine	O
manner	O
via	O
association	O
of	O
tumor	B-Anatomy
cell	I-Anatomy
NRP1	O
and	O
EC	B-Anatomy
KDR	O
.	O
Hypoxic	O
induction	O
of	O
HIF	O
-	O
1alpha	O
and	O
VEGF	O
expression	O
in	O
head	B-Anatomy
and	I-Anatomy
neck	I-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
lines	I-Anatomy
is	O
mediated	O
by	O
stress	O
activated	O
protein	O
kinases	O
.	O
Solid	B-Anatomy
tumors	I-Anatomy
must	O
establish	O
a	O
blood	B-Anatomy
supply	O
in	O
order	O
to	O
proliferate	O
and	O
grow	O
.	O
Cancer	B-Anatomy
cells	I-Anatomy
secrete	O
soluble	O
factors	O
which	O
can	O
induce	O
proliferation	O
and	O
migration	O
of	O
capillary	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
Among	O
the	O
most	O
potent	O
of	O
the	O
angiogenic	O
factors	O
is	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
.	O
Increased	O
VEGF	O
expression	O
by	O
malignant	B-Anatomy
tumors	I-Anatomy
has	O
been	O
associated	O
with	O
high	O
vascularity	O
,	O
increased	O
cancer	B-Anatomy
cell	I-Anatomy
growth	O
,	O
and	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
.	O
Reduced	O
oxygen	O
tension	O
has	O
been	O
shown	O
to	O
increase	O
VEGF	O
production	O
by	O
induction	O
of	O
the	O
transcription	O
factor	O
hypoxia	O
inducible	O
factor	O
1	O
alpha	O
(	O
HIF	O
-	O
1alpha	O
)	O
.	O
The	O
mechanisms	O
by	O
which	O
hypoxic	O
tumor	B-Anatomy
environments	O
induce	O
HIF	O
-	O
1alpha	O
and	O
VEGF	O
expression	O
are	O
largely	O
unknown	O
.	O
Jun	O
N	O
terminal	O
kinase	O
(	O
JNK1	O
)	O
and	O
p38	O
kinase	O
are	O
activated	O
by	O
a	O
variety	O
of	O
stress	O
stimuli	O
.	O
To	O
determine	O
if	O
hypoxic	O
activation	O
of	O
these	O
stress	O
activated	O
protein	O
kinases	O
regulated	O
HIF	O
-	O
1alpha	O
and	O
VEGF	O
expression	O
,	O
we	O
assayed	O
JNK1	O
and	O
p38	O
activity	O
in	O
squamous	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
(	I-Anatomy
SCC	I-Anatomy
)	I-Anatomy
lines	I-Anatomy
grown	O
under	O
normoxic	O
or	O
hypoxic	O
conditions	O
.	O
Hypoxia	O
rapidly	O
induced	O
both	O
JNK1	O
and	O
p38	O
activity	O
in	O
these	O
cells	B-Anatomy
.	O
This	O
activation	O
correlated	O
with	O
induction	O
of	O
HIF	O
-	O
1alpha	O
expression	O
and	O
DNA	O
binding	O
activity	O
which	O
was	O
blocked	O
by	O
the	O
p38	O
inhibitor	O
SB203580	O
.	O
Hypoxia	O
also	O
increased	O
VEGF	O
production	O
by	O
SCC	B-Anatomy
lines	I-Anatomy
,	O
which	O
was	O
inhibited	O
by	O
treatment	O
with	O
SB203580	O
.	O
Overexpression	O
of	O
JNK1	O
or	O
p38	O
was	O
sufficient	O
to	O
induce	O
HIF	O
-	O
1alpha	O
and	O
VEGF	O
expression	O
.	O
These	O
results	O
indicate	O
that	O
induction	O
of	O
SAPKs	O
by	O
hypoxia	O
regulates	O
HIF	O
-	O
1alpha	O
and	O
VEGF	O
expression	O
in	O
head	B-Anatomy
and	I-Anatomy
neck	I-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
In	O
vitro	O
cytotoxic	O
potential	O
and	O
mechanism	O
of	O
action	O
of	O
selected	O
coumarins	O
,	O
using	O
human	O
renal	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
This	O
study	O
determined	O
the	O
selective	O
cytotoxicity	O
of	O
eight	O
coumarin	O
compounds	O
to	O
human	O
renal	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
,	O
relative	O
to	O
non	B-Anatomy
-	I-Anatomy
carcinoma	I-Anatomy
proximal	I-Anatomy
tubular	I-Anatomy
cells	I-Anatomy
.	O
Selectivity	O
cytotoxicity	O
was	O
observed	O
following	O
exposure	O
to	O
6	O
-	O
nitro	O
-	O
7	O
-	O
hydroxycoumarin	O
(	O
6	O
-	O
NO	O
(	O
2	O
)	O
-	O
7	O
-	O
OHC	O
)	O
and	O
7	O
,	O
8	O
-	O
dihydroxycoumarin	O
(	O
7	O
,	O
8	O
-	O
OHC	O
)	O
.	O
6	O
-	O
NO	O
(	O
2	O
)	O
-	O
7	O
-	O
OHC	O
induced	O
cytotoxicity	O
was	O
irreversible	O
in	O
both	O
cell	B-Anatomy
lines	I-Anatomy
,	O
unlike	O
7	O
,	O
8	O
-	O
OHC	O
,	O
which	O
was	O
reversible	O
in	O
the	O
carcinoma	B-Anatomy
cells	I-Anatomy
only	O
.	O
Mobility	O
shift	O
and	O
BrdU	O
incorporation	O
assays	O
showed	O
that	O
both	O
compounds	O
did	O
not	O
intercalate	O
DNA	O
but	O
had	O
a	O
concentration	O
-	O
dependent	O
inhibitory	O
effect	O
on	O
its	O
synthesis	O
.	O
All	O
coumarins	O
studied	O
were	O
found	O
to	O
be	O
non	O
-	O
mutagenic	O
using	O
the	O
standard	O
Ames	O
test	O
.	O
These	O
results	O
would	O
suggest	O
that	O
6	O
-	O
NO	O
(	O
2	O
)	O
-	O
7	O
-	O
OHC	O
and	O
7	O
,	O
8	O
-	O
OHC	O
might	O
have	O
a	O
therapeutic	O
role	O
to	O
play	O
in	O
the	O
treatment	O
of	O
renal	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
[	O
Radiologic	O
-	O
pathologic	O
correlations	O
in	O
breast	B-Anatomy
diseases	O
]	O
The	O
objective	O
of	O
this	O
article	O
is	O
to	O
explain	O
radiologic	O
patterns	O
of	O
benign	B-Anatomy
and	O
malignant	B-Anatomy
breast	I-Anatomy
lesions	I-Anatomy
(	O
masses	B-Anatomy
,	O
microcalcifications	B-Anatomy
)	O
based	O
on	O
histological	O
correlations	O
.	O
The	O
stromal	B-Anatomy
fibrous	I-Anatomy
reaction	O
associated	O
to	O
infiltrating	O
carcinomas	B-Anatomy
is	O
responsible	O
of	O
focal	O
increased	O
density	O
,	O
and	O
architectural	O
distorsion	O
,	O
ultrasound	O
acoustic	O
shadowing	O
;	O
abnormal	O
neoangiogenesis	O
can	O
be	O
detected	O
by	O
Doppler	O
,	O
CT	O
or	O
MR	O
imaging	O
.	O
Invasive	B-Anatomy
carcinomas	I-Anatomy
without	O
spiculated	B-Anatomy
margins	I-Anatomy
are	O
poorly	O
differentiated	O
tumors	B-Anatomy
.	O
Mammographic	O
patterns	O
of	O
microcalcifications	B-Anatomy
depend	O
on	O
their	O
physiopathological	O
process	O
(	O
necrosis	O
,	O
secretion	O
)	O
,	O
and	O
the	O
shape	O
of	O
clusters	B-Anatomy
(	O
round	O
,	O
triangular	O
)	O
typifies	O
their	O
anatomical	B-Anatomy
site	I-Anatomy
of	O
origin	O
(	O
lobular	B-Anatomy
,	O
ductal	B-Anatomy
)	O
.	O
Less	O
frequent	O
lesions	B-Anatomy
(	O
invasive	B-Anatomy
lobular	I-Anatomy
,	O
mucinous	B-Anatomy
,	O
and	O
medullary	B-Anatomy
carcinomas	I-Anatomy
,	O
radial	B-Anatomy
scar	I-Anatomy
)	O
will	O
be	O
also	O
explained	O
based	O
on	O
radiopathological	O
correlations	O
.	O
Knowledge	O
of	O
radiopathological	O
correlations	O
in	O
breast	B-Anatomy
diseases	O
helps	O
the	O
radiologists	O
to	O
analyze	O
and	O
characterize	O
breast	B-Anatomy
lesions	I-Anatomy
.	O
Pten	O
signaling	O
in	O
gliomas	B-Anatomy
.	O
In	O
1997	O
,	O
the	O
PTEN	O
gene	O
(	O
phosphatase	O
and	O
tensin	O
homolog	O
deleted	O
on	O
chromosome	O
10	O
)	O
was	O
identified	O
as	O
a	O
tumor	B-Anatomy
suppressor	O
gene	O
on	O
the	O
long	O
arm	O
of	O
chromosome	B-Anatomy
10	I-Anatomy
.	O
Since	O
then	O
,	O
important	O
progress	O
has	O
been	O
made	O
with	O
respect	O
to	O
the	O
understanding	O
of	O
the	O
role	O
of	O
the	O
Pten	O
protein	O
in	O
the	O
normal	O
development	O
of	O
the	O
brain	B-Anatomy
as	O
well	O
as	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
human	O
gliomas	B-Anatomy
.	O
This	O
review	O
summarizes	O
the	O
current	O
state	O
of	O
the	O
art	O
concerning	O
the	O
involvement	O
of	O
aberrant	O
Pten	O
function	O
in	O
the	O
development	O
of	O
different	O
biologic	O
features	O
of	O
malignant	B-Anatomy
gliomas	I-Anatomy
,	O
such	O
as	O
loss	O
of	O
cell	B-Anatomy
-	O
cycle	O
control	O
and	O
uncontrolled	O
cell	B-Anatomy
proliferation	O
,	O
escape	O
from	O
apoptosis	O
,	O
brain	B-Anatomy
invasion	O
,	O
and	O
aberrant	O
neoangiogenesis	O
.	O
Most	O
of	O
the	O
tumor	B-Anatomy
-	O
suppressive	O
properties	O
of	O
Pten	O
are	O
dependent	O
on	O
its	O
lipid	O
phosphatase	O
activity	O
,	O
which	O
inhibits	O
the	O
phosphatidylinositol	O
-	O
3	O
'	O
-	O
kinase	O
(	O
PI3K	O
)	O
/	O
Akt	O
signaling	O
pathway	O
through	O
dephosphorylation	O
of	O
phosphatidylinositol	O
-	O
(	O
3	O
,	O
4	O
,	O
5	O
)	O
-	O
triphosphate	O
.	O
The	O
additional	O
function	O
of	O
Pten	O
as	O
a	O
dual	O
-	O
specificity	O
protein	O
phosphatase	O
may	O
also	O
play	O
a	O
role	O
in	O
glioma	B-Anatomy
pathogenesis	O
.	O
Besides	O
the	O
wealth	O
of	O
data	O
elucidating	O
the	O
functional	O
roles	O
of	O
Pten	O
,	O
recent	O
studies	O
suggest	O
a	O
diagnostic	O
significance	O
of	O
PTEN	O
gene	O
alterations	O
as	O
a	O
molecular	O
marker	O
for	O
poor	O
prognosis	O
in	O
anaplastic	B-Anatomy
astrocytomas	I-Anatomy
and	O
anaplastic	B-Anatomy
oligodendrogliomas	I-Anatomy
.	O
Furthermore	O
,	O
the	O
possibility	O
of	O
selective	O
targeting	O
of	O
PTEN	B-Anatomy
mutant	I-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
by	O
specific	O
pharmacologic	O
inhibitors	O
of	O
members	O
of	O
the	O
Pten	O
/	O
PI3K	O
/	O
Akt	O
pathway	O
opens	O
up	O
new	O
perspectives	O
for	O
a	O
targeted	O
molecular	O
therapy	O
of	O
malignant	B-Anatomy
gliomas	I-Anatomy
.	O
[	O
A	O
case	O
report	O
of	O
advanced	O
gastric	B-Anatomy
cancer	I-Anatomy
responding	O
to	O
TS	O
-	O
1	O
,	O
a	O
novel	O
oral	B-Anatomy
fluorouracil	O
derivative	O
]	O
.	O
TS	O
-	O
1	O
is	O
a	O
new	O
,	O
oral	B-Anatomy
anticancer	B-Anatomy
agent	O
composed	O
of	O
two	O
modulators	O
,	O
gimeracil	O
(	O
CDHP	O
)	O
and	O
oteracil	O
potassium	O
(	O
Oxo	O
)	O
are	O
mixed	O
with	O
tegafur	O
in	O
a	O
ratio	O
of	O
1	O
:	O
0	O
.	O
4	O
:	O
1	O
.	O
We	O
report	O
one	O
case	O
of	O
advanced	O
gastric	B-Anatomy
cancer	I-Anatomy
with	O
lung	B-Anatomy
and	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
that	O
completely	O
responded	O
to	O
TS	O
-	O
1	O
.	O
A	O
71	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
our	O
hospital	O
because	O
of	O
breathlessness	O
.	O
A	O
diagnosis	O
of	O
advanced	O
gastric	B-Anatomy
cancer	I-Anatomy
with	O
extensive	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
and	O
multiple	O
pulmonary	B-Anatomy
metastases	I-Anatomy
was	O
made	O
.	O
One	O
hundred	O
mg	O
/	O
body	O
/	O
day	O
of	O
TS	O
-	O
1	O
was	O
orally	B-Anatomy
administrated	O
for	O
4	O
weeks	O
.	O
A	O
partial	O
response	O
(	O
PR	O
)	O
was	O
obtained	O
after	O
the	O
first	O
course	O
with	O
regression	O
of	O
multiple	O
pulmonary	B-Anatomy
metastases	I-Anatomy
.	O
After	O
1	O
drug	O
-	O
free	O
week	O
,	O
the	O
second	O
course	O
was	O
administered	O
with	O
120	O
mg	O
/	O
body	O
/	O
day	O
of	O
TS	O
-	O
1	O
for	O
4	O
weeks	O
.	O
After	O
two	O
courses	O
,	O
the	O
primary	B-Anatomy
tumor	I-Anatomy
was	O
reduced	O
to	O
an	O
ulcer	B-Anatomy
scar	I-Anatomy
with	O
pathological	O
confirmation	O
of	O
a	O
complete	O
disappearance	O
of	O
the	O
cancer	B-Anatomy
tissue	I-Anatomy
.	O
Moreover	O
,	O
computed	O
tomography	O
(	O
CT	O
)	O
showed	O
a	O
complete	O
regression	O
of	O
the	O
extensive	O
lymph	B-Anatomy
node	I-Anatomy
and	O
diffuse	O
lung	B-Anatomy
metastases	I-Anatomy
,	O
for	O
a	O
complete	O
response	O
(	O
CR	O
)	O
.	O
The	O
serum	B-Anatomy
level	O
of	O
CEA	O
was	O
reduced	O
from	O
172	O
.	O
7	O
ng	O
/	O
ml	O
to	O
8	O
.	O
1	O
ng	O
/	O
ml	O
after	O
TS	O
-	O
1	O
treatment	O
.	O
As	O
for	O
adverse	O
events	O
,	O
only	O
pigmentation	O
of	O
the	O
skin	B-Anatomy
and	O
Grade	O
2	O
oral	B-Anatomy
aphta	I-Anatomy
were	O
observed	O
.	O
Systemic	O
regulation	O
of	O
distraction	O
osteogenesis	O
:	O
a	O
cascade	O
of	O
biochemical	O
factors	O
.	O
This	O
study	O
investigates	O
the	O
systemic	O
biochemical	O
regulation	O
of	O
fracture	O
healing	O
in	O
distraction	O
osteogenesis	O
compared	O
with	O
rigid	O
osteotomy	O
in	O
a	O
prospective	O
in	O
vivo	O
study	O
in	O
humans	O
.	O
To	O
further	O
clarify	O
the	O
influence	O
of	O
mechanical	O
strain	O
on	O
the	O
regulation	O
of	O
bone	B-Anatomy
formation	O
,	O
bone	B-Anatomy
growth	O
factors	O
(	O
insulin	O
-	O
like	O
growth	O
factor	O
[	O
IGF	O
]	O
I	O
,	O
IGF	O
binding	O
protein	O
[	O
IGFBP	O
]	O
3	O
,	O
transforming	O
growth	O
factor	O
[	O
TGF	O
]	O
beta1	O
,	O
and	O
basic	O
FGF	O
[	O
bFGF	O
]	O
)	O
,	O
bone	B-Anatomy
matrix	I-Anatomy
degrading	O
enzymes	O
(	O
matrix	O
-	O
metalloproteinases	O
[	O
MMPs	O
]	O
1	O
,	O
2	O
,	O
and	O
3	O
)	O
,	O
human	O
growth	O
hormone	O
(	O
hGH	O
)	O
,	O
and	O
bone	B-Anatomy
formation	O
markers	O
(	O
ALP	O
,	O
bone	B-Anatomy
-	O
specific	O
ALP	O
[	O
BAP	O
]	O
,	O
and	O
osteocalcin	O
[	O
OC	O
]	O
)	O
have	O
been	O
analyzed	O
in	O
serum	B-Anatomy
samples	I-Anatomy
from	O
10	O
patients	O
in	O
each	O
group	O
pre	O
-	O
and	O
postoperatively	O
.	O
In	O
the	O
distraction	O
group	O
,	O
a	O
significant	O
postoperative	O
increase	O
in	O
MMP	O
-	O
1	O
,	O
bFGF	O
,	O
ALP	O
,	O
and	O
BAP	O
could	O
be	O
observed	O
during	O
the	O
lengthening	O
and	O
the	O
consolidation	O
period	O
when	O
compared	O
with	O
the	O
baseline	O
levels	O
.	O
Osteotomy	O
fracture	O
healing	O
without	O
the	O
traction	O
stimulus	O
failed	O
to	O
induce	O
a	O
corresponding	O
increase	O
in	O
these	O
factors	O
.	O
In	O
addition	O
,	O
comparison	O
of	O
both	O
groups	O
revealed	O
a	O
significantly	O
higher	O
increase	O
in	O
TGF	O
-	O
beta1	O
,	O
IGF	O
-	O
I	O
,	O
IGFBP	O
-	O
3	O
,	O
and	O
hGH	O
in	O
the	O
lengthening	O
group	O
during	O
the	O
distraction	O
period	O
,	O
indicating	O
key	O
regulatory	O
functions	O
in	O
mechanotransduction	O
.	O
The	O
time	O
courses	O
of	O
changes	O
in	O
MMP	O
-	O
1	O
,	O
bone	B-Anatomy
growth	O
factors	O
(	O
TGF	O
-	O
beta1	O
and	O
bFGF	O
)	O
,	O
and	O
hGH	O
,	O
respectively	O
,	O
correlated	O
significantly	O
during	O
the	O
lengthening	O
phase	O
,	O
indicating	O
common	O
regulatory	O
pathways	O
for	O
these	O
factors	O
in	O
distraction	O
osteogenesis	O
.	O
Significant	O
correlation	O
between	O
the	O
osteoblastic	O
marker	O
BAP	O
,	O
TGF	O
-	O
beta1	O
,	O
and	O
bFGF	O
suggests	O
strain	O
-	O
activated	O
osteoblastic	B-Anatomy
cells	I-Anatomy
as	O
a	O
major	O
source	O
of	O
systemically	O
increased	O
bone	B-Anatomy
growth	O
factors	O
during	O
callus	O
distraction	O
.	O
The	O
systemic	O
increase	O
in	O
bFGF	O
and	O
MMP	O
-	O
1	O
might	O
reflect	O
an	O
increased	O
local	O
stimulation	O
of	O
angiogenesis	O
during	O
distraction	O
osteogenesis	O
.	O
Human	O
papillomavirus	O
oncoprotein	O
E6	O
inactivates	O
the	O
transcriptional	O
coactivator	O
human	O
ADA3	O
.	O
High	O
-	O
risk	O
human	O
papillomaviruses	O
(	O
HPVs	O
)	O
are	O
associated	O
with	O
carcinomas	B-Anatomy
of	O
the	O
cervix	B-Anatomy
and	O
other	O
genital	B-Anatomy
tumors	I-Anatomy
.	O
The	O
HPV	O
oncoprotein	O
E6	O
is	O
essential	O
for	O
oncogenic	O
transformation	O
.	O
We	O
identify	O
here	O
hADA3	O
,	O
human	O
homologue	O
of	O
the	O
yeast	O
transcriptional	O
coactivator	O
yADA3	O
,	O
as	O
a	O
novel	O
E6	O
-	O
interacting	O
protein	O
and	O
a	O
target	O
of	O
E6	O
-	O
induced	O
degradation	O
.	O
hADA3	O
binds	O
selectively	O
to	O
the	O
high	O
-	O
risk	O
HPV	O
E6	O
proteins	O
and	O
only	O
to	O
immortalization	O
-	O
competent	O
E6	O
mutants	O
.	O
hADA3	O
functions	O
as	O
a	O
coactivator	O
for	O
p53	O
-	O
mediated	O
transactivation	O
by	O
stabilizing	O
p53	O
protein	O
.	O
Notably	O
,	O
three	O
immortalizing	O
E6	O
mutants	O
that	O
do	O
not	O
induce	O
direct	O
p53	O
degradation	O
but	O
do	O
interact	O
with	O
hADA3	O
induced	O
the	O
abrogation	O
of	O
p53	O
-	O
mediated	O
transactivation	O
and	O
G	O
(	O
1	O
)	O
cell	B-Anatomy
cycle	O
arrest	O
after	O
DNA	O
damage	O
,	O
comparable	O
to	O
wild	O
-	O
type	O
E6	O
.	O
These	O
findings	O
reveal	O
a	O
novel	O
strategy	O
of	O
HPV	O
E6	O
-	O
induced	O
loss	O
of	O
p53	O
function	O
that	O
is	O
independent	O
of	O
direct	O
p53	O
degradation	O
.	O
Given	O
the	O
likely	O
role	O
of	O
the	O
evolutionarily	O
conserved	O
hADA3	O
in	O
multiple	O
coactivator	O
complexes	O
,	O
inactivation	O
of	O
its	O
function	O
may	O
allow	O
E6	O
to	O
perturb	O
numerous	O
cellular	B-Anatomy
pathways	O
during	O
HPV	O
oncogenesis	O
.	O
Immunohistochemical	O
staining	O
for	O
thyroid	O
transcription	O
factor	O
-	O
1	O
:	O
a	O
helpful	O
aid	O
in	O
discerning	O
primary	O
site	B-Anatomy
of	O
tumor	B-Anatomy
origin	O
in	O
patients	O
with	O
brain	B-Anatomy
metastases	I-Anatomy
.	O
Metastatic	B-Anatomy
carcinoma	I-Anatomy
of	O
unknown	O
primary	O
origin	B-Anatomy
is	O
a	O
perplexing	O
but	O
common	O
problem	O
,	O
accounting	O
for	O
up	O
to	O
10	O
%	O
to	O
15	O
%	O
of	O
all	O
solid	B-Anatomy
tumors	I-Anatomy
at	O
presentation	O
.	O
Many	O
of	O
these	O
metastases	B-Anatomy
presumably	O
arise	O
from	O
primary	B-Anatomy
lung	I-Anatomy
carcinomas	I-Anatomy
,	O
but	O
the	O
morphologic	O
features	O
and	O
immunohistochemical	O
profile	O
of	O
lung	B-Anatomy
cancer	I-Anatomy
is	O
often	O
too	O
nonspecific	O
to	O
permit	O
unequivocal	O
confirmation	O
.	O
Thyroid	O
transcription	O
factor	O
-	O
1	O
(	O
TTF	O
-	O
1	O
)	O
is	O
expressed	O
in	O
lung	B-Anatomy
adenocarcinomas	I-Anatomy
and	O
thyroid	B-Anatomy
carcinomas	I-Anatomy
but	O
not	O
in	O
adenocarcinomas	B-Anatomy
arising	O
from	O
other	O
sites	B-Anatomy
.	O
For	O
patients	O
with	O
adenocarcinomas	B-Anatomy
in	O
the	O
lung	B-Anatomy
,	O
TTF	O
-	O
1	O
staining	O
is	O
now	O
routinely	O
used	O
to	O
distinguish	O
a	O
primary	B-Anatomy
lung	I-Anatomy
cancer	I-Anatomy
from	O
a	O
lung	B-Anatomy
metastasis	O
.	O
Along	O
these	O
same	O
lines	O
,	O
TTF	O
-	O
1	O
staining	O
might	O
prove	O
useful	O
in	O
localizing	O
the	O
tumor	B-Anatomy
origin	O
of	O
adenocarcinomas	B-Anatomy
encountered	O
outside	O
of	O
the	O
lung	B-Anatomy
.	O
The	O
archival	O
surgical	O
pathology	O
files	O
of	O
The	O
Johns	O
Hopkins	O
Hospital	O
were	O
searched	O
for	O
cases	O
of	O
brain	B-Anatomy
metastases	I-Anatomy
biopsied	O
between	O
1990	O
and	O
2000	O
.	O
Tissue	B-Anatomy
blocks	I-Anatomy
were	O
obtained	O
and	O
immunoperoxidase	O
staining	O
was	O
performed	O
using	O
the	O
TTF	O
-	O
1	O
antibody	O
.	O
The	O
medical	O
records	O
were	O
reviewed	O
independent	O
of	O
the	O
staining	O
results	O
to	O
determine	O
site	B-Anatomy
of	O
tumor	B-Anatomy
origin	O
.	O
Seventy	O
-	O
five	O
patients	O
underwent	O
biopsies	O
of	O
carcinomas	B-Anatomy
metastatic	O
to	O
the	O
brain	B-Anatomy
.	O
At	O
the	O
time	O
of	O
brain	B-Anatomy
biopsy	O
,	O
the	O
primary	O
site	B-Anatomy
of	O
tumor	B-Anatomy
origin	O
was	O
known	O
in	O
45	O
cases	O
and	O
unknown	O
in	O
30	O
cases	O
.	O
Ultimately	O
,	O
the	O
primary	O
site	B-Anatomy
was	O
established	O
on	O
clinical	O
and	O
radiographic	O
grounds	O
in	O
71	O
cases	O
(	O
95	O
%	O
)	O
.	O
These	O
included	O
40	O
(	O
56	O
%	O
)	O
metastases	B-Anatomy
from	O
a	O
primary	B-Anatomy
lung	I-Anatomy
carcinoma	I-Anatomy
and	O
31	O
(	O
44	O
%	O
)	O
metastases	B-Anatomy
from	O
some	O
nonpulmonary	B-Anatomy
carcinoma	I-Anatomy
.	O
TTF	O
-	O
1	O
staining	O
was	O
present	O
in	O
31	O
of	O
the	O
40	O
(	O
78	O
%	O
)	O
metastatic	B-Anatomy
lung	I-Anatomy
carcinomas	I-Anatomy
,	O
but	O
in	O
only	O
1	O
of	O
the	O
31	O
(	O
3	O
%	O
)	O
metastatic	B-Anatomy
nonpulmonary	I-Anatomy
carcinomas	I-Anatomy
(	O
a	O
small	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
of	O
the	O
sinonasal	B-Anatomy
tract	I-Anatomy
)	O
.	O
When	O
the	O
metastatic	B-Anatomy
lung	I-Anatomy
carcinomas	I-Anatomy
were	O
subtyped	O
,	O
TTF	O
-	O
1	O
staining	O
was	O
noted	O
in	O
11	O
of	O
11	O
(	O
100	O
%	O
)	O
adenocarcinomas	B-Anatomy
,	O
in	O
6	O
of	O
7	O
(	O
86	O
%	O
)	O
small	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
carcinomas	I-Anatomy
,	O
in	O
15	O
of	O
19	O
(	O
79	O
%	O
)	O
large	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
carcinomas	I-Anatomy
,	O
and	O
in	O
none	O
of	O
3	O
(	O
0	O
%	O
)	O
squamous	B-Anatomy
cell	I-Anatomy
carcinomas	I-Anatomy
.	O
TTF	O
-	O
1	O
staining	O
is	O
very	O
reliable	O
in	O
discerning	O
whether	O
a	O
brain	B-Anatomy
metastasis	O
has	O
arisen	O
from	O
a	O
pulmonary	B-Anatomy
or	O
nonpulmonary	B-Anatomy
site	I-Anatomy
,	O
particularly	O
when	O
dealing	O
with	O
adenocarcinomas	B-Anatomy
and	O
large	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
carcinomas	I-Anatomy
.	O
TTF	O
-	O
1	O
immunohistochemistry	O
could	O
focus	O
the	O
search	O
for	O
the	O
primary	B-Anatomy
tumor	I-Anatomy
for	O
patients	O
presenting	O
with	O
brain	B-Anatomy
metastasis	O
as	O
the	O
initial	O
manifestation	O
.	O
Protein	O
expression	O
profile	O
of	O
primary	B-Anatomy
human	I-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
carcinomas	I-Anatomy
indicative	O
of	O
the	O
incidence	O
of	O
metastases	B-Anatomy
.	O
The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
evaluate	O
firstly	O
whether	O
different	O
protein	O
expression	O
patterns	O
exist	O
in	O
primary	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
carcinomas	I-Anatomy
of	O
patients	O
with	O
and	O
without	O
lymph	B-Anatomy
node	I-Anatomy
involvement	O
and	O
secondly	O
,	O
whether	O
or	O
not	O
different	O
patterns	O
exist	O
in	O
tumours	B-Anatomy
with	O
positive	O
lymph	B-Anatomy
nodes	I-Anatomy
.	O
For	O
this	O
reason	O
,	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
specimens	B-Anatomy
from	O
130	O
patients	O
with	O
squamous	B-Anatomy
cell	I-Anatomy
lung	I-Anatomy
carcinomas	I-Anatomy
were	O
analyzed	O
by	O
immunohistochemistry	O
.	O
In	O
a	O
first	O
step	O
,	O
proteins	O
were	O
selected	O
which	O
showed	O
a	O
relationship	O
to	O
lymph	B-Anatomy
node	I-Anatomy
involvement	O
.	O
The	O
expression	O
of	O
JUN	O
,	O
ERBB2	O
,	O
MYC	O
,	O
cyclin	O
D	O
,	O
PCNA	O
,	O
bFGF	O
,	O
VEGF	O
and	O
Hsp70	O
proteins	O
revealed	O
a	O
positive	O
correlation	O
to	O
lymph	B-Anatomy
node	I-Anatomy
involvement	O
.	O
In	O
contrast	O
,	O
caspase	O
-	O
3	O
,	O
Fas	O
ligand	O
,	O
Fas	O
/	O
CD95	O
,	O
and	O
PAI	O
showed	O
an	O
inverse	O
correlation	O
to	O
lymph	B-Anatomy
node	I-Anatomy
involvement	O
.	O
In	O
a	O
second	O
step	O
,	O
these	O
parameters	O
were	O
further	O
analyzed	O
by	O
hierarchical	O
cluster	O
analyses	O
.	O
The	O
resulting	O
clusters	O
were	O
correlated	O
to	O
patients	O
with	O
or	O
without	O
lymph	B-Anatomy
node	I-Anatomy
involvement	O
.	O
The	O
data	O
show	O
that	O
different	O
protein	O
expression	O
patterns	O
exist	O
between	O
primary	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
carcinomas	I-Anatomy
with	O
and	O
without	O
lymph	B-Anatomy
node	I-Anatomy
involvement	O
and	O
within	O
carcinomas	B-Anatomy
with	O
lymph	B-Anatomy
node	I-Anatomy
involvement	O
.	O
The	O
data	O
suggest	O
that	O
various	O
metastasis	O
profiles	O
exist	O
.	O
Antiangiogenic	O
and	O
antitumor	B-Anatomy
effects	O
of	O
a	O
protein	O
kinase	O
Cbeta	O
inhibitor	O
in	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
and	O
ovarian	B-Anatomy
cancer	I-Anatomy
xenografts	I-Anatomy
.	O
In	O
cell	B-Anatomy
culture	I-Anatomy
,	O
the	O
compound	O
317615	O
2HCl	O
,	O
a	O
potent	O
inhibitor	O
of	O
VEGF	O
-	O
stimulated	O
HUVEC	B-Anatomy
proliferation	O
,	O
was	O
not	O
very	O
effective	O
against	O
MX	B-Anatomy
-	I-Anatomy
1	I-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
(	O
IC50	O
=	O
8	O
.	O
1	O
microM	O
)	O
or	O
SKOV	B-Anatomy
-	I-Anatomy
3	I-Anatomy
ovarian	I-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
(	O
IC50	O
=	O
9	O
.	O
5	O
microM	O
)	O
.	O
Exposure	O
to	O
combinations	O
of	O
paclitaxel	O
or	O
carboplatin	O
and	O
317615	O
x	O
2HCl	O
with	O
MX	B-Anatomy
-	I-Anatomy
1	I-Anatomy
cells	I-Anatomy
in	O
culture	O
resulted	O
in	O
cell	B-Anatomy
survival	O
that	O
reflected	O
primarily	O
additivity	O
of	O
the	O
two	O
agents	O
.	O
Exposure	O
of	O
SKOV	B-Anatomy
-	I-Anatomy
3	I-Anatomy
cells	I-Anatomy
to	O
paclitaxel	O
or	O
carboplatin	O
along	O
with	O
317615	O
2HCl	O
resulted	O
in	O
cell	B-Anatomy
survivals	O
that	O
reflected	O
additivity	O
of	O
317615	O
x	O
2HCl	O
with	O
paclitaxel	O
and	O
greater	O
-	O
than	O
-	O
additive	O
cytotoxicity	O
with	O
carboplatin	O
.	O
Administration	O
of	O
317615	O
x	O
2HCI	O
orally	B-Anatomy
twice	O
daily	O
to	O
nude	O
mice	O
bearing	O
subcutaneous	B-Anatomy
MX	I-Anatomy
-	I-Anatomy
1	I-Anatomy
tumors	I-Anatomy
or	O
SKOV	B-Anatomy
-	I-Anatomy
3	I-Anatomy
tumors	I-Anatomy
resulted	O
in	O
a	O
decreased	O
number	O
of	O
intratumoral	B-Anatomy
vessels	I-Anatomy
as	O
determined	O
by	O
CD31	O
and	O
CD105	O
staining	O
with	O
decreases	O
of	O
35	O
%	O
and	O
43	O
%	O
in	O
MX	B-Anatomy
-	I-Anatomy
1	I-Anatomy
tumors	I-Anatomy
and	O
60	O
%	O
and	O
75	O
%	O
in	O
SKOV	B-Anatomy
-	I-Anatomy
3	I-Anatomy
tumors	I-Anatomy
,	O
respectively	O
.	O
317615	O
x	O
2HCl	O
was	O
an	O
active	O
antitumor	B-Anatomy
agent	O
against	O
the	O
MX	B-Anatomy
-	I-Anatomy
1	I-Anatomy
xenograft	I-Anatomy
and	O
increased	O
the	O
tumor	B-Anatomy
growth	O
delay	O
produced	O
by	O
paclitaxel	O
by	O
1	O
.	O
7	O
-	O
fold	O
and	O
the	O
tumor	B-Anatomy
growth	O
delay	O
produced	O
by	O
carboplatin	O
by	O
3	O
.	O
8	O
-	O
fold	O
.	O
Administration	O
of	O
317615	O
x	O
2HCl	O
also	O
increased	O
the	O
tumor	B-Anatomy
growth	O
delay	O
produced	O
by	O
fractionated	O
radiation	O
therapy	O
in	O
the	O
MX	B-Anatomy
-	I-Anatomy
1	I-Anatomy
tumor	I-Anatomy
.	O
Treatment	O
with	O
317615	O
x	O
2HCl	O
alone	O
increased	O
the	O
lifespan	O
of	O
animals	O
bearing	O
intraperitoneal	B-Anatomy
SKOV	I-Anatomy
-	I-Anatomy
3	I-Anatomy
xenografts	I-Anatomy
by	O
1	O
.	O
9	O
fold	O
compared	O
with	O
untreated	O
control	O
animals	O
.	O
The	O
combination	O
of	O
paclitaxel	O
and	O
317615	O
x	O
2HCl	O
resulted	O
in	O
100	O
%	O
120	O
-	O
day	O
survival	O
of	O
SKOV	B-Anatomy
-	I-Anatomy
3	I-Anatomy
bearing	O
animals	O
.	O
Administration	O
of	O
317615	O
x	O
2HCl	O
along	O
with	O
carboplatin	O
to	O
animals	O
bearing	O
the	O
SKOV	B-Anatomy
-	I-Anatomy
3	I-Anatomy
tumor	I-Anatomy
produced	O
a	O
1	O
.	O
8	O
-	O
fold	O
increase	O
in	O
lifespan	O
compared	O
with	O
carboplatin	O
alone	O
.	O
317615	O
x	O
2HCl	O
is	O
a	O
promising	O
new	O
antiangiogenic	O
agent	O
that	O
is	O
in	O
early	O
phase	O
clinical	O
testing	O
.	O
Expression	O
of	O
CD154	O
on	O
renal	B-Anatomy
cell	I-Anatomy
carcinomas	I-Anatomy
and	O
effect	O
on	O
cell	B-Anatomy
proliferation	O
,	O
motility	O
and	O
platelet	O
-	O
activating	O
factor	O
synthesis	O
.	O
CD40	O
activation	O
by	O
CD154	O
may	O
trigger	O
diverse	O
cellular	B-Anatomy
responses	O
,	O
ranging	O
from	O
proliferation	O
and	O
differentiation	O
to	O
growth	O
suppression	O
and	O
cell	B-Anatomy
death	O
,	O
in	O
normal	O
and	O
malignant	B-Anatomy
cells	I-Anatomy
.	O
However	O
,	O
the	O
pathophysiologic	O
role	O
of	O
CD154	O
expressed	O
by	O
tumor	B-Anatomy
cells	I-Anatomy
remains	O
unclear	O
.	O
We	O
have	O
investigated	O
the	O
expression	O
of	O
the	O
CD40	O
-	O
CD154	O
system	O
in	O
24	O
primary	O
cultures	B-Anatomy
derived	O
from	O
renal	B-Anatomy
cell	I-Anatomy
carcinomas	I-Anatomy
,	O
its	O
correlation	O
with	O
tumor	B-Anatomy
stage	O
and	O
its	O
potential	O
functional	O
significance	O
.	O
We	O
found	O
coexpression	O
of	O
CD40	O
and	O
CD154	O
in	O
most	O
of	O
the	O
renal	B-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
CD154	O
,	O
but	O
not	O
CD40	O
expression	O
,	O
significantly	O
correlated	O
with	O
tumor	B-Anatomy
stage	O
.	O
Moreover	O
,	O
renal	B-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
also	O
released	O
the	O
soluble	O
form	O
of	O
CD154	O
into	O
the	O
supernatant	B-Anatomy
.	O
CD40	O
engagement	O
by	O
CD154	O
did	O
not	O
affect	O
apoptosis	O
or	O
survival	O
.	O
On	O
the	O
contrary	O
,	O
CD154	O
stimulated	O
cell	B-Anatomy
proliferation	O
,	O
motility	O
and	O
production	O
of	O
PAF	O
,	O
a	O
phospholipid	O
mediator	O
of	O
inflammation	O
with	O
angiogenic	O
properties	O
.	O
Furthermore	O
,	O
the	O
renal	B-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
expressed	O
PAF	O
-	O
R	O
.	O
Blockade	O
of	O
PAF	O
-	O
R	O
by	O
WEB	O
-	O
2170	O
,	O
a	O
PAF	O
-	O
R	O
antagonist	O
,	O
abolished	O
the	O
CD154	O
-	O
dependent	O
motility	O
,	O
indicating	O
a	O
role	O
for	O
PAF	O
synthesized	O
after	O
CD154	O
stimulation	O
in	O
renal	B-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
motility	O
.	O
In	O
conclusion	O
,	O
this	O
study	O
identifies	O
new	O
functional	O
properties	O
for	O
CD154	O
,	O
which	O
are	O
potentially	O
relevant	O
for	O
the	O
growth	O
and	O
dissemination	O
of	O
renal	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
.	O
DNA	O
damage	O
induces	O
a	O
novel	O
p53	O
-	O
survivin	O
signaling	O
pathway	O
regulating	O
cell	B-Anatomy
cycle	O
and	O
apoptosis	O
in	O
acute	B-Anatomy
lymphoblastic	I-Anatomy
leukemia	I-Anatomy
cells	I-Anatomy
.	O
Survivin	O
is	O
a	O
novel	O
member	O
of	O
the	O
inhibitor	O
of	O
apoptosis	O
protein	O
(	O
IAP	O
)	O
family	O
.	O
Here	O
we	O
report	O
that	O
the	O
chemotherapeutic	O
drug	O
doxorubicin	O
,	O
a	O
DNA	O
-	O
damaging	O
agent	O
,	O
activates	O
a	O
p53	O
-	O
survivin	O
signaling	O
pathway	O
inducing	O
cell	B-Anatomy
cycle	O
arrest	O
and	O
apoptosis	O
in	O
childhood	O
acute	B-Anatomy
lymphoblastic	I-Anatomy
leukemia	I-Anatomy
(	O
ALL	B-Anatomy
)	O
.	O
Treatment	O
of	O
wild	B-Anatomy
-	I-Anatomy
type	I-Anatomy
(	I-Anatomy
wt	I-Anatomy
)	I-Anatomy
p53	I-Anatomy
ALL	I-Anatomy
cells	I-Anatomy
(	O
EU	B-Anatomy
-	I-Anatomy
3	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
)	O
with	O
doxorubicin	O
caused	O
accumulation	O
of	O
p53	O
,	O
resulting	O
in	O
dramatic	O
down	O
-	O
regulation	O
of	O
survivin	O
,	O
depletion	O
of	O
cells	B-Anatomy
in	O
G	O
(	O
2	O
)	O
/	O
M	O
,	O
and	O
apoptosis	O
(	O
increased	O
sub	O
-	O
G	O
(	O
1	O
)	O
compartment	O
)	O
.	O
In	O
contrast	O
,	O
doxorubicin	O
treatment	O
of	O
mutant	B-Anatomy
(	I-Anatomy
mut	I-Anatomy
)	I-Anatomy
p53	I-Anatomy
cells	I-Anatomy
(	O
EU	B-Anatomy
-	I-Anatomy
6	I-Anatomy
/	I-Anatomy
ALL	I-Anatomy
line	I-Anatomy
)	O
up	O
-	O
regulated	O
survivin	O
and	O
induced	O
G	O
(	O
2	O
)	O
/	O
M	O
arrest	O
without	O
inducing	O
apoptosis	O
.	O
However	O
,	O
treating	O
EU	B-Anatomy
-	I-Anatomy
6	I-Anatomy
with	O
anti	O
-	O
survivin	O
antisense	O
resensitized	O
these	O
cells	B-Anatomy
to	O
doxorubicin	O
,	O
resulting	O
in	O
apoptosis	O
.	O
With	O
a	O
p53	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
(	O
EU	B-Anatomy
-	I-Anatomy
4	I-Anatomy
)	I-Anatomy
,	O
although	O
doxorubicin	O
treatment	O
arrested	O
cells	B-Anatomy
in	O
G	O
(	O
2	O
)	O
/	O
M	O
,	O
survivin	O
expression	O
was	O
unchanged	O
,	O
and	O
cells	B-Anatomy
underwent	O
only	O
limited	O
apoptosis	O
.	O
However	O
,	O
re	O
-	O
expression	O
of	O
wt	O
-	O
p53	O
in	O
EU	B-Anatomy
-	I-Anatomy
4	I-Anatomy
cells	I-Anatomy
could	O
restore	O
the	O
doxorubicin	O
-	O
p53	O
-	O
survivin	O
pathway	O
,	O
resulting	O
in	O
significantly	O
decreased	O
survivin	O
expression	O
and	O
increased	O
apoptosis	O
in	O
these	O
cells	B-Anatomy
after	O
doxorubicin	O
treatment	O
.	O
Following	O
cotransfection	O
of	O
p53	B-Anatomy
-	I-Anatomy
EU	I-Anatomy
-	I-Anatomy
4	I-Anatomy
cells	I-Anatomy
with	O
survivin	O
promoter	O
-	O
luciferase	O
constructs	O
and	O
either	O
wt	O
-	O
p53	O
or	O
different	O
mut	O
-	O
p53	O
expression	O
vectors	O
,	O
wt	O
-	O
p53	O
inhibited	O
survivin	O
promoter	O
activity	O
;	O
p53	O
-	O
mediated	O
inhibition	O
could	O
be	O
abrogated	O
by	O
overexpression	O
of	O
murine	O
double	O
minute2	O
(	O
MDM2	O
)	O
protein	O
.	O
Together	O
,	O
these	O
studies	O
define	O
a	O
novel	O
p53	O
-	O
survivin	O
signaling	O
pathway	O
activated	O
by	O
DNA	O
damage	O
that	O
results	O
in	O
down	O
-	O
regulation	O
of	O
survivin	O
,	O
cell	B-Anatomy
cycle	O
arrest	O
,	O
and	O
apoptosis	O
.	O
Furthermore	O
,	O
our	O
data	O
indicate	O
that	O
loss	O
of	O
wt	O
-	O
p53	O
function	O
in	O
tumor	B-Anatomy
cells	I-Anatomy
may	O
contribute	O
to	O
up	O
-	O
regulation	O
of	O
survivin	O
and	O
resistance	O
to	O
DNA	O
-	O
damaging	O
agents	O
.	O
On	O
the	O
relationship	O
between	O
the	O
population	O
structure	O
and	O
national	O
economic	O
development	O
in	O
China	O
.	O
The	O
authors	O
examine	O
the	O
relationship	O
between	O
population	O
reproduction	O
and	O
the	O
production	O
of	O
material	O
goods	O
,	O
with	O
particular	O
reference	O
to	O
the	O
effect	O
of	O
changes	O
in	O
the	O
age	O
composition	O
of	O
the	O
population	O
on	O
the	O
national	O
economy	O
and	O
national	O
income	O
.	O
An	O
analysis	O
of	O
the	O
population	O
structure	O
of	O
China	O
is	O
presented	O
,	O
with	O
consideration	O
given	O
to	O
age	O
characteristics	O
,	O
occupation	O
,	O
and	O
urban	O
and	O
rural	O
population	O
.	O
Suggestions	O
for	O
improving	O
the	O
population	O
structure	O
to	O
achieve	O
maximum	O
rates	O
of	O
economic	O
development	O
are	O
presented	O
.	O
Regional	O
differences	O
in	O
population	O
structure	O
are	O
also	O
discussed	O
.	O
No	O
evidence	O
for	O
an	O
influence	O
of	O
the	O
human	O
platelet	O
antigen	O
-	O
1	O
polymorphism	O
on	O
the	O
antiplatelet	O
effects	O
of	O
glycoprotein	O
IIb	O
/	O
IIIa	O
inhibitors	O
.	O
This	O
study	O
investigated	O
the	O
hypothesis	O
that	O
the	O
human	O
platelet	O
antigen	O
-	O
1	O
(	O
HPA	O
-	O
1	O
)	O
polymorphism	O
may	O
influence	O
the	O
antiplatelet	O
effects	O
of	O
glycoprotein	O
(	O
GP	O
)	O
IIb	O
/	O
IIIa	O
inhibitors	O
.	O
Adenosine	O
diphosphate	O
(	O
30	O
micro	O
mol	O
)	O
-	O
induced	O
fibrinogen	O
binding	O
was	O
measured	O
by	O
flow	O
cytometry	O
.	O
Abciximab	O
(	O
0	O
.	O
03	O
-	O
3	O
micro	O
g	O
/	O
ml	O
)	O
,	O
tirofiban	O
(	O
0	O
.	O
3	O
-	O
30	O
nmol	O
/	O
l	O
)	O
or	O
eptifibatide	O
(	O
0	O
.	O
01	O
-	O
1	O
micro	O
g	O
/	O
ml	O
)	O
were	O
incubated	O
for	O
15	O
min	O
with	O
the	O
samples	O
prior	O
to	O
stimulation	O
.	O
IC	O
(	O
50	O
)	O
values	O
for	O
the	O
inhibition	O
of	O
fibrinogen	O
binding	O
were	O
determined	O
from	O
each	O
experiment	O
.	O
All	O
subjects	O
were	O
genotyped	O
by	O
GALIOS	O
and	O
automated	O
fluorescence	O
correlation	O
spectroscopy	O
.	O
Although	O
a	O
marked	O
variability	O
in	O
the	O
inhibitory	O
effects	O
of	O
all	O
three	O
GPIIb	O
/	O
IIIa	O
inhibitors	O
was	O
confirmed	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
genotypes	O
with	O
respect	O
to	O
the	O
inhibition	O
of	O
fibrinogen	O
binding	O
.	O
Thus	O
,	O
the	O
present	O
study	O
does	O
not	O
provide	O
evidence	O
for	O
an	O
effect	O
of	O
HPA	O
-	O
1	O
polymorphism	O
on	O
the	O
inter	O
-	O
individual	O
variability	O
in	O
the	O
platelet	B-Anatomy
inhibitory	O
effects	O
of	O
the	O
three	O
GPIIb	O
/	O
IIIa	O
inhibitors	O
approved	O
for	O
clinical	O
use	O
.	O
Effects	O
of	O
4	O
-	O
alkylmorpholine	O
N	O
-	O
oxides	O
on	O
ATP	O
-	O
producing	O
processes	O
in	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
and	O
L1210	B-Anatomy
leukaemia	I-Anatomy
cells	I-Anatomy
.	O
The	O
main	O
purpose	O
of	O
the	O
present	O
investigation	O
was	O
to	O
study	O
the	O
effect	O
of	O
the	O
homologous	O
series	O
of	O
4	O
-	O
alkylmorpholine	O
N	O
-	O
oxides	O
on	O
ATP	O
-	O
producing	O
processes	O
in	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
and	O
L1210	B-Anatomy
murine	I-Anatomy
leukaemia	I-Anatomy
cells	I-Anatomy
.	O
The	O
effects	O
on	O
aerobic	O
glucose	O
consumption	O
,	O
lactic	O
acid	O
formation	O
,	O
content	O
of	O
total	O
(	O
T	O
-	O
SH	O
)	O
and	O
non	O
-	O
protein	O
thiol	O
groups	O
(	O
NP	O
-	O
SH	O
)	O
,	O
endogenous	O
and	O
exogenous	O
respiration	O
and	O
the	O
level	O
of	O
ATP	O
in	O
tumour	B-Anatomy
cells	I-Anatomy
incubated	O
in	O
vitro	O
were	O
investigated	O
.	O
4	O
-	O
Dodecylmorpholine	O
N	O
-	O
oxide	O
(	O
DMNO	O
)	O
,	O
one	O
of	O
the	O
most	O
active	O
compounds	O
,	O
decreased	O
the	O
level	O
of	O
ATP	O
immediately	O
after	O
addition	O
to	O
the	O
suspension	O
of	O
Ehrlich	B-Anatomy
cells	I-Anatomy
in	O
an	O
ice	O
bath	O
.	O
After	O
2	O
h	O
incubation	O
at	O
37	O
degrees	O
C	O
the	O
drop	O
in	O
the	O
ATP	O
level	O
was	O
much	O
lower	O
.	O
A	O
possible	O
explanation	O
for	O
the	O
decrease	O
in	O
the	O
ATP	O
level	O
might	O
be	O
interaction	O
of	O
the	O
amine	O
oxide	O
with	O
the	O
cell	B-Anatomy
membrane	I-Anatomy
.	O
The	O
Acute	O
Dialysis	O
Quality	O
Initiative	O
-	O
-	O
part	O
IV	O
:	O
membranes	B-Anatomy
for	O
CRRT	O
.	O
The	O
extracorporeal	B-Anatomy
membrane	I-Anatomy
used	O
in	O
a	O
continuous	O
renal	B-Anatomy
replacement	O
therapy	O
(	O
CRRT	O
)	O
for	O
the	O
treatment	O
of	O
a	O
critically	O
ill	O
patient	O
with	O
acute	O
renal	B-Anatomy
failure	O
(	O
ARF	O
)	O
is	O
vitally	O
important	O
for	O
several	O
reasons	O
,	O
including	O
its	O
influence	O
on	O
biocompatibility	O
and	O
filter	O
performance	O
.	O
The	O
clinical	O
relevance	O
of	O
membrane	B-Anatomy
-	O
related	O
biocompatibility	O
markers	O
traditionally	O
used	O
in	O
chronic	O
hemodialysis	O
remains	O
unclear	O
in	O
CRRT	O
.	O
Numerous	O
approaches	O
may	O
be	O
used	O
to	O
assess	O
membrane	B-Anatomy
and	O
filter	O
performance	O
in	O
CRRT	O
,	O
but	O
no	O
specific	O
methodology	O
is	O
accepted	O
widely	O
at	O
present	O
.	O
Although	O
a	O
potential	O
benefit	O
of	O
certain	O
membranes	B-Anatomy
used	O
for	O
CRRT	O
is	O
adsorptive	O
removal	O
of	O
inflammatory	O
mediators	O
,	O
this	O
issue	O
has	O
not	O
been	O
assessed	O
carefully	O
in	O
well	O
-	O
designed	O
clinical	O
trials	O
.	O
These	O
and	O
other	O
issues	O
should	O
be	O
the	O
subject	O
of	O
future	O
clinical	O
research	O
efforts	O
.	O
Fibroblast	O
growth	O
factor	O
2	O
promotes	O
microvessel	B-Anatomy
formation	O
from	O
mouse	O
embryonic	B-Anatomy
aorta	I-Anatomy
.	O
To	O
delineate	O
the	O
roles	O
that	O
oxygen	O
and	O
fibroblast	O
growth	O
factors	O
(	O
FGFs	O
)	O
play	O
in	O
the	O
process	O
of	O
angiogenesis	O
from	O
the	O
embryonic	B-Anatomy
aorta	I-Anatomy
,	O
we	O
cultured	O
mouse	O
embryonic	B-Anatomy
aorta	I-Anatomy
explants	I-Anatomy
(	O
thoracic	B-Anatomy
level	O
to	O
lateral	B-Anatomy
vessels	I-Anatomy
supplying	O
the	O
mesonephros	B-Anatomy
and	O
metanephros	B-Anatomy
)	O
in	O
a	O
three	O
-	O
dimensional	O
type	O
I	O
collagen	O
gel	O
matrix	O
.	O
During	O
8	O
days	O
of	O
culture	O
under	O
5	O
%	O
O	O
(	O
2	O
)	O
,	O
but	O
not	O
room	O
air	O
,	O
the	O
addition	O
of	O
FGF2	O
to	O
explants	O
stimulated	O
the	O
formation	O
of	O
Gs	B-Anatomy
-	I-Anatomy
IB	I-Anatomy
(	I-Anatomy
4	I-Anatomy
-	I-Anatomy
)	I-Anatomy
positive	I-Anatomy
,	O
CD31	B-Anatomy
-	I-Anatomy
positive	I-Anatomy
,	O
and	O
Flk	B-Anatomy
-	I-Anatomy
1	I-Anatomy
-	I-Anatomy
positive	I-Anatomy
microvessels	I-Anatomy
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O
FGF2	O
-	O
stimulated	O
microvessel	B-Anatomy
formation	O
was	O
inhibited	O
by	O
sequestration	O
of	O
FGF2	O
via	O
addition	O
of	O
soluble	O
FGF	O
receptor	O
(	O
FGFR	O
)	O
chimera	O
protein	O
or	O
anti	O
-	O
FGF2	O
antibodies	O
.	O
FGFR1	O
and	O
FGFR2	O
were	O
present	O
on	O
explants	O
.	O
Levels	O
of	O
FGFR1	O
,	O
but	O
not	O
FGFR2	O
,	O
were	O
increased	O
in	O
embryonic	B-Anatomy
aorta	I-Anatomy
cultured	O
under	O
5	O
%	O
O	O
(	O
2	O
)	O
relative	O
to	O
room	O
air	O
.	O
Our	O
data	O
suggest	O
that	O
low	O
oxygen	O
upregulates	O
FGFR1	O
expression	O
in	O
embryonic	B-Anatomy
aorta	I-Anatomy
in	O
vitro	O
and	O
renders	O
it	O
more	O
responsive	O
to	O
FGF2	O
.	O
Insulin	O
-	O
like	O
growth	O
factor	O
-	O
I	O
receptor	O
-	O
mediated	O
vasculogenesis	O
/	O
angiogenesis	O
in	O
human	O
lung	B-Anatomy
development	O
.	O
The	O
structural	O
and	O
functional	O
development	O
of	O
the	O
pulmonary	B-Anatomy
system	I-Anatomy
is	O
dependent	O
upon	O
appropriate	O
early	O
vascularization	O
of	O
the	O
embryonic	B-Anatomy
lung	I-Anatomy
.	O
Our	O
previous	O
in	O
vitro	O
studies	O
in	O
a	O
rat	O
model	O
indicated	O
that	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
I	O
(	O
IGF	O
-	O
I	O
)	O
is	O
a	O
potent	O
angiogenic	O
agent	O
for	O
fetal	B-Anatomy
lung	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
To	O
assess	O
its	O
role	O
on	O
human	O
vascular	B-Anatomy
lung	B-Anatomy
development	O
,	O
we	O
first	O
examined	O
the	O
expression	O
of	O
IGF	O
-	O
I	O
/	O
II	O
and	O
IGF	O
receptor	O
type	O
I	O
(	O
IGF	O
-	O
IR	O
)	O
in	O
human	O
embryonic	B-Anatomy
and	O
fetal	B-Anatomy
lung	I-Anatomy
tissues	I-Anatomy
at	O
4	O
-	O
12	O
wk	O
of	O
gestation	O
.	O
Immunohistochemical	O
and	O
in	O
situ	O
hybridization	O
studies	O
revealed	O
the	O
presence	O
of	O
IGF	O
-	O
I	O
/	O
II	O
-	O
IGF	O
-	O
IR	O
ligands	O
and	O
mRNA	O
transcripts	O
in	O
embryonic	B-Anatomy
lungs	I-Anatomy
as	O
early	O
as	O
4	O
wk	O
gestation	O
.	O
Immunotargeting	O
using	O
an	O
anti	O
-	O
IGF	O
-	O
IR	O
neutralizing	O
antibody	O
on	O
human	O
fetal	B-Anatomy
lung	I-Anatomy
explants	I-Anatomy
demonstrated	O
a	O
significant	O
blockade	O
of	O
IGF	O
-	O
IR	O
signaling	O
.	O
Inactivation	O
of	O
IGF	O
-	O
IR	O
resulted	O
in	O
a	O
loss	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
,	O
accompanied	O
by	O
dramatic	O
changes	O
in	O
fetal	B-Anatomy
lung	I-Anatomy
explant	O
morphology	O
.	O
Terminal	O
transferase	O
dUTP	O
end	O
-	O
labeling	O
assay	O
and	O
TEM	O
studies	O
of	O
anti	O
-	O
IGF	O
-	O
IR	O
-	O
treated	O
lungs	B-Anatomy
demonstrated	O
numerous	O
apoptotic	O
mesenchymal	B-Anatomy
cells	I-Anatomy
.	O
Rat	O
embryonic	B-Anatomy
lung	I-Anatomy
explant	O
studies	O
further	O
validated	O
the	O
importance	O
of	O
the	O
IGF	O
-	O
IGF	O
-	O
IR	O
system	O
for	O
lung	B-Anatomy
vascular	I-Anatomy
development	O
.	O
These	O
data	O
provide	O
the	O
first	O
demonstration	O
of	O
IGF	O
-	O
I	O
/	O
II	O
expression	O
in	O
the	O
human	O
lung	B-Anatomy
in	O
early	O
gestation	O
and	O
indicate	O
that	O
the	O
IGF	O
family	O
of	O
growth	O
factors	O
,	O
acting	O
through	O
the	O
IGF	O
-	O
IR	O
,	O
is	O
required	O
as	O
a	O
survival	O
factor	O
during	O
normal	O
human	O
lung	B-Anatomy
vascularization	O
.	O
Enhanced	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
by	O
periodontal	B-Anatomy
pathogens	O
in	O
gingival	B-Anatomy
fibroblasts	I-Anatomy
.	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
has	O
recently	O
attracted	O
attention	O
as	O
a	O
potent	O
inducer	O
of	O
vascular	B-Anatomy
permeability	O
and	O
angiogenesis	O
.	O
Aberrant	O
angiogenesis	O
is	O
often	O
associated	O
with	O
lesion	B-Anatomy
formation	O
in	O
chronic	O
periodontitis	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
properties	O
of	O
VEGF	O
expression	O
in	O
human	O
gingival	B-Anatomy
fibroblasts	I-Anatomy
(	O
HGF	B-Anatomy
)	O
culture	O
.	O
HGF	B-Anatomy
were	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
vesicle	B-Anatomy
(	O
Ve	B-Anatomy
)	O
and	O
outer	O
membrane	O
protein	O
(	O
OMP	O
)	O
from	O
Actinobacillus	O
actinomycetemcomitans	O
and	O
Porphyromonas	O
gingivalis	O
.	O
HGF	B-Anatomy
constitutively	O
produced	O
VEGF	O
and	O
levels	O
were	O
significantly	O
enhanced	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
by	O
stimulation	O
with	O
Ve	B-Anatomy
and	O
OMP	O
from	O
A	O
.	O
actinomycetemcomitans	O
and	O
P	O
.	O
gingivalis	O
at	O
concentrations	O
of	O
10	O
microg	O
/	O
ml	O
or	O
higher	O
.	O
On	O
the	O
other	O
hand	O
,	O
VEGF	O
levels	O
were	O
not	O
increased	O
by	O
LPS	O
stimulation	O
.	O
VEGF	O
mRNA	O
expression	O
was	O
also	O
observed	O
in	O
Ve	B-Anatomy
-	O
and	O
OMP	O
-	O
stimulated	O
HGF	B-Anatomy
.	O
A	O
vascular	B-Anatomy
permeability	O
enhancement	O
(	O
VPE	O
)	O
assay	O
was	O
performed	O
using	O
guinea	O
pigs	O
to	O
ascertain	O
whether	O
supernatant	B-Anatomy
from	O
cultures	B-Anatomy
of	O
Ve	B-Anatomy
-	O
and	O
OMP	O
-	O
stimulated	O
HGF	B-Anatomy
enhance	O
vascular	B-Anatomy
permeability	O
in	O
vivo	O
.	O
Supernatant	B-Anatomy
from	O
cultures	B-Anatomy
of	O
Ve	B-Anatomy
-	O
and	O
OMP	O
-	O
stimulated	O
HGF	B-Anatomy
strongly	O
induced	O
VPE	O
.	O
This	O
was	O
markedly	O
suppressed	O
upon	O
simultaneous	O
injection	O
of	O
anti	O
-	O
VEGF	O
polyclonal	O
antibodies	O
with	O
the	O
supernatant	B-Anatomy
.	O
Heating	O
and	O
protease	O
treatment	O
of	O
the	O
stimulants	O
reduced	O
the	O
VEGF	O
enhancing	O
levels	O
in	O
Ve	B-Anatomy
and	O
OMP	O
in	O
vitro	O
.	O
These	O
results	O
suggest	O
that	O
Ve	B-Anatomy
and	O
OMP	O
may	O
be	O
crucial	O
heat	O
-	O
labile	O
and	O
protease	O
-	O
sensitive	O
components	O
of	O
periodontal	B-Anatomy
pathogens	O
that	O
enhance	O
VEGF	O
expression	O
.	O
In	O
addition	O
,	O
VEGF	O
might	O
be	O
associated	O
with	O
the	O
etiology	O
of	O
periodontitis	O
in	O
its	O
early	O
stages	O
according	O
to	O
neovascularization	O
stimulated	O
by	O
periodontal	B-Anatomy
pathogens	O
causing	O
swelling	O
and	O
edema	B-Anatomy
.	O
NF	O
-	O
kappaB	O
/	O
Rel	O
transcriptional	O
pathway	O
:	O
implications	O
in	O
pancreatic	B-Anatomy
cancer	I-Anatomy
.	O
Despite	O
considerable	O
efforts	O
in	O
understanding	O
the	O
cellular	B-Anatomy
mechanisms	O
contributing	O
to	O
pancreatic	B-Anatomy
cancer	I-Anatomy
,	O
the	O
prognosis	O
of	O
this	O
malignant	B-Anatomy
disease	I-Anatomy
is	O
still	O
extremely	O
poor	O
.	O
Although	O
pancreatic	B-Anatomy
cancer	I-Anatomy
is	O
the	O
fifth	O
common	O
cause	O
of	O
cancer	B-Anatomy
death	O
in	O
Western	O
countries	O
,	O
current	O
options	O
in	O
treatment	O
enable	O
a	O
5	O
-	O
yr	O
survival	O
rate	O
for	O
all	O
stages	O
of	O
less	O
than	O
5	O
%	O
.	O
In	O
the	O
face	O
fo	O
the	O
fatal	O
outcome	O
,	O
new	O
approaches	O
to	O
the	O
therapy	O
have	O
been	O
established	O
.	O
Based	O
on	O
its	O
role	O
in	O
malignant	O
transformation	O
,	O
apoptosis	O
,	O
and	O
cell	B-Anatomy
proliferation	O
,	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
/	O
Rel	O
has	O
gained	O
the	O
attention	O
of	O
many	O
laboratories	O
.	O
This	O
review	O
provides	O
basic	O
information	O
for	O
the	O
understanding	O
of	O
the	O
biology	O
of	O
NF	O
-	O
kappaB	O
and	O
aims	O
at	O
presenting	O
experimental	O
data	O
illustrating	O
the	O
involvement	O
of	O
NF	O
-	O
kappaB	O
/	O
Rel	O
in	O
pancreatic	B-Anatomy
cancer	I-Anatomy
.	O
Sickle	B-Anatomy
cell	I-Anatomy
disease	O
:	O
continuous	O
arterial	B-Anatomy
spin	O
-	O
labeling	O
perfusion	O
MR	O
imaging	O
in	O
children	O
.	O
Cerebral	B-Anatomy
blood	B-Anatomy
flow	O
(	O
CBF	O
)	O
was	O
measured	O
with	O
continuous	O
arterial	B-Anatomy
spin	O
-	O
labeling	O
perfusion	O
magnetic	O
resonance	O
(	O
MR	O
)	O
imaging	O
in	O
14	O
children	O
with	O
sickle	B-Anatomy
cell	I-Anatomy
disease	O
and	O
seven	O
control	O
subjects	O
.	O
Mean	O
CBF	O
values	O
were	O
higher	O
in	O
patients	O
(	O
P	O
<	O
.	O
005	O
)	O
than	O
in	O
control	O
subjects	O
in	O
all	O
cerebral	B-Anatomy
artery	I-Anatomy
territories	O
.	O
Three	O
patients	O
had	O
decreased	O
CBF	O
in	O
right	B-Anatomy
anterior	I-Anatomy
and	O
middle	B-Anatomy
cerebral	I-Anatomy
artery	I-Anatomy
territories	O
compared	O
with	O
CBF	O
on	O
the	O
left	O
,	O
and	O
one	O
patient	O
had	O
a	O
profound	O
decrease	O
in	O
CBF	O
in	O
all	O
three	O
territories	O
in	O
the	O
right	B-Anatomy
hemisphere	I-Anatomy
.	O
Baseline	O
CBF	O
was	O
significantly	O
decreased	O
in	O
territories	O
seen	O
as	O
unaffected	O
on	O
conventional	O
MR	O
images	O
and	O
MR	O
angiograms	O
in	O
four	O
children	O
with	O
sickle	B-Anatomy
cell	I-Anatomy
disease	O
.	O
Combined	O
topical	O
fluconazole	O
and	O
corticosteroid	O
treatment	O
for	O
experimental	O
Candida	O
albicans	O
keratomycosis	O
.	O
PURPOSE	O
:	O
To	O
determine	O
the	O
most	O
efficient	O
time	O
point	O
and	O
concentration	O
of	O
topical	O
corticosteroids	O
in	O
Candida	O
albicans	O
keratitis	O
treated	O
with	O
fluconazole	O
.	O
METHODS	O
:	O
Corneas	B-Anatomy
of	O
105	O
rabbits	O
were	O
infected	O
with	O
viable	O
yeast	O
cells	B-Anatomy
of	O
C	O
.	O
albicans	O
(	O
2	O
.	O
5	O
x	O
10	O
(	O
5	O
)	O
)	O
.	O
After	O
a	O
48	O
-	O
hour	O
incubation	O
period	O
,	O
seven	O
groups	O
of	O
animals	O
were	O
treated	O
for	O
21	O
days	O
with	O
fluconazole	O
,	O
with	O
group	O
I	O
acting	O
as	O
a	O
control	O
,	O
and	O
groups	O
II	O
to	O
VII	O
receiving	O
adjunct	O
therapy	O
with	O
the	O
corticosteroid	O
prednisolone	O
(	O
5	O
or	O
10	O
times	O
daily	O
;	O
3	O
,	O
9	O
,	O
or	O
15	O
days	O
after	O
infection	O
)	O
.	O
The	O
degree	O
of	O
corneal	B-Anatomy
infiltration	O
,	O
ulceration	O
,	O
corneal	B-Anatomy
clouding	O
,	O
hypopyon	O
,	O
conjunctivitis	O
,	O
neovascularization	O
,	O
and	O
corneal	B-Anatomy
perforation	O
was	O
monitored	O
over	O
a	O
24	O
-	O
day	O
period	O
,	O
as	O
well	O
as	O
recultivation	O
and	O
resistance	O
to	O
fluconazole	O
of	O
the	O
C	O
.	O
albicans	O
pathogen	O
.	O
RESULTS	O
:	O
The	O
control	O
group	O
showed	O
the	O
highest	O
level	O
of	O
corneal	B-Anatomy
clouding	O
and	O
neovascularization	O
.	O
In	O
comparison	O
,	O
by	O
day	O
24	O
,	O
the	O
majority	O
of	O
groups	O
also	O
treated	O
with	O
prednisolone	O
displayed	O
significantly	O
less	O
corneal	B-Anatomy
clouding	O
and	O
neovascularization	O
.	O
An	O
immediate	O
decrease	O
in	O
corneal	B-Anatomy
clouding	O
was	O
observed	O
in	O
groups	O
treated	O
with	O
additional	O
low	O
-	O
or	O
high	O
-	O
dose	O
prednisolone	O
from	O
day	O
9	O
after	O
inoculation	O
.	O
After	O
additional	O
prednisolone	O
treatment	O
from	O
day	O
9	O
or	O
15	O
after	O
inoculation	O
,	O
no	O
significant	O
difference	O
was	O
detected	O
in	O
the	O
recultivation	O
rate	O
of	O
C	O
.	O
albicans	O
compared	O
with	O
the	O
control	O
.	O
Early	O
administration	O
of	O
prednisolone	O
(	O
day	O
3	O
,	O
low	O
and	O
high	O
dose	O
)	O
resulted	O
in	O
the	O
recultivation	O
of	O
significantly	O
more	O
C	O
.	O
albicans	O
.	O
CONCLUSIONS	O
:	O
Fluconazole	O
plus	O
adjunct	O
high	O
-	O
dose	O
prednisolone	O
treatment	O
was	O
most	O
effective	O
when	O
administered	O
9	O
days	O
after	O
infection	O
.	O
The	O
delayed	O
application	O
of	O
corticosteroids	O
after	O
treatment	O
with	O
antimycotic	O
drugs	O
in	O
cases	O
of	O
fungal	O
keratitis	O
is	O
therefore	O
not	O
contraindicated	O
and	O
may	O
be	O
beneficial	O
in	O
patients	O
.	O
Solid	B-Anatomy
tumor	I-Anatomy
therapy	O
:	O
manipulation	O
of	O
the	O
vasculature	B-Anatomy
with	O
TNF	O
.	O
Drug	O
delivery	O
to	O
solid	B-Anatomy
tumors	I-Anatomy
is	O
one	O
of	O
the	O
most	O
challenging	O
aspects	O
in	O
cancer	B-Anatomy
therapy	O
.	O
Whereas	O
agents	O
seem	O
promising	O
in	O
the	O
test	O
tube	O
,	O
clinical	O
trials	O
often	O
fail	O
due	O
to	O
unfavorable	O
pharmacokinetics	O
,	O
poor	O
delivery	O
,	O
low	O
local	O
concentrations	O
,	O
and	O
limited	O
accumulation	O
in	O
the	O
target	O
cell	B-Anatomy
.	O
A	O
major	O
step	O
forwards	O
in	O
the	O
treatment	O
of	O
solid	B-Anatomy
tumors	I-Anatomy
is	O
the	O
recognition	O
of	O
the	O
tumor	B-Anatomy
-	O
associated	O
vasculature	B-Anatomy
as	O
an	O
important	O
target	O
for	O
therapy	O
.	O
Inhibition	O
of	O
tumor	B-Anatomy
vascular	I-Anatomy
development	O
has	O
a	O
direct	O
effect	O
on	O
the	O
growth	O
and	O
progression	O
of	O
the	O
tumor	B-Anatomy
.	O
Destruction	O
of	O
an	O
existing	O
vasculature	B-Anatomy
also	O
directly	O
inflicts	O
serious	O
damage	O
to	O
the	O
tumor	B-Anatomy
cell	I-Anatomy
.	O
Moreover	O
,	O
the	O
tumor	B-Anatomy
vascular	I-Anatomy
bed	I-Anatomy
can	O
be	O
manipulated	O
facilitating	O
enhanced	O
permissiveness	O
of	O
the	O
tumor	B-Anatomy
for	O
administered	O
chemotherapeutics	O
.	O
In	O
this	O
review	O
,	O
we	O
focus	O
on	O
the	O
use	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
)	O
in	O
local	O
and	O
systemic	O
therapy	O
in	O
conjunction	O
with	O
chemotherapy	O
.	O
In	O
these	O
settings	O
TNF	O
demonstrates	O
potent	O
and	O
selective	O
activity	O
on	O
the	O
tumor	B-Anatomy
vascular	I-Anatomy
bed	I-Anatomy
,	O
which	O
strongly	O
improves	O
tumor	B-Anatomy
response	O
.	O
The	O
septic	B-Anatomy
abscess	I-Anatomy
wall	I-Anatomy
:	O
a	O
cytokine	O
-	O
generating	O
organ	B-Anatomy
associated	O
with	O
portal	B-Anatomy
venous	I-Anatomy
cytokinemia	O
,	O
hepatic	B-Anatomy
outflow	O
fibrosis	O
,	O
sinusoidal	B-Anatomy
congestion	O
,	O
inflammatory	B-Anatomy
cell	I-Anatomy
sequestration	O
,	O
hepatocellular	B-Anatomy
lipid	O
deposition	O
,	O
and	O
focal	O
cell	B-Anatomy
death	O
.	O
An	O
acute	O
septic	O
inflammatory	O
response	O
with	O
access	O
to	O
the	O
portal	O
circulation	O
was	O
created	O
in	O
a	O
rat	O
model	O
using	O
an	O
intra	B-Anatomy
-	I-Anatomy
abdominal	I-Anatomy
abscess	I-Anatomy
composed	O
of	O
a	O
sterile	O
agar	O
pellet	O
,	O
or	O
one	O
contaminated	O
with	O
102	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
)	O
and	O
109	O
Bacteriodes	O
fragilis	O
(	O
B	O
.	O
fragilis	O
)	O
.	O
After	O
3	O
days	O
postimplantation	O
,	O
a	O
well	O
-	O
formed	O
intra	B-Anatomy
-	I-Anatomy
abdominal	I-Anatomy
abscess	I-Anatomy
occurred	O
whose	O
wall	B-Anatomy
showed	O
IL	O
-	O
6	O
DNA	O
by	O
PCR	O
and	O
IL	O
-	O
6	O
mRNA	O
by	O
in	O
situ	O
hybridization	O
.	O
Portal	B-Anatomy
venous	I-Anatomy
blood	I-Anatomy
draining	O
into	O
the	O
liver	B-Anatomy
from	O
the	O
intra	B-Anatomy
-	I-Anatomy
abdominal	I-Anatomy
abscess	I-Anatomy
had	O
increased	O
levels	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
and	O
IL	O
-	O
6	O
in	O
both	O
sterile	O
and	O
septic	O
groups	O
compared	O
with	O
a	O
control	O
normal	O
animal	O
group	O
.	O
Increased	O
levels	O
of	O
these	O
cytokines	O
were	O
also	O
found	O
in	O
suprahepatic	B-Anatomy
inferior	I-Anatomy
vena	I-Anatomy
caval	I-Anatomy
blood	I-Anatomy
,	O
but	O
were	O
correlated	O
with	O
the	O
higher	O
portal	B-Anatomy
vein	I-Anatomy
levels	O
,	O
suggesting	O
a	O
gradient	O
from	O
abscess	B-Anatomy
wall	I-Anatomy
to	O
portal	B-Anatomy
vein	I-Anatomy
into	O
the	O
systemic	O
circulation	O
via	O
the	O
liver	B-Anatomy
.	O
Liver	B-Anatomy
histology	O
demonstrated	O
sinusoidal	B-Anatomy
congestion	O
centering	O
on	O
the	O
central	B-Anatomy
vein	I-Anatomy
,	O
growing	O
worse	O
with	O
progression	O
from	O
normal	O
in	O
control	O
,	O
to	O
sterile	O
,	O
to	O
septic	O
.	O
Similarly	O
,	O
the	O
degree	O
of	O
intrahepatic	O
myeloperoxidase	O
-	O
positive	O
inflammatory	B-Anatomy
cell	I-Anatomy
infiltration	O
and	O
hepatocellular	B-Anatomy
lipid	O
deposition	O
and	O
apoptosis	O
also	O
increased	O
from	O
control	O
,	O
to	O
sterile	O
,	O
to	O
septic	O
.	O
Gene	O
expression	O
by	O
in	O
situ	O
hybridization	O
demonstrated	O
a	O
significant	O
increase	O
in	O
IL	O
-	O
6	O
and	O
fibrinogen	O
mRNAs	O
in	O
cells	B-Anatomy
surrounding	O
the	O
central	B-Anatomy
vein	I-Anatomy
in	O
sterile	O
and	O
septic	O
animals	O
,	O
being	O
greatest	O
in	O
animals	O
with	O
sepsis	O
,	O
associated	O
with	O
an	O
increased	O
deposition	O
of	O
collagen	O
in	O
the	O
central	B-Anatomy
vein	I-Anatomy
area	I-Anatomy
,	O
most	O
prominent	O
in	O
the	O
septic	B-Anatomy
liver	I-Anatomy
.	O
The	O
pericentral	B-Anatomy
vein	I-Anatomy
cells	I-Anatomy
with	O
IL	O
-	O
6	O
and	O
fibrinogen	O
mRNA	O
increases	O
paralleled	O
the	O
increases	O
in	O
cells	B-Anatomy
containing	O
IL	O
-	O
6	O
and	O
fibrinogen	O
mRNAs	O
in	O
the	O
abscess	B-Anatomy
walls	I-Anatomy
of	O
sterile	O
and	O
septic	O
animals	O
,	O
respectively	O
.	O
The	O
data	O
suggest	O
that	O
an	O
intra	B-Anatomy
-	I-Anatomy
abdominal	I-Anatomy
abscess	I-Anatomy
,	O
especially	O
when	O
contaminated	O
with	O
gram	O
-	O
negative	O
bacteria	O
,	O
induces	O
mRNA	O
-	O
generated	O
cytokine	O
responses	O
in	O
the	O
abscess	B-Anatomy
wall	I-Anatomy
that	O
are	O
related	O
to	O
increased	O
portal	B-Anatomy
venous	I-Anatomy
levels	O
of	O
the	O
inflammatory	O
cytokines	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
and	O
IL	O
-	O
6	O
perfusing	O
the	O
liver	B-Anatomy
.	O
These	O
,	O
in	O
turn	O
,	O
induce	O
localized	O
production	O
of	O
IL	O
-	O
6	O
and	O
fibrinogen	O
mRNAs	O
in	O
cells	B-Anatomy
at	O
the	O
central	B-Anatomy
vein	I-Anatomy
area	I-Anatomy
with	O
resultant	O
outflow	O
fibrosis	O
and	O
increased	O
inflammatory	B-Anatomy
cell	I-Anatomy
sequestration	O
within	O
the	O
liver	B-Anatomy
lobular	I-Anatomy
sinuses	I-Anatomy
.	O
This	O
is	O
associated	O
with	O
a	O
generalized	O
inflammatory	O
response	O
and	O
intrahepatic	O
portal	O
sinusoid	O
congestion	O
.	O
There	O
is	O
also	O
increased	O
hepatocellular	B-Anatomy
lipid	O
deposition	O
and	O
apoptosis	O
.	O
Thus	O
,	O
the	O
cytokine	O
production	O
of	O
the	O
abscess	B-Anatomy
wall	I-Anatomy
itself	O
appears	O
to	O
be	O
a	O
major	O
mediator	O
of	O
the	O
septic	B-Anatomy
hepatic	I-Anatomy
response	O
.	O
Comparison	O
of	O
tissue	B-Anatomy
integration	O
between	O
polyester	O
and	O
polypropylene	O
prostheses	O
in	O
the	O
preperitoneal	B-Anatomy
space	I-Anatomy
.	O
Tissue	B-Anatomy
integration	O
and	O
implant	O
characteristics	O
of	O
various	O
biomaterials	O
commonly	O
used	O
for	O
inguinal	B-Anatomy
hernia	I-Anatomy
repair	O
have	O
not	O
been	O
studied	O
extensively	O
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
compare	O
behavior	O
and	O
tissue	B-Anatomy
response	O
between	O
two	O
new	O
polyester	O
prostheses	O
and	O
a	O
commonly	O
used	O
polypropylene	O
(	O
PP	O
)	O
mesh	O
.	O
The	O
polyester	O
prostheses	O
utilized	O
were	O
polyester	O
flat	O
(	O
PF	O
)	O
and	O
polyester	O
soft	O
three	O
-	O
dimensional	O
(	O
PS	O
)	O
;	O
the	O
PP	O
mesh	O
utilized	O
was	O
Marlex	O
.	O
Eight	O
randomly	O
assigned	O
4	O
x	O
4	O
-	O
cm2	O
pieces	O
of	O
two	O
different	O
meshes	O
were	O
fixed	O
in	O
the	O
preperitoneal	B-Anatomy
space	I-Anatomy
with	O
a	O
centrally	O
placed	O
single	O
suture	O
.	O
Gross	O
evaluation	O
included	O
shrinkage	O
and	O
stiffness	O
.	O
Histological	O
evaluation	O
included	O
amount	O
of	O
fibrous	B-Anatomy
and	O
fat	B-Anatomy
encapsulation	O
,	O
connective	B-Anatomy
tissue	I-Anatomy
,	O
foreign	O
-	O
body	O
reaction	O
,	O
neovascularization	O
,	O
hemorrhage	O
,	O
necrosis	O
,	O
and	O
exudate	B-Anatomy
.	O
Evaluations	O
were	O
graded	O
on	O
a	O
zero	O
to	O
four	O
scale	O
.	O
The	O
area	O
and	O
the	O
area	O
ratio	O
were	O
measured	O
using	O
a	O
calibrated	O
micrometer	O
.	O
PP	O
mesh	O
resulted	O
in	O
more	O
fibrous	B-Anatomy
encapsulation	O
and	O
stiffness	O
than	O
PF	O
and	O
PS	O
prostheses	O
.	O
PP	O
also	O
resulted	O
in	O
less	O
connective	B-Anatomy
tissue	I-Anatomy
formation	O
and	O
foreign	O
-	O
body	O
reaction	O
than	O
PF	O
and	O
PS	O
prostheses	O
.	O
There	O
was	O
no	O
difference	O
in	O
fat	B-Anatomy
encapsulation	O
,	O
necrosis	O
,	O
hemorrhage	O
,	O
or	O
exudate	B-Anatomy
between	O
prostheses	O
.	O
Both	O
polyester	O
prostheses	O
(	O
PF	O
and	O
PS	O
)	O
have	O
better	O
tissue	B-Anatomy
integration	O
than	O
the	O
PP	O
mesh	O
,	O
as	O
evidenced	O
by	O
the	O
higher	O
amount	O
of	O
connective	B-Anatomy
tissue	I-Anatomy
and	O
lower	O
extent	O
of	O
fibrous	B-Anatomy
encapsulation	O
.	O
Therapeutic	O
targeting	O
of	O
the	O
survivin	O
pathway	O
in	O
cancer	B-Anatomy
:	O
initiation	O
of	O
mitochondrial	B-Anatomy
apoptosis	O
and	O
suppression	O
of	O
tumor	B-Anatomy
-	O
associated	O
angiogenesis	O
.	O
PURPOSE	O
:	O
Molecular	O
antagonists	O
of	O
the	O
inhibitor	O
of	O
apoptosis	O
protein	O
survivin	O
have	O
shown	O
promise	O
as	O
novel	O
anticancer	B-Anatomy
strategies	O
for	O
triggering	O
tumor	B-Anatomy
cell	I-Anatomy
apoptosis	O
,	O
dysregulating	O
mitotic	O
progression	O
,	O
and	O
inhibiting	O
tumor	B-Anatomy
growth	O
in	O
preclinical	O
models	O
.	O
However	O
,	O
how	O
survivin	O
couples	O
to	O
the	O
cell	B-Anatomy
death	O
machinery	O
has	O
remained	O
elusive	O
,	O
and	O
the	O
relevant	O
cellular	B-Anatomy
targets	O
of	O
survivin	O
antagonists	O
have	O
not	O
been	O
completely	O
elucidated	O
.	O
Experimental	O
Design	O
:	O
Human	O
umbilical	B-Anatomy
vein	I-Anatomy
and	O
dermal	B-Anatomy
microvascular	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
were	O
infected	O
with	O
replication	O
-	O
deficient	O
adenoviruses	O
encoding	O
survivin	O
(	O
pAd	O
-	O
Survivin	O
)	O
,	O
green	O
fluorescent	O
protein	O
(	O
pAd	O
-	O
GFP	O
)	O
,	O
or	O
a	O
phosphorylation	O
-	O
defective	O
survivin	O
Thr	O
(	O
34	O
)	O
-	O
-	O
>	O
Ala	O
(	O
pAd	O
-	O
T34A	O
)	O
dominant	O
negative	O
mutant	O
.	O
The	O
effect	O
of	O
wild	O
-	O
type	O
or	O
mutant	O
survivin	O
was	O
investigated	O
on	O
capillary	B-Anatomy
network	I-Anatomy
stability	O
,	O
endothelial	B-Anatomy
cell	I-Anatomy
viability	O
,	O
and	O
caspase	O
activation	O
in	O
vitro	O
and	O
on	O
kinetics	O
of	O
tumor	B-Anatomy
growth	O
and	O
development	O
of	O
angiogenesis	O
in	O
a	O
breast	B-Anatomy
cancer	I-Anatomy
xenograft	I-Anatomy
model	O
in	O
vivo	O
.	O
The	O
cell	B-Anatomy
death	O
pathway	O
initiated	O
by	O
survivin	O
targeting	O
was	O
mapped	O
with	O
respect	O
to	O
cytochrome	O
c	O
release	O
,	O
changes	O
in	O
mitochondrial	B-Anatomy
transmembrane	I-Anatomy
potential	O
,	O
and	O
apoptosome	O
requirements	O
using	O
mouse	O
embryonic	B-Anatomy
fibroblasts	I-Anatomy
deficient	O
in	O
Apaf	O
-	O
1	O
or	O
caspase	O
-	O
9	O
.	O
RESULTS	O
:	O
Adenoviral	O
transduction	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
with	O
pAd	O
-	O
Survivin	O
inhibited	O
growth	O
factor	O
deprivation	O
-	O
or	O
ceramide	O
-	O
induced	O
apoptosis	O
,	O
reduced	O
caspase	O
-	O
3	O
and	O
-	O
7	O
generation	O
,	O
and	O
stabilized	O
three	O
-	O
dimensional	O
capillary	B-Anatomy
networks	I-Anatomy
in	O
vitro	O
.	O
Conversely	O
,	O
expression	O
of	O
pAd	O
-	O
T34A	O
caused	O
apoptosis	O
in	O
umbilical	B-Anatomy
vein	I-Anatomy
and	O
dermal	B-Anatomy
microvascular	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
and	O
resulted	O
in	O
caspase	O
-	O
3	O
activity	O
.	O
Cell	B-Anatomy
death	O
induced	O
by	O
survivin	O
targeting	O
exhibited	O
the	O
hallmarks	O
of	O
mitochondrial	B-Anatomy
-	O
dependent	O
apoptosis	O
with	O
release	O
of	O
cytochrome	O
c	O
and	O
loss	O
of	O
mitochondrial	B-Anatomy
transmembrane	I-Anatomy
potential	O
and	O
was	O
suppressed	O
in	O
Apaf	O
-	O
1	O
or	O
caspase	O
-	O
9	O
knockout	O
mouse	O
embryonic	B-Anatomy
fibroblasts	I-Anatomy
.	O
When	O
injected	O
in	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
xenografts	I-Anatomy
,	O
pAd	O
-	O
T34A	O
inhibited	O
growth	O
of	O
established	O
tumors	B-Anatomy
and	O
triggered	O
tumor	B-Anatomy
cell	I-Anatomy
apoptosis	O
in	O
vivo	O
.	O
This	O
was	O
associated	O
with	O
a	O
approximately	O
60	O
%	O
reduction	O
in	O
tumor	B-Anatomy
-	O
derived	O
blood	B-Anatomy
vessels	I-Anatomy
by	O
quantitative	O
morphometry	O
of	O
CD31	O
-	O
stained	O
tumor	B-Anatomy
areas	O
,	O
and	O
appearance	O
of	O
endothelial	B-Anatomy
cell	I-Anatomy
apoptosis	O
by	O
internucleosomal	O
DNA	O
fragmentation	O
in	O
vivo	O
.	O
CONCLUSIONS	O
:	O
Survivin	O
functions	O
as	O
a	O
novel	O
upstream	O
regulator	O
of	O
mitochondrial	B-Anatomy
-	O
dependent	O
apoptosis	O
,	O
and	O
molecular	O
targeting	O
of	O
this	O
pathway	O
results	O
in	O
anticancer	B-Anatomy
activity	O
via	O
a	O
dual	O
mechanism	O
of	O
induction	O
of	O
tumor	B-Anatomy
cell	I-Anatomy
apoptosis	O
and	O
suppression	O
of	O
angiogenesis	O
.	O
Integration	O
of	O
interferon	O
-	O
alpha	O
/	O
beta	O
signalling	O
to	O
p53	O
responses	O
in	O
tumour	B-Anatomy
suppression	O
and	O
antiviral	O
defence	O
.	O
Swift	O
elimination	O
of	O
undesirable	O
cells	B-Anatomy
is	O
an	O
important	O
feature	O
in	O
tumour	B-Anatomy
suppression	O
and	O
immunity	O
.	O
The	O
tumour	B-Anatomy
suppressor	O
p53	O
and	O
interferon	O
-	O
alpha	O
and	O
-	O
beta	O
(	O
IFN	O
-	O
alpha	O
/	O
beta	O
)	O
are	O
essential	O
for	O
the	O
induction	O
of	O
apoptosis	O
in	O
cancerous	B-Anatomy
cells	I-Anatomy
and	O
in	O
antiviral	O
immune	O
responses	O
,	O
respectively	O
,	O
but	O
little	O
is	O
known	O
about	O
their	O
interrelationship	O
.	O
Here	O
we	O
show	O
that	O
transcription	O
of	O
the	O
p53	O
gene	O
is	O
induced	O
by	O
IFN	O
-	O
alpha	O
/	O
beta	O
,	O
accompanied	O
by	O
an	O
increase	O
in	O
p53	O
protein	O
level	O
.	O
IFN	O
-	O
alpha	O
/	O
beta	O
signalling	O
itself	O
does	O
not	O
activate	O
p53	O
;	O
rather	O
,	O
it	O
contributes	O
to	O
boosting	O
p53	O
responses	O
to	O
stress	O
signals	O
.	O
We	O
show	O
examples	O
in	O
which	O
p53	O
gene	O
induction	O
by	O
IFN	O
-	O
alpha	O
/	O
beta	O
contributes	O
to	O
tumour	B-Anatomy
suppression	O
.	O
Furthermore	O
,	O
we	O
show	O
that	O
p53	O
is	O
activated	O
in	O
virally	O
infected	O
cells	B-Anatomy
to	O
evoke	O
an	O
apoptotic	O
response	O
and	O
that	O
p53	O
is	O
critical	O
for	O
antiviral	O
defence	O
of	O
the	O
host	O
.	O
Our	O
study	O
reveals	O
a	O
hitherto	O
unrecognized	O
link	O
between	O
p53	O
and	O
IFN	O
-	O
alpha	O
/	O
beta	O
in	O
tumour	B-Anatomy
suppression	O
and	O
antiviral	O
immunity	O
,	O
which	O
may	O
have	O
therapeutic	O
implications	O
.	O
T140	O
analogs	O
as	O
CXCR4	O
antagonists	O
identified	O
as	O
anti	O
-	O
metastatic	O
agents	O
in	O
the	O
treatment	O
of	O
breast	B-Anatomy
cancer	I-Anatomy
.	O
A	O
chemokine	O
receptor	O
,	O
CXCR4	O
,	O
and	O
its	O
endogenous	O
ligand	O
,	O
stromal	O
cell	O
-	O
derived	O
factor	O
-	O
1	O
(	O
SDF	O
-	O
1	O
)	O
,	O
have	O
been	O
recognized	O
to	O
be	O
involved	O
in	O
the	O
metastasis	O
of	O
several	O
types	O
of	O
cancers	B-Anatomy
.	O
T140	O
analogs	O
are	O
peptidic	O
CXCR4	O
antagonists	O
composed	O
of	O
14	O
amino	O
acid	O
residues	O
that	O
were	O
previously	O
developed	O
as	O
anti	O
-	O
HIV	O
agents	O
having	O
inhibitory	O
activity	O
against	O
HIV	O
-	O
entry	O
through	O
its	O
co	O
-	O
receptor	O
,	O
CXCR4	O
.	O
Herein	O
,	O
we	O
report	O
that	O
these	O
compounds	O
effectively	O
inhibited	O
SDF	O
-	O
1	O
-	O
induced	O
migration	O
of	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
(	O
MDA	B-Anatomy
-	I-Anatomy
MB	I-Anatomy
-	I-Anatomy
231	I-Anatomy
)	O
,	O
human	O
leukemia	B-Anatomy
T	I-Anatomy
cells	I-Anatomy
(	O
Sup	B-Anatomy
-	I-Anatomy
T1	I-Anatomy
)	O
and	O
human	B-Anatomy
umbilical	I-Anatomy
vein	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
at	O
concentrations	O
of	O
10	O
-	O
100	O
nM	O
in	O
vitro	O
.	O
Furthermore	O
,	O
slow	O
release	O
administration	O
by	O
subcutaneous	B-Anatomy
injection	O
using	O
an	O
Alzet	O
osmotic	O
pump	O
of	O
a	O
potent	O
and	O
bio	O
-	O
stable	O
T140	O
analog	O
,	O
4F	O
-	O
benzoyl	O
-	O
TN14003	O
,	O
gave	O
a	O
partial	O
,	O
but	O
statistically	O
significant	O
(	O
P	O
<	O
/	O
=	O
0	O
.	O
05	O
(	O
t	O
-	O
test	O
)	O
)	O
reduction	O
in	O
pulmonary	B-Anatomy
metastasis	O
of	O
MDA	B-Anatomy
-	I-Anatomy
MB	I-Anatomy
-	I-Anatomy
231	I-Anatomy
in	O
SCID	O
mice	O
,	O
even	O
though	O
no	O
attempt	O
was	O
made	O
to	O
inhibit	O
other	O
important	O
targets	O
such	O
as	O
CCR7	O
.	O
These	O
results	O
suggest	O
that	O
T140	O
analogs	O
have	O
potential	O
use	O
for	O
cancer	B-Anatomy
therapy	O
,	O
and	O
that	O
small	O
molecular	O
CXCR4	O
antagonists	O
could	O
potentially	O
replace	O
neutralizing	O
antibodies	O
as	O
anti	O
-	O
metastatic	O
agents	O
for	O
breast	B-Anatomy
cancer	I-Anatomy
.	O
Treatment	O
effects	O
on	O
nigrostriatal	B-Anatomy
projection	O
integrity	O
in	O
partial	O
6	O
-	O
OHDA	O
lesions	B-Anatomy
:	O
comparison	O
of	O
L	O
-	O
DOPA	O
and	O
pramipexole	O
.	O
There	O
is	O
controversy	O
over	O
potential	O
effects	O
of	O
dopaminergic	O
replacement	O
therapies	O
on	O
the	O
partially	O
lesioned	B-Anatomy
nigrostriatal	I-Anatomy
dopaminergic	O
projection	O
.	O
We	O
evaluated	O
indirect	O
(	O
levodopa	O
,	O
L	O
-	O
DOPA	O
)	O
versus	O
direct	O
(	O
pramipexole	O
,	O
PRA	O
)	O
dopaminergic	O
treatment	O
effects	O
on	O
nigrostriatal	B-Anatomy
lesion	I-Anatomy
severity	O
as	O
measured	O
with	O
vesicular	O
monoamine	O
transporter	O
type	O
-	O
2	O
(	O
VMAT2	O
)	O
binding	O
.	O
Prior	O
studies	O
have	O
shown	O
that	O
striatal	B-Anatomy
VMAT2	O
density	O
provides	O
an	O
objective	O
estimate	O
of	O
dopaminergic	O
neuronal	B-Anatomy
integrity	O
,	O
without	O
confounding	O
effects	O
of	O
compensatory	O
regulation	O
.	O
Partial	O
unilateral	B-Anatomy
median	I-Anatomy
forebrain	I-Anatomy
bundle	I-Anatomy
lesions	I-Anatomy
were	O
made	O
by	O
injection	O
of	O
6	O
-	O
hydroxydopamine	O
in	O
adult	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
.	O
Lesion	B-Anatomy
severity	O
was	O
estimated	O
using	O
rotational	O
behavior	O
after	O
injections	O
of	O
apomorphine	O
and	O
amphetamine	O
.	O
Rats	O
were	O
ranked	O
and	O
matched	O
in	O
pairs	O
by	O
rotation	O
and	O
assigned	O
to	O
receive	O
either	O
PRA	O
(	O
1	O
mg	O
/	O
kg	O
/	O
day	O
)	O
or	O
L	O
-	O
DOPA	O
/	O
benserazide	O
(	O
100	O
/	O
25	O
mg	O
/	O
kg	O
/	O
day	O
)	O
ip	O
via	O
osmotic	O
pump	O
.	O
After	O
4	O
weeks	O
of	O
drug	O
treatment	O
,	O
in	O
vitro	O
autoradiography	O
was	O
performed	O
with	O
[	O
(	O
3	O
)	O
H	O
]	O
methoxytetrabenazine	O
to	O
measure	O
striatal	B-Anatomy
VMAT2	O
binding	O
density	O
.	O
Lesion	B-Anatomy
-	O
to	O
-	O
intact	O
VMAT2	O
density	O
correlated	O
with	O
rotation	O
in	O
both	O
treatment	O
groups	O
.	O
There	O
was	O
no	O
treatment	O
effect	O
on	O
VMAT2	O
expression	O
in	O
the	O
partially	O
lesioned	B-Anatomy
striatum	I-Anatomy
and	O
thus	O
no	O
differential	O
effect	O
of	O
indirect	O
versus	O
direct	O
dopamimetic	O
treatment	O
on	O
nigrostriatal	B-Anatomy
integrity	O
.	O
CCL16	O
activates	O
an	O
angiogenic	O
program	O
in	O
vascular	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
Besides	O
regulating	O
leukocyte	B-Anatomy
trafficking	O
in	O
normal	O
and	O
injured	O
tissues	B-Anatomy
,	O
several	O
chemokines	O
may	O
positively	O
or	O
negatively	O
regulate	O
angiogenesis	O
.	O
Here	O
we	O
report	O
that	O
CCL16	O
activates	O
an	O
angiogenic	O
program	O
in	O
vascular	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
by	O
activating	O
CCR1	O
.	O
CCL16	O
induces	O
dose	O
-	O
dependent	O
random	O
and	O
directional	O
migration	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
isolated	O
from	O
large	O
vessels	B-Anatomy
and	O
liver	B-Anatomy
capillaries	I-Anatomy
without	O
inducing	O
their	O
proliferation	O
.	O
It	O
also	O
promotes	O
endothelial	B-Anatomy
differentiation	O
into	O
capillary	B-Anatomy
-	I-Anatomy
like	I-Anatomy
structures	I-Anatomy
in	O
an	O
in	O
vitro	O
assay	O
and	O
is	O
angiogenic	O
in	O
the	O
chick	O
chorionallantoic	B-Anatomy
membrane	I-Anatomy
.	O
These	O
angiogenic	O
activities	O
are	O
neutralized	O
by	O
a	O
specific	O
antibody	O
against	O
CCL16	O
.	O
The	O
direct	O
angiogenic	O
activity	O
of	O
CCL16	O
is	O
further	O
amplified	O
by	O
its	O
ability	O
to	O
prime	O
endothelium	B-Anatomy
to	O
a	O
mitogen	O
signal	O
induced	O
by	O
vascular	O
endothelial	O
growth	O
factor	O
A	O
and	O
to	O
raise	O
their	O
basal	O
production	O
of	O
CXCL8	O
and	O
CCL2	O
,	O
2	O
other	O
angiogenic	O
chemokines	O
.	O
BX471	O
(	O
R	O
-	O
N	O
-	O
[	O
5	O
-	O
chloro	O
-	O
2	O
-	O
[	O
2	O
-	O
[	O
4	O
(	O
4	O
-	O
fluorophenyl	O
)	O
methyl	O
]	O
-	O
2	O
-	O
methyl	O
-	O
1	O
-	O
piperazinyl	O
]	O
-	O
2	O
-	O
oxoethoxy	O
]	O
phenyl	O
]	O
urea	O
hydrochloric	O
acid	O
salt	O
)	O
,	O
a	O
CCR1	O
antagonist	O
,	O
inhibits	O
angiogenic	O
properties	O
of	O
CCL16	O
,	O
whereas	O
blocking	O
of	O
CCR8	O
or	O
desensitizing	O
CCR2	O
,	O
which	O
are	O
both	O
well	O
known	O
receptors	O
for	O
CCL16	O
,	O
did	O
not	O
abolish	O
endothelial	B-Anatomy
activation	O
.	O
CCL16	O
may	O
be	O
specifically	O
cross	O
-	O
linked	O
to	O
CCR1	O
expressed	O
on	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
The	O
largely	O
restricted	O
CCL16	O
expression	O
in	O
the	O
liver	B-Anatomy
suggests	O
that	O
this	O
chemokine	O
may	O
play	O
a	O
role	O
in	O
hepatic	B-Anatomy
vascular	I-Anatomy
formation	O
during	O
development	O
and	O
in	O
angiogenesis	O
associated	O
to	O
hepatic	B-Anatomy
diseases	O
.	O
Simvastatin	O
induces	O
apoptosis	O
of	O
B	B-Anatomy
-	I-Anatomy
CLL	I-Anatomy
cells	I-Anatomy
by	O
activation	O
of	O
mitochondrial	B-Anatomy
caspase	O
9	O
.	O
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Chronic	B-Anatomy
lymphocytic	I-Anatomy
leukemia	I-Anatomy
(	O
CLL	B-Anatomy
)	O
is	O
the	O
most	O
common	O
leukemia	B-Anatomy
in	O
the	O
western	O
world	O
.	O
Despite	O
several	O
advances	O
in	O
therapeutic	O
options	O
,	O
the	O
disease	O
remains	O
incurable	O
.	O
Recently	O
,	O
it	O
was	O
repeatedly	O
demonstrated	O
that	O
statins	O
,	O
competitive	O
inhibitors	O
of	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methyl	O
glutaryl	O
coenzyme	O
A	O
(	O
HMG	O
-	O
CoA	O
)	O
reductase	O
,	O
have	O
antineoplastic	B-Anatomy
effects	O
.	O
Therefore	O
we	O
aimed	O
to	O
study	O
the	O
effects	O
of	O
simvastatin	O
(	O
Sim	O
)	O
on	O
malignant	B-Anatomy
B	I-Anatomy
cells	I-Anatomy
derived	O
from	O
patients	O
with	O
CLL	B-Anatomy
and	O
mechanisms	O
of	O
action	O
of	O
the	O
drug	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
Purified	O
B	B-Anatomy
-	I-Anatomy
CLL	I-Anatomy
cells	I-Anatomy
from	O
15	O
patients	O
were	O
cultured	O
either	O
alone	O
or	O
with	O
Sim	O
at	O
concentrations	O
of	O
10	O
,	O
50	O
,	O
and	O
100	O
microM	O
.	O
Viability	O
,	O
measured	O
by	O
the	O
activity	O
of	O
mitochondrial	B-Anatomy
dehydrogenases	O
,	O
was	O
reduced	O
significantly	O
in	O
the	O
cells	B-Anatomy
treated	O
with	O
Sim	O
at	O
50	O
and	O
100	O
microM	O
for	O
24	O
hours	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
.	O
The	O
level	O
of	O
apoptosis	O
,	O
as	O
measured	O
by	O
annexin	O
binding	O
to	O
exposed	O
phosphatidylserine	O
moieties	O
,	O
increased	O
significantly	O
in	O
the	O
treated	O
cells	B-Anatomy
at	O
concentrations	O
higher	O
than	O
50	O
microM	O
for	O
24	O
hours	O
(	O
p	O
<	O
0	O
.	O
003	O
)	O
.	O
The	O
level	O
of	O
necrosis	O
,	O
as	O
measured	O
by	O
propidium	O
iodide	O
internalization	O
,	O
increased	O
significantly	O
after	O
24	O
hours	O
exposure	O
to	O
Sim	O
at	O
50	O
microM	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
The	O
apoptotic	O
cascade	O
was	O
studied	O
by	O
immunoblot	O
analysis	O
of	O
caspases	O
following	O
Sim	O
treatment	O
.	O
These	O
showed	O
cleavage	O
of	O
caspases	O
9	O
,	O
8	O
,	O
and	O
3	O
.	O
Addition	O
of	O
the	O
caspase	O
inhibitor	O
Z	O
-	O
VAD	O
.	O
fmk	O
inhibited	O
caspase	O
8	O
and	O
3	O
significantly	O
but	O
did	O
not	O
affect	O
caspase	O
9	O
.	O
CONCLUSION	O
:	O
Exposure	O
of	O
clonal	B-Anatomy
B	I-Anatomy
lymphocytes	I-Anatomy
from	O
patients	O
with	O
CLL	B-Anatomy
to	O
simvastatin	O
decreases	O
viability	O
significantly	O
by	O
the	O
induction	O
of	O
apoptosis	O
.	O
The	O
apoptosis	O
induced	O
by	O
Sim	O
is	O
probably	O
initiated	O
by	O
the	O
mitochondrial	B-Anatomy
caspase	O
9	O
,	O
which	O
indirectly	O
leads	O
to	O
activation	O
of	O
caspase	O
3	O
and	O
8	O
.	O
Neutrophil	B-Anatomy
function	O
in	O
chronic	B-Anatomy
neutrophilic	I-Anatomy
leukemia	I-Anatomy
:	O
defective	O
respiratory	B-Anatomy
burst	O
in	O
response	O
to	O
phorbol	O
esters	O
.	O
Functional	O
analyses	O
were	O
performed	O
on	O
neutrophils	B-Anatomy
isolated	O
from	O
6	O
patients	O
from	O
two	O
institutions	O
who	O
displayed	O
features	O
of	O
chronic	B-Anatomy
neutrophilic	I-Anatomy
leukemia	I-Anatomy
(	O
CNL	B-Anatomy
)	O
.	O
These	O
neutrophils	B-Anatomy
demonstrated	O
a	O
consistent	O
deficiency	O
(	O
44	O
+	O
/	O
-	O
8	O
%	O
of	O
control	O
values	O
)	O
in	O
superoxide	O
anion	O
(	O
O2	O
-	O
)	O
production	O
in	O
response	O
to	O
the	O
phorbol	O
ester	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O
O2	O
-	O
production	O
in	O
response	O
to	O
chemotactic	O
peptides	O
was	O
near	O
normal	O
(	O
82	O
.	O
3	O
+	O
/	O
-	O
10	O
.	O
7	O
%	O
of	O
control	O
values	O
)	O
.	O
Bacterial	O
killing	O
was	O
normal	O
in	O
the	O
two	O
patients	O
studied	O
,	O
and	O
chemotaxis	O
was	O
diminished	O
in	O
response	O
to	O
zymosan	O
-	O
activated	O
plasma	B-Anatomy
and	O
to	O
high	O
concentrations	O
of	O
chemotactic	O
peptides	O
in	O
the	O
patients	O
studied	O
.	O
Cytosolic	O
C	O
kinase	O
activity	O
was	O
decreased	O
in	O
one	O
of	O
the	O
two	O
patients	O
studied	O
.	O
These	O
results	O
suggest	O
that	O
a	O
deficient	O
O2	O
-	O
release	O
in	O
response	O
to	O
PMA	O
is	O
a	O
hallmark	O
of	O
neutrophils	B-Anatomy
in	O
CNL	B-Anatomy
and	O
may	O
provide	O
a	O
diagnostic	O
indicator	O
of	O
this	O
condition	O
.	O
In	O
situ	O
alkylation	O
of	O
cysteine	O
residues	O
in	O
a	O
hydrophobic	O
membrane	B-Anatomy
protein	O
immobilized	O
on	O
polyvinylidene	O
difluoride	O
membranes	O
by	O
electroblotting	O
prior	O
to	O
microsequence	O
and	O
amino	O
acid	O
analysis	O
.	O
For	O
identification	O
of	O
cysteine	O
residues	O
on	O
microsequence	O
analysis	O
it	O
is	O
crucial	O
to	O
derivatize	O
the	O
sulfhydryl	O
groups	O
.	O
This	O
reaction	O
requires	O
a	O
desalting	O
step	O
which	O
often	O
represents	O
a	O
major	O
obstacle	O
,	O
especially	O
if	O
the	O
sample	O
consists	O
of	O
limited	O
amounts	O
of	O
a	O
hydrophobic	O
membrane	B-Anatomy
protein	O
.	O
An	O
alkylation	O
procedure	O
is	O
described	O
,	O
allowing	O
efficient	O
derivatization	O
(	O
greater	O
than	O
90	O
%	O
)	O
of	O
cysteines	O
and	O
cystines	O
even	O
in	O
low	O
microgram	O
quantities	O
,	O
as	O
revealed	O
by	O
test	O
analyses	O
with	O
lysozyme	O
and	O
a	O
hydrophobic	O
membrane	B-Anatomy
protein	O
.	O
The	O
modified	O
protein	O
is	O
recovered	O
in	O
high	O
yields	O
in	O
a	O
form	O
suitable	O
for	O
both	O
microsequence	O
analysis	O
and	O
amino	O
acid	O
analysis	O
.	O
The	O
method	O
involves	O
electrophoretic	O
desalting	O
by	O
miniaturized	O
Tricine	O
-	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
in	O
situ	O
alkylation	O
after	O
electro	O
-	O
transfer	O
onto	O
polyvinylidene	O
difluoride	O
membranes	O
.	O
Precautions	O
against	O
NH2	O
-	O
terminal	O
blocking	O
during	O
sample	O
preparations	O
are	O
provided	O
.	O
The	O
general	O
applicability	O
of	O
the	O
method	O
is	O
illustrated	O
by	O
the	O
structural	O
characterization	O
of	O
the	O
low	O
abundance	O
membrane	B-Anatomy
receptor	O
for	O
human	O
urokinase	O
plasminogen	O
activator	O
.	O
The	O
effect	O
of	O
p	O
-	O
chlorophenylalanine	O
on	O
the	O
pethidine	O
-	O
or	O
methadone	O
-	O
induced	O
decrease	O
in	O
locomotor	O
activity	O
of	O
rats	O
.	O
Either	O
pethidine	O
HCl	O
(	O
50	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
or	O
methadone	O
HCl	O
(	O
8	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
produced	O
a	O
prominent	O
decrease	O
in	O
locomotor	O
activity	O
of	O
rats	O
.	O
Pretreatment	O
of	O
rats	O
with	O
p	O
-	O
chlorophenylalanine	O
(	O
p	O
-	O
CPA	O
,	O
320	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
48	O
h	O
before	O
the	O
narcotic	O
injection	O
significantly	O
antagonized	O
the	O
activity	O
-	O
decreasing	O
effects	O
of	O
narcotics	O
.	O
When	O
rats	O
pretreated	O
with	O
p	O
-	O
CPA	O
were	O
given	O
5	O
-	O
hydroxytryptophan	O
(	O
75	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
30	O
min	O
before	O
narcotic	O
administration	O
,	O
the	O
activity	O
-	O
decreasing	O
response	O
to	O
narcotics	O
was	O
restored	O
.	O
Thus	O
,	O
a	O
decrease	O
in	O
locomotor	O
activity	O
induced	O
in	O
rats	O
by	O
either	O
pethidine	O
or	O
methadone	O
is	O
probably	O
mediated	O
by	O
serotonergic	O
mechanisms	O
.	O
Autocrine	O
angiotensin	O
system	O
regulation	O
of	O
bovine	O
aortic	B-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
migration	O
and	O
plasminogen	O
activator	O
involves	O
modulation	O
of	O
proto	O
-	O
oncogene	O
pp60c	O
-	O
src	O
expression	O
.	O
Rapid	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
and	O
inhibition	O
of	O
thrombosis	O
are	O
critical	O
for	O
the	O
resolution	O
of	O
denudation	O
injuries	O
to	O
the	O
vessel	B-Anatomy
wall	I-Anatomy
.	O
Inhibition	O
of	O
the	O
endothelial	B-Anatomy
cell	I-Anatomy
autocrine	O
angiotensin	O
system	O
,	O
with	O
either	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
lisinopril	O
or	O
the	O
angiotensin	O
II	O
receptor	O
antagonist	O
sar1	O
,	O
ile8	O
-	O
angiotensin	O
II	O
,	O
leads	O
to	O
increased	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
and	O
urokinase	O
-	O
like	O
plasminogen	O
activator	O
(	O
u	O
-	O
PA	O
)	O
activity	O
(	O
Bell	O
,	O
L	O
.	O
,	O
and	O
J	O
.	O
A	O
.	O
Madri	O
.	O
1990	O
.	O
Am	O
.	O
J	O
.	O
Pathol	O
.	O
137	O
:	O
7	O
-	O
12	O
)	O
.	O
Inhibition	O
of	O
the	O
autocrine	O
angiotensin	O
system	O
with	O
the	O
converting	O
-	O
enzyme	O
inhibitor	O
or	O
the	O
receptor	O
antagonist	O
also	O
leads	O
to	O
increased	O
expression	O
of	O
the	O
proto	O
-	O
oncogene	O
c	O
-	O
src	O
:	O
pp60c	O
-	O
src	O
mRNA	O
increased	O
7	O
-	O
11	O
-	O
fold	O
,	O
c	O
-	O
src	O
protein	O
3	O
-	O
fold	O
,	O
and	O
c	O
-	O
src	O
kinase	O
activity	O
2	O
-	O
3	O
-	O
fold	O
.	O
Endothelial	B-Anatomy
cell	I-Anatomy
expression	O
of	O
c	O
-	O
src	O
was	O
constitutively	O
elevated	O
after	O
stable	O
infection	O
with	O
a	O
retroviral	O
vector	O
containing	O
the	O
c	O
-	O
src	O
coding	O
sequence	O
.	O
Constitutively	O
increased	O
c	O
-	O
src	O
kinase	O
activity	O
reconstituted	O
the	O
increases	O
in	O
migration	O
and	O
u	O
-	O
PA	O
observed	O
with	O
angiotensin	O
system	O
interruption	O
.	O
Antisera	O
to	O
bovine	O
u	O
-	O
PA	O
blocked	O
the	O
increase	O
in	O
migration	O
associated	O
with	O
increased	O
c	O
-	O
src	O
expression	O
.	O
These	O
data	O
suggest	O
that	O
increases	O
in	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
and	O
plasminogen	O
activator	O
after	O
angiotensin	O
system	O
inhibition	O
are	O
at	O
least	O
partially	O
pp60c	O
-	O
src	O
mediated	O
.	O
Elevated	O
c	O
-	O
src	O
expression	O
with	O
angiotensin	O
system	O
inhibition	O
may	O
act	O
to	O
enhance	O
intimal	B-Anatomy
wound	I-Anatomy
closure	O
and	O
to	O
reduce	O
luminal	B-Anatomy
thrombogenicity	O
in	O
vivo	O
.	O
The	O
presence	O
of	O
nitrite	O
during	O
UVA	O
irradiation	O
protects	O
from	O
apoptosis	O
.	O
Nitrite	O
occurs	O
ubiquitously	O
in	O
biological	B-Anatomy
fluids	I-Anatomy
such	O
as	O
blood	B-Anatomy
and	O
sweat	B-Anatomy
,	O
representing	O
an	O
oxidation	O
product	O
of	O
nitric	O
oxide	O
.	O
Nitrite	O
has	O
been	O
associated	O
with	O
a	O
variety	O
of	O
adverse	O
effects	O
such	O
as	O
mutagenicity	O
,	O
carcinogenesis	O
,	O
and	O
toxicity	O
.	O
In	O
contrast	O
,	O
here	O
we	O
demonstrate	O
that	O
the	O
presence	O
of	O
nitrite	O
,	O
but	O
not	O
nitrate	O
,	O
during	O
irradiation	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
in	O
culture	O
exerts	O
a	O
potent	O
and	O
concentration	O
-	O
dependent	O
protection	O
against	O
UVA	O
-	O
induced	O
apoptotic	O
cell	B-Anatomy
death	O
.	O
Protection	O
is	O
half	O
-	O
maximal	O
at	O
a	O
concentration	O
of	O
3	O
mM	O
,	O
and	O
complete	O
rescue	O
is	O
observed	O
at	O
10	O
mM	O
.	O
Nitrite	O
-	O
mediated	O
protection	O
is	O
mediated	O
via	O
inhibition	O
of	O
lipid	O
peroxidation	O
in	O
a	O
similar	O
manner	O
as	O
seen	O
with	O
butylated	O
hydroxytoluene	O
,	O
a	O
known	O
inhibitor	O
of	O
lipid	O
peroxidation	O
.	O
Interestingly	O
,	O
nitrite	O
-	O
mediated	O
protection	O
is	O
completely	O
abolished	O
by	O
coincubation	O
with	O
the	O
NO	O
scavenger	O
cPTIO	O
.	O
Using	O
electron	O
paramagnetic	O
resonance	O
(	O
EPR	O
)	O
spectroscopy	O
or	O
Faraday	O
modulation	O
spectroscopy	O
,	O
we	O
directly	O
prove	O
UVA	O
-	O
induced	O
NO	O
formation	O
in	O
solutions	O
containing	O
nitrite	O
.	O
In	O
conclusion	O
,	O
evidence	O
is	O
presented	O
that	O
nitrite	O
represents	O
a	O
protective	O
agent	O
against	O
UVA	O
-	O
induced	O
apoptosis	O
due	O
to	O
photodecomposition	O
of	O
nitrite	O
and	O
subsequent	O
formation	O
of	O
NO	O
.	O
Induction	O
of	O
apoptosis	O
in	O
skeletal	B-Anatomy
tissues	I-Anatomy
:	O
phosphate	O
-	O
mediated	O
chick	O
chondrocyte	B-Anatomy
apoptosis	O
is	O
calcium	O
dependent	O
.	O
In	O
an	O
earlier	O
study	O
,	O
we	O
have	O
shown	O
that	O
Pi	O
induced	O
apoptosis	O
of	O
terminally	O
differentiated	O
hypertrophic	O
chondrocytes	B-Anatomy
.	O
To	O
ascertain	O
whether	O
Ca2	O
+	O
modulates	O
Pi	O
-	O
induced	O
cell	B-Anatomy
death	O
,	O
we	O
asked	O
the	O
following	O
two	O
questions	O
:	O
First	O
,	O
can	O
we	O
prevent	O
Pi	O
-	O
induced	O
apoptosis	O
by	O
removing	O
Ca2	O
+	O
from	O
the	O
culture	O
medium	O
;	O
alternatively	O
,	O
can	O
we	O
potentiate	O
cell	B-Anatomy
death	O
by	O
increasing	O
the	O
Ca2	O
+	O
concentration	O
?	O
Second	O
,	O
can	O
we	O
inhibit	O
chondrocyte	B-Anatomy
apoptosis	O
by	O
blocking	O
Pi	O
transport	O
?	O
We	O
also	O
explored	O
the	O
mechanism	O
of	O
apoptosis	O
by	O
evaluating	O
mitochondrial	B-Anatomy
activity	O
and	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
generation	O
in	O
cells	B-Anatomy
treated	O
with	O
the	O
ion	O
pair	O
.	O
We	O
noted	O
that	O
EDTA	O
and	O
EGTA	O
blocked	O
Pi	O
-	O
induced	O
apoptosis	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
While	O
high	O
levels	O
of	O
Ca2	O
+	O
alone	O
had	O
little	O
effect	O
on	O
chondrocyte	B-Anatomy
viability	O
,	O
the	O
cation	O
enhanced	O
Pi	O
-	O
dependent	O
cell	B-Anatomy
death	O
and	O
greatly	O
increased	O
Pi	O
uptake	O
.	O
When	O
Pi	O
transport	O
was	O
blocked	O
,	O
there	O
was	O
complete	O
inhibition	O
of	O
cell	B-Anatomy
killing	O
.	O
The	O
process	O
of	O
cell	B-Anatomy
death	O
was	O
characterized	O
by	O
mitochondrial	B-Anatomy
hyperpolarization	O
;	O
two	O
hours	O
following	O
apoptogen	O
treatment	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
mitochondrial	B-Anatomy
membrane	I-Anatomy
potential	O
.	O
Coincident	O
with	O
the	O
changes	O
in	O
mitochondrial	B-Anatomy
function	O
,	O
there	O
was	O
an	O
increase	O
in	O
intracellular	B-Anatomy
Ca2	O
+	O
that	O
was	O
maintained	O
throughout	O
the	O
experimental	O
period	O
.	O
A	O
raised	O
Ca2	O
+	O
signal	O
was	O
observed	O
in	O
blebs	B-Anatomy
at	O
the	O
cell	B-Anatomy
membrane	I-Anatomy
.	O
Finally	O
,	O
we	O
noted	O
that	O
,	O
75	O
minutes	O
after	O
treatment	O
with	O
the	O
ion	O
pair	O
,	O
there	O
was	O
a	O
six	O
-	O
fold	O
elevation	O
in	O
ROS	O
levels	O
.	O
This	O
increase	O
declined	O
to	O
baseline	O
values	O
after	O
three	O
hours	O
.	O
Based	O
on	O
these	O
observations	O
,	O
we	O
suggest	O
that	O
,	O
at	O
the	O
cartilage	B-Anatomy
mineralization	O
front	O
,	O
an	O
elevation	O
in	O
local	O
environmental	O
Ca2	O
+	O
and	O
Pi	O
concentrations	O
modulates	O
oxidative	O
metabolism	O
,	O
and	O
triggers	O
apoptosis	O
of	O
terminally	O
differentiated	O
chondrocytes	B-Anatomy
.	O
Cell	B-Anatomy
type	O
-	O
specific	O
regulation	O
of	O
angiogenic	O
growth	O
factor	O
gene	O
expression	O
and	O
induction	O
of	O
angiogenesis	O
in	O
nonischemic	O
tissue	B-Anatomy
by	O
a	O
constitutively	O
active	O
form	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
1	O
.	O
Understanding	O
molecular	O
mechanisms	O
regulating	O
angiogenesis	O
may	O
lead	O
to	O
novel	O
therapies	O
for	O
ischemic	O
disorders	O
.	O
Hypoxia	O
-	O
inducible	O
factor	O
1	O
(	O
HIF	O
-	O
1	O
)	O
activates	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
gene	O
expression	O
in	O
hypoxic	O
/	O
ischemic	O
tissue	B-Anatomy
.	O
In	O
this	O
study	O
we	O
demonstrate	O
that	O
exposure	O
of	O
primary	O
cultures	B-Anatomy
of	O
cardiac	B-Anatomy
and	O
vascular	B-Anatomy
cells	I-Anatomy
to	O
hypoxia	O
or	O
AdCA5	O
,	O
an	O
adenovirus	O
encoding	O
a	O
constitutively	O
active	O
form	O
of	O
HIF	O
-	O
1alpha	O
,	O
modulates	O
the	O
expression	O
of	O
genes	O
encoding	O
the	O
angiogenic	O
factors	O
angiopoietin	O
-	O
1	O
(	O
ANGPT1	O
)	O
,	O
ANGPT2	O
,	O
placental	O
growth	O
factor	O
,	O
and	O
platelet	O
-	O
derived	O
growth	O
factor	O
-	O
B	O
.	O
Loss	O
-	O
of	O
-	O
function	O
effects	O
were	O
also	O
observed	O
in	O
HIF	B-Anatomy
-	I-Anatomy
1alpha	I-Anatomy
-	I-Anatomy
embryonic	I-Anatomy
stem	I-Anatomy
cells	I-Anatomy
.	O
Depending	O
on	O
the	O
cell	B-Anatomy
type	O
,	O
expression	O
of	O
ANGPT1	O
and	O
ANGPT2	O
was	O
either	O
activated	O
or	O
repressed	O
in	O
response	O
to	O
hypoxia	O
or	O
AdCA5	O
.	O
In	O
all	O
cases	O
,	O
there	O
was	O
complete	O
concordance	O
between	O
the	O
effects	O
of	O
hypoxia	O
and	O
AdCA5	O
.	O
Injection	O
of	O
AdCA5	O
into	O
mouse	O
eyes	B-Anatomy
induced	O
neovascularization	O
in	O
multiple	O
capillary	B-Anatomy
beds	I-Anatomy
,	O
including	O
those	O
not	O
responsive	O
to	O
VEGF	O
alone	O
.	O
Analysis	O
of	O
gene	O
expression	O
revealed	O
increased	O
expression	O
of	O
ANGPT1	O
,	O
ANGPT2	O
,	O
platelet	O
-	O
derived	O
growth	O
factor	O
-	O
B	O
,	O
placental	O
growth	O
factor	O
,	O
and	O
VEGF	O
mRNA	O
in	O
AdCA5	O
-	O
injected	O
eyes	B-Anatomy
.	O
These	O
results	O
indicate	O
that	O
HIF	O
-	O
1	O
functions	O
as	O
a	O
master	O
regulator	O
of	O
angiogenesis	O
by	O
controlling	O
the	O
expression	O
of	O
multiple	O
angiogenic	O
growth	O
factors	O
and	O
that	O
adenovirus	O
-	O
mediated	O
expression	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
HIF	O
-	O
1alpha	O
is	O
sufficient	O
to	O
induce	O
angiogenesis	O
in	O
nonischemic	O
tissue	B-Anatomy
of	O
an	O
adult	O
animal	O
.	O
Differential	O
regulation	O
of	O
in	O
vivo	O
angiogenesis	O
by	O
angiotensin	O
II	O
receptors	O
.	O
Angiotensin	O
II	O
(	O
ANG	O
II	O
)	O
,	O
a	O
key	O
regulator	O
of	O
blood	B-Anatomy
pressure	O
and	O
body	B-Anatomy
fluid	I-Anatomy
homeostasis	O
,	O
exerts	O
mitogenic	O
effects	O
on	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
We	O
therefore	O
hypothesized	O
that	O
ANG	O
II	O
could	O
be	O
a	O
mediator	O
between	O
homeostatic	O
changes	O
within	O
the	O
vascular	B-Anatomy
perfusion	I-Anatomy
bed	I-Anatomy
and	O
growth	O
factor	O
-	O
driven	O
angiogenesis	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
applied	O
the	O
alginate	O
implant	O
angiogenesis	O
model	O
in	O
mice	O
with	O
normal	O
ANG	O
II	O
levels	O
,	O
elevated	O
ANG	O
II	O
levels	O
by	O
transgenic	O
overexpression	O
of	O
angiotensinogen	O
(	O
AOGEN	O
)	O
,	O
or	O
in	O
AT2	O
receptor	O
-	O
deficient	O
mice	O
.	O
We	O
demonstrate	O
that	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
circulating	O
ANG	O
II	O
by	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
enalapril	O
or	O
the	O
AT1	O
receptor	O
antagonist	O
losartan	O
induced	O
a	O
stimulation	O
of	O
in	O
vivo	O
angiogenesis	O
implying	O
an	O
inhibitory	O
function	O
of	O
ANG	O
II	O
through	O
the	O
AT1	O
receptor	O
.	O
However	O
,	O
the	O
strong	O
increase	O
of	O
angiogenesis	O
in	O
AOGEN	O
-	O
transgenic	O
mice	O
compared	O
with	O
mice	O
with	O
normal	O
ANG	O
II	O
levels	O
suggests	O
additional	O
stimulatory	O
activity	O
.	O
We	O
showed	O
that	O
the	O
ANG	O
II	O
-	O
induced	O
stimulation	O
of	O
angiogenesis	O
is	O
linked	O
to	O
the	O
AT2	O
receptor	O
as	O
an	O
impaired	O
induction	O
of	O
angiogenesis	O
was	O
obtained	O
in	O
AT2	O
receptor	O
knockout	O
mice	O
.	O
These	O
findings	O
provide	O
the	O
first	O
evidence	O
that	O
the	O
AT2	O
receptor	O
mediates	O
a	O
stimulation	O
of	O
in	O
vivo	O
angiogenesis	O
and	O
indicate	O
that	O
ANG	O
II	O
is	O
a	O
humoral	O
regulator	O
of	O
peripheral	O
angiogenesis	O
involving	O
two	O
receptor	O
subtypes	O
with	O
opposing	O
actions	O
.	O
Insulin	O
-	O
like	O
growth	O
factor	O
1	O
receptor	O
enhances	O
invasion	O
and	O
induces	O
resistance	O
to	O
apoptosis	O
of	O
colon	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
through	O
the	O
Akt	O
/	O
Bcl	O
-	O
x	O
(	O
L	O
)	O
pathway	O
.	O
Colon	B-Anatomy
cancer	I-Anatomy
overexpresses	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
(	O
IGF1	O
)	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
receptor	O
(	O
IGF1	O
-	O
R	O
)	O
,	O
as	O
compared	O
with	O
normal	O
or	O
adenomatous	B-Anatomy
mucosa	I-Anatomy
,	O
and	O
it	O
has	O
been	O
postulated	O
that	O
colorectal	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
depend	O
on	O
the	O
IGF1	O
/	O
IGF1	O
-	O
R	O
pathway	O
for	O
their	O
growth	O
and	O
progression	O
.	O
In	O
this	O
study	O
,	O
using	O
the	O
human	O
colon	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
HCT116	I-Anatomy
,	O
we	O
find	O
that	O
established	O
HCT116	B-Anatomy
/	I-Anatomy
IGF1	I-Anatomy
-	I-Anatomy
R	I-Anatomy
transfectants	I-Anatomy
exhibit	O
a	O
more	O
aggressive	O
transformed	O
phenotype	O
than	O
the	O
parental	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
,	O
as	O
demonstrated	O
by	O
their	O
higher	O
proliferation	O
rate	O
in	O
response	O
to	O
IGF1	O
,	O
higher	O
degree	O
of	O
anchorage	O
-	O
independent	O
growth	O
,	O
resistance	O
to	O
serum	B-Anatomy
deprivation	O
-	O
induced	O
apoptosis	O
,	O
and	O
higher	O
migratory	O
capability	O
in	O
a	O
monolayer	B-Anatomy
""""	O
wounding	O
assay	O
.	O
""""	O
When	O
injected	O
into	O
nude	O
mice	O
,	O
HCT116	B-Anatomy
/	I-Anatomy
IGF1	I-Anatomy
-	I-Anatomy
R	I-Anatomy
transfectants	I-Anatomy
were	O
highly	O
invasive	O
and	O
produced	O
distant	O
metastases	B-Anatomy
,	O
whereas	O
the	O
parental	B-Anatomy
cell	I-Anatomy
did	O
not	O
.	O
Moreover	O
,	O
the	O
overexpression	O
of	O
IGF1	O
-	O
R	O
in	O
these	O
cells	B-Anatomy
was	O
associated	O
with	O
IGF1	O
-	O
R	O
-	O
induced	O
activation	O
of	O
Akt	O
and	O
up	O
-	O
regulation	O
of	O
the	O
antiapoptotic	O
protein	O
Bcl	O
-	O
x	O
(	O
L	O
)	O
.	O
We	O
also	O
show	O
that	O
Akt	O
pathway	O
mediates	O
IGF1	O
-	O
R	O
-	O
induced	O
Bcl	O
-	O
x	O
(	O
L	O
)	O
expression	O
at	O
transcriptional	O
level	O
.	O
Our	O
data	O
demonstrate	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
IGF1	O
-	O
R	O
/	O
Akt	O
/	O
Bcl	O
-	O
x	O
(	O
L	O
)	O
pathway	O
may	O
contribute	O
to	O
a	O
more	O
aggressive	O
malignant	O
phenotype	O
,	O
in	O
a	O
subset	O
of	O
colorectal	B-Anatomy
cancers	I-Anatomy
.	O
Expression	O
of	O
EphA2	O
and	O
E	O
-	O
cadherin	O
in	O
colorectal	B-Anatomy
cancer	I-Anatomy
:	O
correlation	O
with	O
cancer	B-Anatomy
metastasis	O
.	O
Recently	O
,	O
overexpression	O
of	O
EphA2	O
,	O
a	O
member	O
of	O
the	O
Eph	O
family	O
of	O
receptor	O
tyrosine	O
kinases	O
,	O
has	O
been	O
reported	O
in	O
several	O
cancers	B-Anatomy
.	O
Reduced	O
expression	O
of	O
E	O
-	O
cadherin	O
,	O
an	O
intercellular	B-Anatomy
adhesion	O
molecule	O
of	O
epithelial	B-Anatomy
cells	I-Anatomy
,	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
aggressive	O
clinicopathological	O
phenotypes	O
in	O
various	O
cancers	B-Anatomy
.	O
In	O
epithelial	B-Anatomy
cells	I-Anatomy
,	O
EphA2	O
and	O
E	O
-	O
cadherin	O
co	O
-	O
localize	O
to	O
sites	O
of	O
cell	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
contact	I-Anatomy
,	O
and	O
it	O
has	O
been	O
shown	O
that	O
E	O
-	O
cadherin	O
regulates	O
EphA2	O
.	O
This	O
study	O
aimed	O
to	O
clarify	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
the	O
EphA2	O
and	O
E	O
-	O
cadherin	O
proteins	O
and	O
clinicopathological	O
characteristics	O
,	O
with	O
reference	O
to	O
the	O
expression	O
levels	O
of	O
both	O
EphA2	O
and	O
E	O
-	O
cadherin	O
,	O
in	O
patients	O
with	O
colorectal	B-Anatomy
cancer	I-Anatomy
.	O
We	O
performed	O
immunohistochemical	O
staining	O
of	O
EphA2	O
and	O
E	O
-	O
cadherin	O
with	O
EphA2	O
and	O
E	O
-	O
cadherin	O
monoclonal	O
antibodies	O
in	O
samples	B-Anatomy
from	O
194	O
primary	B-Anatomy
lesions	I-Anatomy
of	O
colorectal	B-Anatomy
cancer	I-Anatomy
.	O
The	O
expression	O
level	O
of	O
EphA2	O
had	O
a	O
statistically	O
significant	O
relationship	O
with	O
liver	B-Anatomy
metastasis	O
,	O
lymphatic	B-Anatomy
vessel	I-Anatomy
invasion	O
and	O
clinical	O
stage	O
(	O
p	O
=	O
0	O
.	O
0477	O
,	O
0	O
.	O
0316	O
and	O
0	O
.	O
0467	O
,	O
respectively	O
)	O
.	O
In	O
addition	O
,	O
the	O
positivity	O
rate	O
of	O
EphA2	O
was	O
significantly	O
higher	O
in	O
primary	B-Anatomy
lesions	I-Anatomy
with	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
than	O
in	O
those	O
without	O
metastasis	O
(	O
p	O
=	O
0	O
.	O
0014	O
)	O
.	O
However	O
,	O
the	O
expression	O
level	O
of	O
E	O
-	O
cadherin	O
had	O
an	O
inverse	O
relationship	O
with	O
both	O
differentiation	O
level	O
of	O
the	O
tumor	B-Anatomy
and	O
lymphatic	B-Anatomy
vessel	I-Anatomy
invasion	O
(	O
p	O
=	O
0	O
.	O
0430	O
and	O
0	O
.	O
0320	O
,	O
respectively	O
)	O
.	O
Furthermore	O
,	O
a	O
significant	O
relationship	O
between	O
the	O
expression	O
of	O
EphA2	O
and	O
E	O
-	O
cadherin	O
was	O
observed	O
.	O
In	O
conclusion	O
,	O
our	O
study	O
revealed	O
that	O
the	O
overexpression	O
of	O
EphA2	O
protein	O
in	O
colorectal	B-Anatomy
carcinoma	I-Anatomy
tissue	I-Anatomy
correlates	O
closely	O
with	O
cancer	B-Anatomy
progression	O
and	O
hematogenous	O
and	O
lymphogenous	O
metastasis	O
,	O
suggesting	O
that	O
both	O
EphA2	O
and	O
E	O
-	O
cadherin	O
may	O
play	O
an	O
important	O
role	O
in	O
tumor	B-Anatomy
metastasis	O
in	O
colorectal	B-Anatomy
cancer	I-Anatomy
.	O
Outcomes	O
of	O
cefazolin	O
versus	O
ceftriaxone	O
therapy	O
in	O
treating	O
lower	B-Anatomy
respiratory	I-Anatomy
tract	I-Anatomy
infections	O
in	O
adults	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
whether	O
choice	O
of	O
a	O
first	O
-	O
versus	O
third	O
-	O
generation	O
cephalosporin	O
as	O
initial	O
therapy	O
for	O
lower	B-Anatomy
respiratory	I-Anatomy
tract	I-Anatomy
infections	O
in	O
hospitalized	O
adults	O
affects	O
the	O
course	O
and	O
duration	O
of	O
care	O
,	O
both	O
of	O
which	O
may	O
influence	O
antimicrobial	O
treatment	O
cost	O
.	O
DESIGN	O
:	O
Retrospective	O
analysis	O
of	O
discharge	O
abstracts	O
and	O
hospital	O
pharmacy	O
records	O
.	O
SETTING	O
:	O
Forty	O
-	O
eight	O
US	O
acute	O
-	O
care	O
hospitals	O
.	O
PATIENTS	O
:	O
One	O
thousand	O
ninety	O
-	O
two	O
hospitalized	O
adults	O
(	O
aged	O
>	O
17	O
y	O
)	O
with	O
principal	O
diagnoses	O
of	O
lower	B-Anatomy
respiratory	I-Anatomy
tract	I-Anatomy
infections	O
(	O
DRGs	O
79	O
-	O
80	O
,	O
89	O
-	O
90	O
)	O
.	O
INTERVENTIONS	O
:	O
Cefazolin	O
or	O
ceftriaxone	O
,	O
given	O
as	O
sole	O
antimicrobial	O
therapy	O
for	O
at	O
least	O
one	O
day	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
(	O
1	O
)	O
The	O
number	O
of	O
patients	O
who	O
received	O
another	O
parenteral	O
antibiotic	O
anytime	O
prior	O
to	O
hospital	O
discharge	O
;	O
(	O
2	O
)	O
the	O
number	O
of	O
days	O
during	O
which	O
patients	O
received	O
any	O
parenteral	O
antibiotic	O
while	O
in	O
the	O
hospital	O
;	O
and	O
(	O
3	O
)	O
the	O
number	O
of	O
days	O
patients	O
remained	O
hospitalized	O
following	O
the	O
start	O
of	O
antibiotic	O
therapy	O
.	O
RESULTS	O
:	O
Patients	O
treated	O
with	O
cefazolin	O
(	O
n	O
=	O
763	O
)	O
were	O
more	O
likely	O
to	O
receive	O
another	O
parenteral	O
antibiotic	O
while	O
in	O
the	O
hospital	O
(	O
30	O
.	O
3	O
vs	O
.	O
20	O
.	O
7	O
percent	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
received	O
more	O
total	O
days	O
of	O
therapy	O
(	O
7	O
.	O
2	O
vs	O
.	O
6	O
.	O
7	O
d	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
than	O
those	O
treated	O
with	O
ceftriaxone	O
(	O
n	O
=	O
329	O
)	O
.	O
Although	O
the	O
time	O
to	O
hospital	O
discharge	O
did	O
not	O
differ	O
in	O
the	O
full	O
sample	O
(	O
9	O
.	O
2	O
d	O
for	O
both	O
groups	O
)	O
,	O
it	O
was	O
greater	O
among	O
those	O
receiving	O
cefazolin	O
(	O
8	O
.	O
6	O
vs	O
.	O
8	O
.	O
0	O
d	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
when	O
patients	O
with	O
lengths	O
of	O
stay	O
exceeding	O
24	O
days	O
were	O
excluded	O
from	O
both	O
groups	O
.	O
CONCLUSIONS	O
:	O
In	O
addition	O
to	O
acquisition	O
cost	O
,	O
differences	O
in	O
course	O
and	O
duration	O
of	O
care	O
should	O
be	O
considered	O
when	O
determining	O
the	O
most	O
cost	O
-	O
effective	O
choice	O
for	O
antimicrobial	O
therapy	O
.	O
Nuclear	B-Anatomy
translocation	O
of	O
a	O
clusterin	O
isoform	O
is	O
associated	O
with	O
induction	O
of	O
anoikis	O
in	O
SV40	O
-	O
immortalized	O
human	O
prostate	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
.	O
Clusterin	O
gene	O
expression	O
is	O
potently	O
induced	O
in	O
experimental	O
models	O
in	O
which	O
apoptosis	O
is	O
activated	O
,	O
such	O
as	O
rat	O
prostate	B-Anatomy
involution	O
following	O
castration	O
.	O
Nevertheless	O
,	O
its	O
precise	O
physiological	O
role	O
has	O
not	O
yet	O
been	O
established	O
,	O
and	O
both	O
anti	O
-	O
apoptotic	O
and	O
pro	O
-	O
apoptotic	O
functions	O
have	O
been	O
suggested	O
for	O
this	O
gene	O
.	O
Clusterin	O
expression	O
level	O
depends	O
on	O
cell	B-Anatomy
proliferation	O
state	O
,	O
and	O
we	O
recently	O
showed	O
that	O
its	O
over	O
-	O
expression	O
inhibited	O
cell	B-Anatomy
cycle	O
progression	O
of	O
SV40	O
-	O
immortalized	O
human	O
prostate	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
PNT2	I-Anatomy
and	O
PNT1a	B-Anatomy
.	O
Here	O
we	O
studied	O
clusterin	O
expression	O
in	O
PNT1a	B-Anatomy
cells	I-Anatomy
subjected	O
to	O
serum	B-Anatomy
-	O
starvation	O
with	O
the	O
aim	O
of	O
defining	O
clusterin	O
early	O
molecular	O
changes	O
following	O
apoptosis	O
induction	O
.	O
Under	O
serum	B-Anatomy
-	O
starvation	O
conditions	O
,	O
decreased	O
growth	O
rate	O
,	O
slow	O
rounding	O
-	O
up	O
of	O
cells	B-Anatomy
,	O
cell	B-Anatomy
detachment	O
,	O
and	O
formation	O
of	O
apoptotic	B-Anatomy
bodies	I-Anatomy
indicative	O
of	O
anoikis	O
(	O
detachment	O
-	O
induced	O
apoptosis	O
)	O
were	O
preceded	O
by	O
significant	O
downregulation	O
of	O
70	O
kDa	O
clusterin	O
precursor	O
and	O
upregulation	O
of	O
45	O
-	O
40	O
kDa	O
isoforms	O
.	O
On	O
the	O
8th	O
day	O
of	O
serum	B-Anatomy
-	O
free	O
culturing	O
,	O
only	O
the	O
higher	O
molecular	O
weight	O
protein	O
-	O
band	O
of	O
about	O
45	O
kDa	O
was	O
clearly	O
induced	O
and	O
accumulated	O
in	O
detached	O
cells	B-Anatomy
and	O
apoptotic	B-Anatomy
bodies	I-Anatomy
in	O
which	O
PARP	O
was	O
activated	O
.	O
Anoikis	O
was	O
preceded	O
by	O
induction	O
and	O
transloction	O
of	O
a	O
45	O
-	O
kDa	O
clusterin	O
isoform	O
to	O
the	O
nucleus	B-Anatomy
.	O
Thus	O
,	O
nuclear	B-Anatomy
targeting	O
of	O
a	O
specific	O
45	O
-	O
kDa	O
isoform	O
of	O
clusterin	O
appeared	O
to	O
be	O
an	O
early	O
and	O
specific	O
molecular	O
signal	O
triggering	O
anoikis	O
-	O
death	O
.	O
Considering	O
also	O
that	O
clusterin	O
is	O
downregulated	O
during	O
prostate	B-Anatomy
cancer	I-Anatomy
onset	O
and	O
progression	O
,	O
and	O
that	O
its	O
upregulation	O
has	O
inhibited	O
DNA	O
synthesis	O
and	O
cell	B-Anatomy
cycle	O
progression	O
of	O
immortalized	O
human	O
prostate	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
,	O
we	O
suggest	O
that	O
clusterin	O
might	O
be	O
a	O
new	O
anti	O
-	O
oncogene	O
in	O
the	O
prostate	B-Anatomy
.	O
Levels	O
of	O
expression	O
of	O
CYR61	O
and	O
CTGF	O
are	O
prognostic	O
for	O
tumor	B-Anatomy
progression	O
and	O
survival	O
of	O
individuals	O
with	O
gliomas	B-Anatomy
.	O
The	O
biological	O
properties	O
of	O
CCN	O
proteins	O
include	O
stimulation	O
of	O
cell	B-Anatomy
proliferation	O
,	O
migration	O
,	O
and	O
adhesion	O
,	O
as	O
well	O
as	O
angiogenesis	O
and	O
tumorigenesis	O
.	O
We	O
quantified	O
CYR61	O
,	O
CTGF	O
,	O
WISP	O
-	O
1	O
,	O
and	O
NOV	O
mRNA	O
expression	O
levels	O
in	O
samples	B-Anatomy
from	O
sixty	O
-	O
six	O
primary	B-Anatomy
gliomas	I-Anatomy
and	O
five	O
normal	O
brain	B-Anatomy
samples	I-Anatomy
using	O
quantitative	O
real	O
-	O
time	O
PCR	O
assay	O
.	O
Statistical	O
analysis	O
was	O
performed	O
to	O
explore	O
the	O
links	O
between	O
expression	O
of	O
the	O
CCN	O
genes	O
and	O
clinical	O
and	O
pathological	O
parameters	O
.	O
Overexpression	O
of	O
CYR61	O
,	O
CTGF	O
,	O
WISP	O
-	O
1	O
,	O
and	O
NOV	O
occurred	O
in	O
48	O
%	O
(	O
32	O
of	O
66	O
)	O
,	O
58	O
%	O
(	O
38	O
of	O
66	O
)	O
,	O
36	O
%	O
(	O
24	O
of	O
66	O
)	O
,	O
and	O
15	O
%	O
(	O
10	O
of	O
66	O
)	O
of	O
primary	B-Anatomy
gliomas	I-Anatomy
,	O
respectively	O
.	O
Interestingly	O
,	O
significant	O
associations	O
were	O
found	O
between	O
CYR61	O
expression	O
versus	O
tumor	B-Anatomy
grade	O
,	O
pathology	O
,	O
gender	O
,	O
and	O
age	O
at	O
diagnosis	O
.	O
Also	O
,	O
a	O
significant	O
correlation	O
existed	O
between	O
CTGF	O
mRNA	O
levels	O
versus	O
tumor	B-Anatomy
grade	O
,	O
gender	O
,	O
and	O
pathology	O
.	O
In	O
contrast	O
to	O
CYR61	O
and	O
CTGF	O
,	O
no	O
significant	O
association	O
was	O
found	O
between	O
expression	O
of	O
either	O
WISP	O
-	O
1	O
or	O
NOV	O
versus	O
any	O
of	O
the	O
pathological	O
features	O
.	O
Furthermore	O
,	O
Cox	O
regression	O
analysis	O
showed	O
that	O
CYR61	O
and	O
CTGF	O
expression	O
had	O
a	O
significant	O
correlation	O
with	O
patient	O
survival	O
.	O
These	O
results	O
suggest	O
that	O
CYR61	O
and	O
CTGF	O
may	O
play	O
a	O
role	O
in	O
the	O
progression	O
of	O
gliomas	B-Anatomy
;	O
their	O
levels	O
at	O
diagnosis	O
may	O
have	O
prognostic	O
significance	O
;	O
and	O
these	O
proteins	O
might	O
serve	O
as	O
valuable	O
targets	O
for	O
therapeutic	O
intervention	O
.	O
Targeting	O
wide	O
-	O
range	O
oncogenic	O
transformation	O
via	O
PU24FCl	O
,	O
a	O
specific	O
inhibitor	O
of	O
tumor	B-Anatomy
Hsp90	O
.	O
Agents	O
that	O
inhibit	O
Hsp90	O
function	O
hold	O
significant	O
promise	O
in	O
cancer	B-Anatomy
therapy	O
.	O
Here	O
we	O
present	O
PU24FCl	O
,	O
a	O
representative	O
of	O
the	O
first	O
class	O
of	O
designed	O
Hsp90	O
inhibitors	O
.	O
By	O
specifically	O
and	O
potently	O
inhibiting	O
tumor	B-Anatomy
Hsp90	O
,	O
PU24FCl	O
exhibits	O
wide	O
-	O
ranging	O
anti	O
-	O
cancer	B-Anatomy
activities	O
that	O
occur	O
at	O
similar	O
doses	O
in	O
all	O
tested	O
tumor	B-Anatomy
types	O
.	O
Normal	O
cells	B-Anatomy
are	O
10	O
-	O
to	O
50	O
-	O
fold	O
more	O
resistant	O
to	O
these	O
effects	O
.	O
Its	O
Hsp90	O
inhibition	O
results	O
in	O
multiple	O
anti	O
-	O
tumor	B-Anatomy
-	O
specific	O
effects	O
,	O
such	O
as	O
degradation	O
of	O
Hsp90	O
-	O
client	O
proteins	O
involved	O
in	O
cell	B-Anatomy
growth	O
,	O
survival	O
,	O
and	O
specific	O
transformation	O
,	O
inhibition	O
of	O
cancer	B-Anatomy
cell	I-Anatomy
growth	O
,	O
delay	O
of	O
cell	B-Anatomy
cycle	O
progression	O
,	O
induction	O
of	O
morphological	O
and	O
functional	O
changes	O
,	O
and	O
apoptosis	O
.	O
In	O
concordance	O
with	O
its	O
higher	O
affinity	O
for	O
tumor	B-Anatomy
Hsp90	O
,	O
in	O
vivo	O
PU24FCl	O
accumulates	O
in	O
tumors	B-Anatomy
while	O
being	O
rapidly	O
cleared	O
from	O
normal	O
tissue	B-Anatomy
.	O
Concentrations	O
achieved	O
in	O
vivo	O
in	O
tumors	B-Anatomy
lead	O
to	O
single	O
-	O
agent	O
anti	O
-	O
tumor	B-Anatomy
activity	O
at	O
non	O
-	O
toxic	O
doses	O
.	O
Differential	O
proteomic	O
analysis	O
of	O
human	O
hepatocellular	B-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
metastasis	O
-	O
associated	O
proteins	O
.	O
PURPOSE	O
:	O
The	O
comparative	O
study	O
of	O
differentially	O
expression	O
of	O
protein	O
profiles	O
of	O
hepatocellular	B-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
with	O
various	O
metastasic	O
potential	O
and	O
screening	O
key	O
molecules	O
related	O
to	O
hepatocellular	B-Anatomy
carcinoma	I-Anatomy
metastasis	O
and	O
recurrence	O
.	O
METHODS	O
:	O
Using	O
two	O
-	O
dimensional	O
electrophoresis	O
and	O
liquid	O
chromatography	O
-	O
electrospray	O
ionization	O
-	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
ESI	O
-	O
MS	O
/	O
MS	O
)	O
,	O
we	O
analyzed	O
differentially	O
displayed	O
proteomics	O
of	O
human	O
hepatocellular	B-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
Hep3B	I-Anatomy
,	O
MHCC97L	B-Anatomy
,	O
MHCC97H	B-Anatomy
with	O
different	O
metastasic	O
potential	O
.	O
RESULTS	O
:	O
Approximate	O
1	O
,	O
000	O
protein	O
spots	O
were	O
detected	O
on	O
silver	O
-	O
stained	O
gel	O
by	O
ImageMaster	O
(	O
977	O
+	O
/	O
-	O
113	O
spots	O
in	O
Hep3B	B-Anatomy
,	O
1092	O
+	O
/	O
-	O
40	O
in	O
MHCC97L	B-Anatomy
,	O
and	O
889	O
+	O
/	O
-	O
14	O
in	O
MHCC97H	B-Anatomy
)	O
.	O
Fifty	O
distinct	O
different	O
protein	O
spots	O
were	O
analyzed	O
with	O
online	O
LC	O
-	O
ESI	O
-	O
MS	O
/	O
MS	O
.	O
Only	O
26	O
protein	O
spots	O
had	O
a	O
positive	O
result	O
,	O
including	O
annexin1	O
,	O
S100A4	O
,	O
and	O
so	O
on	O
.	O
In	O
comparison	O
with	O
nonmetastasis	O
Hep3B	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
,	O
there	O
were	O
16	O
proteins	O
overexpressed	O
in	O
MHCC97H	B-Anatomy
and	O
MHCC97L	B-Anatomy
,	O
10	O
proteins	O
underexpressed	O
in	O
MHCC97H	B-Anatomy
and	O
MHCC97L	B-Anatomy
.	O
Applying	O
cell	B-Anatomy
immunohistochemistry	O
and	O
RT	O
-	O
PCR	O
,	O
we	O
further	O
validated	O
two	O
interesting	O
and	O
different	O
proteins	O
,	O
annexin1	O
and	O
S100A4	O
.	O
CONCLUSION	O
:	O
The	O
protein	O
profile	O
of	O
metastatic	B-Anatomy
hepatocellular	I-Anatomy
carcinoma	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
displayed	O
obvious	O
differences	O
compared	O
with	O
non	B-Anatomy
-	I-Anatomy
metastatic	I-Anatomy
liver	I-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
The	O
results	O
imply	O
that	O
various	O
different	O
proteins	O
may	O
lead	O
to	O
HCC	B-Anatomy
metastasis	O
together	O
.	O
Clinical	O
implication	O
of	O
expression	O
of	O
cyclooxygenase	O
-	O
2	O
and	O
peroxisome	O
proliferator	O
activated	O
-	O
receptor	O
gamma	O
in	O
epithelial	B-Anatomy
ovarian	I-Anatomy
tumours	I-Anatomy
.	O
Expression	O
of	O
cyclooxygenase	O
(	O
COX	O
)	O
-	O
2	O
plays	O
a	O
key	O
role	O
in	O
tumorigenesis	O
and	O
development	O
and	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
(	O
PPARgamma	O
)	O
has	O
been	O
implicated	O
in	O
the	O
control	O
of	O
COX	O
-	O
2	O
expression	O
in	O
some	O
tissues	B-Anatomy
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
(	O
1	O
)	O
whether	O
expression	O
of	O
COX	O
-	O
2	O
and	O
PPARgamma	O
is	O
associated	O
with	O
ovarian	B-Anatomy
carcinogenesis	O
and	O
progression	O
of	O
ovarian	B-Anatomy
tumours	I-Anatomy
and	O
(	O
2	O
)	O
whether	O
COX	O
-	O
2	O
expression	O
is	O
controlled	O
through	O
ligand	O
-	O
mediated	O
activation	O
of	O
PPARgamma	O
in	O
ovarian	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
.	O
For	O
this	O
purpose	O
,	O
the	O
presence	O
of	O
COX	O
-	O
2	O
and	O
PPARgamma	O
was	O
immunohistochemically	O
examined	O
in	O
71	O
epithelial	B-Anatomy
ovarian	I-Anatomy
carcinomas	I-Anatomy
,	O
18	O
borderline	B-Anatomy
tumours	I-Anatomy
and	O
23	O
benign	B-Anatomy
tumours	I-Anatomy
and	O
the	O
levels	O
of	O
COX	O
-	O
2	O
and	O
PPARgamma	O
proteins	O
were	O
determined	O
by	O
enzyme	O
immunoassay	O
in	O
four	O
benign	B-Anatomy
tumours	I-Anatomy
,	O
three	O
borderline	B-Anatomy
tumours	I-Anatomy
and	O
12	O
carcinomas	B-Anatomy
.	O
The	O
frequency	O
of	O
COX	O
-	O
2	O
and	O
PPARgamma	O
detection	O
was	O
significantly	O
increased	O
and	O
decreased	O
as	O
lesions	B-Anatomy
progressed	O
to	O
carcinoma	B-Anatomy
,	O
respectively	O
.	O
The	O
COX	O
-	O
2	O
protein	O
was	O
not	O
detected	O
in	O
the	O
three	O
borderline	B-Anatomy
tumours	I-Anatomy
,	O
whereas	O
PPARgamma	O
protein	O
was	O
detected	O
in	O
all	O
of	O
them	O
.	O
COX	O
-	O
2	O
protein	O
was	O
detected	O
in	O
eight	O
of	O
the	O
12	O
carcinomas	B-Anatomy
,	O
whereas	O
PPARgamma	O
protein	O
was	O
detected	O
in	O
only	O
two	O
cases	O
.	O
In	O
addition	O
,	O
PPARgamma	O
protein	O
was	O
not	O
detected	O
in	O
all	O
of	O
the	O
eight	O
carcinomas	B-Anatomy
in	O
which	O
COX	O
-	O
2	O
protein	O
was	O
detected	O
,	O
suggesting	O
that	O
expression	O
of	O
PPARgamma	O
and	O
COX	O
-	O
2	O
was	O
in	O
a	O
reciprocal	O
relationship	O
.	O
Furthermore	O
,	O
in	O
cultured	O
ovarian	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
,	O
Western	O
blot	O
revealed	O
that	O
PPARgamma	O
and	O
COX	O
-	O
2	O
expression	O
was	O
regulated	O
conversely	O
as	O
a	O
result	O
of	O
stimulation	O
by	O
15	O
-	O
deoxy	O
-	O
Delta	O
(	O
12	O
,	O
14	O
)	O
PGJ	O
(	O
2	O
)	O
(	O
15	O
-	O
PGJ	O
(	O
2	O
)	O
)	O
,	O
a	O
PPARgamma	O
activator	O
.	O
In	O
addition	O
,	O
15d	O
-	O
PGJ	O
(	O
2	O
)	O
suppressed	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
-	O
induced	O
-	O
COX	O
-	O
2	O
expression	O
,	O
confirming	O
the	O
reciprocal	O
correlation	O
between	O
COX	O
-	O
2	O
and	O
PPARgamma	O
.	O
From	O
these	O
results	O
,	O
it	O
was	O
suggested	O
that	O
PPARgamma	O
activation	O
might	O
suppress	O
COX	O
-	O
2	O
expression	O
via	O
the	O
nuclear	O
factor	O
-	O
kappaB	O
pathway	O
in	O
the	O
ovarian	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
and	O
that	O
low	O
expression	O
of	O
PPARgamma	O
and	O
high	O
expression	O
of	O
COX	O
-	O
2	O
might	O
be	O
involved	O
in	O
carcinogenesis	O
and	O
progression	O
of	O
ovarian	B-Anatomy
tumours	I-Anatomy
.	O
Is	O
there	O
an	O
upper	O
limit	O
of	O
intracranial	B-Anatomy
pressure	O
in	O
patients	O
with	O
severe	O
head	B-Anatomy
injury	O
if	O
cerebral	B-Anatomy
perfusion	O
pressure	O
is	O
maintained	O
?	O
Authors	O
of	O
recent	O
studies	O
have	O
championed	O
the	O
importance	O
of	O
maintaining	O
cerebral	B-Anatomy
perfusion	O
pressure	O
(	O
CPP	O
)	O
to	O
prevent	O
secondary	O
brain	B-Anatomy
injury	O
following	O
traumatic	O
head	B-Anatomy
injury	O
.	O
Data	O
from	O
these	O
studies	O
have	O
provided	O
little	O
information	O
regarding	O
outcome	O
following	O
severe	O
head	B-Anatomy
injury	O
in	O
patients	O
with	O
an	O
intracranial	B-Anatomy
pressure	O
(	O
ICP	O
)	O
greater	O
than	O
40	O
mm	O
Hg	O
,	O
however	O
,	O
in	O
July	O
1997	O
the	O
authors	O
instituted	O
a	O
protocol	O
for	O
the	O
management	O
of	O
severe	O
head	B-Anatomy
injury	O
in	O
patients	O
with	O
a	O
Glasgow	O
Coma	O
Scale	O
score	O
lower	O
than	O
9	O
.	O
The	O
protocol	O
was	O
focused	O
on	O
resuscitation	O
from	O
acidosis	O
,	O
maintenance	O
of	O
a	O
CPP	O
greater	O
than	O
60	O
mm	O
Hg	O
through	O
whatever	O
means	O
necessary	O
as	O
well	O
as	O
elevation	O
of	O
the	O
head	O
of	O
the	O
bed	O
,	O
mannitol	O
infusion	O
,	O
and	O
ventriculostomy	O
with	O
cerebrospinal	B-Anatomy
fluid	I-Anatomy
drainage	O
for	O
control	O
of	O
ICP	O
.	O
Since	O
the	O
institution	O
of	O
this	O
protocol	O
,	O
nine	O
patients	O
had	O
a	O
sustained	O
ICP	O
greater	O
than	O
40	O
mm	O
Hg	O
for	O
2	O
or	O
more	O
hours	O
,	O
and	O
five	O
of	O
these	O
had	O
an	O
ICP	O
greater	O
than	O
75	O
mm	O
Hg	O
on	O
insertion	O
of	O
the	O
ICP	O
monitor	O
and	O
later	O
experienced	O
herniation	O
and	O
expired	O
within	O
24	O
hours	O
.	O
Because	O
of	O
the	O
severe	O
nature	O
of	O
the	O
injuries	O
demonstrated	O
on	O
computerized	O
tomography	O
scans	O
and	O
their	O
physical	O
examinations	O
,	O
these	O
patients	O
were	O
not	O
aggressively	O
treated	O
under	O
this	O
protocol	O
.	O
The	O
authors	O
vigorously	O
attempted	O
to	O
maintain	O
a	O
CPP	O
greater	O
than	O
60	O
mm	O
Hg	O
with	O
intensive	O
fluid	B-Anatomy
resuscitation	O
and	O
the	O
administration	O
of	O
pressor	O
agents	O
in	O
the	O
four	O
remaining	O
patients	O
who	O
had	O
developed	O
an	O
ICP	O
higher	O
than	O
40	O
mm	O
Hg	O
after	O
placement	O
of	O
the	O
ICP	O
monitor	O
.	O
Two	O
patients	O
had	O
an	O
episodic	O
ICP	O
greater	O
than	O
40	O
mm	O
Hg	O
for	O
more	O
than	O
36	O
hours	O
,	O
the	O
third	O
patient	O
had	O
an	O
episodic	O
ICP	O
greater	O
than	O
of	O
50	O
mm	O
Hg	O
for	O
more	O
than	O
36	O
hours	O
,	O
and	O
the	O
fourth	O
patient	O
had	O
an	O
episodic	O
ICP	O
greater	O
than	O
50	O
mm	O
Hg	O
for	O
more	O
than	O
48	O
hours	O
.	O
On	O
discharge	O
,	O
all	O
four	O
patients	O
were	O
able	O
to	O
perform	O
normal	O
activities	O
of	O
daily	O
living	O
with	O
minimal	O
assistance	O
and	O
experience	O
ongoing	O
improvement	O
.	O
Data	O
from	O
this	O
preliminary	O
study	O
indicate	O
that	O
intense	O
,	O
aggressive	O
management	O
of	O
CPP	O
can	O
lead	O
to	O
good	O
neurological	B-Anatomy
outcomes	O
despite	O
extremely	O
high	O
ICP	O
.	O
Aggressive	O
CPP	O
therapy	O
should	O
be	O
performed	O
and	O
maintained	O
even	O
though	O
apparently	O
lethal	O
ICP	O
levels	O
may	O
be	O
present	O
.	O
Further	O
study	O
is	O
needed	O
to	O
support	O
these	O
encouraging	O
results	O
.	O
Newly	O
recognized	O
syndrome	O
with	O
heminasal	O
aplasia	O
and	O
ocular	B-Anatomy
anomalies	O
or	O
wider	O
spectrum	O
of	O
heminasal	O
aplasia	O
/	O
atypical	O
clefting	O
syndrome	O
?	O
We	O
report	O
on	O
five	O
unrelated	O
Brazilian	O
patients	O
with	O
heminasal	O
aplasia	O
associated	O
with	O
diverses	O
anomalies	O
,	O
including	O
lateral	O
proboscis	O
,	O
and	O
anomalies	O
of	O
the	O
eye	B-Anatomy
and	O
first	O
branchial	B-Anatomy
arch	I-Anatomy
.	O
We	O
suggest	O
that	O
these	O
patients	O
represent	O
different	O
conditions	O
within	O
the	O
spectrum	O
of	O
the	O
heminasal	O
aplasia	O
malformation	O
.	O
Clinical	O
,	O
genetic	O
,	O
and	O
differential	O
diagnosis	O
are	O
discussed	O
.	O
Role	O
of	O
osteopontin	O
in	O
adhesion	O
,	O
migration	O
,	O
cell	B-Anatomy
survival	O
and	O
bone	B-Anatomy
remodeling	O
.	O
Osteopontin	O
(	O
OPN	O
)	O
is	O
a	O
secreted	O
adhesive	O
glycophosphoprotein	O
expressed	O
by	O
several	O
cell	B-Anatomy
types	O
.	O
It	O
is	O
normally	O
produced	O
in	O
bone	B-Anatomy
,	O
teeth	B-Anatomy
,	O
kidney	B-Anatomy
and	O
epithelial	B-Anatomy
lining	I-Anatomy
tissues	I-Anatomy
and	O
is	O
found	O
in	O
plasma	B-Anatomy
and	O
breast	B-Anatomy
milk	I-Anatomy
.	O
It	O
is	O
involved	O
in	O
a	O
number	O
of	O
physiologic	O
and	O
pathologic	O
events	O
including	O
angiogenesis	O
,	O
apoptosis	O
,	O
inflammation	O
,	O
wound	B-Anatomy
healing	O
and	O
tumor	B-Anatomy
metastasis	O
.	O
In	O
this	O
review	O
focus	O
will	O
be	O
on	O
OPN	O
in	O
bone	B-Anatomy
and	O
its	O
role	O
in	O
adhesion	O
,	O
migration	O
and	O
cell	B-Anatomy
survival	O
.	O
These	O
aspects	O
of	O
OPN	O
biology	O
are	O
important	O
in	O
tumorigenesis	O
.	O
Neurologic	B-Anatomy
diagnosis	O
and	O
treatment	O
in	O
patients	O
with	O
computed	O
tomography	O
and	O
nasal	B-Anatomy
endoscopy	O
negative	O
facial	B-Anatomy
pain	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
helpfulness	O
of	O
specialist	O
neurology	O
referral	O
for	O
patients	O
with	O
facial	B-Anatomy
pain	O
,	O
a	O
normal	O
sinus	B-Anatomy
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
,	O
and	O
normal	O
nasal	B-Anatomy
endoscopy	O
findings	O
.	O
STUDY	O
DESIGN	O
:	O
Prospective	O
identification	O
of	O
patients	O
and	O
analysis	O
of	O
data	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
.	O
METHODS	O
:	O
The	O
data	O
of	O
104	O
consecutive	O
patients	O
presenting	O
with	O
facial	B-Anatomy
pain	O
,	O
a	O
normal	O
sinus	B-Anatomy
CT	O
scan	O
,	O
and	O
normal	O
nasal	B-Anatomy
endoscopy	O
findings	O
were	O
reviewed	O
.	O
The	O
patients	O
presented	O
to	O
a	O
single	O
rhinologist	O
in	O
a	O
tertiary	O
care	O
institution	O
.	O
All	O
patients	O
were	O
referred	O
for	O
specialist	O
neurologic	B-Anatomy
evaluation	O
and	O
potential	O
treatment	O
.	O
Further	O
information	O
was	O
obtained	O
from	O
a	O
patient	O
survey	O
.	O
RESULTS	O
:	O
Of	O
the	O
104	O
patients	O
,	O
81	O
were	O
women	O
and	O
23	O
were	O
men	O
.	O
The	O
average	O
age	O
was	O
46	O
years	O
(	O
range	O
,	O
22	O
-	O
85	O
)	O
.	O
Fifty	O
-	O
six	O
had	O
clear	O
CT	O
scans	O
,	O
48	O
had	O
minimal	O
change	O
,	O
and	O
all	O
had	O
negative	O
endoscopies	O
.	O
Twenty	O
-	O
nine	O
had	O
previous	O
unsuccessful	O
sinus	B-Anatomy
surgery	O
.	O
The	O
average	O
follow	O
-	O
up	O
period	O
was	O
10	O
.	O
5	O
months	O
.	O
Forty	O
of	O
75	O
patients	O
seeing	O
a	O
neurologist	O
were	O
seen	O
on	O
multiple	O
occasions	O
.	O
Four	O
percent	O
of	O
patients	O
seen	O
by	O
a	O
neurologist	O
had	O
an	O
unsuspected	O
serious	O
intracranial	B-Anatomy
diagnosis	O
.	O
The	O
most	O
common	O
diagnoses	O
were	O
migraine	O
(	O
37	O
%	O
)	O
,	O
rebound	O
headache	O
(	O
17	O
%	O
)	O
,	O
chronic	O
daily	O
headache	O
(	O
17	O
%	O
)	O
,	O
and	O
obstructive	O
sleep	O
apnea	O
(	O
16	O
%	O
)	O
.	O
Overall	O
,	O
58	O
%	O
improved	O
on	O
medical	O
therapy	O
;	O
60	O
%	O
of	O
those	O
with	O
a	O
clear	O
CT	O
scan	O
improved	O
,	O
and	O
53	O
%	O
of	O
those	O
with	O
minimal	O
change	O
on	O
CT	O
scan	O
improved	O
(	O
P	O
=	O
.	O
749	O
)	O
.	O
CONCLUSIONS	O
:	O
Facial	B-Anatomy
pain	O
remains	O
a	O
difficult	O
symptom	O
to	O
diagnose	O
and	O
treat	O
in	O
rhinologic	O
practice	O
.	O
Patients	O
often	O
undergo	O
surgery	O
without	O
help	O
.	O
Most	O
patients	O
with	O
facial	B-Anatomy
pain	O
,	O
a	O
normal	O
sinus	B-Anatomy
CT	O
scan	O
,	O
and	O
normal	O
endoscopy	O
findings	O
benefit	O
from	O
neurologic	B-Anatomy
consultation	O
.	O
Serious	O
intracranial	B-Anatomy
pathologic	O
conditions	O
can	O
be	O
excluded	O
and	O
diagnosis	O
-	O
specific	O
pharmacogenetic	O
therapy	O
instituted	O
with	O
improvement	O
in	O
more	O
than	O
50	O
%	O
.	O
Oxidation	O
in	O
rheumatoid	O
arthritis	O
.	O
Oxygen	O
metabolism	O
has	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
.	O
Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
produced	O
in	O
the	O
course	O
of	O
cellular	B-Anatomy
oxidative	O
phosphorylation	O
,	O
and	O
by	O
activated	O
phagocytic	B-Anatomy
cells	I-Anatomy
during	O
oxidative	O
bursts	O
,	O
exceed	O
the	O
physiological	O
buffering	O
capacity	O
and	O
result	O
in	O
oxidative	O
stress	O
.	O
The	O
excessive	O
production	O
of	O
ROS	O
can	O
damage	O
protein	O
,	O
lipids	O
,	O
nucleic	O
acids	O
,	O
and	O
matrix	B-Anatomy
components	I-Anatomy
.	O
They	O
also	O
serve	O
as	O
important	O
intracellular	B-Anatomy
signaling	O
molecules	O
that	O
amplify	O
the	O
synovial	B-Anatomy
inflammatory	O
-	O
proliferative	O
response	O
.	O
Repetitive	O
cycles	O
of	O
hypoxia	O
and	O
reoxygenation	O
associated	O
with	O
changes	O
in	O
synovial	B-Anatomy
perfusion	O
are	O
postulated	O
to	O
activate	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1alpha	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
,	O
two	O
key	O
transcription	O
factors	O
that	O
are	O
regulated	O
by	O
changes	O
in	O
cellular	B-Anatomy
oxygenation	O
and	O
cytokine	O
stimulation	O
,	O
and	O
that	O
in	O
turn	O
orchestrate	O
the	O
expression	O
of	O
a	O
spectrum	O
of	O
genes	O
critical	O
to	O
the	O
persistence	O
of	O
synovitis	O
.	O
An	O
understanding	O
of	O
the	O
complex	O
interactions	O
involved	O
in	O
these	O
pathways	O
might	O
allow	O
the	O
development	O
of	O
novel	O
therapeutic	O
strategies	O
for	O
rheumatoid	O
arthritis	O
.	O
Glucocorticoid	O
receptor	O
-	O
induced	O
MAPK	O
phosphatase	O
-	O
1	O
(	O
MPK	O
-	O
1	O
)	O
expression	O
inhibits	O
paclitaxel	O
-	O
associated	O
MAPK	O
activation	O
and	O
contributes	O
to	O
breast	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
survival	O
.	O
Glucocorticoid	O
receptor	O
(	O
GR	O
)	O
activation	O
has	O
recently	O
been	O
shown	O
to	O
inhibit	O
apoptosis	O
in	O
breast	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
.	O
We	O
have	O
previously	O
described	O
a	O
group	O
of	O
genes	O
that	O
is	O
rapidly	O
up	O
-	O
regulated	O
in	O
these	O
cells	B-Anatomy
following	O
dexamethasone	O
(	O
Dex	O
)	O
treatment	O
.	O
In	O
an	O
effort	O
to	O
dissect	O
the	O
mechanisms	O
of	O
GR	O
-	O
mediated	O
breast	B-Anatomy
epithelial	I-Anatomy
cell	I-Anatomy
survival	O
,	O
we	O
now	O
examine	O
the	O
molecular	O
events	O
downstream	O
of	O
GR	O
activation	O
.	O
Here	O
we	O
show	O
that	O
GR	O
activation	O
leads	O
to	O
both	O
the	O
rapid	O
induction	O
of	O
MAPK	O
phosphatase	O
-	O
1	O
(	O
MKP	O
-	O
1	O
)	O
mRNA	O
and	O
its	O
sustained	O
expression	O
.	O
Induction	O
of	O
the	O
MKP	O
-	O
1	O
protein	O
in	O
the	O
MCF10A	B-Anatomy
-	I-Anatomy
Myc	I-Anatomy
and	O
MDA	B-Anatomy
-	I-Anatomy
MB	I-Anatomy
-	I-Anatomy
231	I-Anatomy
breast	I-Anatomy
epithelial	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
was	O
also	O
seen	O
.	O
Paclitaxel	O
treatment	O
resulted	O
in	O
MAPK	O
activation	O
and	O
apoptosis	O
of	O
MDA	B-Anatomy
-	I-Anatomy
MB	I-Anatomy
-	I-Anatomy
231	I-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
,	O
and	O
both	O
processes	O
were	O
inhibited	O
by	O
Dex	O
pretreatment	O
.	O
Furthermore	O
,	O
induction	O
of	O
MKP	O
-	O
1	O
correlated	O
with	O
the	O
inhibition	O
of	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK1	O
/	O
2	O
)	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
activity	O
,	O
whereas	O
p38	O
activity	O
was	O
minimally	O
affected	O
.	O
Blocking	O
Dex	O
-	O
induced	O
MKP	O
-	O
1	O
induction	O
using	O
small	O
interfering	O
RNA	O
increased	O
ERK1	O
/	O
2	O
and	O
JNK	O
phosphorylation	O
and	O
decreased	O
cell	B-Anatomy
survival	O
.	O
ERK1	O
/	O
2	O
and	O
JNK	O
inactivation	O
was	O
associated	O
with	O
Ets	O
-	O
like	O
transcription	O
factor	O
-	O
1	O
(	O
ELK	O
-	O
1	O
)	O
dephosphorylation	O
.	O
To	O
explore	O
the	O
gene	O
expression	O
changes	O
that	O
occur	O
downstream	O
of	O
ELK	O
-	O
1	O
dephosphorylation	O
,	O
we	O
used	O
a	O
combination	O
of	O
temporal	O
gene	O
expression	O
data	O
and	O
promoter	O
element	O
analyses	O
.	O
This	O
approach	O
revealed	O
a	O
previously	O
unrecognized	O
transcriptional	O
target	O
of	O
ELK	O
-	O
1	O
,	O
the	O
human	O
tissue	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
.	O
We	O
verified	O
the	O
predicted	O
ELK	O
-	O
1	O
-	O
-	O
>	O
tPA	O
transcriptional	O
regulatory	O
relationship	O
using	O
a	O
luciferase	O
reporter	O
assay	O
.	O
We	O
conclude	O
that	O
GR	O
-	O
mediated	O
MAPK	O
inactivation	O
contributes	O
to	O
cell	B-Anatomy
survival	O
and	O
that	O
the	O
potential	O
transcriptional	O
targets	O
of	O
this	O
inhibition	O
can	O
be	O
identified	O
from	O
large	O
scale	O
gene	O
array	O
analysis	O
.	O
TBX21	O
:	O
a	O
functional	O
variant	O
predicts	O
improvement	O
in	O
asthma	O
with	O
the	O
use	O
of	O
inhaled	O
corticosteroids	O
.	O
TBX21	O
encodes	O
for	O
the	O
transcription	O
factor	O
T	O
-	O
bet	O
(	O
T	O
-	O
box	O
expressed	O
in	O
T	B-Anatomy
cells	I-Anatomy
)	O
,	O
which	O
influences	O
naive	O
T	B-Anatomy
lymphocyte	I-Anatomy
development	O
and	O
has	O
been	O
implicated	O
in	O
asthma	O
pathogenesis	O
.	O
Specifically	O
,	O
the	O
T	O
-	O
bet	O
knockout	O
mouse	O
spontaneously	O
develops	O
airway	B-Anatomy
hyperresponsiveness	O
and	O
other	O
changes	O
consistent	O
with	O
asthma	O
.	O
Because	O
airway	B-Anatomy
responsiveness	O
is	O
moderated	O
by	O
the	O
use	O
of	O
inhaled	O
corticosteroids	O
in	O
asthma	O
,	O
it	O
is	O
conceivable	O
that	O
genetic	O
variation	O
in	O
TBX21	O
may	O
alter	O
asthma	O
phenotypes	O
in	O
a	O
treatment	O
-	O
specific	O
fashion	O
.	O
Here	O
we	O
demonstrate	O
that	O
the	O
nonsynonymous	O
variation	O
in	O
TBX21	O
coding	O
for	O
replacement	O
of	O
histidine	O
33	O
with	O
glutamine	O
is	O
associated	O
with	O
significant	O
improvement	O
in	O
the	O
PC	O
(	O
20	O
)	O
(	O
a	O
measure	O
of	O
airway	B-Anatomy
responsiveness	O
)	O
of	O
asthmatic	O
children	O
in	O
a	O
large	O
clinical	O
trial	O
spanning	O
4	O
years	O
.	O
We	O
note	O
that	O
this	O
increase	O
occurs	O
only	O
in	O
the	O
children	O
randomized	O
to	O
inhaled	O
corticosteroids	O
and	O
that	O
it	O
dramatically	O
enhances	O
the	O
overall	O
improvement	O
in	O
PC	O
(	O
20	O
)	O
associated	O
with	O
inhaled	O
corticosteroid	O
usage	O
.	O
The	O
average	O
PC	O
(	O
20	O
)	O
at	O
trial	O
end	O
for	O
subjects	O
on	O
inhaled	O
corticosteroids	O
possessing	O
a	O
variant	O
allele	O
was	O
in	O
the	O
normal	O
range	O
for	O
nonasthmatics	O
.	O
In	O
cellular	B-Anatomy
models	O
,	O
we	O
show	O
that	O
the	O
TBX21	O
variant	O
increases	O
T	B-Anatomy
helper	I-Anatomy
1	I-Anatomy
and	O
decreases	O
T	B-Anatomy
helper	I-Anatomy
2	I-Anatomy
cytokine	O
expression	O
comparably	O
with	O
wild	O
type	O
.	O
TBX21	O
may	O
thus	O
be	O
an	O
important	O
determinant	O
pharmacogenetic	O
response	O
to	O
the	O
therapy	O
of	O
asthma	O
with	O
inhaled	O
corticosteroids	O
.	O
Investigating	O
the	O
causes	O
of	O
low	O
birth	O
weight	O
in	O
contrasting	O
ovine	O
paradigms	O
.	O
Intrauterine	O
growth	O
restriction	O
(	O
IUGR	O
)	O
still	O
accounts	O
for	O
a	O
large	O
incidence	O
of	O
infant	O
mortality	O
and	O
morbidity	O
worldwide	O
.	O
Many	O
of	O
the	O
circulatory	O
and	O
transport	O
properties	O
of	O
the	O
sheep	O
placenta	B-Anatomy
are	O
similar	O
to	O
those	O
of	O
the	O
human	O
placenta	B-Anatomy
and	O
as	O
such	O
,	O
the	O
pregnant	O
sheep	O
offers	O
an	O
excellent	O
model	O
in	O
which	O
to	O
study	O
the	O
development	O
of	O
IUGR	O
.	O
Two	O
natural	O
models	O
of	O
ovine	O
IUGR	O
are	O
those	O
of	O
hyperthermic	O
exposure	O
during	O
pregnancy	O
,	O
and	O
adolescent	O
overfeeding	O
,	O
also	O
during	O
pregnancy	O
.	O
Both	O
models	O
yield	O
significantly	O
reduced	O
placental	B-Anatomy
weights	O
and	O
an	O
asymmetrically	O
growth	O
-	O
restricted	O
fetus	B-Anatomy
,	O
and	O
display	O
altered	O
maternal	O
hormone	O
concentrations	O
,	O
indicative	O
of	O
an	O
impaired	O
trophoblast	B-Anatomy
capacity	O
.	O
Additionally	O
,	O
impaired	O
placental	B-Anatomy
angiogenesis	O
and	O
uteroplacental	B-Anatomy
blood	I-Anatomy
flow	O
appears	O
to	O
be	O
an	O
early	O
defect	O
in	O
both	O
the	O
hyperthermic	O
and	O
adolescent	O
paradigms	O
.	O
The	O
effects	O
of	O
these	O
alterations	O
in	O
placental	B-Anatomy
functional	O
development	O
appear	O
to	O
be	O
irreversible	O
.	O
IUGR	O
fetuses	B-Anatomy
are	O
both	O
hypoxic	O
and	O
hypoglycaemic	O
,	O
and	O
have	O
reduced	O
insulin	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
1	O
(	O
IGF	O
-	O
1	O
)	O
,	O
and	O
elevated	O
concentrations	O
of	O
lactate	O
.	O
However	O
,	O
fetal	B-Anatomy
utilization	O
of	O
oxygen	O
and	O
glucose	O
,	O
on	O
a	O
weight	O
basis	O
,	O
remain	O
constant	O
compared	O
with	O
control	O
pregnancies	O
.	O
Maintained	O
utilization	O
of	O
these	O
substrates	O
,	O
in	O
a	O
substrate	O
-	O
deficient	O
environment	O
,	O
suggests	O
increased	O
sensitivities	O
to	O
metabolic	O
signals	O
,	O
which	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
metabolic	O
diseases	O
in	O
later	O
adult	O
life	O
.	O
p53	O
mutation	O
heterogeneity	O
in	O
cancer	B-Anatomy
.	O
The	O
p53	O
gene	O
is	O
inactivated	O
in	O
about	O
50	O
%	O
of	O
human	O
cancers	B-Anatomy
and	O
the	O
p53	O
protein	O
is	O
an	O
essential	O
component	O
of	O
the	O
cell	B-Anatomy
response	O
induced	O
by	O
genotoxic	O
stresses	O
such	O
as	O
those	O
generated	O
by	O
radiotherapy	O
or	O
chemotherapy	O
.	O
It	O
is	O
therefore	O
highly	O
likely	O
that	O
these	O
alterations	O
are	O
an	O
important	O
component	O
in	O
tumor	B-Anatomy
resistance	O
to	O
therapy	O
.	O
The	O
particular	O
characteristics	O
of	O
these	O
alterations	O
,	O
80	O
%	O
of	O
which	O
are	O
missense	O
mutations	O
leading	O
to	O
functionally	O
heterogeneous	O
proteins	O
,	O
make	O
p53	O
a	O
unique	O
gene	O
in	O
the	O
class	O
of	O
tumor	B-Anatomy
suppressor	O
genes	O
.	O
A	O
considerable	O
number	O
of	O
mutant	O
p53	O
proteins	O
probably	O
have	O
an	O
oncogenic	O
activity	O
per	O
se	O
and	O
therefore	O
actively	O
participate	O
in	O
cell	B-Anatomy
transformation	O
.	O
The	O
fact	O
that	O
the	O
apoptotic	O
and	O
antiproliferative	O
functions	O
of	O
p53	O
can	O
be	O
dissociated	O
in	O
certain	O
mutants	O
also	O
suggests	O
another	O
level	O
of	O
complexity	O
in	O
the	O
relationships	O
between	O
p53	O
inactivation	O
and	O
neoplasia	B-Anatomy
.	O
Sox9	O
neural	B-Anatomy
crest	I-Anatomy
determinant	O
gene	O
controls	O
patterning	O
and	O
closure	O
of	O
the	O
posterior	B-Anatomy
frontal	I-Anatomy
cranial	I-Anatomy
suture	I-Anatomy
.	O
Cranial	B-Anatomy
suture	I-Anatomy
development	O
involves	O
a	O
complex	O
interaction	O
of	O
genes	O
and	O
tissues	B-Anatomy
derived	O
from	O
neural	B-Anatomy
crest	I-Anatomy
cells	I-Anatomy
(	O
NCC	B-Anatomy
)	O
and	O
paraxial	B-Anatomy
mesoderm	I-Anatomy
.	O
In	O
mice	O
,	O
the	O
posterior	B-Anatomy
frontal	I-Anatomy
(	I-Anatomy
PF	I-Anatomy
)	I-Anatomy
suture	I-Anatomy
closes	O
during	O
the	O
first	O
month	O
of	O
life	O
while	O
other	O
sutures	B-Anatomy
remain	O
patent	O
throughout	O
the	O
life	O
of	O
the	O
animal	O
.	O
Given	O
the	O
unique	O
NCC	B-Anatomy
origin	O
of	O
PF	B-Anatomy
suture	I-Anatomy
complex	O
(	O
analogous	O
to	O
metopic	B-Anatomy
suture	I-Anatomy
in	O
humans	O
)	O
,	O
we	O
performed	O
quantitative	O
real	O
-	O
time	O
PCR	O
and	O
immunohistochemistry	O
to	O
study	O
the	O
expression	O
pattern	O
of	O
the	O
NCC	B-Anatomy
determinant	O
gene	O
Sox9	O
and	O
select	O
markers	O
of	O
extracellular	B-Anatomy
matrix	I-Anatomy
.	O
Our	O
results	O
indicated	O
a	O
unique	O
up	O
-	O
regulated	O
expression	O
of	O
Sox9	O
,	O
a	O
regulator	O
of	O
chondrogenesis	O
,	O
during	O
initiation	O
of	O
PF	B-Anatomy
suture	I-Anatomy
closure	O
,	O
along	O
with	O
the	O
expression	O
of	O
specific	O
cartilage	B-Anatomy
markers	O
(	O
Type	O
II	O
Collagen	O
and	O
Type	O
X	O
Collagen	O
)	O
,	O
as	O
well	O
as	O
cartilage	B-Anatomy
tissue	I-Anatomy
formation	O
in	O
the	O
PF	B-Anatomy
suture	I-Anatomy
.	O
This	O
process	O
was	O
followed	O
by	O
expression	O
of	O
bone	B-Anatomy
markers	O
(	O
Type	O
I	O
Collagen	O
and	O
Osteocalcin	O
)	O
,	O
suggesting	O
endochondral	O
ossification	O
.	O
Moreover	O
,	O
we	O
studied	O
the	O
effect	O
of	O
haploinsufficiency	O
of	O
the	O
NCC	B-Anatomy
determinant	O
gene	O
Sox9	O
in	O
the	O
NCC	B-Anatomy
derived	O
PF	B-Anatomy
suture	I-Anatomy
complex	O
.	O
A	O
decrease	O
in	O
dosage	O
of	O
Sox9	O
by	O
haploinsufficiency	O
in	O
NCC	B-Anatomy
-	I-Anatomy
derived	I-Anatomy
tissues	I-Anatomy
resulted	O
in	O
delayed	O
PF	B-Anatomy
suture	I-Anatomy
closure	O
.	O
These	O
results	O
demonstrate	O
a	O
unique	O
development	O
of	O
the	O
PF	B-Anatomy
suture	I-Anatomy
complex	O
and	O
the	O
role	O
of	O
Sox9	O
as	O
an	O
important	O
contributor	O
to	O
timely	O
and	O
proper	O
closure	O
of	O
the	O
PF	B-Anatomy
suture	I-Anatomy
through	O
endochondral	O
ossification	O
.	O
Randomized	O
,	O
open	O
label	O
,	O
prospective	O
study	O
on	O
the	O
effect	O
of	O
zoledronic	O
acid	O
on	O
the	O
prevention	O
of	O
bone	B-Anatomy
metastases	I-Anatomy
in	O
patients	O
with	O
recurrent	O
solid	B-Anatomy
tumors	I-Anatomy
that	O
did	O
not	O
present	O
with	O
bone	B-Anatomy
metastases	I-Anatomy
at	O
baseline	O
.	O
OBJECTIVES	O
:	O
Bisphosphonates	O
have	O
been	O
used	O
successfully	O
in	O
the	O
treatment	O
of	O
hypercalcemia	O
and	O
to	O
reduce	O
skeletal	B-Anatomy
-	O
related	O
complications	O
of	O
bone	B-Anatomy
metastases	I-Anatomy
.	O
Recent	O
in	O
vitro	O
and	O
in	O
vivo	O
evidence	O
suggest	O
that	O
they	O
may	O
also	O
have	O
direct	O
antitumor	B-Anatomy
effects	O
via	O
induction	O
of	O
apoptosis	O
,	O
inhibition	O
of	O
the	O
invasive	O
potential	O
of	O
tumor	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
in	O
vitro	O
,	O
inhibition	O
of	O
angiogenesis	O
,	O
and	O
reduction	O
in	O
tumor	B-Anatomy
growth	O
indirectly	O
via	O
effects	O
on	O
accessory	B-Anatomy
cells	I-Anatomy
.	O
This	O
is	O
a	O
randomized	O
,	O
open	O
label	O
,	O
prospective	O
study	O
that	O
examined	O
the	O
effect	O
of	O
preventive	O
zoledronic	O
acid	O
treatment	O
on	O
the	O
development	O
of	O
bone	B-Anatomy
metastases	I-Anatomy
in	O
patients	O
with	O
recurrent	O
solid	B-Anatomy
tumors	I-Anatomy
,	O
without	O
bone	B-Anatomy
metastases	I-Anatomy
at	O
the	O
time	O
of	O
randomization	O
.	O
METHODS	O
:	O
Forty	O
patients	O
with	O
recurrent	O
or	O
metastatic	B-Anatomy
advanced	I-Anatomy
cancer	I-Anatomy
,	O
without	O
bone	B-Anatomy
metastases	I-Anatomy
,	O
were	O
randomized	O
into	O
the	O
trial	O
to	O
either	O
receive	O
zoledronic	O
acid	O
or	O
no	O
treatment	O
.	O
Patients	O
were	O
followed	O
up	O
until	O
bone	B-Anatomy
metastases	I-Anatomy
were	O
established	O
.	O
RESULTS	O
:	O
The	O
percentage	O
of	O
patients	O
being	O
bone	B-Anatomy
metastases	I-Anatomy
free	O
at	O
12	O
mo	O
was	O
60	O
%	O
in	O
the	O
zoledronic	O
acid	O
and	O
10	O
%	O
in	O
the	O
control	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
0005	O
)	O
,	O
while	O
the	O
percentages	O
at	O
18	O
mo	O
were	O
20	O
%	O
and	O
5	O
%	O
respectively	O
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
have	O
shown	O
that	O
bisphosphonates	O
as	O
adjuvant	O
treatment	O
might	O
be	O
useful	O
for	O
the	O
prevention	O
of	O
bone	B-Anatomy
metastases	I-Anatomy
;	O
however	O
,	O
there	O
is	O
need	O
for	O
blinded	O
randomized	O
data	O
before	O
such	O
an	O
approach	O
would	O
be	O
confirmed	O
.	O
In	O
the	O
meantime	O
preventive	O
use	O
of	O
bisphosphonates	O
in	O
patients	O
without	O
any	O
bone	B-Anatomy
metastases	I-Anatomy
should	O
not	O
be	O
used	O
outside	O
the	O
scope	O
of	O
a	O
clinical	O
trial	O
.	O
Experimental	O
investigation	O
of	O
equibiaxial	O
extension	O
and	O
breakup	O
of	O
drops	O
in	O
a	O
molten	O
two	O
-	O
phase	O
polymer	O
blend	O
.	O
We	O
experimentally	O
investigate	O
the	O
breakup	O
of	O
an	O
equibiaxially	O
elongated	O
polystyrene	O
(	O
PS	O
)	O
drop	O
in	O
a	O
poly	O
(	O
methyl	O
methacrylate	O
)	O
(	O
PMMA	O
)	O
matrix	O
during	O
relaxation	O
after	O
melt	O
elongation	O
.	O
In	O
equibiaxial	O
elongation	O
,	O
the	O
initially	O
spherical	O
PS	O
drop	O
is	O
deformed	O
into	O
an	O
ellipsoidal	O
disclike	O
shape	O
for	O
our	O
test	O
parameters	O
.	O
Using	O
a	O
hotstage	O
in	O
combination	O
with	O
a	O
light	O
microscope	O
,	O
we	O
observe	O
the	O
evolution	O
of	O
the	O
drop	O
shape	O
during	O
relaxation	O
.	O
In	O
the	O
initial	O
stage	O
of	O
relaxation	O
,	O
fingers	O
and	O
holes	O
are	O
formed	O
.	O
The	O
holes	O
are	O
located	O
preferentially	O
near	O
the	O
rim	O
of	O
the	O
drop	O
.	O
The	O
number	O
and	O
the	O
size	O
of	O
the	O
holes	O
increase	O
with	O
time	O
such	O
that	O
the	O
elongated	O
PS	O
drop	O
attains	O
a	O
complex	O
shape	O
during	O
relaxation	O
.	O
The	O
fingers	O
form	O
bulbous	O
ends	O
which	O
separate	O
from	O
the	O
fingers	O
.	O
We	O
discuss	O
the	O
dynamics	O
of	O
this	O
breakup	O
process	O
by	O
taking	O
into	O
account	O
the	O
interfacial	O
energy	O
between	O
PS	O
and	O
PMMA	O
.	O
Our	O
analysis	O
shows	O
that	O
a	O
very	O
large	O
number	O
of	O
small	O
PS	O
droplets	O
can	O
be	O
generated	O
by	O
the	O
sequential	O
breakup	O
of	O
the	O
elongated	O
PS	O
drop	O
.	O
Management	O
of	O
extremity	O
trauma	O
and	O
related	O
infections	O
occurring	O
in	O
the	O
aquatic	O
environment	O
.	O
Wounds	B-Anatomy
sustained	O
in	O
oceans	O
,	O
lakes	O
,	O
and	O
streams	O
are	O
exposed	O
to	O
a	O
milieu	O
of	O
bacteria	O
rarely	O
encountered	O
in	O
typical	O
land	O
-	O
based	O
injuries	O
.	O
These	O
include	O
Vibrio	O
species	O
,	O
Aeromonas	O
hydrophila	O
,	O
Pseudomonas	O
and	O
Plesiomonas	O
species	O
,	O
Erysipelothrix	O
rhusiopathiae	O
,	O
Mycobacterium	O
marinum	O
,	O
and	O
other	O
microbes	O
.	O
Failure	O
to	O
recognize	O
and	O
treat	O
these	O
less	O
common	O
pathogens	O
in	O
a	O
timely	O
manner	O
may	O
result	O
in	O
significant	O
morbidity	O
or	O
death	O
.	O
Initial	O
antibiotic	O
therapy	O
should	O
address	O
common	O
gram	O
-	O
positive	O
and	O
gram	O
-	O
negative	O
aquatic	O
bacteria	O
,	O
depending	O
on	O
the	O
environment	O
.	O
Trauma	O
occurring	O
in	O
brackish	O
or	O
salt	O
water	O
should	O
be	O
treated	O
with	O
doxycycline	O
and	O
ceftazidime	O
,	O
or	O
a	O
fluoroquinolone	O
(	O
eg	O
,	O
ciprofloxacin	O
or	O
levofloxacin	O
)	O
.	O
Freshwater	O
wounds	B-Anatomy
should	O
be	O
managed	O
with	O
ciprofloxacin	O
,	O
levofloxacin	O
,	O
or	O
a	O
third	O
-	O
or	O
fourth	O
-	O
generation	O
cephalosporin	O
(	O
eg	O
,	O
ceftazidime	O
)	O
.	O
Injuries	O
sustained	O
in	O
a	O
marine	O
or	O
freshwater	O
environment	O
may	O
result	O
from	O
bites	O
or	O
venomous	O
stings	O
of	O
aquatic	O
organisms	O
as	O
well	O
as	O
from	O
accidental	O
trauma	O
.	O
Musculoskeletal	B-Anatomy
trauma	I-Anatomy
caused	O
by	O
venomous	O
underwater	O
species	O
(	O
eg	O
,	O
stingrays	O
,	O
stinging	O
fish	O
,	O
sea	O
urchins	O
,	O
and	O
coral	O
)	O
requires	O
immediate	O
neutralization	O
of	O
the	O
heat	O
-	O
labile	O
toxin	O
with	O
immersion	O
in	O
nonscalding	O
water	O
for	O
30	O
to	O
90	O
minutes	O
.	O
Appropriate	O
management	O
of	O
aquatic	O
wounds	B-Anatomy
requires	O
recognition	O
of	O
the	O
mechanism	O
of	O
injury	O
,	O
neutralization	O
of	O
venom	B-Anatomy
,	O
antibiotic	O
administration	O
,	O
radiographic	O
assessment	O
,	O
surgical	O
debridement	O
with	O
irrigation	O
,	O
wound	B-Anatomy
cultures	O
,	O
and	O
structural	O
repair	O
or	O
amputation	O
as	O
indicated	O
by	O
the	O
severity	O
of	O
the	O
injury	O
.	O
Impaired	O
coronary	B-Anatomy
collateral	I-Anatomy
vessel	I-Anatomy
development	O
in	O
patients	O
with	O
proliferative	O
diabetic	O
retinopathy	O
.	O
BACKGROUND	O
:	O
Diabetic	O
patients	O
have	O
been	O
reported	O
to	O
have	O
impaired	O
coronary	B-Anatomy
collateral	I-Anatomy
vessel	I-Anatomy
growth	O
,	O
although	O
they	O
have	O
excessive	O
neovascularization	O
in	O
the	O
retina	B-Anatomy
.	O
HYPOTHESIS	O
:	O
This	O
study	O
was	O
designed	O
to	O
compare	O
coronary	B-Anatomy
collateral	I-Anatomy
circulation	O
(	O
CCC	O
)	O
in	O
patients	O
with	O
proliferative	O
diabetic	O
retinopathy	O
(	O
PDR	O
)	O
with	O
that	O
in	O
patients	O
without	O
DR	O
.	O
METHODS	O
:	O
Ninety	O
diabetic	O
patients	O
with	O
chronic	O
total	O
occlusion	O
in	O
at	O
least	O
one	O
major	O
epicardial	B-Anatomy
coronary	I-Anatomy
artery	I-Anatomy
were	O
enrolled	O
in	O
the	O
study	O
.	O
Groups	O
1	O
and	O
2	O
consisted	O
of	O
48	O
patients	O
without	O
DR	O
and	O
42	O
patients	O
with	O
PDR	O
,	O
respectively	O
.	O
Coronary	B-Anatomy
collateral	I-Anatomy
circulation	O
(	O
CCC	O
)	O
was	O
analyzed	O
according	O
to	O
the	O
Rentrop	O
system	O
.	O
Each	O
group	O
was	O
also	O
divided	O
into	O
two	O
subgroups	O
according	O
to	O
poor	O
and	O
good	O
CCC	O
.	O
Serum	B-Anatomy
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
levels	O
were	O
measured	O
using	O
the	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
kit	O
.	O
RESULTS	O
:	O
The	O
mean	O
Rentrop	O
collateral	O
score	O
was	O
higher	O
in	O
Group	O
1	O
than	O
in	O
Group	O
2	O
(	O
2	O
.	O
39	O
+	O
/	O
-	O
1	O
.	O
07	O
vs	O
.	O
1	O
.	O
76	O
+	O
/	O
-	O
0	O
.	O
76	O
,	O
respectively	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
When	O
the	O
two	O
groups	O
were	O
compared	O
with	O
respect	O
to	O
poor	O
and	O
good	O
CCC	O
,	O
poor	O
CCC	O
was	O
higher	O
in	O
patients	O
with	O
PDR	O
(	O
64	O
vs	O
.	O
36	O
%	O
,	O
respectively	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O
Serum	B-Anatomy
VEGF	O
levels	O
were	O
higher	O
in	O
patients	O
with	O
PDR	O
than	O
in	O
those	O
without	O
DR	O
(	O
219	O
+	O
/	O
-	O
99	O
vs	O
.	O
139	O
+	O
/	O
-	O
98	O
pg	O
/	O
ml	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
;	O
however	O
,	O
patients	O
with	O
poor	O
and	O
good	O
CCC	O
had	O
similar	O
VEGF	O
levels	O
.	O
CONCLUSIONS	O
:	O
We	O
have	O
shown	O
that	O
patients	O
with	O
PDR	O
have	O
a	O
lower	O
coronary	B-Anatomy
collateral	I-Anatomy
score	O
than	O
patients	O
without	O
DR	O
.	O
Also	O
,	O
serum	B-Anatomy
VEGF	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
PDR	O
than	O
in	O
those	O
without	O
DR	O
.	O
These	O
findings	O
have	O
suggested	O
that	O
diabetes	O
mellitus	O
may	O
have	O
a	O
different	O
action	O
on	O
retinal	B-Anatomy
and	O
coronary	B-Anatomy
circulation	O
.	O
VEGFR1	B-Anatomy
-	I-Anatomy
positive	I-Anatomy
haematopoietic	I-Anatomy
bone	I-Anatomy
marrow	I-Anatomy
progenitors	I-Anatomy
initiate	O
the	O
pre	O
-	O
metastatic	O
niche	O
.	O
The	O
cellular	B-Anatomy
and	O
molecular	O
mechanisms	O
by	O
which	O
a	O
tumour	B-Anatomy
cell	I-Anatomy
undergoes	O
metastasis	O
to	O
a	O
predetermined	O
location	O
are	O
largely	O
unknown	O
.	O
Here	O
we	O
demonstrate	O
that	O
bone	B-Anatomy
marrow	I-Anatomy
-	I-Anatomy
derived	I-Anatomy
haematopoietic	I-Anatomy
progenitor	I-Anatomy
cells	I-Anatomy
that	O
express	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
1	O
(	O
VEGFR1	O
;	O
also	O
known	O
as	O
Flt1	O
)	O
home	O
to	O
tumour	B-Anatomy
-	O
specific	O
pre	B-Anatomy
-	I-Anatomy
metastatic	I-Anatomy
sites	I-Anatomy
and	O
form	O
cellular	B-Anatomy
clusters	I-Anatomy
before	O
the	O
arrival	O
of	O
tumour	B-Anatomy
cells	I-Anatomy
.	O
Preventing	O
VEGFR1	O
function	O
using	O
antibodies	O
or	O
by	O
the	O
removal	O
of	O
VEGFR1	B-Anatomy
(	I-Anatomy
+	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
from	O
the	O
bone	B-Anatomy
marrow	I-Anatomy
of	O
wild	O
-	O
type	O
mice	O
abrogates	O
the	O
formation	O
of	O
these	O
pre	B-Anatomy
-	I-Anatomy
metastatic	I-Anatomy
clusters	I-Anatomy
and	O
prevents	O
tumour	B-Anatomy
metastasis	O
,	O
whereas	O
reconstitution	O
with	O
selected	O
Id3	O
(	O
inhibitor	O
of	O
differentiation	O
3	O
)	O
-	O
competent	O
VEGFR1	B-Anatomy
+	I-Anatomy
cells	I-Anatomy
establishes	O
cluster	B-Anatomy
formation	O
and	O
tumour	B-Anatomy
metastasis	O
in	O
Id3	O
knockout	O
mice	O
.	O
We	O
also	O
show	O
that	O
VEGFR1	B-Anatomy
+	I-Anatomy
cells	I-Anatomy
express	O
VLA	O
-	O
4	O
(	O
also	O
known	O
as	O
integrin	O
alpha4beta1	O
)	O
,	O
and	O
that	O
tumour	B-Anatomy
-	O
specific	O
growth	O
factors	O
upregulate	O
fibronectin	O
-	O
-	O
a	O
VLA	O
-	O
4	O
ligand	O
-	O
-	O
in	O
resident	O
fibroblasts	B-Anatomy
,	O
providing	O
a	O
permissive	O
niche	O
for	O
incoming	O
tumour	B-Anatomy
cells	I-Anatomy
.	O
Conditioned	O
media	O
obtained	O
from	O
distinct	O
tumour	B-Anatomy
types	O
with	O
unique	O
patterns	O
of	O
metastatic	O
spread	O
redirected	O
fibronectin	O
expression	O
and	O
cluster	B-Anatomy
formation	O
,	O
thereby	O
transforming	O
the	O
metastatic	O
profile	O
.	O
These	O
findings	O
demonstrate	O
a	O
requirement	O
for	O
VEGFR1	B-Anatomy
+	I-Anatomy
haematopoietic	I-Anatomy
progenitors	I-Anatomy
in	O
the	O
regulation	O
of	O
metastasis	O
,	O
and	O
suggest	O
that	O
expression	O
patterns	O
of	O
fibronectin	O
and	O
VEGFR1	B-Anatomy
+	I-Anatomy
VLA	I-Anatomy
-	I-Anatomy
4	I-Anatomy
+	I-Anatomy
clusters	I-Anatomy
dictate	O
organ	B-Anatomy
-	O
specific	O
tumour	B-Anatomy
spread	O
.	O
The	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
G	O
protein	O
-	O
coupled	O
receptor	O
as	O
a	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
Kaposi	B-Anatomy
'	I-Anatomy
s	I-Anatomy
sarcoma	I-Anatomy
.	O
The	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
(	O
KSHV	O
)	O
encodes	O
a	O
G	O
protein	O
-	O
coupled	O
receptor	O
(	O
vGPCR	O
)	O
that	O
has	O
been	O
implicated	O
in	O
the	O
initiation	O
of	O
Kaposi	B-Anatomy
'	I-Anatomy
s	I-Anatomy
sarcoma	I-Anatomy
,	O
identifying	O
vGPCR	O
as	O
an	O
attractive	O
target	O
for	O
preventing	O
Kaposi	B-Anatomy
'	I-Anatomy
s	I-Anatomy
sarcoma	I-Anatomy
.	O
However	O
,	O
as	O
only	O
a	O
fraction	O
of	O
cells	B-Anatomy
in	O
advanced	O
Kaposi	B-Anatomy
'	I-Anatomy
s	I-Anatomy
sarcoma	I-Anatomy
lesions	I-Anatomy
express	O
vGPCR	O
,	O
it	O
is	O
unclear	O
whether	O
this	O
unique	O
viral	O
oncogene	O
contributes	O
to	O
Kaposi	B-Anatomy
'	I-Anatomy
s	I-Anatomy
sarcoma	I-Anatomy
progression	O
.	O
We	O
therefore	O
set	O
out	O
to	O
determine	O
whether	O
the	O
few	O
cells	B-Anatomy
that	O
express	O
vGPCR	O
in	O
established	O
tumors	B-Anatomy
represent	O
an	O
appropriate	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
preexisting	O
Kaposi	B-Anatomy
'	I-Anatomy
s	I-Anatomy
sarcoma	I-Anatomy
.	O
To	O
this	O
end	O
,	O
we	O
generated	O
endothelial	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
stably	O
expressing	O
vGPCR	O
or	O
key	O
KSHV	O
latently	O
expressed	O
proteins	O
(	O
vCyclin	O
,	O
vFlip	O
,	O
and	O
LANA1	O
)	O
.	O
The	O
endothelial	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
expressing	O
vGPCR	O
was	O
rendered	O
sensitive	O
to	O
treatment	O
with	O
the	O
nucleoside	O
analogue	O
ganciclovir	O
by	O
using	O
a	O
bicistronic	O
construct	O
coexpressing	O
the	O
herpes	O
simplex	O
virus	O
1	O
thymidine	O
kinase	O
.	O
S	O
.	O
c	O
.	O
injection	O
into	O
nude	O
mice	O
with	O
mixed	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
populations	I-Anatomy
formed	O
tumors	B-Anatomy
that	O
approximate	O
the	O
ratio	O
of	O
vGPCR	O
-	O
expressing	O
and	O
KSHV	O
latent	O
gene	O
-	O
expressing	O
cells	B-Anatomy
.	O
These	O
mice	O
were	O
then	O
treated	O
with	O
ganciclovir	O
to	O
specifically	O
target	O
only	O
the	O
vGPCR	O
-	O
expressing	O
cells	B-Anatomy
.	O
Surprisingly	O
,	O
despite	O
the	O
expression	O
of	O
KSHV	O
latent	O
genes	O
in	O
the	O
vast	O
majority	O
of	O
tumor	B-Anatomy
cells	I-Anatomy
,	O
specifically	O
targeting	O
only	O
the	O
few	O
vGPCR	O
-	O
expressing	O
cells	B-Anatomy
in	O
established	O
tumors	B-Anatomy
resulted	O
in	O
tumor	B-Anatomy
regression	O
.	O
Moreover	O
,	O
we	O
observed	O
an	O
increase	O
in	O
apoptosis	O
of	O
latent	O
gene	O
-	O
expressing	O
cells	B-Anatomy
after	O
the	O
pharmacologic	O
deletion	O
of	O
the	O
vGPCR	O
-	O
expressing	O
cells	B-Anatomy
.	O
These	O
findings	O
indicate	O
that	O
vGPCR	O
may	O
play	O
a	O
key	O
role	O
in	O
Kaposi	B-Anatomy
'	I-Anatomy
s	I-Anatomy
sarcoma	I-Anatomy
progression	O
and	O
provide	O
experimental	O
justification	O
for	O
developing	O
molecular	O
-	O
based	O
therapies	O
specifically	O
targeting	O
vGPCR	O
and	O
its	O
effectors	O
for	O
the	O
treatment	O
of	O
Kaposi	B-Anatomy
'	I-Anatomy
s	I-Anatomy
sarcoma	I-Anatomy
patients	O
.	O
Mechanisms	O
of	O
pericyte	B-Anatomy
recruitment	O
in	O
tumour	B-Anatomy
angiogenesis	O
:	O
a	O
new	O
role	O
for	O
metalloproteinases	O
.	O
Pericytes	B-Anatomy
occur	O
in	O
tumour	B-Anatomy
blood	I-Anatomy
vessels	I-Anatomy
and	O
are	O
critical	O
for	O
the	O
development	O
of	O
a	O
functional	O
vascular	B-Anatomy
network	I-Anatomy
.	O
Targeting	O
tumour	B-Anatomy
pericytes	I-Anatomy
is	O
a	O
promising	O
anti	O
-	O
angiogenic	O
therapy	O
but	O
requires	O
identifying	O
the	O
mechanisms	O
of	O
their	O
recruitment	O
in	O
tumour	B-Anatomy
and	O
addressing	O
whether	O
these	O
mechanisms	O
can	O
be	O
selectively	O
harnessed	O
.	O
Among	O
the	O
pathways	O
involved	O
in	O
pericyte	B-Anatomy
recruitment	O
during	O
embryonic	B-Anatomy
development	O
,	O
the	O
contribution	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
B	O
and	O
sphingosine	O
1	O
-	O
phosphate	O
is	O
confirmed	O
in	O
tumour	B-Anatomy
angiogenesis	O
.	O
The	O
effect	O
of	O
angiopoietin	O
1	O
depends	O
on	O
the	O
tumour	B-Anatomy
model	O
.	O
Transforming	O
growth	O
factor	O
-	O
beta1	O
enhances	O
tumour	B-Anatomy
vascularization	O
and	O
microvessel	B-Anatomy
maturation	O
.	O
Recent	O
reports	O
suggest	O
a	O
participation	O
of	O
matrix	O
metalloproteinases	O
(	O
MMP	O
)	O
in	O
tumour	B-Anatomy
pericyte	I-Anatomy
recruitment	O
that	O
is	O
consistent	O
with	O
the	O
effect	O
of	O
certain	O
MMPs	O
in	O
the	O
development	O
of	O
microvasculature	B-Anatomy
in	O
embryonic	B-Anatomy
development	O
and	O
in	O
in	O
vitro	O
models	O
of	O
vascular	B-Anatomy
remodelling	O
.	O
Here	O
,	O
we	O
discuss	O
the	O
possibility	O
for	O
MMPs	O
to	O
contribute	O
to	O
pericyte	B-Anatomy
recruitment	O
at	O
six	O
levels	O
:	O
(	O
1	O
)	O
direct	O
promotion	O
of	O
pericyte	B-Anatomy
invasion	O
by	O
extracellular	B-Anatomy
matrix	I-Anatomy
degradation	O
;	O
(	O
2	O
)	O
stimulation	O
of	O
pericyte	B-Anatomy
proliferation	O
and	O
protection	O
against	O
apoptosis	O
by	O
modification	O
of	O
the	O
ECM	B-Anatomy
;	O
(	O
3	O
)	O
activation	O
of	O
pericytes	B-Anatomy
through	O
the	O
release	O
of	O
growth	O
factor	O
bound	O
to	O
the	O
ECM	B-Anatomy
;	O
(	O
4	O
)	O
transactivation	O
of	O
angiogenic	O
cell	B-Anatomy
surface	I-Anatomy
receptor	O
;	O
(	O
5	O
)	O
propagation	O
of	O
angiogenic	O
signalling	O
as	O
cofactor	O
;	O
and	O
(	O
6	O
)	O
recruitment	O
of	O
bone	B-Anatomy
marrow	I-Anatomy
-	I-Anatomy
derived	I-Anatomy
stem	I-Anatomy
cells	I-Anatomy
.	O
Involvement	O
of	O
de	O
novo	O
ceramide	O
synthesis	O
in	O
radiocontrast	O
-	O
induced	O
renal	B-Anatomy
tubular	I-Anatomy
cell	I-Anatomy
injury	O
.	O
We	O
reported	O
previously	O
that	O
various	O
radiocontrast	O
media	O
cause	O
apoptosis	O
in	O
porcine	O
proximal	B-Anatomy
tubular	I-Anatomy
(	I-Anatomy
LLC	I-Anatomy
-	I-Anatomy
PK	I-Anatomy
(	I-Anatomy
1	I-Anatomy
)	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
,	O
in	O
which	O
reduction	O
in	O
B	O
-	O
cell	O
lymphoma	O
(	O
Bcl	O
)	O
-	O
2	O
expression	O
and	O
caspase	O
-	O
3	O
activation	O
are	O
implicated	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
a	O
role	O
for	O
ceramide	O
in	O
radiocontrast	O
media	O
-	O
induced	O
apoptosis	O
in	O
renal	B-Anatomy
tubular	I-Anatomy
cells	I-Anatomy
.	O
LLC	B-Anatomy
-	I-Anatomy
PK	I-Anatomy
(	I-Anatomy
1	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
were	O
exposed	O
to	O
radiocontrast	O
media	O
for	O
30	O
min	O
,	O
followed	O
by	O
incubation	O
for	O
24	O
h	O
in	O
normal	O
medium	O
.	O
Cell	B-Anatomy
viability	O
was	O
assessed	O
by	O
2	O
-	O
(	O
2	O
-	O
methoxy	O
-	O
4	O
-	O
nitrophenyl	O
)	O
-	O
3	O
-	O
(	O
4	O
-	O
nitrophenyl	O
)	O
-	O
5	O
-	O
(	O
2	O
,	O
4	O
-	O
disulfophenyl	O
)	O
-	O
2H	O
-	O
tetrazolium	O
monosodium	O
salt	O
assay	O
,	O
while	O
apoptosis	O
was	O
determined	O
by	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
nick	O
end	O
labeling	O
stain	O
.	O
Immunofluorescent	O
stains	O
were	O
performed	O
using	O
antibodies	O
against	O
phosphorylated	O
Akt	O
(	O
pAkt	O
)	O
and	O
cAMP	O
response	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
(	O
pCREB	O
)	O
,	O
and	O
ceramide	O
.	O
The	O
mRNA	O
expression	O
and	O
protein	O
content	O
of	O
Bcl	O
-	O
2	O
were	O
determined	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
and	O
enzyme	O
immunoassay	O
,	O
respectively	O
.	O
In	O
vivo	O
model	O
of	O
contrast	O
-	O
induced	O
renal	B-Anatomy
injury	O
was	O
induced	O
in	O
mice	O
with	O
unilateral	O
renal	B-Anatomy
occlusion	O
.	O
The	O
cell	B-Anatomy
injury	O
induced	O
by	O
the	O
nonionic	O
radiocontrast	O
medium	O
ioversol	O
was	O
reversed	O
by	O
inhibiting	O
de	O
novo	O
ceramide	O
synthesis	O
with	O
fumonisin	O
B	O
(	O
1	O
)	O
(	O
FB	O
(	O
1	O
)	O
)	O
and	O
L	O
-	O
cycloserine	O
,	O
but	O
not	O
by	O
suppressing	O
sphingomyelin	O
breakdown	O
with	O
D609	O
.	O
FB	O
(	O
1	O
)	O
reversed	O
ioversol	O
-	O
induced	O
decrease	O
in	O
the	O
immunoreactivities	O
of	O
pAkt	O
and	O
pCREB	O
,	O
reduction	O
in	O
Bcl	O
-	O
2	O
expression	O
and	O
caspase	O
-	O
3	O
activation	O
.	O
Like	O
ioversol	O
,	O
C2	O
ceramide	O
and	O
the	O
Akt	O
inhibitor	O
Src	O
homology	O
-	O
6	O
induced	O
apoptosis	O
by	O
reducing	O
pAkt	O
and	O
pCREB	O
-	O
like	O
immunoreactivities	O
,	O
lowering	O
Bcl	O
-	O
2	O
expression	O
and	O
enhancing	O
caspase	O
-	O
3	O
activity	O
.	O
Indeed	O
,	O
various	O
radiocontrast	O
media	O
,	O
excluding	O
iodixanol	O
which	O
showed	O
the	O
least	O
nephrotoxicity	O
,	O
enhanced	O
ceramide	O
-	O
like	O
immunoreactivity	O
.	O
The	O
role	O
for	O
de	O
novo	O
ceramide	O
synthesis	O
was	O
also	O
shown	O
in	O
the	O
in	O
vivo	O
model	O
of	O
radiocontrast	O
nephropathy	O
.	O
We	O
demonstrated	O
here	O
for	O
the	O
first	O
time	O
that	O
the	O
enhancement	O
of	O
de	O
novo	O
ceramide	O
synthesis	O
contributes	O
to	O
radiocontrast	O
nephropathy	O
.	O
Sensitization	O
to	O
gimatecan	O
-	O
induced	O
apoptosis	O
by	O
tumor	O
necrosis	O
factor	O
-	O
related	O
apoptosis	O
inducing	O
ligand	O
in	O
prostate	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
.	O
Since	O
the	O
intrinsic	O
resistance	O
of	O
prostate	B-Anatomy
carcinoma	I-Anatomy
likely	O
reflects	O
a	O
low	O
susceptibility	O
to	O
drug	O
-	O
induced	O
apoptosis	O
,	O
in	O
this	O
study	O
we	O
explored	O
the	O
possibility	O
of	O
sensitizing	O
prostate	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
to	O
apoptosis	O
by	O
combination	O
of	O
TRAIL	O
with	O
camptothecins	O
.	O
Indeed	O
,	O
these	O
agents	O
are	O
known	O
to	O
activate	O
different	O
pathways	O
of	O
apoptosis	O
.	O
Topotecan	O
-	O
and	O
gimatecan	O
induced	O
moderate	O
up	O
-	O
regulation	O
of	O
TRAIL	O
-	O
R1	O
and	O
-	O
R2	O
which	O
resulted	O
in	O
a	O
different	O
cell	B-Anatomy
response	O
to	O
the	O
combination	O
in	O
androgen	O
-	O
independent	O
cells	B-Anatomy
(	O
DU	B-Anatomy
-	I-Anatomy
145	I-Anatomy
and	O
PC	B-Anatomy
-	I-Anatomy
3	I-Anatomy
)	O
.	O
In	O
DU	B-Anatomy
-	I-Anatomy
145	I-Anatomy
cells	I-Anatomy
apoptosis	O
was	O
increased	O
by	O
lower	O
TRAIL	O
concentrations	O
and	O
was	O
earlier	O
than	O
in	O
PC	B-Anatomy
-	I-Anatomy
3	I-Anatomy
cells	I-Anatomy
,	O
as	O
shown	O
using	O
Annexin	O
V	O
-	O
binding	O
assay	O
.	O
The	O
relative	O
resistance	O
of	O
PC	B-Anatomy
-	I-Anatomy
3	I-Anatomy
cells	I-Anatomy
to	O
drug	O
-	O
induced	O
apoptosis	O
was	O
associated	O
with	O
constitutive	O
Akt	O
activation	O
,	O
higher	O
levels	O
of	O
cFLIP	O
-	O
L	O
and	O
Bcl	O
-	O
2	O
,	O
and	O
lower	O
levels	O
of	O
Bax	O
.	O
The	O
different	O
expression	O
/	O
activation	O
of	O
apoptosis	O
-	O
related	O
factors	O
appears	O
to	O
influence	O
the	O
sensitization	O
of	O
prostate	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
by	O
TRAIL	O
.	O
Potentiation	O
of	O
camptothecin	O
-	O
induced	O
apoptosis	O
by	O
TRAIL	O
appears	O
dependent	O
on	O
cooperation	O
between	O
extrinsic	O
and	O
intrinsic	O
pathways	O
,	O
as	O
documented	O
by	O
loss	O
of	O
the	O
sensitization	O
to	O
apoptosis	O
following	O
reduction	O
of	O
caspase	O
8	O
after	O
small	O
interfering	O
RNA	O
transfection	O
.	O
The	O
efficacy	O
of	O
the	O
approach	O
may	O
be	O
critically	O
dependent	O
on	O
the	O
intrinsic	O
susceptibility	O
to	O
apoptosis	O
of	O
different	O
tumors	B-Anatomy
.	O
These	O
observations	O
support	O
that	O
the	O
activation	O
of	O
multiple	O
signals	O
could	O
enhance	O
apoptotic	O
response	O
and	O
suggest	O
the	O
therapeutic	O
interest	O
of	O
the	O
TRAIL	O
/	O
camptothecin	O
combination	O
.	O
c	O
-	O
Met	O
expression	O
is	O
regulated	O
by	O
Mitf	O
in	O
the	O
melanocyte	B-Anatomy
lineage	I-Anatomy
.	O
Hepatocyte	O
growth	O
factor	O
(	O
HGF	O
)	O
/	O
c	O
-	O
Met	O
signaling	O
is	O
thought	O
to	O
be	O
a	O
key	O
pathway	O
in	O
both	O
melanocyte	B-Anatomy
development	O
and	O
melanoma	B-Anatomy
metastasis	O
.	O
Here	O
,	O
HGF	O
stimulation	O
of	O
melanocytes	B-Anatomy
was	O
seen	O
to	O
up	O
-	O
regulate	O
c	O
-	O
Met	O
expression	O
.	O
In	O
an	O
effort	O
to	O
decipher	O
the	O
mechanism	O
by	O
which	O
HGF	O
up	O
-	O
regulates	O
its	O
receptor	O
,	O
we	O
found	O
that	O
c	O
-	O
Met	O
is	O
a	O
direct	O
transcriptional	O
target	O
of	O
Mitf	O
.	O
This	O
was	O
confirmed	O
with	O
chromatin	B-Anatomy
immunoprecipitation	O
experiments	O
of	O
the	O
human	O
c	O
-	O
Met	O
promoter	O
,	O
as	O
well	O
as	O
by	O
the	O
ability	O
of	O
adenovirally	O
expressed	O
Mitf	O
to	O
modulate	O
endogenous	O
c	O
-	O
Met	O
protein	O
levels	O
in	O
melanocytes	B-Anatomy
.	O
Disruption	O
of	O
Mitf	O
blocked	O
HGF	O
-	O
dependent	O
increases	O
in	O
endogenous	O
c	O
-	O
Met	O
message	O
and	O
protein	O
levels	O
,	O
indicating	O
that	O
HGF	O
regulates	O
its	O
own	O
receptor	O
levels	O
via	O
Mitf	O
.	O
Finally	O
,	O
dominant	O
-	O
negative	O
inhibition	O
of	O
Mitf	O
resulted	O
in	O
profound	O
resistance	O
of	O
melanocytes	B-Anatomy
and	O
melanoma	B-Anatomy
cells	I-Anatomy
to	O
HGF	O
-	O
dependent	O
matrix	B-Anatomy
invasion	O
,	O
suggesting	O
a	O
physiologic	O
role	O
for	O
this	O
pathway	O
in	O
melanocytic	B-Anatomy
development	O
and	O
melanoma	B-Anatomy
.	O
Targeting	O
PIM	O
kinases	O
impairs	O
survival	O
of	O
hematopoietic	B-Anatomy
cells	I-Anatomy
transformed	O
by	O
kinase	O
inhibitor	O
-	O
sensitive	O
and	O
kinase	O
inhibitor	O
-	O
resistant	O
forms	O
of	O
Fms	O
-	O
like	O
tyrosine	O
kinase	O
3	O
and	O
BCR	O
/	O
ABL	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
activation	O
of	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
5	O
(	O
STAT5	O
)	O
plays	O
an	O
essential	O
role	O
in	O
leukemogenesis	O
mediated	O
through	O
constitutive	O
activated	O
protein	O
tyrosine	O
kinases	O
(	O
PTK	O
)	O
.	O
Because	O
PIM	O
-	O
1	O
is	O
a	O
STAT5	O
target	O
gene	O
,	O
we	O
analyzed	O
the	O
role	O
of	O
the	O
family	O
of	O
PIM	O
serine	O
/	O
threonine	O
kinases	O
(	O
PIM	O
-	O
1	O
to	O
PIM	O
-	O
3	O
)	O
in	O
PTK	O
-	O
mediated	O
transformation	O
of	O
hematopoietic	B-Anatomy
cells	I-Anatomy
.	O
Ba	B-Anatomy
/	I-Anatomy
F3	I-Anatomy
cells	I-Anatomy
transformed	O
to	O
growth	O
factor	O
independence	O
by	O
various	O
oncogenic	O
PTKs	O
(	O
TEL	O
/	O
JAK2	O
,	O
TEL	O
/	O
TRKC	O
,	O
TEL	O
/	O
ABL	O
,	O
BCR	O
/	O
ABL	O
,	O
FLT3	O
-	O
ITD	O
,	O
and	O
H4	O
/	O
PDGFbetaR	O
)	O
show	O
abundant	O
expression	O
of	O
PIM	O
-	O
1	O
and	O
PIM	O
-	O
2	O
.	O
Suppression	O
of	O
PIM	O
-	O
1	O
activity	O
had	O
a	O
negligible	O
effect	O
on	O
transformation	O
.	O
In	O
contrast	O
,	O
expression	O
of	O
kinase	O
-	O
dead	O
PIM	O
-	O
2	O
mutant	O
(	O
PIM	O
-	O
2KD	O
)	O
led	O
to	O
a	O
rapid	O
decline	O
of	O
survival	O
in	O
Ba	B-Anatomy
/	I-Anatomy
F3	I-Anatomy
cells	I-Anatomy
transformed	O
by	O
FLT3	O
-	O
ITD	O
but	O
not	O
by	O
other	O
oncogenic	O
PTKs	O
tested	O
.	O
Coexpression	O
of	O
PIM	O
-	O
1KD	O
and	O
PIM	O
-	O
2KD	O
abrogated	O
growth	O
factor	O
-	O
independent	O
growth	O
of	O
Ba	B-Anatomy
/	I-Anatomy
F3	I-Anatomy
transformed	O
by	O
several	O
PTKs	O
,	O
including	O
BCR	O
/	O
ABL	O
.	O
Targeted	O
down	O
-	O
regulation	O
of	O
PIM	O
-	O
2	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
selectively	O
abrogated	O
survival	O
of	O
Ba	B-Anatomy
/	I-Anatomy
F3	I-Anatomy
cells	I-Anatomy
transformed	O
by	O
various	O
Fms	O
-	O
like	O
tyrosine	O
kinase	O
3	O
(	O
FLT3	O
)	O
-	O
activating	O
mutants	O
[	O
internal	O
tandem	O
duplication	O
(	O
ITD	O
)	O
and	O
kinase	O
domain	O
]	O
and	O
attenuated	O
growth	O
of	O
human	O
cell	B-Anatomy
lines	I-Anatomy
containing	O
FLT3	O
mutations	O
.	O
Interestingly	O
,	O
cells	B-Anatomy
transformed	O
by	O
FLT3	O
and	O
BCR	O
/	O
ABL	O
mutations	O
that	O
confer	O
resistance	O
to	O
small	O
-	O
molecule	O
tyrosine	O
kinase	O
inhibitors	O
were	O
still	O
sensitive	O
to	O
knockdown	O
of	O
PIM	O
-	O
2	O
,	O
or	O
PIM	O
-	O
1	O
and	O
PIM	O
-	O
2	O
by	O
RNAi	O
.	O
Our	O
observations	O
indicate	O
that	O
combined	O
inactivation	O
of	O
PIM	O
-	O
1	O
and	O
PIM	O
-	O
2	O
interferes	O
with	O
oncogenic	O
PTKs	O
and	O
suggest	O
that	O
PIMs	O
are	O
alternative	O
therapeutic	O
targets	O
in	O
PTK	O
-	O
mediated	O
leukemia	B-Anatomy
.	O
Targeting	O
the	O
PIM	O
kinase	O
family	O
could	O
provide	O
a	O
new	O
avenue	O
to	O
overcome	O
resistance	O
against	O
small	O
-	O
molecule	O
tyrosine	O
kinase	O
inhibitors	O
.	O
A	O
potential	O
role	O
for	O
the	O
Src	O
-	O
like	O
adapter	O
protein	O
SLAP	O
-	O
2	O
in	O
signaling	O
by	O
the	O
colony	O
stimulating	O
factor	O
-	O
1	O
receptor	O
.	O
The	O
development	O
of	O
macrophages	B-Anatomy
from	O
myeloid	B-Anatomy
progenitor	I-Anatomy
cells	I-Anatomy
is	O
primarily	O
controlled	O
by	O
the	O
growth	O
factor	O
colony	O
stimulating	O
factor	O
-	O
1	O
(	O
CSF	O
-	O
1	O
)	O
and	O
its	O
cognate	O
receptor	O
,	O
a	O
transmembrane	B-Anatomy
tyrosine	O
kinase	O
encoded	O
by	O
the	O
c	O
-	O
Fms	O
proto	O
-	O
oncogene	O
.	O
The	O
CSF	O
-	O
1	O
receptor	O
exerts	O
its	O
biological	O
effects	O
on	O
cells	B-Anatomy
via	O
a	O
range	O
of	O
signaling	O
proteins	O
including	O
Erk1	O
/	O
2	O
and	O
Akt	O
.	O
Here	O
we	O
have	O
investigated	O
the	O
potential	O
involvement	O
of	O
the	O
Src	O
-	O
like	O
adapter	O
protein	O
(	O
SLAP	O
-	O
2	O
)	O
in	O
signaling	O
by	O
the	O
CSF	O
-	O
1	O
receptor	O
in	O
mouse	O
bone	B-Anatomy
marrow	I-Anatomy
-	O
derived	O
macrophages	B-Anatomy
.	O
RT	O
-	O
PCR	O
analysis	O
revealed	O
constitutive	O
expression	O
of	O
the	O
SLAP	O
-	O
2	O
gene	O
in	O
bone	B-Anatomy
marrow	I-Anatomy
macrophages	I-Anatomy
.	O
Surprisingly	O
,	O
co	O
-	O
immunoprecipitation	O
and	O
GST	O
binding	O
experiments	O
demonstrated	O
that	O
the	O
CSF	O
-	O
1	O
receptor	O
could	O
bind	O
to	O
SLAP	O
-	O
2	O
in	O
a	O
ligand	O
-	O
independent	O
manner	O
.	O
Furthermore	O
,	O
the	O
binding	O
of	O
SLAP	O
-	O
2	O
to	O
the	O
CSF	O
-	O
1	O
receptor	O
involved	O
multiple	O
domains	O
of	O
SLAP	O
-	O
2	O
.	O
SLAP	O
-	O
2	O
also	O
bound	O
c	O
-	O
Cbl	O
,	O
with	O
the	O
interaction	O
being	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
unique	O
C	O
-	O
terminal	O
domain	O
of	O
SLAP	O
-	O
2	O
.	O
Overexpression	O
of	O
SLAP	O
-	O
2	O
in	O
bone	B-Anatomy
marrow	I-Anatomy
macrophages	I-Anatomy
partially	O
suppressed	O
the	O
CSF	O
-	O
1	O
-	O
induced	O
tyrosine	O
phosphorylation	O
and	O
/	O
or	O
expression	O
level	O
of	O
a	O
approximately	O
80	O
kDa	O
protein	O
without	O
affecting	O
CSF	O
-	O
1	O
-	O
induced	O
global	O
tyrosine	O
phosphorylation	O
,	O
or	O
activation	O
of	O
Akt	O
or	O
Erk1	O
/	O
2	O
.	O
Significantly	O
,	O
CSF	O
-	O
1	O
stimulation	O
induced	O
serine	O
phosphorylation	O
of	O
SLAP	O
-	O
2	O
.	O
Pharmacologic	O
inhibition	O
of	O
specific	O
protein	O
kinases	O
revealed	O
that	O
CSF	O
-	O
1	O
-	O
induced	O
phosphorylation	O
of	O
SLAP	O
-	O
2	O
was	O
dependent	O
on	O
JNK	O
activity	O
.	O
Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
SLAP	O
-	O
2	O
could	O
potentially	O
be	O
involved	O
in	O
signaling	O
by	O
the	O
CSF	O
-	O
1	O
receptor	O
.	O
Ectopic	O
localization	O
of	O
mitochondrial	B-Anatomy
ATP	O
synthase	O
:	O
a	O
target	O
for	O
anti	O
-	O
angiogenesis	O
intervention	O
?	O
A	O
receptor	O
for	O
angiostatin	O
was	O
identified	O
on	O
the	O
surface	B-Anatomy
of	O
endothelial	B-Anatomy
cells	I-Anatomy
as	O
F	O
(	O
1	O
)	O
-	O
F	O
(	O
0	O
)	O
ATP	O
synthase	O
(	O
Moser	O
et	O
al	O
.	O
,	O
1999	O
)	O
.	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
U	O
.	O
S	O
.	O
A	O
.	O
96	O
,	O
2811	O
-	O
2816	O
.	O
This	O
ectopic	O
ATP	O
synthase	O
catalyzes	O
ATP	O
synthesis	O
and	O
is	O
inhibited	O
by	O
angiostatin	O
over	O
a	O
wide	O
pH	O
range	O
.	O
Endothelial	B-Anatomy
cells	I-Anatomy
grown	O
at	O
normal	O
pH	O
suffer	O
no	O
ill	O
effects	O
from	O
this	O
angiostatin	O
-	O
mediated	O
inhibition	O
of	O
ATP	O
synthase	O
,	O
whereas	O
endothelial	B-Anatomy
cells	I-Anatomy
grown	O
at	O
low	O
,	O
tumor	B-Anatomy
-	O
like	O
extracellular	B-Anatomy
pH	O
cannot	O
maintain	O
a	O
normal	O
intracellular	B-Anatomy
pH	O
and	O
die	O
.	O
Angiostatin	O
inhibits	O
both	O
ATP	O
synthesis	O
and	O
ATP	O
hydrolysis	O
(	O
Moser	O
et	O
al	O
.	O
,	O
2001	O
)	O
and	O
interferes	O
with	O
intracellular	B-Anatomy
pH	O
regulation	O
(	O
Wahl	O
and	O
Grant	O
,	O
2002	O
;	O
Wahl	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O
Although	O
angiostatin	O
administered	O
intravenously	B-Anatomy
is	O
cleared	O
from	O
the	O
circulation	O
in	O
a	O
matter	O
of	O
minutes	O
,	O
angiostatin	O
-	O
mimetics	O
that	O
are	O
more	O
stable	O
have	O
potential	O
for	O
clinical	O
application	O
.	O
An	O
angiostatin	O
-	O
mimetic	O
activity	O
has	O
recently	O
been	O
observed	O
using	O
a	O
polyclonal	O
antibody	O
against	O
the	O
beta	O
catalytic	O
subunit	O
of	O
ATP	O
synthase	O
.	O
In	O
order	O
to	O
explore	O
the	O
mechanism	O
of	O
action	O
of	O
angiostatin	O
and	O
its	O
mimetics	O
,	O
further	O
work	O
needs	O
to	O
be	O
done	O
to	O
evaluate	O
clinical	O
applicability	O
,	O
specificity	O
,	O
and	O
contraindications	O
for	O
this	O
class	O
of	O
therapeutics	O
.	O
Hepatitis	O
B	O
virus	O
integration	O
event	O
in	O
human	O
chromosome	B-Anatomy
17p	I-Anatomy
near	O
the	O
p53	O
gene	O
identifies	O
the	O
region	O
of	O
the	O
chromosome	B-Anatomy
commonly	O
deleted	O
in	O
virus	B-Anatomy
-	I-Anatomy
positive	I-Anatomy
hepatocellular	I-Anatomy
carcinomas	I-Anatomy
.	O
The	O
development	O
of	O
hepatocellular	B-Anatomy
carcinoma	I-Anatomy
(	O
HCC	B-Anatomy
)	O
presumably	O
occurs	O
in	O
multiple	O
steps	O
and	O
is	O
influenced	O
by	O
numerous	O
factors	O
.	O
Hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
is	O
strongly	O
associated	O
with	O
the	O
development	O
of	O
HCC	B-Anatomy
in	O
people	O
chronically	O
infected	O
with	O
the	O
virus	O
,	O
but	O
the	O
mechanism	O
of	O
viral	O
involvement	O
remains	O
unclear	O
.	O
One	O
possibility	O
is	O
that	O
the	O
gross	O
chromosomal	B-Anatomy
alterations	O
frequently	O
observed	O
in	O
HCC	B-Anatomy
DNA	O
at	O
the	O
site	O
of	O
HBV	O
integration	O
may	O
alter	O
the	O
expression	O
of	O
important	O
nearby	O
cellular	B-Anatomy
genes	O
.	O
We	O
previously	O
reported	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
HBV	O
insert	O
from	O
a	O
Chinese	O
HCC	B-Anatomy
.	O
The	O
viral	O
insert	O
mapped	O
to	O
chromosome	B-Anatomy
17p11	I-Anatomy
.	I-Anatomy
2	I-Anatomy
-	I-Anatomy
12	I-Anatomy
,	O
and	O
cellular	B-Anatomy
sequences	O
were	O
duplicated	O
at	O
the	O
site	O
of	O
viral	O
integration	O
.	O
In	O
the	O
present	O
study	O
a	O
DNA	O
probe	O
derived	O
from	O
cellular	B-Anatomy
DNA	O
sequences	O
adjacent	O
to	O
the	O
previously	O
characterized	O
HBV	O
insert	O
was	O
used	O
to	O
analyze	O
a	O
set	O
of	O
19	O
matched	O
normal	O
liver	B-Anatomy
and	O
HBV	O
-	O
positive	O
hepatoma	B-Anatomy
samples	I-Anatomy
obtained	O
from	O
the	O
same	O
region	O
of	O
China	O
,	O
near	O
Shanghai	O
.	O
Tumor	B-Anatomy
-	O
specific	O
DNA	O
changes	O
were	O
detected	O
in	O
two	O
additional	O
HCCs	B-Anatomy
,	O
suggesting	O
that	O
the	O
small	O
region	O
of	O
chromosome	B-Anatomy
17p	I-Anatomy
defined	O
by	O
the	O
flanking	O
cell	B-Anatomy
DNA	O
probe	O
is	O
commonly	O
altered	O
in	O
hepatomas	B-Anatomy
.	O
Restriction	O
fragment	O
length	O
polymorphism	O
studies	O
demonstrated	O
that	O
the	O
loss	O
of	O
one	O
copy	O
of	O
portions	O
of	O
chromosome	B-Anatomy
17	I-Anatomy
occurred	O
in	O
10	O
(	O
53	O
%	O
)	O
of	O
the	O
19	O
patients	O
.	O
The	O
loss	O
of	O
one	O
allele	O
of	O
the	O
p53	O
gene	O
(	O
located	O
on	O
chromosome	B-Anatomy
17p13	I-Anatomy
)	O
occurred	O
in	O
at	O
least	O
6	O
(	O
60	O
%	O
)	O
of	O
the	O
10	O
patients	O
who	O
were	O
heterozygous	O
at	O
the	O
p53	O
locus	O
.	O
As	O
the	O
p53	O
gene	O
is	O
known	O
to	O
possess	O
tumor	B-Anatomy
suppressor	O
activity	O
,	O
the	O
functional	O
loss	O
of	O
this	O
gene	O
may	O
be	O
a	O
significant	O
step	O
in	O
the	O
development	O
of	O
a	O
subset	O
of	O
HCCs	B-Anatomy
.	O
High	O
levels	O
of	O
allele	O
loss	O
also	O
were	O
detected	O
for	O
chromosomes	B-Anatomy
8q	I-Anatomy
(	O
4	O
of	O
9	O
;	O
44	O
%	O
)	O
and	O
16p	B-Anatomy
(	O
5	O
of	O
6	O
;	O
83	O
%	O
)	O
and	O
may	O
indicate	O
the	O
presence	O
of	O
additional	O
cellular	B-Anatomy
genes	O
whose	O
functional	O
loss	O
is	O
important	O
in	O
the	O
development	O
of	O
HCCs	B-Anatomy
.	O
Prostate	O
-	O
specific	O
membrane	O
antigen	O
regulates	O
angiogenesis	O
by	O
modulating	O
integrin	O
signal	O
transduction	O
.	O
The	O
transmembrane	B-Anatomy
peptidase	O
prostate	O
-	O
specific	O
membrane	O
antigen	O
(	O
PSMA	O
)	O
is	O
universally	O
upregulated	O
in	O
the	O
vasculature	B-Anatomy
of	O
solid	B-Anatomy
tumors	I-Anatomy
,	O
but	O
its	O
functional	O
role	O
in	O
tumor	B-Anatomy
angiogenesis	O
has	O
not	O
been	O
investigated	O
.	O
Here	O
we	O
show	O
that	O
angiogenesis	O
is	O
severely	O
impaired	O
in	O
PSMA	O
-	O
animals	O
and	O
that	O
this	O
angiogenic	O
defect	O
occurs	O
at	O
the	O
level	O
of	O
endothelial	B-Anatomy
cell	I-Anatomy
invasion	O
through	O
the	O
extracellular	B-Anatomy
matrix	I-Anatomy
barrier	I-Anatomy
.	O
Because	O
proteolytic	O
degradation	O
of	O
the	O
extracellular	B-Anatomy
matrix	I-Anatomy
is	O
a	O
critical	O
component	O
of	O
endothelial	B-Anatomy
invasion	O
in	O
angiogenesis	O
,	O
it	O
is	O
logical	O
to	O
assume	O
that	O
PSMA	O
participates	O
in	O
matrix	B-Anatomy
degradation	O
.	O
However	O
,	O
we	O
demonstrate	O
a	O
novel	O
and	O
more	O
complex	O
role	O
for	O
PSMA	O
in	O
angiogenesis	O
,	O
where	O
it	O
is	O
a	O
principal	O
component	O
of	O
a	O
regulatory	O
loop	O
that	O
is	O
tightly	O
modulating	O
laminin	O
-	O
specific	O
integrin	O
signaling	O
and	O
GTPase	O
-	O
dependent	O
,	O
p21	O
-	O
activated	O
kinase	O
1	O
(	O
PAK	O
-	O
1	O
)	O
activity	O
.	O
We	O
show	O
that	O
PSMA	O
inhibition	O
,	O
knockdown	O
,	O
or	O
deficiency	O
decreases	O
endothelial	B-Anatomy
cell	I-Anatomy
invasion	O
in	O
vitro	O
via	O
integrin	O
and	O
PAK	O
,	O
thus	O
abrogating	O
angiogenesis	O
.	O
Interestingly	O
,	O
the	O
neutralization	O
of	O
beta	O
(	O
1	O
)	O
or	O
the	O
inactivation	O
of	O
PAK	O
increases	O
PSMA	O
activity	O
,	O
suggesting	O
that	O
they	O
negatively	O
regulate	O
PSMA	O
.	O
This	O
negative	O
regulation	O
is	O
mediated	O
by	O
the	O
cytoskeleton	B-Anatomy
as	O
the	O
disruption	O
of	O
interactions	O
between	O
the	O
PSMA	O
cytoplasmic	B-Anatomy
tail	O
and	O
the	O
anchor	O
protein	O
filamin	O
A	O
decreases	O
PSMA	O
activity	O
,	O
integrin	O
function	O
,	O
and	O
PAK	O
activation	O
.	O
Finally	O
,	O
the	O
inhibition	O
of	O
PAK	O
activation	O
enhances	O
the	O
PSMA	O
/	O
filamin	O
A	O
interaction	O
and	O
,	O
thus	O
,	O
boosts	O
PSMA	O
activity	O
.	O
These	O
data	O
imply	O
that	O
PSMA	O
participates	O
in	O
an	O
autoregulatory	O
loop	O
,	O
wherein	O
active	O
PSMA	O
facilitates	O
integrin	O
signaling	O
and	O
PAK	O
activation	O
,	O
leading	O
to	O
both	O
productive	O
invasion	O
and	O
downregulation	O
of	O
integrin	O
beta	O
(	O
1	O
)	O
signaling	O
via	O
reduced	O
PSMA	O
activity	O
.	O
Therefore	O
,	O
we	O
have	O
identified	O
a	O
novel	O
role	O
for	O
PSMA	O
as	O
a	O
true	O
molecular	O
interface	O
,	O
integrating	O
both	O
extracellular	B-Anatomy
and	O
intracellular	B-Anatomy
signals	O
during	O
angiogenesis	O
.	O
Heparin	O
immobilized	O
porous	O
PLGA	O
microspheres	O
for	O
angiogenic	O
growth	O
factor	O
delivery	O
.	O
PURPOSE	O
:	O
Heparin	O
immobilized	O
porous	O
poly	O
(	O
D	O
,	O
L	O
-	O
lactic	O
-	O
co	O
-	O
glycolic	O
acid	O
)	O
(	O
PLGA	O
)	O
microspheres	O
were	O
prepared	O
for	O
sustained	O
release	O
of	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
to	O
induce	O
angiogenesis	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Porous	O
PLGA	O
microspheres	O
having	O
primary	O
amine	O
groups	O
on	O
the	O
surface	O
were	O
prepared	O
using	O
an	O
oil	O
-	O
in	O
-	O
water	O
(	O
O	O
/	O
W	O
)	O
single	O
emulsion	O
method	O
using	O
Pluronic	O
F	O
-	O
127	O
as	O
an	O
extractable	O
porogen	O
.	O
Heparin	O
was	O
surface	O
immobilized	O
via	O
covalent	O
conjugation	O
.	O
bFGF	O
was	O
loaded	O
into	O
the	O
heparin	O
functionalized	O
(	O
PLGA	O
-	O
heparin	O
)	O
microspheres	O
by	O
a	O
simple	O
dipping	O
method	O
.	O
The	O
bFGF	O
loaded	O
PLGA	O
-	O
heparin	O
microspheres	O
were	O
tested	O
for	O
in	O
vitro	O
release	O
and	O
in	O
vivo	O
angiogenic	O
activity	O
.	O
RESULTS	O
:	O
PLGA	O
microspheres	O
with	O
an	O
open	O
-	O
porous	O
structure	O
were	O
formed	O
.	O
The	O
amount	O
of	O
conjugated	O
amine	O
group	O
onto	O
the	O
microspheres	O
was	O
1	O
.	O
93	O
+	O
/	O
-	O
0	O
.	O
01	O
nmol	O
/	O
mg	O
-	O
microspheres	O
,	O
while	O
the	O
amount	O
of	O
heparin	O
was	O
95	O
.	O
8	O
pmol	O
/	O
mg	O
-	O
microspheres	O
.	O
PLGA	O
-	O
heparin	O
microspheres	O
released	O
out	O
bFGF	O
in	O
a	O
more	O
sustained	O
manner	O
with	O
a	O
smaller	O
extent	O
of	O
initial	O
burst	O
than	O
PLGA	O
microspheres	O
,	O
indicating	O
that	O
surface	O
immobilized	O
heparin	O
controlled	O
the	O
release	O
rate	O
of	O
bFGF	O
.	O
Subcutaneous	B-Anatomy
implantation	O
of	O
bFGF	O
loaded	O
PLGA	O
-	O
heparin	O
microspheres	O
in	O
mice	O
significantly	O
induced	O
the	O
formation	O
of	O
new	O
vascular	B-Anatomy
microvessels	I-Anatomy
.	O
CONCLUSIONS	O
:	O
PLGA	O
microspheres	O
with	O
an	O
open	O
porous	O
structure	O
allowed	O
significant	O
amount	O
of	O
heparin	O
immobilization	O
and	O
bFGF	O
loading	O
.	O
bFGF	O
loaded	O
PLGA	O
-	O
HP	O
microspheres	O
showed	O
sustained	O
release	O
profiles	O
of	O
bFGF	O
in	O
vitro	O
,	O
demonstrating	O
reversible	O
and	O
specific	O
binding	O
of	O
bFGF	O
to	O
immobilized	O
heparin	O
.	O
They	O
also	O
induced	O
local	O
angiogenesis	O
in	O
vivo	O
in	O
an	O
animal	O
model	O
.	O
The	O
role	O
of	O
syndecans	O
in	O
disease	O
and	O
wound	B-Anatomy
healing	O
.	O
Syndecans	O
are	O
a	O
family	O
of	O
transmembrane	B-Anatomy
heparan	O
sulfate	O
proteoglycans	O
widely	O
expressed	O
in	O
both	O
developing	B-Anatomy
and	O
adult	B-Anatomy
tissues	I-Anatomy
.	O
Until	O
recently	O
,	O
their	O
role	O
in	O
pathogenesis	O
was	O
largely	O
unexplored	O
.	O
In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
reported	O
involvement	O
of	O
syndecans	O
in	O
human	O
cancers	B-Anatomy
,	O
infectious	O
diseases	O
,	O
obesity	O
,	O
wound	B-Anatomy
healing	O
and	O
angiogenesis	O
.	O
In	O
some	O
cancers	B-Anatomy
,	O
syndecan	O
expression	O
has	O
been	O
shown	O
to	O
regulate	O
tumor	B-Anatomy
cell	I-Anatomy
function	O
(	O
e	O
.	O
g	O
.	O
proliferation	O
,	O
adhesion	O
,	O
and	O
motility	O
)	O
and	O
serve	O
as	O
a	O
prognostic	O
marker	O
for	O
tumor	B-Anatomy
progression	O
and	O
patient	O
survival	O
.	O
The	O
ectodomains	O
and	O
heparan	O
sulfate	O
glycosaminoglycan	O
chains	O
of	O
syndecans	O
can	O
also	O
act	O
as	O
receptors	O
/	O
co	O
-	O
receptors	O
for	O
some	O
bacterial	O
and	O
viral	O
pathogens	O
,	O
mediating	O
infection	O
.	O
In	O
addition	O
,	O
syndecans	O
bind	O
to	O
obesity	O
-	O
related	O
factors	O
and	O
regulate	O
their	O
signaling	O
,	O
in	O
turn	O
modulating	O
food	O
consumption	O
and	O
weight	O
balance	O
.	O
In	O
vivo	O
animal	O
models	O
of	O
tissue	B-Anatomy
injury	O
and	O
in	O
vitro	O
data	O
also	O
implicate	O
syndecans	O
in	O
processes	O
necessary	O
for	O
wound	B-Anatomy
healing	O
,	O
including	O
fibroblast	B-Anatomy
and	O
endothelial	B-Anatomy
proliferation	O
,	O
cell	B-Anatomy
motility	O
,	O
angiogenesis	O
,	O
and	O
extracellular	B-Anatomy
matrix	I-Anatomy
organization	O
.	O
These	O
new	O
insights	O
into	O
the	O
involvement	O
of	O
syndecans	O
in	O
disease	O
and	O
tissue	B-Anatomy
repair	O
coupled	O
with	O
the	O
emergence	O
of	O
syndecan	O
-	O
specific	O
molecular	O
tools	O
may	O
lead	O
to	O
novel	O
therapies	O
for	O
a	O
variety	O
of	O
human	O
diseases	O
.	O
Structure	O
of	O
the	O
genetic	O
code	O
suggested	O
by	O
the	O
hydropathy	O
correlation	O
between	O
anticodons	O
and	O
amino	O
acid	O
residues	O
.	O
The	O
correlation	O
between	O
hydropathies	O
of	O
anticodons	O
and	O
amino	O
acids	O
,	O
detected	O
by	O
other	O
authors	O
utilizing	O
scales	O
of	O
amino	O
acid	O
molecules	O
in	O
solution	O
,	O
was	O
improved	O
with	O
the	O
utilization	O
of	O
scales	O
of	O
amino	O
acid	O
residues	O
in	O
proteins	O
.	O
Three	O
partitions	O
were	O
discerned	O
in	O
the	O
correlation	O
plot	O
with	O
the	O
principal	O
dinucleotides	O
of	O
anticodons	O
(	O
pDiN	O
,	O
excluding	O
the	O
wobble	O
position	O
)	O
.	O
(	O
a	O
)	O
The	O
set	O
of	O
outliers	O
of	O
the	O
correlation	O
:	O
Gly	O
-	O
CC	O
,	O
Pro	O
-	O
GG	O
,	O
Ser	O
-	O
GA	O
and	O
Ser	O
-	O
CU	O
.	O
The	O
amino	O
acids	O
are	O
consistently	O
small	O
,	O
hydro	O
-	O
apathetic	O
,	O
stabilizers	O
of	O
protein	O
N	O
-	O
ends	O
,	O
preferred	O
in	O
aperiodic	O
protein	O
conformations	O
and	O
belong	O
to	O
synthetases	O
class	O
II	O
.	O
The	O
pDiN	O
sequences	O
are	O
representative	O
of	O
the	O
homogeneous	O
sector	O
(	O
triplets	O
NRR	O
and	O
NYY	O
)	O
,	O
distinguished	O
from	O
the	O
mixed	O
sector	O
(	O
triplets	O
NRY	O
and	O
NYR	O
)	O
,	O
that	O
depict	O
a	O
70	O
%	O
correspondence	O
to	O
the	O
synthetases	O
class	O
II	O
and	O
I	O
,	O
respectively	O
.	O
The	O
triplet	O
pairs	O
proposed	O
to	O
be	O
responsible	O
for	O
the	O
coherence	O
in	O
the	O
set	O
of	O
outliers	O
are	O
of	O
the	O
palindromic	O
kind	O
,	O
where	O
the	O
lateral	O
bases	O
are	O
the	O
same	O
,	O
CCC	O
:	O
GGG	O
and	O
AGA	O
:	O
UCU	O
.	O
This	O
suggests	O
that	O
UCU	O
previously	O
belonged	O
to	O
Ser	O
,	O
adding	O
to	O
other	O
indications	O
that	O
the	O
attribution	O
of	O
Arg	O
to	O
YCU	O
was	O
due	O
to	O
an	O
expansion	O
of	O
the	O
Arg	O
-	O
tRNA	O
synthetase	O
specificity	O
.	O
The	O
other	O
attributions	O
produced	O
two	O
correlation	O
sets	O
.	O
(	O
b	O
)	O
One	O
corresponds	O
to	O
the	O
remaining	O
pDiN	O
of	O
the	O
homogeneous	O
sector	O
,	O
containing	O
both	O
synthetase	O
classes	O
;	O
its	O
regression	O
line	O
overlapped	O
the	O
one	O
formed	O
by	O
the	O
remaining	O
attributions	O
to	O
class	O
II	O
.	O
(	O
c	O
)	O
The	O
other	O
contains	O
the	O
pDiN	O
of	O
the	O
mixed	O
sector	O
and	O
produced	O
steeper	O
slopes	O
,	O
especially	O
with	O
the	O
class	O
I	O
attributions	O
.	O
It	O
is	O
suggested	O
that	O
the	O
correlation	O
was	O
established	O
when	O
the	O
amino	O
acid	O
composition	O
of	O
the	O
protein	O
synthetases	O
became	O
progressively	O
enriched	O
and	O
that	O
the	O
set	O
of	O
outliers	O
were	O
the	O
earliest	O
to	O
have	O
been	O
fixed	O
.	O
C	O
/	O
EBPbeta	O
is	O
over	O
-	O
expressed	O
in	O
gastric	B-Anatomy
carcinogenesis	O
and	O
is	O
associated	O
with	O
COX	O
-	O
2	O
expression	O
.	O
The	O
CCAAT	O
/	O
enhancer	O
-	O
binding	O
protein	O
beta	O
(	O
C	O
/	O
EBPbeta	O
)	O
transcription	O
factor	O
has	O
been	O
associated	O
with	O
several	O
cancer	B-Anatomy
models	O
.	O
In	O
this	O
study	O
,	O
the	O
expression	O
of	O
C	O
/	O
EBPbeta	O
was	O
analysed	O
in	O
a	O
series	O
of	O
90	O
gastric	B-Anatomy
carcinomas	I-Anatomy
(	O
GCs	B-Anatomy
)	O
.	O
We	O
also	O
assessed	O
the	O
effect	O
of	O
C	O
/	O
EBPbeta	O
on	O
COX	O
-	O
2	O
expression	O
.	O
In	O
normal	O
gastric	B-Anatomy
mucosa	I-Anatomy
,	O
C	O
/	O
EBPbeta	O
expression	O
was	O
restricted	O
to	O
cells	B-Anatomy
in	O
the	O
proliferative	O
zone	B-Anatomy
.	O
In	O
intestinal	B-Anatomy
metaplasia	I-Anatomy
,	O
dysplasia	B-Anatomy
,	O
and	O
GC	B-Anatomy
of	O
the	O
intestinal	B-Anatomy
and	O
atypical	O
subtypes	O
,	O
C	O
/	O
EBPbeta	O
was	O
over	O
-	O
expressed	O
(	O
p	O
<	O
0	O
.	O
0001	O
,	O
for	O
the	O
association	O
with	O
histological	O
type	O
)	O
.	O
C	O
/	O
EBPbeta	O
and	O
Ki67	O
,	O
a	O
marker	O
of	O
cell	B-Anatomy
proliferation	O
,	O
were	O
also	O
co	O
-	O
expressed	O
in	O
primary	B-Anatomy
GC	I-Anatomy
.	O
We	O
also	O
observed	O
an	O
overlap	O
between	O
C	O
/	O
EBPbeta	O
and	O
COX	O
-	O
2	O
expression	O
in	O
GC	B-Anatomy
.	O
Using	O
GC	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
we	O
show	O
that	O
C	O
/	O
EBPbeta	O
can	O
regulate	O
the	O
expression	O
of	O
endogenous	O
COX	O
-	O
2	O
and	O
transactivate	O
the	O
promoter	O
of	O
the	O
COX	O
-	O
2	O
gene	O
,	O
depending	O
on	O
its	O
methylation	O
status	O
.	O
These	O
results	O
suggest	O
that	O
C	O
/	O
EBPbeta	O
may	O
be	O
a	O
marker	O
of	O
neoplastic	B-Anatomy
transformation	O
and	O
also	O
play	O
an	O
active	O
role	O
in	O
gastric	B-Anatomy
tumourigenesis	O
by	O
regulating	O
COX	O
-	O
2	O
expression	O
.	O
Hypocholesterolaemic	O
and	O
antioxidant	O
effects	O
of	O
Glycyrrhiza	O
glabra	O
(	O
Linn	O
)	O
in	O
rats	O
.	O
The	O
hypocholesterolaemic	O
and	O
antioxidant	O
effects	O
of	O
Glycyrrhiza	O
glabra	O
(	O
GG	O
)	O
root	B-Anatomy
powder	O
were	O
examined	O
in	O
hypercholesterolaemic	O
male	O
albino	O
rats	O
.	O
A	O
4	O
-	O
week	O
administration	O
of	O
GG	O
root	B-Anatomy
powder	O
(	O
5	O
and	O
10	O
gm	O
%	O
in	O
diet	O
)	O
to	O
hypercholesterolaemic	O
rats	O
resulted	O
in	O
significant	O
reduction	O
in	O
plasma	B-Anatomy
,	O
hepatic	B-Anatomy
total	O
lipids	O
,	O
cholesterol	O
,	O
triglycerides	O
and	O
plasma	B-Anatomy
low	O
-	O
density	O
lipoprotein	O
and	O
VLDL	O
-	O
cholesterol	O
accompanied	O
by	O
significant	O
increases	O
in	O
HDL	O
-	O
cholesterol	O
levels	O
.	O
Furthermore	O
,	O
significant	O
increases	O
in	O
fecal	B-Anatomy
cholesterol	O
,	O
neutral	O
sterols	O
and	O
bile	B-Anatomy
acid	O
excretion	O
along	O
with	O
an	O
increase	O
in	O
hepatic	B-Anatomy
HMG	O
-	O
CoA	O
reductase	O
activity	O
and	O
bile	B-Anatomy
acid	O
production	O
were	O
observed	O
in	O
these	O
animals	O
.	O
The	O
root	B-Anatomy
powder	O
administration	O
to	O
hypercholesterolaemic	O
rats	O
also	O
decreased	O
hepatic	B-Anatomy
lipid	O
peroxidation	O
with	O
a	O
concomitant	O
increase	O
in	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
and	O
catalase	O
activities	O
and	O
total	O
ascorbic	O
acid	O
content	O
.	O
Thus	O
,	O
the	O
hypocholesterolaemic	O
and	O
antioxidant	O
effects	O
of	O
GG	O
root	B-Anatomy
appeared	O
to	O
be	O
mediated	O
via	O
(	O
i	O
)	O
accelerated	O
cholesterol	O
,	O
neutral	O
sterol	O
and	O
bile	B-Anatomy
acid	O
elimination	O
through	O
fecal	B-Anatomy
matter	I-Anatomy
with	O
an	O
increased	O
hepatic	B-Anatomy
bile	B-Anatomy
acid	O
production	O
and	O
(	O
ii	O
)	O
improving	O
the	O
activities	O
of	O
hepatic	B-Anatomy
SOD	O
,	O
catalase	O
and	O
increasing	O
the	O
ascorbic	O
acid	O
content	O
.	O
The	O
normo	O
-	O
cholesterolaemic	O
animals	O
when	O
fed	O
with	O
GG	O
root	B-Anatomy
powder	O
at	O
10	O
gm	O
%	O
level	O
,	O
registered	O
a	O
significant	O
decline	O
in	O
plasma	B-Anatomy
lipid	O
profiles	O
and	O
an	O
increase	O
in	O
HDL	O
-	O
cholesterol	O
content	O
.	O
The	O
antioxidant	O
status	O
of	O
these	O
animals	O
also	O
was	O
improved	O
upon	O
treatment	O
.	O
Multicentre	O
study	O
on	O
peri	O
-	O
and	O
postoperative	O
central	B-Anatomy
venous	I-Anatomy
oxygen	O
saturation	O
in	O
high	O
-	O
risk	O
surgical	O
patients	O
.	O
INTRODUCTION	O
:	O
Low	O
central	B-Anatomy
venous	I-Anatomy
oxygen	O
saturation	O
(	O
ScvO2	O
)	O
has	O
been	O
associated	O
with	O
increased	O
risk	O
of	O
postoperative	O
complications	O
in	O
high	O
-	O
risk	O
surgery	O
.	O
Whether	O
this	O
association	O
is	O
centre	O
-	O
specific	O
or	O
more	O
generalisable	O
is	O
not	O
known	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
association	O
between	O
peri	O
-	O
and	O
postoperative	O
ScvO2	O
and	O
outcome	O
in	O
high	O
-	O
risk	O
surgical	O
patients	O
in	O
a	O
multicentre	O
setting	O
.	O
METHODS	O
:	O
Three	O
large	O
European	O
university	O
hospitals	O
(	O
two	O
in	O
Finland	O
,	O
one	O
in	O
Switzerland	O
)	O
participated	O
.	O
In	O
60	O
patients	O
with	O
intra	O
-	O
abdominal	B-Anatomy
surgery	O
lasting	O
more	O
than	O
90	O
minutes	O
,	O
the	O
presence	O
of	O
at	O
least	O
two	O
of	O
Shoemaker	O
'	O
s	O
criteria	O
,	O
and	O
ASA	O
(	O
American	O
Society	O
of	O
Anesthesiologists	O
)	O
class	O
greater	O
than	O
2	O
,	O
ScvO2	O
was	O
determined	O
preoperatively	O
and	O
at	O
two	O
hour	O
intervals	O
during	O
the	O
operation	O
until	O
12	O
hours	O
postoperatively	O
.	O
Hospital	O
length	O
of	O
stay	O
(	O
LOS	O
)	O
mortality	O
,	O
and	O
predefined	O
postoperative	O
complications	O
were	O
recorded	O
.	O
RESULTS	O
:	O
The	O
age	O
of	O
the	O
patients	O
was	O
72	O
+	O
/	O
-	O
10	O
years	O
(	O
mean	O
+	O
/	O
-	O
standard	O
deviation	O
)	O
,	O
and	O
simplified	O
acute	O
physiology	O
score	O
(	O
SAPS	O
II	O
)	O
was	O
32	O
+	O
/	O
-	O
12	O
.	O
Hospital	O
LOS	O
was	O
10	O
.	O
5	O
(	O
8	O
to	O
14	O
)	O
days	O
,	O
and	O
28	O
-	O
day	O
hospital	O
mortality	O
was	O
10	O
.	O
0	O
%	O
.	O
Preoperative	O
ScvO2	O
decreased	O
from	O
77	O
%	O
+	O
/	O
-	O
10	O
%	O
to	O
70	O
%	O
+	O
/	O
-	O
11	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
immediately	O
after	O
surgery	O
and	O
remained	O
unchanged	O
12	O
hours	O
later	O
.	O
A	O
total	O
of	O
67	O
postoperative	O
complications	O
were	O
recorded	O
in	O
32	O
patients	O
.	O
After	O
multivariate	O
analysis	O
,	O
mean	O
ScvO2	O
value	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
1	O
.	O
23	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
01	O
to	O
1	O
.	O
50	O
]	O
,	O
p	O
=	O
0	O
.	O
037	O
)	O
,	O
hospital	O
LOS	O
(	O
OR	O
0	O
.	O
75	O
[	O
95	O
%	O
CI	O
0	O
.	O
59	O
to	O
0	O
.	O
94	O
]	O
,	O
p	O
=	O
0	O
.	O
012	O
)	O
,	O
and	O
SAPS	O
II	O
(	O
OR	O
0	O
.	O
90	O
[	O
95	O
%	O
CI	O
0	O
.	O
82	O
to	O
0	O
.	O
99	O
]	O
,	O
p	O
=	O
0	O
.	O
029	O
)	O
were	O
independently	O
associated	O
with	O
postoperative	O
complications	O
.	O
The	O
optimal	O
value	O
of	O
mean	O
ScvO2	O
to	O
discriminate	O
between	O
patients	O
who	O
did	O
or	O
did	O
not	O
develop	O
complications	O
was	O
73	O
%	O
(	O
sensitivity	O
72	O
%	O
,	O
specificity	O
61	O
%	O
)	O
.	O
CONCLUSION	O
:	O
Low	O
ScvO2	O
perioperatively	O
is	O
related	O
to	O
increased	O
risk	O
of	O
postoperative	O
complications	O
in	O
high	O
-	O
risk	O
surgery	O
.	O
This	O
warrants	O
trials	O
with	O
goal	O
-	O
directed	O
therapy	O
using	O
ScvO2	O
as	O
a	O
target	O
in	O
high	O
-	O
risk	O
surgery	O
patients	O
.	O
Lysophosphatidic	O
acid	O
downregulates	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
,	O
which	O
are	O
negatively	O
involved	O
in	O
lysophosphatidic	O
acid	O
-	O
induced	O
cell	B-Anatomy
invasion	O
.	O
Ovarian	B-Anatomy
cancer	I-Anatomy
is	O
a	O
highly	O
metastatic	O
disease	O
.	O
Lysophosphatidic	O
acid	O
(	O
LPA	O
)	O
levels	O
are	O
elevated	O
in	O
ascites	B-Anatomy
from	O
ovarian	B-Anatomy
cancer	I-Anatomy
patients	O
,	O
but	O
its	O
potential	O
role	O
in	O
ovarian	B-Anatomy
cancer	I-Anatomy
metastasis	O
has	O
just	O
begun	O
to	O
be	O
revealed	O
.	O
In	O
this	O
work	O
,	O
we	O
show	O
that	O
LPA	O
stimulates	O
invasion	O
of	O
primary	B-Anatomy
ovarian	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
,	O
but	O
not	O
ovarian	B-Anatomy
epithelial	I-Anatomy
or	O
borderline	B-Anatomy
ovarian	I-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
,	O
although	O
these	O
benign	B-Anatomy
cells	I-Anatomy
indeed	O
respond	O
to	O
LPA	O
in	O
cell	B-Anatomy
migration	O
.	O
We	O
have	O
found	O
that	O
LPA	O
downregulates	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
(	O
TIMPs	O
)	O
.	O
TIMP2	O
and	O
TIMP3	O
play	O
functional	O
role	O
in	O
LPA	O
-	O
induced	O
invasion	O
as	O
negative	O
regulators	O
.	O
G	O
(	O
i	O
)	O
protein	O
,	O
phosphatidylinositol	O
-	O
3	O
kinase	O
(	O
PI3K	O
)	O
,	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
,	O
cytosolic	B-Anatomy
phospholipase	O
A	O
(	O
2	O
)	O
and	O
urokinase	O
type	O
plasminogen	O
activator	O
(	O
uPA	O
)	O
are	O
required	O
for	O
LPA	O
-	O
induced	O
cells	B-Anatomy
invasion	O
.	O
TIMP3	O
may	O
affect	O
two	O
independent	O
downstream	O
targets	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
and	O
p38	O
MAPK	O
.	O
In	O
vivo	O
,	O
LPA	O
stimulates	O
tumor	B-Anatomy
metastasis	O
in	O
an	O
orthotopic	O
ovarian	B-Anatomy
tumor	I-Anatomy
model	O
,	O
which	O
can	O
be	O
inhibited	O
by	O
a	O
PI3K	O
inhibitor	O
,	O
LY294002	O
.	O
In	O
summary	O
,	O
LPA	O
is	O
likely	O
a	O
key	O
component	O
for	O
promoting	O
ovarian	B-Anatomy
metastasis	O
in	O
vivo	O
.	O
LPA	O
downregulates	O
TIMP3	O
,	O
which	O
may	O
have	O
targets	O
other	O
than	O
metalloproteinases	O
.	O
Our	O
in	O
vivo	O
metastasis	O
mouse	O
model	O
is	O
useful	O
for	O
studying	O
the	O
efficacy	O
of	O
therapeutic	O
regimes	O
of	O
ovarian	B-Anatomy
cancer	I-Anatomy
.	O
[	O
Treatment	O
of	O
squamous	B-Anatomy
intraepithelial	I-Anatomy
lesion	I-Anatomy
of	O
type	O
CIN2	O
et	O
CIN3	O
with	O
laser	O
CO2	O
vaporization	O
:	O
retrospective	O
study	O
of	O
52	O
cases	O
]	O
.	O
OBJECTIVES	O
:	O
This	O
study	O
was	O
carried	O
out	O
over	O
an	O
8	O
-	O
year	O
period	O
in	O
order	O
to	O
evaluate	O
the	O
long	O
-	O
term	O
effectiveness	O
of	O
laser	O
CO2	O
vaporization	O
in	O
the	O
treatment	O
of	O
squamous	B-Anatomy
intraepithelial	I-Anatomy
lesion	I-Anatomy
of	O
type	O
CIN2	O
and	O
CIN3	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
A	O
retrospective	O
study	O
of	O
52	O
cases	O
of	O
cervical	B-Anatomy
lesions	I-Anatomy
of	O
type	O
CIN2	O
and	O
CIN3	O
treated	O
in	O
first	O
intention	O
by	O
laser	O
CO2	O
vaporization	O
was	O
carried	O
out	O
at	O
the	O
hospital	O
Jeanne	O
-	O
de	O
-	O
Flandre	O
in	O
CHRU	O
of	O
Lille	O
from	O
1996	O
to	O
2003	O
.	O
This	O
treatment	O
was	O
performed	O
on	O
only	O
high	B-Anatomy
-	I-Anatomy
grade	I-Anatomy
exo	I-Anatomy
-	I-Anatomy
cervical	I-Anatomy
lesions	I-Anatomy
,	O
of	O
small	O
size	O
(	O
<	O
2cm2	O
)	O
,	O
after	O
a	O
complete	O
colposcopic	O
examination	O
.	O
RESULTS	O
:	O
Fifty	O
-	O
two	O
patients	O
were	O
treated	O
by	O
first	O
-	O
intention	O
laser	O
vaporization	O
only	O
.	O
Mean	O
age	O
was	O
29	O
.	O
4	O
years	O
and	O
51	O
.	O
9	O
%	O
were	O
nulliparous	O
.	O
At	O
the	O
first	O
cyto	O
-	O
colposcopic	O
control	O
,	O
there	O
were	O
17	O
persistent	O
lesions	B-Anatomy
(	O
32	O
.	O
7	O
%	O
)	O
.	O
Among	O
the	O
35	O
patients	O
without	O
persistent	O
lesion	B-Anatomy
,	O
29	O
achieved	O
cure	O
(	O
absence	O
of	O
recurrence	O
)	O
,	O
4	O
presented	O
a	O
recurrence	O
and	O
2	O
were	O
lost	O
to	O
follow	O
-	O
up	O
.	O
CONCLUSION	O
:	O
The	O
current	O
data	O
of	O
the	O
literature	O
concerning	O
the	O
treatment	O
by	O
laser	O
CO2	O
vaporization	O
authorize	O
application	O
of	O
this	O
method	O
for	O
certain	O
high	B-Anatomy
-	I-Anatomy
grade	I-Anatomy
exocervical	I-Anatomy
lesions	I-Anatomy
after	O
a	O
complete	O
colposcopic	O
examination	O
.	O
This	O
type	O
of	O
treatment	O
remains	O
less	O
aggressive	O
than	O
a	O
surgical	O
treatment	O
.	O
The	O
high	O
rate	O
of	O
residual	O
lesions	B-Anatomy
in	O
particular	O
in	O
the	O
event	O
of	O
CIN3	O
can	O
be	O
due	O
to	O
an	O
incomplete	O
destruction	O
of	O
the	O
lesion	B-Anatomy
.	O
Patients	O
should	O
thus	O
be	O
advised	O
that	O
monitoring	O
is	O
an	O
integral	O
part	O
of	O
the	O
treatment	O
.	O
Laser	O
vaporization	O
could	O
be	O
limited	O
to	O
CIN1	O
and	O
CIN2	O
lesions	B-Anatomy
.	O
Role	O
of	O
the	O
fibrinolytic	O
and	O
matrix	O
metalloproteinase	O
systems	O
in	O
development	O
of	O
adipose	B-Anatomy
tissue	I-Anatomy
.	O
Obesity	O
is	O
a	O
common	O
disorder	O
and	O
related	O
diseases	O
such	O
as	O
diabetes	O
,	O
atherosclerosis	O
,	O
hypertension	O
,	O
cardiovascular	B-Anatomy
disease	O
and	O
cancer	B-Anatomy
are	O
a	O
major	O
cause	O
of	O
mortality	O
and	O
morbidity	O
in	O
Western	O
-	O
type	O
societies	O
.	O
Development	O
of	O
obesity	O
is	O
associated	O
with	O
extensive	O
modifications	O
in	O
adipose	B-Anatomy
tissue	I-Anatomy
involving	O
adipogenesis	O
,	O
angiogenesis	O
and	O
extracellular	B-Anatomy
matrix	I-Anatomy
proteolysis	O
.	O
The	O
fibrinolytic	O
(	O
plasminogen	O
/	O
plasmin	O
)	O
and	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
systems	O
cooperate	O
in	O
these	O
processes	O
.	O
A	O
nutritionally	O
induced	O
obesity	O
model	O
in	O
transgenic	O
mice	O
has	O
been	O
used	O
extensively	O
to	O
study	O
the	O
role	O
of	O
the	O
fibrinolytic	O
and	O
MMP	O
systems	O
in	O
the	O
development	O
of	O
obesity	O
.	O
These	O
studies	O
support	O
a	O
role	O
of	O
both	O
systems	O
in	O
adipogenesis	O
and	O
obesity	O
;	O
the	O
role	O
of	O
specific	O
members	O
of	O
these	O
families	O
,	O
however	O
,	O
remains	O
to	O
be	O
determined	O
.	O
Recombinant	O
human	O
prothrombin	O
kringle	O
-	O
2	O
inhibits	O
B16F10	B-Anatomy
melanoma	I-Anatomy
metastasis	O
through	O
inhibition	O
of	O
neovascularization	O
and	O
reduction	O
of	O
matrix	O
metalloproteinase	O
expression	O
.	O
Angiogenesis	O
,	O
a	O
multi	O
-	O
step	O
process	O
which	O
involves	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
,	O
adhesion	O
,	O
migration	O
,	O
and	O
basement	B-Anatomy
membrane	I-Anatomy
(	O
BM	B-Anatomy
)	O
degradation	O
,	O
is	O
essential	O
for	O
tumor	B-Anatomy
metastasis	O
.	O
Here	O
we	O
show	O
that	O
recombinant	O
human	O
prothrombin	O
kringle	O
-	O
2	O
(	O
rk	O
-	O
2	O
)	O
inhibited	O
bovine	O
capillary	B-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
migration	O
with	O
an	O
IC	O
(	O
50	O
)	O
(	O
concentration	O
for	O
half	O
maximal	O
inhibition	O
)	O
of	O
38	O
nM	O
and	O
inhibited	O
adhesion	O
to	O
extracellular	B-Anatomy
matrix	I-Anatomy
(	O
ECM	B-Anatomy
)	O
proteins	O
.	O
Because	O
tumor	B-Anatomy
metastasis	O
requires	O
angiogenesis	O
,	O
we	O
examined	O
whether	O
rk	O
-	O
2	O
could	O
inhibit	O
metastases	B-Anatomy
induced	O
by	O
injection	O
of	O
B16F10	B-Anatomy
melanoma	I-Anatomy
cells	I-Anatomy
into	O
mice	O
.	O
The	O
results	O
revealed	O
that	O
the	O
metastatic	B-Anatomy
tumors	I-Anatomy
in	O
mouse	O
lung	B-Anatomy
were	O
markedly	O
decreased	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
acute	O
lung	B-Anatomy
injury	O
induced	O
by	O
B16F10	B-Anatomy
melanoma	I-Anatomy
metastasis	O
was	O
diminished	O
by	O
systemic	O
rk	O
-	O
2	O
treatment	O
.	O
In	O
immunohistochemical	O
analysis	O
,	O
rk	O
-	O
2	O
reduced	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
which	O
is	O
a	O
potent	O
angiogenic	O
activator	O
and	O
neovascularization	O
in	O
the	O
mouse	O
lung	B-Anatomy
.	O
Also	O
,	O
rk	O
-	O
2	O
diminished	O
the	O
expression	O
of	O
matrix	O
metalloproteinase	O
-	O
2	O
and	O
-	O
9	O
in	O
the	O
mouse	O
lung	B-Anatomy
which	O
induces	O
tumor	B-Anatomy
metastasis	O
and	O
angiogenesis	O
.	O
These	O
data	O
suggest	O
that	O
inhibition	O
of	O
B16F10	B-Anatomy
melanoma	I-Anatomy
metastasis	O
by	O
rk	O
-	O
2	O
was	O
caused	O
by	O
inhibition	O
of	O
neovascularization	O
and	O
reduction	O
of	O
matrix	O
metalloproteinase	O
expression	O
.	O
Extracellular	B-Anatomy
matrix	I-Anatomy
as	O
a	O
bioactive	O
material	O
for	O
soft	B-Anatomy
tissue	I-Anatomy
reconstruction	O
.	O
The	O
extracellular	B-Anatomy
matrix	I-Anatomy
(	O
ECM	B-Anatomy
)	O
directs	O
all	O
phases	O
of	O
healing	O
following	O
trauma	O
or	O
disease	O
and	O
is	O
therefore	O
a	O
natural	O
source	O
of	O
prosthetic	O
mesh	O
material	O
that	O
can	O
be	O
used	O
strategically	O
to	O
induce	O
the	O
repair	O
and	O
restoration	O
of	O
soft	B-Anatomy
tissues	I-Anatomy
following	O
surgery	O
.	O
Biomaterials	O
such	O
as	O
Surgisis	O
(	O
Cook	O
Biotech	O
Incorporated	O
,	O
West	O
Lafayette	O
,	O
IN	O
,	O
USA	O
)	O
,	O
which	O
are	O
derived	O
from	O
natural	O
ECM	B-Anatomy
,	O
provide	O
the	O
extracellular	B-Anatomy
components	I-Anatomy
necessary	O
to	O
direct	O
the	O
healing	O
response	O
,	O
allow	O
for	O
the	O
proliferation	O
of	O
new	O
,	O
healthy	O
tissue	B-Anatomy
and	O
restore	O
tissue	B-Anatomy
integrity	O
to	O
the	O
damaged	O
site	B-Anatomy
.	O
The	O
3	O
-	O
D	O
organization	O
of	O
these	O
extracellular	B-Anatomy
components	I-Anatomy
distinguishes	O
the	O
Surgisis	O
mesh	O
from	O
synthetic	O
materials	O
and	O
is	O
associated	O
with	O
constructive	O
tissue	B-Anatomy
remodelling	O
instead	O
of	O
scar	B-Anatomy
tissue	I-Anatomy
.	O
Common	O
features	O
of	O
this	O
ECM	B-Anatomy
-	O
assisted	O
tissue	B-Anatomy
remodelling	O
include	O
angiogenesis	O
,	O
recruitment	O
of	O
circulating	O
progenitor	B-Anatomy
cells	I-Anatomy
and	O
constructive	O
remodelling	O
of	O
damaged	O
tissue	B-Anatomy
structures	O
.	O
The	O
tissue	B-Anatomy
response	O
to	O
this	O
biologic	O
mesh	O
is	O
discussed	O
in	O
the	O
context	O
of	O
recent	O
reports	O
on	O
clinical	O
hernia	B-Anatomy
repair	O
.	O
Segmental	O
atrial	B-Anatomy
contraction	O
in	O
patients	O
restored	O
to	O
sinus	O
rhythm	O
after	O
cardioversion	O
for	O
chronic	O
atrial	B-Anatomy
fibrillation	O
:	O
a	O
colour	O
Doppler	O
tissue	B-Anatomy
imaging	O
study	O
.	O
AIMS	O
:	O
There	O
is	O
little	O
known	O
about	O
segmental	O
atrial	B-Anatomy
function	O
in	O
patients	O
with	O
atrial	B-Anatomy
arrhythmias	O
.	O
We	O
evaluated	O
segmental	O
atrial	B-Anatomy
contractility	O
using	O
colour	O
Doppler	O
tissue	B-Anatomy
imaging	O
(	O
CDTI	O
)	O
in	O
patients	O
with	O
chronic	O
atrial	B-Anatomy
fibrillation	O
(	O
CAF	O
)	O
who	O
were	O
successfully	O
restored	O
and	O
maintained	O
in	O
sinus	O
rhythm	O
(	O
SR	O
)	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
We	O
compared	O
the	O
segmental	O
atrial	B-Anatomy
contractility	O
in	O
39	O
CAF	O
patients	O
who	O
were	O
successfully	O
cardioverted	O
and	O
maintained	O
in	O
SR	O
for	O
6	O
months	O
.	O
Follow	O
up	O
echocardiograms	O
were	O
performed	O
at	O
baseline	O
,	O
1	O
week	O
,	O
1	O
month	O
and	O
6	O
months	O
and	O
compared	O
to	O
a	O
normal	O
age	O
matched	O
cohort	O
(	O
n	O
=	O
34	O
)	O
.	O
Using	O
CDTI	O
,	O
mean	O
peak	O
velocities	O
of	O
atrial	B-Anatomy
contraction	O
were	O
measured	O
from	O
annular	B-Anatomy
,	O
mid	B-Anatomy
and	O
superior	B-Anatomy
segments	I-Anatomy
of	O
lateral	B-Anatomy
and	O
septal	B-Anatomy
walls	I-Anatomy
of	O
the	O
left	B-Anatomy
atrium	I-Anatomy
and	O
right	B-Anatomy
atrium	I-Anatomy
in	O
the	O
apical	O
four	O
-	O
chamber	B-Anatomy
view	O
.	O
Segmental	O
velocities	O
from	O
the	O
posterior	B-Anatomy
and	O
anterior	B-Anatomy
walls	I-Anatomy
of	O
the	O
left	B-Anatomy
atrium	I-Anatomy
were	O
measured	O
from	O
the	O
apical	O
two	O
-	O
chamber	B-Anatomy
view	O
.	O
Segmental	O
left	B-Anatomy
atrial	I-Anatomy
velocities	O
improved	O
over	O
time	O
in	O
the	O
CAF	O
group	O
,	O
with	O
the	O
majority	O
of	O
the	O
recovery	O
occurring	O
in	O
the	O
first	O
month	O
,	O
but	O
failed	O
to	O
normalise	O
even	O
at	O
6	O
months	O
.	O
In	O
comparison	O
,	O
the	O
right	B-Anatomy
atrial	I-Anatomy
velocities	O
in	O
the	O
AF	O
group	O
had	O
normalised	O
at	O
1	O
month	O
.	O
CONCLUSION	O
:	O
Patients	O
with	O
CAF	O
have	O
persistent	O
segmental	O
left	B-Anatomy
atrial	I-Anatomy
dysfunction	O
even	O
6	O
months	O
after	O
restoration	O
and	O
maintenance	O
of	O
SR	O
,	O
though	O
right	B-Anatomy
atrial	I-Anatomy
velocities	O
appear	O
to	O
normalise	O
.	O
This	O
differential	O
recovery	O
indicates	O
that	O
left	B-Anatomy
atrial	I-Anatomy
function	O
remains	O
subnormal	O
in	O
patients	O
with	O
CAF	O
despite	O
maintenance	O
of	O
SR	O
,	O
suggesting	O
underlying	O
atrial	B-Anatomy
myopathy	O
or	O
fibrosis	O
as	O
a	O
consequence	O
of	O
CAF	O
.	O
[	O
Study	O
on	O
the	O
expression	O
of	O
angiogenesis	O
and	O
spontaneous	O
apoptosis	O
and	O
their	O
relevance	O
in	O
laryngeal	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
]	O
OBJECTIVE	O
:	O
To	O
investigate	O
the	O
relationship	O
among	O
angiogenesis	O
,	O
spontaneous	O
apoptosis	O
and	O
clinicopathological	O
parameters	O
in	O
laryngeal	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
(	O
LSCC	B-Anatomy
)	O
.	O
METHOD	O
:	O
The	O
intratumor	B-Anatomy
microvessel	I-Anatomy
density	O
(	O
IMVD	O
)	O
,	O
apoptotic	O
index	O
(	O
AI	O
)	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
were	O
detected	O
by	O
immunohistochemistry	O
SABC	O
and	O
terminal	O
uridine	O
deoxynucleotidyl	O
transferase	O
mediated	O
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
methods	O
in34	O
LSCC	B-Anatomy
patients	O
.	O
RESULT	O
:	O
The	O
average	O
IMVD	O
was	O
(	O
21	O
.	O
50	O
+	O
/	O
-	O
8	O
.	O
87	O
)	O
,	O
and	O
median	O
of	O
AI	O
was	O
1	O
.	O
15	O
%	O
.	O
The	O
average	O
IMVD	O
in	O
positive	O
and	O
negative	O
cervical	B-Anatomy
lymphatic	I-Anatomy
metastasis	O
was	O
(	O
26	O
.	O
33	O
+	O
/	O
-	O
9	O
.	O
70	O
)	O
and	O
(	O
17	O
.	O
68	O
+	O
/	O
-	O
6	O
.	O
06	O
)	O
respectively	O
,	O
and	O
the	O
IMVD	O
with	O
positive	O
lymphatic	B-Anatomy
metastasis	I-Anatomy
tumors	I-Anatomy
was	O
statistical	O
significantly	O
higher	O
than	O
those	O
with	O
negative	O
cervical	B-Anatomy
lymphatic	I-Anatomy
metastasis	I-Anatomy
tumors	I-Anatomy
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
The	O
average	O
IMVD	O
had	O
statistical	O
difference	O
in	O
histological	O
grading	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
and	O
analysis	O
by	O
one	O
to	O
one	O
,	O
the	O
average	O
IMVD	O
had	O
statistical	O
difference	O
between	O
high	O
and	O
median	O
grading	O
.	O
Expression	O
of	O
VEGF	O
had	O
a	O
significantly	O
positive	O
correlation	O
with	O
IMVD	O
(	O
r	O
=	O
0	O
.	O
51	O
,	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
Statistical	O
analysis	O
revealed	O
a	O
significantly	O
inverse	O
correlation	O
between	O
AI	O
and	O
IMVD	O
(	O
r	O
=	O
-	O
0	O
.	O
53	O
,	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
We	O
failed	O
to	O
find	O
the	O
statistical	O
difference	O
between	O
IMVD	O
and	O
tumor	B-Anatomy
T	O
-	O
stage	O
in	O
LSCC	B-Anatomy
.	O
CONCLUSION	O
:	O
IMVD	O
may	O
be	O
an	O
important	O
indicator	O
to	O
predict	O
cervical	B-Anatomy
lymphatic	I-Anatomy
metastasis	O
in	O
LSCC	B-Anatomy
.	O
VEGF	O
might	O
be	O
an	O
important	O
angiogenic	O
factor	O
,	O
and	O
could	O
promote	O
tumor	B-Anatomy
angiogenesis	O
in	O
LSCC	B-Anatomy
.	O
Tumor	B-Anatomy
angiogenesis	O
might	O
contribute	O
to	O
tumor	B-Anatomy
malignant	O
progression	O
by	O
inhibiting	O
spontaneous	O
apoptosis	O
in	O
LSCC	B-Anatomy
.	O
[	O
Anomalous	O
origin	O
of	O
the	O
right	B-Anatomy
coronary	I-Anatomy
artery	I-Anatomy
from	O
the	O
left	B-Anatomy
sinus	I-Anatomy
of	O
Valsalva	O
:	O
case	O
report	O
and	O
literature	O
review	O
]	O
.	O
We	O
describe	O
the	O
case	O
of	O
a	O
patient	O
in	O
whom	O
evaluation	O
of	O
effort	O
angina	O
revealed	O
a	O
tight	O
stenosis	O
of	O
a	O
right	B-Anatomy
coronary	I-Anatomy
artery	I-Anatomy
anomalously	O
arising	O
from	O
the	O
left	B-Anatomy
sinus	I-Anatomy
of	O
Valsalva	O
,	O
which	O
was	O
successfully	O
treated	O
by	O
stent	O
implantation	O
.	O
The	O
abnormal	O
origin	O
of	O
the	O
right	B-Anatomy
coronary	I-Anatomy
artery	I-Anatomy
from	O
the	O
left	B-Anatomy
aortic	I-Anatomy
sinus	I-Anatomy
coursing	O
between	O
the	O
aorta	B-Anatomy
and	O
the	O
pulmonary	B-Anatomy
trunk	I-Anatomy
is	O
a	O
rare	O
congenital	O
anomaly	O
.	O
It	O
may	O
remain	O
asymptomatic	O
,	O
but	O
can	O
also	O
cause	O
major	O
cardiac	B-Anatomy
events	O
,	O
even	O
in	O
the	O
absence	O
of	O
coronary	B-Anatomy
atherosclerosis	O
.	O
We	O
discuss	O
the	O
clinical	O
importance	O
of	O
this	O
anomaly	O
and	O
review	O
the	O
literature	O
concerning	O
current	O
views	O
and	O
therapy	O
.	O
The	O
cancer	B-Anatomy
cell	I-Anatomy
'	O
s	O
""""	O
power	O
plants	O
""""	O
as	O
promising	O
therapeutic	O
targets	O
:	O
an	O
overview	O
.	O
This	O
introductory	O
article	O
to	O
the	O
review	O
series	O
entitled	O
""""	O
The	O
Cancer	B-Anatomy
Cell	I-Anatomy
'	O
s	O
Power	O
Plants	O
as	O
Promising	O
Therapeutic	O
Targets	O
""""	O
is	O
written	O
while	O
more	O
than	O
20	O
million	O
people	O
suffer	O
from	O
cancer	B-Anatomy
.	O
It	O
summarizes	O
strategies	O
to	O
destroy	O
or	O
prevent	O
cancers	B-Anatomy
by	O
targeting	O
their	O
energy	O
production	O
factories	O
,	O
i	O
.	O
e	O
.	O
,	O
""""	O
power	O
plants	O
.	O
""""	O
All	O
nucleated	O
animal	O
/	O
human	O
cells	B-Anatomy
have	O
two	O
types	O
of	O
power	O
plants	O
,	O
i	O
.	O
e	O
.	O
,	O
systems	O
that	O
make	O
the	O
""""	O
high	O
energy	O
""""	O
compound	O
ATP	O
from	O
ADP	O
and	O
P	O
(	O
i	O
)	O
.	O
One	O
type	O
is	O
""""	O
glycolysis	O
,	O
""""	O
the	O
other	O
the	O
""""	O
mitochondria	B-Anatomy
.	O
""""	O
In	O
contrast	O
to	O
most	O
normal	O
cells	B-Anatomy
where	O
the	O
mitochondria	B-Anatomy
are	O
the	O
major	O
ATP	O
producers	O
(	O
>	O
90	O
%	O
)	O
in	O
fueling	O
growth	O
,	O
human	O
cancers	B-Anatomy
detected	O
via	O
Positron	O
Emission	O
Tomography	O
(	O
PET	O
)	O
rely	O
on	O
both	O
types	O
of	O
power	O
plants	O
.	O
In	O
such	O
cancers	B-Anatomy
,	O
glycolysis	O
may	O
contribute	O
nearly	O
half	O
the	O
ATP	O
even	O
in	O
the	O
presence	O
of	O
oxygen	O
(	O
""""	O
Warburg	O
effect	O
""""	O
)	O
.	O
Based	O
solely	O
on	O
cell	B-Anatomy
energetics	O
,	O
this	O
presents	O
a	O
challenge	O
to	O
identify	O
curative	O
agents	O
that	O
destroy	O
only	O
cancer	B-Anatomy
cells	I-Anatomy
as	O
they	O
must	O
destroy	O
both	O
of	O
their	O
power	O
plants	O
causing	O
""""	O
necrotic	O
cell	B-Anatomy
death	O
""""	O
and	O
leave	O
normal	O
cells	B-Anatomy
alone	O
.	O
One	O
such	O
agent	O
,	O
3	O
-	O
bromopyruvate	O
(	O
3	O
-	O
BrPA	O
)	O
,	O
a	O
lactic	O
acid	O
analog	O
,	O
has	O
been	O
shown	O
to	O
inhibit	O
both	O
glycolytic	O
and	O
mitochondrial	B-Anatomy
ATP	O
production	O
in	O
rapidly	O
growing	O
cancers	B-Anatomy
(	O
Ko	O
et	O
al	O
.	O
,	O
Cancer	O
Letts	O
.	O
,	O
173	O
,	O
83	O
-	O
91	O
,	O
2001	O
)	O
,	O
leave	O
normal	O
cells	B-Anatomy
alone	O
,	O
and	O
eradicate	O
advanced	O
cancers	B-Anatomy
(	O
19	O
of	O
19	O
)	O
in	O
a	O
rodent	O
model	O
(	O
Ko	O
et	O
al	O
.	O
,	O
Biochem	O
.	O
Biophys	O
.	O
Res	O
.	O
Commun	O
.	O
,	O
324	O
,	O
269	O
-	O
275	O
,	O
2004	O
)	O
.	O
A	O
second	O
approach	O
is	O
to	O
induce	O
only	O
cancer	B-Anatomy
cells	I-Anatomy
to	O
undergo	O
""""	O
apoptotic	O
cell	B-Anatomy
death	O
.	O
""""	O
Here	O
,	O
mitochondria	B-Anatomy
release	O
cell	B-Anatomy
death	O
inducing	O
factors	O
(	O
e	O
.	O
g	O
.	O
,	O
cytochrome	O
c	O
)	O
.	O
In	O
a	O
third	O
approach	O
,	O
cancer	B-Anatomy
cells	I-Anatomy
are	O
induced	O
to	O
die	O
by	O
both	O
apoptotic	O
and	O
necrotic	O
events	O
.	O
In	O
summary	O
,	O
much	O
effort	O
is	O
being	O
focused	O
on	O
identifying	O
agents	O
that	O
induce	O
""""	O
necrotic	O
,	O
""""	O
""""	O
apoptotic	O
""""	O
or	O
apoptotic	O
plus	O
necrotic	O
cell	O
death	O
only	O
in	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
Regardless	O
how	O
death	O
is	O
inflicted	O
,	O
every	O
cancer	B-Anatomy
cell	I-Anatomy
must	O
die	O
,	O
be	O
it	O
fast	O
or	O
slow	O
.	O
Determination	O
of	O
eprosartan	O
in	O
human	O
plasma	B-Anatomy
and	O
urine	B-Anatomy
by	O
LC	O
/	O
MS	O
/	O
MS	O
.	O
A	O
protein	O
precipitation	O
,	O
liquid	O
chromatography	O
/	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
/	O
MS	O
/	O
MS	O
)	O
method	O
has	O
been	O
developed	O
and	O
validated	O
for	O
the	O
determination	O
of	O
eprosartan	O
in	O
human	O
plasma	B-Anatomy
and	O
urine	B-Anatomy
.	O
The	O
solvent	O
system	O
also	O
served	O
as	O
a	O
protein	O
precipitation	O
reagent	O
.	O
The	O
chromatographic	O
separation	O
was	O
achieved	O
on	O
a	O
CAPCELL	O
PAK	O
C18	O
column	O
(	O
50	O
mmx2	O
.	O
0	O
mm	O
,	O
5	O
microm	O
,	O
Shiseido	O
)	O
.	O
A	O
mobile	O
phase	O
was	O
consisted	O
of	O
0	O
.	O
5	O
%	O
formic	O
acid	O
in	O
water	O
and	O
0	O
.	O
5	O
%	O
formic	O
acid	O
in	O
acetonitrile	O
(	O
72	O
:	O
28	O
)	O
.	O
Detection	O
was	O
by	O
positive	O
ion	O
electrospray	O
tandem	O
mass	O
spectrometry	O
on	O
a	O
Sciex	O
API3000	O
.	O
The	O
standard	O
curves	O
,	O
which	O
ranged	O
from	O
5	O
to	O
2000	O
ng	O
/	O
mL	O
in	O
human	O
plasma	B-Anatomy
and	O
from	O
0	O
.	O
25	O
to	O
50	O
microg	O
/	O
mL	O
in	O
urine	B-Anatomy
,	O
were	O
fitted	O
to	O
a	O
1	O
/	O
x	O
weighted	O
quadratic	O
regression	O
model	O
.	O
The	O
method	O
proved	O
to	O
be	O
accurate	O
,	O
specific	O
and	O
sensitive	O
enough	O
to	O
be	O
successfully	O
applied	O
to	O
a	O
pharmacokinetic	O
study	O
.	O
Pathological	O
animal	O
models	O
in	O
the	O
experimental	O
evaluation	O
of	O
tumour	B-Anatomy
microvasculature	I-Anatomy
with	O
magnetic	O
resonance	O
imaging	O
.	O
PURPOSE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
applications	O
of	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
,	O
and	O
in	O
particular	O
,	O
dynamic	O
contrast	O
-	O
enhanced	O
MRI	O
(	O
DCE	O
-	O
MRI	O
)	O
,	O
in	O
the	O
assessment	O
of	O
tumour	B-Anatomy
microvasculature	I-Anatomy
by	O
means	O
of	O
animal	O
tumour	B-Anatomy
models	O
evaluated	O
before	O
and	O
after	O
antiangiogenic	O
treatment	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
two	O
MRI	O
exams	O
were	O
performed	O
with	O
intravascular	B-Anatomy
contrast	O
media	O
in	O
21	O
rats	O
:	O
tumours	B-Anatomy
were	O
induced	O
by	O
subcutaneous	B-Anatomy
injection	O
of	O
colon	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
in	O
7	O
rats	O
and	O
mammary	B-Anatomy
adenocarcinoma	I-Anatomy
cells	I-Anatomy
in	O
14	O
rats	O
.	O
Perfusion	O
and	O
permeability	O
parameters	O
of	O
the	O
implanted	O
tumours	B-Anatomy
were	O
evaluated	O
by	O
using	O
two	O
contrast	O
media	O
(	O
B22956	O
/	O
1	O
and	O
Gd	O
-	O
DTPA37	O
-	O
albumin	O
)	O
to	O
establish	O
response	O
to	O
treatment	O
with	O
two	O
different	O
antiangiogenic	O
drugs	O
(	O
tamoxifen	O
and	O
SU6668	O
)	O
.	O
These	O
parameters	O
were	O
correlated	O
with	O
histology	O
to	O
obtain	O
a	O
radiological	O
-	O
histological	O
map	O
of	O
tumour	B-Anatomy
microvasculature	I-Anatomy
.	O
RESULTS	O
:	O
DCE	O
-	O
MRI	O
revealed	O
greater	O
enhancement	O
in	O
the	O
peripheral	B-Anatomy
area	I-Anatomy
than	O
in	O
the	O
central	B-Anatomy
area	I-Anatomy
in	O
all	O
the	O
examined	O
animal	O
models	O
.	O
In	O
the	O
mammary	B-Anatomy
carcinoma	I-Anatomy
experiment	O
,	O
vascular	B-Anatomy
permeability	O
measured	O
by	O
means	O
of	O
B22956	O
/	O
1	O
in	O
the	O
animals	O
treated	O
with	O
the	O
antiangiogenic	O
drug	O
(	O
0	O
.	O
0043317	O
+	O
/	O
-	O
0	O
.	O
0040418	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
)	O
was	O
significantly	O
less	O
than	O
in	O
untreated	O
animals	O
(	O
0	O
.	O
0090460	O
+	O
/	O
-	O
0	O
.	O
0043680	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
)	O
,	O
whereas	O
no	O
significant	O
difference	O
was	O
observed	O
with	O
Gd	O
-	O
DTPA	O
-	O
albumin	O
(	O
13	O
.	O
14	O
+	O
/	O
-	O
13	O
.	O
94	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
in	O
treated	O
animals	O
and	O
18	O
.	O
07	O
+	O
/	O
-	O
11	O
.	O
92	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
in	O
untreated	O
animals	O
)	O
.	O
In	O
the	O
colon	B-Anatomy
carcinoma	I-Anatomy
experiment	O
,	O
mean	O
permeability	O
and	O
perfusion	O
decreased	O
by	O
51	O
%	O
(	O
from	O
5	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
1	O
to	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
8	O
ml	O
/	O
100	O
ml	O
)	O
and	O
59	O
%	O
(	O
from	O
0	O
.	O
00165	O
+	O
/	O
-	O
5	O
.	O
1	O
to	O
0	O
.	O
0067	O
+	O
/	O
-	O
4	O
.	O
8	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
of	O
tissue	B-Anatomy
)	O
,	O
respectively	O
,	O
in	O
all	O
animals	O
after	O
antiangiogenic	O
drug	O
administration	O
.	O
CONCLUSIONS	O
:	O
DCE	O
-	O
MRI	O
permits	O
a	O
noninvasive	O
evaluation	O
of	O
tumour	B-Anatomy
microcirculation	O
and	O
in	O
particular	O
of	O
its	O
dynamic	O
characteristics	O
and	O
vascularity	O
before	O
and	O
after	O
antiangiogenic	O
treatment	O
.	O
[	O
Synthetic	O
fragments	O
of	O
the	O
NS1	O
protein	O
of	O
the	O
tick	O
-	O
borne	O
encephalitis	O
virus	O
exhibiting	O
a	O
protective	O
effect	O
]	O
.	O
Potentially	O
immunoactive	O
regions	O
of	O
the	O
NS1	O
nonstructural	O
protein	O
of	O
the	O
tick	O
-	O
borne	O
encephalitis	O
virus	O
that	O
can	O
stimulate	O
the	O
antibody	O
formation	O
in	O
vivo	O
and	O
protect	O
animals	O
from	O
this	O
disease	O
were	O
chosen	O
on	O
the	O
basis	O
of	O
theoretical	O
calculations	O
.	O
Eleven	O
16	O
-	O
to	O
27	O
-	O
aa	O
peptides	O
containing	O
the	O
chosen	O
regions	O
were	O
synthesized	O
.	O
The	O
ability	O
of	O
the	O
free	O
peptides	O
(	O
without	O
any	O
high	O
-	O
molecular	O
-	O
mass	O
carrier	O
)	O
to	O
stimulate	O
the	O
production	O
of	O
antipeptide	O
antibodies	O
in	O
mice	O
of	O
three	O
lines	O
and	O
ensure	O
the	O
formation	O
of	O
protective	O
immunity	O
was	O
studied	O
.	O
Most	O
of	O
these	O
peptides	O
were	O
shown	O
to	O
exhibit	O
the	O
immunogenic	O
activity	O
in	O
a	O
free	O
state	O
.	O
Five	O
fragments	O
that	O
can	O
protect	O
mice	O
from	O
the	O
infection	O
by	O
a	O
lethal	O
dose	O
of	O
tick	O
-	O
borne	O
encephalitis	O
virus	O
were	O
found	O
.	O
Angiogenesis	O
in	O
the	O
caprine	O
caruncles	B-Anatomy
in	O
non	O
-	O
pregnant	O
and	O
pregnant	O
normal	O
and	O
swainsonine	O
-	O
treated	O
does	O
.	O
Microvascular	B-Anatomy
corrosion	O
casts	O
of	O
caruncles	B-Anatomy
from	O
non	O
-	O
pregnant	O
and	O
pregnant	O
doe	O
goats	O
at	O
4	O
,	O
7	O
,	O
10	O
,	O
13	O
,	O
16	O
,	O
and	O
18	O
weeks	O
were	O
examined	O
with	O
scanning	O
electron	O
microscopy	O
.	O
The	O
internal	O
convex	O
surface	B-Anatomy
of	O
the	O
caruncles	B-Anatomy
of	O
non	O
-	O
pregnant	O
does	O
was	O
covered	O
with	O
capillary	B-Anatomy
meshes	I-Anatomy
of	O
regular	O
diameter	O
and	O
form	O
,	O
without	O
crypts	B-Anatomy
.	O
As	O
pregnancy	O
advanced	O
the	O
complexity	O
of	O
the	O
vasculature	B-Anatomy
increased	O
:	O
at	O
4	O
weeks	O
the	O
surface	B-Anatomy
showed	O
a	O
pattern	O
of	O
ridges	O
separated	O
by	O
troughs	O
.	O
At	O
later	O
stages	O
,	O
branches	B-Anatomy
of	O
radial	B-Anatomy
arteries	I-Anatomy
penetrated	O
the	O
periphery	O
forming	O
an	O
extensive	O
mesh	O
of	O
capillaries	B-Anatomy
on	O
the	O
concave	O
surface	B-Anatomy
.	O
Capillary	B-Anatomy
diameters	O
increased	O
significantly	O
during	O
pregnancy	O
,	O
especially	O
after	O
4	O
weeks	O
,	O
when	O
large	O
flattened	O
sinusoids	B-Anatomy
formed	O
.	O
These	O
sinusoids	B-Anatomy
had	O
a	O
great	O
deal	O
of	O
surface	B-Anatomy
area	I-Anatomy
for	O
potential	O
contact	O
with	O
the	O
fetal	B-Anatomy
component	O
.	O
The	O
caprine	O
placenta	B-Anatomy
is	O
usually	O
considered	O
to	O
have	O
increased	O
interhemal	B-Anatomy
distance	O
compared	O
with	O
endotheliochorial	B-Anatomy
and	O
hemochorial	B-Anatomy
types	I-Anatomy
:	O
our	O
results	O
suggest	O
that	O
the	O
very	O
extensive	O
development	O
of	O
sinusoids	B-Anatomy
and	O
crypts	B-Anatomy
may	O
compensate	O
for	O
any	O
negative	O
consequences	O
of	O
the	O
placental	B-Anatomy
architecture	O
.	O
Placental	B-Anatomy
angiogenesis	O
,	O
which	O
is	O
physiologically	O
normal	O
,	O
may	O
serve	O
as	O
a	O
general	O
model	O
of	O
this	O
process	O
in	O
other	O
circumstances	O
,	O
such	O
as	O
tumor	B-Anatomy
.	O
The	O
effect	O
of	O
swainsonine	O
(	O
active	O
compound	O
of	O
locoweed	O
and	O
a	O
potential	O
anticancer	B-Anatomy
drug	O
)	O
on	O
vascular	B-Anatomy
development	O
showed	O
no	O
differences	O
in	O
sinusoidal	B-Anatomy
diameters	O
at	O
7	O
weeks	O
,	O
but	O
a	O
decrease	O
in	O
capillary	B-Anatomy
density	O
was	O
noted	O
.	O
Swainsonine	O
caused	O
a	O
great	O
distortion	O
to	O
the	O
vasculature	B-Anatomy
at	O
18	O
weeks	O
.	O
The	O
effects	O
of	O
this	O
compound	O
on	O
the	O
vascular	B-Anatomy
development	O
lend	O
credibility	O
to	O
its	O
potential	O
as	O
an	O
anticancer	B-Anatomy
agent	O
.	O
High	O
-	O
grade	O
clear	B-Anatomy
cell	I-Anatomy
renal	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
has	O
a	O
higher	O
angiogenic	O
activity	O
than	O
low	O
-	O
grade	O
renal	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
based	O
on	O
histomorphological	O
quantification	O
and	O
qRT	O
-	O
PCR	O
mRNA	O
expression	O
profile	O
.	O
Clear	B-Anatomy
cell	I-Anatomy
renal	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
(	O
CC	B-Anatomy
-	I-Anatomy
RCC	I-Anatomy
)	O
is	O
a	O
highly	O
vascularised	O
tumour	B-Anatomy
and	O
is	O
therefore	O
an	O
attractive	O
disease	O
to	O
study	O
angiogenesis	O
and	O
to	O
test	O
novel	O
angiogenesis	O
inhibitors	O
in	O
early	O
clinical	O
development	O
.	O
Endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
process	O
of	O
angiogenesis	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
angiogenesis	O
parameters	O
in	O
low	O
nuclear	B-Anatomy
grade	O
(	O
n	O
=	O
87	O
)	O
vs	O
high	O
nuclear	B-Anatomy
grade	O
CC	B-Anatomy
-	I-Anatomy
RCC	I-Anatomy
(	O
n	O
=	O
63	O
)	O
.	O
A	O
panel	O
of	O
antibodies	O
was	O
used	O
for	O
immunohistochemistry	O
:	O
CD34	O
/	O
Ki	O
-	O
67	O
,	O
carbonic	O
anhydrase	O
IX	O
,	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1alpha	O
(	O
HIF	O
-	O
1alpha	O
)	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
.	O
Vessel	B-Anatomy
density	O
(	O
MVD	O
-	O
microvessel	B-Anatomy
density	O
)	O
,	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
fraction	O
(	O
ECP	O
%	O
)	O
and	O
tumour	B-Anatomy
cell	I-Anatomy
proliferation	O
fraction	O
(	O
TCP	O
%	O
)	O
were	O
assessed	O
.	O
mRNA	O
expression	O
levels	O
of	O
angiogenesis	O
stimulators	O
and	O
inhibitors	O
were	O
determined	O
by	O
quantitative	O
RT	O
-	O
PCR	O
.	O
High	O
-	O
grade	O
CC	B-Anatomy
-	I-Anatomy
RCC	I-Anatomy
showed	O
a	O
higher	O
ECP	O
%	O
(	O
P	O
=	O
0	O
.	O
049	O
)	O
,	O
a	O
higher	O
TCP	O
%	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
,	O
a	O
higher	O
VEGF	O
protein	O
expression	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
a	O
lower	O
MVD	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
a	O
lower	O
HIF	O
-	O
1alpha	O
protein	O
expression	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
than	O
low	O
-	O
grade	O
CC	B-Anatomy
-	I-Anatomy
RCC	I-Anatomy
.	O
Growth	O
factor	O
mRNA	O
expression	O
analyses	O
revealed	O
a	O
higher	O
expression	O
of	O
angiopoietin	O
2	O
in	O
low	O
-	O
grade	O
CC	B-Anatomy
-	I-Anatomy
RCC	I-Anatomy
.	O
Microvessel	B-Anatomy
density	O
and	O
ECP	O
%	O
were	O
inversely	O
correlated	O
(	O
Rho	O
=	O
-	O
0	O
.	O
26	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O
Because	O
of	O
the	O
imperfect	O
association	O
of	O
nuclear	B-Anatomy
grade	O
and	O
ECP	O
%	O
or	O
MVD	O
,	O
CC	B-Anatomy
-	I-Anatomy
RCC	I-Anatomy
was	O
also	O
grouped	O
based	O
on	O
low	O
/	O
high	O
MVD	O
and	O
ECP	O
%	O
.	O
This	O
analysis	O
revealed	O
a	O
higher	O
expression	O
of	O
vessel	B-Anatomy
maturation	O
and	O
stabilisation	O
factors	O
(	O
placental	O
growth	O
factor	O
,	O
PDGFB1	O
,	O
angiopoietin	O
1	O
)	O
in	O
CC	B-Anatomy
-	I-Anatomy
RCC	I-Anatomy
with	O
high	O
MVD	O
,	O
a	O
group	O
of	O
CC	B-Anatomy
-	I-Anatomy
RCC	I-Anatomy
highly	O
enriched	O
in	O
low	O
nuclear	B-Anatomy
grade	O
CC	B-Anatomy
-	I-Anatomy
RCC	I-Anatomy
,	O
with	O
low	O
ECP	O
%	O
.	O
Our	O
results	O
suggest	O
heterogeneity	O
in	O
angiogenic	O
activity	O
and	O
vessel	B-Anatomy
maturation	O
of	O
CC	B-Anatomy
-	I-Anatomy
RCC	I-Anatomy
,	O
to	O
a	O
large	O
extent	O
linked	O
to	O
nuclear	B-Anatomy
grade	O
,	O
and	O
,	O
with	O
probable	O
therapeutic	O
implications	O
.	O
Deletion	O
of	O
Tip30	O
leads	O
to	O
rapid	O
immortalization	O
of	O
murine	O
mammary	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
and	O
ductal	B-Anatomy
hyperplasia	I-Anatomy
in	O
the	O
mammary	B-Anatomy
gland	I-Anatomy
.	O
Transformation	O
of	O
mammary	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
(	O
MECs	B-Anatomy
)	O
from	O
the	O
normal	O
to	O
the	O
neoplastic	B-Anatomy
stage	O
requires	O
the	O
dysregulation	O
of	O
tumor	B-Anatomy
suppressor	O
genes	O
and	O
proto	O
-	O
oncogenes	O
.	O
Tip30	O
is	O
a	O
tumor	B-Anatomy
suppressor	O
that	O
can	O
inhibit	O
estrogen	O
receptor	O
-	O
mediated	O
transcription	O
in	O
MECs	B-Anatomy
,	O
but	O
its	O
role	O
in	O
MEC	B-Anatomy
proliferation	O
remains	O
unknown	O
.	O
Here	O
,	O
we	O
show	O
that	O
deleting	O
the	O
Tip30	O
gene	O
leads	O
to	O
ductal	B-Anatomy
hyperplasia	I-Anatomy
in	O
mouse	O
mammary	B-Anatomy
glands	I-Anatomy
early	O
in	O
life	O
and	O
extensive	O
mammary	B-Anatomy
hyperplasia	I-Anatomy
with	O
age	O
.	O
Tip30	B-Anatomy
(	I-Anatomy
-	I-Anatomy
/	I-Anatomy
-	I-Anatomy
)	I-Anatomy
mammary	I-Anatomy
glands	I-Anatomy
transplanted	O
into	O
wild	O
-	O
type	O
mammary	B-Anatomy
fat	I-Anatomy
pads	I-Anatomy
also	O
display	O
mammary	B-Anatomy
trees	I-Anatomy
with	O
extensive	O
ductal	B-Anatomy
hyperplasia	I-Anatomy
.	O
Strikingly	O
,	O
Tip30	O
deletion	O
promotes	O
proliferation	O
of	O
primary	O
MECs	B-Anatomy
and	O
results	O
in	O
rapid	O
immortalization	O
of	O
MECs	B-Anatomy
in	O
vitro	O
relative	O
to	O
wild	B-Anatomy
-	I-Anatomy
type	I-Anatomy
cells	I-Anatomy
.	O
Gene	O
array	O
analysis	O
identified	O
significant	O
increases	O
in	O
the	O
expression	O
of	O
mammary	B-Anatomy
epithelial	I-Anatomy
growth	O
factors	O
Wisp2	O
and	O
Igf	O
-	O
1	O
in	O
Tip30	B-Anatomy
(	I-Anatomy
-	I-Anatomy
/	I-Anatomy
-	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
.	O
Knockdown	O
of	O
either	O
Wisp2	O
or	O
Igf	O
-	O
1	O
using	O
short	O
interfering	O
RNA	O
dramatically	O
inhibited	O
proliferation	O
of	O
Tip30	B-Anatomy
(	I-Anatomy
-	I-Anatomy
/	I-Anatomy
-	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
.	O
Together	O
,	O
these	O
results	O
suggest	O
that	O
Tip30	O
is	O
an	O
intrinsic	O
and	O
negative	O
regulator	O
of	O
MEC	B-Anatomy
proliferation	O
partly	O
through	O
the	O
inhibition	O
of	O
Wisp2	O
and	O
Igf	O
-	O
1	O
expression	O
,	O
and	O
its	O
absence	O
in	O
the	O
mammary	B-Anatomy
gland	I-Anatomy
may	O
predispose	O
MECs	B-Anatomy
to	O
neoplastic	B-Anatomy
transformation	O
.	O
Long	O
-	O
term	O
immunosuppression	O
in	O
burned	O
patients	O
assessed	O
by	O
in	O
vitro	O
neutrophil	B-Anatomy
oxidative	O
burst	O
(	O
Phagoburst	O
)	O
.	O
OBJECTIVE	O
:	O
To	O
assess	O
the	O
duration	O
and	O
magnitude	O
of	O
immunosuppression	O
induced	O
by	O
burns	O
as	O
measured	O
by	O
the	O
neutrophil	B-Anatomy
oxidative	O
burst	O
in	O
vitro	O
.	O
DESIGN	O
:	O
Prospective	O
exploratory	O
cohort	O
study	O
.	O
SETTING	O
:	O
Tertiary	O
referral	O
unit	O
,	O
University	O
Hospital	O
,	O
Linkoping	O
,	O
Sweden	O
(	O
National	O
Burn	O
Unit	O
)	O
.	O
PATIENTS	O
AND	O
HEALTHY	O
VOLUNTEERS	O
(	O
CONTROLS	O
)	O
:	O
Twenty	O
-	O
eight	O
subjects	O
consecutively	O
admitted	O
to	O
the	O
Burn	O
Unit	O
.	O
The	O
mean	O
total	O
burn	O
surface	B-Anatomy
area	I-Anatomy
(	O
TBSA	O
%	O
)	O
was	O
36	O
(	O
range	O
13	O
-	O
87	O
)	O
and	O
mean	O
age	O
44	O
years	O
(	O
range	O
14	O
-	O
89	O
)	O
.	O
Patients	O
'	O
data	O
were	O
collected	O
prospectively	O
in	O
the	O
burn	O
unit	O
,	O
which	O
also	O
included	O
sequential	O
organ	B-Anatomy
failure	O
assessment	O
(	O
SOFA	O
)	O
score	O
.	O
INTERVENTIONS	O
:	O
None	O
.	O
MEASUREMENTS	O
AND	O
RESULTS	O
:	O
To	O
assess	O
the	O
changes	O
in	O
the	O
oxidative	O
capacity	O
of	O
neutrophils	B-Anatomy
after	O
the	O
burn	O
,	O
blood	B-Anatomy
samples	I-Anatomy
for	O
the	O
Phagoburst	O
analysis	O
were	O
taken	O
on	O
admission	O
and	O
at	O
least	O
once	O
every	O
second	O
week	O
for	O
the	O
duration	O
of	O
stay	O
in	O
hospital	O
and	O
thereafter	O
monthly	O
up	O
to	O
12	O
months	O
after	O
the	O
burn	O
.	O
Neutrophils	B-Anatomy
were	O
stimulated	O
in	O
vitro	O
by	O
Escherichia	O
coli	O
,	O
phorbol	O
12	O
-	O
phorbol	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
and	O
peptide	O
N	O
-	O
formyl	O
-	O
Met	O
-	O
Leu	O
-	O
Phe	O
(	O
fMLP	O
)	O
.	O
Oxidative	O
burst	O
was	O
measured	O
by	O
flow	O
cytometry	O
.	O
Oxidative	O
capacity	O
of	O
the	O
neutrophils	B-Anatomy
decreased	O
similarly	O
for	O
all	O
three	O
stimulants	O
:	O
there	O
was	O
a	O
pathological	O
decrease	O
shortly	O
after	O
admission	O
,	O
with	O
the	O
lowest	O
value	O
occurring	O
between	O
days	O
7	O
and	O
10	O
,	O
followed	O
by	O
a	O
gradual	O
recovery	O
during	O
the	O
ensuing	O
months	O
.	O
Full	O
recovery	O
(	O
to	O
the	O
values	O
of	O
the	O
controls	O
)	O
was	O
seen	O
first	O
3	O
.	O
5	O
months	O
after	O
the	O
burn	O
.	O
Using	O
multiple	O
regression	O
,	O
we	O
found	O
that	O
only	O
age	O
and	O
time	O
since	O
the	O
burn	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
affected	O
the	O
oxidative	O
burst	O
.	O
White	B-Anatomy
cell	I-Anatomy
count	O
(	O
WCC	O
)	O
and	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
values	O
returned	O
to	O
reference	O
ranges	O
long	O
before	O
the	O
oxidative	O
burst	O
.	O
CONCLUSIONS	O
:	O
This	O
study	O
provides	O
evidence	O
that	O
immunosuppression	O
in	O
those	O
injured	O
by	O
burns	O
,	O
as	O
assessed	O
by	O
the	O
in	O
vitro	O
oxidative	O
burst	O
of	O
neutrophils	B-Anatomy
,	O
remains	O
long	O
after	O
the	O
event	O
of	O
the	O
burn	O
(	O
up	O
to	O
3	O
.	O
5	O
months	O
after	O
burn	O
)	O
.	O
Absence	O
of	O
correlations	O
to	O
TBSA	O
%	O
,	O
FTB	O
%	O
,	O
blood	B-Anatomy
transfusion	O
,	O
opiates	O
provided	O
,	O
and	O
multiple	O
organ	B-Anatomy
failure	O
score	O
and	O
laboratory	O
infection	O
variables	O
together	O
with	O
the	O
finding	O
that	O
decreased	O
oxidative	O
burst	O
was	O
uniform	O
after	O
the	O
injury	O
,	O
suggesting	O
that	O
this	O
immunosuppression	O
is	O
primarily	O
due	O
to	O
the	O
general	O
metabolic	O
response	O
rather	O
than	O
recurring	O
infections	O
.	O
A	O
pivotal	O
role	O
for	O
p53	O
:	O
balancing	O
aerobic	O
respiration	O
and	O
glycolysis	O
.	O
The	O
genetic	O
basis	O
of	O
increased	O
glycolytic	O
activity	O
observed	O
in	O
cancer	B-Anatomy
cells	I-Anatomy
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
complex	O
interactions	O
of	O
multiple	O
regulatory	O
pathways	O
.	O
Here	O
we	O
review	O
the	O
recent	O
evidence	O
of	O
a	O
simple	O
genetic	O
mechanism	O
by	O
which	O
tumor	B-Anatomy
suppressor	O
p53	O
regulates	O
mitochondrial	B-Anatomy
respiration	O
with	O
secondary	O
changes	O
in	O
glycolysis	O
that	O
are	O
reminiscent	O
of	O
the	O
Warburg	O
effect	O
.	O
The	O
biological	O
significance	O
of	O
this	O
regulation	O
of	O
the	O
two	O
major	O
pathways	O
of	O
energy	O
generation	O
by	O
p53	O
remains	O
to	O
be	O
seen	O
.	O
The	O
contribution	O
of	O
Harold	O
F	O
.	O
Dvorak	O
to	O
the	O
study	O
of	O
tumor	B-Anatomy
angiogenesis	O
and	O
stroma	B-Anatomy
generation	O
mechanisms	O
.	O
In	O
1983	O
,	O
Harold	O
Dvorak	O
and	O
his	O
colleagues	O
were	O
the	O
first	O
to	O
show	O
that	O
tumor	B-Anatomy
cells	I-Anatomy
secreted	O
vascular	O
permeability	O
factor	O
(	O
VPF	O
)	O
and	O
that	O
a	O
blocking	O
antibody	O
to	O
VPF	O
could	O
prevent	O
the	O
edema	B-Anatomy
and	O
fluid	B-Anatomy
accumulation	O
that	O
is	O
characteristic	O
of	O
human	O
cancers	B-Anatomy
.	O
In	O
1986	O
,	O
Dvorak	O
went	O
on	O
to	O
demonstrate	O
that	O
VPF	O
was	O
secreted	O
by	O
a	O
variety	O
of	O
human	O
tumor	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
and	O
proposed	O
that	O
VPF	O
was	O
in	O
part	O
responsible	O
for	O
the	O
abnormal	O
vasculature	B-Anatomy
seen	O
in	O
human	O
tumors	B-Anatomy
.	O
As	O
a	O
result	O
,	O
he	O
and	O
other	O
investigators	O
demonstrated	O
that	O
VPF	O
was	O
capable	O
of	O
stimulating	O
endothelial	B-Anatomy
cell	I-Anatomy
growth	O
and	O
angiogenesis	O
.	O
These	O
fundamental	O
discoveries	O
led	O
to	O
additional	O
research	O
conducted	O
by	O
Napoleone	O
Ferrara	O
and	O
his	O
laboratory	O
,	O
confirming	O
the	O
cloning	O
of	O
VPF	O
and	O
renaming	O
the	O
protein	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
.	O
In	O
1986	O
,	O
Dvorak	O
proposed	O
that	O
by	O
secreting	O
VPF	O
,	O
tumors	B-Anatomy
induce	O
angiogenesis	O
by	O
turning	O
on	O
the	O
wound	B-Anatomy
healing	O
response	O
.	O
He	O
noted	O
that	O
wounds	B-Anatomy
,	O
like	O
tumors	B-Anatomy
,	O
secrete	O
VPF	O
,	O
causing	O
blood	B-Anatomy
vessels	I-Anatomy
to	O
leak	O
plasma	B-Anatomy
fibrinogen	O
,	O
which	O
stimulates	O
blood	B-Anatomy
vessel	I-Anatomy
growth	O
and	O
provides	O
a	O
matrix	O
on	O
which	O
they	O
can	O
spread	O
.	O
Unlike	O
wounds	B-Anatomy
,	O
however	O
,	O
that	O
turn	O
off	O
VPF	O
production	O
after	O
healing	O
,	O
tumors	B-Anatomy
did	O
not	O
turn	O
off	O
their	O
VPF	O
production	O
and	O
instead	O
continued	O
to	O
make	O
large	O
amounts	O
of	O
VPF	O
,	O
allowing	O
malignant	B-Anatomy
cells	I-Anatomy
to	O
continue	O
to	O
induce	O
new	O
blood	B-Anatomy
vessels	I-Anatomy
and	O
so	O
to	O
grow	O
and	O
spread	O
.	O
Thus	O
,	O
tumors	B-Anatomy
behave	O
like	O
wounds	B-Anatomy
that	O
fail	O
to	O
heal	O
.	O
This	O
work	O
is	O
again	O
extremely	O
significant	O
for	O
patients	O
worldwide	O
,	O
as	O
Dvorak	O
'	O
s	O
scientific	O
research	O
is	O
leading	O
his	O
colleagues	O
all	O
over	O
the	O
world	O
to	O
examine	O
how	O
to	O
treat	O
a	O
tumor	B-Anatomy
through	O
its	O
blood	B-Anatomy
supply	O
.	O
Neurohypophyseal	B-Anatomy
granulomatous	I-Anatomy
germinoma	I-Anatomy
invading	O
the	O
right	B-Anatomy
cavernous	I-Anatomy
sinus	I-Anatomy
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O
We	O
encountered	O
a	O
rare	O
case	O
of	O
neurohypophyseal	B-Anatomy
germinoma	I-Anatomy
with	O
a	O
prominent	O
granulomatous	O
reaction	O
,	O
which	O
invaded	O
the	O
right	B-Anatomy
cavernous	I-Anatomy
sinus	I-Anatomy
.	O
The	O
neuroimaging	O
and	O
histopathology	O
features	O
in	O
this	O
case	O
were	O
unique	O
,	O
distinguishing	O
it	O
from	O
other	O
types	O
of	O
suprasellar	B-Anatomy
lesions	I-Anatomy
.	O
A	O
13	O
-	O
year	O
-	O
old	O
boy	O
presented	O
with	O
loss	O
of	O
appetite	O
and	O
polyuria	O
;	O
both	O
symptoms	O
were	O
present	O
for	O
1	O
year	O
,	O
and	O
headache	O
,	O
general	O
fatigue	O
and	O
blurred	O
vision	O
present	O
for	O
the	O
prior	O
2	O
months	O
.	O
On	O
admission	O
,	O
neurological	B-Anatomy
examination	O
indicated	O
bitemporal	O
hemianopsia	O
and	O
optic	O
atrophy	O
.	O
Endocrinological	O
exam	O
showed	O
panhypopituitarism	O
.	O
Tumor	B-Anatomy
markers	O
such	O
as	O
alpha	O
-	O
fetoprotein	O
,	O
human	O
growth	O
hormone	O
,	O
carcinoembryonic	O
antigen	O
,	O
and	O
placental	B-Anatomy
alkaline	O
phosphatase	O
were	O
negative	O
.	O
Brain	B-Anatomy
CT	O
revealed	O
a	O
suprasellar	B-Anatomy
tumor	I-Anatomy
with	O
calcification	O
.	O
MR	O
T	O
(	O
1	O
)	O
-	O
weighted	O
and	O
T	O
(	O
2	O
)	O
-	O
weighted	O
images	O
showed	O
the	O
tumor	B-Anatomy
to	O
be	O
isointense	O
to	O
normal	O
brain	B-Anatomy
parenchyma	I-Anatomy
and	O
to	O
be	O
enhanced	O
densely	O
.	O
The	O
tumor	B-Anatomy
also	O
involved	O
the	O
right	B-Anatomy
cavernous	I-Anatomy
sinus	I-Anatomy
,	O
so	O
that	O
a	O
biopsy	O
was	O
performed	O
by	O
the	O
transsphenoidal	B-Anatomy
approach	O
.	O
On	O
pathologic	O
examination	O
of	O
the	O
specimen	B-Anatomy
,	O
typical	O
large	O
tumor	B-Anatomy
cells	I-Anatomy
with	O
lymphocytic	B-Anatomy
cell	I-Anatomy
infiltration	O
and	O
prominent	O
granulomatous	O
reaction	O
were	O
observed	O
.	O
Neurohypophyseal	B-Anatomy
granulomatous	I-Anatomy
germinoma	I-Anatomy
was	O
diagnosed	O
.	O
Radiotherapy	O
was	O
performed	O
with	O
a	O
total	O
dose	O
of	O
51	O
Gy	O
and	O
the	O
tumor	B-Anatomy
shrank	O
remarkably	O
.	O
The	O
patient	O
returned	O
to	O
school	O
under	O
hormone	O
replacement	O
therapy	O
.	O
Melissoidesin	O
G	O
,	O
a	O
diterpenoid	O
purified	O
from	O
Isodon	O
melissoides	O
,	O
induces	O
leukemic	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
apoptosis	O
through	O
induction	O
of	O
redox	O
imbalance	O
and	O
exhibits	O
synergy	O
with	O
other	O
anticancer	B-Anatomy
agents	O
.	O
Melissoidesin	O
G	O
(	O
MOG	O
)	O
is	O
a	O
new	O
diterpenoid	O
purified	O
from	O
Isodon	O
melissoides	O
,	O
a	O
plant	O
used	O
in	O
Chinese	O
traditional	O
medicine	O
as	O
antitumor	B-Anatomy
and	O
anti	O
-	O
inflammatory	O
agents	O
.	O
In	O
our	O
study	O
,	O
MOG	O
was	O
shown	O
to	O
specifically	O
inhibit	O
the	O
growth	O
of	O
human	O
leukemia	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
and	O
primary	B-Anatomy
acute	I-Anatomy
myeloid	I-Anatomy
leukemia	I-Anatomy
(	I-Anatomy
AML	I-Anatomy
)	I-Anatomy
blasts	I-Anatomy
via	O
induction	O
of	O
apoptosis	O
,	O
with	O
the	O
evidence	O
of	O
mitochondrial	B-Anatomy
DeltaPsim	O
loss	O
,	O
reactive	O
oxygen	O
species	O
production	O
,	O
caspases	O
activation	O
and	O
nuclear	B-Anatomy
fragmentation	O
.	O
Furthermore	O
,	O
it	O
was	O
shown	O
that	O
thiol	O
-	O
containing	O
antioxidants	O
completely	O
blocked	O
MOG	O
-	O
induced	O
mitochondrial	B-Anatomy
DeltaPsim	O
loss	O
and	O
subsequent	O
cell	B-Anatomy
apoptosis	O
,	O
while	O
the	O
inhibition	O
of	O
apoptosis	O
by	O
benzyloxy	O
-	O
carbonyl	O
-	O
Val	O
-	O
Ala	O
-	O
Asp	O
-	O
fluoromethylketone	O
only	O
partially	O
attenuated	O
mitochondrial	B-Anatomy
DeltaPsim	O
loss	O
,	O
indicating	O
that	O
MOG	O
-	O
induced	O
redox	O
imbalance	O
is	O
an	O
early	O
event	O
upstream	O
to	O
mitochondrial	B-Anatomy
DeltaPsim	O
loss	O
and	O
caspase	O
-	O
3	O
activation	O
.	O
Consistently	O
,	O
it	O
was	O
found	O
that	O
MOG	O
rapidly	O
decreased	O
the	O
intracellular	B-Anatomy
glutathione	O
(	O
GSH	O
)	O
content	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
the	O
significance	O
of	O
GSH	O
depletion	O
in	O
MOG	O
-	O
induced	O
apoptosis	O
was	O
further	O
supported	O
by	O
the	O
protective	O
effects	O
of	O
tert	O
-	O
butylhydroquinone	O
(	O
tBHQ	O
)	O
and	O
the	O
facilitative	O
effects	O
of	O
DL	O
-	O
buthionine	O
(	O
S	O
,	O
R	O
)	O
-	O
sulfoximine	O
(	O
BSO	O
)	O
.	O
Furthermore	O
,	O
it	O
was	O
showed	O
that	O
GSH	O
depletion	O
induced	O
by	O
MOG	O
rendered	O
some	O
leukemia	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
more	O
sensitive	O
to	O
arsenic	O
trioxide	O
(	O
As2O3	O
)	O
,	O
doxorubicin	O
or	O
cisplatin	O
.	O
Additionally	O
,	O
the	O
synergistic	O
apoptotic	O
effects	O
of	O
MOG	O
with	O
As2O3	O
were	O
detected	O
in	O
HL	B-Anatomy
-	I-Anatomy
60	I-Anatomy
and	O
primary	B-Anatomy
AML	I-Anatomy
cells	I-Anatomy
,	O
but	O
not	O
in	O
normal	O
cells	B-Anatomy
,	O
suggesting	O
the	O
selective	O
toxicity	O
of	O
their	O
combination	O
to	O
the	O
malignant	B-Anatomy
cells	I-Anatomy
.	O
Together	O
,	O
we	O
proposed	O
that	O
MOG	O
alone	O
or	O
administered	O
with	O
other	O
anticancer	B-Anatomy
agents	O
may	O
provide	O
a	O
novel	O
therapeutic	O
strategy	O
for	O
leukemia	B-Anatomy
.	O
Hedgehog	O
signaling	O
in	O
the	O
murine	O
melanoma	B-Anatomy
microenvironment	O
.	O
The	O
Hedgehog	O
intercellular	B-Anatomy
signaling	O
pathway	O
regulates	O
cell	B-Anatomy
proliferation	O
and	O
differentiation	O
.	O
This	O
pathway	O
has	O
been	O
implicated	O
to	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
cancer	B-Anatomy
and	O
in	O
embryonic	B-Anatomy
blood	I-Anatomy
vessel	I-Anatomy
development	O
.	O
In	O
the	O
current	O
study	O
,	O
Hedgehog	O
signaling	O
in	O
tumor	B-Anatomy
related	O
vasculature	B-Anatomy
and	O
microenvironment	O
was	O
examined	O
using	O
human	B-Anatomy
umbilical	I-Anatomy
vein	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
and	O
B16F0	B-Anatomy
(	O
murine	O
melanoma	B-Anatomy
)	O
tumors	B-Anatomy
models	O
.	O
Use	O
of	O
exogenous	O
Sonic	O
hedgehog	O
(	O
Shh	O
)	O
peptide	O
significantly	O
increased	O
BrdU	O
incorporation	O
in	O
endothelial	B-Anatomy
cells	I-Anatomy
in	O
vitro	O
by	O
a	O
factor	O
of	O
2	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
The	O
Hedgehog	O
pathway	O
antagonist	O
cyclopamine	O
effectively	O
reduced	O
Shh	O
-	O
induced	O
proliferation	O
to	O
control	O
levels	O
.	O
To	O
study	O
Hedgehog	O
signaling	O
in	O
vivo	O
a	O
hind	B-Anatomy
limb	I-Anatomy
tumor	I-Anatomy
model	O
with	O
the	O
B16F0	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
was	O
used	O
.	O
Treatment	O
with	O
25	O
mg	O
/	O
kg	O
cyclopamine	O
significantly	O
attenuated	O
BrdU	O
incorporation	O
in	O
tumor	B-Anatomy
cells	I-Anatomy
threefold	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
in	O
tumor	B-Anatomy
related	O
endothelial	B-Anatomy
cells	I-Anatomy
threefold	O
(	O
P	O
=	O
0	O
.	O
004	O
)	O
,	O
and	O
delayed	O
tumor	B-Anatomy
growth	O
by	O
4	O
days	O
.	O
Immunohistochemistry	O
revealed	O
that	O
the	O
Hedgehog	O
receptor	O
Patched	O
was	O
localized	O
to	O
the	O
tumor	B-Anatomy
stroma	I-Anatomy
and	O
that	O
B16F0	B-Anatomy
cells	I-Anatomy
expressed	O
Shh	O
peptide	O
.	O
Furthermore	O
,	O
mouse	O
embryonic	B-Anatomy
fibroblasts	I-Anatomy
required	O
the	O
presence	O
of	O
B16F0	B-Anatomy
cells	I-Anatomy
to	O
express	O
Patched	O
in	O
a	O
co	O
-	O
culture	O
assay	O
system	O
.	O
These	O
studies	O
indicate	O
that	O
Shh	O
peptide	O
produced	O
by	O
melanoma	B-Anatomy
cells	I-Anatomy
induces	O
Patched	O
expression	O
in	O
fibroblasts	B-Anatomy
.	O
To	O
study	O
tumor	B-Anatomy
related	O
angiogenesis	O
a	O
vascular	B-Anatomy
window	O
model	O
was	O
used	O
to	O
monitor	O
tumor	B-Anatomy
vascularity	O
.	O
Treatment	O
with	O
cyclopamine	O
significantly	O
attenuated	O
vascular	B-Anatomy
formation	O
by	O
a	O
factor	O
of	O
2	O
.	O
5	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
altered	O
vascular	B-Anatomy
morphology	O
.	O
Furthermore	O
,	O
cyclopamine	O
reduced	O
tumor	B-Anatomy
blood	I-Anatomy
vessel	I-Anatomy
permeability	O
to	O
FITC	O
labeled	O
dextran	O
while	O
having	O
no	O
effect	O
on	O
normal	O
blood	B-Anatomy
vessels	I-Anatomy
.	O
These	O
studies	O
suggest	O
that	O
Hedgehog	O
signaling	O
regulates	O
melanoma	B-Anatomy
related	O
vascular	B-Anatomy
formation	O
and	O
function	O
.	O
Expression	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
,	O
transforming	O
growth	O
factor	O
-	O
alpha	O
and	O
Ki	O
-	O
67	O
in	O
relationship	O
to	O
malignant	O
transformation	O
of	O
pleomorphic	B-Anatomy
adenoma	I-Anatomy
.	O
CONCLUSION	O
:	O
Quantitative	O
assessment	O
is	O
more	O
sensitive	O
as	O
a	O
measure	O
of	O
cellular	B-Anatomy
protein	O
content	O
as	O
compared	O
with	O
standard	O
optical	O
density	O
measurements	O
.	O
The	O
data	O
support	O
the	O
hypothesis	O
that	O
increased	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
and	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
alpha	O
expression	O
is	O
associated	O
with	O
early	O
events	O
in	O
malignant	O
transformation	O
of	O
pleomorphic	B-Anatomy
adenoma	I-Anatomy
(	O
PA	B-Anatomy
)	O
.	O
OBJECTIVE	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
attempted	O
to	O
identify	O
EGFR	O
and	O
TGF	O
-	O
alpha	O
expression	O
and	O
Ki	O
-	O
67	O
index	O
in	O
carcinoma	B-Anatomy
ex	I-Anatomy
-	I-Anatomy
pleomorphic	I-Anatomy
adenoma	I-Anatomy
(	O
Ca	B-Anatomy
ex	I-Anatomy
-	I-Anatomy
PA	I-Anatomy
)	O
and	O
PA	B-Anatomy
.	O
We	O
also	O
compared	O
the	O
presence	O
of	O
EGFR	O
and	O
TGF	O
-	O
alpha	O
and	O
Ki	O
-	O
67	O
index	O
with	O
clinical	O
data	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
The	O
tissues	B-Anatomy
were	O
stained	O
with	O
monoclonal	O
antibodies	O
to	O
EGFR	O
,	O
TGF	O
-	O
alpha	O
and	O
Ki	O
-	O
67	O
.	O
The	O
results	O
were	O
analysed	O
using	O
quantitative	O
immunohistochemical	O
analysis	O
.	O
We	O
also	O
analysed	O
the	O
association	O
of	O
patients	O
'	O
prognosis	O
with	O
clinical	O
parameters	O
and	O
the	O
histological	O
classification	O
of	O
the	O
carcinomatous	B-Anatomy
component	I-Anatomy
.	O
RESULTS	O
:	O
As	O
regards	O
the	O
association	O
of	O
patients	O
'	O
prognosis	O
with	O
EGFR	O
staining	O
and	O
Ki	O
-	O
67	O
index	O
,	O
a	O
significant	O
increase	O
was	O
observed	O
in	O
patients	O
who	O
died	O
or	O
had	O
residual	O
disease	O
compared	O
with	O
patients	O
who	O
were	O
alive	O
without	O
disease	O
.	O
In	O
the	O
immunohistochemical	O
analysis	O
of	O
EGFR	O
and	O
TGF	O
-	O
alpha	O
and	O
Ki67	O
index	O
,	O
a	O
significant	O
increase	O
was	O
observed	O
in	O
Ca	B-Anatomy
ex	I-Anatomy
-	I-Anatomy
PA	I-Anatomy
,	O
especially	O
with	O
adenocarcinoma	B-Anatomy
,	O
compared	O
with	O
PA	B-Anatomy
and	O
sialadenitis	O
.	O
CX3CR1	O
-	O
dependent	O
subretinal	B-Anatomy
microglia	I-Anatomy
cell	I-Anatomy
accumulation	O
is	O
associated	O
with	O
cardinal	O
features	O
of	O
age	O
-	O
related	O
macular	B-Anatomy
degeneration	O
.	O
The	O
role	O
of	O
retinal	B-Anatomy
microglial	I-Anatomy
cells	I-Anatomy
(	O
MCs	B-Anatomy
)	O
in	O
age	O
-	O
related	O
macular	B-Anatomy
degeneration	O
(	O
AMD	O
)	O
is	O
unclear	O
.	O
Here	O
we	O
demonstrated	O
that	O
all	O
retinal	B-Anatomy
MCs	I-Anatomy
express	O
CX3C	O
chemokine	O
receptor	O
1	O
(	O
CX3CR1	O
)	O
and	O
that	O
homozygosity	O
for	O
the	O
CX3CR1	O
M280	O
allele	O
,	O
which	O
is	O
associated	O
with	O
impaired	O
cell	B-Anatomy
migration	O
,	O
increases	O
the	O
risk	O
of	O
AMD	O
.	O
In	O
humans	O
with	O
AMD	O
,	O
MCs	B-Anatomy
accumulated	O
in	O
the	O
subretinal	B-Anatomy
space	I-Anatomy
at	O
sites	B-Anatomy
of	O
retinal	B-Anatomy
degeneration	O
and	O
choroidal	B-Anatomy
neovascularization	O
(	O
CNV	O
)	O
.	O
In	O
CX3CR1	O
-	O
deficient	O
mice	O
,	O
MCs	B-Anatomy
accumulated	O
subretinally	B-Anatomy
with	O
age	O
and	O
albino	O
background	O
and	O
after	O
laser	O
impact	O
preceding	O
retinal	B-Anatomy
degeneration	O
.	O
Raising	O
the	O
albino	O
mice	O
in	O
the	O
dark	O
prevented	O
both	O
events	O
.	O
The	O
appearance	O
of	O
lipid	O
-	O
bloated	O
subretinal	B-Anatomy
MCs	I-Anatomy
was	O
drusen	B-Anatomy
-	O
like	O
on	O
funduscopy	O
of	O
senescent	O
mice	O
,	O
and	O
CX3CR1	O
-	O
dependent	O
MC	B-Anatomy
accumulation	O
was	O
associated	O
with	O
an	O
exacerbation	O
of	O
experimental	O
CNV	O
.	O
These	O
results	O
show	O
that	O
CX3CR1	O
-	O
dependent	O
accumulation	O
of	O
subretinal	B-Anatomy
MCs	I-Anatomy
evokes	O
cardinal	O
features	O
of	O
AMD	O
.	O
These	O
findings	O
reveal	O
what	O
we	O
believe	O
to	O
be	O
a	O
novel	O
pathogenic	O
process	O
with	O
important	O
implications	O
for	O
the	O
development	O
of	O
new	O
therapies	O
for	O
AMD	O
.	O
Conditional	O
deletion	O
of	O
Smad1	O
and	O
Smad5	O
in	O
somatic	B-Anatomy
cells	I-Anatomy
of	O
male	O
and	O
female	O
gonads	B-Anatomy
leads	O
to	O
metastatic	B-Anatomy
tumor	I-Anatomy
development	O
in	O
mice	O
.	O
The	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGFbeta	O
)	O
family	O
has	O
critical	O
roles	O
in	O
the	O
regulation	O
of	O
fertility	O
.	O
In	O
addition	O
,	O
the	O
pathogenesis	O
of	O
some	O
human	O
cancers	B-Anatomy
is	O
attributed	O
to	O
misregulation	O
of	O
TGFbeta	O
function	O
and	O
SMAD2	O
or	O
SMAD4	O
mutations	O
.	O
There	O
are	O
limited	O
mouse	O
models	O
for	O
the	O
BMP	O
signaling	O
SMADs	O
(	O
BR	O
-	O
SMADs	O
)	O
1	O
,	O
5	O
,	O
and	O
8	O
because	O
of	O
embryonic	B-Anatomy
lethality	O
and	O
suspected	O
genetic	O
redundancy	O
.	O
Using	O
tissue	B-Anatomy
-	O
specific	O
ablation	O
in	O
mice	O
,	O
we	O
deleted	O
the	O
BR	O
-	O
SMADs	O
from	O
somatic	B-Anatomy
cells	I-Anatomy
of	O
ovaries	B-Anatomy
and	O
testes	B-Anatomy
.	O
Single	O
conditional	O
knockouts	O
for	O
Smad1	O
or	O
Smad5	O
or	O
mice	O
homozygous	O
for	O
Smad8	O
are	O
viable	O
and	O
fertile	O
.	O
Female	O
double	O
Smad1	O
Smad5	O
and	O
triple	O
Smad1	O
Smad5	O
Smad8	O
conditional	O
knockout	O
mice	O
become	O
infertile	O
and	O
develop	O
metastatic	B-Anatomy
granulosa	I-Anatomy
cell	I-Anatomy
tumors	I-Anatomy
.	O
Male	O
double	O
Smad1	O
Smad5	O
conditional	O
knockout	O
mice	O
are	O
fertile	O
but	O
demonstrate	O
metastatic	B-Anatomy
testicular	I-Anatomy
tumor	I-Anatomy
development	O
.	O
Microarray	O
analysis	O
indicated	O
significant	O
alterations	O
in	O
expression	O
of	O
genes	O
related	O
to	O
the	O
TGFbeta	O
pathway	O
,	O
as	O
well	O
as	O
genes	O
involved	O
in	O
infertility	O
and	O
extracellular	B-Anatomy
matrix	I-Anatomy
production	O
.	O
These	O
data	O
strongly	O
implicate	O
the	O
BR	O
-	O
SMADs	O
as	O
part	O
of	O
a	O
critical	O
developmental	O
pathway	O
in	O
ovaries	B-Anatomy
and	O
testis	B-Anatomy
that	O
,	O
when	O
disrupted	O
,	O
leads	O
to	O
malignant	O
transformation	O
.	O
Melanoma	B-Anatomy
/	O
skin	B-Anatomy
cancer	I-Anatomy
screening	O
clinics	O
:	O
experiences	O
in	O
The	O
Netherlands	O
.	O
In	O
1989	O
and	O
1990	O
we	O
conducted	O
two	O
free	O
melanoma	B-Anatomy
/	O
skin	B-Anatomy
screening	O
clinics	O
in	O
Oss	O
and	O
Arnhem	O
in	O
the	O
Netherlands	O
.	O
The	O
study	O
was	O
carried	O
out	O
along	O
the	O
lines	O
of	O
the	O
recent	O
campaigns	O
supported	O
by	O
the	O
American	O
Academy	O
of	O
Dermatology	O
.	O
Of	O
2564	O
persons	O
screened	O
,	O
53	O
had	O
melanoma	B-Anatomy
or	O
nonmelanoma	B-Anatomy
skin	I-Anatomy
cancer	I-Anatomy
(	O
2	O
.	O
1	O
%	O
)	O
.	O
Compliance	O
with	O
follow	O
-	O
up	O
for	O
persons	O
with	O
suspected	O
melanoma	B-Anatomy
/	O
skin	B-Anatomy
cancer	I-Anatomy
was	O
adequate	O
(	O
93	O
of	O
103	O
;	O
90	O
.	O
3	O
%	O
)	O
.	O
[	O
Clinical	O
significance	O
of	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
as	O
a	O
prognostic	O
factor	O
of	O
cancer	B-Anatomy
disease	O
]	O
Interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
is	O
proinflammatory	O
cytokine	O
that	O
produces	O
multifunctional	O
effects	O
.	O
It	O
is	O
also	O
involved	O
in	O
the	O
regulation	O
of	O
immune	O
reactions	O
,	O
hematopoiesis	O
and	O
inflammatory	O
state	O
.	O
Interleukin	O
-	O
6	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
tumor	B-Anatomy
progression	O
including	O
inhibition	O
of	O
cancer	B-Anatomy
cells	I-Anatomy
apoptosis	O
and	O
stimulation	O
of	O
angiogenesis	O
.	O
Anti	O
-	O
IL	O
-	O
6	O
therapy	O
is	O
a	O
new	O
strategy	O
in	O
the	O
inflammatory	O
autoimmune	O
diseases	O
and	O
cancer	B-Anatomy
.	O
Clinical	O
studies	O
have	O
shown	O
elevated	O
serum	B-Anatomy
IL	O
-	O
6	O
concentrations	O
in	O
patients	O
with	O
endometrial	B-Anatomy
cancer	I-Anatomy
,	O
non	B-Anatomy
-	I-Anatomy
small	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
carcinoma	I-Anatomy
,	O
colorectal	B-Anatomy
cancer	I-Anatomy
,	O
renal	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
,	O
breast	B-Anatomy
and	O
ovarian	B-Anatomy
cancer	I-Anatomy
.	O
Serum	B-Anatomy
IL	O
-	O
6	O
levels	O
correlate	O
with	O
tumor	B-Anatomy
stage	O
,	O
and	O
survival	O
of	O
patients	O
.	O
In	O
this	O
article	O
we	O
have	O
focused	O
on	O
a	O
role	O
of	O
IL	O
-	O
6	O
as	O
a	O
prognostic	O
factor	O
in	O
several	O
malignancies	B-Anatomy
such	O
as	O
colorectal	B-Anatomy
cancer	I-Anatomy
,	O
breast	B-Anatomy
cancer	I-Anatomy
,	O
gastric	B-Anatomy
cancer	I-Anatomy
and	O
pancreatic	B-Anatomy
cancer	I-Anatomy
.	O
Expression	O
of	O
CDK4	O
or	O
CDK2	O
in	O
mouse	O
oral	B-Anatomy
cavity	I-Anatomy
is	O
retained	O
in	O
adult	O
pituitary	B-Anatomy
with	O
distinct	O
effects	O
on	O
tumorigenesis	O
.	O
The	O
keratin	O
5	O
(	O
K5	O
)	O
promoter	O
drives	O
transgenic	O
expression	O
to	O
the	O
basal	B-Anatomy
cell	I-Anatomy
layer	O
of	O
stratified	O
epithelia	B-Anatomy
.	O
Surprisingly	O
,	O
analysis	O
of	O
K5CDK4	O
and	O
K5CDK2	O
transgenic	O
mouse	O
embryos	B-Anatomy
showed	O
CDK4	O
and	O
CDK2	O
expression	O
not	O
only	O
in	O
the	O
expected	O
tissues	B-Anatomy
,	O
but	O
also	O
in	O
the	O
adenohypophysis	B-Anatomy
.	O
This	O
organ	B-Anatomy
is	O
derived	O
from	O
an	O
upwards	O
growth	O
of	O
the	O
primitive	O
oropharynx	B-Anatomy
,	O
a	O
K5	O
-	O
expressing	O
tissue	B-Anatomy
.	O
We	O
show	O
that	O
transgenic	O
expression	O
of	O
CDKs	O
in	O
the	O
embryonic	B-Anatomy
oral	I-Anatomy
ectoderm	I-Anatomy
is	O
specifically	O
retained	O
in	O
undifferentiated	O
cells	B-Anatomy
from	O
the	O
pars	B-Anatomy
intermedia	I-Anatomy
of	O
the	O
adenohypophysis	B-Anatomy
.	O
Interestingly	O
,	O
we	O
found	O
that	O
K5CDK4	O
mice	O
show	O
a	O
decreased	O
number	O
of	O
pituitary	B-Anatomy
stem	I-Anatomy
cells	I-Anatomy
,	O
even	O
though	O
CDK4	O
is	O
not	O
expressed	O
in	O
the	O
stem	B-Anatomy
cells	I-Anatomy
but	O
in	O
transit	B-Anatomy
-	I-Anatomy
amplifying	I-Anatomy
(	I-Anatomy
TA	I-Anatomy
)	I-Anatomy
-	I-Anatomy
like	I-Anatomy
cells	I-Anatomy
.	O
Interestingly	O
,	O
CDK4	O
-	O
expressing	O
cells	B-Anatomy
,	O
but	O
not	O
CDK2	O
-	O
expressing	O
cells	B-Anatomy
,	O
strongly	O
synergize	O
with	O
lack	O
of	O
p27	O
(	O
Kip1	O
)	O
to	O
generate	O
pituitary	B-Anatomy
carcinomas	I-Anatomy
that	O
appear	O
with	O
shortened	O
latency	O
and	O
are	O
drastically	O
more	O
aggressive	O
than	O
those	O
arising	O
in	O
p27	O
(	O
-	O
/	O
-	O
)	O
mice	O
.	O
Thus	O
,	O
we	O
show	O
that	O
deregulation	O
of	O
CDK	O
expression	O
in	O
the	O
primitive	B-Anatomy
oral	I-Anatomy
epithelium	I-Anatomy
plays	O
a	O
unique	O
function	O
,	O
providing	O
a	O
selective	O
advantage	O
that	O
gives	O
rise	O
to	O
transgene	B-Anatomy
-	I-Anatomy
positive	I-Anatomy
TA	I-Anatomy
-	I-Anatomy
like	I-Anatomy
pituitary	I-Anatomy
cells	I-Anatomy
.	O
Furthermore	O
,	O
retention	O
of	O
CDK4	O
in	O
these	O
TA	B-Anatomy
-	I-Anatomy
like	I-Anatomy
pituitary	I-Anatomy
cells	I-Anatomy
synergizes	O
with	O
loss	O
of	O
p27	O
(	O
Kip1	O
)	O
to	O
induce	O
pituitary	B-Anatomy
adenocarcinomas	I-Anatomy
.	O
This	O
model	O
suggests	O
that	O
forced	O
expression	O
of	O
CDK4	O
sensitizes	O
cells	B-Anatomy
and	O
synergizes	O
with	O
a	O
second	O
change	O
resulting	O
in	O
tumor	B-Anatomy
development	O
.	O
Survivin	O
expression	O
in	O
breast	B-Anatomy
carcinoma	I-Anatomy
:	O
correlation	O
with	O
apoptosis	O
and	O
prognosis	O
.	O
BACKGROUND	O
:	O
Survivin	O
is	O
a	O
novel	O
inhibitor	O
of	O
apoptosis	O
commonly	O
detected	O
in	O
tissues	B-Anatomy
during	O
fetal	B-Anatomy
development	O
and	O
in	O
cancer	B-Anatomy
,	O
but	O
not	O
usually	O
in	O
normal	O
tissues	B-Anatomy
.	O
It	O
has	O
been	O
suggested	O
that	O
the	O
expression	O
of	O
this	O
protein	O
may	O
be	O
of	O
prognostic	O
significance	O
in	O
gastric	B-Anatomy
,	O
colorectal	B-Anatomy
,	O
and	O
bladder	B-Anatomy
carcinomas	I-Anatomy
.	O
We	O
assessed	O
survivin	O
expression	O
in	O
breast	B-Anatomy
carcinomas	I-Anatomy
correlating	O
results	O
with	O
expression	O
of	O
other	O
antiapoptotic	O
(	O
bcl	O
-	O
2	O
,	O
bcl	O
-	O
x	O
)	O
and	O
proapoptotic	O
(	O
bax	O
)	O
markers	O
,	O
with	O
prognostic	O
parameters	O
,	O
and	O
with	O
prognosis	O
.	O
DESIGN	O
:	O
Paraffin	O
-	O
embedded	O
sections	B-Anatomy
of	O
37	O
breast	B-Anatomy
carcinomas	I-Anatomy
were	O
immunostained	O
for	O
survivin	O
,	O
bcl	O
-	O
2	O
,	O
bcl	O
-	O
x	O
,	O
and	O
bax	O
.	O
Expression	O
was	O
evaluated	O
in	O
normal	O
breast	B-Anatomy
tissue	I-Anatomy
and	O
carcinoma	B-Anatomy
,	O
nuclei	B-Anatomy
and	O
cytoplasm	B-Anatomy
,	O
as	O
intensity	O
(	O
0	O
to	O
3	O
+	O
)	O
,	O
and	O
percentage	O
of	O
positive	O
cells	B-Anatomy
.	O
RESULTS	O
:	O
Survivin	O
expression	O
was	O
noted	O
in	O
30	O
(	O
81	O
%	O
)	O
of	O
breast	B-Anatomy
carcinomas	I-Anatomy
,	O
and	O
in	O
normal	O
breast	B-Anatomy
tissue	I-Anatomy
,	O
in	O
nuclei	B-Anatomy
,	O
and	O
cytoplasm	B-Anatomy
.	O
There	O
was	O
a	O
significant	O
correlation	O
(	O
P	O
=	O
0	O
.	O
022	O
)	O
between	O
survivin	O
and	O
bcl	O
-	O
x	O
expression	O
;	O
survivin	O
and	O
bcl	O
-	O
x	O
tended	O
to	O
correlate	O
with	O
overall	O
survival	O
(	O
P	O
=	O
0	O
.	O
072	O
and	O
0	O
.	O
075	O
,	O
respectively	O
)	O
,	O
but	O
not	O
with	O
disease	O
-	O
free	O
survival	O
(	O
P	O
=	O
0	O
.	O
19	O
and	O
0	O
.	O
18	O
,	O
respectively	O
)	O
.	O
There	O
was	O
no	O
correlation	O
of	O
survivin	O
with	O
bcl	O
-	O
2	O
or	O
bax	O
expression	O
,	O
or	O
with	O
other	O
prognostic	O
parameters	O
(	O
age	O
,	O
tumor	B-Anatomy
size	O
,	O
histologic	O
type	O
,	O
histologic	O
grade	O
,	O
nodal	B-Anatomy
status	O
,	O
and	O
tumor	B-Anatomy
stage	O
)	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O
CONCLUSION	O
:	O
The	O
majority	O
(	O
81	O
%	O
)	O
of	O
breast	B-Anatomy
carcinomas	I-Anatomy
show	O
survivin	O
expression	O
which	O
correlates	O
with	O
bcl	O
-	O
x	O
,	O
another	O
antiapoptotic	O
marker	O
,	O
and	O
both	O
markers	O
tend	O
to	O
correlate	O
with	O
prognosis	O
.	O
Impact	O
of	O
dexamethasone	O
-	O
induced	O
immunosuppression	O
on	O
the	O
duration	O
and	O
level	O
of	O
shedding	O
of	O
Escherichia	O
coli	O
O157	O
:	O
H7	O
in	O
calves	O
.	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
immunosuppression	O
plays	O
a	O
role	O
in	O
the	O
level	O
and	O
duration	O
of	O
fecal	B-Anatomy
shedding	O
of	O
Escherichia	O
coli	O
O157	O
.	O
Immunosuppression	O
was	O
induced	O
in	O
calves	O
by	O
administering	O
dexamethasone	O
.	O
Six	O
1	O
-	O
week	O
-	O
old	O
Holstein	O
bull	O
calves	O
were	O
injected	O
intramuscularly	B-Anatomy
with	O
dexamethasone	O
and	O
orally	B-Anatomy
inoculated	O
with	O
10	O
(	O
9	O
)	O
CFU	O
of	O
a	O
mixture	O
of	O
three	O
nalidixic	O
-	O
acid	O
resistant	O
strains	B-Anatomy
of	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
.	O
Five	O
1	O
-	O
week	O
-	O
old	O
Holstein	O
bull	O
calves	O
that	O
were	O
given	O
the	O
same	O
oral	B-Anatomy
inoculation	O
of	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
,	O
but	O
not	O
the	O
dexamethasone	O
injections	O
,	O
served	O
as	O
controls	O
.	O
All	O
calves	O
were	O
examined	O
daily	O
and	O
fecal	B-Anatomy
samples	I-Anatomy
were	O
collected	O
three	O
times	O
a	O
week	O
for	O
detection	O
and	O
enumeration	O
of	O
the	O
nalidixic	O
-	O
acid	O
resistant	O
E	O
.	O
coli	O
O157	O
.	O
Four	O
weeks	O
after	O
the	O
last	O
calf	O
stopped	O
shedding	O
,	O
all	O
calves	O
were	O
necropsied	O
and	O
samples	B-Anatomy
from	O
the	O
gastrointestinal	B-Anatomy
tract	I-Anatomy
were	O
taken	O
for	O
the	O
detection	O
of	O
the	O
nalidixic	O
-	O
acid	O
resistant	O
E	O
.	O
coli	O
O157	O
.	O
Dexamethasone	O
-	O
injected	O
calves	O
shed	O
at	O
higher	O
levels	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
on	O
days	O
4	O
and	O
7	O
postinoculation	O
,	O
but	O
not	O
thereafter	O
.	O
None	O
of	O
the	O
samples	B-Anatomy
collected	O
at	O
necropsy	O
were	O
positive	O
for	O
E	O
.	O
coli	O
O157	O
.	O
Data	O
from	O
this	O
study	O
suggest	O
that	O
there	O
may	O
be	O
a	O
time	O
-	O
dependent	O
relationship	O
between	O
dexamethasone	O
immunosuppression	O
and	O
the	O
fecal	B-Anatomy
concentration	O
of	O
E	O
.	O
coli	O
O157	O
but	O
that	O
transient	O
immunosuppression	O
does	O
not	O
appear	O
to	O
prolong	O
shedding	O
of	O
E	O
.	O
coli	O
O157	O
.	O
Functional	O
significance	O
of	O
VEGF	O
-	O
a	O
in	O
human	O
ovarian	B-Anatomy
carcinoma	I-Anatomy
:	O
role	O
in	O
vasculogenic	O
mimicry	O
.	O
Ovarian	B-Anatomy
cancer	I-Anatomy
is	O
a	O
silent	O
killer	O
,	O
and	O
shows	O
early	O
extensive	O
tumor	B-Anatomy
invasion	O
and	O
peritoneal	B-Anatomy
metastasis	O
.	O
The	O
microcirculation	O
of	O
most	O
tumors	B-Anatomy
includes	O
cooperation	O
of	O
pre	O
-	O
existing	O
vessels	B-Anatomy
,	O
intussusceptive	O
microvascular	B-Anatomy
growth	O
,	O
postnatal	O
vasculogenesis	O
,	O
glomeruloid	B-Anatomy
angiogenesis	O
and	O
vasculogenic	O
mimicry	O
(	O
VM	O
)	O
.	O
VM	O
is	O
critical	O
for	O
a	O
tumor	B-Anatomy
blood	B-Anatomy
supply	O
and	O
is	O
asscociated	O
with	O
aggressive	O
features	O
and	O
metastasis	O
.	O
Our	O
studies	O
highlight	O
the	O
plasticity	O
of	O
aggressive	O
human	O
ovarian	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
and	O
call	O
into	O
question	O
the	O
underlying	O
significance	O
of	O
their	O
ability	O
to	O
form	O
VM	O
in	O
vitro	O
induced	O
by	O
VEGF	O
-	O
a	O
.	O
These	O
studies	O
also	O
show	O
their	O
clinicalpathological	O
features	O
of	O
the	O
cancers	B-Anatomy
with	O
human	O
Paraffin	O
-	O
embedded	O
tumor	B-Anatomy
tissue	I-Anatomy
samples	I-Anatomy
.	O
Results	O
show	O
that	O
the	O
process	O
:	O
VEGF	O
-	O
a	O
-	O
-	O
greater	O
than	O
EphA2	O
-	O
-	O
greater	O
than	O
MMPs	O
-	O
-	O
greater	O
than	O
VM	O
is	O
the	O
main	O
pathway	O
for	O
VM	O
formation	O
and	O
VEGF	O
-	O
a	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
formation	O
of	O
VM	O
based	O
on	O
our	O
in	O
vitro	O
assays	O
and	O
clinical	O
immunohistochemical	O
analyses	O
.	O
VM	O
-	O
targeting	O
strategies	O
for	O
ovarian	B-Anatomy
cancer	I-Anatomy
include	O
anti	O
-	O
VEGF	O
-	O
a	O
treatment	O
,	O
knocking	O
down	O
the	O
EphA2	O
gene	O
and	O
using	O
antibodies	O
against	O
human	O
MMPs	O
if	O
the	O
tumor	B-Anatomy
is	O
VM	O
positive	O
.	O
This	O
strategy	O
may	O
be	O
of	O
significant	O
value	O
in	O
laying	O
the	O
foundation	O
for	O
a	O
more	O
explicit	O
anti	O
-	O
tumor	B-Anatomy
angiogenesis	O
therapy	O
.	O
A	O
novel	O
role	O
of	O
thrombospondin	O
-	O
1	O
in	O
cervical	B-Anatomy
carcinogenesis	O
:	O
inhibit	O
stroma	B-Anatomy
reaction	O
by	O
inhibiting	O
activated	O
fibroblasts	B-Anatomy
from	O
invading	O
cancer	B-Anatomy
.	O
Thrombospondin	O
(	O
TSP	O
)	O
-	O
1	O
,	O
a	O
potent	O
angiogenesis	O
inhibitor	O
,	O
has	O
been	O
shown	O
to	O
exert	O
different	O
biological	O
functions	O
on	O
various	O
cell	B-Anatomy
types	O
.	O
Here	O
,	O
we	O
investigate	O
the	O
role	O
of	O
TSP	O
-	O
1	O
in	O
tumor	B-Anatomy
-	O
stroma	B-Anatomy
reaction	O
,	O
which	O
is	O
mainly	O
characterized	O
by	O
fibroblast	B-Anatomy
activation	O
to	O
create	O
a	O
permissive	O
microenvironment	O
for	O
tumor	B-Anatomy
progression	O
.	O
Immunohistochemistry	O
examinations	O
in	O
the	O
human	O
surgical	B-Anatomy
specimens	I-Anatomy
have	O
shown	O
that	O
a	O
downregulation	O
of	O
TSP	O
-	O
1	O
during	O
the	O
progression	O
of	O
cervical	B-Anatomy
carcinogenesis	O
was	O
accompanied	O
by	O
an	O
emergence	O
in	O
the	O
upregulation	O
of	O
stroma	B-Anatomy
markers	O
,	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
alpha	O
-	O
SMA	O
)	O
and	O
desmin	O
.	O
Transfection	O
of	O
SiHa	B-Anatomy
cervical	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
with	O
a	O
plasmid	B-Anatomy
expressing	O
the	O
TSP	O
-	O
1	O
protein	O
exhibited	O
antiangiogenic	O
activity	O
in	O
vitro	O
and	O
resulted	O
in	O
reduced	O
tumor	B-Anatomy
growth	O
in	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
mice	O
,	O
which	O
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
tumor	B-Anatomy
vascularization	O
and	O
lower	O
expressions	O
of	O
alpha	O
-	O
SMA	O
and	O
desmin	O
than	O
those	O
in	O
the	O
vector	O
controls	O
.	O
Transfection	O
with	O
TSP	O
-	O
1	O
and	O
purified	O
TSP	O
-	O
1	O
added	O
to	O
NIH3T3	B-Anatomy
cells	I-Anatomy
did	O
not	O
alter	O
the	O
protein	O
levels	O
of	O
alpha	O
-	O
SMA	O
and	O
desmin	O
but	O
significantly	O
inhibited	O
matrix	O
metalloprotease	O
-	O
2	O
activity	O
.	O
Transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
,	O
a	O
major	O
factor	O
in	O
the	O
activation	O
of	O
fibroblasts	B-Anatomy
,	O
increased	O
alpha	O
-	O
SMA	O
and	O
desmin	O
expression	O
and	O
the	O
ability	O
of	O
cell	B-Anatomy
migration	O
and	O
invasion	O
in	O
NIH3T3	B-Anatomy
cells	I-Anatomy
.	O
The	O
increased	O
migration	O
ability	O
and	O
the	O
invasive	O
ability	O
into	O
tumor	B-Anatomy
cluster	O
of	O
TGF	O
-	O
beta	O
-	O
treated	O
NIH3T3	B-Anatomy
cells	I-Anatomy
were	O
dose	O
dependently	O
inhibited	O
by	O
TSP	O
-	O
1	O
.	O
In	O
contrast	O
,	O
ectopic	O
TSP	O
-	O
1	O
expression	O
in	O
SiHa	B-Anatomy
cells	I-Anatomy
has	O
little	O
effect	O
on	O
the	O
invasive	O
ability	O
of	O
the	O
NIH3T3	B-Anatomy
cells	I-Anatomy
.	O
Together	O
,	O
our	O
findings	O
demonstrate	O
a	O
novel	O
role	O
of	O
TSP	O
-	O
1	O
to	O
inhibit	O
tumor	B-Anatomy
-	O
stroma	B-Anatomy
reaction	O
that	O
could	O
be	O
attributed	O
to	O
the	O
blockage	O
of	O
activated	O
fibroblasts	B-Anatomy
from	O
invading	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
Targeting	O
a	O
tumor	B-Anatomy
-	O
specific	O
laminin	O
domain	O
critical	O
for	O
human	O
carcinogenesis	O
.	O
Laminin	O
-	O
332	O
is	O
critical	O
for	O
squamous	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
(	O
SCC	B-Anatomy
)	O
tumorigenesis	O
,	O
but	O
targeting	O
it	O
for	O
cancer	B-Anatomy
therapy	O
has	O
been	O
unachievable	O
due	O
to	O
key	O
role	O
of	O
laminin	O
-	O
332	O
in	O
promoting	O
tissue	B-Anatomy
integrity	O
.	O
Here	O
,	O
we	O
show	O
that	O
a	O
portion	O
of	O
laminin	O
-	O
332	O
,	O
termed	O
G45	O
,	O
which	O
is	O
proteolytically	O
removed	O
and	O
absent	O
in	O
normal	O
tissues	B-Anatomy
,	O
is	O
prominently	O
expressed	O
in	O
most	O
human	O
SCC	B-Anatomy
tumors	I-Anatomy
and	O
plays	O
an	O
important	O
role	O
in	O
human	O
SCC	B-Anatomy
tumorigenesis	O
.	O
Primary	O
human	O
keratinocytes	B-Anatomy
lacking	I-Anatomy
G45	I-Anatomy
(	O
DeltaG45	B-Anatomy
)	O
showed	O
alterations	O
of	O
basal	O
receptor	O
organization	O
,	O
impaired	O
matrix	B-Anatomy
deposition	O
,	O
and	O
increased	O
migration	O
.	O
After	O
SCC	B-Anatomy
transformation	O
,	O
the	O
absence	O
of	O
G45	O
domain	O
in	O
DeltaG45	B-Anatomy
cells	I-Anatomy
was	O
associated	O
with	O
deficient	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
and	O
phosphotidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
pathway	O
activation	O
,	O
impaired	O
invasion	O
,	O
deficient	O
metalloproteinase	O
activity	O
,	O
and	O
absent	O
tumorgenicity	O
in	O
vivo	O
.	O
Expression	O
of	O
G45	O
or	O
activated	O
PI3K	O
subunit	O
in	O
DeltaG45	B-Anatomy
cells	I-Anatomy
reversed	O
these	O
abnormalities	O
.	O
G45	O
antibody	O
treatment	O
induced	O
SCC	B-Anatomy
tumor	I-Anatomy
apoptosis	O
,	O
decreased	O
SCC	B-Anatomy
tumor	I-Anatomy
proliferation	O
,	O
and	O
markedly	O
impaired	O
human	O
SCC	B-Anatomy
tumorigenesis	O
in	O
vivo	O
without	O
affecting	O
normal	O
tissue	B-Anatomy
adhesion	O
.	O
These	O
results	O
show	O
a	O
remarkable	O
selectivity	O
of	O
expression	O
and	O
function	O
for	O
laminin	O
-	O
332	O
G45	O
in	O
human	O
SCC	B-Anatomy
tumorigenesis	O
and	O
implicate	O
it	O
as	O
a	O
specific	O
target	O
for	O
anticancer	B-Anatomy
therapy	O
.	O
Analysis	O
of	O
processivity	O
of	O
mungbean	O
dideoxynucleotide	O
-	O
sensitive	O
DNA	O
polymerase	O
and	O
detection	O
of	O
the	O
activity	O
and	O
expression	O
of	O
the	O
enzyme	O
in	O
the	O
meristematic	B-Anatomy
and	O
meiotic	B-Anatomy
tissues	I-Anatomy
and	O
following	O
DNA	O
damaging	O
agent	O
.	O
Analysis	O
of	O
the	O
processivity	O
of	O
mungbean	O
ddNTP	O
-	O
sensitive	O
DNA	O
polymerase	O
showed	O
the	O
incorporation	O
of	O
approximately	O
35	O
-	O
40	O
nucleotides	O
per	O
binding	O
event	O
in	O
the	O
replication	O
assays	O
involving	O
M13	O
ss	O
DNA	O
template	O
with	O
5	O
'	O
-	O
labeled	O
17	O
-	O
mer	O
primer	O
.	O
Optimal	O
processivity	O
was	O
obtained	O
with	O
100	O
-	O
150	O
mM	O
KCl	O
and	O
6	O
-	O
8	O
mM	O
Mg2	O
+	O
at	O
pH	O
7	O
.	O
5	O
.	O
The	O
enzyme	O
showed	O
preference	O
for	O
Mg2	O
+	O
over	O
Mn2	O
+	O
as	O
the	O
metal	O
activator	O
for	O
processivity	O
.	O
2	O
'	O
,	O
3	O
'	O
dideoxythymidine	O
5	O
'	O
triphosphate	O
(	O
ddTTP	O
)	O
and	O
rat	O
DNA	O
pol	O
beta	O
antibody	O
strongly	O
influenced	O
distributive	O
synthesis	O
.	O
Considerable	O
enhancement	O
in	O
processivity	O
was	O
noticed	O
at	O
1mM	O
ATP	O
and	O
2	O
-	O
4	O
mM	O
spermidine	O
while	O
higher	O
concentrations	O
of	O
spermidine	O
caused	O
distributive	O
synthesis	O
.	O
The	O
enzyme	O
was	O
found	O
to	O
be	O
active	O
in	O
both	O
meristematic	B-Anatomy
and	O
meiotic	B-Anatomy
tissues	I-Anatomy
and	O
distinctly	O
induced	O
by	O
EMS	O
treatment	O
.	O
DNA	O
-	O
binding	O
assays	O
revealed	O
distinct	O
binding	O
ability	O
of	O
the	O
enzyme	O
to	O
template	O
/	O
primer	O
and	O
damaged	O
DNA	O
substrate	O
.	O
Together	O
these	O
observations	O
illustrate	O
the	O
probable	O
involvement	O
of	O
the	O
enzyme	O
in	O
replication	O
and	O
repair	O
machinery	O
in	O
higher	O
plants	O
.	O
Management	O
of	O
early	O
and	O
advanced	O
colorectal	B-Anatomy
cancer	I-Anatomy
:	O
therapeutic	O
issues	O
.	O
PURPOSE	O
:	O
The	O
staging	O
of	O
colorectal	B-Anatomy
cancer	I-Anatomy
,	O
therapeutic	O
decision	O
making	O
in	O
the	O
management	O
of	O
early	O
and	O
advanced	O
colorectal	B-Anatomy
cancer	I-Anatomy
,	O
and	O
dilemmas	O
posed	O
by	O
drug	O
-	O
related	O
toxicity	O
are	O
discussed	O
.	O
SUMMARY	O
:	O
Staging	O
of	O
colorectal	B-Anatomy
cancer	I-Anatomy
occurs	O
after	O
surgery	O
and	O
is	O
based	O
on	O
the	O
extent	O
of	O
disease	O
invasiveness	O
and	O
dissemination	O
.	O
Surgery	O
is	O
the	O
primary	O
treatment	O
for	O
stage	O
I	O
disease	O
.	O
Adjuvant	O
chemotherapy	O
is	O
recommended	O
after	O
resection	O
in	O
selected	O
high	O
-	O
risk	O
patients	O
with	O
stage	O
II	O
disease	O
and	O
in	O
all	O
patients	O
with	O
stage	O
III	O
disease	O
.	O
Convenience	O
of	O
administration	O
,	O
tolerability	O
,	O
and	O
patient	O
factors	O
not	O
necessarily	O
age	O
may	O
be	O
considerations	O
in	O
decisions	O
about	O
adjuvant	O
therapy	O
after	O
resection	O
.	O
Treatment	O
of	O
stage	O
IV	O
colorectal	B-Anatomy
cancer	I-Anatomy
is	O
based	O
on	O
the	O
type	O
of	O
prior	O
therapy	O
and	O
patient	O
-	O
specific	O
factors	O
.	O
Recently	O
,	O
significant	O
improvements	O
in	O
survival	O
have	O
been	O
achieved	O
through	O
the	O
use	O
of	O
combination	O
chemotherapy	O
and	O
monoclonal	O
antibody	O
regimens	O
.	O
Bevacizumab	O
in	O
combination	O
with	O
chemotherapy	O
is	O
first	O
-	O
line	O
therapy	O
for	O
stage	O
IV	O
disease	O
.	O
Age	O
alone	O
should	O
not	O
preclude	O
the	O
use	O
of	O
chemotherapy	O
in	O
stage	O
IV	O
colorectal	B-Anatomy
cancer	I-Anatomy
,	O
although	O
the	O
ability	O
to	O
tolerate	O
drug	O
-	O
related	O
toxicity	O
may	O
be	O
a	O
consideration	O
.	O
The	O
optimal	O
duration	O
of	O
chemotherapy	O
in	O
patients	O
with	O
early	O
and	O
metastatic	B-Anatomy
colorectal	I-Anatomy
cancer	I-Anatomy
is	O
unclear	O
.	O
CONCLUSION	O
:	O
The	O
optimal	O
approach	O
to	O
the	O
treatment	O
of	O
colorectal	B-Anatomy
cancer	I-Anatomy
depends	O
on	O
several	O
considerations	O
,	O
including	O
patient	O
-	O
specific	O
factors	O
.	O
Serum	B-Anatomy
and	O
urine	B-Anatomy
levels	O
of	O
interleukin	O
-	O
8	O
in	O
patients	O
with	O
non	B-Anatomy
-	I-Anatomy
Hodgkin	I-Anatomy
'	I-Anatomy
s	I-Anatomy
lymphoma	I-Anatomy
.	O
Angiogenesis	O
plays	O
an	O
important	O
role	O
in	O
many	O
types	O
of	O
cancer	B-Anatomy
.	O
Interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
is	O
known	O
to	O
be	O
a	O
pro	O
-	O
inflammatory	O
and	O
pro	O
-	O
angiogenic	O
cytokine	O
,	O
and	O
IL	O
-	O
8	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
tumor	B-Anatomy
progression	O
,	O
prognosis	O
and	O
survival	O
in	O
several	O
types	O
of	O
cancers	B-Anatomy
.	O
However	O
,	O
the	O
role	O
of	O
IL	O
-	O
8	O
in	O
non	B-Anatomy
-	I-Anatomy
Hodgkin	I-Anatomy
'	I-Anatomy
s	I-Anatomy
lymphoma	I-Anatomy
(	O
NHL	B-Anatomy
)	O
has	O
not	O
been	O
fully	O
determined	O
.	O
Here	O
,	O
we	O
evaluated	O
the	O
usefulness	O
of	O
measuring	O
serum	B-Anatomy
and	O
urine	B-Anatomy
IL	O
-	O
8	O
levels	O
in	O
patients	O
with	O
NHL	B-Anatomy
.	O
We	O
developed	O
reference	O
intervals	O
for	O
serum	B-Anatomy
and	O
urine	B-Anatomy
IL	O
-	O
8	O
level	O
in	O
131	O
control	O
individuals	O
.	O
We	O
measured	O
serum	B-Anatomy
IL	O
-	O
8	O
and	O
urine	B-Anatomy
IL	O
-	O
8	O
levels	O
in	O
patients	O
with	O
NHL	B-Anatomy
,	O
and	O
we	O
compared	O
the	O
concentrations	O
with	O
those	O
of	O
control	O
individuals	O
.	O
The	O
reference	O
intervals	O
for	O
serum	B-Anatomy
IL	O
-	O
8	O
and	O
urine	B-Anatomy
IL	O
-	O
8	O
corrected	O
by	O
creatinine	O
(	O
Cr	O
)	O
were	O
15	O
.	O
9	O
-	O
430	O
.	O
3	O
pg	O
/	O
mL	O
and	O
0	O
.	O
0	O
-	O
28	O
.	O
4	O
pg	O
/	O
mg	O
Cr	O
,	O
respectively	O
.	O
The	O
concentrations	O
of	O
urine	B-Anatomy
IL	O
-	O
8	O
/	O
Cr	O
were	O
significantly	O
higher	O
in	O
patients	O
than	O
in	O
controls	O
(	O
48	O
.	O
9	O
+	O
/	O
-	O
194	O
.	O
4	O
vs	O
.	O
5	O
.	O
2	O
+	O
/	O
-	O
13	O
.	O
8	O
pg	O
/	O
mg	O
Cr	O
,	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
serum	B-Anatomy
IL	O
-	O
8	O
concentrations	O
between	O
NHL	B-Anatomy
patients	O
and	O
controls	O
(	O
159	O
.	O
2	O
+	O
/	O
-	O
40	O
.	O
4	O
vs	O
.	O
99	O
.	O
6	O
+	O
/	O
-	O
107	O
.	O
1	O
pg	O
/	O
mL	O
;	O
P	O
=	O
0	O
.	O
099	O
)	O
.	O
Receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
gave	O
0	O
.	O
83	O
and	O
0	O
.	O
43	O
ROC	O
area	O
values	O
for	O
urine	B-Anatomy
IL	O
-	O
8	O
/	O
Cr	O
and	O
serum	B-Anatomy
IL	O
-	O
8	O
,	O
respectively	O
.	O
There	O
was	O
no	O
correlation	O
between	O
the	O
serum	B-Anatomy
and	O
urine	B-Anatomy
concentrations	O
of	O
IL	O
-	O
8	O
and	O
clinical	O
variables	O
,	O
the	O
only	O
exception	O
being	O
the	O
international	O
prognostic	O
index	O
(	O
IPI	O
)	O
,	O
which	O
showed	O
a	O
marginal	O
correlation	O
with	O
urine	B-Anatomy
IL	O
-	O
8	O
/	O
Cr	O
levels	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O
This	O
study	O
indicated	O
that	O
urine	B-Anatomy
IL	O
-	O
8	O
/	O
Cr	O
levels	O
might	O
be	O
useful	O
as	O
a	O
diagnostic	O
marker	O
of	O
NHL	B-Anatomy
.	O
Microscopic	O
technique	O
for	O
the	O
detection	O
of	O
nitric	O
oxide	O
-	O
dependent	O
angiogenesis	O
in	O
an	O
animal	O
model	O
.	O
Nitric	O
oxide	O
(	O
NO	O
)	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
vascular	B-Anatomy
homeostasis	O
.	O
The	O
importance	O
of	O
NO	O
in	O
the	O
vasculature	B-Anatomy
is	O
demonstrated	O
by	O
several	O
experimental	O
conditions	O
,	O
such	O
as	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
-	O
induced	O
angiogenesis	O
.	O
Thus	O
,	O
the	O
NO	O
metabolic	O
pathway	O
in	O
endothelial	B-Anatomy
cells	I-Anatomy
could	O
be	O
one	O
of	O
the	O
main	O
contributing	O
factors	O
for	O
angiogenesis	O
.	O
Although	O
several	O
methods	O
have	O
been	O
used	O
for	O
measuring	O
in	O
vitro	O
angiogenesis	O
,	O
a	O
proper	O
technique	O
has	O
not	O
been	O
developed	O
for	O
identifying	O
in	O
vivo	O
NO	O
-	O
dependent	O
angiogenesis	O
.	O
This	O
chapter	O
provides	O
a	O
new	O
intravital	O
microscopic	O
method	O
for	O
detecting	O
and	O
measuring	O
NO	O
-	O
dependent	O
angiogenesis	O
in	O
a	O
mouse	O
model	O
.	O
This	O
technique	O
showed	O
strong	O
abdominal	B-Anatomy
neovascularization	O
in	O
wild	O
-	O
type	O
mice	O
,	O
but	O
not	O
eNOS	O
knockout	O
mice	O
,	O
locally	O
injected	O
with	O
VEGF	O
,	O
as	O
well	O
as	O
stimulation	O
of	O
angiogenesis	O
in	O
NO	O
donor	O
-	O
injected	O
mice	O
.	O
This	O
technique	O
also	O
revealed	O
the	O
inhibitory	O
effect	O
of	O
the	O
NOS	O
inhibitor	O
N	O
(	O
G	O
)	O
-	O
iminoethyl	O
-	O
L	O
-	O
ornithine	O
in	O
VEGF	O
-	O
mediated	O
in	O
vivo	O
angiogenesis	O
.	O
This	O
chapter	O
describes	O
intravital	O
microscopy	O
as	O
a	O
new	O
imaging	O
technique	O
for	O
detecting	O
NO	O
-	O
dependent	O
angiogenesis	O
in	O
an	O
animal	O
model	O
.	O
Effects	O
of	O
cyclooxygenase	O
-	O
2	O
non	O
-	O
selective	O
and	O
selective	O
inhibitors	O
on	O
proliferation	O
inhibition	O
and	O
apoptosis	O
induction	O
of	O
esophageal	B-Anatomy
squamous	I-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
.	O
The	O
objective	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
aspirin	O
and	O
nimesulide	O
on	O
cell	B-Anatomy
proliferation	O
,	O
apoptosis	O
and	O
its	O
potential	O
mechanisms	O
in	O
EC9706	B-Anatomy
and	O
EC109	B-Anatomy
esophageal	I-Anatomy
squamous	I-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
.	O
EC9706	B-Anatomy
and	O
EC109	B-Anatomy
cells	I-Anatomy
were	O
incubated	O
with	O
varying	O
concentrations	O
of	O
aspirin	O
and	O
nimesulide	O
,	O
and	O
the	O
effects	O
on	O
cell	B-Anatomy
proliferation	O
and	O
apoptosis	O
were	O
monitored	O
by	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethyl	O
-	O
thiazol	O
-	O
2yl	O
)	O
-	O
2	O
,	O
5	O
-	O
diphenyltetrazolium	O
bromide	O
and	O
flow	O
cytometry	O
.	O
Reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
Western	O
blot	O
assays	O
were	O
used	O
to	O
investigate	O
expression	O
of	O
Bcl	O
-	O
2	O
and	O
Bax	O
.	O
Prostaglandin	O
E2	O
production	O
was	O
measured	O
by	O
enzyme	O
linked	O
immunosorbent	O
assay	O
.	O
Pretreatment	O
with	O
aspirin	O
and	O
nimesulide	O
inhibited	O
EC9706	B-Anatomy
and	O
EC109	B-Anatomy
cell	I-Anatomy
growth	O
in	O
a	O
time	O
and	O
dose	O
-	O
dependent	O
manner	O
,	O
accompanied	O
with	O
a	O
decrease	O
of	O
prostaglandin	O
E2	O
production	O
.	O
In	O
EC9706	B-Anatomy
cells	I-Anatomy
,	O
the	O
mechanism	O
of	O
aspirin	O
and	O
nimesulide	O
induced	O
growth	O
inhibition	O
was	O
a	O
consequence	O
of	O
cell	B-Anatomy
cycle	O
arrest	O
at	O
the	O
G	O
(	O
0	O
)	O
/	O
G	O
(	O
1	O
)	O
check	O
point	O
.	O
In	O
EC109	B-Anatomy
cells	I-Anatomy
,	O
growth	O
arrest	O
was	O
by	O
induction	O
of	O
apoptosis	O
,	O
associated	O
with	O
downregulation	O
of	O
Bcl	O
-	O
2	O
,	O
but	O
not	O
Bax	O
.	O
In	O
conclusion	O
,	O
aspirin	O
and	O
nimesulide	O
could	O
inhibit	O
cell	B-Anatomy
proliferation	O
and	O
induce	O
apoptosis	O
in	O
esophageal	B-Anatomy
squamous	I-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
.	O
Cyclooxygenase	O
-	O
2	O
inhibitor	O
may	O
be	O
a	O
promising	O
therapeutic	O
agent	O
for	O
human	O
esophageal	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
Neurotrophin	O
p75	O
receptor	O
(	O
p75NTR	O
)	O
promotes	O
endothelial	B-Anatomy
cell	I-Anatomy
apoptosis	O
and	O
inhibits	O
angiogenesis	O
:	O
implications	O
for	O
diabetes	O
-	O
induced	O
impaired	O
neovascularization	O
in	O
ischemic	O
limb	B-Anatomy
muscles	I-Anatomy
.	O
Diabetes	O
impairs	O
endothelial	B-Anatomy
function	O
and	O
reparative	O
neovascularization	O
.	O
The	O
p75	O
receptor	O
of	O
neurotrophins	O
(	O
p75	O
(	O
NTR	O
)	O
)	O
,	O
which	O
is	O
scarcely	O
present	O
in	O
healthy	O
endothelial	B-Anatomy
cells	I-Anatomy
(	O
ECs	B-Anatomy
)	O
,	O
becomes	O
strongly	O
expressed	O
by	O
capillary	B-Anatomy
ECs	I-Anatomy
after	O
induction	O
of	O
peripheral	B-Anatomy
ischemia	O
in	O
type	O
-	O
1	O
diabetic	O
mice	O
.	O
Here	O
,	O
we	O
show	O
that	O
gene	O
transfer	O
-	O
induced	O
p75	O
(	O
NTR	O
)	O
expression	O
impairs	O
the	O
survival	O
,	O
proliferation	O
,	O
migration	O
,	O
and	O
adhesion	O
capacities	O
of	O
cultured	O
ECs	B-Anatomy
and	O
endothelial	B-Anatomy
progenitor	I-Anatomy
cells	I-Anatomy
(	O
EPCs	B-Anatomy
)	O
and	O
inhibits	O
angiogenesis	O
in	O
vitro	O
.	O
Moreover	O
,	O
intramuscular	B-Anatomy
p75	O
(	O
NTR	O
)	O
gene	O
delivery	O
impairs	O
neovascularization	O
and	O
blood	B-Anatomy
flow	O
recovery	O
in	O
a	O
mouse	O
model	O
of	O
limb	B-Anatomy
ischemia	O
.	O
These	O
disturbed	O
functions	O
are	O
associated	O
with	O
suppression	O
of	O
signaling	O
mechanisms	O
implicated	O
in	O
EC	B-Anatomy
survival	O
and	O
angiogenesis	O
.	O
In	O
fact	O
,	O
p75	O
(	O
NTR	O
)	O
depresses	O
the	O
VEGF	O
-	O
A	O
/	O
Akt	O
/	O
eNOS	O
/	O
NO	O
pathway	O
and	O
additionally	O
reduces	O
the	O
mRNA	O
levels	O
of	O
ITGB1	O
[	O
beta	O
(	O
1	O
)	O
integrin	O
]	O
,	O
BIRC5	O
(	O
survivin	O
)	O
,	O
PTTG1	O
(	O
securin	O
)	O
and	O
VEZF1	O
.	O
Diabetic	O
mice	O
,	O
which	O
typically	O
show	O
impaired	O
postischemic	O
muscular	B-Anatomy
neovascularization	O
and	O
blood	B-Anatomy
perfusion	O
recovery	O
,	O
have	O
these	O
defects	O
corrected	O
by	O
intramuscular	B-Anatomy
gene	O
transfer	O
of	O
a	O
dominant	O
negative	O
mutant	O
form	O
of	O
p75	O
(	O
NTR	O
)	O
.	O
Collectively	O
,	O
our	O
data	O
newly	O
demonstrate	O
the	O
antiangiogenic	O
action	O
of	O
p75	O
(	O
NTR	O
)	O
and	O
open	O
new	O
avenues	O
for	O
the	O
therapeutic	O
use	O
of	O
p75	O
(	O
NTR	O
)	O
inhibition	O
to	O
combat	O
diabetes	O
-	O
induced	O
microvascular	B-Anatomy
liabilities	O
.	O
Tumor	B-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
targeted	O
cyclic	O
RGD	O
-	O
modified	O
heparin	O
derivative	O
:	O
inhibition	O
of	O
angiogenesis	O
and	O
tumor	B-Anatomy
growth	O
.	O
PURPOSE	O
:	O
We	O
prepared	O
tumor	B-Anatomy
endothelium	I-Anatomy
targeted	O
cRGD	O
-	O
modified	O
heparin	O
derivative	O
(	O
cRGD	O
-	O
HL	O
)	O
by	O
coupling	O
heparin	O
-	O
lithocholic	O
acid	O
(	O
HL	O
)	O
with	O
cRGDyK	O
,	O
and	O
evaluated	O
inhibition	O
effects	O
of	O
cRGD	O
-	O
HL	O
on	O
angiogenesis	O
and	O
tumor	B-Anatomy
growth	O
.	O
METHODS	O
:	O
To	O
evaluate	O
antiangiogenic	O
activity	O
of	O
cRGD	O
-	O
HL	O
,	O
we	O
performed	O
tests	O
on	O
endothelial	B-Anatomy
cell	I-Anatomy
adhesion	O
and	O
migration	O
to	O
vitronectin	O
,	O
tube	B-Anatomy
formation	O
,	O
binding	O
affinity	O
to	O
purified	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
integrin	O
,	O
and	O
in	O
vivo	O
Matrigel	O
plug	O
assay	O
.	O
The	O
antitumor	B-Anatomy
activity	O
of	O
cRGD	O
-	O
HL	O
was	O
also	O
evaluated	O
by	O
monitoring	O
tumor	B-Anatomy
growth	O
and	O
microvessel	B-Anatomy
formation	O
in	O
squamous	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
(	I-Anatomy
SCC7	I-Anatomy
)	I-Anatomy
tumor	I-Anatomy
.	O
RESULTS	O
:	O
The	O
cRGD	O
-	O
HL	O
significantly	O
inhibited	O
adhesion	O
and	O
migration	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
to	O
vitronectin	O
,	O
and	O
tubular	B-Anatomy
structures	I-Anatomy
of	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
Compared	O
to	O
cRGDyK	O
and	O
HL	O
,	O
cRGD	O
-	O
HL	O
has	O
high	O
binding	O
affinity	O
to	O
purified	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
integrin	O
.	O
The	O
enhanced	O
antiangiogenic	O
effect	O
of	O
cRGD	O
-	O
HL	O
was	O
confirmed	O
in	O
Matrigel	O
assay	O
by	O
showing	O
the	O
significant	O
inhibition	O
of	O
bFGF	O
-	O
driven	O
angiogenesis	O
and	O
blood	B-Anatomy
vessel	I-Anatomy
formation	O
.	O
It	O
was	O
thought	O
that	O
potent	O
antiangiogenic	O
effect	O
of	O
cRGD	O
-	O
HL	O
was	O
probably	O
due	O
to	O
the	O
interference	O
of	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
-	O
mediated	O
interaction	O
,	O
resulting	O
in	O
the	O
enhanced	O
antitumoral	B-Anatomy
activity	O
against	O
SCC7	B-Anatomy
tumor	I-Anatomy
.	O
CONCLUSION	O
:	O
These	O
results	O
demonstrated	O
that	O
cRGD	O
-	O
modified	O
heparin	O
derivative	O
enhanced	O
anti	O
-	O
angiotherapeutic	O
effects	O
against	O
solid	B-Anatomy
tumor	I-Anatomy
,	O
and	O
therefore	O
,	O
it	O
could	O
be	O
applied	O
to	O
treat	O
various	O
cancers	B-Anatomy
and	O
angiogenic	O
diseases	O
as	O
a	O
potent	O
angiogenesis	O
inhibitor	O
.	O
[	O
Inhibitory	O
effect	O
of	O
adenovirus	O
-	O
mediated	O
endostatin	O
gene	O
transfer	O
on	O
transplanted	O
lung	B-Anatomy
carcinoma	I-Anatomy
in	O
mice	O
]	O
OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
adenovirus	O
-	O
mediated	O
endostatin	O
gene	O
transfer	O
on	O
transplanted	O
lung	B-Anatomy
cancer	I-Anatomy
in	O
mice	O
and	O
its	O
mechanism	O
of	O
action	O
.	O
METHODS	O
:	O
Transplant	B-Anatomy
tumor	I-Anatomy
model	O
was	O
induced	O
by	O
subcutaneous	B-Anatomy
inoculation	O
of	O
2	O
x	O
10	O
(	O
6	O
)	O
Lewis	B-Anatomy
lung	I-Anatomy
cancer	I-Anatomy
(	I-Anatomy
LLC	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
into	O
the	O
back	B-Anatomy
of	O
C57BL	O
/	O
6	O
mice	O
.	O
The	O
mice	O
were	O
treated	O
by	O
intratumoral	B-Anatomy
injection	O
of	O
2	O
x	O
10	O
(	O
9	O
)	O
pfu	O
Ad	O
-	O
mEndostatin	O
.	O
The	O
expression	O
of	O
endostatin	O
in	O
situ	O
and	O
its	O
maintaining	O
time	O
were	O
detected	O
by	O
immunohistochemistry	O
and	O
Western	O
Blot	O
,	O
respectively	O
.	O
The	O
endostatin	O
level	O
in	O
serum	B-Anatomy
was	O
determined	O
by	O
ELISA	O
.	O
The	O
inhibition	O
of	O
tumor	B-Anatomy
growth	O
and	O
changes	O
of	O
survival	O
were	O
recorded	O
and	O
the	O
microvessel	B-Anatomy
density	O
(	O
MVD	O
)	O
was	O
determined	O
by	O
histochemical	O
stainingwith	O
CD31	O
and	O
CD105	O
antibodies	O
.	O
The	O
tumor	B-Anatomy
apoptosis	O
was	O
observed	O
by	O
electron	O
microscopy	O
.	O
RESULTS	O
:	O
In	O
comparison	O
with	O
controls	O
,	O
intratumoral	B-Anatomy
injection	O
of	O
Ad	O
-	O
mEndostatin	O
significantly	O
inhibited	O
the	O
tumor	B-Anatomy
growth	O
and	O
metastasis	O
,	O
and	O
prolonged	O
the	O
survival	O
rate	O
of	O
mice	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
Strong	O
positive	O
expression	O
of	O
mEndostatin	O
was	O
seen	O
in	O
the	O
tumor	B-Anatomy
tissue	I-Anatomy
after	O
injection	O
of	O
Ad	O
-	O
mEndostatin	O
,	O
immunhistochemically	O
ostained	O
by	O
mouse	O
endostatin	O
monoclonal	O
antibody	O
,	O
while	O
the	O
control	O
groups	O
showed	O
only	O
very	O
low	O
expression	O
or	O
absence	O
.	O
Serum	B-Anatomy
endostatin	O
concentration	O
was	O
1540	O
+	O
/	O
-	O
560	O
ng	O
/	O
ml	O
at	O
the	O
second	O
week	O
of	O
administration	O
,	O
the	O
expression	O
of	O
endostatin	O
diminished	O
a	O
month	O
later	O
.	O
The	O
microvessel	B-Anatomy
density	O
(	O
MVD	O
)	O
)	O
decreased	O
from	O
42	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
8	O
to	O
10	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
2	O
per	O
x	O
200	O
magnificetion	O
microscopic	O
field	O
by	O
CD10	O
staining	O
and	O
from	O
68	O
.	O
5	O
+	O
/	O
-	O
4	O
.	O
5	O
to	O
37	O
.	O
5	O
+	O
/	O
-	O
4	O
.	O
6	O
by	O
CD31	O
staining	O
,	O
respectively	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
More	O
apoptotic	O
tumor	B-Anatomy
cells	I-Anatomy
were	O
seen	O
under	O
the	O
transmission	O
electron	O
microscope	O
.	O
CONCLUSION	O
:	O
Endostatin	O
gene	O
therapy	O
mediated	O
by	O
adenoviral	O
vector	O
efficiently	O
induces	O
expression	O
of	O
endostatin	O
in	O
vivo	O
,	O
and	O
inhibits	O
the	O
growth	O
and	O
metastasis	O
of	O
tumor	B-Anatomy
.	O
It	O
is	O
concluded	O
that	O
its	O
action	O
is	O
targeted	O
to	O
tumor	B-Anatomy
neovasculature	I-Anatomy
and	O
the	O
mechanism	O
is	O
inhibition	O
of	O
tumor	B-Anatomy
angiogenesis	O
.	O
The	O
role	O
of	O
p53	O
in	O
pigmentation	O
,	O
tanning	O
and	O
melanoma	B-Anatomy
.	O
p53	O
has	O
a	O
central	O
role	O
in	O
skin	B-Anatomy
pigmentation	O
and	O
may	O
impact	O
on	O
melanoma	B-Anatomy
at	O
all	O
stages	O
,	O
however	O
,	O
as	O
it	O
'	O
s	O
mutation	O
frequency	O
in	O
melanoma	B-Anatomy
is	O
low	O
,	O
it	O
'	O
s	O
role	O
has	O
been	O
somewhat	O
under	O
-	O
appreciated	O
.	O
During	O
normal	O
skin	B-Anatomy
function	O
,	O
p53	O
in	O
the	O
keratinocyte	B-Anatomy
is	O
a	O
transducer	O
of	O
the	O
skin	B-Anatomy
tanning	O
signal	O
and	O
an	O
essential	O
component	O
of	O
what	O
is	O
effectively	O
a	O
keratinocyte	B-Anatomy
-	O
melanocyte	B-Anatomy
signaling	O
cycle	O
that	O
regulates	O
skin	B-Anatomy
pigmentation	O
.	O
It	O
is	O
clear	O
that	O
this	O
cycle	O
functions	O
optimally	O
in	O
skin	B-Anatomy
of	O
dark	O
pigmentation	O
.	O
When	O
melanin	O
biosynthesis	O
is	O
genetically	O
disrupted	O
in	O
skin	B-Anatomy
of	O
white	O
complexion	O
,	O
we	O
propose	O
that	O
this	O
cycle	O
operates	O
as	O
a	O
promoter	O
of	O
melanocyte	B-Anatomy
proliferation	O
.	O
The	O
cell	B-Anatomy
autonomous	O
function	O
of	O
p53	O
in	O
melanocytes	B-Anatomy
is	O
not	O
well	O
described	O
,	O
however	O
,	O
the	O
balance	O
of	O
the	O
evidence	O
suggests	O
that	O
p53	O
is	O
an	O
effective	O
tumor	B-Anatomy
suppressor	O
and	O
the	O
myriad	O
of	O
mechanisms	O
by	O
which	O
the	O
p53	O
pathway	O
may	O
be	O
dysregulated	O
in	O
tumors	B-Anatomy
attests	O
to	O
it	O
importance	O
as	O
a	O
tumor	B-Anatomy
suppressor	O
.	O
In	O
this	O
review	O
,	O
we	O
outline	O
the	O
known	O
mechanisms	O
that	O
impair	O
p53	O
itself	O
and	O
its	O
immediate	O
regulators	O
or	O
target	O
genes	O
during	O
melanomagenesis	O
.	O
Due	O
to	O
the	O
importance	O
of	O
this	O
pathway	O
,	O
it	O
is	O
clear	O
that	O
p53	O
disruptions	O
may	O
relate	O
directly	O
to	O
a	O
patient	O
'	O
s	O
prognosis	O
.	O
This	O
pathway	O
will	O
continue	O
to	O
be	O
a	O
focus	O
of	O
investigation	O
,	O
particularly	O
with	O
respect	O
to	O
targeted	O
experimental	O
chemotherapeutics	O
.	O
Enhancement	O
of	O
docetaxel	O
-	O
induced	O
cytotoxicity	O
and	O
apoptosis	O
by	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
through	O
downregulation	O
of	O
survivin	O
(	O
BIRC5	O
)	O
,	O
MCL	O
-	O
1	O
and	O
LTbeta	O
-	O
R	O
in	O
hormone	O
-	O
and	O
drug	O
resistant	O
prostate	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
,	O
DU	B-Anatomy
-	I-Anatomy
145	I-Anatomy
.	O
BACKGROUND	O
:	O
The	O
management	O
of	O
hormone	B-Anatomy
-	I-Anatomy
refractory	I-Anatomy
prostate	I-Anatomy
cancer	I-Anatomy
(	O
HRPC	B-Anatomy
)	O
still	O
remains	O
as	O
an	O
important	O
challenge	O
of	O
daily	O
oncology	O
practice	O
.	O
Docetaxel	O
has	O
proved	O
to	O
be	O
a	O
first	O
line	O
treatment	O
choice	O
.	O
All	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
could	O
potently	O
inhibit	O
the	O
growth	O
of	O
prostate	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
in	O
vitro	O
and	O
its	O
combination	O
with	O
various	O
anticancer	B-Anatomy
agents	O
results	O
in	O
increased	O
cytotoxicity	O
.	O
Based	O
on	O
these	O
data	O
,	O
our	O
aim	O
was	O
to	O
examine	O
the	O
synergistic	O
/	O
additive	O
cytotoxic	O
and	O
apoptotic	O
effects	O
of	O
combination	O
of	O
docetaxel	O
and	O
ATRA	O
,	O
in	O
hormone	O
-	O
and	O
drug	O
refractory	O
human	O
DU	B-Anatomy
-	I-Anatomy
145	I-Anatomy
prostate	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Furthermore	O
,	O
we	O
have	O
searched	O
for	O
the	O
underlying	O
mechanisms	O
of	O
apoptosis	O
by	O
demonstrating	O
apoptosis	O
-	O
related	O
genes	O
.	O
METHODS	O
:	O
XTT	B-Anatomy
cell	I-Anatomy
proliferation	O
assay	O
was	O
used	O
for	O
showing	O
cytotoxicity	O
.	O
For	O
verifying	O
apoptosis	O
,	O
both	O
DNA	O
Fragmentation	O
by	O
ELISA	O
assay	O
and	O
caspase	O
3	O
/	O
7	O
activity	O
measurement	O
were	O
used	O
.	O
For	O
detecting	O
the	O
mechanism	O
of	O
apoptosis	O
induced	O
by	O
docetaxel	O
-	O
ATRA	O
combination	O
,	O
OligoGeArray	O
which	O
consists	O
of	O
112	O
apoptosis	O
related	O
genes	O
was	O
used	O
.	O
RESULTS	O
:	O
Our	O
results	O
revealed	O
that	O
docetaxel	O
and	O
ATRA	O
were	O
synergistically	O
cytotoxic	O
and	O
apoptotic	O
in	O
DU	B-Anatomy
-	I-Anatomy
145	I-Anatomy
cells	I-Anatomy
,	O
in	O
a	O
dose	O
-	O
and	O
time	O
dependent	O
manner	O
.	O
It	O
was	O
also	O
shown	O
by	O
our	O
studies	O
that	O
apoptosis	O
was	O
induced	O
in	O
DU	B-Anatomy
-	I-Anatomy
145	I-Anatomy
prostate	I-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
with	O
significant	O
cytotoxicity	O
,	O
no	O
matter	O
which	O
agent	O
applied	O
first	O
.	O
We	O
have	O
found	O
out	O
that	O
docetaxel	O
-	O
ATRA	O
combination	O
significantly	O
downregulates	O
survivin	O
(	O
BIRC5	O
)	O
,	O
myeloid	O
cell	O
leukemia	O
-	O
1	O
(	O
MCL	O
-	O
1	O
)	O
and	O
lymphotoxin	O
beta	O
-	O
receptor	O
(	O
LTbetaR	O
)	O
genes	O
,	O
which	O
all	O
three	O
have	O
pivotal	O
roles	O
in	O
regulation	O
of	O
apoptosis	O
and	O
cell	B-Anatomy
cycle	O
progression	O
.	O
CONCLUSION	O
:	O
In	O
conclusion	O
,	O
we	O
strongly	O
suggest	O
that	O
docetaxel	O
and	O
ATRA	O
combination	O
is	O
a	O
good	O
candidate	O
for	O
this	O
challenging	O
era	O
of	O
daily	O
oncologic	O
practice	O
.	O
Also	O
,	O
the	O
combination	O
of	O
docetaxel	O
and	O
ATRA	O
might	O
allow	O
a	O
reduction	O
in	O
docetaxel	O
doses	O
and	O
by	O
this	O
way	O
may	O
diminish	O
docetaxel	O
adverse	O
effects	O
while	O
maintaining	O
the	O
therapeutic	O
effect	O
in	O
patients	O
with	O
HRPC	B-Anatomy
.	O
Diverse	O
cell	B-Anatomy
signaling	O
events	O
modulated	O
by	O
perlecan	O
.	O
Perlecan	O
is	O
a	O
ubiquitous	O
pericellular	B-Anatomy
proteoglycan	O
ideally	O
placed	O
to	O
mediate	O
cell	B-Anatomy
signaling	O
events	O
controlling	O
migration	O
,	O
proliferation	O
,	O
and	O
differentiation	O
.	O
Its	O
control	O
of	O
growth	O
factor	O
signaling	O
usually	O
involves	O
interactions	O
with	O
the	O
heparan	O
sulfate	O
chains	O
covalently	O
coupled	O
to	O
the	O
protein	O
core	O
'	O
s	O
N	O
-	O
terminus	O
.	O
However	O
,	O
this	O
modular	O
protein	O
core	O
also	O
binds	O
with	O
relatively	O
high	O
affinity	O
to	O
a	O
number	O
of	O
growth	O
factors	O
and	O
surface	B-Anatomy
receptors	O
,	O
thereby	O
stabilizing	O
cell	B-Anatomy
-	O
matrix	B-Anatomy
links	O
.	O
This	O
review	O
will	O
focus	O
on	O
perlecan	O
-	O
growth	O
factor	O
interactions	O
and	O
describe	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
this	O
highly	O
conserved	O
proteoglycan	O
during	O
development	O
,	O
cancer	B-Anatomy
growth	O
,	O
and	O
angiogenesis	O
.	O
The	O
pro	O
-	O
angiogenic	O
capacities	O
of	O
perlecan	O
that	O
involve	O
proliferative	O
and	O
migratory	O
signals	O
in	O
response	O
to	O
bound	O
growth	O
factors	O
will	O
be	O
explored	O
,	O
as	O
well	O
as	O
the	O
anti	O
-	O
angiogenic	O
signals	O
resulting	O
from	O
interactions	O
between	O
the	O
C	O
-	O
terminal	O
domain	O
known	O
as	O
endorepellin	O
and	O
integrins	O
that	O
control	O
adhesion	O
of	O
cells	B-Anatomy
to	O
the	O
extracellular	B-Anatomy
matrix	I-Anatomy
.	O
These	O
two	O
somewhat	O
diametrically	O
opposed	O
roles	O
will	O
be	O
discussed	O
in	O
light	O
of	O
new	O
data	O
emerging	O
from	O
various	O
fields	O
which	O
converge	O
on	O
perlecan	O
as	O
a	O
key	O
regulator	O
of	O
cell	B-Anatomy
growth	O
and	O
angiogenesis	O
.	O
Activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
through	O
a	O
phosphomimetic	O
serine	O
727	O
promotes	O
prostate	B-Anatomy
tumorigenesis	O
independent	O
of	O
tyrosine	O
705	O
phosphorylation	O
.	O
Aberrantly	O
activated	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
Stat3	O
)	O
is	O
implicated	O
in	O
the	O
development	O
of	O
various	O
human	O
cancers	B-Anatomy
.	O
Y705	O
phosphorylation	O
is	O
conventionally	O
thought	O
to	O
be	O
required	O
for	O
Stat3	O
signal	O
-	O
dependent	O
activation	O
and	O
seems	O
to	O
play	O
an	O
essential	O
role	O
in	O
some	O
malignancies	B-Anatomy
.	O
Recently	O
,	O
it	O
was	O
shown	O
that	O
Stat3	O
is	O
activated	O
through	O
novel	O
and	O
noncanonical	O
mechanisms	O
,	O
including	O
phosphorylation	O
at	O
S727	O
.	O
Here	O
,	O
we	O
investigate	O
S727	O
phosphorylation	O
of	O
Stat3	O
and	O
its	O
subsequent	O
effects	O
in	O
prostate	B-Anatomy
cancer	I-Anatomy
development	O
,	O
independent	O
of	O
Y705	O
phosphorylation	O
,	O
using	O
mutated	O
Stat3	O
in	O
the	O
human	O
prostate	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
LNCaP	I-Anatomy
.	O
We	O
show	O
mutation	O
of	O
S727	O
to	O
the	O
phosphomimetic	O
residue	O
Glu	O
,	O
and	O
inactivation	O
of	O
Y705	O
(	O
Y705F	O
/	O
S727E	O
)	O
resulted	O
in	O
a	O
remarkable	O
growth	O
advantage	O
in	O
low	O
-	O
serum	B-Anatomy
,	O
enhanced	O
anchorage	O
-	O
independent	O
growth	O
in	O
soft	O
agar	O
,	O
and	O
increased	O
tumorigenicity	O
in	O
nonobese	O
diabetic	O
/	O
severe	O
combined	O
immunodeficient	O
(	O
NOD	O
/	O
SCID	O
)	O
mice	O
,	O
possibly	O
by	O
direct	O
activation	O
of	O
downstream	O
proto	O
-	O
oncogenes	O
c	O
-	O
myc	O
,	O
mcl	O
-	O
1	O
,	O
and	O
survivin	O
.	O
Y705F	B-Anatomy
/	I-Anatomy
S727E	I-Anatomy
mutant	I-Anatomy
cells	I-Anatomy
were	O
more	O
invasive	O
than	O
Y705F	B-Anatomy
/	I-Anatomy
S727A	I-Anatomy
(	I-Anatomy
inactivation	I-Anatomy
of	I-Anatomy
Y705	I-Anatomy
and	I-Anatomy
S727	I-Anatomy
)	I-Anatomy
mutant	I-Anatomy
cells	I-Anatomy
,	O
and	O
more	O
Y705F	O
/	O
S727E	O
mutant	O
Stat3	O
was	O
localized	O
in	O
the	O
nuclei	B-Anatomy
relative	O
to	O
Y705F	O
/	O
S727A	O
mutant	O
Stat3	O
at	O
the	O
steady	O
state	O
.	O
Furthermore	O
,	O
the	O
Y705F	O
/	O
S727E	O
but	O
not	O
the	O
Y705F	O
/	O
S727A	O
mutant	O
induced	O
anchorage	O
-	O
independent	O
growth	O
of	O
noncancerous	B-Anatomy
prostate	I-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
(	O
RWPE	B-Anatomy
-	I-Anatomy
1	I-Anatomy
)	O
.	O
We	O
further	O
show	O
that	O
Stat3	O
is	O
phosphorylated	O
at	O
S727	O
in	O
65	O
%	O
of	O
malignant	B-Anatomy
prostate	I-Anatomy
tissues	I-Anatomy
(	O
n	O
=	O
20	O
)	O
relative	O
to	O
25	O
%	O
of	O
normal	O
prostate	B-Anatomy
tissues	I-Anatomy
(	O
n	O
=	O
4	O
)	O
.	O
Moreover	O
,	O
there	O
is	O
a	O
positive	O
correlation	O
between	O
phosphoS727	O
-	O
Stat3	O
expression	O
and	O
Gleason	O
score	O
in	O
these	O
prostate	B-Anatomy
cancer	I-Anatomy
tissues	I-Anatomy
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O
Our	O
data	O
suggest	O
for	O
the	O
first	O
time	O
that	O
S727	O
phosphorylation	O
is	O
sufficient	O
to	O
activate	O
Stat3	O
,	O
thereby	O
driving	O
prostate	B-Anatomy
tumorigenesis	O
independent	O
of	O
Y705	O
phosphorylation	O
.	O
Allergic	O
pulmonary	B-Anatomy
inflammation	O
promotes	O
the	O
recruitment	O
of	O
circulating	O
tumor	B-Anatomy
cells	I-Anatomy
to	O
the	O
lung	B-Anatomy
.	O
Allergen	O
-	O
induced	O
respiratory	B-Anatomy
inflammation	O
facilitates	O
and	O
/	O
or	O
elicits	O
the	O
extravasation	O
of	O
proinflammatory	B-Anatomy
leukocytes	I-Anatomy
by	O
well	O
-	O
understood	O
mechanisms	O
that	O
mediate	O
the	O
movement	O
of	O
multiple	O
cell	B-Anatomy
types	O
.	O
The	O
nonspecific	O
character	O
of	O
these	O
pathways	O
led	O
us	O
to	O
hypothesize	O
that	O
circulating	O
cancer	B-Anatomy
cells	I-Anatomy
use	O
similar	O
mechanisms	O
,	O
promoting	O
secondary	B-Anatomy
tumor	I-Anatomy
formation	O
at	O
distal	B-Anatomy
sites	I-Anatomy
.	O
To	O
test	O
this	O
hypothesis	O
,	O
the	O
frequency	O
of	O
metastasis	O
to	O
the	O
lung	B-Anatomy
as	O
a	O
function	O
of	O
allergic	O
pulmonary	B-Anatomy
inflammation	O
was	O
assessed	O
following	O
the	O
i	B-Anatomy
.	I-Anatomy
v	I-Anatomy
.	I-Anatomy
injection	O
of	O
B16	B-Anatomy
-	I-Anatomy
F10	I-Anatomy
melanoma	I-Anatomy
cells	I-Anatomy
in	O
mice	O
.	O
These	O
studies	O
showed	O
that	O
allergen	O
-	O
induced	O
pulmonary	B-Anatomy
inflammation	O
resulted	O
in	O
a	O
>	O
3	O
-	O
fold	O
increase	O
in	O
lung	B-Anatomy
metastases	I-Anatomy
.	O
This	O
increase	O
was	O
dependent	O
on	O
CD4	B-Anatomy
(	I-Anatomy
+	I-Anatomy
)	I-Anatomy
T	I-Anatomy
-	I-Anatomy
cell	I-Anatomy
activities	O
;	O
however	O
,	O
it	O
occurred	O
independent	O
of	O
the	O
induced	O
eosinophilia	O
associated	O
with	O
allergen	O
provocation	O
.	O
Interventional	O
strategies	O
showed	O
that	O
existing	O
therapeutic	O
modalities	O
for	O
asthma	O
,	O
such	O
as	O
inhaled	O
corticosteroids	O
,	O
were	O
sufficient	O
to	O
block	O
the	O
enhanced	O
pulmonary	B-Anatomy
recruitment	O
of	O
cancer	B-Anatomy
cells	I-Anatomy
from	O
circulation	O
.	O
Additional	O
mechanistic	O
studies	O
further	O
suggested	O
that	O
the	O
ability	O
of	O
circulating	O
cancer	B-Anatomy
cells	I-Anatomy
to	O
extravasate	O
to	O
surrounding	O
lung	B-Anatomy
tissues	I-Anatomy
was	O
linked	O
to	O
the	O
activation	O
of	O
the	O
vascular	B-Anatomy
endothelium	I-Anatomy
via	O
one	O
or	O
more	O
Galpha	O
(	O
i	O
)	O
-	O
coupled	O
receptors	O
.	O
Interestingly	O
,	O
a	O
survey	O
of	O
a	O
clinical	O
breast	B-Anatomy
cancer	I-Anatomy
surgical	O
database	O
showed	O
that	O
the	O
incidence	O
of	O
asthma	O
was	O
higher	O
among	O
patients	O
with	O
lung	B-Anatomy
metastases	I-Anatomy
.	O
Thus	O
,	O
our	O
data	O
show	O
that	O
allergic	O
respiratory	B-Anatomy
inflammation	O
may	O
represent	O
a	O
risk	O
factor	O
for	O
the	O
development	O
of	O
lung	B-Anatomy
metastases	I-Anatomy
and	O
suggest	O
that	O
amelioration	O
of	O
the	O
pulmonary	B-Anatomy
inflammation	O
associated	O
with	O
asthma	O
will	O
have	O
a	O
direct	O
and	O
immediate	O
benefit	O
to	O
the	O
7	O
%	O
to	O
8	O
%	O
of	O
breast	B-Anatomy
cancer	I-Anatomy
patients	O
with	O
this	O
lung	B-Anatomy
disease	O
.	O
Inhibition	O
of	O
energy	O
-	O
producing	O
pathways	O
of	O
HepG2	B-Anatomy
cells	I-Anatomy
by	O
3	O
-	O
bromopyruvate	O
.	O
3	O
-	O
BrPA	O
(	O
3	O
-	O
bromopyruvate	O
)	O
is	O
an	O
alkylating	O
agent	O
with	O
anti	O
-	O
tumoral	B-Anatomy
activity	O
on	O
hepatocellular	B-Anatomy
carcinoma	I-Anatomy
.	O
This	O
compound	O
inhibits	O
cellular	B-Anatomy
ATP	O
production	O
owing	O
to	O
its	O
action	O
on	O
glycolysis	O
and	O
oxidative	O
phosphorylation	O
;	O
however	O
,	O
the	O
specific	O
metabolic	O
steps	O
and	O
mechanisms	O
of	O
3	O
-	O
BrPA	O
action	O
in	O
human	O
hepatocellular	B-Anatomy
carcinomas	I-Anatomy
,	O
particularly	O
its	O
effects	O
on	O
mitochondrial	B-Anatomy
energetics	O
,	O
are	O
poorly	O
understood	O
.	O
In	O
the	O
present	O
study	O
it	O
was	O
found	O
that	O
incubation	O
of	O
HepG2	B-Anatomy
cells	I-Anatomy
with	O
a	O
low	O
concentration	O
of	O
3	O
-	O
BrPA	O
for	O
a	O
short	O
period	O
(	O
150	O
microM	O
for	O
30	O
min	O
)	O
significantly	O
affected	O
both	O
glycolysis	O
and	O
mitochondrial	B-Anatomy
respiratory	O
functions	O
.	O
The	O
activity	O
of	O
mitochondrial	B-Anatomy
hexokinase	O
was	O
not	O
inhibited	O
by	O
150	O
microM	O
3	O
-	O
BrPA	O
,	O
but	O
this	O
concentration	O
caused	O
more	O
than	O
70	O
%	O
inhibition	O
of	O
GAPDH	O
(	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
)	O
and	O
3	O
-	O
phosphoglycerate	O
kinase	O
activities	O
.	O
Additionally	O
,	O
3	O
-	O
BrPA	O
treatment	O
significantly	O
impaired	O
lactate	O
production	O
by	O
HepG2	B-Anatomy
cells	I-Anatomy
,	O
even	O
when	O
glucose	O
was	O
withdrawn	O
from	O
the	O
incubation	O
medium	O
.	O
Oxygen	O
consumption	O
of	O
HepG2	B-Anatomy
cells	I-Anatomy
supported	O
by	O
either	O
pyruvate	O
/	O
malate	O
or	O
succinate	O
was	O
inhibited	O
when	O
cells	B-Anatomy
were	O
pre	O
-	O
incubated	O
with	O
3	O
-	O
BrPA	O
in	O
glucose	O
-	O
free	O
medium	O
.	O
On	O
the	O
other	O
hand	O
,	O
when	O
cells	B-Anatomy
were	O
pre	O
-	O
incubated	O
in	O
glucose	O
-	O
supplemented	O
medium	O
,	O
oxygen	O
consumption	O
was	O
affected	O
only	O
when	O
succinate	O
was	O
used	O
as	O
the	O
oxidizable	O
substrate	O
.	O
An	O
increase	O
in	O
oligomycin	O
-	O
independent	O
respiration	O
was	O
observed	O
in	O
HepG2	B-Anatomy
cells	I-Anatomy
treated	O
with	O
3	O
-	O
BrPA	O
only	O
when	O
incubated	O
in	O
glucose	O
-	O
supplemented	O
medium	O
,	O
indicating	O
that	O
3	O
-	O
BrPA	O
induces	O
mitochondrial	B-Anatomy
proton	O
leakage	O
as	O
well	O
as	O
blocking	O
the	O
electron	O
transport	O
system	O
.	O
The	O
activity	O
of	O
succinate	O
dehydrogenase	O
was	O
inhibited	O
by	O
70	O
%	O
by	O
3	O
-	O
BrPA	O
treatment	O
.	O
These	O
results	O
suggest	O
that	O
the	O
combined	O
action	O
of	O
3	O
-	O
BrPA	O
on	O
succinate	O
dehydrogenase	O
and	O
on	O
glycolysis	O
,	O
inhibiting	O
steps	O
downstream	O
of	O
the	O
phosphorylation	O
of	O
glucose	O
,	O
play	O
an	O
important	O
role	O
in	O
HepG2	B-Anatomy
cell	I-Anatomy
death	O
.	O
[	O
Retinochoroidopathy	O
after	O
intravitreal	O
anti	O
-	O
VEGF	O
treatment	O
]	O
A	O
74	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
persistent	O
metamorphopsias	O
of	O
the	O
right	B-Anatomy
eye	I-Anatomy
2	O
weeks	O
after	O
intravitreal	O
injection	O
of	O
bevacizumab	O
to	O
treat	O
choroidal	B-Anatomy
neovascularization	O
due	O
to	O
exudative	O
age	O
-	O
related	O
macular	B-Anatomy
degeneration	O
.	O
The	O
diagnosis	O
reached	O
was	O
retinochoroiditis	O
as	O
an	O
occult	O
manifestation	O
of	O
sarcoidosis	O
,	O
possibly	O
resulting	O
from	O
an	O
intravitreal	O
injection	O
of	O
bevacizumab	O
.	O
The	O
patient	O
received	O
a	O
prescription	O
for	O
100	O
mg	O
Ultralan	O
to	O
be	O
taken	O
daily	O
for	O
3	O
days	O
and	O
then	O
tapered	O
in	O
3	O
day	O
steps	O
.	O
During	O
the	O
further	O
course	O
no	O
deterioration	O
of	O
the	O
condition	O
was	O
observed	O
.	O
The	O
detection	O
of	O
macrosomia	O
at	O
a	O
teaching	O
hospital	O
.	O
We	O
sought	O
to	O
determine	O
the	O
detection	O
(	O
clinical	O
or	O
sonographic	O
)	O
rate	O
of	O
macrosomic	O
newborns	O
(	O
at	O
least	O
4000	O
g	O
)	O
and	O
the	O
peripartum	O
factors	O
among	O
those	O
who	O
were	O
or	O
were	O
not	O
identified	O
accurately	O
.	O
We	O
retrospectively	O
reviewed	O
all	O
deliveries	O
over	O
1	O
year	O
and	O
all	O
maternal	O
and	O
neonatal	O
charts	O
of	O
macrosomic	O
newborns	O
delivered	O
during	O
that	O
year	O
.	O
Odds	O
ratio	O
(	O
ORs	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
calculated	O
.	O
Over	O
a	O
12	O
-	O
month	O
period	O
,	O
the	O
rate	O
of	O
macrosomia	O
was	O
10	O
%	O
(	O
421	O
/	O
4194	O
)	O
and	O
of	O
those	O
,	O
only	O
11	O
%	O
(	O
95	O
%	O
CI	O
8	O
to	O
14	O
%	O
)	O
were	O
suspected	O
clinically	O
or	O
sonographically	O
.	O
None	O
of	O
the	O
newborns	O
weighing	O
4500	O
g	O
or	O
more	O
were	O
recognized	O
before	O
birth	O
(	O
0	O
/	O
57	O
;	O
95	O
%	O
CI	O
0	O
to	O
6	O
%	O
)	O
.	O
The	O
rate	O
of	O
cesarean	O
delivery	O
was	O
significantly	O
higher	O
among	O
newborns	O
correctly	O
identified	O
as	O
macrosomic	O
(	O
58	O
%	O
)	O
versus	O
those	O
missed	O
(	O
36	O
%	O
;	O
OR	O
2	O
.	O
76	O
,	O
95	O
%	O
CI	O
1	O
.	O
46	O
,	O
5	O
.	O
16	O
)	O
.	O
The	O
incidence	O
of	O
newborns	O
weighing	O
in	O
excess	O
of	O
4000	O
g	O
is	O
10	O
%	O
,	O
and	O
approximately	O
90	O
%	O
of	O
these	O
macrosomic	O
newborns	O
were	O
unsuspected	O
before	O
birth	O
.	O
Silencing	O
of	O
directional	O
migration	O
in	O
roundabout4	B-Anatomy
knockdown	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
BACKGROUND	O
:	O
Roundabouts	O
are	O
axon	O
guidance	O
molecules	O
that	O
have	O
recently	O
been	O
identified	O
to	O
play	O
a	O
role	O
in	O
vascular	B-Anatomy
guidance	O
as	O
well	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
gene	O
knockdown	O
analysis	O
of	O
endothelial	B-Anatomy
Robos	O
,	O
in	O
particular	O
roundabout	O
4	O
(	O
robo4	O
)	O
,	O
the	O
predominant	O
Robo	O
in	O
endothelial	B-Anatomy
cells	I-Anatomy
using	O
small	O
interfering	O
RNA	O
technology	O
in	O
vitro	O
.	O
RESULTS	O
:	O
Robo1	B-Anatomy
and	O
Robo4	B-Anatomy
knockdown	I-Anatomy
cells	I-Anatomy
display	O
distinct	O
activity	O
in	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
assay	O
.	O
The	O
knockdown	O
of	O
robo4	O
abrogated	O
the	O
chemotactic	O
response	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
to	O
serum	B-Anatomy
but	O
enhanced	O
a	O
chemokinetic	O
response	O
to	O
Slit2	O
,	O
while	O
robo1	B-Anatomy
knockdown	I-Anatomy
cells	I-Anatomy
do	O
not	O
display	O
chemotactic	O
response	O
to	O
serum	B-Anatomy
or	O
VEGF	O
.	O
Robo4	B-Anatomy
knockdown	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
unexpectedly	O
show	O
up	O
regulation	O
of	O
Rho	O
GTPases	O
.	O
Zebrafish	O
Robo4	O
rescues	O
both	O
Rho	O
GTPase	O
homeostasis	O
and	O
serum	B-Anatomy
reduced	O
chemotaxis	O
in	O
robo4	B-Anatomy
knockdown	I-Anatomy
cells	I-Anatomy
.	O
Robo1	O
and	O
Robo4	O
interact	O
and	O
share	O
molecules	O
such	O
as	O
Slit2	O
,	O
Mena	O
and	O
Vilse	O
,	O
a	O
Cdc42	O
-	O
GAP	O
.	O
In	O
addition	O
,	O
this	O
study	O
mechanistically	O
implicates	O
IRSp53	O
in	O
the	O
signaling	O
nexus	O
between	O
activated	O
Cdc42	O
and	O
Mena	O
,	O
both	O
of	O
which	O
have	O
previously	O
been	O
shown	O
to	O
be	O
involved	O
with	O
Robo4	O
signaling	O
in	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
CONCLUSION	O
:	O
This	O
study	O
identifies	O
specific	O
components	O
of	O
the	O
Robo	O
signaling	O
apparatus	O
that	O
work	O
together	O
to	O
guide	O
directional	O
migration	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
p53	O
hot	O
-	O
spot	O
mutants	O
increase	O
tumor	B-Anatomy
vascularization	O
via	O
ROS	O
-	O
mediated	O
activation	O
of	O
the	O
HIF1	O
/	O
VEGF	O
-	O
A	O
pathway	O
.	O
The	O
function	O
of	O
p53	O
tumor	B-Anatomy
suppressor	O
is	O
often	O
altered	O
in	O
various	O
human	O
tumors	B-Anatomy
predominantly	O
through	O
missense	O
-	O
mutations	O
resulting	O
in	O
accumulation	O
of	O
mutant	O
proteins	O
.	O
We	O
revealed	O
that	O
expression	O
of	O
p53	O
proteins	O
with	O
amino	O
-	O
acid	O
substitutions	O
at	O
codons	O
175	O
(	O
R175H	O
)	O
,	O
248	O
(	O
R248W	O
)	O
,	O
and	O
273	O
(	O
R273H	O
)	O
,	O
representing	O
the	O
hot	O
-	O
spots	O
of	O
mutations	O
in	O
various	O
human	O
tumors	B-Anatomy
,	O
increased	O
the	O
number	O
of	O
vessels	B-Anatomy
in	O
HCT116	B-Anatomy
human	I-Anatomy
colon	I-Anatomy
carcinoma	I-Anatomy
xenografts	I-Anatomy
and	O
,	O
as	O
a	O
result	O
,	O
accelerated	O
their	O
growth	O
.	O
Stimulation	O
of	O
tumor	B-Anatomy
angiogenesis	O
was	O
connected	O
with	O
about	O
2	O
-	O
fold	O
increase	O
in	O
intracellular	B-Anatomy
level	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O
Antioxidant	O
N	O
-	O
acetyl	O
-	O
l	O
-	O
aspartate	O
(	O
NAC	O
)	O
decreased	O
vessels	B-Anatomy
number	O
in	O
tumors	B-Anatomy
formed	O
by	O
cells	B-Anatomy
with	O
inactivated	O
p53	O
and	O
inhibited	O
their	O
growth	O
.	O
Effect	O
of	O
ROS	O
on	O
angiogenesis	O
in	O
tumors	B-Anatomy
expressing	O
hot	O
-	O
spot	O
p53	O
mutants	O
was	O
correlated	O
with	O
their	O
ability	O
to	O
increase	O
a	O
content	O
of	O
HIF1	O
transcriptional	O
factor	O
responsible	O
for	O
up	O
-	O
regulation	O
of	O
VEGF	O
-	O
A	O
mRNAs	O
.	O
The	O
Akt	O
/	O
mTOR	O
pathway	O
assures	O
the	O
synthesis	O
of	O
HIF	O
-	O
1alpha	O
protein	O
in	O
a	O
glucose	O
-	O
and	O
reoxygenation	O
-	O
dependent	O
manner	O
in	O
irradiated	O
tumors	B-Anatomy
.	O
Transcriptional	O
activity	O
of	O
HIF	O
-	O
1	O
(	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
)	O
has	O
been	O
reported	O
to	O
be	O
up	O
-	O
regulated	O
in	O
solid	B-Anatomy
tumors	I-Anatomy
after	O
ionizing	O
radiation	O
;	O
however	O
,	O
the	O
molecular	O
mechanism	O
underlying	O
the	O
response	O
remains	O
to	O
be	O
elucidated	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
performed	O
a	O
series	O
of	O
molecular	O
imaging	O
experiments	O
using	O
a	O
HIF	O
-	O
1	O
-	O
dependent	O
reporter	O
gene	O
,	O
5HREp	O
-	O
ODD	O
-	O
luc	O
,	O
and	O
found	O
an	O
essential	O
role	O
of	O
the	O
Akt	O
/	O
mTOR	O
pathway	O
.	O
Hypoxic	O
tumor	B-Anatomy
cells	I-Anatomy
distant	O
from	O
blood	B-Anatomy
vessels	I-Anatomy
were	O
dramatically	O
reoxygenated	O
at	O
24	O
h	O
postirradiation	O
,	O
and	O
HIF	O
-	O
1	O
activity	O
increased	O
as	O
HIF	O
-	O
1alpha	O
accumulated	O
in	O
the	O
reoxygenated	O
regions	O
.	O
The	O
accumulation	O
was	O
inhibited	O
with	O
a	O
nonmetabolizable	O
glucose	O
analog	O
,	O
2	O
-	O
deoxy	O
-	O
d	O
-	O
glucose	O
,	O
through	O
the	O
suppression	O
of	O
radiation	O
-	O
induced	O
phosphorylation	O
of	O
Akt	O
in	O
the	O
reoxygenated	O
regions	O
.	O
Akt	O
knockdown	O
and	O
an	O
mTOR	O
inhibitor	O
revealed	O
the	O
importance	O
of	O
the	O
Akt	O
/	O
mTOR	O
pathway	O
in	O
the	O
postirradiation	O
accumulation	O
of	O
HIF	O
-	O
1alpha	O
.	O
In	O
vitro	O
experiments	O
confirmed	O
that	O
an	O
increase	O
in	O
glucose	O
availability	O
induced	O
Akt	O
phosphorylation	O
under	O
reoxygenated	O
conditions	O
and	O
consequently	O
up	O
-	O
regulated	O
HIF	O
-	O
1alpha	O
translation	O
.	O
Moreover	O
,	O
both	O
the	O
accelerated	O
translation	O
and	O
the	O
previously	O
reported	O
reactive	O
oxygen	O
species	O
-	O
mediated	O
stabilization	O
of	O
HIF	O
-	O
1alpha	O
protein	O
were	O
essential	O
to	O
the	O
activation	O
of	O
HIF	O
-	O
1	O
.	O
All	O
of	O
these	O
results	O
indicate	O
that	O
Akt	O
/	O
mTOR	O
-	O
dependent	O
translation	O
of	O
HIF	O
-	O
1alpha	O
plays	O
a	O
critical	O
role	O
in	O
the	O
postirradiation	O
up	O
-	O
regulation	O
of	O
intratumoral	B-Anatomy
HIF	O
-	O
1	O
activity	O
in	O
response	O
to	O
radiation	O
-	O
induced	O
alterations	O
of	O
glucose	O
and	O
oxygen	O
availability	O
in	O
a	O
solid	B-Anatomy
tumor	I-Anatomy
.	O
Estradiol	O
increases	O
IL	O
-	O
8	O
secretion	O
of	O
normal	O
human	O
breast	B-Anatomy
tissue	I-Anatomy
and	O
breast	B-Anatomy
cancer	I-Anatomy
in	O
vivo	O
.	O
IL	O
-	O
8	O
or	O
CXCL8	O
has	O
been	O
associated	O
with	O
tumor	B-Anatomy
angiogenesis	O
,	O
metastasis	O
,	O
and	O
poor	O
prognosis	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
.	O
Estrogen	O
is	O
crucial	O
in	O
breast	B-Anatomy
carcinogenesis	O
and	O
tumor	B-Anatomy
progression	O
.	O
Whether	O
sex	O
steroids	O
affect	O
IL	O
-	O
8	O
secretion	O
of	O
normal	O
breast	B-Anatomy
tissue	I-Anatomy
or	O
breast	B-Anatomy
cancer	I-Anatomy
is	O
not	O
known	O
.	O
Several	O
cell	B-Anatomy
types	O
in	O
a	O
tissue	B-Anatomy
secrete	O
IL	O
-	O
8	O
.	O
Hence	O
,	O
regulatory	O
mechanisms	O
of	O
IL	O
-	O
8	O
need	O
to	O
be	O
investigated	O
in	O
whole	O
tissue	B-Anatomy
.	O
We	O
used	O
microdialysis	O
to	O
sample	O
IL	O
-	O
8	O
in	O
normal	O
human	O
breast	B-Anatomy
tissue	I-Anatomy
in	O
situ	O
in	O
pre	O
-	O
and	O
postmenopausal	O
women	O
,	O
preoperatively	O
in	O
breast	B-Anatomy
cancers	I-Anatomy
of	O
women	O
,	O
and	O
in	O
experimental	O
breast	B-Anatomy
cancer	I-Anatomy
in	O
mice	O
.	O
We	O
found	O
a	O
significant	O
positive	O
correlation	O
between	O
IL	O
-	O
8	O
and	O
estradiol	O
in	O
normal	O
breast	B-Anatomy
tissue	I-Anatomy
and	O
hormone	B-Anatomy
-	I-Anatomy
dependent	I-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
in	O
vivo	O
.	O
Ex	O
vivo	O
,	O
estradiol	O
exposure	O
increased	O
the	O
IL	O
-	O
8	O
secretion	O
of	O
normal	O
whole	O
breast	B-Anatomy
tissue	I-Anatomy
in	O
culture	O
.	O
In	O
experimental	O
breast	B-Anatomy
cancer	I-Anatomy
,	O
estradiol	O
increased	O
IL	O
-	O
8	O
whereas	O
the	O
anti	O
-	O
estrogen	O
tamoxifen	O
inhibited	O
the	O
secretion	O
of	O
IL	O
-	O
8	O
both	O
in	O
vitro	O
and	O
extracellularly	B-Anatomy
in	O
vivo	O
in	O
tumors	B-Anatomy
of	O
nude	O
mice	O
.	O
An	O
anti	O
-	O
IL	O
-	O
8	O
Ab	O
inhibited	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
induced	O
by	O
cancer	B-Anatomy
cell	I-Anatomy
produced	O
IL	O
-	O
8	O
and	O
tumors	B-Anatomy
with	O
low	O
IL	O
-	O
8	O
levels	O
exhibited	O
decreased	O
angiogenesis	O
.	O
Our	O
results	O
strongly	O
suggest	O
that	O
estradiol	O
has	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
IL	O
-	O
8	O
in	O
normal	O
human	O
breast	B-Anatomy
tissue	I-Anatomy
and	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
.	O
IL	O
-	O
8	O
may	O
present	O
a	O
novel	O
therapeutic	O
target	O
for	O
estrogen	O
driven	O
breast	B-Anatomy
carcinogenesis	O
and	O
tumor	B-Anatomy
progression	O
.	O
Chemokine	O
receptor	O
CXCR4	O
expression	O
,	O
function	O
,	O
and	O
clinical	O
implications	O
in	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
The	O
chemokine	O
receptor	O
CXCR4	O
is	O
associated	O
with	O
the	O
biological	O
behavior	O
of	O
cancer	B-Anatomy
,	O
but	O
few	O
studies	O
have	O
addressed	O
the	O
expression	O
and	O
function	O
of	O
CXCR4	O
in	O
human	O
gastric	B-Anatomy
cancer	I-Anatomy
and	O
its	O
impact	O
on	O
disease	O
prognosis	O
.	O
We	O
studied	O
the	O
expression	O
of	O
CXCR4	O
using	O
RT	O
-	O
PCR	O
,	O
Western	O
blotting	O
,	O
flow	O
cytometry	O
,	O
and	O
confocal	O
microscopy	O
in	O
five	O
gastric	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
We	O
also	O
examined	O
cell	B-Anatomy
proliferation	O
,	O
migration	O
,	O
and	O
anti	O
-	O
apoptotic	O
activity	O
in	O
response	O
to	O
stromal	O
cell	O
-	O
derived	O
factor	O
(	O
SDF	O
)	O
-	O
1alpha	O
and	O
evaluated	O
SDF	O
-	O
1alpha	O
/	O
CXCR4	O
signaling	O
pathways	O
.	O
Furthermore	O
,	O
we	O
investigated	O
the	O
correlation	O
between	O
CXCR4	O
expression	O
and	O
the	O
clinical	O
features	O
of	O
221	O
gastric	B-Anatomy
cancer	I-Anatomy
tissue	I-Anatomy
samples	I-Anatomy
.	O
CXCR4	O
transcripts	O
and	O
proteins	O
were	O
detectable	O
in	O
all	O
five	O
gastric	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
However	O
,	O
MKN	B-Anatomy
-	I-Anatomy
28	I-Anatomy
,	O
MKN	B-Anatomy
-	I-Anatomy
45	I-Anatomy
,	O
MKN	B-Anatomy
-	I-Anatomy
74	I-Anatomy
,	O
and	O
SNU16	B-Anatomy
cells	I-Anatomy
did	O
not	O
express	O
membrane	B-Anatomy
CXCR4	O
.	O
In	O
contrast	O
,	O
KATO	B-Anatomy
III	I-Anatomy
cells	I-Anatomy
expressed	O
membrane	B-Anatomy
CXCR4	O
.	O
In	O
these	O
cells	B-Anatomy
,	O
SDF	O
-	O
1alpha	O
-	O
induced	O
migration	O
was	O
observed	O
and	O
was	O
blocked	O
by	O
AMD3100	O
,	O
a	O
specific	O
inhibitor	O
of	O
CXCR4	O
.	O
SDF	O
-	O
1alpha	O
induced	O
rapid	O
phosphorylation	O
of	O
Erk1	O
/	O
2	O
MAPK	O
but	O
did	O
not	O
promote	O
phosphorylation	O
of	O
Stat3	O
or	O
Akt	O
.	O
Gastric	B-Anatomy
cancer	I-Anatomy
tissue	I-Anatomy
samples	I-Anatomy
expressed	O
CXCR4	O
with	O
variable	O
intensities	O
.	O
Strong	O
CXCR4	O
expression	O
was	O
significantly	O
associated	O
with	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
(	O
P	O
=	O
0	O
.	O
028	O
)	O
and	O
higher	O
stages	O
III	O
/	O
IV	O
(	O
P	O
=	O
0	O
.	O
047	O
)	O
,	O
and	O
further	O
tended	O
to	O
be	O
correlated	O
with	O
a	O
reduced	O
5	O
-	O
year	O
survival	O
rate	O
(	O
42	O
.	O
6	O
%	O
vs	O
.	O
53	O
.	O
9	O
%	O
;	O
P	O
=	O
0	O
.	O
1	O
)	O
.	O
In	O
conclusion	O
,	O
CXCR4	O
expression	O
is	O
associated	O
with	O
gastric	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
migration	O
in	O
vitro	O
,	O
and	O
strong	O
expression	O
of	O
CXCR4	O
by	O
gastric	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
is	O
significantly	O
associated	O
with	O
lymphatic	B-Anatomy
metastasis	O
in	O
patients	O
with	O
gastric	B-Anatomy
cancer	I-Anatomy
,	O
suggesting	O
that	O
CXCR4	O
plays	O
an	O
important	O
role	O
during	O
gastric	B-Anatomy
cancer	I-Anatomy
progression	O
.	O
Effect	O
of	O
estrogen	O
and	O
progesterone	O
on	O
macrophage	B-Anatomy
activation	O
during	O
wound	B-Anatomy
healing	O
.	O
Age	O
-	O
related	O
impaired	O
wound	B-Anatomy
healing	O
leads	O
to	O
substantial	O
morbidity	O
and	O
mortality	O
along	O
with	O
a	O
large	O
financial	O
burden	O
to	O
health	O
services	O
.	O
There	O
is	O
accumulating	O
evidence	O
that	O
the	O
tissue	B-Anatomy
damage	O
associated	O
with	O
chronic	O
wounds	B-Anatomy
is	O
initiated	O
and	O
propagated	O
by	O
an	O
inappropriately	O
excessive	O
inflammatory	O
response	O
.	O
Research	O
on	O
age	O
-	O
related	O
impaired	O
wound	B-Anatomy
healing	O
suggests	O
that	O
the	O
decline	O
in	O
sex	O
steroid	O
hormones	O
with	O
age	O
may	O
have	O
a	O
substantial	O
influence	O
on	O
the	O
inflammatory	O
response	O
in	O
vivo	O
.	O
Topical	O
and	O
systemic	O
estrogen	O
treatments	O
have	O
shown	O
an	O
increased	O
rate	O
of	O
healing	O
by	O
reducing	O
inflammation	O
,	O
however	O
the	O
underlying	O
mechanisms	O
are	O
little	O
understood	O
.	O
In	O
vitro	O
studies	O
also	O
suggest	O
progesterone	O
may	O
play	O
a	O
role	O
in	O
modulating	O
inflammation	O
.	O
Macrophages	B-Anatomy
are	O
essential	O
mediators	O
of	O
inflammation	O
and	O
wound	B-Anatomy
healing	O
.	O
Macrophages	B-Anatomy
can	O
be	O
activated	O
in	O
a	O
classical	O
or	O
alternative	O
manner	O
in	O
parallel	O
with	O
the	O
T	B-Anatomy
(	I-Anatomy
H	I-Anatomy
)	I-Anatomy
1	I-Anatomy
/	O
T	B-Anatomy
(	I-Anatomy
H	I-Anatomy
)	I-Anatomy
2	I-Anatomy
dichotomy	O
,	O
respectively	O
.	O
Using	O
a	O
murine	O
incisional	O
wound	B-Anatomy
healing	O
model	O
this	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
roles	O
of	O
estrogen	O
and	O
progesterone	O
on	O
macrophage	B-Anatomy
activation	O
during	O
the	O
wound	B-Anatomy
healing	O
response	O
.	O
Our	O
findings	O
suggest	O
with	O
a	O
reduction	O
of	O
steroid	O
hormones	O
following	O
ovariectomy	O
,	O
alternatively	O
activated	O
macrophage	B-Anatomy
markers	O
(	O
Fizz1	O
and	O
Ym1	O
)	O
were	O
reduced	O
,	O
with	O
this	O
effect	O
being	O
reversed	O
with	O
the	O
administration	O
of	O
estrogen	O
or	O
progesterone	O
;	O
suggesting	O
that	O
with	O
the	O
reduction	O
of	O
steroid	O
hormones	O
macrophages	B-Anatomy
are	O
activated	O
in	O
a	O
classical	O
manner	O
,	O
promoting	O
inflammation	O
,	O
whereas	O
estrogen	O
or	O
progesterone	O
are	O
contributing	O
toward	O
macrophage	B-Anatomy
activation	O
in	O
an	O
alternative	O
manner	O
,	O
driving	O
wound	B-Anatomy
repair	O
,	O
angiogenesis	O
,	O
and	O
remodeling	O
.	O
Heart	B-Anatomy
sound	O
and	O
electrocardiogram	O
recording	O
devices	O
for	O
telemedicine	O
environments	O
.	O
There	O
is	O
currently	O
a	O
worldwide	O
trend	O
to	O
bring	O
healthcare	O
services	O
as	O
close	O
as	O
possible	O
to	O
the	O
patient	O
,	O
either	O
through	O
home	O
healthcare	O
systems	O
,	O
or	O
telemedicine	O
.	O
There	O
is	O
thus	O
a	O
general	O
need	O
for	O
equipment	O
that	O
can	O
capture	O
patient	O
data	O
electronically	O
for	O
automated	O
review	O
or	O
analysis	O
by	O
a	O
medical	O
practitioner	O
.	O
This	O
paper	O
presents	O
prototype	O
systems	O
that	O
were	O
developed	O
with	O
the	O
ultimate	O
aim	O
for	O
use	O
in	O
telemedicine	O
settings	O
in	O
rural	O
Africa	O
.	O
These	O
devices	O
can	O
be	O
used	O
to	O
electronically	O
capture	O
data	O
on	O
patients	O
from	O
several	O
sensors	O
in	O
a	O
quick	O
an	O
easy	O
manner	O
.	O
In	O
our	O
presented	O
cases	O
we	O
focus	O
on	O
cardiovascular	B-Anatomy
information	O
.	O
One	O
of	O
the	O
main	O
advantages	O
of	O
the	O
proposed	O
systems	O
is	O
that	O
the	O
data	O
are	O
captured	O
simultaneously	O
from	O
multiple	O
sensors	O
.	O
The	O
data	O
can	O
be	O
stored	O
and	O
sent	O
electronically	O
for	O
review	O
and	O
analysis	O
,	O
and	O
knowledge	O
-	O
based	O
systems	O
or	O
neural	O
network	O
type	O
models	O
can	O
be	O
used	O
in	O
the	O
future	O
for	O
semi	O
-	O
autonomous	O
screening	O
of	O
the	O
recordings	O
,	O
before	O
a	O
patient	O
is	O
referred	O
to	O
a	O
specialist	O
.	O
Effect	O
of	O
platelet	B-Anatomy
-	I-Anatomy
rich	I-Anatomy
plasma	I-Anatomy
and	O
fibrin	O
glue	O
on	O
healing	O
of	O
critical	O
-	O
size	O
calvarial	B-Anatomy
bone	I-Anatomy
defects	O
.	O
Despite	O
the	O
insufficient	O
number	O
of	O
experimental	O
studies	O
,	O
platelet	B-Anatomy
-	I-Anatomy
rich	I-Anatomy
plasma	I-Anatomy
(	O
PRP	B-Anatomy
)	O
including	O
high	O
amounts	O
of	O
growth	O
factors	O
is	O
introduced	O
to	O
clinical	O
use	O
rapidly	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
PRP	B-Anatomy
and	O
platelet	B-Anatomy
-	I-Anatomy
poor	I-Anatomy
plasma	I-Anatomy
(	O
PPP	B-Anatomy
)	O
on	O
healing	O
of	O
critical	O
-	O
size	O
bone	B-Anatomy
defects	O
.	O
Bilateral	O
full	O
-	O
thickness	O
,	O
critical	O
-	O
size	O
bone	B-Anatomy
defects	O
were	O
created	O
in	O
the	O
parietal	B-Anatomy
bones	I-Anatomy
of	O
32	O
rabbits	O
,	O
which	O
had	O
been	O
studied	O
in	O
4	O
groups	O
.	O
Saline	O
,	O
thrombin	O
solution	O
,	O
PPP	B-Anatomy
,	O
and	O
PRP	B-Anatomy
were	O
applied	O
to	O
the	O
created	O
defects	O
before	O
closure	O
.	O
Radiologic	O
defect	O
area	O
measurement	O
results	O
at	O
0	O
,	O
4	O
,	O
and	O
16	O
weeks	O
were	O
compared	O
between	O
the	O
groups	O
.	O
In	O
addition	O
,	O
densities	O
of	O
the	O
newly	O
formed	O
bones	B-Anatomy
at	O
16th	O
week	O
were	O
studied	O
.	O
Histologic	O
parameters	O
(	O
primary	O
and	O
secondary	O
bone	B-Anatomy
trabecula	I-Anatomy
,	O
neovascularization	O
,	O
and	O
bone	B-Anatomy
marrow	I-Anatomy
and	O
connective	B-Anatomy
tissue	I-Anatomy
formation	O
)	O
were	O
compared	O
between	O
4	O
-	O
and	O
16	O
-	O
week	O
groups	O
.	O
More	O
rapid	O
decrease	O
in	O
defect	O
size	O
was	O
observed	O
in	O
groups	O
3	O
and	O
4	O
than	O
in	O
groups	O
1	O
and	O
2	O
,	O
both	O
in	O
the	O
4th	O
and	O
16th	O
weeks	O
.	O
Newly	O
formed	O
bone	B-Anatomy
densities	O
were	O
also	O
found	O
to	O
be	O
higher	O
in	O
these	O
2	O
groups	O
.	O
New	O
bone	B-Anatomy
formation	O
was	O
detected	O
to	O
be	O
more	O
rapid	O
considering	O
histologic	O
parameters	O
,	O
in	O
groups	O
3	O
and	O
4	O
at	O
4th	O
and	O
16th	O
weeks	O
.	O
Study	O
demonstrates	O
that	O
PRP	B-Anatomy
and	O
PPP	B-Anatomy
might	O
have	O
favorable	O
effects	O
on	O
bone	B-Anatomy
healing	O
.	O
Although	O
we	O
cannot	O
reveal	O
any	O
statistical	O
difference	O
between	O
these	O
2	O
substances	O
considering	O
osteoinductive	O
potential	O
,	O
PRP	B-Anatomy
group	O
has	O
demonstrated	O
superior	O
results	O
compared	O
with	O
fibrin	O
glue	O
group	O
.	O
Higher	O
platelet	B-Anatomy
concentrations	O
may	O
expose	O
beneficial	O
effects	O
of	O
PRP	B-Anatomy
.	O
Host	O
-	O
derived	O
angiopoietin	O
-	O
2	O
affects	O
early	O
stages	O
of	O
tumor	B-Anatomy
development	O
and	O
vessel	B-Anatomy
maturation	O
but	O
is	O
dispensable	O
for	O
later	O
stages	O
of	O
tumor	B-Anatomy
growth	O
.	O
The	O
angiopoietin	O
/	O
Tie2	O
system	O
has	O
been	O
identified	O
as	O
the	O
second	O
vascular	B-Anatomy
-	O
specific	O
receptor	O
tyrosine	O
kinase	O
system	O
controlling	O
vessel	B-Anatomy
assembly	O
,	O
maturation	O
,	O
and	O
quiescence	O
.	O
Angiopoietin	O
-	O
2	O
(	O
Ang	O
-	O
2	O
)	O
is	O
prominently	O
up	O
-	O
regulated	O
in	O
the	O
host	O
-	O
derived	O
vasculature	B-Anatomy
of	O
most	O
tumors	B-Anatomy
,	O
making	O
it	O
an	O
attractive	O
candidate	O
for	O
antiangiogenic	O
intervention	O
.	O
Yet	O
,	O
the	O
net	O
outcome	O
of	O
Ang	O
-	O
2	O
functions	O
on	O
tumor	B-Anatomy
angiogenesis	O
is	O
believed	O
to	O
be	O
contextual	O
depending	O
on	O
the	O
local	O
cytokine	O
milieu	O
.	O
Correspondingly	O
,	O
Ang	O
-	O
2	O
manipulatory	O
therapies	O
have	O
been	O
shown	O
to	O
exert	O
protumorigenic	O
as	O
well	O
as	O
antitumorigenic	O
effects	O
.	O
To	O
clarify	O
the	O
role	O
of	O
Ang	O
-	O
2	O
for	O
angiogenesis	O
and	O
tumor	B-Anatomy
growth	O
in	O
a	O
definite	O
genetic	O
experimental	O
setting	O
,	O
the	O
present	O
study	O
was	O
aimed	O
at	O
comparatively	O
studying	O
the	O
growth	O
of	O
different	O
tumors	B-Anatomy
in	O
wild	O
-	O
type	O
and	O
Ang	O
-	O
2	O
-	O
deficient	O
mice	O
.	O
Lewis	B-Anatomy
lung	I-Anatomy
carcinomas	I-Anatomy
,	O
MT	B-Anatomy
-	I-Anatomy
ret	I-Anatomy
melanomas	I-Anatomy
,	O
and	O
B16F10	B-Anatomy
melanomas	I-Anatomy
all	O
grew	O
slower	O
in	O
Ang	O
-	O
2	O
-	O
deficient	O
mice	O
.	O
Yet	O
,	O
tumor	B-Anatomy
growth	O
in	O
wild	O
-	O
type	O
and	O
Ang	O
-	O
2	O
-	O
deficient	O
mice	O
dissociated	O
during	O
early	O
stages	O
of	O
tumor	B-Anatomy
development	O
,	O
whereas	O
tumor	B-Anatomy
growth	O
rates	O
during	O
later	O
stages	O
of	O
primary	B-Anatomy
tumor	I-Anatomy
progression	O
were	O
similar	O
.	O
Analysis	O
of	O
the	O
intratumoral	B-Anatomy
vascular	I-Anatomy
architecture	I-Anatomy
revealed	O
no	O
major	O
differences	O
in	O
microvessel	B-Anatomy
density	O
and	O
perfusion	O
characteristics	O
.	O
However	O
,	O
diameters	O
of	O
intratumoral	B-Anatomy
microvessels	I-Anatomy
were	O
smaller	O
in	O
tumors	B-Anatomy
grown	O
in	O
Ang	O
-	O
2	O
-	O
deficient	O
mice	O
,	O
and	O
the	O
vasculature	B-Anatomy
had	O
an	O
altered	O
pattern	O
of	O
pericyte	B-Anatomy
recruitment	O
and	O
maturation	O
.	O
Ang	B-Anatomy
-	I-Anatomy
2	I-Anatomy
-	I-Anatomy
deficient	I-Anatomy
tumor	I-Anatomy
vessels	I-Anatomy
had	O
higher	O
pericyte	B-Anatomy
coverage	O
indices	O
.	O
Recruited	O
pericytes	B-Anatomy
were	O
desmin	O
and	O
NG2	O
positive	O
and	O
predominately	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
negative	O
,	O
indicative	O
of	O
a	O
more	O
mature	O
pericyte	B-Anatomy
phenotype	O
.	O
Collectively	O
,	O
the	O
experiments	O
define	O
the	O
role	O
of	O
Ang	O
-	O
2	O
during	O
tumor	B-Anatomy
angiogenesis	O
and	O
establish	O
a	O
better	O
rationale	O
for	O
combination	O
therapies	O
involving	O
Ang	O
-	O
2	O
manipulatory	O
therapies	O
.	O
Liposomal	B-Anatomy
honokiol	O
inhibits	O
VEGF	O
-	O
D	O
-	O
induced	O
lymphangiogenesis	O
and	O
metastasis	O
in	O
xenograft	B-Anatomy
tumor	I-Anatomy
model	O
.	O
Lymph	B-Anatomy
nodes	I-Anatomy
metastasis	O
of	O
tumor	B-Anatomy
could	O
be	O
a	O
crucial	O
early	O
step	O
in	O
the	O
metastatic	O
process	O
.	O
Induction	O
of	O
tumor	B-Anatomy
lymphangiogenesis	O
by	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
D	O
may	O
play	O
an	O
important	O
role	O
in	O
promoting	O
tumor	B-Anatomy
metastasis	O
to	O
regional	O
lymph	B-Anatomy
nodes	I-Anatomy
and	O
these	O
processes	O
can	O
be	O
inhibited	O
by	O
inactivation	O
of	O
the	O
VEGFR	O
-	O
3	O
signaling	O
pathway	O
.	O
Honokiol	O
has	O
been	O
reported	O
to	O
possess	O
potent	O
antiangiogenesis	O
and	O
antitumor	B-Anatomy
properties	O
in	O
several	O
cell	B-Anatomy
lines	I-Anatomy
and	O
xenograft	B-Anatomy
tumor	I-Anatomy
models	O
.	O
However	O
,	O
its	O
role	O
in	O
tumor	B-Anatomy
-	O
associated	O
lymphangiogenesis	O
and	O
lymphatic	B-Anatomy
metastasis	O
remains	O
unclear	O
.	O
Here	O
,	O
we	O
established	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
models	O
by	O
injecting	O
overexpressing	O
VEGF	O
-	O
D	O
Lewis	B-Anatomy
lung	I-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
into	O
C57BL	O
/	O
6	O
mice	O
to	O
explore	O
the	O
effect	O
of	O
honokiol	O
on	O
tumor	B-Anatomy
-	O
associated	O
lymphangiogenesis	O
and	O
related	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
.	O
The	O
underlying	O
mechanisms	O
were	O
systematically	O
investigated	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
In	O
in	O
vivo	O
study	O
,	O
liposomal	B-Anatomy
honokiol	O
significantly	O
inhibited	O
the	O
tumor	B-Anatomy
-	O
associated	O
lymphangiogenesis	O
and	O
metastasis	O
in	O
Lewis	B-Anatomy
lung	I-Anatomy
carcinoma	I-Anatomy
model	O
.	O
A	O
remarkable	O
delay	O
of	O
tumor	B-Anatomy
growth	O
and	O
prolonged	O
life	O
span	O
were	O
also	O
observed	O
.	O
In	O
in	O
vitro	O
study	O
,	O
honokiol	O
inhibited	O
VEGF	O
-	O
D	O
-	O
induced	O
survival	O
,	O
proliferation	O
and	O
tube	B-Anatomy
-	I-Anatomy
formation	O
of	O
both	O
human	B-Anatomy
umbilical	I-Anatomy
vein	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
(	O
HUVECs	B-Anatomy
)	O
and	O
lymphatic	B-Anatomy
vascular	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
(	O
HLECs	B-Anatomy
)	O
.	O
Western	O
blotting	O
analysis	O
showed	O
that	O
liposomal	B-Anatomy
honokiol	O
-	O
inhibited	O
Akt	O
and	O
MAPK	O
phosphorylation	O
in	O
2	O
endothelial	B-Anatomy
cells	I-Anatomy
,	O
and	O
downregulated	O
expressions	O
of	O
VEGFR	O
-	O
2	O
of	O
human	O
vascular	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
and	O
VEGFR	O
-	O
3	O
of	O
lymphatic	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
Thus	O
,	O
we	O
identified	O
for	O
the	O
first	O
time	O
that	O
honokiol	O
provided	O
therapeutic	O
benefit	O
not	O
only	O
by	O
direct	O
effects	O
on	O
tumor	B-Anatomy
cells	I-Anatomy
and	O
antiangiogenesis	O
but	O
also	O
by	O
inhibiting	O
lymphangiogenesis	O
and	O
metastasis	O
via	O
the	O
VEGFR	O
-	O
3	O
pathway	O
.	O
The	O
present	O
findings	O
may	O
be	O
of	O
importance	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
spread	O
of	O
cancer	B-Anatomy
via	O
the	O
lymphatics	B-Anatomy
and	O
explore	O
the	O
therapeutical	O
strategy	O
of	O
honokiol	O
on	O
antilymphangiogenesis	O
and	O
antimetastasis	O
.	O
Short	O
pigment	O
epithelial	O
-	O
derived	O
factor	O
-	O
derived	O
peptide	O
inhibits	O
angiogenesis	O
and	O
tumor	B-Anatomy
growth	O
.	O
PURPOSE	O
:	O
Pigment	O
epithelial	O
-	O
derived	O
factor	O
(	O
PEDF	O
)	O
is	O
a	O
potent	O
angiogenesis	O
inhibitor	O
with	O
multiple	O
other	O
functions	O
,	O
some	O
of	O
which	O
enhance	O
tumor	B-Anatomy
growth	O
.	O
Our	O
previous	O
studies	O
mapped	O
PEDF	O
antiangiogenic	O
and	O
prosurvival	O
activities	O
to	O
distinct	O
epitopes	O
.	O
This	O
study	O
was	O
aimed	O
to	O
determine	O
the	O
minimal	O
fragment	O
of	O
PEDF	O
,	O
which	O
maintains	O
antiangiogenic	O
and	O
antitumor	B-Anatomy
efficacy	O
.	O
EXPERIMENTAL	O
DESIGN	O
:	O
We	O
analyzed	O
antigenicity	O
,	O
hydrophilicity	O
,	O
and	O
charge	O
distribution	O
of	O
the	O
angioinhibitory	O
epitope	O
(	O
the	O
34	O
-	O
mer	O
)	O
and	O
designed	O
three	O
peptides	O
covering	O
its	O
COOH	O
terminus	O
,	O
P14	O
,	O
P18	O
,	O
and	O
P23	O
.	O
We	O
analyzed	O
their	O
ability	O
to	O
block	O
endothelial	B-Anatomy
cell	I-Anatomy
chemotaxis	O
and	O
induce	O
apoptosis	O
in	O
vitro	O
and	O
their	O
antiangiogenic	O
activity	O
in	O
vivo	O
.	O
The	O
selected	O
peptide	O
was	O
tested	O
for	O
the	O
antitumor	B-Anatomy
activity	O
against	O
mildly	O
aggressive	O
xenografted	O
prostate	B-Anatomy
carcinoma	I-Anatomy
and	O
highly	O
aggressive	O
renal	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
To	O
verify	O
that	O
P18	O
acts	O
in	O
the	O
same	O
manner	O
as	O
PEDF	O
,	O
we	O
used	O
immunohistochemistry	O
to	O
measure	O
PEDF	O
targets	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
,	O
and	O
CD95	O
ligand	O
expression	O
in	O
P18	O
-	O
treated	O
vasculature	B-Anatomy
.	O
RESULTS	O
:	O
P14	O
and	O
P18	O
blocked	O
endothelial	B-Anatomy
cell	I-Anatomy
chemotaxis	O
;	O
P18	O
and	O
P23	O
induced	O
apoptosis	O
.	O
P18	O
showed	O
the	O
highest	O
IC50	O
and	O
blocked	O
angiogenesis	O
in	O
vivo	O
:	O
P23	O
was	O
inactive	O
and	O
P14	O
was	O
proangiogenic	O
.	O
P18	O
increased	O
the	O
production	O
of	O
CD95	O
ligand	O
and	O
reduced	O
the	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
by	O
the	O
endothelial	B-Anatomy
cells	I-Anatomy
in	O
vivo	O
.	O
In	O
tumor	B-Anatomy
studies	O
,	O
P18	O
was	O
more	O
effective	O
in	O
blocking	O
the	O
angiogenesis	O
and	O
growth	O
of	O
the	O
prostate	B-Anatomy
cancer	I-Anatomy
than	O
parental	O
34	O
-	O
mer	O
;	O
in	O
the	O
renal	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
,	O
P18	O
strongly	O
decreased	O
angiogenesis	O
and	O
halted	O
the	O
progression	O
of	O
established	O
tumors	B-Anatomy
.	O
CONCLUSIONS	O
:	O
P18	O
is	O
a	O
novel	O
and	O
potent	O
antiangiogenic	O
biotherapeutic	O
agent	O
that	O
has	O
potential	O
to	O
be	O
developed	O
for	O
the	O
treatment	O
of	O
prostate	B-Anatomy
and	O
renal	B-Anatomy
cancer	I-Anatomy
.	O
An	O
introduction	O
to	O
evidence	O
-	O
based	O
practice	O
for	O
hand	B-Anatomy
surgeons	O
and	O
therapists	O
.	O
Evidence	O
-	O
based	O
practice	O
is	O
a	O
methodical	O
approach	O
to	O
clinical	O
practice	O
where	O
experience	O
,	O
best	O
research	O
evidence	O
,	O
and	O
patient	O
goals	O
and	O
values	O
are	O
integrated	O
to	O
make	O
optimal	O
decisions	O
when	O
making	O
a	O
diagnosis	O
,	O
selecting	O
a	O
diagnostic	O
test	O
,	O
picking	O
an	O
intervention	O
or	O
determining	O
prognosis	O
.	O
There	O
are	O
five	O
steps	O
in	O
this	O
process	O
.	O
Hand	B-Anatomy
surgeons	O
and	O
therapists	O
can	O
use	O
the	O
evidence	O
-	O
based	O
process	O
to	O
attain	O
optimal	O
management	O
of	O
individual	O
patients	O
,	O
manage	O
their	O
overall	O
practice	O
,	O
guide	O
the	O
ongoing	O
professional	O
development	O
,	O
and	O
deal	O
with	O
funding	O
and	O
policy	O
makers	O
.	O
Prolonged	O
control	O
of	O
patterned	O
biofilm	B-Anatomy
formation	O
by	O
bio	O
-	O
inert	O
surface	O
chemistry	O
.	O
A	O
bio	O
-	O
inert	O
surface	O
chemistry	O
was	O
developed	O
that	O
can	O
confine	O
biofilm	B-Anatomy
formation	O
in	O
designed	O
patterns	O
for	O
at	O
least	O
26	O
days	O
.	O
Women	O
'	O
s	O
attitudes	O
,	O
preferences	O
,	O
and	O
perceived	O
barriers	O
to	O
treatment	O
for	O
perinatal	O
depression	O
.	O
BACKGROUND	O
:	O
Perinatal	O
depression	O
is	O
associated	O
with	O
potential	O
negative	O
consequences	O
for	O
the	O
mother	O
and	O
infant	O
,	O
and	O
therefore	O
efforts	O
to	O
improve	O
treatment	O
access	O
and	O
efficacy	O
are	O
warranted	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
pregnant	O
women	O
'	O
s	O
preferences	O
and	O
attitudes	O
about	O
treatment	O
for	O
depression	O
,	O
and	O
perceived	O
potential	O
barriers	O
to	O
accessing	O
treatment	O
.	O
METHODS	O
:	O
Data	O
were	O
collected	O
by	O
means	O
of	O
a	O
questionnaire	O
from	O
a	O
convenience	O
sample	O
of	O
509	O
predominantly	O
well	O
-	O
educated	O
,	O
high	O
-	O
income	O
,	O
married	O
women	O
in	O
the	O
northeastern	O
United	O
States	O
during	O
the	O
last	O
trimester	O
of	O
pregnancy	O
.	O
Participants	O
were	O
queried	O
as	O
to	O
treatment	O
modalities	O
in	O
which	O
they	O
would	O
most	O
likely	O
participate	O
if	O
they	O
wanted	O
help	O
for	O
depression	O
,	O
their	O
attitudes	O
toward	O
psychotherapeutic	O
and	O
pharmacological	O
treatments	O
,	O
and	O
perceived	O
barriers	O
to	O
receiving	O
help	O
.	O
RESULTS	O
:	O
Most	O
women	O
(	O
92	O
%	O
)	O
indicated	O
that	O
would	O
likely	O
participate	O
in	O
individual	O
therapy	O
if	O
help	O
was	O
needed	O
.	O
Only	O
35	O
percent	O
stated	O
that	O
they	O
would	O
likely	O
take	O
medication	O
if	O
recommended	O
,	O
and	O
14	O
percent	O
indicated	O
that	O
they	O
would	O
participate	O
in	O
group	O
therapy	O
.	O
The	O
greatest	O
perceived	O
potential	O
barriers	O
to	O
treatment	O
were	O
lack	O
of	O
time	O
(	O
65	O
%	O
)	O
,	O
stigma	O
(	O
43	O
%	O
)	O
,	O
and	O
childcare	O
issues	O
(	O
33	O
%	O
)	O
.	O
Most	O
women	O
indicated	O
a	O
preference	O
to	O
receive	O
mental	O
health	O
care	O
at	O
the	O
obstetrics	O
clinic	O
,	O
either	O
from	O
their	O
obstetrics	O
practitioner	O
or	O
from	O
a	O
mental	O
health	O
practitioner	O
located	O
at	O
the	O
clinic	O
.	O
Factors	O
associated	O
with	O
acceptability	O
of	O
various	O
depression	O
treatments	O
are	O
presented	O
.	O
CONCLUSIONS	O
:	O
Understanding	O
what	O
prevents	O
women	O
from	O
seeking	O
or	O
obtaining	O
help	O
for	O
depression	O
and	O
determining	O
what	O
they	O
prefer	O
in	O
the	O
way	O
of	O
treatment	O
may	O
lead	O
to	O
improved	O
depression	O
treatment	O
rates	O
and	O
hold	O
promise	O
for	O
improving	O
the	O
overall	O
health	O
of	O
childbearing	O
women	O
.	O
Distinct	O
role	O
of	O
PLCbeta3	O
in	O
VEGF	O
-	O
mediated	O
directional	O
migration	O
and	O
vascular	B-Anatomy
sprouting	O
.	O
Endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
and	O
migration	O
is	O
essential	O
to	O
angiogenesis	O
.	O
Typically	O
,	O
proliferation	O
and	O
chemotaxis	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
is	O
driven	O
by	O
growth	O
factors	O
such	O
as	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
.	O
VEGF	O
activates	O
phospholipases	O
(	O
PLCs	O
)	O
-	O
specifically	O
PLCgamma1	O
-	O
that	O
are	O
important	O
for	O
tubulogenesis	O
,	O
differentiation	O
and	O
DNA	O
synthesis	O
.	O
However	O
,	O
we	O
show	O
here	O
that	O
VEGF	O
,	O
specifically	O
through	O
VEGFR2	O
,	O
induces	O
phosphorylation	O
of	O
two	O
serine	O
residues	O
on	O
PLCbeta3	O
,	O
and	O
this	O
was	O
confirmed	O
in	O
an	O
ex	O
vivo	O
embryoid	B-Anatomy
body	I-Anatomy
model	O
.	O
Knockdown	O
of	O
PLCbeta3	O
in	O
HUVEC	B-Anatomy
cells	I-Anatomy
affects	O
IP3	O
production	O
,	O
actin	O
reorganization	O
,	O
migration	O
and	O
proliferation	O
;	O
whereas	O
migration	O
is	O
inhibited	O
,	O
proliferation	O
is	O
enhanced	O
.	O
Our	O
data	O
suggest	O
that	O
enhanced	O
proliferation	O
is	O
precipitated	O
by	O
an	O
accelerated	O
cell	B-Anatomy
cycle	O
,	O
and	O
decreased	O
migration	O
by	O
an	O
inability	O
to	O
activate	O
CDC42	O
.	O
Given	O
that	O
PLCbeta3	O
is	O
typically	O
known	O
as	O
an	O
effector	O
of	O
heterotrimeric	O
G	O
-	O
proteins	O
,	O
our	O
data	O
demonstrate	O
a	O
unique	O
crosstalk	O
between	O
the	O
G	O
-	O
protein	O
and	O
receptor	O
tyrosine	O
kinase	O
(	O
RTK	O
)	O
axes	O
and	O
reveal	O
a	O
novel	O
molecular	O
mechanism	O
of	O
VEGF	O
signaling	O
and	O
,	O
thus	O
,	O
angiogenesis	O
.	O
The	O
impact	O
of	O
tracheal	B-Anatomy
intubation	O
on	O
host	O
defenses	O
and	O
risks	O
for	O
nosocomial	O
pneumonia	O
.	O
Nosocomial	O
pneumonia	O
remains	O
a	O
common	O
complication	O
in	O
patients	O
treated	O
with	O
endotracheal	B-Anatomy
intubation	O
and	O
mechanical	O
ventilation	O
and	O
continues	O
to	O
have	O
a	O
significant	O
impact	O
on	O
the	O
mortality	O
rate	O
of	O
these	O
patients	O
.	O
Epidemiologic	O
studies	O
have	O
shown	O
that	O
the	O
risk	O
of	O
pneumonia	O
increases	O
with	O
the	O
duration	O
of	O
intubation	O
but	O
that	O
the	O
period	O
of	O
highest	O
risk	O
is	O
the	O
first	O
2	O
weeks	O
of	O
therapy	O
.	O
Gram	O
-	O
negative	O
bacteria	O
account	O
for	O
most	O
nosocomial	O
pneumonias	O
in	O
intubated	O
patients	O
,	O
but	O
Staphylococcus	O
aureus	O
may	O
also	O
play	O
a	O
role	O
in	O
what	O
may	O
be	O
a	O
polymicrobial	O
infection	O
.	O
In	O
the	O
most	O
seriously	O
ill	O
individuals	O
,	O
and	O
in	O
those	O
treated	O
with	O
long	O
-	O
term	O
mechanical	O
ventilation	O
,	O
Pseudomonas	O
aeruginosa	O
is	O
a	O
common	O
pathogen	O
.	O
Endotracheal	B-Anatomy
intubation	O
and	O
mechanical	O
ventilation	O
predispose	O
to	O
pneumonia	O
for	O
a	O
variety	O
of	O
reasons	O
(	O
see	O
Fig	O
.	O
1	O
)	O
.	O
The	O
endotracheal	B-Anatomy
tube	I-Anatomy
can	O
have	O
direct	O
effects	O
on	O
the	O
airway	B-Anatomy
that	O
result	O
in	O
a	O
reduction	O
in	O
local	O
host	O
defenses	O
.	O
Thus	O
,	O
mucosal	B-Anatomy
injury	O
can	O
reduce	O
mucociliary	B-Anatomy
function	O
,	O
while	O
upper	O
airway	B-Anatomy
defenses	O
are	O
bypassed	O
and	O
the	O
effectiveness	O
of	O
cough	O
is	O
reduced	O
.	O
Indirectly	O
,	O
intubation	O
can	O
result	O
in	O
an	O
enhanced	O
capacity	O
of	O
tracheobronchial	B-Anatomy
cells	I-Anatomy
to	O
bind	O
gram	O
-	O
negative	O
bacteria	O
,	O
an	O
effect	O
that	O
favors	O
airway	B-Anatomy
colonization	O
and	O
pneumonia	O
.	O
The	O
injury	O
to	O
the	O
airway	B-Anatomy
can	O
create	O
binding	O
sites	O
for	O
bacteria	O
in	O
the	O
basement	B-Anatomy
membrane	I-Anatomy
of	O
the	O
bronchial	B-Anatomy
tree	I-Anatomy
and	O
the	O
stimulation	O
of	O
the	O
secretion	O
of	O
mucus	B-Anatomy
,	O
which	O
then	O
stagnates	O
and	O
can	O
create	O
potential	O
sites	O
for	O
bacterial	O
adherence	O
.	O
The	O
endotracheal	B-Anatomy
tube	I-Anatomy
also	O
enhances	O
bacterial	O
entry	O
to	O
the	O
lung	B-Anatomy
by	O
serving	O
as	O
a	O
reservoir	O
for	O
bacteria	O
to	O
remain	O
sequestered	O
,	O
safe	O
from	O
host	O
defenses	O
.	O
Respiratory	B-Anatomy
therapy	O
devices	O
can	O
allow	O
bacteria	O
to	O
proliferate	O
and	O
can	O
then	O
introduce	O
them	O
into	O
the	O
patient	O
if	O
not	O
handled	O
properly	O
.	O
Finally	O
,	O
patients	O
who	O
are	O
ill	O
enough	O
to	O
require	O
intubation	O
also	O
have	O
disease	O
-	O
associated	O
impairments	O
in	O
systemic	O
host	O
defense	O
,	O
which	O
add	O
to	O
the	O
impairments	O
caused	O
by	O
the	O
use	O
of	O
an	O
artificial	O
airway	B-Anatomy
.	O
The	O
host	O
defense	O
impairments	O
that	O
occur	O
in	O
mechanically	O
ventilated	O
patients	O
can	O
lead	O
to	O
respiratory	B-Anatomy
tract	I-Anatomy
infection	O
in	O
the	O
form	O
of	O
either	O
febrile	O
tracheobronchitis	O
or	O
pneumonia	O
.	O
The	O
diagnosis	O
of	O
pneumonia	O
in	O
intubated	O
patients	O
is	O
difficult	O
and	O
controversial	O
.	O
It	O
can	O
be	O
made	O
by	O
either	O
clinical	O
criteria	O
or	O
microbiologic	O
criteria	O
,	O
the	O
latter	O
by	O
using	O
a	O
bronchoscopically	O
directed	O
protected	O
specimen	O
brush	O
.	O
Therapy	O
of	O
pneumonia	O
in	O
mechanically	O
ventilated	O
patients	O
is	O
not	O
always	O
successful	O
,	O
and	O
systemic	O
antibiotics	O
may	O
need	O
to	O
be	O
supplemented	O
by	O
topical	O
antimicrobials	O
.	O
No	O
clearly	O
effective	O
prophylactic	O
strategy	O
currently	O
exists	O
,	O
but	O
our	O
understanding	O
of	O
pneumonia	O
pathogenesis	O
has	O
led	O
to	O
some	O
promising	O
directions	O
.	O
As	O
more	O
data	O
are	O
collected	O
,	O
inhaled	O
antibiotics	O
,	O
selective	O
digestive	O
decontamination	O
,	O
and	O
enhancement	O
of	O
host	O
defenses	O
by	O
cytokines	O
and	O
pre	O
-	O
formed	O
antibodies	O
may	O
emerge	O
as	O
useful	O
approaches	O
.	O
Antivascular	B-Anatomy
actions	O
of	O
microtubule	B-Anatomy
-	O
binding	O
drugs	O
.	O
Microtubule	B-Anatomy
-	O
binding	O
drugs	O
(	O
MBD	O
)	O
are	O
widely	O
used	O
in	O
cancer	B-Anatomy
chemotherapy	O
and	O
also	O
have	O
clinically	O
relevant	O
antiangiogenic	O
and	O
vascular	B-Anatomy
-	O
disrupting	O
properties	O
.	O
These	O
antivascular	B-Anatomy
actions	O
are	O
due	O
in	O
part	O
to	O
direct	O
effects	O
on	O
endothelial	B-Anatomy
cells	I-Anatomy
,	O
and	O
all	O
MBDs	O
(	O
both	O
microtubule	B-Anatomy
-	O
stabilizing	O
and	O
microtubule	B-Anatomy
-	O
destabilizing	O
)	O
inhibit	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
,	O
migration	O
,	O
and	O
tube	B-Anatomy
formation	O
in	O
vitro	O
,	O
actions	O
that	O
are	O
thought	O
to	O
correspond	O
to	O
therapeutic	O
antiangiogenic	O
actions	O
.	O
In	O
addition	O
,	O
the	O
microtubule	B-Anatomy
-	O
destabilizing	O
agents	O
cause	O
prominent	O
changes	O
in	O
endothelial	B-Anatomy
cell	I-Anatomy
morphology	O
,	O
an	O
action	O
associated	O
with	O
rapid	O
vascular	B-Anatomy
collapse	O
in	O
vivo	O
.	O
The	O
effects	O
on	O
endothelial	B-Anatomy
cells	I-Anatomy
occur	O
in	O
vitro	O
at	O
low	O
drug	O
concentrations	O
,	O
which	O
do	O
not	O
affect	O
microtubule	B-Anatomy
gross	O
morphology	O
,	O
do	O
not	O
cause	O
microtubule	B-Anatomy
bundling	O
or	O
microtubule	B-Anatomy
loss	O
and	O
do	O
not	O
induce	O
cell	B-Anatomy
cycle	O
arrest	O
,	O
apoptosis	O
,	O
or	O
cell	B-Anatomy
death	O
.	O
Rather	O
,	O
it	O
has	O
been	O
hypothesized	O
that	O
,	O
at	O
low	O
concentrations	O
,	O
MBDs	O
produce	O
more	O
subtle	O
effects	O
on	O
microtubule	B-Anatomy
dynamics	O
,	O
block	O
critical	O
cell	B-Anatomy
signaling	O
pathways	O
,	O
and	O
prevent	O
the	O
microtubules	B-Anatomy
from	O
properly	O
interacting	O
with	O
transient	O
subcellular	B-Anatomy
assemblies	I-Anatomy
(	O
focal	B-Anatomy
adhesions	I-Anatomy
and	O
adherens	B-Anatomy
junctions	I-Anatomy
)	O
whose	O
subsequent	O
stabilization	O
and	O
/	O
or	O
maturation	O
are	O
required	O
for	O
cell	B-Anatomy
motility	O
and	O
cell	B-Anatomy
-	O
cell	B-Anatomy
interactions	O
.	O
This	O
review	O
will	O
focus	O
on	O
recent	O
studies	O
to	O
define	O
the	O
molecular	O
mechanisms	O
for	O
the	O
antivascular	B-Anatomy
actions	O
of	O
the	O
MBDs	O
,	O
information	O
that	O
could	O
be	O
useful	O
in	O
the	O
identification	O
or	O
design	O
of	O
agents	O
whose	O
actions	O
more	O
selectively	O
target	O
the	O
tumor	B-Anatomy
vasculature	I-Anatomy
.	O
Neurovascular	B-Anatomy
effects	O
of	O
CD47	O
signaling	O
:	O
promotion	O
of	O
cell	B-Anatomy
death	O
,	O
inflammation	O
,	O
and	O
suppression	O
of	O
angiogenesis	O
in	O
brain	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
in	O
vitro	O
.	O
The	O
concept	O
of	O
the	O
neurovascular	B-Anatomy
unit	O
emphasizes	O
that	O
common	O
signals	O
and	O
substrates	O
underlie	O
the	O
physiology	O
and	O
pathophysiology	O
of	O
neuronal	B-Anatomy
and	O
endothelial	B-Anatomy
compartments	I-Anatomy
in	O
brain	B-Anatomy
.	O
Recent	O
data	O
suggest	O
that	O
activation	O
of	O
the	O
integrin	O
-	O
associated	O
protein	O
CD47	O
promotes	O
neuronal	B-Anatomy
cell	I-Anatomy
death	O
.	O
Is	O
it	O
possible	O
that	O
CD47	O
may	O
also	O
negatively	O
affect	O
cerebral	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
?	O
Exposure	O
of	O
wild	O
-	O
type	O
primary	O
mouse	O
cerebral	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
to	O
the	O
CD47	O
ligand	O
thrombospondin	O
1	O
(	O
TSP	O
-	O
1	O
)	O
induced	O
an	O
increasing	O
amount	O
of	O
cell	B-Anatomy
death	O
,	O
whereas	O
cytotoxicity	O
was	O
significantly	O
decreased	O
in	O
cerebral	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
derived	O
from	O
CD47	O
knockout	O
mice	O
.	O
The	O
specific	O
CD47	O
-	O
activating	O
peptide	O
,	O
4N1K	O
,	O
similarly	O
induced	O
cell	B-Anatomy
death	O
in	O
human	O
brain	B-Anatomy
microvascular	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
Promotion	O
of	O
inflammation	O
was	O
also	O
involved	O
because	O
lower	O
TSP	O
-	O
1	O
was	O
able	O
to	O
up	O
-	O
regulate	O
the	O
adhesion	O
molecules	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
and	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
.	O
Finally	O
,	O
CD47	O
signaling	O
may	O
suppress	O
angiogenesis	O
because	O
4N1K	O
significantly	O
inhibited	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
and	O
tube	B-Anatomy
formation	O
in	O
vitro	O
.	O
We	O
conclude	O
that	O
CD47	O
signaling	O
can	O
negatively	O
affect	O
the	O
viability	O
and	O
function	O
of	O
cerebral	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
,	O
further	O
supporting	O
the	O
notion	O
that	O
CD47	O
may	O
be	O
a	O
potential	O
neurovascular	B-Anatomy
target	O
for	O
stroke	O
and	O
brain	B-Anatomy
injury	O
.	O
Cisplatin	O
reduces	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
via	O
regulation	O
of	O
type	O
2	O
-	O
matrix	O
metalloproteinase	O
activity	O
.	O
AIMS	O
:	O
In	O
this	O
study	O
we	O
investigated	O
the	O
effect	O
of	O
cisplatin	O
on	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
,	O
an	O
essential	O
process	O
for	O
vascular	B-Anatomy
remodeling	O
and	O
regeneration	O
in	O
several	O
physiological	O
and	O
pathological	O
situations	O
.	O
MATERIAL	O
AND	O
METHODS	O
:	O
Human	B-Anatomy
umbilical	I-Anatomy
vein	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
(	O
HUVEC	B-Anatomy
)	O
were	O
treated	O
with	O
cisplatin	O
and	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
analyzed	O
by	O
fluorescence	O
and	O
scratch	B-Anatomy
-	I-Anatomy
wound	I-Anatomy
migration	O
assay	O
.	O
MMP2	O
and	O
MMP9	O
activity	O
were	O
determined	O
by	O
zymographic	O
assay	O
,	O
and	O
MAPK	O
activation	O
by	O
Western	O
blotting	O
analysis	O
.	O
RESULTS	O
:	O
We	O
demonstrated	O
that	O
cisplatin	O
provoked	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
decrease	O
of	O
HUVEC	B-Anatomy
migration	O
;	O
this	O
effect	O
was	O
clearly	O
independent	O
from	O
its	O
well	O
known	O
cytotoxic	O
activity	O
.	O
In	O
addition	O
,	O
cisplatin	O
markedly	O
reduced	O
MMP2	O
activity	O
in	O
both	O
conditioned	O
media	O
and	O
cell	B-Anatomy
lysates	I-Anatomy
,	O
increased	O
p38	O
MAPK	O
and	O
JNK	O
phosphorylation	O
,	O
but	O
did	O
not	O
affect	O
ERK	O
phosphorylation	O
.	O
Endothelial	B-Anatomy
cell	I-Anatomy
migration	O
was	O
attenuated	O
by	O
treatment	O
of	O
cells	B-Anatomy
with	O
GM6001	O
,	O
a	O
non	O
-	O
specific	O
inhibitor	O
of	O
MMPs	O
,	O
or	O
by	O
a	O
selective	O
anti	O
-	O
MMP2	O
antibody	O
.	O
However	O
,	O
treatment	O
of	O
cells	B-Anatomy
with	O
SB202190	O
or	O
SP600125	O
,	O
inhibitors	O
of	O
p38	O
MAPK	O
and	O
JNK	O
respectively	O
,	O
did	O
not	O
affect	O
HUVEC	B-Anatomy
migration	O
.	O
CONCLUSION	O
:	O
These	O
results	O
suggested	O
that	O
cisplatin	O
induced	O
a	O
reduction	O
of	O
endothelial	B-Anatomy
cell	I-Anatomy
migration	O
through	O
an	O
inhibition	O
of	O
MMP2	O
activity	O
by	O
downstream	O
signal	O
transduction	O
pathways	O
independent	O
of	O
JNK	O
and	O
p38	O
MAPK	O
activation	O
.	O
The	O
modulation	O
of	O
platelet	B-Anatomy
and	O
endothelial	B-Anatomy
cell	I-Anatomy
adhesion	O
to	O
vascular	B-Anatomy
graft	I-Anatomy
materials	O
by	O
perlecan	O
.	O
Controlled	O
neo	O
-	O
endothelialisation	O
is	O
critical	O
to	O
the	O
patency	O
of	O
small	O
diameter	O
vascular	B-Anatomy
grafts	I-Anatomy
.	O
Endothelialisation	O
and	O
platelet	B-Anatomy
adhesion	O
to	O
purified	O
endothelial	B-Anatomy
cell	I-Anatomy
-	O
derived	O
perlecan	O
,	O
the	O
major	O
heparan	O
sulfate	O
(	O
HS	O
)	O
proteoglycan	O
in	O
basement	B-Anatomy
membranes	I-Anatomy
,	O
were	O
investigated	O
using	O
in	O
vivo	O
and	O
in	O
vitro	O
assays	O
.	O
Expanded	O
polytetrafluoroethylene	O
(	O
ePTFE	O
)	O
vascular	B-Anatomy
grafts	I-Anatomy
were	O
coated	O
with	O
perlecan	O
and	O
tested	O
in	O
an	O
ovine	O
carotid	B-Anatomy
interposition	O
model	O
for	O
a	O
period	O
of	O
6	O
weeks	O
and	O
assessed	O
using	O
light	O
and	O
scanning	O
microscopy	O
.	O
Enhanced	O
endothelial	B-Anatomy
cell	I-Anatomy
growth	O
and	O
reduced	O
platelet	B-Anatomy
adhesion	O
were	O
observed	O
on	O
the	O
perlecan	O
coated	O
grafts	B-Anatomy
when	O
compared	O
to	O
uncoated	O
controls	O
implanted	O
in	O
the	O
same	O
sheep	O
(	O
n	O
=	O
5	O
)	O
.	O
Perlecan	O
was	O
also	O
found	O
to	O
stimulate	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
in	O
vitro	O
over	O
a	O
period	O
of	O
6	O
days	O
in	O
the	O
presence	O
of	O
plasma	B-Anatomy
proteins	O
and	O
fibroblastic	O
growth	O
factor	O
2	O
(	O
FGF	O
-	O
2	O
)	O
,	O
however	O
in	O
the	O
absence	O
of	O
FGF	O
-	O
2	O
endothelial	B-Anatomy
cell	I-Anatomy
growth	O
could	O
not	O
be	O
maintained	O
during	O
this	O
period	O
.	O
Perlecan	O
was	O
found	O
to	O
be	O
anti	O
-	O
adhesive	O
for	O
platelets	B-Anatomy
,	O
however	O
after	O
removal	O
of	O
the	O
HS	O
chains	O
attached	O
to	O
perlecan	O
,	O
platelet	B-Anatomy
adhesion	O
and	O
aggregation	O
were	O
supported	O
.	O
These	O
results	O
suggest	O
a	O
role	O
for	O
HS	O
chains	O
of	O
perlecan	O
in	O
improving	O
graft	B-Anatomy
patency	O
by	O
selectively	O
promoting	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
while	O
modulating	O
platelet	B-Anatomy
adhesion	O
.	O
Tumour	B-Anatomy
angiogenesis	O
:	O
its	O
mechanism	O
and	O
therapeutic	O
implications	O
in	O
malignant	B-Anatomy
gliomas	I-Anatomy
.	O
Angiogenesis	O
is	O
a	O
key	O
event	O
in	O
the	O
progression	O
of	O
malignant	B-Anatomy
gliomas	I-Anatomy
.	O
The	O
presence	O
of	O
microvascular	B-Anatomy
proliferation	O
leads	O
to	O
the	O
histological	O
diagnosis	O
of	O
glioblastoma	B-Anatomy
multiforme	I-Anatomy
.	O
Tumour	B-Anatomy
angiogenesis	O
involves	O
multiple	O
cellular	B-Anatomy
processes	O
including	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
,	O
migration	O
,	O
reorganisation	O
of	O
extracellular	B-Anatomy
matrix	I-Anatomy
and	O
tube	B-Anatomy
formation	O
.	O
These	O
processes	O
are	O
regulated	O
by	O
numerous	O
pro	O
-	O
angiogenic	O
and	O
anti	O
-	O
angiogenic	O
growth	O
factors	O
.	O
Angiogenesis	O
inhibitors	O
have	O
been	O
developed	O
to	O
interrupt	O
the	O
angiogenic	O
process	O
at	O
the	O
growth	O
factor	O
,	O
receptor	O
tyrosine	O
kinase	O
and	O
intracellular	B-Anatomy
kinase	O
levels	O
.	O
Other	O
anti	O
-	O
angiogenic	O
therapies	O
alter	O
the	O
immune	O
response	O
and	O
endogeneous	O
angiogenesis	O
inhibitor	O
levels	O
.	O
Most	O
anti	O
-	O
angiogenic	O
therapies	O
for	O
malignant	B-Anatomy
gliomas	I-Anatomy
are	O
in	O
Phase	O
I	O
/	O
II	O
trials	O
and	O
only	O
modest	O
efficacies	O
are	O
reported	O
for	O
monotherapies	O
.	O
The	O
greatest	O
potential	O
for	O
angiogenesis	O
inhibitors	O
may	O
lie	O
in	O
their	O
ability	O
to	O
combine	O
safely	O
with	O
chemotherapy	O
and	O
radiotherapy	O
.	O
Regulation	O
of	O
thrombospondin	O
-	O
1	O
by	O
natural	O
and	O
synthetic	O
progestins	O
in	O
human	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Our	O
recent	O
studies	O
show	O
that	O
progestins	O
induce	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
in	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
that	O
express	O
mutant	O
p53	O
protein	O
.	O
Here	O
,	O
we	O
show	O
that	O
natural	O
and	O
synthetic	O
progestins	O
also	O
induce	O
thrombospondin	O
-	O
1	O
(	O
TSP	O
-	O
1	O
)	O
mRNA	O
and	O
protein	O
in	O
T47	B-Anatomy
-	I-Anatomy
D	I-Anatomy
and	O
BT	B-Anatomy
-	I-Anatomy
474	I-Anatomy
breast	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
.	O
Antiprogestin	O
RU	O
-	O
486	O
inhibits	O
the	O
induction	O
of	O
VEGF	O
and	O
TSP	O
-	O
1	O
by	O
progestins	O
,	O
suggesting	O
that	O
this	O
effect	O
of	O
progestin	O
is	O
mediated	O
by	O
the	O
progesterone	O
receptor	O
(	O
PR	O
)	O
.	O
Actinomycin	O
-	O
D	O
,	O
but	O
not	O
puromycin	O
,	O
also	O
blocks	O
progestin	O
-	O
dependent	O
induction	O
of	O
TSP	O
-	O
1	O
.	O
A	O
putative	O
progestin	O
-	O
response	O
element	O
was	O
identified	O
in	O
the	O
human	O
TSP	O
-	O
1	O
promoter	O
,	O
which	O
is	O
consistent	O
with	O
the	O
hypothesis	O
that	O
a	O
progestin	O
-	O
PR	O
complex	O
might	O
directly	O
regulate	O
transcription	O
of	O
the	O
TSP	O
-	O
1	O
gene	O
in	O
human	O
cells	B-Anatomy
.	O
Conditioned	O
medium	O
from	O
progestin	O
-	O
treated	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
stimulates	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
in	O
the	O
absence	O
though	O
not	O
in	O
the	O
presence	O
of	O
antibody	O
to	O
TSP	O
-	O
1	O
,	O
indicating	O
that	O
TSP	O
-	O
1	O
secreted	O
by	O
breast	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
could	O
be	O
pro	O
-	O
angiogenic	O
.	O
Since	O
tumor	B-Anatomy
cell	I-Anatomy
-	O
derived	O
TSP	O
-	O
1	O
has	O
the	O
potential	O
to	O
promote	O
angiogenesis	O
in	O
the	O
tumor	B-Anatomy
microenvironment	O
,	O
it	O
could	O
be	O
a	O
potential	O
target	O
for	O
breast	B-Anatomy
cancer	I-Anatomy
therapy	O
.	O
WNT	O
/	O
TCF	O
signaling	O
through	O
LEF1	O
and	O
HOXB9	O
mediates	O
lung	B-Anatomy
adenocarcinoma	I-Anatomy
metastasis	O
.	O
Metastasis	O
from	O
lung	B-Anatomy
adenocarcinoma	I-Anatomy
can	O
occur	O
swiftly	O
to	O
multiple	O
organs	B-Anatomy
within	O
months	O
of	O
diagnosis	O
.	O
The	O
mechanisms	O
that	O
confer	O
this	O
rapid	O
metastatic	O
capacity	O
to	O
lung	B-Anatomy
tumors	I-Anatomy
are	O
unknown	O
.	O
Activation	O
of	O
the	O
canonical	O
WNT	O
/	O
TCF	O
pathway	O
is	O
identified	O
here	O
as	O
a	O
determinant	O
of	O
metastasis	O
to	O
brain	B-Anatomy
and	O
bone	B-Anatomy
during	O
lung	B-Anatomy
adenocarcinoma	I-Anatomy
progression	O
.	O
Gene	O
expression	O
signatures	O
denoting	O
WNT	O
/	O
TCF	O
activation	O
are	O
associated	O
with	O
relapse	O
to	O
multiple	O
organs	B-Anatomy
in	O
primary	B-Anatomy
lung	I-Anatomy
adenocarcinoma	I-Anatomy
.	O
Metastatic	B-Anatomy
subpopulations	I-Anatomy
isolated	O
from	O
independent	O
lymph	B-Anatomy
node	I-Anatomy
-	O
derived	O
lung	B-Anatomy
adenocarcinoma	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
harbor	O
a	O
hyperactive	O
WNT	O
/	O
TCF	O
pathway	O
.	O
Reduction	O
of	O
TCF	O
activity	O
in	O
these	O
cells	B-Anatomy
attenuates	O
their	O
ability	O
to	O
form	O
brain	B-Anatomy
and	O
bone	B-Anatomy
metastases	I-Anatomy
in	O
mice	O
,	O
independently	O
of	O
effects	O
on	O
tumor	B-Anatomy
growth	O
in	O
the	O
lungs	B-Anatomy
.	O
The	O
WNT	O
/	O
TCF	O
target	O
genes	O
HOXB9	O
and	O
LEF1	O
are	O
identified	O
as	O
mediators	O
of	O
chemotactic	O
invasion	O
and	O
colony	B-Anatomy
outgrowth	O
.	O
Thus	O
,	O
a	O
distinct	O
WNT	O
/	O
TCF	O
signaling	O
program	O
through	O
LEF1	O
and	O
HOXB9	O
enhances	O
the	O
competence	O
of	O
lung	B-Anatomy
adenocarcinoma	I-Anatomy
cells	I-Anatomy
to	O
colonize	O
the	O
bones	B-Anatomy
and	O
the	O
brain	B-Anatomy
.	O
For	O
a	O
video	O
summary	O
of	O
this	O
article	O
,	O
see	O
the	O
PaperFlick	O
file	O
available	O
with	O
the	O
online	O
Supplemental	O
Data	O
.	O
c	O
-	O
Ski	O
overexpression	O
promotes	O
tumor	B-Anatomy
growth	O
and	O
angiogenesis	O
through	O
inhibition	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
signaling	O
in	O
diffuse	O
-	O
type	O
gastric	B-Anatomy
carcinoma	I-Anatomy
.	O
c	O
-	O
Ski	O
,	O
originally	O
identified	O
as	O
a	O
proto	O
-	O
oncogene	O
product	O
,	O
is	O
an	O
important	O
negative	O
regulator	O
of	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta	O
family	O
signaling	O
through	O
interaction	O
with	O
Smad2	O
,	O
Smad3	O
,	O
and	O
Smad4	O
.	O
High	O
expression	O
of	O
c	O
-	O
Ski	O
has	O
been	O
found	O
in	O
some	O
cancers	B-Anatomy
,	O
including	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
We	O
previously	O
showed	O
that	O
disruption	O
of	O
TGF	O
-	O
beta	O
signaling	O
by	O
dominant	O
-	O
negative	O
TGF	O
-	O
beta	O
type	O
II	O
receptor	O
in	O
a	O
diffuse	O
-	O
type	O
gastric	B-Anatomy
carcinoma	I-Anatomy
model	O
accelerated	O
tumor	B-Anatomy
growth	O
through	O
induction	O
of	O
tumor	B-Anatomy
angiogenesis	O
by	O
decreased	O
expression	O
of	O
the	O
anti	O
-	O
angiogenic	O
factor	O
thrombospondin	O
(	O
TSP	O
)	O
-	O
1	O
.	O
Here	O
,	O
we	O
examined	O
the	O
function	O
of	O
c	O
-	O
Ski	O
in	O
human	O
diffuse	O
-	O
type	O
gastric	B-Anatomy
carcinoma	I-Anatomy
OCUM	B-Anatomy
-	I-Anatomy
2MLN	I-Anatomy
cells	I-Anatomy
.	O
Overexpression	O
of	O
c	O
-	O
Ski	O
inhibited	O
TGF	O
-	O
beta	O
signaling	O
in	O
OCUM	B-Anatomy
-	I-Anatomy
2MLN	I-Anatomy
cells	I-Anatomy
.	O
Interestingly	O
,	O
c	O
-	O
Ski	O
overexpression	O
resulted	O
in	O
extensive	O
acceleration	O
of	O
the	O
growth	O
of	O
subcutaneous	B-Anatomy
xenografts	I-Anatomy
in	O
BALB	O
/	O
c	O
nu	O
/	O
nu	O
female	O
mice	O
(	O
6	O
weeks	O
of	O
age	O
)	O
.	O
Similar	O
to	O
tumors	B-Anatomy
expressing	O
dominant	O
-	O
negative	O
TGF	O
-	O
beta	O
type	O
II	O
receptor	O
,	O
histochemical	O
studies	O
revealed	O
less	O
fibrosis	O
and	O
increased	O
angiogenesis	O
in	O
xenografted	O
tumors	B-Anatomy
expressing	O
c	O
-	O
Ski	O
compared	O
to	O
control	O
tumors	B-Anatomy
.	O
Induction	O
of	O
TSP	O
-	O
1	O
mRNA	O
by	O
TGF	O
-	O
beta	O
was	O
attenuated	O
by	O
c	O
-	O
Ski	O
in	O
vitro	O
,	O
and	O
expression	O
of	O
TSP	O
-	O
1	O
mRNA	O
was	O
decreased	O
in	O
tumors	B-Anatomy
expressing	O
c	O
-	O
Ski	O
in	O
vivo	O
.	O
These	O
findings	O
suggest	O
that	O
c	O
-	O
Ski	O
overexpression	O
promotes	O
the	O
growth	O
of	O
diffuse	O
-	O
type	O
gastric	B-Anatomy
carcinoma	I-Anatomy
through	O
induction	O
of	O
angiogenesis	O
.	O
Angiogenesis	O
-	O
a	O
novel	O
therapeutic	O
approach	O
for	O
ischemic	O
heart	B-Anatomy
disease	O
.	O
Angiogenesis	O
is	O
the	O
biologic	O
process	O
of	O
forming	O
new	O
blood	B-Anatomy
vessels	I-Anatomy
.	O
Undoubtedly	O
,	O
blood	B-Anatomy
vessels	I-Anatomy
growth	O
regulation	O
is	O
a	O
vital	O
aspect	O
in	O
health	O
and	O
disease	O
.	O
Under	O
physiological	O
conditions	O
,	O
angiogenesis	O
is	O
regulated	O
by	O
local	O
balance	O
between	O
endogenous	O
stimulators	O
and	O
inhibitors	O
of	O
this	O
process	O
.	O
In	O
many	O
diseases	O
state	O
body	B-Anatomy
loses	O
control	O
over	O
angiogenesis	O
.	O
Angiogenesis	O
-	O
dependent	O
diseases	O
result	O
when	O
new	O
blood	B-Anatomy
vessels	I-Anatomy
either	O
grow	O
excessively	O
or	O
insufficiently	O
.	O
Insufficient	O
angiogenesis	O
occurs	O
in	O
diseases	O
such	O
as	O
coronary	B-Anatomy
artery	I-Anatomy
disease	O
,	O
stroke	O
and	O
chronic	O
wounds	B-Anatomy
.	O
Myocardial	B-Anatomy
ischemia	O
both	O
acute	O
and	O
chronic	O
has	O
been	O
clearly	O
shown	O
to	O
stimulate	O
angiogenesis	O
in	O
many	O
experimental	O
models	O
.	O
Therapeutic	O
angiogenesis	O
is	O
the	O
biological	O
agents	O
or	O
bioactive	O
material	O
to	O
stimulate	O
the	O
growth	O
of	O
new	O
blood	B-Anatomy
vessels	I-Anatomy
.	O
Traditional	O
coronary	B-Anatomy
revascularization	O
therapies	O
such	O
as	O
coronary	B-Anatomy
angioplasty	O
or	O
bypass	B-Anatomy
graft	I-Anatomy
surgery	O
,	O
act	O
by	O
restoring	O
blood	B-Anatomy
flow	O
through	O
the	O
preexisting	O
coronary	B-Anatomy
vessels	I-Anatomy
.	O
One	O
limitation	O
of	O
these	O
approaches	O
,	O
however	O
,	O
may	O
be	O
the	O
failure	O
to	O
normalize	O
myocardial	B-Anatomy
perfusion	O
,	O
due	O
to	O
the	O
concomitant	O
presence	O
or	O
small	O
of	O
resistance	O
vessel	B-Anatomy
disease	O
.	O
In	O
contrast	O
,	O
therapeutic	O
angiogenesis	O
is	O
based	O
on	O
the	O
concept	O
that	O
coronary	B-Anatomy
collateral	I-Anatomy
development	O
may	O
be	O
stimulated	O
by	O
pharmacological	O
or	O
molecular	O
means	O
and	O
can	O
limit	O
myocardial	B-Anatomy
ischemia	O
.	O
Studies	O
,	O
both	O
in	O
human	O
and	O
animal	O
models	O
support	O
the	O
notion	O
that	O
,	O
various	O
angiogenic	O
growth	O
factors	O
and	O
progenitor	B-Anatomy
cells	I-Anatomy
can	O
enhance	O
new	O
blood	B-Anatomy
vessels	I-Anatomy
.	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
fibroblast	O
growth	O
factor	O
(	O
FGF	O
)	O
,	O
recombinant	O
proteins	O
and	O
bone	B-Anatomy
marrow	I-Anatomy
stem	I-Anatomy
cells	I-Anatomy
are	O
currently	O
used	O
therapeutic	O
stimulators	O
for	O
angiogenesis	O
.	O
As	O
coronary	B-Anatomy
artery	I-Anatomy
disease	O
is	O
the	O
major	O
cause	O
of	O
death	O
in	O
the	O
developed	O
societies	O
and	O
also	O
an	O
emerging	O
health	O
problem	O
in	O
developing	O
countries	O
like	O
Bangladesh	O
therapeutic	O
angiogenesis	O
may	O
provide	O
hope	O
as	O
a	O
new	O
treatment	O
modality	O
for	O
ischemic	O
heart	B-Anatomy
disease	O
with	O
or	O
in	O
place	O
of	O
current	O
therapies	O
.	O
Use	O
of	O
uteroglobin	O
for	O
the	O
engineering	O
of	O
polyvalent	O
,	O
polyspecific	O
fusion	O
proteins	O
.	O
We	O
report	O
a	O
novel	O
strategy	O
to	O
engineer	O
and	O
express	O
stable	O
and	O
soluble	O
human	O
recombinant	O
polyvalent	O
/	O
polyspecific	O
fusion	O
proteins	O
.	O
The	O
procedure	O
is	O
based	O
on	O
the	O
use	O
of	O
a	O
central	O
skeleton	O
of	O
uteroglobin	O
,	O
a	O
small	O
and	O
very	O
soluble	O
covalently	O
linked	O
homodimeric	O
protein	O
that	O
is	O
very	O
resistant	O
to	O
proteolytic	O
enzymes	O
and	O
to	O
pH	O
variations	O
.	O
Using	O
a	O
human	O
recombinant	O
antibody	O
(	O
scFv	O
)	O
specific	O
for	O
the	O
angiogenesis	O
marker	O
domain	O
B	O
of	O
fibronectin	O
,	O
interleukin	O
2	O
,	O
and	O
an	O
scFv	O
able	O
to	O
neutralize	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
we	O
expressed	O
various	O
biologically	O
active	O
uteroglobin	O
fusion	O
proteins	O
.	O
The	O
results	O
demonstrate	O
the	O
possibility	O
to	O
generate	O
monospecific	O
divalent	O
and	O
tetravalent	O
antibodies	O
,	O
immunocytokines	O
,	O
and	O
dual	O
specificity	O
tetravalent	O
antibodies	O
.	O
Furthermore	O
,	O
compared	O
with	O
similar	O
fusion	O
proteins	O
in	O
which	O
uteroglobin	O
was	O
not	O
used	O
,	O
the	O
use	O
of	O
uteroglobin	O
improved	O
properties	O
of	O
solubility	O
and	O
stability	O
.	O
Indeed	O
,	O
in	O
the	O
reported	O
cases	O
it	O
was	O
possible	O
to	O
vacuum	O
dry	O
and	O
reconstitute	O
the	O
proteins	O
without	O
any	O
aggregation	O
or	O
loss	O
in	O
protein	O
and	O
biological	O
activity	O
.	O
Mapping	O
of	O
the	O
L	O
-	O
methylmalonyl	O
-	O
CoA	O
mutase	O
gene	O
to	O
mouse	O
chromosome	B-Anatomy
17	I-Anatomy
.	O
In	O
humans	O
,	O
methylmalonyl	O
acidemia	O
is	O
caused	O
by	O
a	O
deficiency	O
of	O
L	O
-	O
methylmalonyl	O
-	O
CoA	O
mutase	O
(	O
MUT	O
)	O
controlled	O
by	O
a	O
gene	O
that	O
has	O
been	O
mapped	O
to	O
chromosome	B-Anatomy
6	I-Anatomy
.	O
The	O
mouse	O
homolog	O
of	O
this	O
gene	O
has	O
now	O
been	O
mapped	O
to	O
mouse	O
chromosome	B-Anatomy
17	I-Anatomy
.	O
Recombinant	O
inbred	O
and	O
congenic	O
strains	O
place	O
the	O
mouse	O
Mut	O
locus	O
1	O
.	O
06	O
cM	O
distal	O
to	O
H	O
-	O
2	O
,	O
between	O
Pgk	O
-	O
2	O
and	O
Ce	O
-	O
2	O
.	O
The	O
relative	O
order	O
of	O
syntenic	O
probes	O
flanking	O
H	O
-	O
2	O
on	O
mouse	O
chromosome	B-Anatomy
17	I-Anatomy
and	O
HLA	O
on	O
human	O
chromosome	B-Anatomy
6	I-Anatomy
is	O
shown	O
to	O
be	O
different	O
.	O
Netrin	O
-	O
1	O
up	O
-	O
regulation	O
in	O
inflammatory	O
bowel	B-Anatomy
diseases	O
is	O
required	O
for	O
colorectal	B-Anatomy
cancer	I-Anatomy
progression	O
.	O
Chronic	O
inflammation	O
and	O
cancer	B-Anatomy
are	O
intimately	O
associated	O
.	O
This	O
is	O
particularly	O
true	O
for	O
inflammatory	O
bowel	B-Anatomy
diseases	O
(	O
IBD	O
)	O
,	O
such	O
as	O
ulcerative	B-Anatomy
colitis	O
and	O
Crohn	O
'	O
s	O
disease	O
,	O
which	O
show	O
a	O
major	O
increased	O
risk	O
for	O
colorectal	B-Anatomy
cancer	I-Anatomy
.	O
While	O
the	O
understanding	O
of	O
the	O
molecular	O
pathogenesis	O
of	O
IBD	O
has	O
recently	O
improved	O
,	O
the	O
mechanisms	O
that	O
link	O
these	O
chronic	O
inflammatory	O
states	O
to	O
colorectal	B-Anatomy
cancer	I-Anatomy
development	O
are	O
in	O
large	O
part	O
unknown	O
.	O
One	O
of	O
these	O
mechanisms	O
is	O
NF	O
-	O
kappaB	O
pathway	O
activation	O
which	O
in	O
turn	O
may	O
contribute	O
to	O
tumor	B-Anatomy
formation	O
by	O
providing	O
anti	O
-	O
apoptotic	O
survival	O
signals	O
to	O
the	O
epithelial	B-Anatomy
cells	I-Anatomy
.	O
Based	O
on	O
the	O
observation	O
that	O
netrin	O
-	O
1	O
,	O
the	O
anti	O
-	O
apoptotic	O
ligand	O
for	O
the	O
dependence	O
receptors	O
DCC	O
and	O
UNC5H	O
is	O
up	O
-	O
regulated	O
in	O
colonic	B-Anatomy
crypts	I-Anatomy
in	O
response	O
to	O
NF	O
-	O
kappaB	O
,	O
we	O
show	O
here	O
that	O
colorectal	B-Anatomy
cancers	I-Anatomy
from	O
inflammatory	O
bowel	B-Anatomy
diseases	O
patients	O
have	O
selected	O
up	O
-	O
regulation	O
of	O
netrin	O
-	O
1	O
.	O
Moreover	O
,	O
we	O
demonstrate	O
that	O
this	O
inflammation	O
-	O
driven	O
netrin	O
-	O
1	O
up	O
-	O
regulation	O
is	O
causal	O
for	O
colorectal	B-Anatomy
cancer	I-Anatomy
development	O
as	O
interference	O
with	O
netrin	O
-	O
1	O
autocrine	O
loop	O
in	O
a	O
mouse	O
model	O
for	O
ulcerative	B-Anatomy
colitis	O
-	O
associated	O
colorectal	B-Anatomy
cancer	I-Anatomy
,	O
while	O
showing	O
no	O
effect	O
on	O
inflammation	O
,	O
inhibits	O
colorectal	B-Anatomy
cancer	I-Anatomy
progression	O
.	O
[	O
Prognostic	O
significance	O
of	O
cellular	B-Anatomy
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
in	O
the	O
course	O
of	O
chronic	B-Anatomy
myeloid	I-Anatomy
leukaemia	I-Anatomy
]	O
INTRODUCTION	O
:	O
Increased	O
angiogenesis	O
in	O
bone	B-Anatomy
marrow	I-Anatomy
is	O
one	O
of	O
the	O
characteristics	O
of	O
chronic	B-Anatomy
myeloid	I-Anatomy
leukaemia	I-Anatomy
(	O
CML	B-Anatomy
)	O
,	O
a	O
clonal	O
myeloproliferative	O
disorder	O
that	O
expresses	O
a	O
chimeric	O
bcr	O
/	O
abl	O
protein	O
.	O
Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
one	O
of	O
the	O
most	O
potent	O
and	O
a	O
specific	O
regulator	O
of	O
angiogenesis	O
which	O
principally	O
targets	O
endothelial	B-Anatomy
cells	I-Anatomy
and	O
regulates	O
several	O
of	O
their	O
functions	O
,	O
including	O
mitogenesis	O
,	O
permeability	O
and	O
migration	O
.	O
The	O
impact	O
of	O
elevated	O
VEGF	O
expression	O
on	O
the	O
course	O
of	O
chronic	B-Anatomy
myeloid	I-Anatomy
leukaemia	I-Anatomy
is	O
unknown	O
.	O
OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
the	O
follow	O
-	O
up	O
of	O
VEGF	O
expression	O
during	O
the	O
course	O
of	O
CML	B-Anatomy
.	O
METHODS	O
:	O
We	O
studied	O
VEGF	O
expression	O
of	O
85	O
CML	B-Anatomy
patients	O
(	O
median	O
age	O
50	O
years	O
,	O
range	O
16	O
-	O
75	O
years	O
)	O
.	O
At	O
the	O
commencement	O
of	O
the	O
study	O
,	O
29	O
patients	O
were	O
in	O
chronic	O
phase	O
(	O
CP	O
)	O
,	O
25	O
in	O
an	O
accelerated	O
phase	O
(	O
AP	O
)	O
,	O
and	O
31	O
in	O
the	O
blast	O
crisis	O
(	O
BC	O
)	O
.	O
The	O
temporal	O
expression	O
(	O
percentage	O
positivity	O
per	O
1000	O
analysed	O
cells	B-Anatomy
)	O
VEGF	O
proteins	O
over	O
the	O
course	O
of	O
CML	B-Anatomy
were	O
studied	O
using	O
the	O
immunohistochemical	O
technique	O
utilizing	O
relevant	O
monoclonal	O
antibodies	O
.	O
It	O
was	O
correlated	O
with	O
the	O
laboratory	O
(	O
Hb	O
,	O
WBC	B-Anatomy
and	O
platelet	B-Anatomy
counts	O
,	O
and	O
the	O
percentage	O
of	O
blasts	O
)	O
and	O
clinical	O
parameters	O
(	O
organomegaly	O
,	O
duration	O
of	O
CP	O
,	O
AP	O
,	O
and	O
BC	O
)	O
of	O
disease	O
progression	O
.	O
RESULTS	O
:	O
The	O
expression	O
ofVEGF	O
protein	O
was	O
most	O
pronounced	O
in	O
AP	O
(	O
ANOVA	O
,	O
p	O
=	O
0	O
.	O
033	O
)	O
.	O
The	O
level	O
of	O
VEGF	O
expression	O
correlated	O
inversely	O
with	O
the	O
degree	O
of	O
splenomegaly	B-Anatomy
(	O
Pearson	O
,	O
r	O
=	O
-	O
0	O
.	O
400	O
,	O
p	O
=	O
0	O
.	O
011	O
)	O
.	O
High	O
expression	O
of	O
VEGF	O
correlated	O
with	O
a	O
shorter	O
overall	O
survival	O
(	O
log	O
rank	O
,	O
p	O
=	O
0	O
.	O
042	O
)	O
.	O
CONCLUSION	O
:	O
Immunohistochemically	O
confirmed	O
significance	O
of	O
the	O
expression	O
of	O
VEGF	O
in	O
dependence	O
of	O
the	O
CML	B-Anatomy
stage	O
could	O
be	O
of	O
clinical	O
importance	O
in	O
deciding	O
on	O
the	O
timing	O
therapy	O
.	O
These	O
data	O
suggest	O
that	O
VEGF	O
plays	O
a	O
role	O
in	O
the	O
biology	O
of	O
CML	B-Anatomy
and	O
that	O
VEGF	O
inhibitors	O
should	O
be	O
investigated	O
in	O
CML	B-Anatomy
.	O
Pbx1	O
is	O
a	O
downstream	O
target	O
of	O
Evi	O
-	O
1	O
in	O
hematopoietic	B-Anatomy
stem	I-Anatomy
/	I-Anatomy
progenitors	I-Anatomy
and	O
leukemic	B-Anatomy
cells	I-Anatomy
.	O
Ecotropic	O
viral	O
integration	O
site	O
-	O
1	O
(	O
Evi	O
-	O
1	O
)	O
is	O
a	O
nuclear	B-Anatomy
transcription	O
factor	O
,	O
which	O
is	O
essential	O
for	O
the	O
proliferation	O
/	O
maintenance	O
of	O
hematopoietic	B-Anatomy
stem	I-Anatomy
cells	I-Anatomy
(	O
HSCs	B-Anatomy
)	O
.	O
Aberrant	O
expression	O
of	O
Evi	O
-	O
1	O
has	O
been	O
frequently	O
found	O
in	O
myeloid	B-Anatomy
leukemia	I-Anatomy
,	O
and	O
is	O
associated	O
with	O
a	O
poor	O
patient	O
survival	O
.	O
Recently	O
,	O
we	O
reported	O
candidate	O
target	O
genes	O
of	O
Evi	O
-	O
1	O
shared	O
in	O
HSCs	B-Anatomy
and	O
leukemic	B-Anatomy
cells	I-Anatomy
using	O
gene	O
expression	O
profiling	O
analysis	O
.	O
In	O
this	O
study	O
,	O
we	O
identified	O
Pbx1	O
,	O
a	O
proto	O
-	O
oncogene	O
in	O
hematopoietic	B-Anatomy
malignancy	I-Anatomy
,	O
as	O
a	O
target	O
gene	O
of	O
Evi	O
-	O
1	O
.	O
Overexpression	O
of	O
Evi	O
-	O
1	O
increased	O
Pbx1	O
expression	O
in	O
hematopoietic	B-Anatomy
stem	I-Anatomy
/	I-Anatomy
progenitor	I-Anatomy
cells	I-Anatomy
.	O
An	O
analysis	O
of	O
the	O
Pbx1	O
promoter	O
region	O
revealed	O
that	O
Evi	O
-	O
1	O
upregulates	O
Pbx1	O
transcription	O
.	O
Furthermore	O
,	O
reduction	O
of	O
Pbx1	O
levels	O
through	O
RNAi	O
-	O
mediated	O
knockdown	O
significantly	O
inhibited	O
Evi	O
-	O
1	O
-	O
induced	O
transformation	O
.	O
In	O
contrast	O
,	O
knockdown	O
of	O
Pbx1	O
did	O
not	O
impair	O
bone	B-Anatomy
marrow	I-Anatomy
transformation	O
by	O
E2A	O
/	O
HLF	O
or	O
AML1	O
/	O
ETO	O
,	O
suggesting	O
that	O
Pbx1	O
is	O
specifically	O
required	O
for	O
the	O
maintenance	O
of	O
bone	B-Anatomy
marrow	I-Anatomy
transformation	O
mediated	O
by	O
Evi	O
-	O
1	O
.	O
These	O
results	O
indicate	O
that	O
Pbx1	O
is	O
a	O
target	O
gene	O
of	O
Evi	O
-	O
1	O
involved	O
in	O
Evi	O
-	O
1	O
-	O
mediated	O
leukemogenesis	O
.	O
Tumor	B-Anatomy
Angiogenesis	O
:	O
Initiation	O
and	O
Targeting	O
-	O
Therapeutic	O
Targeting	O
of	O
an	O
FGF	O
-	O
Binding	O
Protein	O
,	O
an	O
Angiogenic	O
Switch	O
Molecule	O
,	O
and	O
Indicator	O
of	O
Early	O
Stages	O
of	O
Gastrointestinal	B-Anatomy
Adenocarcinomas	I-Anatomy
-	O
.	O
Tumor	B-Anatomy
angiogenesis	O
has	O
been	O
related	O
to	O
the	O
initiation	O
as	O
well	O
as	O
progression	O
toward	O
more	O
aggressive	O
behavior	O
of	O
human	O
tumors	B-Anatomy
.	O
In	O
particular	O
,	O
the	O
activity	O
of	O
angiogenic	O
factors	O
is	O
crucial	O
for	O
tumor	B-Anatomy
progression	O
.	O
We	O
previously	O
characterized	O
a	O
secreted	O
fibroblast	O
growth	O
factor	O
-	O
binding	O
protein	O
(	O
FGF	O
-	O
BP	O
)	O
as	O
a	O
chaperone	O
molecule	O
,	O
which	O
binds	O
to	O
various	O
FGFs	O
,	O
enhances	O
FGF	O
-	O
mediated	O
biochemical	O
and	O
biologic	O
events	O
and	O
importantly	O
is	O
a	O
crucial	O
rate	O
-	O
limiting	O
factor	O
for	O
tumor	B-Anatomy
-	O
dependent	O
angiogenesis	O
.	O
We	O
generated	O
monoclonal	O
antibodies	O
that	O
target	O
FGF	O
-	O
BP	O
protein	O
and	O
used	O
them	O
as	O
a	O
tool	O
to	O
evaluate	O
frequency	O
and	O
pattern	O
of	O
FGF	O
-	O
BP	O
expression	O
during	O
the	O
malignant	O
progression	O
of	O
pancreas	B-Anatomy
and	O
colorectal	B-Anatomy
carcinoma	I-Anatomy
in	O
archival	O
tissue	B-Anatomy
samples	I-Anatomy
.	O
We	O
found	O
that	O
FGF	O
-	O
BP	O
is	O
dramatically	O
upregulated	O
during	O
the	O
initiation	O
of	O
colorectal	B-Anatomy
and	O
pancreatic	B-Anatomy
adenocarcinoma	I-Anatomy
.	O
Crucial	O
genetic	O
events	O
underlying	O
the	O
initiation	O
and	O
progression	O
of	O
colorectal	B-Anatomy
and	O
pancreatic	B-Anatomy
adenocarcinoma	I-Anatomy
with	O
a	O
particular	O
focus	O
on	O
the	O
modulation	O
of	O
angiogenesis	O
and	O
antiangiogenic	O
therapies	O
are	O
discussed	O
.	O
We	O
propose	O
that	O
the	O
upregulation	O
of	O
the	O
secreted	O
FGF	O
-	O
BP	O
protein	O
during	O
early	O
phases	O
of	O
pancreas	B-Anatomy
and	O
colon	B-Anatomy
cancer	I-Anatomy
could	O
make	O
this	O
protein	O
a	O
possible	O
serum	B-Anatomy
marker	O
indicating	O
the	O
presence	O
of	O
high	O
-	O
risk	O
premalignant	B-Anatomy
lesions	I-Anatomy
.	O
Furthermore	O
,	O
the	O
biological	O
activity	O
of	O
FGF	O
-	O
BP	O
is	O
neutralized	O
by	O
monoclonal	O
antibodies	O
suggesting	O
the	O
potential	O
for	O
antibody	O
-	O
based	O
therapeutic	O
targeting	O
.	O
Range	O
of	O
motion	O
limitation	O
after	O
rotator	B-Anatomy
cuff	I-Anatomy
repair	O
.	O
HYPOTHESIS	O
:	O
This	O
study	O
was	O
conducted	O
to	O
identify	O
preoperative	O
factors	O
correlating	O
with	O
limited	O
motion	O
after	O
rotator	B-Anatomy
cuff	I-Anatomy
repair	O
(	O
RCR	O
)	O
and	O
to	O
evaluate	O
the	O
affect	O
of	O
loss	O
of	O
motion	O
on	O
outcome	O
.	O
We	O
hypothesized	O
that	O
patients	O
with	O
preoperative	O
ROM	O
loss	O
,	O
diabetes	O
,	O
and	O
workman	O
'	O
s	O
compensation	O
claims	O
would	O
exhibit	O
postoperative	O
ROM	O
loss	O
at	O
3	O
months	O
.	O
MATERIAL	O
AND	O
METHODS	O
:	O
Preoperative	O
and	O
postoperative	O
evaluations	O
,	O
including	O
outcomes	O
assessment	O
and	O
physical	O
examination	O
parameters	O
,	O
were	O
reviewed	O
for	O
345	O
patients	O
who	O
underwent	O
RCR	O
.	O
Correlations	O
between	O
demographic	O
,	O
physical	O
examination	O
,	O
and	O
surgical	O
variables	O
and	O
postoperative	O
limitation	O
of	O
motion	O
and	O
need	O
for	O
capsular	O
release	O
were	O
determined	O
.	O
RESULTS	O
:	O
At	O
3	O
-	O
month	O
follow	O
-	O
up	O
,	O
mean	O
active	O
forward	O
elevation	O
(	O
AFE	O
)	O
,	O
active	O
external	O
rotation	O
(	O
AER	O
)	O
,	O
and	O
passive	O
internal	O
rotation	O
(	O
PIR	O
)	O
were	O
90	O
%	O
,	O
78	O
%	O
,	O
and	O
80	O
%	O
of	O
the	O
contralateral	O
side	O
.	O
Limitation	O
of	O
preoperative	O
motion	O
correlated	O
with	O
limitation	O
of	O
postoperative	O
AFE	O
,	O
AER	O
,	O
and	O
PIR	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O
Forty	O
-	O
seven	O
patients	O
considered	O
clinically	O
stiff	O
were	O
followed	O
at	O
1	O
year	O
postoperatively	O
.	O
Three	O
patients	O
required	O
arthroscopic	O
capsular	O
release	O
for	O
persistent	O
range	O
of	O
motion	O
loss	O
.	O
CONCLUSION	O
:	O
Early	O
postoperative	O
limitation	O
of	O
motion	O
after	O
RCR	O
is	O
associated	O
with	O
restricted	O
preoperative	O
motion	O
.	O
Other	O
factors	O
,	O
including	O
diabetes	O
mellitus	O
and	O
worker	O
'	O
s	O
compensation	O
claim	O
,	O
are	O
also	O
associated	O
with	O
range	O
of	O
motion	O
loss	O
.	O
Most	O
shoulders	B-Anatomy
with	O
early	O
motion	O
loss	O
recover	O
motion	O
and	O
rarely	O
require	O
capsular	O
release	O
.	O
The	O
role	O
of	O
hypoxia	O
in	O
2	O
-	O
butoxyethanol	O
-	O
induced	O
hemangiosarcoma	B-Anatomy
.	O
To	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
compound	O
-	O
induced	O
hemangiosarcomas	B-Anatomy
in	O
mice	O
,	O
and	O
therefore	O
,	O
their	O
human	O
relevance	O
,	O
a	O
systems	O
biology	O
approach	O
was	O
undertaken	O
using	O
transcriptomics	O
and	O
Causal	O
Network	O
Modeling	O
from	O
mice	O
treated	O
with	O
2	O
-	O
butoxyethanol	O
(	O
2	O
-	O
BE	O
)	O
.	O
2	O
-	O
BE	O
is	O
a	O
hemolytic	O
agent	O
that	O
induces	O
hemangiosarcomas	B-Anatomy
in	O
mice	O
.	O
We	O
hypothesized	O
that	O
the	O
hemolysis	O
induced	O
by	O
2	O
-	O
BE	O
would	O
result	O
in	O
local	O
tissue	B-Anatomy
hypoxia	O
,	O
a	O
well	O
-	O
documented	O
trigger	O
for	O
endothelial	B-Anatomy
cell	I-Anatomy
proliferation	O
leading	O
to	O
hemangiosarcoma	B-Anatomy
.	O
Gene	O
expression	O
data	O
from	O
bone	B-Anatomy
marrow	I-Anatomy
(	O
BM	B-Anatomy
)	O
,	O
liver	B-Anatomy
,	O
and	O
spleen	B-Anatomy
of	O
mice	O
exposed	O
to	O
a	O
single	O
dose	O
(	O
4	O
h	O
)	O
or	O
seven	O
daily	O
doses	O
of	O
2	O
-	O
BE	O
were	O
used	O
to	O
develop	O
a	O
mechanistic	O
model	O
of	O
hemangiosarcoma	B-Anatomy
.	O
The	O
resulting	O
mechanistic	O
model	O
confirms	O
previous	O
work	O
proposing	O
that	O
2	O
-	O
BE	O
induces	O
macrophage	B-Anatomy
activation	O
and	O
inflammation	O
in	O
the	O
liver	B-Anatomy
.	O
In	O
addition	O
,	O
the	O
model	O
supports	O
local	O
tissue	B-Anatomy
hypoxia	O
in	O
the	O
liver	B-Anatomy
and	O
spleen	B-Anatomy
,	O
coupled	O
with	O
increased	O
erythropoeitin	O
signaling	O
and	O
erythropoiesis	O
in	O
the	O
spleen	B-Anatomy
and	O
BM	B-Anatomy
,	O
and	O
suppression	O
of	O
mechanisms	O
that	O
contribute	O
to	O
genomic	O
stability	O
,	O
events	O
that	O
could	O
be	O
contributing	O
factors	O
to	O
hemangiosarcoma	B-Anatomy
formation	O
.	O
Finally	O
,	O
an	O
immunohistochemistry	O
method	O
(	O
Hypoxyprobe	O
)	O
demonstrated	O
that	O
tissue	B-Anatomy
hypoxia	O
was	O
present	O
in	O
the	O
spleen	B-Anatomy
and	O
BM	B-Anatomy
.	O
Together	O
,	O
the	O
results	O
of	O
this	O
study	O
identify	O
molecular	O
mechanisms	O
that	O
initiate	O
hemangiosarcoma	B-Anatomy
,	O
a	O
key	O
step	O
in	O
understanding	O
safety	O
concerns	O
that	O
can	O
impact	O
drug	O
decision	O
processes	O
,	O
and	O
identified	O
hypoxia	O
as	O
a	O
possible	O
contributing	O
factor	O
for	O
2	O
-	O
BE	O
-	O
induced	O
hemangiosarcoma	B-Anatomy
in	O
mice	O
.	O
Pancreatic	B-Anatomy
endocrine	I-Anatomy
tumors	I-Anatomy
:	O
expression	O
profiling	O
evidences	O
a	O
role	O
for	O
AKT	O
-	O
mTOR	O
pathway	O
.	O
PURPOSE	O
:	O
We	O
investigated	O
the	O
global	O
gene	O
expression	O
in	O
a	O
large	O
panel	O
of	O
pancreatic	B-Anatomy
endocrine	I-Anatomy
tumors	I-Anatomy
(	O
PETs	B-Anatomy
)	O
aimed	O
at	O
identifying	O
new	O
potential	O
targets	O
for	O
therapy	O
and	O
biomarkers	O
to	O
predict	O
patient	O
outcome	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Using	O
a	O
custom	O
microarray	O
,	O
we	O
analyzed	O
72	O
primary	B-Anatomy
PETs	I-Anatomy
,	O
seven	O
matched	O
metastases	B-Anatomy
,	O
and	O
10	O
normal	O
pancreatic	B-Anatomy
samples	I-Anatomy
.	O
Relevant	O
differentially	O
expressed	O
genes	O
were	O
validated	O
by	O
either	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
or	O
immunohistochemistry	O
on	O
tissue	B-Anatomy
microarrays	O
.	O
RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
:	O
tuberous	O
sclerosis	O
2	O
(	O
TSC2	O
)	O
and	O
phosphatase	O
and	O
tensin	O
homolog	O
(	O
PTEN	O
)	O
were	O
downregulated	O
in	O
most	O
of	O
the	O
primary	B-Anatomy
tumors	I-Anatomy
,	O
and	O
their	O
low	O
expression	O
was	O
significantly	O
associated	O
with	O
shorter	O
disease	O
-	O
free	O
and	O
overall	O
survival	O
;	O
somatostatin	O
receptor	O
2	O
(	O
SSTR2	O
)	O
was	O
absent	O
or	O
very	O
low	O
in	O
insulinomas	B-Anatomy
compared	O
with	O
nonfunctioning	O
tumors	B-Anatomy
;	O
and	O
expression	O
of	O
fibroblast	O
growth	O
factor	O
13	O
(	O
FGF13	O
)	O
gene	O
was	O
significantly	O
associated	O
with	O
the	O
occurrence	O
of	O
liver	B-Anatomy
metastasis	O
and	O
shorter	O
disease	O
-	O
free	O
survival	O
.	O
TSC2	O
and	O
PTEN	O
are	O
two	O
key	O
inhibitors	O
of	O
the	O
Akt	O
/	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
pathway	O
and	O
the	O
specific	O
inhibition	O
of	O
mTOR	O
with	O
rapamycin	O
or	O
RAD001	O
inhibited	O
cell	B-Anatomy
proliferation	O
of	O
PET	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
CONCLUSION	O
:	O
Our	O
results	O
strongly	O
support	O
a	O
role	O
for	O
PI3K	O
/	O
Akt	O
/	O
mTOR	O
pathway	O
in	O
PET	B-Anatomy
,	O
which	O
ties	O
in	O
with	O
the	O
fact	O
that	O
mTOR	O
inhibitors	O
have	O
reached	O
phase	O
III	O
trials	O
in	O
neuroendocrine	B-Anatomy
tumors	I-Anatomy
.	O
The	O
finding	O
of	O
differential	O
SSTR	O
expression	O
raises	O
the	O
potential	O
for	O
SSTR	O
expression	O
to	O
be	O
evaluated	O
as	O
a	O
marker	O
of	O
response	O
to	O
somatostatin	O
analogs	O
.	O
Finally	O
,	O
we	O
identified	O
FGF13	O
as	O
a	O
new	O
prognostic	O
marker	O
that	O
predicted	O
poorer	O
outcome	O
in	O
patients	O
who	O
were	O
clinically	O
considered	O
free	O
from	O
disease	O
.	O
Neural	O
network	O
analysis	O
of	O
spectroscopic	O
data	O
of	O
lycopene	O
and	O
beta	O
-	O
carotene	O
content	O
in	O
food	O
samples	O
compared	O
to	O
HPLC	O
-	O
UV	O
-	O
vis	O
.	O
In	O
this	O
study	O
a	O
neural	O
network	O
(	O
NN	O
)	O
model	O
was	O
designed	O
to	O
predict	O
lycopene	O
and	O
beta	O
-	O
carotene	O
concentrations	O
in	O
food	O
samples	O
,	O
combined	O
with	O
a	O
simple	O
and	O
fast	O
technique	O
,	O
such	O
as	O
UV	O
-	O
vis	O
spectroscopy	O
.	O
The	O
measurement	O
of	O
the	O
absorbance	O
at	O
446	O
and	O
502	O
nm	O
of	O
different	O
beta	O
-	O
carotene	O
and	O
lycopene	O
standard	O
mixtures	O
was	O
used	O
to	O
optimize	O
a	O
neural	O
network	O
based	O
on	O
a	O
multilayer	O
perceptron	O
(	O
MLP	O
)	O
(	O
learning	O
and	O
verification	O
process	O
)	O
.	O
Then	O
,	O
for	O
validation	O
purposes	O
,	O
the	O
optimized	O
NN	O
has	O
been	O
applied	O
to	O
determine	O
the	O
concentration	O
of	O
both	O
compounds	O
in	O
food	O
samples	O
(	O
fresh	O
tomato	B-Anatomy
,	O
tomato	B-Anatomy
concentrate	O
,	O
tomato	B-Anatomy
sauce	O
,	O
ketchup	O
,	O
tomato	B-Anatomy
juice	I-Anatomy
,	O
watermelon	B-Anatomy
,	O
medlar	B-Anatomy
,	O
green	B-Anatomy
pepper	I-Anatomy
,	O
and	O
carrots	B-Anatomy
)	O
,	O
comparing	O
the	O
NN	O
results	O
with	O
the	O
known	O
values	O
of	O
these	O
compounds	O
obtained	O
by	O
analytical	O
techniques	O
(	O
UV	O
-	O
vis	O
and	O
HPLC	O
)	O
.	O
It	O
was	O
concluded	O
that	O
when	O
the	O
MLP	O
-	O
NN	O
is	O
used	O
within	O
the	O
range	O
studied	O
,	O
the	O
optimized	O
NN	O
is	O
able	O
to	O
estimate	O
the	O
beta	O
-	O
carotene	O
and	O
lycopene	O
concentrations	O
in	O
food	O
samples	O
with	O
an	O
adequate	O
accuracy	O
,	O
solving	O
the	O
UV	O
-	O
vis	O
interference	O
of	O
beta	O
-	O
carotene	O
and	O
lycopene	O
.	O
ICAM	O
-	O
3	O
enhances	O
the	O
migratory	O
and	O
invasive	O
potential	O
of	O
human	O
non	B-Anatomy
-	I-Anatomy
small	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
by	O
inducing	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
via	O
Akt	O
and	O
CREB	O
.	O
We	O
have	O
previously	O
reported	O
that	O
intercellular	O
adhesion	O
molecule	O
-	O
3	O
(	O
ICAM	O
-	O
3	O
)	O
is	O
associated	O
with	O
an	O
increase	O
of	O
cellular	B-Anatomy
radio	O
-	O
resistance	O
and	O
cancer	B-Anatomy
cell	I-Anatomy
proliferation	O
.	O
In	O
this	O
study	O
,	O
we	O
hypothesized	O
that	O
ICAM	O
-	O
3	O
has	O
an	O
additional	O
effect	O
on	O
cancer	B-Anatomy
cell	I-Anatomy
migration	O
and	O
invasion	O
because	O
molecules	O
induced	O
by	O
ICAM	O
-	O
3	O
are	O
known	O
as	O
regulators	O
of	O
cell	B-Anatomy
migration	O
and	O
invasion	O
.	O
To	O
examine	O
this	O
hypothesis	O
,	O
we	O
used	O
NCI	B-Anatomy
-	I-Anatomy
H1299	I-Anatomy
non	I-Anatomy
-	I-Anatomy
small	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
cancer	I-Anatomy
(	I-Anatomy
NSCLC	I-Anatomy
)	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
(	O
p53	B-Anatomy
and	I-Anatomy
PTEN	I-Anatomy
cell	I-Anatomy
)	O
and	O
constructed	O
an	O
ICAM	O
-	O
3	O
-	O
over	O
-	O
expressing	O
stable	O
transfectant	B-Anatomy
,	O
which	O
exhibited	O
increased	O
cell	B-Anatomy
migration	O
and	O
invasion	O
.	O
The	O
increased	O
migration	O
and	O
invasion	O
resulted	O
from	O
up	O
-	O
regulation	O
of	O
expression	O
and	O
activities	O
of	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
.	O
ICAM	O
-	O
3	O
also	O
increased	O
Akt	O
phosphorylation	O
,	O
which	O
caused	O
an	O
increase	O
in	O
cellular	B-Anatomy
migration	O
/	O
invasion	O
and	O
MMP	O
activities	O
.	O
Activity	O
of	O
several	O
transcriptional	O
factors	O
located	O
downstream	O
in	O
the	O
Akt	O
pathway	O
was	O
also	O
tested	O
,	O
and	O
constitutive	O
activation	O
of	O
adenosine	O
3	O
'	O
,	O
5	O
'	O
-	O
monophosphate	O
response	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
by	O
ICAM	O
-	O
3	O
was	O
detected	O
.	O
Blockage	O
of	O
the	O
Akt	O
pathway	O
attenuated	O
CREB	O
activation	O
,	O
and	O
a	O
decrease	O
in	O
CREB	O
expression	O
reduced	O
cellular	B-Anatomy
migration	O
/	O
invasion	O
and	O
activity	O
of	O
MMPs	O
.	O
This	O
result	O
indicates	O
that	O
CREB	O
functions	O
in	O
the	O
signaling	O
pathway	O
between	O
Akt	O
and	O
MMP	O
.	O
We	O
also	O
showed	O
ICAM	O
-	O
3	O
-	O
induced	O
cell	B-Anatomy
migration	O
and	O
invasion	O
in	O
NCI	B-Anatomy
-	I-Anatomy
H460	I-Anatomy
NSCLC	I-Anatomy
cells	I-Anatomy
(	O
wild	B-Anatomy
-	I-Anatomy
type	I-Anatomy
p53	I-Anatomy
and	I-Anatomy
PTEN	I-Anatomy
cell	I-Anatomy
)	O
through	O
the	O
same	O
signaling	O
pathway	O
.	O
Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
ICAM	O
-	O
3	O
stimulates	O
cancer	B-Anatomy
cell	I-Anatomy
migration	O
/	O
invasion	O
via	O
ICAM	O
-	O
3	O
/	O
Akt	O
/	O
CREB	O
/	O
MMP	O
pathway	O
regardless	O
of	O
p53	O
and	O
PTEN	O
status	O
,	O
and	O
this	O
reflects	O
the	O
possibility	O
that	O
ICAM	O
-	O
3	O
could	O
be	O
considered	O
as	O
a	O
candidate	O
for	O
anti	O
-	O
cancer	B-Anatomy
drug	O
development	O
and	O
as	O
a	O
cancer	B-Anatomy
diagnostic	O
marker	O
.	O
Costs	O
of	O
hip	B-Anatomy
fracture	O
.	O
Rehabilitation	O
of	O
180	O
patients	O
in	O
primary	O
health	O
care	O
.	O
Costs	O
related	O
to	O
functional	O
status	O
were	O
calculated	O
for	O
180	O
consecutive	O
hip	B-Anatomy
fracture	O
patients	O
(	O
mean	O
age	O
78	O
years	O
)	O
who	O
were	O
admitted	O
from	O
their	O
own	O
home	O
and	O
rehabilitated	O
in	O
primary	O
health	O
care	O
.	O
Within	O
4	O
months	O
after	O
the	O
fracture	O
,	O
75	O
percent	O
of	O
the	O
patients	O
had	O
been	O
discharged	O
to	O
their	O
own	O
home	O
,	O
9	O
percent	O
were	O
dead	O
,	O
and	O
the	O
short	O
-	O
term	O
medical	O
treatment	O
costs	O
per	O
patient	O
were	O
SEK	O
43	O
,	O
000	O
,	O
whereas	O
the	O
total	O
costs	O
including	O
communal	O
help	O
and	O
costs	O
for	O
living	O
accommodations	O
after	O
discharge	O
were	O
twice	O
as	O
high	O
.	O
The	O
total	O
costs	O
per	O
patient	O
for	O
long	O
-	O
term	O
medical	O
treatment	O
(	O
from	O
4	O
months	O
up	O
to	O
3	O
years	O
after	O
fracture	O
)	O
were	O
7	O
percent	O
of	O
the	O
short	O
-	O
term	O
medical	O
treatment	O
costs	O
.	O
Patients	O
with	O
a	O
cervical	B-Anatomy
fracture	O
discharged	O
to	O
their	O
own	O
home	O
and	O
with	O
good	O
functional	O
status	O
consumed	O
only	O
one	O
fifth	O
of	O
the	O
resources	O
that	O
patients	O
with	O
a	O
trochanteric	B-Anatomy
fracture	O
discharged	O
to	O
institutional	O
care	O
and	O
who	O
had	O
reduced	O
functional	O
status	O
consumed	O
.	O
A	O
substantial	O
part	O
of	O
the	O
costs	O
can	O
be	O
saved	O
by	O
improved	O
organization	O
of	O
rehabilitation	O
after	O
discharge	O
from	O
the	O
hospital	O
.	O
A	O
further	O
cost	O
reduction	O
would	O
require	O
a	O
combination	O
of	O
technologic	O
,	O
social	O
,	O
and	O
organizational	O
changes	O
aimed	O
at	O
early	O
discharge	O
and	O
continued	O
follow	O
-	O
up	O
in	O
primary	O
health	O
care	O
.	O
The	O
role	O
of	O
p53	O
in	O
glucose	O
metabolism	O
.	O
The	O
p53	O
protein	O
functions	O
to	O
prevent	O
tumour	B-Anatomy
development	O
by	O
inhibiting	O
the	O
outgrowth	O
of	O
stressed	O
or	O
damaged	O
cells	B-Anatomy
.	O
In	O
addition	O
to	O
well	O
established	O
functions	O
to	O
block	O
cell	B-Anatomy
proliferation	O
,	O
recent	O
studies	O
have	O
revealed	O
a	O
role	O
for	O
p53	O
in	O
the	O
regulation	O
of	O
pathways	O
involved	O
in	O
glucose	O
metabolism	O
.	O
The	O
metabolic	O
functions	O
of	O
p53	O
resist	O
the	O
shift	O
to	O
glycolysis	O
that	O
is	O
characteristically	O
seen	O
in	O
cancers	B-Anatomy
,	O
and	O
also	O
help	O
cells	B-Anatomy
adapt	O
to	O
and	O
survive	O
limited	O
periods	O
of	O
metabolic	O
stress	O
.	O
Such	O
activities	O
of	O
p53	O
would	O
not	O
only	O
help	O
to	O
prevent	O
cancer	B-Anatomy
development	O
,	O
but	O
might	O
also	O
contribute	O
to	O
non	O
-	O
tumour	B-Anatomy
related	O
roles	O
for	O
p53	O
,	O
such	O
as	O
in	O
the	O
regulation	O
of	O
longevity	O
.	O
These	O
new	O
functions	O
of	O
p53	O
are	O
providing	O
interesting	O
possibilities	O
for	O
the	O
development	O
of	O
novel	O
therapies	O
.	O
14	O
-	O
3	O
-	O
3zeta	O
Overexpression	O
and	O
abnormal	O
beta	O
-	O
catenin	O
expression	O
are	O
associated	O
with	O
poor	O
differentiation	O
and	O
progression	O
in	O
stage	B-Anatomy
I	I-Anatomy
non	I-Anatomy
-	I-Anatomy
small	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
cancer	I-Anatomy
.	O
Recent	O
studies	O
have	O
shown	O
that	O
14	O
-	O
3	O
-	O
3zeta	O
interacted	O
with	O
other	O
key	O
cellular	B-Anatomy
proteins	O
involved	O
in	O
the	O
tumor	B-Anatomy
development	O
and	O
progression	O
.	O
Knowledge	O
of	O
14	O
-	O
3	O
-	O
3zeta	O
and	O
beta	O
-	O
catenin	O
expression	O
and	O
clinical	O
significance	O
in	O
the	O
same	O
tumor	B-Anatomy
tissues	I-Anatomy
is	O
limited	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
expression	O
and	O
significance	O
of	O
14	O
-	O
3	O
-	O
3zeta	O
and	O
beta	O
-	O
catenin	O
in	O
stage	O
I	O
non	B-Anatomy
-	I-Anatomy
small	I-Anatomy
-	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
cancer	I-Anatomy
(	O
NSCLC	B-Anatomy
)	O
.	O
Specimens	B-Anatomy
of	O
NSCLC	B-Anatomy
and	O
adjacent	O
normal	O
lung	B-Anatomy
tissues	I-Anatomy
were	O
collected	O
from	O
110	O
patients	O
.	O
The	O
expressions	O
of	O
14	O
-	O
3	O
-	O
3zeta	O
and	O
beta	O
-	O
catenin	O
were	O
detected	O
by	O
western	O
blotting	O
,	O
double	O
labeling	O
immunofluorescence	O
,	O
confocal	O
laser	O
scanning	O
microscopy	O
and	O
immunohistochemistry	O
.	O
The	O
expression	O
of	O
14	O
-	O
3	O
-	O
3zeta	O
was	O
upregulated	O
in	O
stage	B-Anatomy
I	I-Anatomy
NSCLC	I-Anatomy
.	O
Further	O
,	O
the	O
overexpression	O
of	O
14	O
-	O
3	O
-	O
3zeta	O
correlated	O
with	O
histological	O
grades	O
,	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
and	O
poor	O
clinical	O
outcome	O
.	O
Abnormal	O
expression	O
of	O
beta	O
-	O
catenin	O
was	O
significantly	O
correlated	O
with	O
poor	O
differentiation	O
and	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
.	O
Abnormal	O
beta	O
-	O
catenin	O
expression	O
was	O
associated	O
significantly	O
with	O
positive	O
14	O
-	O
3	O
-	O
3zeta	O
expression	O
.	O
In	O
conclusion	O
,	O
14	O
-	O
3	O
-	O
3zeta	O
and	O
beta	O
-	O
catenin	O
might	O
have	O
an	O
important	O
role	O
in	O
development	O
,	O
progression	O
and	O
metastatic	O
process	O
of	O
NSCLC	B-Anatomy
.	O
14	O
-	O
3	O
-	O
3zeta	O
might	O
be	O
used	O
as	O
prognostic	O
biomarkers	O
for	O
NSCLC	B-Anatomy
.	O
A	O
randomized	O
pilot	O
study	O
of	O
the	O
Engaging	O
Moms	O
Program	O
for	O
family	O
drug	O
court	O
.	O
In	O
response	O
to	O
the	O
need	O
for	O
effective	O
drug	O
court	O
interventions	O
,	O
the	O
effectiveness	O
of	O
the	O
Engaging	O
Moms	O
Program	O
(	O
EMP	O
)	O
versus	O
Intensive	O
Case	O
Management	O
Services	O
(	O
ICMS	O
)	O
on	O
multiple	O
outcomes	O
for	O
mothers	O
enrolled	O
in	O
family	O
drug	O
court	O
was	O
investigated	O
.	O
In	O
this	O
intent	O
-	O
to	O
-	O
treat	O
study	O
,	O
mothers	O
(	O
N	O
=	O
62	O
)	O
were	O
randomly	O
assigned	O
to	O
either	O
usual	O
drug	O
court	O
care	O
or	O
the	O
Engaging	O
Moms	O
drug	O
court	O
program	O
.	O
Mothers	O
were	O
assessed	O
at	O
intake	O
and	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
months	O
following	O
intake	O
.	O
Results	O
indicated	O
that	O
at	O
18	O
months	O
post	O
drug	O
court	O
enrollment	O
,	O
77	O
%	O
of	O
mothers	O
assigned	O
to	O
EMP	O
versus	O
55	O
%	O
of	O
mothers	O
assigned	O
to	O
ICMS	O
had	O
positive	O
child	O
welfare	O
dispositions	O
.	O
There	O
were	O
statistically	O
significant	O
time	O
effects	O
for	O
both	O
intervention	O
groups	O
on	O
multiple	O
outcomes	O
including	O
substance	O
use	O
,	O
mental	O
health	O
,	O
parenting	O
practices	O
,	O
and	O
family	O
functioning	O
.	O
EMP	O
showed	O
equal	O
or	O
better	O
improvement	O
than	O
ICMS	O
on	O
all	O
outcomes	O
.	O
The	O
results	O
suggest	O
that	O
EMP	O
in	O
family	O
drug	O
court	O
is	O
a	O
viable	O
and	O
promising	O
intervention	O
approach	O
to	O
reduce	O
maternal	O
addiction	O
and	O
child	O
maltreatment	O
.	O
p24	O
family	O
type	O
1	O
transmembrane	B-Anatomy
proteins	O
are	O
required	O
for	O
insulin	O
biosynthesis	O
and	O
secretion	O
in	O
pancreatic	B-Anatomy
beta	I-Anatomy
-	I-Anatomy
cells	I-Anatomy
.	O
The	O
p24	O
protein	O
family	O
have	O
multiple	O
functions	O
in	O
protein	O
transport	O
in	O
the	O
early	O
secretory	O
pathway	O
.	O
In	O
this	O
study	O
we	O
examined	O
the	O
role	O
of	O
p24	O
proteins	O
in	O
insulin	O
transport	O
.	O
Several	O
members	O
were	O
detected	O
in	O
insulinoma	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
and	O
rat	O
islets	B-Anatomy
and	O
expression	O
levels	O
positively	O
correlated	O
with	O
insulin	O
abundance	O
,	O
particularly	O
for	O
p24delta1	O
and	O
p24beta1	O
.	O
Knocking	O
down	O
p24delta1	O
in	O
insulinoma	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
,	O
which	O
also	O
resulted	O
in	O
the	O
concomitant	O
knock	O
-	O
down	O
of	O
other	O
family	O
members	O
,	O
impaired	O
glucose	O
-	O
stimulated	O
insulin	O
secretion	O
,	O
decreased	O
total	O
cellular	B-Anatomy
insulin	O
content	O
and	O
reduced	O
proinsulin	O
biosynthesis	O
.	O
There	O
was	O
no	O
effect	O
on	O
overall	O
protein	O
biosynthesis	O
or	O
ER	O
stress	O
.	O
These	O
results	O
suggest	O
that	O
p24delta1	O
and	O
possibly	O
other	O
p24	O
family	O
proteins	O
are	O
required	O
for	O
normal	O
insulin	O
biosynthesis	O
and	O
subsequent	O
secretion	O
in	O
pancreatic	B-Anatomy
beta	I-Anatomy
-	I-Anatomy
cells	I-Anatomy
.	O
Absence	O
of	O
microbiota	O
(	O
germ	O
-	O
free	O
conditions	O
)	O
accelerates	O
the	O
atherosclerosis	O
in	O
ApoE	O
-	O
deficient	O
mice	O
fed	O
standard	O
low	O
cholesterol	O
diet	O
.	O
AIM	O
:	O
The	O
aim	O
of	O
our	O
work	O
was	O
to	O
determine	O
the	O
influence	O
of	O
intestinal	B-Anatomy
bacteria	O
on	O
the	O
development	O
of	O
atherosclerotic	B-Anatomy
lesions	I-Anatomy
using	O
apolipoprotein	O
E	O
(	O
ApoE	O
)	O
-	O
deficient	O
knockout	O
mice	O
.	O
METHODS	O
:	O
The	O
experiments	O
were	O
performed	O
on	O
ApoE	O
-	O
/	O
-	O
-	O
deficient	O
mouse	O
strain	O
C57BL	O
/	O
6	O
,	O
bred	O
under	O
germ	O
-	O
free	O
(	O
GF	O
)	O
conditions	O
for	O
two	O
generations	O
or	O
under	O
conventional	O
conditions	O
with	O
defined	O
microflora	O
(	O
CV	O
)	O
.	O
The	O
mice	O
were	O
fed	O
a	O
standard	O
low	O
cholesterol	O
diet	O
or	O
cholesterol	O
-	O
rich	O
diet	O
for	O
3	O
-	O
4	O
months	O
.	O
We	O
studied	O
the	O
development	O
of	O
advanced	O
lesions	B-Anatomy
in	O
the	O
thoracic	B-Anatomy
and	O
abdominal	B-Anatomy
aorta	I-Anatomy
by	O
histological	O
,	O
morphometric	O
and	O
immunohistological	O
methods	O
.	O
RESULTS	O
:	O
Conventionally	O
reared	O
ApoE	O
-	O
/	O
-	O
mice	O
(	O
containing	O
no	O
pathogenic	O
intestinal	B-Anatomy
microbiota	O
)	O
and	O
fed	O
a	O
standard	O
low	O
cholesterol	O
diet	O
in	O
contrast	O
to	O
a	O
high	O
cholesterol	O
diet	O
did	O
not	O
develop	O
atherosclerotic	B-Anatomy
aortic	I-Anatomy
plaques	I-Anatomy
.	O
In	O
contrast	O
,	O
ApoE	O
-	O
/	O
-	O
mice	O
reared	O
under	O
germfree	O
conditions	O
for	O
2	O
generations	O
and	O
fed	O
a	O
low	O
cholesterol	O
diet	O
exhibited	O
atherosclerotic	B-Anatomy
plaques	I-Anatomy
in	O
the	O
aorta	B-Anatomy
.	O
Characteristic	O
lipid	O
deposition	O
with	O
foam	O
cells	B-Anatomy
and	O
macrophages	B-Anatomy
was	O
found	O
in	O
their	O
arterial	B-Anatomy
walls	I-Anatomy
.	O
CONCLUSION	O
:	O
In	O
contrast	O
to	O
the	O
absence	O
of	O
atherosclerotic	B-Anatomy
plaques	I-Anatomy
in	O
conventionally	O
reared	O
ApoE	O
-	O
deficient	O
mice	O
,	O
germ	O
-	O
free	O
ApoE	O
-	O
/	O
-	O
mice	O
consuming	O
the	O
same	O
low	O
cholesterol	O
standard	O
diet	O
developed	O
atherosclerotic	B-Anatomy
plaques	I-Anatomy
in	O
the	O
aorta	B-Anatomy
.	O
Differences	O
in	O
atherosclerotic	B-Anatomy
plaques	I-Anatomy
between	O
GF	O
and	O
CV	O
ApoE	O
-	O
/	O
-	O
mice	O
are	O
not	O
so	O
apparent	O
when	O
mice	O
are	O
fed	O
a	O
high	O
cholesterol	O
diet	O
.	O
Our	O
findings	O
thus	O
document	O
the	O
protective	O
effect	O
of	O
microbiota	O
(	O
commensal	O
bacteria	O
)	O
on	O
atherosclerosis	O
development	O
.	O
Expression	O
of	O
KISS1	O
and	O
MMP	O
-	O
9	O
in	O
non	B-Anatomy
-	I-Anatomy
small	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
cancer	I-Anatomy
and	O
their	O
relations	O
to	O
metastasis	O
and	O
survival	O
.	O
KISS1	O
and	O
matrix	O
metalloproteinase	O
-	O
9	O
(	O
MMP	O
-	O
9	O
)	O
may	O
play	O
important	O
roles	O
as	O
metastasis	O
suppressor	O
and	O
metastasis	O
promoter	O
genes	O
,	O
respectively	O
,	O
in	O
a	O
variety	O
of	O
malignancies	B-Anatomy
.	O
However	O
,	O
there	O
is	O
little	O
information	O
about	O
their	O
possible	O
roles	O
in	O
non	B-Anatomy
-	I-Anatomy
small	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
cancer	I-Anatomy
(	O
NSCLC	B-Anatomy
)	O
.	O
The	O
goals	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
mRNA	O
and	O
protein	O
expressions	O
of	O
KISS1	O
and	O
MMP	O
-	O
9	O
in	O
NSCLC	B-Anatomy
and	O
their	O
relations	O
to	O
metastasis	O
and	O
prognosis	O
.	O
The	O
mRNA	O
and	O
protein	O
expressions	O
of	O
KISS1	O
and	O
of	O
MMP	O
-	O
9	O
protein	O
were	O
detected	O
by	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
respectively	O
in	O
85	O
cases	O
of	O
NSCLC	B-Anatomy
,	O
and	O
their	O
matched	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
.	O
Expressions	O
of	O
KISS1	O
mRNA	O
and	O
protein	O
were	O
significantly	O
higher	O
in	O
low	O
TNM	O
stages	O
of	O
NSCLC	B-Anatomy
(	O
I	O
-	O
II	O
)	O
compared	O
to	O
more	O
advanced	O
stages	O
(	O
III	O
-	O
IV	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Moreover	O
,	O
in	O
advanced	O
TNM	O
stages	O
,	O
cases	O
without	O
metastasis	O
had	O
higher	O
KISS1	O
gene	O
expression	O
compared	O
to	O
those	O
with	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
In	O
contrast	O
,	O
MMP	O
-	O
9	O
expression	O
was	O
higher	O
in	O
stage	O
III	O
-	O
IV	O
NSCLC	B-Anatomy
cases	O
compared	O
to	O
stage	O
I	O
-	O
II	O
tumors	B-Anatomy
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
higher	O
in	O
NSCLC	B-Anatomy
cases	O
with	O
metastasis	O
than	O
those	O
without	O
metastasis	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
There	O
was	O
negative	O
correction	O
between	O
KISS1	O
and	O
MMP	O
-	O
9	O
protein	O
expression	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
The	O
5	O
-	O
year	O
survival	O
rate	O
in	O
cases	O
with	O
higher	O
KISS1	O
protein	O
expression	O
was	O
significantly	O
higher	O
than	O
in	O
those	O
with	O
low	O
expression	O
(	O
20	O
.	O
9	O
vs	O
.	O
2	O
.	O
4	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
However	O
,	O
the	O
5	O
-	O
year	O
survival	O
rate	O
of	O
patients	O
with	O
high	O
MMP	O
-	O
9	O
protein	O
expression	O
were	O
lower	O
than	O
those	O
with	O
low	O
expression	O
(	O
19	O
vs	O
.	O
4	O
.	O
7	O
%	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Our	O
data	O
suggest	O
that	O
KISS1	O
and	O
MMP	O
-	O
9	O
may	O
serve	O
as	O
potential	O
prognostic	O
and	O
therapeutic	O
markers	O
in	O
lung	B-Anatomy
cancer	I-Anatomy
.	O
A	O
generative	O
model	O
for	O
image	O
segmentation	O
based	O
on	O
label	O
fusion	O
.	O
We	O
propose	O
a	O
nonparametric	O
,	O
probabilistic	O
model	O
for	O
the	O
automatic	O
segmentation	O
of	O
medical	O
images	O
,	O
given	O
a	O
training	O
set	O
of	O
images	O
and	O
corresponding	O
label	O
maps	O
.	O
The	O
resulting	O
inference	O
algorithms	O
rely	O
on	O
pairwise	O
registrations	O
between	O
the	O
test	O
image	O
and	O
individual	O
training	O
images	O
.	O
The	O
training	O
labels	O
are	O
then	O
transferred	O
to	O
the	O
test	O
image	O
and	O
fused	O
to	O
compute	O
the	O
final	O
segmentation	O
of	O
the	O
test	O
subject	O
.	O
Such	O
label	O
fusion	O
methods	O
have	O
been	O
shown	O
to	O
yield	O
accurate	O
segmentation	O
,	O
since	O
the	O
use	O
of	O
multiple	O
registrations	O
captures	O
greater	O
inter	O
-	O
subject	O
anatomical	O
variability	O
and	O
improves	O
robustness	O
against	O
occasional	O
registration	O
failures	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
manuscript	O
presents	O
the	O
first	O
comprehensive	O
probabilistic	O
framework	O
that	O
rigorously	O
motivates	O
label	O
fusion	O
as	O
a	O
segmentation	O
approach	O
.	O
The	O
proposed	O
framework	O
allows	O
us	O
to	O
compare	O
different	O
label	O
fusion	O
algorithms	O
theoretically	O
and	O
practically	O
.	O
In	O
particular	O
,	O
recent	O
label	O
fusion	O
or	O
multiatlas	O
segmentation	O
algorithms	O
are	O
interpreted	O
as	O
special	O
cases	O
of	O
our	O
framework	O
.	O
We	O
conduct	O
two	O
sets	O
of	O
experiments	O
to	O
validate	O
the	O
proposed	O
methods	O
.	O
In	O
the	O
first	O
set	O
of	O
experiments	O
,	O
we	O
use	O
39	O
brain	B-Anatomy
MRI	O
scans	O
-	O
with	O
manually	O
segmented	O
white	B-Anatomy
matter	I-Anatomy
,	O
cerebral	B-Anatomy
cortex	I-Anatomy
,	O
ventricles	B-Anatomy
and	O
subcortical	B-Anatomy
structures	I-Anatomy
-	O
to	O
compare	O
different	O
label	O
fusion	O
algorithms	O
and	O
the	O
widely	O
-	O
used	O
FreeSurfer	O
whole	O
-	O
brain	B-Anatomy
segmentation	O
tool	O
.	O
Our	O
results	O
indicate	O
that	O
the	O
proposed	O
framework	O
yields	O
more	O
accurate	O
segmentation	O
than	O
FreeSurfer	O
and	O
previous	O
label	O
fusion	O
algorithms	O
.	O
In	O
a	O
second	O
experiment	O
,	O
we	O
use	O
brain	B-Anatomy
MRI	O
scans	O
of	O
282	O
subjects	O
to	O
demonstrate	O
that	O
the	O
proposed	O
segmentation	O
tool	O
is	O
sufficiently	O
sensitive	O
to	O
robustly	O
detect	O
hippocampal	B-Anatomy
volume	O
changes	O
in	O
a	O
study	O
of	O
aging	O
and	O
Alzheimer	O
'	O
s	O
Disease	O
.	O
Relationship	O
and	O
prognostic	O
significance	O
of	O
SPARC	O
and	O
VEGF	O
protein	O
expression	O
in	O
colon	B-Anatomy
cancer	I-Anatomy
.	O
BACKGROUND	O
:	O
SPARC	O
(	O
secreted	O
protein	O
,	O
acidic	O
and	O
rich	O
in	O
cysteine	O
)	O
is	O
closely	O
related	O
with	O
the	O
progress	O
,	O
invasion	O
and	O
metastasis	O
of	O
malignant	B-Anatomy
tumor	I-Anatomy
and	O
angiogenesis	O
.	O
METHODS	O
:	O
Using	O
human	O
colon	B-Anatomy
adenocarcinoma	I-Anatomy
tissues	I-Anatomy
(	O
hereinafter	O
referred	O
to	O
as	O
colon	B-Anatomy
cancer	I-Anatomy
)	O
and	O
their	O
corresponding	O
non	B-Anatomy
-	I-Anatomy
diseased	I-Anatomy
colon	I-Anatomy
from	O
114	O
patients	O
'	O
biopsies	B-Anatomy
,	O
the	O
expression	O
of	O
SPARC	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
were	O
investigated	O
by	O
immunohistochemistry	O
staining	O
to	O
assessment	O
the	O
relationship	O
between	O
SPARC	O
and	O
VEGF	O
,	O
as	O
well	O
as	O
their	O
prognostic	O
significance	O
in	O
patients	O
.	O
Evaluation	O
of	O
VEGF	O
expression	O
level	O
with	O
the	O
same	O
tissues	B-Anatomy
was	O
used	O
to	O
establish	O
the	O
antigenic	O
profiles	O
,	O
and	O
the	O
marker	O
of	O
CD34	O
staining	O
was	O
used	O
as	O
an	O
indicator	O
of	O
microvessel	B-Anatomy
density	O
(	O
MVD	O
)	O
.	O
RESULTS	O
:	O
SPARC	O
expression	O
was	O
mainly	O
in	O
the	O
stromal	B-Anatomy
cells	I-Anatomy
surrounding	O
the	O
colon	B-Anatomy
cancer	I-Anatomy
,	O
and	O
was	O
significant	O
difference	O
in	O
those	O
tissues	B-Anatomy
with	O
the	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
and	O
differentiation	O
degree	O
of	O
tumor	B-Anatomy
.	O
Expression	O
of	O
SPARC	O
was	O
significantly	O
correlated	O
with	O
the	O
expression	O
of	O
VEGF	O
and	O
MVD	O
in	O
colon	B-Anatomy
cancer	I-Anatomy
tissues	I-Anatomy
.	O
Patients	O
with	O
low	O
or	O
absence	O
expressing	O
SPARC	O
had	O
significantly	O
worse	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
in	O
a	O
Single	O
Factor	O
Analysis	O
;	O
Cox	O
Regression	O
Analysis	O
,	O
SPARC	O
emerged	O
as	O
an	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
independent	O
prognostic	O
factor	O
for	O
colon	B-Anatomy
cancer	I-Anatomy
.	O
CONCLUSION	O
:	O
The	O
low	O
expression	O
or	O
absence	O
of	O
stromal	B-Anatomy
SPARC	O
was	O
an	O
independent	O
prognostic	O
factor	O
for	O
poor	O
prognosis	O
of	O
colon	B-Anatomy
cancer	I-Anatomy
.	O
SPARC	O
maybe	O
involved	O
in	O
the	O
regulation	O
of	O
anti	O
-	O
angiogenesis	O
by	O
which	O
it	O
may	O
serve	O
as	O
a	O
novel	O
target	O
for	O
colon	B-Anatomy
cancer	I-Anatomy
treatment	O
as	O
well	O
as	O
a	O
novel	O
distinctive	O
marker	O
.	O
Listerine	O
:	O
past	O
,	O
present	O
and	O
future	O
-	O
-	O
a	O
test	O
of	O
thyme	O
.	O
Listerine	O
,	O
a	O
mouthrinse	O
composed	O
of	O
a	O
mixture	O
of	O
essential	B-Anatomy
oils	I-Anatomy
,	O
was	O
created	O
in	O
1879	O
and	O
was	O
originally	O
formulated	O
as	O
a	O
surgical	O
antiseptic	O
.	O
In	O
spite	O
of	O
its	O
known	O
antimicrobial	O
properties	O
it	O
was	O
thought	O
of	O
as	O
a	O
product	O
in	O
search	O
of	O
a	O
use	O
and	O
promoted	O
as	O
a	O
deterrent	O
for	O
halitosis	O
and	O
as	O
a	O
floor	O
cleaner	O
.	O
In	O
the	O
last	O
several	O
years	O
Listerine	O
has	O
emerged	O
as	O
a	O
bona	O
fide	O
therapeutic	O
agent	O
for	O
reduction	O
of	O
plaque	B-Anatomy
induced	O
oral	B-Anatomy
diseases	O
.	O
In	O
contrast	O
to	O
the	O
inconsistent	O
history	O
of	O
Listerine	O
,	O
systemic	O
antibiotics	O
discovered	O
in	O
the	O
1940	O
'	O
s	O
were	O
heralded	O
as	O
miracle	O
drugs	O
.	O
However	O
,	O
the	O
value	O
of	O
prophylactic	O
usage	O
of	O
antibiotics	O
has	O
come	O
under	O
scrutiny	O
as	O
a	O
result	O
of	O
increasing	O
resistance	O
and	O
adverse	O
reactions	O
.	O
Moreover	O
,	O
reports	O
by	O
both	O
American	O
and	O
British	O
professional	O
societies	O
have	O
led	O
to	O
a	O
re	O
-	O
evaluation	O
of	O
the	O
relative	O
risks	O
associated	O
with	O
plaque	B-Anatomy
induced	O
bacteremia	O
when	O
twice	O
-	O
yearly	O
visits	O
to	O
dental	B-Anatomy
professionals	O
are	O
compared	O
to	O
daily	O
activities	O
.	O
These	O
new	O
recommendations	O
and	O
revelations	O
open	O
the	O
door	O
for	O
local	O
antimicrobial	O
approaches	O
to	O
reduce	O
the	O
challenge	O
of	O
plaque	B-Anatomy
-	O
induced	O
bacteremias	O
.	O
These	O
issues	O
will	O
be	O
discussed	O
in	O
the	O
context	O
of	O
Listerine	O
,	O
its	O
intricate	O
and	O
complicated	O
past	O
,	O
and	O
its	O
connection	O
to	O
current	O
uses	O
in	O
oral	B-Anatomy
health	O
and	O
beyond	O
.	O
The	O
neural	B-Anatomy
stem	I-Anatomy
cell	I-Anatomy
fate	O
determinant	O
TLX	O
promotes	O
tumorigenesis	O
and	O
genesis	O
of	O
cells	B-Anatomy
resembling	O
glioma	B-Anatomy
stem	I-Anatomy
cells	I-Anatomy
.	O
A	O
growing	O
body	B-Anatomy
of	O
evidence	O
indicates	O
that	O
deregulation	O
of	O
stem	B-Anatomy
cell	I-Anatomy
fate	O
determinants	O
is	O
a	O
hallmark	O
of	O
many	O
types	O
of	O
malignancies	B-Anatomy
.	O
The	O
neural	B-Anatomy
stem	I-Anatomy
cell	I-Anatomy
fate	O
determinant	O
TLX	O
plays	O
a	O
pivotal	O
role	O
in	O
neurogenesis	O
in	O
the	O
adult	O
brain	B-Anatomy
by	O
maintaining	O
neural	B-Anatomy
stem	I-Anatomy
cells	I-Anatomy
.	O
Here	O
,	O
we	O
report	O
a	O
tumorigenic	O
role	O
of	O
TLX	O
in	O
brain	B-Anatomy
tumor	I-Anatomy
initiation	O
and	O
progression	O
.	O
Increased	O
TLX	O
expression	O
was	O
observed	O
in	O
a	O
number	O
of	O
glioma	B-Anatomy
cells	I-Anatomy
and	O
glioma	B-Anatomy
stem	I-Anatomy
cells	I-Anatomy
,	O
and	O
correlated	O
with	O
poor	O
survival	O
of	O
patients	O
with	O
gliomas	B-Anatomy
.	O
Ectopic	O
expression	O
of	O
TLX	O
in	O
the	O
U87MG	B-Anatomy
glioma	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
and	O
Ink4a	B-Anatomy
/	I-Anatomy
Arf	I-Anatomy
-	I-Anatomy
deficient	I-Anatomy
mouse	I-Anatomy
astrocytes	I-Anatomy
(	O
Ink4a	B-Anatomy
/	I-Anatomy
Arf	I-Anatomy
(	I-Anatomy
-	I-Anatomy
/	I-Anatomy
-	I-Anatomy
)	I-Anatomy
astrocytes	I-Anatomy
)	O
induced	O
cell	B-Anatomy
proliferation	O
with	O
a	O
concomitant	O
increase	O
in	O
cyclin	O
D	O
expression	O
,	O
and	O
accelerated	O
foci	B-Anatomy
formation	O
in	O
soft	O
agar	O
and	O
tumor	B-Anatomy
formation	O
in	O
in	O
vivo	O
transplantation	O
assays	O
.	O
Furthermore	O
,	O
overexpression	O
of	O
TLX	O
in	O
Ink4a	B-Anatomy
/	I-Anatomy
Arf	I-Anatomy
(	I-Anatomy
-	I-Anatomy
/	I-Anatomy
-	I-Anatomy
)	I-Anatomy
astrocytes	I-Anatomy
inhibited	O
cell	B-Anatomy
migration	O
and	O
invasion	O
and	O
promoted	O
neurosphere	B-Anatomy
formation	O
and	O
Nestin	O
expression	O
,	O
which	O
are	O
hallmark	O
characteristics	O
of	O
glioma	B-Anatomy
stem	I-Anatomy
cells	I-Anatomy
,	O
under	O
stem	B-Anatomy
cell	I-Anatomy
culture	O
conditions	O
.	O
Our	O
results	O
indicate	O
that	O
TLX	O
is	O
involved	O
in	O
glioma	B-Anatomy
stem	I-Anatomy
cell	I-Anatomy
genesis	O
and	O
represents	O
a	O
potential	O
therapeutic	O
target	O
for	O
this	O
type	O
of	O
malignancy	B-Anatomy
.	O
Acute	O
ablation	O
of	O
Langerhans	B-Anatomy
cells	I-Anatomy
enhances	O
skin	B-Anatomy
immune	O
responses	O
.	O
Understanding	O
the	O
function	O
of	O
Langerhans	B-Anatomy
cells	I-Anatomy
(	O
LCs	B-Anatomy
)	O
in	O
vivo	O
has	O
been	O
complicated	O
by	O
conflicting	O
results	O
from	O
LC	B-Anatomy
-	O
deficient	O
mice	O
.	O
Human	O
Langerin	O
-	O
DTA	O
mice	O
constitutively	O
lack	O
LCs	B-Anatomy
and	O
develop	O
exaggerated	O
contact	O
hypersensitivity	O
(	O
CHS	O
)	O
responses	O
.	O
Murine	O
Langerin	O
-	O
diphtheria	O
toxin	O
receptor	O
(	O
DTR	O
)	O
mice	O
allow	O
for	O
the	O
inducible	O
elimination	O
of	O
LCs	B-Anatomy
and	O
Langerin	B-Anatomy
(	I-Anatomy
+	I-Anatomy
)	I-Anatomy
dermal	I-Anatomy
dendritic	I-Anatomy
cells	I-Anatomy
(	O
dDCs	B-Anatomy
)	O
after	O
administration	O
of	O
diphtheria	O
toxin	O
,	O
which	O
results	O
in	O
reduced	O
CHS	O
.	O
When	O
Langerin	B-Anatomy
(	I-Anatomy
+	I-Anatomy
)	I-Anatomy
dDCs	I-Anatomy
have	O
partially	O
repopulated	O
the	O
skin	B-Anatomy
but	O
LCs	B-Anatomy
are	O
still	O
absent	O
,	O
CHS	O
returns	O
to	O
normal	O
.	O
Thus	O
,	O
LCs	B-Anatomy
appear	O
to	O
be	O
suppressive	O
in	O
human	O
Langerin	O
-	O
DTA	O
mice	O
and	O
redundant	O
in	O
murine	O
Langerin	O
-	O
DTR	O
mice	O
.	O
To	O
determine	O
whether	O
inducible	O
versus	O
constitutive	O
LC	B-Anatomy
ablation	O
explains	O
these	O
results	O
,	O
we	O
engineered	O
human	O
Langerin	O
-	O
DTR	O
mice	O
in	O
which	O
diphtheria	O
toxin	O
ablates	O
LCs	B-Anatomy
without	O
affecting	O
Langerin	B-Anatomy
(	I-Anatomy
+	I-Anatomy
)	I-Anatomy
dDCs	I-Anatomy
.	O
The	O
inducible	O
ablation	O
of	O
LCs	B-Anatomy
in	O
human	O
Langerin	O
-	O
DTR	O
mice	O
resulted	O
in	O
increased	O
CHS	O
.	O
Thus	O
,	O
LC	B-Anatomy
-	O
mediated	O
suppression	O
does	O
not	O
require	O
their	O
absence	O
during	O
ontogeny	O
or	O
during	O
the	O
steady	O
-	O
state	O
and	O
is	O
consistent	O
with	O
a	O
model	O
in	O
which	O
LCs	B-Anatomy
actively	O
suppress	O
Ag	O
-	O
specific	O
CHS	O
responses	O
.	O
The	O
proenkephalin	O
-	O
A	O
-	O
derivative	O
Met	O
-	O
enkephalin	O
-	O
Arg	O
-	O
Gly	O
-	O
Leu	O
is	O
not	O
present	O
in	O
the	O
feline	O
species	O
.	O
No	O
opioid	O
octapeptide	O
Met	O
-	O
enkephalin	O
-	O
Arg	O
-	O
Gly	O
-	O
Leu	O
was	O
detected	O
either	O
in	O
the	O
brain	B-Anatomy
or	O
in	O
the	O
adrenal	B-Anatomy
gland	I-Anatomy
of	O
the	O
cat	O
using	O
a	O
specific	O
radioimmunoassay	O
.	O
Whereas	O
it	O
was	O
possible	O
to	O
determine	O
the	O
Met	O
-	O
enkephalin	O
and	O
Leu	O
-	O
enkephalin	O
contents	O
.	O
The	O
Met	O
-	O
enkephalin	O
versus	O
Leu	O
-	O
enkephalin	O
concentration	O
ratio	O
was	O
around	O
five	O
in	O
each	O
area	B-Anatomy
of	O
the	O
brain	B-Anatomy
assayed	O
.	O
The	O
presence	O
of	O
authentic	O
Met	O
-	O
enkephalin	O
and	O
Leu	O
-	O
enkephalin	O
was	O
confirmed	O
by	O
high	O
performance	O
liquid	O
chromatography	O
analysis	O
.	O
All	O
in	O
all	O
,	O
these	O
data	O
seem	O
to	O
indicate	O
that	O
the	O
cat	O
proenkephalin	O
is	O
partly	O
different	O
from	O
that	O
previously	O
analysed	O
in	O
mammalian	O
species	O
including	O
humans	O
,	O
rats	O
and	O
cows	O
.	O
Expression	O
profiling	O
in	O
progressive	O
stages	O
of	O
fumarate	O
-	O
hydratase	O
deficiency	O
:	O
the	O
contribution	O
of	O
metabolic	O
changes	O
to	O
tumorigenesis	O
.	O
Hereditary	B-Anatomy
leiomyomatosis	I-Anatomy
and	I-Anatomy
renal	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
(	O
HLRCC	B-Anatomy
)	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
Krebs	O
cycle	O
enzyme	O
fumarate	O
hydratase	O
(	O
FH	O
)	O
.	O
It	O
has	O
been	O
proposed	O
that	O
""""	O
pseudohypoxic	O
""""	O
stabilization	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
alpha	O
(	O
HIF	O
-	O
alpha	O
)	O
by	O
fumarate	O
accumulation	O
contributes	O
to	O
tumorigenesis	O
in	O
HLRCC	B-Anatomy
.	O
We	O
hypothesized	O
that	O
an	O
additional	O
direct	O
consequence	O
of	O
FH	O
deficiency	O
is	O
the	O
establishment	O
of	O
a	O
biosynthetic	O
milieu	O
.	O
To	O
investigate	O
this	O
hypothesis	O
,	O
we	O
isolated	O
primary	O
mouse	B-Anatomy
embryonic	I-Anatomy
fibroblast	I-Anatomy
(	I-Anatomy
MEF	I-Anatomy
)	I-Anatomy
lines	I-Anatomy
from	O
Fh1	O
-	O
deficient	O
mice	O
.	O
As	O
predicted	O
,	O
these	O
MEFs	B-Anatomy
upregulated	O
Hif	O
-	O
1alpha	O
and	O
HIF	O
target	O
genes	O
directly	O
as	O
a	O
result	O
of	O
FH	O
deficiency	O
.	O
In	O
addition	O
,	O
detailed	O
metabolic	O
assessment	O
of	O
these	O
MEFs	B-Anatomy
confirmed	O
their	O
dependence	O
on	O
glycolysis	O
,	O
and	O
an	O
elevated	O
rate	O
of	O
lactate	O
efflux	O
,	O
associated	O
with	O
the	O
upregulation	O
of	O
glycolytic	O
enzymes	O
known	O
to	O
be	O
associated	O
with	O
tumorigenesis	O
.	O
Correspondingly	O
,	O
Fh1	B-Anatomy
-	I-Anatomy
deficient	I-Anatomy
benign	I-Anatomy
murine	I-Anatomy
renal	I-Anatomy
cysts	I-Anatomy
and	O
an	O
advanced	O
human	O
HLRCC	B-Anatomy
-	I-Anatomy
related	I-Anatomy
renal	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
manifested	O
a	O
prominent	O
and	O
progressive	O
increase	O
in	O
the	O
expression	O
of	O
HIF	O
-	O
alpha	O
target	O
genes	O
and	O
in	O
genes	O
known	O
to	O
be	O
relevant	O
to	O
tumorigenesis	O
and	O
metastasis	O
.	O
In	O
accord	O
with	O
our	O
hypothesis	O
,	O
in	O
a	O
variety	O
of	O
different	O
FH	B-Anatomy
-	I-Anatomy
deficient	I-Anatomy
tissues	I-Anatomy
,	O
including	O
a	O
novel	O
murine	O
model	O
of	O
Fh1	B-Anatomy
-	I-Anatomy
deficient	I-Anatomy
smooth	I-Anatomy
muscle	I-Anatomy
,	O
we	O
show	O
a	O
striking	O
and	O
progressive	O
upregulation	O
of	O
a	O
tumorigenic	O
metabolic	O
profile	O
,	O
as	O
manifested	O
by	O
increased	O
PKM2	O
and	O
LDHA	O
protein	O
.	O
Based	O
on	O
the	O
models	O
assessed	O
herein	O
,	O
we	O
infer	O
that	O
that	O
FH	O
deficiency	O
compels	O
cells	B-Anatomy
to	O
adopt	O
an	O
early	O
,	O
reversible	O
,	O
and	O
progressive	O
protumorigenic	O
metabolic	O
milieu	O
that	O
is	O
reminiscent	O
of	O
that	O
driving	O
the	O
Warburg	O
effect	O
.	O
Targets	O
identified	O
in	O
these	O
novel	O
and	O
diverse	O
FH	O
-	O
deficient	O
models	O
represent	O
excellent	O
potential	O
candidates	O
for	O
further	O
mechanistic	O
investigation	O
and	O
therapeutic	O
metabolic	O
manipulation	O
in	O
tumors	B-Anatomy
.	O
A	O
STAT3	O
-	O
mediated	O
metabolic	O
switch	O
is	O
involved	O
in	O
tumour	B-Anatomy
transformation	O
and	O
STAT3	O
addiction	O
.	O
The	O
pro	O
-	O
oncogenic	O
transcription	O
factor	O
STAT3	O
is	O
constitutively	O
activated	O
in	O
a	O
wide	O
variety	O
of	O
tumours	B-Anatomy
that	O
often	O
become	O
addicted	O
to	O
its	O
activity	O
,	O
but	O
no	O
unifying	O
view	O
of	O
a	O
core	O
function	O
determining	O
this	O
widespread	O
STAT3	O
-	O
dependence	O
has	O
yet	O
emerged	O
.	O
We	O
show	O
here	O
that	O
constitutively	O
active	O
STAT3	O
acts	O
as	O
a	O
master	O
regulator	O
of	O
cell	B-Anatomy
metabolism	O
,	O
inducing	O
aerobic	O
glycolysis	O
and	O
down	O
-	O
regulating	O
mitochondrial	B-Anatomy
activity	O
both	O
in	O
primary	O
fibroblasts	B-Anatomy
and	O
in	O
STAT3	O
-	O
dependent	O
tumour	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
As	O
a	O
result	O
,	O
cells	B-Anatomy
are	O
protected	O
from	O
apoptosis	O
and	O
senescence	O
while	O
becoming	O
highly	O
sensitive	O
to	O
glucose	O
deprivation	O
.	O
We	O
show	O
that	O
enhanced	O
glycolysis	O
is	O
dependent	O
on	O
HIF	O
-	O
1alpha	O
up	O
-	O
regulation	O
,	O
while	O
reduced	O
mitochondrial	B-Anatomy
activity	O
is	O
HIF	O
-	O
1alpha	O
-	O
independent	O
and	O
likely	O
caused	O
by	O
STAT3	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
mitochondrial	B-Anatomy
proteins	O
.	O
The	O
induction	O
of	O
aerobic	O
glycolysis	O
is	O
an	O
important	O
component	O
of	O
STAT3	O
pro	O
-	O
oncogenic	O
activities	O
,	O
since	O
inhibition	O
of	O
STAT3	O
tyrosine	O
phosphorylation	O
in	O
the	O
tumour	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
down	O
-	O
regulates	O
glycolysis	O
prior	O
to	O
leading	O
to	O
growth	O
arrest	O
and	O
cell	B-Anatomy
death	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
We	O
propose	O
that	O
this	O
novel	O
,	O
central	O
metabolic	O
role	O
is	O
at	O
the	O
core	O
of	O
the	O
addiction	O
for	O
STAT3	O
shown	O
by	O
so	O
many	O
biologically	O
different	O
tumours	B-Anatomy
.	O
Dissecting	O
genetic	O
networks	O
underlying	O
complex	O
phenotypes	O
:	O
the	O
theoretical	O
framework	O
.	O
Great	O
progress	O
has	O
been	O
made	O
in	O
genetic	O
dissection	O
of	O
quantitative	O
trait	O
variation	O
during	O
the	O
past	O
two	O
decades	O
,	O
but	O
many	O
studies	O
still	O
reveal	O
only	O
a	O
small	O
fraction	O
of	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
,	O
and	O
epistasis	O
remains	O
elusive	O
.	O
We	O
integrate	O
contemporary	O
knowledge	O
of	O
signal	O
transduction	O
pathways	O
with	O
principles	O
of	O
quantitative	O
and	O
population	O
genetics	O
to	O
characterize	O
genetic	O
networks	O
underlying	O
complex	O
traits	O
,	O
using	O
a	O
model	O
founded	O
upon	O
one	O
-	O
way	O
functional	O
dependency	O
of	O
downstream	O
genes	O
on	O
upstream	O
regulators	O
(	O
the	O
principle	O
of	O
hierarchy	O
)	O
and	O
mutual	O
functional	O
dependency	O
among	O
related	O
genes	O
(	O
functional	O
genetic	O
units	O
,	O
FGU	O
)	O
.	O
Both	O
simulated	O
and	O
real	O
data	O
suggest	O
that	O
complementary	O
epistasis	O
contributes	O
greatly	O
to	O
quantitative	O
trait	O
variation	O
,	O
and	O
obscures	O
the	O
phenotypic	O
effects	O
of	O
many	O
'	O
downstream	O
'	O
loci	O
in	O
pathways	O
.	O
The	O
mathematical	O
relationships	O
between	O
the	O
main	O
effects	O
and	O
epistatic	O
effects	O
of	O
genes	O
acting	O
at	O
different	O
levels	O
of	O
signaling	O
pathways	O
were	O
established	O
using	O
the	O
quantitative	O
and	O
population	O
genetic	O
parameters	O
.	O
Both	O
loss	O
of	O
function	O
and	O
""""	O
co	O
-	O
adapted	O
""""	O
gene	O
complexes	O
formed	O
by	O
multiple	O
alleles	O
with	O
differentiated	O
functions	O
(	O
effects	O
)	O
are	O
predicted	O
to	O
be	O
frequent	O
types	O
of	O
allelic	O
diversity	O
at	O
loci	O
that	O
contribute	O
to	O
the	O
genetic	O
variation	O
of	O
complex	O
traits	O
in	O
populations	O
.	O
Downstream	O
FGUs	O
appear	O
to	O
be	O
more	O
vulnerable	O
to	O
loss	O
of	O
function	O
than	O
their	O
upstream	O
regulators	O
,	O
but	O
this	O
vulnerability	O
is	O
apparently	O
compensated	O
by	O
different	O
FGUs	O
of	O
similar	O
functions	O
.	O
Other	O
predictions	O
from	O
the	O
model	O
may	O
account	O
for	O
puzzling	O
results	O
regarding	O
responses	O
to	O
selection	O
,	O
genotype	O
by	O
environment	O
interaction	O
,	O
and	O
the	O
genetic	O
basis	O
of	O
heterosis	O
.	O
Roles	O
of	O
brca2	O
(	O
fancd1	O
)	O
in	O
oocyte	B-Anatomy
nuclear	I-Anatomy
architecture	O
,	O
gametogenesis	O
,	O
gonad	B-Anatomy
tumors	I-Anatomy
,	O
and	O
genome	O
stability	O
in	O
zebrafish	O
.	O
Mild	O
mutations	O
in	O
BRCA2	O
(	O
FANCD1	O
)	O
cause	O
Fanconi	O
anemia	O
(	O
FA	O
)	O
when	O
homozygous	O
,	O
while	O
severe	O
mutations	O
cause	O
common	O
cancers	B-Anatomy
including	O
breast	B-Anatomy
,	O
ovarian	B-Anatomy
,	O
and	O
prostate	B-Anatomy
cancers	I-Anatomy
when	O
heterozygous	O
.	O
Here	O
we	O
report	O
a	O
zebrafish	O
brca2	O
insertional	O
mutant	O
that	O
shares	O
phenotypes	O
with	O
human	O
patients	O
and	O
identifies	O
a	O
novel	O
brca2	O
function	O
in	O
oogenesis	O
.	O
Experiments	O
showed	O
that	O
mutant	B-Anatomy
embryos	I-Anatomy
and	O
mutant	B-Anatomy
cells	I-Anatomy
in	O
culture	O
experienced	O
genome	O
instability	O
,	O
as	O
do	O
cells	B-Anatomy
in	O
FA	O
patients	O
.	O
In	O
wild	O
-	O
type	O
zebrafish	O
,	O
meiotic	O
cells	B-Anatomy
expressed	O
brca2	O
;	O
and	O
,	O
unexpectedly	O
,	O
transcripts	O
in	O
oocytes	B-Anatomy
localized	O
asymmetrically	O
to	O
the	O
animal	B-Anatomy
pole	I-Anatomy
.	O
In	O
juvenile	O
brca2	O
mutants	O
,	O
oocytes	B-Anatomy
failed	O
to	O
progress	O
through	O
meiosis	O
,	O
leading	O
to	O
female	O
-	O
to	O
-	O
male	O
sex	O
reversal	O
.	O
Adult	O
mutants	O
became	O
sterile	O
males	O
due	O
to	O
the	O
meiotic	O
arrest	O
of	O
spermatocytes	B-Anatomy
,	O
which	O
then	O
died	O
by	O
apoptosis	O
,	O
followed	O
by	O
neoplastic	B-Anatomy
proliferation	O
of	O
gonad	B-Anatomy
somatic	I-Anatomy
cells	I-Anatomy
that	O
was	O
similar	O
to	O
neoplasia	B-Anatomy
observed	O
in	O
ageing	O
dead	O
end	O
(	O
dnd	O
)	O
-	O
knockdown	O
males	O
,	O
which	O
lack	O
germ	B-Anatomy
cells	I-Anatomy
.	O
The	O
construction	O
of	O
animals	O
doubly	O
mutant	O
for	O
brca2	O
and	O
the	O
apoptotic	O
gene	O
tp53	O
(	O
p53	O
)	O
rescued	O
brca2	O
-	O
dependent	O
sex	O
reversal	O
.	O
Double	O
mutants	O
developed	O
oocytes	B-Anatomy
and	O
became	O
sterile	O
females	O
that	O
produced	O
only	O
aberrant	O
embryos	B-Anatomy
and	O
showed	O
elevated	O
risk	O
for	O
invasive	B-Anatomy
ovarian	I-Anatomy
tumors	I-Anatomy
.	O
Oocytes	B-Anatomy
in	O
double	O
-	O
mutant	O
females	O
showed	O
normal	O
localization	O
of	O
brca2	O
and	O
pou5f1	O
transcripts	O
to	O
the	O
animal	B-Anatomy
pole	I-Anatomy
and	O
vasa	O
transcripts	O
to	O
the	O
vegetal	B-Anatomy
pole	I-Anatomy
,	O
but	O
had	O
a	O
polarized	O
rather	O
than	O
symmetrical	O
nucleus	B-Anatomy
with	O
the	O
distribution	O
of	O
nucleoli	B-Anatomy
and	O
chromosomes	B-Anatomy
to	O
opposite	O
nuclear	B-Anatomy
poles	I-Anatomy
;	O
this	O
result	O
revealed	O
a	O
novel	O
role	O
for	O
Brca2	O
in	O
establishing	O
or	O
maintaining	O
oocyte	B-Anatomy
nuclear	I-Anatomy
architecture	O
.	O
Mutating	O
tp53	O
did	O
not	O
rescue	O
the	O
infertility	O
phenotype	O
in	O
brca2	O
mutant	O
males	O
,	O
suggesting	O
that	O
brca2	O
plays	O
an	O
essential	O
role	O
in	O
zebrafish	O
spermatogenesis	O
.	O
Overall	O
,	O
this	O
work	O
verified	O
zebrafish	O
as	O
a	O
model	O
for	O
the	O
role	O
of	O
Brca2	O
in	O
human	O
disease	O
and	O
uncovered	O
a	O
novel	O
function	O
of	O
Brca2	O
in	O
vertebrate	O
oocyte	B-Anatomy
nuclear	I-Anatomy
architecture	O
.	O
3	O
-	O
[	O
(	O
Methyl	O
-	O
carbamo	O
-	O
yl	O
)	O
amino	O
]	O
-	O
1H	O
-	O
isoindolium	O
chloride	O
.	O
The	O
title	O
compound	O
,	O
C	O
(	O
10	O
)	O
H	O
(	O
12	O
)	O
N	O
(	O
3	O
)	O
O	O
(	O
+	O
)	O
.	O
Cl	O
(	O
-	O
)	O
,	O
is	O
a	O
derivative	O
of	O
o	O
-	O
phthaldehyde	O
and	O
methyl	O
-	O
thio	O
-	O
urea	O
.	O
The	O
mol	O
-	O
ecules	O
form	O
dimers	O
through	O
intra	O
-	O
and	O
inter	O
-	O
molecular	O
N	O
-	O
H	O
.	O
.	O
.	O
O	O
hydrogen	O
bonds	O
.	O
The	O
dimers	O
are	O
further	O
linked	O
into	O
chains	O
through	O
one	O
C	O
-	O
H	O
.	O
.	O
.	O
Cl	O
and	O
two	O
N	O
-	O
H	O
.	O
.	O
.	O
Cl	O
hydrogen	O
bonds	O
.	O
KISS1	O
methylation	O
and	O
expression	O
as	O
tumor	B-Anatomy
stratification	O
biomarkers	O
and	O
clinical	O
outcome	O
prognosticators	O
for	O
bladder	B-Anatomy
cancer	I-Anatomy
patients	O
.	O
KISS1	O
is	O
a	O
metastasis	O
suppressor	O
gene	O
that	O
is	O
lost	O
in	O
several	O
malignancies	B-Anatomy
,	O
including	O
bladder	B-Anatomy
cancer	I-Anatomy
.	O
We	O
tested	O
the	O
epigenetic	O
silencing	O
hypothesis	O
and	O
evaluated	O
the	O
biological	O
influence	O
of	O
KISS1	O
methylation	O
on	O
its	O
expression	O
and	O
clinical	O
relevance	O
in	O
bladder	B-Anatomy
cancer	I-Anatomy
.	O
KISS1	O
hypermethylation	O
was	O
frequent	O
in	O
bladder	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
analyzed	O
by	O
methylation	O
-	O
specific	O
PCR	O
and	O
bisulfite	O
sequencing	O
and	O
was	O
associated	O
with	O
low	O
gene	O
expression	O
,	O
being	O
restored	O
in	O
vitro	O
by	O
demethylating	O
azacytidine	O
.	O
Hypermethylation	O
was	O
also	O
frequently	O
observed	O
in	O
a	O
large	O
series	O
of	O
bladder	B-Anatomy
tumors	I-Anatomy
(	O
83	O
.	O
1	O
%	O
,	O
n	O
=	O
804	O
)	O
.	O
KISS1	O
methylation	O
was	O
associated	O
with	O
increasing	O
stage	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
tumor	B-Anatomy
grade	O
(	O
P	O
=	O
0	O
.	O
010	O
)	O
.	O
KISS1	O
methylation	O
was	O
associated	O
with	O
low	O
KISS1	O
transcript	O
expression	O
by	O
quantitative	O
RT	O
-	O
PCR	O
(	O
P	O
=	O
0	O
.	O
037	O
)	O
.	O
KISS1	O
transcript	O
expression	O
was	O
also	O
associated	O
with	O
histopathological	O
tumor	B-Anatomy
stage	O
(	O
P	O
<	O
0	O
.	O
0005	O
)	O
.	O
Low	O
transcript	O
expression	O
alone	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
or	O
combined	O
with	O
methylation	O
(	O
P	O
=	O
0	O
.	O
019	O
)	O
was	O
associated	O
with	O
poor	O
disease	O
-	O
specific	O
survival	O
(	O
n	O
=	O
205	O
)	O
.	O
KISS1	O
transcript	O
expression	O
remained	O
an	O
independent	O
prognosticator	O
in	O
multivariate	O
analyses	O
(	O
P	O
=	O
0	O
.	O
017	O
)	O
.	O
KISS1	O
hypermethylation	O
was	O
identified	O
in	O
bladder	B-Anatomy
cancer	I-Anatomy
,	O
providing	O
a	O
potential	O
mechanistic	O
explanation	O
(	O
epigenetic	O
silencing	O
)	O
for	O
the	O
observed	O
loss	O
of	O
KISS1	O
in	O
uroepithelial	B-Anatomy
malignancies	I-Anatomy
.	O
Associations	O
of	O
KISS1	O
methylation	O
and	O
its	O
expression	O
with	O
histopathological	O
variables	O
and	O
poor	O
survival	O
suggest	O
the	O
utility	O
of	O
incorporating	O
KISS1	O
measurement	O
using	O
paraffin	O
-	O
embedded	O
material	O
for	O
tumor	B-Anatomy
stratification	O
and	O
clinical	O
outcome	O
prognosis	O
of	O
patients	O
with	O
uroepithelial	B-Anatomy
neoplasias	I-Anatomy
.	O
Oscillatory	O
alpha	O
-	O
band	O
mechanisms	O
and	O
the	O
deployment	O
of	O
spatial	O
attention	O
to	O
anticipated	O
auditory	O
and	O
visual	O
target	O
locations	O
:	O
supramodal	O
or	O
sensory	O
-	O
specific	O
control	O
mechanisms	O
?	O
Oscillatory	O
alpha	O
-	O
band	O
activity	O
(	O
8	O
-	O
15	O
Hz	O
)	O
over	O
parieto	B-Anatomy
-	I-Anatomy
occipital	I-Anatomy
cortex	I-Anatomy
in	O
humans	O
plays	O
an	O
important	O
role	O
in	O
suppression	O
of	O
processing	O
for	O
inputs	O
at	O
to	O
-	O
be	O
-	O
ignored	O
regions	O
of	O
space	O
,	O
with	O
increased	O
alpha	O
-	O
band	O
power	O
observed	O
over	O
cortex	B-Anatomy
contralateral	O
to	O
locations	O
expected	O
to	O
contain	O
distractors	O
.	O
It	O
is	O
unclear	O
whether	O
similar	O
processes	O
operate	O
during	O
deployment	O
of	O
spatial	O
attention	O
in	O
other	O
sensory	O
modalities	O
.	O
Evidence	O
from	O
lesion	B-Anatomy
patients	O
suggests	O
that	O
parietal	B-Anatomy
regions	I-Anatomy
house	O
supramodal	O
representations	O
of	O
space	O
.	O
The	O
parietal	B-Anatomy
lobes	I-Anatomy
are	O
prominent	O
generators	O
of	O
alpha	O
oscillations	O
,	O
raising	O
the	O
possibility	O
that	O
alpha	O
is	O
a	O
neural	B-Anatomy
signature	O
of	O
supramodal	O
spatial	O
attention	O
.	O
Furthermore	O
,	O
when	O
spatial	O
attention	O
is	O
deployed	O
within	O
vision	O
,	O
processing	O
of	O
task	O
-	O
irrelevant	O
auditory	O
inputs	O
at	O
attended	O
locations	O
is	O
also	O
enhanced	O
,	O
pointing	O
to	O
automatic	O
links	O
between	O
spatial	O
deployments	O
across	O
senses	O
.	O
Here	O
,	O
we	O
asked	O
whether	O
lateralized	O
alpha	O
-	O
band	O
activity	O
is	O
also	O
evident	O
in	O
a	O
purely	O
auditory	O
spatial	O
-	O
cueing	O
task	O
and	O
whether	O
it	O
had	O
the	O
same	O
underlying	O
generator	O
configuration	O
as	O
in	O
a	O
purely	O
visuospatial	O
task	O
.	O
If	O
common	O
to	O
both	O
sensory	O
systems	O
,	O
this	O
would	O
provide	O
strong	O
support	O
for	O
""""	O
supramodal	O
""""	O
attention	O
theory	O
.	O
Alternately	O
,	O
alpha	O
-	O
band	O
differences	O
between	O
auditory	O
and	O
visual	O
tasks	O
would	O
support	O
a	O
sensory	O
-	O
specific	O
account	O
.	O
Lateralized	O
shifts	O
in	O
alpha	O
-	O
band	O
activity	O
were	O
indeed	O
observed	O
during	O
a	O
purely	O
auditory	O
spatial	O
task	O
.	O
Crucially	O
,	O
there	O
were	O
clear	O
differences	O
in	O
scalp	B-Anatomy
topographies	O
of	O
this	O
alpha	O
activity	O
depending	O
on	O
the	O
sensory	O
system	O
within	O
which	O
spatial	O
attention	O
was	O
deployed	O
.	O
Findings	O
suggest	O
that	O
parietally	O
generated	O
alpha	O
-	O
band	O
mechanisms	O
are	O
central	O
to	O
attentional	O
deployments	O
across	O
modalities	O
but	O
that	O
they	O
are	O
invoked	O
in	O
a	O
sensory	O
-	O
specific	O
manner	O
.	O
The	O
data	O
support	O
an	O
""""	O
interactivity	O
account	O
,	O
""""	O
whereby	O
a	O
supramodal	O
system	O
interacts	O
with	O
sensory	O
-	O
specific	O
control	O
systems	O
during	O
deployment	O
of	O
spatial	O
attention	O
.	O
Correlation	O
of	O
lymphatic	B-Anatomy
vessel	I-Anatomy
density	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
with	O
nodal	B-Anatomy
metastasis	O
in	O
papillary	B-Anatomy
thyroid	I-Anatomy
microcarcinoma	I-Anatomy
.	O
BACKGROUND	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
not	O
only	O
the	O
intratumoral	B-Anatomy
and	O
peritumoral	B-Anatomy
lymphatic	I-Anatomy
vessel	I-Anatomy
density	O
(	O
ILD	O
and	O
PLD	O
)	O
but	O
also	O
the	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factors	O
(	O
VEGFs	O
)	O
and	O
to	O
test	O
their	O
correlation	O
with	O
regional	O
lymph	B-Anatomy
nodal	I-Anatomy
metastases	I-Anatomy
in	O
papillary	B-Anatomy
thyroid	I-Anatomy
microcarcinoma	I-Anatomy
(	O
PTMC	B-Anatomy
)	O
.	O
METHODS	O
:	O
A	O
clinicopathologic	O
data	O
review	O
was	O
performed	O
in	O
60	O
patients	O
with	O
PTMC	B-Anatomy
treated	O
with	O
total	O
thyroidectomies	O
involving	O
neck	B-Anatomy
dissections	O
.	O
The	O
patterns	O
of	O
lymphatic	B-Anatomy
vessels	I-Anatomy
,	O
the	O
expression	O
of	O
VEGFs	O
,	O
and	O
their	O
correlation	O
with	O
neck	B-Anatomy
metastases	I-Anatomy
were	O
assessed	O
.	O
RESULTS	O
:	O
PLD	O
was	O
significantly	O
higher	O
than	O
ILD	O
(	O
p	O
<	O
.	O
001	O
)	O
.	O
Patients	O
with	O
high	O
PLD	O
(	O
>	O
8	O
.	O
0	O
)	O
showed	O
higher	O
rates	O
of	O
neck	B-Anatomy
metastases	I-Anatomy
than	O
low	O
PLD	O
(	O
<	O
=	O
8	O
.	O
0	O
)	O
(	O
74	O
.	O
0	O
%	O
vs	O
46	O
.	O
8	O
%	O
,	O
p	O
=	O
.	O
03	O
)	O
.	O
Univariate	O
and	O
multivariate	O
analyses	O
revealed	O
high	O
PLD	O
as	O
the	O
only	O
independent	O
variable	O
predictive	O
of	O
neck	B-Anatomy
metastasis	O
.	O
The	O
expression	O
of	O
VEGFs	O
did	O
not	O
correlate	O
with	O
either	O
lymphatic	B-Anatomy
density	O
or	O
neck	B-Anatomy
metastasis	O
.	O
CONCLUSIONS	O
:	O
PLD	O
may	O
be	O
of	O
potential	O
benefit	O
in	O
the	O
prediction	O
of	O
neck	B-Anatomy
metastasis	O
in	O
PTMC	B-Anatomy
.	O
Inhibition	O
of	O
autophagy	O
potentiates	O
the	O
antitumor	B-Anatomy
effect	O
of	O
the	O
multikinase	O
inhibitor	O
sorafenib	O
in	O
hepatocellular	B-Anatomy
carcinoma	I-Anatomy
.	O
Multikinase	O
inhibitor	O
sorafenib	O
inhibits	O
proliferation	O
and	O
angiogenesis	O
of	O
tumors	B-Anatomy
by	O
suppressing	O
the	O
Raf	O
/	O
MEK	O
/	O
ERK	O
signaling	O
pathway	O
and	O
VEGF	O
receptor	O
tyrosine	O
kinase	O
.	O
It	O
significantly	O
prolongs	O
median	O
survival	O
of	O
patients	O
with	O
advanced	O
hepatocellular	B-Anatomy
carcinoma	I-Anatomy
(	O
HCC	B-Anatomy
)	O
but	O
the	O
response	O
is	O
disease	O
-	O
stabilizing	O
and	O
cytostatic	O
rather	O
than	O
one	O
of	O
tumor	B-Anatomy
regression	O
.	O
To	O
examine	O
the	O
mechanisms	O
underlying	O
the	O
relative	O
resistance	O
in	O
HCC	B-Anatomy
,	O
we	O
investigated	O
the	O
role	O
of	O
autophagy	O
,	O
an	O
evolutionarily	O
conserved	O
self	O
-	O
digestion	O
pathway	O
,	O
in	O
hepatoma	B-Anatomy
cells	I-Anatomy
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Sorafenib	O
treatment	O
led	O
to	O
accumulation	O
of	O
autophagosomes	B-Anatomy
as	O
evidenced	O
by	O
conversion	O
from	O
LC3	O
-	O
I	O
to	O
LC3	O
-	O
II	O
observed	O
by	O
immunoblot	O
in	O
Huh7	B-Anatomy
,	O
HLF	B-Anatomy
and	O
PLC	B-Anatomy
/	I-Anatomy
PRF	I-Anatomy
/	I-Anatomy
5	I-Anatomy
cells	I-Anatomy
.	O
This	O
induction	O
was	O
due	O
to	O
activation	O
of	O
autophagic	O
flux	O
,	O
as	O
there	O
was	O
further	O
increase	O
in	O
LC3	O
-	O
II	O
expression	O
upon	O
treatment	O
with	O
lysosomal	O
inhibitors	O
,	O
clear	O
decline	O
of	O
the	O
autophagy	O
substrate	O
p62	O
,	O
and	O
an	O
mRFP	O
-	O
GFP	O
-	O
LC3	O
fluorescence	O
change	O
in	O
sorafenib	O
-	O
treated	O
hepatoma	B-Anatomy
cells	I-Anatomy
.	O
Sorafenib	O
inhibited	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
complex	O
1	O
and	O
its	O
inhibition	O
led	O
to	O
accumulation	O
of	O
LC3	O
-	O
II	O
.	O
Pharmacological	O
inhibition	O
of	O
autophagic	O
flux	O
by	O
chloroquine	O
increased	O
apoptosis	O
and	O
decreased	O
cell	B-Anatomy
viability	O
in	O
hepatoma	B-Anatomy
cells	I-Anatomy
.	O
siRNA	O
-	O
mediated	O
knockdown	O
of	O
the	O
ATG7	O
gene	O
also	O
sensitized	O
hepatoma	B-Anatomy
cells	I-Anatomy
to	O
sorafenib	O
.	O
Finally	O
,	O
sorafenib	O
induced	O
autophagy	O
in	O
Huh7	B-Anatomy
xenograft	I-Anatomy
tumors	I-Anatomy
in	O
nude	O
mice	O
and	O
coadministration	O
with	O
chloroquine	O
significantly	O
suppressed	O
tumor	B-Anatomy
growth	O
compared	O
with	O
sorafenib	O
alone	O
.	O
In	O
conclusion	O
,	O
sorafenib	O
administration	O
induced	O
autophagosome	B-Anatomy
formation	O
and	O
enhanced	O
autophagic	O
activity	O
,	O
which	O
conferred	O
a	O
survival	O
advantage	O
to	O
hepatoma	B-Anatomy
cells	I-Anatomy
.	O
Concomitant	O
inhibition	O
of	O
autophagy	O
may	O
be	O
an	O
attractive	O
strategy	O
for	O
unlocking	O
the	O
antitumor	B-Anatomy
potential	O
of	O
sorafenib	O
in	O
HCC	B-Anatomy
.	O
Desensitization	O
of	O
prostaglandin	O
F2	O
alpha	O
-	O
stimulated	O
inositol	O
phosphate	O
generation	O
in	O
NIH	B-Anatomy
-	I-Anatomy
3T3	I-Anatomy
fibroblasts	I-Anatomy
transformed	O
by	O
overexpression	O
of	O
normal	O
c	O
-	O
Ha	O
-	O
ras	O
-	O
1	O
,	O
c	O
-	O
Ki	O
-	O
ras	O
-	O
2	O
and	O
c	O
-	O
N	O
-	O
ras	O
genes	O
.	O
The	O
stimulation	O
of	O
inositol	O
phosphate	O
generation	O
in	O
control	O
and	O
ras	O
-	O
gene	O
-	O
transformed	O
NIH	B-Anatomy
-	I-Anatomy
3T3	I-Anatomy
cells	I-Anatomy
by	O
prostaglandin	O
F2	O
alpha	O
(	O
PGF2	O
alpha	O
)	O
was	O
investigated	O
.	O
Compared	O
with	O
the	O
control	O
cells	B-Anatomy
,	O
a	O
desensitization	O
of	O
the	O
response	O
was	O
observed	O
in	O
cells	B-Anatomy
transformed	O
by	O
the	O
overexpression	O
of	O
N	O
-	O
,	O
Ha	O
-	O
,	O
or	O
Ki	O
-	O
ras	O
genes	O
.	O
This	O
desensitization	O
was	O
without	O
effect	O
upon	O
the	O
concentration	O
causing	O
half	O
-	O
maximal	O
effect	O
(	O
EC50	O
)	O
,	O
dissociation	O
constant	O
(	O
Kd	O
)	O
or	O
number	O
of	O
PGF2	O
alpha	O
receptors	O
.	O
Inhibition	O
of	O
PG	O
synthesis	O
was	O
without	O
effect	O
upon	O
desensitization	O
,	O
demonstrating	O
that	O
the	O
effect	O
was	O
not	O
agonist	O
-	O
induced	O
.	O
Desensitization	O
could	O
be	O
induced	O
in	O
NIH	B-Anatomy
-	I-Anatomy
3T3	I-Anatomy
cells	I-Anatomy
by	O
culturing	O
under	O
conditions	O
where	O
the	O
cells	B-Anatomy
were	O
all	O
in	O
the	O
exponential	O
growth	O
phase	O
,	O
or	O
by	O
a	O
12	O
h	O
exposure	O
to	O
a	O
C	O
-	O
kinase	O
-	O
activating	O
phorbol	O
ester	O
.	O
These	O
results	O
suggest	O
that	O
desensitization	O
of	O
certain	O
agonist	O
-	O
induced	O
inositol	O
phospholipid	O
responses	O
in	O
ras	O
-	O
transformed	O
cells	B-Anatomy
is	O
a	O
consequence	O
of	O
increased	O
cell	B-Anatomy
proliferation	O
and	O
associated	O
amplification	O
in	O
C	O
-	O
kinase	O
activity	O
and	O
is	O
an	O
indirect	O
consequence	O
of	O
transformation	O
by	O
ras	O
.	O
Absence	O
of	O
antisperm	O
antibodies	O
in	O
anejaculatory	O
men	O
.	O
Antisperm	O
antibodies	O
were	O
assessed	O
in	O
the	O
serum	B-Anatomy
samples	I-Anatomy
of	O
73	O
men	O
unable	O
to	O
ejaculate	O
naturally	O
and	O
on	O
the	O
sperm	B-Anatomy
cells	I-Anatomy
of	O
13	O
of	O
these	O
men	O
.	O
None	O
of	O
the	O
serum	B-Anatomy
samples	I-Anatomy
were	O
found	O
to	O
be	O
positive	O
by	O
sperm	B-Anatomy
agglutination	O
or	O
sperm	B-Anatomy
immobilization	O
methods	O
and	O
antibodies	O
were	O
detected	O
by	O
an	O
immunobead	O
assay	O
on	O
the	O
sperm	B-Anatomy
cells	I-Anatomy
of	O
one	O
of	O
the	O
13	O
men	O
examined	O
.	O
Relationship	O
between	O
of	O
blood	B-Anatomy
flow	O
,	O
glucose	O
metabolism	O
,	O
protein	O
synthesis	O
,	O
glucose	O
and	O
ATP	O
content	O
in	O
experimentally	O
-	O
induced	O
glioma	B-Anatomy
(	O
RG1	B-Anatomy
2	I-Anatomy
.	I-Anatomy
2	I-Anatomy
)	O
of	O
rat	O
brain	B-Anatomy
.	O
In	O
experimental	O
RG1	B-Anatomy
2	I-Anatomy
.	I-Anatomy
2	I-Anatomy
glioma	I-Anatomy
of	O
rat	O
brain	B-Anatomy
,	O
local	O
blood	B-Anatomy
flow	O
,	O
glucose	O
utilization	O
,	O
protein	O
synthesis	O
,	O
glucose	O
and	O
ATP	O
content	O
were	O
measured	O
by	O
means	O
of	O
triple	O
tracer	O
autoradiography	O
and	O
bioluminescence	O
technique	O
,	O
respectively	O
,	O
to	O
determine	O
hemodynamic	O
and	O
metabolic	O
thresholds	O
for	O
local	O
tumor	B-Anatomy
energy	O
failure	O
.	O
Perfusion	O
thresholds	O
were	O
estimated	O
at	O
tumor	B-Anatomy
blood	B-Anatomy
flow	O
values	O
of	O
69	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
estimate	O
+	O
/	O
-	O
standard	O
error	O
)	O
and	O
of	O
69	O
+	O
/	O
-	O
7	O
.	O
1	O
ml	O
/	O
100	O
g	O
/	O
min	O
for	O
the	O
beginning	O
of	O
the	O
decline	O
in	O
regional	O
ATP	O
and	O
glucose	O
content	O
,	O
respectively	O
.	O
Metabolic	O
thresholds	O
were	O
derived	O
at	O
tumor	B-Anatomy
glucose	O
utilization	O
values	O
of	O
70	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
3	O
mumol	O
/	O
100	O
g	O
/	O
min	O
for	O
reduced	O
protein	O
synthesis	O
,	O
of	O
55	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
2	O
mumol	O
/	O
100	O
g	O
/	O
min	O
for	O
the	O
decrease	O
in	O
glucose	O
content	O
,	O
and	O
34	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
7	O
mumol	O
/	O
100	O
g	O
/	O
min	O
for	O
decline	O
in	O
ATP	O
content	O
.	O
Our	O
results	O
suggest	O
that	O
blood	B-Anatomy
flow	O
limits	O
glucose	O
supply	O
to	O
tumor	B-Anatomy
tissue	I-Anatomy
at	O
much	O
higher	O
flow	O
rates	O
than	O
in	O
normal	O
brain	B-Anatomy
which	O
,	O
in	O
turn	O
,	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
tumor	B-Anatomy
glucose	O
utilization	O
.	O
A	O
reduction	O
and	O
not	O
an	O
increase	O
in	O
tumor	B-Anatomy
glucose	O
availability	O
could	O
be	O
a	O
more	O
appropriate	O
strategy	O
for	O
the	O
induction	O
of	O
energy	O
failure	O
in	O
tumors	B-Anatomy
.	O
Inactivation	O
of	O
androgen	O
-	O
induced	O
regulator	O
ARD1	O
inhibits	O
androgen	O
receptor	O
acetylation	O
and	O
prostate	B-Anatomy
tumorigenesis	O
.	O
Androgen	O
signaling	O
through	O
androgen	O
receptor	O
(	O
AR	O
)	O
is	O
critical	O
for	O
prostate	B-Anatomy
tumorigenesis	O
.	O
Given	O
that	O
AR	O
-	O
mediated	O
gene	O
regulation	O
is	O
enhanced	O
by	O
AR	O
coregulators	O
,	O
inactivation	O
of	O
those	O
coregulators	O
is	O
emerging	O
as	O
a	O
promising	O
therapy	O
for	O
prostate	B-Anatomy
cancer	I-Anatomy
(	O
PCa	B-Anatomy
)	O
.	O
Here	O
,	O
we	O
show	O
that	O
the	O
N	O
-	O
acetyltransferase	O
arrest	O
-	O
defect	O
1	O
protein	O
(	O
ARD1	O
)	O
functions	O
as	O
a	O
unique	O
AR	O
regulator	O
in	O
PCa	B-Anatomy
cells	I-Anatomy
.	O
ARD1	O
is	O
up	O
-	O
regulated	O
in	O
human	O
PCa	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
and	O
primary	B-Anatomy
tumor	I-Anatomy
biopsies	I-Anatomy
.	O
The	O
expression	O
of	O
ARD1	O
was	O
augmented	O
by	O
treatment	O
with	O
synthetic	O
androgen	O
(	O
R1881	O
)	O
unless	O
AR	O
is	O
deficient	O
or	O
is	O
inhibited	O
by	O
AR	O
-	O
specific	O
siRNA	O
or	O
androgen	O
inhibitor	O
bicalutamide	O
(	O
Casodex	O
)	O
.	O
Depletion	O
of	O
ARD1	O
by	O
shRNA	O
suppressed	O
PCa	B-Anatomy
cell	I-Anatomy
proliferation	O
,	O
anchorage	O
-	O
independent	O
growth	O
,	O
and	O
xenograft	B-Anatomy
tumor	I-Anatomy
formation	O
in	O
SCID	O
mice	O
,	O
suggesting	O
that	O
AR	O
-	O
dependent	O
ARD1	O
expression	O
is	O
biologically	O
germane	O
.	O
Notably	O
,	O
ARD1	O
was	O
critical	O
for	O
transcriptionally	O
regulating	O
a	O
number	O
of	O
AR	O
target	O
genes	O
that	O
are	O
involved	O
in	O
prostate	B-Anatomy
tumorigenesis	O
.	O
Furthermore	O
,	O
ARD1	O
interacted	O
physically	O
with	O
and	O
acetylated	O
the	O
AR	O
protein	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
Because	O
AR	O
-	O
ARD1	O
interaction	O
facilitated	O
the	O
AR	O
binding	O
to	O
its	O
targeted	O
promoters	O
for	O
gene	O
transcription	O
,	O
we	O
propose	O
that	O
ARD1	O
functions	O
as	O
a	O
unique	O
AR	O
regulator	O
and	O
forms	O
a	O
positive	O
feedback	O
loop	O
for	O
AR	O
-	O
dependent	O
prostate	B-Anatomy
tumorigenesis	O
.	O
Disruption	O
of	O
AR	O
-	O
ARD1	O
interactions	O
may	O
be	O
a	O
potent	O
intervention	O
for	O
androgen	O
-	O
dependent	O
PCa	B-Anatomy
therapy	O
.	O
The	O
role	O
of	O
Hes	O
genes	O
in	O
intestinal	B-Anatomy
development	O
,	O
homeostasis	O
and	O
tumor	B-Anatomy
formation	O
.	O
Notch	O
signaling	O
regulates	O
intestinal	B-Anatomy
development	O
,	O
homeostasis	O
and	O
tumorigenesis	O
,	O
but	O
its	O
precise	O
downstream	O
mechanism	O
remains	O
largely	O
unknown	O
.	O
Here	O
we	O
found	O
that	O
inactivation	O
of	O
the	O
Notch	O
effectors	O
Hes1	O
,	O
Hes3	O
and	O
Hes5	O
,	O
but	O
not	O
Hes1	O
alone	O
,	O
led	O
to	O
reduced	O
cell	B-Anatomy
proliferation	O
,	O
increased	O
secretory	B-Anatomy
cell	I-Anatomy
formation	O
and	O
altered	O
intestinal	B-Anatomy
structures	I-Anatomy
in	O
adult	O
mice	O
.	O
However	O
,	O
in	O
Apc	O
mutation	O
-	O
induced	O
intestinal	B-Anatomy
tumors	I-Anatomy
,	O
inactivation	O
of	O
Hes1	O
alone	O
was	O
sufficient	O
for	O
reducing	O
tumor	B-Anatomy
cell	I-Anatomy
proliferation	O
and	O
inducing	O
differentiation	O
of	O
tumor	B-Anatomy
cells	I-Anatomy
into	O
all	O
types	O
of	O
intestinal	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
,	O
but	O
without	O
affecting	O
the	O
homeostasis	O
of	O
normal	O
crypts	B-Anatomy
owing	O
to	O
genetic	O
redundancy	O
.	O
These	O
results	O
indicated	O
that	O
Hes	O
genes	O
cooperatively	O
regulate	O
intestinal	B-Anatomy
development	O
and	O
homeostasis	O
and	O
raised	O
the	O
possibility	O
that	O
Hes1	O
is	O
a	O
promising	O
target	O
to	O
induce	O
the	O
differentiation	O
of	O
tumor	B-Anatomy
cells	I-Anatomy
.	O
Activation	O
-	O
induced	O
cytidine	O
deaminase	O
in	O
antibody	O
diversification	O
and	O
chromosome	B-Anatomy
translocation	O
.	O
DNA	O
damage	O
,	O
rearrangement	O
,	O
and	O
mutation	O
of	O
the	O
human	O
genome	O
are	O
the	O
basis	O
of	O
carcinogenesis	O
and	O
thought	O
to	O
be	O
avoided	O
at	O
all	O
costs	O
.	O
An	O
exception	O
is	O
the	O
adaptive	O
immune	B-Anatomy
system	I-Anatomy
where	O
lymphocytes	B-Anatomy
utilize	O
programmed	O
DNA	O
damage	O
to	O
effect	O
antigen	O
receptor	O
diversification	O
.	O
Both	O
B	B-Anatomy
and	O
T	B-Anatomy
lymphocytes	I-Anatomy
diversify	O
their	O
antigen	O
receptors	O
through	O
RAG1	O
/	O
2	O
mediated	O
recombination	O
,	O
but	O
B	B-Anatomy
cells	I-Anatomy
undergo	O
two	O
additional	O
processes	O
-	O
-	O
somatic	O
hypermutation	O
(	O
SHM	O
)	O
and	O
class	O
-	O
switch	O
recombination	O
(	O
CSR	O
)	O
,	O
both	O
initiated	O
by	O
activation	O
-	O
induced	O
cytidine	O
deaminase	O
(	O
AID	O
)	O
.	O
AID	O
deaminates	O
cytidines	O
in	O
DNA	O
resulting	O
in	O
U	O
:	O
G	O
mismatches	O
that	O
are	O
processed	O
into	O
point	O
mutations	O
in	O
SHM	O
or	O
double	O
-	O
strand	O
breaks	O
in	O
CSR	O
.	O
Although	O
AID	O
activity	O
is	O
focused	O
at	O
Immunoglobulin	O
(	O
Ig	O
)	O
gene	O
loci	O
,	O
it	O
also	O
targets	O
a	O
wide	O
array	O
of	O
non	O
-	O
Ig	O
genes	O
including	O
oncogenes	O
associated	O
with	O
lymphomas	B-Anatomy
.	O
Here	O
,	O
we	O
review	O
the	O
molecular	O
basis	O
of	O
AID	O
regulation	O
,	O
targeting	O
,	O
and	O
initiation	O
of	O
CSR	O
and	O
SHM	O
,	O
as	O
well	O
as	O
AID	O
'	O
s	O
role	O
in	O
generating	O
chromosome	B-Anatomy
translocations	O
that	O
contribute	O
to	O
lymphomagenesis	O
.	O
Incidence	O
of	O
BRAF	O
p	O
.	O
Val600Glu	O
and	O
p	O
.	O
Val600Lys	O
mutations	O
in	O
a	O
consecutive	O
series	O
of	O
183	O
metastatic	B-Anatomy
melanoma	I-Anatomy
patients	O
from	O
a	O
high	O
incidence	O
region	O
.	O
AIM	O
:	O
Approximately	O
40	O
-	O
60	O
%	O
of	O
melanomas	B-Anatomy
from	O
Caucasian	O
populations	O
carry	O
activating	O
mutations	O
in	O
the	O
BRAF	O
oncogene	O
,	O
with	O
the	O
most	O
common	O
being	O
the	O
p	O
.	O
Val600Glu	O
(	O
V600E	O
)	O
hotspot	O
mutation	O
in	O
exon	O
15	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
frequency	O
of	O
the	O
less	O
common	O
p	O
.	O
Val600Lys	O
(	O
V600K	O
)	O
mutation	O
in	O
metastatic	B-Anatomy
melanoma	I-Anatomy
from	O
a	O
high	O
incidence	O
region	O
.	O
METHOD	O
:	O
Dideoxy	O
sequencing	O
and	O
fluorescent	O
single	O
strand	O
conformation	O
analysis	O
were	O
used	O
to	O
screen	O
for	O
mutations	O
in	O
exon	O
15	O
of	O
BRAF	O
in	O
183	O
cases	O
of	O
metastatic	B-Anatomy
melanoma	I-Anatomy
.	O
RESULTS	O
:	O
The	O
overall	O
incidence	O
of	O
BRAF	O
mutation	O
(	O
89	O
/	O
183	O
,	O
49	O
%	O
)	O
was	O
very	O
similar	O
to	O
other	O
large	O
studies	O
of	O
Caucasian	O
populations	O
.	O
However	O
,	O
the	O
frequency	O
of	O
the	O
p	O
.	O
Val600Lys	O
mutation	O
was	O
higher	O
than	O
in	O
most	O
other	O
studies	O
and	O
comprised	O
almost	O
one	O
-	O
third	O
of	O
all	O
BRAF	O
mutations	O
in	O
our	O
cohort	O
(	O
27	O
/	O
89	O
,	O
30	O
%	O
)	O
.	O
CONCLUSION	O
:	O
BRAF	O
p	O
.	O
Val600Lys	O
mutations	O
were	O
present	O
at	O
a	O
relatively	O
high	O
frequency	O
in	O
this	O
cohort	O
of	O
metastatic	B-Anatomy
melanoma	I-Anatomy
patients	O
(	O
27	O
/	O
183	O
,	O
15	O
%	O
)	O
.	O
Assays	O
used	O
to	O
screen	O
for	O
BRAF	O
mutations	O
in	O
the	O
clinic	O
should	O
be	O
robust	O
enough	O
to	O
detect	O
the	O
p	O
.	O
Val600Lys	O
mutation	O
,	O
as	O
this	O
may	O
have	O
therapeutic	O
implications	O
.	O
[	O
Biotechnological	O
and	O
biomedical	O
aspects	O
of	O
production	O
and	O
study	O
of	O
metal	O
cation	O
-	O
phospholipid	O
complexes	O
]	O
.	O
Problems	O
relating	O
to	O
the	O
technology	O
of	O
a	O
phospholipid	O
preparation	O
from	O
natural	O
materials	O
,	O
liposome	B-Anatomy
production	O
,	O
and	O
studies	O
into	O
the	O
mechanisms	O
of	O
interaction	O
between	O
metal	O
(	O
trace	O
elements	O
)	O
cations	O
and	O
model	O
bilayer	B-Anatomy
lipid	I-Anatomy
membranes	I-Anatomy
are	O
discussed	O
.	O
The	O
proposed	O
technology	O
of	O
extraction	O
allows	O
for	O
preparation	O
of	O
phospholipids	O
utilizable	O
for	O
liposome	B-Anatomy
formation	O
.	O
The	O
cation	O
specificity	O
of	O
lipid	B-Anatomy
bilayers	I-Anatomy
is	O
found	O
to	O
be	O
determined	O
by	O
the	O
presence	O
of	O
anionic	O
phosphate	O
adsorption	O
sites	O
on	O
their	O
surface	B-Anatomy
.	O
Alterations	O
in	O
carbohydrate	O
metabolism	O
in	O
canine	O
lymphoma	B-Anatomy
.	O
Following	O
an	O
overnight	O
fast	O
,	O
blood	B-Anatomy
samples	I-Anatomy
were	O
obtained	O
from	O
14	O
dogs	O
with	O
previously	O
untreated	O
lymphoma	B-Anatomy
before	O
and	O
5	O
,	O
15	O
,	O
30	O
,	O
45	O
,	O
60	O
,	O
and	O
90	O
minutes	O
following	O
an	O
intravenous	B-Anatomy
challenge	O
with	O
500	O
mg	O
/	O
kg	O
dextrose	O
.	O
Samples	B-Anatomy
were	O
assayed	O
for	O
glucose	O
,	O
lactate	O
,	O
and	O
insulin	O
concentrations	O
and	O
compared	O
statistically	O
with	O
ten	O
control	O
dogs	O
of	O
similar	O
weight	O
and	O
age	O
undergoing	O
an	O
identical	O
dextrose	O
challenge	O
.	O
Dogs	O
with	O
lymphoma	B-Anatomy
had	O
similar	O
glucose	O
tolerance	O
curves	O
when	O
compared	O
with	O
controls	O
.	O
Lactate	O
concentrations	O
were	O
significantly	O
higher	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
at	O
baseline	O
and	O
all	O
time	O
periods	O
of	O
the	O
glucose	O
tolerance	O
test	O
in	O
dogs	O
with	O
lymphoma	B-Anatomy
when	O
compared	O
with	O
controls	O
.	O
Rise	O
in	O
lactate	O
concentrations	O
over	O
baseline	O
levels	O
in	O
the	O
first	O
30	O
minutes	O
of	O
the	O
glucose	O
tolerance	O
test	O
were	O
significantly	O
higher	O
in	O
dogs	O
with	O
lymphoma	B-Anatomy
(	O
P	O
=	O
0	O
.	O
011	O
)	O
.	O
Insulin	O
concentrations	O
were	O
significantly	O
higher	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
at	O
baseline	O
and	O
at	O
the	O
5	O
-	O
,	O
45	O
-	O
,	O
60	O
-	O
,	O
and	O
90	O
-	O
minute	O
time	O
periods	O
of	O
the	O
glucose	O
tolerance	O
test	O
in	O
dogs	O
with	O
lymphoma	B-Anatomy
.	O
Rise	O
in	O
insulin	O
concentrations	O
over	O
baseline	O
in	O
the	O
first	O
5	O
minutes	O
of	O
the	O
glucose	O
tolerance	O
test	O
were	O
also	O
significantly	O
greater	O
in	O
dogs	O
with	O
lymphoma	B-Anatomy
(	O
P	O
=	O
0	O
.	O
021	O
)	O
.	O
These	O
results	O
indicate	O
carbohydrate	O
metabolism	O
is	O
altered	O
in	O
dogs	O
with	O
lymphoma	B-Anatomy
.	O
Many	O
of	O
these	O
alterations	O
parallel	O
those	O
observed	O
in	O
human	O
patients	O
suffering	O
from	O
cancer	B-Anatomy
cachexia	I-Anatomy
making	O
canine	O
lymphoma	B-Anatomy
a	O
potential	O
model	O
for	O
further	O
study	O
of	O
the	O
pathogenesis	O
and	O
therapy	O
of	O
cancer	B-Anatomy
cachexia	I-Anatomy
.	O
Members	O
of	O
the	O
src	O
and	O
ras	O
oncogene	O
families	O
supplant	O
the	O
epidermal	O
growth	O
factor	O
requirement	O
of	O
BALB	O
/	O
MK	O
-	O
2	O
keratinocytes	B-Anatomy
and	O
induce	O
distinct	O
alterations	O
in	O
their	O
terminal	O
differentiation	O
program	O
.	O
BALB	O
-	O
/	O
MK	O
-	O
2	O
mouse	O
epidermal	B-Anatomy
keratinocytes	I-Anatomy
required	O
epidermal	O
growth	O
factor	O
for	O
proliferation	O
and	O
terminally	O
differentiated	O
in	O
response	O
to	O
high	O
Ca2	O
+	O
concentration	O
.	O
Infection	O
with	O
retroviruses	O
containing	O
transforming	O
genes	O
of	O
the	O
src	O
and	O
ras	O
oncogene	O
families	O
led	O
to	O
rapid	O
loss	O
of	O
epidermal	O
growth	O
factor	O
dependence	O
,	O
in	O
some	O
cases	O
,	O
accompanied	O
by	O
alterations	O
in	O
cellular	B-Anatomy
morphology	O
.	O
The	O
virus	O
-	O
altered	O
cells	B-Anatomy
continued	O
to	O
proliferate	O
in	O
the	O
presence	O
of	O
high	O
levels	O
of	O
extracellular	B-Anatomy
calcium	O
but	O
exhibited	O
alterations	O
in	O
normal	O
keratinocyte	B-Anatomy
terminal	O
differentiation	O
that	O
appear	O
to	O
be	O
specific	O
to	O
the	O
particular	O
oncogene	O
.	O
These	O
alterations	O
bore	O
similarities	O
to	O
abnormalities	O
in	O
differentiation	O
observed	O
in	O
naturally	O
occurring	O
squamous	B-Anatomy
epithelial	I-Anatomy
malignancies	I-Anatomy
.	O
Experimental	O
drug	O
therapy	O
of	O
peritumoral	B-Anatomy
brain	I-Anatomy
edema	I-Anatomy
.	O
Four	O
drugs	O
with	O
potential	O
anti	O
-	O
peritumoral	B-Anatomy
brain	I-Anatomy
edema	I-Anatomy
activity	O
were	O
studied	O
using	O
the	O
VX2	B-Anatomy
rabbit	O
brain	B-Anatomy
tumor	I-Anatomy
model	O
.	O
Meclofenamate	O
and	O
indomethacin	O
were	O
tested	O
in	O
an	O
attempt	O
to	O
confirm	O
recent	O
reports	O
of	O
anti	O
-	O
edema	B-Anatomy
activity	O
in	O
non	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAID	O
'	O
s	O
)	O
.	O
The	O
'	O
angiostatic	O
'	O
steroids	O
17	O
hydroxyprogesterone	O
and	O
epicortisol	O
were	O
tested	O
because	O
of	O
their	O
lack	O
of	O
glucocorticoid	O
and	O
mineralocorticoid	O
effects	O
and	O
their	O
structural	O
similarity	O
to	O
glucocorticoids	O
.	O
The	O
protein	O
and	O
water	O
component	O
of	O
brain	B-Anatomy
edema	I-Anatomy
were	O
indirectly	O
quantitated	O
.	O
None	O
of	O
the	O
test	O
drugs	O
demonstrated	O
significant	O
anti	O
-	O
edema	B-Anatomy
activity	O
.	O
This	O
work	O
does	O
not	O
confirm	O
reports	O
that	O
NSAID	O
'	O
s	O
have	O
anti	O
-	O
edema	B-Anatomy
activity	O
and	O
suggests	O
that	O
there	O
may	O
be	O
no	O
correlation	O
between	O
'	O
angiostatic	O
'	O
and	O
anti	O
-	O
edema	B-Anatomy
activity	O
in	O
certain	O
steroid	O
compounds	O
.	O
Identification	O
of	O
a	O
small	O
region	O
of	O
the	O
v	O
-	O
fos	O
gene	O
product	O
that	O
is	O
sufficient	O
for	O
transforming	O
potential	O
and	O
growth	O
-	O
stimulating	O
activity	O
.	O
To	O
analyze	O
the	O
structure	O
-	O
function	O
relationship	O
for	O
the	O
v	O
-	O
fos	O
protein	O
,	O
we	O
constructed	O
in	O
-	O
frame	O
insertion	O
and	O
deletion	O
mutants	O
of	O
the	O
v	O
-	O
fos	O
gene	O
carried	O
by	O
FBJ	O
-	O
MuSV	O
,	O
and	O
expressed	O
them	O
in	O
chicken	O
primary	O
cells	B-Anatomy
using	O
retrovirus	O
vectors	O
.	O
We	O
assessed	O
the	O
effects	O
of	O
these	O
mutations	O
on	O
the	O
ability	O
of	O
the	O
v	O
-	O
fos	O
protein	O
to	O
transform	O
chicken	O
embryo	B-Anatomy
fibroblasts	I-Anatomy
and	O
to	O
stimulate	O
cellular	B-Anatomy
proliferation	O
of	O
chicken	O
neuroretinal	B-Anatomy
cells	I-Anatomy
.	O
The	O
mutant	O
which	O
retains	O
only	O
the	O
central	O
region	O
of	O
the	O
v	O
-	O
fos	O
protein	O
(	O
Met111	O
-	O
Ile206	O
)	O
have	O
both	O
activities	O
,	O
but	O
the	O
mutants	O
which	O
have	O
deletions	O
in	O
this	O
region	O
,	O
and	O
one	O
of	O
the	O
mutants	O
that	O
has	O
a	O
four	O
amino	O
acid	O
insertion	O
in	O
it	O
,	O
lost	O
both	O
activities	O
.	O
The	O
central	O
region	O
that	O
is	O
sufficient	O
for	O
these	O
activities	O
includes	O
the	O
evolutionarily	O
highly	O
conserved	O
region	O
among	O
human	O
,	O
mouse	O
and	O
chicken	O
c	O
-	O
fos	O
proteins	O
.	O
Additionally	O
,	O
this	O
sequence	O
shares	O
some	O
homology	O
with	O
the	O
DNA	O
binding	O
domain	O
of	O
GCN4	O
and	O
c	O
-	O
jun	O
protein	O
.	O
The	O
truncated	O
fos	O
protein	O
that	O
contains	O
only	O
part	O
of	O
the	O
central	O
region	O
is	O
not	O
phosphorylated	O
in	O
chicken	O
embryo	B-Anatomy
fibroblasts	I-Anatomy
,	O
indicating	O
that	O
phosphorylation	O
of	O
the	O
fos	O
protein	O
is	O
not	O
necessary	O
for	O
the	O
transforming	O
activity	O
.	O
Inhibition	O
by	O
retinoic	O
acid	O
of	O
type	O
IV	O
collagenolysis	O
and	O
invasion	O
through	O
reconstituted	O
basement	B-Anatomy
membrane	I-Anatomy
by	O
metastatic	O
rat	O
mammary	B-Anatomy
adenocarcinoma	I-Anatomy
cells	I-Anatomy
.	O
The	O
activity	O
of	O
type	O
IV	O
collagenase	O
,	O
which	O
enables	O
tumor	B-Anatomy
cells	I-Anatomy
to	O
degrade	O
collagen	O
type	O
IV	O
found	O
in	O
the	O
subendothelial	B-Anatomy
basement	I-Anatomy
membrane	I-Anatomy
,	O
has	O
been	O
correlated	O
with	O
the	O
metastatic	O
potential	O
in	O
several	O
tumor	B-Anatomy
types	O
,	O
including	O
the	O
rat	O
13762NF	B-Anatomy
mammary	I-Anatomy
adenocarcinoma	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
and	O
its	O
clones	B-Anatomy
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
all	O
-	O
trans	O
-	O
RA	O
)	O
and	O
other	O
retinoids	O
,	O
which	O
exhibit	O
antitumor	B-Anatomy
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
affect	O
the	O
collagenolytic	O
activity	O
of	O
metastatic	O
rat	O
13762NF	B-Anatomy
mammary	I-Anatomy
adenocarcinoma	I-Anatomy
cells	I-Anatomy
.	O
Cells	B-Anatomy
of	O
the	O
highly	O
metastatic	O
lung	B-Anatomy
-	O
colonizing	O
clone	B-Anatomy
MTF7	I-Anatomy
.	I-Anatomy
T35	I-Anatomy
.	I-Anatomy
3	I-Anatomy
,	O
derived	O
from	O
the	O
13762NF	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
,	O
were	O
treated	O
for	O
3	O
days	O
with	O
0	O
.	O
1	O
,	O
1	O
,	O
or	O
10	O
microM	O
all	O
-	O
trans	O
-	O
RA	O
,	O
harvested	O
,	O
and	O
seeded	O
on	O
[	O
3H	O
]	O
proline	O
-	O
labeled	O
extracellular	B-Anatomy
matrix	I-Anatomy
deposited	O
by	O
cultured	O
rat	O
lung	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
or	O
on	O
a	O
film	O
of	O
purified	O
[	O
3H	O
]	O
proline	O
-	O
labeled	O
type	O
IV	O
collagen	O
.	O
The	O
amount	O
of	O
radioactivity	O
released	O
into	O
the	O
medium	O
during	O
the	O
subsequent	O
24	O
to	O
72	O
h	O
was	O
measured	O
,	O
and	O
it	O
was	O
found	O
that	O
all	O
-	O
trans	O
-	O
RA	O
treatment	O
inhibited	O
degradation	O
of	O
extracellular	B-Anatomy
matrix	I-Anatomy
and	O
type	O
IV	O
collagen	O
by	O
50	O
to	O
60	O
%	O
.	O
This	O
effect	O
was	O
observed	O
whether	O
the	O
cells	B-Anatomy
had	O
been	O
treated	O
with	O
all	O
-	O
trans	O
-	O
RA	O
in	O
serum	B-Anatomy
-	O
free	O
medium	O
or	O
in	O
medium	O
supplemented	O
with	O
heat	O
-	O
inactivated	O
or	O
acid	O
-	O
treated	O
fetal	B-Anatomy
bovine	I-Anatomy
serum	I-Anatomy
.	O
The	O
growth	O
of	O
the	O
cells	B-Anatomy
was	O
not	O
inhibited	O
under	O
these	O
conditions	O
,	O
except	O
after	O
treatment	O
with	O
10	O
microM	O
all	O
-	O
trans	O
-	O
RA	O
in	O
serum	B-Anatomy
-	O
free	O
medium	O
.	O
The	O
reduction	O
in	O
collagenolytic	O
activity	O
was	O
observed	O
in	O
viable	O
cells	B-Anatomy
as	O
well	O
as	O
in	O
conditioned	O
medium	O
.	O
A	O
24	O
-	O
h	O
exposure	O
of	O
cells	B-Anatomy
to	O
all	O
-	O
trans	O
-	O
RA	O
was	O
sufficient	O
to	O
cause	O
a	O
30	O
%	O
decrease	O
in	O
the	O
collagenolytic	O
activity	O
,	O
and	O
this	O
inhibitory	O
effect	O
was	O
reversible	O
.	O
The	O
direct	O
addition	O
of	O
all	O
-	O
trans	O
-	O
RA	O
to	O
conditioned	O
medium	O
had	O
no	O
effect	O
on	O
secreted	O
collagenase	O
activity	O
.	O
The	O
apparent	O
molecular	O
weights	O
of	O
the	O
collagenolytic	O
enzymes	O
were	O
determined	O
by	O
electrophoresis	O
of	O
cell	B-Anatomy
extracts	I-Anatomy
and	O
concentrated	O
conditioned	O
medium	O
in	O
type	O
IV	O
collagen	O
-	O
embedded	O
polyacrylamide	O
gels	O
followed	O
by	O
renaturation	O
and	O
activation	O
of	O
the	O
enzymes	O
within	O
the	O
gels	O
.	O
Two	O
major	O
type	O
IV	O
collagenolytic	O
metalloproteinases	O
exhibiting	O
molecular	O
weights	O
of	O
64	O
,	O
000	O
and	O
88	O
,	O
000	O
,	O
respectively	O
,	O
were	O
detected	O
by	O
this	O
method	O
.	O
These	O
two	O
enzymes	O
were	O
also	O
found	O
to	O
have	O
specificity	O
for	O
gelatin	O
.	O
The	O
Mr	O
64	O
,	O
000	O
enzyme	O
could	O
be	O
extracted	O
from	O
viable	O
cells	B-Anatomy
(	O
presumably	O
from	O
the	O
cell	B-Anatomy
membrane	I-Anatomy
)	O
by	O
2	O
%	O
1	O
-	O
butanol	O
.	O
Treatment	O
with	O
all	O
-	O
trans	O
-	O
RA	O
decreased	O
the	O
level	O
of	O
these	O
enzymes	O
in	O
the	O
cellular	B-Anatomy
,	O
cell	B-Anatomy
membrane	I-Anatomy
,	O
and	O
conditioned	O
medium	O
compartments	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
Endoscopic	O
injection	O
therapy	O
for	O
acute	O
upper	B-Anatomy
GI	I-Anatomy
bleeding	O
.	O
In	O
summary	O
,	O
we	O
have	O
found	O
this	O
technique	O
to	O
be	O
useful	O
in	O
patients	O
in	O
whom	O
coagulation	O
therapy	O
is	O
not	O
possible	O
or	O
effective	O
.	O
It	O
must	O
still	O
be	O
considered	O
a	O
technique	O
which	O
is	O
undergoing	O
evaluation	O
.	O
Prospective	O
randomized	O
trials	O
comparing	O
this	O
therapy	O
with	O
other	O
currently	O
available	O
therapies	O
such	O
a	O
electrocoagulation	O
,	O
laser	O
and	O
conservative	O
management	O
must	O
be	O
completed	O
to	O
firmly	O
define	O
its	O
place	O
in	O
treatment	O
strategy	O
for	O
acute	O
upper	B-Anatomy
GI	I-Anatomy
bleeding	O
.	O
Effects	O
of	O
hypertension	O
and	O
sympathetic	O
denervation	O
on	O
cerebral	B-Anatomy
blood	B-Anatomy
flow	O
in	O
newborn	O
pigs	O
.	O
To	O
investigate	O
the	O
potential	O
role	O
of	O
sympathetic	B-Anatomy
nerves	I-Anatomy
in	O
preventing	O
pronounced	O
increases	O
in	O
cerebral	B-Anatomy
blood	B-Anatomy
flow	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
abrupt	O
hypertension	O
on	O
the	O
cerebral	B-Anatomy
circulation	O
of	O
newborn	O
pigs	O
with	O
intact	O
cerebral	B-Anatomy
sympathetic	O
innervation	O
and	O
after	O
cerebral	B-Anatomy
sympathetic	O
denervation	O
.	O
Epinephrine	O
infusion	O
was	O
used	O
to	O
induce	O
abrupt	O
increases	O
in	O
mean	O
(	O
+	O
/	O
-	O
SEM	O
)	O
arterial	B-Anatomy
pressure	O
(	O
innervated	O
pigs	O
,	O
62	O
+	O
/	O
-	O
3	O
mm	O
of	O
Hg	O
to	O
115	O
+	O
/	O
-	O
3	O
mm	O
of	O
Hg	O
;	O
denervated	O
pigs	O
,	O
71	O
+	O
/	O
-	O
4	O
mm	O
of	O
Hg	O
to	O
132	O
+	O
/	O
-	O
4	O
mm	O
of	O
Hg	O
)	O
that	O
remained	O
increased	O
for	O
the	O
3	O
minutes	O
of	O
the	O
study	O
.	O
Abrupt	O
hypertension	O
increased	O
blood	B-Anatomy
flow	O
to	O
all	O
brain	B-Anatomy
regions	O
.	O
In	O
denervated	O
pigs	O
,	O
the	O
increased	O
flow	O
to	O
the	O
cerebrum	B-Anatomy
was	O
prolonged	O
,	O
compared	O
with	O
that	O
in	O
pigs	O
with	O
intact	O
sympathetic	O
innervation	O
.	O
Differences	O
between	O
pigs	O
of	O
the	O
innervated	O
and	O
denervated	O
groups	O
were	O
not	O
apparent	O
,	O
with	O
respect	O
to	O
blood	B-Anatomy
flow	O
to	O
any	O
other	O
region	O
(	O
caudate	B-Anatomy
region	I-Anatomy
,	O
brain	B-Anatomy
stem	I-Anatomy
,	O
cerebellum	B-Anatomy
)	O
.	O
In	O
newborn	O
pigs	O
,	O
sympathetic	B-Anatomy
nerves	I-Anatomy
may	O
attenuate	O
hypertension	O
-	O
induced	O
increases	O
in	O
blood	B-Anatomy
flow	O
to	O
the	O
cerebrum	B-Anatomy
,	O
but	O
do	O
not	O
appear	O
to	O
affect	O
flow	O
to	O
the	O
rest	O
of	O
the	O
brain	B-Anatomy
.	O
Malate	O
-	O
citrate	O
cycle	O
during	O
glycolysis	O
and	O
glutaminolysis	O
in	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
.	O
The	O
malate	O
-	O
citrate	O
cycle	O
was	O
studied	O
during	O
aerobic	O
glycolysis	O
and	O
glutaminolysis	O
in	O
a	O
strain	B-Anatomy
of	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
which	O
showed	O
a	O
very	O
low	O
malate	O
-	O
aspartate	O
shuttle	O
system	O
activity	O
.	O
The	O
experimental	O
approach	O
includes	O
:	O
estimation	O
of	O
mitochondrial	B-Anatomy
NAD	O
[	O
P	O
]	O
+	O
-	O
dependent	O
malic	O
enzyme	O
activity	O
;	O
respiratory	O
activity	O
of	O
freshly	O
harvested	O
or	O
fasted	O
cells	B-Anatomy
,	O
and	O
of	O
isolated	O
mitochondria	B-Anatomy
;	O
and	O
determination	O
of	O
the	O
metabolites	O
involved	O
in	O
the	O
glycolytic	O
and	O
glutaminolytic	O
pathways	O
.	O
The	O
results	O
suggest	O
that	O
in	O
this	O
strain	B-Anatomy
,	O
the	O
malate	O
-	O
citrate	O
shuttle	O
is	O
not	O
an	O
effective	O
pathway	O
for	O
transferring	O
glycolytic	O
reducing	O
equivalents	O
from	O
cytosol	B-Anatomy
to	O
mitochondria	B-Anatomy
.	O
Less	O
than	O
15	O
%	O
of	O
the	O
glucose	O
uptake	O
was	O
affected	O
by	O
the	O
1	O
,	O
2	O
,	O
3	O
-	O
benzenetricarboxylate	O
inhibition	O
of	O
the	O
malate	O
-	O
citrate	O
shuttle	O
.	O
Moreover	O
,	O
in	O
the	O
presence	O
of	O
glucose	O
,	O
the	O
malate	O
-	O
citrate	O
cycle	O
did	O
not	O
appear	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
glutaminolytic	O
process	O
.	O
The	O
present	O
work	O
supports	O
and	O
extends	O
the	O
finding	O
of	O
previous	O
studies	O
,	O
since	O
the	O
results	O
showed	O
that	O
the	O
glucose	O
metabolism	O
depressed	O
the	O
oxidative	O
processes	O
in	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
tumor	I-Anatomy
mitochondria	B-Anatomy
,	O
not	O
only	O
alone	O
,	O
but	O
also	O
in	O
the	O
presence	O
of	O
glutamine	O
.	O
Interestingly	O
,	O
the	O
high	O
glutamine	O
uptake	O
was	O
maintained	O
in	O
the	O
presence	O
of	O
glucose	O
.	O
N	O
-	O
methyl	O
-	O
N	O
-	O
nitrosourea	O
-	O
induced	O
transformation	O
of	O
rat	O
urothelial	B-Anatomy
cells	I-Anatomy
in	O
vitro	O
is	O
not	O
mediated	O
by	O
activation	O
of	O
ras	O
oncogenes	O
.	O
Adult	O
rat	O
urothelial	B-Anatomy
cells	I-Anatomy
were	O
transformed	O
in	O
vitro	O
following	O
treatment	O
with	O
a	O
single	O
dose	O
of	O
N	O
-	O
methyl	O
-	O
N	O
-	O
nitrosourea	O
(	O
MNU	O
)	O
or	O
MNU	O
treatment	O
followed	O
by	O
promotion	O
with	O
sodium	O
saccharin	O
.	O
This	O
in	O
vitro	O
transformation	O
process	O
involves	O
multiple	O
steps	O
:	O
slow	O
-	O
growing	O
'	B-Anatomy
pre	I-Anatomy
-	I-Anatomy
neoplastic	I-Anatomy
'	I-Anatomy
epithelial	I-Anatomy
foci	I-Anatomy
are	O
induced	O
70	O
-	O
100	O
days	O
after	O
MNU	O
treatment	O
and	O
from	O
such	O
foci	B-Anatomy
rapidly	O
proliferating	O
immortal	O
cell	B-Anatomy
lines	I-Anatomy
were	O
established	O
,	O
some	O
of	O
which	O
became	O
tumorigenic	O
after	O
a	O
further	O
latent	O
period	O
.	O
A	O
series	O
of	O
epithelial	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
and	O
a	O
single	O
fibroblast	B-Anatomy
cell	I-Anatomy
line	I-Anatomy
established	O
in	O
this	O
way	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
transforming	O
genes	O
by	O
DNA	O
transfection	O
into	O
NIH3T3	B-Anatomy
cells	I-Anatomy
.	O
None	O
of	O
the	O
epithelial	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
induced	O
foci	B-Anatomy
in	O
a	O
focus	B-Anatomy
formation	O
assay	O
.	O
The	O
single	O
non	B-Anatomy
-	I-Anatomy
epithelial	I-Anatomy
line	I-Anatomy
induced	O
foci	B-Anatomy
and	O
was	O
found	O
to	O
contain	O
an	O
activated	O
c	O
-	O
Ki	O
-	O
ras	O
gene	O
with	O
a	O
G	O
-	O
-	O
-	O
-	O
A	O
transition	O
in	O
codon	O
12	O
.	O
To	O
assay	O
for	O
the	O
possible	O
presence	O
of	O
transforming	O
genes	O
which	O
were	O
not	O
active	O
in	O
a	O
focus	B-Anatomy
formation	O
assay	O
,	O
two	O
of	O
the	O
epithelial	B-Anatomy
lines	I-Anatomy
were	O
analysed	O
further	O
by	O
co	O
-	O
transfection	O
with	O
a	O
dominant	O
selectable	O
marker	O
,	O
followed	O
by	O
selection	O
and	O
inoculation	O
into	O
nude	O
mice	O
.	O
No	O
tumours	B-Anatomy
were	O
induced	O
within	O
the	O
latent	O
period	O
for	O
tumour	B-Anatomy
production	O
by	O
control	O
cells	B-Anatomy
transfected	O
with	O
NIH3T3	B-Anatomy
cell	I-Anatomy
DNA	O
(	O
40	O
-	O
60	O
days	O
)	O
.	O
These	O
results	O
suggest	O
that	O
there	O
is	O
cell	B-Anatomy
type	O
specificity	O
for	O
oncogene	O
activation	O
during	O
in	O
vitro	O
rat	O
bladder	B-Anatomy
transformation	O
initiated	O
by	O
a	O
single	O
carcinogen	O
and	O
that	O
ras	O
gene	O
activation	O
is	O
not	O
a	O
necessary	O
step	O
in	O
urothelial	B-Anatomy
transformation	O
in	O
vitro	O
.	O
Sensitivity	O
analysis	O
of	O
the	O
influence	O
of	O
source	O
-	O
term	O
and	O
environmental	O
parameters	O
on	O
the	O
radiological	O
risk	O
of	O
coal	O
-	O
fired	O
plants	O
.	O
A	O
sensitivity	O
analysis	O
was	O
undertaken	O
to	O
determine	O
the	O
influence	O
of	O
different	O
source	O
-	O
term	O
and	O
environmental	O
parameters	O
on	O
the	O
radiological	O
risks	O
from	O
a	O
coal	O
-	O
fired	O
plant	O
(	O
CFP	O
)	O
.	O
It	O
was	O
found	O
that	O
the	O
release	O
rate	O
of	O
radionuclides	O
and	O
the	O
effective	O
release	O
height	O
most	O
significantly	O
influence	O
radiological	O
risk	O
.	O
Site	O
characteristics	O
,	O
such	O
as	O
rain	O
scavenging	O
coefficients	O
and	O
food	O
acquirement	O
habits	O
,	O
have	O
a	O
lesser	O
influence	O
,	O
and	O
some	O
parameters	O
,	O
such	O
as	O
time	O
delay	O
before	O
ingestion	O
of	O
contaminated	O
food	O
,	O
have	O
practically	O
no	O
influence	O
on	O
the	O
radiological	O
impact	O
of	O
a	O
CFP	O
.	O
The	O
contribution	O
to	O
radiation	O
risks	O
of	O
different	O
exposure	O
modes	O
(	O
i	O
.	O
e	O
.	O
inhalation	O
,	O
ingestion	O
and	O
contact	O
with	O
ground	O
surface	O
)	O
were	O
also	O
analyzed	O
,	O
as	O
well	O
as	O
of	O
specific	O
radionuclides	O
and	O
human	O
body	B-Anatomy
organs	I-Anatomy
.	O
Results	O
of	O
the	O
sensitivity	O
analysis	O
were	O
interpreted	O
in	O
terms	O
of	O
the	O
characteristics	O
of	O
the	O
fuel	O
,	O
facilities	O
and	O
site	O
of	O
a	O
CFP	O
.	O
It	O
is	O
concluded	O
that	O
by	O
proper	O
choice	O
of	O
coal	O
,	O
furnace	O
,	O
ash	O
filtration	O
and	O
stack	O
height	O
,	O
as	O
well	O
as	O
by	O
proper	O
siting	O
,	O
the	O
radiological	O
impact	O
of	O
a	O
CFP	O
can	O
be	O
drastically	O
reduced	O
.	O
Antishock	O
trousers	O
:	O
a	O
collective	O
review	O
.	O
Antishock	O
trousers	O
have	O
become	O
an	O
integral	O
part	O
of	O
emergency	O
medical	O
care	O
for	O
many	O
traumatic	O
and	O
life	O
-	O
threatening	O
emergencies	O
.	O
This	O
article	O
represents	O
a	O
summary	O
of	O
the	O
current	O
state	O
of	O
knowledge	O
concerning	O
the	O
use	O
of	O
this	O
device	O
.	O
A	O
brief	O
history	O
of	O
the	O
development	O
of	O
antishock	O
garments	O
is	O
discussed	O
.	O
This	O
is	O
followed	O
by	O
a	O
discussion	O
of	O
human	O
clinical	O
studies	O
and	O
results	O
of	O
clinical	O
research	O
on	O
hemodynamics	O
,	O
respiration	O
,	O
use	O
in	O
head	B-Anatomy
injury	O
,	O
and	O
effects	O
on	O
vascular	B-Anatomy
hemostasis	O
.	O
Indications	O
,	O
contraindications	O
,	O
complications	O
,	O
and	O
recommended	O
procedure	O
for	O
use	O
are	O
discussed	O
.	O
Based	O
on	O
randomized	O
prospective	O
studies	O
,	O
antishock	O
garments	O
have	O
not	O
,	O
as	O
yet	O
,	O
been	O
shown	O
to	O
improve	O
patient	O
morbidity	O
or	O
mortality	O
.	O
Proper	O
use	O
of	O
antishock	O
garments	O
requires	O
an	O
understanding	O
of	O
both	O
their	O
function	O
and	O
their	O
limitations	O
.	O
Measurement	O
of	O
serum	B-Anatomy
glycosylated	O
proteins	O
and	O
glycosylated	O
low	O
density	O
lipoprotein	O
fraction	O
in	O
diabetes	O
mellitus	O
.	O
A	O
simple	O
method	O
was	O
developed	O
for	O
estimating	O
serum	B-Anatomy
glycosylated	O
protein	O
levels	O
using	O
gel	O
filtration	O
with	O
Bio	O
-	O
Gel	O
P6	O
by	O
determining	O
the	O
protein	O
and	O
sugar	O
content	O
in	O
the	O
void	O
volume	O
fraction	O
.	O
The	O
glycosylated	O
protein	O
levels	O
(	O
GSP	O
)	O
correlated	O
well	O
with	O
fasting	O
blood	B-Anatomy
sugar	O
levels	O
and	O
glycosylated	O
albumin	O
level	O
(	O
G	O
-	O
ALB	O
)	O
determined	O
by	O
affinity	O
chromatography	O
with	O
Blue	O
Sepharose	O
CL6B	O
.	O
The	O
glycosylation	O
level	O
of	O
heparin	O
-	O
citrate	O
precipitable	O
fraction	O
of	O
serum	B-Anatomy
which	O
predominantly	O
contained	O
low	O
density	O
lipoprotein	O
(	O
G	O
-	O
LDL	O
)	O
also	O
correlated	O
well	O
with	O
GSP	O
and	O
LDL	O
-	O
cholesterol	O
levels	O
.	O
Significantly	O
different	O
values	O
were	O
obtained	O
for	O
GSP	O
,	O
G	O
-	O
ALB	O
,	O
and	O
G	O
-	O
LDL	O
between	O
normals	O
and	O
diabetics	O
.	O
The	O
origin	O
of	O
yolk	B-Anatomy
-	O
DNA	O
in	O
Xenopus	O
laevis	O
.	O
Xenopus	O
laevis	O
serum	B-Anatomy
and	O
plasma	B-Anatomy
was	O
found	O
to	O
contain	O
an	O
average	O
of	O
25	O
microgram	O
DNA	O
/	O
ml	O
.	O
Isolated	O
X	O
.	O
laevis	O
oocytes	B-Anatomy
incubated	O
in	O
medium	O
containing	O
25	O
microgram	O
DNA	O
/	O
ml	O
labeled	O
with	O
either	O
125I	O
,	O
32P	O
or	O
14C	O
and	O
from	O
three	O
different	O
sources	O
(	O
bovine	O
,	O
E	O
.	O
coli	O
and	O
X	O
.	O
laevis	O
)	O
,	O
incorporated	O
the	O
label	O
at	O
an	O
average	O
rate	O
of	O
0	O
.	O
11	O
ng	O
.	O
mm	O
-	O
2	O
.	O
hr	O
-	O
1	O
.	O
Sucrose	O
gradient	O
fractionation	O
of	O
oocytes	B-Anatomy
revealed	O
that	O
40	O
-	O
75	O
%	O
of	O
the	O
acid	O
-	O
precipitable	O
label	O
incorporated	O
was	O
associated	O
with	O
the	O
yolk	B-Anatomy
platelets	I-Anatomy
.	O
Additional	O
incubations	O
of	O
oocytes	B-Anatomy
in	O
unlabeled	O
medium	O
demonstrated	O
that	O
the	O
DNA	O
incorporated	O
into	O
the	O
yolk	B-Anatomy
platelets	I-Anatomy
was	O
undergoing	O
turnover	O
;	O
only	O
20	O
%	O
of	O
the	O
yolk	B-Anatomy
-	O
associated	O
DNA	O
was	O
still	O
present	O
after	O
a	O
one	O
-	O
week	O
incubation	O
.	O
Our	O
data	O
suggest	O
that	O
yolk	B-Anatomy
-	O
DNA	O
arises	O
by	O
the	O
adventitious	O
uptake	O
of	O
DNA	O
present	O
in	O
the	O
maternal	O
serum	B-Anatomy
by	O
vitellogenic	O
oocytes	B-Anatomy
.	O
Low	O
-	O
level	O
X	O
-	O
radiation	O
effects	O
on	O
functional	O
vascular	B-Anatomy
changes	O
in	O
Syrian	O
hamster	O
cheek	B-Anatomy
pouch	I-Anatomy
epithelium	I-Anatomy
during	O
hydrocarbon	O
carcinogenesis	O
.	O
Effects	O
of	O
repeated	O
low	O
-	O
level	O
X	O
radiation	O
on	O
functional	O
microvascular	B-Anatomy
changes	O
in	O
hamster	O
cheek	B-Anatomy
pouch	I-Anatomy
epithelium	I-Anatomy
during	O
and	O
following	O
carcinogenesis	O
by	O
7	O
,	O
12	O
-	O
dimethylbenz	O
[	O
a	O
]	O
anthracene	O
(	O
DMBA	O
)	O
were	O
studied	O
.	O
Prior	O
studies	O
showed	O
enhancement	O
of	O
such	O
carcinogenesis	O
by	O
repeated	O
20	O
rad	O
head	B-Anatomy
and	O
neck	B-Anatomy
X	O
-	O
radiation	O
exposures	O
,	O
and	O
it	O
was	O
proposed	O
that	O
one	O
possible	O
mechanism	O
was	O
radiogenic	O
alteration	O
of	O
the	O
functional	O
microvasculature	B-Anatomy
in	O
a	O
manner	O
which	O
favored	O
subsequent	O
tumor	B-Anatomy
development	O
.	O
Hamsters	O
were	O
treated	O
with	O
either	O
radiation	O
,	O
DMBA	O
,	O
radiation	O
+	O
DMBA	O
,	O
or	O
no	O
treatment	O
.	O
Animals	O
were	O
sacrificed	O
at	O
3	O
-	O
week	O
intervals	O
from	O
0	O
to	O
39	O
weeks	O
after	O
treatments	O
began	O
.	O
Pouch	B-Anatomy
vascular	I-Anatomy
volume	O
and	O
permeability	O
changes	O
were	O
studied	O
by	O
fractional	O
distributions	O
of	O
radiotracers	O
and	O
were	O
analyzed	O
by	O
a	O
variety	O
of	O
statistical	O
methods	O
which	O
explored	O
the	O
vascular	B-Anatomy
parameters	O
,	O
treatment	O
types	O
,	O
elapsed	O
time	O
,	O
presence	O
of	O
the	O
carcinogen	O
,	O
and	O
histopathologic	O
changes	O
.	O
All	O
treatments	O
resulted	O
in	O
significant	O
changes	O
in	O
vascular	B-Anatomy
volume	O
with	O
time	O
,	O
while	O
only	O
DMBA	O
treatments	O
alone	O
resulted	O
in	O
significant	O
changes	O
in	O
vascular	B-Anatomy
permeability	O
with	O
time	O
.	O
Prior	O
to	O
the	O
appearances	O
of	O
frank	O
neoplasms	B-Anatomy
,	O
volumetric	O
changes	O
in	O
DMBA	O
only	O
and	O
radiation	O
only	O
groups	O
were	O
similar	O
,	O
while	O
volume	O
changes	O
in	O
DMBA	O
+	O
radiation	O
groups	O
increased	O
slowly	O
to	O
a	O
peak	O
later	O
than	O
in	O
other	O
groups	O
and	O
then	O
declined	O
steadily	O
to	O
levels	O
similar	O
to	O
the	O
radiation	O
only	O
group	O
.	O
As	O
in	O
prior	O
studies	O
,	O
there	O
were	O
significant	O
vascular	B-Anatomy
volume	O
differences	O
between	O
DMBA	O
and	O
DMBA	O
+	O
radiation	O
groups	O
of	O
tumor	B-Anatomy
-	O
bearing	O
cheek	B-Anatomy
pouches	I-Anatomy
.	O
DMBA	O
maxima	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
DMBA	O
+	O
radiation	O
.	O
Radiation	O
significantly	O
affected	O
DMBA	O
-	O
associated	O
vascular	B-Anatomy
volume	O
and	O
permeability	O
changes	O
during	O
carcinogenesis	O
.	O
Several	O
possible	O
explanations	O
for	O
the	O
relationship	O
of	O
these	O
changes	O
to	O
the	O
enhancement	O
of	O
DMBA	O
carcinogenesis	O
include	O
:	O
radiation	O
blocking	O
normal	O
capillary	B-Anatomy
proliferative	O
and	O
/	O
or	O
dilatory	O
responses	O
to	O
inflammation	O
secondary	O
to	O
neoplastic	B-Anatomy
changes	O
;	O
radiation	O
-	O
induced	O
focal	O
increases	O
in	O
the	O
pericapillary	B-Anatomy
connective	I-Anatomy
tissue	I-Anatomy
histohematic	B-Anatomy
barrier	I-Anatomy
,	O
stimulating	O
angiogenesis	O
but	O
reducing	O
nutrient	O
diffusion	O
;	O
radiation	O
exposures	O
sensitizing	O
vascular	B-Anatomy
endothelium	I-Anatomy
to	O
subsequent	O
angiogenic	O
stimulation	O
from	O
premalignant	B-Anatomy
tissues	I-Anatomy
;	O
DMBA	O
vascular	B-Anatomy
and	O
epithelial	B-Anatomy
effects	O
partially	O
or	O
completely	O
blocking	O
radiation	O
effects	O
on	O
epithelial	B-Anatomy
and	O
/	O
or	O
endothelial	B-Anatomy
cells	I-Anatomy
;	O
and	O
radiation	O
damage	O
to	O
vessel	B-Anatomy
walls	I-Anatomy
partially	O
or	O
fully	O
inhibiting	O
normal	O
physiologic	O
mechanisms	O
of	O
repairing	O
DMBA	O
damage	O
to	O
the	O
vessels	B-Anatomy
.	O
Immunoglobulins	O
associated	O
with	O
elevated	O
riboflavin	O
binding	O
by	O
plasma	B-Anatomy
from	O
cancer	B-Anatomy
patients	O
.	O
Plasma	B-Anatomy
from	O
182	O
patients	O
with	O
different	O
malignant	B-Anatomy
diseases	I-Anatomy
was	O
tested	O
for	O
riboflavin	O
binding	O
by	O
immunoglobulins	O
,	O
which	O
have	O
been	O
recently	O
identified	O
as	O
major	O
carriers	O
of	O
this	O
micronutrient	O
.	O
A	O
wide	O
range	O
of	O
binding	O
(	O
5	O
.	O
9	O
to	O
130	O
pmole	O
/	O
ml	O
plasma	B-Anatomy
)	O
was	O
observed	O
,	O
and	O
significant	O
elevations	O
were	O
found	O
for	O
patients	O
having	O
breast	B-Anatomy
cancer	I-Anatomy
(	O
21	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
9	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
melanoma	B-Anatomy
(	O
25	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
9	O
,	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
compared	O
to	O
controls	O
(	O
15	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
9	O
)	O
.	O
The	O
proteins	O
responsible	O
for	O
a	O
majority	O
of	O
the	O
higher	O
binding	O
were	O
identified	O
as	O
immunoglobulins	O
,	O
based	O
on	O
their	O
elution	O
from	O
gel	O
filtration	O
columns	O
and	O
the	O
removal	O
of	O
57	O
-	O
88	O
%	O
of	O
the	O
non	O
-	O
albumin	O
binding	O
by	O
treating	O
of	O
plasma	B-Anatomy
with	O
Protein	O
A	O
-	O
agarose	O
.	O
The	O
binding	O
was	O
only	O
weakly	O
related	O
to	O
the	O
total	O
concentration	O
of	O
immunoglobulins	O
(	O
r	O
=	O
0	O
.	O
11	O
by	O
linear	O
regression	O
analysis	O
)	O
,	O
however	O
,	O
and	O
is	O
apparently	O
due	O
to	O
a	O
subclass	O
that	O
is	O
elevated	O
in	O
some	O
types	O
of	O
cancer	B-Anatomy
.	O
Elevated	O
levels	O
of	O
these	O
immunoglobulins	O
may	O
contribute	O
to	O
the	O
lower	O
urinary	B-Anatomy
levels	O
and	O
clearance	O
of	O
riboflavin	O
in	O
cancer	B-Anatomy
.	O
Postpartum	O
rubella	O
immunization	O
:	O
association	O
with	O
development	O
of	O
prolonged	O
arthritis	O
,	O
neurological	B-Anatomy
sequelae	O
,	O
and	O
chronic	O
rubella	O
viremia	O
.	O
Six	O
women	O
developed	O
chronic	O
long	O
-	O
term	O
arthropathy	O
after	O
postpartum	O
immunization	O
against	O
rubella	O
.	O
All	O
individuals	O
developed	O
acute	O
polyarticular	O
arthritis	O
within	O
12	O
days	O
to	O
three	O
weeks	O
postimmunization	O
and	O
have	O
had	O
continuing	O
chronic	O
or	O
recurrent	O
arthralgia	O
or	O
arthritis	O
for	O
two	O
to	O
seven	O
years	O
after	O
vaccination	O
.	O
Acute	O
neurological	B-Anatomy
manifestations	O
,	O
consisting	O
of	O
carpal	O
tunnel	O
syndrome	O
or	O
multiple	O
paresthesiae	O
,	O
developed	O
postvaccination	O
in	O
three	O
women	O
.	O
Two	O
have	O
developed	O
continuing	O
active	O
or	O
chronic	O
recurrent	O
episodes	O
of	O
blurred	O
vision	O
,	O
paresthesiae	O
,	O
and	O
painful	O
limb	B-Anatomy
syndromes	O
together	O
with	O
recurrent	O
joint	B-Anatomy
symptoms	O
.	O
Chronic	O
rubella	O
viremia	O
has	O
been	O
detected	O
in	O
peripheral	B-Anatomy
blood	I-Anatomy
mononuclear	I-Anatomy
cell	I-Anatomy
(	O
MNC	B-Anatomy
)	O
populations	O
in	O
five	O
of	O
the	O
six	O
women	O
up	O
to	O
six	O
years	O
after	O
vaccination	O
.	O
In	O
addition	O
rubella	O
virus	O
was	O
isolated	O
from	O
breast	B-Anatomy
milk	I-Anatomy
MNCs	I-Anatomy
in	O
one	O
individual	O
at	O
nine	O
months	O
postvaccination	O
and	O
from	O
peripheral	B-Anatomy
blood	I-Anatomy
MNCs	I-Anatomy
in	O
two	O
of	O
four	O
breast	B-Anatomy
-	O
fed	O
infants	O
studied	O
at	O
12	O
-	O
18	O
months	O
of	O
age	O
.	O
Immune	O
responses	O
to	O
rubella	O
virus	O
studied	O
at	O
sequential	O
intervals	O
after	O
vaccination	O
correlated	O
with	O
development	O
of	O
rheumatologic	O
and	O
neurological	B-Anatomy
manifestations	O
.	O
Cardiac	B-Anatomy
gap	O
junction	O
configuration	O
after	O
an	O
uncoupling	O
treatment	O
as	O
a	O
function	O
of	O
time	O
.	O
Rabbit	O
ventricle	B-Anatomy
either	O
was	O
fixed	O
in	O
glutaraldehyde	O
without	O
injury	O
(	O
control	O
)	O
or	O
was	O
injured	O
before	O
fixation	O
,	O
presumably	O
causing	O
electrical	O
uncoupling	O
of	O
the	O
gap	O
junctions	O
.	O
All	O
tissue	B-Anatomy
was	O
then	O
processed	O
for	O
freeze	O
-	O
fracture	O
.	O
Replicas	O
of	O
control	O
gap	O
junctions	O
exhibited	O
irregular	O
packing	O
of	O
the	O
P	O
-	O
face	O
particles	O
and	O
E	O
-	O
face	O
pits	O
.	O
Average	O
center	O
-	O
to	O
-	O
center	O
spacing	O
of	O
the	O
particles	O
was	O
10	O
.	O
5	O
nm	O
.	O
Tissue	B-Anatomy
fixed	O
1	O
-	O
5	O
min	O
after	O
injury	O
showed	O
clumping	O
of	O
gap	O
junctional	O
particles	O
and	O
pits	O
.	O
Within	O
the	O
clumps	O
,	O
the	O
particles	O
and	O
pits	O
were	O
hexagonally	O
packed	O
and	O
the	O
center	O
-	O
to	O
-	O
center	O
spacing	O
of	O
the	O
particles	O
averaged	O
9	O
.	O
5	O
nm	O
.	O
In	O
tissue	B-Anatomy
fixed	O
15	O
-	O
30	O
min	O
after	O
injury	O
,	O
the	O
clumps	O
of	O
gap	O
junctional	O
particles	O
had	O
coalesced	O
into	O
a	O
homogeneous	O
structure	O
in	O
most	O
junctions	O
.	O
The	O
packing	O
of	O
the	O
particles	O
and	O
pits	O
was	O
hexagonal	O
and	O
the	O
spacing	O
of	O
the	O
particles	O
averaged	O
9	O
.	O
5	O
nm	O
.	O
A	O
few	O
pieces	B-Anatomy
of	O
rabbit	O
atrium	B-Anatomy
were	O
frozen	O
without	O
prior	O
fixation	O
or	O
cryoprotection	O
to	O
try	O
to	O
assess	O
the	O
effect	O
of	O
glutarldehyde	O
fixation	O
on	O
gap	O
junction	O
structure	O
.	O
In	O
this	O
tissue	B-Anatomy
the	O
gap	O
junctional	O
particles	O
were	O
irregularly	O
packed	O
and	O
their	O
spacing	O
averaged	O
10	O
.	O
0	O
nm	O
.	O
Absence	O
of	O
effect	O
of	O
prenatal	O
ethanol	O
on	O
adult	O
emotionality	O
and	O
ethanol	O
consumption	O
in	O
rats	O
.	O
Lower	O
peak	O
blood	B-Anatomy
ethanol	O
concentrations	O
after	O
1	O
and	O
2	O
g	O
of	O
ethanol	O
per	O
kg	O
were	O
found	O
in	O
pregnant	O
rats	O
than	O
in	O
virgin	O
females	O
.	O
No	O
significant	O
differences	O
in	O
adult	O
""""	O
emotionality	O
""""	O
or	O
ethanol	O
consumption	O
were	O
found	O
in	O
rats	O
exposed	O
to	O
prenatal	O
alcohol	O
and	O
in	O
pair	O
-	O
fed	O
and	O
untreated	O
controls	O
.	O
Tropical	O
splenomegaly	B-Anatomy
syndrome	O
in	O
Zambia	O
:	O
further	O
observations	O
and	O
effects	O
of	O
cycloguanil	O
and	O
proguanil	O
.	O
Nineteen	O
Zambian	O
patients	O
with	O
the	O
tropical	O
splenomegaly	B-Anatomy
syndrome	O
and	O
sinusoidal	B-Anatomy
lymphocytosis	O
on	O
liver	B-Anatomy
biopsy	O
were	O
studied	O
.	O
The	O
association	O
of	O
macrobulinaemia	O
with	O
the	O
tropical	O
splenomegaly	B-Anatomy
syndrome	O
has	O
again	O
been	O
confirmed	O
.	O
Sixteen	O
patients	O
were	O
treated	O
with	O
antimalarials	O
-	O
12	O
with	O
cycloguanil	O
pamoate	O
alone	O
,	O
3	O
with	O
cycloguanil	O
and	O
proguanil	O
,	O
and	O
1	O
with	O
proguanil	O
alone	O
.	O
Twelve	O
patients	O
were	O
observed	O
for	O
periods	O
of	O
sufficient	O
length	O
for	O
the	O
drug	O
effect	O
to	O
be	O
assessed	O
,	O
and	O
in	O
11	O
there	O
was	O
a	O
good	O
response	O
in	O
terms	O
of	O
decrease	O
in	O
spleen	B-Anatomy
size	O
.	O
Cycloguanil	O
pamoate	O
may	O
be	O
of	O
value	O
both	O
for	O
prophylaxis	O
and	O
treatment	O
in	O
areas	O
where	O
tropical	O
splenomegaly	B-Anatomy
syndrome	O
is	O
endemic	O
.	O
Regulation	O
of	O
glucosyl	O
-	O
and	O
fructosyltransferase	O
synthesis	O
by	O
continuous	O
cultures	B-Anatomy
of	O
Streptococcus	O
mutans	O
.	O
Streptococcus	O
mutans	O
strains	B-Anatomy
Ingbritt	O
,	O
and	O
its	O
derivative	O
B7	O
which	O
had	O
been	O
passaged	O
through	O
monkeys	O
,	O
have	O
been	O
used	O
to	O
investigate	O
how	O
the	O
synthesis	O
of	O
extracellular	B-Anatomy
glucosyl	O
-	O
and	O
fructosyltransferases	O
is	O
regulated	O
.	O
The	O
most	O
active	O
enzyme	O
from	O
carbon	O
-	O
limited	O
continuous	O
cultures	B-Anatomy
was	O
a	O
fructosyltransferase	O
;	O
enzymes	O
catalysing	O
the	O
formation	O
of	O
water	O
-	O
insoluble	O
glucans	O
from	O
sucrose	O
were	O
relatively	O
inactive	O
.	O
Dextransucrase	O
(	O
EC	O
2	O
.	O
4	O
.	O
1	O
.	O
5	O
)	O
,	O
which	O
catalyses	O
soluble	O
glucan	O
synthesis	O
,	O
was	O
most	O
active	O
in	O
the	O
supernatant	B-Anatomy
fluid	O
from	O
cultures	B-Anatomy
grown	O
with	O
excess	O
glucose	O
,	O
fructose	O
or	O
sucrose	O
,	O
but	O
full	O
activity	O
was	O
detected	O
only	O
when	O
the	O
enzyme	O
was	O
incubated	O
with	O
both	O
sucrose	O
and	O
dextran	O
.	O
Little	O
dextransucrase	O
activity	O
was	O
detected	O
in	O
carbon	O
-	O
limited	O
cultures	B-Anatomy
.	O
It	O
is	O
concluded	O
that	O
glucosyl	O
-	O
and	O
fructosyltransferases	O
are	O
constitutive	O
enzymes	O
in	O
that	O
they	O
are	O
synthesized	O
at	O
similar	O
rates	O
during	O
growth	O
with	O
an	O
excess	O
of	O
the	O
substrate	O
or	O
of	O
the	O
products	O
of	O
the	O
reactions	O
which	O
they	O
catalyse	O
.	O
Although	O
the	O
Ingbritt	O
strain	B-Anatomy
was	O
originally	O
isolated	O
from	O
a	O
carious	B-Anatomy
lesion	I-Anatomy
,	O
it	O
is	O
now	O
a	O
poor	O
source	O
of	O
glucosyltransferase	O
activity	O
.	O
Glucosyltransferases	O
were	O
extremely	O
active	O
in	O
cultures	B-Anatomy
of	O
a	O
recent	O
clinical	O
isolate	O
,	O
strain	B-Anatomy
3209	I-Anatomy
,	O
and	O
were	O
apparently	O
induced	O
during	O
growth	O
with	O
excess	O
glucose	O
.	O
Scanning	O
electron	O
microscopy	O
of	O
vascular	B-Anatomy
casts	O
in	O
experimental	O
ocular	B-Anatomy
vasoproliferation	O
.	O
Scanning	O
electron	O
microscopy	O
of	O
vascular	B-Anatomy
casts	O
was	O
used	O
to	O
investigate	O
three	O
experimental	O
models	O
of	O
neovascularization	O
.	O
In	O
each	O
experimental	O
situation	O
,	O
the	O
casts	O
provided	O
a	O
valuable	O
three	O
dimensional	O
representation	O
of	O
the	O
newly	O
formed	O
blood	B-Anatomy
vessels	I-Anatomy
and	O
permitted	O
subclassification	O
of	O
the	O
vessels	B-Anatomy
within	O
normal	O
and	O
proliferating	O
vascular	B-Anatomy
networks	I-Anatomy
.	O
They	O
defined	O
also	O
the	O
predominant	O
origin	O
of	O
new	O
vessels	B-Anatomy
from	O
venules	B-Anatomy
and	O
capillaries	B-Anatomy
,	O
and	O
enabled	O
the	O
evolution	O
of	O
proliferating	O
vessels	B-Anatomy
into	O
arterioles	B-Anatomy
and	O
venules	B-Anatomy
to	O
be	O
documented	O
.	O
Although	O
vascular	B-Anatomy
casts	O
must	O
be	O
interpreted	O
with	O
caution	O
in	O
light	O
of	O
the	O
possibility	O
of	O
incomplete	O
filling	O
and	O
other	O
artifacts	O
,	O
they	O
are	O
a	O
valuable	O
tool	O
in	O
the	O
study	O
of	O
ocular	B-Anatomy
vasoproliferation	O
.	O
Participation	O
of	O
p53	O
cellular	B-Anatomy
tumour	B-Anatomy
antigen	O
in	O
transformation	O
of	O
normal	O
embryonic	B-Anatomy
cells	I-Anatomy
.	O
The	O
cellular	B-Anatomy
tumour	B-Anatomy
antigen	O
p53	O
is	O
found	O
at	O
elevated	O
levels	O
in	O
a	O
wide	O
variety	O
of	O
transformed	O
cells	B-Anatomy
(	O
for	O
reviews	O
see	O
refs	O
1	O
,	O
2	O
)	O
.	O
Very	O
little	O
is	O
yet	O
known	O
about	O
the	O
precise	O
relationship	O
of	O
p53	O
to	O
malignant	O
transformation	O
.	O
Although	O
the	O
increase	O
in	O
p53	O
levels	O
could	O
be	O
a	O
secondary	O
by	O
-	O
product	O
of	O
the	O
transformed	O
state	O
,	O
it	O
is	O
equally	O
possible	O
that	O
p53	O
is	O
actively	O
involved	O
in	O
altering	O
cellular	B-Anatomy
growth	O
properties	O
,	O
especially	O
as	O
it	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
normal	O
cell	B-Anatomy
proliferation	O
.	O
We	O
sought	O
to	O
test	O
whether	O
p53	O
could	O
behave	O
in	O
a	O
manner	O
similar	O
to	O
known	O
genes	O
in	O
a	O
biological	O
test	O
system	O
,	O
and	O
we	O
demonstrate	O
here	O
that	O
p53	O
can	O
cooperate	O
with	O
the	O
activated	O
Ha	O
-	O
ras	O
oncogene	O
to	O
transform	O
normal	O
embryonic	B-Anatomy
cells	I-Anatomy
.	O
The	O
resultant	O
foci	B-Anatomy
contain	O
cells	B-Anatomy
of	O
a	O
markedly	O
altered	O
morphology	O
which	O
produce	O
high	O
levels	O
of	O
p53	O
.	O
Cell	B-Anatomy
lines	I-Anatomy
established	O
from	O
such	O
foci	B-Anatomy
elicit	O
tumours	B-Anatomy
in	O
syngeneic	O
animals	O
.	O
Interaction	O
between	O
cellular	B-Anatomy
and	O
viral	O
genes	O
in	O
the	O
expression	O
of	O
the	O
RSV	O
-	O
induced	O
transformation	O
-	O
specific	O
cell	B-Anatomy
-	I-Anatomy
surface	I-Anatomy
antigen	O
VCSA	O
.	O
Transformation	O
of	O
BHK	B-Anatomy
hamster	I-Anatomy
fibroblasts	I-Anatomy
by	O
an	O
env	O
-	O
strain	O
of	O
Rous	O
sarcoma	O
virus	O
(	O
RSV	O
)	O
leads	O
to	O
the	O
appearance	O
at	O
the	O
cell	B-Anatomy
surface	I-Anatomy
of	O
a	O
virus	O
-	O
induced	O
nonvirion	O
antigen	O
(	O
VCSA	O
)	O
,	O
specific	O
for	O
transformation	O
,	O
whose	O
expression	O
is	O
controlled	O
by	O
the	O
transforming	O
src	O
gene	O
.	O
Previous	O
work	O
has	O
shown	O
that	O
a	O
rabbit	O
anti	O
-	O
VCSA	O
serum	B-Anatomy
lyses	I-Anatomy
specifically	O
,	O
in	O
the	O
presence	O
of	O
complement	O
,	O
51Cr	O
-	O
labelled	O
RSV	O
-	O
transformed	O
cells	B-Anatomy
from	O
different	O
animal	O
species	O
.	O
Now	O
,	O
by	O
competition	O
experiments	O
with	O
a	O
panel	O
of	O
different	O
unlabelled	O
cells	B-Anatomy
we	O
show	O
that	O
the	O
VCSA	O
expressed	O
on	O
RSV	O
-	O
transformed	O
hamster	O
fibroblasts	B-Anatomy
is	O
a	O
complex	O
of	O
at	O
least	O
three	O
distinct	O
antigenic	O
specificities	O
:	O
(	O
1	O
)	O
one	O
expressed	O
on	O
all	O
RSV	O
-	O
transformed	O
fibroblasts	B-Anatomy
,	O
regardless	O
their	O
species	O
and	O
the	O
subgroup	O
or	O
strain	O
of	O
the	O
transforming	O
virus	O
;	O
(	O
2	O
)	O
one	O
cross	O
-	O
reacting	O
with	O
a	O
cell	B-Anatomy
-	I-Anatomy
surface	I-Anatomy
antigen	O
(	O
CSA	O
)	O
expressed	O
at	O
various	O
degrees	O
on	O
untransformed	O
avian	O
fibroblasts	B-Anatomy
,	O
but	O
not	O
on	O
mammalian	B-Anatomy
fibroblasts	I-Anatomy
;	O
(	O
3	O
)	O
one	O
species	O
-	O
specific	O
,	O
present	O
only	O
on	O
RSV	O
-	O
transformed	O
hamster	O
fibroblasts	B-Anatomy
.	O
It	O
is	O
concluded	O
that	O
VCSA	O
is	O
a	O
complex	O
of	O
several	O
antigenic	O
determinants	O
,	O
and	O
that	O
some	O
of	O
these	O
differ	O
in	O
different	O
cells	B-Anatomy
transformed	O
by	O
RSV	O
.	O
This	O
observation	O
indicates	O
that	O
VCSA	O
expression	O
at	O
the	O
cell	B-Anatomy
surface	I-Anatomy
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
the	O
interaction	O
between	O
the	O
viral	O
src	O
gene	O
product	O
pp60src	O
with	O
host	O
cell	B-Anatomy
gene	O
(	O
s	O
)	O
or	O
gene	O
product	O
(	O
s	O
)	O
,	O
rather	O
than	O
the	O
simple	O
expression	O
of	O
this	O
molecule	O
at	O
the	O
cell	B-Anatomy
surface	I-Anatomy
.	O
Role	O
of	O
interleukin	O
1	O
in	O
antigen	O
-	O
specific	O
T	B-Anatomy
cell	I-Anatomy
proliferation	O
.	O
The	O
role	O
of	O
interleukin	O
1	O
(	O
IL	O
1	O
)	O
in	O
human	O
antigen	O
-	O
specific	O
T	B-Anatomy
cell	I-Anatomy
proliferation	O
was	O
examined	O
.	O
Nylon	O
wool	O
-	O
purified	O
T	B-Anatomy
cells	I-Anatomy
proliferated	O
in	O
the	O
presence	O
of	O
autologous	B-Anatomy
monocytes	I-Anatomy
(	O
Mo	B-Anatomy
.	O
)	O
pulsed	O
for	O
18	O
h	O
with	O
tetanus	O
toxoid	O
(	O
TT	O
)	O
antigen	O
(	O
Mo	B-Anatomy
.	O
TT	O
)	O
.	O
Irradiation	O
of	O
Mo	B-Anatomy
.	O
TT	O
with	O
ultraviolet	O
(	O
UV	O
)	O
light	O
(	O
72	O
J	O
/	O
m2	O
)	O
abolished	O
their	O
capacity	O
to	O
support	O
T	B-Anatomy
cell	I-Anatomy
proliferation	O
and	O
drastically	O
reduced	O
their	O
capacity	O
to	O
secrete	O
IL	O
1	O
after	O
stimulation	O
with	O
Staphylococcus	O
albus	O
.	O
The	O
defect	O
in	O
antigen	O
presentation	O
induced	O
by	O
UV	O
irradiation	O
of	O
Mo	B-Anatomy
.	O
TT	O
was	O
reversed	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
the	O
addition	O
of	O
two	O
different	O
preparations	O
containing	O
human	O
interleukin	O
1	O
(	O
IL	O
1	O
)	O
.	O
The	O
first	O
preparation	O
consisted	O
of	O
supernatants	B-Anatomy
of	O
Mo	B-Anatomy
.	O
stimulated	O
with	O
Con	O
A	O
for	O
18	O
hr	O
and	O
in	O
which	O
Con	O
A	O
activity	O
was	O
blocked	O
by	O
alpha	O
-	O
D	O
-	O
methyl	O
-	O
mannoside	O
(	O
Mo	B-Anatomy
.	O
-	O
Con	O
A	O
-	O
Sup	O
)	O
.	O
The	O
second	O
preparation	O
consisted	O
of	O
human	O
IL	O
1	O
partially	O
purified	O
from	O
supernatants	B-Anatomy
of	O
human	O
peripheral	B-Anatomy
blood	I-Anatomy
mononuclear	I-Anatomy
cells	I-Anatomy
stimulated	O
with	O
S	O
.	O
albus	O
.	O
This	O
IL	O
1	O
copurified	O
with	O
human	O
leukocyte	B-Anatomy
pyrogen	O
(	O
LP	O
)	O
and	O
was	O
termed	O
IL	O
1	O
/	O
LP	O
.	O
Both	O
IL	O
1	O
-	O
containing	O
preparations	O
enhanced	O
the	O
response	O
of	O
C57BL	O
/	O
6	O
mouse	O
thymocytes	B-Anatomy
to	O
phytohemagglutinin	O
.	O
A	O
rabbit	O
antibody	O
to	O
human	O
IL	O
1	O
/	O
LP	O
inhibited	O
the	O
capacity	O
of	O
T	B-Anatomy
cells	I-Anatomy
to	O
proliferate	O
in	O
response	O
to	O
Mo	B-Anatomy
.	O
TT	O
and	O
inhibited	O
the	O
capacity	O
of	O
Mo	B-Anatomy
.	O
-	O
Con	O
A	O
-	O
Sup	O
to	O
reconstitute	O
the	O
T	B-Anatomy
cell	I-Anatomy
response	O
to	O
UV	O
-	O
irradiated	O
Mo	B-Anatomy
.	O
TT	O
.	O
IL	O
1	O
/	O
LP	O
was	O
not	O
necessary	O
for	O
T	B-Anatomy
cells	I-Anatomy
to	O
recognize	O
the	O
immunogenic	O
moiety	O
presented	O
by	O
Mo	B-Anatomy
.	O
,	O
because	O
monolayers	B-Anatomy
of	O
UV	O
-	O
irradiated	O
Mo	B-Anatomy
.	O
TT	O
were	O
equivalent	O
to	O
monolayers	B-Anatomy
of	O
unirradiated	O
MO	B-Anatomy
.	O
TT	O
in	O
their	O
capacity	O
to	O
adsorb	O
TT	O
-	O
reactive	O
T	B-Anatomy
cells	I-Anatomy
specifically	O
.	O
Furthermore	O
,	O
the	O
addition	O
of	O
rabbit	O
antibody	O
to	O
IL	O
1	O
/	O
LP	O
did	O
not	O
interfere	O
with	O
the	O
capacity	O
of	O
UV	O
-	O
irradiated	O
Mo	B-Anatomy
.	O
TT	O
to	O
adsorb	O
TT	O
-	O
reactive	O
T	B-Anatomy
cells	I-Anatomy
.	O
The	O
results	O
obtained	O
in	O
this	O
study	O
indicate	O
that	O
IL	O
1	O
is	O
involved	O
in	O
optimal	O
antigen	O
-	O
driven	O
proliferation	O
of	O
human	O
T	B-Anatomy
lymphocytes	I-Anatomy
.	O
Ca	O
+	O
+	O
distribution	O
after	O
Na	O
+	O
pump	O
inhibition	O
in	O
cultured	O
neonatal	O
rat	O
myocardial	B-Anatomy
cells	I-Anatomy
.	O
The	O
influence	O
of	O
inhibition	O
of	O
the	O
Na	O
+	O
pump	O
,	O
with	O
secondary	O
stimulation	O
of	O
Na	O
+	O
-	O
Ca	O
+	O
+	O
exchange	O
,	O
on	O
cellular	B-Anatomy
Ca	O
+	O
+	O
distribution	O
is	O
examined	O
using	O
the	O
on	O
-	O
line	O
scintillation	O
disk	O
technique	O
and	O
cultured	O
neonatal	O
rat	O
myocardial	B-Anatomy
cells	I-Anatomy
.	O
Under	O
control	O
conditions	O
,	O
La	O
+	O
+	O
+	O
displaced	O
78	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
13	O
%	O
(	O
SEM	O
)	O
of	O
the	O
total	O
cell	B-Anatomy
associated	O
45Ca	O
.	O
Application	O
of	O
1	O
mm	O
ouabain	O
or	O
reduction	O
of	O
[	O
K	O
+	O
]	O
o	O
to	O
0	O
.	O
5	O
mM	O
resulted	O
in	O
a	O
net	O
increase	O
of	O
10	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
3	O
%	O
and	O
13	O
.	O
8	O
+	O
/	O
-	O
2	O
%	O
,	O
respectively	O
,	O
in	O
total	O
cell	B-Anatomy
-	O
associated	O
Ca	O
+	O
+	O
.	O
Of	O
this	O
added	O
45Ca	O
,	O
75	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
7	O
%	O
and	O
78	O
.	O
4	O
+	O
/	O
-	O
2	O
.	O
1	O
%	O
,	O
respectively	O
remained	O
La	O
+	O
+	O
+	O
-	O
displaceable	O
.	O
The	O
45Ca	O
-	O
binding	O
characteristics	O
of	O
isolated	O
sarcolemma	B-Anatomy
,	O
prepared	O
from	O
the	O
cultured	O
neonatal	O
rat	O
myocardial	B-Anatomy
cells	I-Anatomy
using	O
the	O
gas	O
dissection	O
technique	O
,	O
were	O
examined	O
.	O
When	O
treated	O
with	O
either	O
ouabain	O
or	O
low	O
[	O
K	O
+	O
]	O
o	O
solutions	O
,	O
sarcolemmal	B-Anatomy
45Ca	O
binding	O
did	O
not	O
change	O
.	O
This	O
result	O
indicates	O
that	O
functional	O
,	O
intact	O
tissue	B-Anatomy
is	O
necessary	O
to	O
observe	O
the	O
Ca	O
+	O
+	O
increase	O
.	O
Treatment	O
of	O
the	O
cells	B-Anatomy
with	O
verapamil	O
before	O
and	O
during	O
ouabain	O
exposure	O
failed	O
to	O
inhibit	O
the	O
ouabain	O
-	O
induced	O
increase	O
in	O
cell	B-Anatomy
-	O
associated	O
45Ca	O
.	O
The	O
evidence	O
indicates	O
that	O
inhibition	O
of	O
the	O
Na	O
+	O
-	O
pump	O
,	O
and	O
secondary	O
stimulation	O
of	O
Na	O
+	O
-	O
Ca	O
+	O
+	O
exchange	O
,	O
result	O
in	O
a	O
net	O
increase	O
of	O
11	O
-	O
15	O
%	O
in	O
cell	O
-	O
associated	O
Ca	O
+	O
+	O
,	O
78	O
%	O
of	O
which	O
remains	O
La	O
+	O
+	O
+	O
-	O
displaceable	O
and	O
is	O
,	O
therefore	O
,	O
localized	O
to	O
the	O
sarcolemma	B-Anatomy
-	O
glycocalyx	B-Anatomy
complex	O
.	O
Oesophageal	B-Anatomy
candidiasis	O
and	O
croup	O
in	O
a	O
child	O
with	O
defective	O
neutrophil	B-Anatomy
motility	O
.	O
Severe	O
oesophageal	B-Anatomy
candidiasis	O
and	O
croup	O
due	O
to	O
involvement	O
of	O
the	O
larynx	B-Anatomy
developed	O
insidiously	O
in	O
a	O
girl	O
aged	O
20	O
months	O
.	O
There	O
had	O
been	O
delayed	O
separation	O
of	O
the	O
umbilical	B-Anatomy
cord	I-Anatomy
and	O
repeated	O
infections	O
associated	O
with	O
a	O
defect	O
of	O
neutrophil	B-Anatomy
motility	O
.	O
The	O
significance	O
of	O
the	O
early	O
clinical	O
features	O
was	O
not	O
fully	O
appreciated	O
and	O
the	O
diagnosis	O
considered	O
only	O
when	O
stricture	O
of	O
the	O
oesophagus	B-Anatomy
became	O
evident	O
.	O
She	O
was	O
treated	O
with	O
oral	B-Anatomy
ketoconazole	O
100	O
mg	O
daily	O
.	O
After	O
one	O
month	O
'	O
s	O
treatment	O
there	O
was	O
striking	O
radiological	O
improvement	O
apart	O
from	O
the	O
persistence	O
of	O
the	O
oesophageal	B-Anatomy
stricture	O
.	O
The	O
croup	O
resolved	O
completely	O
but	O
there	O
was	O
only	O
partial	O
relief	O
of	O
dysphagia	O
because	O
of	O
the	O
residual	O
stricture	O
.	O
We	O
would	O
emphasis	O
that	O
candidiasis	O
should	O
be	O
anticipated	O
and	O
treated	O
vigorously	O
in	O
children	O
with	O
such	O
a	O
defect	O
of	O
neutrophil	B-Anatomy
motility	O
.	O
The	O
effect	O
of	O
translocations	O
on	O
the	O
cellular	B-Anatomy
myc	O
gene	O
in	O
Burkitt	B-Anatomy
lymphomas	I-Anatomy
.	O
Chromosomal	B-Anatomy
translocations	O
are	O
found	O
to	O
be	O
a	O
characteristic	O
feature	O
of	O
Burkitt	B-Anatomy
lymphomas	I-Anatomy
.	O
Similar	O
translocations	O
are	O
found	O
in	O
mouse	O
plasmacytomas	B-Anatomy
and	O
both	O
diseases	O
involve	O
interchanges	O
between	O
one	O
of	O
the	O
immunoglobulin	O
loci	O
and	O
DNA	O
in	O
the	O
vicinity	O
of	O
the	O
myc	O
gene	O
.	O
The	O
structure	O
of	O
the	O
myc	O
gene	O
has	O
been	O
elucidated	O
from	O
studies	O
on	O
translocated	O
versions	O
of	O
the	O
gene	O
.	O
Activation	O
of	O
the	O
myc	O
gene	O
may	O
play	O
a	O
role	O
in	O
transformation	O
by	O
promoting	O
growth	O
of	O
the	O
cells	B-Anatomy
bearing	O
the	O
rearranged	O
chromosomes	B-Anatomy
.	O
[	O
Suppurated	O
acute	O
obstructive	O
cholangitis	O
.	O
Anatomoclinical	O
and	O
therapeutic	O
aspects	O
]	O
.	O
A	O
total	O
of	O
134	O
cases	O
are	O
discussed	O
,	O
with	O
suppurated	O
acute	O
obstructive	O
angiocholitis	O
,	O
that	O
underwent	O
surgical	O
treatment	O
over	O
a	O
period	O
of	O
10	O
years	O
,	O
representing	O
12	O
,	O
8	O
%	O
of	O
the	O
total	O
number	O
of	O
organic	O
obstructions	O
of	O
the	O
hepato	B-Anatomy
-	I-Anatomy
choledocus	I-Anatomy
.	O
From	O
the	O
standpoint	O
of	O
the	O
etiopathogenic	O
mechanisms	O
the	O
angiocholitis	O
was	O
determined	O
by	O
biliary	O
lithiasis	O
in	O
59	O
cases	O
,	O
by	O
sclerosis	O
of	O
the	O
Oddi	B-Anatomy
sphincter	I-Anatomy
in	O
5	O
cases	O
,	O
by	O
postoperative	O
cicatriceal	O
stenosis	O
of	O
the	O
main	O
biliary	O
pathway	O
in	O
2	O
cases	O
,	O
by	O
hepatic	B-Anatomy
hydatitosis	O
in	O
16	O
cases	O
,	O
by	O
Vater	O
ampuloma	O
in	O
10	O
cases	O
by	O
cancers	B-Anatomy
of	O
the	O
main	O
biliary	O
pathway	O
in	O
40	O
cases	O
and	O
by	O
the	O
congenital	O
cyst	B-Anatomy
of	O
the	O
choledocus	B-Anatomy
in	O
one	O
case	O
.	O
The	O
high	O
frequency	O
was	O
noted	O
,	O
of	O
the	O
severe	O
forms	O
of	O
ictero	O
-	O
uremigenic	O
angiocholitis	O
(	O
representing	O
68	O
cases	O
,	O
or	O
50	O
,	O
7	O
%	O
of	O
the	O
total	O
,	O
with	O
a	O
death	O
rate	O
of	O
34	O
%	O
)	O
.	O
Medico	O
-	O
surgical	O
treatment	O
should	O
be	O
performed	O
as	O
early	O
as	O
possible	O
,	O
and	O
it	O
must	O
be	O
intensive	O
,	O
complex	O
,	O
and	O
adapted	O
to	O
the	O
anatomo	O
-	O
clinical	O
forms	O
.	O
The	O
authors	O
performed	O
evacuation	O
choledocotomy	O
with	O
external	O
draining	O
in	O
22	O
cases	O
(	O
3	O
deaths	O
)	O
,	O
and	O
choledoco	O
-	O
duodenal	O
anastomosis	O
in	O
46	O
cases	O
(	O
10	O
deaths	O
)	O
,	O
choledoco	O
-	O
jejunostomia	O
in	O
3	O
cases	O
,	O
Oddi	O
sphincterotomia	O
in	O
12	O
cases	O
(	O
2	O
deaths	O
)	O
ampulectomia	O
in	O
5	O
cases	O
(	O
2	O
deaths	O
)	O
.	O
Peripheral	O
bilio	O
-	O
hepatodigestive	O
anastomoses	O
were	O
performed	O
in	O
40	O
cases	O
with	O
5	O
deaths	O
.	O
[	O
Reactive	O
states	O
among	O
psychopathic	O
personalities	O
of	O
different	O
clinical	O
groups	O
]	O
.	O
On	O
the	O
basis	O
of	O
a	O
clinical	O
follow	O
-	O
up	O
of	O
71	O
psychopaths	O
with	O
manifestations	O
of	O
reactive	O
psychosis	O
,	O
the	O
authors	O
established	O
the	O
clinico	O
-	O
typological	O
characteristics	O
of	O
both	O
groups	O
of	O
pathology	O
and	O
the	O
system	O
of	O
correlations	O
between	O
them	O
.	O
They	O
also	O
described	O
the	O
structure	O
of	O
the	O
psychopathic	O
and	O
psychogenic	O
syndromes	O
,	O
the	O
type	O
of	O
psychopathic	O
personality	O
reaction	O
and	O
the	O
form	O
of	O
psychogenic	O
responses	O
and	O
proved	O
statistically	O
their	O
close	O
interrelationship	O
.	O
Data	O
were	O
obtained	O
on	O
some	O
general	O
regularities	O
of	O
interrelations	O
of	O
reactive	O
psychoses	O
with	O
a	O
psychopathic	O
background	O
which	O
are	O
important	O
for	O
the	O
prognosis	O
,	O
prophylaxis	O
and	O
therapy	O
of	O
reactive	O
states	O
.	O
Inhibition	O
by	O
N	O
-	O
(	O
phosphonacetyl	O
)	O
-	O
L	O
-	O
aspartate	O
of	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
tumour	I-Anatomy
growth	O
and	O
glucose	O
transport	O
.	O
N	O
-	O
(	O
Phosphonacetyl	O
)	O
-	O
L	O
-	O
aspartate	O
(	O
PALA	O
)	O
suppressed	O
the	O
growth	O
of	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
tumour	I-Anatomy
cells	I-Anatomy
in	O
vivo	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
Simultaneously	O
as	O
the	O
growth	O
rate	O
decreased	O
,	O
the	O
cellular	B-Anatomy
uptake	O
of	O
glucose	O
and	O
the	O
density	O
of	O
a	O
class	O
of	O
glucose	O
-	O
reversible	O
binding	O
sites	O
for	O
cytochalasin	O
B	O
on	O
the	O
cell	B-Anatomy
surface	I-Anatomy
were	O
also	O
found	O
to	O
be	O
reduced	O
.	O
There	O
is	O
a	O
highly	O
significant	O
correlation	O
between	O
the	O
magnitude	O
of	O
changes	O
in	O
the	O
number	O
of	O
cytochalasin	O
B	O
binding	O
sites	O
and	O
the	O
magnitude	O
of	O
changes	O
in	O
glucose	O
uptake	O
.	O
The	O
physiological	O
significance	O
of	O
these	O
observations	O
are	O
discussed	O
.	O
Effects	O
of	O
3	O
-	O
chloromethylthiochromone	O
-	O
1	O
,	O
1	O
-	O
dioxide	O
on	O
nucleic	O
acid	O
,	O
protein	O
,	O
and	O
aerobic	O
and	O
anaerobic	O
metabolism	O
of	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
tumor	I-Anatomy
cells	I-Anatomy
.	O
3	O
-	O
Chloromethylthiochromone	O
-	O
1	O
,	O
1	O
-	O
dioxide	O
was	O
observed	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
carcinoma	I-Anatomy
growth	O
and	O
a	O
moderate	O
inhibitor	O
of	O
P	B-Anatomy
-	I-Anatomy
388	I-Anatomy
lymphocytic	I-Anatomy
leukemia	I-Anatomy
growth	O
at	O
10	O
mg	O
/	O
kg	O
/	O
day	O
.	O
Preliminary	O
in	O
vitro	O
studies	O
showed	O
that	O
the	O
agents	O
significantly	O
inhibited	O
RNA	O
and	O
DNA	O
synthesis	O
in	O
Ehrlich	B-Anatomy
ascites	I-Anatomy
cells	I-Anatomy
.	O
In	O
vivo	O
studies	O
after	O
dosing	O
on	O
Days	O
6	O
,	O
7	O
,	O
and	O
8	O
demonstrated	O
the	O
same	O
reductions	O
in	O
nucleic	O
acid	O
synthesis	O
and	O
a	O
moderate	O
reduction	O
in	O
protein	O
synthesis	O
.	O
The	O
primary	O
site	O
of	O
nucleic	O
acid	O
synthesis	O
,	O
which	O
was	O
blocked	O
by	O
3	O
-	O
chloromethylthiochromone	O
,	O
was	O
at	O
orotidine	O
monophosphate	O
decarboxylase	O
in	O
the	O
primidine	O
pathway	O
.	O
Other	O
enzymes	O
,	O
in	O
anaerobic	O
and	O
aerobic	O
glycolysis	O
,	O
which	O
were	O
blocked	O
include	O
hexokinase	O
,	O
phosphofructokinase	O
,	O
succinic	O
and	O
alpha	O
-	O
ketoglutarate	O
dehydrogenases	O
,	O
as	O
well	O
as	O
States	O
3	O
and	O
4	O
of	O
oxidative	O
phosphorylation	O
.	O
An	O
unusual	O
case	O
of	O
benign	O
mucous	B-Anatomy
membrane	I-Anatomy
pemphigoid	O
.	O
This	O
case	O
of	O
benign	O
mucous	B-Anatomy
membrane	I-Anatomy
pemphigoid	O
(	O
BMMP	O
)	O
is	O
unusual	O
in	O
that	O
blistering	O
,	O
scarring	O
lesions	B-Anatomy
were	O
confined	O
to	O
the	O
skin	B-Anatomy
for	O
15	O
years	O
before	O
mucous	B-Anatomy
membranes	I-Anatomy
were	O
involved	O
.	O
The	O
onset	O
of	O
this	O
disorder	O
at	O
the	O
age	O
of	O
38	O
is	O
also	O
unusual	O
.	O
Detailed	O
immunological	O
investigation	O
was	O
performed	O
on	O
this	O
patient	O
but	O
the	O
results	O
in	O
no	O
way	O
clarify	O
the	O
present	O
confusion	O
regarding	O
the	O
immunopathological	O
processes	O
in	O
BMMP	O
related	O
to	O
those	O
operative	O
in	O
bullous	O
pemphigoid	O
.	O
Mast	B-Anatomy
cell	I-Anatomy
heparin	O
stimulates	O
migration	O
of	O
capillary	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
in	O
vitro	O
.	O
Migration	O
of	O
capillary	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
is	O
an	O
important	O
component	O
of	O
angiogenesis	O
in	O
vivo	O
.	O
Increased	O
numbers	O
of	O
mast	B-Anatomy
cells	I-Anatomy
have	O
been	O
associated	O
with	O
several	O
types	O
of	O
angiogenesis	O
.	O
We	O
have	O
used	O
a	O
quantitative	O
assay	O
in	O
vitro	O
to	O
demonstrate	O
that	O
mast	B-Anatomy
cells	I-Anatomy
release	O
a	O
factor	O
that	O
significantly	O
increases	O
bovine	O
capillary	B-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
migration	O
.	O
The	O
factor	O
is	O
present	O
in	O
medium	O
conditioned	O
by	O
mast	B-Anatomy
cells	I-Anatomy
as	O
well	O
as	O
lysates	O
of	O
mast	B-Anatomy
cells	I-Anatomy
.	O
The	O
stimulatory	O
effect	O
of	O
mast	B-Anatomy
cells	I-Anatomy
on	O
migration	O
is	O
specific	O
for	O
capillary	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
Furthermore	O
,	O
mast	B-Anatomy
cells	I-Anatomy
have	O
no	O
mitogenic	O
activity	O
for	O
capillary	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
Of	O
all	O
the	O
secretory	O
products	O
of	O
mast	B-Anatomy
cells	I-Anatomy
tested	O
,	O
only	O
heparin	O
stimulated	O
capillary	B-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
migration	O
in	O
vitro	O
.	O
Heparin	O
preparations	O
from	O
a	O
variety	O
of	O
sources	O
stimulated	O
capillary	B-Anatomy
endothelial	I-Anatomy
cell	I-Anatomy
migration	O
to	O
the	O
same	O
degree	O
but	O
did	O
not	O
stimulate	O
migration	O
of	O
several	O
other	O
cell	B-Anatomy
types	O
.	O
The	O
migration	O
activity	O
of	O
heparin	O
and	O
mast	B-Anatomy
cell	I-Anatomy
conditioned	O
medium	O
was	O
blocked	O
by	O
specific	O
antagonists	O
of	O
heparin	O
(	O
protamine	O
and	O
heparinase	O
)	O
,	O
but	O
not	O
by	O
chondroitinase	O
ABC	O
.	O
The	O
migration	O
activity	O
of	O
mast	B-Anatomy
cell	I-Anatomy
conditioned	O
medium	O
was	O
resistant	O
to	O
heat	O
(	O
100	O
degrees	O
C	O
)	O
and	O
incubation	O
with	O
proteolytic	O
enzymes	O
.	O
These	O
results	O
suggest	O
that	O
the	O
role	O
of	O
mast	B-Anatomy
cells	I-Anatomy
in	O
angiogenesis	O
may	O
be	O
to	O
enhance	O
migration	O
of	O
the	O
endothelial	B-Anatomy
cells	I-Anatomy
of	O
growing	O
capillaries	B-Anatomy
.	O
Cancer	B-Anatomy
progression	O
and	O
p53	O
.	O
In	O
a	O
complex	O
organism	O
,	O
somatic	B-Anatomy
cells	I-Anatomy
are	O
under	O
intermittent	O
selection	O
pressure	O
for	O
the	O
emergence	O
of	O
mutants	O
that	O
can	O
survive	O
environmental	O
insults	O
and	O
that	O
can	O
grow	O
autonomously	O
despite	O
adverse	O
conditions	O
.	O
Repeated	O
rounds	O
of	O
mutation	O
,	O
selection	O
,	O
and	O
proliferation	O
may	O
lead	O
to	O
cancer	B-Anatomy
.	O
The	O
organism	O
prevents	O
malignant	O
transformation	O
by	O
assuring	O
accurate	O
DNA	O
repair	O
before	O
cell	B-Anatomy
division	O
,	O
by	O
forcing	O
the	O
death	O
of	O
cells	B-Anatomy
with	O
excessive	O
DNA	O
damage	O
,	O
and	O
by	O
placing	O
limits	O
on	O
the	O
replicative	O
lifespans	O
of	O
most	O
somatic	B-Anatomy
cells	I-Anatomy
.	O
The	O
p53	O
gene	O
is	O
a	O
""""	O
guardian	O
of	O
the	O
genome	O
""""	O
-	O
-	O
it	O
regulates	O
multiple	O
components	O
of	O
the	O
DNA	O
damage	O
control	O
response	O
and	O
promotes	O
cellular	B-Anatomy
senescence	O
.	O
Disabling	O
mutations	O
and	O
deletions	O
of	O
p53	O
occur	O
in	O
50	O
%	O
of	O
human	O
tumours	B-Anatomy
.	O
p53	B-Anatomy
-	I-Anatomy
deficient	I-Anatomy
cancers	I-Anatomy
are	O
often	O
unstable	O
,	O
aggressive	O
,	O
and	O
resistant	O
to	O
therapy	O
.	O
The	O
Met	O
proto	O
-	O
oncogene	O
mesenchymal	B-Anatomy
to	O
epithelial	B-Anatomy
cell	I-Anatomy
conversion	O
.	O
Coexpression	O
of	O
the	O
human	O
Met	O
receptor	O
and	O
its	O
ligand	O
,	O
hepatocyte	O
growth	O
factor	O
/	O
scatter	O
factor	O
(	O
HGF	O
/	O
SF	O
)	O
,	O
in	O
NIH	B-Anatomy
3T3	I-Anatomy
fibroblasts	I-Anatomy
causes	O
the	O
cells	B-Anatomy
to	O
become	O
tumorigenic	O
in	O
nude	O
mice	O
.	O
The	O
resultant	O
tumors	B-Anatomy
display	O
lumen	B-Anatomy
-	O
like	O
morphology	O
,	O
contain	O
carcinoma	B-Anatomy
-	I-Anatomy
like	I-Anatomy
focal	I-Anatomy
areas	I-Anatomy
with	O
intercellular	B-Anatomy
junctions	I-Anatomy
resembling	O
desmosomes	B-Anatomy
,	O
and	O
coexpress	O
epithelial	B-Anatomy
(	O
cytokeratin	O
)	O
and	O
mesenchymal	B-Anatomy
(	O
vimentin	O
)	O
cytoskeletal	B-Anatomy
markers	O
.	O
The	O
tumor	B-Anatomy
cells	I-Anatomy
also	O
display	O
enhanced	O
expression	O
of	O
desmosomal	B-Anatomy
and	O
tight	B-Anatomy
-	I-Anatomy
junction	I-Anatomy
proteins	O
.	O
The	O
apparent	O
mesenchymal	B-Anatomy
to	O
epithelial	B-Anatomy
conversion	O
of	O
the	O
tumor	B-Anatomy
cells	I-Anatomy
mimics	O
the	O
conversion	O
that	O
occurs	O
during	O
embryonic	B-Anatomy
kidney	I-Anatomy
development	O
,	O
suggesting	O
that	O
Met	O
-	O
HGF	O
/	O
SF	O
signaling	O
plays	O
a	O
role	O
in	O
this	O
process	O
as	O
well	O
as	O
in	O
tumors	B-Anatomy
that	O
express	O
both	O
epithelial	B-Anatomy
and	O
mesenchymal	B-Anatomy
markers	O
.	O
Ultraviolet	O
B	O
irradiation	O
promotes	O
tumorigenic	O
and	O
metastatic	O
properties	O
in	O
primary	B-Anatomy
cutaneous	I-Anatomy
melanoma	I-Anatomy
via	O
induction	O
of	O
interleukin	O
8	O
.	O
UV	O
radiation	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
the	O
initiation	O
of	O
human	O
cutaneous	B-Anatomy
melanoma	I-Anatomy
,	O
but	O
its	O
role	O
in	O
the	O
development	O
of	O
malignant	B-Anatomy
melanoma	I-Anatomy
to	O
the	O
metastatic	O
state	O
is	O
not	O
very	O
well	O
defined	O
.	O
Although	O
previous	O
studies	O
have	O
concentrated	O
on	O
the	O
effect	O
of	O
UV	O
-	O
B	O
on	O
the	O
host	O
immune	O
response	O
,	O
the	O
effect	O
of	O
UV	O
-	O
B	O
on	O
the	O
tumor	B-Anatomy
cells	I-Anatomy
was	O
not	O
elucidated	O
.	O
Here	O
we	O
show	O
that	O
UV	O
-	O
B	O
can	O
induce	O
interleukin	O
8	O
(	O
IL	O
-	O
8	O
)	O
mRNA	O
and	O
protein	O
secretion	O
in	O
human	O
cutaneous	B-Anatomy
melanoma	I-Anatomy
with	O
negligible	O
expression	O
of	O
IL	O
-	O
8	O
.	O
UV	O
-	O
B	O
-	O
induced	O
IL	O
-	O
8	O
was	O
constitutively	O
expressed	O
60	O
days	O
after	O
irradiation	O
in	O
tumors	B-Anatomy
implanted	O
in	O
mice	O
.	O
Induction	O
of	O
IL	O
-	O
8	O
was	O
UV	O
-	O
B	O
dose	O
dependent	O
and	O
blocked	O
by	O
cyclohexamide	O
,	O
indicating	O
that	O
de	O
novo	O
protein	O
synthesis	O
is	O
required	O
for	O
its	O
expression	O
.	O
The	O
UV	O
-	O
irradiated	O
cells	B-Anatomy
demonstrated	O
enhanced	O
tumorigenicity	O
and	O
metastatic	O
potential	O
in	O
nude	O
mice	O
.	O
The	O
increase	O
in	O
tumorigenicity	O
and	O
metastatic	O
ability	O
could	O
be	O
explained	O
by	O
the	O
increase	O
in	O
Mr	O
72	O
,	O
000	O
type	O
IV	O
collagenase	O
activity	O
and	O
angiogenesis	O
attributed	O
to	O
the	O
induction	O
of	O
IL	O
-	O
8	O
after	O
irradiation	O
.	O
The	O
acquisition	O
of	O
the	O
metastatic	O
phenotype	O
induced	O
by	O
UV	O
-	O
B	O
could	O
not	O
be	O
attributed	O
to	O
abnormalities	O
in	O
the	O
p53	O
or	O
MTS	O
-	O
1	O
(	O
p16INK4	O
)	O
genes	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
to	O
show	O
that	O
UV	O
-	O
B	O
can	O
increase	O
the	O
aggressiveness	O
of	O
human	O
cutaneous	B-Anatomy
melanoma	I-Anatomy
for	O
growth	O
and	O
metastasis	O
.	O
The	O
LHRH	O
pulse	O
generator	O
:	O
a	O
mediobasal	B-Anatomy
hypothalamic	I-Anatomy
location	O
.	O
The	O
location	O
and	O
mechanism	O
of	O
LHRH	O
pulse	O
generator	O
are	O
discussed	O
based	O
on	O
our	O
series	O
of	O
experiments	O
.	O
Suckling	O
stimulus	O
is	O
a	O
novel	O
stimulus	O
that	O
inhibits	O
LH	O
pulses	O
without	O
any	O
cooperation	O
from	O
ovarian	B-Anatomy
steroids	O
,	O
unlike	O
other	O
stimuli	O
such	O
as	O
stress	O
,	O
photoperiod	O
etc	O
.	O
It	O
is	O
directly	O
involved	O
in	O
suppressing	O
the	O
activity	O
of	O
the	O
LHRH	O
pulse	O
generator	O
.	O
The	O
information	O
from	O
teats	O
suckled	O
by	O
pups	O
or	O
babies	O
is	O
conveyed	O
dorsally	O
to	O
the	O
mediobasal	B-Anatomy
hypothalamus	I-Anatomy
(	O
MBH	B-Anatomy
)	O
,	O
where	O
the	O
LHRH	O
pulse	O
generator	O
may	O
be	O
located	O
.	O
Experiments	O
using	O
various	O
types	O
of	O
deafferentation	O
and	O
fetal	B-Anatomy
brain	I-Anatomy
tissue	I-Anatomy
transplantation	O
confirmed	O
that	O
the	O
LHRH	O
pulse	O
generator	O
is	O
located	O
in	O
the	O
MBH	B-Anatomy
and	O
suggested	O
that	O
LHRH	O
pulse	O
generator	O
consists	O
of	O
nonLHRH	O
neurons	B-Anatomy
.	O
Endogenous	O
excitatory	O
amino	O
acid	O
is	O
one	O
of	O
the	O
possible	O
neurotransmitters	O
that	O
regulate	O
LHRH	O
release	O
at	O
the	O
nerve	B-Anatomy
terminal	I-Anatomy
in	O
ME	O
.	O
Cancer	B-Anatomy
metastasis	O
:	O
negative	O
regulation	O
by	O
an	O
invasion	O
-	O
suppressor	O
complex	O
.	O
Invasion	O
is	O
the	O
hallmark	O
of	O
tumor	B-Anatomy
malignancy	O
.	O
We	O
situate	O
invasion	O
within	O
microecosystems	O
comprising	O
neoplastic	B-Anatomy
cells	I-Anatomy
as	O
well	O
as	O
host	O
cells	B-Anatomy
.	O
Modulation	O
of	O
invasion	O
within	O
such	O
systems	O
is	O
ascribed	O
to	O
balances	O
between	O
promoter	O
and	O
suppressor	O
pathways	O
.	O
The	O
E	O
-	O
cadherin	O
/	O
alpha	O
-	O
,	O
beta	O
-	O
,	O
gamma	O
-	O
catenin	O
complex	O
has	O
an	O
invasion	O
-	O
suppressor	O
function	O
as	O
evidenced	O
by	O
transfections	O
either	O
with	O
sense	O
cDNA	O
encoding	O
these	O
molecules	O
or	O
with	O
antisense	O
cDNA	O
inhibiting	O
their	O
expression	O
.	O
Loss	O
of	O
heterozygosity	O
at	O
the	O
E	O
-	O
Cadherin	O
(	O
uvo	O
)	O
locus	O
has	O
been	O
reported	O
,	O
but	O
mutations	O
in	O
the	O
E	O
-	O
cadherin	O
gene	O
seem	O
to	O
be	O
rare	O
.	O
Downregulation	O
of	O
E	O
-	O
cadherin	O
occurred	O
at	O
the	O
level	O
of	O
transcription	O
or	O
of	O
mRNA	O
stability	O
.	O
Ex	O
vivo	O
cultures	B-Anatomy
from	O
invasive	B-Anatomy
tumors	I-Anatomy
or	O
metastases	B-Anatomy
produced	O
cells	B-Anatomy
that	O
were	O
homogeneously	O
E	O
-	O
cadherin	O
-	O
positive	O
and	O
noninvasive	O
in	O
vitro	O
.	O
These	O
observations	O
have	O
led	O
to	O
the	O
idea	O
that	O
factors	O
in	O
the	O
host	O
downmodulate	O
the	O
E	O
-	O
cadherin	O
complex	O
and	O
promote	O
invasion	O
most	O
probably	O
in	O
a	O
transient	O
way	O
.	O
Heparin	O
-	O
steroid	O
conjugates	O
:	O
new	O
angiogenesis	O
inhibitors	O
with	O
antitumor	B-Anatomy
activity	O
in	O
mice	O
.	O
Inhibitors	O
of	O
angiogenesis	O
hold	O
potential	O
in	O
the	O
treatment	O
of	O
cancer	B-Anatomy
and	O
other	O
diseases	O
where	O
the	O
disease	O
is	O
caused	O
or	O
maintained	O
by	O
the	O
inappropriate	O
growth	O
of	O
blood	B-Anatomy
vessels	I-Anatomy
.	O
In	O
the	O
present	O
study	O
,	O
a	O
novel	O
inhibitor	O
of	O
angiogenesis	O
was	O
synthesized	O
by	O
covalently	O
linking	O
a	O
nonanticoagulating	O
derivative	O
of	O
heparin	O
,	O
heparin	O
adipic	O
hydrazide	O
(	O
HAH	O
)	O
,	O
by	O
an	O
acid	O
-	O
labile	O
bond	O
to	O
the	O
antiangiogenic	O
steroid	O
,	O
cortisol	O
.	O
The	O
rationale	O
was	O
that	O
the	O
heparin	O
derivative	O
,	O
which	O
binds	O
to	O
sulfated	O
polyanion	O
receptors	O
on	O
endothelial	B-Anatomy
cells	I-Anatomy
,	O
should	O
concentrate	O
the	O
steroid	O
on	O
the	O
surface	B-Anatomy
of	O
vascular	B-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
.	O
Endocytosis	O
of	O
the	O
conjugate	O
and	O
decomposition	O
of	O
the	O
acid	O
-	O
labile	O
linkage	O
inside	O
lysosomes	B-Anatomy
and	O
other	O
acidic	O
intracellular	B-Anatomy
compartments	I-Anatomy
should	O
then	O
lead	O
to	O
release	O
of	O
the	O
cortisol	O
and	O
expression	O
of	O
its	O
antiproliferative	O
activity	O
.	O
Analysis	O
of	O
the	O
stability	O
of	O
HAH	O
-	O
cortisol	O
showed	O
that	O
it	O
was	O
stable	O
at	O
pH	O
7	O
.	O
4	O
and	O
broke	O
down	O
rapidly	O
(	O
t1	O
/	O
2	O
15	O
min	O
)	O
at	O
pH	O
4	O
.	O
8	O
at	O
37	O
degrees	O
C	O
.	O
Treatment	O
of	O
murine	O
pulmonary	B-Anatomy
capillary	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
with	O
HAH	O
-	O
cortisol	O
at	O
10	O
(	O
-	O
5	O
)	O
M	O
(	O
with	O
respect	O
to	O
cortisol	O
)	O
suppressed	O
their	O
DNA	O
synthesis	O
by	O
50	O
%	O
and	O
inhibited	O
their	O
migration	O
into	O
wounded	B-Anatomy
areas	I-Anatomy
of	O
confluent	O
monolayers	B-Anatomy
.	O
HAH	O
-	O
cortisol	O
at	O
10	O
(	O
-	O
4	O
)	O
M	O
(	O
with	O
respect	O
to	O
cortisol	O
)	O
did	O
not	O
suppress	O
the	O
DNA	O
synthesis	O
of	O
Lewis	B-Anatomy
lung	I-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
.	O
Daily	O
i	O
.	O
p	O
.	O
injections	O
of	O
HAH	O
-	O
cortisol	O
into	O
mice	O
bearing	O
s	O
.	O
c	O
.	O
sponge	O
implants	O
retarded	O
vascularization	O
of	O
the	O
sponge	O
,	O
and	O
injections	O
directly	O
into	O
the	O
sponge	O
abolished	O
vascularization	O
for	O
as	O
long	O
as	O
the	O
injections	O
were	O
continued	O
.	O
Daily	O
i	B-Anatomy
.	I-Anatomy
v	I-Anatomy
.	I-Anatomy
injections	O
of	O
HAH	O
-	O
cortisol	O
at	O
doses	O
causing	O
no	O
apparent	O
toxicity	O
retarded	O
the	O
growth	O
of	O
solid	O
s	O
.	O
c	O
.	O
Lewis	B-Anatomy
lung	I-Anatomy
carcinomas	I-Anatomy
in	O
mice	O
by	O
up	O
to	O
65	O
%	O
.	O
In	O
all	O
of	O
these	O
assays	O
,	O
equivalent	O
treatments	O
with	O
a	O
mixture	O
of	O
the	O
HAH	O
plus	O
cortisol	O
was	O
significantly	O
less	O
effective	O
.	O
The	O
antiproliferative	O
effect	O
of	O
HAH	O
-	O
cortisol	O
on	O
endothelial	B-Anatomy
cells	I-Anatomy
appeared	O
independent	O
of	O
the	O
glucocorticoid	O
activity	O
of	O
the	O
steroid	O
since	O
HAH	O
conjugated	O
to	O
5	O
beta	O
-	O
pregnane	O
-	O
3	O
alpha	O
,	O
17	O
alpha	O
,	O
21	O
-	O
triol	O
-	O
20	O
-	O
one	O
,	O
a	O
steroid	O
lacking	O
glucocorticoid	O
or	O
mineralocorticoid	O
activity	O
,	O
was	O
even	O
more	O
effective	O
at	O
inhibiting	O
DNA	O
synthesis	O
by	O
murine	O
pulmonary	B-Anatomy
capillary	I-Anatomy
endothelial	I-Anatomy
cells	I-Anatomy
than	O
was	O
HAH	O
-	O
cortisol	O
.	O
In	O
conclusion	O
,	O
HAH	O
-	O
cortisol	O
represents	O
the	O
prototype	O
of	O
a	O
new	O
class	O
of	O
angiogenesis	O
inhibitors	O
for	O
the	O
treatment	O
of	O
cancer	B-Anatomy
and	O
other	O
angiogenic	O
diseases	O
.	O
Colorimetrical	O
rate	O
assay	O
for	O
urinary	B-Anatomy
dipeptidyl	O
peptidase	O
IV	O
(	O
DPPIV	O
)	O
activity	O
using	O
a	O
new	O
substrate	O
.	O
We	O
synthesized	O
a	O
new	O
substrate	O
glycyl	O
-	O
L	O
-	O
proline	O
3	O
,	O
5	O
-	O
dibromo	O
-	O
4	O
-	O
hydroxyanilide	O
(	O
Gly	O
-	O
Pro	O
-	O
DBAP	O
)	O
,	O
for	O
dipeptidyl	O
peptidase	O
IV	O
(	O
DPPIV	O
)	O
.	O
Its	O
hydrolysis	O
by	O
DPPIV	O
resulted	O
in	O
the	O
formation	O
of	O
a	O
chromophore	O
,	O
2	O
,	O
6	O
-	O
dibromophenol	O
-	O
indo	O
-	O
p	O
-	O
xylenol	O
,	O
and	O
its	O
maximal	O
absorption	O
wavelength	O
(	O
600	O
nm	O
)	O
was	O
longer	O
than	O
that	O
of	O
p	O
-	O
nitroaniline	O
(	O
415	O
nm	O
)	O
released	O
from	O
conventional	O
substrate	O
,	O
glycyl	O
-	O
L	O
-	O
proline	O
p	O
-	O
nitroanilide	O
(	O
Gly	O
-	O
Pro	O
-	O
pNA	O
)	O
.	O
We	O
also	O
established	O
the	O
rate	O
assay	O
for	O
urinary	B-Anatomy
DPPIV	O
activity	O
using	O
Gly	O
-	O
Pro	O
-	O
DBAP	O
.	O
The	O
optimum	O
pH	O
was	O
between	O
8	O
.	O
5	O
and	O
9	O
.	O
0	O
.	O
The	O
apparent	O
Km	O
was	O
1	O
.	O
1	O
mmol	O
/	O
1	O
.	O
The	O
detectable	O
range	O
was	O
2	O
.	O
5	O
-	O
350	O
U	O
/	O
l	O
.	O
No	O
changes	O
in	O
blank	O
values	O
occurred	O
throughout	O
the	O
enzyme	O
reaction	O
in	O
the	O
optimum	O
pH	O
.	O
Its	O
value	O
was	O
also	O
much	O
lower	O
than	O
Gly	O
-	O
Pro	O
-	O
pNA	O
.	O
CVs	O
for	O
within	O
-	O
run	O
and	O
between	O
-	O
run	O
were	O
1	O
.	O
1	O
%	O
(	O
n	O
=	O
10	O
)	O
and	O
3	O
.	O
0	O
%	O
(	O
n	O
=	O
10	O
)	O
,	O
respectively	O
.	O
Among	O
tested	O
peptidases	O
,	O
only	O
DPPIV	O
could	O
hydrolyze	O
Gly	O
-	O
Pro	O
-	O
DBAP	O
.	O
Among	O
the	O
protease	O
inhibitors	O
,	O
only	O
two	O
,	O
diprotin	O
-	O
A	O
and	O
phenylmethylsulfonyl	O
fluoride	O
(	O
PMSA	O
)	O
,	O
could	O
inhibit	O
DPPIV	O
activity	O
.	O
The	O
present	O
method	O
did	O
not	O
interfere	O
with	O
urinary	B-Anatomy
ingredients	O
such	O
as	O
hemoglobin	O
.	O
The	O
correlation	O
between	O
the	O
present	O
(	O
y	O
)	O
and	O
conventional	O
(	O
x	O
)	O
methods	O
is	O
presented	O
by	O
the	O
equation	O
y	O
=	O
1	O
.	O
121x	O
+	O
0	O
.	O
096	O
(	O
r	O
=	O
0	O
.	O
993	O
)	O
.	O
Thus	O
the	O
present	O
method	O
provides	O
practical	O
advantages	O
over	O
the	O
conventional	O
method	O
for	O
routine	O
laboratory	O
use	O
.	O
Primary	O
hyperparathyroidism	O
and	O
the	O
heart	B-Anatomy
:	O
cardiac	B-Anatomy
abnormalities	O
correlated	O
to	O
clinical	O
and	O
biochemical	O
data	O
.	O
Comparing	O
patients	O
with	O
primary	O
hyperparathyroidism	O
(	O
PHP	O
)	O
to	O
a	O
normocalcemic	O
control	O
population	O
,	O
those	O
with	O
PHP	O
have	O
a	O
higher	O
incidence	O
of	O
cardiovascular	B-Anatomy
disease	O
and	O
cardiac	B-Anatomy
abnormalities	O
.	O
This	O
study	O
aimed	O
at	O
correlating	O
cardiac	B-Anatomy
findings	O
(	O
valvular	B-Anatomy
and	O
myocardial	B-Anatomy
calcification	O
,	O
myocardial	B-Anatomy
hypertrophy	O
)	O
with	O
clinical	O
data	O
(	O
age	O
,	O
sex	O
,	O
clinical	O
manifestation	O
,	O
nephrolithiasis	O
,	O
nephrocalcinosis	O
,	O
hypertension	O
,	O
skeletal	B-Anatomy
abnormalities	O
,	O
hypercalcemic	O
syndrome	O
)	O
and	O
biochemical	O
data	O
(	O
serum	B-Anatomy
calcium	O
,	O
serum	B-Anatomy
phosphate	O
,	O
serum	B-Anatomy
iPTH	O
level	O
,	O
serum	B-Anatomy
creatinine	O
)	O
.	O
A	O
group	O
of	O
132	O
consecutive	O
patients	O
with	O
surgically	O
verified	O
PHP	O
(	O
94	O
women	O
,	O
38	O
men	O
;	O
ages	O
15	O
-	O
86	O
,	O
mean	O
age	O
57	O
+	O
/	O
-	O
16	O
years	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O
Blood	B-Anatomy
chemistry	O
,	O
clinical	O
presentation	O
,	O
radiography	O
,	O
and	O
echocardiography	O
were	O
carried	O
out	O
in	O
all	O
patients	O
for	O
univariate	O
and	O
multivariate	O
analyses	O
of	O
all	O
parameters	O
.	O
There	O
was	O
no	O
statistical	O
correlation	O
between	O
clinical	O
symptoms	O
,	O
biochemical	O
data	O
,	O
and	O
cardiac	B-Anatomy
calcific	O
alterations	O
.	O
Typical	O
skeletal	B-Anatomy
manifestations	O
(	O
osteolysis	O
/	O
subperiostal	O
resorption	O
)	O
and	O
valvular	B-Anatomy
calcifications	O
were	O
significantly	O
correlated	O
to	O
left	B-Anatomy
ventricular	I-Anatomy
hypertrophy	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
.	O
Cardiac	B-Anatomy
abnormalities	O
such	O
as	O
calcific	O
myocardial	B-Anatomy
deposits	O
or	O
mitral	B-Anatomy
and	O
aortic	B-Anatomy
valvular	I-Anatomy
calcifications	O
do	O
not	O
correlate	O
with	O
laboratory	O
findings	O
and	O
clinical	O
presentation	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O
There	O
was	O
no	O
biochemical	O
or	O
clinical	O
variable	O
that	O
could	O
predict	O
the	O
frequency	O
or	O
severity	O
of	O
valvular	B-Anatomy
sclerosis	O
or	O
calcific	O
deposits	O
in	O
the	O
myocardium	B-Anatomy
.	O
However	O
,	O
PHP	O
-	O
related	O
skeletal	B-Anatomy
abnormalities	O
and	O
valvular	B-Anatomy
calcification	O
were	O
predicting	O
factors	O
for	O
left	B-Anatomy
ventricular	I-Anatomy
hypertrophy	O
,	O
a	O
reversible	O
cardiac	B-Anatomy
manifestation	O
of	O
PHP	O
.	O
Myocardial	B-Anatomy
hypertrophy	O
is	O
more	O
often	O
found	O
with	O
classic	O
symptomatic	O
PHP	O
with	O
osseous	B-Anatomy
abnormalities	O
.	O
Selenoperoxidase	O
-	O
dependent	O
glutathione	O
cycle	O
activity	O
in	O
peroxide	O
-	O
challenged	O
leukemia	B-Anatomy
cells	I-Anatomy
.	O
Murine	O
leukemia	B-Anatomy
L1210	I-Anatomy
cells	I-Anatomy
rendered	O
deficient	O
in	O
glutathione	O
peroxidase	O
(	O
GPX	O
)	O
and	O
phospholipid	O
hydroperoxide	O
glutathione	O
peroxidase	O
(	O
PHGPX	O
)	O
by	O
Se	O
deprivation	O
(	O
L	B-Anatomy
.	I-Anatomy
Se	I-Anatomy
(	I-Anatomy
-	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
)	O
were	O
found	O
to	O
be	O
more	O
sensitive	O
to	O
tert	O
-	O
butyl	O
hydroperoxide	O
(	O
t	O
-	O
BuOOH	O
)	O
cytotoxicity	O
than	O
Se	O
-	O
replete	O
controls	O
(	O
L	B-Anatomy
.	I-Anatomy
Se	I-Anatomy
(	I-Anatomy
+	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
)	O
.	O
Human	O
K562	B-Anatomy
cells	I-Anatomy
,	O
which	O
express	O
PHGPX	O
,	O
but	O
not	O
GPX	O
,	O
were	O
also	O
more	O
sensitive	O
to	O
t	O
-	O
BuOOH	O
in	O
the	O
Se	O
-	O
deficient	O
(	O
K	B-Anatomy
.	I-Anatomy
Se	I-Anatomy
(	I-Anatomy
-	I-Anatomy
)	I-Anatomy
)	O
than	O
Se	O
-	O
satisfied	O
(	O
K	B-Anatomy
.	I-Anatomy
Se	I-Anatomy
(	I-Anatomy
+	I-Anatomy
)	I-Anatomy
)	O
condition	O
.	O
In	O
examining	O
the	O
metabolic	O
basis	O
for	O
selenoperoxidase	O
-	O
dependent	O
resistance	O
,	O
we	O
found	O
that	O
glucose	O
-	O
replete	O
Se	B-Anatomy
(	I-Anatomy
-	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
reduce	O
t	O
-	O
BuOOH	O
to	O
t	O
-	O
butanol	O
far	O
more	O
slowly	O
than	O
Se	B-Anatomy
(	I-Anatomy
+	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
,	O
the	O
ratio	O
of	O
the	O
first	O
-	O
order	O
rate	O
constants	O
approximating	O
that	O
of	O
the	O
GPX	O
activities	O
(	O
L1210	B-Anatomy
cells	I-Anatomy
)	O
or	O
PHGPX	O
activities	O
(	O
K562	B-Anatomy
cells	I-Anatomy
)	O
.	O
Monitoring	O
peroxide	O
-	O
induced	O
changes	O
in	O
GSH	O
and	O
GSSG	O
gave	O
consistent	O
results	O
;	O
e	O
.	O
g	O
.	O
,	O
glucose	O
-	O
depleted	O
L	B-Anatomy
.	I-Anatomy
Se	I-Anatomy
(	I-Anatomy
+	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
exhibited	O
a	O
first	O
order	O
loss	O
of	O
GSH	O
that	O
was	O
substantially	O
faster	O
than	O
that	O
of	O
glucose	O
-	O
depleted	O
L	B-Anatomy
.	I-Anatomy
Se	I-Anatomy
(	I-Anatomy
-	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
.	O
Under	O
the	O
conditions	O
used	O
,	O
peroxide	O
-	O
induced	O
conversion	O
of	O
GSH	O
to	O
GSSG	O
could	O
be	O
stoichiometrically	O
reversed	O
by	O
resupplying	O
D	O
-	O
glucose	O
,	O
indicating	O
that	O
no	O
significant	O
lysis	O
or	O
GSSG	O
efflux	O
and	O
/	O
or	O
interchange	O
had	O
taken	O
place	O
.	O
The	O
apparent	O
first	O
-	O
order	O
rate	O
constant	O
for	O
GSH	O
decay	O
increased	O
progressively	O
for	O
L1210	B-Anatomy
cells	I-Anatomy
expressing	O
a	O
range	O
of	O
GPX	O
activities	O
from	O
approximately	O
5	O
%	O
to	O
100	O
%	O
,	O
demonstrating	O
that	O
peroxide	O
detoxification	O
is	O
strictly	O
dependent	O
on	O
enzyme	O
content	O
.	O
The	O
initial	O
rate	O
of	O
14CO2	O
release	O
from	O
D	O
-	O
[	O
1	O
-	O
14C	O
]	O
glucose	O
supplied	O
in	O
the	O
medium	O
was	O
much	O
greater	O
for	O
L	B-Anatomy
.	I-Anatomy
Se	I-Anatomy
(	I-Anatomy
+	I-Anatomy
)	I-Anatomy
or	O
K	B-Anatomy
.	I-Anatomy
Se	I-Anatomy
(	I-Anatomy
+	I-Anatomy
)	I-Anatomy
cells	I-Anatomy
than	O
for	O
their	O
respective	O
Se	B-Anatomy
(	I-Anatomy
-	I-Anatomy
)	I-Anatomy
counterparts	O
,	O
consistent	O
with	O
greater	O
hexose	O
monophosphate	O
shunt	O
activity	O
in	O
the	O
former	O
.	O
These	O
results	O
highlight	O
the	O
importance	O
of	O
selenoperoxidase	O
action	O
in	O
the	O
glutathione	O
cycle	O
as	O
a	O
means	O
by	O
which	O
tumor	B-Anatomy
cells	I-Anatomy
cope	O
with	O
hydroperoxide	O
stress	O
.	O
Differential	O
expression	O
and	O
mutation	O
of	O
NME	O
genes	O
in	O
autologous	O
cultured	O
human	O
melanoma	B-Anatomy
cells	I-Anatomy
with	O
different	O
metastatic	O
potentials	O
.	O
The	O
putative	O
metastasis	O
suppressor	O
genes	O
,	O
NME1	O
(	O
nm23	O
-	O
1	O
)	O
and	O
NME2	O
(	O
nm23	O
-	O
2	O
)	O
,	O
were	O
examined	O
in	O
a	O
model	O
system	O
we	O
developed	O
to	O
approximate	O
the	O
dissemination	O
of	O
melanoma	B-Anatomy
from	O
a	O
primary	B-Anatomy
skin	I-Anatomy
tumor	I-Anatomy
.	O
We	O
utilized	O
two	O
autologous	O
human	O
melanoma	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
,	O
IV	B-Anatomy
Cl	I-Anatomy
1	I-Anatomy
and	O
IV	B-Anatomy
Cl	I-Anatomy
3	I-Anatomy
,	O
which	O
displayed	O
qualitatively	O
different	O
metastatic	O
phenotypes	O
following	O
subdermal	B-Anatomy
inoculation	O
into	O
nude	O
mice	O
.	O
Highly	O
metastatic	B-Anatomy
IV	I-Anatomy
Cl	I-Anatomy
1	I-Anatomy
cells	I-Anatomy
expressed	O
approximately	O
5	O
fold	O
lower	O
levels	O
of	O
protein	O
encoded	O
by	O
NME	O
genes	O
than	O
non	B-Anatomy
-	I-Anatomy
metastatic	I-Anatomy
IV	I-Anatomy
Cl	I-Anatomy
3	I-Anatomy
cells	I-Anatomy
.	O
Similar	O
differences	O
in	O
NME	O
protein	O
levels	O
were	O
observed	O
in	O
tumors	B-Anatomy
induced	O
by	O
the	O
two	O
cell	B-Anatomy
lines	I-Anatomy
in	O
nude	O
mice	O
.	O
There	O
were	O
no	O
differences	O
in	O
NME	O
mRNA	O
levels	O
between	O
these	O
two	O
cell	B-Anatomy
lines	I-Anatomy
,	O
suggesting	O
that	O
expression	O
of	O
these	O
proteins	O
is	O
regulated	O
at	O
a	O
post	O
-	O
transcriptional	O
level	O
.	O
We	O
found	O
a	O
ser122	O
-	O
pro	O
mutation	O
in	O
the	O
NME2	O
gene	O
of	O
metastatic	B-Anatomy
IV	I-Anatomy
Cl	I-Anatomy
1	I-Anatomy
cells	I-Anatomy
.	O
A	O
similar	O
ser120	O
-	O
gly	O
mutation	O
in	O
NME1	O
has	O
been	O
found	O
in	O
human	O
neuroblastoma	B-Anatomy
,	O
suggesting	O
that	O
mutation	O
in	O
this	O
region	O
may	O
be	O
a	O
general	O
phenomenon	O
related	O
to	O
tumor	B-Anatomy
progression	O
.	O
These	O
mutations	O
may	O
have	O
functional	O
consequences	O
since	O
they	O
eliminate	O
potential	O
phosphorylation	O
sites	O
and	O
may	O
affect	O
the	O
tertiary	O
structure	O
of	O
mature	O
protein	O
complexes	O
.	O
Image	O
-	O
directed	O
and	O
color	O
Doppler	O
studies	O
of	O
gallbladder	B-Anatomy
tumors	I-Anatomy
.	O
Thirteen	O
cases	O
of	O
primary	B-Anatomy
adenocarcinoma	I-Anatomy
of	O
the	O
gallbladder	B-Anatomy
(	O
GB	B-Anatomy
)	O
,	O
1	O
of	O
malignant	B-Anatomy
fibrous	I-Anatomy
histocytoma	I-Anatomy
,	O
3	O
of	O
metastatic	B-Anatomy
adenocarcinoma	I-Anatomy
,	O
5	O
of	O
adenoma	B-Anatomy
,	O
5	O
of	O
polypus	B-Anatomy
,	O
2	O
of	O
xanthogranuloma	B-Anatomy
,	O
6	O
of	O
chronic	O
cholecystitis	O
,	O
4	O
of	O
acute	O
cholecystitis	O
,	O
and	O
8	O
of	O
subacute	O
cholecystitis	O
were	O
studied	O
by	O
image	O
-	O
directed	O
and	O
color	O
Doppler	O
ultrasonography	O
(	O
CDUS	O
)	O
.	O
All	O
of	O
the	O
14	O
cases	O
of	O
primary	B-Anatomy
GB	I-Anatomy
cancer	I-Anatomy
(	O
10	O
masses	B-Anatomy
,	O
4	O
thickening	O
wall	B-Anatomy
)	O
were	O
found	O
to	O
have	O
a	O
high	O
velocity	O
arterial	B-Anatomy
blood	I-Anatomy
flow	O
signal	O
in	O
the	O
wall	B-Anatomy
of	O
the	O
GB	B-Anatomy
.	O
In	O
contrast	O
,	O
the	O
3	O
cases	O
of	O
metastatic	B-Anatomy
cancer	I-Anatomy
of	O
the	O
GB	B-Anatomy
had	O
no	O
blood	B-Anatomy
flow	O
signal	O
in	O
the	O
wall	B-Anatomy
of	O
the	O
GB	B-Anatomy
.	O
For	O
the	O
30	O
cases	O
of	O
benign	B-Anatomy
lesions	I-Anatomy
of	O
the	O
GB	B-Anatomy
,	O
only	O
in	O
12	O
cases	O
was	O
a	O
low	O
velocity	O
blood	B-Anatomy
flow	O
signal	O
found	O
.	O
Nine	O
of	O
10	O
cases	O
of	O
primary	B-Anatomy
GB	I-Anatomy
malignancy	I-Anatomy
were	O
found	O
to	O
have	O
high	O
velocity	O
arterial	B-Anatomy
blood	I-Anatomy
flow	O
signals	O
in	O
the	O
tumor	B-Anatomy
masses	I-Anatomy
.	O
No	O
blood	B-Anatomy
flow	O
signal	O
was	O
observed	O
in	O
the	O
masses	B-Anatomy
of	O
13	O
cases	O
(	O
3	O
of	O
metastatic	B-Anatomy
adenocarcinoma	I-Anatomy
,	O
5	O
of	O
adenoma	B-Anatomy
,	O
5	O
of	O
polypus	B-Anatomy
)	O
.	O
An	O
abnormal	O
high	O
velocity	O
arterial	B-Anatomy
blood	I-Anatomy
flow	O
signal	O
observed	O
within	O
masses	B-Anatomy
in	O
the	O
GB	B-Anatomy
or	O
in	O
the	O
GB	B-Anatomy
wall	I-Anatomy
is	O
a	O
significant	O
feature	O
of	O
primary	B-Anatomy
GB	I-Anatomy
cancer	I-Anatomy
and	O
thus	O
helps	O
to	O
differentiate	O
primary	B-Anatomy
GB	I-Anatomy
cancer	I-Anatomy
from	O
metastatic	B-Anatomy
and	O
benign	B-Anatomy
lesions	I-Anatomy
of	O
the	O
GB	B-Anatomy
.	O
Inhibition	O
of	O
calmodulin	O
-	O
dependent	O
myosin	O
light	O
-	O
chain	O
kinase	O
by	O
growth	O
-	O
hormone	O
-	O
releasing	O
factor	O
and	O
vasoactive	O
intestinal	B-Anatomy
peptide	O
.	O
In	O
view	O
of	O
the	O
ability	O
of	O
calmodulin	O
to	O
bind	O
vasoactive	O
intestinal	B-Anatomy
peptide	O
(	O
VIP	O
)	O
and	O
growth	O
-	O
hormone	O
-	O
releasing	O
factor	O
(	O
GRF	O
)	O
with	O
high	O
affinity	O
[	O
Stallwood	O
,	O
Brugger	O
,	O
Baggenstoss	O
,	O
Stemmer	O
,	O
Shiraga	O
,	O
Landers	O
and	O
Paul	O
(	O
1992	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
267	O
,	O
19617	O
-	O
19621	O
]	O
,	O
the	O
effects	O
of	O
these	O
neuropeptides	O
on	O
a	O
model	O
calmodulin	O
-	O
dependent	O
enzyme	O
,	O
myosin	O
light	O
-	O
chain	O
kinase	O
(	O
MLCK	O
)	O
,	O
were	O
studied	O
.	O
Both	O
peptides	O
were	O
potent	O
inhibitors	O
of	O
MLCK	O
activity	O
.	O
The	O
inhibition	O
of	O
enzyme	O
activity	O
by	O
VIP	O
and	O
GRF	O
was	O
progressively	O
overcome	O
with	O
increasing	O
calmodulin	O
concentrations	O
,	O
with	O
no	O
inhibition	O
observed	O
at	O
a	O
saturating	O
calmodulin	O
concentration	O
.	O
Nanomolar	O
concentrations	O
of	O
MLCK	O
blocked	O
the	O
formation	O
of	O
calmodulin	O
-	O
[	O
125I	O
-	O
Tyr10	O
]	O
VIP	O
complexes	O
.	O
These	O
data	O
provide	O
support	O
for	O
a	O
functional	O
role	O
of	O
VIP	O
and	O
GRF	O
binding	O
by	O
calmodulin	O
.	O
Cyclin	O
D1	O
/	O
bcl	O
-	O
1	O
cooperates	O
with	O
myc	O
genes	O
in	O
the	O
generation	O
of	O
B	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
lymphoma	I-Anatomy
in	O
transgenic	O
mice	O
.	O
The	O
chromosomal	B-Anatomy
translocation	O
t	O
(	O
11	O
:	O
14	O
)	O
is	O
associated	O
with	O
human	O
lymphoid	B-Anatomy
neoplasia	I-Anatomy
affecting	O
centrocytic	B-Anatomy
B	I-Anatomy
-	I-Anatomy
cells	I-Anatomy
of	O
intermediate	O
differentiation	O
.	O
As	O
a	O
consequence	O
the	O
cyclin	O
D1	O
(	O
bcl	O
-	O
1	O
)	O
gene	O
is	O
juxtaposed	O
to	O
the	O
immunoglobulin	O
heavy	O
chain	O
enhancer	O
E	O
mu	O
.	O
To	O
show	O
that	O
transcriptional	O
activation	O
of	O
cyclin	O
D1	O
is	O
causally	O
involved	O
in	O
the	O
generation	O
of	O
B	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
neoplasia	I-Anatomy
we	O
have	O
generated	O
transgenic	O
mice	O
that	O
carry	O
a	O
cyclin	O
D1	O
gene	O
under	O
the	O
transcriptional	O
control	O
of	O
the	O
E	O
mu	O
element	O
.	O
E	O
mu	O
cyclin	O
D1	O
transgenic	O
mice	O
show	O
only	O
very	O
subtle	O
alterations	O
in	O
the	O
cycling	O
behaviour	O
of	O
B	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
populations	I-Anatomy
in	O
the	O
bone	B-Anatomy
marrow	I-Anatomy
compared	O
with	O
normal	O
mice	O
and	O
do	O
not	O
develop	O
lymphoid	B-Anatomy
tumours	I-Anatomy
.	O
However	O
,	O
E	O
mu	O
-	O
directed	O
coexpression	O
of	O
cyclin	O
D1	O
and	O
N	O
-	O
MYC	O
or	O
L	O
-	O
MYC	O
in	O
double	O
transgenic	O
mice	O
reveals	O
a	O
strong	O
cooperative	O
effect	O
between	O
MYC	O
and	O
cyclin	O
D1	O
provoking	O
the	O
rapid	O
development	O
of	O
clonal	B-Anatomy
pre	I-Anatomy
-	I-Anatomy
B	I-Anatomy
and	O
B	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
lymphomas	I-Anatomy
.	O
Interestingly	O
,	O
crossing	O
of	O
cyclin	O
D1	O
transgenic	O
mice	O
with	O
E	O
mu	O
L	O
-	O
myc	O
transgenics	O
that	O
express	O
their	O
transgene	O
in	O
both	O
B	B-Anatomy
-	I-Anatomy
and	O
T	B-Anatomy
-	I-Anatomy
cells	I-Anatomy
but	O
predominantly	O
develop	O
T	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
tumours	I-Anatomy
leads	O
in	O
double	O
transgenics	O
exclusively	O
to	O
B	B-Anatomy
-	I-Anatomy
cell	I-Anatomy
neoplasia	I-Anatomy
.	O
The	O
data	O
presented	O
here	O
demonstrate	O
that	O
transcriptional	O
activation	O
of	O
cyclin	O
D1	O
can	O
oncogenically	O
transform	O
B	B-Anatomy
-	I-Anatomy
cells	I-Anatomy
in	O
concert	O
with	O
a	O
myc	O
gene	O
.	O
They	O
establish	O
cyclin	O
D1	O
as	O
a	O
proto	O
-	O
oncogene	O
whose	O
activity	O
appears	O
to	O
depend	O
on	O
a	O
specific	O
cell	B-Anatomy
type	O
as	O
well	O
as	O
on	O
a	O
specific	O
cooperating	O
partner	O
and	O
link	O
disturbances	O
in	O
the	O
regulation	O
of	O
cell	B-Anatomy
cycle	O
progression	O
to	O
the	O
development	O
of	O
human	O
malignancies	B-Anatomy
.	O
Elevated	O
expression	O
of	O
the	O
junB	O
proto	O
-	O
oncogene	O
is	O
essential	O
for	O
v	O
-	O
fos	O
induced	O
transformation	O
of	O
Rat	B-Anatomy
-	I-Anatomy
1	I-Anatomy
cells	I-Anatomy
.	O
We	O
previously	O
described	O
the	O
isolation	O
of	O
non	O
-	O
tumorigenic	O
revertants	B-Anatomy
from	O
mutagenized	O
populations	B-Anatomy
of	O
v	O
-	O
fos	O
-	O
transformed	O
Rat	B-Anatomy
-	I-Anatomy
1	I-Anatomy
cells	I-Anatomy
(	O
Zarbl	O
et	O
al	O
.	O
,	O
1987	O
)	O
.	O
In	O
the	O
present	O
study	O
we	O
examined	O
the	O
possibility	O
that	O
the	O
revertant	B-Anatomy
phenotype	O
resulted	O
from	O
mutations	O
that	O
altered	O
the	O
expression	O
or	O
activities	O
of	O
the	O
c	O
-	O
jun	O
or	O
junB	O
proto	O
-	O
oncogenes	O
.	O
The	O
results	O
demonstrated	O
that	O
levels	O
of	O
the	O
c	O
-	O
jun	O
mRNA	O
and	O
protein	O
were	O
unchanged	O
in	O
the	O
revertants	B-Anatomy
when	O
compared	O
to	O
the	O
transformed	O
parental	O
cells	B-Anatomy
,	O
and	O
ectopic	O
overexpression	O
of	O
c	O
-	O
jun	O
failed	O
to	O
retransform	O
the	O
revertants	B-Anatomy
.	O
Although	O
one	O
mutant	O
allele	O
was	O
detected	O
in	O
revertant	B-Anatomy
EMS	I-Anatomy
-	I-Anatomy
1	I-Anatomy
-	I-Anatomy
19	I-Anatomy
,	O
overexpression	O
of	O
this	O
mutant	O
allele	O
failed	O
to	O
inhibit	O
v	O
-	O
fos	O
induced	O
cell	B-Anatomy
transformation	O
.	O
Together	O
these	O
results	O
indicated	O
that	O
the	O
revertant	B-Anatomy
phenotype	O
did	O
not	O
result	O
from	O
altered	O
expression	O
or	O
mutations	O
in	O
the	O
c	O
-	O
jun	O
gene	O
.	O
In	O
contrast	O
to	O
the	O
results	O
obtained	O
with	O
c	O
-	O
jun	O
,	O
the	O
levels	O
of	O
junB	O
mRNA	O
and	O
protein	O
were	O
found	O
to	O
be	O
reduced	O
two	O
-	O
or	O
threefold	O
in	O
revertant	B-Anatomy
EMS	I-Anatomy
-	I-Anatomy
1	I-Anatomy
-	I-Anatomy
19	I-Anatomy
.	O
Ectopic	O
overexpression	O
of	O
junB	O
induced	O
transformation	O
of	O
revertant	B-Anatomy
EMS	I-Anatomy
-	I-Anatomy
1	I-Anatomy
-	I-Anatomy
19	I-Anatomy
,	O
but	O
failed	O
to	O
transform	O
Rat	B-Anatomy
-	I-Anatomy
1	I-Anatomy
cells	I-Anatomy
.	O
Moreover	O
,	O
about	O
10	O
%	O
of	O
v	O
-	O
fos	O
transformed	O
cells	B-Anatomy
transfected	O
with	O
vectors	O
that	O
express	O
antisense	O
junB	O
mRNA	O
acquired	O
a	O
non	O
-	O
transformed	O
phenotype	O
.	O
Together	O
these	O
results	O
indicate	O
that	O
expression	O
of	O
junB	O
above	O
a	O
threshold	O
level	O
is	O
essential	O
for	O
v	O
-	O
fos	O
-	O
induced	O
transformation	O
of	O
Rat	B-Anatomy
-	I-Anatomy
1	I-Anatomy
fibroblasts	I-Anatomy
.	O
Methotrexate	O
osteopathy	O
in	O
rheumatic	O
disease	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
whether	O
two	O
adults	O
with	O
stress	O
fractures	O
receiving	O
low	O
weekly	O
doses	O
of	O
methotrexate	O
had	O
methotrexate	O
osteopathy	O
.	O
CASE	O
REPORTS	O
:	O
Two	O
adult	O
patients	O
developed	O
features	O
consistent	O
with	O
methotrexate	O
osteopathy	O
while	O
receiving	O
low	O
weekly	O
doses	O
of	O
methotrexate	O
.	O
METHODS	O
:	O
Iliac	B-Anatomy
crest	I-Anatomy
biopsy	I-Anatomy
samples	I-Anatomy
were	O
taken	O
and	O
bone	B-Anatomy
histomorphometry	O
carried	O
out	O
.	O
RESULTS	O
:	O
Symptoms	O
resolved	O
when	O
the	O
methotrexate	O
was	O
discontinued	O
.	O
Bone	B-Anatomy
histology	O
showed	O
changes	O
consistent	O
with	O
osteoblast	B-Anatomy
inhibition	O
by	O
methotrexate	O
.	O
CONCLUSIONS	O
:	O
When	O
given	O
in	O
low	O
doses	O
for	O
prolonged	O
periods	O
,	O
methotrexate	O
may	O
have	O
adverse	O
effects	O
on	O
bone	B-Anatomy
,	O
particularly	O
in	O
post	O
-	O
menopausal	O
women	O
.	O
Methodologies	O
for	O
measuring	O
carcinogen	O
adducts	O
in	O
humans	O
.	O
In	O
summary	O
,	O
although	O
some	O
of	O
the	O
more	O
optimistic	O
aspirations	O
for	O
human	O
biomonitoring	O
studies	O
envisaged	O
a	O
decade	O
ago	O
have	O
not	O
been	O
realized	O
thus	O
far	O
,	O
some	O
considerable	O
advances	O
have	O
been	O
made	O
.	O
The	O
examples	O
cited	O
above	O
indicate	O
that	O
the	O
feasibility	O
of	O
biomonitoring	O
has	O
been	O
clearly	O
established	O
.	O
In	O
addition	O
,	O
they	O
demonstrate	O
the	O
need	O
for	O
preliminary	O
biomarker	O
testing	O
and	O
validation	O
through	O
transitional	O
studies	O
prior	O
to	O
their	O
field	O
application	O
.	O
In	O
the	O
next	O
decade	O
of	O
research	O
into	O
carcinogen	O
adducts	O
in	O
humans	O
,	O
continued	O
improvements	O
in	O
the	O
reproducibility	O
and	O
specificity	O
of	O
assays	O
for	O
DNA	O
adducts	O
will	O
be	O
needed	O
.	O
Perhaps	O
the	O
increasing	O
use	O
of	O
hybrid	O
methodologies	O
to	O
concentrate	O
adducts	O
followed	O
by	O
specific	O
chemical	O
analyses	O
will	O
allow	O
such	O
adducts	O
to	O
be	O
monitored	O
more	O
precisely	O
.	O
Of	O
course	O
,	O
further	O
basic	O
research	O
into	O
the	O
mechanisms	O
of	O
carcinogenesis	O
will	O
allow	O
the	O
measurement	O
of	O
specific	O
novel	O
markers	O
which	O
are	O
more	O
closely	O
tied	O
to	O
the	O
disease	O
endpoint	O
than	O
adducts	O
.	O
The	O
development	O
of	O
new	O
assays	O
for	O
determining	O
metabolic	O
phenotypes	O
and	O
genotypes	O
relevant	O
to	O
carcinogenesis	O
should	O
improve	O
our	O
estimates	O
of	O
susceptibility	O
(	O
46	O
-	O
48	O
)	O
.	O
Such	O
new	O
approaches	O
along	O
with	O
the	O
sustained	O
improvement	O
of	O
current	O
assays	O
will	O
allow	O
molecular	O
approaches	O
to	O
continue	O
to	O
enrich	O
cancer	B-Anatomy
epidemiology	O
in	O
the	O
future	O
.	O
[	O
Treatment	O
of	O
the	O
diabetic	O
foot	B-Anatomy
by	O
hyperbaric	O
oxygen	O
]	O
Diabetic	O
foot	B-Anatomy
wounds	I-Anatomy
are	O
consequences	O
of	O
the	O
neuropathy	O
and	O
the	O
small	O
and	O
large	O
vessel	B-Anatomy
disease	O
that	O
complicate	O
diabetes	O
.	O
At	O
the	O
cellular	B-Anatomy
level	O
,	O
the	O
result	O
is	O
hypoxia	O
which	O
impairs	O
wound	B-Anatomy
healing	O
.	O
Hyperbaric	O
oxygenation	O
(	O
HBO	O
)	O
may	O
be	O
a	O
useful	O
adjuvant	O
to	O
wound	B-Anatomy
care	O
.	O
It	O
leads	O
to	O
enhanced	O
oxygenation	O
of	O
the	O
affected	O
tissues	B-Anatomy
,	O
has	O
an	O
antiseptic	O
effect	O
,	O
reduces	O
edema	B-Anatomy
,	O
and	O
accelerates	O
collagen	O
production	O
and	O
angiogenesis	O
,	O
thus	O
enhancing	O
tissue	B-Anatomy
repair	O
.	O
14	O
diabetics	O
with	O
chronic	B-Anatomy
nonhealing	I-Anatomy
wounds	I-Anatomy
which	O
did	O
not	O
respond	O
to	O
treatment	O
for	O
at	O
least	O
3	O
months	O
were	O
treated	O
by	O
HBO	O
.	O
All	O
had	O
palpable	O
pedal	O
pulses	O
.	O
Transcutaneous	B-Anatomy
measurements	O
of	O
tissue	B-Anatomy
pO2	O
showed	O
elevation	O
from	O
20	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
during	O
air	O
breathing	O
to	O
643	O
+	O
/	O
-	O
242	O
mm	O
Hg	O
while	O
breathing	O
pure	O
oxygen	O
at	O
2	O
.	O
5	O
ATA	O
.	O
They	O
were	O
treated	O
with	O
HBO	O
in	O
56	O
+	O
/	O
-	O
10	O
consecutive	O
HBO	O
sessions	O
.	O
In	O
11	O
there	O
was	O
complete	O
wound	B-Anatomy
healing	O
,	O
while	O
in	O
1	O
there	O
was	O
partial	O
response	O
,	O
in	O
1	O
minimal	O
response	O
,	O
and	O
in	O
1	O
a	O
transient	O
response	O
.	O
HBO	O
is	O
useful	O
in	O
chronic	B-Anatomy
nonhealing	I-Anatomy
wounds	I-Anatomy
of	O
the	O
diabetic	O
foot	B-Anatomy
and	O
of	O
the	O
diabetic	O
foot	B-Anatomy
with	O
impending	O
amputation	O
.	O
It	O
is	O
a	O
safe	O
mode	O
of	O
therapy	O
,	O
but	O
further	O
studies	O
are	O
required	O
to	O
establish	O
its	O
efficacy	O
and	O
to	O
ascertain	O
which	O
diabetic	O
patients	O
and	O
wounds	B-Anatomy
will	O
benefit	O
the	O
most	O
from	O
it	O
.	O
Lactotransferrin	O
binding	O
to	O
its	O
platelet	B-Anatomy
receptor	O
inhibits	O
platelet	B-Anatomy
aggregation	O
.	O
A	O
fluorescent	O
lactotransferrin	O
probe	O
was	O
prepared	O
by	O
coupling	O
5	O
-	O
(	O
(	O
[	O
2	O
-	O
(	O
carbhydrazino	O
)	O
methyl	O
]	O
-	O
thio	O
)	O
acetyl	O
)	O
amino	O
fluorescein	O
to	O
aldehyde	O
groups	O
that	O
were	O
produced	O
by	O
a	O
mild	O
periodic	O
-	O
acid	O
oxidation	O
of	O
the	O
glycan	O
moieties	O
of	O
lactotransferrin	O
.	O
In	O
this	O
manner	O
,	O
the	O
receptor	O
-	O
binding	O
site	O
of	O
the	O
lactotransferrin	O
remains	O
active	O
in	O
contrast	O
to	O
the	O
binding	O
site	O
of	O
the	O
lactotransferrin	O
derivatized	O
with	O
fluorescein	O
isothiocyanate	O
.	O
The	O
fluorescent	O
probe	O
allowed	O
us	O
to	O
characterize	O
,	O
by	O
flow	O
cytometry	O
,	O
the	O
binding	O
of	O
lactotransferrin	O
to	O
non	O
-	O
activated	O
human	O
platelets	B-Anatomy
.	O
The	O
putative	O
lactotransferrin	O
platelet	B-Anatomy
receptor	O
was	O
purified	O
and	O
its	O
immunological	O
and	O
physico	O
-	O
chemical	O
properties	O
were	O
found	O
to	O
be	O
very	O
similar	O
to	O
those	O
of	O
the	O
receptor	O
previously	O
isolated	O
from	O
activated	O
human	O
lymphocytes	B-Anatomy
.	O
Lactotransferrin	O
inhibits	O
ADP	O
-	O
induced	O
platelet	B-Anatomy
aggregation	O
at	O
concentrations	O
down	O
to	O
5	O
nM	O
,	O
which	O
can	O
be	O
reached	O
in	O
the	O
plasma	B-Anatomy
after	O
leukocyte	B-Anatomy
degranulation	O
.	O
Inhibition	O
of	O
platelet	B-Anatomy
aggregation	O
was	O
also	O
observed	O
with	O
the	O
N	O
-	O
terminal	O
fragment	O
of	O
lactotransferrin	O
(	O
residues	O
3	O
-	O
281	O
;	O
50	O
%	O
inhibition	O
=	O
2	O
microM	O
)	O
and	O
with	O
CFQWQRNMRKVRGPPVSC	O
synthetic	O
octodecapeptide	O
(	O
residues	O
20	O
-	O
37	O
;	O
50	O
%	O
inhibition	O
=	O
20	O
microM	O
)	O
corresponding	O
to	O
one	O
of	O
the	O
two	O
external	O
loops	O
(	O
residues	O
28	O
-	O
34	O
and	O
39	O
-	O
42	O
)	O
where	O
we	O
recently	O
located	O
the	O
receptor	O
-	O
binding	O
site	O
.	O
The	O
activity	O
(	O
50	O
%	O
inhibition	O
=	O
500	O
microM	O
)	O
of	O
the	O
tetrapeptide	O
KRDS	O
(	O
residues	O
39	O
-	O
42	O
)	O
,	O
which	O
has	O
already	O
been	O
described	O
,	O
was	O
at	O
least	O
25	O
-	O
times	O
and	O
16000	O
-	O
times	O
lower	O
than	O
the	O
activity	O
of	O
the	O
octodecapeptide	O
and	O
of	O
the	O
lactotransferrin	O
molecules	O
,	O
respectively	O
.	O
Finally	O
,	O
the	O
inhibition	O
was	O
demonstrated	O
to	O
be	O
mediated	O
by	O
a	O
mechanism	O
which	O
requires	O
the	O
binding	O
of	O
lactotransferrin	O
to	O
its	O
putative	O
receptor	O
and	O
not	O
to	O
platelet	B-Anatomy
glycoprotein	O
IIb	O
-	O
IIIa	O
.	O
Appearance	O
of	O
tumorous	B-Anatomy
phenotypes	O
in	O
goldfish	O
erythrophores	B-Anatomy
transfected	O
with	O
ras	O
,	O
src	O
,	O
and	O
myc	O
oncogenes	O
and	O
spontaneous	O
differentiation	O
of	O
the	O
transformants	B-Anatomy
in	O
vitro	O
.	O
When	O
goldfish	O
erythrophores	B-Anatomy
isolated	O
from	O
the	O
skin	B-Anatomy
by	O
tissue	B-Anatomy
digestion	O
and	O
centrifugation	O
in	O
a	O
Percoll	O
density	O
gradient	O
were	O
transfected	O
in	O
a	O
monolayer	B-Anatomy
-	I-Anatomy
culture	I-Anatomy
with	O
v	O
-	O
Ha	O
-	O
ras	O
or	O
v	O
-	O
src	O
oncogene	O
either	O
singly	O
or	O
in	O
combination	O
with	O
v	O
-	O
myc	O
by	O
means	O
of	O
calcium	O
phosphate	O
-	O
DNA	O
co	O
-	O
precipitation	O
,	O
there	O
appeared	O
a	O
certain	O
number	O
of	O
transformants	B-Anatomy
manifesting	O
a	O
chromatoblast	B-Anatomy
-	O
like	O
profile	O
and	O
tumorous	B-Anatomy
phenotypes	O
as	O
seen	O
in	O
the	O
capability	O
for	O
unlimited	O
growth	O
,	O
and	O
piling	O
-	O
up	O
in	O
a	O
monolayer	B-Anatomy
-	I-Anatomy
culture	I-Anatomy
or	O
colony	B-Anatomy
formation	O
in	O
semi	O
-	O
solid	O
soft	O
agar	O
.	O
After	O
successive	O
growth	O
in	O
vitro	O
for	O
longer	O
than	O
one	O
month	O
which	O
was	O
scarcely	O
observed	O
with	O
the	O
erythrophores	B-Anatomy
,	O
the	O
vast	O
majority	O
of	O
such	O
transformants	B-Anatomy
began	O
to	O
differentiate	O
into	O
erythrophores	B-Anatomy
and	O
ceased	O
proliferation	O
spontaneously	O
.	O
The	O
onset	O
of	O
their	O
differentiation	O
was	O
ascertained	O
by	O
the	O
deposition	O
of	O
marker	O
pteridine	O
pigments	O
.	O
None	O
of	O
the	O
transformants	B-Anatomy
differentiated	O
into	O
melanophores	B-Anatomy
or	O
iridophores	B-Anatomy
or	O
other	O
neural	B-Anatomy
crest	I-Anatomy
derivatives	O
as	O
seen	O
in	O
goldfish	O
erythrophoroma	B-Anatomy
cells	I-Anatomy
.	O
Little	O
difference	O
was	O
observed	O
in	O
their	O
transforming	O
efficiency	O
(	O
0	O
.	O
2	O
-	O
0	O
.	O
3	O
transformants	B-Anatomy
/	O
micrograms	O
DNA	O
)	O
between	O
the	O
combinations	O
of	O
oncogenes	O
applied	O
but	O
a	O
tendency	O
was	O
noted	O
that	O
cells	B-Anatomy
transfected	O
with	O
ras	O
or	O
src	O
in	O
combination	O
with	O
myc	O
developed	O
the	O
capacity	O
to	O
grow	O
for	O
a	O
longer	O
period	O
and	O
differentiated	O
at	O
a	O
later	O
stage	O
than	O
those	O
transfected	O
solely	O
with	O
ras	O
or	O
src	O
.	O
One	O
cell	B-Anatomy
line	I-Anatomy
(	O
ESM	B-Anatomy
-	I-Anatomy
1	I-Anatomy
)	O
derived	O
from	O
the	O
erythrophores	B-Anatomy
transfected	O
with	O
src	O
/	O
myc	O
grew	O
successively	O
over	O
nine	O
months	O
,	O
indicating	O
its	O
acquisition	O
of	O
immortality	O
.	O
The	O
expression	O
of	O
the	O
transfected	O
oncogenes	O
in	O
this	O
cell	B-Anatomy
line	I-Anatomy
was	O
examined	O
in	O
comparison	O
with	O
the	O
erythrophoroma	B-Anatomy
cells	I-Anatomy
by	O
Western	O
and	O
Northern	O
blot	O
analyses	O
.	O
Immune	O
consequences	O
of	O
burn	O
injury	O
.	O
The	O
purpose	O
of	O
the	O
immune	B-Anatomy
system	I-Anatomy
is	O
to	O
protect	O
cells	B-Anatomy
from	O
invasion	O
by	O
microorganisms	O
.	O
The	O
body	B-Anatomy
has	O
three	O
equally	O
important	O
interactive	O
immune	B-Anatomy
defense	I-Anatomy
systems	I-Anatomy
,	O
all	O
of	O
which	O
are	O
profoundly	O
disrupted	O
with	O
major	O
burn	O
injury	O
.	O
The	O
immune	O
response	O
to	O
burn	O
injury	O
is	O
immediate	O
,	O
prolonged	O
,	O
and	O
severe	O
.	O
The	O
end	O
result	O
in	O
individuals	O
surviving	O
burn	O
shock	O
is	O
immunosuppression	O
,	O
with	O
increased	O
susceptibility	O
to	O
potentially	O
fatal	O
systemic	O
burn	B-Anatomy
wound	I-Anatomy
or	O
pulmonary	B-Anatomy
sepsis	O
.	O
Nursing	O
actions	O
to	O
support	O
the	O
humoral	O
and	O
cell	B-Anatomy
-	O
mediated	O
immune	B-Anatomy
system	I-Anatomy
of	O
the	O
burned	O
patient	O
include	O
providing	O
nutritional	O
support	O
to	O
maintain	O
serum	B-Anatomy
protein	O
levels	O
at	O
optimal	O
levels	O
;	O
measures	O
to	O
decrease	O
edema	B-Anatomy
and	O
promote	O
angiogenesis	O
in	O
areas	O
of	O
partial	O
-	O
thickness	O
injury	O
;	O
meticulous	O
treatment	O
of	O
the	O
wound	B-Anatomy
to	O
prevent	O
infection	O
and	O
promote	O
healing	O
;	O
monitoring	O
of	O
antibiotic	O
use	O
;	O
conservative	O
use	O
of	O
invasive	O
techniques	O
,	O
including	O
intubation	O
and	O
vascular	B-Anatomy
access	O
devices	O
;	O
maintenance	O
of	O
fluid	B-Anatomy
and	O
electrolyte	O
balance	O
and	O
body	B-Anatomy
temperature	O
;	O
and	O
energy	O
conservation	O
measures	O
.	O
Autocrine	O
angiogenic	O
vascular	B-Anatomy
prosthesis	O
with	O
bone	B-Anatomy
marrow	I-Anatomy
transplantation	O
.	O
Synthetic	O
vascular	B-Anatomy
prostheses	O
are	O
foreign	O
bodies	O
,	O
so	O
that	O
blood	B-Anatomy
coagulation	O
can	O
occur	O
on	O
their	O
luminal	B-Anatomy
surfaces	I-Anatomy
,	O
causing	O
graft	B-Anatomy
occlusion	O
very	O
frequently	O
in	O
prostheses	O
of	O
small	O
diameter	O
.	O
A	O
vascular	B-Anatomy
prosthesis	O
needs	O
angiogenesis	O
for	O
endothelialization	O
of	O
the	O
luminal	B-Anatomy
surface	I-Anatomy
,	O
as	O
endothelial	B-Anatomy
cells	I-Anatomy
have	O
natural	O
and	O
permanent	O
antithrombogenic	O
properties	O
.	O
To	O
induce	O
capillary	B-Anatomy
growth	O
into	O
the	O
graft	B-Anatomy
,	O
we	O
developed	O
a	O
method	O
of	O
transplanting	O
bone	B-Anatomy
marrow	I-Anatomy
cells	I-Anatomy
,	O
which	O
are	O
primitive	O
,	O
strong	O
enough	O
to	O
survive	O
,	O
and	O
create	O
blood	B-Anatomy
cells	I-Anatomy
,	O
resulting	O
in	O
the	O
inducement	O
of	O
capillary	B-Anatomy
growth	O
.	O
In	O
an	O
animal	O
experiment	O
,	O
marrow	B-Anatomy
cells	I-Anatomy
were	O
infiltrated	O
into	O
the	O
walls	O
of	O
long	O
-	O
fibril	O
expanded	O
polytetrafluoroethylene	O
(	O
ePTFE	O
)	O
vascular	B-Anatomy
grafts	I-Anatomy
.	O
The	O
grafts	B-Anatomy
were	O
implanted	O
in	O
the	O
abdominal	B-Anatomy
aortic	I-Anatomy
position	O
of	O
24	O
dogs	O
autologously	O
.	O
Marrow	B-Anatomy
cells	I-Anatomy
survived	O
and	O
continued	O
exogenous	O
hemopoiesis	O
for	O
up	O
to	O
six	O
months	O
and	O
were	O
immunohistochemically	O
reactive	O
to	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
.	O
All	O
the	O
grafts	B-Anatomy
older	O
than	O
three	O
weeks	O
had	O
complete	O
endothelialization	O
and	O
maintained	O
their	O
patency	O
.	O
Twenty	O
grafts	B-Anatomy
without	O
bone	B-Anatomy
marrow	I-Anatomy
were	O
implanted	O
as	O
controls	O
.	O
Endothelialization	O
was	O
present	O
at	O
anastomotic	B-Anatomy
sites	I-Anatomy
,	O
but	O
other	O
areas	O
were	O
covered	O
with	O
fresh	O
thrombi	B-Anatomy
.	O
Four	O
out	O
of	O
seven	O
control	O
grafts	B-Anatomy
were	O
patent	O
with	O
endothelial	B-Anatomy
cell	I-Anatomy
lining	O
at	O
six	O
months	O
,	O
but	O
three	O
were	O
occluded	O
and	O
one	O
of	O
the	O
four	O
grafts	B-Anatomy
was	O
still	O
covered	O
with	O
a	O
thrombus	B-Anatomy
layer	I-Anatomy
.	O
Bone	B-Anatomy
marrow	I-Anatomy
with	O
its	O
unique	O
native	O
properties	O
produced	O
autocrine	O
angiogenicity	O
in	O
the	O
graft	B-Anatomy
.	O
Application	O
of	O
clonal	O
analysis	O
.	O
Differential	O
diagnosis	O
for	O
synchronous	O
primary	B-Anatomy
ovarian	I-Anatomy
and	O
endometrial	B-Anatomy
cancers	I-Anatomy
and	O
metastatic	B-Anatomy
cancer	I-Anatomy
.	O
Simultaneous	O
involvement	O
of	O
the	O
endometrium	B-Anatomy
and	O
the	O
ovary	B-Anatomy
by	O
carcinoma	B-Anatomy
is	O
a	O
familiar	O
problem	O
in	O
the	O
routine	O
practice	O
of	O
surgical	O
pathology	O
.	O
Such	O
cases	O
may	O
be	O
considered	O
either	O
examples	O
of	O
a	O
single	O
primary	B-Anatomy
carcinoma	I-Anatomy
with	O
metastasis	O
or	O
as	O
synchronous	B-Anatomy
primary	I-Anatomy
neoplasms	I-Anatomy
.	O
The	O
distinction	O
between	O
these	O
two	O
possibilities	O
is	O
made	O
based	O
on	O
clinicopathologic	O
observations	O
,	O
and	O
therefore	O
may	O
not	O
be	O
definitive	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
authors	O
used	O
molecular	O
techniques	O
to	O
analyze	O
the	O
clonal	O
composition	O
of	O
five	O
cases	O
of	O
concurrent	O
adenocarcinomas	B-Anatomy
of	O
the	O
endometrium	B-Anatomy
and	O
ovary	B-Anatomy
that	O
were	O
clinicopathologically	O
diagnosed	O
as	O
synchronous	B-Anatomy
primary	I-Anatomy
tumors	I-Anatomy
.	O
Patterns	O
of	O
X	B-Anatomy
-	I-Anatomy
chromosome	I-Anatomy
inactivation	O
,	O
mutations	O
in	O
the	O
K	O
-	O
ras	O
gene	O
,	O
mutations	O
or	O
allelic	O
loss	O
of	O
the	O
p53	O
gene	O
,	O
or	O
human	O
papillomavirus	O
detection	O
were	O
identical	O
in	O
both	O
endometrial	B-Anatomy
and	O
ovarian	B-Anatomy
lesions	I-Anatomy
in	O
three	O
of	O
the	O
cases	O
suggesting	O
that	O
those	O
three	O
cases	O
represented	O
single	O
primary	B-Anatomy
tumors	I-Anatomy
with	O
metastases	B-Anatomy
.	O
In	O
both	O
of	O
the	O
other	O
two	O
cases	O
,	O
the	O
patterns	O
of	O
X	B-Anatomy
-	I-Anatomy
chromosome	I-Anatomy
inactivation	O
clearly	O
demonstrated	O
the	O
presence	O
of	O
independent	O
primary	B-Anatomy
tumors	I-Anatomy
.	O
The	O
application	O
of	O
molecular	O
technology	O
may	O
play	O
an	O
important	O
role	O
for	O
the	O
differential	O
diagnosis	O
between	O
synchronous	B-Anatomy
primary	I-Anatomy
carcinomas	I-Anatomy
and	O
a	O
single	O
carcinoma	B-Anatomy
with	O
metastasis	B-Anatomy
.	O
Molecular	O
biology	O
of	O
cervical	B-Anatomy
cancer	I-Anatomy
and	O
its	O
precursors	B-Anatomy
.	O
Cervical	B-Anatomy
cancer	I-Anatomy
develops	O
from	O
well	O
-	O
defined	O
precursor	B-Anatomy
lesions	I-Anatomy
referred	O
to	O
as	O
either	O
cervical	B-Anatomy
intraepithelial	I-Anatomy
neoplasia	I-Anatomy
or	O
squamous	B-Anatomy
intraepithelial	I-Anatomy
lesions	I-Anatomy
.	O
It	O
is	O
now	O
known	O
that	O
specific	O
types	O
of	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
are	O
the	O
principal	O
etiologic	O
agents	O
for	O
both	O
cervical	B-Anatomy
cancer	I-Anatomy
and	O
its	O
precursors	B-Anatomy
.	O
The	O
high	O
-	O
oncogenic	O
-	O
risk	O
HPV	O
types	O
associated	O
with	O
invasive	B-Anatomy
cervical	I-Anatomy
cancer	I-Anatomy
produce	O
two	O
oncoproteins	O
,	O
designated	O
E6	O
and	O
E7	O
,	O
which	O
interact	O
with	O
endogenous	O
cell	B-Anatomy
cycle	O
regulatory	O
proteins	O
,	O
including	O
p53	O
and	O
Rb	O
.	O
The	O
interaction	O
of	O
virally	O
derived	O
and	O
endogenous	O
cellular	B-Anatomy
proteins	O
converges	O
in	O
deregulation	O
of	O
cell	B-Anatomy
cycle	O
progression	O
and	O
appears	O
to	O
be	O
critical	O
for	O
the	O
development	O
of	O
cervical	B-Anatomy
cancers	I-Anatomy
.	O
However	O
,	O
the	O
development	O
of	O
cervical	B-Anatomy
cancer	I-Anatomy
is	O
a	O
multistep	O
process	O
that	O
cannot	O
be	O
explained	O
simply	O
by	O
infection	O
with	O
specific	O
types	O
of	O
HPV	O
.	O
One	O
additional	O
event	O
that	O
appears	O
to	O
play	O
a	O
role	O
in	O
tumor	B-Anatomy
progression	O
is	O
integration	O
of	O
HPV	O
DNA	O
into	O
the	O
host	O
genome	O
.	O
Integration	O
of	O
HPV	O
DNA	O
frequently	O
disrupts	O
the	O
E2	O
open	O
reading	O
frames	O
,	O
resulting	O
in	O
overexpression	O
of	O
the	O
E6	O
and	O
E7	O
oncoproteins	O
and	O
possibly	O
causing	O
genomic	O
instability	O
.	O
Additional	O
cofactors	O
and	O
mutational	O
events	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
invasive	B-Anatomy
cervical	I-Anatomy
cancers	I-Anatomy
and	O
may	O
include	O
chromosomal	B-Anatomy
rearrangements	O
,	O
loss	O
of	O
constitutional	O
heterozygosity	O
,	O
and	O
proto	O
-	O
oncogene	O
activation	O
.	O
The	O
effects	O
of	O
radiation	O
on	O
neovascularization	O
in	O
a	O
rat	O
model	O
.	O
It	O
is	O
thought	O
that	O
radiation	O
treatment	O
inhibits	O
neovascularization	O
of	O
recipient	O
and	O
/	O
or	O
graft	B-Anatomy
tissues	I-Anatomy
,	O
and	O
this	O
may	O
account	O
in	O
part	O
for	O
abnormalities	O
in	O
wound	B-Anatomy
healing	O
associated	O
with	O
radiation	O
therapy	O
.	O
We	O
have	O
examined	O
this	O
hypothesis	O
using	O
a	O
model	O
that	O
measures	O
the	O
neovascularization	O
of	O
an	O
implanted	O
foreign	O
material	O
.	O
Expanded	O
polytetrafluoroethylene	O
(	O
PTFE	O
)	O
sheets	O
were	O
implanted	O
adjacent	O
to	O
both	O
superficial	O
epigastric	B-Anatomy
vascular	I-Anatomy
pedicles	I-Anatomy
of	O
63	O
rats	O
distributed	O
into	O
7	O
groups	O
(	O
n	O
=	O
7	O
)	O
that	O
differed	O
with	O
respect	O
to	O
dose	O
and	O
timing	O
of	O
irradiation	O
.	O
Zero	O
to	O
10	O
daily	O
fractions	O
of	O
electron	O
-	O
beam	O
radiation	O
(	O
300	O
cGy	O
each	O
)	O
were	O
delivered	O
to	O
the	O
implant	O
in	O
the	O
right	B-Anatomy
groin	I-Anatomy
,	O
while	O
the	O
implant	O
in	O
the	O
left	B-Anatomy
groin	I-Anatomy
served	O
as	O
a	O
nonirradiated	O
internal	O
control	O
.	O
Unirradiated	O
animals	O
showed	O
equal	O
neovascularization	O
of	O
both	O
implants	O
.	O
Rats	O
that	O
were	O
irradiated	O
twice	O
(	O
single	O
fractions	O
at	O
0	O
and	O
24	O
hours	O
after	O
implantation	O
)	O
did	O
not	O
show	O
a	O
significant	O
decrease	O
in	O
the	O
neovascularization	O
of	O
the	O
irradiated	O
implant	O
compared	O
with	O
the	O
contralateral	O
control	O
implant	O
.	O
In	O
contrast	O
,	O
the	O
implants	O
that	O
were	O
irradiated	O
three	O
times	O
(	O
single	O
fractions	O
at	O
0	O
,	O
24	O
,	O
and	O
48	O
hours	O
after	O
implantation	O
)	O
demonstrated	O
significantly	O
diminished	O
(	O
greater	O
than	O
25	O
percent	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
neovascularization	O
beyond	O
day	O
7	O
,	O
whereas	O
implants	O
irradiated	O
only	O
at	O
48	O
hours	O
after	O
implantation	O
did	O
not	O
.	O
Interestingly	O
,	O
neovascularization	O
of	O
the	O
implants	O
irradiated	O
with	O
10	O
fractions	O
(	O
3000	O
cGy	O
)	O
was	O
not	O
significantly	O
decreased	O
compared	O
with	O
irradiation	O
with	O
three	O
fractions	O
(	O
900	O
cGy	O
)	O
.	O
Irradiation	O
delivered	O
before	O
implantation	O
(	O
900	O
cGy	O
)	O
inhibited	O
neovascularization	O
significantly	O
less	O
than	O
the	O
same	O
dose	O
administered	O
after	O
implantation	O
.	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
a	O
subclinical	O
cumulative	O
dose	O
of	O
900	O
cGy	O
is	O
the	O
threshold	O
for	O
impaired	O
tissue	B-Anatomy
revascularization	O
provided	O
that	O
treatment	O
is	O
delivered	O
immediately	O
after	O
implantation	O
over	O
a	O
48	O
-	O
hour	O
interval	O
.	O
Prognostic	O
value	O
of	O
angiogenesis	O
in	O
operable	O
non	B-Anatomy
-	I-Anatomy
small	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
cancer	I-Anatomy
.	O
Tumour	B-Anatomy
angiogenesis	O
is	O
an	O
important	O
factor	O
for	O
tumour	B-Anatomy
growth	O
and	O
metastasis	O
.	O
Although	O
some	O
recent	O
reports	O
suggest	O
that	O
microvessel	B-Anatomy
counts	O
in	O
non	B-Anatomy
-	I-Anatomy
small	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
cancer	I-Anatomy
are	O
related	O
to	O
a	O
poor	O
disease	O
outcome	O
,	O
the	O
results	O
were	O
not	O
conclusive	O
and	O
were	O
not	O
compared	O
with	O
other	O
molecular	O
prognostic	O
markers	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
vascular	B-Anatomy
grade	O
was	O
assessed	O
in	O
107	O
(	O
T1	O
,	O
2	O
-	O
N0	O
,	O
1	O
)	O
operable	O
non	B-Anatomy
-	I-Anatomy
small	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
carcinomas	I-Anatomy
,	O
using	O
the	O
JC70	O
monoclonal	O
antibody	O
to	O
CD31	O
.	O
Three	O
vascular	B-Anatomy
grades	O
were	O
defined	O
with	O
appraisal	O
by	O
eye	B-Anatomy
and	O
by	O
Chalkley	O
counting	O
:	O
high	O
(	O
Chalkley	O
score	O
7	O
-	O
12	O
)	O
,	O
medium	O
(	O
5	O
-	O
6	O
)	O
,	O
and	O
low	O
(	O
2	O
-	O
4	O
)	O
.	O
There	O
was	O
a	O
significant	O
correlation	O
between	O
eye	B-Anatomy
appraisal	O
and	O
Chalkley	O
counting	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O
Vascular	B-Anatomy
grade	O
was	O
not	O
related	O
to	O
histology	O
,	O
grade	O
,	O
proliferation	O
index	O
(	O
Ki67	O
)	O
,	O
or	O
EGFR	O
or	O
p53	O
expression	O
.	O
Tumours	B-Anatomy
from	O
younger	O
patients	O
had	O
a	O
higher	O
grade	O
of	O
angiogenesis	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O
Apart	O
from	O
the	O
vascular	B-Anatomy
grade	O
,	O
none	O
of	O
the	O
other	O
factors	O
examined	O
was	O
statistically	O
related	O
to	O
lymph	B-Anatomy
node	I-Anatomy
metastasis	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O
A	O
univariate	O
analysis	O
of	O
survival	O
showed	O
that	O
vascular	B-Anatomy
grade	O
was	O
the	O
most	O
significant	O
prognostic	O
factor	O
(	O
P	O
=	O
0	O
.	O
0004	O
)	O
,	O
followed	O
by	O
N	O
-	O
stage	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O
In	O
a	O
multivariate	O
analysis	O
,	O
N	O
-	O
stage	O
and	O
vascular	B-Anatomy
grade	O
were	O
not	O
found	O
to	O
be	O
independent	O
prognostic	O
factors	O
,	O
since	O
they	O
were	O
strongly	O
related	O
to	O
each	O
other	O
.	O
Excluding	O
N	O
-	O
stage	O
,	O
vascular	B-Anatomy
grade	O
was	O
the	O
only	O
independent	O
prognostic	O
factor	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
.	O
Kaplan	O
-	O
Meier	O
survival	O
curves	O
showed	O
a	O
statistically	O
significant	O
worse	O
prognosis	O
for	O
patients	O
with	O
high	O
vascular	B-Anatomy
grade	O
,	O
but	O
no	O
difference	O
was	O
observed	O
between	O
low	O
and	O
medium	O
vascular	B-Anatomy
grade	O
.	O
These	O
data	O
suggest	O
that	O
angiogenesis	O
in	O
operable	O
non	B-Anatomy
-	I-Anatomy
small	I-Anatomy
cell	I-Anatomy
lung	I-Anatomy
cancer	I-Anatomy
is	O
a	O
major	O
prognostic	O
factor	O
for	O
survival	O
and	O
,	O
among	O
the	O
parameters	O
tested	O
,	O
is	O
the	O
only	O
factor	O
related	O
to	O
cancer	B-Anatomy
cell	I-Anatomy
migration	O
to	O
lymph	B-Anatomy
nodes	I-Anatomy
.	O
The	O
integration	O
of	O
vascular	B-Anatomy
grading	O
in	O
clinical	O
trials	O
on	O
adjuvant	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
could	O
substantially	O
contribute	O
in	O
defining	O
groups	O
of	O
operable	O
patients	O
who	O
might	O
benefit	O
from	O
cytotoxic	O
treatment	O
.	O
Vitamin	O
E	O
inhibits	O
experimental	O
carcinogenesis	O
and	O
tumour	B-Anatomy
angiogenesis	O
.	O
In	O
an	O
experiment	O
in	O
which	O
vitamin	O
E	O
inhibited	O
carcinogenesis	O
,	O
it	O
was	O
found	O
that	O
tumour	B-Anatomy
angiogenesis	O
and	O
tumour	O
growth	O
-	O
factor	O
alpha	O
(	O
TGF	O
alpha	O
)	O
expression	O
were	O
also	O
inhibited	O
.	O
Forty	O
male	O
golden	O
hamsters	O
were	O
divided	O
into	O
four	O
equal	O
groups	O
.	O
Group	O
1	O
animals	O
had	O
the	O
left	B-Anatomy
buccal	I-Anatomy
pouches	I-Anatomy
painted	O
three	O
times	O
weekly	O
with	O
7	O
,	O
12	O
-	O
dimethylbenz	O
(	O
a	O
)	O
anthracene	O
(	O
DMBA	O
)	O
for	O
14	O
weeks	O
.	O
Group	O
2	O
animals	O
had	O
the	O
same	O
procedure	O
of	O
DMBA	O
applications	O
but	O
also	O
received	O
alpha	O
tocopherol	O
.	O
Groups	O
3	O
and	O
4	O
were	O
vitamin	O
E	O
and	O
untreated	O
controls	O
.	O
Angiogenesis	O
was	O
studied	O
with	O
factor	O
8	O
-	O
related	O
antigen	O
(	O
F8	O
-	O
RA	O
)	O
which	O
identifies	O
endothelial	B-Anatomy
cells	I-Anatomy
.	O
TGF	O
alpha	O
was	O
studied	O
with	O
the	O
appropriate	O
antibody	O
.	O
Staining	O
was	O
effected	O
by	O
the	O
standard	O
avidin	O
-	O
biotin	O
horseradish	O
peroxidase	O
system	O
.	O
Mean	O
tumour	B-Anatomy
volume	O
was	O
significantly	O
lower	O
in	O
the	O
DMBA	O
-	O
vitamin	O
E	O
group	O
compared	O
to	O
the	O
tumour	B-Anatomy
control	O
group	O
.	O
Angiogenesis	O
was	O
significantly	O
inhibited	O
in	O
the	O
DMBA	O
-	O
vitamin	O
E	O
group	O
and	O
TGF	O
alpha	O
expression	O
was	O
also	O
inhibited	O
.	O
It	O
is	O
suggested	O
that	O
inhibition	O
of	O
tumour	B-Anatomy
angiogenesis	O
by	O
vitamin	O
E	O
may	O
be	O
an	O
additional	O
mechanism	O
for	O
the	O
anticancer	B-Anatomy
action	O
of	O
vitamin	O
E	O
.	O
Curcumin	O
induces	O
apoptosis	O
in	O
immortalized	O
NIH	B-Anatomy
3T3	I-Anatomy
and	O
malignant	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
lines	I-Anatomy
.	O
Curcumin	O
,	O
which	O
is	O
a	O
widely	O
used	O
dietary	O
pigment	O
and	O
spice	O
,	O
has	O
been	O
demonstrated	O
to	O
be	O
an	O
effective	O
inhibitor	O
of	O
tumor	B-Anatomy
promotion	O
in	O
mouse	O
skin	B-Anatomy
carcinogenesis	O
.	O
We	O
report	O
that	O
curcumin	O
induces	O
cell	B-Anatomy
shrinkage	O
,	O
chromatin	B-Anatomy
condensation	O
,	O
and	O
DNA	O
fragmentation	O
,	O
characteristics	O
of	O
apoptosis	O
,	O
in	O
immortalized	O
mouse	O
embryo	B-Anatomy
fibroblast	I-Anatomy
NIH	I-Anatomy
3T3	I-Anatomy
erb	O
B2	O
oncogene	O
-	O
transformed	O
NIH	B-Anatomy
3T3	I-Anatomy
,	O
mouse	O
sarcoma	B-Anatomy
S180	I-Anatomy
,	O
human	O
colon	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
HT	I-Anatomy
-	I-Anatomy
29	I-Anatomy
,	O
human	O
kidney	B-Anatomy
cancer	I-Anatomy
cell	I-Anatomy
293	I-Anatomy
,	O
and	O
human	O
hepatocellular	B-Anatomy
carcinoma	I-Anatomy
Hep	I-Anatomy
G2	I-Anatomy
cells	I-Anatomy
,	O
but	O
not	O
in	O
primary	O
culture	B-Anatomy
of	O
mouse	O
embryonic	B-Anatomy
fibroblast	I-Anatomy
C3H	I-Anatomy
10T1	I-Anatomy
/	I-Anatomy
2	I-Anatomy
,	O
rat	O
embryonic	B-Anatomy
fibroblast	I-Anatomy
,	O
and	O
human	O
foreskin	B-Anatomy
fibroblast	I-Anatomy
cells	I-Anatomy
in	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O
Many	O
cellular	B-Anatomy
and	O
biochemical	O
effects	O
of	O
curcumin	O
in	O
mouse	O
fibroblast	B-Anatomy
cells	I-Anatomy
have	O
been	O
reported	O
,	O
such	O
as	O
inhibition	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activity	O
induced	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
treatment	O
,	O
inhibition	O
of	O
tyrosine	O
protein	O
kinase	O
activity	O
,	O
and	O
inhibition	O
of	O
arachidonic	O
acid	O
(	O
AA	O
)	O
metabolism	O
.	O
Treatment	O
of	O
NIH	B-Anatomy
3T3	I-Anatomy
cells	I-Anatomy
with	O
the	O
PKC	O
inhibitor	O
staurosporine	O
,	O
the	O
tyrosine	O
kinase	O
inhibitor	O
herbimycin	O
A	O
,	O
and	O
the	O
AA	O
metabolism	O
inhibitor	O
quinacrine	O
induces	O
apoptotic	O
cell	B-Anatomy
death	O
.	O
These	O
results	O
suggest	O
that	O
,	O
in	O
some	O
immortalized	O
and	O
transformed	O
cells	B-Anatomy
,	O
blocking	O
the	O
cellular	B-Anatomy
signal	O
transduction	O
might	O
trigger	O
the	O
induction	O
of	O
apoptosis	O
.	O
Do	O
we	O
know	O
how	O
much	O
people	O
like	O
one	O
another	O
?	O
Metaperception	O
is	O
a	O
person	O
'	O
s	O
perception	O
about	O
a	O
second	O
person	O
'	O
s	O
perception	O
of	O
a	O
third	O
person	O
.	O
The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
examine	O
the	O
accuracy	O
of	O
metaperceptions	O
of	O
liking	O
.	O
A	O
related	O
question	O
concerns	O
whether	O
the	O
heuristics	O
of	O
balance	O
,	O
reciprocity	O
,	O
and	O
agreement	O
are	O
used	O
by	O
perceivers	O
when	O
forming	O
such	O
judgments	O
.	O
The	O
authors	O
present	O
analyses	O
from	O
5	O
diverse	O
research	O
studies	O
that	O
used	O
an	O
adaptation	O
of	O
the	O
social	O
relations	O
model	O
for	O
triads	O
(	O
C	O
.	O
F	O
.	O
Bond	O
,	O
E	O
.	O
M	O
.	O
Horn	O
,	O
&	O
D	O
.	O
A	O
.	O
Kenny	O
,	O
in	O
press	O
)	O
.	O
The	O
results	O
indicate	O
that	O
people	O
know	O
how	O
much	O
people	O
like	O
one	O
another	O
,	O
even	O
with	O
small	O
amounts	O
of	O
information	O
.	O
Although	O
there	O
is	O
evidence	O
for	O
the	O
use	O
of	O
heuristics	O
,	O
particularly	O
reciprocity	O
and	O
agreement	O
,	O
accuracy	O
is	O
sometimes	O
enhanced	O
by	O
using	O
these	O
heuristics	O
.	O
Genetic	O
heterogeneity	O
evidenced	O
by	O
low	O
incidence	O
of	O
KAL	O
-	O
1	O
gene	O
mutations	O
in	O
sporadic	O
cases	O
of	O
gonadotropin	O
-	O
releasing	O
hormone	O
deficiency	O
.	O
Isolated	O
GnRH	O
deficiency	O
is	O
a	O
heritable	O
condition	O
characterized	O
by	O
a	O
functional	O
deficit	O
in	O
GnRH	O
secretion	O
.	O
Familial	O
cases	O
with	O
different	O
modes	O
of	O
inheritance	O
have	O
been	O
described	O
,	O
and	O
the	O
gene	O
responsible	O
for	O
the	O
X	O
-	O
linked	O
form	O
(	O
KAL	O
-	O
1	O
)	O
has	O
been	O
identified	O
.	O
However	O
,	O
sporadic	O
cases	O
with	O
no	O
documented	O
family	O
history	O
of	O
GnRH	O
deficiency	O
account	O
for	O
the	O
majority	O
of	O
the	O
affected	O
patients	O
.	O
For	O
this	O
reason	O
,	O
we	O
sought	O
to	O
determine	O
the	O
frequency	O
with	O
which	O
KAL	O
-	O
1	O
gene	O
mutations	O
occur	O
in	O
patients	O
with	O
sporadic	O
GnRH	O
deficiency	O
.	O
Only	O
1	O
of	O
21	O
patients	O
with	O
sporadic	O
GnRH	O
deficiency	O
was	O
found	O
to	O
bear	O
a	O
defect	O
in	O
the	O
KAL	O
-	O
1	O
gene	O
(	O
a	O
deletion	O
of	O
14	O
bases	O
starting	O
at	O
codon	O
464	O
)	O
.	O
Three	O
types	O
of	O
polymorphic	O
single	O
base	O
substitutions	O
with	O
no	O
apparent	O
correlation	O
with	O
GnRH	O
deficiency	O
were	O
also	O
detected	O
in	O
several	O
patients	O
.	O
In	O
each	O
of	O
3	O
different	O
patients	O
with	O
an	O
X	O
-	O
linked	O
mode	O
of	O
inheritance	O
,	O
3	O
genetic	O
defects	O
,	O
2	O
point	O
mutations	O
and	O
a	O
small	O
intragenic	O
deletion	O
,	O
were	O
detected	O
.	O
These	O
defects	O
consist	O
of	O
a	O
single	O
base	O
mutation	O
introducing	O
a	O
stop	O
codon	O
at	O
position	O
328	O
,	O
a	O
single	O
base	O
mutation	O
resulting	O
in	O
a	O
phenylalanine	O
to	O
leucine	O
substitution	O
at	O
position	O
517	O
,	O
and	O
a	O
9	O
-	O
base	O
deletion	O
at	O
the	O
3	O
'	O
-	O
exon	O
-	O
intron	O
splice	O
site	O
of	O
exon	O
8	O
,	O
respectively	O
.	O
All	O
identified	O
genetic	O
defects	O
occur	O
within	O
the	O
fibronectin	O
type	O
III	O
repeats	O
of	O
the	O
predicted	O
protein	O
encoded	O
by	O
the	O
KAL	O
-	O
1	O
gene	O
.	O
In	O
conclusion	O
,	O
our	O
study	O
indicates	O
that	O
the	O
incidence	O
of	O
genetic	O
defects	O
within	O
the	O
coding	O
region	O
of	O
the	O
KAL	O
-	O
1	O
gene	O
in	O
patients	O
with	O
sporadic	O
GnRH	O
deficiency	O
is	O
low	O
(	O
5	O
-	O
8	O
%	O
)	O
,	O
thus	O
supporting	O
the	O
idea	O
that	O
the	O
X	O
-	O
linked	O
form	O
of	O
inheritance	O
represents	O
the	O
least	O
common	O
form	O
of	O
the	O
disease	O
.	O
The	O
effect	O
of	O
early	O
diagnosis	O
and	O
treatment	O
in	O
cystic	O
fibrosis	O
:	O
a	O
seven	O
-	O
year	O
study	O
of	O
16	O
sibling	O
pairs	O
.	O
Data	O
on	O
16	O
sibling	O
pairs	O
with	O
cystic	O
fibrosis	O
were	O
analyzed	O
to	O
test	O
the	O
hypothesis	O
that	O
early	O
treatment	O
of	O
this	O
condition	O
improves	O
prognosis	O
.	O
Younger	O
siblings	O
'	O
conditions	O
were	O
diagnosed	O
before	O
1	O
year	O
of	O
age	O
,	O
usually	O
before	O
the	O
onset	O
of	O
pulmonary	B-Anatomy
disease	O
.	O
Older	O
siblings	O
'	O
conditions	O
were	O
diagnosed	O
after	O
1	O
year	O
of	O
age	O
and	O
after	O
the	O
onset	O
of	O
pulmonary	B-Anatomy
disease	O
.	O
Although	O
the	O
sibling	O
pairs	O
received	O
similar	O
treatment	O
,	O
comparison	O
at	O
7	O
years	O
of	O
age	O
showed	O
that	O
the	O
younger	O
siblings	O
had	O
significantly	O
better	O
chest	B-Anatomy
roentgenogram	O
scores	O
,	O
total	O
clinical	O
scores	O
,	O
residual	O
lung	B-Anatomy
volumes	O
,	O
and	O
ratios	O
of	O
residual	O
volume	O
to	O
total	O
lung	B-Anatomy
volume	O
.	O
Younger	O
siblings	O
also	O
required	O
fewer	O
hospital	O
admissions	O
to	O
control	O
their	O
lung	B-Anatomy
disease	O
.	O
The	O
results	O
suggest	O
that	O
,	O
in	O
general	O
,	O
early	O
initiation	O
of	O
therapy	O
is	O
beneficial	O
for	O
patients	O
with	O
cystic	O
fibrosis	O
.	O
Fas	O
-	O
signaling	O
and	O
effects	O
on	O
receptor	O
tyrosine	O
kinase	O
signal	O
transduction	O
in	O
human	O
breast	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
.	O
Fas	O
-	O
mediated	O
cell	B-Anatomy
death	O
was	O
examined	O
in	O
MCF	B-Anatomy
-	I-Anatomy
10AT	I-Anatomy
preneoplastic	I-Anatomy
human	I-Anatomy
breast	I-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
.	O
Treatment	O
with	O
anti	O
-	O
Fas	O
for	O
48	O
h	O
induced	O
apoptosis	O
with	O
cells	B-Anatomy
exhibiting	O
typical	O
apoptotic	O
features	O
including	O
loss	O
of	O
cell	B-Anatomy
contact	O
,	O
condensation	O
of	O
chromatin	B-Anatomy
,	O
and	O
increased	O
staining	O
of	O
the	O
nuclear	B-Anatomy
membrane	I-Anatomy
.	O
DNA	O
fragmentation	O
occurred	O
in	O
response	O
to	O
anti	O
-	O
Fas	O
treatment	O
.	O
Anti	O
-	O
Fas	O
treatment	O
resulted	O
in	O
decreased	O
p53	O
protein	O
levels	O
,	O
while	O
bcl	O
-	O
2	O
and	O
bax	O
protein	O
levels	O
remained	O
unaffected	O
.	O
Cells	B-Anatomy
treated	O
with	O
anti	O
-	O
Fas	O
also	O
exhibited	O
increased	O
tyrosine	O
phosphorylation	O
of	O
the	O
c	O
-	O
met	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
.	O
Immunoprecipitation	O
experiments	O
demonstrated	O
that	O
Fas	O
associated	O
with	O
c	O
-	O
erbB2	O
and	O
c	O
-	O
met	O
in	O
untreated	O
cells	B-Anatomy
.	O
Treatment	O
with	O
anti	O
-	O
Fas	O
,	O
however	O
,	O
significantly	O
decreased	O
Fas	O
-	O
c	O
-	O
erbB2	O
and	O
Fas	O
-	O
c	O
-	O
met	O
association	O
.	O
Anti	O
-	O
Fas	O
treatment	O
of	O
these	O
cells	B-Anatomy
caused	O
a	O
significant	O
decrease	O
in	O
p120	O
-	O
GAP	O
levels	O
,	O
ERK	O
-	O
1	O
levels	O
,	O
and	O
phosphorylation	O
,	O
as	O
well	O
as	O
Grb2	O
-	O
Sosl	O
and	O
MEK	O
-	O
1	O
-	O
ERK	O
-	O
1	O
association	O
.	O
These	O
results	O
show	O
that	O
Fas	O
-	O
signaling	O
exerted	O
a	O
suppressive	O
effect	O
on	O
p53	O
levels	O
and	O
on	O
downstream	O
effectors	O
of	O
receptor	O
tyrosine	O
kinase	O
signal	O
transduction	O
,	O
thereby	O
ensuring	O
cell	B-Anatomy
death	O
.	O
Prevention	O
of	O
hepatic	B-Anatomy
tumor	I-Anatomy
metastases	O
in	O
rats	O
with	O
herpes	O
viral	O
vaccines	O
and	O
gamma	O
-	O
interferon	O
.	O
Previous	O
studies	O
showed	O
that	O
gammaIFN	O
decreases	O
metastatic	B-Anatomy
hepatic	I-Anatomy
tumor	I-Anatomy
growth	O
by	O
stimulating	O
Kupffer	B-Anatomy
cells	I-Anatomy
(	O
KC	B-Anatomy
)	O
.	O
The	O
present	O
studies	O
examine	O
whether	O
lymphocyte	B-Anatomy
stimulation	O
via	O
cells	B-Anatomy
engineered	O
to	O
secrete	O
GM	O
-	O
CSF	O
or	O
IL	O
-	O
2	O
decreases	O
hepatic	B-Anatomy
tumor	I-Anatomy
growth	O
,	O
and	O
whether	O
stimulation	O
of	O
both	O
macrophages	B-Anatomy
and	O
lymphocytes	B-Anatomy
is	O
more	O
effective	O
than	O
either	O
individually	O
.	O
Rats	O
were	O
immunized	O
with	O
irradiated	O
hepatoma	B-Anatomy
cells	I-Anatomy
transduced	O
by	O
herpes	O
viral	O
amplicon	O
vectors	O
containing	O
the	O
genes	O
for	O
GM	O
-	O
CSF	O
,	O
IL	O
-	O
2	O
or	O
LacZ	O
.	O
On	O
day	O
18	O
,	O
half	O
of	O
each	O
group	O
was	O
treated	O
with	O
5	O
x	O
10	O
(	O
4	O
)	O
U	O
gammaIFN	O
,	O
or	O
saline	O
intraperitoneally	B-Anatomy
for	O
3	O
d	O
.	O
On	O
day	O
21	O
,	O
all	O
rats	O
received	O
5	O
x	O
10	O
(	O
5	O
)	O
hepatoma	B-Anatomy
cells	I-Anatomy
intrasplenically	B-Anatomy
.	O
On	O
day	O
41	O
,	O
rats	O
were	O
killed	O
and	O
tumor	B-Anatomy
nodules	I-Anatomy
were	O
counted	O
.	O
Separate	O
rats	O
underwent	O
splenocyte	B-Anatomy
and	O
KC	B-Anatomy
harvest	O
for	O
assessment	O
of	O
lymphocyte	B-Anatomy
-	O
and	O
macrophage	B-Anatomy
-	O
mediated	O
tumor	B-Anatomy
cell	I-Anatomy
kill	O
in	O
vitro	O
.	O
GM	O
-	O
CSF	O
or	O
IL	O
-	O
2	O
vaccines	O
or	O
gammaIFN	O
decreased	O
tumor	B-Anatomy
nodules	I-Anatomy
significantly	O
(	O
GM	O
-	O
CSF	O
13	O
+	O
/	O
-	O
4	O
,	O
IL	O
-	O
2	O
14	O
+	O
/	O
-	O
6	O
vs	O
.	O
control	O
75	O
+	O
/	O
-	O
24	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
Combination	O
therapy	O
was	O
more	O
effective	O
,	O
and	O
completely	O
eliminated	O
tumor	B-Anatomy
in	O
4	O
of	O
12	O
IFN	O
-	O
GM	O
-	O
CSF	O
and	O
8	O
of	O
11	O
IFN	O
-	O
IL	O
-	O
2	O
animals	O
.	O
Additional	O
rats	O
underwent	O
partial	O
hepatectomy	O
,	O
an	O
immunosuppressive	O
procedure	O
known	O
to	O
accelerate	O
the	O
growth	O
of	O
hepatic	B-Anatomy
tumor	I-Anatomy
,	O
following	O
tumor	B-Anatomy
challenge	O
.	O
Therapy	O
was	O
equally	O
effective	O
in	O
this	O
immunosuppressive	O
setting	O
.	O
Vaccination	O
is	O
associated	O
with	O
enhancement	O
of	O
splenocyte	B-Anatomy
-	O
mediated	O
tumoricidal	O
activity	O
,	O
whereas	O
the	O
effect	O
of	O
gammaIFN	O
is	O
mediated	O
by	O
KC	B-Anatomy
.	O
GM	O
-	O
CSF	O
and	O
IL	O
-	O
2	O
vaccine	O
therapy	O
and	O
pretreatment	O
with	O
gammaIFN	O
represent	O
effective	O
strategies	O
in	O
reducing	O
hepatic	B-Anatomy
tumor	I-Anatomy
.	O
Combination	O
therapy	O
targets	O
both	O
lymphocytes	B-Anatomy
and	O
macrophages	B-Anatomy
,	O
and	O
is	O
more	O
effective	O
in	O
reducing	O
tumor	B-Anatomy
than	O
either	O
therapy	O
alone	O
.	O
The	O
effects	O
of	O
oxidative	O
stress	O
on	O
in	O
vivo	O
brain	B-Anatomy
GSH	O
turnover	O
in	O
young	O
and	O
mature	O
mice	O
.	O
Glutathione	O
(	O
GSH	O
)	O
synthetase	O
activities	O
and	O
GSH	O
turnover	O
rates	O
were	O
examined	O
during	O
severe	O
oxidative	O
stress	O
in	O
the	O
mouse	O
brain	B-Anatomy
as	O
induced	O
by	O
t	O
-	O
butylhydroperoxide	O
(	O
t	O
-	O
BuOOH	O
)	O
.	O
Brain	B-Anatomy
GSH	O
synthetase	O
activities	O
in	O
8	O
-	O
mo	O
-	O
old	O
mice	O
in	O
the	O
cortex	B-Anatomy
,	O
striatum	B-Anatomy
,	O
thalamus	B-Anatomy
,	O
hippocampus	B-Anatomy
,	O
midbrain	B-Anatomy
,	O
and	O
cerebellum	B-Anatomy
were	O
found	O
to	O
increase	O
following	O
t	O
-	O
BuOOH	O
treatment	O
.	O
The	O
effect	O
of	O
GSH	O
synthesis	O
on	O
brain	B-Anatomy
GSH	O
turnover	O
rates	O
for	O
2	O
-	O
and	O
8	O
-	O
mo	O
-	O
old	O
mice	O
were	O
determined	O
after	O
intracerebroventricular	O
(	O
icv	O
)	O
injection	O
of	O
[	O
35S	O
]	O
cysteine	O
.	O
Rate	O
constants	O
for	O
GSH	O
turnover	O
were	O
determined	O
by	O
least	O
-	O
squares	O
iterative	O
minimization	O
from	O
the	O
specific	O
activity	O
data	O
from	O
20	O
min	O
to	O
108	O
h	O
after	O
[	O
35S	O
]	O
cysteine	O
administration	O
.	O
GSH	O
and	O
glutathione	O
disulfide	O
(	O
GSSG	O
)	O
specific	O
activities	O
were	O
determined	O
after	O
separation	O
by	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
.	O
The	O
half	O
-	O
life	O
of	O
GSH	O
in	O
the	O
2	O
-	O
mo	O
-	O
old	O
mouse	O
was	O
59	O
.	O
5	O
h	O
and	O
in	O
the	O
8	O
-	O
mo	O
-	O
old	O
mouse	O
was	O
79	O
.	O
1	O
h	O
.	O
In	O
summary	O
,	O
defense	O
mechanisms	O
against	O
oxidative	O
stress	O
in	O
the	O
brain	B-Anatomy
differ	O
with	O
age	O
.	O
Young	O
mice	O
can	O
increase	O
the	O
cellular	B-Anatomy
availability	O
of	O
GSH	O
,	O
whereas	O
mature	O
mice	O
can	O
increase	O
GSH	O
synthetase	O
activity	O
during	O
oxidative	O
stress	O
.	O
These	O
differences	O
make	O
mature	O
mice	O
more	O
susceptible	O
to	O
brain	B-Anatomy
oxidative	O
damage	O
.	O
Insulin	O
-	O
like	O
growth	O
factor	O
I	O
induces	O
tumor	B-Anatomy
hexokinase	O
RNA	O
expression	O
in	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
Increased	O
glycolysis	O
is	O
a	O
characteristic	O
of	O
cancer	B-Anatomy
cells	I-Anatomy
.	O
Though	O
less	O
efficient	O
in	O
energy	O
production	O
,	O
it	O
ensures	O
continuous	O
supply	O
of	O
energy	O
and	O
phosphometabolites	O
for	O
biosynthesis	O
enabling	O
metastatic	B-Anatomy
and	O
less	O
vascularized	B-Anatomy
cancer	I-Anatomy
cells	I-Anatomy
to	O
proliferate	O
even	O
under	O
hypoxic	O
conditions	O
.	O
Since	O
hexokinase	O
is	O
the	O
first	O
rate	O
limiting	O
enzyme	O
in	O
the	O
glycolytic	O
pathway	O
,	O
elevated	O
levels	O
of	O
Type	O
II	O
like	O
hexokinase	O
in	O
tumors	B-Anatomy
are	O
of	O
great	O
significance	O
in	O
this	O
context	O
.	O
Under	O
normal	O
conditions	O
insulin	O
regulates	O
expression	O
of	O
hexokinase	O
Type	O
II	O
isoenzyme	O
,	O
which	O
is	O
predominantly	O
expressed	O
in	O
muscle	B-Anatomy
.	O
On	O
the	O
other	O
hand	O
cancer	B-Anatomy
cells	I-Anatomy
overexpress	O
insulin	O
-	O
like	O
growth	O
factors	O
and	O
their	O
receptors	O
which	O
mimic	O
many	O
activities	O
of	O
insulin	O
.	O
This	O
prompted	O
us	O
to	O
examine	O
a	O
hypothesis	O
that	O
insulin	O
-	O
like	O
growth	O
factors	O
may	O
be	O
responsible	O
for	O
overexpression	O
of	O
tumor	B-Anatomy
hexokinase	O
.	O
Our	O
experiments	O
demonstrate	O
that	O
insulin	O
-	O
like	O
growth	O
factor	O
I	O
indeed	O
induces	O
hexokinase	O
gene	O
expression	O
in	O
a	O
concentration	O
and	O
time	O
dependent	O
manner	O
in	O
two	O
cancer	B-Anatomy
cell	I-Anatomy
lines	I-Anatomy
we	O
studied	O
.	O
Suppression	O
of	O
tumor	B-Anatomy
growth	O
by	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
mel	O
-	O
18	O
in	O
3Y1	B-Anatomy
cells	I-Anatomy
transformed	O
by	O
the	O
E6	O
and	O
E7	O
genes	O
of	O
human	O
papillomavirus	O
type	O
18	O
.	O
By	O
introducing	O
a	O
cDNA	O
library	O
derived	O
from	O
rat	O
embryonic	B-Anatomy
fibroblast	I-Anatomy
cells	I-Anatomy
,	O
we	O
isolated	O
several	O
morphologically	O
flat	O
revertants	B-Anatomy
of	O
rat	O
3Y1	B-Anatomy
cells	I-Anatomy
transformed	O
by	O
the	O
E6	O
and	O
E7	O
genes	O
of	O
human	O
papillomavirus	O
type	O
18	O
(	O
HPV18	O
)	O
.	O
From	O
one	O
of	O
the	O
revertants	B-Anatomy
,	O
we	O
recovered	O
a	O
0	O
.	O
2	O
-	O
kb	O
cDNA	O
,	O
N56	O
,	O
that	O
suppresses	O
the	O
tumor	B-Anatomy
growth	O
of	O
the	O
transformed	B-Anatomy
3Y1	I-Anatomy
cells	I-Anatomy
irrespective	O
of	O
the	O
expression	O
of	O
the	O
E6	O
and	O
E7	O
genes	O
.	O
The	O
nucleotide	O
sequence	O
of	O
the	O
cDNA	O
was	O
shown	O
to	O
be	O
identical	O
to	O
that	O
of	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
a	O
putative	O
mammalian	O
polycomb	O
group	O
gene	O
,	O
mel	O
-	O
18	O
.	O
Calretinin	O
.	O
A	O
selective	O
marker	O
of	O
normal	O
and	O
neoplastic	B-Anatomy
mesothelial	I-Anatomy
cells	I-Anatomy
in	O
serous	B-Anatomy
effusions	I-Anatomy
.	O
OBJECTIVE	O
:	O
To	O
document	O
that	O
a	O
polyclonal	O
antiserum	B-Anatomy
to	O
calretinin	O
,	O
a	O
29	O
-	O
kd	O
calcium	O
-	O
binding	O
protein	O
,	O
consistently	O
decorates	O
normal	O
and	O
tumor	B-Anatomy
mesothelial	I-Anatomy
cells	I-Anatomy
in	O
cytologic	B-Anatomy
preparations	I-Anatomy
.	O
STUDY	O
DESIGN	O
:	O
Thirty	O
-	O
three	O
archival	O
cytologic	B-Anatomy
specimens	I-Anatomy
from	O
eight	O
patients	O
with	O
histologically	O
confirmed	O
malignant	B-Anatomy
mesothelioma	I-Anatomy
and	O
13	O
from	O
patients	O
with	O
metastatic	B-Anatomy
serous	I-Anatomy
effusions	I-Anatomy
were	O
destained	O
and	O
then	O
immunostained	O
with	O
anticalretinin	O
antiserum	B-Anatomy
.	O
For	O
investigation	O
of	O
cell	B-Anatomy
suspensions	I-Anatomy
,	O
four	O
pleural	B-Anatomy
fluids	I-Anatomy
were	O
incubated	O
with	O
anticalretinin	O
antiserum	B-Anatomy
.	O
After	O
cytocentrifugation	O
the	O
specimens	B-Anatomy
were	O
stained	O
in	O
accordance	O
with	O
the	O
alkaline	O
phosphatase	O
anti	O
-	O
alkaline	O
phosphatase	O
(	O
APAAP	O
)	O
method	O
.	O
For	O
electron	O
microscopic	O
examination	O
the	O
cell	B-Anatomy
suspensions	I-Anatomy
were	O
then	O
incubated	O
with	O
gold	O
-	O
labeled	O
antirabbit	O
antibody	O
.	O
RESULTS	O
:	O
The	O
diagnostic	O
sensitivity	O
of	O
this	O
new	O
immunocytochemical	O
approach	O
reached	O
100	O
%	O
for	O
the	O
eight	O
malignant	B-Anatomy
mesotheliomas	I-Anatomy
investigated	O
.	O
Only	O
3	O
of	O
the	O
13	O
adenocarcinomas	B-Anatomy
metastatic	O
to	O
the	O
serous	B-Anatomy
membranes	I-Anatomy
included	O
in	O
this	O
study	O
were	O
weakly	O
reactive	O
,	O
accounting	O
for	O
81	O
%	O
specificity	O
.	O
Binding	O
of	O
anticalretinin	O
antiserum	B-Anatomy
to	O
living	O
mesothelial	B-Anatomy
cells	I-Anatomy
was	O
consistently	O
documented	O
in	O
all	O
four	O
cases	O
investigated	O
.	O
CONCLUSION	O
:	O
Calretinin	O
is	O
a	O
very	O
useful	O
marker	O
for	O
positive	O
identification	O
of	O
normal	O
and	O
tumor	B-Anatomy
mesothelial	I-Anatomy
cells	I-Anatomy
in	O
serous	B-Anatomy
effusions	I-Anatomy
.	O
Prognostic	O
value	O
of	O
HLA	O
-	O
DR	O
expression	O
and	O
dendritic	B-Anatomy
cell	I-Anatomy
infiltration	O
in	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
We	O
attempted	O
to	O
correlate	O
the	O
expression	O
of	O
human	O
leukocyte	O
antigen	O
DR	O
(	O
HLA	O
-	O
DR	O
)	O
and	O
tumor	B-Anatomy
infiltration	O
by	O
S	B-Anatomy
-	I-Anatomy
100	I-Anatomy
-	I-Anatomy
protein	I-Anatomy
-	I-Anatomy
positive	I-Anatomy
dendritic	I-Anatomy
cells	I-Anatomy
with	O
clinicopathologic	O
features	O
in	O
165	O
patients	O
with	O
gastric	B-Anatomy
cancer	I-Anatomy
.	O
The	O
expression	O
of	O
HLA	O
-	O
DR	O
was	O
correlated	O
with	O
the	O
histologic	O
type	O
.	O
Infiltration	O
of	O
dendritic	B-Anatomy
cells	I-Anatomy
correlated	O
negatively	O
with	O
distant	O
lymph	B-Anatomy
node	I-Anatomy
metastases	I-Anatomy
,	O
clinical	O
stage	O
,	O
and	O
peritoneal	B-Anatomy
invasion	O
.	O
There	O
was	O
no	O
correlation	O
between	O
the	O
expression	O
of	O
HLA	O
-	O
DR	O
and	O
infiltration	O
by	O
dendritic	B-Anatomy
cells	I-Anatomy
.	O
In	O
patients	O
with	O
resectable	O
gastric	B-Anatomy
cancer	I-Anatomy
,	O
the	O
grade	O
of	O
infiltrating	O
dendritic	B-Anatomy
cells	I-Anatomy
may	O
be	O
a	O
suitable	O
predictor	O
of	O
prognosis	O
.	O
Integrin	O
alphavbeta3	O
requirement	O
for	O
sustained	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
activity	O
during	O
angiogenesis	O
.	O
Angiogenesis	O
depends	O
on	O
growth	O
factors	O
and	O
vascular	B-Anatomy
cell	I-Anatomy
adhesion	O
events	O
.	O
Integrins	O
and	O
growth	O
factors	O
are	O
capable	O
of	O
activating	O
the	O
ras	O
/	O
MAP	O
kinase	O
pathway	O
in	O
vitro	O
,	O
yet	O
how	O
these	O
signals	O
influence	O
endothelial	B-Anatomy
cells	I-Anatomy
during	O
angiogenesis	O
is	O
unknown	O
.	O
Upon	O
initiation	O
of	O
angiogenesis	O
with	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
on	O
the	O
chick	O
chorioallantoic	B-Anatomy
membrane	I-Anatomy
(	O
CAM	B-Anatomy
)	O
,	O
endothelial	B-Anatomy
cell	I-Anatomy
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
(	O
ERK	O
)	O
activity	O
was	O
detected	O
as	O
early	O
as	O
5	O
min	O
yet	O
was	O
sustained	O
for	O
at	O
least	O
20	O
h	O
.	O
The	O
initial	O
wave	O
of	O
ERK	O
activity	O
(	O
5	O
-	O
120	O
min	O
)	O
was	O
refractory	O
to	O
integrin	O
antagonists	O
,	O
whereas	O
the	O
sustained	O
activity	O
(	O
4	O
-	O
20	O
h	O
)	O
depended	O
on	O
integrin	O
alphavbeta3	O
,	O
but	O
not	O
beta1	O
integrins	O
.	O
Inhibition	O
of	O
MAP	O
kinase	O
kinase	O
(	O
MEK	O
)	O
during	O
this	O
sustained	O
alphavbeta3	O
-	O
dependent	O
ERK	O
signal	O
blocked	O
the	O
formation	O
of	O
new	O
blood	B-Anatomy
vessels	I-Anatomy
while	O
not	O
influencing	O
preexisting	O
blood	B-Anatomy
vessels	I-Anatomy
on	O
the	O
CAM	B-Anatomy
.	O
Inhibition	O
of	O
MEK	O
also	O
blocked	O
growth	O
factor	O
induced	O
migration	O
but	O
not	O
adhesion	O
of	O
endothelial	B-Anatomy
cells	I-Anatomy
in	O
vitro	O
.	O
Therefore	O
,	O
angiogenesis	O
depends	O
on	O
sustained	O
ERK	O
activity	O
regulated	O
by	O
the	O
ligation	O
state	O
of	O
both	O
a	O
growth	O
factor	O
receptor	O
and	O
integrin	O
alphavbeta3	O
.	O
Basic	O
fibroblast	O
growth	O
factor	O
:	O
a	O
missing	O
link	O
between	O
collagen	O
VII	O
,	O
increased	O
collagenase	O
,	O
and	O
squamous	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
in	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O
BACKGROUND	O
:	O
Patients	O
with	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
(	O
RDEB	O
)	O
have	O
deficiencies	O
of	O
collagen	O
type	O
VII	O
and	O
have	O
elevated	O
levels	O
of	O
fibroblast	O
collagenase	O
,	O
and	O
a	O
greatly	O
increased	O
risk	O
of	O
cutaneous	B-Anatomy
squamous	I-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
Patients	O
with	O
other	O
genetic	O
blistering	O
disorders	O
do	O
not	O
have	O
elevated	O
collagenase	O
or	O
an	O
increased	O
risk	O
of	O
squamous	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
,	O
despite	O
chronic	O
wounding	O
.	O
The	O
connection	O
between	O
collagen	O
type	O
VII	O
deficiency	O
,	O
increased	O
collagenase	O
,	O
and	O
squamous	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
is	O
not	O
understood	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Urine	B-Anatomy
from	O
81	O
patients	O
with	O
RDEB	O
(	O
39	O
patients	O
)	O
,	O
junctional	O
epidermolysis	O
bullosa	O
(	O
JEB	O
;	O
12	O
patients	O
)	O
,	O
and	O
epidermolysis	O
bullosa	O
simplex	O
(	O
EBS	O
;	O
30	O
patients	O
)	O
,	O
as	O
well	O
as	O
unaffected	O
family	O
members	O
of	O
RDEB	O
patients	O
(	O
33	O
patients	O
)	O
,	O
was	O
tested	O
for	O
the	O
presence	O
of	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
using	O
a	O
sensitive	O
radioimmunoassay	O
.	O
These	O
patients	O
included	O
many	O
who	O
were	O
enrolled	O
in	O
the	O
Epidermolysis	O
Bullosa	O
Registry	O
and	O
others	O
who	O
were	O
referred	O
by	O
their	O
physicians	O
.	O
RESULTS	O
:	O
Fifty	O
-	O
one	O
percent	O
of	O
patients	O
with	O
RDEB	O
had	O
elevated	O
levels	O
(	O
greater	O
than	O
5000	O
pg	O
/	O
g	O
)	O
of	O
urinary	B-Anatomy
bFGF	O
.	O
In	O
contrast	O
,	O
none	O
of	O
the	O
patients	O
with	O
JEB	O
had	O
elevated	O
levels	O
of	O
bFGF	O
.	O
Twenty	O
-	O
one	O
percent	O
of	O
clinically	O
unaffected	O
family	O
members	O
had	O
elevated	O
levels	O
of	O
bFGF	O
,	O
and	O
13	O
%	O
of	O
patients	O
with	O
EBS	O
had	O
elevated	O
levels	O
of	O
bFGF	O
.	O
The	O
frequency	O
of	O
elevated	O
bFGF	O
values	O
among	O
all	O
groups	O
was	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
,	O
and	O
the	O
levels	O
of	O
bFGF	O
in	O
RDEB	O
patients	O
were	O
significantly	O
elevated	O
compared	O
with	O
those	O
of	O
other	O
groups	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
CONCLUSIONS	O
:	O
We	O
have	O
found	O
that	O
patients	O
with	O
RDEB	O
have	O
elevated	O
levels	O
of	O
bFGF	O
,	O
which	O
may	O
contribute	O
to	O
increased	O
fibroblast	O
collagenase	O
and	O
the	O
development	O
of	O
squamous	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
.	O
These	O
results	O
suggest	O
a	O
novel	O
treatment	O
for	O
RDEB	O
,	O
namely	O
,	O
angiogenesis	O
inhibitors	O
,	O
which	O
may	O
antagonize	O
the	O
effects	O
of	O
bFGF	O
in	O
this	O
disorder	O
.	O
There	O
are	O
currently	O
no	O
other	O
means	O
of	O
treatment	O
for	O
this	O
disorder	O
,	O
which	O
has	O
a	O
high	O
morbidity	O
and	O
mortality	O
rate	O
.	O
Multiple	O
phosphotyrosine	O
phosphatase	O
mRNAs	O
are	O
expressed	O
in	O
the	O
human	O
lung	B-Anatomy
fibroblast	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
WI	I-Anatomy
-	I-Anatomy
38	I-Anatomy
.	O
Protein	O
tyrosine	O
phosphatases	O
are	O
important	O
components	O
of	O
signal	O
transduction	O
pathways	O
.	O
The	O
authors	O
have	O
used	O
reverse	O
transcription	O
/	O
polymerase	O
chain	O
reactions	O
to	O
accomplish	O
a	O
comprehensive	O
examination	O
of	O
the	O
RNA	O
expression	O
for	O
58	O
distinct	O
mammalian	O
protein	O
tyrosine	O
and	O
dual	O
specificity	O
phosphatase	O
(	O
PTPase	O
)	O
and	O
PTPase	O
-	O
like	O
genes	O
in	O
the	O
normal	O
human	O
diploid	B-Anatomy
fibroblast	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
WI	I-Anatomy
-	I-Anatomy
38	I-Anatomy
.	O
Thirty	O
-	O
seven	O
of	O
these	O
PTPase	O
genes	O
express	O
easily	O
measurable	O
RNA	O
,	O
and	O
four	O
simultaneously	O
express	O
the	O
RNA	O
for	O
two	O
or	O
more	O
isoforms	O
.	O
Messages	O
for	O
an	O
additional	O
eight	O
PTPase	O
genes	O
are	O
detectable	O
at	O
low	O
levels	O
.	O
Only	O
14	O
known	O
PTPase	O
genes	O
do	O
not	O
express	O
measurable	O
RNA	O
under	O
our	O
conditions	O
.	O
For	O
purposes	O
of	O
comparison	O
,	O
the	O
authors	O
also	O
assessed	O
the	O
PTPases	O
expressed	O
in	O
the	O
WI	B-Anatomy
-	I-Anatomy
38	I-Anatomy
cell	I-Anatomy
line	I-Anatomy
using	O
highly	O
degenerate	O
primers	O
to	O
conserved	O
motifs	O
found	O
in	O
the	O
classical	O
tyrosine	O
-	O
specific	O
PTPases	O
.	O
Only	O
eight	O
of	O
the	O
22	O
classic	O
tyrosine	O
-	O
specific	O
PTPases	O
detected	O
using	O
the	O
specific	O
primers	O
were	O
detected	O
using	O
these	O
degenerate	O
primers	O
.	O
Our	O
panel	O
of	O
specific	O
PTPase	O
primers	O
should	O
be	O
very	O
useful	O
for	O
semiquantitatively	O
assessing	O
the	O
repertoire	O
of	O
PTPases	O
expressed	O
by	O
cells	B-Anatomy
.	O
Epstein	O
-	O
Barr	O
virus	O
-	O
associated	O
nonsmall	B-Anatomy
cell	I-Anatomy
lung	I-Anatomy
carcinoma	I-Anatomy
:	O
undifferentiated	O
""""	B-Anatomy
lymphoepithelioma	I-Anatomy
-	I-Anatomy
like	I-Anatomy
""""	I-Anatomy
carcinoma	I-Anatomy
as	O
a	O
distinct	O
entity	O
with	O
better	O
prognosis	O
.	O
BACKGROUND	O
:	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
in	O
nonsmall	B-Anatomy
cell	I-Anatomy
lung	I-Anatomy
carcinoma	I-Anatomy
(	O
NSCLC	B-Anatomy
)	O
has	O
been	O
demonstrated	O
in	O
some	O
ethnic	O
groups	O
.	O
The	O
pathobiology	O
and	O
the	O
role	O
of	O
EBV	O
and	O
oncoprotein	O
expression	O
in	O
these	O
tumors	B-Anatomy
have	O
not	O
been	O
studied	O
extensively	O
.	O
In	O
this	O
study	O
,	O
the	O
authors	O
investigated	O
EBV	O
-	O
encoded	O
RNA	O
-	O
1	O
(	O
EBER1	O
)	O
transcripts	O
by	O
in	O
situ	O
hybridization	O
and	O
the	O
expression	O
of	O
latent	O
membrane	O
protein	O
-	O
1	O
(	O
LMP	O
-	O
1	O
)	O
and	O
bcl	O
-	O
2	O
protein	O
by	O
immunohistochemistry	O
in	O
NSCLC	B-Anatomy
patients	O
from	O
Taiwan	O
,	O
where	O
nasopharyngeal	B-Anatomy
carcinoma	I-Anatomy
is	O
endemic	O
.	O
METHODS	O
:	O
A	O
total	O
of	O
127	O
cases	O
of	O
NSCLC	B-Anatomy
(	O
43	O
cases	O
of	O
squamous	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
[	O
SCC	B-Anatomy
]	O
,	O
67	O
cases	O
of	O
adenocarcinoma	B-Anatomy
[	O
AD	B-Anatomy
]	O
,	O
12	O
cases	O
of	O
large	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
[	O
LCC	B-Anatomy
]	O
,	O
and	O
5	O
cases	O
of	O
lymphoepithelioma	B-Anatomy
-	I-Anatomy
like	I-Anatomy
carcinoma	I-Anatomy
[	O
LE	B-Anatomy
]	O
)	O
were	O
included	O
.	O
A	O
sensitive	O
polymerase	O
chain	O
reaction	O
-	O
derived	O
,	O
digoxigenin	O
-	O
labeled	O
DNA	O
probe	O
for	O
in	O
situ	O
detection	O
of	O
EBER1	O
transcripts	O
was	O
performed	O
for	O
the	O
detection	O
of	O
EBV	O
.	O
Immunohistochemistry	O
using	O
the	O
avidin	O
-	O
biotin	O
-	O
immunoperoxidase	O
method	O
was	O
also	O
performed	O
to	O
evaluate	O
the	O
expression	O
of	O
bcl	O
-	O
2	O
and	O
LMP	O
-	O
1	O
.	O
RESULTS	O
:	O
EBER1	O
was	O
detected	O
in	O
11	O
of	O
the	O
127	O
NSCLC	B-Anatomy
cases	O
(	O
8	O
.	O
7	O
%	O
;	O
6	O
SCC	B-Anatomy
cases	O
and	O
5	O
LE	B-Anatomy
cases	O
)	O
.	O
All	O
5	O
LE	B-Anatomy
cases	O
were	O
EBV	O
-	O
positive	O
,	O
whereas	O
only	O
6	O
of	O
the	O
43	O
SCC	B-Anatomy
cases	O
(	O
14	O
%	O
)	O
,	O
0	O
of	O
67	O
AD	B-Anatomy
cases	O
,	O
and	O
12	O
LCC	B-Anatomy
cases	O
were	O
EBV	O
-	O
positive	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
All	O
five	O
LE	B-Anatomy
cases	O
showed	O
diffuse	O
,	O
strong	O
,	O
positive	O
staining	O
of	O
tumor	B-Anatomy
cells	I-Anatomy
;	O
five	O
of	O
the	O
six	O
SCC	B-Anatomy
cases	O
showed	O
diffuse	O
but	O
weak	O
staining	O
.	O
Among	O
the	O
nontumor	B-Anatomy
epithelial	I-Anatomy
cells	I-Anatomy
,	O
there	O
was	O
no	O
EBER1	O
staining	O
of	O
any	O
of	O
the	O
11	O
EBER1	O
-	O
positive	O
cases	O
.	O
The	O
mean	O
age	O
of	O
the	O
LE	B-Anatomy
patients	O
was	O
10	O
years	O
younger	O
than	O
that	O
of	O
the	O
patients	O
with	O
other	O
histological	O
types	O
.	O
All	O
5	O
LE	B-Anatomy
patients	O
were	O
nonsmokers	O
,	O
whereas	O
3	O
of	O
the	O
6	O
patients	O
with	O
EBER1	O
-	O
positive	O
SCC	B-Anatomy
(	O
50	O
%	O
)	O
were	O
smokers	O
.	O
EBER1	O
expression	O
did	O
not	O
correlate	O
with	O
the	O
2	O
-	O
year	O
survival	O
rate	O
of	O
overall	O
cases	O
,	O
but	O
all	O
5	O
LE	B-Anatomy
patients	O
were	O
alive	O
without	O
clinical	O
evidence	O
of	O
disease	O
at	O
last	O
follow	O
-	O
up	O
.	O
Gender	O
,	O
lymph	B-Anatomy
node	I-Anatomy
or	O
distant	O
metastasis	O
,	O
and	O
clinical	O
stage	O
were	O
not	O
found	O
to	O
have	O
any	O
correlation	O
with	O
EBER1	O
expression	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O
All	O
LE	B-Anatomy
cases	O
had	O
bcl	O
-	O
2	O
oncoprotein	O
expression	O
(	O
100	O
%	O
)	O
.	O
This	O
frequency	O
was	O
significantly	O
different	O
from	O
other	O
histologic	O
types	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
The	O
LMP	O
-	O
1	O
detection	O
rate	O
was	O
low	O
and	O
demonstrated	O
no	O
correlation	O
with	O
bcl	O
-	O
2	O
expression	O
.	O
CONCLUSIONS	O
:	O
In	O
this	O
study	O
,	O
the	O
authors	O
found	O
that	O
the	O
primary	B-Anatomy
LE	I-Anatomy
of	O
the	O
lung	B-Anatomy
is	O
associated	O
with	O
young	O
age	O
,	O
a	O
history	O
of	O
not	O
smoking	O
,	O
high	O
bcl	O
-	O
2	O
immunoreactivity	O
,	O
and	O
better	O
survival	O
rate	O
.	O
These	O
characteristics	O
demonstrate	O
that	O
EBV	O
-	O
associated	O
LE	B-Anatomy
of	O
the	O
lung	B-Anatomy
is	O
a	O
unique	O
entity	O
.	O
The	O
findings	O
of	O
the	O
current	O
study	O
suggest	O
that	O
EBV	O
infection	O
may	O
play	O
a	O
different	O
role	O
in	O
the	O
tumorigenesis	O
of	O
primary	B-Anatomy
LE	I-Anatomy
of	O
the	O
lung	B-Anatomy
than	O
it	O
does	O
in	O
other	O
EBER1	B-Anatomy
-	I-Anatomy
positive	I-Anatomy
NSCLCs	I-Anatomy
.	O
Antisocial	O
patients	O
:	O
a	O
comparison	O
of	O
those	O
with	O
and	O
those	O
without	O
childhood	O
conduct	O
disorder	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
persons	O
with	O
antisocial	O
personality	O
disorder	O
(	O
ASP	O
)	O
with	O
those	O
who	O
meet	O
the	O
adult	O
criteria	O
for	O
ASP	O
but	O
fail	O
to	O
meet	O
the	O
criteria	O
for	O
childhood	O
conduct	O
disorder	O
.	O
Sociodemographic	O
data	O
,	O
medical	O
history	O
,	O
and	O
psychiatric	O
symptoms	O
exhibited	O
during	O
a	O
recent	O
hospital	O
admission	O
were	O
compared	O
in	O
the	O
two	O
groups	O
by	O
chart	O
review	O
.	O
The	O
two	O
groups	O
were	O
virtually	O
indistinguishable	O
,	O
except	O
that	O
patients	O
without	O
childhood	O
conduct	O
disorder	O
were	O
less	O
likely	O
to	O
smoke	O
or	O
consume	O
alcohol	O
,	O
were	O
less	O
likely	O
to	O
have	O
spent	O
time	O
in	O
a	O
training	O
school	O
/	O
boot	O
camp	O
as	O
a	O
child	O
or	O
adolescent	O
,	O
were	O
less	O
likely	O
to	O
have	O
been	O
admitted	O
for	O
a	O
recent	O
suicide	O
attempt	O
,	O
and	O
were	O
less	O
likely	O
to	O
have	O
conned	O
others	O
.	O
We	O
conclude	O
that	O
persons	O
meeting	O
the	O
adult	O
criteria	O
for	O
ASP	O
but	O
not	O
the	O
childhood	O
conduct	O
disorder	O
criteria	O
essentially	O
suffer	O
the	O
same	O
disorder	O
as	O
those	O
who	O
meet	O
full	O
ASP	O
criteria	O
but	O
are	O
less	O
severely	O
affected	O
.	O
The	O
myoadipose	B-Anatomy
flap	I-Anatomy
:	O
a	O
new	O
composite	O
.	O
A	O
prefabricated	O
composite	B-Anatomy
fat	I-Anatomy
flap	I-Anatomy
consisting	O
of	O
muscle	B-Anatomy
woven	O
into	O
an	O
anatomically	O
distinct	O
fat	B-Anatomy
pad	I-Anatomy
was	O
studied	O
in	O
a	O
rabbit	O
model	O
.	O
In	O
17	O
rabbits	O
,	O
a	O
2	O
-	O
cm	O
strip	B-Anatomy
of	O
latissimus	B-Anatomy
dorsi	I-Anatomy
was	O
woven	O
into	O
the	O
parascapular	B-Anatomy
fat	I-Anatomy
pad	I-Anatomy
on	O
one	O
side	O
,	O
with	O
the	O
contralateral	B-Anatomy
fat	I-Anatomy
pad	I-Anatomy
serving	O
as	O
a	O
control	O
.	O
At	O
3	O
weeks	O
,	O
the	O
endogenous	O
blood	B-Anatomy
supply	O
of	O
both	O
the	O
control	O
and	O
the	O
experimental	O
fat	B-Anatomy
pads	I-Anatomy
was	O
isolated	O
and	O
ligated	O
,	O
and	O
the	O
composite	B-Anatomy
fat	I-Anatomy
/	I-Anatomy
muscle	I-Anatomy
flap	I-Anatomy
was	O
transferred	O
to	O
the	O
chest	B-Anatomy
wall	I-Anatomy
.	O
At	O
6	O
weeks	O
,	O
animals	O
were	O
killed	O
,	O
and	O
flaps	B-Anatomy
were	O
analyzed	O
for	O
length	O
,	O
width	O
,	O
and	O
weight	O
;	O
perfused	O
with	O
fluorescein	O
or	O
lead	O
oxide	O
;	O
and	O
examined	O
histologically	O
.	O
Significant	O
differences	O
were	O
found	O
between	O
the	O
control	O
and	O
experimental	O
fat	B-Anatomy
pads	I-Anatomy
with	O
regard	O
to	O
weight	O
and	O
length	O
.	O
Experimental	O
flaps	B-Anatomy
were	O
found	O
to	O
be	O
perfused	O
fully	O
with	O
fluorescein	O
and	O
lead	O
oxide	O
;	O
control	O
fat	B-Anatomy
pads	I-Anatomy
were	O
found	O
not	O
to	O
be	O
perfused	O
.	O
The	O
lead	O
oxide	O
group	O
revealed	O
extensive	O
growth	O
of	O
blood	B-Anatomy
vessels	I-Anatomy
from	O
the	O
latissimus	B-Anatomy
graft	I-Anatomy
into	O
the	O
experimental	O
fat	B-Anatomy
pad	I-Anatomy
.	O
No	O
vessels	B-Anatomy
were	O
visualized	O
in	O
the	O
controls	O
.	O
Finally	O
,	O
sections	B-Anatomy
of	O
the	O
control	O
and	O
experimental	O
flaps	B-Anatomy
were	O
analyzed	O
histologically	O
.	O
A	O
preponderance	O
of	O
viable	O
fat	B-Anatomy
,	O
with	O
evidence	O
of	O
neovascularization	O
,	O
was	O
found	O
in	O
experimental	O
flaps	B-Anatomy
,	O
compared	O
with	O
the	O
necrotic	O
fat	B-Anatomy
that	O
characterized	O
the	O
controls	O
.	O
We	O
conclude	O
that	O
prefabrication	O
of	O
a	O
fat	B-Anatomy
flap	I-Anatomy
is	O
possible	O
and	O
may	O
have	O
extensive	O
application	O
in	O
various	O
areas	O
of	O
plastic	O
surgery	O
.	O
Brainstem	B-Anatomy
auditory	O
-	O
evoked	O
potential	O
evaluation	O
in	O
children	O
with	O
meningitis	O
.	O
Brainstem	B-Anatomy
auditory	O
-	O
evoked	O
potential	O
(	O
BAEP	O
)	O
was	O
performed	O
on	O
101	O
children	O
with	O
meningitis	O
to	O
assess	O
the	O
incidence	O
of	O
hearing	O
impairment	O
.	O
Fifty	O
-	O
two	O
(	O
51	O
.	O
5	O
%	O
)	O
children	O
had	O
bacterial	O
meningitis	O
,	O
six	O
(	O
5	O
.	O
9	O
%	O
)	O
had	O
viral	O
meningitis	O
,	O
and	O
43	O
(	O
42	O
.	O
6	O
%	O
)	O
had	O
aseptic	O
meningitis	O
.	O
Fifty	O
-	O
one	O
(	O
50	O
.	O
5	O
%	O
)	O
patients	O
were	O
assessed	O
before	O
discharge	O
and	O
50	O
(	O
49	O
.	O
5	O
%	O
)	O
9	O
days	O
to	O
17	O
months	O
later	O
(	O
mean	O
=	O
4	O
months	O
)	O
.	O
BAEP	O
impairment	O
was	O
found	O
in	O
28	O
(	O
27	O
.	O
7	O
%	O
)	O
of	O
101	O
patients	O
;	O
24	O
had	O
sensorineural	O
and	O
four	O
had	O
conductive	O
type	O
of	O
hearing	O
loss	O
,	O
and	O
17	O
(	O
60	O
.	O
7	O
%	O
)	O
had	O
unilateral	O
and	O
11	O
(	O
39	O
.	O
3	O
%	O
)	O
had	O
bilateral	O
impairment	O
.	O
Hearing	O
threshold	O
was	O
elevated	O
in	O
22	O
(	O
21	O
.	O
8	O
%	O
)	O
patients	O
,	O
and	O
the	O
other	O
six	O
had	O
increased	O
latency	O
and	O
interpeak	O
latencies	O
with	O
normal	O
threshold	O
.	O
Frequency	O
of	O
BAEP	O
impairment	O
or	O
hearing	O
loss	O
associated	O
with	O
bacterial	O
meningitis	O
was	O
34	O
.	O
6	O
%	O
and	O
30	O
.	O
8	O
%	O
,	O
respectively	O
;	O
frequency	O
associated	O
with	O
aseptic	O
meningitis	O
was	O
20	O
.	O
9	O
%	O
and	O
13	O
.	O
9	O
%	O
,	O
respectively	O
.	O
One	O
child	O
with	O
viral	O
meningitis	O
(	O
coxsackie	O
virus	O
)	O
had	O
mild	O
BAEP	O
impairment	O
.	O
Most	O
of	O
the	O
BAEP	O
impairment	O
in	O
the	O
bacterial	O
meningitis	O
group	O
was	O
associated	O
with	O
H	O
.	O
influenzae	O
.	O
Prospective	O
BAEP	O
study	O
was	O
performed	O
in	O
20	O
patients	O
randomly	O
at	O
0	O
.	O
3	O
to	O
18	O
months	O
to	O
assess	O
hearing	O
status	O
after	O
antibiotic	O
treatment	O
,	O
10	O
with	O
normal	O
and	O
10	O
with	O
abnormal	O
BAEP	O
.	O
All	O
the	O
initially	O
normal	O
BAEP	O
patients	O
remained	O
normal	O
.	O
Of	O
the	O
10	O
patients	O
with	O
abnormal	O
BAEP	O
results	O
initially	O
,	O
four	O
returned	O
to	O
normal	O
,	O
two	O
improved	O
,	O
three	O
remained	O
unchanged	O
,	O
and	O
one	O
deteriorated	O
.	O
The	O
incidence	O
of	O
hearing	O
loss	O
after	O
bacterial	O
and	O
aseptic	O
meningitis	O
is	O
high	O
.	O
BAEP	O
is	O
useful	O
to	O
screen	O
for	O
possible	O
hearing	O
loss	O
in	O
children	O
with	O
meningitis	O
,	O
and	O
follow	O
-	O
up	O
BAEP	O
is	O
necessary	O
for	O
those	O
patients	O
with	O
initially	O
abnormal	O
BAEP	O
.	O
[	O
The	O
assessment	O
of	O
flow	O
velocity	O
in	O
carotid	B-Anatomy
and	O
intracranial	B-Anatomy
arteries	I-Anatomy
in	O
three	O
different	O
age	O
groups	O
]	O
.	O
In	O
this	O
report	O
we	O
assess	O
the	O
systolic	O
maximal	O
flow	O
velocity	O
in	O
carotid	B-Anatomy
and	O
intracranial	B-Anatomy
arteries	I-Anatomy
in	O
191	O
subjects	O
with	O
no	O
history	O
of	O
cerebral	B-Anatomy
vascular	I-Anatomy
disease	O
in	O
3	O
age	O
groups	O
:	O
20	O
-	O
40	O
years	O
(	O
1	O
group	O
)	O
,	O
41	O
-	O
60	O
years	O
(	O
2	O
group	O
)	O
,	O
and	O
above	O
60	O
years	O
(	O
3	O
group	O
)	O
.	O
The	O
subjects	O
were	O
assessed	O
using	O
Sonomed	O
Transcranial	O
Doppler	O
Spectrograph	O
according	O
to	O
generally	O
accepted	O
principles	O
.	O
The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
establish	O
the	O
mean	O
value	O
of	O
maximal	O
flow	O
velocity	O
in	O
each	O
particular	O
artery	B-Anatomy
in	O
three	O
age	O
groups	O
,	O
and	O
to	O
observe	O
the	O
changes	O
in	O
this	O
parameter	O
with	O
age	O
.	O
The	O
results	O
were	O
analyzed	O
using	O
statistical	O
methods	O
and	O
a	O
significant	O
decrease	O
in	O
blood	B-Anatomy
flow	O
,	O
Vmax	O
,	O
was	O
found	O
in	O
all	O
investigated	O
arteries	B-Anatomy
.	O
A	O
mean	O
decrease	O
of	O
8	O
.	O
02	O
%	O
in	O
flow	O
velocity	O
Vmax	O
was	O
found	O
,	O
when	O
comparing	O
groups	O
2	O
and	O
1	O
,	O
and	O
difference	O
15	O
.	O
99	O
%	O
comparing	O
3	O
and	O
1	O
.	O
Requirement	O
of	O
estrogen	O
receptor	O
expression	O
and	O
function	O
for	O
[	O
12Val	O
]	O
K	O
-	O
Ras	O
-	O
mediated	O
NIH3T3	B-Anatomy
cell	I-Anatomy
transformation	O
.	O
We	O
investigated	O
the	O
biological	O
significance	O
of	O
estrogen	O
receptors	O
(	O
ERs	O
)	O
in	O
NIH3T3	B-Anatomy
cell	I-Anatomy
transformation	O
by	O
the	O
[	O
12Val	O
]	O
K	O
-	O
Ras	O
mutant	O
.	O
This	O
mutant	O
enhanced	O
the	O
steady	O
-	O
level	O
and	O
transcriptional	O
activity	O
of	O
ER	O
.	O
Coexpression	O
of	O
the	O
progesterone	O
receptor	O
with	O
mutant	O
K	O
-	O
Ras	O
led	O
to	O
suppression	O
of	O
tumorigenicity	O
and	O
inhibition	O
of	O
the	O
activation	O
of	O
ER	O
.	O
The	O
antisense	O
oligomers	O
complementary	O
to	O
the	O
ER	O
suppressed	O
proliferation	O
and	O
transformed	O
phenotypes	O
of	O
K12V	B-Anatomy
cells	I-Anatomy
.	O
These	O
observations	O
support	O
the	O
importance	O
of	O
ER	O
in	O
Ras	O
-	O
mediated	O
cell	B-Anatomy
transformation	O
.	O
Gene	O
therapy	O
for	O
gliomas	B-Anatomy
:	O
p53	O
and	O
E2F	O
-	O
1	O
proteins	O
and	O
the	O
target	O
of	O
apoptosis	O
.	O
Current	O
therapy	O
for	O
glioma	B-Anatomy
is	O
suboptimal	O
.	O
The	O
transfer	O
of	O
apoptosis	O
genes	O
to	O
tumors	B-Anatomy
constitutes	O
one	O
of	O
the	O
most	O
promising	O
strategies	O
for	O
cancer	B-Anatomy
gene	O
therapy	O
.	O
We	O
have	O
previously	O
shown	O
that	O
massive	O
apoptosis	O
occurs	O
when	O
wild	O
-	O
type	O
p53	O
or	O
E2F	O
-	O
1	O
expression	O
is	O
induced	O
in	O
glioma	B-Anatomy
.	O
However	O
,	O
the	O
mechanism	O
of	O
action	O
and	O
the	O
efficiency	O
in	O
inducing	O
apoptosis	O
of	O
these	O
two	O
proteins	O
are	O
not	O
similar	O
.	O
Adenovirus	O
-	O
mediated	O
p53	O
gene	O
transfer	O
is	O
ineffective	O
in	O
causing	O
apoptosis	O
in	O
glioma	B-Anatomy
cells	I-Anatomy
that	O
retain	O
wild	O
-	O
type	O
p53	O
genotype	O
or	O
overexpress	O
the	O
p21	O
protein	O
.	O
The	O
p16	O
/	O
Rb	O
/	O
E2F	O
pathway	O
is	O
the	O
most	O
frequent	O
target	O
of	O
genetic	O
alterations	O
in	O
gliomas	B-Anatomy
,	O
and	O
therefore	O
constitutes	O
a	O
suitable	O
target	O
for	O
gene	O
therapy	O
strategies	O
.	O
However	O
,	O
the	O
transfer	O
of	O
either	O
the	O
p16	O
or	O
Rb	O
gene	O
to	O
glioma	B-Anatomy
cells	I-Anatomy
results	O
in	O
cytostatic	O
effect	O
.	O
The	O
E2F	O
-	O
1	O
protein	O
is	O
able	O
to	O
induce	O
generalized	O
apoptosis	O
in	O
gliomas	B-Anatomy
independently	O
of	O
the	O
p53	O
,	O
p16	O
or	O
Rb	O
status	O
.	O
In	O
addition	O
,	O
p21	O
-	O
or	O
p16	O
-	O
mediated	O
growth	O
arrest	O
did	O
not	O
protect	O
glioma	B-Anatomy
cells	I-Anatomy
from	O
E2F	O
-	O
1	O
-	O
mediated	O
apoptosis	O
.	O
The	O
apoptotic	O
molecule	O
bax	O
is	O
induced	O
in	O
p53	O
-	O
mediated	O
apoptosis	O
,	O
but	O
bax	O
is	O
not	O
induced	O
in	O
E2F	O
-	O
1	O
-	O
mediated	O
apoptosis	O
in	O
glioma	B-Anatomy
cells	I-Anatomy
.	O
Careful	O
selection	O
of	O
patients	O
may	O
be	O
necessary	O
before	O
designing	O
therapeutic	O
strategies	O
using	O
either	O
p53	O
or	O
E2F	O
-	O
1	O
as	O
a	O
therapeutic	O
tools	O
for	O
glioma	B-Anatomy
patients	O
.	O
Protective	O
function	O
of	O
von	O
Hippel	O
-	O
Lindau	O
protein	O
against	O
impaired	O
protein	O
processing	O
in	O
renal	B-Anatomy
carcinoma	I-Anatomy
cells	I-Anatomy
.	O
The	O
absence	O
of	O
functional	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
tumor	B-Anatomy
suppressor	O
gene	O
leads	O
to	O
the	O
development	O
of	O
neoplasias	O
characteristic	O
of	O
VHL	O
disease	O
,	O
including	O
renal	B-Anatomy
cell	I-Anatomy
carcinoma	I-Anatomy
(	O
RCC	B-Anatomy
)	O
.	O
Here	O
,	O
we	O
compared	O
the	O
sensitivity	O
of	O
RCC	B-Anatomy
cells	I-Anatomy
lacking	O
VHL	O
gene	O
function	O
with	O
that	O
of	O
RCC	B-Anatomy
cells	I-Anatomy
expressing	O
the	O
wild	O
-	O
type	O
VHL	O
gene	O
(	O
wtVHL	O
)	O
after	O
exposure	O
to	O
various	O
stresses	O
.	O
While	O
the	O
response	O
to	O
most	O
treatments	O
was	O
not	O
affected	O
by	O
the	O
VHL	O
gene	O
status	O
,	O
glucose	O
deprivation	O
was	O
found	O
to	O
be	O
much	O
more	O
cytotoxic	O
for	O
RCC	B-Anatomy
cells	I-Anatomy
lacking	O
VHL	O
gene	O
function	O
than	O
for	O
wtVHL	O
-	O
expressing	O
cells	B-Anatomy
.	O
The	O
heightened	O
sensitivity	O
of	O
VHL	O
-	O
deficient	O
cells	B-Anatomy
was	O
not	O
attributed	O
to	O
dissimilar	O
energy	O
requirements	O
or	O
to	O
differences	O
in	O
glucose	O
uptake	O
,	O
but	O
more	O
likely	O
reflects	O
a	O
lesser	O
ability	O
of	O
VHL	O
-	O
deficient	O
cells	B-Anatomy
to	O
handle	O
abnormally	O
processed	O
proteins	O
arising	O
from	O
impaired	O
glycosylation	O
.	O
In	O
support	O
of	O
this	O
hypothesis	O
,	O
other	O
treatments	O
which	O
act	O
through	O
different	O
mechanisms	O
to	O
interfere	O
with	O
protein	O
processing	O
(	O
i	O
.	O
e	O
.	O
,	O
tunicamycin	O
,	O
brefeldin	O
A	O
,	O
and	O
azetidine	O
)	O
were	O
also	O
found	O
to	O
be	O
much	O
more	O
toxic	O
for	O
VHL	O
-	O
deficient	O
cells	B-Anatomy
.	O
Furthermore	O
,	O
ubiquitination	O
of	O
cellular	B-Anatomy
proteins	O
was	O
elevated	O
in	O
VHL	O
-	O
deficient	O
cells	B-Anatomy
,	O
particularly	O
after	O
glucose	O
deprivation	O
,	O
supporting	O
a	O
role	O
for	O
the	O
VHL	O
gene	O
in	O
ubiquitin	O
-	O
mediated	O
proteolysis	O
.	O
Accordingly	O
,	O
the	O
rate	O
of	O
elimination	O
of	O
abnormal	O
proteins	O
was	O
lower	O
in	O
cells	B-Anatomy
lacking	O
a	O
functional	O
VHL	O
gene	O
than	O
in	O
wtVHL	O
-	O
expressing	O
cells	B-Anatomy
.	O
Thus	O
,	O
pVHL	O
appears	O
to	O
participate	O
in	O
the	O
elimination	O
of	O
misprocessed	O
proteins	O
,	O
such	O
as	O
those	O
arising	O
in	O
the	O
cell	B-Anatomy
due	O
to	O
the	O
unavailability	O
of	O
glucose	O
or	O
to	O
other	O
stresses	O
.	O
Torsade	B-Disease
de	I-Disease
pointes	I-Disease
ventricular	B-Disease
tachycardia	I-Disease
during	O
low	O
dose	O
intermittent	O
dobutamine	B-Chemical
treatment	O
in	O
a	O
patient	O
with	O
dilated	B-Disease
cardiomyopathy	I-Disease
and	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
.	O
The	O
authors	O
describe	O
the	O
case	O
of	O
a	O
56	O
-	O
year	O
-	O
old	O
woman	O
with	O
chronic	O
,	O
severe	O
heart	B-Disease
failure	I-Disease
secondary	O
to	O
dilated	B-Disease
cardiomyopathy	I-Disease
and	O
absence	O
of	O
significant	O
ventricular	B-Disease
arrhythmias	I-Disease
who	O
developed	O
QT	B-Disease
prolongation	I-Disease
and	O
torsade	B-Disease
de	I-Disease
pointes	I-Disease
ventricular	B-Disease
tachycardia	I-Disease
during	O
one	O
cycle	O
of	O
intermittent	O
low	O
dose	O
(	O
2	O
.	O
5	O
mcg	O
/	O
kg	O
per	O
min	O
)	O
dobutamine	B-Chemical
.	O
This	O
report	O
of	O
torsade	B-Disease
de	I-Disease
pointes	I-Disease
ventricular	B-Disease
tachycardia	I-Disease
during	O
intermittent	O
dobutamine	B-Chemical
supports	O
the	O
hypothesis	O
that	O
unpredictable	O
fatal	O
arrhythmias	B-Disease
may	O
occur	O
even	O
with	O
low	O
doses	O
and	O
in	O
patients	O
with	O
no	O
history	O
of	O
significant	O
rhythm	O
disturbances	O
.	O
The	O
mechanisms	O
of	O
proarrhythmic	O
effects	O
of	O
Dubutamine	B-Chemical
are	O
discussed	O
.	O
Positive	O
skin	O
tests	O
in	O
late	O
reactions	O
to	O
radiographic	O
contrast	B-Chemical
media	I-Chemical
.	O
In	O
the	O
last	O
few	O
years	O
delayed	O
reactions	O
several	O
hours	O
after	O
the	O
injection	O
of	O
radiographic	O
and	O
contrast	B-Chemical
materials	I-Chemical
(	O
PRC	B-Chemical
)	O
have	O
been	O
described	O
with	O
increasing	O
frequency	O
.	O
The	O
authors	O
report	O
two	O
observations	O
on	O
patients	O
with	O
delayed	O
reactions	O
in	O
whom	O
intradermoreactions	O
(	O
IDR	O
)	O
and	O
patch	O
tests	O
to	O
a	O
series	O
of	O
ionic	O
and	O
non	O
ionic	O
PRC	B-Chemical
were	O
studied	O
.	O
After	O
angiography	O
by	O
the	O
venous	O
route	O
in	O
patient	O
n	O
degree	O
1	O
a	O
biphasic	O
reaction	O
with	O
an	O
immediate	O
reaction	O
(	O
dyspnea	B-Disease
,	O
loss	B-Disease
of	I-Disease
consciousness	I-Disease
)	O
and	O
delayed	O
macro	B-Disease
-	I-Disease
papular	I-Disease
rash	I-Disease
appeared	O
,	O
whilst	O
patient	O
n	O
degree	O
2	O
developed	O
a	O
generalised	O
sensation	O
of	O
heat	O
,	O
persistent	O
pain	B-Disease
at	O
the	O
site	O
of	O
injection	O
immediately	O
and	O
a	O
generalised	O
macro	O
-	O
papular	O
reaction	O
after	O
24	O
hours	O
.	O
The	O
skin	O
tests	O
revealed	O
positive	O
delayed	O
reactions	O
of	O
24	O
hours	O
and	O
48	O
hours	O
by	O
IDR	O
and	O
patch	O
tests	O
to	O
only	O
some	O
PRC	B-Chemical
with	O
common	O
chains	O
in	O
their	O
structures	O
.	O
The	O
positive	O
skin	O
tests	O
are	O
in	O
favour	O
of	O
immunological	O
reactions	O
and	O
may	O
help	O
in	O
diagnosis	O
of	O
allergy	B-Disease
in	O
the	O
patients	O
.	O
Risk	O
of	O
transient	O
hyperammonemic	B-Disease
encephalopathy	I-Disease
in	O
cancer	B-Disease
patients	O
who	O
received	O
continuous	O
infusion	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
with	O
the	O
complication	O
of	O
dehydration	B-Disease
and	O
infection	B-Disease
.	O
From	O
1986	O
to	O
1998	O
,	O
29	O
cancer	B-Disease
patients	O
who	O
had	O
32	O
episodes	O
of	O
transient	O
hyperammonemic	B-Disease
encephalopathy	I-Disease
related	O
to	O
continuous	O
infusion	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
were	O
identified	O
.	O
None	O
of	O
the	O
patients	O
had	O
decompensated	O
liver	B-Disease
disease	I-Disease
.	O
Onset	O
of	O
hyperammonemic	B-Disease
encephalopathy	I-Disease
varied	O
from	O
0	O
.	O
5	O
to	O
5	O
days	O
(	O
mean	O
:	O
2	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
3	O
days	O
)	O
after	O
the	O
initiation	O
of	O
chemotherapy	O
.	O
Plasma	O
ammonium	B-Chemical
level	O
ranged	O
from	O
248	O
to	O
2387	O
microg	O
%	O
(	O
mean	O
:	O
626	O
+	O
/	O
-	O
431	O
microg	O
%	O
)	O
.	O
Among	O
the	O
32	O
episodes	O
,	O
26	O
(	O
81	O
%	O
)	O
had	O
various	O
degrees	O
of	O
azotemia	B-Disease
,	O
18	O
(	O
56	O
%	O
)	O
occurred	O
during	O
bacterial	B-Disease
infections	I-Disease
and	O
14	O
(	O
44	O
%	O
)	O
without	O
infection	B-Disease
occurred	O
during	O
periods	O
of	O
dehydration	B-Disease
.	O
Higher	O
plasma	O
ammonium	B-Chemical
levels	O
and	O
more	O
rapid	O
onset	O
of	O
hyperammonemia	B-Disease
were	O
seen	O
in	O
18	O
patients	O
with	O
bacterial	B-Disease
infections	I-Disease
(	O
p	O
=	O
0	O
.	O
003	O
and	O
0	O
.	O
0006	O
,	O
respectively	O
)	O
and	O
in	O
nine	O
patients	O
receiving	O
high	O
daily	O
doses	O
(	O
2600	O
or	O
1800	O
mg	O
/	O
m2	O
)	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
(	O
p	O
=	O
0	O
.	O
0001	O
and	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
)	O
.	O
In	O
25	O
out	O
of	O
32	O
episodes	O
(	O
78	O
%	O
)	O
,	O
plasma	O
ammonium	B-Chemical
levels	O
and	O
mental	O
status	O
returned	O
to	O
normal	O
within	O
2	O
days	O
after	O
adequate	O
management	O
.	O
In	O
conclusion	O
,	O
hyperammonemic	B-Disease
encephalopathy	I-Disease
can	O
occur	O
in	O
patients	O
receiving	O
continuous	O
infusion	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O
Azotemia	B-Disease
,	O
body	O
fluid	O
insufficiency	O
and	O
bacterial	B-Disease
infections	I-Disease
were	O
frequently	O
found	O
in	O
these	O
patients	O
.	O
It	O
is	O
therefore	O
important	O
to	O
recognize	O
this	O
condition	O
in	O
patients	O
receiving	O
continuous	O
infusion	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O
The	O
effects	O
of	O
quinine	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
aminopyridine	I-Chemical
on	O
conditioned	O
place	O
preference	O
and	O
changes	O
in	O
motor	O
activity	O
induced	O
by	O
morphine	B-Chemical
in	O
rats	O
.	O
1	O
.	O
The	O
effects	O
of	O
two	O
unselective	O
potassium	B-Chemical
(	O
K	B-Chemical
(	O
+	O
)	O
-	O
)	O
channel	O
blockers	O
,	O
quinine	B-Chemical
(	O
12	O
.	O
5	O
,	O
25	O
and	O
50	O
mg	O
/	O
kg	O
)	O
and	O
4	B-Chemical
-	I-Chemical
aminopyridine	I-Chemical
(	O
1	O
and	O
2	O
mg	O
/	O
kg	O
)	O
,	O
on	O
conditioned	O
place	O
preference	O
and	O
biphasic	O
changes	O
in	O
motor	O
activity	O
induced	O
by	O
morphine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
were	O
tested	O
in	O
Wistar	O
rats	O
.	O
Quinine	B-Chemical
is	O
known	O
to	O
block	O
voltage	O
-	O
,	O
calcium	B-Chemical
-	O
and	O
ATP	B-Chemical
-	O
sensitive	O
K	B-Chemical
(	O
+	O
)	O
-	O
channels	O
while	O
4	B-Chemical
-	I-Chemical
aminopyridine	I-Chemical
is	O
known	O
to	O
block	O
voltage	O
-	O
sensitive	O
K	B-Chemical
(	O
+	O
)	O
-	O
channels	O
.	O
2	O
.	O
In	O
the	O
counterbalanced	O
method	O
,	O
quinine	B-Chemical
attenuated	O
morphine	B-Chemical
-	O
induced	O
place	O
preference	O
,	O
whereas	O
4	B-Chemical
-	I-Chemical
aminopyridine	I-Chemical
was	O
ineffective	O
.	O
In	O
the	O
motor	O
activity	O
test	O
measured	O
with	O
an	O
Animex	O
-	O
activity	O
meter	O
neither	O
of	O
the	O
K	B-Chemical
(	O
+	O
)	O
-	O
channel	O
blockers	O
affected	O
morphine	B-Chemical
-	O
induced	O
hypoactivity	B-Disease
,	O
but	O
both	O
K	B-Chemical
(	O
+	O
)	O
-	O
channel	O
blockers	O
prevented	O
morphine	B-Chemical
-	O
induced	O
secondary	O
hyperactivity	B-Disease
.	O
3	O
.	O
These	O
results	O
suggest	O
the	O
involvement	O
of	O
quinine	B-Chemical
-	O
sensitive	O
but	O
not	O
4	B-Chemical
-	I-Chemical
aminopyridine	I-Chemical
-	O
sensitive	O
K	B-Chemical
(	O
+	O
)	O
-	O
channels	O
in	O
morphine	B-Chemical
reward	O
.	O
It	O
is	O
also	O
suggested	O
that	O
the	O
blockade	O
of	O
K	B-Chemical
(	O
+	O
)	O
-	O
channels	O
sensitive	O
to	O
these	O
blockers	O
is	O
not	O
sufficient	O
to	O
prevent	O
morphine	B-Chemical
-	O
induced	O
hypoactivity	B-Disease
whereas	O
morphine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
seems	O
to	O
be	O
connected	O
to	O
both	O
quinine	B-Chemical
-	O
and	O
4	B-Chemical
-	I-Chemical
aminopyridine	I-Chemical
-	O
sensitive	O
K	B-Chemical
(	O
+	O
)	O
-	O
channels	O
.	O
Nociceptin	B-Chemical
/	O
orphanin	B-Chemical
FQ	I-Chemical
and	O
nocistatin	B-Chemical
on	O
learning	B-Disease
and	I-Disease
memory	I-Disease
impairment	I-Disease
induced	O
by	O
scopolamine	B-Chemical
in	O
mice	O
.	O
1	O
.	O
Nociceptin	B-Chemical
,	O
also	O
known	O
as	O
orphanin	B-Chemical
FQ	I-Chemical
,	O
is	O
an	O
endogenous	O
ligand	O
for	O
the	O
orphan	O
opioid	O
receptor	O
-	O
like	O
receptor	O
1	O
(	O
ORL1	O
)	O
and	O
involves	O
in	O
various	O
functions	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
nocistatin	B-Chemical
is	O
recently	O
isolated	O
from	O
the	O
same	O
precursor	O
as	O
nociceptin	B-Chemical
and	O
blocks	O
nociceptin	B-Chemical
-	O
induced	O
allodynia	B-Disease
and	O
hyperalgesia	B-Disease
.	O
2	O
.	O
Although	O
ORL1	O
receptors	O
which	O
display	O
a	O
high	O
degree	O
of	O
sequence	O
homology	O
with	O
classical	O
opioid	O
receptors	O
are	O
abundant	O
in	O
the	O
hippocampus	O
,	O
little	O
is	O
known	O
regarding	O
their	O
role	O
in	O
learning	O
and	O
memory	O
.	O
3	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
whether	O
nociceptin	B-Chemical
/	O
orphanin	B-Chemical
FQ	I-Chemical
and	O
nocistatin	B-Chemical
could	O
modulate	O
impairment	B-Disease
of	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
induced	O
by	O
scopolamine	B-Chemical
,	O
a	O
muscarinic	O
cholinergic	O
receptor	O
antagonist	O
,	O
using	O
spontaneous	O
alternation	O
of	O
Y	O
-	O
maze	O
and	O
step	O
-	O
down	O
type	O
passive	O
avoidance	O
tasks	O
in	O
mice	O
.	O
4	O
.	O
While	O
nocistatin	B-Chemical
(	O
0	O
.	O
5	O
-	O
5	O
.	O
0	O
nmol	O
mouse	O
-	O
1	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
administered	O
30	O
min	O
before	O
spontaneous	O
alternation	O
performance	O
or	O
the	O
training	O
session	O
of	O
the	O
passive	O
avoidance	O
task	O
,	O
had	O
no	O
effect	O
on	O
spontaneous	O
alternation	O
or	O
passive	O
avoidance	O
behaviours	O
,	O
a	O
lower	O
per	O
cent	O
alternation	O
and	O
shorter	O
median	O
step	O
-	O
down	O
latency	O
in	O
the	O
retention	O
test	O
were	O
obtained	O
in	O
nociceptin	B-Chemical
(	O
1	O
.	O
5	O
and	O
/	O
or	O
5	O
.	O
0	O
nmol	O
mouse	O
-	O
1	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
-	O
treated	O
normal	O
mice	O
.	O
5	O
.	O
Administration	O
of	O
nocistatin	B-Chemical
(	O
1	O
.	O
5	O
and	O
/	O
or	O
5	O
.	O
0	O
nmol	O
mouse	O
-	O
1	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
30	O
min	O
before	O
spontaneous	O
alternation	O
performance	O
or	O
the	O
training	O
session	O
of	O
the	O
passive	O
avoidance	O
task	O
,	O
attenuated	O
the	O
scopolamine	B-Chemical
-	O
induced	O
impairment	O
of	O
spontaneous	O
alternation	O
and	O
passive	O
avoidance	O
behaviours	O
.	O
6	O
.	O
These	O
results	O
indicated	O
that	O
nocistatin	B-Chemical
,	O
a	O
new	O
biologically	O
active	O
peptide	O
,	O
ameliorates	O
impairments	O
of	O
spontaneous	O
alternation	O
and	O
passive	O
avoidance	O
induced	O
by	O
scopolamine	B-Chemical
,	O
and	O
suggested	O
that	O
these	O
peptides	O
play	O
opposite	O
roles	O
in	O
learning	O
and	O
memory	O
.	O
Meloxicam	B-Chemical
-	O
induced	O
liver	B-Disease
toxicity	I-Disease
.	O
We	O
report	O
the	O
case	O
of	O
a	O
female	O
patient	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
who	O
developed	O
acute	O
cytolytic	O
hepatitis	B-Disease
due	O
to	O
meloxicam	B-Chemical
.	O
Recently	O
introduced	O
in	O
Belgium	O
,	O
meloxicam	B-Chemical
is	O
the	O
first	O
nonsteroidal	O
antiinflammatory	O
drug	O
with	O
selective	O
action	O
on	O
the	O
inducible	O
form	O
of	O
cyclooxygenase	O
2	O
.	O
The	O
acute	O
cytolytic	O
hepatitis	B-Disease
occurred	O
rapidly	O
after	O
meloxicam	B-Chemical
administration	O
and	O
was	O
associated	O
with	O
the	O
development	O
of	O
antinuclear	O
antibodies	O
suggesting	O
a	O
hypersensitivity	B-Disease
mechanism	O
.	O
This	O
first	O
case	O
of	O
meloxicam	B-Chemical
related	O
liver	B-Disease
toxicity	I-Disease
demonstrates	O
the	O
potential	O
of	O
this	O
drug	O
to	O
induce	O
hepatic	B-Disease
damage	I-Disease
.	O
Induction	O
of	O
apoptosis	O
by	O
remoxipride	B-Chemical
metabolites	O
in	O
HL60	O
and	O
CD34	O
+	O
/	O
CD19	O
-	O
human	O
bone	O
marrow	O
progenitor	O
cells	O
:	O
potential	O
relevance	O
to	O
remoxipride	B-Chemical
-	O
induced	O
aplastic	B-Disease
anemia	I-Disease
.	O
The	O
antipsychotic	O
agent	O
,	O
remoxipride	B-Chemical
[	O
(	B-Chemical
S	I-Chemical
)	I-Chemical
-	I-Chemical
(	I-Chemical
-	I-Chemical
)	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
bromo	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
[	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
ethyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
pyrrolidinyl	I-Chemical
)	I-Chemical
methyl	I-Chemical
]	I-Chemical
-	I-Chemical
2	I-Chemical
,	I-Chemical
6	I-Chemical
-	I-Chemical
dimethoxybenz	I-Chemical
amide	I-Chemical
]	O
has	O
been	O
associated	O
with	O
acquired	O
aplastic	B-Disease
anemia	I-Disease
.	O
We	O
have	O
examined	O
the	O
ability	O
of	O
remoxipride	B-Chemical
,	O
three	O
pyrrolidine	B-Chemical
ring	O
metabolites	O
and	O
five	O
aromatic	O
ring	O
metabolites	O
of	O
the	O
parent	O
compound	O
to	O
induce	O
apoptosis	O
in	O
HL60	O
cells	O
and	O
human	O
bone	O
marrow	O
progenitor	O
(	O
HBMP	O
)	O
cells	O
.	O
Cells	O
were	O
treated	O
for	O
0	O
-	O
24	O
h	O
with	O
each	O
compound	O
(	O
0	O
-	O
200	O
microM	O
)	O
.	O
Apoptosis	O
was	O
assessed	O
by	O
fluorescence	O
microscopy	O
in	O
Hoechst	B-Chemical
33342	I-Chemical
-	O
and	O
propidium	B-Chemical
iodide	I-Chemical
stained	O
cell	O
samples	O
.	O
Results	O
were	O
confirmed	O
by	O
determination	O
of	O
internucleosomal	O
DNA	O
fragmentation	O
using	O
gel	O
electrophoresis	O
for	O
HL60	O
cell	O
samples	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
assay	O
in	O
HBMP	O
cells	O
.	O
The	O
catechol	B-Chemical
and	O
hydroquinone	B-Chemical
metabolites	O
,	O
NCQ436	B-Chemical
and	O
NCQ344	B-Chemical
,	O
induced	O
apoptosis	O
in	O
HL60	O
and	O
HBMP	O
cells	O
in	O
a	O
time	O
-	O
and	O
concentration	O
dependent	O
manner	O
,	O
while	O
the	O
phenols	B-Chemical
,	O
NCR181	O
,	O
FLA873	O
,	O
and	O
FLA797	B-Chemical
,	O
and	O
the	O
derivatives	O
formed	O
by	O
oxidation	O
of	O
the	O
pyrrolidine	B-Chemical
ring	O
,	O
FLA838	O
,	O
NCM001	O
,	O
and	O
NCL118	O
,	O
had	O
no	O
effect	O
.	O
No	O
necrosis	B-Disease
was	O
observed	O
in	O
cells	O
treated	O
with	O
NCQ436	B-Chemical
but	O
NCQ344	B-Chemical
had	O
a	O
biphasic	O
effect	O
in	O
both	O
cell	O
types	O
,	O
inducing	O
apoptosis	O
at	O
lower	O
concentrations	O
and	O
necrosis	B-Disease
at	O
higher	O
concentrations	O
.	O
These	O
data	O
show	O
that	O
the	O
catechol	B-Chemical
and	O
hydroquinone	B-Chemical
metabolites	O
of	O
remoxipride	B-Chemical
have	O
direct	O
toxic	O
effects	O
in	O
HL60	O
and	O
HBMP	O
cells	O
,	O
leading	O
to	O
apoptosis	O
,	O
while	O
the	O
phenol	B-Chemical
metabolites	O
were	O
inactive	O
.	O
Similarly	O
,	O
benzene	B-Chemical
-	O
derived	O
catechol	B-Chemical
and	O
hydroquinone	B-Chemical
,	O
but	O
not	O
phenol	B-Chemical
,	O
induce	O
apoptosis	O
in	O
HBMP	O
cells	O
[	O
Moran	O
et	O
al	O
.	O
,	O
Mol	O
.	O
Pharmacol	O
.	O
,	O
50	O
(	O
1996	O
)	O
610	O
-	O
615	O
]	O
.	O
We	O
propose	O
that	O
remoxipride	B-Chemical
and	O
benzene	B-Chemical
may	O
induce	O
aplastic	B-Disease
anemia	I-Disease
via	O
production	O
of	O
similar	O
reactive	O
metabolites	O
and	O
that	O
the	O
ability	O
of	O
NCQ436	B-Chemical
and	O
NCQ344	B-Chemical
to	O
induce	O
apoptosis	O
in	O
HBMP	O
cells	O
may	O
contribute	O
to	O
the	O
mechanism	O
underlying	O
acquired	O
aplastic	B-Disease
anemia	I-Disease
that	O
has	O
been	O
associated	O
with	O
remoxipride	B-Chemical
.	O
Synthesis	O
and	O
preliminary	O
pharmacological	O
investigations	O
of	O
1	B-Chemical
-	I-Chemical
(	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
dihydro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
acenaphthylenyl	I-Chemical
)	I-Chemical
piperazine	I-Chemical
derivatives	O
as	O
potential	O
atypical	O
antipsychotic	O
agents	O
in	O
mice	O
.	O
In	O
research	O
towards	O
the	O
development	O
of	O
new	O
atypical	O
antipsychotic	O
agents	O
,	O
one	O
strategy	O
is	O
that	O
the	O
dopaminergic	O
system	O
can	O
be	O
modulated	O
through	O
manipulation	O
of	O
the	O
serotonergic	O
system	O
.	O
The	O
synthesis	O
and	O
preliminary	O
pharmacological	O
evaluation	O
of	O
a	O
series	O
of	O
potential	O
atypical	O
antipsychotic	O
agents	O
based	O
on	O
the	O
structure	O
of	O
1	B-Chemical
-	I-Chemical
(	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
dihydro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
acenaphthylenyl	I-Chemical
)	I-Chemical
piperazine	I-Chemical
(	O
7	O
)	O
is	O
described	O
.	O
Compound	O
7e	O
,	O
5	B-Chemical
-	I-Chemical
{	I-Chemical
2	I-Chemical
-	I-Chemical
[	I-Chemical
4	I-Chemical
-	I-Chemical
(	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
-	I-Chemical
dihydro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
acenaphthylenyl	I-Chemical
)	I-Chemical
piperazinyl	I-Chemical
]	I-Chemical
ethyl	I-Chemical
}	I-Chemical
-	I-Chemical
2	I-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
dihy	I-Chemical
dro	I-Chemical
-	I-Chemical
1H	I-Chemical
-	I-Chemical
indol	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
one	I-Chemical
,	O
from	O
this	O
series	O
showed	O
significant	O
affinities	O
at	O
the	O
5	O
-	O
HT1A	O
and	O
5	O
-	O
HT2A	O
receptors	O
and	O
moderate	O
affinity	O
at	O
the	O
D2	O
receptor	O
.	O
7e	O
exhibits	O
a	O
high	O
reversal	O
of	O
catalepsy	B-Disease
induced	O
by	O
haloperidol	B-Chemical
indicating	O
its	O
atypical	O
antipsychotic	O
nature	O
.	O
Sub	O
-	O
chronic	O
inhibition	O
of	O
nitric	B-Chemical
-	I-Chemical
oxide	I-Chemical
synthesis	O
modifies	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
and	O
the	O
number	O
of	O
NADPH	B-Chemical
-	O
diaphorase	O
neurons	O
in	O
mice	O
.	O
RATIONALE	O
:	O
NG	B-Chemical
-	I-Chemical
nitro	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
(	O
L	B-Chemical
-	I-Chemical
NOARG	I-Chemical
)	O
,	O
an	O
inhibitor	O
of	O
nitric	B-Chemical
-	I-Chemical
oxide	I-Chemical
synthase	O
(	O
NOS	O
)	O
,	O
induces	O
catalepsy	B-Disease
in	O
mice	O
.	O
This	O
effect	O
undergoes	O
rapid	O
tolerance	O
,	O
showing	O
a	O
significant	O
decrease	O
after	O
2	O
days	O
of	O
sub	O
-	O
chronic	O
L	B-Chemical
-	I-Chemical
NOARG	I-Chemical
treatment	O
.	O
Nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
has	O
been	O
shown	O
to	O
influence	O
dopaminergic	O
neurotransmission	O
in	O
the	O
striatum	O
.	O
Neuroleptic	O
drugs	O
such	O
as	O
haloperidol	B-Chemical
,	O
which	O
block	O
dopamine	B-Chemical
receptors	O
,	O
also	O
cause	O
catalepsy	B-Disease
in	O
rodents	O
.	O
OBJECTIVES	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
subchronic	O
L	B-Chemical
-	I-Chemical
NOARG	I-Chemical
treatment	O
in	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
and	O
the	O
number	O
of	O
NOS	O
neurons	O
in	O
areas	O
related	O
to	O
motor	O
control	O
.	O
METHODS	O
:	O
Male	O
albino	O
Swiss	O
mice	O
were	O
treated	O
sub	O
-	O
chronically	O
(	O
twice	O
a	O
day	O
for	O
4	O
days	O
)	O
with	O
L	B-Chemical
-	I-Chemical
NOARG	I-Chemical
(	O
40	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
or	O
haloperidol	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O
Catalepsy	B-Disease
was	O
evaluated	O
at	O
the	O
beginning	O
and	O
the	O
end	O
of	O
the	O
treatments	O
.	O
Reduced	O
nicotinamide	B-Chemical
adenine	I-Chemical
dinucleotide	I-Chemical
phosphate	I-Chemical
-	O
diaphorase	O
(	O
NADPH	B-Chemical
-	O
d	O
)	O
histochemistry	O
was	O
also	O
employed	O
to	O
visualize	O
NOS	O
as	O
an	O
index	O
of	O
enzyme	O
expression	O
in	O
mice	O
brain	O
regions	O
related	O
to	O
motor	O
control	O
.	O
RESULTS	O
:	O
L	B-Chemical
-	I-Chemical
NOARG	I-Chemical
sub	O
-	O
chronic	O
administration	O
produced	O
tolerance	O
of	O
L	B-Chemical
-	I-Chemical
NOARG	I-Chemical
and	O
of	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
.	O
It	O
also	O
induced	O
an	O
increase	O
in	O
the	O
number	O
of	O
NADPH	B-Chemical
-	O
d	O
-	O
positive	O
cells	O
in	O
the	O
dorsal	O
part	O
of	O
the	O
caudate	O
and	O
accumbens	O
nuclei	O
compared	O
with	O
haloperidol	B-Chemical
and	O
in	O
the	O
pedunculopontine	O
tegmental	O
nucleus	O
compared	O
with	O
saline	O
.	O
In	O
contrast	O
,	O
there	O
was	O
a	O
decrease	O
in	O
NADPH	B-Chemical
-	O
d	O
neuron	O
number	O
in	O
the	O
substantia	O
nigra	O
,	O
pars	O
compacta	O
in	O
both	O
haloperidol	B-Chemical
-	O
treated	O
and	O
L	B-Chemical
-	I-Chemical
NOARG	I-Chemical
-	O
treated	O
animals	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
give	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
NO	B-Chemical
plays	O
a	O
role	O
in	O
motor	O
behavior	O
control	O
and	O
suggest	O
that	O
it	O
may	O
take	O
part	O
in	O
the	O
synaptic	O
changes	O
produced	O
by	O
antipsychotic	O
treatment	O
.	O
Prolonged	O
left	B-Disease
ventricular	I-Disease
dysfunction	I-Disease
occurs	O
in	O
patients	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
after	O
both	O
dobutamine	B-Chemical
and	O
exercise	O
induced	O
myocardial	B-Disease
ischaemia	I-Disease
.	O
OBJECTIVE	O
:	O
To	O
determine	O
whether	O
pharmacological	O
stress	O
leads	O
to	O
prolonged	O
but	O
reversible	O
left	B-Disease
ventricular	I-Disease
dysfunction	I-Disease
in	O
patients	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
,	O
similar	O
to	O
that	O
seen	O
after	O
exercise	O
.	O
DESIGN	O
:	O
A	O
randomised	O
crossover	O
study	O
of	O
recovery	O
time	O
of	O
systolic	O
and	O
diastolic	O
left	O
ventricular	O
function	O
after	O
exercise	O
and	O
dobutamine	B-Chemical
induced	O
ischaemia	B-Disease
.	O
SUBJECTS	O
:	O
10	O
patients	O
with	O
stable	B-Disease
angina	I-Disease
,	O
angiographically	O
proven	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
,	O
and	O
normal	O
left	O
ventricular	O
function	O
.	O
INTERVENTIONS	O
:	O
Treadmill	O
exercise	O
and	O
dobutamine	B-Chemical
stress	O
were	O
performed	O
on	O
different	O
days	O
.	O
Quantitative	O
assessment	O
of	O
systolic	O
and	O
diastolic	O
left	O
ventricular	O
function	O
was	O
performed	O
using	O
transthoracic	O
echocardiography	O
at	O
baseline	O
and	O
at	O
regular	O
intervals	O
after	O
each	O
test	O
.	O
RESULTS	O
:	O
Both	O
forms	O
of	O
stress	O
led	O
to	O
prolonged	O
but	O
reversible	O
systolic	O
and	O
diastolic	O
dysfunction	O
.	O
There	O
was	O
no	O
difference	O
in	O
the	O
maximum	O
double	O
product	O
(	O
p	O
=	O
0	O
.	O
53	O
)	O
or	O
ST	O
depression	B-Disease
(	O
p	O
=	O
0	O
.	O
63	O
)	O
with	O
either	O
form	O
of	O
stress	O
.	O
After	O
exercise	O
,	O
ejection	O
fraction	O
was	O
reduced	O
at	O
15	O
and	O
30	O
minutes	O
compared	O
with	O
baseline	O
(	O
mean	O
(	O
SEM	O
)	O
,	O
-	O
5	O
.	O
6	O
(	O
1	O
.	O
5	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
and	O
-	O
6	O
.	O
1	O
(	O
2	O
.	O
2	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
at	O
30	O
and	O
45	O
minutes	O
after	O
dobutamine	B-Chemical
(	O
-	O
10	O
.	O
8	O
(	O
1	O
.	O
8	O
)	O
%	O
and	O
-	O
5	O
.	O
5	O
(	O
1	O
.	O
8	O
)	O
%	O
,	O
both	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
Regional	O
analysis	O
showed	O
a	O
reduction	O
in	O
the	O
worst	O
affected	O
segment	O
15	O
and	O
30	O
minutes	O
after	O
exercise	O
(	O
-	O
27	O
.	O
9	O
(	O
7	O
.	O
2	O
)	O
%	O
and	O
-	O
28	O
.	O
6	O
(	O
5	O
.	O
7	O
)	O
%	O
,	O
both	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
at	O
30	O
minutes	O
after	O
dobutamine	B-Chemical
(	O
-	O
32	O
(	O
5	O
.	O
3	O
)	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
The	O
isovolumic	O
relaxation	O
period	O
was	O
prolonged	O
45	O
minutes	O
after	O
each	O
form	O
of	O
stress	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
CONCLUSIONS	O
:	O
In	O
patients	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
,	O
dobutamine	B-Chemical
induced	O
ischaemia	B-Disease
results	O
in	O
prolonged	O
reversible	O
left	B-Disease
ventricular	I-Disease
dysfunction	I-Disease
,	O
presumed	O
to	O
be	O
myocardial	B-Disease
stunning	I-Disease
,	O
similar	O
to	O
that	O
seen	O
after	O
exercise	O
.	O
Dobutamine	B-Chemical
induced	O
ischaemia	B-Disease
could	O
therefore	O
be	O
used	O
to	O
study	O
the	O
pathophysiology	O
of	O
this	O
phenomenon	O
further	O
in	O
patients	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
.	O
Anorexigens	O
and	O
pulmonary	B-Disease
hypertension	I-Disease
in	O
the	O
United	O
States	O
:	O
results	O
from	O
the	O
surveillance	O
of	O
North	O
American	O
pulmonary	B-Disease
hypertension	I-Disease
.	O
BACKGROUND	O
:	O
The	O
use	O
of	O
appetite	O
suppressants	O
in	O
Europe	O
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
primary	B-Disease
pulmonary	I-Disease
hypertension	I-Disease
(	O
PPH	B-Disease
)	O
.	O
Recently	O
,	O
fenfluramine	B-Chemical
appetite	O
suppressants	O
became	O
widely	O
used	O
in	O
the	O
United	O
States	O
but	O
were	O
withdrawn	O
in	O
September	O
1997	O
because	O
of	O
concerns	O
over	O
adverse	O
effects	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
We	O
conducted	O
a	O
prospective	O
surveillance	O
study	O
on	O
patients	O
diagnosed	O
with	O
pulmonary	B-Disease
hypertension	I-Disease
at	O
12	O
large	O
referral	O
centers	O
in	O
North	O
America	O
.	O
Data	O
collected	O
on	O
patients	O
seen	O
from	O
September	O
1	O
,	O
1996	O
,	O
to	O
December	O
31	O
,	O
1997	O
,	O
included	O
the	O
cause	O
of	O
the	O
pulmonary	B-Disease
hypertension	I-Disease
and	O
its	O
severity	O
.	O
Patients	O
with	O
no	O
identifiable	O
cause	O
of	O
pulmonary	B-Disease
hypertension	I-Disease
were	O
classed	O
as	O
PPH	B-Disease
.	O
A	O
history	O
of	O
drug	O
exposure	O
also	O
was	O
taken	O
with	O
special	O
attention	O
on	O
the	O
use	O
of	O
antidepressants	O
,	O
anorexigens	O
,	O
and	O
amphetamines	B-Chemical
.	O
RESULTS	O
:	O
Five	O
hundred	O
seventy	O
-	O
nine	O
patients	O
were	O
studied	O
,	O
205	O
with	O
PPH	B-Disease
and	O
374	O
with	O
pulmonary	B-Disease
hypertension	I-Disease
from	O
other	O
causes	O
(	O
secondary	O
pulmonary	B-Disease
hypertension	I-Disease
[	O
SPH	O
]	O
)	O
.	O
The	O
use	O
of	O
anorexigens	O
was	O
common	O
in	O
both	O
groups	O
.	O
However	O
,	O
of	O
the	O
medications	O
surveyed	O
,	O
only	O
the	O
fenfluramines	B-Chemical
had	O
a	O
significant	O
preferential	O
association	O
with	O
PPH	B-Disease
as	O
compared	O
with	O
SPH	O
(	O
adjusted	O
odds	O
ratio	O
for	O
use	O
>	O
6	O
months	O
,	O
7	O
.	O
5	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
7	O
to	O
32	O
.	O
4	O
)	O
.	O
The	O
association	O
was	O
stronger	O
with	O
longer	O
duration	O
of	O
use	O
when	O
compared	O
to	O
shorter	O
duration	O
of	O
use	O
and	O
was	O
more	O
pronounced	O
in	O
recent	O
users	O
than	O
in	O
remote	O
users	O
.	O
An	O
unexpectedly	O
high	O
(	O
11	O
.	O
4	O
%	O
)	O
number	O
of	O
patients	O
with	O
SPH	O
had	O
used	O
anorexigens	O
.	O
CONCLUSION	O
:	O
The	O
magnitude	O
of	O
the	O
association	O
with	O
PPH	B-Disease
,	O
the	O
increase	O
of	O
association	O
with	O
increasing	O
duration	O
of	O
use	O
,	O
and	O
the	O
specificity	O
for	O
fenfluramines	B-Chemical
are	O
consistent	O
with	O
previous	O
studies	O
indicating	O
that	O
fenfluramines	B-Chemical
are	O
causally	O
related	O
to	O
PPH	B-Disease
.	O
The	O
high	O
prevalence	O
of	O
anorexigen	O
use	O
in	O
patients	O
with	O
SPH	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
drugs	O
precipitate	O
pulmonary	B-Disease
hypertension	I-Disease
in	O
patients	O
with	O
underlying	O
conditions	O
associated	O
with	O
SPH	O
.	O
Clinical	O
aspects	O
of	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
and	O
thrombosis	B-Disease
and	O
other	O
side	O
effects	O
of	O
heparin	B-Chemical
therapy	O
.	O
Heparin	B-Chemical
,	O
first	O
used	O
to	O
prevent	O
the	O
clotting	O
of	O
blood	O
in	O
vitro	O
,	O
has	O
been	O
clinically	O
used	O
to	O
treat	O
thrombosis	B-Disease
for	O
more	O
than	O
50	O
years	O
.	O
Although	O
several	O
new	O
anticoagulant	O
drugs	O
are	O
in	O
development	O
,	O
heparin	B-Chemical
remains	O
the	O
anticoagulant	O
of	O
choice	O
to	O
treat	O
acute	O
thrombotic	B-Disease
episodes	O
.	O
The	O
clinical	O
effects	O
of	O
heparin	B-Chemical
are	O
meritorious	O
,	O
but	O
side	O
effects	O
do	O
exist	O
.	O
Bleeding	B-Disease
is	O
the	O
primary	O
untoward	O
effect	O
of	O
heparin	B-Chemical
.	O
Major	O
bleeding	B-Disease
is	O
of	O
primary	O
concern	O
in	O
patients	O
receiving	O
heparin	B-Chemical
therapy	O
.	O
However	O
,	O
additional	O
important	O
untoward	O
effects	O
of	O
heparin	B-Chemical
therapy	O
include	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
,	O
heparin	B-Chemical
-	O
associated	O
osteoporosis	B-Disease
,	O
eosinophilia	B-Disease
,	O
skin	B-Disease
reactions	I-Disease
,	O
allergic	B-Disease
reactions	I-Disease
other	O
than	O
thrombocytopenia	B-Disease
,	O
alopecia	B-Disease
,	O
transaminasemia	O
,	O
hyperkalemia	B-Disease
,	O
hypoaldosteronism	B-Disease
,	O
and	O
priapism	B-Disease
.	O
These	O
side	O
effects	O
are	O
relatively	O
rare	O
in	O
a	O
given	O
individual	O
,	O
but	O
given	O
the	O
extremely	O
widespread	O
use	O
of	O
heparin	B-Chemical
,	O
some	O
are	O
quite	O
common	O
,	O
particularly	O
HITT	B-Disease
and	O
osteoporosis	B-Disease
.	O
Although	O
reasonable	O
incidences	O
of	O
many	O
of	O
these	O
side	O
effects	O
can	O
be	O
""""	O
softly	O
""""	O
deduced	O
from	O
current	O
reports	O
dealing	O
with	O
unfractionated	O
heparin	B-Chemical
,	O
at	O
present	O
the	O
incidences	O
of	O
these	O
side	O
effects	O
with	O
newer	O
low	O
molecular	O
weight	O
heparins	B-Chemical
appear	O
to	O
be	O
much	O
less	O
common	O
.	O
However	O
,	O
only	O
longer	O
experience	O
will	O
more	O
clearly	O
define	O
the	O
incidence	O
of	O
each	O
side	O
effect	O
with	O
low	O
molecular	O
weight	O
preparations	O
.	O
A	O
case	O
of	O
bilateral	O
optic	B-Disease
neuropathy	I-Disease
in	O
a	O
patient	O
on	O
tacrolimus	B-Chemical
(	O
FK506	B-Chemical
)	O
therapy	O
after	O
liver	O
transplantation	O
.	O
PURPOSE	O
:	O
To	O
report	O
a	O
case	O
of	O
bilateral	O
optic	B-Disease
neuropathy	I-Disease
in	O
a	O
patient	O
receiving	O
tacrolimus	B-Chemical
(	O
FK	B-Chemical
506	I-Chemical
,	O
Prograf	O
;	O
Fujisawa	O
USA	O
,	O
Inc	O
,	O
Deerfield	O
,	O
Illinois	O
)	O
for	O
immunosuppression	O
after	O
orthotropic	O
liver	O
transplantation	O
.	O
METHOD	O
:	O
Case	O
report	O
.	O
In	O
a	O
58	O
-	O
year	O
-	O
old	O
man	O
receiving	O
tacrolimus	B-Chemical
after	O
orthotropic	O
liver	O
transplantation	O
,	O
serial	O
neuro	O
-	O
ophthalmologic	O
examinations	O
and	O
laboratory	O
studies	O
were	O
performed	O
.	O
RESULTS	O
:	O
The	O
patient	O
had	O
episodic	O
deterioration	O
of	O
vision	O
in	O
both	O
eyes	O
,	O
with	O
clinical	O
features	O
resembling	O
ischemic	B-Disease
optic	I-Disease
neuropathies	I-Disease
.	O
Deterioration	B-Disease
of	I-Disease
vision	I-Disease
occurred	O
despite	O
discontinuation	O
of	O
the	O
tacrolimus	B-Chemical
.	O
CONCLUSION	O
:	O
Tacrolimus	B-Chemical
and	O
other	O
immunosuppressive	O
agents	O
may	O
be	O
associated	O
with	O
optic	B-Disease
nerve	I-Disease
toxicity	I-Disease
.	O
Hypercalcemia	B-Disease
,	O
arrhythmia	B-Disease
,	O
and	O
mood	O
stabilizers	O
.	O
Recent	O
findings	O
in	O
a	O
bipolar	B-Disease
patient	O
receiving	O
maintenance	O
lithium	B-Chemical
therapy	O
who	O
developed	O
hypercalcemia	B-Disease
and	O
severe	O
bradyarrhythmia	B-Disease
prompted	O
the	O
authors	O
to	O
conduct	O
a	O
retrospective	O
study	O
of	O
bipolar	B-Disease
patients	O
with	O
lithium	B-Chemical
-	O
associated	O
hypercalcemia	B-Disease
.	O
A	O
printout	O
of	O
all	O
cases	O
of	O
hypercalcemia	B-Disease
that	O
presented	O
during	O
a	O
1	O
-	O
year	O
period	O
was	O
generated	O
.	O
After	O
eliminating	O
spurious	O
hypercalcemias	B-Disease
or	O
those	O
associated	O
with	O
intravenous	O
fluids	O
,	O
the	O
authors	O
identified	O
18	O
non	O
-	O
lithium	B-Chemical
-	O
treated	O
patients	O
with	O
hypercalcemias	B-Disease
related	O
to	O
malignancies	B-Disease
and	O
other	O
medical	O
conditions	O
(	O
group	O
A	O
)	O
and	O
12	O
patients	O
with	O
lithium	B-Chemical
-	O
associated	O
hypercalcemia	B-Disease
(	O
group	O
B	O
)	O
.	O
Patients	O
in	O
group	O
B	O
were	O
not	O
comparable	O
to	O
those	O
in	O
group	O
A	O
,	O
as	O
the	O
latter	O
were	O
medically	O
compromised	O
and	O
were	O
receiving	O
multiple	O
pharmacotherapies	O
.	O
Thus	O
,	O
two	O
control	O
groups	O
were	O
generated	O
:	O
group	O
C1	O
,	O
which	O
included	O
age	O
-	O
and	O
sex	O
-	O
comparable	O
lithium	B-Chemical
-	O
treated	O
bipolar	B-Disease
normocalcemic	O
patients	O
,	O
and	O
group	O
C2	O
,	O
which	O
included	O
bipolar	B-Disease
normocalcemic	O
patients	O
treated	O
with	O
anticonvulsant	O
mood	O
stabilizers	O
.	O
The	O
electrocardiographic	O
(	O
ECG	O
)	O
findings	O
for	O
patients	O
in	O
group	O
B	O
were	O
compared	O
with	O
those	O
of	O
patients	O
in	O
groups	O
C1	O
and	O
C2	O
.	O
It	O
was	O
found	O
that	O
these	O
groups	O
did	O
not	O
differ	O
in	O
their	O
overall	O
frequency	O
of	O
ECG	O
abnormalities	O
;	O
however	O
,	O
there	O
were	O
significant	O
differences	O
in	O
the	O
frequency	O
of	O
conduction	O
defects	O
.	O
Patients	O
with	O
hypercalcemia	B-Disease
resulting	O
from	O
medical	O
diseases	O
and	O
bipolar	B-Disease
patients	O
with	O
lithium	B-Chemical
-	O
associated	O
hypercalcemia	B-Disease
had	O
significantly	O
higher	O
frequencies	O
of	O
conduction	O
defects	O
.	O
Patients	O
in	O
group	O
A	O
had	O
significant	O
mortality	O
at	O
2	O
-	O
year	O
follow	O
-	O
up	O
(	O
28	O
%	O
)	O
,	O
in	O
contrast	O
to	O
zero	O
mortality	O
in	O
the	O
other	O
three	O
groups	O
.	O
The	O
clinical	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
.	O
Attenuation	O
of	O
nephrotoxicity	B-Disease
by	O
a	O
novel	O
lipid	O
nanosphere	O
(	O
NS	O
-	O
718	O
)	O
incorporating	O
amphotericin	B-Chemical
B	I-Chemical
.	O
NS	O
-	O
718	O
,	O
a	O
lipid	O
nanosphere	O
incorporating	O
amphotericin	B-Chemical
B	I-Chemical
,	O
is	O
effective	O
against	O
pathogenic	O
fungi	O
and	O
has	O
low	O
toxicity	B-Disease
.	O
We	O
compared	O
the	O
toxicity	B-Disease
of	O
NS	O
-	O
718	O
with	O
that	O
of	O
Fungizone	B-Chemical
(	O
amphotericin	B-Chemical
B	I-Chemical
-	I-Chemical
sodium	I-Chemical
deoxycholate	I-Chemical
;	O
D	B-Chemical
-	I-Chemical
AmB	I-Chemical
)	O
in	O
vitro	O
using	O
renal	O
cell	O
cultures	O
and	O
in	O
vivo	O
by	O
biochemical	O
analysis	O
,	O
histopathological	O
study	O
of	O
the	O
kidney	O
and	O
pharmacokinetic	O
study	O
of	O
amphotericin	B-Chemical
B	I-Chemical
following	O
intravenous	O
infusion	O
of	O
the	O
formulation	O
in	O
rats	O
.	O
Incubation	O
with	O
NS	O
-	O
718	O
resulted	O
in	O
significantly	O
less	O
damage	O
of	O
cultured	O
human	O
renal	O
proximal	O
tubular	O
epithelial	O
cells	O
compared	O
with	O
D	B-Chemical
-	I-Chemical
AmB	I-Chemical
.	O
Serum	O
blood	O
urea	B-Chemical
and	O
creatinine	B-Chemical
concentrations	O
increased	O
significantly	O
in	O
rats	O
given	O
an	O
iv	O
infusion	O
of	O
D	B-Chemical
-	I-Chemical
AmB	I-Chemical
3	O
mg	O
/	O
kg	O
but	O
not	O
in	O
those	O
given	O
the	O
same	O
dose	O
of	O
NS	O
-	O
718	O
.	O
Histopathological	O
examination	O
of	O
the	O
kidney	O
showed	O
tubular	B-Disease
necrosis	I-Disease
in	O
D	B-Chemical
-	I-Chemical
AmB	I-Chemical
-	O
treated	O
rats	O
but	O
no	O
change	O
in	O
NS	O
-	O
718	O
-	O
treated	O
rats	O
.	O
Amphotericin	B-Chemical
B	I-Chemical
concentrations	O
in	O
the	O
kidney	O
in	O
NS	O
-	O
718	O
-	O
treated	O
rats	O
were	O
higher	O
than	O
those	O
in	O
D	B-Chemical
-	I-Chemical
AmB	I-Chemical
-	O
treated	O
rats	O
.	O
Our	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
suggest	O
that	O
incorporation	O
of	O
amphotericin	B-Chemical
B	I-Chemical
into	O
lipid	O
nanospheres	O
of	O
NS	O
-	O
718	O
attenuates	O
the	O
nephrotoxicity	B-Disease
of	O
amphotericin	B-Chemical
B	I-Chemical
.	O
Patterns	O
of	O
sulfadiazine	B-Chemical
acute	B-Disease
nephrotoxicity	I-Disease
.	O
Sulfadiazine	B-Chemical
acute	B-Disease
nephrotoxicity	I-Disease
is	O
reviving	O
specially	O
because	O
of	O
its	O
use	O
in	O
toxoplasmosis	B-Disease
in	O
HIV	O
-	O
positive	O
patients	O
.	O
We	O
report	O
4	O
cases	O
,	O
one	O
of	O
them	O
in	O
a	O
previously	O
healthy	O
person	O
.	O
Under	O
treatment	O
with	O
sulfadiazine	B-Chemical
they	O
developed	O
oliguria	B-Disease
,	O
abdominal	B-Disease
pain	I-Disease
,	O
renal	B-Disease
failure	I-Disease
and	O
showed	O
multiple	O
radiolucent	O
renal	B-Disease
calculi	I-Disease
in	O
echography	O
.	O
All	O
patients	O
recovered	O
their	O
previous	O
normal	O
renal	O
function	O
after	O
adequate	O
hydration	O
and	O
alcalinization	O
.	O
A	O
nephrostomy	O
tube	O
had	O
to	O
be	O
placed	O
in	O
one	O
of	O
the	O
patients	O
for	O
ureteral	B-Disease
lithiasis	I-Disease
in	O
a	O
single	O
functional	O
kidney	O
.	O
None	O
of	O
them	O
needed	O
dialysis	O
or	O
a	O
renal	O
biopsy	O
because	O
of	O
a	O
typical	O
benign	O
course	O
.	O
Treatment	O
with	O
sulfadiazine	B-Chemical
requires	O
exquisite	O
control	O
of	O
renal	O
function	O
,	O
an	O
increase	O
in	O
water	O
ingestion	O
and	O
possibly	O
the	O
alcalinization	O
of	O
the	O
urine	O
.	O
We	O
communicate	O
a	O
case	O
in	O
a	O
previously	O
healthy	O
person	O
,	O
a	O
fact	O
not	O
found	O
in	O
the	O
recent	O
literature	O
.	O
Probably	O
many	O
more	O
cases	O
are	O
not	O
detected	O
.	O
We	O
think	O
that	O
a	O
prospective	O
study	O
would	O
be	O
useful	O
.	O
Downbeat	B-Disease
nystagmus	I-Disease
associated	O
with	O
intravenous	O
patient	O
-	O
controlled	O
administration	O
of	O
morphine	B-Chemical
.	O
IMPLICATIONS	O
:	O
This	O
case	O
documents	O
a	O
patient	O
who	O
developed	O
dizziness	B-Disease
with	O
downbeating	B-Disease
nystagmus	I-Disease
while	O
receiving	O
a	O
relatively	O
large	O
dose	O
of	O
IV	O
patient	O
-	O
controlled	O
analgesia	O
morphine	B-Chemical
.	O
Although	O
there	O
have	O
been	O
case	O
reports	O
of	O
epidural	O
morphine	B-Chemical
with	O
these	O
symptoms	O
and	O
signs	O
,	O
this	O
has	O
not	O
been	O
previously	O
documented	O
with	O
IV	O
or	O
patient	O
-	O
controlled	O
analgesia	O
morphine	B-Chemical
.	O
Hemodynamic	O
and	O
antiadrenergic	O
effects	O
of	O
dronedarone	B-Chemical
and	O
amiodarone	B-Chemical
in	O
animals	O
with	O
a	O
healed	O
myocardial	B-Disease
infarction	I-Disease
.	O
The	O
hemodynamic	O
and	O
antiadrenergic	O
effects	O
of	O
dronedarone	B-Chemical
,	O
a	O
noniodinated	O
compound	O
structurally	O
related	O
to	O
amiodarone	B-Chemical
,	O
were	O
compared	O
with	O
those	O
of	O
amiodarone	B-Chemical
after	O
prolonged	O
oral	O
administration	O
,	O
both	O
at	O
rest	O
and	O
during	O
sympathetic	O
stimulation	O
in	O
conscious	O
dogs	O
with	O
a	O
healed	O
myocardial	B-Disease
infarction	I-Disease
.	O
All	O
dogs	O
(	O
n	O
=	O
6	O
)	O
randomly	O
received	O
orally	O
dronedarone	B-Chemical
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
,	O
amiodarone	B-Chemical
(	O
10	O
and	O
30	O
mg	O
/	O
kg	O
)	O
,	O
and	O
placebo	O
twice	O
daily	O
for	O
7	O
days	O
,	O
with	O
a	O
3	O
-	O
week	O
washout	O
between	O
consecutive	O
treatments	O
.	O
Heart	O
rate	O
(	O
HR	O
)	O
,	O
mean	O
arterial	O
pressure	O
(	O
MBP	O
)	O
,	O
positive	O
rate	O
of	O
increase	O
of	O
left	O
ventricular	O
pressure	O
(	O
+	O
LVdP	O
/	O
dt	O
)	O
,	O
echocardiographically	O
assessed	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
,	O
and	O
fractional	O
shortening	O
(	O
FS	O
)	O
,	O
as	O
well	O
as	O
chronotropic	O
response	O
to	O
isoproterenol	B-Chemical
and	O
exercise	O
-	O
induced	O
sympathetic	O
stimulation	O
were	O
evaluated	O
under	O
baseline	O
and	O
posttreatment	O
conditions	O
.	O
Resting	O
values	O
of	O
LVEF	O
,	O
FS	O
,	O
+	O
LVdP	O
/	O
dt	O
,	O
and	O
MBP	O
remained	O
unchanged	O
whatever	O
the	O
drug	O
and	O
the	O
dosing	O
regimen	O
,	O
whereas	O
resting	O
HR	O
was	O
significantly	O
and	O
dose	O
-	O
dependently	O
lowered	O
after	O
dronedarone	B-Chemical
and	O
to	O
a	O
lesser	O
extent	O
after	O
amiodarone	B-Chemical
.	O
Both	O
dronedarone	B-Chemical
and	O
amiodarone	B-Chemical
significantly	O
reduced	O
the	O
exercise	O
-	O
induced	O
tachycardia	B-Disease
and	O
,	O
at	O
the	O
highest	O
dose	O
,	O
decreased	O
the	O
isoproterenol	B-Chemical
-	O
induced	O
tachycardia	B-Disease
.	O
Thus	O
,	O
dronedarone	B-Chemical
and	O
amiodarone	B-Chemical
displayed	O
a	O
similar	O
level	O
of	O
antiadrenergic	O
effect	O
and	O
did	O
not	O
impair	O
the	O
resting	O
left	O
ventricular	O
function	O
.	O
Consequently	O
,	O
dronedarone	B-Chemical
might	O
be	O
particularly	O
suitable	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
various	O
clinical	O
arrhythmias	B-Disease
,	O
without	O
compromising	O
the	O
left	O
ventricular	O
function	O
.	O
Phase	O
2	O
trial	O
of	O
liposomal	O
doxorubicin	B-Chemical
(	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
in	O
platinum	B-Chemical
/	O
paclitaxel	B-Chemical
-	O
refractory	O
ovarian	B-Disease
and	I-Disease
fallopian	I-Disease
tube	I-Disease
cancers	I-Disease
and	O
primary	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
peritoneum	I-Disease
.	O
BACKGROUND	O
:	O
Several	O
studies	O
have	O
demonstrated	O
liposomal	O
doxorubicin	B-Chemical
(	O
Doxil	B-Chemical
)	O
to	O
be	O
an	O
active	O
antineoplastic	O
agent	O
in	O
platinum	B-Chemical
-	O
resistant	O
ovarian	B-Disease
cancer	I-Disease
,	O
with	O
dose	O
limiting	O
toxicity	B-Disease
of	O
the	O
standard	O
dosing	O
regimen	O
(	O
50	O
mg	O
/	O
m	O
(	O
2	O
)	O
q	O
4	O
weeks	O
)	O
being	O
severe	O
erythrodysesthesia	B-Disease
(	O
""""	O
hand	B-Disease
-	I-Disease
foot	I-Disease
syndrome	I-Disease
""""	O
)	O
and	O
stomatitis	B-Disease
.	O
We	O
wished	O
to	O
develop	O
a	O
more	O
tolerable	O
liposomal	O
doxorubicin	B-Chemical
treatment	O
regimen	O
and	O
document	O
its	O
level	O
of	O
activity	O
in	O
a	O
well	O
-	O
defined	O
patient	O
population	O
with	O
platinum	B-Chemical
/	O
paclitaxel	B-Chemical
-	O
refractory	O
disease	O
.	O
METHODS	O
AND	O
MATERIALS	O
:	O
Patients	O
with	O
ovarian	B-Disease
or	I-Disease
fallopian	I-Disease
tube	I-Disease
cancers	I-Disease
or	O
primary	O
peritoneal	B-Disease
carcinoma	I-Disease
with	O
platinum	B-Chemical
/	O
paclitaxel	B-Chemical
-	O
refractory	O
disease	O
(	O
stable	O
or	O
progressive	O
disease	O
following	O
treatment	O
with	O
these	O
agents	O
or	O
previous	O
objective	O
response	O
<	O
3	O
months	O
in	O
duration	O
)	O
were	O
treated	O
with	O
liposomal	O
doxorubicin	B-Chemical
at	O
a	O
dose	O
of	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
q	O
4	O
weeks	O
.	O
RESULTS	O
:	O
A	O
total	O
of	O
49	O
patients	O
(	O
median	O
age	O
:	O
60	O
;	O
range	O
41	O
-	O
81	O
)	O
entered	O
this	O
phase	O
2	O
trial	O
.	O
The	O
median	O
number	O
of	O
prior	O
regimens	O
was	O
2	O
(	O
range	O
:	O
1	O
-	O
6	O
)	O
.	O
Six	O
(	O
12	O
%	O
)	O
and	O
4	O
(	O
8	O
%	O
)	O
patients	O
experienced	O
grade	O
2	O
hand	B-Disease
-	I-Disease
foot	I-Disease
syndrome	I-Disease
and	O
stomatitis	B-Disease
,	O
respectively	O
(	O
no	O
episodes	O
of	O
grade	O
3	O
)	O
.	O
One	O
patient	O
developed	O
grade	O
3	O
diarrhea	B-Disease
requiring	O
hospitalization	O
for	O
hydration	O
.	O
Six	O
(	O
12	O
%	O
)	O
individuals	O
required	O
dose	O
reductions	O
.	O
The	O
median	O
number	O
of	O
courses	O
of	O
liposomal	O
doxorubicin	B-Chemical
administered	O
on	O
this	O
protocol	O
was	O
2	O
(	O
range	O
:	O
1	O
-	O
12	O
)	O
.	O
Four	O
of	O
44	O
patients	O
(	O
9	O
%	O
)	O
evaluable	O
for	O
response	O
exhibited	O
objective	O
and	O
subjective	O
evidence	O
of	O
an	O
antineoplastic	O
effect	O
of	O
therapy	O
.	O
CONCLUSION	O
:	O
This	O
modified	O
liposomal	O
doxorubicin	B-Chemical
regimen	O
results	O
in	O
less	O
toxicity	B-Disease
(	O
stomatitis	B-Disease
,	O
hand	B-Disease
-	I-Disease
foot	I-Disease
syndrome	I-Disease
)	O
than	O
the	O
standard	O
FDA	O
-	O
approved	O
dose	O
schedule	O
.	O
Definite	O
,	O
although	O
limited	O
,	O
antineoplastic	O
activity	O
is	O
observed	O
in	O
patients	O
with	O
well	O
-	O
defined	O
platinum	B-Chemical
-	O
and	O
paclitaxel	B-Chemical
-	O
refractory	O
ovarian	B-Disease
cancer	I-Disease
.	O
Efficacy	O
of	O
olanzapine	B-Chemical
in	O
acute	O
bipolar	B-Disease
mania	I-Disease
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O
The	O
Olanzipine	B-Chemical
HGGW	O
Study	O
Group	O
.	O
BACKGROUND	O
:	O
We	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
olanzapine	B-Chemical
vs	O
placebo	O
for	O
the	O
treatment	O
of	O
acute	O
bipolar	B-Disease
mania	I-Disease
.	O
METHODS	O
:	O
Four	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
study	O
.	O
A	O
total	O
of	O
115	O
patients	O
with	O
a	O
DSM	O
-	O
IV	O
diagnosis	O
of	O
bipolar	B-Disease
disorder	I-Disease
,	O
manic	B-Disease
or	O
mixed	O
,	O
were	O
randomized	O
to	O
olanzapine	B-Chemical
,	O
5	O
to	O
20	O
mg	O
/	O
d	O
(	O
n	O
=	O
55	O
)	O
,	O
or	O
placebo	O
(	O
n	O
=	O
60	O
)	O
.	O
The	O
primary	O
efficacy	O
measure	O
was	O
the	O
Young	O
-	O
Mania	B-Disease
Rating	O
Scale	O
(	O
Y	O
-	O
MRS	O
)	O
total	O
score	O
.	O
Response	O
and	O
euthymia	O
were	O
defined	O
,	O
a	O
priori	O
,	O
as	O
at	O
least	O
a	O
50	O
%	O
improvement	O
from	O
baseline	O
to	O
end	O
point	O
and	O
as	O
a	O
score	O
of	O
no	O
less	O
than	O
12	O
at	O
end	O
point	O
in	O
the	O
Y	O
-	O
MRS	O
total	O
score	O
,	O
respectively	O
.	O
Safety	O
was	O
assessed	O
using	O
adverse	O
events	O
,	O
Extrapyramidal	B-Disease
Symptom	I-Disease
(	O
EPS	B-Disease
)	O
rating	O
scales	O
,	O
laboratory	O
values	O
,	O
electrocardiograms	O
,	O
vital	O
signs	O
,	O
and	O
weight	O
change	O
.	O
RESULTS	O
:	O
Olanzapine	B-Chemical
-	O
treated	O
patients	O
demonstrated	O
a	O
statistically	O
significant	O
greater	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
improvement	O
in	O
Y	O
-	O
MRS	O
total	O
score	O
than	O
placebo	O
-	O
treated	O
patients	O
(	O
-	O
14	O
.	O
8	O
+	O
/	O
-	O
12	O
.	O
5	O
and	O
-	O
8	O
.	O
1	O
+	O
/	O
-	O
12	O
.	O
7	O
,	O
respectively	O
;	O
P	O
<	O
.	O
001	O
)	O
,	O
which	O
was	O
evident	O
at	O
the	O
first	O
postbaseline	O
observation	O
1	O
week	O
after	O
randomization	O
and	O
was	O
maintained	O
throughout	O
the	O
study	O
(	O
last	O
observation	O
carried	O
forward	O
)	O
.	O
Olanzapine	B-Chemical
-	O
treated	O
patients	O
demonstrated	O
a	O
higher	O
rate	O
of	O
response	O
(	O
65	O
%	O
vs	O
43	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.	O
02	O
)	O
and	O
euthymia	O
(	O
61	O
%	O
vs	O
36	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.	O
01	O
)	O
than	O
placebo	O
-	O
treated	O
patients	O
.	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
EPSs	B-Disease
between	O
groups	O
.	O
However	O
,	O
olanzapine	B-Chemical
-	O
treated	O
patients	O
had	O
a	O
statistically	O
significant	O
greater	O
mean	O
(	O
+	O
/	O
-	O
SD	O
)	O
weight	B-Disease
gain	I-Disease
than	O
placebo	O
-	O
treated	O
patients	O
(	O
2	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
8	O
vs	O
0	O
.	O
45	O
+	O
/	O
-	O
2	O
.	O
3	O
kg	O
,	O
respectively	O
)	O
and	O
also	O
experienced	O
more	O
treatment	O
-	O
emergent	O
somnolence	B-Disease
(	O
21	O
patients	O
[	O
38	O
.	O
2	O
%	O
]	O
vs	O
5	O
[	O
8	O
.	O
3	O
%	O
]	O
,	O
respectively	O
)	O
.	O
CONCLUSION	O
:	O
Olanzapine	B-Chemical
demonstrated	O
greater	O
efficacy	O
than	O
placebo	O
in	O
the	O
treatment	O
of	O
acute	O
bipolar	B-Disease
mania	I-Disease
and	O
was	O
generally	O
well	O
tolerated	O
.	O
The	O
effect	O
of	O
pupil	B-Disease
dilation	I-Disease
with	O
tropicamide	B-Chemical
on	O
vision	O
and	O
driving	O
simulator	O
performance	O
.	O
PURPOSE	O
:	O
To	O
assess	O
the	O
effect	O
of	O
pupil	B-Disease
dilation	I-Disease
on	O
vision	O
and	O
driving	O
ability	O
.	O
METHODS	O
:	O
A	O
series	O
of	O
tests	O
on	O
various	O
parameters	O
of	O
visual	O
function	O
and	O
driving	O
simulator	O
performance	O
were	O
performed	O
on	O
12	O
healthy	O
drivers	O
,	O
before	O
and	O
after	O
pupil	B-Disease
dilation	I-Disease
using	O
guttae	O
tropicamide	B-Chemical
1	O
%	O
.	O
A	O
driving	O
simulator	O
(	O
Transport	O
Research	O
Laboratory	O
)	O
was	O
used	O
to	O
measure	O
reaction	O
time	O
(	O
RT	O
)	O
,	O
speed	O
maintenance	O
and	O
steering	O
accuracy	O
.	O
Tests	O
of	O
basic	O
visual	O
function	O
included	O
high	O
-	O
and	O
low	O
-	O
contrast	O
visual	O
acuity	O
(	O
HCVA	O
and	O
LCVA	O
)	O
,	O
Pelli	O
-	O
Robson	O
contrast	O
threshold	O
(	O
CT	O
)	O
and	O
Goldmann	O
perimetry	O
(	O
FIELDS	O
)	O
.	O
Useful	O
Field	O
of	O
View	O
(	O
UFOV	O
-	O
-	O
a	O
test	O
of	O
visual	O
attention	O
)	O
was	O
also	O
undertaken	O
.	O
The	O
mean	O
differences	O
in	O
the	O
pre	O
-	O
and	O
post	O
-	O
dilatation	O
measurements	O
were	O
tested	O
for	O
statistical	O
significance	O
at	O
the	O
95	O
%	O
level	O
using	O
one	O
-	O
tail	O
paired	O
t	O
-	O
tests	O
.	O
RESULTS	O
:	O
Pupillary	B-Disease
dilation	I-Disease
resulted	O
in	O
a	O
statistically	O
significant	O
deterioration	O
in	O
CT	O
and	O
HCVA	O
only	O
.	O
Five	O
of	O
12	O
drivers	O
also	O
exhibited	O
deterioration	O
in	O
LCVA	O
,	O
CT	O
and	O
RT	O
.	O
Little	O
evidence	O
emerged	O
for	O
deterioration	O
in	O
FIELDS	O
and	O
UFOV	O
.	O
Also	O
,	O
7	O
of	O
12	O
drivers	O
appeared	O
to	O
adjust	O
their	O
driving	O
behaviour	O
by	O
reducing	O
their	O
speed	O
on	O
the	O
driving	O
simulator	O
,	O
leading	O
to	O
improved	O
steering	O
accuracy	O
.	O
CONCLUSIONS	O
:	O
Pupillary	B-Disease
dilation	I-Disease
may	O
lead	O
to	O
a	O
decrease	O
in	O
vision	O
and	O
daylight	O
driving	O
performance	O
in	O
young	O
people	O
.	O
A	O
larger	O
study	O
,	O
including	O
a	O
broader	O
spectrum	O
of	O
subjects	O
,	O
is	O
warranted	O
before	O
guidelines	O
can	O
be	O
recommended	O
.	O
A	O
case	O
of	O
isotretinoin	B-Disease
embryopathy	I-Disease
with	O
bilateral	O
anotia	B-Disease
and	O
Taussig	B-Disease
-	I-Disease
Bing	I-Disease
malformation	I-Disease
.	O
We	O
report	O
a	O
newborn	O
infant	O
with	O
multiple	O
congenital	O
anomalies	O
(	O
anotia	B-Disease
and	O
Taussig	B-Disease
-	I-Disease
Bing	I-Disease
malformation	I-Disease
)	O
due	O
to	O
exposure	O
to	O
isotretinoin	B-Chemical
within	O
the	O
first	O
trimester	O
.	O
In	O
this	O
paper	O
we	O
aim	O
to	O
draw	O
to	O
the	O
fact	O
that	O
caution	O
is	O
needed	O
when	O
prescribing	O
vitamin	B-Chemical
A	I-Chemical
-	O
containing	O
drugs	O
to	O
women	O
of	O
childbearing	O
years	O
.	O
Effect	O
of	O
methoxamine	B-Chemical
on	O
maximum	O
urethral	O
pressure	O
in	O
women	O
with	O
genuine	O
stress	B-Disease
incontinence	I-Disease
:	O
a	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
crossover	O
study	O
.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
potential	O
role	O
for	O
a	O
selective	O
alpha1	O
-	O
adrenoceptor	O
agonist	O
in	O
the	O
treatment	O
of	O
urinary	B-Disease
stress	I-Disease
incontinence	I-Disease
.	O
A	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
study	O
design	O
was	O
employed	O
.	O
Half	O
log	O
incremental	O
doses	O
of	O
intravenous	O
methoxamine	B-Chemical
or	O
placebo	O
(	O
saline	O
)	O
were	O
administered	O
to	O
a	O
group	O
of	O
women	O
with	O
genuine	O
stress	B-Disease
incontinence	I-Disease
while	O
measuring	O
maximum	O
urethral	O
pressure	O
(	O
MUP	O
)	O
,	O
blood	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
symptomatic	O
side	O
effects	O
.	O
Methoxamine	B-Chemical
evoked	O
non	O
-	O
significant	O
increases	O
in	O
MUP	O
and	O
diastolic	O
blood	O
pressure	O
but	O
caused	O
a	B-Disease
significant	I-Disease
rise	I-Disease
in	I-Disease
systolic	I-Disease
blood	I-Disease
pressure	I-Disease
and	O
significant	O
fall	O
in	O
heart	O
rate	O
at	O
maximum	O
dosage	O
.	O
Systemic	O
side	O
effects	O
including	O
piloerection	O
,	O
headache	B-Disease
,	O
and	O
cold	O
extremities	O
were	O
experienced	O
in	O
all	O
subjects	O
.	O
The	O
results	O
indicate	O
that	O
the	O
clinical	O
usefulness	O
of	O
direct	O
,	O
peripherally	O
acting	O
sub	O
-	O
type	O
-	O
selective	O
alpha1	O
-	O
adrenoceptor	O
agonists	O
in	O
the	O
medical	O
treatment	O
of	O
stress	B-Disease
incontinence	I-Disease
may	O
be	O
limited	O
by	O
associated	O
piloerection	O
and	O
cardiovascular	O
side	O
effects	O
.	O
Hyperglycemic	B-Disease
effect	O
of	O
amino	B-Chemical
compounds	O
structurally	O
related	O
to	O
caproate	B-Chemical
in	O
rats	O
.	O
The	O
chronic	O
feeding	O
of	O
small	O
amounts	O
(	O
0	O
.	O
3	O
-	O
3	O
%	O
of	O
diet	O
weight	O
)	O
of	O
certain	O
amino	B-Chemical
derivatives	O
of	O
caproate	B-Chemical
resulted	O
in	O
hyperglycemia	B-Disease
,	O
an	O
elevated	O
glucose	B-Chemical
tolerance	O
curve	O
and	O
,	O
occasionally	O
,	O
glucosuria	B-Disease
.	O
Effective	O
compounds	O
included	O
norleucine	B-Chemical
,	O
norvaline	B-Chemical
,	O
glutamate	B-Chemical
,	O
epsilon	B-Chemical
-	I-Chemical
aminocaproate	I-Chemical
,	O
methionine	B-Chemical
,	O
and	O
leucine	B-Chemical
.	O
Toleration	O
of	O
high	O
doses	O
of	O
angiotensin	B-Chemical
-	I-Chemical
converting	I-Chemical
enzyme	I-Chemical
inhibitors	I-Chemical
in	O
patients	O
with	O
chronic	O
heart	B-Disease
failure	I-Disease
:	O
results	O
from	O
the	O
ATLAS	O
trial	O
.	O
The	O
Assessment	O
of	O
Treatment	O
with	O
Lisinopril	B-Chemical
and	O
Survival	O
.	O
BACKGROUND	O
:	O
Treatment	O
with	O
angiotensin	B-Chemical
-	I-Chemical
converting	I-Chemical
enzyme	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
inhibitors	I-Chemical
reduces	O
mortality	O
and	O
morbidity	O
in	O
patients	O
with	O
chronic	O
heart	B-Disease
failure	I-Disease
(	O
CHF	B-Disease
)	O
,	O
but	O
most	O
affected	O
patients	O
are	O
not	O
receiving	O
these	O
agents	O
or	O
are	O
being	O
treated	O
with	O
doses	O
lower	O
than	O
those	O
found	O
to	O
be	O
efficacious	O
in	O
trials	O
,	O
primarily	O
because	O
of	O
concerns	O
about	O
the	O
safety	O
and	O
tolerability	O
of	O
these	O
agents	O
,	O
especially	O
at	O
the	O
recommended	O
doses	O
.	O
The	O
present	O
study	O
examines	O
the	O
safety	O
and	O
tolerability	O
of	O
high	O
-	O
compared	O
with	O
low	O
-	O
dose	O
lisinopril	B-Chemical
in	O
CHF	B-Disease
.	O
METHODS	O
:	O
The	O
Assessment	O
of	O
Lisinopril	B-Chemical
and	O
Survival	O
study	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
in	O
which	O
patients	O
with	O
or	O
without	O
previous	O
ACE	B-Chemical
inhibitor	I-Chemical
treatment	O
were	O
stabilized	O
receiving	O
medium	O
-	O
dose	O
lisinopril	B-Chemical
(	O
12	O
.	O
5	O
or	O
15	O
.	O
0	O
mg	O
once	O
daily	O
[	O
OD	O
]	O
)	O
for	O
2	O
to	O
4	O
weeks	O
and	O
then	O
randomized	O
to	O
high	O
-	O
(	O
35	O
.	O
0	O
or	O
32	O
.	O
5	O
mg	O
OD	O
)	O
or	O
low	O
-	O
dose	O
(	O
5	O
.	O
0	O
or	O
2	O
.	O
5	O
mg	O
OD	O
)	O
groups	O
.	O
Patients	O
with	O
New	O
York	O
Heart	O
Association	O
classes	O
II	O
to	O
IV	O
CHF	B-Disease
and	O
left	O
ventricular	O
ejection	O
fractions	O
of	O
no	O
greater	O
than	O
0	O
.	O
30	O
(	O
n	O
=	O
3164	O
)	O
were	O
randomized	O
and	O
followed	O
up	O
for	O
a	O
median	O
of	O
46	O
months	O
.	O
We	O
examined	O
the	O
occurrence	O
of	O
adverse	O
events	O
and	O
the	O
need	O
for	O
discontinuation	O
and	O
dose	O
reduction	O
during	O
treatment	O
,	O
with	O
a	O
focus	O
on	O
hypotension	B-Disease
and	O
renal	B-Disease
dysfunction	I-Disease
.	O
RESULTS	O
:	O
Of	O
405	O
patients	O
not	O
previously	O
receiving	O
an	O
ACE	B-Chemical
inhibitor	I-Chemical
,	O
doses	O
in	O
only	O
4	O
.	O
2	O
%	O
could	O
not	O
be	O
titrated	O
to	O
the	O
medium	O
doses	O
required	O
for	O
randomization	O
because	O
of	O
symptoms	O
possibly	O
related	O
to	O
hypotension	B-Disease
(	O
2	O
.	O
0	O
%	O
)	O
or	O
because	O
of	O
renal	B-Disease
dysfunction	I-Disease
or	O
hyperkalemia	B-Disease
(	O
2	O
.	O
3	O
%	O
)	O
.	O
Doses	O
in	O
more	O
than	O
90	O
%	O
of	O
randomized	O
patients	O
in	O
the	O
high	O
-	O
and	O
low	O
-	O
dose	O
groups	O
were	O
titrated	O
to	O
their	O
assigned	O
target	O
,	O
and	O
the	O
mean	O
doses	O
of	O
blinded	O
medication	O
in	O
both	O
groups	O
remained	O
similar	O
throughout	O
the	O
study	O
.	O
Withdrawals	O
occurred	O
in	O
27	O
.	O
1	O
%	O
of	O
the	O
high	O
-	O
and	O
30	O
.	O
7	O
%	O
of	O
the	O
low	O
-	O
dose	O
groups	O
.	O
Subgroups	O
presumed	O
to	O
be	O
at	O
higher	O
risk	O
for	O
ACE	B-Chemical
inhibitor	I-Chemical
intolerance	O
(	O
blood	O
pressure	O
,	O
<	O
120	O
mm	O
Hg	O
;	O
creatinine	B-Chemical
,	O
>	O
or	O
=	O
132	O
.	O
6	O
micromol	O
/	O
L	O
[	O
>	O
or	O
=	O
1	O
.	O
5	O
mg	O
/	O
dL	O
]	O
;	O
age	O
,	O
>	O
or	O
=	O
70	O
years	O
;	O
and	O
patients	O
with	O
diabetes	B-Disease
)	O
generally	O
tolerated	O
the	O
high	O
-	O
dose	O
strategy	O
.	O
CONCLUSIONS	O
:	O
These	O
findings	O
demonstrate	O
that	O
ACE	B-Chemical
inhibitor	I-Chemical
therapy	O
in	O
most	O
patients	O
with	O
CHF	B-Disease
can	O
be	O
successfully	O
titrated	O
to	O
and	O
maintained	O
at	O
high	O
doses	O
,	O
and	O
that	O
more	O
aggressive	O
use	O
of	O
these	O
agents	O
is	O
warranted	O
.	O
Cocaine	B-Chemical
,	O
ethanol	B-Chemical
,	O
and	O
cocaethylene	B-Chemical
cardiotoxity	B-Disease
in	O
an	O
animal	O
model	O
of	O
cocaine	B-Disease
and	I-Disease
ethanol	I-Disease
abuse	I-Disease
.	O
OBJECTIVES	O
:	O
Simultaneous	O
abuse	B-Disease
of	I-Disease
cocaine	I-Disease
and	I-Disease
ethanol	I-Disease
affects	O
12	O
million	O
Americans	O
annually	O
.	O
In	O
combination	O
,	O
these	O
substances	O
are	O
substantially	O
more	O
toxic	O
than	O
either	O
drug	O
alone	O
.	O
Their	O
combined	O
cardiac	B-Disease
toxicity	I-Disease
may	O
be	O
due	O
to	O
independent	O
effects	O
of	O
each	O
drug	O
;	O
however	O
,	O
they	O
may	O
also	O
be	O
due	O
to	O
cocaethylene	B-Chemical
(	O
CE	B-Chemical
)	O
,	O
a	O
cocaine	B-Chemical
metabolite	O
formed	O
only	O
in	O
the	O
presence	O
of	O
ethanol	B-Chemical
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
delineate	O
the	O
role	O
of	O
CE	B-Chemical
in	O
the	O
combined	O
cardiotoxicity	B-Disease
of	O
cocaine	B-Chemical
and	O
ethanol	B-Chemical
in	O
a	O
model	O
simulating	O
their	O
abuse	O
.	O
METHODS	O
:	O
Twenty	O
-	O
three	O
dogs	O
were	O
randomized	O
to	O
receive	O
either	O
1	O
)	O
three	O
intravenous	O
(	O
IV	O
)	O
boluses	O
of	O
cocaine	B-Chemical
7	O
.	O
5	O
mg	O
/	O
kg	O
with	O
ethanol	B-Chemical
(	O
1	O
g	O
/	O
kg	O
)	O
as	O
an	O
IV	O
infusion	O
(	O
C	O
+	O
E	O
,	O
n	O
=	O
8	O
)	O
,	O
2	O
)	O
three	O
cocaine	B-Chemical
boluses	O
only	O
(	O
C	O
,	O
n	O
=	O
6	O
)	O
,	O
3	O
)	O
ethanol	B-Chemical
infusion	O
only	O
(	O
E	O
,	O
n	O
=	O
5	O
)	O
,	O
or	O
4	O
)	O
placebo	O
boluses	O
and	O
infusion	O
(	O
n	O
=	O
4	O
)	O
.	O
Hemodynamic	O
measurements	O
,	O
electrocardiograms	O
,	O
and	O
serum	O
drug	O
concentrations	O
were	O
obtained	O
at	O
baseline	O
,	O
and	O
then	O
at	O
fixed	O
time	O
intervals	O
after	O
each	O
drug	O
was	O
administered	O
.	O
RESULTS	O
:	O
Two	O
of	O
eight	O
dogs	O
in	O
the	O
C	O
+	O
E	O
group	O
experienced	O
cardiovascular	B-Disease
collapse	I-Disease
.	O
The	O
most	O
dramatic	O
hemodynamic	O
changes	O
occurred	O
after	O
each	O
cocaine	B-Chemical
bolus	O
in	O
the	O
C	O
+	O
E	O
and	O
C	O
only	O
groups	O
;	O
however	O
,	O
persistent	O
hemodynamic	O
changes	O
occurred	O
in	O
the	O
C	O
+	O
E	O
group	O
.	O
Peak	O
CE	B-Chemical
levels	O
were	O
associated	O
with	O
a	O
45	O
%	O
(	O
SD	O
+	O
/	O
-	O
22	O
%	O
,	O
95	O
%	O
CI	O
=	O
22	O
%	O
to	O
69	O
%	O
)	O
decrease	B-Disease
in	I-Disease
cardiac	I-Disease
output	I-Disease
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
a	O
56	O
%	O
(	O
SD	O
+	O
/	O
-	O
23	O
%	O
,	O
95	O
%	O
CI	O
=	O
32	O
%	O
to	O
80	O
%	O
)	O
decrease	O
in	O
dP	O
/	O
dt	O
(	O
max	O
)	O
(	O
p	O
<	O
.	O
006	O
)	O
,	O
and	O
a	O
23	O
%	O
(	O
SD	O
+	O
/	O
-	O
15	O
%	O
,	O
95	O
%	O
CI	O
=	O
7	O
%	O
to	O
49	O
%	O
)	O
decrease	O
in	O
SVO	O
(	O
2	O
)	O
(	O
p	O
<	O
0	O
.	O
025	O
)	O
.	O
Ventricular	B-Disease
arrhythmias	I-Disease
were	O
primarily	O
observed	O
in	O
the	O
C	O
+	O
E	O
group	O
,	O
in	O
which	O
four	O
of	O
eight	O
dogs	O
experienced	O
ventricular	B-Disease
tachycardia	I-Disease
.	O
CONCLUSIONS	O
:	O
Cocaine	B-Chemical
and	O
ethanol	B-Chemical
in	O
combination	O
were	O
more	O
toxic	O
than	O
either	O
substance	O
alone	O
.	O
Co	O
-	O
administration	O
resulted	O
in	O
prolonged	O
cardiac	B-Disease
toxicity	I-Disease
and	O
was	O
dysrhythmogenic	O
.	O
Peak	O
serum	O
cocaethylene	B-Chemical
concentrations	O
were	O
associated	O
with	O
prolonged	O
myocardial	B-Disease
depression	I-Disease
.	O
Worsening	O
of	O
Parkinsonism	B-Disease
after	O
the	O
use	O
of	O
veralipride	B-Chemical
for	O
treatment	O
of	O
menopause	O
:	O
case	O
report	O
.	O
We	O
describe	O
a	O
female	O
patient	O
with	O
stable	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
who	O
has	O
shown	O
a	O
marked	O
worsening	O
of	O
her	O
motor	O
functions	O
following	O
therapy	O
of	O
menopause	O
related	O
symptoms	O
with	O
veralipride	B-Chemical
,	O
as	O
well	O
as	O
the	O
improvement	O
of	O
her	O
symptoms	O
back	O
to	O
baseline	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O
We	O
emphasize	O
the	O
anti	O
-	O
dopaminergic	O
effect	O
of	O
veralipride	B-Chemical
.	O
Viracept	B-Chemical
and	O
irregular	B-Disease
heartbeat	I-Disease
warning	O
.	O
A	O
group	O
of	O
doctors	O
in	O
Boston	O
warn	O
that	O
the	O
protease	O
inhibitor	O
Viracept	B-Chemical
may	O
cause	O
an	O
irregular	B-Disease
heart	I-Disease
beat	I-Disease
,	O
known	O
as	O
bradycardia	B-Disease
,	O
in	O
people	O
with	O
HIV	O
.	O
Bradycardia	B-Disease
occurred	O
in	O
a	O
45	O
-	O
year	O
-	O
old	O
male	O
patient	O
who	O
was	O
Viracept	B-Chemical
in	O
combination	O
with	O
other	O
anti	O
-	O
HIV	O
drugs	O
.	O
The	O
symptoms	O
ceased	O
after	O
switching	O
to	O
another	O
drug	O
combination	O
.	O
Frequency	O
of	O
appearance	O
of	O
myeloperoxidase	O
-	O
antineutrophil	O
cytoplasmic	O
antibody	O
(	O
MPO	O
-	O
ANCA	O
)	O
in	O
Graves	B-Disease
'	I-Disease
disease	I-Disease
patients	O
treated	O
with	O
propylthiouracil	B-Chemical
and	O
the	O
relationship	O
between	O
MPO	O
-	O
ANCA	O
and	O
clinical	O
manifestations	O
.	O
OBJECTIVE	O
:	O
Myeloperoxidase	O
antineutrophil	O
cytoplasmic	O
antibody	O
(	O
MPO	O
-	O
ANCA	O
)	O
-	O
positive	O
vasculitis	B-Disease
has	O
been	O
reported	O
in	O
patients	O
with	O
Graves	B-Disease
'	I-Disease
disease	I-Disease
who	O
were	O
treated	O
with	O
propylthiouracil	B-Chemical
(	O
PTU	B-Chemical
)	O
.	O
The	O
appearance	O
of	O
MPO	O
-	O
ANCA	O
in	O
these	O
cases	O
was	O
suspected	O
of	O
being	O
related	O
to	O
PTU	B-Chemical
because	O
the	O
titres	O
of	O
MPO	O
-	O
ANCA	O
decreased	O
when	O
PTU	B-Chemical
was	O
stopped	O
.	O
Nevertheless	O
,	O
there	O
have	O
been	O
no	O
studies	O
on	O
the	O
temporal	O
relationship	O
between	O
the	O
appearance	O
of	O
MPO	O
-	O
ANCA	O
and	O
vasculitis	B-Disease
during	O
PTU	B-Chemical
therapy	O
,	O
or	O
on	O
the	O
incidence	O
of	O
MPO	O
-	O
ANCA	O
in	O
untreated	O
Graves	B-Disease
'	I-Disease
disease	I-Disease
patients	O
.	O
Therefore	O
,	O
we	O
sought	O
to	O
address	O
these	O
parameters	O
in	O
patients	O
with	O
Graves	B-Disease
'	I-Disease
disease	I-Disease
.	O
PATIENTS	O
:	O
We	O
investigated	O
102	O
untreated	O
patients	O
with	O
hyperthyroidism	B-Disease
due	O
to	O
Graves	B-Disease
'	I-Disease
disease	I-Disease
for	O
the	O
presence	O
of	O
MPO	O
-	O
ANCA	O
,	O
and	O
for	O
the	O
development	O
vasculitis	B-Disease
after	O
starting	O
PTU	B-Chemical
therapy	O
.	O
Twenty	O
-	O
nine	O
of	O
them	O
were	O
later	O
excluded	O
because	O
of	O
adverse	O
effects	O
of	O
PTU	B-Chemical
or	O
because	O
the	O
observation	O
period	O
was	O
less	O
than	O
3	O
months	O
.	O
The	O
remaining	O
73	O
patients	O
(	O
55	O
women	O
and	O
18	O
men	O
)	O
,	O
all	O
of	O
whom	O
were	O
examined	O
for	O
more	O
than	O
3	O
months	O
,	O
were	O
adopted	O
as	O
the	O
subjects	O
of	O
the	O
investigation	O
.	O
The	O
median	O
observation	O
period	O
was	O
23	O
.	O
6	O
months	O
(	O
range	O
:	O
3	O
-	O
37	O
months	O
)	O
.	O
MEASUREMENTS	O
:	O
MPO	O
-	O
ANCA	O
was	O
measured	O
at	O
intervals	O
of	O
2	O
-	O
6	O
months	O
.	O
RESULTS	O
:	O
Before	O
treatment	O
,	O
the	O
MPO	O
-	O
ANCA	O
titres	O
of	O
all	O
102	O
untreated	O
Graves	B-Disease
'	I-Disease
disease	I-Disease
patients	O
were	O
within	O
the	O
reference	O
range	O
(	O
below	O
10	O
U	O
/	O
ml	O
)	O
.	O
Three	O
(	O
4	O
.	O
1	O
%	O
)	O
of	O
the	O
73	O
patients	O
were	O
positive	O
for	O
MPO	O
-	O
ANCA	O
at	O
13	O
,	O
16	O
and	O
17	O
months	O
,	O
respectively	O
,	O
after	O
the	O
start	O
of	O
PTU	B-Chemical
therapy	O
.	O
In	O
two	O
of	O
them	O
,	O
the	O
MPO	O
-	O
ANCA	O
titres	O
transiently	O
increased	O
to	O
12	O
.	O
8	O
and	O
15	O
.	O
0	O
U	O
/	O
ml	O
,	O
respectively	O
,	O
despite	O
continued	O
PTU	B-Chemical
therapy	O
,	O
but	O
no	O
vasculitic	B-Disease
disorders	I-Disease
developed	O
.	O
In	O
the	O
third	O
patient	O
,	O
the	O
MPO	O
-	O
ANCA	O
titre	O
increased	O
to	O
204	O
U	O
/	O
ml	O
and	O
she	O
developed	O
a	O
higher	O
fever	B-Disease
,	O
oral	B-Disease
ulcers	I-Disease
and	O
polyarthralgia	B-Disease
,	O
but	O
the	O
symptoms	O
resolved	O
2	O
weeks	O
after	O
stopping	O
PTU	B-Chemical
therapy	O
,	O
and	O
the	O
MPO	O
-	O
ANCA	O
titre	O
decreased	O
to	O
20	O
.	O
7	O
U	O
/	O
ml	O
by	O
4	O
months	O
after	O
discontinuing	O
PTU	B-Chemical
.	O
CONCLUSIONS	O
:	O
PTU	B-Chemical
therapy	O
may	O
be	O
related	O
to	O
the	O
appearance	O
of	O
MPO	O
-	O
ANCA	O
,	O
but	O
MPO	O
-	O
ANCA	O
does	O
not	O
appear	O
to	O
be	O
closely	O
related	O
to	O
vasculitis	B-Disease
.	O
Prevalence	O
of	O
heart	B-Disease
disease	I-Disease
in	O
asymptomatic	O
chronic	O
cocaine	B-Chemical
users	O
.	O
To	O
determine	O
the	O
prevalence	O
of	O
heart	B-Disease
disease	I-Disease
in	O
outpatient	O
young	O
asymptomatic	O
chronic	O
cocaine	B-Chemical
users	O
,	O
35	O
cocaine	B-Chemical
users	O
and	O
32	O
age	O
-	O
matched	O
controls	O
underwent	O
resting	O
and	O
exercise	O
electrocardiography	O
(	O
ECG	O
)	O
and	O
Doppler	O
echocardiography	O
.	O
Findings	O
consistent	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
were	O
detected	O
in	O
12	O
(	O
34	O
%	O
)	O
patients	O
and	O
3	O
(	O
9	O
%	O
)	O
controls	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O
Decreased	O
left	O
ventricular	O
systolic	O
function	O
was	O
demonstrated	O
in	O
5	O
(	O
14	O
%	O
)	O
patients	O
,	O
but	O
in	O
none	O
of	O
the	O
controls	O
(	O
p	O
=	O
0	O
.	O
055	O
)	O
.	O
Finally	O
,	O
resting	O
and	O
peak	O
exercise	O
abnormal	B-Disease
left	I-Disease
ventricular	I-Disease
filling	I-Disease
was	O
detected	O
in	O
38	O
and	O
35	O
%	O
of	O
patients	O
as	O
compared	O
to	O
19	O
and	O
9	O
%	O
of	O
controls	O
,	O
respectively	O
(	O
p	O
=	O
0	O
.	O
11	O
and	O
0	O
.	O
02	O
,	O
respectively	O
)	O
.	O
We	O
conclude	O
that	O
coronary	B-Disease
artery	I-Disease
or	I-Disease
myocardial	I-Disease
disease	I-Disease
is	O
common	O
(	O
38	O
%	O
)	O
in	O
young	O
asymptomatic	O
chronic	O
cocaine	B-Chemical
users	O
.	O
Therefore	O
,	O
screening	O
ECG	O
and	O
echocardiography	O
may	O
be	O
warranted	O
in	O
these	O
patients	O
.	O
Cardioprotective	O
effects	O
of	O
Picrorrhiza	O
kurroa	O
against	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	O
stress	O
in	O
rats	O
.	O
The	O
cardioprotective	O
effect	O
of	O
the	O
ethanol	B-Chemical
extract	O
of	O
Picrorrhiza	O
kurroa	O
rhizomes	O
and	O
roots	O
(	O
PK	O
)	O
on	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	O
with	O
respect	O
to	O
lipid	O
metabolism	O
in	O
serum	O
and	O
heart	O
tissue	O
has	O
been	O
investigated	O
.	O
Oral	O
pre	O
-	O
treatment	O
with	O
PK	O
(	O
80	O
mg	O
kg	O
(	O
-	O
1	O
)	O
day	O
(	O
-	O
1	O
)	O
for	O
15	O
days	O
)	O
significantly	O
prevented	O
the	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
and	O
maintained	O
the	O
rats	O
at	O
near	O
normal	O
status	O
.	O
Phase	O
2	O
early	O
afterdepolarization	O
as	O
a	O
trigger	O
of	O
polymorphic	O
ventricular	B-Disease
tachycardia	I-Disease
in	O
acquired	O
long	B-Disease
-	I-Disease
QT	I-Disease
syndrome	I-Disease
:	O
direct	O
evidence	O
from	O
intracellular	O
recordings	O
in	O
the	O
intact	O
left	O
ventricular	O
wall	O
.	O
BACKGROUND	O
:	O
This	O
study	O
examined	O
the	O
role	O
of	O
phase	O
2	O
early	O
afterdepolarization	O
(	O
EAD	O
)	O
in	O
producing	O
a	O
trigger	O
to	O
initiate	O
torsade	B-Disease
de	I-Disease
pointes	I-Disease
(	O
TdP	B-Disease
)	O
with	O
QT	B-Disease
prolongation	I-Disease
induced	O
by	O
dl	O
-	O
sotalol	B-Chemical
and	O
azimilide	B-Chemical
.	O
The	O
contribution	O
of	O
transmural	O
dispersion	O
of	O
repolarization	O
(	O
TDR	O
)	O
to	O
transmural	O
propagation	O
of	O
EAD	O
and	O
the	O
maintenance	O
of	O
TdP	B-Disease
was	O
also	O
evaluated	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
Transmembrane	O
action	O
potentials	O
from	O
epicardium	O
,	O
midmyocardium	O
,	O
and	O
endocardium	O
were	O
recorded	O
simultaneously	O
,	O
together	O
with	O
a	O
transmural	O
ECG	O
,	O
in	O
arterially	O
perfused	O
canine	O
and	O
rabbit	O
left	O
ventricular	O
preparations	O
.	O
dl	O
-	O
Sotalol	B-Chemical
preferentially	O
prolonged	O
action	O
potential	O
duration	O
(	O
APD	O
)	O
in	O
M	O
cells	O
dose	O
-	O
dependently	O
(	O
1	O
to	O
100	O
micromol	O
/	O
L	O
)	O
,	O
leading	O
to	O
QT	B-Disease
prolongation	I-Disease
and	O
an	O
increase	O
in	O
TDR	O
.	O
Azimilide	B-Chemical
,	O
however	O
,	O
significantly	O
prolonged	O
APD	O
and	O
QT	O
interval	O
at	O
concentrations	O
from	O
0	O
.	O
1	O
to	O
10	O
micromol	O
/	O
L	O
but	O
shortened	O
them	O
at	O
30	O
micromol	O
/	O
L	O
.	O
Unlike	O
dl	O
-	O
sotalol	B-Chemical
,	O
azimilide	B-Chemical
(	O
>	O
3	O
micromol	O
/	O
L	O
)	O
increased	O
epicardial	O
APD	O
markedly	O
,	O
causing	O
a	O
diminished	O
TDR	O
.	O
Although	O
both	O
dl	O
-	O
sotalol	B-Chemical
and	O
azimilide	B-Chemical
rarely	O
induced	O
EADs	O
in	O
canine	O
left	O
ventricles	O
,	O
they	O
produced	O
frequent	O
EADs	O
in	O
rabbits	O
,	O
in	O
which	O
more	O
pronounced	O
QT	B-Disease
prolongation	I-Disease
was	O
seen	O
.	O
An	O
increase	O
in	O
TDR	O
by	O
dl	O
-	O
sotalol	B-Chemical
facilitated	O
transmural	O
propagation	O
of	O
EADs	O
that	O
initiated	O
multiple	O
episodes	O
of	O
spontaneous	O
TdP	B-Disease
in	O
3	O
of	O
6	O
rabbit	O
left	O
ventricles	O
.	O
Of	O
note	O
,	O
although	O
azimilide	B-Chemical
(	O
3	O
to	O
10	O
micromol	O
/	O
L	O
)	O
increased	O
APD	O
more	O
than	O
dl	O
-	O
sotalol	B-Chemical
,	O
its	O
EADs	O
often	O
failed	O
to	O
propagate	O
transmurally	O
,	O
probably	O
because	O
of	O
a	O
diminished	O
TDR	O
.	O
CONCLUSIONS	O
:	O
This	O
study	O
provides	O
the	O
first	O
direct	O
evidence	O
from	O
intracellular	O
action	O
potential	O
recordings	O
that	O
phase	O
2	O
EAD	O
can	O
be	O
generated	O
from	O
intact	O
ventricular	O
wall	O
and	O
produce	O
a	O
trigger	O
to	O
initiate	O
the	O
onset	O
of	O
TdP	B-Disease
under	O
QT	B-Disease
prolongation	I-Disease
.	O
A	O
pilot	O
study	O
to	O
assess	O
the	O
safety	O
of	O
dobutamine	B-Chemical
stress	O
echocardiography	O
in	O
the	O
emergency	O
department	O
evaluation	O
of	O
cocaine	B-Chemical
-	O
associated	O
chest	B-Disease
pain	I-Disease
.	O
STUDY	O
OBJECTIVE	O
:	O
Chest	B-Disease
pain	I-Disease
in	O
the	O
setting	O
of	O
cocaine	B-Chemical
use	O
poses	O
a	O
diagnostic	O
dilemma	O
.	O
Dobutamine	B-Chemical
stress	O
echocardiography	O
(	O
DSE	O
)	O
is	O
a	O
widely	O
available	O
and	O
sensitive	O
test	O
for	O
evaluating	O
cardiac	O
ischemia	B-Disease
.	O
Because	O
of	O
the	O
theoretical	O
concern	O
regarding	O
administration	O
of	O
dobutamine	B-Chemical
in	O
the	O
setting	O
of	O
cocaine	B-Chemical
use	O
,	O
we	O
conducted	O
a	O
pilot	O
study	O
to	O
assess	O
the	O
safety	O
of	O
DSE	O
in	O
emergency	O
department	O
patients	O
with	O
cocaine	B-Chemical
-	O
associated	O
chest	B-Disease
pain	I-Disease
.	O
METHODS	O
:	O
A	O
prospective	O
case	O
series	O
was	O
conducted	O
in	O
the	O
intensive	O
diagnostic	O
and	O
treatment	O
unit	O
in	O
the	O
ED	O
of	O
an	O
urban	O
tertiary	O
-	O
care	O
teaching	O
hospital	O
.	O
Patients	O
were	O
eligible	O
for	O
DSE	O
if	O
they	O
had	O
used	O
cocaine	B-Chemical
within	O
24	O
hours	O
preceding	O
the	O
onset	O
of	O
chest	B-Disease
pain	I-Disease
and	O
had	O
a	O
normal	O
ECG	O
and	O
tropinin	O
I	O
level	O
.	O
Patients	O
exhibiting	O
signs	O
of	O
continuing	O
cocaine	B-Chemical
toxicity	B-Disease
were	O
excluded	O
from	O
the	O
study	O
.	O
All	O
patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
serial	O
testing	O
after	O
the	O
DSE	O
testing	O
in	O
the	O
intensive	O
diagnostic	O
and	O
treatment	O
unit	O
.	O
RESULTS	O
:	O
Twenty	O
-	O
four	O
patients	O
were	O
enrolled	O
.	O
Two	O
patients	O
had	O
inadequate	O
resting	O
images	O
,	O
one	O
DSE	O
was	O
terminated	O
because	O
of	O
inferior	O
hypokinesis	B-Disease
,	O
another	O
DSE	O
was	O
terminated	O
because	O
of	O
a	O
rate	O
-	O
related	O
atrial	O
conduction	O
deficit	O
,	O
and	O
1	O
patient	O
did	O
not	O
reach	O
the	O
target	O
heart	O
rate	O
.	O
Thus	O
,	O
19	O
patients	O
completed	O
a	O
DSE	O
and	O
reached	O
their	O
target	O
heart	O
rates	O
.	O
None	O
of	O
the	O
patients	O
experienced	O
signs	O
of	O
exaggerated	O
adrenergic	O
response	O
,	O
which	O
was	O
defined	O
as	O
a	O
systolic	O
blood	O
pressure	O
of	O
greater	O
than	O
200	O
mm	O
Hg	O
or	O
the	O
occurrence	O
of	O
tachydysrhythmias	B-Disease
(	O
excluding	O
sinus	B-Disease
tachycardia	I-Disease
)	O
.	O
Further	O
suggesting	O
lack	O
of	O
exaggerated	O
adrenergic	O
response	O
,	O
13	O
(	O
65	O
%	O
)	O
of	O
20	O
patients	O
required	O
supplemental	O
atropine	B-Chemical
to	O
reach	O
their	O
target	O
heart	O
rates	O
.	O
CONCLUSION	O
:	O
No	O
exaggerated	O
adrenergic	O
response	O
was	O
detected	O
when	O
dobutamine	B-Chemical
was	O
administered	O
to	O
patients	O
with	O
cocaine	B-Chemical
-	O
related	O
chest	B-Disease
pain	I-Disease
.	O
Prenatal	O
cocaine	B-Chemical
exposure	O
and	O
cranial	O
sonographic	O
findings	O
in	O
preterm	B-Disease
infants	I-Disease
.	O
PURPOSE	O
:	O
Prenatal	O
cocaine	B-Chemical
exposure	O
has	O
been	O
linked	O
with	O
subependymal	O
hemorrhage	B-Disease
and	O
the	O
formation	O
of	O
cysts	B-Disease
that	O
are	O
detectable	O
on	O
cranial	O
sonography	O
in	O
neonates	O
born	O
at	O
term	O
.	O
We	O
sought	O
to	O
determine	O
if	O
prenatal	O
cocaine	B-Chemical
exposure	O
increases	O
the	O
incidence	O
of	O
subependymal	B-Disease
cysts	I-Disease
in	O
preterm	B-Disease
infants	I-Disease
.	O
METHODS	O
:	O
We	O
retrospectively	O
reviewed	O
the	O
medical	O
records	O
and	O
cranial	O
sonograms	O
obtained	O
during	O
a	O
1	O
-	O
year	O
period	O
on	O
122	O
premature	B-Disease
(	I-Disease
<	I-Disease
36	I-Disease
weeks	I-Disease
of	I-Disease
gestation	I-Disease
)	I-Disease
infants	I-Disease
.	O
Infants	O
were	O
categorized	O
into	O
1	O
of	O
2	O
groups	O
:	O
those	O
exposed	O
to	O
cocaine	B-Chemical
and	O
those	O
not	O
exposed	O
to	O
cocaine	B-Chemical
.	O
Infants	O
were	O
assigned	O
to	O
the	O
cocaine	B-Chemical
-	O
exposed	O
group	O
if	O
there	O
was	O
a	O
maternal	O
history	O
of	O
cocaine	B-Disease
abuse	I-Disease
during	O
pregnancy	O
or	O
if	O
maternal	O
or	O
neonatal	O
urine	O
toxicology	O
results	O
were	O
positive	O
at	O
the	O
time	O
of	O
delivery	O
.	O
RESULTS	O
:	O
Five	O
of	O
the	O
122	O
infants	O
were	O
excluded	O
from	O
the	O
study	O
because	O
of	O
insufficient	O
medical	O
and	O
drug	O
histories	O
.	O
The	O
incidence	O
of	O
subependymal	B-Disease
cysts	I-Disease
in	O
the	O
117	O
remaining	O
infants	O
was	O
14	O
%	O
(	O
16	O
of	O
117	O
)	O
.	O
The	O
incidence	O
of	O
subependymal	B-Disease
cysts	I-Disease
in	O
infants	O
exposed	O
to	O
cocaine	B-Chemical
prenatally	O
was	O
44	O
%	O
(	O
8	O
of	O
18	O
)	O
compared	O
with	O
8	O
%	O
(	O
8	O
of	O
99	O
)	O
in	O
the	O
unexposed	O
group	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
CONCLUSIONS	O
:	O
We	O
found	O
an	O
increased	O
incidence	O
of	O
subependymal	B-Disease
cyst	I-Disease
formation	O
in	O
preterm	B-Disease
infants	I-Disease
who	O
were	O
exposed	O
to	O
cocaine	B-Chemical
prenatally	O
.	O
This	O
result	O
is	O
consistent	O
with	O
results	O
of	O
similar	O
studies	O
in	O
term	O
infants	O
.	O
Thalidomide	B-Chemical
neuropathy	B-Disease
in	O
patients	O
treated	O
for	O
metastatic	O
prostate	B-Disease
cancer	I-Disease
.	O
We	O
prospectively	O
evaluated	O
thalidomide	B-Chemical
-	O
induced	O
neuropathy	B-Disease
using	O
electrodiagnostic	O
studies	O
.	O
Sixty	O
-	O
seven	O
men	O
with	O
metastatic	O
androgen	B-Chemical
-	O
independent	O
prostate	B-Disease
cancer	I-Disease
in	O
an	O
open	O
-	O
label	O
trial	O
of	O
oral	O
thalidomide	B-Chemical
underwent	O
neurologic	O
examinations	O
and	O
nerve	O
conduction	O
studies	O
(	O
NCS	O
)	O
prior	O
to	O
and	O
at	O
3	O
-	O
month	O
intervals	O
during	O
treatment	O
.	O
NCS	O
included	O
recording	O
of	O
sensory	O
nerve	O
action	O
potentials	O
(	O
SNAPs	O
)	O
from	O
median	O
,	O
radial	O
,	O
ulnar	O
,	O
and	O
sural	O
nerves	O
.	O
SNAP	O
amplitudes	O
for	O
each	O
nerve	O
were	O
expressed	O
as	O
the	O
percentage	O
of	O
its	O
baseline	O
,	O
and	O
the	O
mean	O
of	O
the	O
four	O
was	O
termed	O
the	O
SNAP	O
index	O
.	O
A	O
40	O
%	O
decline	O
in	O
the	O
SNAP	O
index	O
was	O
considered	O
clinically	O
significant	O
.	O
Thalidomide	B-Chemical
was	O
discontinued	O
in	O
55	O
patients	O
for	O
lack	O
of	O
therapeutic	O
response	O
.	O
Of	O
67	O
patients	O
initially	O
enrolled	O
,	O
24	O
remained	O
on	O
thalidomide	B-Chemical
for	O
3	O
months	O
,	O
8	O
remained	O
at	O
6	O
months	O
,	O
and	O
3	O
remained	O
at	O
9	O
months	O
.	O
Six	O
patients	O
developed	O
neuropathy	B-Disease
.	O
Clinical	O
symptoms	O
and	O
a	O
decline	O
in	O
the	O
SNAP	O
index	O
occurred	O
concurrently	O
.	O
Older	O
age	O
and	O
cumulative	O
dose	O
were	O
possible	O
contributing	O
factors	O
.	O
Neuropathy	B-Disease
may	O
thus	O
be	O
a	O
common	O
complication	O
of	O
thalidomide	B-Chemical
in	O
older	O
patients	O
.	O
The	O
SNAP	O
index	O
can	O
be	O
used	O
to	O
monitor	O
peripheral	B-Disease
neuropathy	I-Disease
,	O
but	O
not	O
for	O
early	O
detection	O
.	O
Overexpression	O
of	O
copper	B-Chemical
/	O
zinc	B-Chemical
-	O
superoxide	B-Chemical
dismutase	O
protects	O
from	O
kanamycin	B-Chemical
-	O
induced	O
hearing	B-Disease
loss	I-Disease
.	O
The	O
participation	O
of	O
reactive	O
oxygen	B-Chemical
species	O
in	O
aminoglycoside	B-Chemical
-	O
induced	O
ototoxicity	B-Disease
has	O
been	O
deduced	O
from	O
observations	O
that	O
aminoglycoside	B-Chemical
-	O
iron	B-Chemical
complexes	O
catalyze	O
the	O
formation	O
of	O
superoxide	B-Chemical
radicals	O
in	O
vitro	O
and	O
that	O
antioxidants	O
attenuate	O
ototoxicity	B-Disease
in	O
vivo	O
.	O
We	O
therefore	O
hypothesized	O
that	O
overexpression	O
of	O
Cu	B-Chemical
/	O
Zn	B-Chemical
-	O
superoxide	B-Chemical
dismutase	O
(	O
h	O
-	O
SOD1	O
)	O
should	O
protect	O
transgenic	O
mice	O
from	O
ototoxicity	B-Disease
.	O
Immunocytochemistry	O
confirmed	O
expression	O
of	O
h	O
-	O
SOD1	O
in	O
inner	O
ear	O
tissues	O
of	O
transgenic	O
C57BL	O
/	O
6	O
-	O
TgN	O
[	O
SOD1	O
]	O
3Cje	O
mice	O
.	O
Transgenic	O
and	O
nontransgenic	O
littermates	O
received	O
kanamycin	B-Chemical
(	O
400	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
day	O
)	O
for	O
10	O
days	O
beginning	O
on	O
day	O
10	O
after	O
birth	O
.	O
Auditory	O
thresholds	O
were	O
tested	O
by	O
evoked	O
auditory	O
brain	O
stem	O
responses	O
at	O
1	O
month	O
after	O
birth	O
.	O
In	O
nontransgenic	O
animals	O
,	O
the	O
threshold	O
in	O
the	O
kanamycin	B-Chemical
-	O
treated	O
group	O
was	O
45	O
-	O
50	O
dB	O
higher	O
than	O
in	O
saline	O
-	O
injected	O
controls	O
.	O
In	O
the	O
transgenic	O
group	O
,	O
kanamycin	B-Chemical
increased	O
the	O
threshold	O
by	O
only	O
15	O
dB	O
over	O
the	O
respective	O
controls	O
.	O
The	O
effects	O
were	O
similar	O
at	O
12	O
and	O
24	O
kHz	O
.	O
The	O
protection	O
by	O
overexpression	O
of	O
superoxide	B-Chemical
dismutase	O
supports	O
the	O
hypothesis	O
that	O
oxidant	O
stress	O
plays	O
a	O
significant	O
role	O
in	O
aminoglycoside	B-Chemical
-	O
induced	O
ototoxicity	B-Disease
.	O
The	O
results	O
also	O
suggest	O
transgenic	O
animals	O
as	O
suitable	O
models	O
to	O
investigate	O
the	O
underlying	O
mechanisms	O
and	O
possible	O
strategies	O
for	O
prevention	O
.	O
Fatty	B-Disease
liver	I-Disease
induced	O
by	O
tetracycline	B-Chemical
in	O
the	O
rat	O
.	O
Dose	O
-	O
response	O
relationships	O
and	O
effect	O
of	O
sex	O
.	O
Dose	O
-	O
response	O
relationships	O
,	O
biochemical	O
mechanisms	O
,	O
and	O
sex	O
differences	O
in	O
the	O
experimental	O
fatty	B-Disease
liver	I-Disease
induced	O
by	O
tetracycline	B-Chemical
were	O
studied	O
in	O
the	O
intact	O
rat	O
and	O
with	O
the	O
isolated	O
perfused	O
rat	O
liver	O
in	O
vitro	O
.	O
In	O
the	O
intact	O
male	O
and	O
female	O
rat	O
,	O
no	O
direct	O
relationship	O
was	O
observed	O
between	O
dose	O
of	O
tetracycline	B-Chemical
and	O
hepatic	O
accumulation	O
of	O
triglyceride	B-Chemical
.	O
With	O
provision	O
of	O
adequate	O
oleic	B-Chemical
acid	I-Chemical
as	O
a	O
substrate	O
for	O
the	O
isolated	O
perfused	O
liver	O
,	O
a	O
direct	O
relationship	O
was	O
observed	O
between	O
dose	O
of	O
tetracycline	B-Chemical
and	O
both	O
accumulation	O
of	O
triglyceride	B-Chemical
in	O
the	O
liver	O
and	O
depression	B-Disease
of	O
output	O
of	O
triglyceride	B-Chemical
by	O
livers	O
from	O
male	O
and	O
female	O
rats	O
.	O
Marked	O
differences	O
were	O
observed	O
between	O
female	O
and	O
male	O
rats	O
with	O
regard	O
to	O
base	O
line	O
(	O
control	O
)	O
hepatic	O
concentration	O
of	O
triglyceride	B-Chemical
and	O
output	O
of	O
triglyceride	B-Chemical
.	O
Accumulation	O
of	O
hepatic	O
triglyceride	B-Chemical
,	O
as	O
a	O
per	O
cent	O
of	O
control	O
values	O
,	O
in	O
response	O
to	O
graded	O
doses	O
of	O
tetracycline	B-Chemical
,	O
did	O
not	O
differ	O
significantly	O
between	O
male	O
,	O
female	O
and	O
pregnant	O
rat	O
livers	O
.	O
However	O
,	O
livers	O
from	O
female	O
,	O
and	O
especially	O
pregnant	O
female	O
rats	O
,	O
were	O
strikingly	O
resistant	O
to	O
the	O
effects	O
of	O
tetracycline	B-Chemical
on	O
depression	B-Disease
of	O
output	O
of	O
triglyceride	B-Chemical
under	O
these	O
experimental	O
conditions	O
.	O
These	O
differences	O
between	O
the	O
sexes	O
could	O
not	O
be	O
related	O
to	O
altered	O
disposition	O
of	O
tetracycline	B-Chemical
or	O
altered	O
uptake	O
of	O
oleic	B-Chemical
acid	I-Chemical
.	O
Depressed	O
hepatic	O
secretion	O
of	O
triglyceride	B-Chemical
accounted	O
only	O
for	O
30	O
to	O
50	O
%	O
of	O
accumulated	O
hepatic	O
triglyceride	B-Chemical
,	O
indicating	O
that	O
additional	O
mechanisms	O
must	O
be	O
involved	O
in	O
the	O
production	O
of	O
the	O
triglyceride	B-Chemical
-	O
rich	O
fatty	B-Disease
liver	I-Disease
in	O
response	O
to	O
tetracycline	B-Chemical
.	O
Prednisone	B-Chemical
induces	O
anxiety	B-Disease
and	O
glial	O
cerebral	O
changes	O
in	O
rats	O
.	O
OBJECTIVE	O
:	O
To	O
assess	O
whether	O
prednisone	B-Chemical
(	O
PDN	B-Chemical
)	O
produces	O
anxiety	B-Disease
and	O
/	O
or	O
cerebral	O
glial	O
changes	O
in	O
rats	O
.	O
METHODS	O
:	O
Male	O
Wistar	O
rats	O
were	O
studied	O
and	O
3	O
groups	O
were	O
formed	O
(	O
8	O
rats	O
per	O
group	O
)	O
.	O
The	O
moderate	O
-	O
dose	O
group	O
received	O
5	O
mg	O
/	O
kg	O
/	O
day	O
PDN	B-Chemical
released	O
from	O
a	O
subcutaneous	O
implant	O
.	O
In	O
the	O
high	O
-	O
dose	O
group	O
,	O
implants	O
containing	O
PDN	B-Chemical
equivalent	O
to	O
60	O
mg	O
/	O
kg	O
/	O
day	O
were	O
applied	O
.	O
In	O
the	O
control	O
group	O
implants	O
contained	O
no	O
PDN	B-Chemical
.	O
Anxiety	B-Disease
was	O
assessed	O
using	O
an	O
open	O
field	O
and	O
elevated	O
plus	O
-	O
maze	O
devices	O
.	O
The	O
number	O
of	O
cells	O
and	O
cytoplasmic	O
transformation	O
of	O
astrocytes	O
and	O
microglia	O
cells	O
were	O
assessed	O
by	O
immunohistochemical	O
analyses	O
.	O
RESULTS	O
:	O
Anxiety	B-Disease
was	O
documented	O
in	O
both	O
groups	O
of	O
PDN	B-Chemical
treated	O
rats	O
compared	O
with	O
controls	O
.	O
The	O
magnitude	O
of	O
transformation	O
of	O
the	O
microglia	O
assessed	O
by	O
the	O
number	O
of	O
intersections	O
was	O
significantly	O
higher	O
in	O
the	O
PDN	B-Chemical
groups	O
than	O
in	O
controls	O
in	O
the	O
prefrontal	O
cortex	O
(	O
moderate	O
-	O
dose	O
,	O
24	O
.	O
1	O
;	O
high	O
-	O
dose	O
,	O
23	O
.	O
6	O
;	O
controls	O
18	O
.	O
7	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
striatum	O
(	O
moderate	O
-	O
dose	O
25	O
.	O
6	O
;	O
high	O
-	O
dose	O
26	O
.	O
3	O
;	O
controls	O
18	O
.	O
9	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
but	O
not	O
in	O
hippocampus	O
.	O
The	O
number	O
of	O
stained	O
microglia	O
cells	O
was	O
significantly	O
higher	O
in	O
the	O
PDN	B-Chemical
treated	O
groups	O
in	O
the	O
prefrontal	O
cortex	O
than	O
in	O
controls	O
(	O
moderate	O
-	O
dose	O
,	O
29	O
.	O
1	O
;	O
high	O
-	O
dose	O
,	O
28	O
.	O
4	O
;	O
control	O
,	O
17	O
.	O
7	O
cells	O
per	O
field	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
Stained	O
microglia	O
cells	O
were	O
significantly	O
more	O
numerous	O
striatum	O
and	O
hippocampus	O
in	O
the	O
high	O
-	O
dose	O
group	O
compared	O
to	O
controls	O
.	O
CONCLUSION	O
:	O
Subacute	O
exposure	O
to	O
PDN	B-Chemical
induced	O
anxiety	B-Disease
and	O
reactivity	O
of	O
microglia	O
.	O
The	O
relevance	O
of	O
these	O
features	O
for	O
patients	O
using	O
PDN	B-Chemical
remains	O
to	O
be	O
elucidated	O
.	O
Phase	O
II	O
study	O
of	O
carboplatin	B-Chemical
and	O
liposomal	O
doxorubicin	B-Chemical
in	O
patients	O
with	O
recurrent	O
squamous	B-Disease
cell	I-Disease
carcinoma	I-Disease
of	I-Disease
the	I-Disease
cervix	I-Disease
.	O
BACKGROUND	O
:	O
The	O
activity	O
of	O
the	O
combination	O
of	O
carboplatin	B-Chemical
and	O
liposomal	O
doxorubicin	B-Chemical
was	O
tested	O
in	O
a	O
Phase	O
II	O
study	O
of	O
patients	O
with	O
recurrent	O
cervical	B-Disease
carcinoma	I-Disease
.	O
METHODS	O
:	O
The	O
combination	O
of	O
carboplatin	B-Chemical
(	O
area	O
under	O
the	O
concentration	O
curve	O
[	O
AUC	O
]	O
,	O
5	O
)	O
and	O
liposomal	O
doxorubicin	B-Chemical
(	O
Doxil	B-Chemical
;	O
starting	O
dose	O
,	O
40	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
was	O
administered	O
intravenously	O
every	O
28	O
days	O
to	O
37	O
patients	O
with	O
recurrent	O
squamous	B-Disease
cell	I-Disease
cervical	I-Disease
carcinoma	I-Disease
to	O
determine	O
antitumor	O
activity	O
and	O
toxicity	B-Disease
profile	O
.	O
RESULTS	O
:	O
Twenty	O
-	O
nine	O
patients	O
were	O
assessable	O
for	O
response	O
,	O
and	O
35	O
patients	O
were	O
assessable	O
for	O
toxicity	B-Disease
.	O
The	O
overall	O
response	O
rate	O
was	O
38	O
%	O
,	O
the	O
median	O
time	O
to	O
response	O
was	O
10	O
weeks	O
,	O
the	O
median	O
duration	O
of	O
response	O
was	O
26	O
weeks	O
,	O
and	O
the	O
median	O
survival	O
was	O
37	O
weeks	O
.	O
The	O
main	O
toxic	O
effect	O
was	O
myelosuppression	B-Disease
,	O
with	O
Grade	O
3	O
and	O
4	O
neutropenia	B-Disease
in	O
16	O
patients	O
,	O
anemia	B-Disease
in	O
12	O
patients	O
,	O
thrombocytopenia	B-Disease
in	O
11	O
patients	O
,	O
and	O
neutropenic	B-Disease
fever	I-Disease
in	O
3	O
patients	O
.	O
Four	O
patients	O
had	O
five	O
infusion	O
-	O
related	O
reactions	O
during	O
the	O
infusion	O
of	O
liposomal	O
doxorubicin	B-Chemical
,	O
leading	O
to	O
treatment	O
discontinuation	O
in	O
three	O
patients	O
.	O
Grade	O
>	O
or	O
=	O
2	O
nonhematologic	O
toxicity	B-Disease
included	O
nausea	B-Disease
in	O
17	O
patients	O
,	O
emesis	B-Disease
in	O
14	O
patients	O
,	O
fatigue	B-Disease
in	O
9	O
patients	O
,	O
mucositis	B-Disease
and	O
/	O
or	O
stomatitis	B-Disease
in	O
8	O
patients	O
,	O
constipation	B-Disease
in	O
6	O
patients	O
,	O
weight	B-Disease
loss	I-Disease
in	O
5	O
patients	O
,	O
hand	B-Disease
-	I-Disease
foot	I-Disease
syndrome	I-Disease
in	O
2	O
patients	O
,	O
and	O
skin	B-Disease
reactions	I-Disease
in	O
3	O
patients	O
.	O
CONCLUSIONS	O
:	O
The	O
combination	O
of	O
carboplatin	B-Chemical
and	O
liposomal	O
doxorubicin	B-Chemical
has	O
modest	O
activity	O
in	O
patients	O
with	O
recurrent	O
cervical	B-Disease
carcinoma	I-Disease
.	O
Antimicrobial	O
-	O
induced	O
mania	B-Disease
(	O
antibiomania	B-Disease
)	O
:	O
a	O
review	O
of	O
spontaneous	O
reports	O
.	O
The	O
authors	O
reviewed	O
reported	O
cases	O
of	O
antibiotic	O
-	O
induced	O
manic	B-Disease
episodes	O
by	O
means	O
of	O
a	O
MEDLINE	O
and	O
PsychLit	O
search	O
for	O
reports	O
of	O
antibiotic	O
-	O
induced	O
mania	B-Disease
.	O
Unpublished	O
reports	O
were	O
requested	O
from	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
and	O
the	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
.	O
Twenty	O
-	O
one	O
reports	O
of	O
antimicrobial	O
-	O
induced	O
mania	B-Disease
were	O
found	O
in	O
the	O
literature	O
.	O
There	O
were	O
6	O
cases	O
implicating	O
clarithromycin	B-Chemical
,	O
13	O
implicating	O
isoniazid	B-Chemical
,	O
and	O
1	O
case	O
each	O
implicating	O
erythromycin	B-Chemical
and	O
amoxicillin	B-Chemical
.	O
The	O
WHO	O
reported	O
82	O
cases	O
.	O
Of	O
these	O
,	O
clarithromycin	B-Chemical
was	O
implicated	O
in	O
23	O
(	O
27	O
.	O
6	O
%	O
)	O
cases	O
,	O
ciprofloxacin	B-Chemical
in	O
12	O
(	O
14	O
.	O
4	O
%	O
)	O
cases	O
,	O
and	O
ofloxacin	B-Chemical
in	O
10	O
(	O
12	O
%	O
)	O
cases	O
.	O
Cotrimoxazole	B-Chemical
,	O
metronidazole	B-Chemical
,	O
and	O
erythromycin	B-Chemical
were	O
involved	O
in	O
15	O
reported	O
manic	B-Disease
episodes	O
.	O
Cases	O
reported	O
by	O
the	O
FDA	O
showed	O
clarithromycin	B-Chemical
and	O
ciprofloxacin	B-Chemical
to	O
be	O
the	O
most	O
frequently	O
associated	O
with	O
the	O
development	O
of	O
mania	B-Disease
.	O
Statistical	O
analysis	O
of	O
the	O
data	O
would	O
not	O
have	O
demonstrated	O
a	O
significant	O
statistical	O
correlative	O
risk	O
and	O
was	O
therefore	O
not	O
undertaken	O
.	O
Patients	O
have	O
an	O
increased	O
risk	O
of	O
developing	O
mania	B-Disease
while	O
being	O
treated	O
with	O
antimicrobials	O
.	O
Although	O
this	O
is	O
not	O
a	O
statistically	O
significant	O
risk	O
,	O
physicians	O
must	O
be	O
aware	O
of	O
the	O
effect	O
and	O
reversibility	O
.	O
Further	O
research	O
clearly	O
is	O
required	O
to	O
determine	O
the	O
incidence	O
of	O
antimicrobial	O
-	O
induced	O
mania	B-Disease
,	O
the	O
relative	O
risk	O
factors	O
of	O
developing	O
an	O
antimicrobial	O
-	O
induced	O
manic	B-Disease
episode	O
among	O
various	O
demographic	O
populations	O
,	O
and	O
the	O
incidence	O
of	O
patients	O
who	O
continue	O
to	O
have	O
persistent	O
affective	O
disorders	O
once	O
the	O
initial	O
episode	O
,	O
which	O
occurs	O
while	O
the	O
patient	O
is	O
taking	O
antibiotics	O
,	O
subsides	O
.	O
The	O
authors	O
elected	O
to	O
name	O
this	O
syndrome	O
""""	O
antibiomania	B-Disease
.	O
""""	O
Levodopa	B-Chemical
-	O
induced	O
ocular	B-Disease
dyskinesias	I-Disease
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
Levodopa	B-Chemical
-	O
induced	O
ocular	B-Disease
dyskinesias	I-Disease
are	O
very	O
uncommon	O
.	O
Usually	O
they	O
occur	O
simultaneously	O
with	O
limb	O
peak	O
-	O
dose	O
choreatic	B-Disease
dyskinesias	I-Disease
.	O
We	O
report	O
on	O
a	O
patient	O
with	O
leftward	O
and	O
upward	O
deviations	O
of	O
gaze	O
during	O
the	O
peak	O
effect	O
of	O
levodopa	B-Chemical
,	O
and	O
hypothesize	O
that	O
a	O
severe	O
dopaminergic	O
denervation	O
in	O
the	O
caudate	O
nucleus	O
is	O
needed	O
for	O
the	O
appearance	O
of	O
these	O
levodopa	B-Chemical
-	O
induce	O
ocular	B-Disease
dyskinesias	I-Disease
.	O
A	O
comparison	O
of	O
glyceryl	B-Chemical
trinitrate	I-Chemical
with	O
diclofenac	B-Chemical
for	O
the	O
treatment	O
of	O
primary	O
dysmenorrhea	B-Disease
:	O
an	O
open	O
,	O
randomized	O
,	O
cross	O
-	O
over	O
trial	O
.	O
Primary	O
dysmenorrhea	B-Disease
is	O
a	O
syndrome	O
characterized	O
by	O
painful	O
uterine	O
contractility	O
caused	O
by	O
a	O
hypersecretion	O
of	O
endometrial	O
prostaglandins	B-Chemical
;	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
are	O
the	O
first	O
choice	O
for	O
its	O
treatment	O
.	O
However	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
have	O
demonstrated	O
that	O
myometrial	O
cells	O
are	O
also	O
targets	O
of	O
the	O
relaxant	O
effects	O
of	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
efficacy	O
of	O
glyceryl	B-Chemical
trinitrate	I-Chemical
(	O
GTN	B-Chemical
)	O
,	O
an	O
NO	B-Chemical
donor	O
,	O
in	O
the	O
resolution	O
of	O
primary	O
dysmenorrhea	B-Disease
in	O
comparison	O
with	O
diclofenac	B-Chemical
(	O
DCF	B-Chemical
)	O
.	O
A	O
total	O
of	O
24	O
patients	O
with	O
the	O
diagnosis	O
of	O
severe	O
primary	O
dysmenorrhea	B-Disease
were	O
studied	O
during	O
two	O
consecutive	O
menstrual	O
cycles	O
.	O
In	O
an	O
open	O
,	O
cross	O
-	O
over	O
,	O
controlled	O
design	O
,	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
DCF	B-Chemical
per	O
os	O
or	O
GTN	B-Chemical
patches	O
the	O
first	O
days	O
of	O
menses	O
,	O
when	O
menstrual	O
cramps	O
became	O
unendurable	O
.	O
In	O
the	O
subsequent	O
cycle	O
the	O
other	O
treatment	O
was	O
used	O
.	O
Patients	O
received	O
up	O
to	O
3	O
doses	O
/	O
day	O
of	O
50	O
mg	O
DCF	B-Chemical
or	O
2	O
.	O
5	O
mg	O
/	O
24	O
h	O
transdermal	O
GTN	B-Chemical
for	O
the	O
first	O
3	O
days	O
of	O
the	O
cycle	O
,	O
according	O
to	O
their	O
needs	O
.	O
The	O
participants	O
recorded	O
menstrual	O
symptoms	O
and	O
possible	O
side	O
-	O
effects	O
at	O
different	O
times	O
(	O
0	O
,	O
30	O
,	O
60	O
,	O
120	O
minutes	O
)	O
after	O
the	O
first	O
dose	O
of	O
medication	O
on	O
the	O
first	O
day	O
of	O
the	O
cycle	O
,	O
with	O
both	O
drugs	O
.	O
The	O
difference	O
in	O
pain	B-Disease
intensity	O
score	O
(	O
DPI	O
)	O
was	O
the	O
main	O
outcome	O
variable	O
.	O
Both	O
treatments	O
significantly	O
reduced	O
DPI	O
by	O
the	O
30th	O
minute	O
(	O
GTN	B-Chemical
,	O
-	O
12	O
.	O
8	O
+	O
/	O
-	O
17	O
.	O
9	O
;	O
DCF	B-Chemical
,	O
-	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
6	O
)	O
.	O
However	O
,	O
DCF	B-Chemical
continued	O
to	O
be	O
effective	O
in	O
reducing	O
pelvic	B-Disease
pain	I-Disease
for	O
two	O
hours	O
,	O
whereas	O
GTN	B-Chemical
scores	O
remained	O
more	O
or	O
less	O
stable	O
after	O
30	O
min	O
and	O
significantly	O
higher	O
than	O
those	O
for	O
DFC	O
(	O
after	O
one	O
hour	O
:	O
GTN	B-Chemical
,	O
-	O
12	O
.	O
8	O
+	O
/	O
-	O
17	O
.	O
9	O
;	O
DFC	O
,	O
-	O
18	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
6	O
and	O
after	O
two	O
hours	O
:	O
GTN	B-Chemical
,	O
-	O
23	O
.	O
7	O
+	O
/	O
-	O
20	O
.	O
5	O
;	O
DFC	O
,	O
-	O
59	O
.	O
7	O
+	O
/	O
-	O
17	O
.	O
9	O
,	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O
Low	B-Disease
back	I-Disease
pain	I-Disease
was	O
also	O
relieved	O
by	O
both	O
drugs	O
.	O
Headache	B-Disease
was	O
significantly	O
increased	O
by	O
GTN	B-Chemical
but	O
not	O
by	O
DCF	B-Chemical
.	O
Eight	O
patients	O
stopped	O
using	O
GTN	B-Chemical
because	O
headache	B-Disease
-	O
-	O
attributed	O
to	O
its	O
use	O
-	O
-	O
became	O
intolerable	O
.	O
These	O
findings	O
indicate	O
that	O
GTN	B-Chemical
has	O
a	O
reduced	O
efficacy	O
and	O
tolerability	O
by	O
comparison	O
with	O
DCF	B-Chemical
in	O
the	O
treatment	O
of	O
primary	O
dysmenorrhea	B-Disease
.	O
Temocapril	B-Chemical
,	O
a	O
long	O
-	O
acting	O
non	O
-	O
SH	O
group	O
angiotensin	B-Chemical
converting	O
enzyme	O
inhibitor	O
,	O
modulates	O
glomerular	B-Disease
injury	I-Disease
in	O
chronic	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
whether	O
chronic	O
administration	O
of	O
temocapril	B-Chemical
,	O
a	O
long	O
-	O
acting	O
non	O
-	O
SH	O
group	O
angiotensin	B-Chemical
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
,	O
reduced	O
proteinuria	B-Disease
,	O
inhibited	O
glomerular	O
hypertrophy	B-Disease
and	O
prevented	O
glomerulosclerosis	B-Disease
in	O
chronic	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
-	O
induced	O
nephrotic	B-Disease
rats	O
.	O
Nephrosis	B-Disease
was	O
induced	O
by	O
injection	O
of	O
PAN	B-Chemical
(	O
15mg	O
/	O
100g	O
body	O
weight	O
)	O
in	O
male	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
.	O
Four	O
groups	O
were	O
used	O
,	O
i	O
)	O
the	O
PAN	B-Chemical
group	O
(	O
14	O
)	O
,	O
ii	O
)	O
PAN	B-Chemical
/	O
temocapril	B-Chemical
(	O
13	O
)	O
,	O
iii	O
)	O
temocapril	B-Chemical
(	O
14	O
)	O
and	O
iv	O
)	O
untreated	O
controls	O
(	O
15	O
)	O
.	O
Temocapril	B-Chemical
(	O
8	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
administered	O
to	O
the	O
rats	O
which	O
were	O
killed	O
at	O
weeks	O
4	O
,	O
14	O
or	O
20	O
.	O
At	O
each	O
time	O
point	O
,	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
,	O
urinary	O
protein	O
excretion	O
and	O
renal	O
histopathological	O
findings	O
were	O
evaluated	O
,	O
and	O
morphometric	O
image	O
analysis	O
was	O
done	O
.	O
Systolic	O
BP	O
in	O
the	O
PAN	B-Chemical
group	O
was	O
significantly	O
high	O
at	O
4	O
,	O
14	O
and	O
20	O
weeks	O
,	O
but	O
was	O
normal	O
in	O
the	O
PAN	B-Chemical
/	O
temocapril	B-Chemical
group	O
.	O
Urinary	O
protein	O
excretion	O
in	O
the	O
PAN	B-Chemical
group	O
increased	O
significantly	O
,	O
peaking	O
at	O
8	O
days	O
,	O
then	O
decreased	O
at	O
4	O
weeks	O
,	O
but	O
rose	O
again	O
significantly	O
at	O
14	O
and	O
20	O
weeks	O
.	O
Temocapril	B-Chemical
did	O
not	O
attenuate	O
proteinuria	B-Disease
at	O
8	O
days	O
,	O
but	O
it	O
did	O
markedly	O
lower	O
it	O
from	O
weeks	O
4	O
to	O
20	O
.	O
The	O
glomerulosclerosis	B-Disease
index	O
(	O
GSI	O
)	O
was	O
6	O
.	O
21	O
%	O
at	O
4	O
weeks	O
and	O
respectively	O
25	O
.	O
35	O
%	O
and	O
30	O
.	O
49	O
%	O
at	O
14	O
and	O
20	O
weeks	O
in	O
the	O
PAN	B-Chemical
group	O
.	O
There	O
was	O
a	O
significant	O
correlation	O
between	O
urinary	O
protein	O
excretion	O
and	O
GSI	O
(	O
r	O
=	O
0	O
.	O
808	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O
The	O
ratio	O
of	O
glomerular	O
tuft	O
area	O
to	O
the	O
area	O
of	O
Bowman	O
'	O
s	O
capsules	O
(	O
GT	O
/	O
BC	O
)	O
in	O
the	O
PAN	B-Chemical
group	O
was	O
significantly	O
increased	O
,	O
but	O
it	O
was	O
significantly	O
lower	O
in	O
the	O
PAN	B-Chemical
/	O
temocapril	B-Chemical
group	O
.	O
It	O
appears	O
that	O
temocapril	B-Chemical
was	O
effective	O
in	O
retarding	O
renal	O
progression	O
and	O
protected	O
renal	O
function	O
in	O
PAN	B-Chemical
neprotic	B-Disease
rats	O
.	O
Pulmonary	B-Disease
hypertension	I-Disease
after	O
ibuprofen	B-Chemical
prophylaxis	O
in	O
very	O
preterm	O
infants	O
.	O
We	O
report	O
three	O
cases	O
of	O
severe	O
hypoxaemia	B-Disease
after	O
ibuprofen	B-Chemical
administration	O
during	O
a	O
randomised	O
controlled	O
trial	O
of	O
prophylactic	O
treatment	O
of	O
patent	B-Disease
ductus	I-Disease
arteriosus	I-Disease
with	O
ibuprofen	B-Chemical
in	O
premature	O
infants	O
born	O
at	O
less	O
than	O
28	O
weeks	O
of	O
gestation	O
.	O
Echocardiography	O
showed	O
severely	O
decreased	O
pulmonary	O
blood	O
flow	O
.	O
Hypoxaemia	B-Disease
resolved	O
quickly	O
on	O
inhaled	O
nitric	B-Chemical
oxide	I-Chemical
therapy	O
.	O
We	O
suggest	O
that	O
investigators	O
involved	O
in	O
similar	O
trials	O
pay	O
close	O
attention	O
to	O
pulmonary	O
pressure	O
if	O
hypoxaemia	B-Disease
occurs	O
after	O
prophylactic	O
administration	O
of	O
ibuprofen	B-Chemical
.	O
Hyponatremia	B-Disease
and	O
syndrome	B-Disease
of	I-Disease
inappropriate	I-Disease
anti	I-Disease
-	I-Disease
diuretic	I-Disease
hormone	I-Disease
reported	O
with	O
the	O
use	O
of	O
Vincristine	B-Chemical
:	O
an	O
over	O
-	O
representation	O
of	O
Asians	O
?	O
PURPOSE	O
:	O
This	O
retrospective	O
study	O
used	O
a	O
pharmaceutical	O
company	O
'	O
s	O
global	O
safety	O
database	O
to	O
determine	O
the	O
reporting	O
rate	O
of	O
hyponatremia	B-Disease
and	O
/	O
or	O
syndrome	B-Disease
of	I-Disease
inappropriate	I-Disease
secretion	I-Disease
of	I-Disease
anti	I-Disease
-	I-Disease
diuretic	I-Disease
hormone	I-Disease
(	O
SIADH	B-Disease
)	O
among	O
vincristine	B-Chemical
-	O
treated	O
patients	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
at	O
-	O
risk	O
population	O
subgroups	O
.	O
METHOD	O
:	O
We	O
searched	O
the	O
Eli	O
Lilly	O
and	O
Company	O
'	O
s	O
computerized	O
adverse	O
event	O
database	O
for	O
all	O
reported	O
cases	O
of	O
hyponatremia	B-Disease
and	O
/	O
or	O
SIADH	B-Disease
as	O
of	O
1	O
November	O
1999	O
that	O
had	O
been	O
reported	O
during	O
the	O
use	O
of	O
vincristine	B-Chemical
.	O
RESULTS	O
:	O
A	O
total	O
of	O
76	O
cases	O
of	O
hyponatremia	B-Disease
and	O
/	O
or	O
SIADH	B-Disease
associated	O
with	O
vincristine	B-Chemical
use	O
were	O
identified	O
.	O
The	O
overall	O
reporting	O
rate	O
was	O
estimated	O
to	O
be	O
1	O
.	O
3	O
/	O
100	O
,	O
000	O
treated	O
patients	O
.	O
The	O
average	O
age	O
of	O
patients	O
was	O
35	O
.	O
6	O
+	O
/	O
-	O
28	O
.	O
3	O
years	O
,	O
and	O
62	O
%	O
were	O
males	O
.	O
Approximately	O
75	O
%	O
of	O
the	O
patients	O
were	O
receiving	O
treatment	O
for	O
leukemia	B-Disease
or	O
lymphoma	B-Disease
.	O
Among	O
the	O
39	O
reports	O
that	O
included	O
information	O
on	O
race	O
,	O
the	O
racial	O
distribution	O
was	O
:	O
1	O
Black	O
,	O
3	O
Caucasian	O
,	O
and	O
35	O
Asian	O
.	O
CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
Asian	O
patients	O
may	O
be	O
at	O
increased	O
risk	O
of	O
hyponatremia	B-Disease
and	O
/	O
or	O
SIADH	B-Disease
associated	O
with	O
vincristine	B-Chemical
use	O
.	O
Although	O
the	O
overall	O
reported	O
rate	O
of	O
SIADH	B-Disease
associated	O
with	O
vincristine	B-Chemical
is	O
very	O
low	O
,	O
physicians	O
caring	O
for	O
Asian	O
oncology	O
patients	O
should	O
be	O
aware	O
of	O
this	O
potential	O
serious	O
but	O
reversible	O
adverse	O
event	O
.	O
Delayed	O
toxicity	B-Disease
of	O
cyclophosphamide	B-Chemical
on	O
the	O
bladder	O
of	O
DBA	O
/	O
2	O
and	O
C57BL	O
/	O
6	O
female	O
mouse	O
.	O
The	O
present	O
study	O
describes	O
the	O
delayed	O
development	O
of	O
a	O
severe	O
bladder	O
pathology	O
in	O
a	O
susceptible	O
strain	O
of	O
mice	O
(	O
DBA	O
/	O
2	O
)	O
but	O
not	O
in	O
a	O
resistant	O
strain	O
(	O
C57BL	O
/	O
6	O
)	O
when	O
both	O
were	O
treated	O
with	O
a	O
single	O
300	O
mg	O
/	O
kg	O
dose	O
of	O
cyclophosphamide	B-Chemical
(	O
CY	B-Chemical
)	O
.	O
Inbred	O
DBA	O
/	O
2	O
and	O
C57BL	O
/	O
6	O
female	O
mice	O
were	O
injected	O
with	O
CY	B-Chemical
,	O
and	O
the	O
effect	O
of	O
the	O
drug	O
on	O
the	O
bladder	O
was	O
assessed	O
during	O
100	O
days	O
by	O
light	O
microscopy	O
using	O
different	O
staining	O
procedures	O
,	O
and	O
after	O
30	O
days	O
by	O
conventional	O
electron	O
microscopy	O
.	O
Early	O
CY	B-Chemical
toxicity	B-Disease
caused	O
a	O
typical	O
haemorrhagic	B-Disease
cystitis	B-Disease
in	O
both	O
strains	O
that	O
was	O
completely	O
repaired	O
in	O
about	O
7	O
-	O
10	O
days	O
.	O
After	O
30	O
days	O
of	O
CY	B-Chemical
injection	O
ulcerous	O
and	O
non	O
-	O
ulcerous	O
forms	O
of	O
chronic	O
cystitis	B-Disease
appeared	O
in	O
86	O
%	O
of	O
DBA	O
/	O
2	O
mice	O
but	O
only	O
in	O
4	O
%	O
of	O
C57BL	O
/	O
6	O
mice	O
.	O
Delayed	O
cystitis	B-Disease
was	O
characterized	O
by	O
infiltration	O
and	O
transepithelial	O
passage	O
into	O
the	O
lumen	O
of	O
inflammatory	O
cells	O
and	O
by	O
frequent	O
exfoliation	O
of	O
the	O
urothelium	O
.	O
Mast	O
cells	O
appeared	O
in	O
the	O
connective	O
and	O
muscular	O
layers	O
of	O
the	O
bladder	O
at	O
a	O
much	O
higher	O
number	O
in	O
DBA	O
/	O
2	O
mice	O
than	O
in	O
C57BL	O
/	O
6	O
mice	O
or	O
untreated	O
controls	O
.	O
Electron	O
microscopy	O
disclosed	O
the	O
absence	O
of	O
the	O
typical	O
discoidal	O
vesicles	O
normally	O
present	O
in	O
the	O
cytoplasm	O
of	O
surface	O
cells	O
.	O
Instead	O
,	O
numerous	O
abnormal	O
vesicles	O
containing	O
one	O
or	O
several	O
dark	O
granules	O
were	O
observed	O
in	O
the	O
cytoplasm	O
of	O
cells	O
from	O
all	O
the	O
epithelial	O
layers	O
.	O
Delayed	O
cystitis	B-Disease
still	O
persisted	O
in	O
DBA	O
/	O
2	O
mice	O
100	O
days	O
after	O
treatment	O
.	O
These	O
results	O
indicate	O
that	O
delayed	O
toxicity	B-Disease
of	O
CY	B-Chemical
in	O
female	O
DBA	O
/	O
2	O
mice	O
causes	O
a	O
bladder	O
pathology	O
that	O
is	O
not	O
observed	O
in	O
C57BL	O
/	O
6	O
mice	O
.	O
This	O
pathology	O
resembles	O
interstitial	B-Disease
cystitis	I-Disease
in	O
humans	O
and	O
could	O
perhaps	O
be	O
used	O
as	O
an	O
animal	O
model	O
for	O
studies	O
on	O
the	O
disease	O
.	O
High	O
-	O
dose	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
/	O
folinic	B-Chemical
acid	I-Chemical
in	O
combination	O
with	O
three	O
-	O
weekly	O
mitomycin	B-Chemical
C	I-Chemical
in	O
the	O
treatment	O
of	O
advanced	O
gastric	B-Disease
cancer	I-Disease
.	O
A	O
phase	O
II	O
study	O
.	O
BACKGROUND	O
:	O
The	O
24	O
-	O
hour	O
continuous	O
infusion	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
and	O
folinic	B-Chemical
acid	I-Chemical
(	O
FA	B-Chemical
)	O
as	O
part	O
of	O
several	O
new	O
multidrug	O
chemotherapy	O
regimens	O
in	O
advanced	O
gastric	B-Disease
cancer	I-Disease
(	O
AGC	B-Disease
)	O
has	O
shown	O
to	O
be	O
effective	O
,	O
with	O
low	O
toxicity	B-Disease
.	O
In	O
a	O
previous	O
phase	O
II	O
study	O
with	O
3	O
-	O
weekly	O
bolus	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
,	O
FA	B-Chemical
and	O
mitomycin	B-Chemical
C	I-Chemical
(	O
MMC	B-Chemical
)	O
we	O
found	O
a	O
low	O
toxicity	B-Disease
rate	O
and	O
response	O
rates	O
comparable	O
to	O
those	O
of	O
regimens	O
such	O
as	O
ELF	O
,	O
FAM	O
or	O
FAMTX	O
,	O
and	O
a	O
promising	O
median	O
overall	O
survival	O
.	O
In	O
order	O
to	O
improve	O
this	O
MMC	B-Chemical
-	O
dependent	O
schedule	O
we	O
initiated	O
a	O
phase	O
II	O
study	O
with	O
high	O
-	O
dose	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
/	O
FA	B-Chemical
and	O
3	O
-	O
weekly	O
bolus	O
MMC	B-Chemical
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
From	O
February	O
,	O
1998	O
to	O
September	O
,	O
2000	O
we	O
recruited	O
33	O
patients	O
with	O
AGC	B-Disease
to	O
receive	O
weekly	O
24	O
-	O
hour	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
2	O
,	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
preceded	O
by	O
2	O
-	O
hour	O
FA	B-Chemical
500	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
6	O
weeks	O
,	O
followed	O
by	O
a	O
2	O
-	O
week	O
rest	O
period	O
.	O
Bolus	O
MMC	B-Chemical
10	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
added	O
in	O
3	O
-	O
weekly	O
intervals	O
.	O
Treatment	O
given	O
on	O
an	O
outpatient	O
basis	O
,	O
using	O
portable	O
pump	O
systems	O
,	O
was	O
repeated	O
on	O
day	O
57	O
.	O
Patients	O
'	O
characteristics	O
were	O
:	O
male	O
/	O
female	O
ratio	O
20	O
/	O
13	O
;	O
median	O
age	O
57	O
(	O
27	O
-	O
75	O
)	O
years	O
;	O
median	O
WHO	O
status	O
1	O
(	O
0	O
-	O
2	O
)	O
.	O
18	O
patients	O
had	O
a	O
primary	O
AGC	B-Disease
,	O
and	O
15	O
showed	O
a	O
relapsed	O
AGC	B-Disease
.	O
Median	O
follow	O
-	O
up	O
was	O
11	O
.	O
8	O
months	O
(	O
range	O
of	O
those	O
surviving	O
:	O
2	O
.	O
7	O
-	O
11	O
.	O
8	O
months	O
)	O
.	O
RESULTS	O
:	O
32	O
patients	O
were	O
evaluable	O
for	O
response	O
-	O
complete	O
remission	O
9	O
.	O
1	O
%	O
(	O
n	O
=	O
3	O
)	O
,	O
partial	O
remission	O
45	O
.	O
5	O
%	O
(	O
n	O
=	O
15	O
)	O
,	O
no	O
change	O
27	O
.	O
3	O
%	O
(	O
n	O
=	O
9	O
)	O
,	O
progressive	O
disease	O
15	O
.	O
1	O
%	O
(	O
n	O
=	O
5	O
)	O
.	O
Median	O
overall	O
survival	O
time	O
was	O
10	O
.	O
2	O
months	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
8	O
.	O
7	O
-	O
11	O
.	O
6	O
]	O
,	O
and	O
median	O
progression	O
-	O
free	O
survival	O
time	O
was	O
7	O
.	O
6	O
months	O
(	O
95	O
%	O
CI	O
:	O
4	O
.	O
4	O
-	O
10	O
.	O
9	O
)	O
.	O
The	O
worst	O
toxicities	B-Disease
(	O
%	O
)	O
observed	O
were	O
(	O
CTC	O
-	O
NCI	O
1	O
/	O
2	O
/	O
3	O
)	O
:	O
leukopenia	B-Disease
45	O
.	O
5	O
/	O
18	O
.	O
2	O
/	O
6	O
.	O
1	O
,	O
thrombocytopenia	B-Disease
33	O
.	O
3	O
/	O
9	O
.	O
1	O
/	O
6	O
.	O
1	O
,	O
vomitus	B-Disease
24	O
.	O
2	O
/	O
9	O
.	O
1	O
/	O
0	O
,	O
diarrhea	B-Disease
36	O
.	O
4	O
/	O
6	O
.	O
1	O
/	O
3	O
.	O
0	O
,	O
stomatitis	B-Disease
18	O
.	O
2	O
/	O
9	O
.	O
1	O
/	O
0	O
,	O
hand	B-Disease
-	I-Disease
foot	I-Disease
syndrome	I-Disease
12	O
.	O
1	O
/	O
0	O
/	O
0	O
.	O
Two	O
patients	O
developed	O
hemolytic	B-Disease
-	I-Disease
uremic	I-Disease
syndrome	I-Disease
(	O
HUS	B-Disease
)	O
.	O
CONCLUSIONS	O
:	O
High	O
-	O
dose	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
/	O
FA	B-Chemical
/	O
MMC	B-Chemical
is	O
an	O
effective	O
and	O
well	O
-	O
tolerated	O
outpatient	O
regimen	O
for	O
AGC	B-Disease
(	O
objective	O
response	O
rate	O
54	O
.	O
6	O
%	O
)	O
.	O
It	O
may	O
serve	O
as	O
an	O
alternative	O
to	O
cisplatin	B-Chemical
-	O
containing	O
regimens	O
;	O
however	O
,	O
it	O
has	O
to	O
be	O
considered	O
that	O
possibly	O
HUS	B-Disease
may	O
occur	O
.	O
Persistent	O
sterile	O
leukocyturia	B-Disease
is	O
associated	O
with	O
impaired	B-Disease
renal	I-Disease
function	I-Disease
in	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
type	I-Disease
1	I-Disease
-	I-Disease
infected	I-Disease
children	O
treated	O
with	O
indinavir	B-Chemical
.	O
BACKGROUND	O
:	O
Prolonged	O
administration	O
of	O
indinavir	B-Chemical
is	O
associated	O
with	O
the	O
occurrence	O
of	O
a	O
variety	O
of	O
renal	O
complications	O
in	O
adults	O
.	O
These	O
well	O
-	O
documented	O
side	O
effects	O
have	O
restricted	O
the	O
use	O
of	O
this	O
potent	O
protease	O
inhibitor	O
in	O
children	O
.	O
DESIGN	O
:	O
A	O
prospective	O
study	O
to	O
monitor	O
indinavir	B-Chemical
-	O
related	O
nephrotoxicity	B-Disease
in	O
a	O
cohort	O
of	O
30	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
type	I-Disease
1	I-Disease
-	I-Disease
infected	I-Disease
children	O
treated	O
with	O
indinavir	B-Chemical
.	O
METHODS	O
:	O
Urinary	O
pH	O
,	O
albumin	O
,	O
creatinine	B-Chemical
,	O
the	O
presence	O
of	O
erythrocytes	O
,	O
leukocytes	O
,	O
bacteria	O
and	O
crystals	O
,	O
and	O
culture	O
were	O
analyzed	O
every	O
3	O
months	O
for	O
96	O
weeks	O
.	O
Serum	O
creatinine	B-Chemical
levels	O
were	O
routinely	O
determined	O
at	O
the	O
same	O
time	O
points	O
.	O
Steady	O
-	O
state	O
pharmacokinetics	O
of	O
indinavir	B-Chemical
were	O
done	O
at	O
week	O
4	O
after	O
the	O
initiation	O
of	O
indinavir	B-Chemical
.	O
RESULTS	O
:	O
The	O
cumulative	O
incidence	O
of	O
persistent	O
sterile	O
leukocyturia	B-Disease
(	O
>	O
or	O
=	O
75	O
cells	O
/	O
micro	O
L	O
in	O
at	O
least	O
2	O
consecutive	O
visits	O
)	O
after	O
96	O
weeks	O
was	O
53	O
%	O
.	O
Persistent	O
sterile	O
leukocyturia	B-Disease
was	O
frequently	O
associated	O
with	O
a	O
mild	O
increase	O
in	O
the	O
urine	O
albumin	O
/	O
creatinine	B-Chemical
ratio	O
and	O
by	O
microscopic	O
hematuria	B-Disease
.	O
The	O
cumulative	O
incidence	O
of	O
serum	O
creatinine	B-Chemical
levels	O
>	O
50	O
%	O
above	O
normal	O
was	O
33	O
%	O
after	O
96	O
weeks	O
.	O
Children	O
with	O
persistent	O
sterile	O
leukocyturia	B-Disease
more	O
frequently	O
had	O
serum	O
creatinine	B-Chemical
levels	O
of	O
50	O
%	O
above	O
normal	O
than	O
those	O
children	O
without	O
persistent	O
sterile	O
leukocyturia	B-Disease
.	O
In	O
children	O
younger	O
than	O
5	O
.	O
6	O
years	O
,	O
persistent	O
sterile	O
leukocyturia	B-Disease
was	O
significantly	O
more	O
frequent	O
than	O
in	O
older	O
children	O
.	O
A	O
higher	O
cumulative	O
incidence	O
of	O
persistent	O
leukocyturia	B-Disease
was	O
found	O
in	O
children	O
with	O
an	O
area	O
under	O
the	O
curve	O
>	O
19	O
mg	O
/	O
L	O
x	O
h	O
or	O
a	O
peak	O
serum	O
level	O
of	O
indinavir	B-Chemical
>	O
12	O
mg	O
/	O
L	O
.	O
In	O
4	O
children	O
,	O
indinavir	B-Chemical
was	O
discontinued	O
because	O
of	O
nephrotoxicity	B-Disease
.	O
Subsequently	O
,	O
the	O
serum	O
creatinine	B-Chemical
levels	O
decreased	O
,	O
the	O
urine	O
albumin	O
/	O
creatinine	B-Chemical
ratios	O
returned	O
to	O
zero	O
,	O
and	O
the	O
leukocyturia	B-Disease
disappeared	O
within	O
3	O
months	O
.	O
CONCLUSIONS	O
:	O
Children	O
treated	O
with	O
indinavir	B-Chemical
have	O
a	O
high	O
cumulative	O
incidence	O
of	O
persistent	O
sterile	O
leukocyturia	B-Disease
.	O
Children	O
with	O
persistent	O
sterile	O
leukocyturia	B-Disease
more	O
frequently	O
had	O
an	O
increase	O
in	O
serum	O
creatinine	B-Chemical
levels	O
of	O
>	O
50	O
%	O
above	O
normal	O
.	O
Younger	O
children	O
have	O
an	O
additional	O
risk	O
for	O
renal	O
complications	O
.	O
The	O
impairment	B-Disease
of	I-Disease
the	I-Disease
renal	I-Disease
function	I-Disease
in	O
these	O
children	O
occurred	O
in	O
the	O
absence	O
of	O
clinical	O
symptoms	O
of	O
nephrolithiasis	B-Disease
.	O
Indinavir	B-Chemical
-	O
associated	O
nephrotoxicity	B-Disease
must	O
be	O
monitored	O
closely	O
,	O
especially	O
in	O
children	O
with	O
risk	O
factors	O
such	O
as	O
persistent	O
sterile	O
leukocyturia	B-Disease
,	O
age	O
<	O
5	O
.	O
6	O
years	O
,	O
an	O
area	O
under	O
the	O
curve	O
of	O
indinavir	B-Chemical
>	O
19	O
mg	O
/	O
L	O
x	O
h	O
,	O
and	O
a	O
C	O
(	O
max	O
)	O
>	O
12	O
mg	O
/	O
L	O
.	O
Utility	O
of	O
troponin	O
I	O
in	O
patients	O
with	O
cocaine	B-Chemical
-	O
associated	O
chest	B-Disease
pain	I-Disease
.	O
Baseline	O
electrocardiogram	O
abnormalities	O
and	O
market	O
elevations	O
not	O
associated	O
with	O
myocardial	B-Disease
necrosis	I-Disease
make	O
accurate	O
diagnosis	O
of	O
myocardial	B-Disease
infarction	I-Disease
(	O
MI	B-Disease
)	O
difficult	O
in	O
patients	O
with	O
cocaine	B-Chemical
-	O
associated	O
chest	B-Disease
pain	I-Disease
.	O
Troponin	O
sampling	O
may	O
offer	O
greater	O
diagnostic	O
utility	O
in	O
these	O
patients	O
.	O
OBJECTIVE	O
:	O
To	O
assess	O
outcomes	O
based	O
on	O
troponin	O
positivity	O
in	O
patients	O
with	O
cocaine	B-Chemical
chest	B-Disease
pain	I-Disease
admitted	O
for	O
exclusion	O
of	O
MI	B-Disease
.	O
METHODS	O
:	O
Outcomes	O
were	O
examined	O
in	O
patients	O
admitted	O
for	O
possible	O
MI	B-Disease
after	O
cocaine	B-Chemical
use	O
.	O
All	O
patients	O
underwent	O
a	O
rapid	O
rule	O
-	O
in	O
protocol	O
that	O
included	O
serial	O
sampling	O
of	O
creatine	B-Chemical
kinase	O
(	O
CK	O
)	O
,	O
CK	O
-	O
MB	O
,	O
and	O
cardiac	O
troponin	O
I	O
(	O
cTnI	O
)	O
over	O
eight	O
hours	O
.	O
Outcomes	O
included	O
CK	O
-	O
MB	O
MI	B-Disease
(	O
CK	O
-	O
MB	O
>	O
or	O
=	O
8	O
ng	O
/	O
mL	O
with	O
a	O
relative	O
index	O
[	O
(	O
CK	O
-	O
MB	O
x	O
100	O
)	O
/	O
total	O
CK	O
]	O
>	O
or	O
=	O
4	O
,	O
cardiac	B-Disease
death	I-Disease
,	O
and	O
significant	O
coronary	B-Disease
disease	I-Disease
(	O
>	O
or	O
=	O
50	O
%	O
)	O
.	O
RESULTS	O
:	O
Of	O
the	O
246	O
admitted	O
patients	O
,	O
34	O
(	O
14	O
%	O
)	O
met	O
CK	O
-	O
MB	O
criteria	O
for	O
MI	B-Disease
and	O
38	O
(	O
16	O
%	O
)	O
had	O
cTnI	O
elevations	O
.	O
Angiography	O
was	O
performed	O
in	O
29	O
of	O
38	O
patients	O
who	O
were	O
cTnI	O
-	O
positive	O
,	O
with	O
significant	O
disease	O
present	O
in	O
25	O
(	O
86	O
%	O
)	O
.	O
Three	O
of	O
the	O
four	O
patients	O
without	O
significant	O
disease	O
who	O
had	O
cTnI	O
elevations	O
met	O
CK	O
-	O
MB	O
criteria	O
for	O
MI	B-Disease
,	O
and	O
the	O
other	O
had	O
a	O
peak	O
CK	O
-	O
MB	O
level	O
of	O
13	O
ng	O
/	O
mL	O
.	O
Sensitivities	O
,	O
specificities	O
,	O
and	O
positive	O
and	O
negative	O
likelihood	O
ratios	O
for	O
predicting	O
cardiac	B-Disease
death	I-Disease
or	O
significant	O
disease	O
were	O
high	O
for	O
both	O
CK	O
-	O
MB	O
MI	B-Disease
and	O
cTnI	O
and	O
were	O
not	O
significantly	O
different	O
.	O
CONCLUSIONS	O
:	O
Most	O
patients	O
with	O
cTnI	O
elevations	O
meet	O
CK	O
-	O
MB	O
criteria	O
for	O
MI	B-Disease
,	O
as	O
well	O
as	O
have	O
a	O
high	O
incidence	O
of	O
underlying	O
significant	O
disease	O
.	O
Troponin	O
appears	O
to	O
have	O
an	O
equivalent	O
diagnostic	O
accuracy	O
compared	O
with	O
CK	O
-	O
MB	O
for	O
diagnosing	O
necrosis	B-Disease
in	O
patients	O
with	O
cocaine	B-Chemical
-	O
associated	O
chest	B-Disease
pain	I-Disease
and	O
suspected	O
MI	B-Disease
.	O
Acute	O
interstitial	B-Disease
nephritis	I-Disease
due	O
to	O
nicergoline	B-Chemical
(	O
Sermion	B-Chemical
)	O
.	O
We	O
report	O
a	O
case	O
of	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
(	O
AIN	B-Disease
)	O
due	O
to	O
nicergoline	B-Chemical
(	O
Sermion	B-Chemical
)	O
.	O
A	O
50	O
-	O
year	O
-	O
old	O
patient	O
admitted	O
to	O
our	O
hospital	O
for	O
fever	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O
Before	O
admission	O
,	O
he	O
had	O
been	O
taking	O
nicergoline	B-Chemical
and	O
bendazac	B-Chemical
lysine	I-Chemical
due	O
to	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
at	O
ophthalmologic	O
department	O
.	O
Thereafter	O
,	O
he	O
experienced	O
intermittent	O
fever	B-Disease
and	O
skin	B-Disease
rash	I-Disease
.	O
On	O
admission	O
,	O
clinical	O
symptoms	O
(	O
i	O
.	O
e	O
.	O
arthralgia	B-Disease
and	O
fever	B-Disease
)	O
and	O
laboratory	O
findings	O
(	O
i	O
.	O
e	O
.	O
eosinophilia	B-Disease
and	O
renal	B-Disease
failure	I-Disease
)	O
suggested	O
AIN	B-Disease
,	O
and	O
which	O
was	O
confirmed	O
by	O
pathologic	O
findings	O
on	O
renal	O
biopsy	O
.	O
A	O
lymphocyte	O
transformation	O
test	O
demonstrated	O
a	O
positive	O
result	O
against	O
nicergoline	B-Chemical
.	O
Treatment	O
was	O
consisted	O
of	O
withdrawal	O
of	O
nicergoline	B-Chemical
and	O
intravenous	O
methylprednisolone	B-Chemical
,	O
and	O
his	O
renal	O
function	O
was	O
completely	O
recovered	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
nicergoline	B-Chemical
-	O
associated	O
AIN	B-Disease
.	O
Neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
complicated	O
by	O
massive	O
intestinal	O
bleeding	B-Disease
in	O
a	O
patient	O
with	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
.	O
A	O
patient	O
with	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
(	O
CRF	B-Disease
)	O
developed	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
(	O
NMS	B-Disease
)	O
after	O
administration	O
of	O
risperidone	B-Chemical
and	O
levomepromazine	B-Chemical
.	O
In	O
addition	O
to	O
the	O
typical	O
symptoms	O
of	O
NMS	B-Disease
,	O
massive	O
intestinal	O
bleeding	B-Disease
was	O
observed	O
during	O
the	O
episode	O
.	O
This	O
report	O
suggests	O
that	O
NMS	B-Disease
in	O
a	O
patient	O
with	O
CRF	B-Disease
may	O
be	O
complicated	O
by	O
intestinal	O
bleeding	B-Disease
and	O
needs	O
special	O
caution	O
for	O
this	O
complication	O
.	O
Blood	O
brain	O
barrier	O
in	O
right	O
-	O
and	O
left	O
-	O
pawed	O
female	O
rats	O
assessed	O
by	O
a	O
new	O
staining	O
method	O
.	O
The	O
asymmetrical	O
breakdown	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
was	O
studied	O
in	O
female	O
rats	O
.	O
Paw	O
preference	O
was	O
assessed	O
by	O
a	O
food	O
reaching	O
test	O
.	O
Adrenaline	B-Chemical
-	O
induced	O
hypertension	B-Disease
was	O
used	O
to	O
destroy	O
the	O
BBB	O
,	O
which	O
was	O
evaluated	O
using	O
triphenyltetrazolium	B-Chemical
(	O
TTC	B-Chemical
)	O
staining	O
of	O
the	O
brain	O
slices	O
just	O
after	O
giving	O
adrenaline	B-Chemical
for	O
30	O
s	O
.	O
In	O
normal	O
rats	O
,	O
the	O
whole	O
brain	O
sections	O
exhibited	O
complete	O
staining	O
with	O
TTC	B-Chemical
.	O
After	O
adrenaline	B-Chemical
infusion	O
for	O
30	O
s	O
,	O
there	O
were	O
large	O
unstained	O
areas	O
in	O
the	O
left	O
brain	O
in	O
right	O
-	O
pawed	O
animals	O
,	O
and	O
vice	O
versa	O
in	O
left	O
-	O
pawed	O
animals	O
.	O
Similar	O
results	O
were	O
obtained	O
in	O
seizure	B-Disease
-	O
induced	O
breakdown	O
of	O
BBB	O
.	O
These	O
results	O
were	O
explained	O
by	O
an	O
asymmetric	O
cerebral	O
blood	O
flow	O
depending	O
upon	O
the	O
paw	O
preference	O
in	O
rats	O
.	O
It	O
was	O
suggested	O
that	O
this	O
new	O
method	O
and	O
the	O
results	O
are	O
consistent	O
with	O
contralateral	O
motor	O
control	O
that	O
may	O
be	O
important	O
in	O
determining	O
the	O
dominant	O
cerebral	O
hemisphere	O
in	O
animals	O
.	O
Carvedilol	B-Chemical
protects	O
against	O
doxorubicin	B-Chemical
-	O
induced	O
mitochondrial	O
cardiomyopathy	B-Disease
.	O
Several	O
cytopathic	O
mechanisms	O
have	O
been	O
suggested	O
to	O
mediate	O
the	O
dose	O
-	O
limiting	O
cumulative	O
and	O
irreversible	O
cardiomyopathy	B-Disease
caused	O
by	O
doxorubicin	B-Chemical
.	O
Recent	O
evidence	O
indicates	O
that	O
oxidative	O
stress	O
and	O
mitochondrial	B-Disease
dysfunction	I-Disease
are	O
key	O
factors	O
in	O
the	O
pathogenic	O
process	O
.	O
The	O
objective	O
of	O
this	O
investigation	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
carvedilol	B-Chemical
,	O
a	O
nonselective	O
beta	O
-	O
adrenergic	O
receptor	O
antagonist	O
with	O
potent	O
antioxidant	O
properties	O
,	O
protects	O
against	O
the	O
cardiac	O
and	O
hepatic	O
mitochondrial	O
bioenergetic	O
dysfunction	O
associated	O
with	O
subchronic	O
doxorubicin	B-Chemical
toxicity	B-Disease
.	O
Heart	O
and	O
liver	O
mitochondria	O
were	O
isolated	O
from	O
rats	O
treated	O
for	O
7	O
weeks	O
with	O
doxorubicin	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
sc	O
/	O
week	O
)	O
,	O
carvedilol	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
ip	O
/	O
week	O
)	O
,	O
or	O
the	O
combination	O
of	O
the	O
two	O
drugs	O
.	O
Heart	O
mitochondria	O
isolated	O
from	O
doxorubicin	B-Chemical
-	O
treated	O
rats	O
exhibited	O
depressed	O
rates	O
for	O
state	O
3	O
respiration	O
(	O
336	O
+	O
/	O
-	O
26	O
versus	O
425	O
+	O
/	O
-	O
53	O
natom	O
O	O
/	O
min	O
/	O
mg	O
protein	O
)	O
and	O
a	O
lower	O
respiratory	O
control	O
ratio	O
(	O
RCR	O
)	O
(	O
4	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
6	O
versus	O
5	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
4	O
)	O
compared	O
with	O
cardiac	O
mitochondria	O
isolated	O
from	O
saline	O
-	O
treated	O
rats	O
.	O
Mitochondrial	O
calcium	B-Chemical
-	O
loading	O
capacity	O
and	O
the	O
activity	O
of	O
NADH	O
-	O
dehydrogenase	O
were	O
also	O
suppressed	O
in	O
cardiac	O
mitochondria	O
from	O
doxorubicin	B-Chemical
-	O
treated	O
rats	O
.	O
Doxorubicin	B-Chemical
treatment	O
also	O
caused	O
a	O
decrease	O
in	O
RCR	O
for	O
liver	O
mitochondria	O
(	O
3	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
9	O
versus	O
5	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
for	O
control	O
rats	O
)	O
and	O
inhibition	O
of	O
hepatic	O
cytochrome	O
oxidase	O
activity	O
.	O
Coadministration	O
of	O
carvedilol	B-Chemical
decreased	O
the	O
extent	O
of	O
cellular	O
vacuolization	O
in	O
cardiac	O
myocytes	O
and	O
prevented	O
the	O
inhibitory	O
effect	O
of	O
doxorubicin	B-Chemical
on	O
mitochondrial	O
respiration	O
in	O
both	O
heart	O
and	O
liver	O
.	O
Carvedilol	B-Chemical
also	O
prevented	O
the	O
decrease	O
in	O
mitochondrial	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
loading	O
capacity	O
and	O
the	O
inhibition	O
of	O
the	O
respiratory	O
complexes	O
of	O
heart	O
mitochondria	O
caused	O
by	O
doxorubicin	B-Chemical
.	O
Carvedilol	B-Chemical
by	O
itself	O
did	O
not	O
affect	O
any	O
of	O
the	O
parameters	O
measured	O
for	O
heart	O
or	O
liver	O
mitochondria	O
.	O
It	O
is	O
concluded	O
that	O
this	O
protection	O
by	O
carvedilol	B-Chemical
against	O
both	O
the	O
structural	O
and	O
functional	O
cardiac	O
tissue	O
damage	O
may	O
afford	O
significant	O
clinical	O
advantage	O
in	O
minimizing	O
the	O
dose	O
-	O
limiting	O
mitochondrial	B-Disease
dysfunction	I-Disease
and	O
cardiomyopathy	B-Disease
that	O
accompanies	O
long	O
-	O
term	O
doxorubicin	B-Chemical
therapy	O
in	O
cancer	B-Disease
patients	O
.	O
Cocaine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
is	O
more	O
influenced	O
by	O
adenosine	B-Chemical
receptor	O
agonists	O
than	O
amphetamine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
.	O
The	O
influence	O
of	O
adenosine	B-Chemical
receptor	O
agonists	O
and	O
antagonists	O
on	O
cocaine	B-Chemical
-	O
and	O
amphetamine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
was	O
examined	O
in	O
mice	O
.	O
All	O
adenosine	B-Chemical
receptor	O
agonists	O
significantly	O
decreased	B-Disease
the	I-Disease
locomotor	I-Disease
activity	I-Disease
in	O
mice	O
,	O
and	O
the	O
effects	O
were	O
dose	O
-	O
dependent	O
.	O
It	O
seems	O
that	O
adenosine	B-Chemical
A1	O
and	O
A2	O
receptors	O
might	O
be	O
involved	O
in	O
this	O
reaction	O
.	O
Moreover	O
,	O
all	O
adenosine	B-Chemical
receptor	O
agonists	O
:	O
2	B-Chemical
-	I-Chemical
p	I-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
carboxyethyl	I-Chemical
)	I-Chemical
phenethylamino	I-Chemical
-	I-Chemical
5	I-Chemical
'	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
ethylcarboxamidoadenosine	I-Chemical
(	O
CGS	B-Chemical
21680	I-Chemical
)	O
,	O
A2A	O
receptor	O
agonist	O
,	O
N6	B-Chemical
-	I-Chemical
cyclopentyladenosine	I-Chemical
(	O
CPA	B-Chemical
)	O
,	O
A1	O
receptor	O
agonist	O
,	O
and	O
5	B-Chemical
'	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
ethylcarboxamidoadenosine	I-Chemical
(	O
NECA	B-Chemical
)	O
,	O
A2	O
/	O
A1	O
receptor	O
agonist	O
significantly	O
and	O
dose	O
-	O
dependently	O
decreased	O
cocaine	B-Chemical
-	O
induced	O
locomotor	O
activity	O
.	O
CPA	B-Chemical
reduced	O
cocaine	B-Chemical
action	O
at	O
the	O
doses	O
which	O
,	O
given	O
alone	O
,	O
did	O
not	O
influence	O
motility	O
,	O
while	O
CGS	B-Chemical
21680	I-Chemical
and	O
NECA	B-Chemical
decreased	O
the	O
action	O
of	O
cocaine	B-Chemical
at	O
the	O
doses	O
which	O
,	O
given	O
alone	O
,	O
decreased	O
locomotor	O
activity	O
in	O
animals	O
.	O
These	O
results	O
suggest	O
the	O
involvement	O
of	O
both	O
adenosine	B-Chemical
receptors	O
in	O
the	O
action	O
of	O
cocaine	B-Chemical
although	O
agonists	O
of	O
A1	O
receptors	O
seem	O
to	O
have	O
stronger	O
influence	O
on	O
it	O
.	O
The	O
selective	O
blockade	O
of	O
A2	O
adenosine	B-Chemical
receptor	O
by	O
DMPX	B-Chemical
(	O
3	B-Chemical
,	I-Chemical
7	I-Chemical
-	I-Chemical
dimethyl	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
propargylxanthine	I-Chemical
)	O
significantly	O
enhanced	O
cocaine	B-Chemical
-	O
induced	O
locomotor	O
activity	O
of	O
animals	O
.	O
Caffeine	B-Chemical
had	O
similar	O
action	O
but	O
the	O
effect	O
was	O
not	O
significant	O
.	O
CPT	B-Chemical
(	O
8	B-Chemical
-	I-Chemical
cyclopentyltheophylline	I-Chemical
)	O
-	O
-	O
A1	O
receptor	O
antagonist	O
,	O
did	O
not	O
show	O
any	O
influence	O
in	O
this	O
test	O
.	O
Similarly	O
,	O
all	O
adenosine	B-Chemical
receptor	O
agonists	O
decreased	O
amphetamine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
,	O
but	O
at	O
the	O
higher	O
doses	O
than	O
those	O
which	O
were	O
active	O
in	O
cocaine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
.	O
The	O
selective	O
blockade	O
of	O
A2	O
adenosine	B-Chemical
receptors	O
(	O
DMPX	B-Chemical
)	O
and	O
non	O
-	O
selective	O
blockade	O
of	O
adenosine	B-Chemical
receptors	O
(	O
caffeine	B-Chemical
)	O
significantly	O
increased	O
the	O
action	O
of	O
amphetamine	B-Chemical
in	O
the	O
locomotor	O
activity	O
test	O
.	O
Our	O
results	O
have	O
shown	O
that	O
all	O
adenosine	B-Chemical
receptor	O
agonists	O
(	O
A1	O
and	O
A2	O
)	O
reduce	O
cocaine	B-Chemical
-	O
and	O
amphetamine	B-Chemical
-	O
induced	O
locomotor	O
activity	O
and	O
indicate	O
that	O
cocaine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
is	O
more	O
influenced	O
by	O
adenosine	B-Chemical
receptor	O
agonists	O
(	O
particularly	O
A1	O
receptors	O
)	O
than	O
amphetamine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
.	O
Amiodarone	B-Chemical
and	O
the	O
risk	O
of	O
bradyarrhythmia	B-Disease
requiring	O
permanent	O
pacemaker	O
in	O
elderly	O
patients	O
with	O
atrial	B-Disease
fibrillation	I-Disease
and	O
prior	O
myocardial	B-Disease
infarction	I-Disease
.	O
OBJECTIVES	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
use	O
of	O
amiodarone	B-Chemical
in	O
patients	O
with	O
atrial	B-Disease
fibrillation	I-Disease
(	O
AF	B-Disease
)	O
increases	O
the	O
risk	O
of	O
bradyarrhythmia	B-Disease
requiring	O
a	O
permanent	O
pacemaker	O
.	O
BACKGROUND	O
:	O
Reports	O
of	O
severe	O
bradyarrhythmia	B-Disease
during	O
amiodarone	B-Chemical
therapy	O
are	O
infrequent	O
and	O
limited	O
to	O
studies	O
assessing	O
the	O
therapy	O
'	O
s	O
use	O
in	O
the	O
management	O
of	O
patients	O
with	O
ventricular	B-Disease
arrhythmias	I-Disease
.	O
METHODS	O
:	O
A	O
study	O
cohort	O
of	O
8	O
,	O
770	O
patients	O
age	O
>	O
or	O
=	O
65	O
years	O
with	O
a	O
new	O
diagnosis	O
of	O
AF	B-Disease
was	O
identified	O
from	O
a	O
provincewide	O
database	O
of	O
Quebec	O
residents	O
with	O
a	O
myocardial	B-Disease
infarction	I-Disease
(	O
MI	B-Disease
)	O
between	O
1991	O
and	O
1999	O
.	O
Using	O
a	O
nested	O
case	O
-	O
control	O
design	O
,	O
477	O
cases	O
of	O
bradyarrhythmia	B-Disease
requiring	O
a	O
permanent	O
pacemaker	O
were	O
matched	O
(	O
1	O
:	O
4	O
)	O
to	O
1	O
,	O
908	O
controls	O
.	O
Multivariable	O
logistic	O
regression	O
was	O
used	O
to	O
estimate	O
the	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
pacemaker	O
insertion	O
associated	O
with	O
amiodarone	B-Chemical
use	O
,	O
controlling	O
for	O
baseline	O
risk	O
factors	O
and	O
exposure	O
to	O
sotalol	B-Chemical
,	O
Class	O
I	O
antiarrhythmic	O
agents	O
,	O
beta	O
-	O
blockers	O
,	O
calcium	B-Chemical
channel	O
blockers	O
,	O
and	O
digoxin	B-Chemical
.	O
RESULTS	O
:	O
amiodarone	B-Chemical
use	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
pacemaker	O
insertion	O
(	O
OR	O
:	O
2	O
.	O
14	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1	O
.	O
30	O
to	O
3	O
.	O
54	O
)	O
.	O
This	O
effect	O
was	O
modified	O
by	O
gender	O
,	O
with	O
a	O
greater	O
risk	O
in	O
women	O
versus	O
men	O
(	O
OR	O
:	O
3	O
.	O
86	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
70	O
to	O
8	O
.	O
75	O
vs	O
.	O
OR	O
:	O
1	O
.	O
52	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
80	O
to	O
2	O
.	O
89	O
)	O
.	O
Digoxin	B-Chemical
was	O
the	O
only	O
other	O
medication	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
pacemaker	O
insertion	O
(	O
OR	O
:	O
1	O
.	O
78	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
37	O
to	O
2	O
.	O
31	O
)	O
.	O
CONCLUSIONS	O
:	O
This	O
study	O
suggests	O
that	O
the	O
use	O
of	O
amiodarone	B-Chemical
in	O
elderly	O
patients	O
with	O
AF	B-Disease
and	O
a	O
previous	O
MI	B-Disease
increases	O
the	O
risk	O
of	O
bradyarrhythmia	B-Disease
requiring	O
a	O
permanent	O
pacemaker	O
.	O
The	O
finding	O
of	O
an	O
augmented	O
risk	O
of	O
pacemaker	O
insertion	O
in	O
elderly	O
women	O
receiving	O
amiodarone	B-Chemical
requires	O
further	O
investigation	O
.	O
Indomethacin	B-Chemical
-	O
induced	O
morphologic	O
changes	O
in	O
the	O
rat	O
urinary	O
bladder	O
epithelium	O
.	O
OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
morphologic	O
changes	O
in	O
rat	O
urothelium	O
induced	O
by	O
indomethacin	B-Chemical
.	O
Nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
-	O
induced	O
cystitis	B-Disease
is	O
a	O
poorly	O
recognized	O
and	O
under	O
-	O
reported	O
condition	O
.	O
In	O
addition	O
to	O
tiaprofenic	B-Chemical
acid	I-Chemical
,	O
indomethacin	B-Chemical
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
this	O
condition	O
.	O
METHODS	O
:	O
Three	O
groups	O
were	O
established	O
:	O
a	O
control	O
group	O
(	O
n	O
=	O
10	O
)	O
,	O
a	O
high	O
-	O
dose	O
group	O
(	O
n	O
=	O
10	O
)	O
,	O
treated	O
with	O
one	O
intraperitoneal	O
injection	O
of	O
indomethacin	B-Chemical
20	O
mg	O
/	O
kg	O
,	O
and	O
a	O
therapeutic	O
dose	O
group	O
(	O
n	O
=	O
10	O
)	O
in	O
which	O
oral	O
indomethacin	B-Chemical
was	O
administered	O
3	O
.	O
25	O
mg	O
/	O
kg	O
body	O
weight	O
daily	O
for	O
3	O
weeks	O
.	O
The	O
animals	O
were	O
then	O
killed	O
and	O
the	O
bladders	O
removed	O
for	O
light	O
and	O
electron	O
microscopic	O
studies	O
.	O
RESULTS	O
:	O
The	O
light	O
microscopic	O
findings	O
showed	O
some	O
focal	O
epithelial	O
degeneration	O
that	O
was	O
more	O
prominent	O
in	O
the	O
high	O
-	O
dose	O
group	O
.	O
When	O
compared	O
with	O
the	O
control	O
group	O
,	O
both	O
indomethacin	B-Chemical
groups	O
revealed	O
statistically	O
increased	O
numbers	O
of	O
mast	O
cells	O
in	O
the	O
mucosa	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
penetration	O
of	O
lanthanum	B-Chemical
nitrate	I-Chemical
through	O
intercellular	O
areas	O
of	O
the	O
epithelium	O
.	O
Furthermore	O
,	O
the	O
difference	O
in	O
mast	O
cell	O
counts	O
between	O
the	O
high	O
and	O
therapeutic	O
dose	O
groups	O
was	O
also	O
statistically	O
significant	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
CONCLUSIONS	O
:	O
Indomethacin	B-Chemical
resulted	O
in	O
histopathologic	O
findings	O
typical	O
of	O
interstitial	B-Disease
cystitis	I-Disease
,	O
such	O
as	O
leaky	O
bladder	O
epithelium	O
and	O
mucosal	O
mastocytosis	B-Disease
.	O
The	O
true	O
incidence	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
-	O
induced	O
cystitis	B-Disease
in	O
humans	O
must	O
be	O
clarified	O
by	O
prospective	O
clinical	O
trials	O
.	O
An	O
open	O
-	O
label	O
phase	O
II	O
study	O
of	O
low	O
-	O
dose	O
thalidomide	B-Chemical
in	O
androgen	B-Chemical
-	O
independent	O
prostate	B-Disease
cancer	I-Disease
.	O
The	O
antiangiogenic	O
effects	O
of	O
thalidomide	B-Chemical
have	O
been	O
assessed	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
various	O
solid	O
and	O
haematological	B-Disease
malignancies	I-Disease
.	O
Thalidomide	B-Chemical
blocks	O
the	O
activity	O
of	O
angiogenic	O
agents	O
including	O
bFGF	O
,	O
VEGF	O
and	O
IL	O
-	O
6	O
.	O
We	O
undertook	O
an	O
open	O
-	O
label	O
study	O
using	O
thalidomide	B-Chemical
100	O
mg	O
once	O
daily	O
for	O
up	O
to	O
6	O
months	O
in	O
20	O
men	O
with	O
androgen	B-Chemical
-	O
independent	O
prostate	B-Disease
cancer	I-Disease
.	O
The	O
mean	O
time	O
of	O
study	O
was	O
109	O
days	O
(	O
median	O
107	O
,	O
range	O
4	O
-	O
184	O
days	O
)	O
.	O
Patients	O
underwent	O
regular	O
measurement	O
of	O
prostate	O
-	O
specific	O
antigen	O
(	O
PSA	O
)	O
,	O
urea	B-Chemical
and	O
electrolytes	O
,	O
serum	O
bFGF	O
and	O
VEGF	O
.	O
Three	O
men	O
(	O
15	O
%	O
)	O
showed	O
a	O
decline	O
in	O
serum	O
PSA	O
of	O
at	O
least	O
50	O
%	O
,	O
sustained	O
throughout	O
treatment	O
.	O
Of	O
16	O
men	O
treated	O
for	O
at	O
least	O
2	O
months	O
,	O
six	O
(	O
37	O
.	O
5	O
%	O
)	O
showed	O
a	O
fall	O
in	O
absolute	O
PSA	O
by	O
a	O
median	O
of	O
48	O
%	O
.	O
Increasing	O
levels	O
of	O
serum	O
bFGF	O
and	O
VEGF	O
were	O
associated	O
with	O
progressive	O
disease	O
;	O
five	O
of	O
six	O
men	O
who	O
demonstrated	O
a	O
fall	O
in	O
PSA	O
also	O
showed	O
a	O
decline	O
in	O
bFGF	O
and	O
VEGF	O
levels	O
,	O
and	O
three	O
of	O
four	O
men	O
with	O
a	O
rising	O
PSA	O
showed	O
an	O
increase	O
in	O
both	O
growth	O
factors	O
.	O
Adverse	O
effects	O
included	O
constipation	B-Disease
,	O
morning	O
drowsiness	B-Disease
,	O
dizziness	B-Disease
and	O
rash	B-Disease
,	O
and	O
resulted	O
in	O
withdrawal	O
from	O
the	O
study	O
by	O
three	O
men	O
.	O
Evidence	O
of	O
peripheral	B-Disease
sensory	I-Disease
neuropathy	I-Disease
was	O
found	O
in	O
nine	O
of	O
13	O
men	O
before	O
treatment	O
.	O
In	O
the	O
seven	O
men	O
who	O
completed	O
six	O
months	O
on	O
thalidomide	B-Chemical
,	O
subclinical	O
evidence	O
of	O
peripheral	B-Disease
neuropathy	I-Disease
was	O
found	O
in	O
four	O
before	O
treatment	O
,	O
but	O
in	O
all	O
seven	O
at	O
repeat	O
testing	O
.	O
The	O
findings	O
indicate	O
that	O
thalidomide	B-Chemical
may	O
be	O
an	O
option	O
for	O
patients	O
who	O
have	O
failed	O
other	O
forms	O
of	O
therapy	O
,	O
provided	O
close	O
follow	O
-	O
up	O
is	O
maintained	O
for	O
development	O
of	O
peripheral	B-Disease
neuropathy	I-Disease
.	O
Central	B-Disease
nervous	I-Disease
system	I-Disease
toxicity	I-Disease
following	O
the	O
administration	O
of	O
levobupivacaine	B-Chemical
for	O
lumbar	O
plexus	O
block	O
:	O
A	O
report	O
of	O
two	O
cases	O
.	O
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Central	B-Disease
nervous	I-Disease
system	I-Disease
and	I-Disease
cardiac	I-Disease
toxicity	I-Disease
following	O
the	O
administration	O
of	O
local	O
anesthetics	O
is	O
a	O
recognized	O
complication	O
of	O
regional	O
anesthesia	O
.	O
Levobupivacaine	B-Chemical
,	O
the	O
pure	O
S	O
(	O
-	O
)	O
enantiomer	O
of	O
bupivacaine	B-Chemical
,	O
was	O
developed	O
to	O
improve	O
the	O
cardiac	O
safety	O
profile	O
of	O
bupivacaine	B-Chemical
.	O
We	O
describe	O
2	O
cases	O
of	O
grand	B-Disease
mal	I-Disease
seizures	I-Disease
following	O
accidental	O
intravascular	O
injection	O
of	O
levobupivacaine	B-Chemical
.	O
CASE	O
REPORT	O
:	O
Two	O
patients	O
presenting	O
for	O
elective	O
orthopedic	O
surgery	O
of	O
the	O
lower	O
limb	O
underwent	O
blockade	O
of	O
the	O
lumbar	O
plexus	O
via	O
the	O
posterior	O
approach	O
.	O
Immediately	O
after	O
the	O
administration	O
of	O
levobupivacaine	B-Chemical
0	O
.	O
5	O
%	O
with	O
epinephrine	B-Chemical
2	O
.	O
5	O
microgram	O
/	O
mL	O
,	O
the	O
patients	O
developed	O
grand	B-Disease
mal	I-Disease
seizures	I-Disease
,	O
despite	O
negative	O
aspiration	O
for	O
blood	O
and	O
no	O
clinical	O
signs	O
of	O
intravenous	O
epinephrine	B-Chemical
administration	O
.	O
The	O
seizures	B-Disease
were	O
successfully	O
treated	O
with	O
sodium	B-Chemical
thiopental	I-Chemical
in	O
addition	O
to	O
succinylcholine	B-Chemical
in	O
1	O
patient	O
.	O
Neither	O
patient	O
developed	O
signs	O
of	O
cardiovascular	B-Disease
toxicity	I-Disease
.	O
Both	O
patients	O
were	O
treated	O
preoperatively	O
with	O
beta	O
-	O
adrenergic	O
antagonist	O
medications	O
,	O
which	O
may	O
have	O
masked	O
the	O
cardiovascular	O
signs	O
of	O
the	O
unintentional	O
intravascular	O
administration	O
of	O
levobupivacaine	B-Chemical
with	O
epinephrine	B-Chemical
.	O
CONCLUSIONS	O
:	O
Although	O
levobupivacaine	B-Chemical
may	O
have	O
a	O
safer	O
cardiac	B-Disease
toxicity	I-Disease
profile	O
than	O
racemic	O
bupivacaine	B-Chemical
,	O
if	O
adequate	O
amounts	O
of	O
levobupivacaine	B-Chemical
reach	O
the	O
circulation	O
,	O
it	O
will	O
result	O
in	O
convulsions	B-Disease
.	O
Plasma	O
concentrations	O
sufficient	O
to	O
result	O
in	O
central	B-Disease
nervous	I-Disease
system	I-Disease
toxicity	I-Disease
did	O
not	O
produce	O
manifestations	O
of	O
cardiac	B-Disease
toxicity	I-Disease
in	O
these	O
2	O
patients	O
.	O
Amiodarone	B-Chemical
-	O
induced	O
torsade	B-Disease
de	I-Disease
pointes	I-Disease
during	O
bladder	O
irrigation	O
:	O
an	O
unusual	O
presentation	O
-	O
-	O
a	O
case	O
report	O
.	O
The	O
authors	O
present	O
a	O
case	O
of	O
early	O
(	O
within	O
4	O
days	O
)	O
development	O
of	O
torsade	B-Disease
de	I-Disease
pointes	I-Disease
(	O
TdP	B-Disease
)	O
associated	O
with	O
oral	O
amiodarone	B-Chemical
therapy	O
.	O
Consistent	O
with	O
other	O
reports	O
this	O
case	O
of	O
TdP	B-Disease
occurred	O
in	O
the	O
context	O
of	O
multiple	O
exacerbating	O
factors	O
including	O
hypokalemia	B-Disease
and	O
digoxin	B-Chemical
excess	O
.	O
Transient	O
prolongation	O
of	O
the	O
QT	O
during	O
bladder	O
irrigation	O
prompted	O
the	O
episode	O
of	O
TdP	B-Disease
.	O
It	O
is	O
well	O
known	O
that	O
bradycardia	B-Disease
exacerbates	O
acquired	O
TdP	B-Disease
.	O
The	O
authors	O
speculate	O
that	O
the	O
increased	O
vagal	O
tone	O
during	O
bladder	O
irrigation	O
,	O
a	O
vagal	O
maneuver	O
,	O
in	O
the	O
context	O
of	O
amiodarone	B-Chemical
therapy	O
resulted	O
in	O
amiodarone	B-Chemical
-	O
induced	O
proarrhythmia	B-Disease
.	O
In	O
the	O
absence	O
of	O
amiodarone	B-Chemical
therapy	O
,	O
a	O
second	O
bladder	O
irrigation	O
did	O
not	O
induce	O
TdP	B-Disease
despite	O
hypokalemia	B-Disease
and	O
hypomagnesemia	B-Disease
.	O
Anaesthetic	O
complications	O
associated	O
with	O
myotonia	B-Disease
congenita	I-Disease
:	O
case	O
study	O
and	O
comparison	O
with	O
other	O
myotonic	B-Disease
disorders	I-Disease
.	O
Myotonia	B-Disease
congenita	I-Disease
(	O
MC	B-Disease
)	O
is	O
caused	O
by	O
a	O
defect	O
in	O
the	O
skeletal	O
muscle	O
chloride	B-Chemical
channel	O
function	O
,	O
which	O
may	O
cause	O
sustained	B-Disease
membrane	I-Disease
depolarisation	I-Disease
.	O
We	O
describe	O
a	O
previously	O
healthy	O
32	O
-	O
year	O
-	O
old	O
woman	O
who	O
developed	O
a	O
life	O
-	O
threatening	O
muscle	B-Disease
spasm	I-Disease
and	O
secondary	O
ventilation	O
difficulties	O
following	O
a	O
preoperative	O
injection	O
of	O
suxamethonium	B-Chemical
.	O
The	O
muscle	B-Disease
spasms	I-Disease
disappeared	O
spontaneously	O
and	O
the	O
surgery	O
proceeded	O
without	O
further	O
problems	O
.	O
When	O
subsequently	O
questioned	O
,	O
she	O
reported	O
minor	O
symptoms	O
suggesting	O
a	O
myotonic	B-Disease
condition	I-Disease
.	O
Myotonia	B-Disease
was	O
found	O
on	O
clinical	O
examination	O
and	O
EMG	O
.	O
The	O
diagnosis	O
MC	B-Disease
was	O
confirmed	O
genetically	O
.	O
Neither	O
the	O
patient	O
nor	O
the	O
anaesthetist	O
were	O
aware	O
of	O
the	O
diagnosis	O
before	O
this	O
potentially	O
lethal	O
complication	O
occurred	O
.	O
We	O
give	O
a	O
brief	O
overview	O
of	O
ion	B-Disease
channel	I-Disease
disorders	I-Disease
including	O
malignant	B-Disease
hyperthermia	I-Disease
and	O
their	O
anaesthetic	O
considerations	O
.	O
Respiratory	O
pattern	O
in	O
a	O
rat	O
model	O
of	O
epilepsy	B-Disease
.	O
PURPOSE	O
:	O
Apnea	B-Disease
is	O
known	O
to	O
occur	O
during	O
seizures	B-Disease
,	O
but	O
systematic	O
studies	O
of	O
ictal	O
respiratory	O
changes	O
in	O
adults	O
are	O
few	O
.	O
Data	O
regarding	O
respiratory	O
pattern	O
defects	O
during	O
interictal	O
periods	O
also	O
are	O
scarce	O
.	O
Here	O
we	O
sought	O
to	O
generate	O
information	O
with	O
regard	O
to	O
the	O
interictal	O
period	O
in	O
animals	O
with	O
pilocarpine	B-Chemical
-	O
induced	O
epilepsy	B-Disease
.	O
METHODS	O
:	O
Twelve	O
rats	O
(	O
six	O
chronically	O
epileptic	B-Disease
animals	O
and	O
six	O
controls	O
)	O
were	O
anesthetized	O
,	O
given	O
tracheotomies	O
,	O
and	O
subjected	O
to	O
hyperventilation	B-Disease
or	O
hypoventilation	O
conditions	O
.	O
Breathing	O
movements	O
caused	O
changes	O
in	O
thoracic	O
volume	O
and	O
forced	O
air	O
to	O
flow	O
tidally	O
through	O
a	O
pneumotachograph	O
.	O
This	O
flow	O
was	O
measured	O
by	O
using	O
a	O
differential	O
pressure	O
transducer	O
,	O
passed	O
through	O
a	O
polygraph	O
,	O
and	O
from	O
this	O
to	O
a	O
computer	O
with	O
custom	O
software	O
that	O
derived	O
ventilation	O
(	O
VE	O
)	O
,	O
tidal	O
volume	O
(	O
VT	O
)	O
,	O
inspiratory	O
time	O
(	O
TI	O
)	O
,	O
expiratory	O
time	O
(	O
TE	O
)	O
,	O
breathing	O
frequency	O
(	O
f	O
)	O
,	O
and	O
mean	O
inspiratory	O
flow	O
(	O
VT	O
/	O
TI	O
)	O
on	O
a	O
breath	O
-	O
by	O
-	O
breath	O
basis	O
.	O
RESULTS	O
:	O
The	O
hyperventilation	B-Disease
maneuver	O
caused	O
a	O
decrease	O
in	O
spontaneous	O
ventilation	O
in	O
pilocarpine	B-Chemical
-	O
treated	O
and	O
control	O
rats	O
.	O
Although	O
VE	O
had	O
a	O
similar	O
decrease	O
in	O
both	O
groups	O
,	O
in	O
the	O
epileptic	B-Disease
group	O
,	O
the	O
decrease	O
in	O
VE	O
was	O
due	O
to	O
a	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
increase	O
in	O
TE	O
peak	O
in	O
relation	O
to	O
that	O
of	O
the	O
control	O
animals	O
.	O
The	O
hypoventilation	O
maneuver	O
led	O
to	O
an	O
increase	O
in	O
the	O
arterial	O
Paco2	O
,	O
followed	O
by	O
an	O
increase	O
in	O
VE	O
.	O
In	O
the	O
epileptic	B-Disease
group	O
,	O
the	O
increase	O
in	O
VE	O
was	O
mediated	O
by	O
a	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
decrease	O
in	O
TE	O
peak	O
compared	O
with	O
the	O
control	O
group	O
.	O
Systemic	O
application	O
of	O
KCN	O
,	O
to	O
evaluate	O
the	O
effects	O
of	O
peripheral	O
chemoreception	O
activation	O
on	O
ventilation	O
,	O
led	O
to	O
a	O
similar	O
increase	O
in	O
VE	O
for	O
both	O
groups	O
.	O
CONCLUSIONS	O
:	O
The	O
data	O
indicate	O
that	O
pilocarpine	B-Chemical
-	O
treated	O
animals	O
have	O
an	O
altered	O
ability	O
to	O
react	O
to	O
(	O
or	O
compensate	O
for	O
)	O
blood	O
gas	O
changes	O
with	O
changes	O
in	O
ventilation	O
and	O
suggest	O
that	O
it	O
is	O
centrally	O
determined	O
.	O
We	O
speculate	O
on	O
the	O
possible	O
relation	O
of	O
the	O
current	O
findings	O
on	O
treating	O
different	O
epilepsy	B-Disease
-	O
associated	O
conditions	O
.	O
Fatal	O
myeloencephalopathy	B-Disease
due	O
to	O
intrathecal	O
vincristine	B-Chemical
administration	O
.	O
Vincristine	B-Chemical
was	O
accidentally	O
given	O
intrathecally	O
to	O
a	O
child	O
with	O
leukaemia	B-Disease
,	O
producing	O
sensory	B-Disease
and	I-Disease
motor	I-Disease
dysfunction	I-Disease
followed	O
by	O
encephalopathy	B-Disease
and	O
death	O
.	O
Separate	O
times	O
for	O
administering	O
vincristine	B-Chemical
and	O
intrathecal	O
therapy	O
is	O
recommended	O
.	O
Progesterone	B-Chemical
potentiation	O
of	O
bupivacaine	B-Chemical
arrhythmogenicity	O
in	O
pentobarbital	B-Chemical
-	O
anesthetized	O
rats	O
and	O
beating	O
rat	O
heart	O
cell	O
cultures	O
.	O
The	O
effects	O
of	O
progesterone	B-Chemical
treatment	O
on	O
bupivacaine	B-Chemical
arrhythmogenicity	O
in	O
beating	O
rat	O
heart	O
myocyte	O
cultures	O
and	O
on	O
anesthetized	O
rats	O
were	O
determined	O
.	O
After	O
determining	O
the	O
bupivacaine	B-Chemical
AD50	O
(	O
the	O
concentration	O
of	O
bupivacaine	B-Chemical
that	O
caused	O
50	O
%	O
of	O
all	O
beating	O
rat	O
heart	O
myocyte	O
cultures	O
to	O
become	O
arrhythmic	B-Disease
)	O
,	O
we	O
determined	O
the	O
effect	O
of	O
1	O
-	O
hour	O
progesterone	B-Chemical
HCl	B-Chemical
exposure	O
on	O
myocyte	O
contractile	O
rhythm	O
.	O
Each	O
concentration	O
of	O
progesterone	B-Chemical
(	O
6	O
.	O
25	O
,	O
12	O
.	O
5	O
,	O
25	O
,	O
and	O
50	O
micrograms	O
/	O
ml	O
)	O
caused	O
a	O
significant	O
and	O
concentration	O
-	O
dependent	O
reduction	O
in	O
the	O
AD50	O
for	O
bupivacaine	B-Chemical
.	O
Estradiol	B-Chemical
treatment	O
also	O
increased	O
the	O
arrhythmogenicity	O
of	O
bupivacaine	B-Chemical
in	O
myocyte	O
cultures	O
,	O
but	O
was	O
only	O
one	O
fourth	O
as	O
potent	O
as	O
progesterone	B-Chemical
.	O
Neither	O
progesterone	B-Chemical
nor	O
estradiol	B-Chemical
effects	O
on	O
bupivacaine	B-Chemical
arrhythmogenicity	O
were	O
potentiated	O
by	O
epinephrine	B-Chemical
.	O
Chronic	O
progesterone	B-Chemical
pretreatment	O
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
for	O
21	O
days	O
)	O
caused	O
a	O
significant	O
increase	O
in	O
bupivacaine	B-Chemical
arrhythmogenicity	O
in	O
intact	O
pentobarbital	B-Chemical
-	O
anesthetized	O
rats	O
.	O
There	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
time	O
to	O
onset	O
of	O
arrhythmia	B-Disease
as	O
compared	O
with	O
control	O
nonprogesterone	O
-	O
treated	O
rats	O
(	O
6	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
3	O
vs	O
.	O
30	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
5	O
min	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
.	O
The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
progesterone	B-Chemical
can	O
potentiate	O
bupivacaine	B-Chemical
arrhythmogenicity	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
Potentiation	O
of	O
bupivacaine	B-Chemical
arrhythmia	B-Disease
in	O
myocyte	O
cultures	O
suggests	O
that	O
this	O
effect	O
is	O
at	O
least	O
partly	O
mediated	O
at	O
the	O
myocyte	O
level	O
.	O
Increased	O
serum	O
soluble	O
Fas	O
in	O
patients	O
with	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
due	O
to	O
paracetamol	B-Chemical
overdose	B-Disease
.	O
BACKGROUND	O
/	O
AIMS	O
:	O
Experimental	O
studies	O
have	O
suggested	O
that	O
apoptosis	O
via	O
the	O
Fas	O
/	O
Fas	O
Ligand	O
signaling	O
system	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
.	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
soluble	O
form	O
of	O
Fas	O
in	O
patients	O
with	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
.	O
METHODOLOGY	O
:	O
Serum	O
levels	O
of	O
sFas	O
(	O
soluble	O
Fas	O
)	O
were	O
measured	O
by	O
ELISA	O
in	O
24	O
patients	O
with	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
and	O
10	O
normal	O
control	O
subjects	O
.	O
Serum	O
levels	O
of	O
tumor	B-Disease
necrosis	B-Disease
factor	O
-	O
alpha	O
and	O
interferon	O
-	O
gamma	O
were	O
also	O
determined	O
by	O
ELISA	O
.	O
RESULTS	O
:	O
Serum	O
sFas	O
was	O
significantly	O
increased	O
in	O
patients	O
with	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
(	O
median	O
,	O
26	O
.	O
8	O
U	O
/	O
mL	O
;	O
range	O
,	O
6	O
.	O
9	O
-	O
52	O
.	O
7	O
U	O
/	O
mL	O
)	O
compared	O
to	O
the	O
normal	O
controls	O
(	O
median	O
,	O
8	O
.	O
6	O
U	O
/	O
mL	O
;	O
range	O
,	O
6	O
.	O
5	O
-	O
12	O
.	O
0	O
U	O
/	O
mL	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
Levels	O
were	O
significantly	O
greater	O
in	O
patients	O
with	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
due	O
to	O
paracetamol	B-Chemical
overdose	B-Disease
(	O
median	O
,	O
28	O
.	O
7	O
U	O
/	O
mL	O
;	O
range	O
,	O
12	O
.	O
8	O
-	O
52	O
.	O
7	O
U	O
/	O
mL	O
,	O
n	O
=	O
17	O
)	O
than	O
those	O
due	O
to	O
non	O
-	O
A	O
to	O
E	O
hepatitis	B-Disease
(	O
median	O
,	O
12	O
.	O
5	O
U	O
/	O
mL	O
;	O
range	O
,	O
6	O
.	O
9	O
-	O
46	O
.	O
0	O
U	O
/	O
mL	O
,	O
n	O
=	O
7	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
There	O
was	O
no	O
relationship	O
of	O
sFas	O
to	O
eventual	O
outcome	O
in	O
the	O
patients	O
.	O
A	O
significant	O
correlation	O
was	O
observed	O
between	O
serum	O
sFas	O
levels	O
and	O
aspartate	B-Chemical
aminotransferase	O
(	O
r	O
=	O
0	O
.	O
613	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
increased	O
concentration	O
of	O
sFas	O
in	O
serum	O
of	O
patients	O
with	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
may	O
reflect	O
activation	O
of	O
Fas	O
-	O
mediated	O
apoptosis	O
in	O
the	O
liver	O
and	O
this	O
together	O
with	O
increased	O
tumor	B-Disease
necrosis	B-Disease
factor	O
-	O
alpha	O
may	O
be	O
an	O
important	O
factor	O
in	O
liver	O
cell	O
loss	O
.	O
Bilateral	O
subthalamic	O
nucleus	O
stimulation	O
for	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
High	O
frequency	O
stimulation	O
of	O
the	O
subthalamic	O
nucleus	O
(	O
STN	O
)	O
is	O
known	O
to	O
ameliorate	O
the	O
signs	O
and	O
symptoms	O
of	O
advanced	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
AIM	O
:	O
We	O
studied	O
the	O
effect	O
of	O
high	O
frequency	O
STN	O
stimulation	O
in	O
23	O
patients	O
.	O
METHOD	O
:	O
Twenty	O
-	O
three	O
patients	O
suffering	O
from	O
severe	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
Stages	O
III	O
-	O
V	O
on	O
Hoehn	O
and	O
Yahr	O
scale	O
)	O
and	O
,	O
particularly	O
bradykinesia	B-Disease
,	O
rigidity	B-Disease
,	O
and	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
underwent	O
bilateral	O
implantation	O
of	O
electrodes	O
in	O
the	O
STN	O
.	O
Preoperative	O
and	O
postoperative	O
assessments	O
of	O
these	O
patients	O
at	O
1	O
,	O
3	O
,	O
6	O
and	O
12	O
months	O
follow	O
-	O
up	O
,	O
in	O
""""	O
on	O
""""	O
and	O
""""	O
off	O
""""	O
drug	O
conditions	O
,	O
was	O
carried	O
out	O
using	O
Unified	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
Disease	I-Disease
Rating	O
Scale	O
,	O
Hoehn	O
and	O
Yahr	O
staging	O
,	O
England	O
activities	O
of	O
daily	O
living	O
score	O
and	O
video	O
recordings	O
.	O
RESULTS	O
:	O
After	O
one	O
year	O
of	O
electrical	O
stimulation	O
of	O
the	O
STN	O
,	O
the	O
patients	O
'	O
scores	O
for	O
activities	O
of	O
daily	O
living	O
and	O
motor	O
examination	O
scores	O
(	O
Unified	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
Disease	I-Disease
Rating	O
Scale	O
parts	O
II	O
and	O
III	O
)	O
off	O
medication	O
improved	O
by	O
62	O
%	O
and	O
61	O
%	O
respectively	O
(	O
p	O
<	O
0	O
.	O
0005	O
)	O
.	O
The	O
subscores	O
for	O
the	O
akinesia	B-Disease
,	O
rigidity	B-Disease
,	O
tremor	B-Disease
and	O
gait	O
also	O
improved	O
.	O
(	O
p	O
<	O
0	O
.	O
0005	O
)	O
.	O
The	O
average	O
levodopa	B-Chemical
dose	O
decreased	O
from	O
813	O
mg	O
to	O
359	O
mg	O
.	O
The	O
cognitive	O
functions	O
remained	O
unchanged	O
.	O
Two	O
patients	O
developed	O
device	O
-	O
related	O
complications	O
and	O
two	O
patients	O
experienced	O
abnormal	O
weight	O
gain	O
.	O
CONCLUSION	O
:	O
Bilateral	O
subthalamic	O
nucleus	O
stimulation	O
is	O
an	O
effective	O
treatment	O
for	O
advanced	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
It	O
reduces	O
the	O
severity	O
of	O
""""	O
off	O
""""	O
phase	O
symptoms	O
,	O
improves	O
the	O
axial	O
symptoms	O
and	O
reduces	O
levodopa	B-Chemical
requirements	O
.	O
The	O
reduction	O
in	O
the	O
levodopa	B-Chemical
dose	O
is	O
useful	O
in	O
controlling	O
drug	B-Disease
-	I-Disease
induced	I-Disease
dyskinesias	I-Disease
.	O
Acute	B-Disease
renal	I-Disease
failure	I-Disease
occurring	O
during	O
intravenous	O
desferrioxamine	B-Chemical
therapy	O
:	O
recovery	O
after	O
haemodialysis	O
.	O
A	O
patient	O
with	O
transfusion	O
-	O
dependent	O
thalassemia	B-Disease
was	O
undergoing	O
home	O
intravenous	O
desferrioxamine	B-Chemical
(	O
DFX	B-Chemical
)	O
treatment	O
by	O
means	O
of	O
a	O
totally	O
implanted	O
system	O
because	O
of	O
his	O
poor	O
compliance	O
with	O
the	O
nightly	O
subcutaneous	O
therapy	O
.	O
Due	O
to	O
an	O
accidental	O
malfunctioning	O
of	O
the	O
infusion	O
pump	O
,	O
the	O
patient	O
was	O
inadvertently	O
administered	O
a	O
toxic	O
dosage	O
of	O
the	O
drug	O
which	O
caused	O
renal	B-Disease
insufficiency	I-Disease
.	O
Given	O
the	O
progressive	O
deterioration	O
of	O
the	O
symptoms	O
and	O
of	O
the	O
laboratory	O
values	O
,	O
despite	O
adequate	O
medical	O
treatment	O
,	O
a	O
decision	O
was	O
made	O
to	O
introduce	O
haemodialytical	O
therapy	O
in	O
order	O
to	O
remove	O
the	O
drug	O
and	O
therapy	O
reduce	O
the	O
nephrotoxicity	B-Disease
.	O
From	O
the	O
results	O
obtained	O
,	O
haemodialysis	O
can	O
therefore	O
be	O
suggested	O
as	O
a	O
useful	O
therapy	O
in	O
rare	O
cases	O
of	O
progressive	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
caused	O
by	O
desferrioxamine	B-Chemical
.	O
Ocular	O
motility	O
changes	O
after	O
subtenon	O
carboplatin	B-Chemical
chemotherapy	O
for	O
retinoblastoma	B-Disease
.	O
BACKGROUND	O
:	O
Focal	O
subtenon	O
carboplatin	B-Chemical
injections	O
have	O
recently	O
been	O
used	O
as	O
a	O
presumably	O
toxicity	B-Disease
-	O
free	O
adjunct	O
to	O
systemic	O
chemotherapy	O
for	O
intraocular	O
retinoblastoma	B-Disease
.	O
OBJECTIVE	O
:	O
To	O
report	O
our	O
clinical	O
experience	O
with	O
abnormal	B-Disease
ocular	I-Disease
motility	I-Disease
in	O
patients	O
treated	O
with	O
subtenon	O
carboplatin	B-Chemical
chemotherapy	O
.	O
METHODS	O
:	O
We	O
noted	O
abnormal	B-Disease
ocular	I-Disease
motility	I-Disease
in	O
10	O
consecutive	O
patients	O
with	O
retinoblastoma	B-Disease
who	O
had	O
received	O
subtenon	O
carboplatin	B-Chemical
.	O
During	O
ocular	O
manipulation	O
under	O
general	O
anesthesia	O
,	O
we	O
assessed	O
their	O
eyes	O
by	O
forced	O
duction	O
testing	O
,	O
comparing	O
ocular	O
motility	O
after	O
tumor	B-Disease
control	O
with	O
ocular	O
motility	O
at	O
diagnosis	O
.	O
Eyes	O
subsequently	O
enucleated	O
because	O
of	O
treatment	O
failure	O
(	O
n	O
=	O
4	O
)	O
were	O
examined	O
histologically	O
.	O
RESULTS	O
:	O
Limitation	O
of	O
ocular	O
motility	O
was	O
detected	O
in	O
all	O
12	O
eyes	O
of	O
10	O
patients	O
treated	O
for	O
intraocular	O
retinoblastoma	B-Disease
with	O
1	O
to	O
6	O
injections	O
of	O
subtenon	O
carboplatin	B-Chemical
as	O
part	O
of	O
multimodality	O
therapy	O
.	O
Histopathological	O
examination	O
revealed	O
many	O
lipophages	O
in	O
the	O
periorbital	O
fat	O
surrounding	O
the	O
optic	O
nerve	O
in	O
1	O
eye	O
,	O
indicative	O
of	O
phagocytosis	O
of	O
previously	O
existing	O
fat	O
cells	O
and	O
suggesting	O
prior	O
fat	O
necrosis	B-Disease
.	O
The	O
enucleations	O
were	O
technically	O
difficult	O
and	O
hazardous	O
for	O
globe	O
rupture	B-Disease
because	O
of	O
extensive	O
orbital	O
soft	O
tissue	O
adhesions	O
.	O
CONCLUSIONS	O
:	O
Subtenon	O
carboplatin	B-Chemical
chemotherapy	O
is	O
associated	O
with	O
significant	O
fibrosis	B-Disease
of	O
orbital	O
soft	O
tissues	O
,	O
leading	O
to	O
mechanical	O
restriction	O
of	O
eye	O
movements	O
and	O
making	O
subsequent	O
enucleation	O
difficult	O
.	O
Subtenon	O
carboplatin	B-Chemical
is	O
not	O
free	O
of	O
toxicity	B-Disease
,	O
and	O
its	O
use	O
is	O
best	O
restricted	O
to	O
specific	O
indications	O
.	O
Ethambutol	B-Chemical
and	O
optic	B-Disease
neuropathy	I-Disease
.	O
PURPOSE	O
:	O
To	O
demonstrate	O
the	O
association	O
between	O
ethambutol	B-Chemical
and	O
optic	B-Disease
neuropathy	I-Disease
.	O
METHOD	O
:	O
Thirteen	O
patients	O
who	O
developed	O
optic	B-Disease
neuropathy	I-Disease
after	O
being	O
treated	O
with	O
ethambutol	B-Chemical
for	O
tuberculosis	B-Disease
of	I-Disease
the	I-Disease
lung	I-Disease
or	I-Disease
lymph	I-Disease
node	I-Disease
at	O
Siriraj	O
Hospital	O
between	O
1997	O
and	O
2001	O
were	O
retrospectively	O
reviewed	O
.	O
The	O
clinical	O
characteristics	O
and	O
initial	O
and	O
final	O
visual	O
acuity	O
were	O
analyzed	O
to	O
determine	O
visual	O
outcome	O
.	O
RESULTS	O
:	O
All	O
patients	O
had	O
optic	B-Disease
neuropathy	I-Disease
between	O
1	O
to	O
6	O
months	O
(	O
mean	O
=	O
2	O
.	O
9	O
months	O
)	O
after	O
starting	O
ethambutol	B-Chemical
therapy	O
at	O
a	O
dosage	O
ranging	O
from	O
13	O
to	O
20	O
mg	O
/	O
kg	O
/	O
day	O
(	O
mean	O
=	O
17	O
mg	O
/	O
kg	O
/	O
day	O
)	O
.	O
Seven	O
(	O
54	O
%	O
)	O
of	O
the	O
13	O
patients	O
experienced	O
visual	O
recovery	O
after	O
stopping	O
the	O
drug	O
.	O
Of	O
6	O
patients	O
with	O
irreversible	O
visual	B-Disease
impairment	I-Disease
,	O
4	O
patients	O
had	O
diabetes	B-Disease
mellitus	I-Disease
,	O
glaucoma	B-Disease
and	O
a	O
history	O
of	O
heavy	O
smoking	O
.	O
CONCLUSION	O
:	O
Early	O
recognition	O
of	O
optic	B-Disease
neuropathy	I-Disease
should	O
be	O
considered	O
in	O
patients	O
with	O
ethambutol	B-Chemical
therapy	O
.	O
A	O
low	O
dose	O
and	O
prompt	O
discontinuation	O
of	O
the	O
drug	O
is	O
recommended	O
particularly	O
in	O
individuals	O
with	O
diabetes	B-Disease
mellitus	I-Disease
,	O
glaucoma	B-Disease
or	O
who	O
are	O
heavy	O
smokers	O
.	O
Treatment	O
of	O
compensatory	O
gustatory	B-Disease
hyperhidrosis	I-Disease
with	O
topical	O
glycopyrrolate	B-Chemical
.	O
Gustatory	B-Disease
hyperhidrosis	I-Disease
is	O
facial	O
sweating	B-Disease
usually	O
associated	O
with	O
the	O
eating	O
of	O
hot	O
spicy	O
food	O
or	O
even	O
smelling	O
this	O
food	O
.	O
Current	O
options	O
of	O
treatment	O
include	O
oral	O
anticholinergic	O
drugs	O
,	O
the	O
topical	O
application	O
of	O
anticholinergics	O
or	O
aluminum	B-Chemical
chloride	I-Chemical
,	O
and	O
the	O
injection	O
of	O
botulinum	O
toxin	O
.	O
Thirteen	O
patients	O
have	O
been	O
treated	O
to	O
date	O
with	O
1	O
.	O
5	O
%	O
or	O
2	O
%	O
topical	O
glycopyrrolate	B-Chemical
.	O
All	O
patients	O
had	O
gustatory	B-Disease
hyperhidrosis	I-Disease
,	O
which	O
interfered	O
with	O
their	O
social	O
activities	O
,	O
after	O
transthroacic	O
endoscopic	O
sympathectomy	O
,	O
and	O
which	O
was	O
associated	O
with	O
compensatory	O
focal	O
hyperhidrosis	B-Disease
.	O
After	O
applying	O
topical	O
glycopyrrolate	B-Chemical
,	O
the	O
subjective	O
effect	O
was	O
excellent	O
(	O
no	O
sweating	B-Disease
after	O
eating	O
hot	O
spicy	O
food	O
)	O
in	O
10	O
patients	O
(	O
77	O
%	O
)	O
,	O
and	O
fair	O
(	O
clearly	O
reduced	O
sweating	B-Disease
)	O
in	O
3	O
patients	O
(	O
23	O
%	O
)	O
.	O
All	O
had	O
reported	O
incidents	O
of	O
being	O
very	O
embarrassed	O
whilst	O
eating	O
hot	O
spicy	O
foods	O
.	O
Adverse	O
effects	O
included	O
a	O
mildly	O
dry	B-Disease
mouth	I-Disease
and	O
a	O
sore	B-Disease
throat	I-Disease
in	O
2	O
patients	O
(	O
2	O
%	O
glycopyrrolate	B-Chemical
)	O
,	O
a	O
light	O
headache	B-Disease
in	O
1	O
patient	O
(	O
1	O
.	O
5	O
%	O
glycopyrrolate	B-Chemical
)	O
.	O
The	O
topical	O
application	O
of	O
a	O
glycopyrrolate	B-Chemical
pad	O
appeared	O
to	O
be	O
safe	O
,	O
efficacious	O
,	O
well	O
tolerated	O
,	O
and	O
a	O
convenient	O
method	O
of	O
treatment	O
for	O
moderate	O
to	O
severe	O
symptoms	O
of	O
gustatory	B-Disease
hyperhidrosis	I-Disease
in	O
post	O
transthoracic	O
endoscopic	O
sympathectomy	O
or	O
sympathicotomy	O
patients	O
,	O
with	O
few	O
side	O
effects	O
.	O
Neuroleptic	B-Chemical
-	O
associated	O
hyperprolactinemia	B-Disease
.	O
Can	O
it	O
be	O
treated	O
with	O
bromocriptine	B-Chemical
?	O
Six	O
stable	O
psychiatric	O
outpatients	O
with	O
hyperprolactinemia	B-Disease
and	O
amenorrhea	B-Disease
/	O
oligomenorrhea	B-Disease
associated	O
with	O
their	O
neuroleptic	B-Chemical
medications	I-Chemical
were	O
treated	O
with	O
bromocriptine	B-Chemical
.	O
Daily	O
dosages	O
of	O
5	O
-	O
10	O
mg	O
corrected	O
the	O
hyperprolactinemia	B-Disease
and	O
restored	O
menstruation	O
in	O
four	O
of	O
the	O
six	O
patients	O
.	O
One	O
woman	O
,	O
however	O
,	O
developed	O
worsened	O
psychiatric	B-Disease
symptoms	I-Disease
while	O
taking	O
bromocriptine	B-Chemical
,	O
and	O
it	O
was	O
discontinued	O
.	O
Thus	O
,	O
three	O
of	O
six	O
patients	O
had	O
their	O
menstrual	O
irregularity	O
successfully	O
corrected	O
with	O
bromocriptine	B-Chemical
.	O
This	O
suggests	O
that	O
bromocriptine	B-Chemical
should	O
be	O
further	O
evaluated	O
as	O
potential	O
therapy	O
for	O
neuroleptic	B-Chemical
-	O
associated	O
hyperprolactinemia	B-Disease
and	O
amenorrhea	B-Disease
/	O
galactorrhea	B-Disease
.	O
Ethacrynic	B-Chemical
acid	I-Chemical
-	O
induced	O
convulsions	B-Disease
and	O
brain	O
neurotransmitters	O
in	O
mice	O
.	O
Intracerebroventricular	O
injection	O
of	O
ethacrynic	B-Chemical
acid	I-Chemical
(	O
50	O
%	O
convulsive	B-Disease
dose	O
;	O
50	O
micrograms	O
/	O
mouse	O
)	O
accelerated	O
the	O
synthesis	O
/	O
turnover	O
of	O
5	B-Chemical
-	I-Chemical
hydroxytryptamine	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
but	O
suppressed	O
the	O
synthesis	O
of	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
and	O
acetylcholine	B-Chemical
in	O
mouse	O
brain	O
.	O
These	O
effects	O
were	O
completely	O
antagonized	O
by	O
pretreatment	O
with	O
a	O
glutamate	B-Chemical
/	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
antagonist	O
,	O
aminophosphonovaleric	B-Chemical
acid	I-Chemical
.	O
In	O
ethacrynic	B-Chemical
acid	I-Chemical
-	O
induced	O
convulsions	B-Disease
,	O
these	O
neurotransmitter	O
systems	O
may	O
be	O
differentially	O
modulated	O
,	O
probably	O
through	O
activation	O
of	O
glutaminergic	O
neurons	O
in	O
the	O
brain	O
.	O
Pharmacology	O
of	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acidA	I-Chemical
receptor	O
complex	O
after	O
the	O
in	O
vivo	O
administration	O
of	O
the	O
anxioselective	O
and	O
anticonvulsant	O
beta	B-Chemical
-	I-Chemical
carboline	I-Chemical
derivative	O
abecarnil	B-Chemical
.	O
In	O
rodents	O
,	O
the	O
effect	O
of	O
the	O
beta	B-Chemical
-	I-Chemical
carboline	I-Chemical
derivative	O
isopropyl	B-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
benzyloxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methoxymethyl	I-Chemical
-	I-Chemical
beta	I-Chemical
-	I-Chemical
carboline	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
(	O
abecarrnil	B-Chemical
)	O
,	O
a	O
new	O
ligand	O
for	O
benzodiazepine	B-Chemical
receptors	O
possessing	O
anxiolytic	O
and	O
anticonvulsant	O
properties	O
,	O
was	O
evaluated	O
on	O
the	O
function	O
of	O
central	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
(	O
GABA	B-Chemical
)	O
A	O
receptor	O
complex	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Added	O
in	O
vitro	O
to	O
rat	O
cortical	O
membrane	O
preparation	O
,	O
abecarnil	B-Chemical
increased	O
[	O
3H	O
]	O
GABA	B-Chemical
binding	O
,	O
enhanced	O
muscimol	B-Chemical
-	O
stimulated	O
36Cl	O
-	O
uptake	O
and	O
reduced	O
the	O
binding	O
of	O
t	B-Chemical
-	I-Chemical
[	I-Chemical
35S	I-Chemical
]	I-Chemical
butylbicyclophosphorothionate	I-Chemical
(	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TBPS	I-Chemical
)	O
.	O
These	O
effects	O
were	O
similar	O
to	O
those	O
induced	O
by	O
diazepam	B-Chemical
,	O
whereas	O
the	O
partial	O
agonist	O
Ro	B-Chemical
16	I-Chemical
-	I-Chemical
6028	I-Chemical
(	O
tert	B-Chemical
-	I-Chemical
butyl	I-Chemical
-	I-Chemical
(	I-Chemical
S	I-Chemical
)	I-Chemical
-	I-Chemical
8	I-Chemical
-	I-Chemical
bromo	I-Chemical
-	I-Chemical
11	I-Chemical
,	I-Chemical
12	I-Chemical
,	I-Chemical
13	I-Chemical
,	I-Chemical
13a	I-Chemical
-	I-Chemical
tetrahydro	I-Chemical
-	I-Chemical
9	I-Chemical
-	I-Chemical
oxo	I-Chemical
-	I-Chemical
9H	I-Chemical
-	I-Chemical
imidazo	I-Chemical
[	I-Chemical
1	I-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
a	I-Chemical
]	I-Chemical
-	I-Chemical
pyrrolo	I-Chemical
-	I-Chemical
[	I-Chemical
2	I-Chemical
,	I-Chemical
1	I-Chemical
-	I-Chemical
c	I-Chemical
]	I-Chemical
[	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
]	I-Chemical
benzodiazepine	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
)	O
showed	O
very	O
weak	O
efficacy	O
in	O
these	O
biochemical	O
tests	O
.	O
After	O
i	O
.	O
p	O
.	O
injection	O
to	O
rats	O
,	O
abecarnil	B-Chemical
and	O
diazepam	B-Chemical
decreased	O
in	O
a	O
time	O
-	O
dependent	O
and	O
dose	O
-	O
related	O
(	O
0	O
.	O
25	O
-	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
manner	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TBPS	I-Chemical
binding	O
measured	O
ex	O
vivo	O
in	O
the	O
cerebral	O
cortex	O
.	O
Moreover	O
,	O
both	O
drugs	O
at	O
the	O
dose	O
of	O
0	O
.	O
5	O
mg	O
/	O
kg	O
antagonized	O
completely	O
the	O
convulsant	O
activity	O
and	O
the	O
increase	O
of	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TBPS	I-Chemical
binding	O
induced	O
by	O
isoniazide	B-Chemical
(	O
350	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
as	O
well	O
as	O
the	O
increase	O
of	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TBPS	I-Chemical
binding	O
induced	O
by	O
foot	O
-	O
shock	O
stress	O
.	O
To	O
better	O
correlate	O
the	O
biochemical	O
and	O
the	O
pharmacological	O
effects	O
,	O
we	O
studied	O
the	O
action	O
of	O
abecarnil	B-Chemical
on	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TBPS	I-Chemical
binding	O
,	O
exploratory	O
motility	O
and	O
on	O
isoniazid	B-Chemical
-	O
induced	O
biochemical	O
and	O
pharmacological	O
effects	O
in	O
mice	O
.	O
In	O
these	O
animals	O
,	O
abecarnil	B-Chemical
produced	O
a	O
paralleled	O
dose	O
-	O
dependent	O
(	O
0	O
.	O
05	O
-	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
reduction	O
of	O
both	O
motor	O
behavior	O
and	O
cortical	O
[	O
35S	O
]	O
TBPS	O
binding	O
.	O
Moreover	O
,	O
0	O
.	O
05	O
mg	O
/	O
kg	O
of	O
this	O
beta	B-Chemical
-	I-Chemical
carboline	I-Chemical
reduced	O
markedly	O
the	O
increase	O
of	O
[	B-Chemical
35S	I-Chemical
]	I-Chemical
TBPS	I-Chemical
binding	O
and	O
the	O
convulsions	B-Disease
induced	O
by	O
isoniazid	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Recurrent	O
myocardial	B-Disease
infarction	I-Disease
in	O
a	O
postpartum	O
patient	O
receiving	O
bromocriptine	B-Chemical
.	O
Myocardial	B-Disease
infarction	I-Disease
in	O
puerperium	O
is	O
infrequently	O
reported	O
.	O
Spasm	B-Disease
,	O
coronary	O
dissection	O
,	O
or	O
atheromatous	O
etiology	O
has	O
been	O
described	O
.	O
Bromocriptine	B-Chemical
has	O
been	O
implicated	O
in	O
several	O
previous	O
case	O
reports	O
of	O
myocardial	B-Disease
infarction	I-Disease
in	O
the	O
puerperium	O
.	O
Our	O
case	O
(	O
including	O
an	O
inadvertent	O
rechallenge	O
)	O
suggests	O
such	O
a	O
relationship	O
.	O
Although	O
generally	O
regarded	O
as	O
""""	O
safe	O
,	O
""""	O
possible	O
serious	O
cardiac	O
effects	O
of	O
bromocriptine	B-Chemical
should	O
be	O
acknowledged	O
.	O
Asterixis	B-Disease
induced	O
by	O
carbamazepine	B-Chemical
therapy	O
.	O
There	O
are	O
very	O
few	O
reports	O
about	O
asterixis	B-Disease
as	O
a	O
side	O
effect	O
of	O
treatment	O
with	O
psychopharmacologic	O
agents	O
.	O
In	O
this	O
report	O
we	O
present	O
four	O
patients	O
treated	O
with	O
a	O
combination	O
of	O
different	O
psychotropic	O
drugs	O
,	O
in	O
whom	O
asterixis	B-Disease
was	O
triggered	O
either	O
by	O
adding	O
carbamazepine	B-Chemical
(	O
CBZ	B-Chemical
)	O
to	O
a	O
treatment	O
regimen	O
,	O
or	O
by	O
increasing	O
its	O
dosage	O
.	O
Neither	O
dosage	O
nor	O
serum	O
levels	O
of	O
CBZ	B-Chemical
were	O
in	O
a	O
higher	O
range	O
.	O
We	O
consider	O
asterixis	B-Disease
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotoxicity	B-Disease
,	O
which	O
may	O
occur	O
even	O
at	O
low	O
or	O
moderate	O
dosage	O
levels	O
,	O
if	O
certain	O
drugs	O
as	O
lithium	B-Chemical
or	O
clozapine	B-Chemical
are	O
used	O
in	O
combination	O
with	O
CBZ	B-Chemical
.	O
Pharmacodynamics	O
of	O
the	O
hypotensive	B-Disease
effect	O
of	O
levodopa	B-Chemical
in	O
parkinsonian	B-Disease
patients	O
.	O
Blood	O
pressure	O
effects	O
of	O
i	O
.	O
v	O
.	O
levodopa	B-Chemical
were	O
examined	O
in	O
parkinsonian	B-Disease
patients	O
with	O
stable	O
and	O
fluctuating	O
responses	O
to	O
levodopa	B-Chemical
.	O
The	O
magnitude	O
of	O
the	O
hypotensive	B-Disease
effect	O
of	O
levodopa	B-Chemical
was	O
concentration	O
dependent	O
and	O
was	O
fit	O
to	O
an	O
Emax	O
model	O
in	O
fluctuating	O
responders	O
.	O
Stable	O
responders	O
demonstrated	O
a	O
small	O
hypotensive	B-Disease
response	O
.	O
Baseline	O
blood	O
pressures	O
were	O
higher	O
in	O
fluctuating	O
patients	O
;	O
a	O
higher	O
baseline	O
blood	O
pressure	O
correlated	O
with	O
greater	O
hypotensive	B-Disease
effects	O
.	O
Antiparkinsonian	O
effects	O
of	O
levodopa	B-Chemical
temporally	O
correlated	O
with	O
blood	O
pressure	O
changes	O
.	O
Phenylalanine	B-Chemical
,	O
a	O
large	O
neutral	O
amino	B-Chemical
acid	I-Chemical
(	O
LNAA	O
)	O
competing	O
with	O
levodopa	B-Chemical
for	O
transport	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
reduced	O
the	O
hypotensive	B-Disease
and	O
antiparkinsonian	O
effects	O
of	O
levodopa	B-Chemical
.	O
We	O
conclude	O
that	O
levodopa	B-Chemical
has	O
a	O
central	O
hypotensive	B-Disease
action	O
that	O
parallels	O
the	O
motor	O
effects	O
in	O
fluctuating	O
patients	O
.	O
The	O
hypotensive	B-Disease
effect	O
appears	O
to	O
be	O
related	O
to	O
the	O
higher	O
baseline	O
blood	O
pressure	O
we	O
observed	O
in	O
fluctuating	O
patients	O
relative	O
to	O
stable	O
patients	O
.	O
Syndrome	B-Disease
of	I-Disease
inappropriate	I-Disease
secretion	I-Disease
of	I-Disease
antidiuretic	I-Disease
hormone	I-Disease
after	O
infusional	O
vincristine	B-Chemical
.	O
A	O
77	O
-	O
year	O
-	O
old	O
woman	O
with	O
refractory	O
multiple	B-Disease
myeloma	I-Disease
was	O
treated	O
with	O
a	O
4	O
-	O
day	O
continuous	O
intravenous	O
infusion	O
of	O
vincristine	B-Chemical
and	O
doxorubicin	B-Chemical
and	O
4	O
days	O
of	O
oral	O
dexamethasone	B-Chemical
.	O
Nine	O
days	O
after	O
her	O
second	O
cycle	O
she	O
presented	O
with	O
lethargy	B-Disease
and	O
weakness	B-Disease
associated	O
with	O
hyponatremia	B-Disease
.	O
Evaluation	O
revealed	O
the	O
syndrome	B-Disease
of	I-Disease
inappropriate	I-Disease
secretion	I-Disease
of	I-Disease
antidiuretic	I-Disease
hormone	I-Disease
,	O
which	O
was	O
attributed	O
to	O
the	O
vincristine	B-Chemical
infusion	O
.	O
After	O
normal	O
serum	O
sodium	B-Chemical
levels	O
returned	O
,	O
further	O
doxorubicin	B-Chemical
and	O
dexamethasone	B-Chemical
chemotherapy	O
without	O
vincristine	B-Chemical
did	O
not	O
produce	O
this	O
complication	O
.	O
Heart	B-Disease
failure	I-Disease
:	O
to	O
digitalise	O
or	O
not	O
?	O
The	O
view	O
against	O
.	O
Despite	O
extensive	O
clinical	O
experience	O
the	O
role	O
of	O
digoxin	B-Chemical
is	O
still	O
not	O
well	O
defined	O
.	O
In	O
patients	O
with	O
atrial	B-Disease
fibrillation	I-Disease
digoxin	B-Chemical
is	O
beneficial	O
for	O
ventricular	O
rate	O
control	O
.	O
For	O
patients	O
in	O
sinus	O
rhythm	O
and	O
heart	B-Disease
failure	I-Disease
the	O
situation	O
is	O
less	O
clear	O
.	O
Digoxin	B-Chemical
has	O
a	O
narrow	O
therapeutic	O
:	O
toxic	O
ratio	O
and	O
concentrations	O
are	O
affected	O
by	O
a	O
number	O
of	O
drugs	O
.	O
Also	O
,	O
digoxin	B-Chemical
has	O
undesirable	O
effects	O
such	O
as	O
increasing	O
peripheral	O
resistance	O
and	O
myocardial	O
demands	O
,	O
and	O
causing	O
arrhythmias	B-Disease
.	O
There	O
is	O
a	O
paucity	O
of	O
data	O
from	O
well	O
-	O
designed	O
trials	O
.	O
The	O
trials	O
that	O
are	O
available	O
are	O
generally	O
small	O
with	O
limitations	O
in	O
design	O
and	O
these	O
show	O
variation	O
in	O
patient	O
benefit	O
.	O
More	O
convincing	O
evidence	O
is	O
required	O
showing	O
that	O
digoxin	B-Chemical
improves	O
symptoms	O
or	O
exercise	O
capacity	O
.	O
Furthermore	O
,	O
no	O
trial	O
has	O
had	O
sufficient	O
power	O
to	O
evaluate	O
mortality	O
.	O
Pooled	O
analysis	O
of	O
the	O
effects	O
of	O
other	O
inotropic	O
drugs	O
shows	O
an	O
excess	O
mortality	O
and	O
there	O
is	O
a	O
possibility	O
that	O
digoxin	B-Chemical
may	O
increase	O
mortality	O
after	O
myocardial	B-Disease
infarction	I-Disease
(	O
MI	B-Disease
)	O
.	O
Angiotensin	B-Chemical
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitors	O
should	O
be	O
used	O
first	O
as	O
they	O
are	O
safer	O
,	O
do	O
not	O
require	O
blood	O
level	O
monitoring	O
,	O
modify	O
progression	O
of	O
disease	O
,	O
relieve	O
symptoms	O
,	O
improve	O
exercise	O
tolerance	O
and	O
reduce	O
mortality	O
.	O
Caution	O
should	O
be	O
exercised	O
in	O
using	O
digoxin	B-Chemical
until	O
large	O
mortality	O
trials	O
are	O
completed	O
showing	O
either	O
benefit	O
or	O
harm	O
.	O
Until	O
then	O
digoxin	B-Chemical
should	O
be	O
considered	O
a	O
third	O
-	O
line	O
therapy	O
.	O
Isradipine	B-Chemical
treatment	O
for	O
hypertension	B-Disease
in	O
general	O
practice	O
in	O
Hong	O
Kong	O
.	O
A	O
6	O
-	O
week	O
open	O
study	O
of	O
the	O
introduction	O
of	O
isradipine	B-Chemical
treatment	O
was	O
conducted	O
in	O
general	O
practice	O
in	O
Hong	O
Kong	O
.	O
303	O
Chinese	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	B-Disease
entered	O
the	O
study	O
.	O
Side	O
effects	O
were	O
reported	O
in	O
21	O
%	O
of	O
patients	O
and	O
caused	O
withdrawal	O
from	O
the	O
study	O
in	O
3	O
patients	O
.	O
The	O
main	O
side	O
-	O
effects	O
were	O
headache	B-Disease
,	O
dizziness	B-Disease
,	O
palpitation	B-Disease
and	O
flushing	B-Disease
and	O
these	O
were	O
not	O
more	O
frequent	O
than	O
reported	O
in	O
other	O
studies	O
with	O
isradipine	B-Chemical
or	O
with	O
placebo	O
.	O
Supine	O
blood	O
pressure	O
was	O
reduced	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
from	O
170	O
+	O
/	O
-	O
20	O
/	O
102	O
+	O
/	O
-	O
6	O
mmHg	O
to	O
153	O
+	O
/	O
-	O
19	O
/	O
92	O
+	O
/	O
-	O
8	O
,	O
147	O
+	O
/	O
-	O
18	O
/	O
88	O
+	O
/	O
-	O
7	O
and	O
144	O
+	O
/	O
-	O
14	O
/	O
87	O
+	O
/	O
-	O
6	O
mmHg	O
at	O
2	O
,	O
4	O
and	O
6	O
weeks	O
respectively	O
in	O
evaluable	O
patients	O
.	O
Similar	O
reductions	O
occurred	O
in	O
standing	O
blood	O
pressure	O
and	O
there	O
was	O
no	O
evidence	O
of	O
postural	B-Disease
hypotension	I-Disease
.	O
Normalization	O
and	O
responder	O
rates	O
at	O
6	O
weeks	O
were	O
86	O
%	O
and	O
69	O
%	O
respectively	O
.	O
Dosage	O
was	O
increased	O
from	O
2	O
.	O
5	O
mg	O
b	O
.	O
d	O
.	O
to	O
5	O
mg	O
b	O
.	O
d	O
.	O
at	O
4	O
weeks	O
in	O
patients	O
with	O
diastolic	O
blood	O
pressure	O
greater	O
than	O
90	O
mmHg	O
and	O
their	O
further	O
response	O
was	O
greater	O
than	O
those	O
remaining	O
on	O
2	O
.	O
5	O
mg	O
b	O
.	O
d	O
.	O
Pharmacological	O
characteristics	O
and	O
side	O
effects	O
of	O
a	O
new	O
galenic	O
formulation	O
of	O
propofol	B-Chemical
without	O
soyabean	O
oil	O
.	O
We	O
compared	O
the	O
pharmacokinetics	O
,	O
pharmacodynamics	O
and	O
safety	O
profile	O
of	O
a	O
new	O
galenic	O
formulation	O
of	O
propofol	B-Chemical
(	O
AM149	O
1	O
%	O
)	O
,	O
which	O
does	O
not	O
contain	O
soyabean	O
oil	O
,	O
with	O
a	O
standard	O
formulation	O
of	O
propofol	B-Chemical
(	O
Disoprivan	B-Chemical
1	O
%	O
)	O
.	O
In	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
cross	O
-	O
over	O
study	O
,	O
30	O
healthy	O
volunteers	O
received	O
a	O
single	O
intravenous	O
bolus	O
injection	O
of	O
2	O
.	O
5	O
mg	O
.	O
kg	O
-	O
1	O
propofol	B-Chemical
.	O
Plasma	O
propofol	B-Chemical
levels	O
were	O
measured	O
for	O
48	O
h	O
following	O
drug	O
administration	O
and	O
evaluated	O
according	O
to	O
a	O
three	O
-	O
compartment	O
model	O
.	O
The	O
pharmacodynamic	O
parameters	O
assessed	O
included	O
induction	O
and	O
emergence	O
times	O
,	O
respiratory	O
and	O
cardiovascular	O
effects	O
,	O
and	O
pain	B-Disease
on	O
injection	O
.	O
Patients	O
were	O
monitored	O
for	O
side	O
effects	O
over	O
48	O
h	O
.	O
Owing	O
to	O
a	O
high	O
incidence	O
of	O
thrombophlebitis	B-Disease
,	O
the	O
study	O
was	O
terminated	O
prematurely	O
and	O
only	O
the	O
data	O
of	O
the	O
two	O
parallel	O
treatment	O
groups	O
(	O
15	O
patients	O
in	O
each	O
group	O
)	O
were	O
analysed	O
.	O
Plasma	O
concentrations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
formulations	O
.	O
Anaesthesia	O
induction	O
and	O
emergence	O
times	O
,	O
respiratory	O
and	O
cardiovascular	O
variables	O
showed	O
no	O
significant	O
differences	O
between	O
the	O
two	O
treatment	O
groups	O
.	O
Pain	B-Disease
on	O
injection	O
(	O
80	O
vs	O
.	O
20	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
thrombophlebitis	B-Disease
(	O
93	O
.	O
3	O
vs	O
.	O
6	O
.	O
6	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
occurred	O
more	O
frequently	O
with	O
AM149	O
than	O
with	O
Disoprivan	B-Chemical
.	O
Although	O
both	O
formulations	O
had	O
similar	O
pharmacokinetic	O
and	O
pharmacodynamic	O
profiles	O
the	O
new	O
formulation	O
is	O
not	O
suitable	O
for	O
clinical	O
use	O
due	O
to	O
the	O
high	O
incidence	O
of	O
thrombophlebitis	B-Disease
produced	O
.	O
Pure	B-Disease
red	I-Disease
cell	I-Disease
aplasia	I-Disease
,	O
toxic	B-Disease
dermatitis	I-Disease
and	O
lymphadenopathy	B-Disease
in	O
a	O
patient	O
taking	O
diphenylhydantoin	B-Chemical
.	O
A	O
patient	O
taking	O
diphenylhydantoin	B-Chemical
for	O
3	O
weeks	O
developed	O
a	O
generalized	O
skin	B-Disease
rash	I-Disease
,	O
lymphadenopathy	B-Disease
and	O
pure	B-Disease
red	I-Disease
cell	I-Disease
aplasia	I-Disease
.	O
After	O
withdrawal	O
of	O
the	O
pharmacon	O
all	O
symptoms	O
disappeared	O
spontaneously	O
.	O
Skin	B-Disease
rash	I-Disease
is	O
a	O
well	O
-	O
known	O
complication	O
of	O
diphenylhydantoin	B-Chemical
treatment	O
as	O
is	O
benign	O
and	O
malignant	O
lymphadenopathy	B-Disease
.	O
Pure	B-Disease
red	I-Disease
cell	I-Disease
aplasia	I-Disease
associated	O
with	O
diphenylhydantoin	B-Chemical
medication	O
has	O
been	O
reported	O
in	O
3	O
patients	O
.	O
The	O
exact	O
mechanism	O
by	O
which	O
diphenylhydantoin	B-Chemical
exerts	O
its	O
toxic	O
effects	O
is	O
not	O
known	O
.	O
In	O
this	O
patient	O
the	O
time	O
relation	O
between	O
the	O
ingestion	O
of	O
diphenylhydantoin	B-Chemical
and	O
the	O
occurrence	O
of	O
the	O
skin	B-Disease
rash	I-Disease
,	O
lymphadenopathy	B-Disease
and	O
pure	B-Disease
red	I-Disease
cell	I-Disease
aplasia	I-Disease
is	O
very	O
suggestive	O
of	O
a	O
direct	O
connection	O
.	O
Vinorelbine	B-Chemical
-	O
related	O
cardiac	O
events	O
:	O
a	O
meta	O
-	O
analysis	O
of	O
randomized	O
clinical	O
trials	O
.	O
Several	O
cases	O
of	O
cardiac	O
adverse	O
reactions	O
related	O
to	O
vinorelbine	B-Chemical
(	O
VNR	B-Chemical
)	O
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O
In	O
order	O
to	O
quantify	O
the	O
incidence	O
of	O
these	O
cardiac	O
events	O
,	O
we	O
performed	O
a	O
meta	O
-	O
analysis	O
of	O
clinical	O
trials	O
comparing	O
VNR	B-Chemical
with	O
other	O
chemotherapeutic	O
agents	O
in	O
the	O
treatment	O
of	O
various	O
malignancies	B-Disease
.	O
Randomized	O
clinical	O
trials	O
comparing	O
VNR	B-Chemical
with	O
other	O
drugs	O
in	O
the	O
treatment	O
of	O
cancer	B-Disease
were	O
searched	O
in	O
Medline	O
,	O
Embase	O
,	O
Evidence	O
-	O
based	O
Medicine	O
Reviews	O
databases	O
and	O
the	O
Cochrane	O
library	O
from	O
1987	O
to	O
2002	O
.	O
Outcomes	O
of	O
interest	O
were	O
severe	O
cardiac	O
events	O
,	O
toxic	O
deaths	O
and	O
cardiac	O
event	O
-	O
related	O
deaths	O
reported	O
in	O
each	O
publication	O
.	O
We	O
found	O
19	O
trials	O
,	O
involving	O
2441	O
patients	O
treated	O
by	O
VNR	B-Chemical
and	O
2050	O
control	O
patients	O
.	O
The	O
incidence	O
of	O
cardiac	O
events	O
with	O
VNR	B-Chemical
was	O
1	O
.	O
19	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
(	O
0	O
.	O
75	O
;	O
1	O
.	O
67	O
)	O
]	O
.	O
There	O
was	O
no	O
difference	O
in	O
the	O
risk	O
of	O
cardiac	O
events	O
between	O
VNR	B-Chemical
and	O
other	O
drugs	O
[	O
odds	O
ratio	O
:	O
0	O
.	O
92	O
,	O
95	O
%	O
CI	O
(	O
0	O
.	O
54	O
;	O
1	O
.	O
55	O
)	O
]	O
.	O
The	O
risk	O
of	O
VNR	B-Chemical
cardiac	O
events	O
was	O
similar	O
to	O
vindesine	B-Chemical
(	O
VDS	B-Chemical
)	O
and	O
other	O
cardiotoxic	B-Disease
drugs	O
[	O
fluorouracil	B-Chemical
,	O
anthracyclines	B-Chemical
,	O
gemcitabine	B-Chemical
(	O
GEM	B-Chemical
)	O
em	O
leader	O
]	O
.	O
Even	O
if	O
it	O
did	O
not	O
reach	O
statistical	O
significance	O
because	O
of	O
a	O
few	O
number	O
of	O
cases	O
,	O
the	O
risk	O
was	O
lower	O
in	O
trials	O
excluding	O
patients	O
with	O
cardiac	O
history	O
,	O
and	O
seemed	O
to	O
be	O
higher	O
in	O
trials	O
including	O
patients	O
with	O
pre	O
-	O
existing	O
cardiac	B-Disease
diseases	I-Disease
.	O
Vinorelbine	B-Chemical
-	O
related	O
cardiac	O
events	O
concern	O
about	O
1	O
%	O
of	O
treated	O
patients	O
in	O
clinical	O
trials	O
.	O
However	O
,	O
the	O
risk	O
associated	O
with	O
VNR	B-Chemical
seems	O
to	O
be	O
similar	O
to	O
that	O
of	O
other	O
chemotherapeutic	O
agents	O
in	O
the	O
same	O
indications	O
.	O
MRI	O
findings	O
of	O
hypoxic	O
cortical	O
laminar	O
necrosis	B-Disease
in	O
a	O
child	O
with	O
hemolytic	B-Disease
anemia	I-Disease
crisis	O
.	O
We	O
present	O
magnetic	O
resonance	O
imaging	O
findings	O
of	O
a	O
5	O
-	O
year	O
-	O
old	O
girl	O
who	O
had	O
a	O
rapidly	O
installing	O
hemolytic	B-Disease
anemia	I-Disease
crisis	O
induced	O
by	O
trimethoprim	B-Chemical
-	I-Chemical
sulfomethoxazole	I-Chemical
,	O
resulting	O
in	O
cerebral	B-Disease
anoxia	I-Disease
leading	O
to	O
permanent	O
damage	O
.	O
Magnetic	O
Resonance	O
imaging	O
revealed	O
cortical	O
laminar	O
necrosis	B-Disease
in	O
arterial	O
border	O
zones	O
in	O
both	O
cerebral	O
hemispheres	O
,	O
ischemic	O
changes	O
in	O
subcortical	O
white	O
matter	O
of	O
left	O
cerebral	O
hemisphere	O
,	O
and	O
in	O
the	O
left	O
putamen	O
.	O
Although	O
cortical	O
laminar	O
necrosis	B-Disease
is	O
a	O
classic	O
entity	O
in	O
adulthood	O
related	O
to	O
conditions	O
of	O
energy	O
depletions	O
,	O
there	O
are	O
few	O
reports	O
available	O
in	O
children	O
.	O
A	O
wide	O
review	O
of	O
the	O
literature	O
is	O
also	O
presented	O
.	O
The	O
natural	O
history	O
of	O
Vigabatrin	B-Chemical
associated	O
visual	B-Disease
field	I-Disease
defects	I-Disease
in	O
patients	O
electing	O
to	O
continue	O
their	O
medication	O
.	O
PURPOSE	O
:	O
To	O
determine	O
the	O
natural	O
history	O
of	O
visual	B-Disease
field	I-Disease
defects	I-Disease
in	O
a	O
group	O
of	O
patients	O
known	O
to	O
have	O
Vigabatrin	B-Chemical
-	O
associated	O
changes	O
who	O
elected	O
to	O
continue	O
the	O
medication	O
because	O
of	O
good	O
seizure	B-Disease
control	O
.	O
METHODS	O
:	O
All	O
patients	O
taking	O
Vigabatrin	B-Chemical
alone	O
or	O
in	O
combination	O
with	O
other	O
antiepileptic	O
drugs	O
for	O
at	O
least	O
5	O
years	O
(	O
range	O
5	O
-	O
12	O
years	O
)	O
were	O
entered	O
into	O
a	O
visual	O
surveillance	O
programme	O
.	O
Patients	O
were	O
followed	O
up	O
at	O
6	O
-	O
monthly	O
intervals	O
for	O
not	O
less	O
than	O
18	O
months	O
(	O
range	O
18	O
-	O
43	O
months	O
)	O
.	O
In	O
all	O
,	O
16	O
patients	O
with	O
unequivocal	O
defects	O
continued	O
the	O
medication	O
.	O
Following	O
already	O
published	O
methodology	O
(	O
Eye	O
2002	O
;	O
16	O
;	O
567	O
-	O
571	O
)	O
monocular	O
mean	O
radial	O
degrees	O
(	O
MRDs	O
)	O
to	O
the	O
I	O
/	O
4e	O
isopter	O
on	O
Goldmann	O
perimetry	O
was	O
calculated	O
for	O
the	O
right	O
eye	O
at	O
the	O
time	O
of	O
discovery	O
of	O
a	O
visual	B-Disease
field	I-Disease
defect	I-Disease
and	O
again	O
after	O
not	O
less	O
than	O
18	O
months	O
follow	O
-	O
up	O
.	O
RESULTS	O
:	O
Mean	O
right	O
eye	O
MRD	O
at	O
presentation	O
was	O
36	O
.	O
98	O
degrees	O
(	O
range	O
22	O
.	O
25	O
-	O
51	O
.	O
0	O
)	O
,	O
compared	O
to	O
38	O
.	O
40	O
degrees	O
(	O
range	O
22	O
.	O
5	O
-	O
49	O
.	O
75	O
)	O
after	O
follow	O
-	O
up	O
;	O
P	O
=	O
0	O
.	O
338	O
unpaired	O
t	O
-	O
test	O
.	O
Only	O
one	O
patient	O
demonstrated	O
a	O
deterioration	B-Disease
in	I-Disease
visual	I-Disease
field	I-Disease
during	O
the	O
study	O
period	O
and	O
discontinued	O
treatment	O
.	O
CONCLUSION	O
:	O
Established	O
visual	B-Disease
field	I-Disease
defects	I-Disease
presumed	O
to	O
be	O
due	O
to	O
Vigabatrin	B-Chemical
therapy	O
did	O
not	O
usually	O
progress	O
in	O
spite	O
of	O
continuing	O
use	O
of	O
the	O
medication	O
.	O
These	O
data	O
give	O
support	O
to	O
the	O
hypothesis	O
that	O
the	O
pathogenesis	O
of	O
Vigabatrin	B-Chemical
-	O
associated	O
visual	B-Disease
field	I-Disease
defects	I-Disease
may	O
be	O
an	O
idiosyncratic	O
adverse	O
drug	O
reaction	O
rather	O
than	O
dose	O
-	O
dependent	O
toxicity	B-Disease
.	O
Induction	O
of	O
rosaceiform	O
dermatitis	B-Disease
during	O
treatment	O
of	O
facial	B-Disease
inflammatory	I-Disease
dermatoses	I-Disease
with	O
tacrolimus	B-Chemical
ointment	O
.	O
BACKGROUND	O
:	O
Tacrolimus	B-Chemical
ointment	O
is	O
increasingly	O
used	O
for	O
anti	O
-	O
inflammatory	O
treatment	O
of	O
sensitive	O
areas	O
such	O
as	O
the	O
face	O
,	O
and	O
recent	O
observations	O
indicate	O
that	O
the	O
treatment	O
is	O
effective	O
in	O
steroid	B-Chemical
-	O
aggravated	O
rosacea	B-Disease
and	O
perioral	B-Disease
dermatitis	I-Disease
.	O
We	O
report	O
on	O
rosaceiform	O
dermatitis	B-Disease
as	O
a	O
complication	O
of	O
treatment	O
with	O
tacrolimus	B-Chemical
ointment	O
.	O
OBSERVATIONS	O
:	O
Six	O
adult	O
patients	O
with	O
inflammatory	B-Disease
facial	I-Disease
dermatoses	I-Disease
were	O
treated	O
with	O
tacrolimus	B-Chemical
ointment	O
because	O
of	O
the	O
ineffectiveness	O
of	O
standard	O
treatments	O
.	O
Within	O
2	O
to	O
3	O
weeks	O
of	O
initially	O
effective	O
and	O
well	O
-	O
tolerated	O
treatment	O
,	O
3	O
patients	O
with	O
a	O
history	O
of	O
rosacea	B-Disease
and	O
1	O
with	O
a	O
history	O
of	O
acne	B-Disease
experienced	O
sudden	O
worsening	O
with	O
pustular	O
rosaceiform	O
lesions	O
.	O
Biopsy	O
revealed	O
an	O
abundance	O
of	O
Demodex	O
mites	O
in	O
2	O
of	O
these	O
patients	O
.	O
In	O
1	O
patient	O
with	O
eyelid	O
eczema	B-Disease
,	O
rosaceiform	O
periocular	B-Disease
dermatitis	I-Disease
gradually	O
appeared	O
after	O
3	O
weeks	O
of	O
treatment	O
.	O
In	O
1	O
patient	O
with	O
atopic	B-Disease
dermatitis	I-Disease
,	O
telangiectatic	O
and	O
papular	B-Disease
rosacea	I-Disease
insidiously	O
appeared	O
after	O
5	O
months	O
of	O
treatment	O
.	O
CONCLUSIONS	O
:	O
Our	O
observations	O
suggest	O
that	O
the	O
spectrum	O
of	O
rosaceiform	O
dermatitis	B-Disease
as	O
a	O
complication	O
of	O
treatment	O
with	O
tacrolimus	B-Chemical
ointment	O
is	O
heterogeneous	O
.	O
A	O
variety	O
of	O
factors	O
,	O
such	O
as	O
vasoactive	O
properties	O
of	O
tacrolimus	B-Chemical
,	O
proliferation	O
of	O
Demodex	O
due	O
to	O
local	O
immunosuppression	O
,	O
and	O
the	O
occlusive	O
properties	O
of	O
the	O
ointment	O
,	O
may	O
be	O
involved	O
in	O
the	O
observed	O
phenomena	O
.	O
Future	O
studies	O
are	O
needed	O
to	O
identify	O
individual	O
risk	O
factors	O
.	O
Intravascular	O
hemolysis	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
following	O
intermittent	O
rifampin	B-Chemical
therapy	O
.	O
Renal	B-Disease
failure	I-Disease
is	O
a	O
rare	O
complication	O
associated	O
with	O
the	O
use	O
of	O
rifampin	B-Chemical
.	O
Intravascular	O
hemolysis	B-Disease
leading	O
to	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
following	O
rifampin	B-Chemical
therapy	O
is	O
extremely	O
rare	O
.	O
Two	O
patients	O
with	O
leprosy	B-Disease
who	O
developed	O
hemolysis	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
following	O
rifampin	B-Chemical
are	O
reported	O
.	O
Structural	O
abnormalities	O
in	O
the	O
brains	O
of	O
human	O
subjects	O
who	O
use	O
methamphetamine	B-Chemical
.	O
We	O
visualize	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
profile	O
of	O
structural	B-Disease
deficits	I-Disease
in	I-Disease
the	I-Disease
human	I-Disease
brain	I-Disease
associated	O
with	O
chronic	O
methamphetamine	B-Chemical
(	O
MA	B-Chemical
)	O
abuse	O
.	O
Studies	O
of	O
human	O
subjects	O
who	O
have	O
used	O
MA	B-Chemical
chronically	O
have	O
revealed	O
deficits	O
in	O
dopaminergic	O
and	O
serotonergic	O
systems	O
and	O
cerebral	O
metabolic	B-Disease
abnormalities	I-Disease
.	O
Using	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
and	O
new	O
computational	O
brain	O
-	O
mapping	O
techniques	O
,	O
we	O
determined	O
the	O
pattern	O
of	O
structural	O
brain	O
alterations	O
associated	O
with	O
chronic	O
MA	B-Chemical
abuse	O
in	O
human	O
subjects	O
and	O
related	O
these	O
deficits	O
to	O
cognitive	B-Disease
impairment	I-Disease
.	O
We	O
used	O
high	O
-	O
resolution	O
MRI	O
and	O
surface	O
-	O
based	O
computational	O
image	O
analyses	O
to	O
map	O
regional	O
abnormalities	B-Disease
in	I-Disease
the	I-Disease
cortex	I-Disease
,	I-Disease
hippocampus	I-Disease
,	I-Disease
white	I-Disease
matter	I-Disease
,	I-Disease
and	I-Disease
ventricles	I-Disease
in	O
22	O
human	O
subjects	O
who	O
used	O
MA	B-Chemical
and	O
21	O
age	O
-	O
matched	O
,	O
healthy	O
controls	O
.	O
Cortical	O
maps	O
revealed	O
severe	O
gray	O
-	O
matter	O
deficits	O
in	O
the	O
cingulate	O
,	O
limbic	O
,	O
and	O
paralimbic	O
cortices	O
of	O
MA	B-Chemical
abusers	O
(	O
averaging	O
11	O
.	O
3	O
%	O
below	O
control	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
On	O
average	O
,	O
MA	B-Chemical
abusers	O
had	O
7	O
.	O
8	O
%	O
smaller	O
hippocampal	O
volumes	O
than	O
control	O
subjects	O
(	O
p	O
<	O
0	O
.	O
01	O
;	O
left	O
,	O
p	O
=	O
0	O
.	O
01	O
;	O
right	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
significant	O
white	O
-	O
matter	O
hypertrophy	B-Disease
(	O
7	O
.	O
0	O
%	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
Hippocampal	O
deficits	O
were	O
mapped	O
and	O
correlated	O
with	O
memory	O
performance	O
on	O
a	O
word	O
-	O
recall	O
test	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
MRI	O
-	O
based	O
maps	O
suggest	O
that	O
chronic	O
methamphetamine	B-Chemical
abuse	O
causes	O
a	O
selective	O
pattern	O
of	O
cerebral	O
deterioration	O
that	O
contributes	O
to	O
impaired	B-Disease
memory	I-Disease
performance	I-Disease
.	O
MA	B-Chemical
may	O
selectively	O
damage	O
the	O
medial	O
temporal	O
lobe	O
and	O
,	O
consistent	O
with	O
metabolic	O
studies	O
,	O
the	O
cingulate	O
-	O
limbic	O
cortex	O
,	O
inducing	O
neuroadaptation	O
,	O
neuropil	O
reduction	O
,	O
or	O
cell	O
death	O
.	O
Prominent	O
white	O
-	O
matter	O
hypertrophy	B-Disease
may	O
result	O
from	O
altered	O
myelination	O
and	O
adaptive	O
glial	O
changes	O
,	O
including	O
gliosis	B-Disease
secondary	O
to	O
neuronal	B-Disease
damage	I-Disease
.	O
These	O
brain	O
substrates	O
may	O
help	O
account	O
for	O
the	O
symptoms	O
of	O
MA	B-Chemical
abuse	O
,	O
providing	O
therapeutic	O
targets	O
for	O
drug	O
-	O
induced	O
brain	B-Disease
injury	I-Disease
.	O
Disruption	O
of	O
hepatic	O
lipid	O
homeostasis	O
in	O
mice	O
after	O
amiodarone	B-Chemical
treatment	O
is	O
associated	O
with	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
alpha	O
target	O
gene	O
activation	O
.	O
Amiodarone	B-Chemical
,	O
an	O
efficacious	O
and	O
widely	O
used	O
antiarrhythmic	O
agent	O
,	O
has	O
been	O
reported	O
to	O
cause	O
hepatotoxicity	B-Disease
in	O
some	O
patients	O
.	O
To	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
this	O
unwanted	O
effect	O
,	O
mice	O
were	O
administered	O
various	O
doses	O
of	O
amiodarone	B-Chemical
and	O
examined	O
for	O
changes	O
in	O
hepatic	O
histology	O
and	O
gene	O
regulation	O
.	O
Amiodarone	B-Chemical
induced	O
hepatomegaly	B-Disease
,	O
hepatocyte	O
microvesicular	O
lipid	O
accumulation	O
,	O
and	O
a	O
significant	O
decrease	O
in	O
serum	O
triglycerides	B-Chemical
and	O
glucose	B-Chemical
.	O
Northern	O
blot	O
analysis	O
of	O
hepatic	O
RNA	O
revealed	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
expression	O
of	O
a	O
number	O
of	O
genes	O
critical	O
for	O
fatty	B-Chemical
acid	I-Chemical
oxidation	O
,	O
lipoprotein	O
assembly	O
,	O
and	O
lipid	O
transport	O
.	O
Many	O
of	O
these	O
genes	O
are	O
regulated	O
by	O
the	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
alpha	O
(	O
PPARalpha	O
)	O
,	O
a	O
ligand	O
-	O
activated	O
nuclear	O
hormone	O
receptor	O
transcription	O
factor	O
.	O
The	O
absence	O
of	O
induction	O
of	O
these	O
genes	O
as	O
well	O
as	O
hepatomegaly	B-Disease
in	O
PPARalpha	O
knockout	O
[	O
PPARalpha	O
-	O
/	O
-	O
]	O
mice	O
indicated	O
that	O
the	O
effects	O
of	O
amiodarone	B-Chemical
were	O
dependent	O
upon	O
the	O
presence	O
of	O
a	O
functional	O
PPARalpha	O
gene	O
.	O
Compared	O
to	O
wild	O
-	O
type	O
mice	O
,	O
treatment	O
of	O
PPARalpha	O
-	O
/	O
-	O
mice	O
with	O
amiodarone	B-Chemical
resulted	O
in	O
an	O
increased	O
rate	O
and	O
extent	O
of	O
total	O
body	O
weight	B-Disease
loss	I-Disease
.	O
The	O
inability	O
of	O
amiodarone	B-Chemical
to	O
directly	O
activate	O
either	O
human	O
or	O
mouse	O
PPARalpha	O
transiently	O
expressed	O
in	O
human	O
HepG2	O
hepatoma	B-Disease
cells	O
indicates	O
that	O
the	O
effects	O
of	O
amiodarone	B-Chemical
on	O
the	O
function	O
of	O
this	O
receptor	O
were	O
indirect	O
.	O
Based	O
upon	O
these	O
results	O
,	O
we	O
conclude	O
that	O
amiodarone	B-Chemical
disrupts	O
hepatic	O
lipid	O
homeostasis	O
and	O
that	O
the	O
increased	O
expression	O
of	O
PPARalpha	O
target	O
genes	O
is	O
secondary	O
to	O
this	O
toxic	O
effect	O
.	O
These	O
results	O
provide	O
important	O
new	O
mechanistic	O
information	O
regarding	O
the	O
hepatotoxic	B-Disease
effects	O
of	O
amiodarone	B-Chemical
and	O
indicate	O
that	O
PPARalpha	O
protects	O
against	O
amiodarone	B-Chemical
-	O
induced	O
hepatotoxicity	B-Disease
.	O
Safety	O
and	O
compliance	O
with	O
once	O
-	O
daily	O
niacin	B-Chemical
extended	I-Chemical
-	I-Chemical
release	I-Chemical
/	I-Chemical
lovastatin	I-Chemical
as	O
initial	O
therapy	O
in	O
the	O
Impact	O
of	O
Medical	O
Subspecialty	O
on	O
Patient	O
Compliance	O
to	O
Treatment	O
(	O
IMPACT	O
)	O
study	O
.	O
Niacin	B-Chemical
extended	I-Chemical
-	I-Chemical
release	I-Chemical
/	I-Chemical
lovastatin	I-Chemical
is	O
a	O
new	O
combination	O
product	O
approved	O
for	O
treatment	O
of	O
primary	O
hypercholesterolemia	B-Disease
and	O
mixed	O
dyslipidemia	B-Disease
.	O
This	O
open	O
-	O
labeled	O
,	O
multicenter	O
study	O
evaluated	O
the	O
safety	O
of	O
bedtime	O
niacin	B-Chemical
extended	I-Chemical
-	I-Chemical
release	I-Chemical
/	I-Chemical
lovastatin	I-Chemical
when	O
dosed	O
as	O
initial	O
therapy	O
and	O
patient	O
compliance	O
to	O
treatment	O
in	O
various	O
clinical	O
practice	O
settings	O
.	O
A	O
total	O
of	O
4	O
,	O
499	O
patients	O
with	O
dyslipidemia	B-Disease
requiring	O
drug	O
intervention	O
was	O
enrolled	O
at	O
1	O
,	O
081	O
sites	O
.	O
Patients	O
were	O
treated	O
with	O
1	O
tablet	O
(	O
500	O
mg	O
of	O
niacin	B-Chemical
extended	O
-	O
release	O
/	O
20	O
mg	O
of	O
lovastatin	B-Chemical
)	O
once	O
nightly	O
for	O
4	O
weeks	O
and	O
then	O
2	O
tablets	O
for	O
8	O
weeks	O
.	O
Patients	O
also	O
received	O
dietary	O
counseling	O
,	O
educational	O
materials	O
,	O
and	O
reminders	O
to	O
call	O
a	O
toll	O
-	O
free	O
number	O
that	O
provided	O
further	O
education	O
about	O
dyslipidemia	B-Disease
and	O
niacin	B-Chemical
extended	I-Chemical
-	I-Chemical
release	I-Chemical
/	I-Chemical
lovastatin	I-Chemical
.	O
Primary	O
end	O
points	O
were	O
study	O
compliance	O
,	O
increases	O
in	O
liver	O
transaminases	O
to	O
>	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
,	O
and	O
clinical	O
myopathy	B-Disease
.	O
Final	O
study	O
status	O
was	O
available	O
for	O
4	O
,	O
217	O
patients	O
(	O
94	O
%	O
)	O
.	O
Compliance	O
to	O
niacin	B-Chemical
extended	I-Chemical
-	I-Chemical
release	I-Chemical
/	I-Chemical
lovastatin	I-Chemical
was	O
77	O
%	O
,	O
with	O
3	O
,	O
245	O
patients	O
completing	O
the	O
study	O
.	O
Patients	O
in	O
the	O
southeast	O
and	O
those	O
enrolled	O
by	O
endocrinologists	O
had	O
the	O
lowest	O
compliance	O
and	O
highest	O
adverse	O
event	O
rates	O
.	O
Flushing	B-Disease
was	O
the	O
most	O
common	O
adverse	O
event	O
,	O
reported	O
by	O
18	O
%	O
of	O
patients	O
and	O
leading	O
to	O
discontinuation	O
by	O
6	O
%	O
.	O
Incidence	O
of	O
increased	O
aspartate	B-Chemical
aminotransferase	O
and	O
/	O
or	O
alanine	B-Chemical
aminotransferase	O
>	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
was	O
<	O
0	O
.	O
3	O
%	O
.	O
An	O
increase	O
of	O
creatine	B-Chemical
phosphokinase	O
to	O
>	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
occurred	O
in	O
0	O
.	O
24	O
%	O
of	O
patients	O
,	O
and	O
no	O
cases	O
of	O
drug	O
-	O
induced	O
myopathy	B-Disease
were	O
observed	O
.	O
Niacin	B-Chemical
extended	I-Chemical
-	I-Chemical
release	I-Chemical
/	I-Chemical
lovastatin	I-Chemical
1	O
,	O
000	O
/	O
40	O
mg	O
,	O
dosed	O
as	O
initial	O
therapy	O
,	O
was	O
associated	O
with	O
good	O
compliance	O
and	O
safety	O
and	O
had	O
very	O
low	O
incidences	O
of	O
increased	O
liver	O
and	O
muscle	O
enzymes	O
.	O
Protective	O
effect	O
of	O
Terminalia	B-Chemical
chebula	I-Chemical
against	O
experimental	O
myocardial	B-Disease
injury	I-Disease
induced	O
by	O
isoproterenol	B-Chemical
.	O
Cardioprotective	O
effect	O
of	O
ethanolic	B-Chemical
extract	I-Chemical
of	I-Chemical
Terminalia	I-Chemical
chebula	I-Chemical
fruits	I-Chemical
(	O
500	O
mg	O
/	O
kg	O
body	O
wt	O
)	O
was	O
examined	O
in	O
isoproterenol	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
body	O
wt	O
)	O
induced	O
myocardial	B-Disease
damage	I-Disease
in	O
rats	O
.	O
In	O
isoproterenol	B-Chemical
administered	O
rats	O
,	O
the	O
level	O
of	O
lipid	O
peroxides	B-Chemical
increased	O
significantly	O
in	O
the	O
serum	O
and	O
heart	O
.	O
A	O
significant	O
decrease	O
was	O
observed	O
in	O
the	O
activity	O
of	O
the	O
myocardial	O
marker	O
enzymes	O
with	O
a	O
concomitant	O
increase	O
in	O
their	O
activity	O
in	O
serum	O
.	O
Histopathological	O
examination	O
was	O
carried	O
out	O
to	O
confirm	O
the	O
myocardial	O
necrosis	B-Disease
.	O
T	B-Chemical
.	I-Chemical
chebula	I-Chemical
extract	I-Chemical
pretreatment	O
was	O
found	O
to	O
ameliorate	O
the	O
effect	O
of	O
isoproterenol	B-Chemical
on	O
lipid	O
peroxide	B-Chemical
formation	O
and	O
retained	O
the	O
activities	O
of	O
the	O
diagnostic	O
marker	O
enzymes	O
.	O
A	O
case	O
of	O
postoperative	O
anxiety	B-Disease
due	O
to	O
low	O
dose	O
droperidol	B-Chemical
used	O
with	O
patient	O
-	O
controlled	O
analgesia	O
.	O
A	O
multiparous	O
woman	O
in	O
good	O
psychological	O
health	O
underwent	O
urgent	O
caesarean	O
section	O
in	O
labour	O
.	O
Postoperatively	O
,	O
she	O
was	O
given	O
a	O
patient	O
-	O
controlled	O
analgesia	O
device	O
delivering	O
boluses	O
of	O
diamorphine	B-Chemical
0	O
.	O
5	O
mg	O
and	O
droperidol	B-Chemical
0	O
.	O
025	O
mg	O
.	O
Whilst	O
using	O
the	O
device	O
she	O
gradually	O
became	O
anxious	O
,	O
the	O
feeling	O
worsening	O
after	O
each	O
bolus	O
.	O
The	O
diagnosis	O
of	O
droperidol	B-Chemical
-	O
induced	O
psychological	B-Disease
disturbance	I-Disease
was	O
not	O
made	O
straight	O
away	O
although	O
on	O
subsequent	O
close	O
questioning	O
the	O
patient	O
gave	O
a	O
very	O
clear	O
history	O
.	O
After	O
she	O
had	O
received	O
a	O
total	O
of	O
only	O
0	O
.	O
9	O
mg	O
droperidol	B-Chemical
,	O
a	O
syringe	O
containing	O
diamorphine	B-Chemical
only	O
was	O
substituted	O
and	O
her	O
unease	O
resolved	O
completely	O
.	O
We	O
feel	O
that	O
,	O
although	O
the	O
dramatic	O
extrapyramidal	O
side	O
effects	O
of	O
dopaminergic	O
antiemetics	O
are	O
well	O
known	O
,	O
more	O
subtle	O
manifestations	O
may	O
easily	O
be	O
overlooked	O
.	O
Accurate	O
patient	O
history	O
contributes	O
to	O
differentiating	O
diabetes	B-Disease
insipidus	I-Disease
:	O
a	O
case	O
study	O
.	O
This	O
case	O
study	O
highlights	O
the	O
important	O
contribution	O
of	O
nursing	O
in	O
obtaining	O
an	O
accurate	O
health	O
history	O
.	O
The	O
case	O
discussed	O
herein	O
initially	O
appeared	O
to	O
be	O
neurogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
(	O
DI	B-Disease
)	O
secondary	O
to	O
a	O
traumatic	B-Disease
brain	I-Disease
injury	I-Disease
.	O
The	O
nursing	O
staff	O
,	O
by	O
reviewing	O
the	O
patient	O
'	O
s	O
health	O
history	O
with	O
his	O
family	O
,	O
discovered	O
a	O
history	O
of	O
polydipsia	B-Disease
and	O
long	O
-	O
standing	O
lithium	B-Chemical
use	O
.	O
Lithium	B-Chemical
is	O
implicated	O
in	O
drug	O
-	O
induced	O
nephrogenic	B-Disease
DI	I-Disease
,	O
and	O
because	O
the	O
patient	O
had	O
not	O
received	O
lithium	B-Chemical
since	O
being	O
admitted	O
to	O
the	O
hospital	O
,	O
his	O
treatment	O
changed	O
to	O
focus	O
on	O
nephrogenic	B-Disease
DI	I-Disease
.	O
By	O
combining	O
information	O
from	O
the	O
patient	O
history	O
,	O
the	O
physical	O
examination	O
,	O
and	O
radiologic	O
and	O
laboratory	O
studies	O
,	O
the	O
critical	O
care	O
team	O
demonstrated	O
that	O
the	O
patient	O
had	O
been	O
self	O
-	O
treating	O
his	O
lithium	B-Chemical
-	O
induced	O
nephrogenic	B-Disease
DI	I-Disease
and	O
developed	O
neurogenic	B-Disease
DI	I-Disease
secondary	O
to	O
brain	B-Disease
trauma	I-Disease
.	O
Thus	O
successful	O
treatment	O
required	O
that	O
nephrogenic	O
and	O
neurogenic	B-Disease
DI	I-Disease
be	O
treated	O
concomitantly	O
.	O
Factors	O
contributing	O
to	O
ribavirin	B-Chemical
-	O
induced	O
anemia	B-Disease
.	O
BACKGROUND	O
AND	O
AIM	O
:	O
Interferon	B-Chemical
and	O
ribavirin	B-Chemical
combination	O
therapy	O
for	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
produces	O
hemolytic	B-Disease
anemia	I-Disease
.	O
This	O
study	O
was	O
conducted	O
to	O
identify	O
the	O
factors	O
contributing	O
to	O
ribavirin	B-Chemical
-	O
induced	O
anemia	B-Disease
.	O
METHODS	O
:	O
Eighty	O
-	O
eight	O
patients	O
with	O
chronic	B-Disease
hepatitis	I-Disease
C	I-Disease
who	O
received	O
interferon	B-Chemical
-	I-Chemical
alpha	I-Chemical
-	I-Chemical
2b	I-Chemical
at	O
a	O
dose	O
of	O
6	O
MU	O
administered	O
intramuscularly	O
for	O
24	O
weeks	O
in	O
combination	O
with	O
ribavirin	B-Chemical
administered	O
orally	O
at	O
a	O
dose	O
of	O
600	O
mg	O
or	O
800	O
mg	O
participated	O
in	O
the	O
study	O
.	O
A	O
hemoglobin	O
concentration	O
of	O
<	O
10	O
g	O
/	O
dL	O
was	O
defined	O
as	O
ribavirin	B-Chemical
-	O
induced	O
anemia	B-Disease
.	O
RESULTS	O
:	O
Ribavirin	B-Chemical
-	O
induced	O
anemia	B-Disease
occurred	O
in	O
18	O
(	O
20	O
.	O
5	O
%	O
)	O
patients	O
during	O
treatment	O
.	O
A	O
2	O
g	O
/	O
dL	O
decrease	O
in	O
hemoglobin	O
concentrations	O
in	O
patients	O
with	O
anemia	B-Disease
was	O
observed	O
at	O
week	O
2	O
after	O
the	O
start	O
of	O
treatment	O
.	O
The	O
hemoglobin	O
concentration	O
in	O
patients	O
with	O
>	O
or	O
=	O
2	O
g	O
/	O
dL	O
decrease	O
at	O
week	O
2	O
was	O
observed	O
to	O
be	O
significantly	O
lower	O
even	O
after	O
week	O
2	O
than	O
in	O
patients	O
with	O
<	O
2	O
g	O
/	O
dL	O
decrease	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
A	O
significant	O
relationship	O
was	O
observed	O
between	O
the	O
rate	O
of	O
reduction	O
of	O
hemoglobin	O
concentrations	O
at	O
week	O
2	O
and	O
the	O
severity	O
of	O
anemia	B-Disease
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
Such	O
factors	O
as	O
sex	O
(	O
female	O
)	O
,	O
age	O
(	O
>	O
or	O
=	O
60	O
years	O
old	O
)	O
,	O
and	O
the	O
ribavirin	B-Chemical
dose	O
by	O
body	O
weight	O
(	O
12	O
mg	O
/	O
kg	O
or	O
more	O
)	O
were	O
significant	O
by	O
univariate	O
analysis	O
.	O
CONCLUSIONS	O
:	O
Careful	O
administration	O
is	O
necessary	O
in	O
patients	O
>	O
or	O
=	O
60	O
years	O
old	O
,	O
in	O
female	O
patients	O
,	O
and	O
in	O
patients	O
receiving	O
a	O
ribavirin	B-Chemical
dose	O
of	O
12	O
mg	O
/	O
kg	O
or	O
more	O
.	O
Patients	O
who	O
experience	O
a	O
fall	O
in	O
hemoglobin	O
concentrations	O
of	O
2	O
g	O
/	O
dL	O
or	O
more	O
at	O
week	O
2	O
after	O
the	O
start	O
of	O
treatment	O
should	O
be	O
monitored	O
with	O
particular	O
care	O
.	O
Zidovudine	B-Chemical
-	O
induced	O
hepatitis	B-Disease
.	O
A	O
case	O
of	O
acute	O
hepatitis	B-Disease
induced	O
by	O
zidovudine	B-Chemical
in	O
a	O
38	O
-	O
year	O
-	O
old	O
patient	O
with	O
AIDS	B-Disease
is	O
presented	O
.	O
The	O
mechanism	O
whereby	O
the	O
hepatitis	B-Disease
was	O
induced	O
is	O
not	O
known	O
.	O
However	O
,	O
the	O
patient	O
tolerated	O
well	O
an	O
alternative	O
reverse	O
transcriptase	O
inhibitor	O
,	O
2	B-Chemical
'	I-Chemical
3	I-Chemical
'	I-Chemical
dideoxyinosine	I-Chemical
.	O
Physicians	O
caring	O
for	O
patients	O
with	O
AIDS	B-Disease
should	O
be	O
aware	O
of	O
this	O
hitherto	O
rarely	O
reported	O
complication	O
.	O
Oxidative	O
damage	O
precedes	O
nitrative	O
damage	O
in	O
adriamycin	B-Chemical
-	O
induced	O
cardiac	O
mitochondrial	B-Disease
injury	I-Disease
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
elevated	O
reactive	O
oxygen	B-Chemical
(	O
ROS	O
)	O
/	O
nitrogen	B-Chemical
species	O
(	O
RNS	O
)	O
reported	O
to	O
be	O
present	O
in	O
adriamycin	B-Chemical
(	O
ADR	B-Chemical
)	O
-	O
induced	O
cardiotoxicity	B-Disease
actually	O
resulted	O
in	O
cardiomyocyte	O
oxidative	O
/	O
nitrative	O
damage	O
,	O
and	O
to	O
quantitatively	O
determine	O
the	O
time	O
course	O
and	O
subcellular	O
localization	O
of	O
these	O
postulated	O
damage	O
products	O
using	O
an	O
in	O
vivo	O
approach	O
.	O
B6C3	O
mice	O
were	O
treated	O
with	O
a	O
single	O
dose	O
of	O
20	O
mg	O
/	O
kg	O
ADR	B-Chemical
.	O
Ultrastructural	O
damage	O
and	O
levels	O
of	O
4	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
nonenal	I-Chemical
(	O
4HNE	B-Chemical
)	O
-	O
protein	O
adducts	O
and	O
3	B-Chemical
-	I-Chemical
nitrotyrosine	I-Chemical
(	O
3NT	B-Chemical
)	O
were	O
analyzed	O
.	O
Quantitative	O
ultrastructural	O
damage	O
using	O
computerized	O
image	O
techniques	O
showed	O
cardiomyocyte	O
injury	O
as	O
early	O
as	O
3	O
hours	O
,	O
with	O
mitochondria	O
being	O
the	O
most	O
extensively	O
and	O
progressively	O
injured	O
subcellular	O
organelle	O
.	O
Analysis	O
of	O
4HNE	B-Chemical
protein	O
adducts	O
by	O
immunogold	O
electron	O
microscopy	O
showed	O
appearance	O
of	O
4HNE	B-Chemical
protein	O
adducts	O
in	O
mitochondria	O
as	O
early	O
as	O
3	O
hours	O
,	O
with	O
a	O
peak	O
at	O
6	O
hours	O
and	O
subsequent	O
decline	O
at	O
24	O
hours	O
.	O
3NT	B-Chemical
levels	O
were	O
significantly	O
increased	O
in	O
all	O
subcellular	O
compartments	O
at	O
6	O
hours	O
and	O
subsequently	O
declined	O
at	O
24	O
hours	O
.	O
Our	O
data	O
showed	O
ADR	B-Chemical
induced	O
4HNE	B-Chemical
-	O
protein	O
adducts	O
in	O
mitochondria	O
at	O
the	O
same	O
time	O
point	O
as	O
when	O
mitochondrial	B-Disease
injury	I-Disease
initially	O
appeared	O
.	O
These	O
results	O
document	O
for	O
the	O
first	O
time	O
in	O
vivo	O
that	O
mitochondrial	B-Disease
oxidative	I-Disease
damage	I-Disease
precedes	O
nitrative	O
damage	O
.	O
The	O
progressive	O
nature	O
of	O
mitochondrial	B-Disease
injury	I-Disease
suggests	O
that	O
mitochondria	O
,	O
not	O
other	O
subcellular	O
organelles	O
,	O
are	O
the	O
major	O
site	O
of	O
intracellular	O
injury	O
.	O
Sotalol	B-Chemical
-	O
induced	O
coronary	B-Disease
spasm	I-Disease
in	O
a	O
patient	O
with	O
dilated	B-Disease
cardiomyopathy	I-Disease
associated	O
with	O
sustained	O
ventricular	B-Disease
tachycardia	I-Disease
.	O
A	O
54	O
-	O
year	O
-	O
old	O
man	O
with	O
severe	O
left	O
ventricular	B-Disease
dysfunction	I-Disease
due	O
to	O
dilated	B-Disease
cardiomyopathy	I-Disease
was	O
referred	O
to	O
our	O
hospital	O
for	O
symptomatic	O
incessant	O
sustained	O
ventricular	B-Disease
tachycardia	I-Disease
(	O
VT	B-Disease
)	O
.	O
After	O
the	O
administration	O
of	O
nifekalant	B-Chemical
hydrochloride	I-Chemical
,	O
sustained	O
VT	B-Disease
was	O
terminated	O
.	O
An	O
alternate	O
class	O
III	O
agent	O
,	O
sotalol	B-Chemical
,	O
was	O
also	O
effective	O
for	O
the	O
prevention	O
of	O
VT	B-Disease
.	O
However	O
,	O
one	O
month	O
after	O
switching	O
over	O
nifekalant	B-Chemical
to	O
sotalol	B-Chemical
,	O
a	O
short	O
duration	O
of	O
ST	O
elevation	O
was	O
documented	O
in	O
ECG	O
monitoring	O
at	O
almost	O
the	O
same	O
time	O
for	O
three	O
consecutive	O
days	O
.	O
ST	O
elevation	O
with	O
chest	O
discomfort	O
disappeared	O
since	O
he	O
began	O
taking	O
long	O
-	O
acting	O
diltiazem	B-Chemical
.	O
Coronary	B-Disease
vasospasm	I-Disease
may	O
be	O
induced	O
by	O
the	O
non	O
-	O
selective	O
beta	O
-	O
blocking	O
properties	O
of	O
sotalol	B-Chemical
.	O
Effects	O
of	O
the	O
antidepressant	O
trazodone	B-Chemical
,	O
a	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2A	O
/	O
2C	O
receptor	O
antagonist	O
,	O
on	O
dopamine	B-Chemical
-	O
dependent	O
behaviors	O
in	O
rats	O
.	O
RATIONALE	O
:	O
5	B-Chemical
-	I-Chemical
Hydroxytryptamine	I-Chemical
,	O
via	O
stimulation	O
of	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2C	O
receptors	O
,	O
exerts	O
a	O
tonic	O
inhibitory	O
influence	O
on	O
dopaminergic	O
neurotransmission	O
,	O
whereas	O
activation	O
of	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2A	O
receptors	O
enhances	O
stimulated	O
DAergic	O
neurotransmission	O
.	O
The	O
antidepressant	O
trazodone	B-Chemical
is	O
a	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2A	O
/	O
2C	O
receptor	O
antagonist	O
.	O
OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
trazodone	B-Chemical
treatment	O
on	O
behaviors	O
dependent	O
on	O
the	O
functional	O
status	O
of	O
the	O
nigrostriatal	O
DAergic	O
system	O
.	O
METHODS	O
:	O
The	O
effect	O
of	O
pretreatment	O
with	O
trazodone	B-Chemical
on	O
dexamphetamine	B-Chemical
-	O
and	O
apomorphine	B-Chemical
-	O
induced	O
oral	B-Disease
stereotypies	I-Disease
,	O
on	O
catalepsy	B-Disease
induced	O
by	O
haloperidol	B-Chemical
and	O
apomorphine	B-Chemical
(	O
0	O
.	O
05	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
on	O
ergometrine	B-Chemical
-	O
induced	O
wet	O
dog	O
shake	O
(	O
WDS	O
)	O
behavior	O
and	O
fluoxetine	B-Chemical
-	O
induced	O
penile	O
erections	O
was	O
studied	O
in	O
rats	O
.	O
We	O
also	O
investigated	O
whether	O
trazodone	B-Chemical
induces	O
catalepsy	B-Disease
in	O
rats	O
.	O
RESULTS	O
:	O
Trazodone	B-Chemical
at	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
did	O
not	O
induce	O
catalepsy	B-Disease
,	O
and	O
did	O
not	O
antagonize	O
apomorphine	B-Chemical
(	O
1	O
.	O
5	O
and	O
3	O
mg	O
/	O
kg	O
)	O
stereotypy	O
and	O
apomorphine	B-Chemical
(	O
0	O
.	O
05	O
mg	O
/	O
kg	O
)	O
-	O
induced	O
catalepsy	B-Disease
.	O
However	O
,	O
pretreatment	O
with	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
trazodone	B-Chemical
enhanced	O
dexamphetamine	B-Chemical
stereotypy	O
,	O
and	O
antagonized	O
haloperidol	B-Chemical
catalepsy	B-Disease
,	O
ergometrine	B-Chemical
-	O
induced	O
WDS	O
behavior	O
and	O
fluoxetine	B-Chemical
-	O
induced	O
penile	O
erections	O
.	O
Trazodone	B-Chemical
at	O
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
induced	O
catalepsy	B-Disease
and	O
antagonized	O
apomorphine	B-Chemical
and	O
dexamphetamine	B-Chemical
stereotypies	O
.	O
CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
trazodone	B-Chemical
at	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
kg	O
does	O
not	O
block	O
pre	O
-	O
and	O
postsynaptic	O
striatal	O
D2	O
DA	O
receptors	O
,	O
while	O
at	O
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
it	O
blocks	O
postsynaptic	O
striatal	O
D2	O
DA	O
receptors	O
.	O
Furthermore	O
,	O
at	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
,	O
trazodone	B-Chemical
blocks	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2A	O
and	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2C	O
receptors	O
.	O
We	O
suggest	O
that	O
trazodone	B-Chemical
(	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
)	O
,	O
by	O
blocking	O
the	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
2C	O
receptors	O
,	O
releases	O
the	O
nigrostriatal	O
DAergic	O
neurons	O
from	O
tonic	O
inhibition	O
caused	O
by	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
,	O
and	O
thereby	O
potentiates	O
dexamphetamine	B-Chemical
stereotypy	O
and	O
antagonizes	O
haloperidol	B-Chemical
catalepsy	B-Disease
.	O
Swallowing	B-Disease
abnormalities	I-Disease
and	O
dyskinesia	B-Disease
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
Gastrointestinal	B-Disease
abnormalities	I-Disease
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
have	O
been	O
known	O
for	O
almost	O
two	O
centuries	O
,	O
but	O
many	O
aspects	O
concerning	O
their	O
pathophysiology	O
have	O
not	O
been	O
completely	O
clarified	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
oropharyngeal	O
dynamics	O
in	O
PD	B-Disease
patients	O
with	O
and	O
without	O
levodopa	B-Chemical
-	O
induced	O
dyskinesia	B-Disease
.	O
Fifteen	O
dyskinetic	B-Disease
,	O
12	O
nondyskinetic	O
patients	O
,	O
and	O
a	O
control	O
group	O
were	O
included	O
.	O
Patients	O
were	O
asked	O
about	O
dysphagia	B-Disease
and	O
evaluated	O
with	O
the	O
Unified	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
Disease	I-Disease
Rating	O
Scale	O
Parts	O
II	O
and	O
III	O
and	O
the	O
Hoehn	O
and	O
Yahr	O
scale	O
.	O
Deglutition	O
was	O
assessed	O
using	O
modified	O
barium	B-Chemical
swallow	O
with	O
videofluoroscopy	O
.	O
Nondyskinetic	O
patients	O
,	O
but	O
not	O
the	O
dyskinetic	B-Disease
ones	O
,	O
showed	O
less	O
oropharyngeal	O
swallowing	O
efficiency	O
(	O
OPSE	O
)	O
for	O
liquid	O
food	O
than	O
controls	O
(	O
Dunnett	O
,	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O
Dyskinetic	B-Disease
patients	O
tended	O
to	O
have	O
a	O
greater	O
OPSE	O
than	O
nondyskinetic	O
(	O
Dunnett	O
,	O
P	O
=	O
0	O
.	O
06	O
)	O
.	O
Patients	O
who	O
were	O
using	O
a	O
higher	O
dose	O
of	O
levodopa	B-Chemical
had	O
a	O
greater	O
OPSE	O
and	O
a	O
trend	O
toward	O
a	O
smaller	O
oral	O
transit	O
time	O
(	O
Pearson	O
'	O
s	O
correlation	O
,	O
P	O
=	O
0	O
.	O
01	O
and	O
0	O
.	O
08	O
,	O
respectively	O
)	O
.	O
Neither	O
the	O
report	O
of	O
dysphagia	B-Disease
nor	O
any	O
of	O
the	O
PD	B-Disease
severity	O
parameters	O
correlated	O
to	O
the	O
videofluoroscopic	O
variables	O
.	O
In	O
the	O
current	O
study	O
,	O
dyskinetic	B-Disease
patients	O
performed	O
better	O
in	O
swallowing	O
function	O
,	O
which	O
could	O
be	O
explained	O
on	O
the	O
basis	O
of	O
a	O
greater	O
levodopa	B-Chemical
dose	O
.	O
Our	O
results	O
suggest	O
a	O
role	O
for	O
levodopa	B-Chemical
in	O
the	O
oral	O
phase	O
of	O
deglutition	O
and	O
confirm	O
that	O
dysphagia	B-Disease
is	O
not	O
a	O
good	O
predictor	O
of	O
deglutition	O
alterations	O
in	O
PD	B-Disease
.	O
Inhibition	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
attenuates	O
tubulointerstitial	B-Disease
nephritis	I-Disease
induced	O
by	O
gentamicin	B-Chemical
.	O
BACKGROUND	O
:	O
Animals	O
treated	O
with	O
gentamicin	B-Chemical
can	O
show	O
residual	O
areas	O
of	O
interstitial	O
fibrosis	B-Disease
in	O
the	O
renal	O
cortex	O
.	O
This	O
study	O
investigated	O
the	O
expression	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
and	O
macrophages	O
in	O
the	O
renal	O
cortex	O
and	O
structural	O
and	O
functional	O
renal	O
changes	O
of	O
rats	O
treated	O
with	O
gentamicin	B-Chemical
or	O
gentamicin	B-Chemical
+	O
pyrrolidine	B-Chemical
dithiocarbamate	I-Chemical
(	O
PDTC	B-Chemical
)	O
,	O
an	O
NF	O
-	O
kappaB	O
inhibitor	O
.	O
METHODS	O
:	O
38	O
female	O
Wistar	O
rats	O
were	O
injected	O
with	O
gentamicin	B-Chemical
,	O
40	O
mg	O
/	O
kg	O
,	O
twice	O
a	O
day	O
for	O
9	O
days	O
,	O
38	O
with	O
gentamicin	B-Chemical
+	O
PDTC	B-Chemical
,	O
and	O
28	O
with	O
0	O
.	O
15	O
M	O
NaCl	B-Chemical
solution	O
.	O
The	O
animals	O
were	O
killed	O
5	O
and	O
30	O
days	O
after	O
these	O
injections	O
and	O
the	O
kidneys	O
were	O
removed	O
for	O
histological	O
and	O
immunohistochemical	O
studies	O
.	O
The	O
results	O
of	O
the	O
immunohistochemical	O
studies	O
were	O
scored	O
according	O
to	O
the	O
extent	O
of	O
staining	O
.	O
The	O
fractional	O
interstitial	O
area	O
was	O
determined	O
by	O
morphometry	O
.	O
RESULTS	O
:	O
Gentamicin	B-Chemical
-	O
treated	O
rats	O
presented	O
a	O
transitory	O
increase	O
in	O
plasma	O
creatinine	B-Chemical
levels	O
.	O
Increased	O
ED	O
-	O
1	O
,	O
MAP	O
kinases	O
and	O
NF	O
-	O
kappaB	O
staining	O
were	O
also	O
observed	O
in	O
the	O
renal	O
cortex	O
from	O
all	O
gentamicin	B-Chemical
-	O
treated	O
rats	O
compared	O
to	O
control	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
The	O
animals	O
killed	O
on	O
day	O
30	O
also	O
presented	O
fibrosis	B-Disease
in	O
the	O
renal	O
cortex	O
despite	O
the	O
recovery	O
of	O
renal	O
function	O
.	O
Treatment	O
with	O
PDTC	B-Chemical
reduced	O
the	O
functional	O
and	O
structural	O
changes	O
induced	O
by	O
gentamicin	B-Chemical
.	O
CONCLUSIONS	O
:	O
These	O
data	O
show	O
that	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
attenuates	O
tubulointerstitial	B-Disease
nephritis	I-Disease
induced	O
by	O
gentamicin	B-Chemical
.	O
Glucose	B-Chemical
metabolism	O
in	O
patients	O
with	O
schizophrenia	B-Disease
treated	O
with	O
atypical	O
antipsychotic	O
agents	O
:	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-Chemical
tolerance	O
test	O
and	O
minimal	O
model	O
analysis	O
.	O
BACKGROUND	O
:	O
While	O
the	O
incidence	O
of	O
new	O
-	O
onset	O
diabetes	B-Disease
mellitus	I-Disease
may	O
be	O
increasing	O
in	O
patients	O
with	O
schizophrenia	B-Disease
treated	O
with	O
certain	O
atypical	O
antipsychotic	O
agents	O
,	O
it	O
remains	O
unclear	O
whether	O
atypical	O
agents	O
are	O
directly	O
affecting	O
glucose	B-Chemical
metabolism	O
or	O
simply	O
increasing	O
known	O
risk	O
factors	O
for	O
diabetes	B-Disease
.	O
OBJECTIVE	O
:	O
To	O
study	O
the	O
2	O
drugs	O
most	O
clearly	O
implicated	O
(	O
clozapine	B-Chemical
and	O
olanzapine	B-Chemical
)	O
and	O
risperidone	B-Chemical
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-Chemical
tolerance	O
test	O
.	O
DESIGN	O
:	O
A	O
cross	O
-	O
sectional	O
design	O
in	O
stable	O
,	O
treated	O
patients	O
with	O
schizophrenia	B-Disease
evaluated	O
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-Chemical
tolerance	O
test	O
and	O
the	O
Bergman	O
minimal	O
model	O
analysis	O
.	O
SETTING	O
:	O
Subjects	O
were	O
recruited	O
from	O
an	O
urban	O
community	O
mental	O
health	O
clinic	O
and	O
were	O
studied	O
at	O
a	O
general	O
clinical	O
research	O
center	O
.	O
Patients	O
Fifty	O
subjects	O
signed	O
informed	O
consent	O
and	O
41	O
underwent	O
the	O
frequently	O
sampled	O
intravenous	O
glucose	B-Chemical
tolerance	O
test	O
.	O
Thirty	O
-	O
six	O
nonobese	O
subjects	O
with	O
schizophrenia	B-Disease
or	O
schizoaffective	B-Disease
disorder	I-Disease
,	O
matched	O
by	O
body	O
mass	O
index	O
and	O
treated	O
with	O
either	O
clozapine	B-Chemical
,	O
olanzapine	B-Chemical
,	O
or	O
risperidone	B-Chemical
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
Fasting	O
plasma	O
glucose	B-Chemical
and	O
fasting	O
serum	O
insulin	O
levels	O
,	O
insulin	B-Disease
sensitivity	I-Disease
index	O
,	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B-Disease
resistance	I-Disease
,	O
and	O
glucose	B-Chemical
effectiveness	O
.	O
RESULTS	O
:	O
The	O
mean	O
+	O
/	O
-	O
SD	O
duration	O
of	O
treatment	O
with	O
the	O
identified	O
atypical	O
antipsychotic	O
agent	O
was	O
68	O
.	O
3	O
+	O
/	O
-	O
28	O
.	O
9	O
months	O
(	O
clozapine	B-Chemical
)	O
,	O
29	O
.	O
5	O
+	O
/	O
-	O
17	O
.	O
5	O
months	O
(	O
olanzapine	B-Chemical
)	O
,	O
and	O
40	O
.	O
9	O
+	O
/	O
-	O
33	O
.	O
7	O
(	O
risperidone	B-Chemical
)	O
.	O
Fasting	O
serum	O
insulin	O
concentrations	O
differed	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
3	O
.	O
35	O
;	O
P	O
=	O
.	O
047	O
)	O
(	O
clozapine	B-Chemical
>	O
olanzapine	B-Chemical
>	O
risperidone	B-Chemical
)	O
with	O
significant	O
differences	O
between	O
clozapine	B-Chemical
and	O
risperidone	B-Chemical
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
32	O
;	O
P	O
=	O
.	O
03	O
)	O
and	O
olanzapine	B-Chemical
and	O
risperidone	B-Chemical
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
15	O
;	O
P	O
=	O
.	O
04	O
)	O
.	O
There	O
was	O
a	O
significant	O
difference	O
in	O
insulin	B-Disease
sensitivity	I-Disease
index	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
10	O
.	O
66	O
;	O
P	O
<	O
.	O
001	O
)	O
(	O
clozapine	B-Chemical
<	O
olanzapine	B-Chemical
<	O
risperidone	B-Chemical
)	O
,	O
with	O
subjects	O
who	O
received	O
clozapine	B-Chemical
and	O
olanzapine	B-Chemical
exhibiting	O
significant	O
insulin	B-Disease
resistance	I-Disease
compared	O
with	O
subjects	O
who	O
were	O
treated	O
with	O
risperidone	B-Chemical
(	O
clozapine	B-Chemical
vs	O
risperidone	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
-	O
4	O
.	O
29	O
;	O
P	O
<	O
.	O
001	O
;	O
olanzapine	B-Chemical
vs	O
risperidone	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
-	O
3	O
.	O
62	O
;	O
P	O
=	O
.	O
001	O
[	O
P	O
<	O
.	O
001	O
]	O
)	O
.	O
The	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B-Disease
resistance	I-Disease
also	O
differed	O
significantly	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
4	O
.	O
92	O
;	O
P	O
=	O
.	O
01	O
)	O
(	O
clozapine	B-Chemical
>	O
olanzapine	B-Chemical
>	O
risperidone	B-Chemical
)	O
(	O
clozapine	B-Chemical
vs	O
risperidone	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
94	O
;	O
P	O
=	O
.	O
006	O
;	O
olanzapine	B-Chemical
vs	O
risperidone	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
42	O
;	O
P	O
=	O
.	O
02	O
)	O
.	O
There	O
was	O
a	O
significant	O
difference	O
among	O
groups	O
in	O
glucose	B-Chemical
effectiveness	O
(	O
F	O
(	O
30	O
)	O
=	O
4	O
.	O
18	O
;	O
P	O
=	O
.	O
02	O
)	O
(	O
clozapine	B-Chemical
<	O
olanzapine	B-Chemical
<	O
risperidone	B-Chemical
)	O
with	O
significant	O
differences	O
between	O
clozapine	B-Chemical
and	O
risperidone	B-Chemical
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
59	O
;	O
P	O
=	O
.	O
02	O
)	O
and	O
olanzapine	B-Chemical
and	O
risperidone	B-Chemical
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
34	O
,	O
P	O
=	O
.	O
03	O
)	O
.	O
CONCLUSIONS	O
:	O
Both	O
nonobese	O
clozapine	B-Chemical
-	O
and	O
olanzapine	B-Chemical
-	O
treated	O
groups	O
displayed	O
significant	O
insulin	B-Disease
resistance	I-Disease
and	O
impairment	O
of	O
glucose	B-Chemical
effectiveness	O
compared	O
with	O
risperidone	B-Chemical
-	O
treated	O
subjects	O
.	O
Patients	O
taking	O
clozapine	B-Chemical
and	O
olanzapine	B-Chemical
must	O
be	O
examined	O
for	O
insulin	B-Disease
resistance	I-Disease
and	O
its	O
consequences	O
.	O
Thoracic	B-Disease
hematomyelia	I-Disease
secondary	O
to	O
coumadin	B-Chemical
anticoagulant	O
therapy	O
:	O
a	O
case	O
report	O
.	O
A	O
case	O
of	O
thoracic	B-Disease
hematomyelia	I-Disease
secondary	O
to	O
anticoagulant	O
therapy	O
is	O
presented	O
.	O
Clinical	O
features	O
,	O
similar	O
to	O
2	O
other	O
previously	O
reported	O
cases	O
,	O
are	O
discussed	O
.	O
A	O
high	O
index	O
of	O
suspicion	O
may	O
lead	O
to	O
a	O
quick	O
diagnostic	O
procedure	O
and	O
successful	O
decompressive	O
surgery	O
.	O
Mania	B-Disease
associated	O
with	O
fluoxetine	B-Chemical
treatment	O
in	O
adolescents	O
.	O
Fluoxetine	B-Chemical
,	O
a	O
selective	O
serotonin	B-Chemical
reuptake	O
inhibitor	O
,	O
is	O
gaining	O
increased	O
acceptance	O
in	O
the	O
treatment	O
of	O
adolescent	O
depression	B-Disease
.	O
Generally	O
safe	O
and	O
well	O
tolerated	O
by	O
adults	O
,	O
fluoxetine	B-Chemical
has	O
been	O
reported	O
to	O
induce	O
mania	B-Disease
.	O
The	O
cases	O
of	O
five	O
depressed	B-Disease
adolescents	O
,	O
14	O
-	O
16	O
years	O
of	O
age	O
,	O
who	O
developed	O
mania	B-Disease
during	O
pharmacotherapy	O
with	O
fluoxetine	B-Chemical
,	O
are	O
reported	O
here	O
.	O
Apparent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
mania	B-Disease
or	O
hypomania	B-Disease
during	O
fluoxetine	B-Chemical
pharmacotherapy	O
in	O
this	O
population	O
were	O
the	O
combination	O
of	O
attention	B-Disease
-	I-Disease
deficit	I-Disease
hyperactivity	I-Disease
disorder	I-Disease
and	O
affective	O
instability	O
;	O
major	O
depression	B-Disease
with	O
psychotic	B-Disease
features	O
;	O
a	O
family	O
history	O
of	O
affective	B-Disease
disorder	I-Disease
,	O
especially	O
bipolar	B-Disease
disorder	I-Disease
;	O
and	O
a	O
diagnosis	O
of	O
bipolar	B-Disease
disorder	I-Disease
.	O
Further	O
study	O
is	O
needed	O
to	O
determine	O
the	O
optimal	O
dosage	O
and	O
to	O
identify	O
risk	O
factors	O
that	O
increase	O
individual	O
vulnerability	O
to	O
fluoxetine	B-Chemical
induced	O
mania	B-Disease
in	O
adolescents	O
.	O
Acute	B-Disease
renal	I-Disease
insufficiency	I-Disease
after	O
high	O
-	O
dose	O
melphalan	B-Chemical
in	O
patients	O
with	O
primary	B-Disease
systemic	I-Disease
amyloidosis	I-Disease
during	O
stem	O
cell	O
transplantation	O
.	O
BACKGROUND	O
:	O
Patients	O
with	O
primary	B-Disease
systemic	I-Disease
amyloidosis	I-Disease
(	O
AL	B-Disease
)	O
have	O
a	O
poor	O
prognosis	O
.	O
Median	O
survival	O
time	O
from	O
standard	O
treatments	O
is	O
only	O
17	O
months	O
.	O
High	O
-	O
dose	O
intravenous	O
melphalan	B-Chemical
followed	O
by	O
peripheral	O
blood	O
stem	O
cell	O
transplant	O
(	O
PBSCT	O
)	O
appears	O
to	O
be	O
the	O
most	O
promising	O
therapy	O
,	O
but	O
treatment	O
mortality	O
can	O
be	O
high	O
.	O
The	O
authors	O
have	O
noted	O
the	O
development	O
of	O
acute	B-Disease
renal	I-Disease
insufficiency	I-Disease
immediately	O
after	O
melphalan	B-Chemical
conditioning	O
.	O
This	O
study	O
was	O
undertaken	O
to	O
further	O
examine	O
its	O
risk	O
factors	O
and	O
impact	O
on	O
posttransplant	O
mortality	O
.	O
METHODS	O
:	O
Consecutive	O
AL	B-Disease
patients	O
who	O
underwent	O
PBSCT	O
were	O
studied	O
retrospectively	O
.	O
Acute	B-Disease
renal	I-Disease
insufficiency	I-Disease
(	O
ARI	B-Disease
)	O
after	O
high	O
-	O
dose	O
melphalan	B-Chemical
was	O
defined	O
by	O
a	O
minimum	O
increase	O
of	O
0	O
.	O
5	O
mg	O
/	O
dL	O
(	O
44	O
micromol	O
/	O
L	O
)	O
in	O
the	O
serum	O
creatinine	B-Chemical
level	O
that	O
is	O
greater	O
than	O
50	O
%	O
of	O
baseline	O
immediately	O
after	O
conditioning	O
.	O
Urine	O
sediment	O
score	O
was	O
the	O
sum	O
of	O
the	O
individual	O
types	O
of	O
sediment	O
identified	O
on	O
urine	O
microscopy	O
.	O
RESULTS	O
:	O
Of	O
the	O
80	O
patients	O
studied	O
,	O
ARI	B-Disease
developed	O
in	O
18	O
.	O
8	O
%	O
of	O
the	O
patients	O
after	O
high	O
-	O
dose	O
melphalan	B-Chemical
.	O
Univariate	O
analysis	O
identified	O
age	O
,	O
hypoalbuminemia	B-Disease
,	O
heavy	O
proteinuria	B-Disease
,	O
diuretic	O
use	O
,	O
and	O
urine	O
sediment	O
score	O
(	O
>	O
3	O
)	O
as	O
risk	O
factors	O
.	O
Age	O
and	O
urine	O
sediment	O
score	O
remained	O
independently	O
significant	O
risk	O
factors	O
in	O
the	O
multivariate	O
analysis	O
.	O
Patients	O
who	O
had	O
ARI	B-Disease
after	O
high	O
-	O
dose	O
melphalan	B-Chemical
underwent	O
dialysis	O
more	O
often	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
,	O
and	O
had	O
a	O
worse	O
1	O
-	O
year	O
survival	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O
CONCLUSION	O
:	O
The	O
timing	O
of	O
renal	B-Disease
injury	I-Disease
strongly	O
suggests	O
melphalan	B-Chemical
as	O
the	O
causative	O
agent	O
.	O
Ongoing	O
tubular	B-Disease
injury	I-Disease
may	O
be	O
a	O
prerequisite	O
for	O
renal	B-Disease
injury	I-Disease
by	O
melphalan	B-Chemical
as	O
evidenced	O
by	O
the	O
active	O
urinary	O
sediment	O
.	O
Development	O
of	O
ARI	B-Disease
adversely	O
affected	O
the	O
outcome	O
after	O
PBSCT	O
.	O
Effective	O
preventive	O
measures	O
may	O
help	O
decrease	O
the	O
treatment	O
mortality	O
of	O
PBSCT	O
in	O
AL	B-Disease
patients	O
.	O
Focal	O
cerebral	B-Disease
ischemia	I-Disease
in	O
rats	O
:	O
effect	O
of	O
phenylephrine	B-Chemical
-	O
induced	O
hypertension	B-Disease
during	O
reperfusion	O
.	O
After	O
180	O
min	O
of	O
temporary	O
middle	B-Disease
cerebral	I-Disease
artery	I-Disease
occlusion	I-Disease
in	O
spontaneously	O
hypertensive	B-Disease
rats	O
,	O
the	O
effect	O
of	O
phenylephrine	B-Chemical
-	O
induced	O
hypertension	B-Disease
on	O
ischemic	B-Disease
brain	I-Disease
injury	I-Disease
and	O
blood	O
-	O
brain	O
barrier	O
permeability	O
was	O
determined	O
.	O
Blood	O
pressure	O
was	O
manipulated	O
by	O
one	O
of	O
the	O
following	O
schedules	O
during	O
120	O
min	O
of	O
reperfusion	O
:	O
Control	O
,	O
normotensive	O
reperfusion	O
;	O
90	O
/	O
hypertension	B-Disease
(	O
90	O
/	O
HTN	B-Disease
)	O
,	O
blood	O
pressure	O
was	O
increased	O
by	O
35	O
mm	O
Hg	O
during	O
the	O
initial	O
90	O
min	O
of	O
reperfusion	O
only	O
;	O
15	O
/	O
hypertension	B-Disease
(	O
15	O
/	O
HTN	B-Disease
)	O
,	O
normotensive	O
reperfusion	O
for	O
30	O
min	O
followed	O
by	O
15	O
min	O
of	O
hypertension	B-Disease
and	O
75	O
min	O
of	O
normotension	O
.	O
Part	O
A	O
,	O
for	O
eight	O
rats	O
in	O
each	O
group	O
brain	B-Disease
injury	I-Disease
was	O
evaluated	O
by	O
staining	O
tissue	O
using	O
2	B-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
triphenyltetrazolium	I-Chemical
chloride	I-Chemical
and	O
edema	B-Disease
was	O
evaluated	O
by	O
microgravimetry	O
.	O
Part	O
B	O
,	O
for	O
eight	O
different	O
rats	O
in	O
each	O
group	O
blood	O
-	O
brain	O
barrier	O
permeability	O
was	O
evaluated	O
by	O
measuring	O
the	O
amount	O
and	O
extent	O
of	O
extravasation	O
of	O
Evans	O
Blue	O
dye	O
.	O
Brain	B-Disease
injury	I-Disease
(	O
percentage	O
of	O
the	O
ischemic	B-Disease
hemisphere	I-Disease
)	O
was	O
less	O
in	O
the	O
15	O
/	O
HTN	B-Disease
group	O
(	O
16	O
+	O
/	O
-	O
6	O
,	O
mean	O
+	O
/	O
-	O
SD	O
)	O
versus	O
the	O
90	O
/	O
HTN	B-Disease
group	O
(	O
30	O
+	O
/	O
-	O
6	O
)	O
,	O
which	O
was	O
in	O
turn	O
less	O
than	O
the	O
control	O
group	O
(	O
42	O
+	O
/	O
-	O
5	O
)	O
.	O
Specific	O
gravity	O
was	O
greater	O
in	O
the	O
15	O
/	O
HTN	B-Disease
group	O
(	O
1	O
.	O
043	O
+	O
/	O
-	O
0	O
.	O
002	O
)	O
versus	O
the	O
90	O
/	O
HTN	B-Disease
(	O
1	O
.	O
036	O
+	O
/	O
-	O
0	O
.	O
003	O
)	O
and	O
control	O
(	O
1	O
.	O
037	O
+	O
/	O
-	O
0	O
.	O
003	O
)	O
groups	O
.	O
Evans	B-Chemical
Blue	I-Chemical
(	O
mug	O
g	O
-	O
1	O
of	O
brain	O
tissue	O
)	O
was	O
greater	O
in	O
the	O
90	O
/	O
HTN	B-Disease
group	O
(	O
24	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
0	O
)	O
versus	O
the	O
control	O
group	O
(	O
12	O
.	O
3	O
+	O
/	O
-	O
4	O
.	O
1	O
)	O
,	O
which	O
was	O
in	O
turn	O
greater	O
than	O
the	O
15	O
/	O
HTN	B-Disease
group	O
(	O
7	O
.	O
3	O
+	O
/	O
-	O
3	O
.	O
2	O
)	O
.	O
This	O
study	O
supports	O
a	O
hypothesis	O
that	O
during	O
reperfusion	O
,	O
a	O
short	O
interval	O
of	O
hypertension	B-Disease
decreases	O
brain	B-Disease
injury	I-Disease
and	O
edema	B-Disease
;	O
and	O
that	O
sustained	O
hypertension	B-Disease
increases	O
the	O
risk	O
of	O
vasogenic	B-Disease
edema	I-Disease
.	O
People	O
aged	O
over	O
75	O
in	O
atrial	B-Disease
fibrillation	I-Disease
on	O
warfarin	B-Chemical
:	O
the	O
rate	O
of	O
major	O
hemorrhage	B-Disease
and	O
stroke	B-Disease
in	O
more	O
than	O
500	O
patient	O
-	O
years	O
of	O
follow	O
-	O
up	O
.	O
OBJECTIVES	O
:	O
To	O
determine	O
the	O
incidence	O
of	O
major	O
hemorrhage	B-Disease
and	O
stroke	B-Disease
in	O
people	O
aged	O
76	O
and	O
older	O
with	O
atrial	B-Disease
fibrillation	I-Disease
on	O
adjusted	O
-	O
dose	O
warfarin	B-Chemical
who	O
had	O
been	O
recently	O
been	O
admitted	O
to	O
hospital	O
.	O
DESIGN	O
:	O
A	O
retrospective	O
observational	O
cohort	O
study	O
.	O
SETTING	O
:	O
A	O
major	O
healthcare	O
network	O
involving	O
four	O
tertiary	O
hospitals	O
.	O
PARTICIPANTS	O
:	O
Two	O
hundred	O
thirty	O
-	O
five	O
patients	O
aged	O
76	O
and	O
older	O
admitted	O
to	O
a	O
major	O
healthcare	O
network	O
between	O
July	O
1	O
,	O
2001	O
,	O
and	O
June	O
30	O
,	O
2002	O
,	O
with	O
atrial	B-Disease
fibrillation	I-Disease
on	O
warfarin	B-Chemical
were	O
enrolled	O
.	O
MEASUREMENTS	O
:	O
Information	O
regarding	O
major	O
bleeding	B-Disease
episodes	O
,	O
strokes	B-Disease
,	O
and	O
warfarin	B-Chemical
use	O
was	O
obtained	O
from	O
patients	O
,	O
relatives	O
,	O
primary	O
physicians	O
,	O
and	O
medical	O
records	O
.	O
RESULTS	O
:	O
Two	O
hundred	O
twenty	O
-	O
eight	O
patients	O
(	O
42	O
%	O
men	O
)	O
with	O
a	O
mean	O
age	O
of	O
81	O
.	O
1	O
(	O
range	O
76	O
-	O
94	O
)	O
were	O
included	O
in	O
the	O
analysis	O
.	O
Total	O
follow	O
-	O
up	O
on	O
warfarin	B-Chemical
was	O
530	O
years	O
(	O
mean	O
28	O
months	O
)	O
.	O
There	O
were	O
53	O
major	O
hemorrhages	B-Disease
,	O
for	O
an	O
annual	O
rate	O
of	O
10	O
.	O
0	O
%	O
,	O
including	O
24	O
(	O
45	O
.	O
3	O
%	O
)	O
life	O
-	O
threatening	O
and	O
five	O
(	O
9	O
.	O
4	O
%	O
)	O
fatal	O
bleeds	O
.	O
The	O
annual	O
stroke	B-Disease
rate	O
after	O
initiation	O
of	O
warfarin	B-Chemical
was	O
2	O
.	O
6	O
%	O
.	O
CONCLUSION	O
:	O
The	O
rate	O
of	O
major	O
hemorrhage	B-Disease
was	O
high	O
in	O
this	O
old	O
,	O
frail	O
group	O
,	O
but	O
excluding	O
fatalities	O
,	O
resulted	O
in	O
no	O
long	O
-	O
term	O
sequelae	O
,	O
and	O
the	O
stroke	B-Disease
rate	O
on	O
warfarin	B-Chemical
was	O
low	O
,	O
demonstrating	O
how	O
effective	O
warfarin	B-Chemical
treatment	O
is	O
.	O
Safety	O
of	O
celecoxib	B-Chemical
in	O
patients	O
with	O
adverse	O
skin	B-Disease
reactions	I-Disease
to	O
acetaminophen	B-Chemical
(	O
paracetamol	B-Chemical
)	O
and	O
nimesulide	B-Chemical
associated	O
or	O
not	O
with	O
common	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
.	O
BACKGROUND	O
:	O
Acetaminophen	B-Chemical
(	O
paracetamol	B-Chemical
-	O
-	O
P	B-Chemical
)	O
and	O
Nimesulide	B-Chemical
(	O
N	B-Chemical
)	O
are	O
widely	O
used	O
analgesic	O
-	O
antipyretic	O
/	O
anti	O
-	O
inflammatory	O
drugs	O
.	O
The	O
rate	O
of	O
adverse	O
hypersensitivity	B-Disease
reactions	O
to	O
these	O
agents	O
is	O
generally	O
low	O
.	O
On	O
the	O
contrary	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
are	O
commonly	O
involved	O
in	O
such	O
reactions	O
.	O
Celecoxib	B-Chemical
(	O
CE	B-Chemical
)	O
is	O
a	O
novel	O
drug	O
,	O
with	O
high	O
selectivity	O
and	O
affinity	O
for	O
COX	O
-	O
2	O
enzyme	O
.	O
OBJECTIVE	O
:	O
We	O
evaluated	O
the	O
tolerability	O
of	O
CE	B-Chemical
in	O
a	O
group	O
of	O
patients	O
with	O
documented	O
history	O
of	O
adverse	O
cutaneous	B-Disease
reactions	I-Disease
to	O
P	B-Chemical
and	O
N	B-Chemical
associated	O
or	O
not	O
to	O
classic	O
NSAIDs	O
.	O
METHODS	O
:	O
We	O
studied	O
9	O
patients	O
with	O
hypersensitivity	B-Disease
to	O
P	B-Chemical
and	O
N	B-Chemical
with	O
or	O
without	O
associated	O
reactions	O
to	O
classic	O
NSAIDs	O
.	O
The	O
diagnosis	O
of	O
P	B-Chemical
and	O
N	B-Chemical
-	O
induced	O
skin	B-Disease
reactions	I-Disease
was	O
based	O
in	O
vivo	O
challenge	O
.	O
The	O
placebo	O
was	O
blindly	O
administered	O
at	O
the	O
beginning	O
of	O
each	O
challenge	O
.	O
After	O
three	O
days	O
,	O
a	O
cumulative	O
dosage	O
of	O
200	O
mg	O
of	O
CE	B-Chemical
in	O
refracted	O
doses	O
were	O
given	O
.	O
After	O
2	O
-	O
3	O
days	O
,	O
a	O
single	O
dose	O
of	O
200	O
mg	O
was	O
administered	O
.	O
All	O
patients	O
were	O
observed	O
for	O
6	O
hours	O
after	O
each	O
challenge	O
,	O
and	O
controlled	O
again	O
after	O
24	O
hours	O
to	O
exclude	O
delayed	O
reactions	O
.	O
The	O
challenge	O
was	O
considered	O
positive	O
if	O
one	O
or	O
more	O
of	O
the	O
following	O
appeared	O
:	O
erythema	B-Disease
,	O
rush	O
or	O
urticaria	B-Disease
-	O
angioedema	B-Disease
.	O
RESULTS	O
:	O
No	O
reaction	O
was	O
observed	O
with	O
placebo	O
and	O
eight	O
patients	O
(	O
88	O
.	O
8	O
%	O
)	O
tolerated	O
CE	B-Chemical
.	O
Only	O
one	O
patient	O
developed	O
a	O
moderate	O
angioedema	B-Disease
of	O
the	O
lips	O
.	O
CONCLUSION	O
:	O
Only	O
one	O
hypersensitivity	B-Disease
reaction	O
to	O
CE	B-Chemical
was	O
documented	O
among	O
9	O
P	B-Chemical
and	O
N	B-Chemical
-	O
highly	O
NSAIDs	O
intolerant	O
patients	O
.	O
Thus	O
,	O
we	O
conclude	O
that	O
CE	B-Chemical
is	O
a	O
reasonably	O
safe	O
alternative	O
to	O
be	O
used	O
in	O
subjects	O
who	O
do	O
not	O
tolerate	O
P	B-Chemical
and	O
N	B-Chemical
.	O
Case	O
-	O
control	O
study	O
of	O
regular	O
analgesic	O
and	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
use	O
and	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
.	O
BACKGROUND	O
:	O
Studies	O
on	O
the	O
association	O
between	O
the	O
long	O
-	O
term	O
use	O
of	O
aspirin	B-Chemical
and	O
other	O
analgesic	O
and	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
and	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
have	O
given	O
conflicting	O
results	O
.	O
In	O
order	O
to	O
examine	O
this	O
association	O
,	O
a	O
case	O
-	O
control	O
study	O
with	O
incident	O
cases	O
of	O
ESRD	B-Disease
was	O
carried	O
out	O
.	O
METHODS	O
:	O
The	O
cases	O
were	O
all	O
patients	O
entering	O
the	O
local	O
dialysis	O
program	O
because	O
of	O
ESRD	B-Disease
in	O
the	O
study	O
area	O
between	O
June	O
1	O
,	O
1995	O
and	O
November	O
30	O
,	O
1997	O
.	O
They	O
were	O
classified	O
according	O
to	O
the	O
underlying	O
disease	O
,	O
which	O
had	O
presumably	O
led	O
them	O
to	O
ESRD	B-Disease
.	O
Controls	O
were	O
patients	O
admitted	O
to	O
the	O
same	O
hospitals	O
from	O
where	O
the	O
cases	O
arose	O
,	O
also	O
matched	O
by	O
age	O
and	O
sex	O
.	O
Odds	O
ratios	O
were	O
calculated	O
using	O
a	O
conditional	O
logistic	O
model	O
,	O
including	O
potential	O
confounding	O
factors	O
,	O
both	O
for	O
the	O
whole	O
study	O
population	O
and	O
for	O
the	O
various	O
underlying	O
diseases	O
.	O
RESULTS	O
:	O
Five	O
hundred	O
and	O
eighty	O
-	O
three	O
cases	O
and	O
1190	O
controls	O
were	O
included	O
in	O
the	O
analysis	O
.	O
Long	O
-	O
term	O
use	O
of	O
any	O
analgesic	O
was	O
associated	O
with	O
an	O
overall	O
odds	O
ratio	O
of	O
1	O
.	O
22	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
89	O
-	O
1	O
.	O
66	O
)	O
.	O
For	O
specific	O
groups	O
of	O
drugs	O
,	O
the	O
risks	O
were	O
1	O
.	O
56	O
(	O
1	O
.	O
05	O
-	O
2	O
.	O
30	O
)	O
for	O
aspirin	B-Chemical
,	O
1	O
.	O
03	O
(	O
0	O
.	O
60	O
-	O
1	O
.	O
76	O
)	O
for	O
pyrazolones	B-Chemical
,	O
0	O
.	O
80	O
(	O
0	O
.	O
39	O
-	O
1	O
.	O
63	O
)	O
for	O
paracetamol	B-Chemical
,	O
and	O
0	O
.	O
94	O
(	O
0	O
.	O
57	O
-	O
1	O
.	O
56	O
)	O
for	O
nonaspirin	O
NSAIDs	O
.	O
The	O
risk	O
of	O
ESRD	B-Disease
associated	O
with	O
aspirin	B-Chemical
was	O
related	O
to	O
the	O
cumulated	O
dose	O
and	O
duration	O
of	O
use	O
,	O
and	O
it	O
was	O
particularly	O
high	O
among	O
the	O
subset	O
of	O
patients	O
with	O
vascular	O
nephropathy	B-Disease
as	O
underlying	O
disease	O
[	O
2	O
.	O
35	O
(	O
1	O
.	O
17	O
-	O
4	O
.	O
72	O
)	O
]	O
.	O
CONCLUSION	O
:	O
Our	O
data	O
indicate	O
that	O
long	O
-	O
term	O
use	O
of	O
nonaspirin	O
analgesic	O
drugs	O
and	O
NSAIDs	O
is	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
ESRD	B-Disease
.	O
However	O
,	O
the	O
chronic	O
use	O
of	O
aspirin	B-Chemical
may	O
increase	O
the	O
risk	O
of	O
ESRD	B-Disease
.	O
Two	O
cases	O
of	O
amisulpride	B-Chemical
overdose	B-Disease
:	O
a	O
cause	O
for	O
prolonged	B-Disease
QT	I-Disease
syndrome	I-Disease
.	O
Two	O
cases	O
of	O
deliberate	O
self	O
-	O
poisoning	B-Disease
with	O
5	O
g	O
and	O
3	O
.	O
6	O
g	O
of	O
amisulpride	B-Chemical
,	O
respectively	O
,	O
are	O
reported	O
.	O
In	O
both	O
cases	O
,	O
QT	B-Disease
prolongation	I-Disease
and	O
hypocalcaemia	B-Disease
were	O
noted	O
.	O
The	O
QT	B-Disease
prolongation	I-Disease
appeared	O
to	O
respond	O
to	O
administration	O
of	O
i	O
.	O
v	O
.	O
calcium	B-Chemical
gluconate	I-Chemical
.	O
Growth	O
-	O
associated	O
protein	O
43	O
expression	O
in	O
hippocampal	O
molecular	O
layer	O
of	O
chronic	O
epileptic	B-Disease
rats	O
treated	O
with	O
cycloheximide	B-Chemical
.	O
PURPOSE	O
:	O
GAP43	O
has	O
been	O
thought	O
to	O
be	O
linked	O
with	O
mossy	O
fiber	O
sprouting	O
(	O
MFS	O
)	O
in	O
various	O
experimental	O
models	O
of	O
epilepsy	B-Disease
.	O
To	O
investigate	O
how	O
GAP43	O
expression	O
(	O
GAP43	O
-	O
ir	O
)	O
correlates	O
with	O
MFS	O
,	O
we	O
assessed	O
the	O
intensity	O
(	O
densitometry	O
)	O
and	O
extension	O
(	O
width	O
)	O
of	O
GAP43	O
-	O
ir	O
in	O
the	O
inner	O
molecular	O
layer	O
of	O
the	O
dentate	O
gyrus	O
(	O
IML	O
)	O
of	O
rats	O
subject	O
to	O
status	B-Disease
epilepticus	I-Disease
induced	O
by	O
pilocarpine	B-Chemical
(	O
Pilo	B-Chemical
)	O
,	O
previously	O
injected	O
or	O
not	O
with	O
cycloheximide	B-Chemical
(	O
CHX	B-Chemical
)	O
,	O
which	O
has	O
been	O
shown	O
to	O
inhibit	O
MFS	O
.	O
METHODS	O
:	O
CHX	B-Chemical
was	O
injected	O
before	O
the	O
Pilo	B-Chemical
injection	O
in	O
adult	O
Wistar	O
rats	O
.	O
The	O
Pilo	B-Chemical
group	O
was	O
injected	O
with	O
the	O
same	O
drugs	O
,	O
except	O
for	O
CHX	B-Chemical
.	O
Animals	O
were	O
killed	O
between	O
30	O
and	O
60	O
days	O
later	O
,	O
and	O
brain	O
sections	O
were	O
processed	O
for	O
GAP43	O
immunohistochemistry	O
.	O
RESULTS	O
:	O
Densitometry	O
showed	O
no	O
significant	O
difference	O
regarding	O
GAP43	O
-	O
ir	O
in	O
the	O
IML	O
between	O
Pilo	B-Chemical
,	O
CHX	B-Chemical
+	O
Pilo	B-Chemical
,	O
and	O
control	O
groups	O
.	O
However	O
,	O
the	O
results	O
of	O
the	O
width	O
of	O
the	O
GAP43	O
-	O
ir	O
band	O
in	O
the	O
IML	O
showed	O
that	O
CHX	B-Chemical
+	O
Pilo	B-Chemical
and	O
control	O
animals	O
had	O
a	O
significantly	O
larger	O
band	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
as	O
compared	O
with	O
that	O
in	O
the	O
Pilo	B-Chemical
group	O
.	O
CONCLUSIONS	O
:	O
Our	O
current	O
finding	O
that	O
animals	O
in	O
the	O
CHX	B-Chemical
+	O
Pilo	B-Chemical
group	O
have	O
a	O
GAP43	O
-	O
ir	O
band	O
in	O
the	O
IML	O
,	O
similar	O
to	O
that	O
of	O
controls	O
,	O
reinforces	O
prior	O
data	O
on	O
the	O
blockade	O
of	O
MFS	O
in	O
these	O
animals	O
.	O
The	O
change	O
in	O
GAP43	O
-	O
ir	O
present	O
in	O
Pilo	B-Chemical
-	O
treated	O
animals	O
was	O
a	O
thinning	O
of	O
the	O
band	O
to	O
a	O
very	O
narrow	O
layer	O
just	O
above	O
the	O
granule	O
cell	O
layer	O
that	O
is	O
likely	O
to	O
be	O
associated	O
with	O
the	O
loss	O
of	O
hilar	O
cell	O
projections	O
that	O
express	O
GAP	O
-	O
43	O
.	O
Nicotine	B-Chemical
antagonizes	O
caffeine	B-Chemical
-	O
but	O
not	O
pentylenetetrazole	B-Chemical
-	O
induced	O
anxiogenic	O
effect	O
in	O
mice	O
.	O
RATIONALE	O
:	O
Nicotine	B-Chemical
and	O
caffeine	B-Chemical
are	O
widely	O
consumed	O
licit	O
psychoactive	O
drugs	O
worldwide	O
.	O
Epidemiological	O
studies	O
showed	O
that	O
they	O
were	O
generally	O
used	O
concurrently	O
.	O
Although	O
some	O
studies	O
in	O
experimental	O
animals	O
indicate	O
clear	O
pharmacological	O
interactions	O
between	O
them	O
,	O
no	O
studies	O
have	O
shown	O
a	O
specific	O
interaction	O
on	O
anxiety	B-Disease
responses	O
.	O
OBJECTIVES	O
:	O
The	O
present	O
study	O
investigates	O
the	O
effects	O
of	O
nicotine	B-Chemical
on	O
anxiety	B-Disease
induced	O
by	O
caffeine	B-Chemical
and	O
another	O
anxiogenic	O
drug	O
,	O
pentylenetetrazole	B-Chemical
,	O
in	O
mice	O
.	O
The	O
elevated	O
plus	O
-	O
maze	O
(	O
EPM	O
)	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
effects	O
of	O
drugs	O
on	O
anxiety	B-Disease
.	O
METHODS	O
:	O
Adult	O
male	O
Swiss	O
Webster	O
mice	O
(	O
25	O
-	O
32	O
g	O
)	O
were	O
given	O
nicotine	B-Chemical
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
or	O
saline	O
10	O
min	O
before	O
caffeine	B-Chemical
(	O
70	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
or	O
pentylenetetrazole	B-Chemical
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
injections	O
.	O
After	O
15	O
min	O
,	O
mice	O
were	O
evaluated	O
for	O
their	O
open	O
-	O
and	O
closed	O
-	O
arm	O
time	O
and	O
entries	O
on	O
the	O
EPM	O
for	O
a	O
10	O
-	O
min	O
session	O
.	O
Locomotor	O
activity	O
was	O
recorded	O
for	O
individual	O
groups	O
by	O
using	O
the	O
same	O
treatment	O
protocol	O
with	O
the	O
EPM	O
test	O
.	O
RESULTS	O
:	O
Nicotine	B-Chemical
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
itself	O
did	O
not	O
produce	O
any	O
significant	O
effect	O
in	O
the	O
EPM	O
test	O
,	O
whereas	O
caffeine	B-Chemical
(	O
70	O
mg	O
/	O
kg	O
)	O
and	O
pentylenetetrazole	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
produced	O
an	O
anxiogenic	O
effect	O
,	O
apparent	O
with	O
decreases	O
in	O
open	O
-	O
arm	O
time	O
and	O
entry	O
.	O
Nicotine	B-Chemical
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
pretreatment	O
blocked	O
the	O
caffeine	B-Chemical
-	O
but	O
not	O
pentylenetetrazole	B-Chemical
-	O
induced	O
anxiety	B-Disease
.	O
Administration	O
of	O
each	O
drug	O
and	O
their	O
combinations	O
did	O
not	O
produce	O
any	O
effect	O
on	O
locomotor	O
activity	O
.	O
CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
antagonistic	O
effect	O
of	O
nicotine	B-Chemical
on	O
caffeine	B-Chemical
-	O
induced	O
anxiety	B-Disease
is	O
specific	O
to	O
caffeine	B-Chemical
,	O
instead	O
of	O
a	O
non	O
-	O
specific	O
anxiolytic	O
effect	O
.	O
Thus	O
,	O
it	O
may	O
extend	O
the	O
current	O
findings	O
on	O
the	O
interaction	O
between	O
nicotine	B-Chemical
and	O
caffeine	B-Chemical
.	O
Long	O
term	O
hormone	O
therapy	O
for	O
perimenopausal	O
and	O
postmenopausal	O
women	O
.	O
BACKGROUND	O
:	O
Hormone	O
therapy	O
(	O
HT	O
)	O
is	O
widely	O
used	O
for	O
controlling	O
menopausal	B-Disease
symptoms	I-Disease
.	O
It	O
has	O
also	O
been	O
used	O
for	O
the	O
management	O
and	O
prevention	O
of	O
cardiovascular	B-Disease
disease	I-Disease
,	O
osteoporosis	B-Disease
and	O
dementia	B-Disease
in	O
older	O
women	O
but	O
the	O
evidence	O
supporting	O
its	O
use	O
for	O
these	O
indications	O
is	O
largely	O
observational	O
.	O
OBJECTIVES	O
:	O
To	O
assess	O
the	O
effect	O
of	O
long	O
-	O
term	O
HT	O
on	O
mortality	O
,	O
heart	B-Disease
disease	I-Disease
,	O
venous	B-Disease
thromboembolism	I-Disease
,	O
stroke	B-Disease
,	O
transient	B-Disease
ischaemic	I-Disease
attacks	I-Disease
,	O
breast	B-Disease
cancer	I-Disease
,	O
colorectal	B-Disease
cancer	I-Disease
,	O
ovarian	B-Disease
cancer	I-Disease
,	O
endometrial	B-Disease
cancer	I-Disease
,	O
gallbladder	B-Disease
disease	I-Disease
,	O
cognitive	O
function	O
,	O
dementia	B-Disease
,	O
fractures	B-Disease
and	O
quality	O
of	O
life	O
.	O
SEARCH	O
STRATEGY	O
:	O
We	O
searched	O
the	O
following	O
databases	O
up	O
to	O
November	O
2004	O
:	O
the	O
Cochrane	O
Menstrual	O
Disorders	O
and	O
Subfertility	O
Group	O
Trials	O
Register	O
,	O
Cochrane	O
Central	O
Register	O
of	O
Controlled	O
Trials	O
(	O
CENTRAL	O
)	O
,	O
MEDLINE	O
,	O
EMBASE	O
,	O
Biological	O
Abstracts	O
.	O
Relevant	O
non	O
-	O
indexed	O
journals	O
and	O
conference	O
abstracts	O
were	O
also	O
searched	O
.	O
SELECTION	O
CRITERIA	O
:	O
Randomised	O
double	O
-	O
blind	O
trials	O
of	O
HT	O
(	O
oestrogens	B-Chemical
with	O
or	O
without	O
progestogens	B-Chemical
)	O
versus	O
placebo	O
,	O
taken	O
for	O
at	O
least	O
one	O
year	O
by	O
perimenopausal	O
or	O
postmenopausal	O
women	O
.	O
DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Fifteen	O
RCTs	O
were	O
included	O
.	O
Trials	O
were	O
assessed	O
for	O
quality	O
and	O
two	O
review	O
authors	O
extracted	O
data	O
independently	O
.	O
They	O
calculated	O
risk	O
ratios	O
for	O
dichotomous	O
outcomes	O
and	O
weighted	O
mean	O
differences	O
for	O
continuous	O
outcomes	O
.	O
Clinical	O
heterogeneity	O
precluded	O
meta	O
-	O
analysis	O
for	O
most	O
outcomes	O
.	O
MAIN	O
RESULTS	O
:	O
All	O
the	O
statistically	O
significant	O
results	O
were	O
derived	O
from	O
the	O
two	O
biggest	O
trials	O
.	O
In	O
relatively	O
healthy	O
women	O
,	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
or	O
coronary	O
event	O
(	O
after	O
one	O
year	O
'	O
s	O
use	O
)	O
,	O
stroke	B-Disease
(	O
after	O
3	O
years	O
)	O
,	O
breast	B-Disease
cancer	I-Disease
(	O
after	O
5	O
years	O
)	O
and	O
gallbladder	B-Disease
disease	I-Disease
.	O
Long	O
-	O
term	O
oestrogen	B-Chemical
-	O
only	O
HT	O
also	O
significantly	O
increased	O
the	O
risk	O
of	O
stroke	B-Disease
and	O
gallbladder	B-Disease
disease	I-Disease
.	O
Overall	O
,	O
the	O
only	O
statistically	O
significant	O
benefits	O
of	O
HT	O
were	O
a	O
decreased	O
incidence	O
of	O
fractures	B-Disease
and	O
colon	B-Disease
cancer	I-Disease
with	O
long	O
-	O
term	O
use	O
.	O
Among	O
relatively	O
healthy	O
women	O
over	O
65	O
years	O
taking	O
continuous	O
combined	O
HT	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
increase	O
in	O
the	O
incidence	O
of	O
dementia	B-Disease
.	O
Among	O
women	O
with	O
cardiovascular	B-Disease
disease	I-Disease
,	O
long	O
-	O
term	O
use	O
of	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
.	O
No	O
trials	O
focussed	O
specifically	O
on	O
younger	O
women	O
.	O
However	O
,	O
one	O
trial	O
analysed	O
subgroups	O
of	O
2839	O
relatively	O
healthy	O
50	O
to	O
59	O
year	O
-	O
old	O
women	O
taking	O
combined	O
continuous	O
HT	O
and	O
1637	O
taking	O
oestrogen	B-Chemical
-	O
only	O
HT	O
,	O
versus	O
similar	O
-	O
sized	O
placebo	O
groups	O
.	O
The	O
only	O
significantly	O
increased	O
risk	O
reported	O
was	O
for	O
venous	B-Disease
thromboembolism	I-Disease
in	O
women	O
taking	O
combined	O
continuous	O
HT	O
;	O
their	O
absolute	O
risk	O
remained	O
very	O
low	O
.	O
AUTHORS	O
'	O
CONCLUSIONS	O
:	O
HT	O
is	O
not	O
indicated	O
for	O
the	O
routine	O
management	O
of	O
chronic	B-Disease
disease	I-Disease
.	O
We	O
need	O
more	O
evidence	O
on	O
the	O
safety	O
of	O
HT	O
for	O
menopausal	O
symptom	O
control	O
,	O
though	O
short	O
-	O
term	O
use	O
appears	O
to	O
be	O
relatively	O
safe	O
for	O
healthy	O
younger	O
women	O
.	O
Drug	B-Disease
-	I-Disease
induced	I-Disease
liver	I-Disease
injury	I-Disease
:	O
an	O
analysis	O
of	O
461	O
incidences	O
submitted	O
to	O
the	O
Spanish	O
registry	O
over	O
a	O
10	O
-	O
year	O
period	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
Progress	O
in	O
the	O
understanding	O
of	O
susceptibility	O
factors	O
to	O
drug	B-Disease
-	I-Disease
induced	I-Disease
liver	I-Disease
injury	I-Disease
(	O
DILI	B-Disease
)	O
and	O
outcome	O
predictability	O
are	O
hampered	O
by	O
the	O
lack	O
of	O
systematic	O
programs	O
to	O
detect	O
bona	O
fide	O
cases	O
.	O
METHODS	O
:	O
A	O
cooperative	O
network	O
was	O
created	O
in	O
1994	O
in	O
Spain	O
to	O
identify	O
all	O
suspicions	O
of	O
DILI	B-Disease
following	O
a	O
prospective	O
structured	O
report	O
form	O
.	O
The	O
liver	B-Disease
damage	I-Disease
was	O
characterized	O
according	O
to	O
hepatocellular	O
,	O
cholestatic	B-Disease
,	O
and	O
mixed	O
laboratory	O
criteria	O
and	O
to	O
histologic	O
criteria	O
when	O
available	O
.	O
Further	O
evaluation	O
of	O
causality	O
assessment	O
was	O
centrally	O
performed	O
.	O
RESULTS	O
:	O
Since	O
April	O
1994	O
to	O
August	O
2004	O
,	O
461	O
out	O
of	O
570	O
submitted	O
cases	O
,	O
involving	O
505	O
drugs	O
,	O
were	O
deemed	O
to	O
be	O
related	O
to	O
DILI	B-Disease
.	O
The	O
antiinfective	O
group	O
of	O
drugs	O
was	O
the	O
more	O
frequently	O
incriminated	O
,	O
amoxicillin	B-Chemical
-	I-Chemical
clavulanate	I-Chemical
accounting	O
for	O
the	O
12	O
.	O
8	O
%	O
of	O
the	O
whole	O
series	O
.	O
The	O
hepatocellular	O
pattern	O
of	O
damage	O
was	O
the	O
most	O
common	O
(	O
58	O
%	O
)	O
,	O
was	O
inversely	O
correlated	O
with	O
age	O
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
and	O
had	O
the	O
worst	O
outcome	O
(	O
Cox	O
regression	O
,	O
P	O
<	O
.	O
034	O
)	O
.	O
Indeed	O
,	O
the	O
incidence	O
of	O
liver	O
transplantation	O
and	O
death	O
in	O
this	O
group	O
was	O
11	O
.	O
7	O
%	O
if	O
patients	O
had	O
jaundice	B-Disease
at	O
presentation	O
,	O
whereas	O
the	O
corresponding	O
figure	O
was	O
3	O
.	O
8	O
%	O
in	O
nonjaundiced	O
patients	O
(	O
P	O
<	O
.	O
04	O
)	O
.	O
Factors	O
associated	O
with	O
the	O
development	O
of	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
were	O
female	O
sex	O
(	O
OR	O
=	O
25	O
;	O
95	O
%	O
CI	O
:	O
4	O
.	O
1	O
-	O
151	O
;	O
P	O
<	O
.	O
0001	O
)	O
,	O
hepatocellular	O
damage	O
(	O
OR	O
=	O
7	O
.	O
9	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
6	O
-	O
37	O
;	O
P	O
<	O
.	O
009	O
)	O
,	O
and	O
higher	O
baseline	O
plasma	O
bilirubin	B-Chemical
value	O
(	O
OR	O
=	O
1	O
.	O
15	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
09	O
-	O
1	O
.	O
22	O
;	O
P	O
<	O
.	O
0001	O
)	O
.	O
CONCLUSIONS	O
:	O
Patients	O
with	O
drug	O
-	O
induced	O
hepatocellular	O
jaundice	B-Disease
have	O
11	O
.	O
7	O
%	O
chance	O
of	O
progressing	O
to	O
death	O
or	O
transplantation	O
.	O
Amoxicillin	B-Chemical
-	I-Chemical
clavulanate	I-Chemical
stands	O
out	O
as	O
the	O
most	O
common	O
drug	O
related	O
to	O
DILI	B-Disease
.	O
Morphological	O
evaluation	O
of	O
the	O
effect	O
of	O
d	B-Chemical
-	I-Chemical
ribose	I-Chemical
on	O
adriamycin	B-Chemical
-	O
evoked	O
cardiotoxicity	B-Disease
in	O
rats	O
.	O
The	O
influence	O
of	O
d	B-Chemical
-	I-Chemical
ribose	I-Chemical
on	O
adriamycin	B-Chemical
-	O
induced	O
myocardiopathy	B-Disease
in	O
rats	O
was	O
studied	O
.	O
Adriamycin	B-Chemical
in	O
the	O
cumulative	O
dose	O
of	O
25	O
mg	O
/	O
kg	O
evoked	O
fully	O
developed	O
cardiac	B-Disease
toxicity	I-Disease
.	O
D	B-Chemical
-	I-Chemical
ribose	I-Chemical
in	O
the	O
multiple	O
doses	O
of	O
200	O
mg	O
/	O
kg	O
did	O
not	O
influence	O
ADR	B-Chemical
cardiotoxicity	B-Disease
.	O
In	O
vivo	O
evidences	O
suggesting	O
the	O
role	O
of	O
oxidative	O
stress	O
in	O
pathogenesis	O
of	O
vancomycin	B-Chemical
-	O
induced	O
nephrotoxicity	B-Disease
:	O
protection	O
by	O
erdosteine	B-Chemical
.	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
examine	O
vancomycin	B-Chemical
(	O
VCM	B-Chemical
)	O
-	O
induced	O
oxidative	O
stress	O
that	O
promotes	O
production	O
of	O
reactive	O
oxygen	B-Chemical
species	O
(	O
ROS	O
)	O
and	O
to	O
investigate	O
the	O
role	O
of	O
erdosteine	B-Chemical
,	O
an	O
expectorant	O
agent	O
,	O
which	O
has	O
also	O
antioxidant	O
properties	O
,	O
on	O
kidney	O
tissue	O
against	O
the	O
possible	O
VCM	B-Chemical
-	O
induced	O
renal	B-Disease
impairment	I-Disease
in	O
rats	O
.	O
Rats	O
were	O
divided	O
into	O
three	O
groups	O
:	O
sham	O
,	O
VCM	B-Chemical
and	O
VCM	B-Chemical
plus	O
erdosteine	B-Chemical
.	O
VCM	B-Chemical
was	O
administrated	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
with	O
200mgkg	O
(	O
-	O
1	O
)	O
twice	O
daily	O
for	O
7	O
days	O
.	O
Erdosteine	B-Chemical
was	O
administered	O
orally	O
.	O
VCM	B-Chemical
administration	O
to	O
control	O
rats	O
significantly	O
increased	O
renal	O
malondialdehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
and	O
urinary	O
N	O
-	O
acetyl	O
-	O
beta	O
-	O
d	O
-	O
glucosaminidase	O
(	O
NAG	O
,	O
a	O
marker	O
of	O
renal	B-Disease
tubular	I-Disease
injury	I-Disease
)	O
excretion	O
but	O
decreased	O
superoxide	B-Chemical
dismutase	O
(	O
SOD	O
)	O
and	O
catalase	O
(	O
CAT	O
)	O
activities	O
.	O
Erdosteine	B-Chemical
administration	O
with	O
VCM	B-Chemical
injections	O
caused	O
significantly	O
decreased	O
renal	O
MDA	B-Chemical
and	O
urinary	O
NAG	O
excretion	O
,	O
and	O
increased	O
SOD	O
activity	O
,	O
but	O
not	O
CAT	O
activity	O
in	O
renal	O
tissue	O
when	O
compared	O
with	O
VCM	B-Chemical
alone	O
.	O
Erdosteine	B-Chemical
showed	O
histopathological	O
protection	O
against	O
VCM	B-Chemical
-	O
induced	O
nephrotoxicity	B-Disease
.	O
There	O
were	O
a	O
significant	O
dilatation	O
of	O
tubular	O
lumens	O
,	O
extensive	O
epithelial	O
cell	O
vacuolization	O
,	O
atrophy	B-Disease
,	O
desquamation	B-Disease
,	O
and	O
necrosis	B-Disease
in	O
VCM	B-Chemical
-	O
treated	O
rats	O
more	O
than	O
those	O
of	O
the	O
control	O
and	O
the	O
erdosteine	B-Chemical
groups	O
.	O
Erdosteine	B-Chemical
caused	O
a	O
marked	O
reduction	O
in	O
the	O
extent	O
of	O
tubular	O
damage	O
.	O
It	O
is	O
concluded	O
that	O
oxidative	O
tubular	O
damage	O
plays	O
an	O
important	O
role	O
in	O
the	O
VCM	B-Chemical
-	O
induced	O
nephrotoxicity	B-Disease
and	O
the	O
modulation	O
of	O
oxidative	O
stress	O
with	O
erdosteine	B-Chemical
reduces	O
the	O
VCM	B-Chemical
-	O
induced	O
kidney	B-Disease
damage	I-Disease
both	O
at	O
the	O
biochemical	O
and	O
histological	O
levels	O
.	O
Gemfibrozil	B-Chemical
-	O
lovastatin	B-Chemical
therapy	O
for	O
primary	O
hyperlipoproteinemias	B-Disease
.	O
The	O
specific	O
aim	O
of	O
this	O
retrospective	O
,	O
observational	O
study	O
was	O
to	O
assess	O
safety	O
and	O
efficacy	O
of	O
long	O
-	O
term	O
(	O
21	O
months	O
/	O
patient	O
)	O
,	O
open	O
-	O
label	O
,	O
gemfibrozil	B-Chemical
-	O
lovastatin	B-Chemical
treatment	O
in	O
80	O
patients	O
with	O
primary	O
mixed	O
hyperlipidemia	B-Disease
(	O
68	O
%	O
of	O
whom	O
had	O
atherosclerotic	B-Disease
vascular	I-Disease
disease	I-Disease
)	O
.	O
Because	O
ideal	O
lipid	O
targets	O
were	O
not	O
reached	O
(	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	B-Chemical
less	O
than	O
130	O
mg	O
/	O
dl	O
,	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	B-Chemical
greater	O
than	O
35	O
mg	O
/	O
dl	O
,	O
or	O
total	O
cholesterol	B-Chemical
/	O
HDL	O
cholesterol	B-Chemical
less	O
than	O
4	O
.	O
5	O
mg	O
/	O
dl	O
)	O
with	O
diet	O
plus	O
a	O
single	O
drug	O
,	O
gemfibrozil	B-Chemical
(	O
1	O
.	O
2	O
g	O
/	O
day	O
)	O
-	O
lovastatin	B-Chemical
(	O
primarily	O
20	O
or	O
40	O
mg	O
)	O
treatment	O
was	O
given	O
.	O
Follow	O
-	O
up	O
visits	O
were	O
scheduled	O
with	O
2	O
-	O
drug	O
therapy	O
every	O
6	O
to	O
8	O
weeks	O
,	O
an	O
average	O
of	O
10	O
.	O
3	O
visits	O
per	O
patient	O
,	O
with	O
741	O
batteries	O
of	O
6	O
liver	O
function	O
tests	O
and	O
714	O
creatine	B-Chemical
phosphokinase	O
levels	O
measured	O
.	O
Only	O
1	O
of	O
the	O
4	O
,	O
446	O
liver	O
function	O
tests	O
(	O
0	O
.	O
02	O
%	O
)	O
,	O
a	O
gamma	O
glutamyl	O
transferase	O
,	O
was	O
greater	O
than	O
or	O
equal	O
to	O
3	O
times	O
the	O
upper	O
normal	O
limit	O
.	O
Of	O
the	O
714	O
creatine	B-Chemical
phosphokinase	O
levels	O
,	O
9	O
%	O
were	O
high	O
;	O
only	O
1	O
(	O
0	O
.	O
1	O
%	O
)	O
was	O
greater	O
than	O
or	O
equal	O
to	O
3	O
times	O
the	O
upper	O
normal	O
limit	O
.	O
With	O
2	O
-	O
drug	O
therapy	O
,	O
mean	O
total	O
cholesterol	B-Chemical
decreased	O
22	O
%	O
from	O
255	O
to	O
200	O
mg	O
/	O
dl	O
,	O
triglyceride	B-Chemical
levels	O
decreased	O
35	O
%	O
from	O
236	O
to	O
154	O
mg	O
/	O
dl	O
,	O
LDL	O
cholesterol	B-Chemical
decreased	O
26	O
%	O
from	O
176	O
to	O
131	O
mg	O
/	O
dl	O
,	O
and	O
the	O
total	O
cholesterol	B-Chemical
/	O
HDL	O
cholesterol	B-Chemical
ratio	O
decreased	O
24	O
%	O
from	O
7	O
.	O
1	O
to	O
5	O
.	O
4	O
,	O
all	O
p	O
less	O
than	O
or	O
equal	O
to	O
0	O
.	O
0001	O
.	O
Myositis	B-Disease
,	O
attributable	O
to	O
the	O
drug	O
combination	O
and	O
symptomatic	O
enough	O
to	O
discontinue	O
it	O
,	O
occurred	O
in	O
3	O
%	O
of	O
patients	O
,	O
and	O
in	O
1	O
%	O
with	O
concurrent	O
high	O
creatine	B-Chemical
phosphokinase	O
(	O
769	O
U	O
/	O
liter	O
)	O
;	O
no	O
patients	O
had	O
rhabdomyolysis	B-Disease
or	O
myoglobinuria	B-Disease
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Does	O
domperidone	B-Chemical
potentiate	O
mirtazapine	B-Chemical
-	O
associated	O
restless	B-Disease
legs	I-Disease
syndrome	I-Disease
?	O
There	O
is	O
now	O
evidence	O
to	O
suggest	O
a	O
central	O
role	O
for	O
the	O
dopaminergic	O
system	O
in	O
restless	B-Disease
legs	I-Disease
syndrome	I-Disease
(	O
RLS	B-Disease
)	O
.	O
For	O
example	O
,	O
the	O
symptoms	O
of	O
RLS	B-Disease
can	O
be	O
dramatically	O
improved	O
by	O
levodopa	B-Chemical
and	O
dopamine	B-Chemical
agonists	O
,	O
whereas	O
central	O
dopamine	B-Chemical
D2	O
receptor	O
antagonists	O
can	O
induce	O
or	O
aggravate	O
RLS	B-Disease
symptoms	O
.	O
To	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
previous	O
report	O
regarding	O
whether	O
domperidone	B-Chemical
,	O
a	O
peripheral	O
dopamine	B-Chemical
D2	O
receptor	O
antagonist	O
,	O
can	O
also	O
induce	O
or	O
aggravate	O
symptoms	O
of	O
RLS	B-Disease
.	O
Mirtazapine	B-Chemical
,	O
the	O
first	O
noradrenergic	O
and	O
specific	O
serotonergic	O
antidepressant	O
(	O
NaSSA	O
)	O
,	O
has	O
been	O
associated	O
with	O
RLS	B-Disease
in	O
several	O
recent	O
publications	O
.	O
The	O
authors	O
report	O
here	O
a	O
depressed	O
patient	O
comorbid	O
with	O
postprandial	B-Disease
dyspepsia	I-Disease
who	O
developed	O
RLS	B-Disease
after	O
mirtazapine	B-Chemical
had	O
been	O
added	O
to	O
his	O
domperidone	B-Chemical
therapy	O
.	O
Our	O
patient	O
started	O
to	O
have	O
symptoms	O
of	O
RLS	B-Disease
only	O
after	O
he	O
had	O
been	O
treated	O
with	O
mirtazapine	B-Chemical
,	O
and	O
his	O
RLS	B-Disease
symptoms	O
resolved	O
completely	O
upon	O
discontinuation	O
of	O
his	O
mirtazapine	B-Chemical
.	O
Such	O
a	O
temporal	O
relationship	O
between	O
the	O
use	O
of	O
mirtazapine	B-Chemical
and	O
the	O
symptoms	O
of	O
RLS	B-Disease
in	O
our	O
patient	O
did	O
not	O
support	O
a	O
potentiating	O
effect	O
of	O
domperione	B-Chemical
on	O
mirtazapine	B-Chemical
-	O
associated	O
RLS	B-Disease
.	O
However	O
,	O
physicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
mirtazapine	B-Chemical
can	O
be	O
associated	O
with	O
RLS	B-Disease
in	O
some	O
individuals	O
,	O
especially	O
those	O
receiving	O
concomitant	O
dopamine	B-Chemical
D2	O
receptor	O
antagonists	O
.	O
Antiandrogenic	O
therapy	O
can	O
cause	O
coronary	B-Disease
arterial	I-Disease
disease	I-Disease
.	O
AIM	O
:	O
To	O
study	O
the	O
change	O
of	O
lipid	O
metabolism	O
by	O
antiandrogen	O
therapy	O
in	O
patients	O
with	O
prostate	B-Disease
cancer	I-Disease
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
We	O
studied	O
with	O
a	O
2	O
.	O
5	O
years	O
follow	O
-	O
up	O
the	O
changes	O
in	O
plasma	O
cholesterols	B-Chemical
(	O
C	B-Chemical
)	O
,	O
triglycerides	B-Chemical
(	O
TG	B-Chemical
)	O
,	O
lipoproteins	O
(	O
LP	O
)	O
,	O
and	O
apolipoproteins	O
(	O
Apo	O
)	O
B	O
-	O
100	O
,	O
A	O
-	O
I	O
,	O
and	O
A	O
-	O
II	O
pro	O
fi	O
les	O
in	O
24	O
patients	O
of	O
mean	O
age	O
60	O
years	O
with	O
low	O
risk	O
prostate	B-Disease
cancer	I-Disease
(	O
stage	O
:	O
T1cN0M0	O
,	O
Gleason	O
score	O
:	O
2	O
-	O
5	O
)	O
during	O
treatment	O
with	O
cyproterone	B-Chemical
acetate	I-Chemical
(	O
CPA	B-Chemical
)	O
without	O
surgical	O
management	O
or	O
radiation	O
therapy	O
.	O
RESULTS	O
:	O
Significant	O
decreases	O
of	O
HDL	O
-	O
C	O
,	O
Apo	O
A	O
-	O
I	O
and	O
Apo	O
A	O
-	O
II	O
and	O
an	O
increase	O
of	O
triglyceride	B-Chemical
levels	O
in	O
VLDL	O
were	O
induced	O
by	O
CPA	B-Chemical
.	O
After	O
a	O
period	O
of	O
2	O
.	O
5	O
years	O
on	O
CPA	B-Chemical
treatment	O
,	O
four	O
patients	O
out	O
of	O
twenty	O
-	O
four	O
were	O
found	O
to	O
be	O
affected	O
by	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
.	O
CONCLUSIONS	O
:	O
Ischaemic	O
coronary	B-Disease
arteriosclerosis	I-Disease
with	O
an	O
incidence	O
rate	O
of	O
16	O
.	O
6	O
%	O
as	O
caused	O
by	O
prolonged	O
CPA	B-Chemical
therapy	O
is	O
mediated	O
through	O
changes	O
in	O
HDL	O
cholesterol	B-Chemical
,	O
Apo	O
A	O
-	O
I	O
and	O
Apo	O
A	O
-	O
II	O
pro	O
fi	O
les	O
,	O
other	O
than	O
the	O
well	O
-	O
known	O
hyperglyceridemic	B-Disease
effect	I-Disease
caused	O
by	O
estrogen	B-Chemical
.	O
5	B-Chemical
-	I-Chemical
Fluorouracil	I-Chemical
cardiotoxicity	B-Disease
induced	O
by	O
alpha	B-Chemical
-	I-Chemical
fluoro	I-Chemical
-	I-Chemical
beta	I-Chemical
-	I-Chemical
alanine	I-Chemical
.	O
Cardiotoxicity	B-Disease
is	O
a	O
rare	O
complication	O
occurring	O
during	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
treatment	O
for	O
malignancies	B-Disease
.	O
We	O
herein	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
man	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
,	O
in	O
whom	O
a	O
high	O
serum	O
level	O
of	O
alpha	B-Chemical
-	I-Chemical
fluoro	I-Chemical
-	I-Chemical
beta	I-Chemical
-	I-Chemical
alanine	I-Chemical
(	O
FBAL	B-Chemical
)	O
was	O
observed	O
.	O
The	O
patient	O
,	O
who	O
had	O
unresectable	O
colon	B-Disease
cancer	I-Disease
metastases	O
to	O
the	O
liver	O
and	O
lung	O
,	O
was	O
referred	O
to	O
us	O
for	O
chemotherapy	O
from	O
an	O
affiliated	O
hospital	O
;	O
he	O
had	O
no	O
cardiac	O
history	O
.	O
After	O
admission	O
,	O
the	O
patient	O
received	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
(	O
1000	O
mg	O
/	O
day	O
)	O
,	O
during	O
which	O
precordial	B-Disease
pain	I-Disease
with	O
right	B-Disease
bundle	I-Disease
branch	I-Disease
block	I-Disease
occurred	O
concomitantly	O
with	O
a	O
high	O
serum	O
FBAL	B-Chemical
concentration	O
of	O
1955	O
ng	O
/	O
ml	O
.	O
Both	O
the	O
precordial	B-Disease
pain	I-Disease
and	O
the	O
electrocardiographic	O
changes	O
disappeared	O
spontaneously	O
after	O
the	O
discontinuation	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O
As	O
the	O
precordial	B-Disease
pain	I-Disease
in	O
this	O
patient	O
was	O
considered	O
to	O
have	O
been	O
due	O
to	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
,	O
the	O
administration	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
was	O
abandoned	O
.	O
Instead	O
,	O
oral	O
administration	O
of	O
S	O
-	O
1	O
(	O
a	O
derivative	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
,	O
at	O
200	O
mg	O
/	O
day	O
twice	O
a	O
week	O
,	O
was	O
instituted	O
,	O
because	O
S	O
-	O
1	O
has	O
a	O
strong	O
inhibitory	O
effect	O
on	O
dihydropyrimidine	B-Chemical
dehydrogenase	O
,	O
which	O
catalyzes	O
the	O
degradative	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
into	O
FBAL	B-Chemical
.	O
The	O
serum	O
FBAL	B-Chemical
concentration	O
subsequently	O
decreased	O
to	O
352	O
ng	O
/	O
ml	O
,	O
the	O
same	O
as	O
the	O
value	O
measured	O
on	O
the	O
first	O
day	O
of	O
S	O
-	O
1	O
administration	O
.	O
Thereafter	O
,	O
no	O
cardiac	B-Disease
symptoms	I-Disease
were	O
observed	O
.	O
The	O
patient	O
achieved	O
a	O
partial	O
response	O
6	O
months	O
after	O
the	O
initiation	O
of	O
the	O
S	O
-	O
1	O
treatment	O
.	O
The	O
experience	O
of	O
this	O
case	O
,	O
together	O
with	O
a	O
review	O
of	O
the	O
literature	O
,	O
suggests	O
that	O
FBAL	B-Chemical
is	O
related	O
to	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
S	O
-	O
1	O
may	O
be	O
administered	O
safely	O
to	O
patients	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
Hepatocellular	B-Disease
carcinoma	I-Disease
in	O
Fanconi	B-Disease
'	I-Disease
s	I-Disease
anemia	I-Disease
treated	O
with	O
androgen	B-Chemical
and	O
corticosteroid	B-Chemical
.	O
The	O
case	O
of	O
an	O
11	O
-	O
year	O
-	O
old	O
boy	O
is	O
reported	O
who	O
was	O
known	O
to	O
have	O
Fanconi	B-Disease
'	I-Disease
s	I-Disease
anemia	I-Disease
for	O
3	O
years	O
and	O
was	O
treated	O
with	O
androgens	B-Chemical
,	O
corticosteroids	B-Chemical
and	O
transfusions	O
.	O
Two	O
weeks	O
before	O
his	O
death	O
he	O
was	O
readmitted	O
because	O
of	O
aplastic	O
crisis	O
with	O
septicemia	B-Disease
and	O
marked	O
abnormalities	O
in	O
liver	O
function	O
and	O
died	O
of	O
hemorrhagic	B-Disease
bronchopneumonia	I-Disease
.	O
At	O
autopsy	O
peliosis	B-Disease
and	O
multiple	O
hepatic	B-Disease
tumors	I-Disease
were	O
found	O
which	O
histologically	O
proved	O
to	O
be	O
well	O
-	O
differentiated	O
hepatocellular	B-Disease
carcinoma	I-Disease
.	O
This	O
case	O
contributes	O
to	O
the	O
previous	O
observations	O
that	O
non	O
-	O
metastasizing	O
hepatic	B-Disease
neoplasms	I-Disease
and	O
peliosis	B-Disease
can	O
develop	O
in	O
patients	O
with	O
androgen	B-Chemical
-	O
and	O
corticosteroid	B-Chemical
-	O
treated	O
Fanconi	B-Disease
'	I-Disease
s	I-Disease
anemia	I-Disease
.	O
The	O
influence	O
of	O
the	O
time	O
interval	O
between	O
monoHER	B-Chemical
and	O
doxorubicin	B-Chemical
administration	O
on	O
the	O
protection	O
against	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
in	O
mice	O
.	O
PURPOSE	O
:	O
Despite	O
its	O
well	O
-	O
known	O
cardiotoxicity	B-Disease
,	O
the	O
anthracyclin	O
doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
continues	O
to	O
be	O
an	O
effective	O
and	O
widely	O
used	O
chemotherapeutic	O
agent	O
.	O
DOX	B-Chemical
-	O
induced	O
cardiac	B-Disease
damage	I-Disease
presumably	O
results	O
from	O
the	O
formation	O
of	O
free	O
radicals	O
by	O
DOX	B-Chemical
.	O
Reactive	O
oxygen	B-Chemical
species	O
particularly	O
affect	O
the	O
cardiac	O
myocytes	O
because	O
these	O
cells	O
seem	O
to	O
have	O
a	O
relatively	O
poor	O
antioxidant	O
defense	O
system	O
.	O
The	O
semisynthetic	O
flavonoid	B-Chemical
monohydroxyethylrutoside	B-Chemical
(	O
monoHER	B-Chemical
)	O
showed	O
cardioprotection	O
against	O
DOX	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
through	O
its	O
radical	O
scavenging	O
and	O
iron	B-Chemical
chelating	O
properties	O
.	O
Because	O
of	O
the	O
relatively	O
short	O
final	O
half	O
-	O
life	O
of	O
monoHER	B-Chemical
(	O
about	O
30	O
min	O
)	O
,	O
it	O
is	O
expected	O
that	O
the	O
time	O
interval	O
between	O
monoHER	B-Chemical
and	O
DOX	B-Chemical
might	O
be	O
of	O
influence	O
on	O
the	O
cardioprotective	O
effect	O
of	O
monoHER	B-Chemical
.	O
Therefore	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
this	O
possible	O
effect	O
.	O
METHODS	O
:	O
Six	O
groups	O
of	O
6	O
BALB	O
/	O
c	O
mice	O
were	O
treated	O
with	O
saline	O
,	O
DOX	B-Chemical
alone	O
or	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
preceded	O
by	O
monoHER	B-Chemical
(	O
500	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
with	O
an	O
interval	O
of	O
10	O
,	O
30	O
,	O
60	O
or	O
120	O
min	O
.	O
After	O
a	O
6	O
-	O
week	O
treatment	O
period	O
and	O
additional	O
observation	O
for	O
2	O
weeks	O
,	O
the	O
mice	O
were	O
sacrificed	O
.	O
Their	O
cardiac	O
tissues	O
were	O
processed	O
for	O
light	O
microscopy	O
,	O
after	O
which	O
cardiomyocyte	B-Disease
damage	I-Disease
was	O
evaluated	O
according	O
to	O
Billingham	O
(	O
in	O
Cancer	B-Disease
Treat	O
Rep	O
62	O
(	O
6	O
)	O
:	O
865	O
-	O
872	O
,	O
1978	O
)	O
.	O
Microscopic	O
evaluation	O
revealed	O
that	O
treatment	O
with	O
DOX	B-Chemical
alone	O
induced	O
significant	O
cardiac	B-Disease
damage	I-Disease
in	O
comparison	O
to	O
the	O
saline	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
RESULTS	O
:	O
The	O
number	O
of	O
damaged	O
cardiomyocytes	O
was	O
9	O
.	O
6	O
-	O
fold	O
(	O
95	O
%	O
CI	O
4	O
.	O
4	O
-	O
21	O
.	O
0	O
)	O
higher	O
in	O
mice	O
treated	O
with	O
DOX	B-Chemical
alone	O
than	O
that	O
in	O
animals	O
of	O
the	O
control	O
group	O
.	O
The	O
ratio	O
of	O
aberrant	O
cardiomyocytes	O
in	O
mice	O
treated	O
with	O
DOX	B-Chemical
preceded	O
by	O
monoHER	B-Chemical
and	O
those	O
in	O
mice	O
treated	O
with	O
saline	O
ranged	O
from	O
1	O
.	O
6	O
to	O
2	O
.	O
8	O
(	O
mean	O
2	O
.	O
2	O
,	O
95	O
%	O
CI	O
1	O
.	O
2	O
-	O
4	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
019	O
)	O
.	O
The	O
mean	O
protective	O
effect	O
by	O
adding	O
monoHER	B-Chemical
before	O
DOX	B-Chemical
led	O
to	O
a	O
significant	O
4	O
.	O
4	O
-	O
fold	O
reduction	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
95	O
%	O
CI	O
2	O
.	O
3	O
-	O
8	O
.	O
2	O
)	O
of	O
abnormal	O
cardiomyocytes	O
.	O
This	O
protective	O
effect	O
did	O
not	O
depend	O
on	O
the	O
time	O
interval	O
between	O
monoHER	B-Chemical
and	O
DOX	B-Chemical
administration	O
(	O
P	O
=	O
0	O
.	O
345	O
)	O
.	O
CONCLUSION	O
:	O
The	O
results	O
indicate	O
that	O
in	O
an	O
outpatient	O
clinical	O
setting	O
monoHER	B-Chemical
may	O
be	O
administered	O
shortly	O
before	O
DOX	B-Chemical
.	O
Clinical	O
evaluation	O
of	O
adverse	O
effects	O
during	O
bepridil	B-Chemical
administration	O
for	O
atrial	B-Disease
fibrillation	I-Disease
and	I-Disease
flutter	I-Disease
.	O
BACKGROUND	O
:	O
Bepridil	B-Chemical
hydrochloride	I-Chemical
(	O
Bpd	B-Chemical
)	O
has	O
attracted	O
attention	O
as	O
an	O
effective	O
drug	O
for	O
atrial	B-Disease
fibrillation	I-Disease
(	O
AF	B-Disease
)	O
and	O
atrial	B-Disease
flutter	I-Disease
(	O
AFL	B-Disease
)	O
.	O
However	O
,	O
serious	O
adverse	O
effects	O
,	O
including	O
torsade	B-Disease
de	I-Disease
pointes	I-Disease
(	O
Tdp	B-Disease
)	O
,	O
have	O
been	O
reported	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
Adverse	O
effects	O
of	O
Bpd	B-Chemical
requiring	O
discontinuation	O
of	O
treatment	O
were	O
evaluated	O
.	O
Bpd	B-Chemical
was	O
administered	O
to	O
459	O
patients	O
(	O
361	O
males	O
,	O
63	O
+	O
/	O
-	O
12	O
years	O
old	O
)	O
comprising	O
378	O
AF	B-Disease
and	O
81	O
AFL	B-Disease
cases	O
.	O
Mean	O
left	O
ventricular	O
ejection	O
fraction	O
and	O
atrial	O
dimension	O
(	O
LAD	O
)	O
were	O
66	O
+	O
/	O
-	O
11	O
%	O
and	O
40	O
+	O
/	O
-	O
6	O
mm	O
,	O
respectively	O
.	O
Adverse	O
effects	O
were	O
observed	O
in	O
19	O
patients	O
(	O
4	O
%	O
)	O
during	O
an	O
average	O
follow	O
-	O
up	O
of	O
20	O
months	O
.	O
There	O
was	O
marked	O
QT	B-Disease
prolongation	I-Disease
greater	O
than	O
0	O
.	O
55	O
s	O
in	O
13	O
patients	O
,	O
bradycardia	B-Disease
less	O
than	O
40	O
beats	O
/	O
min	O
in	O
6	O
patients	O
,	O
dizziness	B-Disease
and	O
general	O
fatigue	B-Disease
in	O
1	O
patient	O
each	O
.	O
In	O
4	O
of	O
13	O
patients	O
with	O
QT	B-Disease
prolongation	I-Disease
,	O
Tdp	B-Disease
occurred	O
.	O
The	O
major	O
triggering	O
factors	O
of	O
Tdp	B-Disease
were	O
hypokalemia	B-Disease
and	O
sudden	O
decrease	O
in	O
heart	O
rate	O
.	O
There	O
were	O
no	O
differences	O
in	O
the	O
clinical	O
backgrounds	O
of	O
the	O
patients	O
with	O
and	O
without	O
Tdp	B-Disease
other	O
than	O
LAD	O
and	O
age	O
,	O
which	O
were	O
larger	O
and	O
older	O
in	O
the	O
patients	O
with	O
Tdp	B-Disease
.	O
CONCLUSION	O
:	O
Careful	O
observation	O
of	O
serum	O
potassium	B-Chemical
concentration	O
and	O
the	O
ECG	O
should	O
always	O
be	O
done	O
during	O
Bpd	B-Chemical
administration	O
,	O
particularly	O
in	O
elderly	O
patients	O
.	O
Enhanced	O
isoproterenol	B-Chemical
-	O
induced	O
cardiac	B-Disease
hypertrophy	I-Disease
in	O
transgenic	O
rats	O
with	O
low	O
brain	O
angiotensinogen	O
.	O
We	O
have	O
previously	O
shown	O
that	O
a	O
permanent	O
deficiency	O
in	O
the	O
brain	O
renin	O
-	O
angiotensin	B-Chemical
system	O
(	O
RAS	O
)	O
may	O
increase	O
the	O
sensitivity	O
of	O
the	O
baroreflex	O
control	O
of	O
heart	O
rate	O
.	O
In	O
this	O
study	O
we	O
aimed	O
at	O
studying	O
the	O
involvement	O
of	O
the	O
brain	O
RAS	O
in	O
the	O
cardiac	O
reactivity	O
to	O
the	O
beta	O
-	O
adrenoceptor	O
(	O
beta	O
-	O
AR	O
)	O
agonist	O
isoproterenol	B-Chemical
(	O
Iso	B-Chemical
)	O
.	O
Transgenic	O
rats	O
with	O
low	O
brain	O
angiotensinogen	O
(	O
TGR	O
)	O
were	O
used	O
.	O
In	O
isolated	O
hearts	O
,	O
Iso	B-Chemical
induced	O
a	O
significantly	O
greater	O
increase	O
in	O
left	O
ventricular	O
(	O
LV	O
)	O
pressure	O
and	O
maximal	O
contraction	O
(	O
+	O
dP	O
/	O
dt	O
(	O
max	O
)	O
)	O
in	O
the	O
TGR	O
than	O
in	O
the	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
.	O
LV	B-Disease
hypertrophy	I-Disease
induced	O
by	O
Iso	B-Chemical
treatment	O
was	O
significantly	O
higher	O
in	O
TGR	O
than	O
in	O
SD	O
rats	O
(	O
in	O
g	O
LV	O
wt	O
/	O
100	O
g	O
body	O
wt	O
,	O
0	O
.	O
28	O
+	O
/	O
-	O
0	O
.	O
004	O
vs	O
.	O
0	O
.	O
24	O
+	O
/	O
-	O
0	O
.	O
004	O
,	O
respectively	O
)	O
.	O
The	O
greater	O
LV	B-Disease
hypertrophy	I-Disease
in	O
TGR	O
rats	O
was	O
associated	O
with	O
more	O
pronounced	O
downregulation	O
of	O
beta	O
-	O
AR	O
and	O
upregulation	O
of	O
LV	O
beta	O
-	O
AR	O
kinase	O
-	O
1	O
mRNA	O
levels	O
compared	O
with	O
those	O
in	O
SD	O
rats	O
.	O
The	O
decrease	O
in	O
the	O
heart	O
rate	O
(	O
HR	O
)	O
induced	O
by	O
the	O
beta	O
-	O
AR	O
antagonist	O
metoprolol	B-Chemical
in	O
conscious	O
rats	O
was	O
significantly	O
attenuated	O
in	O
TGR	O
compared	O
with	O
SD	O
rats	O
(	O
-	O
9	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
7	O
%	O
vs	O
.	O
-	O
18	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
5	O
%	O
)	O
,	O
whereas	O
the	O
effect	O
of	O
parasympathetic	O
blockade	O
by	O
atropine	B-Chemical
on	O
HR	O
was	O
similar	O
in	O
both	O
strains	O
.	O
These	O
results	O
indicate	O
that	O
TGR	O
are	O
more	O
sensitive	O
to	O
beta	O
-	O
AR	O
agonist	O
-	O
induced	O
cardiac	B-Disease
inotropic	I-Disease
response	O
and	O
hypertrophy	B-Disease
,	O
possibly	O
due	O
to	O
chronically	O
low	O
sympathetic	O
outflow	O
directed	O
to	O
the	O
heart	O
.	O
Drug	O
-	O
induced	O
long	B-Disease
QT	I-Disease
syndrome	I-Disease
in	O
injection	O
drug	O
users	O
receiving	O
methadone	B-Chemical
:	O
high	O
frequency	O
in	O
hospitalized	O
patients	O
and	O
risk	O
factors	O
.	O
BACKGROUND	O
:	O
Drug	O
-	O
induced	O
long	B-Disease
QT	I-Disease
syndrome	I-Disease
is	O
a	O
serious	O
adverse	O
drug	O
reaction	O
.	O
Methadone	B-Chemical
prolongs	O
the	O
QT	O
interval	O
in	O
vitro	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
In	O
the	O
inpatient	O
setting	O
,	O
the	O
frequency	O
of	O
QT	B-Disease
interval	I-Disease
prolongation	I-Disease
with	O
methadone	B-Chemical
treatment	O
,	O
its	O
dose	O
dependence	O
,	O
and	O
the	O
importance	O
of	O
cofactors	O
such	O
as	O
drug	O
-	O
drug	O
interactions	O
remain	O
unknown	O
.	O
METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
,	O
retrospective	O
study	O
comparing	O
active	O
or	O
former	O
intravenous	O
drug	O
users	O
receiving	O
methadone	B-Chemical
and	O
those	O
not	O
receiving	O
methadone	B-Chemical
among	O
all	O
patients	O
hospitalized	O
over	O
a	O
5	O
-	O
year	O
period	O
in	O
a	O
tertiary	O
care	O
hospital	O
.	O
A	O
total	O
of	O
167	O
patients	O
receiving	O
methadone	B-Chemical
fulfilled	O
the	O
inclusion	O
criteria	O
and	O
were	O
compared	O
with	O
a	O
control	O
group	O
of	O
80	O
injection	O
drug	O
users	O
not	O
receiving	O
methadone	B-Chemical
.	O
In	O
addition	O
to	O
methadone	B-Chemical
dose	O
,	O
15	O
demographic	O
,	O
biological	O
,	O
and	O
pharmacological	O
variables	O
were	O
considered	O
as	O
potential	O
risk	O
factors	O
for	O
QT	B-Disease
prolongation	I-Disease
.	O
RESULTS	O
:	O
Among	O
167	O
methadone	B-Chemical
maintenance	O
patients	O
,	O
the	O
prevalence	O
of	O
QTc	O
prolongation	O
to	O
0	O
.	O
50	O
second	O
(	O
(	O
1	O
/	O
2	O
)	O
)	O
or	O
longer	O
was	O
16	O
.	O
2	O
%	O
compared	O
with	O
0	O
%	O
in	O
80	O
control	O
subjects	O
.	O
Six	O
patients	O
(	O
3	O
.	O
6	O
%	O
)	O
in	O
the	O
methadone	B-Chemical
group	O
presented	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
.	O
QTc	O
length	O
was	O
weakly	O
but	O
significantly	O
associated	O
with	O
methadone	B-Chemical
daily	O
dose	O
(	O
Spearman	O
rank	O
correlation	O
coefficient	O
,	O
0	O
.	O
20	O
;	O
P	O
<	O
.	O
01	O
)	O
.	O
Multivariate	O
regression	O
analysis	O
allowed	O
attribution	O
of	O
31	O
.	O
8	O
%	O
of	O
QTc	O
variability	O
to	O
methadone	B-Chemical
dose	O
,	O
cytochrome	O
P	O
-	O
450	O
3A4	O
drug	O
-	O
drug	O
interactions	O
,	O
hypokalemia	B-Disease
,	O
and	O
altered	O
liver	O
function	O
.	O
CONCLUSIONS	O
:	O
QT	B-Disease
interval	I-Disease
prolongation	I-Disease
in	O
methadone	B-Chemical
maintenance	O
patients	O
hospitalized	O
in	O
a	O
tertiary	O
care	O
center	O
is	O
a	O
frequent	O
finding	O
.	O
Methadone	B-Chemical
dose	O
,	O
presence	O
of	O
cytochrome	O
P	O
-	O
450	O
3A4	O
inhibitors	O
,	O
potassium	B-Chemical
level	O
,	O
and	O
liver	O
function	O
contribute	O
to	O
QT	B-Disease
prolongation	I-Disease
.	O
Long	B-Disease
QT	I-Disease
syndrome	I-Disease
can	O
occur	O
with	O
low	O
doses	O
of	O
methadone	B-Chemical
.	O
Mechanisms	O
of	O
hypertension	B-Disease
induced	O
by	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
deficiency	O
:	O
focus	O
on	O
venous	O
function	O
.	O
Loss	O
of	O
endothelial	O
cell	O
-	O
derived	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
in	O
hypertension	B-Disease
is	O
a	O
hallmark	O
of	O
arterial	B-Disease
dysfunction	I-Disease
.	O
Experimental	O
hypertension	B-Disease
created	O
by	O
the	O
removal	O
of	O
NO	B-Chemical
,	O
however	O
,	O
involves	O
mechanisms	O
in	O
addition	O
to	O
decreased	O
arterial	O
vasodilator	O
activity	O
.	O
These	O
include	O
augmented	O
endothelin	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
release	O
,	O
increased	O
sympathetic	O
nervous	O
system	O
activity	O
,	O
and	O
elevated	O
tissue	O
oxidative	O
stress	O
.	O
We	O
hypothesized	O
that	O
increased	O
venous	O
smooth	O
muscle	O
(	O
venomotor	O
)	O
tone	O
plays	O
a	O
role	O
in	O
Nomega	B-Chemical
-	I-Chemical
nitro	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
(	O
LNNA	B-Chemical
)	O
hypertension	B-Disease
through	O
these	O
mechanisms	O
.	O
Rats	O
were	O
treated	O
with	O
the	O
NO	B-Chemical
synthase	O
inhibitor	O
LNNA	B-Chemical
(	O
0	O
.	O
5	O
g	O
/	O
L	O
in	O
drinking	O
water	O
)	O
for	O
2	O
weeks	O
.	O
Mean	O
arterial	O
pressure	O
of	O
conscious	O
rats	O
was	O
119	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
in	O
control	O
and	O
194	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
in	O
LNNA	B-Chemical
rats	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
Carotid	O
arteries	O
and	O
vena	O
cava	O
were	O
removed	O
for	O
measurement	O
of	O
isometric	O
contraction	O
.	O
Maximal	O
contraction	O
to	O
norepinephrine	B-Chemical
was	O
modestly	O
reduced	O
in	O
arteries	O
from	O
LNNA	B-Chemical
compared	O
with	O
control	O
rats	O
whereas	O
the	O
maximum	O
contraction	O
to	O
ET	O
-	O
1	O
was	O
significantly	O
reduced	O
(	O
54	O
%	O
control	O
)	O
.	O
Maximum	O
contraction	O
of	O
vena	O
cava	O
to	O
norepinephrine	B-Chemical
(	O
37	O
%	O
control	O
)	O
also	O
was	O
reduced	O
but	O
no	O
change	O
in	O
response	O
to	O
ET	O
-	O
1	O
was	O
observed	O
.	O
Mean	O
circulatory	O
filling	O
pressure	O
,	O
an	O
in	O
vivo	O
measure	O
of	O
venomotor	O
tone	O
,	O
was	O
not	O
elevated	O
in	O
LNNA	B-Chemical
hypertension	B-Disease
at	O
1	O
or	O
2	O
weeks	O
after	O
LNNA	B-Chemical
.	O
The	O
superoxide	B-Chemical
scavenger	O
tempol	B-Chemical
(	O
30	O
,	O
100	O
,	O
and	O
300	O
micromol	O
kg	O
(	O
-	O
1	O
)	O
,	O
IV	O
)	O
did	O
not	O
change	O
arterial	O
pressure	O
in	O
control	O
rats	O
but	O
caused	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
LNNA	B-Chemical
rats	O
(	O
-	O
18	O
+	O
/	O
-	O
8	O
,	O
-	O
26	O
+	O
/	O
-	O
15	O
,	O
and	O
-	O
54	O
+	O
/	O
-	O
11	O
mm	O
Hg	O
)	O
.	O
Similarly	O
,	O
ganglionic	O
blockade	O
with	O
hexamethonium	B-Chemical
caused	O
a	O
significantly	O
greater	O
fall	O
in	O
LNNA	B-Chemical
hypertensive	B-Disease
rats	O
(	O
76	O
+	O
/	O
-	O
9	O
mm	O
Hg	O
)	O
compared	O
with	O
control	O
rats	O
(	O
35	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
)	O
.	O
Carotid	O
arteries	O
,	O
vena	O
cava	O
,	O
and	O
sympathetic	O
ganglia	O
from	O
LNNA	B-Chemical
rats	O
had	O
higher	O
basal	O
levels	O
of	O
superoxide	B-Chemical
compared	O
with	O
those	O
from	O
control	O
rats	O
.	O
These	O
data	O
suggest	O
that	O
while	O
NO	B-Chemical
deficiency	O
increases	O
oxidative	O
stress	O
and	O
sympathetic	O
activity	O
in	O
both	O
arterial	O
and	O
venous	O
vessels	O
,	O
the	O
impact	O
on	O
veins	O
does	O
not	O
make	O
a	O
major	O
contribution	O
to	O
this	O
form	O
of	O
hypertension	B-Disease
.	O
Association	O
of	O
DRD2	O
polymorphisms	O
and	O
chlorpromazine	B-Chemical
-	O
induced	O
extrapyramidal	B-Disease
syndrome	I-Disease
in	O
Chinese	O
schizophrenic	B-Disease
patients	O
.	O
AIM	O
:	O
Extrapyramidal	B-Disease
syndrome	I-Disease
(	O
EPS	B-Disease
)	O
is	O
most	O
commonly	O
affected	O
by	O
typical	O
antipsychotic	O
drugs	O
that	O
have	O
a	O
high	O
affinity	O
with	O
the	O
D2	O
receptor	O
.	O
Recently	O
,	O
many	O
research	O
groups	O
have	O
reported	O
on	O
the	O
positive	O
relationship	O
between	O
the	O
genetic	O
variations	O
in	O
the	O
DRD2	O
gene	O
and	O
the	O
therapeutic	O
response	O
in	O
schizophrenia	B-Disease
patients	O
as	O
a	O
result	O
of	O
the	O
role	O
of	O
variations	O
in	O
the	O
receptor	O
in	O
modulating	O
receptor	O
expression	O
.	O
In	O
this	O
study	O
,	O
we	O
evaluate	O
the	O
role	O
DRD2	O
plays	O
in	O
chlorpromazine	B-Chemical
-	O
induced	O
EPS	B-Disease
in	O
schizophrenic	B-Disease
patients	O
.	O
METHODS	O
:	O
We	O
identified	O
seven	O
SNP	O
(	O
single	O
nucleotide	O
polymorphism	O
)	O
(	O
-	O
141Cins	O
>	O
del	O
,	O
TaqIB	O
,	O
TaqID	O
,	O
Ser311Cys	O
,	O
rs6275	O
,	O
rs6277	O
and	O
TaqIA	O
)	O
in	O
the	O
DRD2	O
gene	O
in	O
146	O
schizophrenic	B-Disease
inpatients	O
(	O
59	O
with	O
EPS	B-Disease
and	O
87	O
without	O
EPS	B-Disease
according	O
to	O
the	O
Simpson	O
-	O
Angus	O
Scale	O
)	O
treated	O
with	O
chlorpromazine	B-Chemical
after	O
8	O
weeks	O
.	O
The	O
alleles	O
of	O
all	O
loci	O
were	O
determined	O
by	O
PCR	O
(	O
polymerase	O
chain	O
reaction	O
)	O
.	O
RESULTS	O
:	O
Polymorphisms	O
TaqID	O
,	O
Ser311Cys	O
and	O
rs6277	O
were	O
not	O
polymorphic	O
in	O
the	O
population	O
recruited	O
in	O
the	O
present	O
study	O
.	O
No	O
statistical	O
significance	O
was	O
found	O
in	O
the	O
allele	O
distribution	O
of	O
-	O
141Cins	O
>	O
del	O
,	O
TaqIB	O
,	O
rs6275	O
and	O
TaqIA	O
or	O
in	O
the	O
estimated	O
haplotypes	O
(	O
constituted	O
by	O
TaqIB	O
,	O
rs6275	O
and	O
TaqIA	O
)	O
in	O
linkage	O
disequilibrium	O
between	O
the	O
two	O
groups	O
.	O
CONCLUSION	O
:	O
Our	O
results	O
did	O
not	O
lend	O
strong	O
support	O
to	O
the	O
view	O
that	O
the	O
genetic	O
variation	O
of	O
the	O
DRD2	O
gene	O
plays	O
a	O
major	O
role	O
in	O
the	O
individually	O
variable	O
adverse	O
effect	O
induced	O
by	O
chlorpromazine	B-Chemical
,	O
at	O
least	O
in	O
Chinese	O
patients	O
with	O
schizophrenia	B-Disease
.	O
Our	O
results	O
confirmed	O
a	O
previous	O
study	O
on	O
the	O
relationship	O
between	O
DRD2	O
and	O
EPS	B-Disease
in	O
Caucasians	O
.	O
Physical	O
training	O
decreases	O
susceptibility	O
to	O
subsequent	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
in	O
the	O
rat	O
.	O
Regular	O
motor	O
activity	O
has	O
many	O
benefits	O
for	O
mental	O
and	O
physical	O
condition	O
but	O
its	O
implications	O
for	O
epilepsy	B-Disease
are	O
still	O
controversial	O
.	O
In	O
order	O
to	O
elucidate	O
this	O
problem	O
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
long	O
-	O
term	O
physical	O
activity	O
on	O
susceptibility	O
to	O
subsequent	O
seizures	B-Disease
.	O
Male	O
Wistar	O
rats	O
were	O
subjected	O
to	O
repeated	O
training	O
sessions	O
in	O
a	O
treadmill	O
and	O
swimming	O
pool	O
.	O
Thereafter	O
,	O
seizures	B-Disease
were	O
induced	O
by	O
pilocarpine	B-Chemical
injections	O
in	O
trained	O
and	O
non	O
-	O
trained	O
control	O
groups	O
.	O
During	O
the	O
acute	O
period	O
of	O
status	B-Disease
epilepticus	I-Disease
,	O
we	O
measured	O
:	O
(	O
1	O
)	O
the	O
latency	O
of	O
the	O
first	O
motor	O
sign	O
,	O
(	O
2	O
)	O
the	O
intensity	O
of	O
seizures	B-Disease
,	O
(	O
3	O
)	O
the	O
time	O
when	O
it	O
occurred	O
within	O
the	O
6	O
-	O
h	O
observation	O
period	O
,	O
and	O
(	O
4	O
)	O
the	O
time	O
when	O
the	O
acute	O
period	O
ended	O
.	O
All	O
these	O
behavioral	O
parameters	O
showed	O
statistically	O
significant	O
changes	O
suggesting	O
that	O
regular	O
physical	O
exercises	O
decrease	O
susceptibility	O
to	O
subsequently	O
induced	O
seizures	B-Disease
and	O
ameliorate	O
the	O
course	O
of	O
experimentally	O
induced	O
status	B-Disease
epilepticus	I-Disease
.	O
Tonic	O
dopaminergic	O
stimulation	O
impairs	B-Disease
associative	I-Disease
learning	I-Disease
in	O
healthy	O
subjects	O
.	O
Endogenous	O
dopamine	B-Chemical
plays	O
a	O
central	O
role	O
in	O
salience	O
coding	O
during	O
associative	O
learning	O
.	O
Administration	O
of	O
the	O
dopamine	B-Chemical
precursor	O
levodopa	B-Chemical
enhances	O
learning	O
in	O
healthy	O
subjects	O
and	O
stroke	B-Disease
patients	O
.	O
Because	O
levodopa	B-Chemical
increases	O
both	O
phasic	O
and	O
tonic	O
dopaminergic	O
neurotransmission	O
,	O
the	O
critical	O
mechanism	O
mediating	O
the	O
enhancement	O
of	O
learning	O
is	O
unresolved	O
.	O
We	O
here	O
probed	O
how	O
selective	O
tonic	O
dopaminergic	O
stimulation	O
affects	O
associative	O
learning	O
.	O
Forty	O
healthy	O
subjects	O
were	O
trained	O
in	O
a	O
novel	O
vocabulary	O
of	O
45	O
concrete	O
nouns	O
over	O
the	O
course	O
of	O
5	O
consecutive	O
training	O
days	O
in	O
a	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
design	O
.	O
Subjects	O
received	O
the	O
tonically	O
stimulating	O
dopamine	B-Chemical
-	O
receptor	O
agonist	O
pergolide	B-Chemical
(	O
0	O
.	O
1	O
mg	O
)	O
vs	O
placebo	O
120	O
min	O
before	O
training	O
on	O
each	O
training	O
day	O
.	O
The	O
dopamine	B-Chemical
agonist	O
significantly	O
impaired	B-Disease
novel	I-Disease
word	I-Disease
learning	I-Disease
compared	O
to	O
placebo	O
.	O
This	O
learning	O
decrement	O
persisted	O
up	O
to	O
the	O
last	O
follow	O
-	O
up	O
4	O
weeks	O
post	O
-	O
training	O
.	O
Subjects	O
treated	O
with	O
pergolide	B-Chemical
also	O
showed	O
restricted	O
emotional	O
responses	O
compared	O
to	O
the	O
PLACEBO	O
group	O
.	O
The	O
extent	O
of	O
'	O
flattened	O
'	O
affect	O
with	O
pergolide	B-Chemical
was	O
related	O
to	O
the	O
degree	O
of	O
learning	O
inhibition	O
.	O
These	O
findings	O
suggest	O
that	O
tonic	O
occupation	O
of	O
dopamine	B-Chemical
receptors	O
impairs	O
learning	O
by	O
competition	O
with	O
phasic	O
dopamine	B-Chemical
signals	O
.	O
Thus	O
,	O
phasic	O
signaling	O
seems	O
to	O
be	O
the	O
critical	O
mechanism	O
by	O
which	O
dopamine	B-Chemical
enhances	O
associative	O
learning	O
in	O
healthy	O
subjects	O
and	O
stroke	B-Disease
patients	O
.	O
Minocycline	B-Chemical
-	O
induced	O
vasculitis	B-Disease
fulfilling	O
the	O
criteria	O
of	O
polyarteritis	B-Disease
nodosa	I-Disease
.	O
A	O
47	O
-	O
year	O
-	O
old	O
man	O
who	O
had	O
been	O
taking	O
minocycline	B-Chemical
for	O
palmoplantar	B-Disease
pustulosis	I-Disease
developed	O
fever	B-Disease
,	O
myalgias	B-Disease
,	O
polyneuropathy	B-Disease
,	O
and	O
testicular	B-Disease
pain	I-Disease
,	O
with	O
elevated	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
.	O
Neither	O
myeloperoxidase	O
-	O
nor	O
proteinase	O
-	O
3	O
-	O
antineutrophil	O
cytoplasmic	O
antibody	O
was	O
positive	O
.	O
These	O
manifestations	O
met	O
the	O
American	O
College	O
of	O
Rheumatology	O
1990	O
criteria	O
for	O
the	O
classification	O
of	O
polyarteritis	B-Disease
nodosa	I-Disease
.	O
Stopping	O
minocycline	B-Chemical
led	O
to	O
amelioration	O
of	O
symptoms	O
and	O
normalization	O
of	O
CRP	O
level	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
second	O
case	O
of	O
minocycline	B-Chemical
-	O
induced	O
vasculitis	B-Disease
satisfying	O
the	O
criteria	O
.	O
Differential	O
diagnosis	O
for	O
drug	O
-	O
induced	O
disease	O
is	O
invaluable	O
even	O
for	O
patients	O
with	O
classical	O
polyarteritis	B-Disease
nodosa	I-Disease
.	O
Intramuscular	O
hepatitis	B-Disease
B	I-Disease
immune	O
globulin	O
combined	O
with	O
lamivudine	B-Chemical
in	O
prevention	O
of	O
hepatitis	B-Disease
B	I-Disease
recurrence	O
after	O
liver	O
transplantation	O
.	O
BACKGROUND	O
:	O
Combined	O
hepatitis	B-Disease
B	I-Disease
immune	O
globulin	O
(	O
HBIg	O
)	O
and	O
lamivudine	B-Chemical
in	O
prophylaxis	O
of	O
the	O
recurrence	O
of	O
hepatitis	B-Disease
B	I-Disease
after	O
liver	O
transplantation	O
has	O
significantly	O
improved	O
the	O
survival	O
of	O
HBsAg	B-Chemical
positive	O
patients	O
.	O
This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
outcomes	O
of	O
liver	O
transplantation	O
for	O
patients	O
with	O
hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
.	O
METHODS	O
:	O
A	O
retrospective	O
chart	O
analysis	O
and	O
a	O
review	O
of	O
the	O
organ	O
transplant	O
database	O
identified	O
51	O
patients	O
(	O
43	O
men	O
and	O
8	O
women	O
)	O
transplanted	O
for	O
benign	O
HBV	O
-	O
related	O
cirrhotic	B-Disease
diseases	I-Disease
between	O
June	O
2002	O
and	O
December	O
2004	O
who	O
had	O
survived	O
more	O
than	O
3	O
months	O
.	O
HBIg	O
was	O
administered	O
intravenously	O
during	O
the	O
first	O
week	O
and	O
intramuscularly	O
thereafter	O
.	O
RESULTS	O
:	O
At	O
a	O
median	O
follow	O
-	O
up	O
of	O
14	O
.	O
1	O
months	O
,	O
the	O
overall	O
recurrence	O
rate	O
in	O
the	O
51	O
patients	O
was	O
3	O
.	O
9	O
%	O
(	O
2	O
/	O
51	O
)	O
.	O
The	O
overall	O
patient	O
survival	O
was	O
88	O
.	O
3	O
%	O
,	O
and	O
82	O
.	O
4	O
%	O
after	O
1	O
and	O
2	O
years	O
,	O
respectively	O
.	O
A	O
daily	O
oral	O
dose	O
of	O
100	O
mg	O
lamivudine	B-Chemical
for	O
2	O
weeks	O
before	O
transplantation	O
for	O
10	O
patients	O
enabled	O
57	O
.	O
1	O
%	O
(	O
4	O
/	O
7	O
)	O
and	O
62	O
.	O
5	O
%	O
(	O
5	O
/	O
8	O
)	O
of	O
HBV	O
-	O
DNA	O
and	O
HBeAg	B-Chemical
positive	O
patients	O
respectively	O
to	O
convert	O
to	O
be	O
negative	O
.	O
Intramuscular	O
HBIg	O
was	O
well	O
tolerated	O
in	O
all	O
patients	O
.	O
CONCLUSION	O
:	O
Lamivudine	B-Chemical
combined	O
with	O
intramuscular	O
HBIg	O
can	O
effectively	O
prevent	O
allograft	O
from	O
the	O
recurrence	O
of	O
HBV	O
after	O
liver	O
transplantation	O
.	O
Anticonvulsant	O
effect	O
of	O
eslicarbazepine	B-Chemical
acetate	I-Chemical
(	O
BIA	B-Chemical
2	I-Chemical
-	I-Chemical
093	I-Chemical
)	O
on	O
seizures	B-Disease
induced	O
by	O
microperfusion	O
of	O
picrotoxin	B-Chemical
in	O
the	O
hippocampus	O
of	O
freely	O
moving	O
rats	O
.	O
Eslicarbazepine	B-Chemical
acetate	I-Chemical
(	O
BIA	B-Chemical
2	I-Chemical
-	I-Chemical
093	I-Chemical
,	O
S	B-Chemical
-	I-Chemical
(	I-Chemical
-	I-Chemical
)	I-Chemical
-	I-Chemical
10	I-Chemical
-	I-Chemical
acetoxy	I-Chemical
-	I-Chemical
10	I-Chemical
,	I-Chemical
11	I-Chemical
-	I-Chemical
dihydro	I-Chemical
-	I-Chemical
5H	I-Chemical
-	I-Chemical
dibenzo	I-Chemical
/	I-Chemical
b	I-Chemical
,	I-Chemical
f	I-Chemical
/	I-Chemical
azepine	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
carboxamide	I-Chemical
)	O
is	O
a	O
novel	O
antiepileptic	O
drug	O
,	O
now	O
in	O
Phase	O
III	O
clinical	O
trials	O
,	O
designed	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
and	O
safety	O
in	O
comparison	O
with	O
the	O
structurally	O
related	O
drugs	O
carbamazepine	B-Chemical
(	O
CBZ	B-Chemical
)	O
and	O
oxcarbazepine	B-Chemical
(	O
OXC	B-Chemical
)	O
.	O
We	O
have	O
studied	O
the	O
effects	O
of	O
oral	O
treatment	O
with	O
eslicarbazepine	B-Chemical
acetate	I-Chemical
on	O
a	O
whole	O
-	O
animal	O
model	O
in	O
which	O
partial	O
seizures	B-Disease
can	O
be	O
elicited	O
repeatedly	O
on	O
different	O
days	O
without	O
changes	O
in	O
threshold	O
or	O
seizure	B-Disease
patterns	O
.	O
In	O
the	O
animals	O
treated	O
with	O
threshold	O
doses	O
of	O
picrotoxin	B-Chemical
,	O
the	O
average	O
number	O
of	O
seizures	B-Disease
was	O
2	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
2	O
,	O
and	O
average	O
seizure	B-Disease
duration	O
was	O
39	O
.	O
5	O
+	O
/	O
-	O
8	O
.	O
4s	O
.	O
Pre	O
-	O
treatment	O
with	O
a	O
dose	O
of	O
30	O
mg	O
/	O
kg	O
2h	O
before	O
picrotoxin	B-Chemical
microperfusion	O
prevented	O
seizures	B-Disease
in	O
the	O
75	O
%	O
of	O
the	O
rats	O
.	O
Lower	O
doses	O
(	O
3	O
and	O
10mg	O
/	O
kg	O
)	O
did	O
not	O
suppress	O
seizures	B-Disease
,	O
however	O
,	O
after	O
administration	O
of	O
10mg	O
/	O
kg	O
,	O
significant	O
reductions	O
in	O
seizures	B-Disease
duration	O
(	O
24	O
.	O
3	O
+	O
/	O
-	O
6	O
.	O
8s	O
)	O
and	O
seizure	B-Disease
number	O
(	O
1	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
34	O
)	O
were	O
found	O
.	O
No	O
adverse	O
effects	O
of	O
eslicarbazepine	B-Chemical
acetate	I-Chemical
were	O
observed	O
in	O
the	O
behavioral	O
/	O
EEG	O
patterns	O
studied	O
,	O
including	O
sleep	O
/	O
wakefulness	O
cycle	O
,	O
at	O
the	O
doses	O
studied	O
.	O
Acute	B-Disease
renal	I-Disease
failure	I-Disease
associated	O
with	O
prolonged	O
intake	O
of	O
slimming	O
pills	O
containing	O
anthraquinones	B-Chemical
.	O
Chinese	B-Chemical
herbal	I-Chemical
medicine	O
preparations	O
are	O
widely	O
available	O
and	O
often	O
regarded	O
by	O
the	O
public	O
as	O
natural	O
and	O
safe	O
remedies	O
for	O
a	O
variety	O
of	O
medical	O
conditions	O
.	O
Nephropathy	B-Disease
caused	O
by	O
Chinese	B-Chemical
herbs	I-Chemical
has	O
previously	O
been	O
reported	O
,	O
usually	O
involving	O
the	O
use	O
of	O
aristolochic	B-Chemical
acids	I-Chemical
.	O
We	O
report	O
a	O
23	O
-	O
year	O
-	O
old	O
woman	O
who	O
developed	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
following	O
prolonged	O
use	O
of	O
a	O
proprietary	O
Chinese	B-Chemical
herbal	I-Chemical
slimming	O
pill	O
that	O
contained	O
anthraquinone	B-Chemical
derivatives	O
,	O
extracted	O
from	O
Rhizoma	O
Rhei	O
(	O
rhubarb	O
)	O
.	O
The	O
renal	B-Disease
injury	I-Disease
was	O
probably	O
aggravated	O
by	O
the	O
concomitant	O
intake	O
of	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
diclofenac	B-Chemical
.	O
Renal	O
pathology	O
was	O
that	O
of	O
hypocellular	O
interstitial	O
fibrosis	B-Disease
.	O
Spontaneous	O
renal	O
recovery	O
occurred	O
upon	O
cessation	O
of	O
the	O
slimming	O
pills	O
,	O
but	O
mild	O
interstitial	O
fibrosis	B-Disease
and	O
tubular	O
atrophy	B-Disease
was	O
still	O
evident	O
histologically	O
4	O
months	O
later	O
.	O
Although	O
a	O
causal	O
relationship	O
between	O
the	O
use	O
of	O
an	O
anthraquinone	B-Chemical
-	O
containing	O
herbal	O
agent	O
and	O
renal	B-Disease
injury	I-Disease
remains	O
to	O
be	O
proven	O
,	O
phytotherapy	O
-	O
associated	O
interstitial	O
nephropathy	B-Disease
should	O
be	O
considered	O
in	O
patients	O
who	O
present	O
with	O
unexplained	O
renal	B-Disease
failure	I-Disease
.	O
Chloroacetaldehyde	B-Chemical
as	O
a	O
sulfhydryl	B-Chemical
reagent	O
:	O
the	O
role	O
of	O
critical	O
thiol	B-Chemical
groups	O
in	O
ifosfamide	B-Chemical
nephropathy	B-Disease
.	O
Chloroacetaldehyde	B-Chemical
(	O
CAA	B-Chemical
)	O
is	O
a	O
metabolite	O
of	O
the	O
alkylating	O
agent	O
ifosfamide	B-Chemical
(	O
IFO	B-Chemical
)	O
and	O
putatively	O
responsible	O
for	O
renal	B-Disease
damage	I-Disease
following	O
anti	O
-	O
tumor	B-Disease
therapy	O
with	O
IFO	B-Chemical
.	O
Depletion	O
of	O
sulfhydryl	B-Chemical
(	O
SH	B-Chemical
)	O
groups	O
has	O
been	O
reported	O
from	O
cell	O
culture	O
,	O
animal	O
and	O
clinical	O
studies	O
.	O
In	O
this	O
work	O
the	O
effect	O
of	O
CAA	B-Chemical
on	O
human	O
proximal	O
tubule	O
cells	O
in	O
primary	O
culture	O
(	O
hRPTEC	O
)	O
was	O
investigated	O
.	O
Toxicity	B-Disease
of	O
CAA	B-Chemical
was	O
determined	O
by	O
protein	O
content	O
,	O
cell	O
number	O
,	O
LDH	O
release	O
,	O
trypan	B-Chemical
blue	I-Chemical
exclusion	O
assay	O
and	O
caspase	O
-	O
3	O
activity	O
.	O
Free	O
thiols	B-Chemical
were	O
measured	O
by	O
the	O
method	O
of	O
Ellman	O
.	O
CAA	B-Chemical
reduced	O
hRPTEC	O
cell	O
number	O
and	O
protein	O
,	O
induced	O
a	O
loss	O
in	O
free	O
intracellular	O
thiols	B-Chemical
and	O
an	O
increase	O
in	O
necrosis	B-Disease
markers	O
.	O
CAA	B-Chemical
but	O
not	O
acrolein	B-Chemical
inhibited	O
the	O
cysteine	B-Chemical
proteases	O
caspase	O
-	O
3	O
,	O
caspase	O
-	O
8	O
and	O
cathepsin	O
B	O
.	O
Caspase	O
activation	O
by	O
cisplatin	B-Chemical
was	O
inhibited	O
by	O
CAA	B-Chemical
.	O
In	O
cells	O
stained	O
with	O
fluorescent	O
dyes	O
targeting	O
lysosomes	O
,	O
CAA	B-Chemical
induced	O
an	O
increase	O
in	O
lysosomal	O
size	O
and	O
lysosomal	O
leakage	O
.	O
The	O
effects	O
of	O
CAA	B-Chemical
on	O
cysteine	B-Chemical
protease	O
activities	O
and	O
thiols	B-Chemical
could	O
be	O
reproduced	O
in	O
cell	O
lysate	O
.	O
Acidification	O
,	O
which	O
slowed	O
the	O
reaction	O
of	O
CAA	B-Chemical
with	O
thiol	B-Chemical
donors	O
,	O
could	O
also	O
attenuate	O
effects	O
of	O
CAA	B-Chemical
on	O
necrosis	B-Disease
markers	O
,	O
thiol	B-Chemical
depletion	O
and	O
cysteine	B-Chemical
protease	O
inhibition	O
in	O
living	O
cells	O
.	O
Thus	O
,	O
CAA	B-Chemical
directly	O
reacts	O
with	O
cellular	O
protein	O
and	O
non	O
-	O
protein	O
thiols	B-Chemical
,	O
mediating	O
its	O
toxicity	B-Disease
on	O
hRPTEC	O
.	O
This	O
effect	O
can	O
be	O
reduced	O
by	O
acidification	O
.	O
Therefore	O
,	O
urinary	O
acidification	O
could	O
be	O
an	O
option	O
to	O
prevent	O
IFO	B-Chemical
nephropathy	B-Disease
in	O
patients	O
.	O
Stereological	O
methods	O
reveal	O
the	O
robust	O
size	O
and	O
stability	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
after	O
pilocarpine	B-Chemical
-	O
induced	O
status	B-Disease
epilepticus	I-Disease
in	O
the	O
adult	O
rat	O
.	O
Following	O
status	B-Disease
epilepticus	I-Disease
in	O
the	O
rat	O
,	O
dentate	O
granule	O
cell	O
neurogenesis	O
increases	O
greatly	O
,	O
and	O
many	O
of	O
the	O
new	O
neurons	O
appear	O
to	O
develop	O
ectopically	O
,	O
in	O
the	O
hilar	O
region	O
of	O
the	O
hippocampal	O
formation	O
.	O
It	O
has	O
been	O
suggested	O
that	O
the	O
ectopic	O
hilar	O
granule	O
cells	O
could	O
contribute	O
to	O
the	O
spontaneous	O
seizures	B-Disease
that	O
ultimately	O
develop	O
after	O
status	B-Disease
epilepticus	I-Disease
.	O
However	O
,	O
the	O
population	O
has	O
never	O
been	O
quantified	O
,	O
so	O
it	O
is	O
unclear	O
whether	O
it	O
is	O
substantial	O
enough	O
to	O
have	O
a	O
strong	O
influence	O
on	O
epileptogenesis	O
.	O
To	O
quantify	O
this	O
population	O
,	O
the	O
total	O
number	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
was	O
estimated	O
using	O
unbiased	O
stereology	O
at	O
different	O
times	O
after	O
pilocarpine	B-Chemical
-	O
induced	O
status	B-Disease
epilepticus	I-Disease
.	O
The	O
number	O
of	O
hilar	O
neurons	O
immunoreactive	O
for	O
Prox	O
-	O
1	O
,	O
a	O
granule	O
-	O
cell	O
-	O
specific	O
marker	O
,	O
was	O
estimated	O
using	O
the	O
optical	O
fractionator	O
method	O
.	O
The	O
results	O
indicate	O
that	O
the	O
size	O
of	O
the	O
hilar	O
ectopic	O
granule	O
cell	O
population	O
after	O
status	B-Disease
epilepticus	I-Disease
is	O
substantial	O
,	O
and	O
stable	O
over	O
time	O
.	O
Interestingly	O
,	O
the	O
size	O
of	O
the	O
population	O
appears	O
to	O
be	O
correlated	O
with	O
the	O
frequency	O
of	O
behavioral	O
seizures	B-Disease
,	O
because	O
animals	O
with	O
more	O
ectopic	O
granule	O
cells	O
in	O
the	O
hilus	O
have	O
more	O
frequent	O
behavioral	O
seizures	B-Disease
.	O
The	O
hilar	O
ectopic	O
granule	O
cell	O
population	O
does	O
not	O
appear	O
to	O
vary	O
systematically	O
across	O
the	O
septotemporal	O
axis	O
,	O
although	O
it	O
is	O
associated	O
with	O
an	O
increase	O
in	O
volume	O
of	O
the	O
hilus	O
.	O
The	O
results	O
provide	O
new	O
insight	O
into	O
the	O
potential	O
role	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
in	O
the	O
pilocarpine	B-Chemical
model	O
of	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
.	O
A	O
prospective	O
,	O
open	O
-	O
label	O
trial	O
of	O
galantamine	B-Chemical
in	O
autistic	B-Disease
disorder	I-Disease
.	O
OBJECTIVE	O
:	O
Post	O
-	O
mortem	O
studies	O
have	O
reported	O
abnormalities	O
of	O
the	O
cholinergic	O
system	O
in	O
autism	B-Disease
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
use	O
of	O
galantamine	B-Chemical
,	O
an	O
acetylcholinesterase	O
inhibitor	O
and	O
nicotinic	O
receptor	O
modulator	O
,	O
in	O
the	O
treatment	O
of	O
interfering	O
behaviors	O
in	O
children	O
with	O
autism	B-Disease
.	O
METHODS	O
:	O
Thirteen	O
medication	O
-	O
free	O
children	O
with	O
autism	B-Disease
(	O
mean	O
age	O
,	O
8	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
5	O
years	O
)	O
participated	O
in	O
a	O
12	O
-	O
week	O
,	O
open	O
-	O
label	O
trial	O
of	O
galantamine	B-Chemical
.	O
Patients	O
were	O
rated	O
monthly	O
by	O
parents	O
on	O
the	O
Aberrant	O
Behavior	O
Checklist	O
(	O
ABC	O
)	O
and	O
the	O
Conners	O
'	O
Parent	O
Rating	O
Scale	O
-	O
Revised	O
,	O
and	O
by	O
a	O
physician	O
using	O
the	O
Children	O
'	O
s	O
Psychiatric	O
Rating	O
Scale	O
and	O
the	O
Clinical	O
Global	O
Impressions	O
scale	O
.	O
RESULTS	O
:	O
Patients	O
showed	O
a	O
significant	O
reduction	O
in	O
parent	O
-	O
rated	O
irritability	B-Disease
and	O
social	O
withdrawal	O
on	O
the	O
ABC	O
as	O
well	O
as	O
significant	O
improvements	O
in	O
emotional	O
lability	O
and	O
inattention	O
on	O
the	O
Conners	O
'	O
Parent	O
Rating	O
Scale	O
-	O
-	O
Revised	O
.	O
Similarly	O
,	O
clinician	O
ratings	O
showed	O
reductions	O
in	O
the	O
anger	O
subscale	O
of	O
the	O
Children	O
'	O
s	O
Psychiatric	O
Rating	O
Scale	O
.	O
Eight	O
of	O
13	O
participants	O
were	O
rated	O
as	O
responders	O
on	O
the	O
basis	O
of	O
their	O
improvement	O
scores	O
on	O
the	O
Clinical	O
Global	O
Impressions	O
scale	O
.	O
Overall	O
,	O
galantamine	B-Chemical
was	O
well	O
-	O
tolerated	O
,	O
with	O
no	O
significant	O
adverse	O
effects	O
apart	O
from	O
headaches	B-Disease
in	O
one	O
patient	O
.	O
CONCLUSION	O
:	O
In	O
this	O
open	O
trial	O
,	O
galantamine	B-Chemical
was	O
well	O
-	O
tolerated	O
and	O
appeared	O
to	O
be	O
beneficial	O
for	O
the	O
treatment	O
of	O
interfering	O
behaviors	O
in	O
children	O
with	O
autism	B-Disease
,	O
particularly	O
aggression	B-Disease
,	O
behavioral	B-Disease
dyscontrol	I-Disease
,	O
and	O
inattention	B-Disease
.	O
Further	O
controlled	O
trials	O
are	O
warranted	O
.	O
Randomized	O
comparison	O
of	O
olanzapine	B-Chemical
versus	O
risperidone	B-Chemical
for	O
the	O
treatment	O
of	O
first	O
-	O
episode	O
schizophrenia	B-Disease
:	O
4	O
-	O
month	O
outcomes	O
.	O
OBJECTIVE	O
:	O
The	O
authors	O
compared	O
4	O
-	O
month	O
treatment	O
outcomes	O
for	O
olanzapine	B-Chemical
versus	O
risperidone	B-Chemical
in	O
patients	O
with	O
first	O
-	O
episode	O
schizophrenia	B-Disease
spectrum	O
disorders	O
.	O
METHOD	O
:	O
One	O
hundred	O
twelve	O
subjects	O
(	O
70	O
%	O
male	O
;	O
mean	O
age	O
=	O
23	O
.	O
3	O
years	O
[	O
SD	O
=	O
5	O
.	O
1	O
]	O
)	O
with	O
first	O
-	O
episode	O
schizophrenia	B-Disease
(	O
75	O
%	O
)	O
,	O
schizophreniform	B-Disease
disorder	I-Disease
(	O
17	O
%	O
)	O
,	O
or	O
schizoaffective	B-Disease
disorder	I-Disease
(	O
8	O
%	O
)	O
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
olanzapine	B-Chemical
(	O
2	O
.	O
5	O
-	O
20	O
mg	O
/	O
day	O
)	O
or	O
risperidone	B-Chemical
(	O
1	O
-	O
6	O
mg	O
/	O
day	O
)	O
.	O
RESULTS	O
:	O
Response	O
rates	O
did	O
not	O
significantly	O
differ	O
between	O
olanzapine	B-Chemical
(	O
43	O
.	O
7	O
%	O
,	O
95	O
%	O
CI	O
=	O
28	O
.	O
8	O
%	O
-	O
58	O
.	O
6	O
%	O
)	O
and	O
risperidone	B-Chemical
(	O
54	O
.	O
3	O
%	O
,	O
95	O
%	O
CI	O
=	O
39	O
.	O
9	O
%	O
-	O
68	O
.	O
7	O
%	O
)	O
.	O
Among	O
those	O
responding	O
to	O
treatment	O
,	O
more	O
subjects	O
in	O
the	O
olanzapine	B-Chemical
group	O
(	O
40	O
.	O
9	O
%	O
,	O
95	O
%	O
CI	O
=	O
16	O
.	O
8	O
%	O
-	O
65	O
.	O
0	O
%	O
)	O
than	O
in	O
the	O
risperidone	B-Chemical
group	O
(	O
18	O
.	O
9	O
%	O
,	O
95	O
%	O
CI	O
=	O
0	O
%	O
-	O
39	O
.	O
2	O
%	O
)	O
had	O
subsequent	O
ratings	O
not	O
meeting	O
response	O
criteria	O
.	O
Negative	O
symptom	O
outcomes	O
and	O
measures	O
of	O
parkinsonism	B-Disease
and	O
akathisia	B-Disease
did	O
not	O
differ	O
between	O
medications	O
.	O
Extrapyramidal	B-Disease
symptom	I-Disease
severity	O
scores	O
were	O
1	O
.	O
4	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
2	O
-	O
1	O
.	O
6	O
)	O
with	O
risperidone	B-Chemical
and	O
1	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
0	O
-	O
1	O
.	O
4	O
)	O
with	O
olanzapine	B-Chemical
.	O
Significantly	O
more	O
weight	B-Disease
gain	I-Disease
occurred	O
with	O
olanzapine	B-Chemical
than	O
with	O
risperidone	B-Chemical
:	O
the	O
increase	O
in	O
weight	O
at	O
4	O
months	O
relative	O
to	O
baseline	O
weight	O
was	O
17	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
=	O
14	O
.	O
2	O
%	O
-	O
20	O
.	O
5	O
%	O
)	O
with	O
olanzapine	B-Chemical
and	O
11	O
.	O
3	O
%	O
(	O
95	O
%	O
CI	O
=	O
8	O
.	O
4	O
%	O
-	O
14	O
.	O
3	O
%	O
)	O
with	O
risperidone	B-Chemical
.	O
Body	O
mass	O
index	O
at	O
baseline	O
and	O
at	O
4	O
months	O
was	O
24	O
.	O
3	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
8	O
-	O
25	O
.	O
7	O
)	O
versus	O
28	O
.	O
2	O
(	O
95	O
%	O
CI	O
=	O
26	O
.	O
7	O
-	O
29	O
.	O
7	O
)	O
with	O
olanzapine	B-Chemical
and	O
23	O
.	O
9	O
(	O
95	O
%	O
CI	O
=	O
22	O
.	O
5	O
-	O
25	O
.	O
3	O
)	O
versus	O
26	O
.	O
7	O
(	O
95	O
%	O
CI	O
=	O
25	O
.	O
2	O
-	O
28	O
.	O
2	O
)	O
with	O
risperidone	B-Chemical
.	O
CONCLUSIONS	O
:	O
Clinical	O
outcomes	O
with	O
risperidone	B-Chemical
were	O
equal	O
to	O
those	O
with	O
olanzapine	B-Chemical
,	O
and	O
response	O
may	O
be	O
more	O
stable	O
.	O
Olanzapine	B-Chemical
may	O
have	O
an	O
advantage	O
for	O
motor	O
side	O
effects	O
.	O
Both	O
medications	O
caused	O
substantial	O
rapid	O
weight	B-Disease
gain	I-Disease
,	O
but	O
weight	B-Disease
gain	I-Disease
was	O
greater	O
with	O
olanzapine	B-Chemical
.	O
Early	O
paracentral	O
visual	B-Disease
field	I-Disease
loss	I-Disease
in	O
patients	O
taking	O
hydroxychloroquine	B-Chemical
.	O
OBJECTIVE	O
:	O
To	O
review	O
the	O
natural	O
history	O
and	O
ocular	O
and	O
systemic	O
adverse	O
effects	O
of	O
patients	O
taking	O
hydroxychloroquine	B-Chemical
sulfate	I-Chemical
who	O
attended	O
an	O
ophthalmic	O
screening	O
program	O
.	O
DESIGN	O
:	O
Retrospective	O
study	O
.	O
RESULTS	O
:	O
Records	O
of	O
262	O
patients	O
who	O
were	O
taking	O
hydroxychloroquine	B-Chemical
and	O
screened	O
in	O
the	O
Department	O
of	O
Ophthalmology	O
were	O
reviewed	O
.	O
Of	O
the	O
262	O
patients	O
,	O
14	O
(	O
18	O
%	O
)	O
of	O
76	O
who	O
had	O
stopped	O
treatment	O
at	O
the	O
time	O
of	O
the	O
study	O
experienced	O
documented	O
adverse	O
effects	O
.	O
Systemic	O
adverse	O
effects	O
occurred	O
in	O
8	O
patients	O
(	O
10	O
.	O
5	O
%	O
)	O
and	O
ocular	O
adverse	O
effects	O
,	O
in	O
5	O
(	O
6	O
.	O
5	O
%	O
)	O
.	O
Thirty	O
-	O
five	O
patients	O
(	O
13	O
.	O
4	O
%	O
)	O
had	O
visual	B-Disease
field	I-Disease
abnormalities	I-Disease
,	O
which	O
were	O
attributed	O
to	O
hydroxychloroquine	B-Chemical
treatment	O
in	O
4	O
patients	O
(	O
1	O
.	O
5	O
%	O
)	O
.	O
Three	O
of	O
the	O
4	O
patients	O
were	O
taking	O
less	O
than	O
6	O
.	O
5	O
mg	O
/	O
kg	O
per	O
day	O
and	O
all	O
patients	O
had	O
normal	O
renal	O
and	O
liver	O
function	O
test	O
results	O
.	O
CONCLUSIONS	O
:	O
The	O
current	O
study	O
used	O
a	O
protocol	O
of	O
visual	O
acuity	O
and	O
color	O
vision	O
assessment	O
,	O
funduscopy	O
,	O
and	O
Humphrey	O
10	O
-	O
2	O
visual	O
field	O
testing	O
and	O
shows	O
that	O
visual	B-Disease
field	I-Disease
defects	I-Disease
appeared	O
before	O
any	O
corresponding	O
changes	O
in	O
any	O
other	O
tested	O
clinical	O
parameters	O
;	O
the	O
defects	O
were	O
reproducible	O
and	O
the	O
test	O
parameters	O
were	O
reliable	O
.	O
Patients	O
taking	O
hydroxychloroquine	B-Chemical
can	O
demonstrate	O
a	O
toxic	O
reaction	O
in	O
the	O
retina	O
despite	O
the	O
absence	O
of	O
known	O
risk	O
factors	O
.	O
Screening	O
,	O
including	O
Humphrey	O
10	O
-	O
2	O
visual	O
field	O
assessment	O
,	O
is	O
recommended	O
2	O
years	O
after	O
the	O
initial	O
baseline	O
and	O
yearly	O
thereafter	O
.	O
Peri	O
-	O
operative	O
atrioventricular	B-Disease
block	I-Disease
as	O
a	O
result	O
of	O
chemotherapy	O
with	O
epirubicin	B-Chemical
and	O
paclitaxel	B-Chemical
.	O
A	O
47	O
-	O
year	O
-	O
old	O
woman	O
presented	O
for	O
mastectomy	O
and	O
immediate	O
latissimus	O
dorsi	O
flap	O
reconstruction	O
having	O
been	O
diagnosed	O
with	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
breast	I-Disease
6	O
months	O
previously	O
.	O
In	O
the	O
preceding	O
months	O
she	O
had	O
received	O
neo	O
-	O
adjuvant	O
chemotherapy	O
with	O
epirubicin	B-Chemical
,	O
paclitaxel	B-Chemical
(	O
Taxol	B-Chemical
)	O
and	O
cyclophosphamide	B-Chemical
.	O
This	O
had	O
been	O
apparently	O
uncomplicated	O
and	O
she	O
had	O
maintained	O
a	O
remarkably	O
high	O
level	O
of	O
physical	O
activity	O
.	O
She	O
was	O
found	O
to	O
be	O
bradycardic	B-Disease
at	O
pre	O
-	O
operative	O
assessment	O
but	O
had	O
no	O
cardiac	O
symptoms	O
.	O
Second	O
degree	O
Mobitz	O
type	O
II	O
atrioventricular	B-Disease
block	I-Disease
was	O
diagnosed	O
on	O
electrocardiogram	O
,	O
and	O
temporary	O
transvenous	O
ventricular	O
pacing	O
instituted	O
in	O
the	O
peri	O
-	O
operative	O
period	O
.	O
We	O
discuss	O
how	O
evidence	O
-	O
based	O
guidelines	O
would	O
not	O
have	O
been	O
helpful	O
in	O
this	O
case	O
,	O
and	O
how	O
chemotherapy	O
can	O
exhibit	O
substantial	O
cardiotoxicity	B-Disease
that	O
may	O
develop	O
over	O
many	O
years	O
.	O
We	O
suggest	O
that	O
patients	O
who	O
have	O
received	O
chemotherapy	O
at	O
any	O
time	O
should	O
have	O
a	O
pre	O
-	O
operative	O
electrocardiogram	O
even	O
if	O
they	O
are	O
asymptomatic	O
.	O
Risks	O
and	O
benefits	O
of	O
COX	B-Chemical
-	I-Chemical
2	I-Chemical
inhibitors	I-Chemical
vs	O
non	O
-	O
selective	O
NSAIDs	O
:	O
does	O
their	O
cardiovascular	O
risk	O
exceed	O
their	O
gastrointestinal	O
benefit	O
?	O
A	O
retrospective	O
cohort	O
study	O
.	O
OBJECTIVES	O
:	O
The	O
risk	O
of	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
(	O
AMI	B-Disease
)	O
with	O
COX	B-Chemical
-	I-Chemical
2	I-Chemical
inhibitors	I-Chemical
may	O
offset	O
their	O
gastrointestinal	O
(	O
GI	O
)	O
benefit	O
compared	O
with	O
non	O
-	O
selective	O
(	O
NS	O
)	O
non	B-Chemical
-	I-Chemical
steroidal	I-Chemical
anti	I-Chemical
-	I-Chemical
inflammatory	I-Chemical
drugs	I-Chemical
(	O
NSAIDs	O
)	O
.	O
We	O
aimed	O
to	O
compare	O
the	O
risks	O
of	O
hospitalization	O
for	O
AMI	B-Disease
and	O
GI	B-Disease
bleeding	I-Disease
among	O
elderly	O
patients	O
using	O
COX	B-Chemical
-	I-Chemical
2	I-Chemical
inhibitors	I-Chemical
,	O
NS	O
-	O
NSAIDs	O
and	O
acetaminophen	B-Chemical
.	O
METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
cohort	O
study	O
using	O
administrative	O
data	O
of	O
patients	O
>	O
or	O
=	O
65	O
years	O
of	O
age	O
who	O
filled	O
a	O
prescription	O
for	O
NSAID	O
or	O
acetaminophen	B-Chemical
during	O
1999	O
-	O
2002	O
.	O
Outcomes	O
were	O
compared	O
using	O
Cox	O
regression	O
models	O
with	O
time	O
-	O
dependent	O
exposures	O
.	O
RESULTS	O
:	O
Person	O
-	O
years	O
of	O
exposure	O
among	O
non	O
-	O
users	O
of	O
aspirin	B-Chemical
were	O
:	O
75	O
,	O
761	O
to	O
acetaminophen	B-Chemical
,	O
42	O
,	O
671	O
to	O
rofecoxib	B-Chemical
65	O
,	O
860	O
to	O
celecoxib	B-Chemical
,	O
and	O
37	O
,	O
495	O
to	O
NS	O
-	O
NSAIDs	O
.	O
Among	O
users	O
of	O
aspirin	B-Chemical
,	O
they	O
were	O
:	O
14	O
,	O
671	O
to	O
rofecoxib	B-Chemical
,	O
22	O
,	O
875	O
to	O
celecoxib	B-Chemical
,	O
9	O
,	O
832	O
to	O
NS	O
-	O
NSAIDs	O
and	O
38	O
,	O
048	O
to	O
acetaminophen	B-Chemical
.	O
Among	O
non	O
-	O
users	O
of	O
aspirin	B-Chemical
,	O
the	O
adjusted	O
hazard	O
ratios	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
of	O
hospitalization	O
for	O
AMI	B-Disease
/	O
GI	O
vs	O
the	O
acetaminophen	B-Chemical
(	O
with	O
no	O
aspirin	B-Chemical
)	O
group	O
were	O
:	O
rofecoxib	B-Chemical
1	O
.	O
27	O
(	O
1	O
.	O
13	O
,	O
1	O
.	O
42	O
)	O
,	O
celecoxib	B-Chemical
0	O
.	O
93	O
(	O
0	O
.	O
83	O
,	O
1	O
.	O
03	O
)	O
,	O
naproxen	B-Chemical
1	O
.	O
59	O
(	O
1	O
.	O
31	O
,	O
1	O
.	O
93	O
)	O
,	O
diclofenac	B-Chemical
1	O
.	O
17	O
(	O
0	O
.	O
99	O
,	O
1	O
.	O
38	O
)	O
and	O
ibuprofen	B-Chemical
1	O
.	O
05	O
(	O
0	O
.	O
74	O
,	O
1	O
.	O
51	O
)	O
.	O
Among	O
users	O
of	O
aspirin	B-Chemical
,	O
they	O
were	O
:	O
rofecoxib	B-Chemical
1	O
.	O
73	O
(	O
1	O
.	O
52	O
,	O
1	O
.	O
98	O
)	O
,	O
celecoxib	B-Chemical
1	O
.	O
34	O
(	O
1	O
.	O
19	O
,	O
1	O
.	O
52	O
)	O
,	O
ibuprofen	B-Chemical
1	O
.	O
51	O
(	O
0	O
.	O
95	O
,	O
2	O
.	O
41	O
)	O
,	O
diclofenac	B-Chemical
1	O
.	O
69	O
(	O
1	O
.	O
35	O
,	O
2	O
.	O
10	O
)	O
,	O
naproxen	B-Chemical
1	O
.	O
35	O
(	O
0	O
.	O
97	O
,	O
1	O
.	O
88	O
)	O
and	O
acetaminophen	B-Chemical
1	O
.	O
29	O
(	O
1	O
.	O
17	O
,	O
1	O
.	O
42	O
)	O
.	O
CONCLUSION	O
:	O
Among	O
non	O
-	O
users	O
of	O
aspirin	B-Chemical
,	O
naproxen	B-Chemical
seemed	O
to	O
carry	O
the	O
highest	O
risk	O
for	O
AMI	B-Disease
/	O
GI	B-Disease
bleeding	I-Disease
.	O
The	O
AMI	B-Disease
/	O
GI	O
toxicity	B-Disease
of	O
celecoxib	B-Chemical
was	O
similar	O
to	O
that	O
of	O
acetaminophen	B-Chemical
and	O
seemed	O
to	O
be	O
better	O
than	O
those	O
of	O
rofecoxib	B-Chemical
and	O
NS	O
-	O
NSAIDs	O
.	O
Among	O
users	O
of	O
aspirin	B-Chemical
,	O
both	O
celecoxib	B-Chemical
and	O
naproxen	B-Chemical
seemed	O
to	O
be	O
the	O
least	O
toxic	O
.	O
Quinine	B-Chemical
-	O
induced	O
arrhythmia	B-Disease
in	O
a	O
patient	O
with	O
severe	B-Disease
malaria	I-Disease
.	O
It	O
was	O
reported	O
that	O
there	O
was	O
a	O
case	O
of	O
severe	B-Disease
malaria	I-Disease
patient	O
with	O
jaundice	B-Disease
who	O
presented	O
with	O
arrhythmia	B-Disease
(	O
premature	B-Disease
ventricular	I-Disease
contraction	I-Disease
)	O
while	O
getting	O
quinine	B-Chemical
infusion	O
was	O
reported	O
.	O
A	O
man	O
,	O
25	O
years	O
old	O
,	O
was	O
admitted	O
to	O
hospital	O
with	O
high	O
fever	B-Disease
,	O
chill	B-Disease
,	O
vomiting	B-Disease
,	O
jaundice	B-Disease
.	O
The	O
patient	O
was	O
fully	O
conscious	O
,	O
blood	O
pressure	O
120	O
/	O
80	O
mmHg	O
,	O
pulse	O
rate	O
100	O
x	O
/	O
minute	O
,	O
regular	O
.	O
On	O
admission	O
,	O
laboratory	O
examination	O
showed	O
Plasmodium	O
falciparum	O
(	O
+	O
+	O
+	O
+	O
)	O
,	O
total	O
bilirubin	B-Chemical
8	O
.	O
25	O
mg	O
/	O
dL	O
,	O
conjugated	O
bilirubin	B-Chemical
4	O
.	O
36	O
mg	O
/	O
dL	O
,	O
unconjugated	O
bilirubin	B-Chemical
3	O
.	O
89	O
mg	O
/	O
dL	O
,	O
potassium	B-Chemical
3	O
.	O
52	O
meq	O
/	O
L	O
Patient	O
was	O
diagnosed	O
as	O
severe	B-Disease
malaria	I-Disease
with	O
jaundice	B-Disease
and	O
got	O
quinine	B-Chemical
infusion	O
in	O
dextrose	B-Chemical
5	O
%	O
500	O
mg	O
/	O
8	O
hour	O
.	O
On	O
the	O
second	O
day	O
the	O
patient	O
had	O
vomitus	B-Disease
,	O
diarrhea	B-Disease
,	O
tinnitus	B-Disease
,	O
loss	B-Disease
of	I-Disease
hearing	I-Disease
.	O
After	O
30	O
hours	O
of	O
quinine	B-Chemical
infusion	O
the	O
patient	O
felt	O
palpitation	B-Disease
and	O
electrocardiography	O
(	O
ECG	O
)	O
recording	O
showed	O
premature	B-Disease
ventricular	I-Disease
contraction	I-Disease
(	O
PVC	B-Disease
)	O
>	O
5	O
x	O
/	O
minute	O
,	O
trigemini	O
,	O
constant	O
type	O
-	O
-	O
sinoatrial	B-Disease
block	I-Disease
,	O
positive	O
U	O
wave	O
.	O
He	O
was	O
treated	O
with	O
lidocaine	B-Chemical
50	O
mg	O
intravenously	O
followed	O
by	O
infusion	O
1500	O
mg	O
in	O
dextrose	B-Chemical
5	O
%	O
/	O
24	O
hour	O
and	O
potassium	B-Chemical
aspartate	I-Chemical
tablet	O
.	O
Quinine	B-Chemical
infusion	O
was	O
discontinued	O
and	O
changed	O
with	O
sulfate	O
quinine	B-Chemical
tablets	O
.	O
Three	O
hours	O
later	O
the	O
patient	O
felt	O
better	O
,	O
the	O
frequency	O
of	O
PVC	B-Disease
reduced	O
to	O
4	O
-	O
5	O
x	O
/	O
minute	O
and	O
on	O
the	O
third	O
day	O
ECG	O
was	O
normal	O
,	O
potassium	B-Chemical
level	O
was	O
3	O
.	O
34	O
meq	O
/	O
L	O
.	O
He	O
was	O
discharged	O
on	O
7th	O
day	O
in	O
good	O
condition	O
.	O
Quinine	B-Chemical
,	O
like	O
quinidine	B-Chemical
,	O
is	O
a	O
chincona	O
alkaloid	O
that	O
has	O
anti	O
-	O
arrhythmic	B-Disease
property	O
,	O
although	O
it	O
also	O
pro	O
-	O
arrhythmic	B-Disease
that	O
can	O
cause	O
various	O
arrhythmias	B-Disease
,	O
including	O
severe	O
arrhythmia	B-Disease
such	O
as	O
multiple	O
PVC	B-Disease
.	O
Administration	O
of	O
parenteral	O
quinine	B-Chemical
must	O
be	O
done	O
carefully	O
and	O
with	O
good	O
observation	O
because	O
of	O
its	O
pro	O
-	O
arrhythmic	B-Disease
effect	O
,	O
especially	O
in	O
older	O
patients	O
who	O
have	O
heart	B-Disease
diseases	I-Disease
or	O
patients	O
with	O
electrolyte	B-Disease
disorder	I-Disease
(	O
hypokalemia	B-Disease
)	O
which	O
frequently	O
occurs	O
due	O
to	O
vomiting	B-Disease
and	O
or	O
diarrhea	B-Disease
in	O
malaria	B-Disease
cases	O
.	O
Penicillamine	B-Chemical
-	O
related	O
lichenoid	B-Disease
dermatitis	I-Disease
and	O
utility	O
of	O
zinc	B-Chemical
acetate	I-Chemical
in	O
a	O
Wilson	B-Disease
disease	I-Disease
patient	O
with	O
hepatic	O
presentation	O
,	O
anxiety	B-Disease
and	O
SPECT	O
abnormalities	O
.	O
Wilson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
is	O
an	O
autosomal	O
recessive	O
disorder	O
of	O
hepatic	O
copper	B-Chemical
metabolism	O
with	O
consequent	O
copper	B-Chemical
accumulation	O
and	O
toxicity	B-Disease
in	O
many	O
tissues	O
and	O
consequent	O
hepatic	B-Disease
,	I-Disease
neurologic	I-Disease
and	I-Disease
psychiatric	I-Disease
disorders	I-Disease
.	O
We	O
report	O
a	O
case	O
of	O
Wilson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
with	O
chronic	B-Disease
liver	I-Disease
disease	I-Disease
;	O
moreover	O
,	O
in	O
our	O
patient	O
,	O
presenting	O
also	O
with	O
high	O
levels	O
of	O
state	O
anxiety	B-Disease
without	O
depression	B-Disease
,	O
99mTc	O
-	O
ECD	O
-	O
SPECT	O
showed	O
cortical	O
hypoperfusion	O
in	O
frontal	O
lobes	O
,	O
more	O
marked	O
on	O
the	O
left	O
frontal	O
lobe	O
.	O
During	O
the	O
follow	O
-	O
up	O
of	O
our	O
patient	O
,	O
penicillamine	B-Chemical
was	O
interrupted	O
after	O
the	O
appearance	O
of	O
a	O
lichenoid	B-Disease
dermatitis	I-Disease
,	O
and	O
zinc	B-Chemical
acetate	I-Chemical
permitted	O
to	O
continue	O
the	O
successful	O
treatment	O
of	O
the	O
patient	O
without	O
side	O
-	O
effects	O
.	O
In	O
our	O
case	O
the	O
therapy	O
with	O
zinc	B-Chemical
acetate	I-Chemical
represented	O
an	O
effective	O
treatment	O
for	O
a	O
Wilson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patient	O
in	O
which	O
penicillamine	B-Chemical
-	O
related	O
side	O
effects	O
appeared	O
.	O
The	O
safety	O
of	O
the	O
zinc	B-Chemical
acetate	I-Chemical
allowed	O
us	O
to	O
avoid	O
other	O
potentially	O
toxic	O
chelating	O
drugs	O
;	O
this	O
observation	O
is	O
in	O
line	O
with	O
the	O
growing	O
evidence	O
on	O
the	O
efficacy	O
of	O
the	O
drug	O
in	O
the	O
treatment	O
of	O
Wilson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
Since	O
most	O
of	O
Wilson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
penicillamine	B-Chemical
-	O
treated	O
patients	O
do	O
not	O
seem	O
to	O
develop	O
this	O
skin	B-Disease
lesion	I-Disease
,	O
it	O
could	O
be	O
conceivable	O
that	O
a	O
specific	O
genetic	O
factor	O
is	O
involved	O
in	O
drug	O
response	O
.	O
Further	O
studies	O
are	O
needed	O
for	O
a	O
better	O
clarification	O
of	O
Wilson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
therapy	O
,	O
and	O
in	O
particular	O
to	O
differentiate	O
specific	O
therapies	O
for	O
different	O
Wilson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
phenotypes	O
.	O
A	O
dramatic	O
drop	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
following	O
prehospital	O
GTN	B-Chemical
administration	O
.	O
A	O
male	O
in	O
his	O
sixties	O
with	O
no	O
history	O
of	O
cardiac	O
chest	B-Disease
pain	I-Disease
awoke	O
with	O
chest	B-Disease
pain	I-Disease
following	O
an	O
afternoon	O
sleep	O
.	O
The	O
patient	O
did	O
not	O
self	O
medicate	O
.	O
The	O
patient	O
'	O
s	O
observations	O
were	O
within	O
normal	O
limits	O
,	O
he	O
was	O
administered	O
oxygen	B-Chemical
via	O
a	O
face	O
mask	O
and	O
glyceryl	B-Chemical
trinitrate	I-Chemical
(	O
GTN	B-Chemical
)	O
.	O
Several	O
minutes	O
after	O
the	O
GTN	B-Chemical
the	O
patient	O
experienced	O
a	O
sudden	O
drop	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
and	O
heart	O
rate	O
,	O
this	O
was	O
rectified	O
by	O
atropine	B-Chemical
sulphate	I-Chemical
and	O
a	O
fluid	O
challenge	O
.	O
There	O
was	O
no	O
further	O
deterioration	O
in	O
the	O
patient	O
'	O
s	O
condition	O
during	O
transport	O
to	O
hospital	O
.	O
There	O
are	O
very	O
few	O
documented	O
case	O
like	O
this	O
in	O
the	O
prehospital	O
scientific	O
literature	O
.	O
The	O
cause	O
appears	O
to	O
be	O
the	O
Bezold	O
-	O
Jarish	O
reflex	O
,	O
stimulation	O
of	O
the	O
ventricular	O
walls	O
which	O
in	O
turn	O
decreases	O
sympathetic	O
outflow	O
from	O
the	O
vasomotor	O
centre	O
.	O
Prehospital	O
care	O
providers	O
who	O
are	O
managing	O
any	O
patient	O
with	O
a	O
syncopal	B-Disease
episode	I-Disease
that	O
fails	O
to	O
recover	O
within	O
a	O
reasonable	O
time	O
frame	O
should	O
consider	O
the	O
Bezold	O
-	O
Jarisch	O
reflex	O
as	O
the	O
cause	O
and	O
manage	O
the	O
patient	O
accordingly	O
.	O
Chronic	O
lesion	O
of	O
rostral	O
ventrolateral	O
medulla	O
in	O
spontaneously	O
hypertensive	B-Disease
rats	O
.	O
We	O
studied	O
the	O
effects	O
of	O
chronic	O
selective	O
neuronal	O
lesion	O
of	O
rostral	O
ventrolateral	O
medulla	O
on	O
mean	O
arterial	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
neurogenic	O
tone	O
in	O
conscious	O
,	O
unrestrained	O
spontaneously	O
hypertensive	B-Disease
rats	O
.	O
The	O
lesions	O
were	O
placed	O
via	O
bilateral	O
microinjections	O
of	O
30	O
nmol	O
/	O
200	O
nl	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartic	I-Chemical
acid	I-Chemical
.	O
The	O
restimulation	O
of	O
this	O
area	O
with	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartic	I-Chemical
acid	I-Chemical
15	O
days	O
postlesion	O
failed	O
to	O
produce	O
a	O
pressor	O
response	O
.	O
One	O
day	O
postlesion	O
,	O
the	O
resting	O
mean	O
arterial	O
pressure	O
was	O
significantly	O
decreased	O
in	O
lesioned	O
rats	O
when	O
compared	O
with	O
sham	O
rats	O
(	O
100	O
+	O
/	O
-	O
7	O
versus	O
173	O
+	O
/	O
-	O
4	O
mm	O
Hg	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
Fifteen	O
days	O
later	O
,	O
the	O
lesioned	O
group	O
still	O
showed	O
values	O
significantly	O
lower	O
than	O
the	O
sham	O
group	O
(	O
150	O
+	O
/	O
-	O
6	O
versus	O
167	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
No	O
significant	O
heart	O
rate	O
differences	O
were	O
observed	O
between	O
the	O
sham	O
and	O
lesioned	O
groups	O
.	O
The	O
ganglionic	O
blocker	O
trimethaphan	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
caused	O
similar	O
reductions	O
in	O
mean	O
arterial	O
pressure	O
in	O
both	O
lesioned	O
and	O
sham	O
groups	O
.	O
The	O
trimethaphan	B-Chemical
-	O
induced	O
hypotension	B-Disease
was	O
accompanied	O
by	O
a	O
significant	O
bradycardia	B-Disease
in	O
lesioned	O
rats	O
(	O
-	O
32	O
+	O
/	O
-	O
13	O
beats	O
per	O
minute	O
)	O
but	O
a	O
tachycardia	B-Disease
in	O
sham	O
rats	O
(	O
+	O
33	O
+	O
/	O
-	O
12	O
beats	O
per	O
minute	O
)	O
1	O
day	O
postlesion	O
.	O
Therefore	O
,	O
rostral	O
ventrolateral	O
medulla	O
neurons	O
appear	O
to	O
play	O
a	O
significant	O
role	O
in	O
maintaining	O
hypertension	B-Disease
in	O
conscious	O
spontaneously	O
hypertensive	B-Disease
rats	O
.	O
Spinal	O
or	O
suprabulbar	O
structures	O
could	O
be	O
responsible	O
for	O
the	O
gradual	O
recovery	O
of	O
the	O
hypertension	B-Disease
in	O
the	O
lesioned	O
rats	O
.	O
Acute	B-Disease
encephalopathy	I-Disease
and	O
cerebral	B-Disease
vasospasm	I-Disease
after	O
multiagent	O
chemotherapy	O
including	O
PEG	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
and	O
intrathecal	O
cytarabine	B-Chemical
for	O
the	O
treatment	O
of	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
.	O
A	O
7	O
-	O
year	O
-	O
old	O
girl	O
with	O
an	O
unusual	O
reaction	O
to	O
induction	O
chemotherapy	O
for	O
precursor	O
B	O
-	O
cell	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
(	O
ALL	B-Disease
)	O
is	O
described	O
.	O
The	O
patient	O
developed	O
acute	B-Disease
encephalopathy	I-Disease
evidenced	O
by	O
behavioral	O
changes	O
,	O
aphasia	B-Disease
,	O
incontinence	B-Disease
,	O
visual	B-Disease
hallucinations	I-Disease
,	O
and	O
right	O
-	O
sided	O
weakness	B-Disease
with	O
diffuse	O
cerebral	B-Disease
vasospasm	I-Disease
on	O
magnetic	O
resonance	O
angiography	O
after	O
the	O
administration	O
of	O
intrathecal	O
cytarabine	B-Chemical
.	O
Vincristine	B-Chemical
,	O
dexamethasone	B-Chemical
,	O
and	O
polyethylene	B-Chemical
glycol	I-Chemical
-	I-Chemical
asparaginase	I-Chemical
were	O
also	O
administered	O
before	O
the	O
episode	O
as	O
part	O
of	O
induction	O
therapy	O
.	O
Neurologic	O
status	O
returned	O
to	O
baseline	O
within	O
10	O
days	O
of	O
the	O
acute	O
event	O
,	O
and	O
magnetic	O
resonance	O
angiography	O
findings	O
returned	O
to	O
normal	O
4	O
months	O
later	O
.	O
Comparison	O
of	O
valsartan	B-Chemical
/	O
hydrochlorothiazide	B-Chemical
combination	O
therapy	O
at	O
doses	O
up	O
to	O
320	O
/	O
25	O
mg	O
versus	O
monotherapy	O
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
followed	O
by	O
long	O
-	O
term	O
combination	O
therapy	O
in	O
hypertensive	B-Disease
adults	O
.	O
BACKGROUND	O
:	O
One	O
third	O
of	O
patients	O
treated	O
for	O
hypertension	B-Disease
attain	O
adequate	O
blood	O
pressure	O
(	O
BP	O
)	O
control	O
,	O
and	O
multidrug	O
regimens	O
are	O
often	O
required	O
.	O
Given	O
the	O
lifelong	O
nature	O
of	O
hypertension	B-Disease
,	O
there	O
is	O
a	O
need	O
to	O
evaluate	O
the	O
long	O
-	O
term	O
efficacy	O
and	O
tolerability	O
of	O
higher	O
doses	O
of	O
combination	O
anti	O
-	O
hypertensive	B-Disease
therapies	O
.	O
OBJECTIVE	O
:	O
This	O
study	O
investigated	O
the	O
efficacy	O
and	O
tolerability	O
of	O
valsartan	B-Chemical
(	O
VAL	B-Chemical
)	O
or	O
hydrochlorothiazide	B-Chemical
(	O
HCTZ	B-Chemical
)	O
-	O
monotherapy	O
and	O
higher	O
-	O
dose	O
combinations	O
in	O
patients	O
with	O
essential	B-Disease
hypertension	I-Disease
.	O
METHODS	O
:	O
The	O
first	O
part	O
of	O
this	O
study	O
was	O
an	O
8	O
-	O
week	O
,	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
controlled	O
,	O
parallel	O
-	O
group	O
trial	O
.	O
Patients	O
with	O
essential	B-Disease
hypertension	I-Disease
(	O
mean	O
sitting	O
diastolic	O
BP	O
[	O
MSDBP	O
]	O
,	O
>	O
or	O
=	O
95	O
mm	O
Hg	O
and	O
<	O
110	O
mm	O
Hg	O
)	O
were	O
randomized	O
to	O
1	O
of	O
8	O
treatment	O
groups	O
:	O
VAL	B-Chemical
160	O
or	O
320	O
mg	O
;	O
HCTZ	B-Chemical
12	O
.	O
5	O
or	O
25	O
mg	O
;	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
160	O
/	O
12	O
.	O
5	O
,	O
320	O
/	O
12	O
.	O
5	O
,	O
or	O
320	O
/	O
25	O
mg	O
;	O
or	O
placebo	O
.	O
Mean	O
changes	O
in	O
MSDBP	O
and	O
mean	O
sitting	O
systolic	O
BP	O
(	O
MSSBP	O
)	O
were	O
analyzed	O
at	O
the	O
8	O
-	O
week	O
core	O
study	O
end	O
point	O
.	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
320	O
/	O
12	O
.	O
5	O
and	O
320	O
/	O
25	O
mg	O
were	O
further	O
investigated	O
in	O
a	O
54	O
-	O
week	O
,	O
open	O
-	O
label	O
extension	O
.	O
Response	O
was	O
defined	O
as	O
MSDBP	O
<	O
90	O
mm	O
Hg	O
or	O
a	O
>	O
or	O
=	O
10	O
mm	O
Hg	O
decrease	O
compared	O
to	O
baseline	O
.	O
Control	O
was	O
defined	O
as	O
MSDBP	O
<	O
90	O
mm	O
Hg	O
compared	O
with	O
baseline	O
.	O
Tolerability	O
was	O
assessed	O
by	O
monitoring	O
adverse	O
events	O
at	O
randomization	O
and	O
all	O
subsequent	O
study	O
visits	O
and	O
regular	O
evaluation	O
of	O
hematology	O
and	O
blood	O
chemistry	O
.	O
RESULTS	O
:	O
A	O
total	O
of	O
1346	O
patients	O
were	O
randomized	O
into	O
the	O
8	O
-	O
week	O
core	O
study	O
(	O
734	O
men	O
,	O
612	O
women	O
;	O
924	O
white	O
,	O
291	O
black	O
,	O
23	O
Asian	O
,	O
108	O
other	O
;	O
mean	O
age	O
,	O
52	O
.	O
7	O
years	O
;	O
mean	O
weight	O
,	O
92	O
.	O
6	O
kg	O
)	O
.	O
All	O
active	O
treatments	O
were	O
associated	O
with	O
significantly	O
reduced	O
MSSBP	O
and	O
MSDBP	O
during	O
the	O
core	O
8	O
-	O
week	O
study	O
,	O
with	O
each	O
monotherapy	O
significantly	O
contributing	O
to	O
the	O
overall	O
effect	O
of	O
combination	O
therapy	O
(	O
VAL	B-Chemical
and	O
HCTZ	B-Chemical
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
Each	O
combination	O
was	O
associated	O
with	O
significantly	O
greater	O
reductions	O
in	O
MSSBP	O
and	O
MSDBP	O
compared	O
with	O
the	O
monotherapies	O
and	O
placebo	O
(	O
all	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
The	O
mean	O
reduction	O
in	O
MSSBP	O
/	O
MSDBP	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
320	O
/	O
25	O
mg	O
was	O
24	O
.	O
7	O
/	O
16	O
.	O
6	O
mm	O
Hg	O
,	O
compared	O
with	O
5	O
.	O
9	O
/	O
7	O
.	O
0	O
mm	O
Hg	O
with	O
placebo	O
.	O
The	O
reduction	O
in	O
MSSBP	O
was	O
significantly	O
greater	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
320	O
/	O
25	O
mg	O
compared	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
160	O
/	O
12	O
.	O
5	O
mg	O
(	O
P	O
<	O
0	O
.	O
002	O
)	O
.	O
Rates	O
of	O
response	O
and	O
BP	O
control	O
were	O
significantly	O
higher	O
in	O
the	O
groups	O
that	O
received	O
combination	O
treatment	O
compared	O
with	O
those	O
that	O
received	O
monotherapy	O
.	O
The	O
incidence	O
of	O
hypokalemia	B-Disease
was	O
lower	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
combinations	O
(	O
1	O
.	O
8	O
%	O
-	O
6	O
.	O
1	O
%	O
)	O
than	O
with	O
HCTZ	B-Chemical
monotherapies	O
(	O
7	O
.	O
1	O
%	O
-	O
13	O
.	O
3	O
%	O
)	O
.	O
The	O
majority	O
of	O
adverse	O
events	O
in	O
the	O
core	O
study	O
were	O
of	O
mild	O
to	O
moderate	O
severity	O
.	O
The	O
efficacy	O
and	O
tolerability	O
of	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
combinations	O
were	O
maintained	O
during	O
the	O
extension	O
(	O
797	O
patients	O
)	O
.	O
CONCLUSIONS	O
:	O
In	O
this	O
study	O
population	O
,	O
combination	O
therapies	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
were	O
associated	O
with	O
significantly	O
greater	O
BP	O
reductions	O
compared	O
with	O
either	O
monotherapy	O
,	O
were	O
well	O
tolerated	O
,	O
and	O
were	O
associated	O
with	O
less	O
hypokalemia	B-Disease
than	O
HCTZ	B-Chemical
alone	O
.	O
Succimer	B-Chemical
chelation	O
improves	O
learning	O
,	O
attention	O
,	O
and	O
arousal	O
regulation	O
in	O
lead	B-Chemical
-	O
exposed	O
rats	O
but	O
produces	O
lasting	O
cognitive	B-Disease
impairment	I-Disease
in	O
the	O
absence	O
of	O
lead	B-Chemical
exposure	O
.	O
BACKGROUND	O
:	O
There	O
is	O
growing	O
pressure	O
for	O
clinicians	O
to	O
prescribe	O
chelation	O
therapy	O
at	O
only	O
slightly	O
elevated	O
blood	O
lead	B-Chemical
levels	O
.	O
However	O
,	O
very	O
few	O
studies	O
have	O
evaluated	O
whether	O
chelation	O
improves	O
cognitive	O
outcomes	O
in	O
Pb	B-Chemical
-	O
exposed	O
children	O
,	O
or	O
whether	O
these	O
agents	O
have	O
adverse	O
effects	O
that	O
may	O
affect	O
brain	O
development	O
in	O
the	O
absence	O
of	O
Pb	B-Chemical
exposure	O
.	O
OBJECTIVES	O
:	O
The	O
present	O
study	O
was	O
designed	O
to	O
answer	O
these	O
questions	O
,	O
using	O
a	O
rodent	O
model	O
of	O
early	O
childhood	O
Pb	B-Chemical
exposure	O
and	O
treatment	O
with	O
succimer	B-Chemical
,	O
a	O
widely	O
used	O
chelating	O
agent	O
for	O
the	O
treatment	O
of	O
Pb	B-Disease
poisoning	I-Disease
.	O
RESULTS	O
:	O
Pb	B-Chemical
exposure	O
produced	O
lasting	O
impairments	B-Disease
in	I-Disease
learning	I-Disease
,	I-Disease
attention	I-Disease
,	I-Disease
inhibitory	I-Disease
control	I-Disease
,	I-Disease
and	I-Disease
arousal	I-Disease
regulation	I-Disease
,	O
paralleling	O
the	O
areas	O
of	O
dysfunction	O
seen	O
in	O
Pb	B-Chemical
-	O
exposed	O
children	O
.	O
Succimer	B-Chemical
treatment	O
of	O
the	O
Pb	B-Chemical
-	O
exposed	O
rats	O
significantly	O
improved	O
learning	O
,	O
attention	O
,	O
and	O
arousal	O
regulation	O
,	O
although	O
the	O
efficacy	O
of	O
the	O
treatment	O
varied	O
as	O
a	O
function	O
of	O
the	O
Pb	B-Chemical
exposure	O
level	O
and	O
the	O
specific	O
functional	O
deficit	O
.	O
In	O
contrast	O
,	O
succimer	B-Chemical
treatment	O
of	O
rats	O
not	O
previously	O
exposed	O
to	O
Pb	B-Chemical
produced	O
lasting	O
and	O
pervasive	O
cognitive	B-Disease
and	I-Disease
affective	I-Disease
dysfunction	I-Disease
comparable	O
in	O
magnitude	O
to	O
that	O
produced	O
by	O
the	O
higher	O
Pb	B-Chemical
exposure	O
regimen	O
.	O
CONCLUSIONS	O
:	O
These	O
are	O
the	O
first	O
data	O
,	O
to	O
our	O
knowledge	O
,	O
to	O
show	O
that	O
treatment	O
with	O
any	O
chelating	O
agent	O
can	O
alleviate	O
cognitive	B-Disease
deficits	I-Disease
due	O
to	O
Pb	B-Chemical
exposure	O
.	O
These	O
findings	O
suggest	O
that	O
it	O
may	O
be	O
possible	O
to	O
identify	O
a	O
succimer	B-Chemical
treatment	O
protocol	O
that	O
improves	O
cognitive	O
outcomes	O
in	O
Pb	B-Chemical
-	O
exposed	O
children	O
.	O
However	O
,	O
they	O
also	O
suggest	O
that	O
succimer	B-Chemical
treatment	O
should	O
be	O
strongly	O
discouraged	O
for	O
children	O
who	O
do	O
not	O
have	O
elevated	O
tissue	O
levels	O
of	O
Pb	B-Chemical
or	O
other	O
heavy	O
metals	O
.	O
Caffeine	B-Chemical
challenge	O
test	O
in	O
panic	B-Disease
disorder	I-Disease
and	O
depression	B-Disease
with	O
panic	B-Disease
attacks	I-Disease
.	O
Our	O
aim	O
was	O
to	O
observe	O
if	O
patients	O
with	O
panic	B-Disease
disorder	I-Disease
(	O
PD	B-Disease
)	O
and	O
patients	O
with	O
major	B-Disease
depression	I-Disease
with	O
panic	B-Disease
attacks	I-Disease
(	O
MDP	B-Disease
)	O
(	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	B-Disease
Disorders	I-Disease
,	O
Fourth	O
Edition	O
criteria	O
)	O
respond	O
in	O
a	O
similar	O
way	O
to	O
the	O
induction	O
of	O
panic	B-Disease
attacks	I-Disease
by	O
an	O
oral	O
caffeine	B-Chemical
challenge	O
test	O
.	O
We	O
randomly	O
selected	O
29	O
patients	O
with	O
PD	B-Disease
,	O
27	O
with	O
MDP	B-Disease
,	O
25	O
with	O
major	B-Disease
depression	I-Disease
without	O
panic	B-Disease
attacks	I-Disease
(	O
MD	B-Disease
)	O
,	O
and	O
28	O
healthy	O
volunteers	O
.	O
The	O
patients	O
had	O
no	O
psychotropic	O
drug	O
for	O
at	O
least	O
a	O
4	O
-	O
week	O
period	O
.	O
In	O
a	O
randomized	O
double	O
-	O
blind	O
experiment	O
performed	O
in	O
2	O
occasions	O
7	O
days	O
apart	O
,	O
480	O
mg	O
caffeine	B-Chemical
and	O
a	O
caffeine	B-Chemical
-	O
free	O
(	O
placebo	O
)	O
solution	O
were	O
administered	O
in	O
a	O
coffee	O
form	O
and	O
anxiety	B-Disease
scales	O
were	O
applied	O
before	O
and	O
after	O
each	O
test	O
.	O
A	O
total	O
of	O
58	O
.	O
6	O
%	O
(	O
n	O
=	O
17	O
)	O
of	O
patients	O
with	O
PD	B-Disease
,	O
44	O
.	O
4	O
%	O
(	O
n	O
=	O
12	O
)	O
of	O
patients	O
with	O
MDP	B-Disease
,	O
12	O
.	O
0	O
%	O
(	O
n	O
=	O
3	O
)	O
of	O
patients	O
with	O
MD	B-Disease
,	O
and	O
7	O
.	O
1	O
%	O
(	O
n	O
=	O
2	O
)	O
of	O
control	O
subjects	O
had	O
a	O
panic	B-Disease
attack	I-Disease
after	O
the	O
480	O
-	O
mg	O
caffeine	B-Chemical
challenge	O
test	O
(	O
chi	O
(	O
2	O
)	O
(	O
3	O
)	O
=	O
16	O
.	O
22	O
,	O
P	O
=	O
.	O
001	O
)	O
.	O
The	O
patients	O
with	O
PD	B-Disease
and	O
MDP	B-Disease
were	O
more	O
sensitive	O
to	O
caffeine	B-Chemical
than	O
were	O
patients	O
with	O
MD	B-Disease
and	O
healthy	O
volunteers	O
.	O
No	O
panic	B-Disease
attack	I-Disease
was	O
observed	O
after	O
the	O
caffeine	B-Chemical
-	O
free	O
solution	O
intake	O
.	O
The	O
patients	O
with	O
MD	B-Disease
had	O
a	O
lower	O
heart	O
rate	O
response	O
to	O
the	O
test	O
than	O
all	O
the	O
other	O
groups	O
(	O
2	O
-	O
way	O
analysis	O
of	O
variance	O
,	O
group	O
by	O
time	O
interaction	O
with	O
Greenhouse	O
-	O
Geisser	O
correction	O
:	O
F	O
(	O
3	O
,	O
762	O
)	O
=	O
2	O
.	O
85	O
,	O
P	O
=	O
.	O
026	O
)	O
.	O
Our	O
data	O
suggest	O
that	O
there	O
is	O
an	O
association	O
between	O
panic	B-Disease
attacks	I-Disease
,	O
no	O
matter	O
if	O
associated	O
with	O
PD	B-Disease
or	O
MDP	B-Disease
,	O
and	O
hyperreactivity	O
to	O
an	O
oral	O
caffeine	B-Chemical
challenge	O
test	O
.	O
Mitral	O
annuloplasty	O
as	O
a	O
ventricular	O
restoration	O
method	O
for	O
the	O
failing	B-Disease
left	I-Disease
ventricle	I-Disease
:	O
a	O
pilot	O
study	O
.	O
BACKGROUND	O
AND	O
AIM	O
OF	O
THE	O
STUDY	O
:	O
Undersized	O
mitral	O
annuloplasty	O
(	O
MAP	O
)	O
is	O
effective	O
in	O
patients	O
with	O
dilated	B-Disease
cardiomyopathy	I-Disease
and	O
functional	O
mitral	B-Disease
regurgitation	I-Disease
(	O
MR	B-Disease
)	O
since	O
,	O
as	O
well	O
as	O
addressing	O
the	O
MR	B-Disease
,	O
the	O
MAP	O
may	O
also	O
reshape	O
the	O
dilated	O
left	O
ventricular	O
(	O
LV	O
)	O
base	O
.	O
However	O
,	O
the	O
direct	O
benefits	O
of	O
this	O
possible	O
reshaping	O
on	O
LV	O
function	O
in	O
the	O
absence	O
of	O
underlying	O
MR	B-Disease
remain	O
incompletely	O
understood	O
.	O
The	O
study	O
aim	O
was	O
to	O
identify	O
these	O
benefits	O
in	O
a	O
canine	O
model	O
of	O
acute	O
heart	B-Disease
failure	I-Disease
.	O
METHODS	O
:	O
Six	O
dogs	O
underwent	O
MAP	O
with	O
a	O
prosthetic	O
band	O
on	O
the	O
posterior	O
mitral	O
annulus	O
,	O
using	O
four	O
mattress	O
sutures	O
.	O
The	O
sutures	O
were	O
passed	O
individually	O
through	O
four	O
tourniquets	O
and	O
exteriorized	O
untied	O
via	O
the	O
left	O
atriotomy	O
.	O
Sonomicrometry	O
crystals	O
were	O
implanted	O
around	O
the	O
mitral	O
annulus	O
and	O
left	O
ventricle	O
to	O
measure	O
geometry	O
and	O
regional	O
function	O
.	O
Acute	O
heart	B-Disease
failure	I-Disease
was	O
induced	O
by	O
propranolol	B-Chemical
and	O
volume	O
loading	O
after	O
weaning	O
from	O
cardiopulmonary	O
bypass	O
;	O
an	O
absence	O
of	O
MR	B-Disease
was	O
confirmed	O
by	O
echocardiography	O
.	O
MAP	O
was	O
accomplished	O
by	O
cinching	O
the	O
tourniquets	O
.	O
Data	O
were	O
acquired	O
at	O
baseline	O
,	O
after	O
induction	O
of	O
acute	O
heart	B-Disease
failure	I-Disease
,	O
and	O
after	O
MAP	O
.	O
RESULTS	O
:	O
MAP	O
decreased	O
mitral	O
annular	O
dimensions	O
in	O
both	O
commissure	O
-	O
commissure	O
and	O
septal	O
-	O
lateral	O
directions	O
.	O
Concomitantly	O
,	O
the	O
diastolic	O
diameter	O
of	O
the	O
LV	O
base	O
and	O
LV	O
sphericity	O
decreased	O
(	O
i	O
.	O
e	O
.	O
,	O
improved	O
)	O
from	O
37	O
.	O
4	O
+	O
/	O
-	O
9	O
.	O
3	O
to	O
35	O
.	O
9	O
+	O
/	O
-	O
10	O
mm	O
(	O
p	O
=	O
0	O
.	O
063	O
)	O
,	O
and	O
from	O
67	O
.	O
9	O
+	O
/	O
-	O
18	O
.	O
6	O
%	O
to	O
65	O
.	O
3	O
+	O
/	O
-	O
18	O
.	O
9	O
%	O
(	O
p	O
=	O
0	O
.	O
016	O
)	O
,	O
respectively	O
.	O
Decreases	O
were	O
evident	O
in	O
both	O
LV	O
end	O
-	O
diastolic	O
pressure	O
(	O
from	O
17	O
+	O
/	O
-	O
7	O
to	O
15	O
+	O
/	O
-	O
6	O
mmHg	O
,	O
p	O
=	O
0	O
.	O
0480	O
and	O
Tau	O
(	O
from	O
48	O
+	O
/	O
-	O
8	O
to	O
45	O
+	O
/	O
-	O
8	O
ms	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
while	O
fractional	O
shortening	O
at	O
the	O
LV	O
base	O
increased	O
from	O
7	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
5	O
%	O
to	O
9	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
5	O
%	O
(	O
p	O
=	O
0	O
.	O
045	O
)	O
.	O
After	O
MAP	O
,	O
increases	O
were	O
identified	O
in	O
both	O
cardiac	O
output	O
(	O
from	O
1	O
.	O
54	O
+	O
/	O
-	O
0	O
.	O
57	O
to	O
1	O
.	O
65	O
+	O
/	O
-	O
0	O
.	O
57	O
1	O
/	O
min	O
)	O
and	O
Emax	O
(	O
from	O
1	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
9	O
to	O
2	O
.	O
41	O
+	O
/	O
-	O
1	O
.	O
31	O
mmHg	O
/	O
ml	O
)	O
.	O
CONCLUSION	O
:	O
The	O
data	O
acquired	O
suggest	O
that	O
isolated	O
MAP	O
may	O
have	O
certain	O
benefits	O
on	O
LV	O
dimension	O
/	O
function	O
in	O
acute	O
heart	B-Disease
failure	I-Disease
,	O
even	O
in	O
the	O
absence	O
of	O
MR	B-Disease
.	O
However	O
,	O
further	O
investigations	O
are	O
warranted	O
in	O
a	O
model	O
of	O
chronic	O
heart	B-Disease
failure	I-Disease
.	O
Piperacillin	B-Chemical
/	I-Chemical
tazobactam	I-Chemical
-	O
induced	O
seizure	B-Disease
rapidly	O
reversed	O
by	O
high	O
flux	O
hemodialysis	O
in	O
a	O
patient	O
on	O
peritoneal	O
dialysis	O
.	O
Despite	O
popular	O
use	O
of	O
piperacillin	B-Chemical
,	O
the	O
dire	O
neurotoxicity	B-Disease
associated	O
with	O
piperacillin	B-Chemical
still	O
goes	O
unrecognized	O
,	O
leading	O
to	O
a	O
delay	O
in	O
appropriate	O
management	O
.	O
We	O
report	O
a	O
57	O
-	O
year	O
-	O
old	O
woman	O
with	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
receiving	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
,	O
who	O
developed	O
slurred	O
speech	O
,	O
tremor	B-Disease
,	O
bizarre	O
behavior	O
,	O
progressive	O
mental	O
confusion	B-Disease
,	O
and	O
2	O
episodes	O
of	O
generalized	O
tonic	B-Disease
-	I-Disease
clonic	I-Disease
seizure	I-Disease
(	O
GTCS	B-Disease
)	O
after	O
5	O
doses	O
of	O
piperacillin	B-Chemical
/	I-Chemical
tazobactam	I-Chemical
(	O
2	O
g	O
/	O
250	O
mg	O
)	O
were	O
given	O
for	O
bronchiectasis	B-Disease
with	O
secondary	B-Disease
infection	I-Disease
.	O
The	O
laboratory	O
data	O
revealed	O
normal	O
plasma	O
electrolyte	O
and	O
ammonia	B-Chemical
levels	O
but	O
leukocytosis	B-Disease
.	O
Neurologic	O
examinations	O
showed	O
dysarthria	B-Disease
and	O
bilateral	O
Babinski	O
sign	O
.	O
Computed	O
tomography	O
of	O
brain	O
and	O
electroencephalogram	O
were	O
unremarkable	O
.	O
Despite	O
the	O
use	O
of	O
antiepileptic	O
agents	O
,	O
another	O
GTCS	B-Disease
episode	O
recurred	O
after	O
the	O
sixth	O
dose	O
of	O
piperacillin	B-Chemical
/	I-Chemical
tazobactam	I-Chemical
.	O
Brain	O
magnetic	O
resonance	O
imaging	O
did	O
not	O
demonstrate	O
acute	O
infarction	B-Disease
and	O
organic	B-Disease
brain	I-Disease
lesions	I-Disease
.	O
Initiation	O
of	O
high	O
-	O
flux	O
hemodialysis	O
rapidly	O
reversed	O
the	O
neurologic	O
symptoms	O
within	O
4	O
hours	O
.	O
Piperacillin	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
should	O
be	O
considered	O
in	O
any	O
uremic	B-Disease
patients	O
with	O
unexplained	O
neurological	O
manifestations	O
.	O
CAPD	O
is	O
inefficient	O
in	O
removing	O
piperacillin	B-Chemical
,	O
whereas	O
hemodialysis	O
can	O
rapidly	O
terminate	O
the	O
piperacillin	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
.	O
Frequency	O
of	O
transient	O
ipsilateral	O
vocal	B-Disease
cord	I-Disease
paralysis	I-Disease
in	O
patients	O
undergoing	O
carotid	O
endarterectomy	O
under	O
local	O
anesthesia	O
.	O
BACKGROUND	O
:	O
Especially	O
because	O
of	O
improvements	O
in	O
clinical	O
neurologic	O
monitoring	O
,	O
carotid	O
endarterectomy	O
done	O
under	O
local	O
anesthesia	O
has	O
become	O
the	O
technique	O
of	O
choice	O
in	O
several	O
centers	O
.	O
Temporary	O
ipsilateral	O
vocal	B-Disease
nerve	I-Disease
palsies	I-Disease
due	O
to	O
local	O
anesthetics	O
have	O
been	O
described	O
,	O
however	O
.	O
Such	O
complications	O
are	O
most	O
important	O
in	O
situations	O
where	O
there	O
is	O
a	O
pre	O
-	O
existing	O
contralateral	O
paralysis	B-Disease
.	O
We	O
therefore	O
examined	O
the	O
effect	O
of	O
local	O
anesthesia	O
on	O
vocal	O
cord	O
function	O
to	O
better	O
understand	O
its	O
possible	O
consequences	O
.	O
METHODS	O
:	O
This	O
prospective	O
study	O
included	O
28	O
patients	O
undergoing	O
carotid	O
endarterectomy	O
under	O
local	O
anesthesia	O
.	O
Vocal	O
cord	O
function	O
was	O
evaluated	O
before	O
,	O
during	O
,	O
and	O
after	O
surgery	O
(	O
postoperative	O
day	O
1	O
)	O
using	O
flexible	O
laryngoscopy	O
.	O
Anesthesia	O
was	O
performed	O
by	O
injecting	O
20	O
to	O
40	O
mL	O
of	O
a	O
mixture	O
of	O
long	O
-	O
acting	O
(	O
ropivacaine	B-Chemical
)	O
and	O
short	O
-	O
acting	O
(	O
prilocaine	B-Chemical
)	O
anesthetic	O
.	O
RESULTS	O
:	O
All	O
patients	O
had	O
normal	O
vocal	O
cord	O
function	O
preoperatively	O
.	O
Twelve	O
patients	O
(	O
43	O
%	O
)	O
were	O
found	O
to	O
have	O
intraoperative	O
ipsilateral	O
vocal	B-Disease
cord	I-Disease
paralysis	I-Disease
.	O
It	O
resolved	O
in	O
all	O
cases	O
<	O
or	O
=	O
24	O
hours	O
.	O
There	O
were	O
no	O
significant	O
differences	O
in	O
operating	O
time	O
or	O
volume	O
or	O
frequency	O
of	O
anesthetic	O
administration	O
in	O
patients	O
with	O
temporary	O
vocal	B-Disease
cord	I-Disease
paralysis	I-Disease
compared	O
with	O
those	O
without	O
.	O
CONCLUSION	O
:	O
Local	O
anesthesia	O
led	O
to	O
temporary	O
ipsilateral	O
vocal	B-Disease
cord	I-Disease
paralysis	I-Disease
in	O
almost	O
half	O
of	O
these	O
patients	O
.	O
Because	O
pre	O
-	O
existing	O
paralysis	B-Disease
is	O
of	O
a	O
relevant	O
frequency	O
(	O
up	O
to	O
3	O
%	O
)	O
,	O
a	O
preoperative	O
evaluation	O
of	O
vocal	O
cord	O
function	O
before	O
carotid	O
endarterectomy	O
under	O
local	O
anesthesia	O
is	O
recommended	O
to	O
avoid	O
intraoperative	O
bilateral	O
paralysis	B-Disease
.	O
In	O
patients	O
with	O
preoperative	O
contralateral	O
vocal	B-Disease
cord	I-Disease
paralysis	I-Disease
,	O
surgery	O
under	O
general	O
anesthesia	O
should	O
be	O
considered	O
.	O
Impaired	B-Disease
fear	I-Disease
recognition	I-Disease
in	O
regular	O
recreational	O
cocaine	B-Chemical
users	O
.	O
INTRODUCTION	O
:	O
The	O
ability	O
to	O
read	O
facial	O
expressions	O
is	O
essential	O
for	O
normal	O
human	O
social	O
interaction	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
conduct	O
the	O
first	O
investigation	O
of	O
facial	O
expression	O
recognition	O
performance	O
in	O
recreational	O
cocaine	B-Chemical
users	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Three	O
groups	O
,	O
comprised	O
of	O
21	O
cocaine	B-Chemical
naive	O
participants	O
(	O
CN	O
)	O
,	O
30	O
occasional	O
cocaine	B-Chemical
(	O
OC	O
)	O
,	O
and	O
48	O
regular	O
recreational	O
cocaine	B-Chemical
(	O
RC	O
)	O
users	O
,	O
were	O
compared	O
.	O
An	O
emotional	O
facial	O
expression	O
(	O
EFE	O
)	O
task	O
consisting	O
of	O
a	O
male	O
and	O
female	O
face	O
expressing	O
six	O
basic	O
emotions	O
(	O
happiness	O
,	O
surprise	O
,	O
sadness	O
,	O
anger	O
,	O
fear	O
,	O
and	O
disgust	O
)	O
was	O
administered	O
.	O
Mean	O
percent	O
accuracy	O
and	O
latencies	O
for	O
correct	O
responses	O
across	O
eight	O
presentations	O
of	O
each	O
basic	O
emotion	O
were	O
derived	O
.	O
Participants	O
were	O
also	O
assessed	O
with	O
the	O
""""	O
Eyes	O
task	O
""""	O
to	O
investigate	O
their	O
ability	O
to	O
recognize	O
more	O
complex	O
emotional	O
states	O
and	O
the	O
Symptom	O
CheckList	O
-	O
90	O
-	O
Revised	O
to	O
measure	O
psychopathology	O
.	O
RESULTS	O
:	O
There	O
were	O
no	O
group	O
differences	O
in	O
psychopathology	O
or	O
""""	O
eyes	O
task	O
""""	O
performance	O
,	O
but	O
the	O
RC	O
group	O
,	O
who	O
otherwise	O
had	O
similar	O
illicit	O
substance	O
use	O
histories	O
to	O
the	O
OC	O
group	O
,	O
exhibited	O
impaired	B-Disease
fear	I-Disease
recognition	I-Disease
accuracy	O
compared	O
to	O
the	O
OC	O
and	O
CN	O
groups	O
.	O
The	O
RC	O
group	O
also	O
correctly	O
identified	O
anger	O
,	O
fear	O
,	O
happiness	O
,	O
and	O
surprise	O
,	O
more	O
slowly	O
than	O
CN	O
,	O
but	O
not	O
OC	O
participants	O
.	O
The	O
OC	O
group	O
was	O
slower	O
than	O
CN	O
when	O
correctly	O
identifying	O
disgust	O
.	O
The	O
selective	O
deficit	B-Disease
in	I-Disease
fear	I-Disease
recognition	I-Disease
accuracy	O
manifested	O
by	O
the	O
RC	O
group	O
cannot	O
be	O
explained	O
by	O
the	O
subacute	O
effects	O
of	O
cocaine	B-Chemical
,	O
or	O
ecstasy	B-Chemical
,	O
because	O
recent	O
and	O
less	O
recent	O
users	O
of	O
these	O
drugs	O
within	O
this	O
group	O
were	O
similarly	O
impaired	O
.	O
Possible	O
parallels	O
between	O
RC	O
users	O
and	O
psychopaths	B-Disease
with	O
respect	O
to	O
impaired	B-Disease
fear	I-Disease
recognition	I-Disease
,	O
amygdala	B-Disease
dysfunction	I-Disease
,	O
and	O
etiology	O
are	O
discussed	O
.	O
Damage	B-Disease
of	I-Disease
substantia	I-Disease
nigra	I-Disease
pars	I-Disease
reticulata	I-Disease
during	O
pilocarpine	B-Chemical
-	O
induced	O
status	B-Disease
epilepticus	I-Disease
in	O
the	O
rat	O
:	O
immunohistochemical	O
study	O
of	O
neurons	O
,	O
astrocytes	O
and	O
serum	O
-	O
protein	O
extravasation	O
.	O
The	O
substantia	O
nigra	O
has	O
a	O
gating	O
function	O
controlling	O
the	O
spread	O
of	O
epileptic	B-Disease
seizure	I-Disease
activity	O
.	O
Additionally	O
,	O
in	O
models	O
of	O
prolonged	B-Disease
status	I-Disease
epilepticus	I-Disease
the	O
pars	O
reticulata	O
of	O
substantia	O
nigra	O
(	O
SNR	O
)	O
suffers	O
from	O
a	O
massive	O
lesion	O
which	O
may	O
arise	O
from	O
a	O
massive	O
metabolic	B-Disease
derangement	I-Disease
and	O
hyperexcitation	O
developing	O
in	O
the	O
activated	O
SNR	O
.	O
In	O
this	O
study	O
,	O
status	B-Disease
epilepticus	I-Disease
was	O
induced	O
by	O
systemic	O
injection	O
of	O
pilocarpine	B-Chemical
in	O
rats	O
.	O
The	O
neuropathology	O
of	O
SNR	O
was	O
investigated	O
using	O
immunohistochemical	O
techniques	O
with	O
the	O
major	O
emphasis	O
on	O
the	O
time	O
-	O
course	O
of	O
changes	O
in	O
neurons	O
and	O
astrocytes	O
.	O
Animals	O
surviving	O
20	O
,	O
30	O
,	O
40	O
,	O
60	O
min	O
,	O
2	O
,	O
3	O
,	O
6	O
hours	O
,	O
1	O
,	O
2	O
,	O
and	O
3	O
days	O
after	O
induction	O
of	O
status	B-Disease
epilepticus	I-Disease
were	O
perfusion	O
-	O
fixed	O
,	O
and	O
brains	O
processed	O
for	O
immunohistochemical	O
staining	O
of	O
SNR	O
.	O
Nissl	O
-	O
staining	O
and	O
antibodies	O
against	O
the	O
neuron	O
-	O
specific	O
calcium	B-Chemical
-	O
binding	O
protein	O
,	O
parvalbumin	O
,	O
served	O
to	O
detect	O
neuronal	B-Disease
damage	I-Disease
in	O
SNR	O
.	O
Antibodies	O
against	O
the	O
astroglia	O
-	O
specific	O
cytoskeletal	O
protein	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
,	O
and	O
against	O
the	O
glial	O
calcium	B-Chemical
-	O
binding	O
protein	O
,	O
S	O
-	O
100	O
protein	O
,	O
were	O
used	O
to	O
assess	O
the	O
status	O
of	O
astrocytes	O
.	O
Immunohistochemical	O
staining	O
for	O
serum	O
-	O
albumin	O
and	O
immunoglobulins	O
in	O
brain	O
tissue	O
was	O
taken	O
as	O
indicator	O
of	O
blood	O
-	O
brain	O
barrier	O
disturbances	O
and	O
vasogenic	B-Disease
edema	I-Disease
formation	O
.	O
Immunohistochemical	O
staining	O
indicated	O
loss	O
of	O
GFAP	O
-	O
staining	O
already	O
at	O
30	O
min	O
after	O
induction	O
of	O
seizures	B-Disease
in	O
an	O
oval	O
focus	O
situated	O
in	O
the	O
center	O
of	O
SNR	O
while	O
sparing	O
medial	O
and	O
lateral	O
aspects	O
.	O
At	O
1	O
h	O
there	O
was	O
additional	O
vacuolation	O
in	O
S	O
-	O
100	O
protein	O
staining	O
.	O
By	O
2	O
hours	O
,	O
parvalbumin	O
-	O
staining	O
changed	O
in	O
the	O
central	O
SNR	O
indicating	O
neuronal	B-Disease
damage	I-Disease
,	O
and	O
Nissl	O
-	O
staining	O
visualized	O
some	O
neuronal	O
distortion	O
.	O
Staining	O
for	O
serum	O
-	O
proteins	O
occurred	O
in	O
a	O
patchy	O
manner	O
throughout	O
the	O
forebrain	O
during	O
the	O
first	O
hours	O
.	O
By	O
6	O
h	O
,	O
vasogenic	B-Disease
edema	I-Disease
covered	O
the	O
lesioned	B-Disease
SNR	I-Disease
.	O
By	O
24	O
h	O
,	O
glial	O
and	O
neuronal	O
markers	O
indicated	O
a	O
massive	O
lesion	O
in	O
the	O
center	O
of	O
SNR	O
.	O
By	O
48	O
-	O
72	O
h	O
,	O
astrocytes	O
surrounding	O
the	O
lesion	O
increased	O
in	O
size	O
,	O
and	O
polymorphic	O
phagocytotic	O
cells	O
invaded	O
the	O
damaged	O
area	O
.	O
In	O
a	O
further	O
group	O
of	O
animals	O
surviving	O
1	O
to	O
5	O
days	O
,	O
conventional	O
paraffin	O
-	O
sections	O
confirmed	O
the	O
neuronal	O
and	O
glial	O
damage	B-Disease
of	I-Disease
SNR	I-Disease
.	O
Additional	O
pathology	O
of	O
similar	O
quality	O
was	O
found	O
in	O
the	O
globus	O
pallidus	O
.	O
Since	O
astrocytes	O
were	O
always	O
damaged	O
in	O
parallel	O
with	O
neurons	O
in	O
SNR	O
it	O
is	O
proposed	O
that	O
the	O
anatomical	O
and	O
functional	O
interrelationship	O
between	O
neurons	O
and	O
astrocytes	O
is	O
particularly	O
tight	O
in	O
SNR	O
.	O
Both	O
cell	O
elements	O
may	O
suffer	O
in	O
common	O
from	O
metabolic	O
disturbance	O
and	O
neurotransmitter	B-Disease
dysfunction	I-Disease
as	O
occur	O
during	O
massive	O
status	B-Disease
epilepticus	I-Disease
.	O
Neuroprotective	O
effects	O
of	O
melatonin	B-Chemical
upon	O
the	O
offspring	O
cerebellar	O
cortex	O
in	O
the	O
rat	O
model	O
of	O
BCNU	B-Chemical
-	O
induced	O
cortical	B-Disease
dysplasia	I-Disease
.	O
Cortical	B-Disease
dysplasia	I-Disease
is	O
a	O
malformation	O
characterized	O
by	O
defects	O
in	O
proliferation	O
,	O
migration	O
and	O
maturation	O
.	O
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
alterations	O
in	O
offspring	O
rat	O
cerebellum	O
induced	O
by	O
maternal	O
exposure	O
to	O
carmustine	B-Chemical
-	O
[	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
chloroethyl	I-Chemical
)	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
nitrosoure	I-Chemical
]	O
(	O
BCNU	B-Chemical
)	O
and	O
to	O
investigate	O
the	O
effects	O
of	O
exogenous	O
melatonin	B-Chemical
upon	O
cerebellar	O
BCNU	B-Chemical
-	O
induced	O
cortical	B-Disease
dysplasia	I-Disease
,	O
using	O
histological	O
and	O
biochemical	O
analyses	O
.	O
Pregnant	O
Wistar	O
rats	O
were	O
assigned	O
to	O
five	O
groups	O
:	O
intact	O
-	O
control	O
,	O
saline	O
-	O
control	O
,	O
melatonin	B-Chemical
-	O
treated	O
,	O
BCNU	B-Chemical
-	O
exposed	O
and	O
BCNU	B-Chemical
-	O
exposed	O
plus	O
melatonin	B-Chemical
.	O
Rats	O
were	O
exposed	O
to	O
BCNU	B-Chemical
on	O
embryonic	O
day	O
15	O
and	O
melatonin	B-Chemical
was	O
given	O
until	O
delivery	O
.	O
Immuno	O
/	O
histochemistry	O
and	O
electron	O
microscopy	O
were	O
carried	O
out	O
on	O
the	O
offspring	O
cerebellum	O
,	O
and	O
levels	O
of	O
malondialdehyde	B-Chemical
and	O
superoxide	B-Chemical
dismutase	O
were	O
determined	O
.	O
Histopathologically	O
,	O
typical	O
findings	O
were	O
observed	O
in	O
the	O
cerebella	O
from	O
the	O
control	O
groups	O
,	O
but	O
the	O
findings	O
consistent	O
with	O
early	O
embryonic	O
development	O
were	O
noted	O
in	O
BCNU	B-Chemical
-	O
exposed	O
cortical	B-Disease
dysplasia	I-Disease
group	O
.	O
There	O
was	O
a	O
marked	O
increase	O
in	O
the	O
number	O
of	O
TUNEL	O
positive	O
cells	O
and	O
nestin	O
positive	O
cells	O
in	O
BCNU	B-Chemical
-	O
exposed	O
group	O
,	O
but	O
a	O
decreased	O
immunoreactivity	O
to	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
synaptophysin	O
and	O
transforming	O
growth	O
factor	O
beta1	O
was	O
observed	O
,	O
indicating	O
a	O
delayed	O
maturation	O
,	O
and	O
melatonin	B-Chemical
significantly	O
reversed	O
these	O
changes	O
.	O
Malondialdehyde	B-Chemical
level	O
in	O
BCNU	B-Chemical
-	O
exposed	O
group	O
was	O
higher	O
than	O
those	O
in	O
control	O
groups	O
and	O
melatonin	B-Chemical
decreased	O
malondialdehyde	B-Chemical
levels	O
in	O
BCNU	B-Chemical
group	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
while	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
superoxide	B-Chemical
dismutase	O
levels	O
between	O
these	O
groups	O
.	O
These	O
data	O
suggest	O
that	O
exposure	O
of	O
animals	O
to	O
BCNU	B-Chemical
during	O
pregnancy	O
leads	O
to	O
delayed	O
maturation	O
of	O
offspring	O
cerebellum	O
and	O
melatonin	B-Chemical
protects	O
the	O
cerebellum	O
against	O
the	O
effects	O
of	O
BCNU	B-Chemical
.	O
Reduced	O
cardiotoxicity	B-Disease
of	O
doxorubicin	B-Chemical
given	O
in	O
the	O
form	O
of	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
hydroxypropyl	I-Chemical
)	I-Chemical
methacrylamide	I-Chemical
conjugates	O
:	O
and	O
experimental	O
study	O
in	O
the	O
rat	O
.	O
A	O
rat	O
model	O
was	O
used	O
to	O
evaluate	O
the	O
general	O
acute	O
toxicity	B-Disease
and	O
the	O
late	O
cardiotoxicity	B-Disease
of	O
4	O
mg	O
/	O
kg	O
doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
given	O
either	O
as	O
free	O
drug	O
or	O
in	O
the	O
form	O
of	O
three	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
hydroxypropyl	I-Chemical
)	I-Chemical
methacrylamide	I-Chemical
(	O
HPMA	B-Chemical
)	O
copolymer	O
conjugates	O
.	O
In	O
these	O
HPMA	B-Chemical
copolymers	O
,	O
DOX	B-Chemical
was	O
covalently	O
bound	O
via	O
peptide	O
linkages	O
that	O
were	O
either	O
non	O
-	O
biodegradable	O
(	O
Gly	O
-	O
Gly	O
)	O
or	O
degradable	O
by	O
lysosomal	O
proteinases	O
(	O
Gly	B-Chemical
-	I-Chemical
Phe	I-Chemical
-	I-Chemical
Leu	I-Chemical
-	I-Chemical
Gly	I-Chemical
)	O
.	O
In	O
addition	O
,	O
one	O
biodegradable	O
conjugate	O
containing	O
galactosamine	B-Chemical
was	O
used	O
;	O
this	O
residue	O
was	O
targeted	O
to	O
the	O
liver	O
.	O
Over	O
the	O
first	O
3	O
weeks	O
after	O
the	O
i	O
.	O
v	O
.	O
administration	O
of	O
free	O
and	O
polymer	O
-	O
bound	O
DOX	B-Chemical
,	O
all	O
animals	O
showed	O
a	O
transient	O
reduction	O
in	O
body	O
weight	O
.	O
However	O
,	O
the	O
maximal	O
reduction	O
in	O
body	O
weight	O
seen	O
in	O
animals	O
that	O
received	O
polymer	O
-	O
bound	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
)	O
was	O
significantly	O
lower	O
than	O
that	O
observed	O
in	O
those	O
that	O
received	O
free	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
)	O
or	O
a	O
mixture	O
of	O
the	O
unmodified	O
parent	O
HPMA	B-Chemical
copolymer	O
and	O
free	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
;	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
Throughout	O
the	O
study	O
(	O
20	O
weeks	O
)	O
,	O
deaths	O
related	O
to	O
cardiotoxicity	B-Disease
were	O
observed	O
only	O
in	O
animals	O
that	O
received	O
either	O
free	O
DOX	B-Chemical
or	O
the	O
mixture	O
of	O
HPMA	B-Chemical
copolymer	O
and	O
free	O
DOX	B-Chemical
;	O
in	O
these	O
cases	O
,	O
histological	O
investigations	O
revealed	O
marked	O
changes	O
in	O
the	O
heart	O
that	O
were	O
consistent	O
with	O
DOX	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
Sequential	O
measurements	O
of	O
cardiac	O
output	O
in	O
surviving	O
animals	O
that	O
received	O
either	O
free	O
DOX	B-Chemical
or	O
the	O
mixture	O
of	O
HPMA	B-Chemical
copolymer	O
and	O
free	O
DOX	B-Chemical
showed	O
a	O
reduction	O
of	O
approximately	O
30	O
%	O
in	O
function	O
beginning	O
at	O
the	O
4th	O
week	O
after	O
drug	O
administration	O
.	O
The	O
heart	O
rate	O
in	O
these	O
animals	O
was	O
approximately	O
12	O
%	O
lower	O
than	O
that	O
measured	O
in	O
age	O
-	O
matched	O
control	O
rats	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
Animals	O
that	O
were	O
given	O
the	O
HPMA	B-Chemical
copolymer	O
conjugates	O
containing	O
DOX	B-Chemical
exhibited	O
no	O
significant	O
change	O
in	O
cardiac	O
output	O
throughout	O
the	O
study	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
In	O
addition	O
,	O
no	O
significant	O
histological	O
change	O
was	O
observed	O
in	O
the	O
heart	O
of	O
animals	O
that	O
received	O
DOX	B-Chemical
in	O
the	O
form	O
of	O
HPMA	B-Chemical
copolymer	O
conjugates	O
and	O
were	O
killed	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O
However	O
,	O
these	O
animals	O
had	O
shown	O
a	O
significant	O
increase	O
in	O
heart	O
rate	O
beginning	O
at	O
8	O
weeks	O
after	O
drug	O
administration	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
Corneal	B-Disease
ulcers	I-Disease
associated	O
with	O
aerosolized	O
crack	B-Chemical
cocaine	I-Chemical
use	O
.	O
PURPOSE	O
:	O
We	O
report	O
4	O
cases	O
of	O
corneal	B-Disease
ulcers	I-Disease
associated	O
with	O
drug	B-Disease
abuse	I-Disease
.	O
The	O
pathogenesis	O
of	O
these	O
ulcers	B-Disease
and	O
management	O
of	O
these	O
patients	O
are	O
also	O
reviewed	O
.	O
METHODS	O
:	O
Review	O
of	O
all	O
cases	O
of	O
corneal	B-Disease
ulcers	I-Disease
associated	O
with	O
drug	B-Disease
abuse	I-Disease
seen	O
at	O
our	O
institution	O
from	O
July	O
2006	O
to	O
December	O
2006	O
.	O
RESULTS	O
:	O
Four	O
patients	O
with	O
corneal	B-Disease
ulcers	I-Disease
associated	O
with	O
crack	B-Chemical
cocaine	I-Chemical
use	O
were	O
reviewed	O
.	O
All	O
corneal	B-Disease
ulcers	I-Disease
were	O
cultured	O
,	O
and	O
the	O
patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
intensive	O
topical	O
antibiotic	O
treatment	O
.	O
Each	O
patient	O
received	O
comprehensive	O
health	O
care	O
,	O
including	O
medical	O
and	O
substance	B-Disease
abuse	I-Disease
consultations	O
.	O
Streptococcal	O
organisms	O
were	O
found	O
in	O
3	O
cases	O
and	O
Capnocytophaga	O
and	O
Brevibacterium	O
casei	O
in	O
1	O
patient	O
.	O
The	O
infections	B-Disease
responded	O
to	O
antibiotic	O
treatment	O
.	O
Two	O
patients	O
needed	O
a	O
lateral	O
tarsorrhaphy	O
for	O
persistent	O
epithelial	B-Disease
defects	I-Disease
.	O
CONCLUSIONS	O
:	O
Aerosolized	O
crack	B-Chemical
cocaine	I-Chemical
use	O
can	O
be	O
associated	O
with	O
the	O
development	O
of	O
corneal	B-Disease
ulcers	I-Disease
.	O
Drug	B-Disease
abuse	I-Disease
provides	O
additional	O
challenges	O
for	O
management	O
.	O
Not	O
only	O
treatment	O
of	O
their	O
infections	B-Disease
but	O
also	O
the	O
overall	O
poor	O
health	O
of	O
the	O
patients	O
and	O
increased	O
risk	O
of	O
noncompliance	O
need	O
to	O
be	O
addressed	O
.	O
Comprehensive	O
care	O
may	O
provide	O
the	O
patient	O
the	O
opportunity	O
to	O
discontinue	O
their	O
substance	B-Disease
abuse	I-Disease
,	O
improve	O
their	O
overall	O
health	O
,	O
and	O
prevent	O
future	O
corneal	O
complications	O
.	O
Topical	O
0	O
.	O
025	O
%	O
capsaicin	B-Chemical
in	O
chronic	O
post	B-Disease
-	I-Disease
herpetic	I-Disease
neuralgia	I-Disease
:	O
efficacy	O
,	O
predictors	O
of	O
response	O
and	O
long	O
-	O
term	O
course	O
.	O
In	O
order	O
to	O
evaluate	O
the	O
efficacy	O
,	O
time	O
-	O
course	O
of	O
action	O
and	O
predictors	O
of	O
response	O
to	O
topical	O
capsaicin	B-Chemical
,	O
39	O
patients	O
with	O
chronic	O
post	B-Disease
-	I-Disease
herpetic	I-Disease
neuralgia	I-Disease
(	O
PHN	B-Disease
)	O
,	O
median	O
duration	O
24	O
months	O
,	O
were	O
treated	O
with	O
0	O
.	O
025	O
%	O
capsaicin	B-Chemical
cream	O
for	O
8	O
weeks	O
.	O
During	O
therapy	O
the	O
patients	O
rated	O
their	O
pain	B-Disease
on	O
a	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
and	O
a	O
verbal	O
outcome	O
scale	O
.	O
A	O
follow	O
-	O
up	O
investigation	O
was	O
performed	O
10	O
-	O
12	O
months	O
after	O
study	O
onset	O
on	O
the	O
patients	O
who	O
had	O
improved	O
.	O
Nineteen	O
patients	O
(	O
48	O
.	O
7	O
%	O
)	O
substantially	O
improved	O
after	O
the	O
8	O
-	O
week	O
trial	O
;	O
5	O
(	O
12	O
.	O
8	O
%	O
)	O
discontinued	O
therapy	O
due	O
to	O
side	O
-	O
effects	O
such	O
as	O
intolerable	O
capsaicin	B-Chemical
-	O
induced	O
burning	O
sensations	O
(	O
4	O
)	O
or	O
mastitis	B-Disease
(	O
1	O
)	O
;	O
15	O
(	O
38	O
.	O
5	O
%	O
)	O
reported	O
no	O
benefit	O
.	O
The	O
decrease	O
in	O
VAS	O
ratings	O
was	O
significant	O
after	O
2	O
weeks	O
of	O
continuous	O
application	O
.	O
Of	O
the	O
responders	O
72	O
.	O
2	O
%	O
were	O
still	O
improved	O
at	O
the	O
follow	O
-	O
up	O
;	O
only	O
one	O
-	O
third	O
of	O
them	O
had	O
continued	O
application	O
irregularly	O
.	O
Treatment	O
effect	O
was	O
not	O
dependent	O
on	O
patient	O
'	O
s	O
age	O
,	O
duration	O
or	O
localization	O
of	O
PHN	B-Disease
(	O
trigeminal	O
involvement	O
was	O
excluded	O
)	O
,	O
sensory	B-Disease
disturbance	I-Disease
or	O
pain	B-Disease
character	O
.	O
Treatment	O
response	O
was	O
not	O
correlated	O
with	O
the	O
incidence	O
,	O
time	O
-	O
course	O
or	O
severity	O
of	O
capsaicin	B-Chemical
-	O
induced	O
burning	O
.	O
If	O
confirmed	O
in	O
controlled	O
trials	O
,	O
the	O
long	O
-	O
term	O
results	O
of	O
this	O
open	O
,	O
non	O
-	O
randomized	O
study	O
might	O
indicate	O
that	O
the	O
analgesic	O
effect	O
of	O
capsaicin	B-Chemical
in	O
PHN	B-Disease
is	O
mediated	O
by	O
both	O
interference	O
with	O
neuropeptide	O
metabolism	O
and	O
morphological	O
changes	O
(	O
perhaps	O
degeneration	O
)	O
of	O
nociceptive	O
afferents	O
.	O
Myo	B-Chemical
-	I-Chemical
inositol	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
phosphate	I-Chemical
(	O
MIP	B-Chemical
)	O
synthase	O
inhibition	O
:	O
in	O
-	O
vivo	O
study	O
in	O
rats	O
.	O
Lithium	B-Chemical
and	O
valproate	B-Chemical
are	O
the	O
prototypic	O
mood	O
stabilizers	O
and	O
have	O
diverse	O
structures	O
and	O
targets	O
.	O
Both	O
drugs	O
influence	O
inositol	B-Chemical
metabolism	O
.	O
Lithium	B-Chemical
inhibits	O
IMPase	O
and	O
valproate	B-Chemical
inhibits	O
MIP	B-Chemical
synthase	O
.	O
This	O
study	O
shows	O
that	O
MIP	B-Chemical
synthase	O
inhibition	O
does	O
not	O
replicate	O
or	O
augment	O
the	O
effects	O
of	O
lithium	B-Chemical
in	O
the	O
inositol	B-Chemical
sensitive	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
model	O
.	O
This	O
lack	O
of	O
effects	O
may	O
stem	O
from	O
the	O
low	O
contribution	O
of	O
de	O
-	O
novo	O
synthesis	O
to	O
cellular	O
inositol	B-Chemical
supply	O
or	O
to	O
the	O
inhibition	O
of	O
the	O
de	O
-	O
novo	O
synthesis	O
by	O
lithium	B-Chemical
itself	O
.	O
Non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
-	O
associated	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
with	O
granular	O
tubular	O
basement	O
membrane	O
deposits	O
.	O
Acute	B-Disease
tubulo	I-Disease
-	I-Disease
interstitial	I-Disease
nephritis	I-Disease
(	O
ATIN	B-Disease
)	O
is	O
an	O
important	O
cause	O
of	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
resulting	O
from	O
a	O
variety	O
of	O
insults	O
,	O
including	O
immune	O
complex	O
-	O
mediated	O
tubulo	B-Disease
-	I-Disease
interstitial	I-Disease
injury	I-Disease
,	O
but	O
drugs	O
such	O
as	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
are	O
a	O
far	O
more	O
frequent	O
cause	O
.	O
Overall	O
,	O
as	O
an	O
entity	O
,	O
ATIN	B-Disease
remains	O
under	O
-	O
diagnosed	O
,	O
as	O
symptoms	O
resolve	O
spontaneously	O
if	O
the	O
medication	O
is	O
stopped	O
.	O
We	O
report	O
on	O
a	O
14	O
-	O
year	O
-	O
old	O
boy	O
who	O
developed	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
2	O
weeks	O
after	O
aortic	O
valve	O
surgery	O
.	O
He	O
was	O
put	O
on	O
aspirin	B-Chemical
following	O
surgery	O
and	O
took	O
ibuprofen	B-Chemical
for	O
fever	B-Disease
for	O
nearly	O
a	O
week	O
prior	O
to	O
presentation	O
.	O
He	O
then	O
presented	O
to	O
the	O
emergency	O
department	O
feeling	O
quite	O
ill	O
and	O
was	O
found	O
to	O
have	O
a	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
(	O
BUN	B-Chemical
)	O
concentration	O
of	O
of	O
147	O
mg	O
/	O
dl	O
,	O
creatinine	B-Chemical
of	O
15	O
.	O
3	O
mg	O
/	O
dl	O
and	O
serum	O
potassium	B-Chemical
of	O
8	O
.	O
7	O
mEq	O
/	O
l	O
.	O
Dialysis	O
was	O
immediately	O
initiated	O
.	O
A	O
kidney	O
biopsy	O
showed	O
inflammatory	O
infiltrate	O
consistent	O
with	O
ATIN	B-Disease
.	O
However	O
,	O
in	O
the	O
tubular	O
basement	O
membrane	O
(	O
TBM	O
)	O
,	O
very	O
intense	O
granular	O
deposits	O
of	O
polyclonal	O
IgG	O
and	O
C3	O
were	O
noted	O
.	O
He	O
needed	O
dialysis	O
for	O
2	O
weeks	O
and	O
was	O
treated	O
successfully	O
with	O
steroids	B-Chemical
for	O
6	O
months	O
.	O
His	O
renal	O
recovery	O
and	O
disappearance	O
of	O
proteinuria	B-Disease
took	O
a	O
year	O
.	O
In	O
conclusion	O
,	O
this	O
is	O
a	O
first	O
report	O
of	O
NSAIDs	O
-	O
associated	O
ATIN	B-Disease
,	O
showing	O
deposits	O
of	O
granular	O
immune	O
complex	O
present	O
only	O
in	O
the	O
TBM	O
and	O
not	O
in	O
the	O
glomeruli	O
.	O
Rifampicin	B-Chemical
-	O
associated	O
segmental	O
necrotizing	O
glomerulonephritis	B-Disease
in	O
staphylococcal	B-Disease
endocarditis	I-Disease
.	O
Segmental	O
necrotising	O
glomerulonephritis	B-Disease
has	O
been	O
reported	O
as	O
complication	O
of	O
rifampicin	B-Chemical
therapy	O
in	O
patients	O
receiving	O
treatment	O
for	O
tuberculosis	B-Disease
.	O
Changing	O
epidemiology	O
of	O
infections	B-Disease
such	O
as	O
infective	B-Disease
endocarditis	I-Disease
(	O
IE	B-Disease
)	O
has	O
led	O
to	O
an	O
increase	O
in	O
the	O
use	O
of	O
rifampicin	B-Chemical
for	O
Staphylococcal	B-Disease
infections	I-Disease
.	O
We	O
describe	O
a	O
case	O
of	O
a	O
patient	O
with	O
Staphylococcal	B-Disease
IE	I-Disease
who	O
developed	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
secondary	O
to	O
a	O
segmental	O
necrotising	O
glomerulonephritis	B-Disease
while	O
being	O
treated	O
with	O
rifampicin	B-Chemical
,	O
and	O
review	O
the	O
literature	O
regarding	O
this	O
complication	O
of	O
rifampicin	B-Chemical
therapy	O
.	O
Rate	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine	B-Chemical
-	O
untreated	O
Iranian	O
patients	O
with	O
chronic	B-Disease
hepatitis	I-Disease
B	I-Disease
virus	I-Disease
infection	I-Disease
.	O
BACKGROUND	O
:	O
Lamivudine	B-Chemical
is	O
used	O
for	O
the	O
treatment	O
of	O
chronic	B-Disease
hepatitis	I-Disease
B	I-Disease
patients	O
.	O
Recent	O
studies	O
show	O
that	O
the	O
YMDD	O
motif	O
mutants	O
(	O
resistant	O
hepatitis	B-Disease
B	I-Disease
virus	O
)	O
occur	O
as	O
natural	O
genome	O
variability	O
in	O
lamivudine	B-Chemical
-	O
untreated	O
chronic	B-Disease
hepatitis	I-Disease
B	I-Disease
patients	O
.	O
In	O
this	O
study	O
we	O
aimed	O
to	O
determine	O
the	O
rate	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine	B-Chemical
-	O
untreated	O
chronic	B-Disease
hepatitis	I-Disease
B	I-Disease
patients	O
in	O
Iran	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
77	O
chronic	B-Disease
hepatitis	I-Disease
B	I-Disease
patients	O
who	O
had	O
not	O
been	O
treated	O
with	O
lamivudine	B-Chemical
were	O
included	O
in	O
the	O
study	O
.	O
Serum	O
samples	O
from	O
patients	O
were	O
tested	O
by	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
for	O
detection	O
of	O
YMDD	O
motif	O
mutants	O
.	O
All	O
patients	O
were	O
also	O
tested	O
for	O
liver	O
enzymes	O
,	O
anti	O
-	O
HCV	O
,	O
HBeAg	B-Chemical
,	O
and	O
anti	O
-	O
HBe	O
.	O
RESULTS	O
:	O
Of	O
the	O
77	O
patients	O
enrolled	O
in	O
the	O
study	O
,	O
73	O
%	O
were	O
male	O
and	O
27	O
%	O
were	O
female	O
.	O
Mean	O
ALT	O
and	O
AST	O
levels	O
were	O
124	O
.	O
4	O
+	O
/	O
-	O
73	O
.	O
4	O
and	O
103	O
.	O
1	O
+	O
/	O
-	O
81	O
IU	O
/	O
l	O
,	O
respectively	O
.	O
HBeAg	B-Chemical
was	O
positive	O
in	O
40	O
%	O
and	O
anti	O
-	O
HBe	O
in	O
60	O
%	O
of	O
the	O
patients	O
.	O
Anti	O
-	O
HCV	O
was	O
negative	O
in	O
all	O
of	O
them	O
.	O
YMDD	O
motif	O
mutants	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
patients	O
despite	O
the	O
liver	O
enzyme	O
levels	O
and	O
the	O
presence	O
of	O
HBeAg	B-Chemical
or	O
anti	O
-	O
HBe	O
.	O
CONCLUSION	O
:	O
Although	O
the	O
natural	O
occurrence	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine	B-Chemical
-	O
untreated	O
patients	O
with	O
chronic	B-Disease
hepatitis	I-Disease
B	I-Disease
has	O
been	O
reported	O
,	O
these	O
mutants	O
were	O
not	O
detected	O
in	O
Iranian	O
lamivudine	B-Chemical
-	O
untreated	O
chronic	B-Disease
hepatitis	I-Disease
B	I-Disease
patients	O
.	O
Branch	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
and	O
fluoxetine	B-Chemical
.	O
A	O
case	O
of	O
branch	O
retinal	B-Disease
vein	I-Disease
occlusion	I-Disease
associated	O
with	O
fluoxetine	B-Chemical
-	O
induced	O
secondary	O
hypertension	B-Disease
is	O
described	O
.	O
Although	O
an	O
infrequent	O
complication	O
of	O
selective	O
serotonin	B-Chemical
reuptake	O
inhibitor	O
therapy	O
,	O
it	O
is	O
important	O
that	O
ophthalmologists	O
are	O
aware	O
that	O
these	O
agents	O
can	O
cause	O
hypertension	B-Disease
because	O
this	O
class	O
of	O
drugs	O
is	O
widely	O
prescribed	O
.	O
The	O
differential	O
effects	O
of	O
bupivacaine	B-Chemical
and	O
lidocaine	B-Chemical
on	O
prostaglandin	B-Chemical
E2	I-Chemical
release	O
,	O
cyclooxygenase	O
gene	O
expression	O
and	O
pain	B-Disease
in	O
a	O
clinical	O
pain	B-Disease
model	O
.	O
BACKGROUND	O
:	O
In	O
addition	O
to	O
blocking	O
nociceptive	O
input	O
from	O
surgical	O
sites	O
,	O
long	O
-	O
acting	O
local	O
anesthetics	O
might	O
directly	O
modulate	O
inflammation	B-Disease
.	O
In	O
the	O
present	O
study	O
,	O
we	O
describe	O
the	O
proinflammatory	O
effects	O
of	O
bupivacaine	B-Chemical
on	O
local	O
prostaglandin	B-Chemical
E2	I-Chemical
(	O
PGE2	B-Chemical
)	O
production	O
and	O
cyclooxygenase	O
(	O
COX	O
)	O
gene	O
expression	O
that	O
increases	O
postoperative	B-Disease
pain	I-Disease
in	O
human	O
subjects	O
.	O
METHODS	O
:	O
Subjects	O
(	O
n	O
=	O
114	O
)	O
undergoing	O
extraction	O
of	O
impacted	O
third	O
molars	O
received	O
either	O
2	O
%	O
lidocaine	B-Chemical
or	O
0	O
.	O
5	O
%	O
bupivacaine	B-Chemical
before	O
surgery	O
and	O
either	O
rofecoxib	B-Chemical
50	O
mg	O
or	O
placebo	O
orally	O
90	O
min	O
before	O
surgery	O
and	O
for	O
the	O
following	O
48	O
h	O
.	O
Oral	O
mucosal	O
biopsies	O
were	O
taken	O
before	O
surgery	O
and	O
48	O
h	O
after	O
surgery	O
.	O
After	O
extraction	O
,	O
a	O
microdialysis	O
probe	O
was	O
placed	O
at	O
the	O
surgical	O
site	O
for	O
PGE2	B-Chemical
and	O
thromboxane	B-Chemical
B2	I-Chemical
(	O
TXB2	B-Chemical
)	O
measurements	O
.	O
RESULTS	O
:	O
The	O
bupivacaine	B-Chemical
/	O
rofecoxib	B-Chemical
group	O
reported	O
significantly	O
less	O
pain	B-Disease
,	O
as	O
assessed	O
by	O
a	O
visual	O
analog	O
scale	O
,	O
compared	O
with	O
the	O
other	O
three	O
treatment	O
groups	O
over	O
the	O
first	O
4	O
h	O
.	O
However	O
,	O
the	O
bupivacaine	B-Chemical
/	O
placebo	O
group	O
reported	O
significantly	O
more	O
pain	B-Disease
at	O
24	O
h	O
and	O
PGE2	B-Chemical
levels	O
during	O
the	O
first	O
4	O
h	O
were	O
significantly	O
higher	O
than	O
the	O
other	O
three	O
treatment	O
groups	O
.	O
Moreover	O
,	O
bupivacaine	B-Chemical
significantly	O
increased	O
COX	O
-	O
2	O
gene	O
expression	O
at	O
48	O
h	O
as	O
compared	O
with	O
the	O
lidocaine	B-Chemical
/	O
placebo	O
group	O
.	O
Thromboxane	B-Chemical
levels	O
were	O
not	O
significantly	O
affected	O
by	O
any	O
of	O
the	O
treatments	O
,	O
indicating	O
that	O
the	O
effects	O
seen	O
were	O
attributable	O
to	O
inhibition	O
of	O
COX	O
-	O
2	O
,	O
but	O
not	O
COX	O
-	O
1	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
bupivacaine	B-Chemical
stimulates	O
COX	O
-	O
2	O
gene	O
expression	O
after	O
tissue	B-Disease
injury	I-Disease
,	O
which	O
is	O
associated	O
with	O
higher	O
PGE2	B-Chemical
production	O
and	O
pain	B-Disease
after	O
the	O
local	O
anesthetic	O
effect	O
dissipates	O
.	O
p75NTR	O
expression	O
in	O
rat	O
urinary	O
bladder	O
sensory	O
neurons	O
and	O
spinal	O
cord	O
with	O
cyclophosphamide	B-Chemical
-	O
induced	O
cystitis	B-Disease
.	O
A	O
role	O
for	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
in	O
contributing	O
to	O
increased	O
voiding	O
frequency	O
and	O
altered	O
sensation	O
from	O
the	O
urinary	O
bladder	O
has	O
been	O
suggested	O
.	O
Previous	O
studies	O
have	O
examined	O
the	O
expression	O
and	O
regulation	O
of	O
tyrosine	B-Chemical
kinase	O
receptors	O
(	O
Trks	O
)	O
in	O
micturition	O
reflexes	O
with	O
urinary	B-Disease
bladder	I-Disease
inflammation	I-Disease
.	O
The	O
present	O
studies	O
examine	O
the	O
expression	O
and	O
regulation	O
of	O
another	O
receptor	O
known	O
to	O
bind	O
NGF	O
,	O
p75	O
(	O
NTR	O
)	O
,	O
after	O
various	O
durations	O
of	O
bladder	B-Disease
inflammation	I-Disease
induced	O
by	O
cyclophosphamide	B-Chemical
(	O
CYP	B-Chemical
)	O
.	O
CYP	B-Chemical
-	O
induced	O
cystitis	B-Disease
increased	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
p75	O
(	O
NTR	O
)	O
expression	O
in	O
the	O
superficial	O
lateral	O
and	O
medial	O
dorsal	O
horn	O
in	O
L1	O
-	O
L2	O
and	O
L6	O
-	O
S1	O
spinal	O
segments	O
.	O
The	O
number	O
of	O
p75	O
(	O
NTR	O
)	O
-	O
immunoreactive	O
(	O
-	O
IR	O
)	O
cells	O
in	O
the	O
lumbosacral	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
also	O
increased	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
05	O
)	O
with	O
CYP	B-Chemical
-	O
induced	O
cystitis	B-Disease
(	O
acute	O
,	O
intermediate	O
,	O
and	O
chronic	O
)	O
.	O
Quantitative	O
,	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
also	O
demonstrated	O
significant	O
increases	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
in	O
p75	O
(	O
NTR	O
)	O
mRNA	O
in	O
DRG	O
with	O
intermediate	O
and	O
chronic	O
CYP	B-Chemical
-	O
induced	O
cystitis	B-Disease
.	O
Retrograde	O
dye	O
-	O
tracing	O
techniques	O
with	O
Fastblue	O
were	O
used	O
to	O
identify	O
presumptive	O
bladder	O
afferent	O
cells	O
in	O
the	O
lumbosacral	O
DRG	O
.	O
In	O
bladder	O
afferent	O
cells	O
in	O
DRG	O
,	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
was	O
also	O
increased	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
01	O
)	O
with	O
cystitis	B-Disease
.	O
In	O
addition	O
to	O
increases	O
in	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
in	O
DRG	O
cell	O
bodies	O
,	O
increases	O
(	O
P	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
in	O
pericellular	O
(	O
encircling	O
DRG	O
cells	O
)	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
in	O
DRG	O
also	O
increased	O
.	O
Confocal	O
analyses	O
demonstrated	O
that	O
pericellular	O
p75	O
(	O
NTR	O
)	O
-	O
IR	O
was	O
not	O
colocalized	O
with	O
the	O
glial	O
marker	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
.	O
These	O
studies	O
demonstrate	O
that	O
p75	O
(	O
NTR	O
)	O
expression	O
in	O
micturition	O
reflexes	O
is	O
present	O
constitutively	O
and	O
modified	O
by	O
bladder	B-Disease
inflammation	I-Disease
.	O
The	O
functional	O
significance	O
of	O
p75	O
(	O
NTR	O
)	O
expression	O
in	O
micturition	O
reflexes	O
remains	O
to	O
be	O
determined	O
.	O
Azathioprine	B-Chemical
-	O
induced	O
suicidal	O
erythrocyte	O
death	O
.	O
BACKGROUND	O
:	O
Azathioprine	B-Chemical
is	O
widely	O
used	O
as	O
an	O
immunosuppressive	O
drug	O
.	O
The	O
side	O
effects	O
of	O
azathioprine	B-Chemical
include	O
anemia	B-Disease
,	O
which	O
has	O
been	O
attributed	O
to	O
bone	O
marrow	O
suppression	O
.	O
Alternatively	O
,	O
anemia	B-Disease
could	O
result	O
from	O
accelerated	O
suicidal	O
erythrocyte	O
death	O
or	O
eryptosis	O
,	O
which	O
is	O
characterized	O
by	O
exposure	O
of	O
phosphatidylserine	B-Chemical
(	O
PS	B-Chemical
)	O
at	O
the	O
erythrocyte	O
surface	O
and	O
by	O
cell	O
shrinkage	O
.	O
METHODS	O
:	O
The	O
present	O
experiments	O
explored	O
whether	O
azathioprine	B-Chemical
influences	O
eryptosis	O
.	O
According	O
to	O
annexin	O
V	O
binding	O
,	O
erythrocytes	O
from	O
patients	O
indeed	O
showed	O
a	O
significant	O
increase	O
of	O
PS	B-Chemical
exposure	O
within	O
1	O
week	O
of	O
treatment	O
with	O
azathioprine	B-Chemical
.	O
In	O
a	O
second	O
series	O
,	O
cytosolic	O
Ca2	B-Chemical
+	O
activity	O
(	O
Fluo3	B-Chemical
fluorescence	O
)	O
,	O
cell	O
volume	O
(	O
forward	O
scatter	O
)	O
,	O
and	O
PS	B-Chemical
-	O
exposure	O
(	O
annexin	O
V	O
binding	O
)	O
were	O
determined	O
by	O
FACS	O
analysis	O
in	O
erythrocytes	O
from	O
healthy	O
volunteers	O
.	O
RESULTS	O
:	O
Exposure	O
to	O
azathioprine	B-Chemical
(	O
>	O
or	O
=	O
2	O
microg	O
/	O
mL	O
)	O
for	O
48	O
hours	O
increased	O
cytosolic	O
Ca2	B-Chemical
+	O
activity	O
and	O
annexin	O
V	O
binding	O
and	O
decreased	O
forward	O
scatter	O
.	O
The	O
effect	O
of	O
azathioprine	B-Chemical
on	O
both	O
annexin	O
V	O
binding	O
and	O
forward	O
scatter	O
was	O
significantly	O
blunted	O
in	O
the	O
nominal	O
absence	O
of	O
extracellular	O
Ca2	B-Chemical
+	O
.	O
CONCLUSIONS	O
:	O
Azathioprine	B-Chemical
triggers	O
suicidal	O
erythrocyte	O
death	O
,	O
an	O
effect	O
presumably	O
contributing	O
to	O
azathioprine	B-Chemical
-	O
induced	O
anemia	B-Disease
.	O
Levetiracetam	B-Chemical
as	O
an	O
adjunct	O
to	O
phenobarbital	B-Chemical
treatment	O
in	O
cats	O
with	O
suspected	O
idiopathic	B-Disease
epilepsy	I-Disease
.	O
OBJECTIVE	O
:	O
To	O
assess	O
pharmacokinetics	O
,	O
efficacy	O
,	O
and	O
tolerability	O
of	O
oral	O
levetiracetam	B-Chemical
administered	O
as	O
an	O
adjunct	O
to	O
phenobarbital	B-Chemical
treatment	O
in	O
cats	O
with	O
poorly	O
controlled	O
suspected	O
idiopathic	B-Disease
epilepsy	I-Disease
.	O
DESIGN	O
-	O
Open	O
-	O
label	O
,	O
noncomparative	O
clinical	O
trial	O
.	O
ANIMALS	O
:	O
12	O
cats	O
suspected	O
to	O
have	O
idiopathic	B-Disease
epilepsy	I-Disease
that	O
was	O
poorly	O
controlled	O
with	O
phenobarbital	B-Chemical
or	O
that	O
had	O
unacceptable	O
adverse	O
effects	O
when	O
treated	O
with	O
phenobarbital	B-Chemical
.	O
PROCEDURES	O
:	O
Cats	O
were	O
treated	O
with	O
levetiracetam	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
[	O
9	O
.	O
1	O
mg	O
/	O
lb	O
]	O
,	O
PO	O
,	O
q	O
8	O
h	O
)	O
.	O
After	O
a	O
minimum	O
of	O
1	O
week	O
of	O
treatment	O
,	O
serum	O
levetiracetam	B-Chemical
concentrations	O
were	O
measured	O
before	O
and	O
2	O
,	O
4	O
,	O
and	O
6	O
hours	O
after	O
drug	O
administration	O
,	O
and	O
maximum	O
and	O
minimum	O
serum	O
concentrations	O
and	O
elimination	O
half	O
-	O
life	O
were	O
calculated	O
.	O
Seizure	B-Disease
frequencies	O
before	O
and	O
after	O
initiation	O
of	O
levetiracetam	B-Chemical
treatment	O
were	O
compared	O
,	O
and	O
adverse	O
effects	O
were	O
recorded	O
.	O
RESULTS	O
:	O
Median	O
maximum	O
serum	O
levetiracetam	B-Chemical
concentration	O
was	O
25	O
.	O
5	O
microg	O
/	O
mL	O
,	O
median	O
minimum	O
serum	O
levetiracetam	B-Chemical
concentration	O
was	O
8	O
.	O
3	O
microg	O
/	O
mL	O
,	O
and	O
median	O
elimination	O
half	O
-	O
life	O
was	O
2	O
.	O
9	O
hours	O
.	O
Median	O
seizure	B-Disease
frequency	O
prior	O
to	O
treatment	O
with	O
levetiracetam	B-Chemical
(	O
2	O
.	O
1	O
seizures	B-Disease
/	O
mo	O
)	O
was	O
significantly	O
higher	O
than	O
median	O
seizure	B-Disease
frequency	O
after	O
initiation	O
of	O
levetiracetam	B-Chemical
treatment	O
(	O
0	O
.	O
42	O
seizures	B-Disease
/	O
mo	O
)	O
,	O
and	O
7	O
of	O
10	O
cats	O
were	O
classified	O
as	O
having	O
responded	O
to	O
levetiracetam	B-Chemical
treatment	O
(	O
ie	O
,	O
reduction	O
in	O
seizure	B-Disease
frequency	O
of	O
>	O
or	O
=	O
50	O
%	O
)	O
.	O
Two	O
cats	O
had	O
transient	O
lethargy	B-Disease
and	O
inappetence	B-Disease
.	O
CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
:	O
Results	O
suggested	O
that	O
levetiracetam	B-Chemical
is	O
well	O
tolerated	O
in	O
cats	O
and	O
may	O
be	O
useful	O
as	O
an	O
adjunct	O
to	O
phenobarbital	B-Chemical
treatment	O
in	O
cats	O
with	O
idiopathic	B-Disease
epilepsy	I-Disease
.	O
Serotonin	B-Chemical
reuptake	O
inhibitors	O
,	O
paranoia	B-Disease
,	O
and	O
the	O
ventral	O
basal	O
ganglia	O
.	O
Antidepressants	O
have	O
previously	O
been	O
associated	O
with	O
paranoid	B-Disease
reactions	O
in	O
psychiatric	O
patients	O
.	O
Five	O
cases	O
of	O
paranoid	B-Disease
exacerbation	O
with	O
the	O
serotonin	B-Chemical
reuptake	O
inhibitors	O
fluoxetine	B-Chemical
and	O
amitriptyline	B-Chemical
are	O
reported	O
here	O
.	O
Elements	O
common	O
to	O
these	O
cases	O
included	O
a	O
history	O
of	O
paranoid	B-Disease
symptomatology	O
and	O
the	O
concomitant	O
occurrence	O
of	O
depressive	B-Disease
and	I-Disease
psychotic	I-Disease
symptoms	I-Disease
.	O
Complicated	O
depressive	B-Disease
disorders	I-Disease
(	O
including	O
atypicality	O
of	O
course	O
and	O
symptomatology	O
,	O
chronicity	O
,	O
psychosis	B-Disease
,	O
bipolarity	O
,	O
and	O
secondary	O
onset	O
in	O
the	O
course	O
of	O
a	O
primary	O
psychosis	B-Disease
)	O
may	O
present	O
particular	O
vulnerability	O
to	O
paranoid	B-Disease
exacerbations	O
associated	O
with	O
serotonin	B-Chemical
reuptake	O
inhibitors	O
.	O
Although	O
the	O
pharmacology	O
and	O
neurobiology	O
of	O
paranoia	B-Disease
remain	O
cryptic	O
,	O
several	O
mechanisms	O
,	O
including	O
5HT3	O
receptor	O
-	O
mediated	O
dopamine	B-Chemical
release	O
,	O
beta	O
-	O
noradrenergic	O
receptor	O
downregulation	O
,	O
or	O
GABAB	O
receptor	O
upregulation	O
acting	O
in	O
the	O
vicinity	O
of	O
the	O
ventral	O
basal	O
ganglia	O
(	O
possibly	O
in	O
lateral	O
orbitofrontal	O
or	O
anterior	O
cingulate	O
circuits	O
)	O
,	O
might	O
apply	O
to	O
this	O
phenomenon	O
.	O
These	O
cases	O
call	O
attention	O
to	O
possible	O
paranoid	B-Disease
exacerbations	O
with	O
serotonin	B-Chemical
reuptake	O
blockers	O
in	O
select	O
patients	O
and	O
raise	O
neurobiological	O
considerations	O
regarding	O
paranoia	B-Disease
.	O
Clinical	O
comparison	O
of	O
cardiorespiratory	O
effects	O
during	O
unilateral	O
and	O
conventional	O
spinal	O
anaesthesia	O
.	O
BACKGROUND	O
:	O
Spinal	O
anaesthesia	O
is	O
widely	O
employed	O
in	O
clinical	O
practice	O
but	O
has	O
the	O
main	O
drawback	O
of	O
post	O
-	O
spinal	O
block	O
hypotension	B-Disease
.	O
Efforts	O
must	O
therefore	O
continue	O
to	O
be	O
made	O
to	O
obviate	O
this	O
setback	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
cardiovascular	O
and	O
respiratory	O
changes	O
during	O
unilateral	O
and	O
conventional	O
spinal	O
anaesthesia	O
.	O
METHODS	O
:	O
With	O
ethical	O
approval	O
,	O
we	O
studied	O
74	O
American	O
Society	O
of	O
Anesthesiologists	O
(	O
ASA	O
)	O
,	O
physical	O
status	O
class	O
1	O
and	O
2	O
patients	O
scheduled	O
for	O
elective	O
unilateral	O
lower	O
limb	O
surgery	O
.	O
Patients	O
were	O
randomly	O
allocated	O
into	O
one	O
of	O
two	O
groups	O
:	O
lateral	O
and	O
conventional	O
spinal	O
anaesthesia	O
groups	O
.	O
In	O
the	O
lateral	O
position	O
with	O
operative	O
side	O
down	O
,	O
patients	O
recived	O
10	O
mg	O
(	O
2mls	O
)	O
of	O
0	O
.	O
5	O
%	O
hyperbaric	O
bupivacaine	B-Chemical
through	O
a	O
25	O
-	O
gauge	O
spinal	O
needle	O
.	O
Patients	O
in	O
the	O
unilateral	O
group	O
were	O
maintained	O
in	O
the	O
lateral	O
position	O
for	O
15	O
minutes	O
following	O
spinal	O
injection	O
while	O
those	O
in	O
the	O
conventional	O
group	O
were	O
turned	O
supine	O
immediately	O
after	O
injection	O
.	O
Blood	O
pressure	O
,	O
heart	O
rate	O
,	O
respiratory	O
rate	O
and	O
oxygen	B-Chemical
saturation	O
were	O
monitored	O
over	O
1	O
hour	O
.	O
RESULTS	O
:	O
Three	O
patients	O
(	O
8	O
.	O
1	O
%	O
)	O
in	O
the	O
unilateral	O
group	O
and	O
5	O
(	O
13	O
.	O
5	O
%	O
)	O
in	O
the	O
conventional	O
group	O
developed	O
hypotension	B-Disease
,	O
P	O
=	O
0	O
.	O
71	O
.	O
Four	O
(	O
10	O
.	O
8	O
%	O
)	O
patients	O
in	O
the	O
conventional	O
group	O
and	O
1	O
(	O
2	O
.	O
7	O
%	O
)	O
in	O
the	O
unilateral	O
group	O
,	O
P	O
=	O
0	O
.	O
17	O
required	O
epinephrine	B-Chemical
infusion	O
to	O
treat	O
hypotension	B-Disease
.	O
Patients	O
in	O
the	O
conventional	O
group	O
had	O
statistically	O
significant	O
greater	O
fall	O
in	O
the	O
systolic	O
blood	O
pressures	O
at	O
15	O
,	O
30	O
and	O
45	O
minutes	O
when	O
compared	O
to	O
the	O
baseline	O
(	O
P	O
=	O
0	O
.	O
003	O
,	O
0	O
.	O
001	O
and	O
0	O
.	O
004	O
)	O
.	O
The	O
mean	O
respiratory	O
rate	O
and	O
oxygen	B-Chemical
saturations	O
in	O
the	O
two	O
groups	O
were	O
similar	O
.	O
CONCLUSION	O
:	O
Compared	O
to	O
conventional	O
spinal	O
anaesthesia	O
,	O
unilateral	O
spinal	O
anaesthesia	O
was	O
associated	O
with	O
fewer	O
cardiovascular	O
perturbations	O
.	O
Also	O
,	O
the	O
type	O
of	O
spinal	O
block	O
instituted	O
affected	O
neither	O
the	O
respiratory	O
rate	O
nor	O
the	O
arterial	O
oxygen	B-Chemical
saturation	O
.	O
Spectrum	O
of	O
adverse	O
events	O
after	O
generic	O
HAART	O
in	O
southern	O
Indian	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
patients	O
.	O
To	O
determine	O
the	O
incidence	O
of	O
clinically	O
significant	O
adverse	O
events	O
after	O
long	O
-	O
term	O
,	O
fixed	O
-	O
dose	O
,	O
generic	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
use	O
among	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
individuals	O
in	O
South	O
India	O
,	O
we	O
examined	O
the	O
experiences	O
of	O
3154	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
individuals	O
who	O
received	O
a	O
minimum	O
of	O
3	O
months	O
of	O
generic	O
HAART	O
between	O
February	O
1996	O
and	O
December	O
2006	O
at	O
a	O
tertiary	O
HIV	O
care	O
referral	O
center	O
in	O
South	O
India	O
.	O
The	O
most	O
common	O
regimens	O
were	O
3TC	B-Chemical
+	O
d4T	B-Chemical
+	O
nevirapine	B-Chemical
(	O
NVP	B-Chemical
)	O
(	O
54	O
.	O
8	O
%	O
)	O
,	O
zidovudine	B-Chemical
(	O
AZT	B-Chemical
)	O
+	O
3TC	B-Chemical
+	O
NVP	B-Chemical
(	O
14	O
.	O
5	O
%	O
)	O
,	O
3TC	B-Chemical
+	O
d4T	B-Chemical
+	O
efavirenz	B-Chemical
(	O
EFV	B-Chemical
)	O
(	O
20	O
.	O
1	O
%	O
)	O
,	O
and	O
AZT	B-Chemical
+	O
3TC	B-Chemical
+	O
EFV	B-Chemical
(	O
5	O
.	O
4	O
%	O
)	O
.	O
The	O
most	O
common	O
adverse	O
events	O
and	O
median	O
CD4	O
at	O
time	O
of	O
event	O
were	O
rash	B-Disease
(	O
15	O
.	O
2	O
%	O
;	O
CD4	O
,	O
285	O
cells	O
/	O
microL	O
)	O
and	O
peripheral	B-Disease
neuropathy	I-Disease
(	O
9	O
.	O
0	O
%	O
and	O
348	O
cells	O
/	O
microL	O
)	O
.	O
Clinically	O
significant	O
anemia	B-Disease
(	O
hemoglobin	O
<	O
7	O
g	O
/	O
dL	O
)	O
was	O
observed	O
in	O
5	O
.	O
4	O
%	O
of	O
patients	O
(	O
CD4	O
,	O
165	O
cells	O
/	O
microL	O
)	O
and	O
hepatitis	B-Disease
(	O
clinical	O
jaundice	B-Disease
with	O
alanine	B-Chemical
aminotransferase	O
>	O
5	O
times	O
upper	O
limits	O
of	O
normal	O
)	O
in	O
3	O
.	O
5	O
%	O
of	O
patients	O
(	O
CD4	O
,	O
260	O
cells	O
/	O
microL	O
)	O
.	O
Women	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
lactic	B-Disease
acidosis	I-Disease
,	O
while	O
men	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
immune	B-Disease
reconstitution	I-Disease
syndrome	I-Disease
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Among	O
the	O
patients	O
with	O
1	O
year	O
of	O
follow	O
-	O
up	O
,	O
NVP	B-Chemical
therapy	O
was	O
significantly	O
associated	O
with	O
developing	O
rash	B-Disease
and	O
d4T	B-Chemical
therapy	O
with	O
developing	O
peripheral	B-Disease
neuropathy	I-Disease
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Anemia	B-Disease
and	O
hepatitis	B-Disease
often	O
occur	O
within	O
12	O
weeks	O
of	O
initiating	O
generic	O
HAART	O
.	O
Frequent	O
and	O
early	O
monitoring	O
for	O
these	O
toxicities	B-Disease
is	O
warranted	O
in	O
developing	O
countries	O
where	O
generic	O
HAART	O
is	O
increasingly	O
available	O
.	O
Thalidomide	B-Chemical
and	O
sensory	B-Disease
neurotoxicity	I-Disease
:	O
a	O
neurophysiological	O
study	O
.	O
BACKGROUND	O
:	O
Recent	O
studies	O
confirmed	O
a	O
high	O
incidence	O
of	O
sensory	B-Disease
axonal	I-Disease
neuropathy	I-Disease
in	O
patients	O
treated	O
with	O
different	O
doses	O
of	O
thalidomide	B-Chemical
.	O
The	O
study	O
'	O
s	O
aims	O
were	O
to	O
measure	O
variations	O
in	O
sural	O
nerve	O
sensory	O
action	O
potential	O
(	O
SAP	O
)	O
amplitude	O
in	O
patients	O
with	O
refractory	O
cutaneous	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
CLE	B-Disease
)	O
treated	O
with	O
thalidomide	B-Chemical
and	O
use	O
these	O
findings	O
to	O
identify	O
the	O
neurotoxic	B-Disease
potential	O
of	O
thalidomide	B-Chemical
and	O
the	O
recovery	O
capacity	O
of	O
sensory	O
fibres	O
after	O
discontinuation	O
of	O
treatment	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Clinical	O
and	O
electrophysiological	O
data	O
in	O
12	O
female	O
patients	O
with	O
CLE	B-Disease
during	O
treatment	O
with	O
thalidomide	B-Chemical
and	O
up	O
to	O
47	O
months	O
after	O
discontinuation	O
of	O
treatment	O
were	O
analysed	O
.	O
Sural	O
nerve	O
SAP	O
amplitude	O
reduction	O
>	O
or	O
=	O
40	O
%	O
was	O
the	O
criteria	O
for	O
discontinuing	O
therapy	O
.	O
RESULTS	O
:	O
During	O
treatment	O
,	O
11	O
patients	O
showed	O
a	O
reduction	O
in	O
sural	O
nerve	O
SAP	O
amplitude	O
compared	O
to	O
baseline	O
values	O
(	O
9	O
with	O
a	O
reduction	O
>	O
or	O
=	O
50	O
%	O
and	O
2	O
<	O
50	O
%	O
)	O
.	O
One	O
patient	O
showed	O
no	O
changes	O
in	O
SAP	O
amplitude	O
.	O
Five	O
patients	O
complained	O
of	O
paresthesias	B-Disease
and	O
leg	O
cramps	B-Disease
.	O
After	O
thalidomide	B-Chemical
treatment	O
,	O
sural	O
SAP	O
amplitude	O
recovered	O
in	O
3	O
patients	O
.	O
At	O
detection	O
of	O
reduction	O
in	O
sural	O
nerve	O
SAP	O
amplitude	O
,	O
the	O
median	O
thalidomide	B-Chemical
cumulative	O
dose	O
was	O
21	O
.	O
4	O
g	O
.	O
The	O
threshold	O
neurotoxic	B-Disease
dosage	O
is	O
lower	O
than	O
previously	O
reported	O
.	O
CONCLUSIONS	O
:	O
Sural	O
nerve	O
SAP	O
amplitude	O
reduction	O
is	O
a	O
reliable	O
and	O
sensitive	O
marker	O
of	O
degeneration	O
and	O
recovery	O
of	O
sensory	O
fibres	O
.	O
This	O
electrophysiological	O
parameter	O
provides	O
information	O
about	O
subclinical	O
neurotoxic	B-Disease
potential	O
of	O
thalidomide	B-Chemical
but	O
is	O
not	O
helpful	O
in	O
predicting	O
the	O
appearance	O
of	O
sensory	O
symptoms	O
.	O
Five	O
cases	O
of	O
encephalitis	B-Disease
during	O
treatment	O
of	O
loiasis	B-Disease
with	O
diethylcarbamazine	B-Chemical
.	O
Five	O
cases	O
of	O
encephalitis	B-Disease
following	O
treatment	O
with	O
diethylcarbamazine	B-Chemical
(	O
DEC	B-Chemical
)	O
were	O
observed	O
in	O
Congolese	O
patients	O
with	O
Loa	O
loa	O
filariasis	B-Disease
.	O
Two	O
cases	O
had	O
a	O
fatal	O
outcome	O
and	O
one	O
resulted	O
in	O
severe	O
sequelae	O
.	O
The	O
notable	O
fact	O
was	O
that	O
this	O
complication	O
occurred	O
in	O
three	O
patients	O
hospitalized	O
before	O
treatment	O
began	O
,	O
with	O
whom	O
particularly	O
strict	O
therapeutic	O
precautions	O
were	O
taken	O
,	O
i	O
.	O
e	O
.	O
,	O
initial	O
dose	O
less	O
than	O
10	O
mg	O
of	O
DEC	B-Chemical
,	O
very	O
gradual	O
dose	O
increases	O
,	O
and	O
associated	O
anti	O
-	O
allergic	O
treatment	O
.	O
This	O
type	O
of	O
drug	O
-	O
induced	O
complication	O
may	O
not	O
be	O
that	O
uncommon	O
in	O
highly	O
endemic	O
regions	O
.	O
It	O
occurs	O
primarily	O
,	O
but	O
not	O
exclusively	O
,	O
in	O
subjects	O
presenting	O
with	O
a	O
high	O
microfilarial	O
load	O
.	O
The	O
relationship	O
between	O
the	O
occurrence	O
of	O
encephalitis	B-Disease
and	O
the	O
decrease	O
in	O
microfilaremia	B-Disease
is	O
evident	O
.	O
The	O
pathophysiological	O
mechanisms	O
are	O
discussed	O
in	O
the	O
light	O
of	O
these	O
observations	O
and	O
the	O
few	O
other	O
comments	O
on	O
this	O
subject	O
published	O
in	O
the	O
literature	O
.	O
Amiodarone	B-Chemical
-	O
related	O
pulmonary	B-Disease
mass	I-Disease
and	O
unique	O
membranous	B-Disease
glomerulonephritis	I-Disease
in	O
a	O
patient	O
with	O
valvular	B-Disease
heart	I-Disease
disease	I-Disease
:	O
Diagnostic	O
pitfall	O
and	O
new	O
findings	O
.	O
Amiodarone	B-Chemical
is	O
an	O
anti	O
-	O
arrhythmic	B-Disease
drug	O
for	O
life	O
-	O
threatening	O
tachycardia	B-Disease
,	O
but	O
various	O
adverse	O
effects	O
have	O
been	O
reported	O
.	O
Reported	O
herein	O
is	O
an	O
autopsy	O
case	O
of	O
valvular	B-Disease
heart	I-Disease
disease	I-Disease
,	O
in	O
a	O
patient	O
who	O
developed	O
a	O
lung	B-Disease
mass	I-Disease
(	O
1	O
.	O
5	O
cm	O
in	O
diameter	O
)	O
and	O
proteinuria	B-Disease
(	O
2	O
.	O
76	O
g	O
/	O
day	O
)	O
after	O
treatment	O
with	O
amiodarone	B-Chemical
for	O
a	O
long	O
time	O
.	O
The	O
lung	B-Disease
mass	I-Disease
was	O
highly	O
suspected	O
to	O
be	O
lung	B-Disease
cancer	I-Disease
on	O
CT	O
and	O
positron	O
emission	O
tomography	O
,	O
but	O
histologically	O
the	O
lesion	O
was	O
composed	O
of	O
lymphoplasmacytic	O
infiltrates	O
in	O
alveolar	O
walls	O
and	O
intra	O
-	O
alveolar	O
accumulation	O
of	O
foamy	O
macrophages	O
containing	O
characteristic	O
myelinoid	O
bodies	O
,	O
indicating	O
that	O
it	O
was	O
an	O
amiodarone	B-Chemical
-	O
related	O
lesion	O
.	O
In	O
addition	O
,	O
the	O
lung	O
tissue	O
had	O
unevenly	O
distributed	O
hemosiderin	B-Disease
deposition	O
,	O
and	O
abnormally	O
tortuous	O
capillaries	O
were	O
seen	O
in	O
the	O
mass	O
and	O
in	O
heavily	O
hemosiderotic	B-Disease
lung	O
portions	O
outside	O
the	O
mass	O
.	O
In	O
the	O
kidneys	O
,	O
glomeruli	O
had	O
membrane	O
spikes	O
,	O
prominent	O
swelling	O
of	O
podocytes	O
and	O
subepithelial	O
deposits	O
,	O
which	O
were	O
sometimes	O
large	O
and	O
hump	O
-	O
like	O
.	O
Autoimmune	B-Disease
diseases	I-Disease
,	O
viral	B-Disease
hepatitis	I-Disease
,	O
malignant	O
neoplasms	B-Disease
or	O
other	O
diseases	O
with	O
a	O
known	O
relationship	O
to	O
membranous	B-Disease
glomerulonephritis	I-Disease
were	O
not	O
found	O
.	O
The	O
present	O
case	O
highlights	O
the	O
possibility	O
that	O
differential	O
diagnosis	O
between	O
an	O
amiodarone	B-Chemical
-	O
related	O
pulmonary	B-Disease
lesion	I-Disease
and	O
a	O
neoplasm	B-Disease
can	O
be	O
very	O
difficult	O
radiologically	O
,	O
and	O
suggests	O
that	O
membranous	B-Disease
glomerulonephritis	I-Disease
might	O
be	O
another	O
possible	O
complication	O
of	O
amiodarone	B-Chemical
treatment	O
.	O
Risk	O
of	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
associated	O
with	O
initial	O
sulphonylurea	B-Chemical
treatment	O
of	O
patients	O
with	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
:	O
a	O
matched	O
case	O
-	O
control	O
study	O
.	O
AIMS	O
:	O
This	O
study	O
sought	O
to	O
assess	O
the	O
risk	O
of	O
developing	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
(	O
CAD	B-Disease
)	O
associated	O
with	O
initial	O
treatment	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
with	O
different	O
sulphonylureas	B-Chemical
.	O
METHODS	O
:	O
In	O
type	B-Disease
2	I-Disease
diabetic	I-Disease
patients	O
,	O
cases	O
who	O
developed	O
CAD	B-Disease
were	O
compared	O
retrospectively	O
with	O
controls	O
that	O
did	O
not	O
.	O
The	O
20	O
-	O
year	O
risk	O
of	O
CAD	B-Disease
at	O
diagnosis	O
of	O
diabetes	B-Disease
,	O
using	O
the	O
UKPDS	O
risk	O
engine	O
,	O
was	O
used	O
to	O
match	O
cases	O
with	O
controls	O
.	O
RESULTS	O
:	O
The	O
76	O
cases	O
of	O
CAD	B-Disease
were	O
compared	O
with	O
152	O
controls	O
.	O
The	O
hazard	O
of	O
developing	O
CAD	B-Disease
(	O
95	O
%	O
CI	O
)	O
associated	O
with	O
initial	O
treatment	O
increased	O
by	O
2	O
.	O
4	O
-	O
fold	O
(	O
1	O
.	O
3	O
-	O
4	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
004	O
)	O
with	O
glibenclamide	B-Chemical
;	O
2	O
-	O
fold	O
(	O
0	O
.	O
9	O
-	O
4	O
.	O
6	O
,	O
P	O
=	O
0	O
.	O
099	O
)	O
with	O
glipizide	B-Chemical
;	O
2	O
.	O
9	O
-	O
fold	O
(	O
1	O
.	O
6	O
-	O
5	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
with	O
either	O
,	O
and	O
was	O
unchanged	O
with	O
metformin	B-Chemical
.	O
The	O
hazard	O
decreased	O
0	O
.	O
3	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
7	O
,	O
P	O
=	O
0	O
.	O
385	O
)	O
with	O
glimepiride	B-Chemical
,	O
0	O
.	O
4	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
192	O
)	O
with	O
gliclazide	B-Chemical
,	O
and	O
0	O
.	O
4	O
-	O
fold	O
(	O
0	O
.	O
7	O
-	O
1	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
09	O
)	O
with	O
either	O
.	O
CONCLUSIONS	O
:	O
Initiating	O
treatment	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
with	O
glibenclamide	B-Chemical
or	O
glipizide	B-Chemical
is	O
associated	O
with	O
increased	O
risk	O
of	O
CAD	B-Disease
in	O
comparison	O
to	O
gliclazide	B-Chemical
or	O
glimepiride	B-Chemical
.	O
If	O
confirmed	O
,	O
this	O
may	O
be	O
important	O
because	O
most	O
Indian	O
patients	O
receive	O
the	O
cheaper	O
older	O
sulphonylureas	B-Chemical
,	O
and	O
present	O
guidelines	O
do	O
not	O
distinguish	O
between	O
individual	O
agents	O
.	O
Reduced	O
progression	O
of	O
adriamycin	B-Chemical
nephropathy	B-Disease
in	O
spontaneously	O
hypertensive	B-Disease
rats	O
treated	O
by	O
losartan	B-Chemical
.	O
BACKGROUND	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
antihypertensive	O
effects	O
of	O
angiotensin	B-Chemical
II	I-Chemical
type	O
-	O
1	O
receptor	O
blocker	O
,	O
losartan	B-Chemical
,	O
and	O
its	O
potential	O
in	O
slowing	O
down	O
renal	B-Disease
disease	I-Disease
progression	O
in	O
spontaneously	O
hypertensive	B-Disease
rats	O
(	O
SHR	O
)	O
with	O
adriamycin	B-Chemical
(	O
ADR	B-Chemical
)	O
nephropathy	B-Disease
.	O
METHODS	O
:	O
Six	O
-	O
month	O
-	O
old	O
female	O
SHR	O
were	O
randomly	O
selected	O
in	O
six	O
groups	O
.	O
Two	O
control	O
groups	O
(	O
SH	O
(	O
6	O
)	O
,	O
SH	O
(	O
12	O
)	O
)	O
received	O
vehicle	O
.	O
Groups	O
ADR	B-Chemical
(	O
6	O
)	O
,	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
6	O
)	O
and	O
ADR	B-Chemical
(	O
12	O
)	O
,	O
and	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
12	O
)	O
received	O
ADR	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
/	O
b	O
.	O
w	O
.	O
i	O
.	O
v	O
.	O
)	O
twice	O
in	O
a	O
3	O
-	O
week	O
interval	O
.	O
Group	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
6	O
)	O
received	O
losartan	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
/	O
b	O
.	O
w	O
.	O
/	O
day	O
by	O
gavages	O
)	O
for	O
6	O
weeks	O
and	O
group	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
12	O
)	O
for	O
12	O
weeks	O
after	O
second	O
injection	O
of	O
ADR	B-Chemical
.	O
Animals	O
were	O
killed	O
after	O
6	O
or	O
12	O
weeks	O
,	O
respectively	O
.	O
Haemodynamic	O
measurements	O
were	O
performed	O
on	O
anaesthetized	O
animals	O
,	O
blood	O
and	O
urine	O
samples	O
were	O
taken	O
for	O
biochemical	O
analysis	O
and	O
the	O
left	O
kidney	O
was	O
processed	O
for	O
morphological	O
studies	O
.	O
RESULTS	O
:	O
Short	O
-	O
term	O
losartan	B-Chemical
treatment	O
,	O
besides	O
antihypertensive	O
effect	O
,	O
improved	O
glomerular	O
filtration	O
rate	O
and	O
ameliorated	O
glomerulosclerosis	B-Disease
resulting	O
in	O
decreased	O
proteinuria	B-Disease
.	O
Prolonged	O
treatment	O
with	O
losartan	B-Chemical
showed	O
further	O
reduction	O
of	O
glomerulosclerosis	B-Disease
associated	O
with	O
reduced	O
progression	O
of	O
tubular	O
atrophy	B-Disease
and	O
interstitial	B-Disease
fibrosis	I-Disease
,	O
thus	O
preventing	O
heavy	O
proteinuria	B-Disease
and	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
.	O
Losartan	B-Chemical
reduced	O
uraemia	B-Disease
and	O
increased	O
urea	B-Chemical
clearance	O
in	O
advanced	O
ADR	B-Chemical
nephropathy	B-Disease
in	O
SHR	O
.	O
Histological	O
examination	O
showed	O
that	O
losartan	B-Chemical
could	O
prevent	O
tubular	O
atrophy	B-Disease
,	O
interstitial	O
infiltration	O
and	O
fibrosis	B-Disease
in	O
ADR	B-Chemical
nephropathy	B-Disease
.	O
CONCLUSION	O
:	O
Losartan	B-Chemical
reduces	O
the	O
rate	O
of	O
progression	O
of	O
ADR	B-Chemical
-	O
induced	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
to	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
in	O
SHR	O
.	O
The	O
risks	O
of	O
aprotinin	O
and	O
tranexamic	B-Chemical
acid	I-Chemical
in	O
cardiac	O
surgery	O
:	O
a	O
one	O
-	O
year	O
follow	O
-	O
up	O
of	O
1188	O
consecutive	O
patients	O
.	O
BACKGROUND	O
:	O
Our	O
aim	O
was	O
to	O
investigate	O
postoperative	O
complications	O
and	O
mortality	O
after	O
administration	O
of	O
aprotinin	O
compared	O
to	O
tranexamic	B-Chemical
acid	I-Chemical
in	O
an	O
unselected	O
,	O
consecutive	O
cohort	O
.	O
METHODS	O
:	O
Perioperative	O
data	O
from	O
consecutive	O
cardiac	O
surgery	O
patients	O
were	O
prospectively	O
collected	O
between	O
September	O
2005	O
and	O
June	O
2006	O
in	O
a	O
university	O
-	O
affiliated	O
clinic	O
(	O
n	O
=	O
1188	O
)	O
.	O
During	O
the	O
first	O
5	O
mo	O
,	O
596	O
patients	O
received	O
aprotinin	O
(	O
Group	O
A	O
)	O
;	O
in	O
the	O
next	O
5	O
mo	O
,	O
592	O
patients	O
were	O
treated	O
with	O
tranexamic	B-Chemical
acid	I-Chemical
(	O
Group	O
T	O
)	O
.	O
Except	O
for	O
antifibrinolytic	O
therapy	O
,	O
the	O
anesthetic	O
and	O
surgical	O
protocols	O
remained	O
unchanged	O
.	O
RESULTS	O
:	O
The	O
pre	O
-	O
and	O
intraoperative	O
variables	O
were	O
comparable	O
between	O
the	O
treatment	O
groups	O
.	O
Postoperatively	O
,	O
a	O
significantly	O
higher	O
incidence	O
of	O
seizures	B-Disease
was	O
found	O
in	O
Group	O
T	O
(	O
4	O
.	O
6	O
%	O
vs	O
1	O
.	O
2	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
This	O
difference	O
was	O
also	O
significant	O
in	O
the	O
primary	O
valve	O
surgery	O
and	O
the	O
high	O
risk	O
surgery	O
subgroups	O
(	O
7	O
.	O
9	O
%	O
vs	O
1	O
.	O
2	O
%	O
,	O
P	O
=	O
0	O
.	O
003	O
;	O
7	O
.	O
3	O
%	O
vs	O
2	O
.	O
4	O
%	O
,	O
P	O
=	O
0	O
.	O
035	O
,	O
respectively	O
)	O
.	O
Persistent	O
atrial	O
fibrillation	O
(	O
7	O
.	O
9	O
%	O
vs	O
2	O
.	O
3	O
%	O
,	O
P	O
=	O
0	O
.	O
020	O
)	O
and	O
renal	B-Disease
failure	I-Disease
(	O
9	O
.	O
7	O
%	O
vs	O
1	O
.	O
7	O
%	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
were	O
also	O
more	O
common	O
in	O
Group	O
T	O
,	O
in	O
the	O
primary	O
valve	O
surgery	O
subgroup	O
.	O
On	O
the	O
contrary	O
,	O
among	O
primary	O
coronary	O
artery	O
bypass	O
surgery	O
patients	O
,	O
there	O
were	O
more	O
acute	O
myocardial	B-Disease
infarctions	I-Disease
and	O
renal	B-Disease
dysfunction	I-Disease
in	O
Group	O
A	O
(	O
5	O
.	O
8	O
%	O
vs	O
2	O
.	O
0	O
%	O
,	O
P	O
=	O
0	O
.	O
027	O
;	O
22	O
.	O
5	O
%	O
vs	O
15	O
.	O
2	O
%	O
,	O
P	O
=	O
0	O
.	O
036	O
,	O
respectively	O
)	O
.	O
The	O
1	O
-	O
yr	O
mortality	O
was	O
significantly	O
higher	O
after	O
aprotinin	O
treatment	O
in	O
the	O
high	O
risk	O
surgery	O
group	O
(	O
17	O
.	O
7	O
%	O
vs	O
9	O
.	O
8	O
%	O
,	O
P	O
=	O
0	O
.	O
034	O
)	O
.	O
CONCLUSION	O
:	O
Both	O
antifibrinolytic	O
drugs	O
bear	O
the	O
risk	O
of	O
adverse	O
outcome	O
depending	O
on	O
the	O
type	O
of	O
cardiac	O
surgery	O
.	O
Administration	O
of	O
aprotinin	O
should	O
be	O
avoided	O
in	O
coronary	O
artery	O
bypass	O
graft	O
and	O
high	O
risk	O
patients	O
,	O
whereas	O
administration	O
of	O
tranexamic	B-Chemical
acid	I-Chemical
is	O
not	O
recommended	O
in	O
valve	O
surgery	O
.	O
Delirium	B-Disease
in	O
an	O
elderly	O
woman	O
possibly	O
associated	O
with	O
administration	O
of	O
misoprostol	B-Chemical
.	O
Misoprostol	B-Chemical
has	O
been	O
associated	O
with	O
adverse	O
reactions	O
,	O
including	O
gastrointestinal	O
symptoms	O
,	O
gynecologic	O
problems	O
,	O
and	O
headache	B-Disease
.	O
Changes	O
in	O
mental	O
status	O
,	O
however	O
,	O
have	O
not	O
been	O
reported	O
.	O
We	O
present	O
a	O
case	O
in	O
which	O
an	O
89	O
-	O
year	O
-	O
old	O
woman	O
in	O
a	O
long	O
-	O
term	O
care	O
facility	O
became	O
confused	O
after	O
the	O
initiation	O
of	O
misoprostol	B-Chemical
therapy	O
.	O
The	O
patient	O
'	O
s	O
change	O
in	O
mental	O
status	O
was	O
first	O
reported	O
nine	O
days	O
after	O
the	O
initiation	O
of	O
therapy	O
.	O
Her	O
delirium	B-Disease
significantly	O
improved	O
after	O
misoprostol	B-Chemical
was	O
discontinued	O
and	O
her	O
mental	O
status	O
returned	O
to	O
normal	O
within	O
a	O
week	O
.	O
Because	O
no	O
other	O
factors	O
related	O
to	O
this	O
patient	O
changed	O
significantly	O
,	O
the	O
delirium	B-Disease
experienced	O
by	O
this	O
patient	O
possibly	O
resulted	O
from	O
misoprostol	B-Chemical
therapy	O
.	O
The	O
biological	O
properties	O
of	O
the	O
optical	O
isomers	O
of	O
propranolol	B-Chemical
and	O
their	O
effects	O
on	O
cardiac	B-Disease
arrhythmias	I-Disease
.	O
1	O
.	O
The	O
optical	O
isomers	O
of	O
propranolol	B-Chemical
have	O
been	O
compared	O
for	O
their	O
beta	O
-	O
blocking	O
and	O
antiarrhythmic	O
activities	O
.	O
2	O
.	O
In	O
blocking	O
the	O
positive	O
inotropic	O
and	O
chronotropic	O
responses	O
to	O
isoprenaline	B-Chemical
,	O
(	O
+	O
)	O
-	O
propranolol	B-Chemical
had	O
less	O
than	O
one	O
hundredth	O
the	O
potency	O
of	O
(	O
-	O
)	O
-	O
propranolol	B-Chemical
.	O
At	O
dose	O
levels	O
of	O
(	O
+	O
)	O
-	O
propranolol	B-Chemical
which	O
attenuated	O
the	O
responses	O
to	O
isoprenaline	B-Chemical
,	O
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram	O
.	O
3	O
.	O
The	O
metabolic	O
responses	O
to	O
isoprenaline	B-Chemical
in	O
dogs	O
(	O
an	O
increase	O
in	O
circulating	O
glucose	B-Chemical
,	O
lactate	B-Chemical
and	O
free	O
fatty	B-Chemical
acids	I-Chemical
)	O
were	O
all	O
blocked	O
by	O
(	O
-	O
)	O
-	O
propranolol	B-Chemical
.	O
(	O
+	O
)	O
-	O
Propranolol	B-Chemical
had	O
no	O
effect	O
on	O
fatty	B-Chemical
acid	I-Chemical
mobilization	O
but	O
significantly	O
reduced	O
the	O
increments	O
in	O
both	O
lactate	B-Chemical
and	O
glucose	B-Chemical
.	O
4	O
.	O
Both	O
isomers	O
of	O
propranolol	B-Chemical
possessed	O
similar	O
depressant	O
potency	O
on	O
isolated	O
atrial	O
muscle	O
taken	O
from	O
guinea	O
-	O
pigs	O
.	O
5	O
.	O
The	O
isomers	O
of	O
propranolol	B-Chemical
exhibited	O
similar	O
local	O
anaesthetic	O
potencies	O
on	O
an	O
isolated	O
frog	O
nerve	O
preparation	O
at	O
a	O
level	O
approximately	O
three	O
times	O
that	O
of	O
procaine	B-Chemical
.	O
The	O
racemic	O
compound	O
was	O
significantly	O
less	O
potent	O
than	O
either	O
isomer	O
.	O
6	O
.	O
Both	O
isomers	O
of	O
propranolol	B-Chemical
were	O
capable	O
of	O
preventing	O
adrenaline	B-Chemical
-	O
induced	O
cardiac	B-Disease
arrhythmias	I-Disease
in	O
cats	O
anaesthetized	O
with	O
halothane	B-Chemical
,	O
but	O
the	O
mean	O
dose	O
of	O
(	O
-	O
)	O
-	O
propranolol	B-Chemical
was	O
0	O
.	O
09	O
+	O
/	O
-	O
0	O
.	O
02	O
mg	O
/	O
kg	O
whereas	O
that	O
of	O
(	O
+	O
)	O
-	O
propranolol	B-Chemical
was	O
4	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
mg	O
/	O
kg	O
.	O
At	O
the	O
effective	O
dose	O
level	O
of	O
(	O
+	O
)	O
-	O
propranolol	B-Chemical
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram	O
.	O
Blockade	O
of	O
arrhythmias	B-Disease
with	O
both	O
isomers	O
was	O
surmountable	O
by	O
increasing	O
the	O
dose	O
of	O
adrenaline	B-Chemical
.	O
7	O
.	O
Both	O
isomers	O
of	O
propranolol	B-Chemical
were	O
also	O
capable	O
of	O
reversing	O
ventricular	B-Disease
tachycardia	I-Disease
caused	O
by	O
ouabain	B-Chemical
in	O
anaesthetized	O
cats	O
and	O
dogs	O
.	O
The	O
dose	O
of	O
(	O
-	O
)	O
-	O
propranolol	B-Chemical
was	O
significantly	O
smaller	O
than	O
that	O
of	O
(	O
+	O
)	O
-	O
propranolol	B-Chemical
in	O
both	O
species	O
but	O
much	O
higher	O
than	O
that	O
required	O
to	O
produce	O
evidence	O
of	O
beta	O
-	O
blockade	O
.	O
8	O
.	O
The	O
implications	O
of	O
these	O
results	O
are	O
discussed	O
.	O
Topotecan	B-Chemical
in	O
combination	O
with	O
radiotherapy	O
in	O
unresectable	O
glioblastoma	B-Disease
:	O
a	O
phase	O
2	O
study	O
.	O
Improving	O
glioblastoma	B-Disease
multiforme	I-Disease
(	O
GBM	B-Disease
)	O
treatment	O
with	O
radio	O
-	O
chemotherapy	O
remains	O
a	O
challenge	O
.	O
Topotecan	B-Chemical
is	O
an	O
attractive	O
option	O
as	O
it	O
exhibits	O
growth	O
inhibition	O
of	O
human	O
glioma	B-Disease
as	O
well	O
as	O
brain	O
penetration	O
.	O
The	O
present	O
study	O
assessed	O
the	O
combination	O
of	O
radiotherapy	O
(	O
60	O
Gy	O
/	O
30	O
fractions	O
/	O
40	O
days	O
)	O
and	O
topotecan	B-Chemical
(	O
0	O
.	O
9	O
mg	O
/	O
m	O
(	O
2	O
)	O
/	O
day	O
on	O
days	O
1	O
-	O
5	O
on	O
weeks	O
1	O
,	O
3	O
and	O
5	O
)	O
in	O
50	O
adults	O
with	O
histologically	O
proven	O
and	O
untreated	O
GBM	B-Disease
.	O
The	O
incidence	O
of	O
non	O
-	O
hematological	O
toxicities	B-Disease
was	O
low	O
and	O
grade	O
3	O
-	O
4	O
hematological	O
toxicities	B-Disease
were	O
reported	O
in	O
20	O
patients	O
(	O
mainly	O
lymphopenia	B-Disease
and	O
neutropenia	B-Disease
)	O
.	O
Partial	O
response	O
and	O
stabilization	O
rates	O
were	O
2	O
%	O
and	O
32	O
%	O
,	O
respectively	O
,	O
with	O
an	O
overall	O
time	O
to	O
progression	O
of	O
12	O
weeks	O
.	O
One	O
-	O
year	O
overall	O
survival	O
(	O
OS	O
)	O
rate	O
was	O
42	O
%	O
,	O
with	O
a	O
median	O
OS	O
of	O
40	O
weeks	O
.	O
Topotecan	B-Chemical
in	O
combination	O
with	O
radiotherapy	O
was	O
well	O
tolerated	O
.	O
However	O
,	O
while	O
response	O
and	O
stabilization	O
concerned	O
one	O
-	O
third	O
of	O
the	O
patients	O
,	O
the	O
study	O
did	O
not	O
show	O
increased	O
benefits	O
in	O
terms	O
of	O
survival	O
in	O
patients	O
with	O
unresectable	O
GBM	B-Disease
.	O
Long	O
-	O
term	O
lithium	B-Chemical
therapy	O
leading	O
to	O
hyperparathyroidism	B-Disease
:	O
a	O
case	O
report	O
.	O
PURPOSE	O
:	O
This	O
paper	O
reviews	O
the	O
effect	O
of	O
chronic	O
lithium	B-Chemical
therapy	O
on	O
serum	O
calcium	B-Chemical
level	O
and	O
parathyroid	O
glands	O
,	O
its	O
pathogenesis	O
,	O
and	O
treatment	O
options	O
.	O
We	O
examined	O
the	O
case	O
of	O
a	O
lithium	B-Chemical
-	O
treated	O
patient	O
who	O
had	O
recurrent	O
hypercalcemia	B-Disease
to	O
better	O
understand	O
the	O
disease	O
process	O
.	O
CONCLUSION	O
:	O
Primary	B-Disease
hyperparathyroidism	I-Disease
is	O
a	O
rare	O
but	O
potentially	O
life	O
-	O
threatening	O
side	O
effect	O
of	O
long	O
-	O
term	O
lithium	B-Chemical
therapy	O
.	O
Careful	O
patient	O
selection	O
and	O
long	O
-	O
term	O
follow	O
-	O
up	O
can	O
reduce	O
morbidity	O
.	O
PRACTICAL	O
IMPLICATIONS	O
:	O
As	O
much	O
as	O
15	O
%	O
of	O
lithium	B-Chemical
-	O
treated	O
patients	O
become	O
hypercalcemic	B-Disease
.	O
By	O
routinely	O
monitoring	O
serum	O
calcium	B-Chemical
levels	O
,	O
healthcare	O
providers	O
can	O
improve	O
the	O
quality	O
of	O
life	O
of	O
this	O
patient	O
group	O
.	O
Comparison	O
of	O
laryngeal	O
mask	O
with	O
endotracheal	O
tube	O
for	O
anesthesia	O
in	O
endoscopic	O
sinus	O
surgery	O
.	O
BACKGROUND	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
surgical	O
conditions	O
,	O
including	O
the	O
amount	O
of	O
intraoperative	O
bleeding	B-Disease
as	O
well	O
as	O
intraoperative	O
blood	O
pressure	O
,	O
during	O
functional	O
endoscopic	O
sinus	O
surgery	O
(	O
FESS	O
)	O
using	O
flexible	O
reinforced	O
laryngeal	O
mask	O
airway	O
(	O
FRLMA	O
)	O
versus	O
endotracheal	O
tube	O
(	O
ETT	O
)	O
in	O
maintaining	O
controlled	O
hypotension	B-Disease
anesthesia	O
induced	O
by	O
propofol	B-Chemical
-	O
remifentanil	B-Chemical
total	O
i	O
.	O
v	O
.	O
anesthesia	O
(	O
TIVA	O
)	O
.	O
METHODS	O
:	O
Sixty	O
normotensive	O
American	O
Society	O
of	O
Anesthesiologists	O
I	O
-	O
II	O
adult	O
patients	O
undergoing	O
FESS	O
under	O
controlled	O
hypotension	B-Disease
anesthesia	O
caused	O
by	O
propofol	B-Chemical
-	O
remifentanil	B-Chemical
-	O
TIVA	O
were	O
randomly	O
assigned	O
into	O
two	O
groups	O
:	O
group	O
I	O
,	O
FRLMA	O
;	O
group	O
II	O
,	O
ETT	O
.	O
Hemorrhage	B-Disease
was	O
measured	O
and	O
the	O
visibility	O
of	O
the	O
operative	O
field	O
was	O
evaluated	O
according	O
to	O
a	O
six	O
-	O
point	O
scale	O
.	O
RESULTS	O
:	O
Controlled	O
hypotension	B-Disease
was	O
achieved	O
within	O
a	O
shorter	O
period	O
using	O
laryngeal	O
mask	O
using	O
lower	O
rates	O
of	O
remifentanil	B-Chemical
infusion	O
and	O
lower	O
total	O
dose	O
of	O
remifentanil	B-Chemical
.	O
CONCLUSION	O
:	O
In	O
summary	O
,	O
our	O
results	O
indicate	O
that	O
airway	O
management	O
using	O
FRLMA	O
during	O
controlled	O
hypotension	B-Disease
anesthesia	O
provided	O
better	O
surgical	O
conditions	O
in	O
terms	O
of	O
quality	O
of	O
operative	O
field	O
and	O
blood	O
loss	O
and	O
allowed	O
for	O
convenient	O
induced	O
hypotension	B-Disease
with	O
low	O
doses	O
of	O
remifentanil	B-Chemical
during	O
TIVA	O
in	O
patients	O
undergoing	O
FESS	O
.	O
Nonalcoholic	B-Disease
fatty	I-Disease
liver	I-Disease
disease	I-Disease
during	O
valproate	B-Chemical
therapy	O
.	O
Valproic	B-Chemical
acid	I-Chemical
(	O
VPA	B-Chemical
)	O
is	O
effective	O
for	O
the	O
treatment	O
of	O
many	O
types	O
of	O
epilepsy	B-Disease
,	O
but	O
its	O
use	O
can	O
be	O
associated	O
with	O
an	O
increase	O
in	O
body	O
weight	O
.	O
We	O
report	O
a	O
case	O
of	O
nonalcoholic	B-Disease
fatty	I-Disease
liver	I-Disease
disease	I-Disease
(	O
NAFLD	B-Disease
)	O
arising	O
in	O
a	O
child	O
who	O
developed	O
obesity	B-Disease
during	O
VPA	B-Chemical
treatment	O
.	O
Laboratory	O
data	O
revealed	O
hyperinsulinemia	B-Disease
with	O
insulin	B-Disease
resistance	I-Disease
.	O
After	O
the	O
withdrawal	O
of	O
VPA	B-Chemical
therapy	O
,	O
our	O
patient	O
showed	O
a	O
significant	O
weight	B-Disease
loss	I-Disease
,	O
a	O
decrease	O
of	O
body	O
mass	O
index	O
,	O
and	O
normalization	O
of	O
metabolic	O
and	O
endocrine	O
parameters	O
;	O
moreover	O
,	O
ultrasound	O
measurements	O
showed	O
a	O
complete	O
normalization	O
.	O
The	O
present	O
case	O
suggests	O
that	O
obesity	B-Disease
,	O
hyperinsulinemia	B-Disease
,	O
insulin	B-Disease
resistance	I-Disease
,	O
and	O
long	O
-	O
term	O
treatment	O
with	O
VPA	B-Chemical
may	O
be	O
all	O
associated	O
with	O
the	O
development	O
of	O
NAFLD	B-Disease
;	O
this	O
side	O
effect	O
is	O
reversible	O
after	O
VPA	B-Chemical
withdrawal	O
.	O
Carbimazole	B-Chemical
induced	O
ANCA	B-Disease
positive	I-Disease
vasculitis	I-Disease
.	O
Anti	B-Chemical
-	I-Chemical
thyroid	I-Chemical
drugs	I-Chemical
,	O
like	O
carbimazole	B-Chemical
and	O
propylthiouracil	B-Chemical
(	O
PTU	B-Chemical
)	O
are	O
commonly	O
prescribed	O
for	O
the	O
treatment	O
of	O
hyperthyroidism	B-Disease
.	O
One	O
should	O
be	O
aware	O
of	O
the	O
side	O
effects	O
of	O
antithyroid	B-Chemical
medications	I-Chemical
.	O
Antineutrophil	B-Disease
cytoplasmic	I-Disease
antibody	I-Disease
(	I-Disease
ANCA	I-Disease
)	I-Disease
-	I-Disease
-	I-Disease
associated	I-Disease
vasculitis	I-Disease
is	O
a	O
potentially	O
life	O
-	O
threatening	O
adverse	O
effect	O
of	O
antithyroidmedications	B-Chemical
.	O
We	O
report	O
a	O
patient	O
with	O
Graves	B-Disease
'	I-Disease
disease	I-Disease
who	O
developed	O
ANCA	O
positive	O
carbimazole	B-Chemical
induced	O
vasculitis	B-Disease
.	O
The	O
episode	O
was	O
characterized	O
by	O
a	O
vasculitic	B-Disease
skin	B-Disease
rash	I-Disease
associated	O
with	O
large	O
joint	O
arthritis	B-Disease
,	O
pyrexia	B-Disease
and	O
parotiditis	B-Disease
but	O
no	O
renal	O
or	O
pulmonary	O
involvement	O
.	O
He	O
was	O
referred	O
to	O
us	O
for	O
neurological	O
evaluation	O
because	O
he	O
had	O
difficulty	O
in	O
getting	O
up	O
from	O
squatting	O
position	O
and	O
was	O
suspected	O
to	O
have	O
myositis	B-Disease
.	O
Carbimazole	B-Chemical
and	O
methimazole	B-Chemical
have	O
a	O
lower	O
incidence	O
of	O
reported	O
ANCA	O
positive	O
side	O
effects	O
than	O
PUT	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
ANCA	O
positive	O
carbimazole	B-Chemical
induced	O
vasculitis	B-Disease
case	O
reported	O
from	O
India	O
.	O
Aspirin	B-Chemical
for	O
the	O
primary	O
prevention	O
of	O
cardiovascular	O
events	O
:	O
an	O
update	O
of	O
the	O
evidence	O
for	O
the	O
U	O
.	O
S	O
.	O
Preventive	O
Services	O
Task	O
Force	O
.	O
BACKGROUND	O
:	O
Coronary	B-Disease
heart	I-Disease
disease	I-Disease
and	O
cerebrovascular	B-Disease
disease	I-Disease
are	O
leading	O
causes	O
of	O
death	O
in	O
the	O
United	O
States	O
.	O
In	O
2002	O
,	O
the	O
U	O
.	O
S	O
.	O
Preventive	O
Services	O
Task	O
Force	O
(	O
USPSTF	O
)	O
strongly	O
recommended	O
that	O
clinicians	O
discuss	O
aspirin	B-Chemical
with	O
adults	O
who	O
are	O
at	O
increased	O
risk	O
for	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
.	O
PURPOSE	O
:	O
To	O
determine	O
the	O
benefits	O
and	O
harms	O
of	O
taking	O
aspirin	B-Chemical
for	O
the	O
primary	O
prevention	O
of	O
myocardial	B-Disease
infarctions	I-Disease
,	O
strokes	B-Disease
,	O
and	O
death	O
.	O
DATA	O
SOURCES	O
:	O
MEDLINE	O
and	O
Cochrane	O
Library	O
(	O
search	O
dates	O
,	O
1	O
January	O
2001	O
to	O
28	O
August	O
2008	O
)	O
,	O
recent	O
systematic	O
reviews	O
,	O
reference	O
lists	O
of	O
retrieved	O
articles	O
,	O
and	O
suggestions	O
from	O
experts	O
.	O
STUDY	O
SELECTION	O
:	O
English	O
-	O
language	O
randomized	O
,	O
controlled	O
trials	O
(	O
RCTs	O
)	O
;	O
case	O
-	O
control	O
studies	O
;	O
meta	O
-	O
analyses	O
;	O
and	O
systematic	O
reviews	O
of	O
aspirin	B-Chemical
versus	O
control	O
for	O
the	O
primary	O
prevention	O
of	O
cardiovascular	B-Disease
disease	I-Disease
(	O
CVD	B-Disease
)	O
were	O
selected	O
to	O
answer	O
the	O
following	O
questions	O
:	O
Does	O
aspirin	B-Chemical
decrease	O
coronary	O
heart	O
events	O
,	O
strokes	B-Disease
,	O
death	O
from	O
coronary	O
heart	O
events	O
or	O
stroke	B-Disease
,	O
or	O
all	O
-	O
cause	O
mortality	O
in	O
adults	O
without	O
known	O
CVD	B-Disease
?	O
Does	O
aspirin	B-Chemical
increase	O
gastrointestinal	B-Disease
bleeding	I-Disease
or	O
hemorrhagic	B-Disease
strokes	I-Disease
?	O
DATA	O
EXTRACTION	O
:	O
All	O
studies	O
were	O
reviewed	O
,	O
abstracted	O
,	O
and	O
rated	O
for	O
quality	O
by	O
using	O
predefined	O
USPSTF	O
criteria	O
.	O
DATA	O
SYNTHESIS	O
:	O
New	O
evidence	O
from	O
1	O
good	O
-	O
quality	O
RCT	O
,	O
1	O
good	O
-	O
quality	O
meta	O
-	O
analysis	O
,	O
and	O
2	O
fair	O
-	O
quality	O
subanalyses	O
of	O
RCTs	O
demonstrates	O
that	O
aspirin	B-Chemical
use	O
reduces	O
the	O
number	O
of	O
CVD	B-Disease
events	O
in	O
patients	O
without	O
known	O
CVD	B-Disease
.	O
Men	O
in	O
these	O
studies	O
experienced	O
fewer	O
myocardial	B-Disease
infarctions	I-Disease
and	O
women	O
experienced	O
fewer	O
ischemic	O
strokes	B-Disease
.	O
Aspirin	B-Chemical
does	O
not	O
seem	O
to	O
affect	O
CVD	B-Disease
mortality	O
or	O
all	O
-	O
cause	O
mortality	O
in	O
either	O
men	O
or	O
women	O
.	O
The	O
use	O
of	O
aspirin	B-Chemical
for	O
primary	O
prevention	O
increases	O
the	O
risk	O
for	O
major	O
bleeding	B-Disease
events	O
,	O
primarily	O
gastrointestinal	B-Disease
bleeding	I-Disease
events	O
,	O
in	O
both	O
men	O
and	O
women	O
.	O
Men	O
have	O
an	O
increased	O
risk	O
for	O
hemorrhagic	B-Disease
strokes	I-Disease
with	O
aspirin	B-Chemical
use	O
.	O
A	O
new	O
RCT	O
and	O
meta	O
-	O
analysis	O
suggest	O
that	O
the	O
risk	O
for	O
hemorrhagic	B-Disease
strokes	I-Disease
in	O
women	O
is	O
not	O
statistically	O
significantly	O
increased	O
.	O
LIMITATIONS	O
:	O
New	O
evidence	O
on	O
aspirin	B-Chemical
for	O
the	O
primary	O
prevention	O
of	O
CVD	B-Disease
is	O
limited	O
.	O
The	O
dose	O
of	O
aspirin	B-Chemical
used	O
in	O
the	O
RCTs	O
varied	O
,	O
which	O
prevented	O
the	O
estimation	O
of	O
the	O
most	O
appropriate	O
dose	O
for	O
primary	O
prevention	O
.	O
Several	O
of	O
the	O
RCTs	O
were	O
conducted	O
within	O
populations	O
of	O
health	O
professionals	O
,	O
which	O
potentially	O
limits	O
generalizability	O
.	O
CONCLUSION	O
:	O
Aspirin	B-Chemical
reduces	O
the	O
risk	O
for	O
myocardial	B-Disease
infarction	I-Disease
in	O
men	O
and	O
strokes	B-Disease
in	O
women	O
.	O
Aspirin	B-Chemical
use	O
increases	O
the	O
risk	O
for	O
serious	O
bleeding	B-Disease
events	O
.	O
Reducing	O
harm	O
associated	O
with	O
anticoagulation	O
:	O
practical	O
considerations	O
of	O
argatroban	B-Chemical
therapy	O
in	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
.	O
Argatroban	B-Chemical
is	O
a	O
hepatically	O
metabolized	O
,	O
direct	O
thrombin	O
inhibitor	O
used	O
for	O
prophylaxis	O
or	O
treatment	O
of	O
thrombosis	B-Disease
in	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
(	O
HIT	B-Disease
)	O
and	O
for	O
patients	O
with	O
or	O
at	O
risk	O
of	O
HIT	B-Disease
undergoing	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
.	O
The	O
objective	O
of	O
this	O
review	O
is	O
to	O
summarize	O
practical	O
considerations	O
of	O
argatroban	B-Chemical
therapy	O
in	O
HIT	B-Disease
.	O
The	O
US	O
FDA	O
-	O
recommended	O
argatroban	B-Chemical
dose	O
in	O
HIT	B-Disease
is	O
2	O
microg	O
/	O
kg	O
/	O
min	O
(	O
reduced	O
in	O
patients	O
with	O
hepatic	B-Disease
impairment	I-Disease
and	O
in	O
paediatric	O
patients	O
)	O
,	O
adjusted	O
to	O
achieve	O
activated	O
partial	O
thromboplastin	O
times	O
(	O
aPTTs	O
)	O
1	O
.	O
5	O
-	O
3	O
times	O
baseline	O
(	O
not	O
>	O
100	O
seconds	O
)	O
.	O
Contemporary	O
experiences	O
indicate	O
that	O
reduced	O
doses	O
are	O
also	O
needed	O
in	O
patients	O
with	O
conditions	O
associated	O
with	O
hepatic	O
hypoperfusion	O
,	O
e	O
.	O
g	O
.	O
heart	B-Disease
failure	I-Disease
,	O
yet	O
are	O
unnecessary	O
for	O
renal	B-Disease
dysfunction	I-Disease
,	O
adult	O
age	O
,	O
sex	O
,	O
race	O
/	O
ethnicity	O
or	O
obesity	B-Disease
.	O
Argatroban	B-Chemical
0	O
.	O
5	O
-	O
1	O
.	O
2	O
microg	O
/	O
kg	O
/	O
min	O
typically	O
supports	O
therapeutic	O
aPTTs	O
.	O
The	O
FDA	O
-	O
recommended	O
dose	O
during	O
PCI	O
is	O
25	O
microg	O
/	O
kg	O
/	O
min	O
(	O
350	O
microg	O
/	O
kg	O
initial	O
bolus	O
)	O
,	O
adjusted	O
to	O
achieve	O
activated	O
clotting	O
times	O
(	O
ACTs	O
)	O
of	O
300	O
-	O
450	O
sec	O
.	O
For	O
PCI	O
,	O
argatroban	B-Chemical
has	O
not	O
been	O
investigated	O
in	O
hepatically	O
impaired	O
patients	O
;	O
dose	O
adjustment	O
is	O
unnecessary	O
for	O
adult	O
age	O
,	O
sex	O
,	O
race	O
/	O
ethnicity	O
or	O
obesity	B-Disease
,	O
and	O
lesser	O
doses	O
may	O
be	O
adequate	O
with	O
concurrent	O
glycoprotein	O
IIb	O
/	O
IIIa	O
inhibition	O
.	O
Argatroban	B-Chemical
prolongs	O
the	O
International	O
Normalized	O
Ratio	O
,	O
and	O
published	O
approaches	O
for	O
monitoring	O
the	O
argatroban	B-Chemical
-	O
to	O
-	O
warfarin	B-Chemical
transition	O
should	O
be	O
followed	O
.	O
Major	O
bleeding	B-Disease
with	O
argatroban	B-Chemical
is	O
0	O
-	O
10	O
%	O
in	O
the	O
non	O
-	O
interventional	O
setting	O
and	O
0	O
-	O
5	O
.	O
8	O
%	O
periprocedurally	O
.	O
Argatroban	B-Chemical
has	O
no	O
specific	O
antidote	O
,	O
and	O
if	O
excessive	O
anticoagulation	O
occurs	O
,	O
argatroban	B-Chemical
infusion	O
should	O
be	O
stopped	O
or	O
reduced	O
.	O
Improved	O
familiarity	O
of	O
healthcare	O
professionals	O
with	O
argatroban	B-Chemical
therapy	O
in	O
HIT	B-Disease
,	O
including	O
in	O
special	O
populations	O
and	O
during	O
PCI	O
,	O
may	O
facilitate	O
reduction	O
of	O
harm	O
associated	O
with	O
HIT	B-Disease
(	O
e	O
.	O
g	O
.	O
fewer	O
thromboses	O
)	O
or	O
its	O
treatment	O
(	O
e	O
.	O
g	O
.	O
fewer	O
argatroban	B-Chemical
medication	O
errors	O
)	O
.	O
Rhabdomyolysis	B-Disease
and	O
brain	O
ischemic	B-Disease
stroke	I-Disease
in	O
a	O
heroin	B-Chemical
-	O
dependent	O
male	O
under	O
methadone	B-Chemical
maintenance	O
therapy	O
.	O
OBJECTIVE	O
:	O
There	O
are	O
several	O
complications	O
associated	O
with	O
heroin	B-Disease
abuse	I-Disease
,	O
some	O
of	O
which	O
are	O
life	O
-	O
threatening	O
.	O
Methadone	B-Chemical
may	O
aggravate	O
this	O
problem	O
.	O
METHOD	O
:	O
A	O
clinical	O
case	O
description	O
.	O
RESULTS	O
:	O
A	O
33	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
rhabdomyolysis	B-Disease
and	O
cerebral	O
ischemic	B-Disease
stroke	I-Disease
after	O
intravenous	O
heroin	B-Chemical
.	O
He	O
had	O
used	O
heroin	B-Chemical
since	O
age	O
20	O
,	O
and	O
had	O
used	O
150	O
mg	O
methadone	B-Chemical
daily	O
for	O
6	O
months	O
.	O
He	O
was	O
found	O
unconsciousness	B-Disease
at	O
home	O
and	O
was	O
sent	O
to	O
our	O
hospital	O
.	O
In	O
the	O
ER	O
,	O
his	O
opiate	O
level	O
was	O
4497	O
ng	O
/	O
ml	O
.	O
In	O
the	O
ICU	O
,	O
we	O
found	O
rhabdomyolysis	B-Disease
,	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
and	O
acute	O
respiratory	B-Disease
failure	I-Disease
.	O
After	O
transfer	O
to	O
an	O
internal	O
ward	O
,	O
we	O
noted	O
aphasia	B-Disease
and	O
weakness	B-Disease
of	O
his	O
left	O
limbs	O
.	O
After	O
MRI	O
,	O
we	O
found	O
cerebral	B-Disease
ischemic	I-Disease
infarction	I-Disease
.	O
CONCLUSION	O
:	O
Those	O
using	O
methadone	B-Chemical
and	O
heroin	B-Chemical
simultaneously	O
may	O
increase	O
risk	O
of	O
rhabdomyolysis	B-Disease
and	O
ischemic	B-Disease
stroke	I-Disease
.	O
Patients	O
under	O
methadone	B-Chemical
maintenance	O
therapy	O
should	O
be	O
warned	O
regarding	O
these	O
serious	O
adverse	O
events	O
.	O
Hypotheses	O
of	O
heroin	B-Chemical
-	O
related	O
rhabdomyolysis	B-Disease
and	O
stroke	B-Disease
in	O
heroin	B-Chemical
abusers	O
are	O
discussed	O
.	O
Increased	O
vulnerability	O
to	O
6	B-Chemical
-	I-Chemical
hydroxydopamine	I-Chemical
lesion	O
and	O
reduced	O
development	O
of	O
dyskinesias	B-Disease
in	O
mice	O
lacking	O
CB1	O
cannabinoid	O
receptors	O
.	O
Motor	O
impairment	O
,	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
neuronal	O
activity	O
and	O
proenkephalin	B-Chemical
(	O
PENK	B-Chemical
)	O
gene	O
expression	O
in	O
the	O
caudate	O
-	O
putamen	O
(	O
CPu	O
)	O
were	O
measured	O
in	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
-	O
lesioned	O
and	O
treated	O
(	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
+	I-Chemical
benserazide	I-Chemical
)	O
CB1	O
KO	O
and	O
WT	O
mice	O
.	O
A	O
lesion	O
induced	O
by	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
produced	O
more	O
severe	O
motor	O
deterioration	O
in	O
CB1	O
KO	O
mice	O
accompanied	O
by	O
more	O
loss	O
of	O
DA	B-Chemical
neurons	O
and	O
increased	O
PENK	B-Chemical
gene	O
expression	O
in	O
the	O
CPu	O
.	O
Oxidative	O
/	O
nitrosative	O
and	O
neuroinflammatory	O
parameters	O
were	O
estimated	O
in	O
the	O
CPu	O
and	O
cingulate	O
cortex	O
(	O
Cg	O
)	O
.	O
CB1	O
KO	O
mice	O
exhibited	O
higher	O
MDA	B-Chemical
levels	O
and	O
iNOS	O
protein	O
expression	O
in	O
the	O
CPu	O
and	O
Cg	O
compared	O
to	O
WT	O
mice	O
.	O
Treatment	O
with	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
+	I-Chemical
benserazide	I-Chemical
(	O
12	O
weeks	O
)	O
resulted	O
in	O
less	O
severe	O
dyskinesias	B-Disease
in	O
CB1	O
KO	O
than	O
in	O
WT	O
mice	O
.	O
The	O
results	O
revealed	O
that	O
the	O
lack	O
of	O
cannabinoid	O
CB1	O
receptors	O
increased	O
the	O
severity	O
of	O
motor	O
impairment	O
and	O
DA	B-Chemical
lesion	O
,	O
and	O
reduced	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
-	O
induced	O
dyskinesias	B-Disease
.	O
These	O
results	O
suggest	O
that	O
activation	O
of	O
CB1	O
receptors	O
offers	O
neuroprotection	O
against	O
dopaminergic	O
lesion	O
and	O
the	O
development	O
of	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
-	O
induced	O
dyskinesias	B-Disease
.	O
Hepatocellular	O
oxidant	O
stress	O
following	O
intestinal	O
ischemia	B-Disease
-	O
reperfusion	B-Disease
injury	I-Disease
.	O
Reperfusion	O
of	O
ischemic	B-Disease
intestine	O
results	O
in	O
acute	O
liver	B-Disease
dysfunction	I-Disease
characterized	O
by	O
hepatocellular	O
enzyme	O
release	O
into	O
plasma	O
,	O
reduction	O
in	O
bile	O
flow	O
rate	O
,	O
and	O
neutrophil	O
sequestration	O
within	O
the	O
liver	O
.	O
The	O
pathophysiology	O
underlying	O
this	O
acute	O
hepatic	B-Disease
injury	I-Disease
is	O
unknown	O
.	O
This	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
oxidants	O
are	O
associated	O
with	O
the	O
hepatic	B-Disease
injury	I-Disease
and	O
to	O
determine	O
the	O
relative	O
value	O
of	O
several	O
indirect	O
methods	O
of	O
assessing	O
oxidant	O
exposure	O
in	O
vivo	O
.	O
Rats	O
were	O
subjected	O
to	O
a	O
standardized	O
intestinal	O
ischemia	B-Disease
-	O
reperfusion	B-Disease
injury	I-Disease
.	O
Hepatic	O
tissue	O
was	O
assayed	O
for	O
lipid	O
peroxidation	O
products	O
and	O
oxidized	B-Chemical
and	I-Chemical
reduced	I-Chemical
glutathione	I-Chemical
.	O
There	O
was	O
no	O
change	O
in	O
hepatic	O
tissue	O
total	O
glutathione	B-Chemical
following	O
intestinal	O
ischemia	B-Disease
-	O
reperfusion	B-Disease
injury	I-Disease
.	O
Oxidized	B-Chemical
glutathione	I-Chemical
(	O
GSSG	B-Chemical
)	O
increased	O
significantly	O
following	O
30	O
and	O
60	O
min	O
of	O
reperfusion	O
.	O
There	O
was	O
no	O
increase	O
in	O
any	O
of	O
the	O
products	O
of	O
lipid	O
peroxidation	O
associated	O
with	O
this	O
injury	O
.	O
An	O
increase	O
in	O
GSSG	B-Chemical
within	O
hepatic	O
tissue	O
during	O
intestinal	O
reperfusion	O
suggests	O
exposure	O
of	O
hepatocytes	O
to	O
an	O
oxidant	O
stress	O
.	O
The	O
lack	O
of	O
a	O
significant	O
increase	O
in	O
products	O
of	O
lipid	O
peroxidation	O
suggests	O
that	O
the	O
oxidant	O
stress	O
is	O
of	O
insufficient	O
magnitude	O
to	O
result	O
in	O
irreversible	O
injury	O
to	O
hepatocyte	O
cell	O
membranes	O
.	O
These	O
data	O
also	O
suggest	O
that	O
the	O
measurement	O
of	O
tissue	O
GSSG	B-Chemical
may	O
be	O
a	O
more	O
sensitive	O
indicator	O
of	O
oxidant	O
stress	O
than	O
measurement	O
of	O
products	O
of	O
lipid	O
peroxidation	O
.	O
Animal	O
model	O
of	O
mania	B-Disease
induced	O
by	O
ouabain	B-Chemical
:	O
Evidence	O
of	O
oxidative	O
stress	O
in	O
submitochondrial	O
particles	O
of	O
the	O
rat	O
brain	O
.	O
The	O
intracerebroventricular	O
(	O
ICV	O
)	O
administration	O
of	O
ouabain	B-Chemical
(	O
a	O
Na	B-Chemical
(	O
+	O
)	O
/	O
K	B-Chemical
(	O
+	O
)	O
-	O
ATPase	O
inhibitor	O
)	O
in	O
rats	O
has	O
been	O
suggested	O
to	O
mimic	O
some	O
symptoms	O
of	O
human	O
bipolar	B-Disease
mania	I-Disease
.	O
Clinical	O
studies	O
have	O
shown	O
that	O
bipolar	B-Disease
disorder	I-Disease
may	O
be	O
related	O
to	O
mitochondrial	B-Disease
dysfunction	I-Disease
.	O
Herein	O
,	O
we	O
investigated	O
the	O
behavioral	O
and	O
biochemical	O
effects	O
induced	O
by	O
the	O
ICV	O
administration	O
of	O
ouabain	B-Chemical
in	O
rats	O
.	O
To	O
achieve	O
this	O
aim	O
,	O
the	O
effects	O
of	O
ouabain	B-Chemical
injection	O
immediately	O
after	O
and	O
7	O
days	O
following	O
a	O
single	O
ICV	O
administration	O
(	O
at	O
concentrations	O
of	O
10	O
(	O
-	O
2	O
)	O
and	O
10	O
(	O
-	O
3	O
)	O
M	O
)	O
on	O
locomotion	O
was	O
measured	O
using	O
the	O
open	O
-	O
field	O
test	O
.	O
Additionally	O
,	O
thiobarbituric	B-Chemical
acid	I-Chemical
reactive	O
substances	O
(	O
TBARSs	O
)	O
and	O
superoxide	B-Chemical
production	O
were	O
measured	O
in	O
submitochondrial	O
particles	O
of	O
the	O
prefrontal	O
cortex	O
,	O
hippocampus	O
,	O
striatum	O
and	O
amygdala	O
.	O
Our	O
findings	O
demonstrated	O
that	O
ouabain	B-Chemical
at	O
10	O
(	O
-	O
2	O
)	O
and	O
10	O
(	O
-	O
3	O
)	O
M	O
induced	O
hyperlocomotion	B-Disease
in	O
rats	O
,	O
and	O
this	O
response	O
remained	O
up	O
to	O
7	O
days	O
following	O
a	O
single	O
ICV	O
injection	O
.	O
In	O
addition	O
,	O
we	O
observed	O
that	O
the	O
persistent	O
increase	O
in	O
the	O
rat	O
spontaneous	O
locomotion	O
is	O
associated	O
with	O
increased	O
TBARS	O
levels	O
and	O
superoxide	B-Chemical
generation	O
in	O
submitochondrial	O
particles	O
in	O
the	O
prefrontal	O
cortex	O
,	O
striatum	O
and	O
amygdala	O
.	O
In	O
conclusion	O
,	O
ouabain	B-Chemical
-	O
induced	O
mania	B-Disease
-	O
like	O
behavior	O
may	O
provide	O
a	O
useful	O
animal	O
model	O
to	O
test	O
the	O
hypothesis	O
of	O
the	O
involvement	O
of	O
oxidative	O
stress	O
in	O
bipolar	B-Disease
disorder	I-Disease
.	O
Intraoperative	O
dialysis	O
during	O
liver	O
transplantation	O
with	O
citrate	B-Chemical
dialysate	O
.	O
Liver	O
transplantation	O
for	O
acutely	O
ill	O
patients	O
with	O
fulminant	B-Disease
liver	I-Disease
failure	I-Disease
carries	O
high	O
intraoperative	O
and	O
immediate	O
postoperative	O
risks	O
.	O
These	O
are	O
increased	O
with	O
the	O
presence	O
of	O
concomitant	O
acute	B-Disease
kidney	I-Disease
injury	I-Disease
(	O
AKI	B-Disease
)	O
and	O
intraoperative	O
dialysis	O
is	O
sometimes	O
required	O
to	O
allow	O
the	O
transplant	O
to	O
proceed	O
.	O
The	O
derangements	O
in	O
the	O
procoagulant	O
and	O
anticoagulant	O
pathways	O
during	O
fulminant	B-Disease
liver	I-Disease
failure	I-Disease
can	O
lead	O
to	O
difficulties	O
with	O
anticoagulation	O
during	O
dialysis	O
,	O
especially	O
when	O
continued	O
in	O
the	O
operating	O
room	O
.	O
Systemic	O
anticoagulation	O
is	O
unsafe	O
and	O
regional	O
citrate	B-Chemical
anticoagulation	O
in	O
the	O
absence	O
of	O
a	O
functional	O
liver	O
carries	O
the	O
risk	O
of	O
citrate	B-Chemical
toxicity	B-Disease
.	O
Citrate	B-Chemical
dialysate	O
,	O
a	O
new	O
dialysate	O
with	O
citric	B-Chemical
acid	I-Chemical
can	O
be	O
used	O
for	O
anticoagulation	O
in	O
patients	O
who	O
cannot	O
tolerate	O
heparin	B-Chemical
or	O
regional	O
citrate	B-Chemical
.	O
We	O
report	O
a	O
case	O
of	O
a	O
40	O
-	O
year	O
-	O
old	O
female	O
with	O
acetaminophen	B-Chemical
-	O
induced	O
fulminant	B-Disease
liver	I-Disease
failure	I-Disease
with	O
associated	O
AKI	B-Disease
who	O
underwent	O
intraoperative	O
dialytic	O
support	O
during	O
liver	O
transplantation	O
anticoagulated	O
with	O
citrate	B-Chemical
dialysate	O
during	O
the	O
entire	O
procedure	O
.	O
The	O
patient	O
tolerated	O
the	O
procedure	O
well	O
without	O
any	O
signs	O
of	O
citrate	B-Chemical
toxicity	B-Disease
and	O
maintained	O
adequate	O
anticoagulation	O
for	O
patency	O
of	O
the	O
dialysis	O
circuit	O
.	O
Citrate	B-Chemical
dialysate	O
is	O
a	O
safe	O
alternative	O
for	O
intradialytic	O
support	O
of	O
liver	O
transplantation	O
in	O
fulminant	B-Disease
liver	I-Disease
failure	I-Disease
.	O
Delirium	B-Disease
in	O
a	O
patient	O
with	O
toxic	O
flecainide	B-Chemical
plasma	O
concentrations	O
:	O
the	O
role	O
of	O
a	O
pharmacokinetic	O
drug	O
interaction	O
with	O
paroxetine	B-Chemical
.	O
OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
flecainide	B-Chemical
-	O
induced	O
delirium	B-Disease
associated	O
with	O
a	O
pharmacokinetic	O
drug	O
interaction	O
with	O
paroxetine	B-Chemical
.	O
CASE	O
SUMMARY	O
:	O
A	O
69	O
-	O
year	O
-	O
old	O
white	O
female	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
a	O
history	O
of	O
confusion	B-Disease
and	O
paranoia	B-Disease
over	O
the	O
past	O
several	O
days	O
.	O
On	O
admission	O
the	O
patient	O
was	O
taking	O
carvedilol	B-Chemical
12	O
mg	O
twice	O
daily	O
,	O
warfarin	B-Chemical
2	O
mg	O
/	O
day	O
,	O
folic	B-Chemical
acid	I-Chemical
1	O
mg	O
/	O
day	O
,	O
levothyroxine	B-Chemical
100	O
microg	O
/	O
day	O
,	O
pantoprazole	B-Chemical
40	O
mg	O
/	O
day	O
,	O
paroxetine	B-Chemical
40	O
mg	O
/	O
day	O
,	O
and	O
flecainide	B-Chemical
100	O
mg	O
twice	O
daily	O
.	O
Flecainide	B-Chemical
had	O
been	O
started	O
2	O
weeks	O
prior	O
for	O
atrial	B-Disease
fibrillation	I-Disease
.	O
Laboratory	O
test	O
findings	O
on	O
admission	O
were	O
notable	O
only	O
for	O
a	O
flecainide	B-Chemical
plasma	O
concentration	O
of	O
1360	O
microg	O
/	O
L	O
(	O
reference	O
range	O
200	O
-	O
1000	O
)	O
.	O
A	O
metabolic	O
drug	O
interaction	O
between	O
flecainide	B-Chemical
and	O
paroxetine	B-Chemical
,	O
which	O
the	O
patient	O
had	O
been	O
taking	O
for	O
more	O
than	O
5	O
years	O
,	O
was	O
considered	O
.	O
Paroxetine	B-Chemical
was	O
discontinued	O
and	O
the	O
dose	O
of	O
flecainide	B-Chemical
was	O
reduced	O
to	O
50	O
mg	O
twice	O
daily	O
.	O
Her	O
delirium	B-Disease
resolved	O
3	O
days	O
later	O
.	O
DISCUSSION	O
:	O
Flecainide	B-Chemical
and	O
pharmacologically	O
similar	O
agents	O
that	O
interact	O
with	O
sodium	B-Chemical
channels	O
may	O
cause	O
delirium	B-Disease
in	O
susceptible	O
patients	O
.	O
A	O
MEDLINE	O
search	O
(	O
1966	O
-	O
January	O
2009	O
)	O
revealed	O
one	O
in	O
vivo	O
pharmacokinetic	O
study	O
on	O
the	O
interaction	O
between	O
flecainide	B-Chemical
,	O
a	O
CYP2D6	O
substrate	O
,	O
and	O
paroxetine	B-Chemical
,	O
a	O
CYP2D6	O
inhibitor	O
,	O
as	O
well	O
as	O
3	O
case	O
reports	O
of	O
flecainide	B-Chemical
-	O
induced	O
delirium	B-Disease
.	O
According	O
to	O
the	O
Naranjo	O
probability	O
scale	O
,	O
flecainide	B-Chemical
was	O
the	O
probable	O
cause	O
of	O
the	O
patient	O
'	O
s	O
delirium	B-Disease
;	O
the	O
Horn	O
Drug	O
Interaction	O
Probability	O
Scale	O
indicates	O
a	O
possible	O
pharmacokinetic	O
drug	O
interaction	O
between	O
flecainide	B-Chemical
and	O
paroxetine	B-Chemical
.	O
CONCLUSIONS	O
:	O
Supratherapeutic	O
flecainide	B-Chemical
plasma	O
concentrations	O
may	O
cause	O
delirium	B-Disease
.	O
Because	O
toxicity	B-Disease
may	O
occur	O
when	O
flecainide	B-Chemical
is	O
prescribed	O
with	O
paroxetine	B-Chemical
and	O
other	O
potent	O
CYP2D6	O
inhibitors	O
,	O
flecainide	B-Chemical
plasma	O
concentrations	O
should	O
be	O
monitored	O
closely	O
with	O
commencement	O
of	O
CYP2D6	O
inhibitors	O
.	O
Efficacy	O
of	O
everolimus	B-Chemical
(	O
RAD001	B-Chemical
)	O
in	O
patients	O
with	O
advanced	O
NSCLC	B-Disease
previously	O
treated	O
with	O
chemotherapy	O
alone	O
or	O
with	O
chemotherapy	O
and	O
EGFR	O
inhibitors	O
.	O
BACKGROUND	O
:	O
Treatment	O
options	O
are	O
scarce	O
in	O
pretreated	O
advanced	O
non	B-Disease
-	I-Disease
small	I-Disease
-	I-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
(	O
NSCLC	B-Disease
)	O
patients	O
.	O
RAD001	B-Chemical
,	O
an	O
oral	O
inhibitor	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	B-Chemical
(	O
mTOR	O
)	O
,	O
has	O
shown	O
phase	O
I	O
efficacy	O
in	O
NSCLC	B-Disease
.	O
METHODS	O
:	O
Stage	O
IIIb	O
or	O
IV	O
NSCLC	B-Disease
patients	O
,	O
with	O
two	O
or	O
fewer	O
prior	O
chemotherapy	O
regimens	O
,	O
one	O
platinum	B-Chemical
based	O
(	O
stratum	O
1	O
)	O
or	O
both	O
chemotherapy	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	B-Chemical
kinase	O
inhibitors	O
(	O
stratum	O
2	O
)	O
,	O
received	O
RAD001	B-Chemical
10	O
mg	O
/	O
day	O
until	O
progression	O
or	O
unacceptable	O
toxicity	B-Disease
.	O
Primary	O
objective	O
was	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
.	O
Analyses	O
of	O
markers	O
associated	O
with	O
the	O
mTOR	O
pathway	O
were	O
carried	O
out	O
on	O
archival	O
tumor	B-Disease
from	O
a	O
subgroup	O
using	O
immunohistochemistry	O
(	O
IHC	O
)	O
and	O
direct	O
mutation	O
sequencing	O
.	O
RESULTS	O
:	O
Eighty	O
-	O
five	O
patients	O
were	O
enrolled	O
,	O
42	O
in	O
stratum	O
1	O
and	O
43	O
in	O
stratum	O
.	O
ORR	O
was	O
4	O
.	O
7	O
%	O
(	O
7	O
.	O
1	O
%	O
stratum	O
1	O
;	O
2	O
.	O
3	O
%	O
stratum	O
2	O
)	O
.	O
Overall	O
disease	O
control	O
rate	O
was	O
47	O
.	O
1	O
%	O
.	O
Median	O
progression	O
-	O
free	O
survivals	O
(	O
PFSs	O
)	O
were	O
2	O
.	O
6	O
(	O
stratum	O
1	O
)	O
and	O
2	O
.	O
7	O
months	O
(	O
stratum	O
2	O
)	O
.	O
Common	O
>	O
or	O
=	O
grade	O
3	O
events	O
were	O
fatigue	B-Disease
,	O
dyspnea	B-Disease
,	O
stomatitis	B-Disease
,	O
anemia	B-Disease
,	O
and	O
thrombocytopenia	B-Disease
.	O
Pneumonitis	B-Disease
,	O
probably	O
or	O
possibly	O
related	O
,	O
mainly	O
grade	O
1	O
/	O
2	O
,	O
occurred	O
in	O
25	O
%	O
.	O
Cox	O
regression	O
analysis	O
of	O
IHC	O
scores	O
found	O
that	O
only	O
phospho	O
AKT	O
(	O
pAKT	O
)	O
was	O
a	O
significant	O
independent	O
predictor	O
of	O
worse	O
PFS	O
.	O
CONCLUSIONS	O
:	O
RAD001	B-Chemical
10	O
mg	O
/	O
day	O
was	O
well	O
tolerated	O
,	O
showing	O
modest	O
clinical	O
activity	O
in	O
pretreated	O
NSCLC	B-Disease
.	O
Evaluation	O
of	O
RAD001	B-Chemical
plus	O
standard	O
therapy	O
for	O
metastatic	O
NSCLC	B-Disease
continues	O
.	O
Posttransplant	O
anemia	B-Disease
:	O
the	O
role	O
of	O
sirolimus	B-Chemical
.	O
Posttransplant	O
anemia	B-Disease
is	O
a	O
common	O
problem	O
that	O
may	O
hinder	O
patients	O
'	O
quality	O
of	O
life	O
.	O
It	O
occurs	O
in	O
12	O
to	O
76	O
%	O
of	O
patients	O
,	O
and	O
is	O
most	O
common	O
in	O
the	O
immediate	O
posttransplant	O
period	O
.	O
A	O
variety	O
of	O
factors	O
have	O
been	O
identified	O
that	O
increase	O
the	O
risk	O
of	O
posttransplant	O
anemia	B-Disease
,	O
of	O
which	O
the	O
level	O
of	O
renal	O
function	O
is	O
most	O
important	O
.	O
Sirolimus	B-Chemical
,	O
a	O
mammalian	O
target	O
of	O
rapamycin	B-Chemical
inhibitor	O
,	O
has	O
been	O
implicated	O
as	O
playing	O
a	O
special	O
role	O
in	O
posttransplant	O
anemia	B-Disease
.	O
This	O
review	O
considers	O
anemia	B-Disease
associated	O
with	O
sirolimus	B-Chemical
,	O
including	O
its	O
presentation	O
,	O
mechanisms	O
,	O
and	O
management	O
.	O
Coronary	O
computerized	O
tomography	O
angiography	O
for	O
rapid	O
discharge	O
of	O
low	O
-	O
risk	O
patients	O
with	O
cocaine	B-Chemical
-	O
associated	O
chest	B-Disease
pain	I-Disease
.	O
BACKGROUND	O
:	O
Most	O
patients	O
presenting	O
to	O
emergency	O
departments	O
(	O
EDs	O
)	O
with	O
cocaine	B-Chemical
-	O
associated	O
chest	B-Disease
pain	I-Disease
are	O
admitted	O
for	O
at	O
least	O
12	O
hours	O
and	O
receive	O
a	O
""""	O
rule	O
out	O
acute	B-Disease
coronary	I-Disease
syndrome	I-Disease
""""	O
protocol	O
,	O
often	O
with	O
noninvasive	O
testing	O
prior	O
to	O
discharge	O
.	O
In	O
patients	O
without	O
cocaine	B-Chemical
use	O
,	O
coronary	O
computerized	O
tomography	O
angiography	O
(	O
CTA	O
)	O
has	O
been	O
shown	O
to	O
be	O
useful	O
for	O
identifying	O
a	O
group	O
of	O
patients	O
at	O
low	O
risk	O
for	O
cardiac	O
events	O
who	O
can	O
be	O
safely	O
discharged	O
.	O
It	O
is	O
unclear	O
whether	O
a	O
coronary	O
CTA	O
strategy	O
would	O
be	O
efficacious	O
in	O
cocaine	B-Chemical
-	O
associated	O
chest	B-Disease
pain	I-Disease
,	O
as	O
coronary	B-Disease
vasospasm	I-Disease
may	O
account	O
for	O
some	O
of	O
the	O
ischemia	B-Disease
.	O
We	O
studied	O
whether	O
a	O
negative	O
coronary	O
CTA	O
in	O
patients	O
with	O
cocaine	B-Chemical
-	O
associated	O
chest	B-Disease
pain	I-Disease
could	O
identify	O
a	O
subset	O
safe	O
for	O
discharge	O
.	O
METHODS	O
:	O
We	O
prospectively	O
evaluated	O
the	O
safety	O
of	O
coronary	O
CTA	O
for	O
low	O
-	O
risk	O
patients	O
who	O
presented	O
to	O
the	O
ED	O
with	O
cocaineassociated	O
chest	B-Disease
pain	I-Disease
(	O
self	O
-	O
reported	O
or	O
positive	O
urine	O
test	O
)	O
.	O
Consecutive	O
patients	O
received	O
either	O
immediate	O
coronary	O
CTA	O
in	O
the	O
ED	O
(	O
without	O
serial	O
markers	O
)	O
or	O
underwent	O
coronary	O
CTA	O
after	O
a	O
brief	O
observation	O
period	O
with	O
serial	O
cardiac	O
marker	O
measurements	O
.	O
Patients	O
with	O
negative	O
coronary	O
CTA	O
(	O
maximal	O
stenosis	B-Disease
less	O
than	O
50	O
%	O
)	O
were	O
discharged	O
.	O
The	O
main	O
outcome	O
was	O
30	O
-	O
day	O
cardiovascular	O
death	O
or	O
myocardial	B-Disease
infarction	I-Disease
.	O
RESULTS	O
:	O
A	O
total	O
of	O
59	O
patients	O
with	O
cocaine	B-Chemical
-	O
associated	O
chest	B-Disease
pain	I-Disease
were	O
evaluated	O
.	O
Patients	O
had	O
a	O
mean	O
age	O
of	O
45	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
6	O
yrs	O
and	O
were	O
86	O
%	O
black	O
,	O
66	O
%	O
male	O
.	O
Seventy	O
-	O
nine	O
percent	O
had	O
a	O
normal	O
or	O
nonspecific	O
ECG	O
and	O
85	O
%	O
had	O
a	O
TIMI	O
score	O
<	O
2	O
.	O
Twenty	O
patients	O
received	O
coronary	O
CTA	O
immediately	O
in	O
the	O
ED	O
,	O
18	O
of	O
whom	O
were	O
discharged	O
following	O
CTA	O
(	O
90	O
%	O
)	O
.	O
Thirty	O
-	O
nine	O
received	O
coronary	O
CTA	O
after	O
a	O
brief	O
observation	O
period	O
,	O
with	O
37	O
discharged	O
home	O
following	O
CTA	O
(	O
95	O
%	O
)	O
.	O
Six	O
patients	O
had	O
coronary	B-Disease
stenosis	I-Disease
>	O
or	O
=	O
50	O
%	O
.	O
During	O
the	O
30	O
-	O
day	O
follow	O
-	O
up	O
period	O
,	O
no	O
patients	O
died	O
of	O
a	O
cardiovascular	O
event	O
(	O
0	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
-	O
6	O
.	O
1	O
%	O
)	O
and	O
no	O
patient	O
sustained	O
a	O
nonfatal	O
myocardial	B-Disease
infarction	I-Disease
(	O
0	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
-	O
6	O
.	O
1	O
%	O
)	O
.	O
CONCLUSIONS	O
:	O
Although	O
cocaine	B-Chemical
-	O
associated	O
myocardial	B-Disease
ischemia	I-Disease
can	O
result	O
from	O
coronary	O
vasoconstriction	O
,	O
patients	O
with	O
cocaine	B-Chemical
associated	O
chest	B-Disease
pain	I-Disease
,	O
a	O
non	O
-	O
ischemic	B-Disease
ECG	O
,	O
and	O
a	O
TIMI	O
risk	O
score	O
<	O
2	O
may	O
be	O
safely	O
discharged	O
from	O
the	O
ED	O
after	O
a	O
negative	O
coronary	O
CTA	O
with	O
a	O
low	O
risk	O
of	O
30	O
-	O
day	O
adverse	O
events	O
.	O
Bilateral	O
haemorrhagic	B-Disease
infarction	I-Disease
of	I-Disease
the	I-Disease
globus	I-Disease
pallidus	I-Disease
after	O
cocaine	B-Chemical
and	O
alcohol	B-Chemical
intoxication	O
.	O
Cocaine	B-Chemical
is	O
a	O
risk	O
factor	O
for	O
both	O
ischemic	B-Disease
and	I-Disease
haemorrhagic	I-Disease
stroke	I-Disease
.	O
We	O
present	O
the	O
case	O
of	O
a	O
31	O
-	O
year	O
-	O
old	O
man	O
with	O
bilateral	O
ischemia	B-Disease
of	I-Disease
the	I-Disease
globus	I-Disease
pallidus	I-Disease
after	O
excessive	O
alcohol	B-Chemical
and	O
intranasal	O
cocaine	B-Chemical
use	O
.	O
Drug	O
-	O
related	O
globus	B-Disease
pallidus	I-Disease
infarctions	I-Disease
are	O
most	O
often	O
associated	O
with	O
heroin	B-Chemical
.	O
Bilateral	O
basal	B-Disease
ganglia	I-Disease
infarcts	I-Disease
after	O
the	O
use	O
of	O
cocaine	B-Chemical
,	O
without	O
concurrent	O
heroin	B-Chemical
use	O
,	O
have	O
never	O
been	O
reported	O
.	O
In	O
our	O
patient	O
,	O
transient	O
cardiac	B-Disease
arrhythmia	I-Disease
or	O
respiratory	B-Disease
dysfunction	I-Disease
related	O
to	O
cocaine	B-Chemical
and	O
/	O
or	O
ethanol	B-Chemical
use	O
were	O
the	O
most	O
likely	O
causes	O
of	O
cerebral	B-Disease
hypoperfusion	I-Disease
.	O
Late	O
fulminant	O
posterior	B-Disease
reversible	I-Disease
encephalopathy	I-Disease
syndrome	I-Disease
after	O
liver	O
transplant	O
.	O
OBJECTIVES	O
:	O
Posterior	B-Disease
leukoencephalopathy	I-Disease
due	O
to	O
calcineurin	O
-	O
inhibitor	O
-	O
related	O
neurotoxicity	B-Disease
is	O
a	O
rare	O
but	O
severe	O
complication	O
that	O
results	O
from	O
treatment	O
with	O
immunosuppressive	O
agents	O
(	O
primarily	O
those	O
administered	O
after	O
a	O
liver	O
or	O
kidney	O
transplant	O
)	O
.	O
The	O
pathophysiologic	O
mechanisms	O
of	O
that	O
disorder	O
remain	O
unknown	O
.	O
CASE	O
:	O
We	O
report	O
the	O
case	O
of	O
a	O
46	O
-	O
year	O
-	O
old	O
woman	O
who	O
received	O
a	O
liver	O
transplant	O
in	O
our	O
center	O
as	O
treatment	O
for	O
alcoholic	B-Disease
cirrhosis	I-Disease
and	O
in	O
whom	O
either	O
a	O
fulminant	O
course	O
of	O
posterior	B-Disease
leukoencephalopathy	I-Disease
or	O
posterior	B-Disease
reversible	I-Disease
encephalopathy	I-Disease
syndrome	I-Disease
developed	O
110	O
days	O
after	O
transplant	O
.	O
After	O
an	O
initially	O
uneventful	O
course	O
after	O
the	O
transplant	O
,	O
the	O
patient	O
rapidly	O
fell	O
into	O
deep	O
coma	O
.	O
RESULTS	O
:	O
Cerebral	O
MRI	O
scan	O
showed	O
typical	O
signs	O
of	O
enhancement	O
in	O
the	O
pontine	O
and	O
posterior	O
regions	O
.	O
Switching	O
the	O
immunosuppressive	O
regimen	O
from	O
tacrolimus	B-Chemical
to	O
cyclosporine	B-Chemical
did	O
not	O
improve	O
the	O
clinical	O
situation	O
.	O
The	O
termination	O
of	O
treatment	O
with	O
any	O
calcineurin	O
inhibitor	O
resulted	O
in	O
a	O
complete	O
resolution	O
of	O
that	O
complication	O
.	O
CONCLUSIONS	O
:	O
Posterior	B-Disease
reversible	I-Disease
encephalopathy	I-Disease
syndrome	I-Disease
after	O
liver	O
transplant	O
is	O
rare	O
.	O
We	O
recommend	O
a	O
complete	O
cessation	O
of	O
any	O
calcineurin	O
inhibitor	O
rather	O
than	O
a	O
dose	O
reduction	O
.	O
Prolonged	O
hypothermia	B-Disease
as	O
a	O
bridge	O
to	O
recovery	O
for	O
cerebral	B-Disease
edema	I-Disease
and	O
intracranial	B-Disease
hypertension	I-Disease
associated	O
with	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
.	O
BACKGROUND	O
:	O
To	O
review	O
evidence	O
-	O
based	O
treatment	O
options	O
in	O
patients	O
with	O
cerebral	B-Disease
edema	I-Disease
complicating	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
(	O
FHF	B-Disease
)	O
and	O
discuss	O
the	O
potential	O
applications	O
of	O
hypothermia	B-Disease
.	O
METHOD	O
:	O
Case	O
-	O
based	O
observations	O
from	O
a	O
medical	O
intensive	O
care	O
unit	O
(	O
MICU	O
)	O
in	O
a	O
tertiary	O
care	O
facility	O
in	O
a	O
27	O
-	O
year	O
-	O
old	O
female	O
with	O
FHF	B-Disease
from	O
acetaminophen	B-Chemical
and	O
resultant	O
cerebral	B-Disease
edema	I-Disease
.	O
RESULTS	O
:	O
Our	O
patient	O
was	O
admitted	O
to	O
the	O
MICU	O
after	O
being	O
found	O
unresponsive	O
with	O
presumed	O
toxicity	B-Disease
from	O
acetaminophen	B-Chemical
which	O
was	O
ingested	O
over	O
a	O
2	O
-	O
day	O
period	O
.	O
The	O
patient	O
had	O
depressed	O
of	O
mental	O
status	O
lasting	O
at	O
least	O
24	O
h	O
prior	O
to	O
admission	O
.	O
Initial	O
evaluation	O
confirmed	O
FHF	B-Disease
from	O
acetaminophen	B-Chemical
and	O
cerebral	B-Disease
edema	I-Disease
.	O
The	O
patient	O
was	O
treated	O
with	O
hyperosmolar	O
therapy	O
,	O
hyperventilation	B-Disease
,	O
sedation	O
,	O
and	O
chemical	O
paralysis	B-Disease
.	O
Her	O
intracranial	O
pressure	O
remained	O
elevated	O
despite	O
maximal	O
medical	O
therapy	O
.	O
We	O
then	O
initiated	O
therapeutic	O
hypothermia	B-Disease
which	O
was	O
continued	O
for	O
5	O
days	O
.	O
At	O
re	O
-	O
warming	O
,	O
patient	O
had	O
resolution	O
of	O
her	O
cerebral	B-Disease
edema	I-Disease
and	O
intracranial	B-Disease
hypertension	I-Disease
.	O
At	O
discharge	O
,	O
she	O
had	O
complete	O
recovery	O
of	O
neurological	O
and	O
hepatic	O
functions	O
.	O
CONCLUSION	O
:	O
In	O
patients	O
with	O
FHF	B-Disease
and	O
cerebral	B-Disease
edema	I-Disease
from	O
acetaminophen	B-Chemical
overdose	B-Disease
,	O
prolonged	O
therapeutic	O
hypothermia	B-Disease
could	O
potentially	O
be	O
used	O
as	O
a	O
life	O
saving	O
therapy	O
and	O
a	O
bridge	O
to	O
hepatic	O
and	O
neurological	O
recovery	O
.	O
A	O
clinical	O
trial	O
of	O
hypothermia	B-Disease
in	O
patients	O
with	O
this	O
condition	O
is	O
warranted	O
.	O
Binasal	B-Disease
visual	I-Disease
field	I-Disease
defects	I-Disease
are	O
not	O
specific	O
to	O
vigabatrin	B-Chemical
.	O
This	O
study	O
investigated	O
the	O
visual	B-Disease
defects	I-Disease
associated	O
with	O
the	O
antiepileptic	O
drug	O
vigabatrin	B-Chemical
(	O
VGB	B-Chemical
)	O
.	O
Two	O
hundred	O
four	O
people	O
with	O
epilepsy	B-Disease
were	O
grouped	O
on	O
the	O
basis	O
of	O
antiepileptic	O
drug	O
therapy	O
(	O
current	O
,	O
previous	O
,	O
or	O
no	O
exposure	O
to	O
VGB	B-Chemical
)	O
.	O
Groups	O
were	O
matched	O
with	O
respect	O
to	O
age	O
,	O
gender	O
,	O
and	O
seizure	B-Disease
frequency	O
.	O
All	O
patients	O
underwent	O
objective	O
assessment	O
of	O
electrophysiological	O
function	O
(	O
wide	O
-	O
field	O
multifocal	O
electroretinography	O
)	O
and	O
conventional	O
visual	O
field	O
testing	O
(	O
static	O
perimetry	O
)	O
.	O
Bilateral	O
visual	O
field	O
constriction	O
was	O
observed	O
in	O
59	O
%	O
of	O
patients	O
currently	O
taking	O
VGB	B-Chemical
,	O
43	O
%	O
of	O
patients	O
who	O
previously	O
took	O
VGB	B-Chemical
,	O
and	O
24	O
%	O
of	O
patients	O
with	O
no	O
exposure	O
to	O
VGB	B-Chemical
.	O
Assessment	O
of	O
retinal	O
function	O
revealed	O
abnormal	O
responses	O
in	O
48	O
%	O
of	O
current	O
VGB	B-Chemical
users	O
and	O
22	O
%	O
of	O
prior	O
VGB	B-Chemical
users	O
,	O
but	O
in	O
none	O
of	O
the	O
patients	O
without	O
previous	O
exposure	O
to	O
VGB	B-Chemical
.	O
Bilateral	B-Disease
visual	I-Disease
field	I-Disease
abnormalities	I-Disease
are	O
common	O
in	O
the	O
treated	O
epilepsy	B-Disease
population	O
,	O
irrespective	O
of	O
drug	O
history	O
.	O
Assessment	O
by	O
conventional	O
static	O
perimetry	O
may	O
neither	O
be	O
sufficiently	O
sensitive	O
nor	O
specific	O
to	O
reliably	O
identify	O
retinal	B-Disease
toxicity	I-Disease
associated	O
with	O
VGB	B-Chemical
.	O
Smoking	O
of	O
crack	B-Chemical
cocaine	I-Chemical
as	O
a	O
risk	O
factor	O
for	O
HIV	B-Disease
infection	I-Disease
among	O
people	O
who	O
use	O
injection	O
drugs	O
.	O
BACKGROUND	O
:	O
Little	O
is	O
known	O
about	O
the	O
possible	O
role	O
that	O
smoking	O
crack	B-Chemical
cocaine	I-Chemical
has	O
on	O
the	O
incidence	O
of	O
HIV	B-Disease
infection	I-Disease
.	O
Given	O
the	O
increasing	O
use	O
of	O
crack	B-Chemical
cocaine	I-Chemical
,	O
we	O
sought	O
to	O
examine	O
whether	O
use	O
of	O
this	O
illicit	O
drug	O
has	O
become	O
a	O
risk	O
factor	O
for	O
HIV	B-Disease
infection	I-Disease
.	O
METHODS	O
:	O
We	O
included	O
data	O
from	O
people	O
participating	O
in	O
the	O
Vancouver	O
Injection	O
Drug	O
Users	O
Study	O
who	O
reported	O
injecting	O
illicit	O
drugs	O
at	O
least	O
once	O
in	O
the	O
month	O
before	O
enrolment	O
,	O
lived	O
in	O
the	O
greater	O
Vancouver	O
area	O
,	O
were	O
HIV	O
-	O
negative	O
at	O
enrolment	O
and	O
completed	O
at	O
least	O
1	O
follow	O
-	O
up	O
study	O
visit	O
.	O
To	O
determine	O
whether	O
the	O
risk	O
of	O
HIV	B-Disease
seroconversion	I-Disease
among	O
daily	O
smokers	O
of	O
crack	B-Chemical
cocaine	I-Chemical
changed	O
over	O
time	O
,	O
we	O
used	O
Cox	O
proportional	O
hazards	O
regression	O
and	O
divided	O
the	O
study	O
into	O
3	O
periods	O
:	O
May	O
1	O
,	O
1996	O
-	O
Nov	O
.	O
30	O
,	O
1999	O
(	O
period	O
1	O
)	O
,	O
Dec	O
.	O
1	O
,	O
1999	O
-	O
Nov	O
.	O
30	O
,	O
2002	O
(	O
period	O
2	O
)	O
,	O
and	O
Dec	O
.	O
1	O
,	O
2002	O
-	O
Dec	O
.	O
30	O
,	O
2005	O
(	O
period	O
3	O
)	O
.	O
RESULTS	O
:	O
Overall	O
,	O
1048	O
eligible	O
injection	O
drug	O
users	O
were	O
included	O
in	O
our	O
study	O
.	O
Of	O
these	O
,	O
137	O
acquired	O
HIV	B-Disease
infection	I-Disease
during	O
follow	O
-	O
up	O
.	O
The	O
mean	O
proportion	O
of	O
participants	O
who	O
reported	O
daily	O
smoking	O
of	O
crack	B-Chemical
cocaine	I-Chemical
increased	O
from	O
11	O
.	O
6	O
%	O
in	O
period	O
1	O
to	O
39	O
.	O
7	O
%	O
in	O
period	O
3	O
.	O
After	O
adjusting	O
for	O
potential	O
confounders	O
,	O
we	O
found	O
that	O
the	O
risk	O
of	O
HIV	B-Disease
seroconversion	I-Disease
among	O
participants	O
who	O
were	O
daily	O
smokers	O
of	O
crack	B-Chemical
cocaine	I-Chemical
increased	O
over	O
time	O
(	O
period	O
1	O
:	O
hazard	O
ratio	O
[	O
HR	O
]	O
1	O
.	O
03	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
0	O
.	O
57	O
-	O
1	O
.	O
85	O
;	O
period	O
2	O
:	O
HR	O
1	O
.	O
68	O
,	O
95	O
%	O
CI	O
1	O
.	O
01	O
-	O
2	O
.	O
80	O
;	O
and	O
period	O
3	O
:	O
HR	O
2	O
.	O
74	O
,	O
95	O
%	O
CI	O
1	O
.	O
06	O
-	O
7	O
.	O
11	O
)	O
.	O
INTERPRETATION	O
:	O
Smoking	O
of	O
crack	B-Chemical
cocaine	I-Chemical
was	O
found	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
HIV	B-Disease
seroconversion	I-Disease
among	O
people	O
who	O
were	O
injection	O
drug	O
users	O
.	O
This	O
finding	O
points	O
to	O
the	O
urgent	O
need	O
for	O
evidence	O
-	O
based	O
public	O
health	O
initiatives	O
targeted	O
at	O
people	O
who	O
smoke	O
crack	B-Chemical
cocaine	I-Chemical
.	O
Fluoxetine	B-Chemical
improves	O
the	O
memory	B-Disease
deficits	I-Disease
caused	O
by	O
the	O
chemotherapy	O
agent	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
.	O
Cancer	B-Disease
patients	O
who	O
have	O
been	O
treated	O
with	O
systemic	O
adjuvant	O
chemotherapy	O
have	O
described	O
experiencing	O
deteriorations	O
in	O
cognition	O
.	O
A	O
widely	O
used	O
chemotherapeutic	O
agent	O
,	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
,	O
readily	O
crosses	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
so	O
could	O
have	O
a	O
direct	O
effect	O
on	O
brain	O
function	O
.	O
In	O
particular	O
this	O
anti	O
mitotic	O
drug	O
could	O
reduce	O
cell	O
proliferation	O
in	O
the	O
neurogenic	O
regions	O
of	O
the	O
adult	O
brain	O
.	O
In	O
contrast	O
reports	O
indicate	O
that	O
hippocampal	O
dependent	O
neurogenesis	O
and	O
cognition	O
are	O
enhanced	O
by	O
the	O
SSRI	B-Chemical
antidepressant	O
Fluoxetine	B-Chemical
.	O
In	O
this	O
investigation	O
the	O
behavioural	O
effects	O
of	O
chronic	O
(	O
two	O
week	O
)	O
treatment	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
(	O
three	O
weeks	O
)	O
with	O
Fluoxetine	B-Chemical
either	O
separately	O
or	O
in	O
combination	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
were	O
tested	O
on	O
adult	O
Lister	O
hooded	O
rats	O
.	O
Behavioural	O
effects	O
were	O
tested	O
using	O
a	O
context	O
dependent	O
conditioned	O
emotional	O
response	O
test	O
(	O
CER	O
)	O
which	O
showed	O
that	O
animals	O
treated	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
had	O
a	O
significant	O
reduction	O
in	O
freezing	O
time	O
compared	O
to	O
controls	O
.	O
A	O
separate	O
group	O
of	O
animals	O
was	O
tested	O
using	O
a	O
hippocampal	O
dependent	O
spatial	O
working	O
memory	O
test	O
,	O
the	O
object	O
location	O
recognition	O
test	O
(	O
OLR	O
)	O
.	O
Animals	O
treated	O
only	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
showed	O
significant	O
deficits	O
in	O
their	O
ability	O
to	O
carry	O
out	O
the	O
OLR	O
task	O
but	O
co	O
administration	O
of	O
Fluoxetine	B-Chemical
improved	O
their	O
performance	O
.	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
chemotherapy	O
caused	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
proliferating	O
cells	O
in	O
the	O
sub	O
granular	O
zone	O
of	O
the	O
dentate	O
gyrus	O
compared	O
to	O
controls	O
.	O
This	O
reduction	O
was	O
eliminated	O
when	O
Fluoxetine	B-Chemical
was	O
co	O
administered	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O
Fluoxetine	B-Chemical
on	O
its	O
own	O
had	O
no	O
effect	O
on	O
proliferating	O
cell	O
number	O
or	O
behaviour	O
.	O
These	O
findings	O
suggest	O
that	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
can	O
negatively	O
affect	O
both	O
cell	O
proliferation	O
and	O
hippocampal	O
dependent	O
working	O
memory	O
and	O
that	O
these	O
deficits	O
can	O
be	O
reversed	O
by	O
the	O
simultaneous	O
administration	O
of	O
the	O
antidepressant	O
Fluoxetine	B-Chemical
.	O
Liver	O
-	O
specific	O
ablation	O
of	O
integrin	O
-	O
linked	O
kinase	O
in	O
mice	O
results	O
in	O
enhanced	O
and	O
prolonged	O
cell	O
proliferation	O
and	O
hepatomegaly	B-Disease
after	O
phenobarbital	B-Chemical
administration	O
.	O
We	O
have	O
recently	O
demonstrated	O
that	O
disruption	O
of	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
/	O
integrin	O
signaling	O
via	O
elimination	O
of	O
integrin	O
-	O
linked	O
kinase	O
(	O
ILK	O
)	O
in	O
hepatocytes	O
interferes	O
with	O
signals	O
leading	O
to	O
termination	O
of	O
liver	O
regeneration	O
.	O
This	O
study	O
investigates	O
the	O
role	O
of	O
ILK	O
in	O
liver	O
enlargement	O
induced	O
by	O
phenobarbital	B-Chemical
(	O
PB	B-Chemical
)	O
.	O
Wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
ILK	O
:	O
liver	O
-	O
/	O
-	O
mice	O
were	O
given	O
PB	B-Chemical
(	O
0	O
.	O
1	O
%	O
in	O
drinking	O
water	O
)	O
for	O
10	O
days	O
.	O
Livers	O
were	O
harvested	O
on	O
2	O
,	O
5	O
,	O
and	O
10	O
days	O
during	O
PB	B-Chemical
administration	O
.	O
In	O
the	O
hepatocyte	O
-	O
specific	O
ILK	O
/	O
liver	O
-	O
/	O
-	O
mice	O
,	O
the	O
liver	O
:	O
body	O
weight	O
ratio	O
was	O
more	O
than	O
double	O
as	O
compared	O
to	O
0	O
h	O
at	O
day	O
2	O
(	O
2	O
.	O
5	O
times	O
)	O
,	O
while	O
at	O
days	O
5	O
and	O
10	O
,	O
it	O
was	O
enlarged	O
three	O
times	O
.	O
In	O
the	O
WT	O
mice	O
,	O
the	O
increase	O
was	O
as	O
expected	O
from	O
previous	O
literature	O
(	O
1	O
.	O
8	O
times	O
)	O
and	O
seems	O
to	O
have	O
leveled	O
off	O
after	O
day	O
2	O
.	O
There	O
were	O
slightly	O
increased	O
proliferating	O
cell	O
nuclear	O
antigen	O
-	O
positive	O
cells	O
in	O
the	O
ILK	O
/	O
liver	O
-	O
/	O
-	O
animals	O
at	O
day	O
2	O
as	O
compared	O
to	O
WT	O
after	O
PB	B-Chemical
administration	O
.	O
In	O
the	O
WT	O
animals	O
,	O
the	O
proliferative	O
response	O
had	O
come	O
back	O
to	O
normal	O
by	O
days	O
5	O
and	O
10	O
.	O
Hepatocytes	O
of	O
the	O
ILK	O
/	O
liver	O
-	O
/	O
-	O
mice	O
continued	O
to	O
proliferate	O
up	O
until	O
day	O
10	O
.	O
ILK	O
/	O
liver	O
-	O
/	O
-	O
mice	O
also	O
showed	O
increased	O
expression	O
of	O
key	O
genes	O
involved	O
in	O
hepatocyte	O
proliferation	O
at	O
different	O
time	O
points	O
during	O
PB	B-Chemical
administration	O
.	O
In	O
summary	O
,	O
ECM	O
proteins	O
communicate	O
with	O
the	O
signaling	O
machinery	O
of	O
dividing	O
cells	O
via	O
ILK	O
to	O
regulate	O
hepatocyte	O
proliferation	O
and	O
termination	O
of	O
the	O
proliferative	O
response	O
.	O
Lack	O
of	O
ILK	O
in	O
the	O
hepatocytes	O
imparts	O
prolonged	O
proliferative	O
response	O
not	O
only	O
to	O
stimuli	O
related	O
to	O
liver	O
regeneration	O
but	O
also	O
to	O
xenobiotic	O
chemical	O
mitogens	O
,	O
such	O
as	O
PB	B-Chemical
.	O
Decreased	O
Expression	O
of	O
Na	B-Chemical
/	O
K	B-Chemical
-	O
ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
AQP1	O
and	O
OAT	O
in	O
Gentamicin	B-Chemical
-	O
induced	O
Nephropathy	B-Disease
.	O
The	O
present	O
study	O
was	O
aimed	O
to	O
determine	O
whether	O
there	O
is	O
an	O
altered	O
regulation	O
of	O
tubular	O
transporters	O
in	O
gentamicin	B-Chemical
-	O
induced	O
nephropathy	B-Disease
.	O
Sprague	O
-	O
Dawley	O
male	O
rats	O
(	O
200	O
~	O
250	O
g	O
)	O
were	O
subcutaneously	O
injected	O
with	O
gentamicin	B-Chemical
(	O
100	O
mg	O
/	O
kg	O
per	O
day	O
)	O
for	O
7	O
days	O
,	O
and	O
the	O
expression	O
of	O
tubular	O
transporters	O
was	O
determined	O
by	O
immunoblotting	O
and	O
immunohistochemistry	O
.	O
The	O
mRNA	O
and	O
protein	O
expression	O
of	O
OAT	O
was	O
also	O
determined	O
.	O
Gentamicin	B-Chemical
-	O
treated	O
rats	O
exhibited	O
significantly	O
decreased	O
creatinine	B-Chemical
clearance	O
along	O
with	O
increased	O
plasma	O
creatinine	B-Chemical
levels	O
.	O
Accordingly	O
,	O
the	O
fractional	O
excretion	O
of	O
sodium	B-Chemical
increased	O
.	O
Urine	O
volume	O
was	O
increased	O
,	O
while	O
urine	O
osmolality	O
and	O
free	O
water	O
reabsorption	O
were	O
decreased	O
.	O
Immunoblotting	O
and	O
immunohistochemistry	O
revealed	O
decreased	O
expression	O
of	O
Na	B-Chemical
(	O
+	O
)	O
/	O
K	B-Chemical
(	O
+	O
)	O
-	O
ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
and	O
AQP1	O
in	O
the	O
kidney	O
of	O
gentamicin	B-Chemical
-	O
treated	O
rats	O
.	O
The	O
expression	O
of	O
OAT1	O
and	O
OAT3	O
was	O
also	O
decreased	O
.	O
Gentamicin	B-Chemical
-	O
induced	O
nephropathy	B-Disease
may	O
at	O
least	O
in	O
part	O
be	O
causally	O
related	O
with	O
a	O
decreased	O
expression	O
of	O
Na	B-Chemical
(	O
+	O
)	O
/	O
K	B-Chemical
(	O
+	O
)	O
-	O
ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
AQP1	O
and	O
OAT	O
.	O
Acute	B-Disease
renal	I-Disease
failure	I-Disease
after	O
high	O
-	O
dose	O
methotrexate	B-Chemical
therapy	O
in	O
a	O
patient	O
with	O
ileostomy	O
.	O
High	O
-	O
dose	O
methotrexate	B-Chemical
(	O
HD	O
-	O
MTX	B-Chemical
)	O
is	O
an	O
important	O
treatment	O
for	O
Burkitt	B-Disease
lymphoma	I-Disease
,	O
but	O
can	O
cause	O
hepatic	B-Disease
and	I-Disease
renal	I-Disease
toxicity	I-Disease
when	O
its	O
clearance	O
is	O
delayed	O
.	O
We	O
report	O
a	O
case	O
of	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
after	O
HD	O
-	O
MTX	B-Chemical
therapy	O
in	O
a	O
patient	O
with	O
ileostomy	O
,	O
The	O
patient	O
was	O
a	O
3	O
-	O
year	O
-	O
old	O
boy	O
who	O
had	O
received	O
a	O
living	O
-	O
related	O
liver	O
transplantation	O
for	O
congenital	O
biliary	B-Disease
atresia	I-Disease
.	O
At	O
day	O
833	O
after	O
the	O
transplantation	O
,	O
he	O
was	O
diagnosed	O
with	O
PTLD	B-Disease
(	O
post	B-Disease
-	I-Disease
transplantation	I-Disease
lymphoproliferative	I-Disease
disorder	I-Disease
,	O
Burkitt	B-Disease
-	I-Disease
type	I-Disease
malignant	I-Disease
lymphoma	I-Disease
)	O
.	O
During	O
induction	O
therapy	O
,	O
he	O
suffered	O
ileal	O
perforation	O
and	O
ileostomy	O
was	O
performed	O
.	O
Subsequent	O
HD	O
-	O
MTX	B-Chemical
therapy	O
caused	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
that	O
required	O
continuous	O
hemodialysis	O
.	O
We	O
supposed	O
that	O
intravascular	O
hypovolemia	B-Disease
due	O
to	O
substantial	O
drainage	O
from	O
the	O
ileostoma	O
caused	O
acute	B-Disease
prerenal	I-Disease
failure	I-Disease
.	O
After	O
recovery	O
of	O
his	O
renal	O
function	O
,	O
we	O
could	O
safely	O
treat	O
the	O
patient	O
with	O
HD	O
-	O
MTX	B-Chemical
therapy	O
by	O
controlling	O
drainage	O
from	O
ileostoma	O
with	O
total	O
parenteral	O
nutrition	O
.	O
Longitudinal	O
association	O
of	O
alcohol	B-Chemical
use	O
with	O
HIV	B-Disease
disease	I-Disease
progression	O
and	O
psychological	O
health	O
of	O
women	O
with	O
HIV	O
.	O
We	O
evaluated	O
the	O
association	O
of	O
alcohol	B-Chemical
consumption	O
and	O
depression	B-Disease
,	O
and	O
their	O
effects	O
on	O
HIV	B-Disease
disease	I-Disease
progression	O
among	O
women	O
with	O
HIV	O
.	O
The	O
study	O
included	O
871	O
women	O
with	O
HIV	O
who	O
were	O
recruited	O
from	O
1993	O
-	O
1995	O
in	O
four	O
US	O
cities	O
.	O
The	O
participants	O
had	O
physical	O
examination	O
,	O
medical	O
record	O
extraction	O
,	O
and	O
venipuncture	O
,	O
CD4	O
+	O
T	O
-	O
cell	O
counts	O
determination	O
,	O
measurement	O
of	O
depression	B-Disease
symptoms	O
(	O
using	O
the	O
self	O
-	O
report	O
Center	O
for	O
Epidemiological	O
Studies	O
-	O
Depression	B-Disease
Scale	O
)	O
,	O
and	O
alcohol	B-Chemical
use	O
assessment	O
at	O
enrollment	O
,	O
and	O
semiannually	O
until	O
March	O
2000	O
.	O
Multilevel	O
random	O
coefficient	O
ordinal	O
models	O
as	O
well	O
as	O
multilevel	O
models	O
with	O
joint	O
responses	O
were	O
used	O
in	O
the	O
analysis	O
.	O
There	O
was	O
no	O
significant	O
association	O
between	O
level	O
of	O
alcohol	B-Chemical
use	O
and	O
CD4	O
+	O
T	O
-	O
cell	O
counts	O
.	O
When	O
participants	O
were	O
stratified	O
by	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
use	O
,	O
the	O
association	O
between	O
alcohol	B-Chemical
and	O
CD4	O
+	O
T	O
-	O
cell	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O
The	O
association	O
between	O
alcohol	B-Chemical
consumption	O
and	O
depression	B-Disease
was	O
significant	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
Depression	B-Disease
had	O
a	O
significant	O
negative	O
effect	O
on	O
CD4	O
+	O
T	O
-	O
cell	O
counts	O
over	O
time	O
regardless	O
of	O
ART	O
use	O
.	O
Our	O
findings	O
suggest	O
that	O
alcohol	B-Chemical
consumption	O
has	O
a	O
direct	O
association	O
with	O
depression	B-Disease
.	O
Moreover	O
,	O
depression	B-Disease
is	O
associated	O
with	O
HIV	B-Disease
disease	I-Disease
progression	O
.	O
Our	O
findings	O
have	O
implications	O
for	O
the	O
provision	O
of	O
alcohol	B-Chemical
use	O
interventions	O
and	O
psychological	O
resources	O
to	O
improve	O
the	O
health	O
of	O
women	O
with	O
HIV	O
.	O
Chemokine	O
CCL2	O
and	O
its	O
receptor	O
CCR2	O
are	O
increased	O
in	O
the	O
hippocampus	O
following	O
pilocarpine	B-Chemical
-	O
induced	O
status	B-Disease
epilepticus	I-Disease
.	O
BACKGROUND	O
:	O
Neuroinflammation	B-Disease
occurs	O
after	O
seizures	B-Disease
and	O
is	O
implicated	O
in	O
epileptogenesis	O
.	O
CCR2	O
is	O
a	O
chemokine	O
receptor	O
for	O
CCL2	O
and	O
their	O
interaction	O
mediates	O
monocyte	O
infiltration	O
in	O
the	O
neuroinflammatory	B-Disease
cascade	O
triggered	O
in	O
different	O
brain	O
pathologies	O
.	O
In	O
this	O
work	O
CCR2	O
and	O
CCL2	O
expression	O
were	O
examined	O
following	O
status	B-Disease
epilepticus	I-Disease
(	O
SE	B-Disease
)	O
induced	O
by	O
pilocarpine	B-Chemical
injection	O
.	O
METHODS	O
:	O
SE	B-Disease
was	O
induced	O
by	O
pilocarpine	B-Chemical
injection	O
.	O
Control	O
rats	O
were	O
injected	O
with	O
saline	O
instead	O
of	O
pilocarpine	B-Chemical
.	O
Five	O
days	O
after	O
SE	B-Disease
,	O
CCR2	O
staining	O
in	O
neurons	O
and	O
glial	O
cells	O
was	O
examined	O
using	O
imunohistochemical	O
analyses	O
.	O
The	O
number	O
of	O
CCR2	O
positive	O
cells	O
was	O
determined	O
using	O
stereology	O
probes	O
in	O
the	O
hippocampus	O
.	O
CCL2	O
expression	O
in	O
the	O
hippocampus	O
was	O
examined	O
by	O
molecular	O
assay	O
.	O
RESULTS	O
:	O
Increased	O
CCR2	O
was	O
observed	O
in	O
the	O
hippocampus	O
after	O
SE	B-Disease
.	O
Seizures	B-Disease
also	O
resulted	O
in	O
alterations	O
to	O
the	O
cell	O
types	O
expressing	O
CCR2	O
.	O
Increased	O
numbers	O
of	O
neurons	O
that	O
expressed	O
CCR2	O
was	O
observed	O
following	O
SE	B-Disease
.	O
Microglial	O
cells	O
were	O
more	O
closely	O
apposed	O
to	O
the	O
CCR2	O
-	O
labeled	O
cells	O
in	O
SE	B-Disease
rats	O
.	O
In	O
addition	O
,	O
rats	O
that	O
experienced	O
SE	B-Disease
exhibited	O
CCR2	O
-	O
labeling	O
in	O
populations	O
of	O
hypertrophied	B-Disease
astrocytes	O
,	O
especially	O
in	O
CA1	O
and	O
dentate	O
gyrus	O
.	O
These	O
CCR2	O
+	O
astroctytes	O
were	O
not	O
observed	O
in	O
control	O
rats	O
.	O
Examination	O
of	O
CCL2	O
expression	O
showed	O
that	O
it	O
was	O
elevated	O
in	O
the	O
hippocampus	O
following	O
SE	B-Disease
.	O
CONCLUSION	O
:	O
The	O
data	O
show	O
that	O
CCR2	O
and	O
CCL2	O
are	O
up	O
-	O
regulated	O
in	O
the	O
hippocampus	O
after	O
pilocarpine	B-Chemical
-	O
induced	O
SE	B-Disease
.	O
Seizures	B-Disease
also	O
result	O
in	O
changes	O
to	O
CCR2	O
receptor	O
expression	O
in	O
neurons	O
and	O
astrocytes	O
.	O
These	O
changes	O
might	O
be	O
involved	O
in	O
detrimental	O
neuroplasticity	O
and	O
neuroinflammatory	B-Disease
changes	O
that	O
occur	O
following	O
seizures	B-Disease
.	O
Metallothionein	B-Chemical
induction	O
reduces	O
caspase	O
-	O
3	O
activity	O
and	O
TNFalpha	O
levels	O
with	O
preservation	O
of	O
cognitive	O
function	O
and	O
intact	O
hippocampal	O
neurons	O
in	O
carmustine	B-Chemical
-	O
treated	O
rats	O
.	O
Hippocampal	O
integrity	O
is	O
essential	O
for	O
cognitive	O
functions	O
.	O
On	O
the	O
other	O
hand	O
,	O
induction	O
of	O
metallothionein	B-Chemical
(	O
MT	B-Chemical
)	O
by	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
and	O
its	O
role	O
in	O
neuroprotection	O
has	O
been	O
documented	O
.	O
The	O
present	O
study	O
aimed	O
to	O
explore	O
the	O
effect	O
of	O
MT	B-Chemical
induction	O
on	O
carmustine	B-Chemical
(	O
BCNU	B-Chemical
)	O
-	O
induced	O
hippocampal	O
cognitive	B-Disease
dysfunction	I-Disease
in	O
rats	O
.	O
A	O
total	O
of	O
60	O
male	O
Wistar	O
albino	O
rats	O
were	O
randomly	O
divided	O
into	O
four	O
groups	O
(	O
15	O
/	O
group	O
)	O
:	O
The	O
control	O
group	O
injected	O
with	O
single	O
doses	O
of	O
normal	O
saline	O
(	O
i	O
.	O
c	O
.	O
v	O
)	O
followed	O
24	O
h	O
later	O
by	O
BCNU	B-Chemical
solvent	O
(	O
i	O
.	O
v	O
)	O
.	O
The	O
second	O
group	O
administered	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
microl	O
normal	O
saline	O
,	O
i	O
.	O
c	O
.	O
v	O
,	O
once	O
)	O
then	O
BCNU	B-Chemical
solvent	O
(	O
i	O
.	O
v	O
)	O
after	O
24	O
h	O
.	O
Third	O
group	O
received	O
BCNU	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
,	O
once	O
)	O
24	O
h	O
after	O
injection	O
with	O
normal	O
saline	O
(	O
i	O
.	O
c	O
.	O
v	O
)	O
.	O
Fourth	O
group	O
received	O
a	O
single	O
dose	O
of	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
(	O
0	O
.	O
1	O
micromol	O
/	O
10	O
microl	O
normal	O
saline	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
then	O
BCNU	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
,	O
once	O
)	O
after	O
24	O
h	O
.	O
The	O
obtained	O
data	O
revealed	O
that	O
BCNU	B-Chemical
administration	O
resulted	O
in	O
deterioration	B-Disease
of	I-Disease
learning	I-Disease
and	I-Disease
short	I-Disease
-	I-Disease
term	I-Disease
memory	I-Disease
(	O
STM	O
)	O
,	O
as	O
measured	O
by	O
using	O
radial	O
arm	O
water	O
maze	O
,	O
accompanied	O
with	O
decreased	O
hippocampal	O
glutathione	B-Chemical
reductase	O
(	O
GR	O
)	O
activity	O
and	O
reduced	O
glutathione	B-Chemical
(	O
GSH	B-Chemical
)	O
content	O
.	O
Also	O
,	O
BCNU	B-Chemical
administration	O
increased	O
serum	O
tumor	B-Disease
necrosis	B-Disease
factor	O
-	O
alpha	O
(	O
TNFalpha	O
)	O
,	O
hippocampal	O
MT	B-Chemical
and	O
malondialdehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
contents	O
as	O
well	O
as	O
caspase	O
-	O
3	O
activity	O
in	O
addition	O
to	O
histological	O
alterations	O
.	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
pretreatment	O
counteracted	O
BCNU	B-Chemical
-	O
induced	O
inhibition	O
of	O
GR	O
and	O
depletion	O
of	O
GSH	B-Chemical
and	O
resulted	O
in	O
significant	O
reduction	O
in	O
the	O
levels	O
of	O
MDA	B-Chemical
and	O
TNFalpha	O
as	O
well	O
as	O
the	O
activity	O
of	O
caspase	O
-	O
3	O
.	O
The	O
histological	O
features	O
were	O
improved	O
in	O
hippocampus	O
of	O
rats	O
treated	O
with	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
+	O
BCNU	B-Chemical
compared	O
to	O
only	O
BCNU	B-Chemical
-	O
treated	O
animals	O
.	O
In	O
conclusion	O
,	O
MT	B-Chemical
induction	O
halts	O
BCNU	B-Chemical
-	O
induced	O
hippocampal	O
toxicity	B-Disease
as	O
it	O
prevented	O
GR	O
inhibition	O
and	O
GSH	B-Chemical
depletion	O
and	O
counteracted	O
the	O
increased	O
levels	O
of	O
TNFalpha	O
,	O
MDA	B-Chemical
and	O
caspase	O
-	O
3	O
activity	O
with	O
subsequent	O
preservation	O
of	O
cognition	O
.	O
Fatal	O
carbamazepine	B-Chemical
induced	O
fulminant	B-Disease
eosinophilic	I-Disease
(	O
hypersensitivity	B-Disease
)	O
myocarditis	B-Disease
:	O
emphasis	O
on	O
anatomical	O
and	O
histological	O
characteristics	O
,	O
mechanisms	O
and	O
genetics	O
of	O
drug	B-Disease
hypersensitivity	I-Disease
and	O
differential	O
diagnosis	O
.	O
The	O
most	O
severe	O
adverse	O
reactions	O
to	O
carbamazepine	B-Chemical
have	O
been	O
observed	O
in	O
the	O
haemopoietic	O
system	O
,	O
the	O
liver	O
and	O
the	O
cardiovascular	O
system	O
.	O
A	O
frequently	O
fatal	O
,	O
although	O
exceptionally	O
rare	O
side	O
effect	O
of	O
carbamazepine	B-Chemical
is	O
necrotizing	O
eosinophilic	O
(	O
hypersensitivity	B-Disease
)	O
myocarditis	B-Disease
.	O
We	O
report	O
a	O
case	O
of	O
hypersensitivity	B-Disease
myocarditis	B-Disease
secondary	O
to	O
administration	O
of	O
carbamazepine	B-Chemical
.	O
Acute	O
hypersensitivity	B-Disease
myocarditis	B-Disease
was	O
not	O
suspected	O
clinically	O
,	O
and	O
the	O
diagnosis	O
was	O
made	O
post	O
-	O
mortem	O
.	O
Histology	O
revealed	O
diffuse	O
infiltration	O
of	O
the	O
myocardium	O
by	O
eosinophils	O
and	O
lymphocytes	O
with	O
myocyte	O
damage	O
.	O
Clinically	O
,	O
death	O
was	O
due	O
to	O
cardiogenic	B-Disease
shock	I-Disease
.	O
To	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
second	O
case	O
of	O
fatal	O
carbamazepine	B-Chemical
induced	O
myocarditis	B-Disease
reported	O
in	O
English	O
literature	O
.	O
Neuropsychiatric	O
behaviors	O
in	O
the	O
MPTP	B-Chemical
marmoset	O
model	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
OBJECTIVES	O
:	O
Neuropsychiatric	O
symptoms	O
are	O
increasingly	O
recognised	O
as	O
a	O
significant	O
problem	O
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
.	O
These	O
symptoms	O
may	O
be	O
due	O
to	O
'	O
sensitisation	O
'	O
following	O
repeated	O
levodopa	B-Chemical
treatment	O
or	O
a	O
direct	O
effect	O
of	O
dopamine	B-Chemical
on	O
the	O
disease	O
state	O
.	O
The	O
levodopa	B-Chemical
-	O
treated	O
MPTP	B-Chemical
-	O
lesioned	O
marmoset	O
was	O
used	O
as	O
a	O
model	O
of	O
neuropsychiatric	B-Disease
symptoms	I-Disease
in	O
PD	B-Disease
patients	O
.	O
Here	O
we	O
compare	O
the	O
time	O
course	O
of	O
levodopa	B-Chemical
-	O
induced	O
motor	O
fluctuations	O
and	O
neuropsychiatric	B-Disease
-	I-Disease
like	I-Disease
behaviors	I-Disease
to	O
determine	O
the	O
relationship	O
between	O
duration	O
of	O
treatment	O
and	O
onset	O
of	O
symptoms	O
.	O
METHODS	O
:	O
Marmosets	O
were	O
administered	O
1	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
phenyl	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
6	I-Chemical
-	I-Chemical
tetrahydropyridine	I-Chemical
(	O
2	O
.	O
0	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
for	O
five	O
days	O
,	O
resulting	O
in	O
stable	O
parkinsonism	B-Disease
.	O
Levodopa	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
and	O
benserazide	B-Chemical
,	O
3	O
.	O
75	O
mg	O
/	O
kg	O
)	O
p	O
.	O
o	O
.	O
b	O
.	O
i	O
.	O
d	O
,	O
was	O
administered	O
for	O
30	O
days	O
.	O
Animals	O
were	O
evaluated	O
for	O
parkinsonian	B-Disease
disability	I-Disease
,	O
dyskinesia	B-Disease
and	O
on	O
-	O
time	O
(	O
motor	O
fluctuations	O
)	O
and	O
neuropsychiatric	B-Disease
-	I-Disease
like	I-Disease
behaviors	I-Disease
on	O
Day	O
0	O
(	O
prior	O
to	O
levodopa	B-Chemical
)	O
and	O
on	O
Days	O
1	O
,	O
7	O
,	O
13	O
,	O
27	O
and	O
30	O
of	O
treatment	O
using	O
post	O
hoc	O
DVD	O
analysis	O
by	O
a	O
trained	O
rater	O
,	O
blind	O
to	O
the	O
treatment	O
day	O
.	O
RESULTS	O
:	O
The	O
neuropsychiatric	B-Disease
-	I-Disease
like	I-Disease
behavior	I-Disease
rating	O
scale	O
demonstrated	O
high	O
interrater	O
reliability	O
between	O
three	O
trained	O
raters	O
of	O
differing	O
professional	O
backgrounds	O
.	O
As	O
anticipated	O
,	O
animals	O
exhibited	O
a	O
progressive	O
increase	O
in	O
levodopa	B-Chemical
-	O
induced	O
motor	O
fluctuations	O
,	O
dyskinesia	B-Disease
and	O
wearing	O
-	O
off	O
,	O
that	O
correlated	O
with	O
the	O
duration	O
of	O
levodopa	B-Chemical
therapy	O
.	O
In	O
contrast	O
,	O
levodopa	B-Chemical
-	O
induced	O
neuropsychiatric	B-Disease
-	I-Disease
like	I-Disease
behaviors	I-Disease
were	O
present	O
on	O
Day	O
1	O
of	O
levodopa	B-Chemical
treatment	O
and	O
their	O
severity	O
did	O
not	O
correlate	O
with	O
duration	O
of	O
treatment	O
.	O
CONCLUSIONS	O
:	O
The	O
data	O
suggest	O
that	O
neuropsychiatric	B-Disease
disorders	I-Disease
in	O
PD	B-Disease
are	O
more	O
likely	O
an	O
interaction	O
between	O
levodopa	B-Chemical
and	O
the	O
disease	O
state	O
than	O
a	O
consequence	O
of	O
sensitisation	O
to	O
repeated	O
dopaminergic	O
therapy	O
.	O
Contrast	B-Chemical
medium	I-Chemical
nephrotoxicity	B-Disease
after	O
renal	O
artery	O
and	O
coronary	O
angioplasty	O
.	O
BACKGROUND	O
:	O
Renal	B-Disease
dysfunction	I-Disease
induced	O
by	O
iodinated	O
contrast	B-Chemical
medium	I-Chemical
(	O
CM	B-Chemical
)	O
administration	O
can	O
minimize	O
the	O
benefit	O
of	O
the	O
interventional	O
procedure	O
in	O
patients	O
undergoing	O
renal	O
angioplasty	O
(	O
PTRA	O
)	O
.	O
PURPOSE	O
:	O
To	O
compare	O
the	O
susceptibility	O
to	O
nephrotoxic	B-Disease
effect	O
of	O
CM	B-Chemical
in	O
patients	O
undergoing	O
PTRA	O
with	O
that	O
of	O
patients	O
submitted	O
to	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
.	O
MATERIAL	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
33	O
patients	O
successfully	O
treated	O
with	O
PTRA	O
(	O
PTRA	O
group	O
,	O
mean	O
age	O
70	O
+	O
/	O
-	O
12	O
years	O
,	O
23	O
female	O
,	O
basal	O
creatinine	B-Chemical
1	O
.	O
46	O
+	O
/	O
-	O
0	O
.	O
79	O
,	O
range	O
0	O
.	O
7	O
-	O
4	O
.	O
9	O
mg	O
/	O
dl	O
)	O
were	O
compared	O
with	O
33	O
patients	O
undergoing	O
successful	O
PCI	O
(	O
PCI	O
group	O
)	O
,	O
matched	O
for	O
basal	O
creatinine	B-Chemical
(	O
1	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
6	O
,	O
range	O
0	O
.	O
7	O
-	O
3	O
.	O
4	O
mg	O
/	O
dl	O
)	O
,	O
gender	O
,	O
and	O
age	O
.	O
In	O
both	O
groups	O
postprocedural	O
(	O
48	O
h	O
)	O
serum	O
creatinine	B-Chemical
was	O
measured	O
.	O
RESULTS	O
:	O
Postprocedural	O
creatinine	B-Chemical
level	O
decreased	O
nonsignificantly	O
in	O
the	O
PTRA	O
group	O
(	O
1	O
.	O
46	O
+	O
/	O
-	O
0	O
.	O
8	O
vs	O
.	O
1	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
dl	O
,	O
P	O
=	O
NS	O
)	O
and	O
increased	O
significantly	O
in	O
the	O
PCI	O
group	O
(	O
1	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
6	O
vs	O
.	O
1	O
.	O
57	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
/	O
dl	O
,	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O
Changes	O
in	O
serum	O
creatinine	B-Chemical
after	O
intervention	O
(	O
after	O
-	O
before	O
)	O
were	O
significantly	O
different	O
between	O
the	O
PTRA	O
and	O
PCI	O
groups	O
(	O
-	O
0	O
.	O
12	O
+	O
/	O
-	O
0	O
.	O
5	O
vs	O
.	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
3	O
,	O
P	O
=	O
0	O
.	O
014	O
)	O
.	O
This	O
difference	O
was	O
not	O
related	O
to	O
either	O
a	O
different	O
clinical	O
risk	O
profile	O
or	O
to	O
the	O
volume	O
of	O
CM	B-Chemical
administered	O
.	O
CONCLUSION	O
:	O
In	O
this	O
preliminary	O
study	O
patients	O
submitted	O
to	O
PTRA	O
showed	O
a	O
lower	O
susceptibility	O
to	O
renal	B-Disease
damage	I-Disease
induced	O
by	O
CM	B-Chemical
administration	O
than	O
PCI	O
patients	O
.	O
The	O
effectiveness	O
of	O
PTRA	O
on	O
renal	O
function	O
seems	O
to	O
be	O
barely	O
influenced	O
by	O
CM	B-Chemical
toxicity	B-Disease
.	O
Diphenhydramine	B-Chemical
prevents	O
the	O
haemodynamic	O
changes	O
of	O
cimetidine	B-Chemical
in	O
ICU	O
patients	O
.	O
Cimetidine	B-Chemical
,	O
a	O
histamine	B-Chemical
2	O
(	O
H2	O
)	O
antagonist	O
,	O
produces	O
a	O
decrease	O
in	O
arterial	O
pressure	O
due	O
to	O
vasodilatation	O
,	O
especially	O
in	O
critically	O
ill	O
patients	O
.	O
This	O
may	O
be	O
because	O
cimetidine	B-Chemical
acts	O
as	O
a	O
histamine	B-Chemical
agonist	O
.	O
We	O
,	O
therefore	O
,	O
investigated	O
the	O
effects	O
of	O
the	O
histamine	B-Chemical
1	O
(	O
H1	O
)	O
receptor	O
antagonist	O
,	O
diphenhydramine	B-Chemical
,	O
on	O
the	O
haemodynamic	O
changes	O
observed	O
after	O
cimetidine	B-Chemical
in	O
ICU	O
patients	O
.	O
Each	O
patient	O
was	O
studied	O
on	O
two	O
separate	O
days	O
.	O
In	O
a	O
random	O
fashion	O
,	O
they	O
received	O
cimetidine	B-Chemical
200	O
mg	O
iv	O
on	O
one	O
day	O
,	O
and	O
on	O
the	O
other	O
,	O
a	O
pretreatment	O
of	O
diphenhydramine	B-Chemical
40	O
mg	O
iv	O
with	O
cimetidine	B-Chemical
200	O
mg	O
iv	O
.	O
In	O
the	O
non	O
-	O
pretreatment	O
group	O
,	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
decreased	O
from	O
107	O
.	O
4	O
+	O
/	O
-	O
8	O
.	O
4	O
mmHg	O
to	O
86	O
.	O
7	O
+	O
/	O
-	O
11	O
.	O
4	O
mmHg	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
two	O
minutes	O
after	O
cimetidine	B-Chemical
.	O
Also	O
,	O
systemic	O
vascular	O
resistance	O
(	O
SVR	O
)	O
decreased	O
during	O
the	O
eight	O
-	O
minute	O
observation	O
period	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
In	O
contrast	O
,	O
in	O
the	O
pretreatment	O
group	O
,	O
little	O
haemodynamic	O
change	O
was	O
seen	O
.	O
We	O
conclude	O
that	O
an	O
H1	O
antagonist	O
may	O
be	O
useful	O
in	O
preventing	O
hypotension	B-Disease
caused	O
by	O
iv	O
cimetidine	B-Chemical
,	O
since	O
the	O
vasodilating	O
activity	O
of	O
cimetidine	B-Chemical
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
H1	O
receptor	O
.	O
Medical	O
and	O
psychiatric	O
outcomes	O
for	O
patients	O
transplanted	O
for	O
acetaminophen	B-Chemical
-	O
induced	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
:	O
a	O
case	O
-	O
control	O
study	O
.	O
BACKGROUND	O
:	O
Acetaminophen	B-Chemical
-	O
induced	O
hepatotoxicity	B-Disease
is	O
the	O
most	O
common	O
cause	O
of	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
(	O
ALF	B-Disease
)	O
in	O
the	O
UK	O
.	O
Patients	O
often	O
consume	O
the	O
drug	O
with	O
suicidal	O
intent	O
or	O
with	O
a	O
background	O
of	O
substance	O
dependence	O
.	O
AIMS	O
AND	O
METHODS	O
:	O
We	O
compared	O
the	O
severity	O
of	O
pretransplant	O
illness	O
,	O
psychiatric	O
co	O
-	O
morbidity	O
,	O
medical	O
and	O
psychosocial	O
outcomes	O
of	O
all	O
patients	O
who	O
had	O
undergone	O
liver	O
transplantation	O
(	O
LT	O
)	O
emergently	O
between	O
1999	O
-	O
2004	O
for	O
acetaminophen	B-Chemical
-	O
induced	O
ALF	B-Disease
(	O
n	O
=	O
36	O
)	O
with	O
age	O
-	O
and	O
sex	O
-	O
matched	O
patients	O
undergoing	O
emergent	O
LT	O
for	O
non	O
-	O
acetaminophen	B-Chemical
-	O
induced	O
ALF	B-Disease
(	O
n	O
=	O
35	O
)	O
and	O
elective	O
LT	O
for	O
chronic	B-Disease
liver	I-Disease
disease	I-Disease
(	O
CLD	B-Disease
,	O
n	O
=	O
34	O
)	O
.	O
RESULTS	O
:	O
Acetaminophen	B-Chemical
-	O
induced	O
ALF	B-Disease
patients	O
undergoing	O
LT	O
had	O
a	O
greater	O
severity	O
of	O
pre	O
-	O
LT	O
illness	O
reflected	O
by	O
higher	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
and	O
requirement	O
for	O
organ	O
support	O
compared	O
with	O
the	O
other	O
two	O
groups	O
.	O
Twenty	O
(	O
56	O
%	O
)	O
acetaminophen	B-Chemical
-	O
induced	O
ALF	B-Disease
patients	O
had	O
a	O
formal	O
psychiatric	O
diagnosis	O
before	O
LT	O
(	O
non	O
-	O
acetaminophen	B-Chemical
-	O
induced	O
ALF	B-Disease
=	O
0	O
/	O
35	O
,	O
CLD	B-Disease
=	O
2	O
/	O
34	O
;	O
P	O
<	O
0	O
.	O
01	O
for	O
all	O
)	O
and	O
nine	O
(	O
25	O
%	O
)	O
had	O
a	O
previous	O
suicide	O
attempt	O
.	O
During	O
follow	O
-	O
up	O
(	O
median	O
5	O
years	O
)	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
rejection	O
(	O
acute	O
and	O
chronic	O
)	O
,	O
graft	O
failure	O
or	O
survival	O
between	O
the	O
groups	O
(	O
acetaminophen	B-Chemical
-	O
induced	O
ALF	B-Disease
1	O
year	O
87	O
%	O
,	O
5	O
years	O
75	O
%	O
;	O
non	O
-	O
acetaminophen	B-Chemical
-	O
induced	O
ALF	B-Disease
88	O
%	O
,	O
78	O
%	O
;	O
CLD	B-Disease
93	O
%	O
,	O
82	O
%	O
:	O
P	O
>	O
0	O
.	O
6	O
log	O
rank	O
)	O
.	O
Two	O
acetaminophen	B-Chemical
-	O
induced	O
ALF	B-Disease
patients	O
reattempted	O
suicide	O
post	O
-	O
LT	O
(	O
one	O
died	O
8	O
years	O
post	O
-	O
LT	O
)	O
.	O
CONCLUSIONS	O
:	O
Despite	O
a	O
high	O
prevalence	O
of	O
psychiatric	O
disturbance	O
,	O
outcomes	O
for	O
patients	O
transplanted	O
emergently	O
for	O
acetaminophen	B-Chemical
-	O
induced	O
ALF	B-Disease
were	O
comparable	O
to	O
those	O
transplanted	O
for	O
non	O
-	O
acetaminophen	B-Chemical
-	O
induced	O
ALF	B-Disease
and	O
electively	O
for	O
CLD	B-Disease
.	O
Multidisciplinary	O
approaches	O
with	O
long	O
-	O
term	O
psychiatric	O
follow	O
-	O
up	O
may	O
contribute	O
to	O
low	O
post	O
-	O
transplant	O
suicide	O
rates	O
seen	O
and	O
low	O
rates	O
of	O
graft	O
loss	O
because	O
of	O
non	O
-	O
compliance	O
.	O
Antithrombotic	O
drug	O
use	O
,	O
cerebral	B-Disease
microbleeds	I-Disease
,	O
and	O
intracerebral	B-Disease
hemorrhage	I-Disease
:	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
studies	O
.	O
BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cerebral	B-Disease
microbleeds	I-Disease
(	O
MB	B-Disease
)	O
are	O
potential	O
risk	O
factors	O
for	O
intracerebral	B-Disease
hemorrhage	I-Disease
(	O
ICH	B-Disease
)	O
,	O
but	O
it	O
is	O
unclear	O
if	O
they	O
are	O
a	O
contraindication	O
to	O
using	O
antithrombotic	O
drugs	O
.	O
Insights	O
could	O
be	O
gained	O
by	O
pooling	O
data	O
on	O
MB	B-Disease
frequency	O
stratified	O
by	O
antithrombotic	O
use	O
in	O
cohorts	O
with	O
ICH	B-Disease
and	O
ischemic	B-Disease
stroke	I-Disease
(	O
IS	B-Disease
)	O
/	O
transient	B-Disease
ischemic	I-Disease
attack	I-Disease
(	O
TIA	B-Disease
)	O
.	O
METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
data	O
from	O
cohorts	O
with	O
stroke	B-Disease
or	O
TIA	B-Disease
to	O
compare	O
the	O
presence	O
of	O
MB	B-Disease
in	O
:	O
(	O
1	O
)	O
antithrombotic	O
users	O
vs	O
nonantithrombotic	O
users	O
with	O
ICH	B-Disease
;	O
(	O
2	O
)	O
antithrombotic	O
users	O
vs	O
nonusers	O
with	O
IS	B-Disease
/	O
TIA	B-Disease
;	O
and	O
(	O
3	O
)	O
ICH	B-Disease
vs	O
ischemic	B-Disease
events	O
stratified	O
by	O
antithrombotic	O
use	O
.	O
We	O
also	O
analyzed	O
published	O
and	O
unpublished	O
follow	O
-	O
up	O
data	O
to	O
determine	O
the	O
risk	O
of	O
ICH	B-Disease
in	O
antithrombotic	O
users	O
with	O
MB	B-Disease
.	O
RESULTS	O
:	O
In	O
a	O
pooled	O
analysis	O
of	O
1460	O
ICH	B-Disease
and	O
3817	O
IS	B-Disease
/	O
TIA	B-Disease
,	O
MB	B-Disease
were	O
more	O
frequent	O
in	O
ICH	B-Disease
vs	O
IS	B-Disease
/	O
TIA	B-Disease
in	O
all	O
treatment	O
groups	O
,	O
but	O
the	O
excess	O
increased	O
from	O
2	O
.	O
8	O
(	O
odds	O
ratio	O
;	O
range	O
,	O
2	O
.	O
3	O
-	O
3	O
.	O
5	O
)	O
in	O
nonantithrombotic	O
users	O
to	O
5	O
.	O
7	O
(	O
range	O
,	O
3	O
.	O
4	O
-	O
9	O
.	O
7	O
)	O
in	O
antiplatelet	O
users	O
and	O
8	O
.	O
0	O
(	O
range	O
,	O
3	O
.	O
5	O
-	O
17	O
.	O
8	O
)	O
in	O
warfarin	B-Chemical
users	O
(	O
P	O
difference	O
=	O
0	O
.	O
01	O
)	O
.	O
There	O
was	O
also	O
an	O
excess	O
of	O
MB	B-Disease
in	O
warfarin	B-Chemical
users	O
vs	O
nonusers	O
with	O
ICH	B-Disease
(	O
OR	O
,	O
2	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
6	O
-	O
4	O
.	O
4	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
but	O
none	O
in	O
warfarin	B-Chemical
users	O
with	O
IS	B-Disease
/	O
TIA	B-Disease
(	O
OR	O
,	O
1	O
.	O
3	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
9	O
-	O
1	O
.	O
7	O
;	O
P	O
=	O
0	O
.	O
33	O
;	O
P	O
difference	O
=	O
0	O
.	O
01	O
)	O
.	O
There	O
was	O
a	O
smaller	O
excess	O
of	O
MB	B-Disease
in	O
antiplatelet	O
users	O
vs	O
nonusers	O
with	O
ICH	B-Disease
(	O
OR	O
,	O
1	O
.	O
7	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
2	O
.	O
3	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
findings	O
were	O
similar	O
for	O
antiplatelet	O
users	O
with	O
IS	B-Disease
/	O
TIA	B-Disease
(	O
OR	O
,	O
1	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
1	O
.	O
7	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
P	O
difference	O
=	O
0	O
.	O
25	O
)	O
.	O
In	O
pooled	O
follow	O
-	O
up	O
data	O
for	O
768	O
antithrombotic	O
users	O
,	O
presence	O
of	O
MB	B-Disease
at	O
baseline	O
was	O
associated	O
with	O
a	O
substantially	O
increased	O
risk	O
of	O
subsequent	O
ICH	B-Disease
(	O
OR	O
,	O
12	O
.	O
1	O
;	O
95	O
%	O
CI	O
,	O
3	O
.	O
4	O
-	O
42	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
excess	O
of	O
MB	B-Disease
in	O
warfarin	B-Chemical
users	O
with	O
ICH	B-Disease
compared	O
to	O
other	O
groups	O
suggests	O
that	O
MB	B-Disease
increase	O
the	O
risk	O
of	O
warfarin	B-Chemical
-	O
associated	O
ICH	B-Disease
.	O
Limited	O
prospective	O
data	O
corroborate	O
these	O
findings	O
,	O
but	O
larger	O
prospective	O
studies	O
are	O
urgently	O
required	O
.	O
Studies	O
of	O
synergy	O
between	O
morphine	B-Chemical
and	O
a	O
novel	O
sodium	B-Chemical
channel	O
blocker	O
,	O
CNSB002	B-Chemical
,	O
in	O
rat	O
models	O
of	O
inflammatory	O
and	O
neuropathic	B-Disease
pain	I-Disease
.	O
OBJECTIVE	O
:	O
This	O
study	O
determined	O
the	O
antihyperalgesic	O
effect	O
of	O
CNSB002	B-Chemical
,	O
a	O
sodium	B-Chemical
channel	O
blocker	O
with	O
antioxidant	O
properties	O
given	O
alone	O
and	O
in	O
combinations	O
with	O
morphine	B-Chemical
in	O
rat	O
models	O
of	O
inflammatory	O
and	O
neuropathic	B-Disease
pain	I-Disease
.	O
DESIGN	O
:	O
Dose	O
response	O
curves	O
for	O
nonsedating	O
doses	O
of	O
morphine	B-Chemical
and	O
CNSB002	B-Chemical
given	O
intraperitoneally	O
alone	O
and	O
together	O
in	O
combinations	O
were	O
constructed	O
for	O
antihyperalgesic	O
effect	O
using	O
paw	O
withdrawal	O
from	O
noxious	O
heat	O
in	O
two	O
rat	O
pain	B-Disease
models	O
:	O
carrageenan	B-Chemical
-	O
induced	O
paw	O
inflammation	B-Disease
and	O
streptozotocin	B-Chemical
(	O
STZ	B-Chemical
)	O
-	O
induced	O
diabetic	B-Disease
neuropathy	I-Disease
.	O
RESULTS	O
:	O
The	O
maximum	O
nonsedating	O
doses	O
were	O
:	O
morphine	B-Chemical
,	O
3	O
.	O
2	O
mg	O
/	O
kg	O
;	O
CNSB002	B-Chemical
10	O
.	O
0	O
mg	O
/	O
kg	O
;	O
5	O
.	O
0	O
mg	O
/	O
kg	O
CNSB002	B-Chemical
with	O
morphine	B-Chemical
3	O
.	O
2	O
mg	O
/	O
kg	O
in	O
combination	O
.	O
The	O
doses	O
calculated	O
to	O
cause	O
50	O
%	O
reversal	O
of	O
hyperalgesia	B-Disease
(	O
ED50	O
)	O
were	O
7	O
.	O
54	O
(	O
1	O
.	O
81	O
)	O
and	O
4	O
.	O
83	O
(	O
1	O
.	O
54	O
)	O
in	O
the	O
carrageenan	B-Chemical
model	O
and	O
44	O
.	O
18	O
(	O
1	O
.	O
37	O
)	O
and	O
9	O
.	O
14	O
(	O
1	O
.	O
24	O
)	O
in	O
the	O
STZ	B-Chemical
-	O
induced	O
neuropathy	B-Disease
model	O
for	O
CNSB002	B-Chemical
and	O
morphine	B-Chemical
,	O
respectively	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O
These	O
values	O
were	O
greater	O
than	O
the	O
maximum	O
nonsedating	O
doses	O
.	O
The	O
ED50	O
values	O
for	O
morphine	B-Chemical
when	O
given	O
in	O
combination	O
with	O
CNSB002	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
)	O
were	O
less	O
than	O
the	O
maximum	O
nonsedating	O
dose	O
:	O
0	O
.	O
56	O
(	O
1	O
.	O
55	O
)	O
in	O
the	O
carrageenan	B-Chemical
model	O
and	O
1	O
.	O
37	O
(	O
1	O
.	O
23	O
)	O
in	O
the	O
neuropathy	B-Disease
model	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O
The	O
antinociception	O
after	O
morphine	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
)	O
was	O
increased	O
by	O
co	O
-	O
administration	O
with	O
CNSB002	B-Chemical
from	O
28	O
.	O
0	O
and	O
31	O
.	O
7	O
%	O
to	O
114	O
.	O
6	O
and	O
56	O
.	O
9	O
%	O
reversal	O
of	O
hyperalgesia	B-Disease
in	O
the	O
inflammatory	O
and	O
neuropathic	B-Disease
models	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
01	O
;	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
-	O
significantly	O
greater	O
than	O
either	O
drug	O
given	O
alone	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
maximum	O
antihyperalgesic	O
effect	O
achievable	O
with	O
nonsedating	O
doses	O
of	O
morphine	B-Chemical
may	O
be	O
increased	O
significantly	O
when	O
the	O
drug	O
is	O
used	O
in	O
combination	O
with	O
CNSB002	B-Chemical
.	O
Heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
:	O
a	O
practical	O
review	O
.	O
Heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
(	O
HIT	B-Disease
)	O
remains	O
under	O
-	O
recognized	O
despite	O
its	O
potentially	O
devastating	O
outcomes	O
.	O
It	O
begins	O
when	O
heparin	B-Chemical
exposure	O
stimulates	O
the	O
formation	O
of	O
heparin	B-Chemical
-	O
platelet	O
factor	O
4	O
antibodies	O
,	O
which	O
in	O
turn	O
triggers	O
the	O
release	O
of	O
procoagulant	O
platelet	O
particles	O
.	O
Thrombosis	B-Disease
and	O
thrombocytopenia	B-Disease
that	O
follow	O
comprise	O
the	O
2	O
hallmark	O
traits	O
of	O
HIT	B-Disease
,	O
with	O
the	O
former	O
largely	O
responsible	O
for	O
significant	O
vascular	O
complications	O
.	O
The	O
prevalence	O
of	O
HIT	B-Disease
varies	O
among	O
several	O
subgroups	O
,	O
with	O
greater	O
incidence	O
in	O
surgical	O
as	O
compared	O
with	O
medical	O
populations	O
.	O
HIT	B-Disease
must	O
be	O
acknowledged	O
for	O
its	O
intense	O
predilection	O
for	O
thrombosis	B-Disease
and	O
suspected	O
whenever	O
thrombosis	B-Disease
occurs	O
after	O
heparin	B-Chemical
exposure	O
.	O
Early	O
recognition	O
that	O
incorporates	O
the	O
clinical	O
and	O
serologic	O
clues	O
is	O
paramount	O
to	O
timely	O
institution	O
of	O
treatment	O
,	O
as	O
its	O
delay	O
may	O
result	O
in	O
catastrophic	O
outcomes	O
.	O
The	O
treatment	O
of	O
HIT	B-Disease
mandates	O
an	O
immediate	O
cessation	O
of	O
all	O
heparin	B-Chemical
exposure	O
and	O
the	O
institution	O
of	O
an	O
antithrombotic	O
therapy	O
,	O
most	O
commonly	O
using	O
a	O
direct	B-Chemical
thrombin	I-Chemical
inhibitor	I-Chemical
.	O
Current	O
""""	O
diagnostic	O
""""	O
tests	O
,	O
which	O
primarily	O
include	O
functional	O
and	O
antigenic	O
assays	O
,	O
have	O
more	O
of	O
a	O
confirmatory	O
than	O
diagnostic	O
role	O
in	O
the	O
management	O
of	O
HIT	B-Disease
.	O
Special	O
attention	O
must	O
be	O
paid	O
to	O
cardiac	O
patients	O
who	O
are	O
often	O
exposed	O
to	O
heparin	B-Chemical
multiple	O
times	O
during	O
their	O
course	O
of	O
treatment	O
.	O
Direct	B-Chemical
thrombin	I-Chemical
inhibitors	I-Chemical
are	O
appropriate	O
,	O
evidence	O
-	O
based	O
alternatives	O
to	O
heparin	B-Chemical
in	O
patients	O
with	O
a	O
history	O
of	O
HIT	B-Disease
,	O
who	O
need	O
to	O
undergo	O
percutaneous	O
coronary	O
intervention	O
.	O
As	O
heparin	B-Chemical
remains	O
one	O
of	O
the	O
most	O
frequently	O
used	O
medications	O
today	O
with	O
potential	O
for	O
HIT	B-Disease
with	O
every	O
heparin	B-Chemical
exposure	O
,	O
a	O
close	O
vigilance	O
of	O
platelet	O
counts	O
must	O
be	O
practiced	O
whenever	O
heparin	B-Chemical
is	O
initiated	O
.	O
Abductor	O
paralysis	B-Disease
after	O
botox	B-Chemical
injection	O
for	O
adductor	B-Disease
spasmodic	I-Disease
dysphonia	I-Disease
.	O
OBJECTIVES	O
/	O
HYPOTHESIS	O
:	O
Botulinum	O
toxin	O
(	O
Botox	B-Chemical
)	O
injections	O
into	O
the	O
thyroarytenoid	O
muscles	O
are	O
the	O
current	O
standard	O
of	O
care	O
for	O
adductor	B-Disease
spasmodic	I-Disease
dysphonia	I-Disease
(	O
ADSD	B-Disease
)	O
.	O
Reported	O
adverse	O
effects	O
include	O
a	O
period	O
of	O
breathiness	O
,	O
throat	B-Disease
pain	I-Disease
,	O
and	O
difficulty	O
with	O
swallowing	O
liquids	O
.	O
Here	O
we	O
report	O
multiple	O
cases	O
of	O
bilateral	O
abductor	O
paralysis	B-Disease
following	O
Botox	B-Chemical
injections	O
for	O
ADSD	B-Disease
,	O
a	O
complication	O
previously	O
unreported	O
.	O
STUDY	O
DESIGN	O
:	O
Retrospective	O
case	O
series	O
.	O
METHODS	O
:	O
Patients	O
that	O
received	O
Botox	B-Chemical
injections	O
for	O
spasmodic	B-Disease
dysphonia	I-Disease
between	O
January	O
2000	O
and	O
October	O
2009	O
were	O
evaluated	O
.	O
Patients	O
with	O
ADSD	B-Disease
were	O
identified	O
.	O
The	O
number	O
of	O
treatments	O
received	O
and	O
adverse	O
effects	O
were	O
noted	O
.	O
For	O
patients	O
with	O
bilateral	O
abductor	O
paralysis	B-Disease
,	O
age	O
,	O
sex	O
,	O
paralytic	O
Botox	B-Chemical
dose	O
,	O
prior	O
Botox	B-Chemical
dose	O
,	O
and	O
course	O
following	O
paralysis	B-Disease
were	O
noted	O
.	O
RESULTS	O
:	O
From	O
a	O
database	O
of	O
452	O
patients	O
receiving	O
Botox	B-Chemical
,	O
352	O
patients	O
had	O
been	O
diagnosed	O
with	O
ADSD	B-Disease
.	O
Of	O
these	O
352	O
patients	O
,	O
eight	O
patients	O
suffered	O
bilateral	O
abductor	O
paralysis	B-Disease
,	O
and	O
two	O
suffered	O
this	O
complication	O
twice	O
.	O
All	O
affected	O
patients	O
were	O
females	O
over	O
the	O
age	O
of	O
50	O
years	O
.	O
Most	O
patients	O
had	O
received	O
treatments	O
prior	O
to	O
abductor	O
paralysis	B-Disease
and	O
continued	O
receiving	O
after	O
paralysis	B-Disease
.	O
Seven	O
patients	O
recovered	O
after	O
a	O
brief	O
period	O
of	O
activity	O
restrictions	O
,	O
and	O
one	O
underwent	O
a	O
tracheotomy	O
.	O
The	O
incidence	O
of	O
abductor	O
paralysis	B-Disease
after	O
Botox	B-Chemical
injection	O
for	O
ADSD	B-Disease
was	O
0	O
.	O
34	O
%	O
.	O
CONCLUSIONS	O
:	O
Bilateral	O
abductor	O
paralysis	B-Disease
is	O
a	O
rare	O
complication	O
of	O
Botox	B-Chemical
injections	O
for	O
ADSD	B-Disease
,	O
causing	O
difficulty	O
with	O
breathing	O
upon	O
exertion	O
.	O
The	O
likely	O
mechanism	O
of	O
paralysis	B-Disease
is	O
diffusion	O
of	O
Botox	B-Chemical
around	O
the	O
muscular	O
process	O
of	O
the	O
arytenoid	O
to	O
the	O
posterior	O
cricoarytenoid	O
muscles	O
.	O
The	O
paralysis	B-Disease
is	O
temporary	O
,	O
and	O
watchful	O
waiting	O
with	O
restriction	O
of	O
activity	O
is	O
the	O
recommended	O
management	O
.	O
Mitochondrial	B-Disease
impairment	I-Disease
contributes	O
to	O
cocaine	B-Chemical
-	O
induced	O
cardiac	B-Disease
dysfunction	I-Disease
:	O
Prevention	O
by	O
the	O
targeted	O
antioxidant	O
MitoQ	B-Chemical
.	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
mitochondrial	O
function	O
and	O
ROS	O
production	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	B-Chemical
-	O
induced	O
cardiac	B-Disease
dysfunction	I-Disease
.	O
We	O
hypothesized	O
that	O
cocaine	B-Disease
abuse	I-Disease
may	O
lead	O
to	O
altered	O
mitochondrial	O
function	O
that	O
in	O
turn	O
may	O
cause	O
left	B-Disease
ventricular	I-Disease
dysfunction	I-Disease
.	O
Seven	O
days	O
of	O
cocaine	B-Chemical
administration	O
to	O
rats	O
led	O
to	O
an	O
increased	O
oxygen	B-Chemical
consumption	O
detected	O
in	O
cardiac	O
fibers	O
,	O
specifically	O
through	O
complex	O
I	O
and	O
complex	O
III	O
.	O
ROS	O
levels	O
were	O
increased	O
,	O
specifically	O
in	O
interfibrillar	O
mitochondria	O
.	O
In	O
parallel	O
there	O
was	O
a	O
decrease	O
in	O
ATP	B-Chemical
synthesis	O
,	O
whereas	O
no	O
difference	O
was	O
observed	O
in	O
subsarcolemmal	O
mitochondria	O
.	O
This	O
uncoupling	O
effect	O
on	O
oxidative	O
phosphorylation	O
was	O
not	O
detectable	O
after	O
short	O
-	O
term	O
exposure	O
to	O
cocaine	B-Chemical
,	O
suggesting	O
that	O
these	O
mitochondrial	B-Disease
abnormalities	I-Disease
were	O
a	O
late	O
rather	O
than	O
a	O
primary	O
event	O
in	O
the	O
pathological	O
response	O
to	O
cocaine	B-Chemical
.	O
MitoQ	B-Chemical
,	O
a	O
mitochondrial	O
-	O
targeted	O
antioxidant	O
,	O
was	O
shown	O
to	O
completely	O
prevent	O
these	O
mitochondrial	B-Disease
abnormalities	I-Disease
as	O
well	O
as	O
cardiac	B-Disease
dysfunction	I-Disease
characterized	O
here	O
by	O
a	O
diastolic	B-Disease
dysfunction	I-Disease
studied	O
with	O
a	O
conductance	O
catheter	O
to	O
obtain	O
pressure	O
-	O
volume	O
data	O
.	O
Taken	O
together	O
,	O
these	O
results	O
extend	O
previous	O
studies	O
and	O
demonstrate	O
that	O
cocaine	B-Chemical
-	O
induced	O
cardiac	B-Disease
dysfunction	I-Disease
may	O
be	O
due	O
to	O
a	O
mitochondrial	B-Disease
defect	I-Disease
.	O
Trimethoprim	B-Chemical
-	O
induced	O
immune	O
hemolytic	B-Disease
anemia	I-Disease
in	O
a	O
pediatric	O
oncology	O
patient	O
presenting	O
as	O
an	O
acute	O
hemolytic	O
transfusion	O
reaction	O
.	O
A	O
10	O
-	O
year	O
-	O
old	O
male	O
with	O
acute	B-Disease
leukemia	I-Disease
presented	O
with	O
post	O
-	O
chemotherapy	O
anemia	B-Disease
.	O
During	O
red	O
cell	O
transfusion	O
,	O
he	O
developed	O
hemoglobinuria	B-Disease
.	O
Transfusion	O
reaction	O
workup	O
was	O
negative	O
.	O
Drug	O
-	O
induced	O
immune	O
hemolytic	B-Disease
anemia	I-Disease
was	O
suspected	O
because	O
of	O
positive	O
direct	O
antiglobulin	O
test	O
,	O
negative	O
eluate	O
,	O
and	O
microspherocytes	O
on	O
smear	O
pre	O
-	O
and	O
post	O
-	O
transfusion	O
.	O
Drug	O
studies	O
using	O
the	O
indirect	O
antiglobulin	O
test	O
were	O
strongly	O
positive	O
with	O
trimethoprim	B-Chemical
and	O
trimethoprim	B-Chemical
-	I-Chemical
sulfamethoxazole	I-Chemical
but	O
negative	O
with	O
sulfamethoxazole	B-Chemical
.	O
The	O
patient	O
recovered	O
after	O
discontinuing	O
the	O
drug	O
,	O
with	O
no	O
recurrence	O
in	O
2	O
years	O
.	O
Other	O
causes	O
of	O
anemia	B-Disease
should	O
be	O
considered	O
in	O
patients	O
with	O
worse	O
-	O
than	O
-	O
expected	O
anemia	B-Disease
after	O
chemotherapy	O
.	O
Furthermore	O
,	O
hemolysis	B-Disease
during	O
transfusion	O
is	O
not	O
always	O
a	O
transfusion	O
reaction	O
.	O
Verapamil	B-Chemical
stimulation	O
test	O
in	O
hyperprolactinemia	B-Disease
:	O
loss	O
of	O
prolactin	O
response	O
in	O
anatomic	O
or	O
functional	O
stalk	O
effect	O
.	O
AIM	O
:	O
Verapamil	B-Chemical
stimulation	O
test	O
was	O
previously	O
investigated	O
as	O
a	O
tool	O
for	O
differential	O
diagnosis	O
of	O
hyperprolactinemia	B-Disease
,	O
but	O
with	O
conflicting	O
results	O
.	O
Macroprolactinemia	B-Disease
was	O
never	O
considered	O
in	O
those	O
previous	O
studies	O
.	O
Here	O
,	O
we	O
aimed	O
to	O
re	O
-	O
investigate	O
the	O
diagnostic	O
value	O
of	O
verapamil	B-Chemical
in	O
a	O
population	O
who	O
were	O
all	O
screened	O
for	O
macroprolactinemia	B-Disease
.	O
Prolactin	O
responses	O
to	O
verapamil	B-Chemical
in	O
65	O
female	O
patients	O
(	O
age	O
:	O
29	O
.	O
9	O
+	O
/	O
-	O
8	O
.	O
1	O
years	O
)	O
with	O
hyperprolactinemia	B-Disease
were	O
tested	O
in	O
a	O
descriptive	O
,	O
matched	O
case	O
-	O
control	O
study	O
.	O
METHODS	O
:	O
Verapamil	B-Chemical
80	O
mg	O
,	O
p	O
.	O
o	O
.	O
was	O
administered	O
,	O
and	O
then	O
PRL	O
levels	O
were	O
measured	O
at	O
8th	O
and	O
16th	O
hours	O
,	O
by	O
immunometric	O
chemiluminescence	O
.	O
Verapamil	B-Chemical
responsiveness	O
was	O
determined	O
by	O
peak	O
percent	O
change	O
in	O
basal	O
prolactin	O
levels	O
(	O
PRL	O
)	O
.	O
RESULTS	O
:	O
Verapamil	B-Chemical
significantly	O
increased	O
PRL	O
levels	O
in	O
healthy	O
controls	O
(	O
N	O
.	O
8	O
,	O
PRL	O
:	O
183	O
%	O
)	O
,	O
macroprolactinoma	B-Disease
(	O
N	O
.	O
8	O
,	O
PRL	O
:	O
7	O
%	O
)	O
,	O
microprolactinoma	B-Disease
(	O
N	O
.	O
19	O
,	O
PRL	O
:	O
21	O
%	O
)	O
,	O
macroprolactinemia	B-Disease
(	O
N	O
.	O
23	O
,	O
PRL	O
:	O
126	O
%	O
)	O
,	O
but	O
not	O
in	O
pseudoprolactinoma	B-Disease
(	O
N	O
.	O
8	O
,	O
PRL	O
:	O
0	O
.	O
8	O
%	O
)	O
,	O
and	O
risperidone	B-Chemical
-	O
induced	O
hyperprolactinemia	B-Disease
(	O
N	O
.	O
7	O
,	O
PRL	O
:	O
3	O
%	O
)	O
.	O
ROC	O
curve	O
analysis	O
revealed	O
that	O
unresponsiveness	O
to	O
verapamil	B-Chemical
defined	O
as	O
PRL	O
<	O
7	O
%	O
,	O
discriminated	O
anatomical	O
or	O
functional	O
stalk	O
effect	O
(	O
sensitivity	O
:	O
74	O
%	O
,	O
specificity	O
:	O
73	O
%	O
,	O
AUC	O
:	O
0	O
.	O
855	O
+	O
/	O
-	O
0	O
.	O
04	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
CI	O
:	O
0	O
.	O
768	O
-	O
0	O
.	O
942	O
)	O
associated	O
with	O
pseudoprolactinoma	B-Disease
or	O
risperidone	B-Chemical
-	O
induced	O
hyperprolactinemia	B-Disease
,	O
respectively	O
.	O
CONCLUSION	O
:	O
Verapamil	B-Chemical
responsiveness	O
is	O
not	O
a	O
reliable	O
finding	O
for	O
the	O
differential	O
diagnosis	O
of	O
hyperprolactinemia	B-Disease
.	O
However	O
,	O
verapamil	B-Chemical
unresponsiveness	O
discriminates	O
stalk	O
effect	O
(	O
i	O
.	O
e	O
.	O
,	O
anatomically	O
or	O
functionally	O
inhibited	O
dopaminergic	O
tonus	O
)	O
from	O
other	O
causes	O
of	O
hyperprolactinemia	B-Disease
with	O
varying	O
degrees	O
of	O
responsiveness	O
.	O
Blockade	O
of	O
endothelial	O
-	O
mesenchymal	O
transition	O
by	O
a	O
Smad3	O
inhibitor	O
delays	O
the	O
early	O
development	O
of	O
streptozotocin	B-Chemical
-	O
induced	O
diabetic	B-Disease
nephropathy	I-Disease
.	O
OBJECTIVE	O
:	O
A	O
multicenter	O
,	O
controlled	O
trial	O
showed	O
that	O
early	O
blockade	O
of	O
the	O
renin	O
-	O
angiotensin	B-Chemical
system	O
in	O
patients	O
with	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
and	O
normoalbuminuria	O
did	O
not	O
retard	O
the	O
progression	O
of	O
nephropathy	B-Disease
,	O
suggesting	O
that	O
other	O
mechanism	O
(	O
s	O
)	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
early	O
diabetic	B-Disease
nephropathy	I-Disease
(	O
diabetic	B-Disease
nephropathy	I-Disease
)	O
.	O
We	O
have	O
previously	O
demonstrated	O
that	O
endothelial	O
-	O
mesenchymal	O
-	O
transition	O
(	O
EndoMT	O
)	O
contributes	O
to	O
the	O
early	O
development	O
of	O
renal	O
interstitial	O
fibrosis	B-Disease
independently	O
of	O
microalbuminuria	O
in	O
mice	O
with	O
streptozotocin	B-Chemical
(	O
STZ	B-Chemical
)	O
-	O
induced	O
diabetes	B-Disease
.	O
In	O
the	O
present	O
study	O
,	O
we	O
hypothesized	O
that	O
blocking	O
EndoMT	O
reduces	O
the	O
early	O
development	O
of	O
diabetic	B-Disease
nephropathy	I-Disease
.	O
RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
EndoMT	O
was	O
induced	O
in	O
a	O
mouse	O
pancreatic	O
microvascular	O
endothelial	O
cell	O
line	O
(	O
MMEC	O
)	O
in	O
the	O
presence	O
of	O
advanced	O
glycation	O
end	O
products	O
(	O
AGEs	O
)	O
and	O
in	O
the	O
endothelial	O
lineage	O
-	O
traceble	O
mouse	O
line	O
Tie2	O
-	O
Cre	O
;	O
Loxp	O
-	O
EGFP	O
by	O
administration	O
of	O
AGEs	O
,	O
with	O
nonglycated	O
mouse	O
albumin	O
serving	O
as	O
a	O
control	O
.	O
Phosphorylated	O
Smad3	O
was	O
detected	O
by	O
immunoprecipitation	O
/	O
Western	O
blotting	O
and	O
confocal	O
microscopy	O
.	O
Blocking	O
studies	O
using	O
receptor	O
for	O
AGE	O
siRNA	O
and	O
a	O
specific	O
inhibitor	O
of	O
Smad3	O
(	O
SIS3	O
)	O
were	O
performed	O
in	O
MMECs	O
and	O
in	O
STZ	B-Chemical
-	O
induced	O
diabetic	B-Disease
nephropathy	I-Disease
in	O
Tie2	O
-	O
Cre	O
;	O
Loxp	O
-	O
EGFP	O
mice	O
.	O
RESULTS	O
:	O
Confocal	O
microscopy	O
and	O
real	O
-	O
time	O
PCR	O
demonstrated	O
that	O
AGEs	O
induced	O
EndoMT	O
in	O
MMECs	O
and	O
in	O
Tie2	O
-	O
Cre	O
;	O
Loxp	O
-	O
EGFP	O
mice	O
.	O
Immunoprecipitation	O
/	O
Western	O
blotting	O
showed	O
that	O
Smad3	O
was	O
activated	O
by	O
AGEs	O
but	O
was	O
inhibited	O
by	O
SIS3	O
in	O
MMECs	O
and	O
in	O
STZ	B-Chemical
-	O
induced	O
diabetic	B-Disease
nephropathy	I-Disease
.	O
Confocal	O
microscopy	O
and	O
real	O
-	O
time	O
PCR	O
further	O
demonstrated	O
that	O
SIS3	O
abrogated	O
EndoMT	O
,	O
reduced	O
renal	O
fibrosis	B-Disease
,	O
and	O
retarded	O
progression	O
of	O
nephropathy	B-Disease
.	O
CONCLUSIONS	O
:	O
EndoMT	O
is	O
a	O
novel	O
pathway	O
leading	O
to	O
early	O
development	O
of	O
diabetic	B-Disease
nephropathy	I-Disease
.	O
Blockade	O
of	O
EndoMT	O
by	O
SIS3	O
may	O
provide	O
a	O
new	O
strategy	O
to	O
retard	O
the	O
progression	O
of	O
diabetic	B-Disease
nephropathy	I-Disease
and	O
other	O
diabetes	B-Disease
complications	I-Disease
.	O
Cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
of	O
temsirolimus	B-Chemical
in	O
refractory	O
mantle	B-Disease
cell	I-Disease
lymphoma	I-Disease
.	O
Mantle	B-Disease
cell	I-Disease
lymphoma	I-Disease
(	O
MCL	B-Disease
)	O
is	O
a	O
rare	O
and	O
aggressive	O
type	O
of	O
B	B-Disease
-	I-Disease
cell	I-Disease
non	I-Disease
-	I-Disease
Hodgkin	I-Disease
'	I-Disease
s	I-Disease
lymphoma	I-Disease
.	O
Patients	O
become	O
progressively	O
refractory	O
to	O
conventional	O
chemotherapy	O
,	O
and	O
their	O
prognosis	O
is	O
poor	O
.	O
However	O
,	O
a	O
38	O
%	O
remission	O
rate	O
has	O
been	O
recently	O
reported	O
in	O
refractory	O
MCL	B-Disease
treated	O
with	O
temsirolimus	B-Chemical
,	O
a	O
mTOR	O
inhibitor	O
.	O
Here	O
we	O
had	O
the	O
opportunity	O
to	O
study	O
a	O
case	O
of	O
refractory	O
MCL	B-Disease
who	O
had	O
tumor	B-Disease
regression	O
two	O
months	O
after	O
temsirolimus	B-Chemical
treatment	O
,	O
and	O
a	O
progression	O
-	O
free	O
survival	O
of	O
10	O
months	O
.	O
In	O
this	O
case	O
,	O
lymph	O
node	O
biopsies	O
were	O
performed	O
before	O
and	O
six	O
months	O
after	O
temsirolimus	B-Chemical
therapy	O
.	O
Comparison	O
of	O
the	O
two	O
biopsies	O
showed	O
that	O
temsirolimus	B-Chemical
inhibited	O
tumor	B-Disease
cell	O
proliferation	O
through	O
cell	O
cycle	O
arrest	O
,	O
but	O
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
number	O
of	O
apoptotic	O
tumor	B-Disease
cells	O
.	O
Apart	O
from	O
this	O
cytostatic	O
effect	O
,	O
temsirolimus	B-Chemical
had	O
an	O
antiangiogenic	O
effect	O
with	O
decrease	O
of	O
tumor	B-Disease
microvessel	O
density	O
and	O
of	O
VEGF	O
expression	O
.	O
Moreover	O
,	O
numerous	O
patchy	O
,	O
well	O
-	O
limited	O
fibrotic	O
areas	O
,	O
compatible	O
with	O
post	O
-	O
necrotic	B-Disease
tissue	O
repair	O
,	O
were	O
found	O
after	O
6	O
-	O
month	O
temsirolimus	B-Chemical
therapy	O
.	O
Thus	O
,	O
temsirolimus	B-Chemical
reduced	O
tumor	B-Disease
burden	O
through	O
associated	O
cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
.	O
This	O
dual	O
effect	O
of	O
temsirolimus	B-Chemical
on	O
tumor	B-Disease
tissue	O
could	O
contribute	O
to	O
its	O
recently	O
reported	O
efficiency	O
in	O
refractory	O
MCL	B-Disease
resistant	O
to	O
conventional	O
chemotherapy	O
.	O
Acute	B-Disease
renal	I-Disease
failure	I-Disease
due	O
to	O
rifampicin	B-Chemical
.	O
A	O
23	O
-	O
year	O
-	O
old	O
male	O
patient	O
with	O
bacteriologically	O
proven	O
pulmonary	B-Disease
tuberculosis	I-Disease
was	O
treated	O
with	O
the	O
various	O
regimens	O
of	O
antituberculosis	O
drugs	O
for	O
nearly	O
15	O
months	O
.	O
Rifampicin	B-Chemical
was	O
administered	O
thrice	O
as	O
one	O
of	O
the	O
3	O
-	O
4	O
drug	O
regimen	O
and	O
each	O
time	O
he	O
developed	O
untoward	O
side	O
effects	O
like	O
nausea	B-Disease
,	O
vomiting	B-Disease
and	O
fever	B-Disease
with	O
chills	O
and	O
rigors	O
.	O
The	O
last	O
such	O
episode	O
was	O
of	O
acute	O
renal	O
failure	O
at	O
which	O
stage	O
the	O
patient	O
was	O
seen	O
by	O
the	O
authors	O
of	O
this	O
report	O
.	O
The	O
patient	O
,	O
however	O
,	O
made	O
a	O
full	O
recovery	O
.	O
Syncope	B-Disease
caused	O
by	O
hyperkalemia	B-Disease
during	O
use	O
of	O
a	O
combined	O
therapy	O
with	O
the	O
angiotensin	B-Chemical
-	O
converting	O
enzyme	O
inhibitor	O
and	O
spironolactone	B-Chemical
.	O
A	O
76	O
year	O
-	O
old	O
woman	O
with	O
a	O
history	O
of	O
coronary	O
artery	O
bypass	O
grafting	O
and	O
prior	O
myocardial	B-Disease
infarction	I-Disease
was	O
transferred	O
to	O
the	O
emergency	O
room	O
with	O
loss	B-Disease
of	I-Disease
consciousness	I-Disease
due	O
to	O
marked	O
bradycardia	B-Disease
caused	O
by	O
hyperkalemia	B-Disease
.	O
The	O
concentration	O
of	O
serum	O
potassium	B-Chemical
was	O
high	O
,	O
and	O
normal	O
sinus	O
rhythm	O
was	O
restored	O
after	O
correction	O
of	O
the	O
serum	O
potassium	B-Chemical
level	O
.	O
The	O
cause	O
of	O
hyperkalemia	B-Disease
was	O
considered	O
to	O
be	O
several	O
doses	O
of	O
spiranolactone	B-Chemical
,	O
an	O
aldosterone	B-Chemical
antagonist	O
,	O
in	O
addition	O
to	O
the	O
long	O
-	O
term	O
intake	O
of	O
ramipril	B-Chemical
,	O
an	O
ACE	O
inhibitor	O
.	O
This	O
case	O
is	O
a	O
good	O
example	O
of	O
electrolyte	O
imbalance	O
causing	O
acute	O
life	O
-	O
threatening	O
cardiac	O
events	O
.	O
Clinicians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
hyperkalemia	B-Disease
,	O
especially	O
in	O
elderly	O
patients	O
using	O
ACE	O
/	O
ARB	O
in	O
combination	O
with	O
potassium	B-Chemical
sparing	O
agents	O
and	O
who	O
have	O
mild	O
renal	B-Disease
disturbance	I-Disease
.	O
Diffuse	O
skeletal	O
pain	B-Disease
after	O
administration	O
of	O
alendronate	B-Chemical
.	O
BACKGROUND	O
:	O
Osteoporosis	B-Disease
is	O
caused	O
by	O
bone	O
resorption	O
in	O
excess	O
of	O
bone	O
formation	O
,	O
and	O
bisphosphonates	B-Chemical
,	O
are	O
used	O
to	O
inhibit	O
bone	O
resorption	O
.	O
Alendronate	B-Chemical
,	O
a	O
biphosphonate	B-Chemical
,	O
is	O
effective	O
for	O
both	O
the	O
treatment	O
and	O
prevention	O
of	O
osteoporosis	B-Disease
in	O
postmenopausal	O
women	O
.	O
Side	O
effects	O
are	O
relatively	O
few	O
and	O
prominently	O
gastrointestinal	O
.	O
Musculoskeletal	B-Disease
pain	I-Disease
may	O
be	O
an	O
important	O
side	O
effect	O
in	O
these	O
patients	O
.	O
We	O
presented	O
a	O
patient	O
admitted	O
to	O
our	O
out	O
-	O
patient	O
clinic	O
with	O
diffuse	O
skeletal	O
pain	B-Disease
after	O
three	O
consecutive	O
administration	O
of	O
alendronate	B-Chemical
.	O
CONCLUSION	O
:	O
We	O
conclude	O
that	O
patients	O
with	O
osteoporosis	B-Disease
can	O
report	O
pain	B-Disease
,	O
and	O
bisphosphonate	B-Chemical
-	O
related	O
pain	B-Disease
should	O
also	O
be	O
considered	O
before	O
ascribing	O
this	O
complaint	O
to	O
osteoporosis	B-Disease
.	O
Cerebrospinal	O
fluid	O
penetration	O
of	O
high	O
-	O
dose	O
daptomycin	B-Chemical
in	O
suspected	O
Staphylococcus	O
aureus	O
meningitis	B-Disease
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
methicillin	B-Chemical
-	O
sensitive	O
Staphylococcus	O
aureus	O
(	O
MSSA	O
)	O
bacteremia	B-Disease
with	O
suspected	O
MSSA	O
meningitis	B-Disease
treated	O
with	O
high	O
-	O
dose	O
daptomycin	B-Chemical
assessed	O
with	O
concurrent	O
serum	O
and	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
concentrations	O
.	O
CASE	O
SUMMARY	O
:	O
A	O
54	O
-	O
year	O
-	O
old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
generalized	O
weakness	B-Disease
and	O
presumed	O
health	O
-	O
care	O
-	O
associated	O
pneumonia	B-Disease
shown	O
on	O
chest	O
radiograph	O
.	O
Treatment	O
was	O
empirically	O
initiated	O
with	O
vancomycin	B-Chemical
,	O
levofloxacin	B-Chemical
,	O
and	O
piperacillin	B-Chemical
/	O
tazobactam	B-Chemical
.	O
Blood	O
cultures	O
revealed	O
S	O
.	O
aureus	O
susceptible	O
to	O
oxacillin	B-Chemical
.	O
Empiric	O
antibiotic	O
treatment	O
was	O
narrowed	O
to	O
nafcillin	B-Chemical
on	O
day	O
4	O
.	O
On	O
day	O
8	O
,	O
the	O
patient	O
developed	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
(	O
serum	O
creatinine	B-Chemical
1	O
.	O
9	O
mg	O
/	O
dL	O
,	O
increased	O
from	O
1	O
.	O
2	O
mg	O
/	O
dL	O
the	O
previous	O
day	O
and	O
0	O
.	O
8	O
mg	O
/	O
dL	O
on	O
admission	O
)	O
.	O
The	O
patient	O
'	O
s	O
Glasgow	O
Coma	O
Score	O
was	O
3	O
,	O
with	O
normal	O
findings	O
shown	O
on	O
computed	O
tomography	O
scan	O
of	O
the	O
head	O
72	O
hours	O
following	O
an	O
episode	O
of	O
cardiac	B-Disease
arrest	I-Disease
on	O
day	O
10	O
.	O
The	O
patient	O
experienced	O
relapsing	O
MSSA	O
bacteremia	B-Disease
on	O
day	O
9	O
,	O
increasing	O
the	O
suspicion	O
for	O
a	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
infection	B-Disease
.	O
Nafcillin	B-Chemical
was	O
discontinued	O
and	O
daptomycin	B-Chemical
9	O
mg	O
/	O
kg	O
daily	O
was	O
initiated	O
for	O
suspected	O
meningitis	B-Disease
and	O
was	O
continued	O
until	O
the	O
patient	O
'	O
s	O
death	O
on	O
day	O
16	O
.	O
Daptomycin	B-Chemical
serum	O
and	O
CSF	O
trough	O
concentrations	O
were	O
11	O
.	O
21	O
ug	O
/	O
mL	O
and	O
0	O
.	O
52	O
ug	O
/	O
mL	O
,	O
respectively	O
,	O
prior	O
to	O
the	O
third	O
dose	O
.	O
Lumbar	O
puncture	O
results	O
were	O
inconclusive	O
and	O
no	O
further	O
blood	O
cultures	O
were	O
positive	O
for	O
MSSA	O
.	O
Creatine	B-Chemical
kinase	O
levels	O
were	O
normal	O
prior	O
to	O
daptomycin	B-Chemical
therapy	O
and	O
were	O
not	O
reassessed	O
.	O
DISCUSSION	O
:	O
Daptomycin	B-Chemical
was	O
initiated	O
in	O
our	O
patient	O
secondary	O
to	O
possible	O
nafcillin	B-Chemical
-	O
induced	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
and	O
relapsing	O
bacteremia	B-Disease
.	O
At	O
a	O
dose	O
of	O
9	O
mg	O
/	O
kg	O
,	O
resultant	O
penetration	O
of	O
5	O
%	O
was	O
higher	O
than	O
in	O
previous	O
reports	O
,	O
more	O
consistent	O
with	O
inflamed	O
meninges	O
.	O
CONCLUSIONS	O
:	O
High	O
-	O
dose	O
daptomycin	B-Chemical
may	O
be	O
an	O
alternative	O
option	O
for	O
MSSA	O
bacteremia	B-Disease
with	O
or	O
without	O
a	O
CNS	O
source	O
in	O
patients	O
who	O
have	O
failed	O
or	O
cannot	O
tolerate	O
standard	O
therapy	O
.	O
Further	O
clinical	O
evaluation	O
in	O
patients	O
with	O
confirmed	O
meningitis	B-Disease
is	O
warranted	O
.	O
The	O
role	O
of	O
nitric	B-Chemical
oxide	I-Chemical
in	O
convulsions	B-Disease
induced	O
by	O
lindane	B-Chemical
in	O
rats	O
.	O
Lindane	B-Chemical
is	O
an	O
organochloride	O
pesticide	O
and	O
scabicide	O
.	O
It	O
evokes	O
convulsions	B-Disease
mainly	O
trough	O
the	O
blockage	O
of	O
GABA	B-Chemical
(	O
A	O
)	O
receptors	O
.	O
Nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
,	O
gaseous	O
neurotransmitter	O
,	O
has	O
contradictor	O
role	O
in	O
epileptogenesis	O
due	O
to	O
opposite	O
effects	O
of	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
,	O
precursor	O
of	O
NO	B-Chemical
syntheses	O
(	O
NOS	O
)	O
,	O
and	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
(	O
NOS	O
inhibitor	O
)	O
observed	O
in	O
different	O
epilepsy	B-Disease
models	O
.	O
The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
NO	B-Chemical
on	O
the	O
behavioral	O
and	O
EEG	O
characteristics	O
of	O
lindane	B-Chemical
-	O
induced	O
epilepsy	B-Disease
in	O
male	O
Wistar	O
albino	O
rats	O
.	O
The	O
administration	O
of	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
(	O
600	O
,	O
800	O
and	O
1000	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
in	O
dose	O
-	O
dependent	O
manner	O
significantly	O
increased	O
convulsion	B-Disease
incidence	O
and	O
severity	O
and	O
shortened	O
latency	O
time	O
to	O
first	O
convulsion	B-Disease
elicited	O
by	O
lower	O
lindane	B-Chemical
dose	O
(	O
4	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O
On	O
the	O
contrary	O
,	O
pretreatment	O
with	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
(	O
500	O
,	O
700	O
and	O
900	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
decreased	O
convulsion	B-Disease
incidence	O
and	O
severity	O
and	O
prolonged	O
latency	O
time	O
to	O
convulsion	B-Disease
following	O
injection	O
with	O
a	O
convulsive	B-Disease
dose	O
of	O
lindane	B-Chemical
(	O
8	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O
EEG	O
analyses	O
showed	O
increase	O
of	O
number	O
and	O
duration	O
of	O
ictal	O
periods	O
in	O
EEG	O
of	O
rats	O
receiving	O
l	B-Chemical
-	I-Chemical
arginine	I-Chemical
prior	O
to	O
lindane	B-Chemical
and	O
decrease	O
of	O
this	O
number	O
in	O
rats	O
pretreated	O
with	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
.	O
These	O
results	O
support	O
the	O
conclusion	O
that	O
NO	B-Chemical
plays	O
a	O
role	O
of	O
endogenous	O
convulsant	O
in	O
rat	O
model	O
of	O
lindane	B-Chemical
seizures	B-Disease
.	O
Severe	O
polyneuropathy	B-Disease
and	O
motor	O
loss	O
after	O
intrathecal	O
thiotepa	B-Chemical
combination	O
chemotherapy	O
:	O
description	O
of	O
two	O
cases	O
.	O
Two	O
cases	O
of	O
severe	O
delayed	O
neurologic	B-Disease
toxicity	I-Disease
related	O
to	O
the	O
administration	O
of	O
intrathecal	O
(	O
IT	O
)	O
combination	O
chemotherapy	O
including	O
thiotepa	B-Chemical
(	O
TSPA	B-Chemical
)	O
are	O
presented	O
.	O
Both	O
cases	O
developed	O
axonal	B-Disease
neuropathy	I-Disease
with	O
motor	O
predominance	O
in	O
the	O
lower	O
extremities	O
1	O
and	O
6	O
months	O
after	O
IT	O
chemotherapy	O
was	O
administered	O
.	O
Neurologic	B-Disease
toxicities	I-Disease
have	O
been	O
described	O
with	O
IT	O
-	O
methotrexate	B-Chemical
,	O
IT	O
-	O
cytosine	B-Chemical
arabinoside	I-Chemical
and	O
IT	O
-	O
TSPA	B-Chemical
.	O
To	O
our	O
knowledge	O
,	O
however	O
,	O
axonal	B-Disease
neuropathy	I-Disease
following	O
administration	O
of	O
these	O
three	O
agents	O
has	O
not	O
been	O
previously	O
described	O
.	O
In	O
spite	O
of	O
the	O
fact	O
that	O
TSPA	B-Chemical
is	O
a	O
useful	O
IT	O
agent	O
,	O
its	O
combination	O
with	O
MTX	B-Chemical
,	O
ara	B-Chemical
-	I-Chemical
C	I-Chemical
and	O
radiotherapy	O
could	O
cause	O
severe	O
neurotoxicity	B-Disease
.	O
This	O
unexpected	O
complication	O
indicates	O
the	O
need	O
for	O
further	O
toxicology	O
research	O
on	O
IT	O
-	O
TSPA	B-Chemical
.	O
Effects	O
of	O
cromakalim	B-Chemical
and	O
pinacidil	B-Chemical
on	O
large	O
epicardial	O
and	O
small	O
coronary	O
arteries	O
in	O
conscious	O
dogs	O
.	O
The	O
effects	O
of	O
i	O
.	O
v	O
.	O
bolus	O
administration	O
of	O
cromakalim	B-Chemical
(	O
1	O
-	O
10	O
micrograms	O
/	O
kg	O
)	O
and	O
pinacidil	B-Chemical
(	O
3	O
-	O
100	O
micrograms	O
/	O
kg	O
)	O
on	O
large	O
(	O
circumflex	O
artery	O
)	O
and	O
small	O
coronary	O
arteries	O
and	O
on	O
systemic	O
hemodynamics	O
were	O
investigated	O
in	O
chronically	O
instrumented	O
conscious	O
dogs	O
and	O
compared	O
to	O
those	O
of	O
nitroglycerin	B-Chemical
(	O
0	O
.	O
03	O
-	O
10	O
micrograms	O
/	O
kg	O
)	O
.	O
Nitroglycerin	B-Chemical
,	O
up	O
to	O
0	O
.	O
3	O
micrograms	O
/	O
kg	O
,	O
selectively	O
increased	O
circumflex	O
artery	O
diameter	O
(	O
CxAD	O
)	O
without	O
simultaneously	O
affecting	O
any	O
other	O
cardiac	O
or	O
systemic	O
hemodynamic	O
parameter	O
.	O
In	O
contrast	O
,	O
cromakalim	B-Chemical
and	O
pinacidil	B-Chemical
at	O
all	O
doses	O
and	O
nitroglycerin	B-Chemical
at	O
doses	O
higher	O
than	O
0	O
.	O
3	O
micrograms	O
/	O
kg	O
simultaneously	O
and	O
dose	O
-	O
dependently	O
increased	O
CxAD	O
,	O
coronary	O
blood	O
flow	O
and	O
heart	O
rate	O
and	O
decreased	O
coronary	O
vascular	O
resistance	O
and	O
aortic	O
pressure	O
.	O
Cromakalim	B-Chemical
was	O
approximately	O
8	O
-	O
to	O
9	O
.	O
5	O
-	O
fold	O
more	O
potent	O
than	O
pinacidil	B-Chemical
in	O
increasing	O
CxAD	O
.	O
Vasodilation	O
of	O
large	O
and	O
small	O
coronary	O
vessels	O
and	O
hypotension	B-Disease
induced	O
by	O
cromakalim	B-Chemical
and	O
pinacidil	B-Chemical
were	O
not	O
affected	O
by	O
prior	O
combined	O
beta	B-Chemical
adrenergic	I-Chemical
and	I-Chemical
muscarinic	I-Chemical
receptors	I-Chemical
blockade	I-Chemical
but	O
drug	O
-	O
induced	O
tachycardia	B-Disease
was	O
abolished	O
.	O
When	O
circumflex	O
artery	O
blood	O
flow	O
was	O
maintained	O
constant	O
,	O
the	O
increases	O
in	O
CxAD	O
induced	O
by	O
cromakalim	B-Chemical
(	O
10	O
micrograms	O
/	O
kg	O
)	O
,	O
pinacidil	B-Chemical
(	O
30	O
micrograms	O
/	O
kg	O
)	O
and	O
nitroglycerin	B-Chemical
(	O
10	O
micrograms	O
/	O
kg	O
)	O
were	O
reduced	O
by	O
68	O
+	O
/	O
-	O
7	O
,	O
54	O
+	O
/	O
-	O
9	O
and	O
1	O
+	O
/	O
-	O
1	O
%	O
,	O
respectively	O
.	O
Thus	O
,	O
whereas	O
nitroglycerin	B-Chemical
preferentially	O
and	O
flow	O
-	O
independently	O
dilates	O
large	O
coronary	O
arteries	O
,	O
cromakalim	B-Chemical
and	O
pinacidil	B-Chemical
dilate	O
both	O
large	O
and	O
small	O
coronary	O
arteries	O
and	O
this	O
effect	O
is	O
not	O
dependent	O
upon	O
the	O
simultaneous	O
beta	O
adrenoceptors	O
-	O
mediated	O
rise	O
in	O
myocardial	O
metabolic	O
demand	O
.	O
Finally	O
,	O
two	O
mechanisms	O
at	O
least	O
,	O
direct	O
vasodilation	O
and	O
flow	O
dependency	O
,	O
are	O
involved	O
in	O
the	O
cromakalim	B-Chemical
-	O
and	O
pinacidil	B-Chemical
-	O
induced	O
increase	O
in	O
CxAD	O
.	O
Mefenamic	B-Chemical
acid	I-Chemical
-	O
induced	O
neutropenia	B-Disease
and	O
renal	B-Disease
failure	I-Disease
in	O
elderly	O
females	O
with	O
hypothyroidism	B-Disease
.	O
We	O
report	O
mefenamic	B-Chemical
acid	I-Chemical
-	O
induced	O
non	O
-	O
oliguric	O
renal	B-Disease
failure	I-Disease
and	O
severe	O
neutropenia	B-Disease
occurring	O
simultaneously	O
in	O
two	O
elderly	O
females	O
.	O
The	O
neutropenia	B-Disease
was	O
due	O
to	O
maturation	O
arrest	O
of	O
the	O
myeloid	O
series	O
in	O
one	O
patient	O
.	O
Both	O
patients	O
were	O
also	O
hypothyroid	B-Disease
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
was	O
a	O
predisposing	O
factor	O
to	O
the	O
development	O
of	O
these	O
adverse	O
reactions	O
.	O
However	O
,	O
it	O
would	O
seem	O
prudent	O
not	O
to	O
use	O
mefenamic	B-Chemical
acid	I-Chemical
in	O
hypothyroid	B-Disease
patients	O
until	O
the	O
hypothyroidism	B-Disease
has	O
been	O
corrected	O
.	O
Etiology	O
of	O
hypercalcemia	B-Disease
in	O
hemodialysis	O
patients	O
on	O
calcium	B-Chemical
carbonate	I-Chemical
therapy	O
.	O
Fourteen	O
of	O
39	O
dialysis	O
patients	O
(	O
36	O
%	O
)	O
became	O
hypercalcemic	B-Disease
after	O
switching	O
to	O
calcium	B-Chemical
carbonate	I-Chemical
as	O
their	O
principal	O
phosphate	B-Chemical
binder	O
.	O
In	O
order	O
to	O
identify	O
risk	O
factors	O
associated	O
with	O
the	O
development	O
of	O
hypercalcemia	B-Disease
,	O
indirect	O
parameters	O
of	O
intestinal	O
calcium	B-Chemical
reabsorption	O
and	O
bone	O
turnover	O
rate	O
in	O
these	O
14	O
patients	O
were	O
compared	O
with	O
results	O
in	O
14	O
eucalcemic	O
patients	O
matched	O
for	O
age	O
,	O
sex	O
,	O
length	O
of	O
time	O
on	O
dialysis	O
,	O
and	O
etiology	O
of	O
renal	B-Disease
disease	I-Disease
.	O
In	O
addition	O
to	O
experiencing	O
hypercalcemic	B-Disease
episodes	O
with	O
peak	O
calcium	B-Chemical
values	O
of	O
2	O
.	O
7	O
to	O
3	O
.	O
8	O
mmol	O
/	O
L	O
(	O
10	O
.	O
7	O
to	O
15	O
.	O
0	O
mg	O
/	O
dL	O
)	O
,	O
patients	O
in	O
the	O
hypercalcemic	B-Disease
group	O
exhibited	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
calcium	B-Chemical
concentration	O
obtained	O
during	O
6	O
months	O
before	O
the	O
switch	O
,	O
compared	O
with	O
the	O
mean	O
value	O
obtained	O
during	O
the	O
7	O
months	O
of	O
observation	O
after	O
the	O
switch	O
(	O
2	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
03	O
to	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
03	O
mmol	O
/	O
L	O
[	O
9	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
2	O
to	O
10	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
1	O
mg	O
/	O
dL	O
]	O
,	O
P	O
=	O
0	O
.	O
006	O
)	O
.	O
In	O
contrast	O
,	O
eucalcemic	O
patients	O
exhibited	O
no	O
change	O
in	O
mean	O
calcium	B-Chemical
values	O
over	O
the	O
same	O
time	O
period	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
05	O
to	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
05	O
mmol	O
/	O
L	O
[	O
9	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
to	O
9	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
mg	O
/	O
dL	O
]	O
)	O
.	O
CaCO3	B-Chemical
dosage	O
,	O
calculated	O
dietary	O
calcium	B-Chemical
intake	O
,	O
and	O
circulating	O
levels	O
of	O
vitamin	B-Chemical
D	I-Chemical
metabolites	O
were	O
similar	O
in	O
both	O
groups	O
.	O
Physical	O
activity	O
index	O
and	O
predialysis	O
serum	O
bicarbonate	B-Chemical
levels	O
also	O
were	O
similar	O
in	O
both	O
groups	O
.	O
However	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
parameters	O
reflecting	O
bone	O
turnover	O
rates	O
between	O
groups	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Late	O
-	O
onset	O
scleroderma	B-Disease
renal	I-Disease
crisis	I-Disease
induced	O
by	O
tacrolimus	B-Chemical
and	O
prednisolone	B-Chemical
:	O
a	O
case	O
report	O
.	O
Scleroderma	B-Disease
renal	I-Disease
crisis	I-Disease
(	O
SRC	B-Disease
)	O
is	O
a	O
rare	O
complication	O
of	O
systemic	B-Disease
sclerosis	I-Disease
(	O
SSc	B-Disease
)	O
but	O
can	O
be	O
severe	O
enough	O
to	O
require	O
temporary	O
or	O
permanent	O
renal	O
replacement	O
therapy	O
.	O
Moderate	O
to	O
high	O
dose	O
corticosteroid	B-Chemical
use	O
is	O
recognized	O
as	O
a	O
major	O
risk	O
factor	O
for	O
SRC	B-Disease
.	O
Furthermore	O
,	O
there	O
have	O
been	O
reports	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
precipitated	O
by	O
cyclosporine	B-Chemical
in	O
patients	O
with	O
SSc	B-Disease
.	O
In	O
this	O
article	O
,	O
we	O
report	O
a	O
patient	O
with	O
SRC	B-Disease
induced	O
by	O
tacrolimus	B-Chemical
and	O
corticosteroids	B-Chemical
.	O
The	O
aim	O
of	O
this	O
work	O
is	O
to	O
call	O
attention	O
to	O
the	O
risk	O
of	O
tacrolimus	B-Chemical
use	O
in	O
patients	O
with	O
SSc	B-Disease
.	O
Methyldopa	B-Chemical
-	O
induced	O
hemolytic	B-Disease
anemia	I-Disease
in	O
a	O
15	O
year	O
old	O
presenting	O
as	O
near	O
-	O
syncope	B-Disease
.	O
Methyldopa	B-Chemical
is	O
an	O
antihypertensive	O
medication	O
which	O
is	O
available	O
generically	O
and	O
under	O
the	O
trade	O
name	O
Aldomet	B-Chemical
that	O
is	O
widely	O
prescribed	O
in	O
the	O
adult	O
population	O
and	O
infrequently	O
used	O
in	O
children	O
.	O
Methyldopa	B-Chemical
causes	O
an	O
autoimmune	B-Disease
hemolytic	I-Disease
anemia	I-Disease
in	O
a	O
small	O
percentage	O
of	O
patients	O
who	O
take	O
the	O
drug	O
.	O
We	O
report	O
a	O
case	O
of	O
methyldopa	B-Chemical
-	O
induced	O
hemolytic	B-Disease
anemia	I-Disease
in	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
who	O
presented	O
to	O
the	O
emergency	B-Disease
department	I-Disease
with	O
near	O
-	O
syncope	B-Disease
.	O
The	O
boy	O
had	O
been	O
treated	O
with	O
intravenous	O
methyldopa	B-Chemical
during	O
a	O
trauma	B-Disease
admission	O
seven	O
weeks	O
prior	O
to	O
presentation	O
.	O
Evaluation	O
revealed	O
a	O
hemoglobin	O
of	O
three	O
grams	O
,	O
3	O
+	O
Coombs	O
'	O
test	O
with	O
polyspecific	O
anti	O
-	O
human	O
globulin	O
and	O
monospecific	O
IgG	O
reagents	O
,	O
and	O
a	O
warm	O
reacting	O
autoantibody	O
.	O
Transfusion	O
and	O
corticosteroid	B-Chemical
therapy	O
resulted	O
in	O
a	O
complete	O
recovery	O
of	O
the	O
patient	O
.	O
Emergency	O
physicians	O
treating	O
children	O
must	O
be	O
aware	O
of	O
this	O
syndrome	O
in	O
order	O
to	O
diagnose	O
and	O
treat	O
it	O
correctly	O
.	O
A	O
brief	O
review	O
of	O
autoimmune	O
and	O
drug	O
-	O
induced	O
hemolytic	B-Disease
anemias	I-Disease
is	O
provided	O
.	O
The	O
risk	O
and	O
associated	O
factors	O
of	O
methamphetamine	B-Chemical
psychosis	B-Disease
in	O
methamphetamine	B-Chemical
-	O
dependent	O
patients	O
in	O
Malaysia	O
.	O
OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
risk	O
of	O
lifetime	O
and	O
current	O
methamphetamine	B-Chemical
-	O
induced	O
psychosis	B-Disease
in	O
patients	O
with	O
methamphetamine	B-Chemical
dependence	O
.	O
The	O
association	O
between	O
psychiatric	O
co	O
-	O
morbidity	O
and	O
methamphetamine	B-Chemical
-	O
induced	O
psychosis	B-Disease
was	O
also	O
studied	O
.	O
METHODS	O
:	O
This	O
was	O
a	O
cross	O
-	O
sectional	O
study	O
conducted	O
concurrently	O
at	O
a	O
teaching	O
hospital	O
and	O
a	O
drug	O
rehabilitation	O
center	O
in	O
Malaysia	O
.	O
Patients	O
with	O
the	O
diagnosis	O
of	O
methamphetamine	B-Chemical
based	O
on	O
DSM	O
-	O
IV	O
were	O
interviewed	O
using	O
the	O
Mini	O
International	O
Neuropsychiatric	O
Interview	O
(	O
M	O
.	O
I	O
.	O
N	O
.	O
I	O
.	O
)	O
for	O
methamphetamine	B-Chemical
-	O
induced	O
psychosis	B-Disease
and	O
other	O
Axis	O
I	O
psychiatric	B-Disease
disorders	I-Disease
.	O
The	O
information	O
on	O
sociodemographic	O
background	O
and	O
drug	O
use	O
history	O
was	O
obtained	O
from	O
interview	O
or	O
medical	O
records	O
.	O
RESULTS	O
:	O
Of	O
292	O
subjects	O
,	O
47	O
.	O
9	O
%	O
of	O
the	O
subjects	O
had	O
a	O
past	O
history	O
of	O
psychotic	B-Disease
symptoms	I-Disease
and	O
13	O
.	O
0	O
%	O
of	O
the	O
patients	O
were	O
having	O
current	O
psychotic	B-Disease
symptoms	I-Disease
.	O
Co	O
-	O
morbid	O
major	O
depressive	B-Disease
disorder	I-Disease
(	O
OR	O
=	O
7	O
.	O
18	O
,	O
95	O
CI	O
=	O
2	O
.	O
612	O
-	O
19	O
.	O
708	O
)	O
,	O
bipolar	B-Disease
disorder	I-Disease
(	O
OR	O
=	O
13	O
.	O
807	O
,	O
95	O
CI	O
=	O
5	O
.	O
194	O
-	O
36	O
.	O
706	O
)	O
,	O
antisocial	B-Disease
personality	I-Disease
disorder	I-Disease
(	O
OR	O
=	O
12	O
.	O
619	O
,	O
95	O
CI	O
=	O
6	O
.	O
702	O
-	O
23	O
.	O
759	O
)	O
and	O
heavy	O
methamphetamine	B-Chemical
uses	O
were	O
significantly	O
associated	O
with	O
lifetime	O
methamphetamine	B-Chemical
-	O
induced	O
psychosis	B-Disease
after	O
adjusted	O
for	O
other	O
factors	O
.	O
Major	B-Disease
depressive	I-Disease
disorder	I-Disease
(	O
OR	O
=	O
2	O
.	O
870	O
,	O
CI	O
=	O
1	O
.	O
154	O
-	O
7	O
.	O
142	O
)	O
and	O
antisocial	B-Disease
personality	I-Disease
disorder	I-Disease
(	O
OR	O
=	O
3	O
.	O
299	O
,	O
95	O
CI	O
=	O
1	O
.	O
375	O
-	O
7	O
.	O
914	O
)	O
were	O
the	O
only	O
factors	O
associated	O
with	O
current	O
psychosis	B-Disease
.	O
CONCLUSION	O
:	O
There	O
was	O
a	O
high	O
risk	O
of	O
psychosis	B-Disease
in	O
patients	O
with	O
methamphetamine	B-Chemical
dependence	O
.	O
It	O
was	O
associated	O
with	O
co	O
-	O
morbid	O
affective	B-Disease
disorder	I-Disease
,	O
antisocial	B-Disease
personality	I-Disease
,	O
and	O
heavy	O
methamphetamine	B-Chemical
use	O
.	O
It	O
is	O
recommended	O
that	O
all	O
cases	O
of	O
methamphetamine	B-Chemical
dependence	O
should	O
be	O
screened	O
for	O
psychotic	B-Disease
symptoms	I-Disease
.	O
Cerebellar	O
sensory	O
processing	O
alterations	O
impact	O
motor	O
cortical	O
plasticity	O
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
:	O
clues	O
from	O
dyskinetic	B-Disease
patients	O
.	O
The	O
plasticity	O
of	O
primary	O
motor	O
cortex	O
(	O
M1	O
)	O
in	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
and	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
(	O
LIDs	B-Disease
)	O
is	O
severely	O
impaired	O
.	O
We	O
recently	O
reported	O
in	O
young	O
healthy	O
subjects	O
that	O
inhibitory	O
cerebellar	O
stimulation	O
enhanced	O
the	O
sensorimotor	O
plasticity	O
of	O
M1	O
that	O
was	O
induced	O
by	O
paired	O
associative	O
stimulation	O
(	O
PAS	O
)	O
.	O
This	O
study	O
demonstrates	O
that	O
the	O
deficient	O
sensorimotor	O
M1	O
plasticity	O
in	O
16	O
patients	O
with	O
LIDs	B-Disease
could	O
be	O
reinstated	O
by	O
a	O
single	O
session	O
of	O
real	O
inhibitory	O
cerebellar	O
stimulation	O
but	O
not	O
sham	O
stimulation	O
.	O
This	O
was	O
evident	O
only	O
when	O
a	O
sensory	O
component	O
was	O
involved	O
in	O
the	O
induction	O
of	O
plasticity	O
,	O
indicating	O
that	O
cerebellar	O
sensory	O
processing	O
function	O
is	O
involved	O
in	O
the	O
resurgence	O
of	O
M1	O
plasticity	O
.	O
The	O
benefit	O
of	O
inhibitory	O
cerebellar	O
stimulation	O
on	O
LIDs	B-Disease
is	O
known	O
.	O
To	O
explore	O
whether	O
this	O
benefit	O
is	O
linked	O
to	O
the	O
restoration	O
of	O
sensorimotor	O
plasticity	O
of	O
M1	O
,	O
we	O
conducted	O
an	O
additional	O
study	O
looking	O
at	O
changes	O
in	O
LIDs	B-Disease
and	O
PAS	O
-	O
induced	O
plasticity	O
after	O
10	O
sessions	O
of	O
either	O
bilateral	O
,	O
real	O
inhibitory	O
cerebellar	O
stimulation	O
or	O
sham	O
stimulation	O
.	O
Only	O
real	O
and	O
not	O
sham	O
stimulation	O
had	O
an	O
antidyskinetic	O
effect	O
and	O
it	O
was	O
paralleled	O
by	O
a	O
resurgence	O
in	O
the	O
sensorimotor	O
plasticity	O
of	O
M1	O
.	O
These	O
results	O
suggest	O
that	O
alterations	O
in	O
cerebellar	O
sensory	O
processing	O
function	O
,	O
occurring	O
secondary	O
to	O
abnormal	O
basal	O
ganglia	O
signals	O
reaching	O
it	O
,	O
may	O
be	O
an	O
important	O
element	O
contributing	O
to	O
the	O
maladaptive	O
sensorimotor	O
plasticity	O
of	O
M1	O
and	O
the	O
emergence	O
of	O
abnormal	B-Disease
involuntary	I-Disease
movements	I-Disease
.	O
The	O
long	O
-	O
term	O
safety	O
of	O
danazol	B-Chemical
in	O
women	O
with	O
hereditary	B-Disease
angioedema	I-Disease
.	O
Although	O
the	O
short	O
-	O
term	O
safety	O
(	O
less	O
than	O
or	O
equal	O
to	O
6	O
months	O
)	O
of	O
danazol	B-Chemical
has	O
been	O
established	O
in	O
a	O
variety	O
of	O
settings	O
,	O
no	O
information	O
exists	O
as	O
to	O
its	O
long	O
-	O
term	O
safety	O
.	O
We	O
therefore	O
investigated	O
the	O
long	O
-	O
term	O
safety	O
of	O
danazol	B-Chemical
by	O
performing	O
a	O
retrospective	O
chart	O
review	O
of	O
60	O
female	O
patients	O
with	O
hereditary	B-Disease
angioedema	I-Disease
treated	O
with	O
danazol	B-Chemical
for	O
a	O
continuous	O
period	O
of	O
6	O
months	O
or	O
longer	O
.	O
The	O
mean	O
age	O
of	O
the	O
patients	O
was	O
35	O
.	O
2	O
years	O
and	O
the	O
mean	O
duration	O
of	O
therapy	O
was	O
59	O
.	O
7	O
months	O
.	O
Virtually	O
all	O
patients	O
experienced	O
one	O
or	O
more	O
adverse	O
reactions	O
.	O
Menstrual	B-Disease
abnormalities	I-Disease
(	O
79	O
%	O
)	O
,	O
weight	B-Disease
gain	I-Disease
(	O
60	O
%	O
)	O
,	O
muscle	B-Disease
cramps	I-Disease
/	O
myalgias	B-Disease
(	O
40	O
%	O
)	O
,	O
and	O
transaminase	O
elevations	O
(	O
40	O
%	O
)	O
were	O
the	O
most	O
common	O
adverse	O
reactions	O
.	O
The	O
drug	O
was	O
discontinued	O
due	O
to	O
adverse	O
reactions	O
in	O
8	O
patients	O
.	O
No	O
patient	O
has	O
died	O
or	O
suffered	O
any	O
apparent	O
long	O
-	O
term	O
sequelae	O
that	O
were	O
directly	O
attributable	O
to	O
the	O
drug	O
.	O
We	O
conclude	O
that	O
,	O
despite	O
a	O
relatively	O
high	O
incidence	O
of	O
adverse	O
reactions	O
,	O
danazol	B-Chemical
has	O
proven	O
to	O
be	O
remarkably	O
safe	O
over	O
the	O
long	O
-	O
term	O
in	O
this	O
group	O
of	O
patients	O
.	O
The	O
function	O
of	O
P2X3	O
receptor	O
and	O
NK1	O
receptor	O
antagonists	O
on	O
cyclophosphamide	B-Chemical
-	O
induced	O
cystitis	B-Disease
in	O
rats	O
.	O
PURPOSE	O
:	O
The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
explore	O
the	O
function	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
antagonists	O
on	O
cyclophosphamide	B-Chemical
(	O
CYP	B-Chemical
)	O
-	O
induced	O
cystitis	B-Disease
in	O
rats	O
.	O
METHODS	O
:	O
Sixty	O
female	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
.	O
The	O
rats	O
in	O
the	O
control	O
group	O
were	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
injected	O
with	O
0	O
.	O
9	O
%	O
saline	O
(	O
4	O
ml	O
/	O
kg	O
)	O
;	O
the	O
rats	O
in	O
the	O
model	O
group	O
were	O
i	O
.	O
p	O
.	O
injected	O
with	O
CYP	B-Chemical
(	O
150	O
mg	O
/	O
kg	O
)	O
;	O
and	O
the	O
rats	O
in	O
the	O
intervention	O
group	O
were	O
i	O
.	O
p	O
.	O
injected	O
with	O
CYP	B-Chemical
with	O
subsequently	O
perfusion	O
of	O
bladder	O
with	O
P2X3	O
and	O
NK1	O
receptors	O
'	O
antagonists	O
,	O
Suramin	B-Chemical
and	O
GR	B-Chemical
82334	I-Chemical
.	O
Spontaneous	O
pain	B-Disease
behaviors	O
following	O
the	O
administration	O
of	O
CYP	B-Chemical
were	O
observed	O
.	O
Urodynamic	O
parameters	O
,	O
bladder	O
pressure	O
-	O
volume	O
curve	O
,	O
maximum	O
voiding	O
pressure	O
(	O
MVP	O
)	O
,	O
and	O
maximum	O
cystometric	O
capacity	O
(	O
MCC	O
)	O
,	O
were	O
recorded	O
.	O
Pathological	O
changes	O
in	O
bladder	O
tissue	O
were	O
observed	O
.	O
Immunofluorescence	O
was	O
used	O
to	O
detect	O
the	O
expression	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
in	O
bladder	O
.	O
RESULTS	O
:	O
Cyclophosphamide	B-Chemical
treatment	O
increased	O
the	O
spontaneous	O
pain	B-Disease
behaviors	O
scores	O
.	O
The	O
incidence	O
of	O
bladder	O
instability	O
during	O
urine	O
storage	O
period	O
of	O
model	O
group	O
was	O
significantly	O
higher	O
than	O
intervention	O
group	O
(	O
X	O
(	O
2	O
)	O
=	O
7	O
.	O
619	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
and	O
control	O
group	O
(	O
X	O
(	O
2	O
)	O
=	O
13	O
.	O
755	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
.	O
MCC	O
in	O
the	O
model	O
group	O
was	O
lower	O
than	O
the	O
control	O
and	O
intervention	O
groups	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
Histological	O
changes	O
evident	O
in	O
model	O
and	O
intervention	O
groups	O
rats	O
'	O
bladder	O
included	O
edema	B-Disease
,	O
vasodilation	O
,	O
and	O
infiltration	O
of	O
inflammatory	O
cells	O
.	O
In	O
model	O
group	O
,	O
the	O
expression	O
of	O
P2X3	O
receptor	O
increased	O
in	O
urothelium	O
and	O
suburothelium	O
,	O
and	O
NK1	O
receptor	O
increased	O
in	O
suburothelium	O
,	O
while	O
the	O
expression	O
of	O
them	O
in	O
intervention	O
group	O
was	O
lower	O
.	O
CONCLUSIONS	O
:	O
In	O
CYP	B-Chemical
-	O
induced	O
cystitis	B-Disease
,	O
the	O
expression	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
increased	O
in	O
urothelium	O
and	O
/	O
or	O
suburothelium	O
.	O
Perfusion	O
of	O
bladder	O
with	O
P2X3	O
and	O
NK1	O
receptors	O
antagonists	O
ameliorated	O
the	O
bladder	O
function	O
.	O
Patient	O
tolerance	O
study	O
of	O
topical	O
chlorhexidine	B-Chemical
diphosphanilate	I-Chemical
:	O
a	O
new	O
topical	O
agent	O
for	O
burns	B-Disease
.	O
Effective	O
topical	O
antimicrobial	O
agents	O
decrease	O
infection	B-Disease
and	O
mortality	O
in	O
burn	B-Disease
patients	O
.	O
Chlorhexidine	B-Chemical
phosphanilate	I-Chemical
(	O
CHP	B-Chemical
)	O
,	O
a	O
new	O
broad	O
-	O
spectrum	O
antimicrobial	O
agent	O
,	O
has	O
been	O
evaluated	O
as	O
a	O
topical	O
burn	B-Disease
wound	O
dressing	O
in	O
cream	O
form	O
,	O
but	O
preliminary	O
clinical	O
trials	O
reported	O
that	O
it	O
was	O
painful	O
upon	O
application	O
.	O
This	O
study	O
compared	O
various	O
concentrations	O
of	O
CHP	B-Chemical
to	O
determine	O
if	O
a	O
tolerable	O
concentration	O
could	O
be	O
identified	O
with	O
retention	O
of	O
antimicrobial	O
efficacy	O
.	O
Twenty	O
-	O
nine	O
burn	B-Disease
patients	O
,	O
each	O
with	O
two	O
similar	O
burns	B-Disease
which	O
could	O
be	O
separately	O
treated	O
,	O
were	O
given	O
pairs	O
of	O
treatments	O
at	O
successive	O
12	O
-	O
h	O
intervals	O
over	O
a	O
3	O
-	O
day	O
period	O
.	O
One	O
burn	B-Disease
site	O
was	O
treated	O
with	O
each	O
of	O
four	O
different	O
CHP	B-Chemical
concentrations	O
,	O
from	O
0	O
.	O
25	O
per	O
cent	O
to	O
2	O
per	O
cent	O
,	O
their	O
vehicle	O
,	O
and	O
1	O
per	O
cent	O
silver	B-Chemical
sulphadiazine	I-Chemical
(	O
AgSD	B-Chemical
)	O
cream	O
,	O
an	O
antimicrobial	O
agent	O
frequently	O
used	O
for	O
topical	O
treatment	O
of	O
burn	B-Disease
wounds	O
.	O
The	O
other	O
site	O
was	O
always	O
treated	O
with	O
AgSD	B-Chemical
cream	O
.	O
There	O
was	O
a	O
direct	O
relationship	O
between	O
CHP	B-Chemical
concentration	O
and	O
patients	O
'	O
ratings	O
of	O
pain	B-Disease
on	O
an	O
analogue	O
scale	O
.	O
The	O
0	O
.	O
25	O
per	O
cent	O
CHP	B-Chemical
cream	O
was	O
closest	O
to	O
AgSD	B-Chemical
in	O
pain	B-Disease
tolerance	O
;	O
however	O
,	O
none	O
of	O
the	O
treatments	O
differed	O
statistically	O
from	O
AgSD	B-Chemical
or	O
from	O
each	O
other	O
.	O
In	O
addition	O
,	O
ease	O
of	O
application	O
of	O
CHP	B-Chemical
creams	O
was	O
less	O
satisfactory	O
than	O
that	O
of	O
AgSD	B-Chemical
.	O
It	O
was	O
concluded	O
that	O
formulations	O
at	O
or	O
below	O
0	O
.	O
5	O
per	O
cent	O
CHP	B-Chemical
may	O
prove	O
acceptable	O
for	O
wound	O
care	O
,	O
but	O
the	O
vehicle	O
system	O
needs	O
pharmaceutical	O
improvement	O
to	O
render	O
it	O
more	O
tolerable	O
and	O
easier	O
to	O
use	O
.	O
Acute	O
hepatitis	B-Disease
associated	O
with	O
clopidogrel	B-Chemical
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O
Drug	O
-	O
induced	O
hepatotoxicity	B-Disease
is	O
a	O
common	O
cause	O
of	O
acute	O
hepatitis	B-Disease
,	O
and	O
the	O
recognition	O
of	O
the	O
responsible	O
drug	O
may	O
be	O
difficult	O
.	O
We	O
describe	O
a	O
case	O
of	O
clopidogrel	B-Chemical
-	O
related	O
acute	O
hepatitis	B-Disease
.	O
The	O
diagnosis	O
is	O
strongly	O
suggested	O
by	O
an	O
accurate	O
medical	O
history	O
and	O
liver	O
biopsy	O
.	O
Reports	O
about	O
cases	O
of	O
hepatotoxicity	B-Disease
due	O
to	O
clopidogrel	B-Chemical
are	O
increasing	O
in	O
the	O
last	O
few	O
years	O
,	O
after	O
the	O
increased	O
use	O
of	O
this	O
drug	O
.	O
In	O
conclusion	O
,	O
we	O
believe	O
that	O
physicians	O
should	O
carefully	O
consider	O
the	O
risk	O
of	O
drug	O
-	O
induced	O
hepatic	B-Disease
injury	I-Disease
when	O
clopidogrel	B-Chemical
is	O
prescribed	O
.	O
Bortezomib	B-Chemical
and	O
dexamethasone	B-Chemical
as	O
salvage	O
therapy	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	B-Disease
myeloma	I-Disease
:	O
analysis	O
of	O
long	O
-	O
term	O
clinical	O
outcomes	O
.	O
Bortezomib	B-Chemical
(	O
bort	B-Chemical
)	O
-	O
dexamethasone	B-Chemical
(	O
dex	B-Chemical
)	O
is	O
an	O
effective	O
therapy	O
for	O
relapsed	O
/	O
refractory	O
(	O
R	O
/	O
R	O
)	O
multiple	B-Disease
myeloma	I-Disease
(	O
MM	B-Disease
)	O
.	O
This	O
retrospective	O
study	O
investigated	O
the	O
combination	O
of	O
bort	B-Chemical
(	O
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
every	O
3	O
weeks	O
)	O
and	O
dex	B-Chemical
(	O
20	O
mg	O
on	O
the	O
day	O
of	O
and	O
the	O
day	O
after	O
bort	B-Chemical
)	O
as	O
salvage	O
treatment	O
in	O
85	O
patients	O
with	O
R	O
/	O
R	O
MM	B-Disease
after	O
prior	O
autologous	O
stem	O
cell	O
transplantation	O
or	O
conventional	O
chemotherapy	O
.	O
The	O
median	O
number	O
of	O
prior	O
lines	O
of	O
therapy	O
was	O
2	O
.	O
Eighty	O
-	O
seven	O
percent	O
of	O
the	O
patients	O
had	O
received	O
immunomodulatory	O
drugs	O
included	O
in	O
some	O
line	O
of	O
therapy	O
before	O
bort	B-Chemical
-	O
dex	B-Chemical
.	O
The	O
median	O
number	O
of	O
bort	B-Chemical
-	O
dex	B-Chemical
cycles	O
was	O
6	O
,	O
up	O
to	O
a	O
maximum	O
of	O
12	O
cycles	O
.	O
On	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
,	O
55	O
%	O
of	O
the	O
patients	O
achieved	O
at	O
least	O
partial	O
response	O
,	O
including	O
19	O
%	O
CR	O
and	O
35	O
%	O
achieved	O
at	O
least	O
very	O
good	O
partial	O
response	O
.	O
Median	O
durations	O
of	O
response	O
,	O
time	O
to	O
next	O
therapy	O
and	O
treatment	O
-	O
free	O
interval	O
were	O
8	O
,	O
11	O
.	O
2	O
,	O
and	O
5	O
.	O
1	O
months	O
,	O
respectively	O
.	O
The	O
most	O
relevant	O
adverse	O
event	O
was	O
peripheral	B-Disease
neuropathy	I-Disease
,	O
which	O
occurred	O
in	O
78	O
%	O
of	O
the	O
patients	O
(	O
grade	O
II	O
,	O
38	O
%	O
;	O
grade	O
III	O
,	O
21	O
%	O
)	O
and	O
led	O
to	O
treatment	O
discontinuation	O
in	O
6	O
%	O
.	O
With	O
a	O
median	O
follow	O
up	O
of	O
22	O
months	O
,	O
median	O
time	O
to	O
progression	O
,	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
8	O
.	O
9	O
,	O
8	O
.	O
7	O
,	O
and	O
22	O
months	O
,	O
respectively	O
.	O
Prolonged	O
PFS	O
and	O
OS	O
were	O
observed	O
in	O
patients	O
achieving	O
CR	O
and	O
receiving	O
bort	B-Chemical
-	O
dex	B-Chemical
a	O
single	O
line	O
of	O
prior	O
therapy	O
.	O
Bort	B-Chemical
-	O
dex	B-Chemical
was	O
an	O
effective	O
salvage	O
treatment	O
for	O
MM	B-Disease
patients	O
,	O
particularly	O
for	O
those	O
in	O
first	O
relapse	O
.	O
Pubertal	O
exposure	O
to	O
Bisphenol	B-Chemical
A	I-Chemical
increases	O
anxiety	B-Disease
-	O
like	O
behavior	O
and	O
decreases	O
acetylcholinesterase	O
activity	O
of	O
hippocampus	O
in	O
adult	O
male	O
mice	O
.	O
The	O
negative	O
effects	O
of	O
Bisphenol	B-Chemical
A	I-Chemical
(	O
BPA	B-Chemical
)	O
on	O
neurodevelopment	O
and	O
behaviors	O
have	O
been	O
well	O
established	O
.	O
Acetylcholinesterase	O
(	O
AChE	O
)	O
is	O
a	O
regulatory	O
enzyme	O
which	O
is	O
involved	O
in	O
anxiety	B-Disease
-	O
like	O
behavior	O
.	O
This	O
study	O
investigated	O
behavioral	O
phenotypes	O
and	O
AChE	O
activity	O
in	O
male	O
mice	O
following	O
BPA	B-Chemical
exposure	O
during	O
puberty	O
.	O
On	O
postnatal	O
day	O
(	O
PND	O
)	O
35	O
,	O
male	O
mice	O
were	O
exposed	O
to	O
50mg	O
BPA	B-Chemical
/	O
kg	O
diet	O
per	O
day	O
for	O
a	O
period	O
of	O
35	O
days	O
.	O
On	O
PND71	O
,	O
a	O
behavioral	O
assay	O
was	O
performed	O
using	O
the	O
elevated	O
plus	O
maze	O
(	O
EPM	O
)	O
and	O
the	O
light	O
/	O
dark	O
test	O
.	O
In	O
addition	O
,	O
AChE	O
activity	O
was	O
measured	O
in	O
the	O
prefrontal	O
cortex	O
,	O
hypothalamus	O
,	O
cerebellum	O
and	O
hippocampus	O
.	O
Results	O
from	O
our	O
behavioral	O
phenotyping	O
indicated	O
that	O
anxiety	B-Disease
-	O
like	O
behavior	O
was	O
increased	O
in	O
mice	O
exposed	O
to	O
BPA	B-Chemical
.	O
AChE	O
activity	O
was	O
significantly	O
decreased	O
in	O
the	O
hippocampus	O
of	O
mice	O
with	O
BPA	B-Chemical
compared	O
to	O
control	O
mice	O
,	O
whereas	O
no	O
difference	O
was	O
found	O
in	O
the	O
prefrontal	O
cortex	O
,	O
hypothalamus	O
and	O
cerebellum	O
.	O
Our	O
findings	O
showed	O
that	O
pubertal	O
BPA	B-Chemical
exposure	O
increased	O
anxiety	B-Disease
-	O
like	O
behavior	O
,	O
which	O
may	O
be	O
associated	O
with	O
decreased	O
AChE	O
activity	O
of	O
the	O
hippocampus	O
in	O
adult	O
male	O
mice	O
.	O
Further	O
studies	O
are	O
necessary	O
to	O
investigate	O
the	O
cholinergic	O
signaling	O
of	O
the	O
hippocampus	O
in	O
PBE	O
induced	O
anxiety	B-Disease
-	O
like	O
behaviors	O
.	O
Biochemical	O
effects	O
of	O
Solidago	O
virgaurea	O
extract	O
on	O
experimental	O
cardiotoxicity	B-Disease
.	O
Cardiovascular	B-Disease
diseases	I-Disease
(	O
CVDs	B-Disease
)	O
are	O
the	O
major	O
health	O
problem	O
of	O
advanced	O
as	O
well	O
as	O
developing	O
countries	O
of	O
the	O
world	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
the	O
Solidago	O
virgaurea	O
extract	O
on	O
isoproterenol	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
in	O
rats	O
.	O
The	O
subcutaneous	O
injection	O
of	O
isoproterenol	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
into	O
rats	O
twice	O
at	O
an	O
interval	O
of	O
24	O
h	O
,	O
for	O
two	O
consecutive	O
days	O
,	O
led	O
to	O
a	O
significant	O
increase	O
in	O
serum	O
lactate	B-Chemical
dehydrogenase	O
,	O
creatine	B-Chemical
phosphokinase	O
,	O
alanine	B-Chemical
transaminase	O
,	O
aspartate	B-Chemical
transaminase	O
,	O
and	O
angiotensin	B-Chemical
-	O
converting	O
enzyme	O
activities	O
,	O
total	O
cholesterol	B-Chemical
,	O
triglycerides	B-Chemical
,	O
free	O
serum	O
fatty	B-Chemical
acid	I-Chemical
,	O
cardiac	O
tissue	O
malondialdehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
,	O
and	O
nitric	B-Chemical
oxide	I-Chemical
levels	O
and	O
a	O
significant	O
decrease	O
in	O
levels	O
of	O
glutathione	B-Chemical
and	O
superoxide	B-Chemical
dismutase	O
in	O
cardiac	O
tissue	O
as	O
compared	O
to	O
the	O
normal	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
Pretreatment	O
with	O
S	O
.	O
virgaurea	O
extract	O
for	O
5	O
weeks	O
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
followed	O
by	O
isoproterenol	B-Chemical
injection	O
significantly	O
prevented	O
the	O
observed	O
alterations	O
.	O
Captopril	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
,	O
given	O
orally	O
)	O
,	O
an	O
inhibitor	O
of	O
angiotensin	B-Chemical
-	O
converting	O
enzyme	O
used	O
as	O
a	O
standard	O
cardioprotective	O
drug	O
,	O
was	O
used	O
as	O
a	O
positive	O
control	O
in	O
this	O
study	O
.	O
The	O
data	O
of	O
the	O
present	O
study	O
suggest	O
that	O
S	O
.	O
virgaurea	O
extract	O
exerts	O
its	O
protective	O
effect	O
by	O
decreasing	O
MDA	B-Chemical
level	O
and	O
increasing	O
the	O
antioxidant	O
status	O
in	O
isoproterenol	B-Chemical
-	O
treated	O
rats	O
.	O
The	O
study	O
emphasizes	O
the	O
beneficial	O
action	O
of	O
S	O
.	O
virgaurea	O
extract	O
as	O
a	O
cardioprotective	O
agent	O
.	O
""""	O
Real	O
-	O
world	O
""""	O
data	O
on	O
the	O
efficacy	O
and	O
safety	O
of	O
lenalidomide	B-Chemical
and	O
dexamethasone	B-Chemical
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	B-Disease
myeloma	I-Disease
who	O
were	O
treated	O
according	O
to	O
the	O
standard	O
clinical	O
practice	O
:	O
a	O
study	O
of	O
the	O
Greek	O
Myeloma	B-Disease
Study	O
Group	O
.	O
Lenalidomide	B-Chemical
and	O
dexamethasone	B-Chemical
(	O
RD	B-Chemical
)	O
is	O
a	O
standard	O
of	O
care	O
for	O
relapsed	O
/	O
refractory	O
multiple	B-Disease
myeloma	I-Disease
(	O
RRMM	B-Disease
)	O
,	O
but	O
there	O
is	O
limited	O
published	O
data	O
on	O
its	O
efficacy	O
and	O
safety	O
in	O
the	O
""""	O
real	O
world	O
""""	O
(	O
RW	O
)	O
,	O
according	O
to	O
the	O
International	O
Society	O
of	O
Pharmacoeconomics	O
and	O
Outcomes	O
Research	O
definition	O
.	O
We	O
studied	O
212	O
RRMM	B-Disease
patients	O
who	O
received	O
RD	B-Chemical
in	O
RW	O
.	O
Objective	O
response	O
(	O
>	O
PR	O
(	O
partial	O
response	O
)	O
)	O
rate	O
was	O
77	O
.	O
4	O
%	O
(	O
complete	O
response	O
(	O
CR	O
)	O
,	O
20	O
.	O
2	O
%	O
)	O
.	O
Median	O
time	O
to	O
first	O
and	O
best	O
response	O
was	O
2	O
and	O
5	O
months	O
,	O
respectively	O
.	O
Median	O
time	O
to	O
CR	O
when	O
RD	B-Chemical
was	O
given	O
as	O
2nd	O
or	O
>	O
2	O
(	O
nd	O
)	O
-	O
line	O
treatment	O
at	O
4	O
and	O
11	O
months	O
,	O
respectively	O
.	O
Quality	O
of	O
response	O
was	O
independent	O
of	O
previous	O
lines	O
of	O
therapies	O
or	O
previous	O
exposure	O
to	O
thalidomide	B-Chemical
or	O
bortezomib	B-Chemical
.	O
Median	O
duration	O
of	O
response	O
was	O
34	O
.	O
4	O
months	O
,	O
and	O
it	O
was	O
higher	O
in	O
patients	O
who	O
received	O
RD	B-Chemical
until	O
progression	O
(	O
not	O
reached	O
versus	O
19	O
months	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
Improvement	O
of	O
humoral	O
immunity	O
occurred	O
in	O
60	O
%	O
of	O
responders	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
in	O
the	O
majority	O
of	O
patients	O
who	O
achieved	O
stable	O
disease	O
.	O
Adverse	O
events	O
were	O
reported	O
in	O
68	O
.	O
9	O
%	O
of	O
patients	O
(	O
myelosuppression	B-Disease
in	O
49	O
.	O
4	O
%	O
)	O
and	O
12	O
.	O
7	O
%	O
of	O
patients	O
needed	O
hospitalization	O
.	O
Peripheral	B-Disease
neuropathy	I-Disease
was	O
observed	O
only	O
in	O
2	O
.	O
5	O
%	O
of	O
patients	O
and	O
deep	B-Disease
vein	I-Disease
thrombosis	I-Disease
in	O
5	O
.	O
7	O
%	O
.	O
Dose	O
reductions	O
were	O
needed	O
in	O
31	O
%	O
of	O
patients	O
and	O
permanent	O
discontinuation	O
in	O
38	O
.	O
9	O
%	O
.	O
Median	O
time	O
to	O
treatment	O
discontinuation	O
was	O
16	O
.	O
8	O
months	O
.	O
Performance	O
status	O
(	O
PS	O
)	O
and	O
initial	O
lenalidomide	B-Chemical
dose	O
predicted	O
for	O
treatment	O
discontinuation	O
.	O
Extra	O
-	O
medullary	O
relapses	O
occurred	O
in	O
3	O
.	O
8	O
%	O
of	O
patients	O
.	O
Our	O
study	O
confirms	O
that	O
RD	B-Chemical
is	O
effective	O
and	O
safe	O
in	O
RRMM	B-Disease
in	O
the	O
RW	O
;	O
it	O
produces	O
durable	O
responses	O
especially	O
in	O
patients	O
who	O
continue	O
on	O
treatment	O
till	O
progression	O
and	O
improves	O
humoral	O
immunity	O
even	O
in	O
patients	O
with	O
stable	O
disease	O
.	O
The	O
cytogenetic	O
action	O
of	O
ifosfamide	B-Chemical
,	O
mesna	B-Chemical
,	O
and	O
their	O
combination	O
on	O
peripheral	O
rabbit	O
lymphocytes	O
:	O
an	O
in	O
vivo	O
/	O
in	O
vitro	O
cytogenetic	O
study	O
.	O
Ifosfamide	B-Chemical
(	O
IFO	B-Chemical
)	O
is	O
an	O
alkylating	O
nitrogen	B-Chemical
mustard	O
,	O
administrated	O
as	O
an	O
antineoplasmic	O
agent	O
.	O
It	O
is	O
characterized	O
by	O
its	O
intense	O
urotoxic	O
action	O
,	O
leading	O
to	O
hemorrhagic	B-Disease
cystitis	I-Disease
.	O
This	O
side	O
effect	O
of	O
IFO	B-Chemical
raises	O
the	O
requirement	O
for	O
the	O
co	O
-	O
administration	O
with	O
sodium	B-Chemical
2	I-Chemical
-	I-Chemical
sulfanylethanesulfonate	I-Chemical
(	O
Mesna	B-Chemical
)	O
aiming	O
to	O
avoid	O
or	O
minimize	O
this	O
effect	O
.	O
IFO	B-Chemical
and	O
Mesna	B-Chemical
were	O
administrated	O
separately	O
on	O
rabbit	O
'	O
s	O
lymphocytes	O
in	O
vivo	O
,	O
which	O
were	O
later	O
developed	O
in	O
vitro	O
.	O
Cytogenetic	O
markers	O
for	O
sister	O
chromatid	O
exchanges	O
(	O
SCEs	O
)	O
,	O
proliferation	O
rate	O
index	O
(	O
PRI	O
)	O
and	O
Mitotic	O
Index	O
were	O
recorded	O
.	O
Mesna	B-Chemical
'	O
s	O
action	O
,	O
in	O
conjunction	O
with	O
IFO	B-Chemical
reduces	O
the	O
frequency	O
of	O
SCEs	O
,	O
in	O
comparison	O
with	O
the	O
SCEs	O
recordings	O
obtained	O
when	O
IFO	B-Chemical
is	O
administered	O
alone	O
.	O
In	O
addition	O
to	O
this	O
,	O
when	O
high	O
concentrations	O
of	O
Mesna	B-Chemical
were	O
administered	O
alone	O
significant	O
reductions	O
of	O
the	O
PRI	O
were	O
noted	O
,	O
than	O
with	O
IFO	B-Chemical
acting	O
at	O
the	O
same	O
concentration	O
on	O
the	O
lymphocytes	O
.	O
Mesna	B-Chemical
significantly	O
reduces	O
IFO	B-Chemical
'	O
s	O
genotoxicity	B-Disease
,	O
while	O
when	O
administered	O
in	O
high	O
concentrations	O
it	O
acts	O
in	O
an	O
inhibitory	O
fashion	O
on	O
the	O
cytostatic	O
action	O
of	O
the	O
drug	O
.	O
Risk	O
factors	O
and	O
predictors	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesia	B-Disease
among	O
multiethnic	O
Malaysians	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
Chronic	O
pulsatile	O
levodopa	B-Chemical
therapy	O
for	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
leads	O
to	O
the	O
development	O
of	O
motor	O
fluctuations	O
and	O
dyskinesia	B-Disease
.	O
We	O
studied	O
the	O
prevalence	O
and	O
predictors	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesia	B-Disease
among	O
multiethnic	O
Malaysian	O
patients	O
with	O
PD	B-Disease
.	O
METHODS	O
:	O
This	O
is	O
a	O
cross	O
-	O
sectional	O
study	O
involving	O
95	O
patients	O
with	O
PD	B-Disease
on	O
uninterrupted	O
levodopa	B-Chemical
therapy	O
for	O
at	O
least	O
6	O
months	O
.	O
The	O
instrument	O
used	O
was	O
the	O
UPDRS	O
questionnaires	O
.	O
The	O
predictors	O
of	O
dyskinesia	B-Disease
were	O
determined	O
using	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O
RESULTS	O
:	O
The	O
mean	O
age	O
was	O
65	O
.	O
6	O
+	O
8	O
.	O
5	O
years	O
.	O
The	O
mean	O
onset	O
age	O
was	O
58	O
.	O
5	O
+	O
9	O
.	O
8	O
years	O
.	O
The	O
median	O
disease	O
duration	O
was	O
6	O
(	O
7	O
)	O
years	O
.	O
Dyskinesia	B-Disease
was	O
present	O
in	O
44	O
%	O
(	O
n	O
=	O
42	O
)	O
with	O
median	O
levodopa	B-Chemical
therapy	O
of	O
3	O
years	O
.	O
There	O
were	O
64	O
.	O
3	O
%	O
Chinese	O
,	O
31	O
%	O
Malays	O
,	O
and	O
3	O
.	O
7	O
%	O
Indians	O
and	O
other	O
ethnic	O
groups	O
.	O
Eighty	O
-	O
one	O
percent	O
of	O
patients	O
with	O
dyskinesia	B-Disease
had	O
clinical	O
fluctuations	O
.	O
Patients	O
with	O
dyskinesia	B-Disease
had	O
lower	O
onset	O
age	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
longer	O
duration	O
of	O
levodopa	B-Chemical
therapy	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
longer	O
disease	O
duration	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
higher	O
total	O
daily	O
levodopa	B-Chemical
dose	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
higher	O
total	O
UPDRS	O
scores	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
than	O
patients	O
without	O
dyskinesia	B-Disease
.	O
The	O
three	O
significant	O
predictors	O
of	O
dyskinesia	B-Disease
were	O
duration	O
of	O
levodopa	B-Chemical
therapy	O
,	O
onset	O
age	O
,	O
and	O
total	O
daily	O
levodopa	B-Chemical
dose	O
.	O
CONCLUSIONS	O
:	O
The	O
prevalence	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesia	B-Disease
in	O
our	O
patients	O
was	O
44	O
%	O
.	O
The	O
most	O
significant	O
predictors	O
were	O
duration	O
of	O
levodopa	B-Chemical
therapy	O
,	O
total	O
daily	O
levodopa	B-Chemical
dose	O
,	O
and	O
onset	O
age	O
.	O
Dose	O
-	O
dependent	O
neurotoxicity	B-Disease
of	O
high	O
-	O
dose	O
busulfan	B-Chemical
in	O
children	O
:	O
a	O
clinical	O
and	O
pharmacological	O
study	O
.	O
Busulfan	B-Chemical
is	O
known	O
to	O
be	O
neurotoxic	B-Disease
in	O
animals	O
and	O
humans	O
,	O
but	O
its	O
acute	O
neurotoxicity	B-Disease
remains	O
poorly	O
characterized	O
in	O
children	O
.	O
We	O
report	O
here	O
a	O
retrospective	O
study	O
of	O
123	O
children	O
(	O
median	O
age	O
,	O
6	O
.	O
5	O
years	O
)	O
receiving	O
high	O
-	O
dose	O
busulfan	B-Chemical
in	O
combined	O
chemotherapy	O
before	O
bone	O
marrow	O
transplantation	O
for	O
malignant	O
solid	O
tumors	B-Disease
,	O
brain	B-Disease
tumors	I-Disease
excluded	O
.	O
Busulfan	B-Chemical
was	O
given	O
p	O
.	O
o	O
.	O
,	O
every	O
6	O
hours	O
for	O
16	O
doses	O
over	O
4	O
days	O
.	O
Two	O
total	O
doses	O
were	O
consecutively	O
used	O
:	O
16	O
mg	O
/	O
kg	O
,	O
then	O
600	O
mg	O
/	O
m2	O
.	O
The	O
dose	O
calculation	O
on	O
the	O
basis	O
of	O
body	O
surface	O
area	O
results	O
in	O
higher	O
doses	O
in	O
young	O
children	O
than	O
in	O
older	O
patients	O
(	O
16	O
to	O
28	O
mg	O
/	O
kg	O
)	O
.	O
Ninety	O
-	O
six	O
patients	O
were	O
not	O
given	O
anticonvulsive	O
prophylaxis	O
;	O
7	O
(	O
7	O
.	O
5	O
%	O
)	O
developed	O
seizures	B-Disease
during	O
the	O
4	O
days	O
of	O
the	O
busulfan	B-Chemical
course	O
or	O
within	O
24	O
h	O
after	O
the	O
last	O
dosing	O
.	O
When	O
the	O
total	O
busulfan	B-Chemical
dose	O
was	O
taken	O
into	O
account	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
terms	O
of	O
neurotoxicity	B-Disease
incidence	O
among	O
patients	O
under	O
16	O
mg	O
/	O
kg	O
(	O
1	O
of	O
57	O
,	O
1	O
.	O
7	O
%	O
)	O
and	O
patients	O
under	O
600	O
mg	O
/	O
m2	O
(	O
6	O
of	O
39	O
,	O
15	O
.	O
4	O
%	O
)	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
.	O
Twenty	O
-	O
seven	O
patients	O
were	O
given	O
a	O
600	O
-	O
mg	O
/	O
m2	O
busulfan	B-Chemical
total	O
dose	O
with	O
continuous	O
i	O
.	O
v	O
.	O
infusion	O
of	O
clonazepam	B-Chemical
;	O
none	O
had	O
any	O
neurological	B-Disease
symptoms	I-Disease
.	O
Busulfan	B-Chemical
levels	O
were	O
measured	O
by	O
a	O
gas	O
chromatographic	O
-	O
mass	O
spectrometry	O
assay	O
in	O
the	O
plasma	O
and	O
cerebrospinal	O
fluid	O
of	O
9	O
children	O
without	O
central	B-Disease
nervous	I-Disease
system	I-Disease
disease	I-Disease
under	O
600	O
mg	O
/	O
m2	O
busulfan	B-Chemical
with	O
clonazepam	B-Chemical
:	O
busulfan	B-Chemical
cerebrospinal	O
fluid	O
:	O
plasma	O
ratio	O
was	O
1	O
.	O
39	O
.	O
This	O
was	O
significantly	O
different	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
from	O
the	O
cerebrospinal	O
fluid	O
:	O
plasma	O
ratio	O
previously	O
defined	O
in	O
children	O
receiving	O
a	O
16	O
-	O
mg	O
/	O
kg	O
total	O
dose	O
of	O
busulfan	B-Chemical
.	O
This	O
study	O
shows	O
that	O
busulfan	B-Chemical
neurotoxicity	B-Disease
is	O
dose	O
-	O
dependent	O
in	O
children	O
and	O
efficiently	O
prevented	O
by	O
clonazepam	B-Chemical
.	O
A	O
busulfan	B-Chemical
dose	O
calculated	O
on	O
the	O
basis	O
of	O
body	O
surface	O
area	O
,	O
resulting	O
in	O
higher	O
doses	O
in	O
young	O
children	O
,	O
was	O
followed	O
by	O
increased	O
neurotoxicity	B-Disease
,	O
close	O
to	O
neurotoxicity	B-Disease
incidence	O
observed	O
in	O
adults	O
.	O
Since	O
plasma	O
pharmacokinetic	O
studies	O
showed	O
a	O
faster	O
busulfan	B-Chemical
clearance	O
in	O
children	O
than	O
in	O
adults	O
,	O
this	O
new	O
dose	O
may	O
approximate	O
more	O
closely	O
the	O
adult	O
systemic	O
exposure	O
obtained	O
after	O
the	O
usual	O
16	O
-	O
mg	O
/	O
kg	O
total	O
dose	O
,	O
with	O
potential	O
inferences	O
in	O
terms	O
of	O
anticancer	O
or	O
myeloablative	O
effects	O
.	O
The	O
busulfan	B-Chemical
dose	O
in	O
children	O
and	O
infants	O
undergoing	O
bone	O
marrow	O
transplantation	O
should	O
be	O
reconsidered	O
on	O
the	O
basis	O
of	O
pharmacokinetic	O
studies	O
.	O
An	O
unexpected	O
diagnosis	O
in	O
a	O
renal	O
-	O
transplant	O
patient	O
with	O
proteinuria	B-Disease
treated	O
with	O
everolimus	B-Chemical
:	O
AL	B-Disease
amyloidosis	B-Disease
.	O
Proteinuria	B-Disease
is	O
an	O
expected	O
complication	O
in	O
transplant	O
patients	O
treated	O
with	O
mammalian	O
target	O
of	O
rapamycin	B-Chemical
inhibitors	O
(	O
mTOR	O
-	O
i	O
)	O
.	O
However	O
,	O
clinical	O
suspicion	O
should	O
always	O
be	O
supported	O
by	O
histological	O
evidence	O
in	O
order	O
to	O
investigate	O
potential	O
alternate	O
diagnoses	O
such	O
as	O
acute	O
or	O
chronic	O
rejection	O
,	O
interstitial	O
fibrosis	B-Disease
and	O
tubular	O
atrophy	B-Disease
,	O
or	O
recurrent	O
or	O
de	O
novo	O
glomerulopathy	B-Disease
.	O
In	O
this	O
case	O
we	O
report	O
the	O
unexpected	O
diagnosis	O
of	O
amyloidosis	B-Disease
in	O
a	O
renal	O
-	O
transplant	O
patient	O
with	O
pre	O
-	O
transplant	O
monoclonal	O
gammapathy	O
of	O
undetermined	O
significance	O
who	O
developed	O
proteinuria	B-Disease
after	O
conversion	O
from	O
tacrolimus	B-Chemical
to	O
everolimus	B-Chemical
.	O
Long	O
-	O
term	O
oral	O
galactose	B-Chemical
treatment	O
prevents	O
cognitive	B-Disease
deficits	I-Disease
in	O
male	O
Wistar	O
rats	O
treated	O
intracerebroventricularly	O
with	O
streptozotocin	B-Chemical
.	O
Basic	O
and	O
clinical	O
research	O
has	O
demonstrated	O
that	O
dementia	B-Disease
of	O
sporadic	O
Alzheimer	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
(	O
sAD	O
)	O
type	O
is	O
associated	O
with	O
dysfunction	O
of	O
the	O
insulin	O
-	O
receptor	O
(	O
IR	O
)	O
system	O
followed	O
by	O
decreased	O
glucose	B-Chemical
transport	O
via	O
glucose	B-Chemical
transporter	O
GLUT4	O
and	O
decreased	O
glucose	B-Chemical
metabolism	O
in	O
brain	O
cells	O
.	O
An	O
alternative	O
source	O
of	O
energy	O
is	O
d	B-Chemical
-	I-Chemical
galactose	I-Chemical
(	O
the	O
C	O
-	O
4	O
-	O
epimer	O
of	O
d	B-Chemical
-	I-Chemical
glucose	I-Chemical
)	O
which	O
is	O
transported	O
into	O
the	O
brain	O
by	O
insulin	O
-	O
independent	O
GLUT3	O
transporter	O
where	O
it	O
might	O
be	O
metabolized	O
to	O
glucose	B-Chemical
via	O
the	O
Leloir	O
pathway	O
.	O
Exclusively	O
parenteral	O
daily	O
injections	O
of	O
galactose	B-Chemical
induce	O
memory	B-Disease
deterioration	I-Disease
in	O
rodents	O
and	O
are	O
used	O
to	O
generate	O
animal	O
aging	O
model	O
,	O
but	O
the	O
effects	O
of	O
oral	O
galactose	B-Chemical
treatment	O
on	O
cognitive	O
functions	O
have	O
never	O
been	O
tested	O
.	O
We	O
have	O
investigated	O
the	O
effects	O
of	O
continuous	O
daily	O
oral	O
galactose	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
/	O
day	O
)	O
treatment	O
on	O
cognitive	B-Disease
deficits	I-Disease
in	O
streptozotocin	B-Chemical
-	O
induced	O
(	O
STZ	B-Chemical
-	O
icv	O
)	O
rat	O
model	O
of	O
sAD	O
,	O
tested	O
by	O
Morris	O
Water	O
Maze	O
and	O
Passive	O
Avoidance	O
test	O
,	O
respectively	O
.	O
One	O
month	O
of	O
oral	O
galactose	B-Chemical
treatment	O
initiated	O
immediately	O
after	O
the	O
STZ	B-Chemical
-	O
icv	O
administration	O
,	O
successfully	O
prevented	O
development	O
of	O
the	O
STZ	B-Chemical
-	O
icv	O
-	O
induced	O
cognitive	B-Disease
deficits	I-Disease
.	O
Beneficial	O
effect	O
of	O
oral	O
galactose	B-Chemical
was	O
independent	O
of	O
the	O
rat	O
age	O
and	O
of	O
the	O
galactose	B-Chemical
dose	O
ranging	O
from	O
100	O
to	O
300	O
mg	O
/	O
kg	O
/	O
day	O
.	O
Additionally	O
,	O
oral	O
galactose	B-Chemical
administration	O
led	O
to	O
the	O
appearance	O
of	O
galactose	B-Chemical
in	O
the	O
blood	O
.	O
The	O
increase	O
of	O
galactose	B-Chemical
concentration	O
in	O
the	O
cerebrospinal	O
fluid	O
was	O
several	O
times	O
lower	O
after	O
oral	O
than	O
after	O
parenteral	O
administration	O
of	O
the	O
same	O
galactose	B-Chemical
dose	O
.	O
Oral	O
galactose	B-Chemical
exposure	O
might	O
have	O
beneficial	O
effects	O
on	O
learning	O
and	O
memory	O
ability	O
and	O
could	O
be	O
worth	O
investigating	O
for	O
improvement	O
of	O
cognitive	B-Disease
deficits	I-Disease
associated	O
with	O
glucose	B-Disease
hypometabolism	I-Disease
in	O
AD	B-Disease
.	O
An	O
investigation	O
of	O
the	O
pattern	O
of	O
kidney	B-Disease
injury	I-Disease
in	O
HIV	O
-	O
positive	O
persons	O
exposed	O
to	O
tenofovir	B-Chemical
disoproxil	I-Chemical
fumarate	I-Chemical
:	O
an	O
examination	O
of	O
a	O
large	O
population	O
database	O
(	O
MHRA	O
database	O
)	O
.	O
The	O
potential	O
for	O
tenofovir	B-Chemical
to	O
cause	O
a	O
range	O
of	O
kidney	O
syndromes	O
has	O
been	O
established	O
from	O
mechanistic	O
and	O
randomised	O
clinical	O
trials	O
.	O
However	O
,	O
the	O
exact	O
pattern	O
of	O
kidney	O
involvement	O
is	O
still	O
uncertain	O
.	O
We	O
undertook	O
a	O
descriptive	O
analysis	O
of	O
Yellow	O
Card	O
records	O
of	O
407	O
HIV	O
-	O
positive	O
persons	O
taking	O
tenofovir	B-Chemical
disoproxil	I-Chemical
fumarate	I-Chemical
(	O
TDF	B-Chemical
)	O
as	O
part	O
of	O
their	O
antiretroviral	O
therapy	O
regimen	O
and	O
submitted	O
to	O
the	O
Medicines	O
and	O
Healthcare	O
Products	O
Regulatory	O
Agency	O
(	O
MHRA	O
)	O
with	O
suspected	O
kidney	O
adverse	O
effects	O
.	O
Reports	O
that	O
satisfy	O
defined	O
criteria	O
were	O
classified	O
as	O
acute	B-Disease
kidney	I-Disease
injury	I-Disease
,	O
kidney	B-Disease
tubular	I-Disease
dysfunction	I-Disease
and	O
Fanconi	B-Disease
syndrome	I-Disease
.	O
Of	O
the	O
407	O
Yellow	O
Card	O
records	O
analysed	O
,	O
106	O
satisfied	O
criteria	O
for	O
TDF	B-Chemical
-	O
related	O
kidney	B-Disease
disease	I-Disease
,	O
of	O
which	O
53	O
(	O
50	O
%	O
)	O
had	O
features	O
of	O
kidney	B-Disease
tubular	I-Disease
dysfunction	I-Disease
,	O
35	O
(	O
33	O
%	O
)	O
were	O
found	O
to	O
have	O
features	O
of	O
glomerular	B-Disease
dysfunction	I-Disease
and	O
18	O
(	O
17	O
%	O
)	O
had	O
Fanconi	B-Disease
syndrome	I-Disease
.	O
The	O
median	O
TDF	B-Chemical
exposure	O
was	O
316	O
days	O
(	O
interquartile	O
range	O
120	O
-	O
740	O
)	O
.	O
The	O
incidence	O
of	O
hospitalisation	O
for	O
TDF	B-Chemical
kidney	O
adverse	O
effects	O
was	O
high	O
,	O
particularly	O
amongst	O
patients	O
with	O
features	O
of	O
Fanconi	B-Disease
syndrome	I-Disease
.	O
The	O
pattern	O
of	O
kidney	O
syndromes	O
in	O
this	O
population	O
series	O
mirrors	O
that	O
reported	O
in	O
randomised	O
clinical	O
trials	O
.	O
Cessation	O
of	O
TDF	B-Chemical
was	O
associated	O
with	O
complete	O
restoration	O
of	O
kidney	O
function	O
in	O
up	O
half	O
of	O
the	O
patients	O
in	O
this	O
report	O
.	O
Incidence	O
of	O
postoperative	B-Disease
delirium	I-Disease
is	O
high	O
even	O
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
.	O
PURPOSE	O
:	O
Postoperative	B-Disease
delirium	I-Disease
is	O
a	O
recognized	O
complication	O
in	O
populations	O
at	O
risk	O
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
prevalence	O
of	O
early	O
postoperative	B-Disease
delirium	I-Disease
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
admitted	O
to	O
the	O
ICU	O
for	O
postoperative	O
monitoring	O
after	O
elective	O
major	O
surgery	O
.	O
The	O
secondary	O
outcome	O
investigated	O
is	O
to	O
identify	O
eventual	O
independent	O
risk	O
factors	O
among	O
demographic	O
data	O
and	O
anesthetic	O
drugs	O
used	O
.	O
METHODS	O
:	O
An	O
observational	O
,	O
prospective	O
study	O
was	O
conducted	O
on	O
a	O
consecutive	O
cohort	O
of	O
patients	O
admitted	O
to	O
our	O
ICU	O
within	O
and	O
for	O
at	O
least	O
24	O
h	O
after	O
major	O
surgical	O
procedures	O
.	O
Exclusion	O
criteria	O
were	O
any	O
preexisting	O
predisposing	O
factor	O
for	O
delirium	B-Disease
or	O
other	O
potentially	O
confounding	O
neurological	B-Disease
dysfunctions	I-Disease
.	O
Patients	O
were	O
assessed	O
daily	O
using	O
the	O
confusion	B-Disease
assessment	O
method	O
for	O
the	O
ICU	O
scale	O
for	O
3	O
days	O
after	O
the	O
surgical	O
procedure	O
.	O
Early	O
postoperative	B-Disease
delirium	I-Disease
incidence	O
risk	O
factors	O
were	O
then	O
assessed	O
through	O
three	O
different	O
multiple	O
regression	O
models	O
.	O
RESULTS	O
:	O
According	O
to	O
the	O
confusion	O
assessment	O
method	O
for	O
the	O
ICU	O
scale	O
,	O
28	O
%	O
of	O
patients	O
were	O
diagnosed	O
with	O
early	O
postoperative	B-Disease
delirium	I-Disease
.	O
The	O
use	O
of	O
thiopentone	B-Chemical
was	O
significantly	O
associated	O
with	O
an	O
eight	O
-	O
fold	O
-	O
higher	O
risk	O
for	O
delirium	B-Disease
compared	O
to	O
propofol	B-Chemical
(	O
57	O
.	O
1	O
%	O
vs	O
.	O
7	O
.	O
1	O
%	O
,	O
RR	O
=	O
8	O
.	O
0	O
,	O
X2	O
=	O
4	O
.	O
256	O
;	O
df	O
=	O
1	O
;	O
0	O
.	O
05	O
<	O
p	O
<	O
0	O
.	O
02	O
)	O
.	O
CONCLUSION	O
:	O
In	O
this	O
study	O
early	O
postoperative	B-Disease
delirium	I-Disease
was	O
found	O
to	O
be	O
a	O
very	O
common	O
complication	O
after	O
major	O
surgery	O
,	O
even	O
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
.	O
Thiopentone	B-Chemical
was	O
independently	O
associated	O
with	O
an	O
increase	O
in	O
its	O
relative	O
risk	O
.	O
A	O
single	O
neurotoxic	B-Disease
dose	O
of	O
methamphetamine	B-Chemical
induces	O
a	O
long	O
-	O
lasting	O
depressive	B-Disease
-	O
like	O
behaviour	O
in	O
mice	O
.	O
Methamphetamine	B-Chemical
(	O
METH	B-Chemical
)	O
triggers	O
a	O
disruption	O
of	O
the	O
monoaminergic	O
system	O
and	O
METH	B-Chemical
abuse	O
leads	O
to	O
negative	O
emotional	O
states	O
including	O
depressive	B-Disease
symptoms	I-Disease
during	O
drug	O
withdrawal	O
.	O
However	O
,	O
it	O
is	O
currently	O
unknown	O
if	O
the	O
acute	O
toxic	O
dosage	O
of	O
METH	B-Chemical
also	O
causes	O
a	O
long	O
-	O
lasting	O
depressive	B-Disease
phenotype	O
and	O
persistent	O
monoaminergic	O
deficits	O
.	O
Thus	O
,	O
we	O
now	O
assessed	O
the	O
depressive	B-Disease
-	O
like	O
behaviour	O
in	O
mice	O
at	O
early	O
and	O
long	O
-	O
term	O
periods	O
following	O
a	O
single	O
high	O
METH	B-Chemical
dose	O
(	O
30	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
.	O
METH	B-Chemical
did	O
not	O
alter	O
the	O
motor	O
function	O
and	O
procedural	O
memory	O
of	O
mice	O
as	O
assessed	O
by	O
swimming	O
speed	O
and	O
escape	O
latency	O
to	O
find	O
the	O
platform	O
in	O
a	O
cued	O
version	O
of	O
the	O
water	O
maze	O
task	O
.	O
However	O
,	O
METH	B-Chemical
significantly	O
increased	O
the	O
immobility	O
time	O
in	O
the	O
tail	O
suspension	O
test	O
at	O
3	O
and	O
49	O
days	O
post	O
-	O
administration	O
.	O
This	O
depressive	B-Disease
-	O
like	O
profile	O
induced	O
by	O
METH	B-Chemical
was	O
accompanied	O
by	O
a	O
marked	O
depletion	O
of	O
frontostriatal	O
dopaminergic	O
and	O
serotonergic	O
neurotransmission	O
,	O
indicated	O
by	O
a	O
reduction	O
in	O
the	O
levels	O
of	O
dopamine	B-Chemical
,	O
DOPAC	B-Chemical
and	O
HVA	B-Chemical
,	O
tyrosine	B-Chemical
hydroxylase	O
and	O
serotonin	B-Chemical
,	O
observed	O
at	O
both	O
3	O
and	O
49	O
days	O
post	O
-	O
administration	O
.	O
In	O
parallel	O
,	O
another	O
neurochemical	O
feature	O
of	O
depression	B-Disease
-	O
-	O
astroglial	O
dysfunction	O
-	O
-	O
was	O
unaffected	O
in	O
the	O
cortex	O
and	O
the	O
striatal	O
levels	O
of	O
the	O
astrocytic	O
protein	O
marker	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
were	O
only	O
transiently	O
increased	O
at	O
3	O
days	O
.	O
These	O
findings	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
a	O
single	O
high	O
dose	O
of	O
METH	B-Chemical
induces	O
long	O
-	O
lasting	O
depressive	B-Disease
-	O
like	O
behaviour	O
in	O
mice	O
associated	O
with	O
a	O
persistent	O
disruption	O
of	O
frontostriatal	O
dopaminergic	O
and	O
serotonergic	O
homoeostasis	O
.	O
Linezolid	B-Chemical
-	O
induced	O
optic	B-Disease
neuropathy	I-Disease
.	O
Many	O
systemic	O
antimicrobials	O
have	O
been	O
implicated	O
to	O
cause	O
ocular	O
adverse	O
effects	O
.	O
This	O
is	O
especially	O
relevant	O
in	O
multidrug	O
therapy	O
where	O
more	O
than	O
one	O
drug	O
can	O
cause	O
a	O
similar	O
ocular	O
adverse	O
effect	O
.	O
We	O
describe	O
a	O
case	O
of	O
progressive	O
loss	B-Disease
of	I-Disease
vision	I-Disease
associated	O
with	O
linezolid	B-Chemical
therapy	O
.	O
A	O
45	O
-	O
year	O
-	O
old	O
male	O
patient	O
who	O
was	O
on	O
treatment	O
with	O
multiple	O
second	O
-	O
line	O
anti	O
-	O
tuberculous	O
drugs	O
including	O
linezolid	B-Chemical
and	O
ethambutol	B-Chemical
for	O
extensively	B-Disease
drug	I-Disease
-	I-Disease
resistant	I-Disease
tuberculosis	I-Disease
(	O
XDR	B-Disease
-	I-Disease
TB	I-Disease
)	O
presented	O
to	O
us	O
with	O
painless	O
progressive	O
loss	B-Disease
of	I-Disease
vision	I-Disease
in	O
both	O
eyes	O
.	O
Color	O
vision	O
was	O
defective	O
and	O
fundus	O
examination	O
revealed	O
optic	B-Disease
disc	I-Disease
edema	I-Disease
in	O
both	O
eyes	O
.	O
Ethambutol	B-Chemical
-	O
induced	O
toxic	B-Disease
optic	I-Disease
neuropathy	I-Disease
was	O
suspected	O
and	O
tablet	O
ethambutol	B-Chemical
was	O
withdrawn	O
.	O
Deterioration	B-Disease
of	I-Disease
vision	I-Disease
occurred	O
despite	O
withdrawal	O
of	O
ethambutol	B-Chemical
.	O
Discontinuation	O
of	O
linezolid	B-Chemical
resulted	O
in	O
marked	O
improvement	O
of	O
vision	O
.	O
Our	O
report	O
emphasizes	O
the	O
need	O
for	O
monitoring	O
of	O
visual	O
function	O
in	O
patients	O
on	O
long	O
-	O
term	O
linezolid	B-Chemical
treatment	O
.	O
Resuscitation	O
with	O
lipid	O
,	O
epinephrine	B-Chemical
,	O
or	O
both	O
in	O
levobupivacaine	B-Chemical
-	O
induced	O
cardiac	B-Disease
toxicity	I-Disease
in	O
newborn	O
piglets	O
.	O
BACKGROUND	O
:	O
The	O
optimal	O
dosing	O
regimens	O
of	O
lipid	O
emulsion	O
,	O
epinephrine	B-Chemical
,	O
or	O
both	O
are	O
not	O
yet	O
determined	O
in	O
neonates	O
in	O
cases	O
of	O
local	O
anaesthetic	O
systemic	O
toxicity	B-Disease
(	O
LAST	O
)	O
.	O
METHODS	O
:	O
Newborn	O
piglets	O
received	O
levobupivacaine	B-Chemical
until	O
cardiovascular	B-Disease
collapse	I-Disease
occurred	O
.	O
Standard	O
cardiopulmonary	O
resuscitation	O
was	O
started	O
and	O
electrocardiogram	O
(	O
ECG	O
)	O
was	O
monitored	O
for	O
ventricular	B-Disease
tachycardia	I-Disease
,	O
fibrillation	B-Disease
,	O
or	O
QRS	O
prolongation	O
.	O
Piglets	O
were	O
then	O
randomly	O
allocated	O
to	O
four	O
groups	O
:	O
control	O
(	O
saline	O
)	O
,	O
Intralipid	O
(	O
)	O
alone	O
,	O
epinephrine	B-Chemical
alone	O
,	O
or	O
a	O
combination	O
of	O
Intralipd	O
plus	O
epinephrine	B-Chemical
.	O
Resuscitation	O
continued	O
for	O
30	O
min	O
or	O
until	O
there	O
was	O
a	O
return	O
of	O
spontaneous	O
circulation	O
(	O
ROSC	O
)	O
accompanied	O
by	O
a	O
mean	O
arterial	O
pressure	O
at	O
or	O
superior	O
to	O
the	O
baseline	O
pressure	O
and	O
normal	O
sinus	O
rhythm	O
for	O
a	O
period	O
of	O
30	O
min	O
.	O
RESULTS	O
:	O
ROSC	O
was	O
achieved	O
in	O
only	O
one	O
of	O
the	O
control	O
piglets	O
compared	O
with	O
most	O
of	O
the	O
treated	O
piglets	O
.	O
Mortality	O
was	O
not	O
significantly	O
different	O
between	O
the	O
three	O
treatment	O
groups	O
,	O
but	O
was	O
significantly	O
lower	O
in	O
all	O
the	O
treatment	O
groups	O
compared	O
with	O
control	O
.	O
The	O
number	O
of	O
ECG	O
abnormalities	O
was	O
zero	O
in	O
the	O
Intralipid	O
only	O
group	O
,	O
but	O
14	O
and	O
17	O
,	O
respectively	O
,	O
in	O
the	O
epinephrine	B-Chemical
and	O
epinephrine	B-Chemical
plus	O
lipid	O
groups	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
CONCLUSIONS	O
:	O
Lipid	O
emulsion	O
with	O
or	O
without	O
epinephrine	B-Chemical
,	O
or	O
epinephrine	B-Chemical
alone	O
were	O
equally	O
effective	O
in	O
achieving	O
a	O
return	O
to	O
spontaneous	O
circulation	O
in	O
this	O
model	O
of	O
LAST	O
.	O
Epinephrine	B-Chemical
alone	O
or	O
in	O
combination	O
with	O
lipid	O
was	O
associated	O
with	O
an	O
increased	O
number	O
of	O
ECG	O
abnormalities	O
compared	O
with	O
lipid	O
emulsion	O
alone	O
.	O
Incidence	O
of	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
type	I-Disease
II	I-Disease
and	O
postoperative	O
recovery	O
of	O
platelet	O
count	O
in	O
liver	O
graft	O
recipients	O
:	O
a	O
retrospective	O
cohort	O
analysis	O
.	O
BACKGROUND	O
:	O
Thrombocytopenia	B-Disease
in	O
patients	O
with	O
end	B-Disease
-	I-Disease
stage	I-Disease
liver	I-Disease
disease	I-Disease
is	O
a	O
common	O
disorder	O
caused	O
mainly	O
by	O
portal	B-Disease
hypertension	I-Disease
,	O
low	O
levels	O
of	O
thrombopoetin	O
,	O
and	O
endotoxemia	B-Disease
.	O
The	O
impact	O
of	O
immune	O
-	O
mediated	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
type	I-Disease
II	I-Disease
(	O
HIT	B-Disease
type	I-Disease
II	I-Disease
)	O
as	O
a	O
cause	O
of	O
thrombocytopenia	B-Disease
after	O
liver	O
transplantation	O
is	O
not	O
yet	O
understood	O
,	O
with	O
few	O
literature	O
citations	O
reporting	O
contradictory	O
results	O
.	O
The	O
aim	O
of	O
our	O
study	O
was	O
to	O
demonstrate	O
the	O
perioperative	O
course	O
of	O
thrombocytopenia	B-Disease
after	O
liver	O
transplantation	O
and	O
determine	O
the	O
occurrence	O
of	O
clinical	O
HIT	B-Disease
type	I-Disease
II	I-Disease
.	O
METHOD	O
:	O
We	O
retrospectively	O
evaluated	O
the	O
medical	O
records	O
of	O
205	O
consecutive	O
adult	O
patients	O
who	O
underwent	O
full	O
-	O
size	O
liver	O
transplantation	O
between	O
January	O
2006	O
and	O
December	O
2010	O
due	O
to	O
end	B-Disease
-	I-Disease
stage	I-Disease
or	I-Disease
malignant	I-Disease
liver	I-Disease
disease	I-Disease
.	O
Preoperative	O
platelet	O
count	O
,	O
postoperative	O
course	O
of	O
platelets	O
,	O
and	O
clinical	O
signs	O
of	O
HIT	B-Disease
type	I-Disease
II	I-Disease
were	O
analyzed	O
.	O
RESULTS	O
:	O
A	O
total	O
of	O
155	O
(	O
75	O
.	O
6	O
%	O
)	O
of	O
205	O
patients	O
had	O
thrombocytopenia	B-Disease
before	O
transplantation	O
,	O
significantly	O
influenced	O
by	O
Model	O
of	O
End	B-Disease
-	I-Disease
Stage	I-Disease
Liver	I-Disease
Disease	I-Disease
score	O
and	O
liver	B-Disease
cirrhosis	I-Disease
.	O
The	O
platelet	O
count	O
exceeded	O
100	O
,	O
000	O
/	O
uL	O
in	O
most	O
of	O
the	O
patients	O
(	O
n	O
=	O
193	O
)	O
at	O
a	O
medium	O
of	O
7	O
d	O
.	O
Regarding	O
HIT	B-Disease
II	I-Disease
,	O
there	O
were	O
four	O
(	O
1	O
.	O
95	O
%	O
)	O
patients	O
with	O
a	O
background	O
of	O
HIT	B-Disease
type	I-Disease
II	I-Disease
.	O
CONCLUSIONS	O
:	O
The	O
incidence	O
of	O
HIT	B-Disease
in	O
patients	O
with	O
end	B-Disease
-	I-Disease
stage	I-Disease
hepatic	I-Disease
failure	I-Disease
is	O
,	O
with	O
about	O
1	O
.	O
95	O
%	O
,	O
rare	O
.	O
For	O
further	O
reduction	O
of	O
HIT	B-Disease
type	I-Disease
II	I-Disease
,	O
the	O
use	O
of	O
intravenous	O
heparin	B-Chemical
should	O
be	O
avoided	O
and	O
the	O
prophylactic	O
anticoagulation	O
should	O
be	O
performed	O
with	O
low	O
-	O
molecular	O
-	O
weight	O
heparin	B-Chemical
after	O
normalization	O
of	O
platelet	O
count	O
.	O
Takotsubo	B-Disease
syndrome	I-Disease
(	O
or	O
apical	B-Disease
ballooning	I-Disease
syndrome	I-Disease
)	O
secondary	O
to	O
Zolmitriptan	B-Chemical
.	O
Takotsubo	B-Disease
syndrome	I-Disease
(	O
TS	B-Disease
)	O
,	O
also	O
known	O
as	O
broken	B-Disease
heart	I-Disease
syndrome	I-Disease
,	O
is	O
characterized	O
by	O
left	O
ventricle	O
apical	O
ballooning	O
with	O
elevated	O
cardiac	O
biomarkers	O
and	O
electrocardiographic	O
changes	O
suggestive	O
of	O
an	O
acute	B-Disease
coronary	I-Disease
syndrome	I-Disease
(	O
ie	O
,	O
ST	O
-	O
segment	O
elevation	O
,	O
T	O
wave	O
inversions	O
,	O
and	O
pathologic	O
Q	O
waves	O
)	O
.	O
We	O
report	O
a	O
case	O
of	O
54	O
-	O
year	O
-	O
old	O
woman	O
with	O
medical	O
history	O
of	O
mitral	B-Disease
valve	I-Disease
prolapse	I-Disease
and	O
migraines	B-Disease
,	O
who	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
substernal	O
chest	B-Disease
pain	I-Disease
and	O
electrocardiogram	O
demonstrated	O
1	O
/	O
2	O
mm	O
ST	O
-	O
segment	O
elevation	O
in	O
leads	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
,	O
and	O
V6	O
and	O
positive	O
troponin	O
I	O
.	O
Emergent	O
coronary	O
angiogram	O
revealed	O
normal	O
coronary	O
arteries	O
with	O
moderately	O
reduced	O
left	O
ventricular	O
ejection	O
fraction	O
with	O
wall	O
motion	O
abnormalities	O
consistent	O
with	O
TS	B-Disease
.	O
Detailed	O
history	O
obtained	O
retrospectively	O
revealed	O
that	O
the	O
patient	O
took	O
zolmitriptan	B-Chemical
sparingly	O
only	O
when	O
she	O
had	O
migraines	B-Disease
.	O
But	O
before	O
this	O
event	O
,	O
she	O
was	O
taking	O
zolmitriptan	B-Chemical
2	O
-	O
3	O
times	O
daily	O
for	O
several	O
days	O
because	O
of	O
a	O
persistent	O
migraine	B-Disease
headache	I-Disease
.	O
She	O
otherwise	O
reported	O
that	O
she	O
is	O
quite	O
active	O
,	O
rides	O
horses	O
,	O
and	O
does	O
show	O
jumping	O
without	O
any	O
limitations	O
in	O
her	O
physical	O
activity	O
.	O
There	O
was	O
no	O
evidence	O
of	O
any	O
recent	O
stress	O
or	O
status	B-Disease
migrainosus	I-Disease
.	O
Extensive	O
literature	O
search	O
revealed	O
multiple	O
cases	O
of	O
coronary	B-Disease
artery	I-Disease
vasospasm	I-Disease
secondary	O
to	O
zolmitriptan	B-Chemical
,	O
but	O
none	O
of	O
the	O
cases	O
were	O
associated	O
with	O
TS	B-Disease
.	O
Depression	B-Disease
,	O
impulsiveness	B-Disease
,	O
sleep	O
,	O
and	O
memory	O
in	O
past	O
and	O
present	O
polydrug	O
users	O
of	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
methylenedioxymethamphetamine	I-Chemical
(	O
MDMA	B-Chemical
,	O
ecstasy	B-Chemical
)	O
.	O
RATIONALE	O
:	O
Ecstasy	B-Chemical
(	O
3	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
methylenedioxymethamphetamine	I-Chemical
,	O
MDMA	B-Chemical
)	O
is	O
a	O
worldwide	O
recreational	O
drug	O
of	O
abuse	O
.	O
Unfortunately	O
,	O
the	O
results	O
from	O
human	O
research	O
investigating	O
its	O
psychological	O
effects	O
have	O
been	O
inconsistent	O
.	O
OBJECTIVES	O
:	O
The	O
present	O
study	O
aimed	O
to	O
be	O
the	O
largest	O
to	O
date	O
in	O
sample	O
size	O
and	O
5HT	O
-	O
related	O
behaviors	O
;	O
the	O
first	O
to	O
compare	O
present	O
ecstasy	B-Chemical
users	O
with	O
past	O
users	O
after	O
an	O
abstinence	O
of	O
4	O
or	O
more	O
years	O
,	O
and	O
the	O
first	O
to	O
include	O
robust	O
controls	O
for	O
other	O
recreational	O
substances	O
.	O
METHODS	O
:	O
A	O
sample	O
of	O
997	O
participants	O
(	O
52	O
%	O
male	O
)	O
was	O
recruited	O
to	O
four	O
control	O
groups	O
(	O
non	O
-	O
drug	O
(	O
ND	O
)	O
,	O
alcohol	B-Chemical
/	O
nicotine	B-Chemical
(	O
AN	B-Chemical
)	O
,	O
cannabis	B-Chemical
/	O
alcohol	B-Chemical
/	O
nicotine	B-Chemical
(	O
CAN	B-Chemical
)	O
,	O
non	O
-	O
ecstasy	B-Chemical
polydrug	O
(	O
PD	O
)	O
)	O
,	O
and	O
two	O
ecstasy	B-Chemical
polydrug	O
groups	O
(	O
present	O
(	O
MDMA	B-Chemical
)	O
and	O
past	O
users	O
(	O
EX	O
-	O
MDMA	B-Chemical
)	O
.	O
Participants	O
completed	O
a	O
drug	O
history	O
questionnaire	O
,	O
Beck	O
Depression	B-Disease
Inventory	O
,	O
Barratt	O
Impulsiveness	B-Disease
Scale	O
,	O
Pittsburgh	O
Sleep	O
Quality	O
Index	O
,	O
and	O
Wechsler	O
Memory	O
Scale	O
-	O
Revised	O
which	O
,	O
in	O
total	O
,	O
provided	O
13	O
psychometric	O
measures	O
.	O
RESULTS	O
:	O
While	O
the	O
CAN	B-Chemical
and	O
PD	O
groups	O
tended	O
to	O
record	O
greater	O
deficits	O
than	O
the	O
non	O
-	O
drug	O
controls	O
,	O
the	O
MDMA	B-Chemical
and	O
EX	O
-	O
MDMA	B-Chemical
groups	O
recorded	O
greater	O
deficits	O
than	O
all	O
the	O
control	O
groups	O
on	O
ten	O
of	O
the	O
13	O
psychometric	O
measures	O
.	O
Strikingly	O
,	O
despite	O
prolonged	O
abstinence	O
(	O
mean	O
,	O
4	O
.	O
98	O
;	O
range	O
,	O
4	O
-	O
9	O
years	O
)	O
,	O
past	O
ecstasy	B-Chemical
users	O
showed	O
few	O
signs	O
of	O
recovery	O
.	O
Compared	O
with	O
present	O
ecstasy	B-Chemical
users	O
,	O
the	O
past	O
users	O
showed	O
no	O
change	O
for	O
ten	O
measures	O
,	O
increased	O
impairment	O
for	O
two	O
measures	O
,	O
and	O
improvement	O
on	O
just	O
one	O
measure	O
.	O
CONCLUSIONS	O
:	O
Given	O
this	O
record	O
of	O
impaired	B-Disease
memory	I-Disease
and	O
clinically	O
significant	O
levels	O
of	O
depression	B-Disease
,	O
impulsiveness	B-Disease
,	O
and	O
sleep	B-Disease
disturbance	I-Disease
,	O
the	O
prognosis	O
for	O
the	O
current	O
generation	O
of	O
ecstasy	B-Chemical
users	O
is	O
a	O
major	O
cause	O
for	O
concern	O
.	O
Association	O
of	O
common	O
genetic	O
variants	O
of	O
HOMER1	O
gene	O
with	O
levodopa	B-Chemical
adverse	O
effects	O
in	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
patients	O
.	O
Levodopa	B-Chemical
is	O
the	O
most	O
effective	O
symptomatic	O
therapy	O
for	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
,	O
but	O
its	O
chronic	O
use	O
could	O
lead	O
to	O
chronic	O
adverse	O
outcomes	O
,	O
such	O
as	O
motor	O
fluctuations	O
,	O
dyskinesia	B-Disease
and	O
visual	B-Disease
hallucinations	I-Disease
.	O
HOMER1	O
is	O
a	O
protein	O
with	O
pivotal	O
function	O
in	O
glutamate	B-Chemical
transmission	O
,	O
which	O
has	O
been	O
related	O
to	O
the	O
pathogenesis	O
of	O
these	O
complications	O
.	O
This	O
study	O
investigates	O
whether	O
polymorphisms	O
in	O
the	O
HOMER1	O
gene	O
promoter	O
region	O
are	O
associated	O
with	O
the	O
occurrence	O
of	O
the	O
chronic	O
complications	O
of	O
levodopa	B-Chemical
therapy	O
.	O
A	O
total	O
of	O
205	O
patients	O
with	O
idiopathic	B-Disease
Parkinson	I-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
were	O
investigated	O
.	O
Patients	O
were	O
genotyped	O
for	O
rs4704559	O
,	O
rs10942891	O
and	O
rs4704560	O
by	O
allelic	O
discrimination	O
with	O
Taqman	O
assays	O
.	O
The	O
rs4704559	O
G	O
allele	O
was	O
associated	O
with	O
a	O
lower	O
prevalence	O
of	O
dyskinesia	B-Disease
(	O
prevalence	O
ratio	O
(	O
PR	O
)	O
=	O
0	O
.	O
615	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
426	O
-	O
0	O
.	O
887	O
,	O
P	O
=	O
0	O
.	O
009	O
)	O
and	O
visual	B-Disease
hallucinations	I-Disease
(	O
PR	O
=	O
0	O
.	O
515	O
,	O
95	O
%	O
CI	O
0	O
.	O
295	O
-	O
0	O
.	O
899	O
,	O
P	O
=	O
0	O
.	O
020	O
)	O
.	O
Our	O
data	O
suggest	O
that	O
HOMER1	O
rs4704559	O
G	O
allele	O
has	O
a	O
protective	O
role	O
for	O
the	O
development	O
of	O
levodopa	B-Chemical
adverse	O
effects	O
.	O
Crocin	B-Chemical
improves	O
lipid	O
dysregulation	O
in	O
subacute	O
diazinon	B-Chemical
exposure	O
through	O
ERK1	O
/	O
2	O
pathway	O
in	O
rat	O
liver	O
.	O
INTRODUCTION	O
:	O
Diazinon	B-Chemical
Yis	O
one	O
of	O
the	O
most	O
broadly	O
used	O
organophosphorus	B-Chemical
insecticides	O
in	O
agriculture	O
.	O
It	O
has	O
been	O
shown	O
that	O
exposure	O
to	O
diazinon	B-Chemical
may	O
interfere	O
with	O
lipid	O
metabolism	O
.	O
Moreover	O
,	O
the	O
hypolipidemic	O
effect	O
of	O
crocin	B-Chemical
has	O
been	O
established	O
.	O
Earlier	O
studies	O
revealed	O
the	O
major	O
role	O
of	O
Extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
pathways	O
in	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
(	O
LDLr	O
)	O
expression	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
changes	O
in	O
the	O
regulation	O
of	O
lipid	O
metabolism	O
,	O
ERK	O
and	O
LDLr	O
expression	O
in	O
the	O
liver	O
of	O
rats	O
exposed	O
to	O
subacute	O
diazinon	B-Chemical
.	O
Furthermore	O
ameliorating	O
effect	O
of	O
crocin	B-Chemical
on	O
diazinon	B-Chemical
induced	O
disturbed	O
cholesterol	B-Chemical
homeostasis	O
was	O
studied	O
.	O
METHODS	O
:	O
24	O
Rats	O
were	O
divided	O
into	O
4	O
groups	O
and	O
received	O
following	O
treatments	O
for	O
4	O
weeks	O
;	O
Corn	O
oil	O
(	O
control	O
)	O
,	O
diazinon	B-Chemical
(	O
15mg	O
/	O
kg	O
per	O
day	O
,	O
orally	O
)	O
and	O
crocin	B-Chemical
(	O
12	O
.	O
5	O
and	O
25mg	O
/	O
kg	O
per	O
day	O
,	O
intraperitoneally	O
)	O
in	O
combination	O
with	O
diazinon	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
)	O
.	O
The	O
levels	O
of	O
cholesterol	B-Chemical
,	O
triglyceride	B-Chemical
and	O
LDL	O
in	O
blood	O
of	O
rats	O
were	O
analyzed	O
.	O
Moreover	O
mRNA	O
levels	O
of	O
LDLr	O
and	O
ERK1	O
/	O
2	O
as	O
well	O
as	O
protein	O
levels	O
of	O
total	O
and	O
activated	O
forms	O
of	O
ERK1	O
/	O
2	O
in	O
rat	O
liver	O
were	O
evaluated	O
by	O
Western	O
blotting	O
and	O
quantitative	O
real	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O
RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
subacute	O
exposure	O
to	O
diazinon	B-Chemical
significantly	O
increased	O
concentrations	O
of	O
cholesterol	B-Chemical
,	O
triglyceride	B-Chemical
and	O
LDL	O
.	O
Moreover	O
diazinon	B-Chemical
decreased	O
ERK1	O
/	O
2	O
protein	O
phosphorylation	O
and	O
LDLr	O
transcript	O
.	O
Crocin	B-Chemical
reduced	O
inhibition	O
of	O
ERK	O
activation	O
and	O
diazinon	B-Chemical
-	O
induced	O
hyperlipemia	B-Disease
and	O
increased	O
levels	O
of	O
LDLr	O
transcript	O
.	O
CONCLUSIONS	O
:	O
Crocin	B-Chemical
may	O
be	O
considered	O
as	O
a	O
novel	O
protective	O
agent	O
in	O
diazinon	B-Chemical
-	O
induced	O
hyperlipemia	B-Disease
through	O
modulating	O
of	O
ERK	O
pathway	O
and	O
increase	O
of	O
LDLr	O
expression	O
.	O
GEM	B-Chemical
-	O
P	O
chemotherapy	O
is	O
active	O
in	O
the	O
treatment	O
of	O
relapsed	O
Hodgkin	B-Disease
lymphoma	I-Disease
.	O
Hodgkin	B-Disease
lymphoma	I-Disease
(	O
HL	B-Disease
)	O
is	O
a	O
relatively	O
chemosensitive	O
malignancy	B-Disease
.	O
However	O
,	O
for	O
those	O
who	O
relapse	O
,	O
high	O
-	O
dose	O
chemotherapy	O
with	O
autologous	O
stem	O
cell	O
transplant	O
is	O
the	O
treatment	O
of	O
choice	O
which	O
relies	O
on	O
adequate	O
disease	O
control	O
with	O
salvage	O
chemotherapy	O
.	O
Regimens	O
commonly	O
used	O
often	O
require	O
inpatient	O
administration	O
and	O
can	O
be	O
difficult	O
to	O
deliver	O
due	O
to	O
toxicity	B-Disease
.	O
Gemcitabine	B-Chemical
and	O
cisplatin	B-Chemical
have	O
activity	O
in	O
HL	B-Disease
,	O
non	O
-	O
overlapping	O
toxicity	B-Disease
with	O
first	O
-	O
line	O
chemotherapeutics	O
,	O
and	O
may	O
be	O
delivered	O
in	O
an	O
outpatient	O
setting	O
.	O
In	O
this	O
retrospective	O
single	O
-	O
centre	O
analysis	O
,	O
patients	O
with	O
relapsed	O
or	O
refractory	O
HL	B-Disease
treated	O
with	O
gemcitabine	B-Chemical
1	O
,	O
000	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
(	O
D	O
)	O
1	O
,	O
D8	O
and	O
D15	O
;	O
methylprednisolone	B-Chemical
1	O
,	O
000	O
mg	O
D1	O
-	O
5	O
;	O
and	O
cisplatin	B-Chemical
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
D15	O
,	O
every	O
28	O
days	O
(	O
GEM	B-Chemical
-	O
P	O
)	O
were	O
included	O
.	O
Demographic	O
,	O
survival	O
,	O
response	O
and	O
toxicity	B-Disease
data	O
were	O
recorded	O
.	O
Forty	O
-	O
one	O
eligible	O
patients	O
were	O
identified	O
:	O
median	O
age	O
27	O
.	O
One	O
hundred	O
and	O
twenty	O
-	O
two	O
cycles	O
of	O
GEM	B-Chemical
-	O
P	O
were	O
administered	O
in	O
total	O
(	O
median	O
3	O
cycles	O
;	O
range	O
1	O
-	O
6	O
)	O
.	O
Twenty	O
of	O
41	O
(	O
48	O
%	O
)	O
patients	O
received	O
GEM	B-Chemical
-	O
P	O
as	O
second	O
-	O
line	O
treatment	O
and	O
11	O
/	O
41	O
(	O
27	O
%	O
)	O
as	O
third	O
-	O
line	O
therapy	O
.	O
Overall	O
response	O
rate	O
(	O
ORR	O
)	O
to	O
GEM	B-Chemical
-	O
P	O
in	O
the	O
entire	O
cohort	O
was	O
80	O
%	O
(	O
complete	O
response	O
(	O
CR	O
)	O
37	O
%	O
,	O
partial	O
response	O
44	O
%	O
)	O
with	O
14	O
/	O
15	O
CR	O
confirmed	O
as	O
a	O
metabolic	O
CR	O
on	O
PET	O
and	O
ORR	O
of	O
85	O
%	O
in	O
the	O
20	O
second	O
-	O
line	O
patients	O
.	O
The	O
most	O
common	O
grade	O
3	O
/	O
4	O
toxicities	B-Disease
were	O
haematological	O
:	O
neutropenia	B-Disease
54	O
%	O
and	O
thrombocytopenia	B-Disease
51	O
%	O
.	O
Median	O
follow	O
-	O
up	O
from	O
the	O
start	O
of	O
GEM	B-Chemical
-	O
P	O
was	O
4	O
.	O
5	O
years	O
.	O
Following	O
GEM	B-Chemical
-	O
P	O
,	O
5	O
-	O
year	O
progression	O
-	O
free	O
survival	O
was	O
46	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
30	O
-	O
62	O
%	O
)	O
and	O
5	O
-	O
year	O
overall	O
survival	O
was	O
59	O
%	O
(	O
95	O
%	O
CI	O
,	O
43	O
-	O
74	O
%	O
)	O
.	O
Fourteen	O
of	O
41	O
patients	O
proceeded	O
directly	O
to	O
autologous	O
transplant	O
.	O
GEM	B-Chemical
-	O
P	O
is	O
a	O
salvage	O
chemotherapy	O
with	O
relatively	O
high	O
response	O
rates	O
,	O
leading	O
to	O
successful	O
transplantation	O
in	O
appropriate	O
patients	O
,	O
in	O
the	O
treatment	O
of	O
relapsed	O
or	O
refractory	O
HL	B-Disease
.	O
Basal	O
functioning	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
and	O
psychological	O
distress	O
in	O
recreational	O
ecstasy	B-Chemical
polydrug	O
users	O
.	O
RATIONALE	O
:	O
Ecstasy	B-Chemical
(	O
MDMA	B-Chemical
)	O
is	O
a	O
psychostimulant	O
drug	O
which	O
is	O
increasingly	O
associated	O
with	O
psychobiological	B-Disease
dysfunction	I-Disease
.	O
While	O
some	O
recent	O
studies	O
suggest	O
acute	O
changes	O
in	O
neuroendocrine	O
function	O
,	O
less	O
is	O
known	O
about	O
long	O
-	O
term	O
changes	O
in	O
HPA	O
functionality	O
in	O
recreational	O
users	O
.	O
OBJECTIVES	O
:	O
The	O
current	O
study	O
is	O
the	O
first	O
to	O
explore	O
the	O
effects	O
of	O
ecstasy	B-Chemical
-	O
polydrug	O
use	O
on	O
psychological	O
distress	O
and	O
basal	O
functioning	O
of	O
the	O
HPA	O
axis	O
through	O
assessing	O
the	O
secretion	O
of	O
cortisol	B-Chemical
across	O
the	O
diurnal	O
period	O
.	O
METHOD	O
:	O
Seventy	O
-	O
six	O
participants	O
(	O
21	O
nonusers	O
,	O
29	O
light	O
ecstasy	B-Chemical
-	O
polydrug	O
users	O
,	O
26	O
heavy	O
ecstasy	B-Chemical
-	O
polydrug	O
users	O
)	O
completed	O
a	O
substance	O
use	O
inventory	O
and	O
measures	O
of	O
psychological	O
distress	O
at	O
baseline	O
,	O
then	O
two	O
consecutive	O
days	O
of	O
cortisol	B-Chemical
sampling	O
(	O
on	O
awakening	O
,	O
30	O
min	O
post	O
awakening	O
,	O
between	O
1400	O
and	O
1600	O
hours	O
and	O
pre	O
bedtime	O
)	O
.	O
On	O
day	O
2	O
,	O
participants	O
also	O
attended	O
the	O
laboratory	O
to	O
complete	O
a	O
20	O
-	O
min	O
multitasking	O
stressor	O
.	O
RESULTS	O
:	O
Both	O
user	O
groups	O
exhibited	O
significantly	O
greater	O
levels	O
of	O
anxiety	B-Disease
and	O
depression	B-Disease
than	O
nonusers	O
.	O
On	O
day	O
1	O
,	O
all	O
participants	O
exhibited	O
a	O
typical	O
cortisol	B-Chemical
profile	O
,	O
though	O
light	O
users	O
had	O
significantly	O
elevated	O
levels	O
pre	O
-	O
bed	O
.	O
On	O
day	O
2	O
,	O
heavy	O
users	O
demonstrated	O
elevated	O
levels	O
upon	O
awakening	O
and	O
all	O
ecstasy	B-Chemical
-	O
polydrug	O
users	O
demonstrated	O
elevated	O
pre	O
-	O
bed	O
levels	O
compared	O
to	O
non	O
-	O
users	O
.	O
Significant	O
between	O
group	O
differences	O
were	O
also	O
observed	O
in	O
afternoon	O
cortisol	B-Chemical
levels	O
and	O
in	O
overall	O
cortisol	B-Chemical
secretion	O
across	O
the	O
day	O
.	O
CONCLUSIONS	O
:	O
The	O
increases	O
in	O
anxiety	B-Disease
and	O
depression	B-Disease
are	O
in	O
line	O
with	O
previous	O
observations	O
in	O
recreational	O
ecstasy	B-Chemical
-	O
polydrug	O
users	O
.	O
Dysregulated	O
diurnal	O
cortisol	B-Chemical
may	O
be	O
indicative	O
of	O
inappropriate	O
anticipation	O
of	O
forthcoming	O
demands	O
and	O
hypersecretion	O
may	O
lead	O
to	O
the	O
increased	O
psychological	O
and	O
physical	O
morbidity	O
associated	O
with	O
heavy	O
recreational	O
use	O
of	O
ecstasy	B-Chemical
.	O
Ifosfamide	B-Chemical
related	O
encephalopathy	B-Disease
:	O
the	O
need	O
for	O
a	O
timely	O
EEG	O
evaluation	O
.	O
BACKGROUND	O
:	O
Ifosfamide	B-Chemical
is	O
an	O
alkylating	O
agent	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
wide	O
range	O
of	O
cancers	B-Disease
including	O
sarcomas	B-Disease
,	O
lymphoma	B-Disease
,	O
gynecologic	B-Disease
and	I-Disease
testicular	I-Disease
cancers	I-Disease
.	O
Encephalopathy	B-Disease
has	O
been	O
reported	O
in	O
10	O
-	O
40	O
%	O
of	O
patients	O
receiving	O
high	O
-	O
dose	O
IV	O
ifosfamide	B-Chemical
.	O
OBJECTIVE	O
:	O
To	O
highlight	O
the	O
role	O
of	O
electroencephalogram	O
(	O
EEG	O
)	O
in	O
the	O
early	O
detection	O
and	O
management	O
of	O
ifosfamide	B-Chemical
related	O
encephalopathy	B-Disease
.	O
METHODS	O
:	O
Retrospective	O
chart	O
review	O
including	O
clinical	O
data	O
and	O
EEG	O
recordings	O
was	O
done	O
on	O
five	O
patients	O
,	O
admitted	O
to	O
MD	O
Anderson	O
Cancer	B-Disease
Center	O
between	O
years	O
2009	O
and	O
2012	O
,	O
who	O
developed	O
ifosfamide	B-Chemical
related	O
acute	O
encephalopathy	B-Disease
.	O
RESULTS	O
:	O
All	O
five	O
patients	O
experienced	O
symptoms	O
of	O
encephalopathy	B-Disease
soon	O
after	O
(	O
within	O
12	O
h	O
-	O
2	O
days	O
)	O
receiving	O
ifosfamide	B-Chemical
.	O
Two	O
patients	O
developed	O
generalized	O
convulsions	B-Disease
while	O
one	O
patient	O
developed	O
continuous	O
non	B-Disease
-	I-Disease
convulsive	I-Disease
status	I-Disease
epilepticus	I-Disease
(	O
NCSE	B-Disease
)	O
that	O
required	O
ICU	O
admission	O
and	O
intubation	O
.	O
Initial	O
EEG	O
showed	O
epileptiform	O
discharges	O
in	O
three	O
patients	O
;	O
run	O
of	O
triphasic	O
waves	O
in	O
one	O
patient	O
and	O
moderate	O
degree	O
diffuse	O
generalized	O
slowing	O
.	O
Mixed	O
pattern	O
with	O
the	O
presence	O
of	O
both	O
sharps	O
and	O
triphasic	O
waves	O
were	O
also	O
noted	O
.	O
Repeat	O
EEGs	O
within	O
24	O
_	O
h	O
of	O
symptom	O
onset	O
showed	O
marked	O
improvement	O
that	O
was	O
correlated	O
with	O
clinical	O
improvement	O
.	O
CONCLUSIONS	O
:	O
Severity	O
of	O
ifosfamide	B-Chemical
related	O
encephalopathy	B-Disease
correlates	O
with	O
EEG	O
changes	O
.	O
We	O
suggest	O
a	O
timely	O
EEG	O
evaluation	O
for	O
patients	O
receiving	O
ifosfamide	B-Chemical
who	O
develop	O
features	O
of	O
encephalopathy	B-Disease
.	O
Incidence	O
of	O
contrast	B-Chemical
-	O
induced	O
nephropathy	B-Disease
in	O
hospitalised	O
patients	O
with	O
cancer	B-Disease
.	O
OBJECTIVES	O
:	O
To	O
determine	O
the	O
frequency	O
of	O
and	O
possible	O
factors	O
related	O
to	O
contrast	B-Chemical
-	O
induced	O
nephropathy	B-Disease
(	O
CIN	O
)	O
in	O
hospitalised	O
patients	O
with	O
cancer	B-Disease
.	O
METHODS	O
:	O
Ninety	O
adult	O
patients	O
were	O
enrolled	O
.	O
Patients	O
with	O
risk	O
factors	O
for	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
were	O
excluded	O
.	O
Blood	O
samples	O
were	O
examined	O
the	O
day	O
before	O
contrast	B-Chemical
-	O
enhanced	O
computed	O
tomography	O
(	O
CT	O
)	O
and	O
serially	O
for	O
3	O
days	O
thereafter	O
.	O
CIN	O
was	O
defined	O
as	O
an	O
increase	O
in	O
serum	O
creatinine	B-Chemical
(	O
Cr	B-Chemical
)	O
of	O
0	O
.	O
5	O
mg	O
/	O
dl	O
or	O
more	O
,	O
or	O
elevation	O
of	O
Cr	B-Chemical
to	O
25	O
%	O
over	O
baseline	O
.	O
Relationships	O
between	O
CIN	O
and	O
possible	O
risk	O
factors	O
were	O
investigated	O
.	O
RESULTS	O
:	O
CIN	O
was	O
detected	O
in	O
18	O
/	O
90	O
(	O
20	O
%	O
)	O
patients	O
.	O
CIN	O
developed	O
in	O
25	O
.	O
5	O
%	O
patients	O
who	O
underwent	O
chemotherapy	O
and	O
in	O
11	O
%	O
patients	O
who	O
did	O
not	O
(	O
P	O
=	O
0	O
.	O
1	O
)	O
.	O
CIN	O
more	O
frequently	O
developed	O
in	O
patients	O
who	O
had	O
undergone	O
CT	O
within	O
45	O
days	O
after	O
the	O
last	O
chemotherapy	O
(	O
P	O
=	O
0	O
.	O
005	O
)	O
;	O
it	O
was	O
also	O
an	O
independent	O
risk	O
factor	O
(	O
P	O
=	O
0	O
.	O
017	O
)	O
.	O
CIN	O
was	O
significantly	O
more	O
after	O
treatment	O
with	O
bevacizumab	B-Chemical
/	O
irinotecan	B-Chemical
(	O
P	O
=	O
0	O
.	O
021	O
)	O
and	O
in	O
patients	O
with	O
hypertension	B-Disease
(	O
P	O
=	O
0	O
.	O
044	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
incidence	O
of	O
CIN	O
after	O
CT	O
in	O
hospitalised	O
oncological	O
patients	O
was	O
20	O
%	O
.	O
CIN	O
developed	O
4	O
.	O
5	O
-	O
times	O
more	O
frequently	O
in	O
patients	O
with	O
cancer	B-Disease
who	O
had	O
undergone	O
recent	O
chemotherapy	O
.	O
Hypertension	B-Disease
and	O
the	O
combination	O
of	O
bevacizumab	B-Chemical
/	O
irinotecan	B-Chemical
may	O
be	O
additional	O
risk	O
factors	O
for	O
CIN	O
development	O
.	O
KEY	O
POINTS	O
:	O
.	O
Contrast	B-Chemical
-	O
induced	O
nephropathy	B-Disease
(	O
CIN	O
)	O
is	O
a	O
concern	O
for	O
oncological	O
patients	O
undergoing	O
CT	O
.	O
.	O
CIN	O
occurs	O
more	O
often	O
when	O
CT	O
is	O
performed	O
<	O
45	O
days	O
after	O
chemotherapy	O
.	O
.	O
Hypertension	B-Disease
and	O
treatment	O
with	O
bevacizumab	B-Chemical
appear	O
to	O
be	O
additional	O
risk	O
factors	O
.	O
Syndrome	B-Disease
of	I-Disease
inappropriate	I-Disease
antidiuretic	I-Disease
hormone	I-Disease
secretion	O
associated	O
with	O
desvenlafaxine	B-Chemical
.	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
syndrome	B-Disease
of	I-Disease
inappropriate	I-Disease
anti	I-Disease
-	I-Disease
diuretic	I-Disease
hormone	I-Disease
(	O
SIADH	B-Disease
)	O
secretion	O
associated	O
with	O
desvenlafaxine	B-Chemical
.	O
CASE	O
SUMMARY	O
:	O
A	O
57	O
-	O
year	O
old	O
female	O
with	O
hyponatraemia	B-Disease
.	O
Her	O
medications	O
included	O
desvenlafaxine	B-Chemical
,	O
and	O
symptoms	O
included	O
nausea	B-Disease
,	O
anxiety	B-Disease
and	O
confusion	B-Disease
.	O
The	O
serum	O
sodium	B-Chemical
at	O
this	O
time	O
was	O
120	O
mmol	O
/	O
L	O
,	O
serum	O
osmolality	O
was	O
263	O
mosmol	O
/	O
kg	O
,	O
urine	O
osmolality	O
410	O
mosmol	O
/	O
kg	O
and	O
urine	O
sodium	B-Chemical
63	O
mmol	O
/	O
L	O
,	O
consistent	O
with	O
a	O
diagnosis	O
of	O
SIADH	B-Disease
.	O
Desvenlafaxine	B-Chemical
was	O
ceased	O
and	O
fluid	O
restriction	O
implemented	O
.	O
After	O
4	O
days	O
the	O
sodium	B-Chemical
increased	O
to	O
128	O
mmol	O
/	O
L	O
and	O
fluid	O
restriction	O
was	O
relaxed	O
.	O
During	O
her	O
further	O
3	O
weeks	O
inpatient	O
admission	O
the	O
serum	O
sodium	B-Chemical
ranged	O
from	O
134	O
to	O
137	O
mmol	O
/	O
L	O
during	O
treatment	O
with	O
mirtazapine	B-Chemical
.	O
DISCUSSION	O
:	O
SIADH	B-Disease
has	O
been	O
widely	O
reported	O
with	O
a	O
range	O
of	O
antidepressants	O
.	O
This	O
case	O
report	O
suggests	O
that	O
desvenlafaxine	B-Chemical
might	O
cause	O
clinically	O
significant	O
hyponatremia	B-Disease
.	O
CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
antidepressants	O
to	O
cause	O
hyponatremia	B-Disease
,	O
and	O
take	O
appropriate	O
corrective	O
action	O
where	O
necessary	O
.	O
Oxidative	O
stress	O
on	O
cardiotoxicity	B-Disease
after	O
treatment	O
with	O
single	O
and	O
multiple	O
doses	O
of	O
doxorubicin	B-Chemical
.	O
The	O
mechanism	O
of	O
doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
-	O
induced	O
cardiotoxicity	B-Disease
remains	O
controversial	O
.	O
Wistar	O
rats	O
(	O
n	O
=	O
66	O
)	O
received	O
DOX	B-Chemical
injections	O
intraperitoneally	O
and	O
were	O
randomly	O
assigned	O
to	O
2	O
experimental	O
protocols	O
:	O
(	O
1	O
)	O
rats	O
were	O
killed	O
before	O
(	O
-	O
24	O
h	O
,	O
n	O
=	O
8	O
)	O
and	O
24	O
h	O
after	O
(	O
+	O
24	O
h	O
,	O
n	O
=	O
8	O
)	O
a	O
single	O
dose	O
of	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
to	O
determine	O
the	O
DOX	B-Chemical
acute	O
effect	O
and	O
(	O
2	O
)	O
rats	O
(	O
n	O
=	O
58	O
)	O
received	O
4	O
injections	O
of	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
week	O
)	O
and	O
were	O
killed	O
before	O
the	O
first	O
injection	O
(	O
M0	O
)	O
and	O
1	O
week	O
after	O
each	O
injection	O
(	O
M1	O
,	O
M2	O
,	O
M3	O
,	O
and	O
M4	O
)	O
to	O
determine	O
the	O
chronological	O
effects	O
.	O
Animals	O
used	O
at	O
M0	O
(	O
n	O
=	O
8	O
)	O
were	O
also	O
used	O
at	O
moment	O
-	O
24	O
h	O
of	O
acute	O
study	O
.	O
Cardiac	O
total	O
antioxidant	O
performance	O
(	O
TAP	O
)	O
,	O
DNA	O
damage	O
,	O
and	O
morphology	O
analyses	O
were	O
carried	O
out	O
at	O
each	O
time	O
point	O
.	O
Single	O
dose	O
of	O
DOX	B-Chemical
was	O
associated	O
with	O
increased	O
cardiac	B-Disease
disarrangement	I-Disease
,	O
necrosis	B-Disease
,	O
and	O
DNA	O
damage	O
(	O
strand	O
breaks	O
(	O
SBs	O
)	O
and	O
oxidized	O
pyrimidines	O
)	O
and	O
decreased	O
TAP	O
.	O
The	O
chronological	O
study	O
showed	O
an	O
effect	O
of	O
a	O
cumulative	O
dose	O
on	O
body	O
weight	O
(	O
R	O
=	O
-	O
0	O
.	O
99	O
,	O
p	O
=	O
0	O
.	O
011	O
)	O
,	O
necrosis	B-Disease
(	O
R	O
=	O
1	O
.	O
00	O
,	O
p	O
=	O
0	O
.	O
004	O
)	O
,	O
TAP	O
(	O
R	O
=	O
0	O
.	O
95	O
,	O
p	O
=	O
0	O
.	O
049	O
)	O
,	O
and	O
DNA	O
SBs	O
(	O
R	O
=	O
-	O
0	O
.	O
95	O
,	O
p	O
=	O
0	O
.	O
049	O
)	O
.	O
DNA	O
SBs	O
damage	O
was	O
negatively	O
associated	O
with	O
TAP	O
(	O
R	O
=	O
-	O
0	O
.	O
98	O
,	O
p	O
=	O
0	O
.	O
018	O
)	O
,	O
and	O
necrosis	B-Disease
(	O
R	O
=	O
-	O
0	O
.	O
97	O
,	O
p	O
=	O
0	O
.	O
027	O
)	O
.	O
Our	O
results	O
suggest	O
that	O
oxidative	O
damage	O
is	O
associated	O
with	O
acute	O
cardiotoxicity	B-Disease
induced	O
by	O
a	O
single	O
dose	O
of	O
DOX	B-Chemical
only	O
.	O
Increased	O
resistance	O
to	O
the	O
oxidative	O
stress	O
is	O
plausible	O
for	O
the	O
multiple	O
dose	O
of	O
DOX	B-Chemical
.	O
Thus	O
,	O
different	O
mechanisms	O
may	O
be	O
involved	O
in	O
acute	O
toxicity	B-Disease
versus	O
chronic	O
toxicity	B-Disease
.	O
Tacrolimus	B-Chemical
-	O
related	O
seizure	B-Disease
after	O
pediatric	O
liver	O
transplantation	O
-	O
-	O
a	O
single	O
-	O
center	O
experience	O
.	O
To	O
identify	O
the	O
risk	O
factors	O
for	O
new	O
-	O
onset	O
seizures	B-Disease
after	O
pediatric	O
LT	O
and	O
to	O
assess	O
their	O
clinical	O
implications	O
and	O
long	O
-	O
term	O
prognosis	O
.	O
The	O
clinical	O
and	O
laboratory	O
data	O
of	O
27	O
consecutive	O
children	O
who	O
underwent	O
LT	O
from	O
January	O
2007	O
to	O
December	O
2010	O
in	O
our	O
center	O
were	O
analyzed	O
retrospectively	O
.	O
Patients	O
were	O
divided	O
into	O
seizures	B-Disease
group	O
and	O
a	O
non	O
-	O
seizures	B-Disease
group	O
.	O
Pre	O
-	O
operative	O
,	O
intra	O
-	O
operative	O
,	O
and	O
post	O
-	O
operative	O
data	O
were	O
collected	O
.	O
Seizures	B-Disease
occurred	O
in	O
four	O
children	O
,	O
an	O
incidence	O
of	O
14	O
.	O
8	O
%	O
.	O
All	O
exhibited	O
generalized	O
tonic	B-Disease
-	I-Disease
clonic	I-Disease
seizures	I-Disease
within	O
the	O
first	O
two	O
wk	O
after	O
LT	O
.	O
Univariate	O
analysis	O
showed	O
that	O
the	O
risk	O
factors	O
associated	O
with	O
seizures	B-Disease
after	O
pediatric	O
LT	O
included	O
gender	O
,	O
pediatric	O
end	B-Disease
-	I-Disease
stage	I-Disease
liver	I-Disease
disease	I-Disease
score	O
before	O
surgery	O
,	O
Child	O
-	O
Pugh	O
score	O
before	O
surgery	O
,	O
serum	O
total	O
bilirubin	B-Chemical
after	O
surgery	O
,	O
and	O
trough	O
TAC	B-Chemical
level	O
.	O
Multivariate	O
analysis	O
showed	O
that	O
trough	O
TAC	B-Chemical
level	O
was	O
the	O
only	O
independent	O
risk	O
factor	O
associated	O
with	O
the	O
seizures	B-Disease
.	O
All	O
children	O
who	O
experienced	O
seizures	B-Disease
survived	O
with	O
good	O
graft	O
function	O
and	O
remained	O
seizure	B-Disease
-	O
free	O
without	O
anti	O
-	O
epileptic	B-Disease
drugs	O
over	O
a	O
mean	O
follow	O
-	O
up	O
period	O
of	O
33	O
.	O
7	O
+	O
14	O
.	O
6	O
months	O
.	O
High	O
trough	O
TAC	B-Chemical
level	O
was	O
the	O
predominant	O
factor	O
that	O
contributed	O
to	O
seizures	B-Disease
in	O
the	O
early	O
post	O
-	O
operative	O
period	O
after	O
pediatric	O
LT	O
.	O
High	O
PELD	O
and	O
Child	O
-	O
Pugh	O
scores	O
before	O
LT	O
and	O
high	O
post	O
-	O
operative	O
serum	O
Tbil	O
may	O
be	O
contributory	O
risk	O
factors	O
for	O
TAC	B-Chemical
-	O
related	O
seizures	B-Disease
.	O
The	O
flavonoid	B-Chemical
apigenin	B-Chemical
delays	O
forgetting	O
of	O
passive	O
avoidance	O
conditioning	O
in	O
rats	O
.	O
The	O
present	O
experiments	O
were	O
performed	O
to	O
study	O
the	O
effect	O
of	O
the	O
flavonoid	B-Chemical
apigenin	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
,	O
1	O
h	O
before	O
acquisition	O
)	O
,	O
on	O
24	O
h	O
retention	O
performance	O
and	O
forgetting	O
of	O
a	O
step	O
-	O
through	O
passive	O
avoidance	O
task	O
,	O
in	O
young	O
male	O
Wistar	O
rats	O
.	O
There	O
were	O
no	O
differences	O
between	O
saline	O
-	O
and	O
apigenin	B-Chemical
-	O
treated	O
groups	O
in	O
the	O
24	O
h	O
retention	O
trial	O
.	O
Furthermore	O
,	O
apigenin	B-Chemical
did	O
not	O
prevent	O
the	O
amnesia	B-Disease
induced	O
by	O
scopolamine	B-Chemical
(	O
1mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
30	O
min	O
before	O
the	O
acquisition	O
)	O
.	O
The	O
saline	O
-	O
and	O
apigenin	B-Chemical
-	O
treated	O
rats	O
that	O
did	O
not	O
step	O
through	O
into	O
the	O
dark	O
compartment	O
during	O
the	O
cut	O
-	O
off	O
time	O
(	O
540	O
s	O
)	O
were	O
retested	O
weekly	O
for	O
up	O
to	O
eight	O
weeks	O
.	O
In	O
the	O
saline	O
treated	O
group	O
,	O
the	O
first	O
significant	O
decline	O
in	O
passive	O
avoidance	O
response	O
was	O
observed	O
at	O
four	O
weeks	O
,	O
and	O
complete	O
memory	B-Disease
loss	I-Disease
was	O
found	O
five	O
weeks	O
after	O
the	O
acquisition	O
of	O
the	O
passive	O
avoidance	O
task	O
.	O
At	O
the	O
end	O
of	O
the	O
experimental	O
period	O
,	O
60	O
%	O
of	O
the	O
animals	O
treated	O
with	O
apigenin	B-Chemical
still	O
did	O
not	O
step	O
through	O
.	O
These	O
data	O
suggest	O
that	O
1	O
)	O
apigenin	B-Chemical
delays	O
the	O
long	O
-	O
term	O
forgetting	O
but	O
did	O
not	O
modulate	O
the	O
24	O
h	O
retention	O
of	O
fear	O
memory	O
and	O
2	O
)	O
the	O
obtained	O
beneficial	O
effect	O
of	O
apigenin	B-Chemical
on	O
the	O
passive	O
avoidance	O
conditioning	O
is	O
mediated	O
by	O
mechanisms	O
that	O
do	O
not	O
implicate	O
its	O
action	O
on	O
the	O
muscarinic	O
cholinergic	O
system	O
.	O
Histamine	B-Chemical
antagonists	O
and	O
d	B-Chemical
-	I-Chemical
tubocurarine	I-Chemical
-	O
induced	O
hypotension	B-Disease
in	O
cardiac	O
surgical	O
patients	O
.	O
Hemodynamic	O
effects	O
and	O
histamine	B-Chemical
release	O
by	O
bolus	O
injection	O
of	O
0	O
.	O
35	O
mg	O
/	O
kg	O
of	O
d	B-Chemical
-	I-Chemical
tubocurarine	I-Chemical
were	O
studied	O
in	O
24	O
patients	O
.	O
H1	O
-	O
and	O
H2	O
-	O
histamine	B-Chemical
antagonists	O
or	O
placebo	O
were	O
given	O
before	O
dosing	O
with	O
d	B-Chemical
-	I-Chemical
tubocurarine	I-Chemical
in	O
a	O
randomized	O
double	O
-	O
blind	O
fashion	O
to	O
four	O
groups	O
:	O
group	O
1	O
-	O
-	O
placebo	O
;	O
group	O
2	O
-	O
-	O
cimetidine	B-Chemical
,	O
4	O
mg	O
/	O
kg	O
,	O
plus	O
placebo	O
;	O
group	O
3	O
-	O
-	O
chlorpheniramine	B-Chemical
,	O
0	O
.	O
1	O
mg	O
/	O
kg	O
,	O
plus	O
placebo	O
;	O
and	O
group	O
4	O
-	O
-	O
cimetidine	B-Chemical
plus	O
chlorpheniramine	B-Chemical
.	O
Histamine	B-Chemical
release	O
occurred	O
in	O
most	O
patients	O
,	O
the	O
highest	O
level	O
2	O
minutes	O
after	O
d	B-Chemical
-	I-Chemical
tubocurarine	I-Chemical
dosing	O
.	O
Group	O
1	O
had	O
a	O
moderate	O
negative	O
correlation	O
between	O
plasma	O
histamine	B-Chemical
change	O
and	O
systemic	O
vascular	O
resistance	O
(	O
r	O
=	O
0	O
.	O
58	O
;	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
not	O
present	O
in	O
group	O
4	O
.	O
Prior	O
dosing	O
with	O
antagonists	O
partially	O
prevented	O
the	O
fall	O
in	O
systemic	O
vascular	O
resistance	O
.	O
These	O
data	O
demonstrate	O
that	O
the	O
hemodynamic	O
changes	O
associated	O
with	O
d	B-Chemical
-	I-Chemical
tubocurarine	I-Chemical
dosing	O
are	O
only	O
partially	O
explained	O
by	O
histamine	B-Chemical
release	O
.	O
Thus	O
prior	O
dosing	O
with	O
H1	O
-	O
and	O
H2	O
-	O
antagonists	O
provides	O
only	O
partial	O
protection	O
.	O
Cholecystokinin	B-Chemical
-	I-Chemical
octapeptide	I-Chemical
restored	O
morphine	B-Chemical
-	O
induced	O
hippocampal	O
long	O
-	O
term	O
potentiation	O
impairment	O
in	O
rats	O
.	O
Cholecystokinin	B-Chemical
-	I-Chemical
octapeptide	I-Chemical
(	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
)	O
,	O
which	O
is	O
a	O
typical	O
brain	O
-	O
gut	O
peptide	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
activities	O
on	O
the	O
central	O
nervous	O
system	O
.	O
We	O
have	O
previously	O
reported	O
that	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
significantly	O
alleviated	O
morphine	B-Chemical
-	O
induced	O
amnesia	B-Disease
and	O
reversed	O
spine	O
density	O
decreases	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
in	O
morphine	B-Chemical
-	O
treated	O
animals	O
.	O
Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
on	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
in	O
the	O
lateral	O
perforant	O
path	O
(	O
LPP	O
)	O
-	O
granule	O
cell	O
synapse	O
of	O
rat	O
dentate	O
gyrus	O
(	O
DG	O
)	O
in	O
acute	O
saline	O
or	O
morphine	B-Chemical
-	O
treated	O
rats	O
.	O
Population	O
spikes	O
(	O
PS	O
)	O
,	O
which	O
were	O
evoked	O
by	O
stimulation	O
of	O
the	O
LPP	O
,	O
were	O
recorded	O
in	O
the	O
DG	O
region	O
.	O
Acute	O
morphine	B-Chemical
(	O
30mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
treatment	O
significantly	O
attenuated	O
hippocampal	O
LTP	O
and	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
(	O
1ug	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
restored	O
the	O
amplitude	O
of	O
PS	O
that	O
was	O
attenuated	O
by	O
morphine	B-Chemical
injection	O
.	O
Furthermore	O
,	O
microinjection	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
(	O
0	O
.	O
1	O
and	O
1ug	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
also	O
significantly	O
augmented	O
hippocampal	O
LTP	O
in	O
saline	O
-	O
treated	O
(	O
1ml	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
rats	O
.	O
Pre	O
-	O
treatment	O
of	O
the	O
CCK2	O
receptor	O
antagonist	O
L	O
-	O
365	O
,	O
260	O
(	O
10ug	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
reversed	O
the	O
effects	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
,	O
but	O
the	O
CCK1	O
receptor	O
antagonist	O
L	O
-	O
364	O
,	O
718	O
(	O
10ug	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
did	O
not	O
.	O
The	O
present	O
results	O
demonstrate	O
that	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
attenuates	O
the	O
effect	O
of	O
morphine	B-Chemical
on	O
hippocampal	O
LTP	O
through	O
CCK2	O
receptors	O
and	O
suggest	O
an	O
ameliorative	O
function	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
on	O
morphine	B-Chemical
-	O
induced	O
memory	B-Disease
impairment	I-Disease
.	O
Glial	O
activation	O
and	O
post	O
-	O
synaptic	O
neurotoxicity	B-Disease
:	O
the	O
key	O
events	O
in	O
Streptozotocin	B-Chemical
(	O
ICV	O
)	O
induced	O
memory	B-Disease
impairment	I-Disease
in	O
rats	O
.	O
In	O
the	O
present	O
study	O
the	O
role	O
of	O
glial	O
activation	O
and	O
post	O
synaptic	O
toxicity	B-Disease
in	O
ICV	O
Streptozotocin	B-Chemical
(	O
STZ	B-Chemical
)	O
induced	O
memory	B-Disease
impaired	I-Disease
rats	O
was	O
explored	O
.	O
In	O
experiment	O
set	O
up	O
1	O
:	O
Memory	B-Disease
deficit	I-Disease
was	O
found	O
in	O
Morris	O
water	O
maze	O
test	O
on	O
14	O
-	O
16	O
days	O
after	O
STZ	B-Chemical
(	O
ICV	O
;	O
3mg	O
/	O
Kg	O
)	O
administration	O
.	O
STZ	B-Chemical
causes	O
increased	O
expression	O
of	O
GFAP	O
,	O
CD11b	O
and	O
TNF	O
-	O
a	O
indicating	O
glial	O
activation	O
and	O
neuroinflammation	B-Disease
.	O
STZ	B-Chemical
also	O
significantly	O
increased	O
the	O
level	O
of	O
ROS	O
,	O
nitrite	B-Chemical
,	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
and	O
reduced	O
the	O
mitochondrial	O
activity	O
in	O
synaptosomal	O
preparation	O
illustrating	O
free	O
radical	O
generation	O
and	O
excitotoxicity	B-Disease
.	O
Increased	O
expression	O
and	O
activity	O
of	O
Caspase	O
-	O
3	O
was	O
also	O
observed	O
in	O
STZ	B-Chemical
treated	O
rat	O
which	O
specify	O
apoptotic	O
cell	O
death	O
in	O
hippocampus	O
and	O
cortex	O
.	O
STZ	B-Chemical
treatment	O
showed	O
decrease	O
expression	O
of	O
post	O
synaptic	O
markers	O
CaMKIIa	O
and	O
PSD	O
-	O
95	O
,	O
while	O
,	O
expression	O
of	O
pre	O
synaptic	O
markers	O
(	O
synaptophysin	O
and	O
SNAP	O
-	O
25	O
)	O
remains	O
unaltered	O
indicating	O
selective	O
post	O
synaptic	O
neurotoxicity	B-Disease
.	O
Oral	O
treatment	O
with	O
Memantine	B-Chemical
(	O
10mg	O
/	O
kg	O
)	O
and	O
Ibuprofen	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
)	O
daily	O
for	O
13	O
days	O
attenuated	O
STZ	B-Chemical
induced	O
glial	O
activation	O
,	O
apoptotic	O
cell	O
death	O
and	O
post	O
synaptic	O
neurotoxicity	B-Disease
in	O
rat	O
brain	O
.	O
Further	O
,	O
in	O
experiment	O
set	O
up	O
2	O
:	O
where	O
memory	O
function	O
was	O
not	O
affected	O
i	O
.	O
e	O
.	O
7	O
-	O
9	O
days	O
after	O
STZ	B-Chemical
treatment	O
.	O
The	O
level	O
of	O
GFAP	O
,	O
CD11b	O
,	O
TNF	O
-	O
a	O
,	O
ROS	O
and	O
nitrite	B-Chemical
levels	O
were	O
increased	O
.	O
On	O
the	O
other	O
hand	O
,	O
apoptotic	O
marker	O
,	O
synaptic	O
markers	O
,	O
mitochondrial	O
activity	O
and	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
levels	O
remained	O
unaffected	O
.	O
Collective	O
data	O
indicates	O
that	O
neuroinflammatory	B-Disease
process	O
and	O
oxidative	O
stress	O
occurs	O
earlier	O
to	O
apoptosis	O
and	O
does	O
not	O
affect	O
memory	O
function	O
.	O
Present	O
study	O
clearly	O
suggests	O
that	O
glial	O
activation	O
and	O
post	O
synaptic	O
neurotoxicity	B-Disease
are	O
the	O
key	O
factors	O
in	O
STZ	B-Chemical
induced	O
memory	B-Disease
impairment	I-Disease
and	O
neuronal	O
cell	O
death	O
.	O
Comparison	O
of	O
effects	O
of	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
with	O
diltiazem	B-Chemical
in	O
prevention	O
of	O
contrast	B-Chemical
-	O
induced	O
nephropathy	B-Disease
.	O
INTRODUCTION	O
AND	O
OBJECTIVE	O
:	O
Contrast	B-Chemical
-	O
induced	O
nephropathy	B-Disease
(	O
CIN	O
)	O
significantly	O
increases	O
the	O
morbidity	O
and	O
mortality	O
of	O
patients	O
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
and	O
compare	O
the	O
protective	O
effects	O
of	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
with	O
sodium	B-Chemical
bicarbonate	I-Chemical
infusion	O
and	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
infusion	O
with	O
diltiazem	B-Chemical
,	O
a	O
calcium	B-Chemical
channel	O
blocker	O
,	O
in	O
preventing	O
CIN	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Our	O
study	O
included	O
patients	O
who	O
were	O
administered	O
30	O
-	O
60	O
mL	O
of	O
iodinated	O
contrast	B-Chemical
agent	O
for	O
percutaneous	O
coronary	O
angiography	O
(	O
PCAG	O
)	O
,	O
all	O
with	O
creatinine	B-Chemical
values	O
between	O
1	O
.	O
1	O
and	O
3	O
.	O
1	O
mg	O
/	O
dL	O
.	O
Patients	O
were	O
divided	O
into	O
three	O
groups	O
and	O
each	O
group	O
had	O
20	O
patients	O
.	O
The	O
first	O
group	O
of	O
patients	O
was	O
administered	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
;	O
the	O
second	O
group	O
was	O
administered	O
a	O
solution	O
that	O
of	O
5	O
%	O
dextrose	B-Chemical
and	O
sodium	B-Chemical
bicarbonate	I-Chemical
,	O
while	O
the	O
third	O
group	O
was	O
administered	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
before	O
and	O
after	O
the	O
contrast	B-Chemical
injection	O
.	O
The	O
third	O
group	O
received	O
an	O
additional	O
injection	O
of	O
diltiazem	B-Chemical
the	O
day	O
before	O
and	O
first	O
2	O
days	O
after	O
the	O
contrast	B-Chemical
injection	O
.	O
All	O
of	O
the	O
patients	O
'	O
plasma	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
(	O
BUN	B-Chemical
)	O
and	O
creatinine	B-Chemical
levels	O
were	O
measured	O
on	O
the	O
second	O
and	O
seventh	O
day	O
after	O
the	O
administration	O
of	O
intravenous	O
contrast	B-Chemical
material	O
.	O
RESULTS	O
:	O
The	O
basal	O
creatinine	B-Chemical
levels	O
were	O
similar	O
for	O
all	O
three	O
groups	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O
Among	O
a	O
total	O
of	O
60	O
patients	O
included	O
in	O
the	O
study	O
,	O
16	O
patients	O
developed	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
(	O
ARF	B-Disease
)	O
on	O
the	O
second	O
day	O
after	O
contrast	B-Chemical
material	O
was	O
injected	O
(	O
26	O
.	O
6	O
%	O
)	O
.	O
The	O
number	O
of	O
patients	O
who	O
developed	O
ARF	B-Disease
on	O
the	O
second	O
day	O
after	O
the	O
injection	O
in	O
the	O
first	O
group	O
was	O
five	O
(	O
25	O
%	O
)	O
,	O
in	O
the	O
second	O
group	O
was	O
six	O
(	O
30	O
%	O
)	O
and	O
the	O
third	O
group	O
was	O
five	O
(	O
25	O
%	O
)	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O
CONCLUSION	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
,	O
sodium	B-Chemical
bicarbonate	I-Chemical
and	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
with	O
diltiazem	B-Chemical
application	O
in	O
prevention	O
of	O
CIN	O
.	O
Neurocognitive	O
and	O
neuroradiologic	O
central	O
nervous	O
system	O
late	O
effects	O
in	O
children	O
treated	O
on	O
Pediatric	O
Oncology	O
Group	O
(	O
POG	O
)	O
P9605	O
(	O
standard	O
risk	O
)	O
and	O
P9201	O
(	O
lesser	O
risk	O
)	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
protocols	O
(	O
ACCL0131	O
)	O
:	O
a	O
methotrexate	B-Chemical
consequence	O
?	O
A	O
report	O
from	O
the	O
Children	O
'	O
s	O
Oncology	O
Group	O
.	O
Concerns	O
about	O
long	O
-	O
term	O
methotrexate	B-Chemical
(	O
MTX	B-Chemical
)	O
neurotoxicity	B-Disease
in	O
the	O
1990s	O
led	O
to	O
modifications	O
in	O
intrathecal	O
(	O
IT	O
)	O
therapy	O
,	O
leucovorin	O
rescue	O
,	O
and	O
frequency	O
of	O
systemic	O
MTX	B-Chemical
administration	O
in	O
children	O
with	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
.	O
In	O
this	O
study	O
,	O
neurocognitive	O
outcomes	O
and	O
neuroradiologic	O
evidence	O
of	O
leukoencephalopathy	B-Disease
were	O
compared	O
in	O
children	O
treated	O
with	O
intense	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
-	O
directed	O
therapy	O
(	O
P9605	O
)	O
versus	O
those	O
receiving	O
fewer	O
CNS	O
-	O
directed	O
treatment	O
days	O
during	O
intensive	O
consolidation	O
(	O
P9201	O
)	O
.	O
A	O
total	O
of	O
66	O
children	O
from	O
16	O
Pediatric	O
Oncology	O
Group	O
institutions	O
with	O
""""	O
standard	O
-	O
risk	O
""""	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
,	O
1	O
.	O
00	O
to	O
9	O
.	O
99	O
years	O
at	O
diagnosis	O
,	O
without	O
evidence	O
of	O
CNS	O
leukemia	B-Disease
at	O
diagnosis	O
were	O
enrolled	O
on	O
ACCL0131	O
:	O
28	O
from	O
P9201	O
and	O
38	O
from	O
P9605	O
.	O
Magnetic	O
resonance	O
imaging	O
scans	O
and	O
standard	O
neuropsychological	O
tests	O
were	O
performed	O
>	O
2	O
.	O
6	O
years	O
after	O
the	O
end	O
of	O
treatment	O
.	O
Significantly	O
more	O
P9605	O
patients	O
developed	O
leukoencephalopathy	B-Disease
compared	O
with	O
P9201	O
patients	O
(	O
68	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
49	O
%	O
-	O
83	O
%	O
vs	O
.	O
22	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
5	O
%	O
-	O
44	O
%	O
;	O
P	O
=	O
0	O
.	O
001	O
)	O
identified	O
as	O
late	O
as	O
7	O
.	O
7	O
years	O
after	O
the	O
end	O
of	O
treatment	O
.	O
Overall	O
,	O
40	O
%	O
of	O
patients	O
scored	O
<	O
85	O
on	O
either	O
Verbal	O
or	O
Performance	O
IQ	O
.	O
Children	O
on	O
both	O
studies	O
had	O
significant	O
attention	B-Disease
problems	I-Disease
,	O
but	O
P9605	O
children	O
scored	O
below	O
average	O
on	O
more	O
neurocognitive	O
measures	O
than	O
those	O
treated	O
on	O
P9201	O
(	O
82	O
%	O
,	O
14	O
/	O
17	O
measures	O
vs	O
.	O
24	O
%	O
,	O
4	O
/	O
17	O
measures	O
)	O
.	O
This	O
supports	O
ongoing	O
concerns	O
about	O
intensive	O
MTX	B-Chemical
exposure	O
as	O
a	O
major	O
contributor	O
to	O
CNS	O
late	O
effects	O
.	O
Tranexamic	B-Chemical
acid	I-Chemical
overdosage	O
-	O
induced	O
generalized	O
seizure	B-Disease
in	O
renal	B-Disease
failure	I-Disease
.	O
We	O
report	O
a	O
45	O
-	O
year	O
-	O
old	O
lady	O
with	O
chronic	B-Disease
kidney	I-Disease
disease	I-Disease
stage	O
4	O
due	O
to	O
chronic	O
tubulointerstial	B-Disease
disease	I-Disease
.	O
She	O
was	O
admitted	O
to	O
our	O
center	O
for	O
severe	O
anemia	B-Disease
due	O
to	O
menorrhagia	B-Disease
and	O
deterioration	B-Disease
of	I-Disease
renal	I-Disease
function	I-Disease
.	O
She	O
was	O
infused	O
three	O
units	O
of	O
packed	O
cells	O
during	O
a	O
session	O
of	O
hemodialysis	O
.	O
Tranexamic	B-Chemical
acid	I-Chemical
(	O
TNA	B-Chemical
)	O
1	O
g	O
8	O
-	O
hourly	O
was	O
administered	O
to	O
her	O
to	O
control	O
bleeding	B-Disease
per	O
vaginum	O
.	O
Two	O
hours	O
after	O
the	O
sixth	O
dose	O
of	O
TNA	B-Chemical
,	O
she	O
had	O
an	O
episode	O
of	O
generalized	O
tonic	B-Disease
clonic	I-Disease
convulsions	I-Disease
.	O
TNA	B-Chemical
was	O
discontinued	O
.	O
Investigations	O
of	O
the	O
patient	O
revealed	O
no	O
biochemical	O
or	O
structural	O
central	O
nervous	B-Disease
system	I-Disease
abnormalities	I-Disease
that	O
could	O
have	O
provoked	O
the	O
convulsions	B-Disease
.	O
She	O
did	O
not	O
require	O
any	O
further	O
dialytic	O
support	O
.	O
She	O
had	O
no	O
further	O
episodes	O
of	O
convulsion	B-Disease
till	O
dis	O
-	O
charge	O
and	O
during	O
the	O
two	O
months	O
of	O
follow	O
-	O
up	O
.	O
Thus	O
,	O
the	O
precipitating	O
cause	O
of	O
convulsions	B-Disease
was	O
believed	O
to	O
be	O
an	O
overdose	B-Disease
of	O
TNA	B-Chemical
.	O
Pre	O
-	O
treatment	O
of	O
bupivacaine	B-Chemical
-	O
induced	O
cardiovascular	B-Disease
depression	I-Disease
using	O
different	O
lipid	O
formulations	O
of	O
propofol	B-Chemical
.	O
BACKGROUND	O
:	O
Pre	O
-	O
treatment	O
with	O
lipid	O
emulsions	O
has	O
been	O
shown	O
to	O
increase	O
lethal	O
doses	O
of	O
bupivacaine	B-Chemical
,	O
and	O
the	O
lipid	O
content	O
of	O
propofol	B-Chemical
may	O
alleviate	O
bupivacaine	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
propofol	B-Chemical
in	O
intralipid	O
or	O
medialipid	O
emulsions	O
on	O
bupivacaine	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
METHODS	O
:	O
Rats	O
were	O
anaesthetised	O
with	O
ketamine	B-Chemical
and	O
were	O
given	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
min	O
propofol	B-Chemical
in	O
intralipid	O
(	O
Group	O
P	O
)	O
,	O
propofol	B-Chemical
in	O
medialipid	O
(	O
Group	O
L	O
)	O
,	O
or	O
saline	O
(	O
Group	O
C	O
)	O
over	O
20	O
min	O
.	O
Thereafter	O
,	O
2	O
mg	O
/	O
kg	O
/	O
min	O
bupivacaine	B-Chemical
0	O
.	O
5	O
%	O
was	O
infused	O
.	O
We	O
recorded	O
time	O
to	O
first	O
dysrhythmia	B-Disease
occurrence	O
,	O
respective	O
times	O
to	O
25	O
%	O
and	O
50	O
%	O
reduction	O
of	O
the	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
mean	O
arterial	O
pressure	O
,	O
and	O
time	O
to	O
asystole	B-Disease
and	O
total	O
amount	O
of	O
bupivacaine	B-Chemical
consumption	O
.	O
Blood	O
and	O
tissue	O
samples	O
were	O
collected	O
following	O
asystole	B-Disease
.	O
RESULTS	O
:	O
The	O
time	O
to	O
first	O
dysrhythmia	B-Disease
occurrence	O
,	O
time	O
to	O
25	O
%	O
and	O
50	O
%	O
reductions	O
in	O
HR	O
,	O
and	O
time	O
to	O
asystole	B-Disease
were	O
longer	O
in	O
Group	O
P	O
than	O
the	O
other	O
groups	O
.	O
The	O
cumulative	O
bupivacaine	B-Chemical
dose	O
given	O
at	O
those	O
time	O
points	O
was	O
higher	O
in	O
Group	O
P	O
.	O
Plasma	O
bupivacaine	B-Chemical
levels	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
than	O
in	O
Group	O
C	O
.	O
Bupivacaine	B-Chemical
levels	O
in	O
the	O
brain	O
and	O
heart	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
and	O
Group	O
L	O
than	O
in	O
Group	O
C	O
.	O
CONCLUSION	O
:	O
We	O
conclude	O
that	O
pre	O
-	O
treatment	O
with	O
propofol	B-Chemical
in	O
intralipid	O
,	O
compared	O
with	O
propofol	B-Chemical
in	O
medialipid	O
or	O
saline	O
,	O
delayed	O
the	O
onset	O
of	O
bupivacaine	B-Chemical
-	O
induced	O
cardiotoxic	B-Disease
effects	O
as	O
well	O
as	O
reduced	O
plasma	O
bupivacaine	B-Chemical
levels	O
.	O
Further	O
studies	O
are	O
needed	O
to	O
explore	O
tissue	O
bupivacaine	B-Chemical
levels	O
of	O
propofol	B-Chemical
in	O
medialipid	O
and	O
adapt	O
these	O
results	O
to	O
clinical	O
practice	O
.	O
Drug	B-Disease
-	I-Disease
Induced	I-Disease
Acute	I-Disease
Liver	I-Disease
Injury	I-Disease
Within	O
12	O
Hours	O
After	O
Fluvastatin	B-Chemical
Therapy	O
.	O
Although	O
statins	B-Chemical
are	O
generally	O
well	O
-	O
tolerated	O
drugs	O
,	O
recent	O
cases	O
of	O
drug	B-Disease
-	I-Disease
induced	I-Disease
liver	I-Disease
injury	I-Disease
associated	O
with	O
their	O
use	O
have	O
been	O
reported	O
.	O
A	O
52	O
-	O
year	O
-	O
old	O
Chinese	O
man	O
reported	O
with	O
liver	B-Disease
damage	I-Disease
,	O
which	O
appeared	O
12	O
hours	O
after	O
beginning	O
treatment	O
with	O
fluvastatin	B-Chemical
.	O
Patient	O
presented	O
with	O
complaints	O
of	O
increasing	O
nausea	B-Disease
,	O
anorexia	B-Disease
,	O
and	O
upper	O
abdominal	B-Disease
pain	I-Disease
.	O
His	O
laboratory	O
values	O
showed	O
elevated	O
creatine	B-Chemical
kinase	O
and	O
transaminases	O
.	O
Testing	O
for	O
autoantibodies	O
was	O
also	O
negative	O
.	O
The	O
liver	O
biochemistries	O
eventually	O
normalized	O
within	O
3	O
weeks	O
of	O
stopping	O
the	O
fluvastatin	B-Chemical
.	O
Therefore	O
,	O
when	O
prescribing	O
statins	O
,	O
the	O
possibility	O
of	O
hepatic	B-Disease
damage	I-Disease
should	O
be	O
taken	O
into	O
account	O
.	O
Fluconazole	B-Chemical
associated	O
agranulocytosis	B-Disease
and	O
thrombocytopenia	B-Disease
.	O
CASE	O
:	O
We	O
describe	O
a	O
second	O
case	O
of	O
fluconazole	B-Chemical
associated	O
agranulocytosis	B-Disease
with	O
thrombocytopenia	B-Disease
and	O
recovery	O
upon	O
discontinuation	O
of	O
therapy	O
.	O
The	O
patient	O
began	O
to	O
have	O
changes	O
in	O
white	O
blood	O
cells	O
and	O
platelets	O
within	O
48	O
h	O
of	O
administration	O
of	O
fluconazole	B-Chemical
and	O
began	O
to	O
recover	O
with	O
48	O
h	O
of	O
discontinuation	O
.	O
This	O
case	O
highlights	O
that	O
drug	O
-	O
induced	O
blood	B-Disease
dyscrasias	I-Disease
can	O
occur	O
unexpectedly	O
as	O
a	O
result	O
of	O
treatment	O
with	O
a	O
commonly	O
used	O
drug	O
thought	O
to	O
be	O
""""	O
safe	O
""""	O
.	O
CONCLUSION	O
:	O
According	O
to	O
Naranjo	O
'	O
s	O
algorithm	O
the	O
likelihood	O
that	O
our	O
patient	O
'	O
s	O
agranulocytosis	B-Disease
and	O
thrombocytopenia	B-Disease
occurred	O
as	O
a	O
result	O
of	O
therapy	O
with	O
fluconazole	B-Chemical
is	O
probable	O
,	O
with	O
a	O
total	O
of	O
six	O
points	O
.	O
We	O
feel	O
that	O
the	O
weight	O
of	O
the	O
overall	O
evidence	O
of	O
this	O
evidence	O
is	O
strong	O
.	O
In	O
particular	O
the	O
temporal	O
relationship	O
of	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
to	O
the	O
initiation	O
of	O
fluconazole	B-Chemical
and	O
the	O
abatement	O
of	O
symptoms	O
that	O
rapidly	O
reversed	O
immediately	O
following	O
discontinuation	O
.	O
Two	O
-	O
dimensional	O
speckle	O
tracking	O
echocardiography	O
combined	O
with	O
high	O
-	O
sensitive	O
cardiac	O
troponin	O
T	O
in	O
early	O
detection	O
and	O
prediction	O
of	O
cardiotoxicity	B-Disease
during	O
epirubicine	B-Chemical
-	O
based	O
chemotherapy	O
.	O
AIMS	O
:	O
To	O
investigate	O
whether	O
alterations	O
of	O
myocardial	B-Disease
strain	I-Disease
and	O
high	O
-	O
sensitive	O
cardiac	O
troponin	O
T	O
(	O
cTnT	O
)	O
could	O
predict	O
future	O
cardiac	B-Disease
dysfunction	I-Disease
in	O
patients	O
after	O
epirubicin	B-Chemical
exposure	O
.	O
METHODS	O
:	O
Seventy	O
-	O
five	O
patients	O
with	O
non	B-Disease
-	I-Disease
Hodgkin	I-Disease
lymphoma	I-Disease
treated	O
with	O
epirubicin	B-Chemical
were	O
studied	O
.	O
Blood	O
collection	O
and	O
echocardiography	O
were	O
performed	O
at	O
baseline	O
,	O
1	O
day	O
after	O
the	O
third	O
cycle	O
,	O
and	O
1	O
day	O
after	O
completion	O
of	O
chemotherapy	O
.	O
Patients	O
were	O
studied	O
using	O
echocardiography	O
during	O
follow	O
-	O
up	O
.	O
Global	O
longitudinal	O
(	O
GLS	O
)	O
,	O
circumferential	O
(	O
GCS	O
)	O
,	O
and	O
radial	O
strain	O
(	O
GRS	O
)	O
were	O
calculated	O
using	O
speckle	O
tracking	O
echocardiography	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
was	O
analysed	O
by	O
real	O
-	O
time	O
3D	O
echocardiography	O
.	O
Cardiotoxicity	B-Disease
was	O
defined	O
as	O
a	O
reduction	O
of	O
the	O
LVEF	O
of	O
>	O
5	O
%	O
to	O
<	O
55	O
%	O
with	O
symptoms	O
of	O
heart	B-Disease
failure	I-Disease
or	O
an	O
asymptomatic	O
reduction	O
of	O
the	O
LVEF	O
of	O
>	O
10	O
%	O
to	O
<	O
55	O
%	O
.	O
RESULTS	O
:	O
Fourteen	O
patients	O
(	O
18	O
.	O
67	O
%	O
)	O
developed	O
cardiotoxicity	B-Disease
after	O
treatment	O
.	O
GLS	O
(	O
-	O
18	O
.	O
48	O
+	O
1	O
.	O
72	O
%	O
vs	O
.	O
-	O
15	O
.	O
96	O
+	O
1	O
.	O
6	O
%	O
)	O
,	O
GCS	O
(	O
-	O
20	O
.	O
93	O
+	O
2	O
.	O
86	O
%	O
vs	O
.	O
-	O
19	O
.	O
20	O
+	O
3	O
.	O
21	O
%	O
)	O
,	O
and	O
GRS	O
(	O
39	O
.	O
23	O
+	O
6	O
.	O
44	O
%	O
vs	O
.	O
34	O
.	O
98	O
+	O
6	O
.	O
2	O
%	O
)	O
were	O
markedly	O
reduced	O
and	O
cTnT	O
was	O
elevated	O
from	O
0	O
.	O
0010	O
+	O
0	O
.	O
0020	O
to	O
0	O
.	O
0073	O
+	O
0	O
.	O
0038	O
ng	O
/	O
mL	O
(	O
P	O
all	O
<	O
0	O
.	O
01	O
)	O
at	O
the	O
completion	O
of	O
chemotherapy	O
compared	O
with	O
baseline	O
values	O
.	O
A	O
>	O
15	O
.	O
9	O
%	O
decrease	O
in	O
GLS	O
[	O
sensitivity	O
,	O
86	O
%	O
;	O
specificity	O
,	O
75	O
%	O
;	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
=	O
0	O
.	O
815	O
;	O
P	O
=	O
0	O
.	O
001	O
]	O
and	O
a	O
>	O
0	O
.	O
004	O
ng	O
/	O
mL	O
elevation	O
in	O
cTnT	O
(	O
sensitivity	O
,	O
79	O
%	O
;	O
specificity	O
,	O
64	O
%	O
;	O
AUC	O
=	O
0	O
.	O
757	O
;	O
P	O
=	O
0	O
.	O
005	O
)	O
from	O
baseline	O
to	O
the	O
third	O
cycle	O
of	O
chemotherapy	O
predicted	O
later	O
cardiotoxicity	B-Disease
.	O
The	O
decrease	O
in	O
GLS	O
remained	O
the	O
only	O
independent	O
predictor	O
of	O
cardiotoxicity	B-Disease
(	O
P	O
=	O
0	O
.	O
000	O
)	O
.	O
CONCLUSIONS	O
:	O
GLS	O
combined	O
with	O
cTnT	O
may	O
provide	O
a	O
reliable	O
and	O
non	O
-	O
invasive	O
method	O
to	O
predict	O
cardiac	B-Disease
dysfunction	I-Disease
in	O
patients	O
receiving	O
anthracycline	B-Chemical
-	O
based	O
chemotherapy	O
.	O
Prevention	O
of	O
etomidate	B-Chemical
-	O
induced	O
myoclonus	B-Disease
:	O
which	O
is	O
superior	O
:	O
Fentanyl	B-Chemical
,	O
midazolam	B-Chemical
,	O
or	O
a	O
combination	O
?	O
A	O
Retrospective	O
comparative	O
study	O
.	O
BACKGROUND	O
:	O
In	O
this	O
retrospective	O
comparative	O
study	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
effectiveness	O
of	O
fentanyl	B-Chemical
,	O
midazolam	B-Chemical
,	O
and	O
a	O
combination	O
of	O
fentanyl	B-Chemical
and	O
midazolam	B-Chemical
to	O
prevent	O
etomidate	B-Chemical
-	O
induced	O
myoclonus	B-Disease
.	O
MATERIAL	O
AND	O
METHODS	O
:	O
This	O
study	O
was	O
performed	O
based	O
on	O
anesthesia	O
records	O
.	O
Depending	O
on	O
the	O
drugs	O
that	O
would	O
be	O
given	O
before	O
the	O
induction	O
of	O
anesthesia	O
with	O
etomidate	B-Chemical
,	O
the	O
patients	O
were	O
separated	O
into	O
4	O
groups	O
:	O
no	O
pretreatment	O
(	O
Group	O
NP	O
)	O
,	O
fentanyl	B-Chemical
1	O
ug	O
.	O
kg	O
-	O
1	O
(	O
Group	O
F	O
)	O
,	O
midazolam	B-Chemical
0	O
.	O
03	O
mg	O
.	O
kg	O
-	O
1	O
(	O
Group	O
M	O
)	O
,	O
and	O
midazolam	B-Chemical
0	O
.	O
015	O
mg	O
.	O
kg	O
-	O
1	O
+	O
fentanyl	B-Chemical
0	O
.	O
5	O
ug	O
.	O
kg	O
-	O
1	O
(	O
Group	O
FM	O
)	O
.	O
Patients	O
who	O
received	O
the	O
same	O
anesthetic	O
procedure	O
were	O
selected	O
:	O
2	O
minutes	O
after	O
intravenous	O
injections	O
of	O
the	O
pretreatment	O
drugs	O
,	O
anesthesia	O
is	O
induced	O
with	O
0	O
.	O
3	O
mg	O
.	O
kg	O
-	O
1	O
etomidate	B-Chemical
injected	O
intravenously	O
over	O
a	O
period	O
of	O
20	O
-	O
30	O
seconds	O
.	O
Myoclonic	B-Disease
movements	I-Disease
are	O
evaluated	O
,	O
which	O
were	O
observed	O
and	O
graded	O
according	O
to	O
clinical	O
severity	O
during	O
the	O
2	O
minutes	O
after	O
etomidate	B-Chemical
injection	O
.	O
The	O
severity	O
of	O
pain	B-Disease
due	O
to	O
etomidate	B-Chemical
injection	O
,	O
mean	O
arterial	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
adverse	O
effects	O
were	O
also	O
evaluated	O
.	O
RESULTS	O
:	O
Study	O
results	O
showed	O
that	O
myoclonus	B-Disease
incidence	O
was	O
85	O
%	O
,	O
40	O
%	O
,	O
70	O
%	O
,	O
and	O
25	O
%	O
in	O
Group	O
NP	O
,	O
Group	O
F	O
,	O
Group	O
M	O
,	O
and	O
Group	O
FM	O
,	O
respectively	O
,	O
and	O
were	O
significantly	O
lower	O
in	O
Group	O
F	O
and	O
Group	O
FM	O
.	O
CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
pretreatment	O
with	O
fentanyl	B-Chemical
or	O
combination	O
of	O
fentanyl	B-Chemical
and	O
midazolam	B-Chemical
was	O
effective	O
in	O
preventing	O
etomidate	B-Chemical
-	O
induced	O
myoclonus	B-Disease
.	O
Convulsant	O
effect	O
of	O
lindane	B-Chemical
and	O
regional	O
brain	O
concentration	O
of	O
GABA	B-Chemical
and	O
dopamine	B-Chemical
.	O
Lindane	B-Chemical
(	O
gamma	B-Chemical
-	I-Chemical
hexachlorocyclohexane	I-Chemical
)	O
is	O
an	O
organochlorine	O
insecticide	O
with	O
known	O
neurotoxic	B-Disease
effects	O
.	O
Its	O
mechanism	O
of	O
action	O
is	O
not	O
well	O
understood	O
although	O
it	O
has	O
been	O
proposed	O
that	O
lindane	B-Chemical
acts	O
as	O
a	O
non	O
-	O
competitive	O
antagonist	O
at	O
the	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
(	O
GABA	B-Chemical
)	O
-	O
A	O
receptor	O
.	O
We	O
studied	O
the	O
effect	O
of	O
lindane	B-Chemical
(	O
150	O
mg	O
/	O
kg	O
)	O
on	O
the	O
GABAergic	O
and	O
dopaminergic	O
systems	O
by	O
measuring	O
the	O
concentration	O
of	O
GABA	B-Chemical
,	O
dopamine	B-Chemical
and	O
its	O
metabolites	O
in	O
7	O
brain	O
areas	O
at	O
the	O
onset	O
of	O
seizures	B-Disease
.	O
All	O
animals	O
suffered	O
tonic	O
convulsions	B-Disease
at	O
18	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
4	O
min	O
after	O
lindane	B-Chemical
administration	O
.	O
The	O
concentration	O
of	O
GABA	B-Chemical
was	O
only	O
slightly	O
but	O
significantly	O
decreased	O
in	O
the	O
colliculi	O
without	O
modifications	O
in	O
the	O
other	O
areas	O
.	O
The	O
concentration	O
of	O
dopamine	B-Chemical
was	O
increased	O
in	O
the	O
mesencephalon	O
and	O
that	O
of	O
its	O
metabolite	O
DOPAC	B-Chemical
was	O
also	O
increased	O
in	O
the	O
mesencephalon	O
and	O
the	O
striatum	O
.	O
Cholestatic	B-Disease
presentation	O
of	O
yellow	O
phosphorus	B-Chemical
poisoning	B-Disease
.	O
Yellow	O
phosphorus	B-Chemical
,	O
a	O
component	O
of	O
certain	O
pesticide	O
pastes	O
and	O
fireworks	O
,	O
is	O
well	O
known	O
to	O
cause	O
hepatotoxicity	B-Disease
.	O
Poisoning	B-Disease
with	O
yellow	O
phosphorus	B-Chemical
classically	O
manifests	O
with	O
acute	B-Disease
hepatitis	I-Disease
leading	O
to	O
acute	B-Disease
liver	I-Disease
failure	I-Disease
which	O
may	O
need	O
liver	O
transplantation	O
.	O
We	O
present	O
a	O
case	O
of	O
yellow	O
phosphorus	B-Chemical
poisoning	B-Disease
in	O
which	O
a	O
patient	O
presented	O
with	O
florid	O
clinical	O
features	O
of	O
cholestasis	B-Disease
highlighting	O
the	O
fact	O
that	O
cholestasis	B-Disease
can	O
rarely	O
be	O
a	O
presenting	O
feature	O
of	O
yellow	O
phosphorus	B-Chemical
hepatotoxicity	B-Disease
.	O
Vasovagal	B-Disease
syncope	I-Disease
and	O
severe	O
bradycardia	B-Disease
following	O
intranasal	O
dexmedetomidine	B-Chemical
for	O
pediatric	O
procedural	O
sedation	O
.	O
We	O
report	O
syncope	B-Disease
and	O
bradycardia	B-Disease
in	O
an	O
11	O
-	O
year	O
-	O
old	O
girl	O
following	O
administration	O
of	O
intranasal	O
dexmedetomidine	B-Chemical
for	O
sedation	O
for	O
a	O
voiding	O
cystourethrogram	O
.	O
Following	O
successful	O
completion	O
of	O
VCUG	O
and	O
a	O
60	O
-	O
min	O
recovery	O
period	O
,	O
the	O
patient	O
'	O
s	O
level	O
of	O
consciousness	O
and	O
vital	O
signs	O
returned	O
to	O
presedation	O
levels	O
.	O
Upon	O
leaving	O
the	O
sedation	O
area	O
,	O
the	O
patient	O
collapsed	O
,	O
with	O
no	O
apparent	O
inciting	O
event	O
.	O
The	O
patient	O
quickly	O
regained	O
consciousness	O
and	O
no	O
injury	O
occurred	O
.	O
The	O
primary	O
abnormality	O
found	O
was	O
persistent	O
bradycardia	B-Disease
,	O
and	O
she	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
telemetric	O
observation	O
.	O
The	O
bradycardia	B-Disease
lasted	O
~	O
2	O
h	O
,	O
and	O
further	O
cardiac	O
workup	O
revealed	O
no	O
underlying	O
abnormality	O
.	O
Unanticipated	O
and	O
previously	O
unreported	O
outcomes	O
may	O
be	O
witnessed	O
as	O
we	O
expand	O
the	O
use	O
of	O
certain	O
sedatives	O
to	O
alternative	O
routes	O
of	O
administration	O
.	O
Paradoxical	O
severe	O
agitation	B-Disease
induced	O
by	O
add	O
-	O
on	O
high	O
-	O
doses	O
quetiapine	B-Chemical
in	O
schizo	B-Disease
-	I-Disease
affective	I-Disease
disorder	I-Disease
.	O
We	O
report	O
the	O
case	O
of	O
a	O
35	O
-	O
year	O
-	O
old	O
patient	O
suffering	O
from	O
schizo	B-Disease
-	I-Disease
affective	I-Disease
disorder	I-Disease
since	O
the	O
age	O
of	O
19	O
years	O
,	O
treated	O
by	O
a	O
combination	O
of	O
first	O
-	O
generation	O
antipsychotics	O
,	O
zuclopenthixol	B-Chemical
(	O
100	O
mg	O
/	O
day	O
)	O
and	O
lithium	B-Chemical
(	O
1200	O
mg	O
/	O
day	O
)	O
(	O
serum	O
lithium	B-Chemical
=	O
0	O
.	O
85	O
mEq	O
/	O
l	O
)	O
.	O
This	O
patient	O
had	O
no	O
associated	O
personality	B-Disease
disorder	I-Disease
(	O
particularly	O
no	O
antisocial	B-Disease
disorder	I-Disease
)	O
and	O
no	O
substance	B-Disease
abuse	I-Disease
disorder	I-Disease
.	O
Within	O
the	O
48	O
h	O
following	O
the	O
gradual	O
introduction	O
of	O
quetiapine	B-Chemical
(	O
up	O
to	O
600	O
mg	O
/	O
day	O
)	O
,	O
the	O
patient	O
presented	O
severe	O
agitation	B-Disease
without	O
an	O
environmental	O
explanation	O
,	O
contrasting	O
with	O
the	O
absence	O
of	O
a	O
history	O
of	O
aggressiveness	B-Disease
or	O
personality	B-Disease
disorder	I-Disease
.	O
The	O
diagnoses	O
of	O
manic	B-Disease
shift	O
and	O
akathisia	B-Disease
were	O
dismissed	O
.	O
The	O
withdrawal	O
and	O
the	O
gradual	O
reintroduction	O
of	O
quetiapine	B-Chemical
2	O
weeks	O
later	O
,	O
which	O
led	O
to	O
another	O
severe	O
agitation	B-Disease
,	O
enabled	O
us	O
to	O
attribute	O
the	O
agitation	B-Disease
specifically	O
to	O
quetiapine	B-Chemical
.	O
Antioxidant	O
effects	O
of	O
bovine	O
lactoferrin	O
on	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
rat	O
.	O
Dexamethasone	B-Chemical
-	O
(	O
Dex	B-Chemical
-	O
)	O
induced	O
hypertension	B-Disease
is	O
associated	O
with	O
enhanced	O
oxidative	O
stress	O
.	O
Lactoferrin	O
(	O
LF	O
)	O
is	O
an	O
iron	B-Chemical
-	O
binding	O
glycoprotein	O
with	O
antihypertensive	O
properties	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
administration	O
of	O
LF	O
on	O
oxidative	O
stress	O
and	O
hypertension	B-Disease
upon	O
Dex	B-Chemical
administration	O
.	O
Male	O
Wistar	O
rats	O
were	O
treated	O
by	O
Dex	B-Chemical
(	O
30	O
u	O
g	O
/	O
kg	O
/	O
day	O
subcutaneously	O
)	O
or	O
saline	O
for	O
14	O
days	O
.	O
Oral	O
bovine	O
LF	O
(	O
30	O
,	O
100	O
,	O
300	O
mg	O
/	O
kg	O
)	O
was	O
given	O
from	O
day	O
8	O
to	O
14	O
in	O
a	O
reversal	O
study	O
.	O
In	O
a	O
prevention	O
study	O
,	O
rats	O
received	O
4	O
days	O
of	O
LF	O
treatment	O
followed	O
by	O
Dex	B-Chemical
and	O
continued	O
during	O
the	O
test	O
period	O
.	O
Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
measured	O
using	O
tail	O
-	O
cuff	O
method	O
.	O
Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	O
activity	O
.	O
Plasma	O
hydrogen	B-Chemical
peroxide	I-Chemical
(	O
H2O2	B-Chemical
)	O
concentration	O
and	O
ferric	O
reducing	O
antioxidant	O
power	O
(	O
FRAP	O
)	O
value	O
were	O
determined	O
.	O
Dexamethasone	B-Chemical
significantly	O
increased	O
SBP	O
and	O
plasma	O
H2O2	B-Chemical
level	O
and	O
decreased	O
thymus	O
and	O
body	O
weights	O
.	O
LF	O
lowered	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
dose	O
dependently	O
prevented	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
Dex	B-Chemical
-	O
induced	O
hypertension	B-Disease
.	O
LF	O
prevented	O
body	O
weight	B-Disease
loss	I-Disease
and	O
significantly	O
reduced	O
the	O
elevated	O
plasma	O
H2O2	B-Chemical
and	O
increased	O
FRAP	O
values	O
.	O
Chronic	O
administration	O
of	O
LF	O
strongly	O
reduced	O
the	O
blood	O
pressure	O
and	O
production	O
of	O
ROS	O
and	O
improved	O
antioxidant	O
capacity	O
in	O
Dex	B-Chemical
-	O
induced	O
hypertension	B-Disease
,	O
suggesting	O
the	O
role	O
of	O
inhibition	O
of	O
oxidative	O
stress	O
as	O
another	O
mechanism	O
of	O
antihypertensive	O
action	O
of	O
LF	O
.	O
The	O
association	O
between	O
tranexamic	B-Chemical
acid	I-Chemical
and	O
convulsive	B-Disease
seizures	B-Disease
after	O
cardiac	O
surgery	O
:	O
a	O
multivariate	O
analysis	O
in	O
11	O
529	O
patients	O
.	O
Because	O
of	O
a	O
lack	O
of	O
contemporary	O
data	O
regarding	O
seizures	B-Disease
after	O
cardiac	O
surgery	O
,	O
we	O
undertook	O
a	O
retrospective	O
analysis	O
of	O
prospectively	O
collected	O
data	O
from	O
11	O
529	O
patients	O
in	O
whom	O
cardiopulmonary	O
bypass	O
was	O
used	O
from	O
January	O
2004	O
to	O
December	O
2010	O
.	O
A	O
convulsive	B-Disease
seizure	B-Disease
was	O
defined	O
as	O
a	O
transient	O
episode	O
of	O
disturbed	O
brain	O
function	O
characterised	O
by	O
abnormal	B-Disease
involuntary	I-Disease
motor	I-Disease
movements	I-Disease
.	O
Multivariate	O
regression	O
analysis	O
was	O
performed	O
to	O
identify	O
independent	O
predictors	O
of	O
postoperative	O
seizures	B-Disease
.	O
A	O
total	O
of	O
100	O
(	O
0	O
.	O
9	O
%	O
)	O
patients	O
developed	O
postoperative	O
convulsive	B-Disease
seizures	B-Disease
.	O
Generalised	B-Disease
and	I-Disease
focal	I-Disease
seizures	I-Disease
were	O
identified	O
in	O
68	O
and	O
32	O
patients	O
,	O
respectively	O
.	O
The	O
median	O
(	O
IQR	O
[	O
range	O
]	O
)	O
time	O
after	O
surgery	O
when	O
the	O
seizure	B-Disease
occurred	O
was	O
7	O
(	O
6	O
-	O
12	O
[	O
1	O
-	O
216	O
]	O
)	O
h	O
and	O
8	O
(	O
6	O
-	O
11	O
[	O
4	O
-	O
18	O
]	O
)	O
h	O
,	O
respectively	O
.	O
Epileptiform	O
findings	O
on	O
electroencephalography	O
were	O
seen	O
in	O
19	O
patients	O
.	O
Independent	O
predictors	O
of	O
postoperative	O
seizures	B-Disease
included	O
age	O
,	O
female	O
sex	O
,	O
redo	O
cardiac	O
surgery	O
,	O
calcification	O
of	O
ascending	O
aorta	O
,	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
,	O
deep	O
hypothermic	B-Disease
circulatory	O
arrest	O
,	O
duration	O
of	O
aortic	O
cross	O
-	O
clamp	O
and	O
tranexamic	B-Chemical
acid	I-Chemical
.	O
When	O
tested	O
in	O
a	O
multivariate	O
regression	O
analysis	O
,	O
tranexamic	B-Chemical
acid	I-Chemical
was	O
a	O
strong	O
independent	O
predictor	O
of	O
seizures	B-Disease
(	O
OR	O
14	O
.	O
3	O
,	O
95	O
%	O
CI	O
5	O
.	O
5	O
-	O
36	O
.	O
7	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
Patients	O
with	O
convulsive	B-Disease
seizures	B-Disease
had	O
2	O
.	O
5	O
times	O
higher	O
in	O
-	O
hospital	O
mortality	O
rates	O
and	O
twice	O
the	O
length	O
of	O
hospital	O
stay	O
compared	O
with	O
patients	O
without	O
convulsive	B-Disease
seizures	B-Disease
.	O
Mean	O
(	O
IQR	O
[	O
range	O
]	O
)	O
length	O
of	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
was	O
115	O
(	O
49	O
-	O
228	O
[	O
32	O
-	O
481	O
]	O
)	O
h	O
in	O
patients	O
with	O
convulsive	B-Disease
seizures	B-Disease
compared	O
with	O
26	O
(	O
22	O
-	O
69	O
[	O
14	O
-	O
1080	O
]	O
)	O
h	O
in	O
patients	O
without	O
seizures	B-Disease
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O
Convulsive	B-Disease
seizures	B-Disease
are	O
a	O
serious	O
postoperative	B-Disease
complication	I-Disease
after	O
cardiac	O
surgery	O
.	O
As	O
tranexamic	B-Chemical
acid	I-Chemical
is	O
the	O
only	O
modifiable	O
factor	O
,	O
its	O
administration	O
,	O
particularly	O
in	O
doses	O
exceeding	O
80	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
,	O
should	O
be	O
weighed	O
against	O
the	O
risk	O
of	O
postoperative	O
seizures	B-Disease
.	O
Dysfunctional	B-Disease
overnight	I-Disease
memory	I-Disease
consolidation	O
in	O
ecstasy	B-Chemical
users	O
.	O
Sleep	O
plays	O
an	O
important	O
role	O
in	O
the	O
consolidation	O
and	O
integration	O
of	O
memory	O
in	O
a	O
process	O
called	O
overnight	O
memory	O
consolidation	O
.	O
Previous	O
studies	O
indicate	O
that	O
ecstasy	B-Chemical
users	O
have	O
marked	O
and	O
persistent	O
neurocognitive	O
and	O
sleep	B-Disease
-	I-Disease
related	I-Disease
impairments	I-Disease
.	O
We	O
extend	O
past	O
research	O
by	O
examining	O
overnight	O
memory	O
consolidation	O
among	O
regular	O
ecstasy	B-Chemical
users	O
(	O
n	O
=	O
12	O
)	O
and	O
drug	O
naive	O
healthy	O
controls	O
(	O
n	O
=	O
26	O
)	O
.	O
Memory	O
recall	O
of	O
word	O
pairs	O
was	O
evaluated	O
before	O
and	O
after	O
a	O
period	O
of	O
sleep	O
,	O
with	O
and	O
without	O
interference	O
prior	O
to	O
testing	O
.	O
In	O
addition	O
,	O
we	O
assessed	O
neurocognitive	O
performances	O
across	O
tasks	O
of	O
learning	O
,	O
memory	O
and	O
executive	O
functioning	O
.	O
Ecstasy	B-Chemical
users	O
demonstrated	O
impaired	B-Disease
overnight	I-Disease
memory	I-Disease
consolidation	O
,	O
a	O
finding	O
that	O
was	O
more	O
pronounced	O
following	O
associative	O
interference	O
.	O
Additionally	O
,	O
ecstasy	B-Chemical
users	O
demonstrated	O
impairments	O
on	O
tasks	O
recruiting	O
frontostriatal	O
and	O
hippocampal	O
neural	O
circuitry	O
,	O
in	O
the	O
domains	O
of	O
proactive	O
interference	O
memory	O
,	O
long	O
-	O
term	O
memory	O
,	O
encoding	O
,	O
working	O
memory	O
and	O
complex	O
planning	O
.	O
We	O
suggest	O
that	O
ecstasy	B-Chemical
-	O
associated	O
dysfunction	O
in	O
fronto	O
-	O
temporal	O
circuitry	O
may	O
underlie	O
overnight	O
consolidation	O
memory	B-Disease
impairments	I-Disease
in	O
regular	O
ecstasy	B-Chemical
users	O
.	O
Normoammonemic	O
encephalopathy	B-Disease
:	O
solely	O
valproate	B-Chemical
induced	O
or	O
multiple	O
mechanisms	O
?	O
A	O
77	O
-	O
year	O
-	O
old	O
woman	O
presented	O
with	O
subacute	O
onset	O
progressive	O
confusion	B-Disease
,	O
aggression	B-Disease
,	O
auditory	B-Disease
hallucinations	I-Disease
and	O
delusions	B-Disease
.	O
In	O
the	O
preceding	O
months	O
,	O
the	O
patient	O
had	O
a	O
number	O
of	O
admissions	O
with	O
transient	O
unilateral	O
hemiparesis	B-Disease
with	O
facial	O
droop	O
,	O
and	O
had	O
been	O
started	O
on	O
valproate	B-Chemical
for	O
presumed	O
hemiplegic	B-Disease
migraine	I-Disease
.	O
Valproate	B-Chemical
was	O
withdrawn	O
soon	O
after	O
admission	O
and	O
her	O
cognitive	O
abilities	O
have	O
gradually	O
improved	O
over	O
3	O
months	O
of	O
follow	O
-	O
up	O
.	O
Valproate	B-Chemical
levels	O
taken	O
prior	O
to	O
withdrawal	O
were	O
subtherapeutic	O
and	O
the	O
patient	O
was	O
normoammonaemic	O
.	O
EEG	O
undertaken	O
during	O
inpatient	O
stay	O
showed	O
changes	O
consistent	O
with	O
encephalopathy	B-Disease
,	O
and	O
low	O
titre	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	B-Chemical
)	O
receptor	O
antibodies	O
were	O
present	O
in	O
this	O
patient	O
.	O
The	O
possible	O
aetiologies	O
of	O
valproate	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
and	O
NMDA	B-Chemical
receptor	O
-	O
associated	O
encephalitis	B-Disease
present	O
a	O
diagnostic	O
dilemma	O
.	O
We	O
present	O
a	O
putative	O
combinatorial	O
hypothesis	O
to	O
explain	O
this	O
patient	O
'	O
s	O
symptoms	O
.	O
Cerebellar	B-Disease
and	I-Disease
oculomotor	I-Disease
dysfunction	I-Disease
induced	O
by	O
rapid	O
infusion	O
of	O
pethidine	B-Chemical
.	O
Pethidine	B-Chemical
is	O
an	O
opioid	O
that	O
gains	O
its	O
popularity	O
for	O
the	O
effective	O
pain	B-Disease
control	O
through	O
acting	O
on	O
the	O
opioid	O
-	O
receptors	O
.	O
However	O
,	O
rapid	O
pain	B-Disease
relief	O
sometimes	O
brings	O
about	O
unfavourable	O
side	O
effects	O
that	O
largely	O
limit	O
its	O
clinical	O
utility	O
.	O
Common	O
side	O
effects	O
include	O
nausea	B-Disease
,	O
vomiting	B-Disease
and	O
hypotension	B-Disease
.	O
In	O
patients	O
with	O
impaired	B-Disease
renal	I-Disease
and	I-Disease
liver	I-Disease
function	I-Disease
,	O
and	O
those	O
who	O
need	O
long	O
-	O
term	O
pain	B-Disease
control	O
,	O
pethidine	B-Chemical
may	O
cause	O
excitatory	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
effects	O
through	O
its	O
neurotoxic	B-Disease
metabolite	O
,	O
norpethidine	B-Chemical
,	O
resulting	O
in	O
irritability	B-Disease
and	O
seizure	B-Disease
attack	O
.	O
On	O
the	O
contrary	O
,	O
though	O
not	O
clinically	O
apparent	O
,	O
pethidine	B-Chemical
potentially	O
causes	O
inhibitory	O
impacts	O
on	O
the	O
CNS	O
and	O
impairs	O
normal	O
cerebellar	O
and	O
oculomotor	O
function	O
in	O
the	O
short	O
term	O
.	O
In	O
this	O
case	O
report	O
,	O
we	O
highlight	O
opioid	O
'	O
s	O
inhibitory	O
side	O
effects	O
on	O
the	O
cerebellar	O
structure	O
that	O
causes	O
dysmetria	B-Disease
,	O
dysarthria	B-Disease
,	O
reduced	O
smooth	O
pursuit	O
gain	O
and	O
decreased	O
saccadic	O
velocity	O
.	O
Baboon	B-Disease
syndrome	I-Disease
induced	O
by	O
ketoconazole	B-Chemical
.	O
A	O
27	O
-	O
year	O
-	O
old	O
male	O
patient	O
presented	O
with	O
a	O
maculopapular	B-Disease
eruption	I-Disease
on	O
the	O
flexural	O
areas	O
and	O
buttocks	O
after	O
using	O
oral	O
ketoconazole	B-Chemical
.	O
The	O
patient	O
was	O
diagnosed	O
with	O
drug	O
-	O
induced	O
baboon	B-Disease
syndrome	I-Disease
based	O
on	O
his	O
history	O
,	O
which	O
included	O
prior	O
sensitivity	O
to	O
topical	O
ketoconazole	B-Chemical
,	O
a	O
physical	O
examination	O
,	O
and	O
histopathological	O
findings	O
.	O
Baboon	B-Disease
syndrome	I-Disease
is	O
a	O
drug	O
-	O
or	O
contact	O
allergen	O
-	O
related	O
maculopapular	B-Disease
eruption	I-Disease
that	O
typically	O
involves	O
the	O
flexural	O
and	O
gluteal	O
areas	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
ketoconazole	B-Chemical
-	O
induced	O
baboon	B-Disease
syndrome	I-Disease
in	O
the	O
English	O
literature	O
.	O
A	O
Case	O
of	O
Sudden	B-Disease
Cardiac	I-Disease
Death	I-Disease
due	O
to	O
Pilsicainide	B-Chemical
-	O
Induced	O
Torsades	B-Disease
de	I-Disease
Pointes	I-Disease
.	O
An	O
84	O
-	O
year	O
-	O
old	O
male	O
received	O
oral	O
pilsicainide	B-Chemical
,	O
a	O
pure	O
sodium	B-Chemical
channel	O
blocker	O
with	O
slow	O
recovery	O
kinetics	O
,	O
to	O
convert	O
his	O
paroxysmal	O
atrial	B-Disease
fibrillation	I-Disease
to	O
a	O
sinus	O
rhythm	O
;	O
the	O
patient	O
developed	O
sudden	B-Disease
cardiac	I-Disease
death	I-Disease
two	O
days	O
later	O
.	O
The	O
Holter	O
electrocardiogram	O
,	O
which	O
was	O
worn	O
by	O
chance	O
,	O
revealed	O
torsade	B-Disease
de	I-Disease
pointes	I-Disease
with	O
gradually	O
prolonged	O
QT	O
intervals	O
.	O
This	O
drug	O
is	O
rapidly	O
absorbed	O
from	O
the	O
gastrointestinal	O
tract	O
,	O
and	O
most	O
of	O
it	O
is	O
excreted	O
from	O
the	O
kidney	O
.	O
Although	O
the	O
patient	O
'	O
s	O
renal	O
function	O
was	O
not	O
highly	O
impaired	O
and	O
the	O
dose	O
of	O
pilsicainide	B-Chemical
was	O
low	O
,	O
the	O
plasma	O
concentration	O
of	O
pilsicainide	B-Chemical
may	O
have	O
been	O
high	O
,	O
which	O
can	O
produce	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
in	O
the	O
octogenarian	O
.	O
Although	O
the	O
oral	O
administration	O
of	O
class	O
IC	O
drugs	O
,	O
including	O
pilsicainide	B-Chemical
,	O
is	O
effective	O
to	O
terminate	O
atrial	B-Disease
fibrillation	I-Disease
,	O
careful	O
consideration	O
must	O
be	O
taken	O
before	O
giving	O
these	O
drugs	O
to	O
octogenarians	O
.	O
All	B-Chemical
-	I-Chemical
trans	I-Chemical
retinoic	I-Chemical
acid	I-Chemical
-	O
induced	O
inflammatory	O
myositis	B-Disease
in	O
a	O
patient	O
with	O
acute	B-Disease
promyelocytic	I-Disease
leukemia	I-Disease
.	O
All	B-Chemical
-	I-Chemical
trans	I-Chemical
retinoic	I-Chemical
acid	I-Chemical
(	O
ATRA	B-Chemical
)	O
,	O
a	O
component	O
of	O
standard	O
therapy	O
for	O
acute	B-Disease
promyelocytic	I-Disease
leukemia	I-Disease
(	O
APL	B-Disease
)	O
,	O
is	O
associated	O
with	O
potentially	O
serious	O
but	O
treatable	O
adverse	O
effects	O
involving	O
numerous	O
organ	O
systems	O
,	O
including	O
rare	O
skeletal	O
muscle	O
involvement	O
.	O
Only	O
a	O
handful	O
of	O
cases	O
of	O
ATRA	B-Chemical
-	O
induced	O
myositis	B-Disease
in	O
children	O
have	O
been	O
reported	O
,	O
and	O
none	O
in	O
the	O
radiology	O
literature	O
.	O
We	O
present	O
such	O
a	O
case	O
in	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
APL	B-Disease
,	O
where	O
recognition	O
of	O
imaging	O
findings	O
played	O
a	O
crucial	O
role	O
in	O
making	O
the	O
diagnosis	O
and	O
facilitated	O
prompt	O
,	O
effective	O
treatment	O
.	O
Tolerability	O
of	O
lomustine	B-Chemical
in	O
combination	O
with	O
cyclophosphamide	B-Chemical
in	O
dogs	O
with	O
lymphoma	B-Disease
.	O
This	O
retrospective	O
study	O
describes	O
toxicity	B-Disease
associated	O
with	O
a	O
protocol	O
of	O
lomustine	B-Chemical
(	O
CCNU	B-Chemical
)	O
and	O
cyclophosphamide	B-Chemical
(	O
CTX	B-Chemical
)	O
in	O
dogs	O
with	O
lymphoma	B-Disease
.	O
CCNU	B-Chemical
was	O
administered	O
per	O
os	O
(	O
PO	O
)	O
at	O
a	O
targeted	O
dosage	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
body	O
surface	O
area	O
on	O
day	O
0	O
,	O
CTX	B-Chemical
was	O
administered	O
PO	O
at	O
a	O
targeted	O
dosage	O
of	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
divided	O
over	O
days	O
0	O
through	O
4	O
,	O
and	O
all	O
dogs	O
received	O
prophylactic	O
antibiotics	O
.	O
Ninety	O
treatments	O
were	O
given	O
to	O
the	O
57	O
dogs	O
included	O
in	O
the	O
study	O
.	O
Neutropenia	B-Disease
was	O
the	O
principal	O
toxic	O
effect	O
,	O
and	O
the	O
overall	O
frequency	O
of	O
grade	O
4	O
neutropenia	B-Disease
after	O
the	O
first	O
treatment	O
of	O
CCNU	B-Chemical
/	O
CTX	B-Chemical
was	O
30	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
19	O
-	O
43	O
%	O
)	O
.	O
The	O
mean	O
body	O
weight	O
of	O
dogs	O
with	O
grade	O
4	O
neutropenia	B-Disease
(	O
19	O
.	O
7	O
kg	O
+	O
13	O
.	O
4	O
kg	O
)	O
was	O
significantly	O
less	O
than	O
the	O
mean	O
body	O
weight	O
of	O
dogs	O
that	O
did	O
not	O
develop	O
grade	O
4	O
neutropenia	B-Disease
(	O
31	O
.	O
7	O
kg	O
+	O
12	O
.	O
4	O
kg	O
;	O
P	O
=	O
.	O
005	O
)	O
.	O
One	O
dog	O
(	O
3	O
%	O
)	O
developed	O
hematologic	O
changes	O
suggestive	O
of	O
hepatotoxicity	B-Disease
.	O
No	O
dogs	O
had	O
evidence	O
of	O
either	O
renal	B-Disease
toxicity	I-Disease
or	O
hemorrhagic	B-Disease
cystitis	I-Disease
.	O
Adverse	O
gastrointestinal	O
effects	O
were	O
uncommon	O
.	O
On	O
the	O
basis	O
of	O
the	O
findings	O
reported	O
herein	O
,	O
a	O
dose	O
of	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
CCNU	B-Chemical
combined	O
with	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
CTX	B-Chemical
(	O
divided	O
over	O
5	O
days	O
)	O
q	O
4	O
wk	O
is	O
tolerable	O
in	O
tumor	B-Disease
-	O
bearing	O
dogs	O
.	O
Nelarabine	B-Chemical
neurotoxicity	B-Disease
with	O
concurrent	O
intrathecal	O
chemotherapy	O
:	O
Case	O
report	O
and	O
review	O
of	O
literature	O
.	O
Severe	O
nelarabine	B-Chemical
neurotoxicity	B-Disease
in	O
a	O
patient	O
who	O
received	O
concurrent	O
intrathecal	O
(	O
IT	O
)	O
chemotherapy	O
is	O
reported	O
.	O
A	O
37	O
-	O
year	O
-	O
old	O
Caucasian	O
woman	O
with	O
a	O
history	O
of	O
T	B-Disease
-	I-Disease
cell	I-Disease
lymphoblastic	I-Disease
lymphoma	I-Disease
was	O
admitted	O
for	O
relapsed	O
disease	O
.	O
She	O
was	O
originally	O
treated	O
with	O
induction	O
chemotherapy	O
followed	O
by	O
an	O
autologous	O
transplant	O
.	O
She	O
developed	O
relapsed	O
disease	O
10	O
months	O
later	O
with	O
leukemic	B-Disease
involvement	O
.	O
She	O
was	O
re	O
-	O
induced	O
with	O
nelarabine	B-Chemical
1500	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
,	O
3	O
,	O
and	O
5	O
with	O
1	O
dose	O
of	O
IT	O
cytarabine	B-Chemical
100	O
mg	O
on	O
day	O
2	O
as	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
prophylaxis	O
.	O
At	O
the	O
time	O
of	O
treatment	O
,	O
she	O
was	O
on	O
continuous	O
renal	O
replacement	O
therapy	O
due	O
to	O
sequelae	O
of	O
tumor	B-Disease
lysis	I-Disease
syndrome	I-Disease
(	O
TLS	B-Disease
)	O
.	O
She	O
tolerated	O
therapy	O
well	O
,	O
entered	O
a	O
complete	O
remission	O
,	O
and	O
recovered	O
her	O
renal	O
function	O
.	O
She	O
received	O
a	O
second	O
cycle	O
of	O
nelarabine	B-Chemical
without	O
additional	O
IT	O
prophylaxis	O
one	O
month	O
later	O
.	O
A	O
week	O
after	O
this	O
second	O
cycle	O
,	O
she	O
noted	O
numbness	O
in	O
her	O
lower	O
extremities	O
.	O
Predominantly	O
sensory	O
,	O
though	O
also	O
motor	O
and	O
autonomic	O
,	O
peripheral	B-Disease
neuropathy	I-Disease
started	O
in	O
her	O
feet	O
,	O
ascended	O
proximally	O
to	O
the	O
mid	O
-	O
thoracic	O
region	O
,	O
and	O
eventually	O
included	O
her	O
distal	O
upper	O
extremities	O
.	O
A	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
of	O
her	O
spine	O
demonstrated	O
changes	O
from	O
C2	O
to	O
C6	O
consistent	O
with	O
subacute	O
combined	O
degeneration	O
.	O
Nelarabine	B-Chemical
was	O
felt	O
to	O
be	O
the	O
cause	O
of	O
her	O
symptoms	O
.	O
Her	O
neuropathy	B-Disease
stabilized	O
and	O
showed	O
slight	O
improvement	O
and	O
ultimately	O
received	O
an	O
unrelated	O
,	O
reduced	O
-	O
intensity	O
allogeneic	O
transplant	O
while	O
in	O
complete	O
remission	O
,	O
but	O
relapsed	O
disease	O
10	O
weeks	O
later	O
.	O
She	O
is	O
currently	O
being	O
treated	O
with	O
best	O
supportive	O
care	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
published	O
case	O
report	O
of	O
severe	O
neurotoxicity	B-Disease
caused	O
by	O
nelarabine	B-Chemical
in	O
a	O
patient	O
who	O
received	O
concurrent	O
IT	O
chemotherapy	O
.	O
Valproate	B-Chemical
-	O
induced	O
hyperammonemic	B-Disease
encephalopathy	B-Disease
in	O
a	O
renal	O
transplanted	O
patient	O
.	O
Neurological	B-Disease
complications	I-Disease
after	O
renal	O
transplantation	O
constitute	O
an	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
.	O
Their	O
differential	O
diagnosis	O
is	O
difficult	O
and	O
essential	O
for	O
subsequent	O
patient	O
'	O
s	O
management	O
.	O
Valproate	B-Chemical
-	O
induced	O
hyperammonemic	B-Disease
encephalopathy	B-Disease
is	O
an	O
uncommon	O
but	O
serious	O
effect	O
of	O
valproate	B-Chemical
treatment	O
.	O
Here	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
15	O
-	O
year	O
-	O
old	O
girl	O
who	O
was	O
on	O
a	O
long	O
-	O
term	O
therapy	O
with	O
valproate	B-Chemical
due	O
to	O
epilepsy	B-Disease
and	O
revealed	O
impaired	B-Disease
consciousness	I-Disease
with	O
hyperammonemia	B-Disease
12	O
days	O
after	O
renal	O
transplantation	O
.	O
After	O
withdraw	O
of	O
valproate	B-Chemical
,	O
patients	O
'	O
symptoms	O
resolved	O
within	O
24	O
h	O
.	O
Clinicians	O
should	O
increase	O
their	O
awareness	O
for	O
potential	O
complication	O
of	O
valproate	B-Chemical
,	O
especially	O
in	O
transplanted	O
patients	O
.	O
Necrotising	B-Disease
fasciitis	I-Disease
after	O
bortezomib	B-Chemical
and	O
dexamethasone	B-Chemical
-	O
containing	O
regimen	O
in	O
an	O
elderly	O
patient	O
of	O
Waldenstrom	B-Disease
macroglobulinaemia	I-Disease
.	O
Bortezomib	B-Chemical
and	O
high	O
-	O
dose	O
dexamethasone	B-Chemical
-	O
containing	O
regimens	O
are	O
considered	O
to	O
be	O
generally	O
tolerable	O
with	O
few	O
severe	O
bacterial	B-Disease
infections	I-Disease
in	O
patients	O
with	O
B	O
-	O
cell	O
malignancies	B-Disease
.	O
However	O
,	O
information	O
is	O
limited	O
concerning	O
the	O
safety	O
of	O
the	O
regimen	O
in	O
elderly	O
patients	O
.	O
We	O
report	O
a	O
case	O
of	O
a	O
76	O
-	O
year	O
-	O
old	O
man	O
with	O
Waldenstrom	B-Disease
macroglobulinaemia	I-Disease
who	O
suffered	O
necrotising	B-Disease
fasciitis	I-Disease
without	O
neutropenia	B-Disease
after	O
the	O
combination	O
treatment	O
with	O
bortezomib	B-Chemical
,	O
high	O
-	O
dose	O
dexamethasone	B-Chemical
and	O
rituximab	O
.	O
Despite	O
immediate	O
intravenous	O
antimicrobial	O
therapy	O
,	O
he	O
succumbed	O
23	O
h	O
after	O
the	O
onset	O
.	O
Physicians	O
should	O
recognise	O
the	O
possibility	O
of	O
fatal	O
bacterial	B-Disease
infections	I-Disease
related	O
to	O
bortezomib	B-Chemical
plus	O
high	O
-	O
dose	O
dexamethasone	B-Chemical
in	O
elderly	O
patients	O
,	O
and	O
we	O
believe	O
this	O
case	O
warrants	O
further	O
investigation	O
.	O
An	O
integrated	O
characterization	O
of	O
serological	O
,	O
pathological	O
,	O
and	O
functional	O
events	O
in	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
Many	O
efficacious	O
cancer	B-Disease
treatments	O
cause	O
significant	O
cardiac	O
morbidity	O
,	O
yet	O
biomarkers	O
or	O
functional	O
indices	O
of	O
early	O
damage	O
,	O
which	O
would	O
allow	O
monitoring	O
and	O
intervention	O
,	O
are	O
lacking	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
utilized	O
a	O
rat	O
model	O
of	O
progressive	O
doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
-	O
induced	O
cardiomyopathy	B-Disease
,	O
applying	O
multiple	O
approaches	O
,	O
including	O
cardiac	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
,	O
to	O
provide	O
the	O
most	O
comprehensive	O
characterization	O
to	O
date	O
of	O
the	O
timecourse	O
of	O
serological	O
,	O
pathological	O
,	O
and	O
functional	O
events	O
underlying	O
this	O
toxicity	B-Disease
.	O
Hannover	O
Wistar	O
rats	O
were	O
dosed	O
with	O
1	O
.	O
25	O
mg	O
/	O
kg	O
DOX	B-Chemical
weekly	O
for	O
8	O
weeks	O
followed	O
by	O
a	O
4	O
week	O
off	O
-	O
dosing	O
""""	O
recovery	O
""""	O
period	O
.	O
Electron	O
microscopy	O
of	O
the	O
myocardium	O
revealed	O
subcellular	B-Disease
degeneration	I-Disease
and	O
marked	O
mitochondrial	O
changes	O
after	O
a	O
single	O
dose	O
.	O
Histopathological	O
analysis	O
revealed	O
progressive	O
cardiomyocyte	B-Disease
degeneration	I-Disease
,	O
hypertrophy	B-Disease
/	O
cytomegaly	O
,	O
and	O
extensive	O
vacuolation	O
after	O
two	O
doses	O
.	O
Extensive	O
replacement	O
fibrosis	B-Disease
(	O
quantified	O
by	O
Sirius	O
red	O
staining	O
)	O
developed	O
during	O
the	O
off	O
-	O
dosing	O
period	O
.	O
Functional	O
indices	O
assessed	O
by	O
cardiac	O
MRI	O
(	O
including	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
,	O
cardiac	O
output	O
,	O
and	O
E	O
/	O
A	O
ratio	O
)	O
declined	O
progressively	O
,	O
reaching	O
statistical	O
significance	O
after	O
two	O
doses	O
and	O
culminating	O
in	O
""""	O
clinical	O
""""	O
LV	B-Disease
dysfunction	I-Disease
by	O
12	O
weeks	O
.	O
Significant	O
increases	O
in	O
peak	O
myocardial	O
contrast	O
enhancement	O
and	O
serological	O
cardiac	O
troponin	O
I	O
(	O
cTnI	O
)	O
emerged	O
after	O
eight	O
doses	O
,	O
importantly	O
preceding	O
the	O
LVEF	O
decline	O
to	O
<	O
50	O
%	O
.	O
Troponin	O
I	O
levels	O
positively	O
correlated	O
with	O
delayed	O
and	O
peak	O
gadolinium	B-Chemical
contrast	O
enhancement	O
,	O
histopathological	O
grading	O
,	O
and	O
diastolic	B-Disease
dysfunction	I-Disease
.	O
In	O
summary	O
,	O
subcellular	O
cardiomyocyte	B-Disease
degeneration	I-Disease
was	O
the	O
earliest	O
marker	O
,	O
followed	O
by	O
progressive	O
functional	O
decline	O
and	O
histopathological	O
manifestations	O
.	O
Myocardial	O
contrast	O
enhancement	O
and	O
elevations	O
in	O
cTnI	O
occurred	O
later	O
.	O
However	O
,	O
all	O
indices	O
predated	O
""""	O
clinical	O
""""	O
LV	B-Disease
dysfunction	I-Disease
and	O
thus	O
warrant	O
further	O
evaluation	O
as	O
predictive	O
biomarkers	O
.	O
Intradermal	O
glutamate	B-Chemical
and	O
capsaicin	B-Chemical
injections	O
:	O
intra	O
-	O
and	O
interindividual	O
variability	O
of	O
provoked	O
hyperalgesia	B-Disease
and	O
allodynia	B-Disease
.	O
Intradermal	O
injections	O
of	O
glutamate	B-Chemical
and	O
capsaicin	B-Chemical
are	O
attractive	O
to	O
use	O
in	O
human	O
experimental	O
pain	B-Disease
models	O
because	O
hyperalgesia	B-Disease
and	O
allodynia	B-Disease
mimic	O
isolated	O
aspects	O
of	O
clinical	O
pain	B-Disease
disorders	I-Disease
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
reproducibility	O
of	O
these	O
models	O
.	O
Twenty	O
healthy	O
male	O
volunteers	O
(	O
mean	O
age	O
24	O
years	O
;	O
range	O
18	O
-	O
38	O
years	O
)	O
received	O
intradermal	O
injections	O
of	O
glutamate	B-Chemical
and	O
capsaicin	B-Chemical
in	O
the	O
volar	O
forearm	O
.	O
Magnitudes	O
of	O
secondary	O
pinprick	O
hyperalgesia	B-Disease
and	O
brush	O
-	O
evoked	O
allodynia	B-Disease
were	O
investigated	O
using	O
von	O
Frey	O
filaments	O
(	O
gauges	O
10	O
,	O
15	O
,	O
60	O
and	O
100	O
g	O
)	O
and	O
brush	O
strokes	O
.	O
Areas	O
of	O
secondary	B-Disease
hyperalgesia	I-Disease
and	O
allodynia	B-Disease
were	O
quantified	O
immediately	O
after	O
injection	O
and	O
after	O
15	O
,	O
30	O
and	O
60	O
min	O
.	O
Two	O
identical	O
experiments	O
separated	O
by	O
at	O
least	O
7	O
days	O
were	O
performed	O
.	O
Reproducibility	O
across	O
and	O
within	O
volunteers	O
(	O
inter	O
-	O
and	O
intra	O
-	O
individual	O
variation	O
,	O
respectively	O
)	O
was	O
assessed	O
using	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
and	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
.	O
Secondary	O
pinprick	O
hyperalgesia	B-Disease
was	O
observed	O
as	O
a	O
marked	O
increase	O
in	O
the	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
response	O
to	O
von	O
Frey	O
gauges	O
60	O
and	O
100	O
g	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
after	O
glutamate	B-Chemical
injection	O
.	O
For	O
capsaicin	B-Chemical
,	O
secondary	O
pinprick	O
hyperalgesia	B-Disease
was	O
detected	O
with	O
all	O
von	O
Frey	O
gauges	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
Glutamate	B-Chemical
evoked	O
reproducible	O
VAS	O
response	O
to	O
all	O
von	O
Frey	O
gauges	O
(	O
ICC	O
>	O
0	O
.	O
60	O
)	O
and	O
brush	O
strokes	O
(	O
ICC	O
>	O
0	O
.	O
83	O
)	O
.	O
Capsaicin	B-Chemical
injection	O
was	O
reproducible	O
for	O
secondary	B-Disease
hyperalgesia	I-Disease
(	O
ICC	O
>	O
0	O
.	O
70	O
)	O
and	O
allodynia	B-Disease
(	O
ICC	O
>	O
0	O
.	O
71	O
)	O
.	O
Intra	O
-	O
individual	O
variability	O
was	O
generally	O
lower	O
for	O
the	O
VAS	O
response	O
to	O
von	O
Frey	O
and	O
brush	O
compared	O
with	O
areas	O
of	O
secondary	B-Disease
hyperalgesia	I-Disease
and	O
allodynia	B-Disease
.	O
In	O
conclusion	O
,	O
glutamate	B-Chemical
and	O
capsaicin	B-Chemical
yield	O
reproducible	O
hyperalgesic	B-Disease
and	O
allodynic	B-Disease
responses	O
,	O
and	O
the	O
present	O
model	O
is	O
well	O
suited	O
for	O
basic	O
research	O
,	O
as	O
well	O
as	O
for	O
assessing	O
the	O
modulation	O
of	O
central	O
phenomena	O
.	O
Ocular	O
-	O
specific	O
ER	O
stress	O
reduction	O
rescues	O
glaucoma	B-Disease
in	O
murine	O
glucocorticoid	O
-	O
induced	O
glaucoma	B-Disease
.	O
Administration	O
of	O
glucocorticoids	O
induces	O
ocular	B-Disease
hypertension	I-Disease
in	O
some	O
patients	O
.	O
If	O
untreated	O
,	O
these	O
patients	O
can	O
develop	O
a	O
secondary	O
glaucoma	B-Disease
that	O
resembles	O
primary	B-Disease
open	I-Disease
-	I-Disease
angle	I-Disease
glaucoma	I-Disease
(	O
POAG	B-Disease
)	O
.	O
The	O
underlying	O
pathology	O
of	O
glucocorticoid	O
-	O
induced	O
glaucoma	B-Disease
is	O
not	O
fully	O
understood	O
,	O
due	O
in	O
part	O
to	O
lack	O
of	O
an	O
appropriate	O
animal	O
model	O
.	O
Here	O
,	O
we	O
developed	O
a	O
murine	O
model	O
of	O
glucocorticoid	O
-	O
induced	O
glaucoma	B-Disease
that	O
exhibits	O
glaucoma	B-Disease
features	O
that	O
are	O
observed	O
in	O
patients	O
.	O
Treatment	O
of	O
WT	O
mice	O
with	O
topical	O
ocular	O
0	O
.	O
1	O
%	O
dexamethasone	B-Chemical
led	O
to	O
elevation	O
of	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
,	O
functional	O
and	O
structural	O
loss	O
of	O
retinal	B-Disease
ganglion	I-Disease
cells	O
,	O
and	O
axonal	B-Disease
degeneration	I-Disease
,	O
resembling	O
glucocorticoid	O
-	O
induced	O
glaucoma	B-Disease
in	O
human	O
patients	O
.	O
Furthermore	O
,	O
dexamethasone	B-Chemical
-	O
induced	O
ocular	B-Disease
hypertension	I-Disease
was	O
associated	O
with	O
chronic	O
ER	O
stress	O
of	O
the	O
trabecular	O
meshwork	O
(	O
TM	O
)	O
.	O
Similar	O
to	O
patients	O
,	O
withdrawal	O
of	O
dexamethasone	B-Chemical
treatment	O
reduced	O
elevated	O
IOP	O
and	O
ER	O
stress	O
in	O
this	O
animal	O
model	O
.	O
Dexamethasone	B-Chemical
induced	O
the	O
transcriptional	O
factor	O
CHOP	O
,	O
a	O
marker	O
for	O
chronic	O
ER	O
stress	O
,	O
in	O
the	O
anterior	O
segment	O
tissues	O
,	O
and	O
Chop	O
deletion	O
reduced	O
ER	O
stress	O
in	O
these	O
tissues	O
and	O
prevented	O
dexamethasone	B-Chemical
-	O
induced	O
ocular	B-Disease
hypertension	I-Disease
.	O
Furthermore	O
,	O
reduction	O
of	O
ER	O
stress	O
in	O
the	O
TM	O
with	O
sodium	B-Chemical
4	I-Chemical
-	I-Chemical
phenylbutyrate	I-Chemical
prevented	O
dexamethasone	B-Chemical
-	O
induced	O
ocular	B-Disease
hypertension	I-Disease
in	O
WT	O
mice	O
.	O
Our	O
data	O
indicate	O
that	O
ER	O
stress	O
contributes	O
to	O
glucocorticoid	O
-	O
induced	O
ocular	B-Disease
hypertension	I-Disease
and	O
suggest	O
that	O
reducing	O
ER	O
stress	O
has	O
potential	O
as	O
a	O
therapeutic	O
strategy	O
for	O
treating	O
glucocorticoid	O
-	O
induced	O
glaucoma	B-Disease
.	O
Effects	O
of	O
ginsenosides	B-Chemical
on	O
opioid	O
-	O
induced	O
hyperalgesia	B-Disease
in	O
mice	O
.	O
Opioid	O
-	O
induced	O
hyperalgesia	B-Disease
(	O
OIH	B-Disease
)	O
is	O
characterized	O
by	O
nociceptive	O
sensitization	O
caused	O
by	O
the	O
cessation	O
of	O
chronic	O
opioid	O
use	O
.	O
OIH	B-Disease
can	O
limit	O
the	O
clinical	O
use	O
of	O
opioid	O
analgesics	O
and	O
complicate	O
withdrawal	O
from	O
opioid	B-Disease
addiction	I-Disease
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
Re	B-Chemical
,	I-Chemical
Rg1	I-Chemical
,	I-Chemical
and	I-Chemical
Rb1	I-Chemical
ginsenosides	I-Chemical
,	O
the	O
bioactive	O
components	O
of	O
ginseng	O
,	O
on	O
OIH	B-Disease
.	O
OIH	B-Disease
was	O
achieved	O
in	O
mice	O
after	O
subcutaneous	O
administration	O
of	O
morphine	B-Chemical
for	O
7	O
consecutive	O
days	O
three	O
times	O
per	O
day	O
.	O
During	O
withdrawal	O
(	O
days	O
8	O
and	O
9	O
)	O
,	O
these	O
mice	O
were	O
administered	O
Re	B-Chemical
,	O
Rg1	B-Chemical
,	O
or	O
Rb1	B-Chemical
intragastrically	O
two	O
times	O
per	O
day	O
.	O
On	O
the	O
test	O
day	O
(	O
day	O
10	O
)	O
,	O
mice	O
were	O
subjected	O
to	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	B-Chemical
acid	I-Chemical
-	O
induced	O
writhing	O
test	O
.	O
Re	B-Chemical
(	O
300	O
mg	O
/	O
kg	O
)	O
inhibited	O
OIH	B-Disease
in	O
both	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	B-Chemical
acid	I-Chemical
-	O
induced	O
writhing	O
test	O
.	O
However	O
,	O
the	O
Rg1	B-Chemical
and	I-Chemical
Rb1	I-Chemical
ginsenosides	I-Chemical
failed	O
to	O
prevent	O
OIH	B-Disease
in	O
either	O
test	O
.	O
Furthermore	O
,	O
Rg1	B-Chemical
showed	O
a	O
tendency	O
to	O
aggravate	O
OIH	B-Disease
in	O
the	O
acetic	B-Chemical
acid	I-Chemical
-	O
induced	O
writhing	O
test	O
.	O
Our	O
data	O
suggested	O
that	O
the	O
ginsenoside	B-Chemical
Re	I-Chemical
,	O
but	O
not	O
Rg1	B-Chemical
or	O
Rb1	B-Chemical
,	O
may	O
contribute	O
toward	O
reversal	O
of	O
OIH	B-Disease
.	O
A	O
comparison	O
of	O
severe	O
hemodynamic	O
disturbances	O
between	O
dexmedetomidine	B-Chemical
and	O
propofol	B-Chemical
for	O
sedation	O
in	O
neurocritical	O
care	O
patients	O
.	O
OBJECTIVE	O
:	O
Dexmedetomidine	B-Chemical
and	O
propofol	B-Chemical
are	O
commonly	O
used	O
sedatives	O
in	O
neurocritical	O
care	O
as	O
they	O
allow	O
for	O
frequent	O
neurologic	O
examinations	O
.	O
However	O
,	O
both	O
agents	O
are	O
associated	O
with	O
significant	O
hemodynamic	O
side	O
effects	O
.	O
The	O
primary	O
objective	O
of	O
this	O
study	O
is	O
to	O
compare	O
the	O
prevalence	O
of	O
severe	O
hemodynamic	O
effects	O
in	O
neurocritical	O
care	O
patients	O
receiving	O
dexmedetomidine	B-Chemical
and	O
propofol	B-Chemical
.	O
DESIGN	O
:	O
Multicenter	O
,	O
retrospective	O
,	O
propensity	O
-	O
matched	O
cohort	O
study	O
.	O
SETTING	O
:	O
Neurocritical	O
care	O
units	O
at	O
two	O
academic	O
medical	O
centers	O
with	O
dedicated	O
neurocritical	O
care	O
teams	O
and	O
board	O
-	O
certified	O
neurointensivists	O
.	O
PATIENTS	O
:	O
Neurocritical	O
care	O
patients	O
admitted	O
between	O
July	O
2009	O
and	O
September	O
2012	O
were	O
evaluated	O
and	O
then	O
matched	O
1	O
:	O
1	O
based	O
on	O
propensity	O
scoring	O
of	O
baseline	O
characteristics	O
.	O
INTERVENTIONS	O
:	O
Continuous	O
sedation	O
with	O
dexmedetomidine	B-Chemical
or	O
propofol	B-Chemical
.	O
MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
A	O
total	O
of	O
342	O
patients	O
(	O
105	O
dexmedetomidine	B-Chemical
and	O
237	O
propofol	B-Chemical
)	O
were	O
included	O
in	O
the	O
analysis	O
,	O
with	O
190	O
matched	O
(	O
95	O
in	O
each	O
group	O
)	O
by	O
propensity	O
score	O
.	O
The	O
primary	O
outcome	O
of	O
this	O
study	O
was	O
a	O
composite	O
of	O
severe	O
hypotension	B-Disease
(	O
mean	O
arterial	O
pressure	O
<	O
60	O
mm	O
Hg	O
)	O
and	O
bradycardia	B-Disease
(	O
heart	O
rate	O
<	O
50	O
beats	O
/	O
min	O
)	O
during	O
sedative	O
infusion	O
.	O
No	O
difference	O
in	O
the	O
primary	O
composite	O
outcome	O
in	O
both	O
the	O
unmatched	O
(	O
30	O
%	O
vs	O
30	O
%	O
,	O
p	O
=	O
0	O
.	O
94	O
)	O
or	O
matched	O
cohorts	O
(	O
28	O
%	O
vs	O
34	O
%	O
,	O
p	O
=	O
0	O
.	O
35	O
)	O
could	O
be	O
found	O
.	O
When	O
analyzed	O
separately	O
,	O
no	O
differences	O
could	O
be	O
found	O
in	O
the	O
prevalence	O
of	O
severe	O
hypotension	B-Disease
or	O
bradycardia	B-Disease
in	O
either	O
the	O
unmatched	O
or	O
matched	O
cohorts	O
.	O
CONCLUSIONS	O
:	O
Severe	O
hypotension	B-Disease
and	O
bradycardia	B-Disease
occur	O
at	O
similar	O
prevalence	O
in	O
neurocritical	O
care	O
patients	O
who	O
receive	O
dexmedetomidine	B-Chemical
or	O
propofol	B-Chemical
.	O
Providers	O
should	O
similarly	O
consider	O
the	O
likelihood	O
of	O
hypotension	B-Disease
or	O
bradycardia	B-Disease
before	O
starting	O
either	O
sedative	O
.	O
Hydroxytyrosol	B-Chemical
ameliorates	O
oxidative	O
stress	O
and	O
mitochondrial	B-Disease
dysfunction	I-Disease
in	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
in	O
rats	O
with	O
breast	B-Disease
cancer	I-Disease
.	O
Oxidative	O
stress	O
is	O
involved	O
in	O
several	O
processes	O
including	O
cancer	B-Disease
,	O
aging	O
and	O
cardiovascular	B-Disease
disease	I-Disease
,	O
and	O
has	O
been	O
shown	O
to	O
potentiate	O
the	O
therapeutic	O
effect	O
of	O
drugs	O
such	O
as	O
doxorubicin	B-Chemical
.	O
Doxorubicin	B-Chemical
causes	O
significant	O
cardiotoxicity	B-Disease
characterized	O
by	O
marked	O
increases	O
in	O
oxidative	O
stress	O
and	O
mitochondrial	B-Disease
dysfunction	I-Disease
.	O
Herein	O
,	O
we	O
investigate	O
whether	O
doxorubicin	B-Chemical
-	O
associated	O
chronic	O
cardiac	B-Disease
toxicity	I-Disease
can	O
be	O
ameliorated	O
with	O
the	O
antioxidant	O
hydroxytyrosol	B-Chemical
in	O
rats	O
with	O
breast	B-Disease
cancer	I-Disease
.	O
Thirty	O
-	O
six	O
rats	O
bearing	O
breast	B-Disease
tumors	I-Disease
induced	O
chemically	O
were	O
divided	O
into	O
4	O
groups	O
:	O
control	O
,	O
hydroxytyrosol	B-Chemical
(	O
0	O
.	O
5mg	O
/	O
kg	O
,	O
5days	O
/	O
week	O
)	O
,	O
doxorubicin	B-Chemical
(	O
1mg	O
/	O
kg	O
/	O
week	O
)	O
,	O
and	O
doxorubicin	B-Chemical
plus	O
hydroxytyrosol	B-Chemical
.	O
Cardiac	B-Disease
disturbances	I-Disease
at	O
the	O
cellular	O
and	O
mitochondrial	O
level	O
,	O
mitochondrial	O
electron	O
transport	O
chain	O
complexes	O
I	O
-	O
IV	O
and	O
apoptosis	O
-	O
inducing	O
factor	O
,	O
and	O
oxidative	O
stress	O
markers	O
have	O
been	O
analyzed	O
.	O
Hydroxytyrosol	B-Chemical
improved	O
the	O
cardiac	B-Disease
disturbances	I-Disease
enhanced	O
by	O
doxorubicin	B-Chemical
by	O
significantly	O
reducing	O
the	O
percentage	O
of	O
altered	O
mitochondria	O
and	O
oxidative	O
damage	O
.	O
These	O
results	O
suggest	O
that	O
hydroxytyrosol	B-Chemical
improve	O
the	O
mitochondrial	O
electron	O
transport	O
chain	O
.	O
This	O
study	O
demonstrates	O
that	O
hydroxytyrosol	B-Chemical
protect	O
rat	O
heart	B-Disease
damage	I-Disease
provoked	O
by	O
doxorubicin	B-Chemical
decreasing	O
oxidative	O
damage	O
and	O
mitochondrial	O
alterations	O
.	O
Amiodarone	B-Chemical
-	O
induced	O
myxoedema	B-Disease
coma	I-Disease
.	O
A	O
62	O
-	O
year	O
-	O
old	O
man	O
was	O
found	O
to	O
have	O
bradycardia	B-Disease
,	O
hypothermia	B-Disease
and	O
respiratory	B-Disease
failure	I-Disease
3	O
weeks	O
after	O
initiation	O
of	O
amiodarone	B-Chemical
therapy	O
for	O
atrial	B-Disease
fibrillation	I-Disease
.	O
Thyroid	O
-	O
stimulating	O
hormone	O
was	O
found	O
to	O
be	O
168	O
uIU	O
/	O
mL	O
(	O
nl	O
.	O
0	O
.	O
3	O
-	O
5	O
uIU	O
/	O
mL	O
)	O
and	O
free	O
thyroxine	B-Chemical
(	O
FT4	O
)	O
was	O
<	O
0	O
.	O
2	O
ng	O
/	O
dL	O
(	O
nl	O
.	O
0	O
.	O
8	O
-	O
1	O
.	O
8	O
ng	O
/	O
dL	O
)	O
.	O
He	O
received	O
intravenous	O
fluids	O
,	O
vasopressor	O
therapy	O
and	O
stress	O
dose	O
steroids	B-Chemical
;	O
he	O
was	O
intubated	O
and	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
.	O
He	O
received	O
500	O
ug	O
of	O
intravenous	O
levothyroxine	B-Chemical
in	O
the	O
first	O
18	O
h	O
of	O
therapy	O
,	O
and	O
150	O
ug	O
intravenous	O
daily	O
thereafter	O
.	O
Haemodynamic	O
improvement	O
,	O
along	O
with	O
complete	O
recovery	O
of	O
mental	O
status	O
,	O
occurred	O
after	O
48	O
h	O
.	O
Twelve	O
hours	O
after	O
the	O
initiation	O
of	O
therapy	O
,	O
FT4	O
was	O
0	O
.	O
96	O
ng	O
/	O
dL	O
.	O
The	O
patient	O
was	O
maintained	O
on	O
levothyroxine	B-Chemical
175	O
(	O
g	O
POorally	O
daily	O
.	O
A	O
thyroid	O
ultrasound	O
showed	O
diffuse	O
heterogeneity	O
.	O
The	O
24	O
hour	O
excretion	O
of	O
iodine	B-Chemical
was	O
3657	O
(	O
mcg	O
(	O
25	O
-	O
756	O
(	O
mcg	O
)	O
.	O
The	O
only	O
two	O
cases	O
of	O
amiodarone	B-Chemical
-	O
induced	O
myxoedema	B-Disease
coma	I-Disease
in	O
the	O
literature	O
report	O
patient	O
death	O
despite	O
supportive	O
therapy	O
and	O
thyroid	O
hormone	O
replacement	O
.	O
This	O
case	O
represents	O
the	O
most	O
thoroughly	O
investigated	O
case	O
of	O
amiodarone	B-Chemical
-	O
induced	O
myxoedema	B-Disease
coma	I-Disease
with	O
a	O
history	O
significant	O
for	O
subclinical	O
thyroid	B-Disease
disease	I-Disease
.	O
Use	O
of	O
argatroban	B-Chemical
and	O
catheter	O
-	O
directed	O
thrombolysis	B-Disease
with	O
alteplase	O
in	O
an	O
oncology	O
patient	O
with	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
with	O
thrombosis	B-Disease
.	O
PURPOSE	O
:	O
The	O
case	O
of	O
an	O
oncology	O
patient	O
who	O
developed	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
with	O
thrombosis	B-Disease
(	O
HITT	B-Disease
)	O
and	O
was	O
treated	O
with	O
argatroban	B-Chemical
plus	O
catheter	O
-	O
directed	O
thrombolysis	B-Disease
(	O
CDT	O
)	O
with	O
alteplase	O
is	O
presented	O
.	O
SUMMARY	O
:	O
A	O
63	O
-	O
year	O
-	O
old	O
Caucasian	O
man	O
with	O
renal	O
amyloidosis	B-Disease
undergoing	O
peripheral	O
blood	O
stem	O
cell	O
collection	O
for	O
an	O
autologous	O
stem	O
cell	O
transplant	O
developed	O
extensive	O
bilateral	O
upper	B-Disease
-	I-Disease
extremity	I-Disease
deep	I-Disease
venous	I-Disease
thrombosis	I-Disease
(	O
DVT	B-Disease
)	O
and	O
pulmonary	B-Disease
embolism	I-Disease
secondary	O
to	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
.	O
A	O
continuous	O
i	O
.	O
v	O
.	O
infusion	O
of	O
argatroban	B-Chemical
was	O
initiated	O
,	O
and	O
the	O
patient	O
was	O
managed	O
on	O
the	O
general	O
medical	O
floor	O
.	O
After	O
one	O
week	O
of	O
therapy	O
,	O
he	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
with	O
cardiopulmonary	O
compromise	O
related	O
to	O
superior	B-Disease
vena	I-Disease
cava	I-Disease
(	I-Disease
SVC	I-Disease
)	I-Disease
syndrome	I-Disease
.	O
A	O
percutaneous	O
mechanical	O
thrombectomy	O
and	O
CDT	O
with	O
alteplase	O
were	O
attempted	O
,	O
but	O
the	O
procedure	O
was	O
aborted	O
due	O
to	O
epistaxis	B-Disease
.	O
The	O
epistaxis	B-Disease
resolved	O
the	O
next	O
day	O
,	O
and	O
the	O
patient	O
was	O
restarted	O
on	O
argatroban	B-Chemical
.	O
A	O
second	O
percutaneous	O
mechanical	O
thrombectomy	O
was	O
performed	O
six	O
days	O
later	O
and	O
resulted	O
in	O
partial	O
revascularization	O
of	O
the	O
SVC	O
and	O
central	O
veins	O
.	O
Postthrombectomy	O
continuous	O
CDT	O
with	O
alteplase	O
was	O
commenced	O
while	O
argatroban	B-Chemical
was	O
withheld	O
,	O
and	O
complete	O
patency	O
of	O
the	O
SVC	O
and	O
central	O
veins	O
was	O
achieved	O
after	O
three	O
days	O
of	O
therapy	O
.	O
Alteplase	O
was	O
discontinued	O
,	O
and	O
the	O
patient	O
was	O
reinitiated	O
on	O
argatroban	B-Chemical
;	O
ultimately	O
,	O
he	O
was	O
transitioned	O
to	O
warfarin	B-Chemical
for	O
long	O
-	O
term	O
anticoagulation	O
.	O
Although	O
the	O
patient	O
recovered	O
,	O
he	O
experienced	O
permanent	O
vision	B-Disease
and	I-Disease
hearing	I-Disease
loss	I-Disease
,	O
as	O
well	O
as	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
.	O
CONCLUSION	O
:	O
A	O
63	O
-	O
year	O
-	O
old	O
man	O
with	O
renal	O
amyloidosis	B-Disease
and	O
SVC	B-Disease
syndrome	I-Disease
secondary	O
to	O
HITT	B-Disease
was	O
successfully	O
treated	O
with	O
argatroban	B-Chemical
and	O
CDT	O
with	O
alteplase	O
.	O
Effects	O
of	O
dehydroepiandrosterone	B-Chemical
in	O
amphetamine	B-Chemical
-	O
induced	O
schizophrenia	B-Disease
models	O
in	O
mice	O
.	O
OBJECTIVE	O
:	O
To	O
examine	O
the	O
effects	O
of	O
dehydroepiandrosterone	B-Chemical
(	O
DHEA	B-Chemical
)	O
on	O
animal	O
models	O
of	O
schizophrenia	B-Disease
.	O
METHODS	O
:	O
Seventy	O
Swiss	O
albino	O
female	O
mice	O
(	O
25	O
-	O
35	O
g	O
)	O
were	O
divided	O
into	O
4	O
groups	O
:	O
amphetamine	B-Chemical
-	O
free	O
(	O
control	O
)	O
,	O
amphetamine	B-Chemical
,	O
50	O
,	O
and	O
100	O
mg	O
/	O
kg	O
DHEA	B-Chemical
.	O
The	O
DHEA	B-Chemical
was	O
administered	O
intraperitoneally	O
(	O
ip	O
)	O
for	O
5	O
days	O
.	O
Amphetamine	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
ip	O
)	O
induced	O
hyper	B-Disease
locomotion	O
,	O
apomorphine	B-Chemical
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
subcutaneously	O
[	O
sc	O
]	O
)	O
induced	O
climbing	O
,	O
and	O
haloperidol	B-Chemical
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
sc	O
)	O
induced	O
catalepsy	B-Disease
tests	O
were	O
used	O
as	O
animal	O
models	O
of	O
schizophrenia	B-Disease
.	O
The	O
study	O
was	O
conducted	O
at	O
the	O
Animal	O
Experiment	O
Laboratories	O
,	O
Department	O
of	O
Pharmacology	O
,	O
Medical	O
School	O
,	O
Eskisehir	O
Osmangazi	O
University	O
,	O
Eskisehir	O
,	O
Turkey	O
between	O
March	O
and	O
May	O
2012	O
.	O
Statistical	O
analysis	O
was	O
carried	O
out	O
using	O
Kruskal	O
-	O
Wallis	O
test	O
for	O
hyper	B-Disease
locomotion	O
,	O
and	O
one	O
-	O
way	O
ANOVA	O
for	O
climbing	O
and	O
catalepsy	B-Disease
tests	O
.	O
RESULTS	O
:	O
In	O
the	O
amphetamine	B-Chemical
-	O
induced	O
locomotion	O
test	O
,	O
there	O
were	O
significant	O
increases	O
in	O
all	O
movements	O
compared	O
with	O
the	O
amphetamine	B-Chemical
-	O
free	O
group	O
.	O
Both	O
DHEA	B-Chemical
50	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
100	O
mg	O
/	O
kg	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
significantly	O
decreased	O
all	O
movements	O
compared	O
with	O
the	O
amphetamine	B-Chemical
-	O
induced	O
locomotion	O
group	O
.	O
There	O
was	O
a	O
significant	O
difference	O
between	O
groups	O
in	O
the	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
test	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
There	O
was	O
no	O
significant	O
difference	O
between	O
groups	O
in	O
terms	O
of	O
total	O
climbing	O
time	O
in	O
the	O
apomorphine	B-Chemical
-	O
induced	O
climbing	O
test	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O
CONCLUSION	O
:	O
We	O
observed	O
that	O
DHEA	B-Chemical
reduced	O
locomotor	O
activity	O
and	O
increased	O
catalepsy	B-Disease
at	O
both	O
doses	O
,	O
while	O
it	O
had	O
no	O
effect	O
on	O
climbing	O
behavior	O
.	O
We	O
suggest	O
that	O
DHEA	B-Chemical
displays	O
typical	O
neuroleptic	O
-	O
like	O
effects	O
,	O
and	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
schizophrenia	B-Disease
.	O
Availability	O
of	O
human	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
in	O
assessment	O
of	O
drug	O
potential	O
for	O
QT	B-Disease
prolongation	I-Disease
.	O
Field	O
potential	O
duration	O
(	O
FPD	O
)	O
in	O
human	O
-	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
(	O
hiPS	O
-	O
CMs	O
)	O
,	O
which	O
can	O
express	O
QT	O
interval	O
in	O
an	O
electrocardiogram	O
,	O
is	O
reported	O
to	O
be	O
a	O
useful	O
tool	O
to	O
predict	O
K	B-Chemical
(	O
+	O
)	O
channel	O
and	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
channel	O
blocker	O
effects	O
on	O
QT	O
interval	O
.	O
However	O
,	O
there	O
is	O
no	O
report	O
showing	O
that	O
this	O
technique	O
can	O
be	O
used	O
to	O
predict	O
multichannel	O
blocker	O
potential	O
for	O
QT	B-Disease
prolongation	I-Disease
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
show	O
that	O
FPD	O
from	O
MEA	O
(	O
Multielectrode	O
array	O
)	O
of	O
hiPS	O
-	O
CMs	O
can	O
detect	O
QT	B-Disease
prolongation	I-Disease
induced	O
by	O
multichannel	O
blockers	O
.	O
hiPS	O
-	O
CMs	O
were	O
seeded	O
onto	O
MEA	O
and	O
FPD	O
was	O
measured	O
for	O
2min	O
every	O
10min	O
for	O
30min	O
after	O
drug	O
exposure	O
for	O
the	O
vehicle	O
and	O
each	O
drug	O
concentration	O
.	O
IKr	O
and	O
IKs	O
blockers	O
concentration	O
-	O
dependently	O
prolonged	O
corrected	O
FPD	O
(	O
FPDc	O
)	O
,	O
whereas	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
channel	O
blockers	O
concentration	O
-	O
dependently	O
shortened	O
FPDc	O
.	O
Also	O
,	O
the	O
multichannel	O
blockers	O
Amiodarone	B-Chemical
,	O
Paroxetine	B-Chemical
,	O
Terfenadine	B-Chemical
and	O
Citalopram	B-Chemical
prolonged	O
FPDc	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O
Finally	O
,	O
the	O
IKr	O
blockers	O
,	O
Terfenadine	B-Chemical
and	O
Citalopram	B-Chemical
,	O
which	O
are	O
reported	O
to	O
cause	O
Torsade	B-Disease
de	I-Disease
Pointes	I-Disease
(	O
TdP	B-Disease
)	O
in	O
clinical	O
practice	O
,	O
produced	O
early	O
afterdepolarization	O
(	O
EAD	O
)	O
.	O
hiPS	O
-	O
CMs	O
using	O
MEA	O
system	O
and	O
FPDc	O
can	O
predict	O
the	O
effects	O
of	O
drug	O
candidates	O
on	O
QT	O
interval	O
.	O
This	O
study	O
also	O
shows	O
that	O
this	O
assay	O
can	O
help	O
detect	O
EAD	O
for	O
drugs	O
with	O
TdP	B-Disease
potential	O
.	O
Dermal	O
developmental	O
toxicity	B-Disease
of	O
N	O
-	O
phenylimide	O
herbicides	O
in	O
rats	O
.	O
BACKGROUND	O
:	O
S	B-Chemical
-	I-Chemical
53482	I-Chemical
and	O
S	B-Chemical
-	I-Chemical
23121	I-Chemical
are	O
N	O
-	O
phenylimide	O
herbicides	O
and	O
produced	O
embryolethality	B-Disease
,	O
teratogenicity	B-Disease
(	O
mainly	O
ventricular	B-Disease
septal	I-Disease
defects	I-Disease
and	O
wavy	O
ribs	O
)	O
,	O
and	O
growth	B-Disease
retardation	I-Disease
in	O
rats	O
in	O
conventional	O
oral	O
developmental	O
toxicity	B-Disease
studies	O
.	O
Our	O
objective	O
in	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
compounds	O
induce	O
developmental	O
toxicity	B-Disease
via	O
the	O
dermal	O
route	O
,	O
which	O
is	O
more	O
relevant	O
to	O
occupational	O
exposure	O
,	O
hence	O
better	O
addressing	O
human	O
health	O
risks	O
.	O
METHODS	O
:	O
S	B-Chemical
-	I-Chemical
53482	I-Chemical
was	O
administered	O
dermally	O
to	O
rats	O
at	O
30	O
,	O
100	O
,	O
and	O
300	O
mg	O
/	O
kg	O
during	O
organogenesis	O
,	O
and	O
S	B-Chemical
-	I-Chemical
23121	I-Chemical
was	O
administered	O
at	O
200	O
,	O
400	O
,	O
and	O
800	O
mg	O
/	O
kg	O
(	O
the	O
maximum	O
applicable	O
dose	O
level	O
)	O
.	O
Fetuses	O
were	O
obtained	O
by	O
a	O
Cesarean	O
section	O
and	O
examined	O
for	O
external	O
,	O
visceral	O
,	O
and	O
skeletal	O
alterations	O
.	O
RESULTS	O
:	O
Dermal	O
exposure	O
of	O
rats	O
to	O
S	B-Chemical
-	I-Chemical
53482	I-Chemical
at	O
300	O
mg	O
/	O
kg	O
produced	O
patterns	O
of	O
developmental	O
toxicity	B-Disease
similar	O
to	O
those	O
resulting	O
from	O
oral	O
exposure	O
.	O
Toxicity	B-Disease
included	O
embryolethality	B-Disease
,	O
teratogenicity	B-Disease
,	O
and	O
growth	B-Disease
retardation	I-Disease
.	O
Dermal	O
administration	O
of	O
S	B-Chemical
-	I-Chemical
23121	I-Chemical
at	O
800	O
mg	O
/	O
kg	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
embryonic	B-Disease
death	I-Disease
and	O
ventricular	B-Disease
septal	I-Disease
defect	I-Disease
,	O
but	O
retarded	O
fetal	O
growth	O
was	O
not	O
observed	O
as	O
it	O
was	O
following	O
oral	O
exposure	O
to	O
S	B-Chemical
-	I-Chemical
23121	I-Chemical
.	O
CONCLUSIONS	O
:	O
Based	O
on	O
the	O
results	O
,	O
S	B-Chemical
-	I-Chemical
53482	I-Chemical
and	O
S	B-Chemical
-	I-Chemical
23121	I-Chemical
were	O
teratogenic	B-Disease
when	O
administered	O
dermally	O
to	O
pregnant	O
rats	O
as	O
were	O
the	O
compounds	O
administered	O
orally	O
.	O
Thus	O
,	O
investigation	O
of	O
the	O
mechanism	O
and	O
its	O
human	O
relevancy	O
become	O
more	O
important	O
.	O
Rates	O
of	O
Renal	B-Disease
Toxicity	I-Disease
in	O
Cancer	B-Disease
Patients	O
Receiving	O
Cisplatin	B-Chemical
With	O
and	O
Without	O
Mannitol	B-Chemical
.	O
BACKGROUND	O
:	O
Cisplatin	B-Chemical
is	O
a	O
widely	O
used	O
antineoplastic	O
.	O
One	O
of	O
the	O
major	O
complications	O
of	O
cisplatin	B-Chemical
use	O
is	O
dose	O
-	O
limiting	O
nephrotoxicity	B-Disease
.	O
There	O
are	O
many	O
strategies	O
to	O
prevent	O
this	O
toxicity	B-Disease
,	O
including	O
the	O
use	O
of	O
mannitol	B-Chemical
as	O
a	O
nephroprotectant	O
in	O
combination	O
with	O
hydration	O
.	O
OBJECTIVE	O
:	O
We	O
aimed	O
to	O
evaluate	O
the	O
rates	O
of	O
cisplatin	B-Chemical
-	O
induced	O
nephrotoxicity	B-Disease
in	O
cancer	B-Disease
patients	O
receiving	O
single	O
-	O
agent	O
cisplatin	B-Chemical
with	O
and	O
without	O
mannitol	B-Chemical
.	O
METHODS	O
:	O
This	O
single	O
-	O
center	O
retrospective	O
analysis	O
was	O
a	O
quasi	O
experiment	O
created	O
by	O
the	O
national	O
mannitol	B-Chemical
shortage	O
.	O
Data	O
were	O
collected	O
on	O
adult	O
cancer	B-Disease
patients	O
receiving	O
single	O
-	O
agent	O
cisplatin	B-Chemical
as	O
an	O
outpatient	O
from	O
January	O
2011	O
to	O
September	O
2012	O
.	O
The	O
primary	O
outcome	O
was	O
acute	B-Disease
kidney	I-Disease
injury	I-Disease
(	O
AKI	B-Disease
)	O
.	O
RESULTS	O
:	O
We	O
evaluated	O
143	O
patients	O
who	O
received	O
single	O
-	O
agent	O
cisplatin	B-Chemical
;	O
97	O
.	O
2	O
%	O
of	O
patients	O
had	O
head	B-Disease
and	I-Disease
neck	I-Disease
cancer	I-Disease
as	O
their	O
primary	O
malignancy	B-Disease
.	O
Patients	O
who	O
did	O
not	O
receive	O
mannitol	B-Chemical
were	O
more	O
likely	O
to	O
develop	O
nephrotoxicity	B-Disease
:	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
2	O
.	O
646	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
008	O
,	O
6	O
.	O
944	O
;	O
P	O
=	O
0	O
.	O
048	O
)	O
.	O
Patients	O
who	O
received	O
the	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
dosing	O
and	O
patients	O
who	O
had	O
a	O
history	O
of	O
hypertension	B-Disease
also	O
had	O
a	O
higher	O
likelihood	O
of	O
developing	O
nephrotoxicity	B-Disease
:	O
OR	O
=	O
11	O
.	O
494	O
(	O
95	O
%	O
CI	O
=	O
4	O
.	O
149	O
,	O
32	O
.	O
258	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
OR	O
=	O
3	O
.	O
219	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
228	O
,	O
8	O
.	O
439	O
;	O
P	O
=	O
0	O
.	O
017	O
)	O
,	O
respectively	O
.	O
CONCLUSIONS	O
:	O
When	O
limited	O
quantities	O
of	O
mannitol	B-Chemical
are	O
available	O
,	O
it	O
should	O
preferentially	O
be	O
given	O
to	O
patients	O
at	O
particularly	O
high	O
risk	O
of	O
nephrotoxicity	B-Disease
.	O
Our	O
analysis	O
suggests	O
that	O
those	O
patients	O
receiving	O
the	O
dosing	O
schedule	O
of	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
cisplatin	B-Chemical
every	O
3	O
weeks	O
and	O
those	O
with	O
hypertension	B-Disease
are	O
at	O
the	O
greatest	O
risk	O
of	O
nephrotoxicity	B-Disease
and	O
would	O
benefit	O
from	O
the	O
addition	O
of	O
mannitol	B-Chemical
.	O
Metformin	B-Chemical
protects	O
against	O
seizures	B-Disease
,	O
learning	B-Disease
and	I-Disease
memory	I-Disease
impairments	I-Disease
and	O
oxidative	O
damage	O
induced	O
by	O
pentylenetetrazole	B-Chemical
-	O
induced	O
kindling	O
in	O
mice	O
.	O
Cognitive	B-Disease
impairment	I-Disease
,	O
the	O
most	O
common	O
and	O
severe	O
comorbidity	O
of	O
epilepsy	B-Disease
,	O
greatly	O
diminishes	O
the	O
quality	O
of	O
life	O
.	O
However	O
,	O
current	O
therapeutic	O
interventions	O
for	O
epilepsy	B-Disease
can	O
also	O
cause	O
untoward	O
cognitive	O
effects	O
.	O
Thus	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
new	O
kinds	O
of	O
agents	O
targeting	O
both	O
seizures	B-Disease
and	O
cognition	B-Disease
deficits	I-Disease
.	O
Oxidative	O
stress	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
epileptogenesis	O
and	O
cognitive	B-Disease
deficits	I-Disease
,	O
and	O
antioxidants	O
have	O
a	O
putative	O
antiepileptic	O
potential	O
.	O
Metformin	B-Chemical
,	O
the	O
most	O
commonly	O
prescribed	O
antidiabetic	O
oral	O
drug	O
,	O
has	O
antioxidant	O
properties	O
.	O
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
ameliorative	O
effects	O
of	O
metformin	B-Chemical
on	O
seizures	B-Disease
,	O
cognitive	B-Disease
impairment	I-Disease
and	O
brain	O
oxidative	O
stress	O
markers	O
observed	O
in	O
pentylenetetrazole	B-Chemical
-	O
induced	O
kindling	O
animals	O
.	O
Male	O
C57BL	O
/	O
6	O
mice	O
were	O
administered	O
with	O
subconvulsive	O
dose	O
of	O
pentylenetetrazole	B-Chemical
(	O
37	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
every	O
other	O
day	O
for	O
14	O
injections	O
.	O
Metformin	B-Chemical
was	O
injected	O
intraperitoneally	O
in	O
dose	O
of	O
200mg	O
/	O
kg	O
along	O
with	O
alternate	O
-	O
day	O
PTZ	B-Chemical
.	O
We	O
found	O
that	O
metformin	B-Chemical
suppressed	O
the	O
progression	O
of	O
kindling	O
,	O
ameliorated	O
the	O
cognitive	B-Disease
impairment	I-Disease
and	O
decreased	O
brain	O
oxidative	O
stress	O
.	O
Thus	O
the	O
present	O
study	O
concluded	O
that	O
metformin	B-Chemical
may	O
be	O
a	O
potential	O
agent	O
for	O
the	O
treatment	O
of	O
epilepsy	B-Disease
as	O
well	O
as	O
a	O
protective	O
medicine	O
against	O
cognitive	B-Disease
impairment	I-Disease
induced	O
by	O
seizures	B-Disease
.	O
P53	O
inhibition	O
exacerbates	O
late	O
-	O
stage	O
anthracycline	B-Chemical
cardiotoxicity	B-Disease
.	O
AIMS	O
:	O
Doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
is	O
an	O
effective	O
anti	O
-	O
cancer	B-Disease
therapeutic	O
,	O
but	O
is	O
associated	O
with	O
both	O
acute	O
and	O
late	O
-	O
stage	O
cardiotoxicity	B-Disease
.	O
Children	O
are	O
particularly	O
sensitive	O
to	O
DOX	B-Chemical
-	O
induced	O
heart	B-Disease
failure	I-Disease
.	O
Here	O
,	O
the	O
impact	O
of	O
p53	O
inhibition	O
on	O
acute	O
vs	O
.	O
late	O
-	O
stage	O
DOX	B-Chemical
cardiotoxicity	B-Disease
was	O
examined	O
in	O
a	O
juvenile	O
model	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
Two	O
-	O
week	O
-	O
old	O
MHC	O
-	O
CB7	O
mice	O
(	O
which	O
express	O
dominant	O
-	O
interfering	O
p53	O
in	O
cardiomyocytes	O
)	O
and	O
their	O
non	O
-	O
transgenic	O
(	O
NON	O
-	O
TXG	O
)	O
littermates	O
received	O
weekly	O
DOX	B-Chemical
injections	O
for	O
5	O
weeks	O
(	O
25	O
mg	O
/	O
kg	O
cumulative	O
dose	O
)	O
.	O
One	O
week	O
after	O
the	O
last	O
DOX	B-Chemical
treatment	O
(	O
acute	O
stage	O
)	O
,	O
MHC	O
-	O
CB7	O
mice	O
exhibited	O
improved	O
cardiac	O
function	O
and	O
lower	O
levels	O
of	O
cardiomyocyte	O
apoptosis	O
when	O
compared	O
with	O
the	O
NON	O
-	O
TXG	O
mice	O
.	O
Surprisingly	O
,	O
by	O
13	O
weeks	O
following	O
the	O
last	O
DOX	B-Chemical
treatment	O
(	O
late	O
stage	O
)	O
,	O
MHC	O
-	O
CB7	O
exhibited	O
a	O
progressive	O
decrease	O
in	O
cardiac	O
function	O
and	O
higher	O
rates	O
of	O
cardiomyocyte	O
apoptosis	O
when	O
compared	O
with	O
NON	O
-	O
TXG	O
mice	O
.	O
p53	O
inhibition	O
blocked	O
transient	O
DOX	B-Chemical
-	O
induced	O
STAT3	O
activation	O
in	O
MHC	O
-	O
CB7	O
mice	O
,	O
which	O
was	O
associated	O
with	O
enhanced	O
induction	O
of	O
the	O
DNA	O
repair	O
proteins	O
Ku70	O
and	O
Ku80	O
.	O
Mice	O
with	O
cardiomyocyte	O
-	O
restricted	O
deletion	O
of	O
STAT3	O
exhibited	O
worse	O
cardiac	O
function	O
,	O
higher	O
levels	O
of	O
cardiomyocyte	O
apoptosis	O
,	O
and	O
a	O
greater	O
induction	O
of	O
Ku70	O
and	O
Ku80	O
in	O
response	O
to	O
DOX	B-Chemical
treatment	O
during	O
the	O
acute	O
stage	O
when	O
compared	O
with	O
control	O
animals	O
.	O
CONCLUSION	O
:	O
These	O
data	O
support	O
a	O
model	O
wherein	O
a	O
p53	O
-	O
dependent	O
cardioprotective	O
pathway	O
,	O
mediated	O
via	O
STAT3	O
activation	O
,	O
mitigates	O
DOX	B-Chemical
-	O
induced	O
myocardial	O
stress	O
during	O
drug	O
delivery	O
.	O
Furthermore	O
,	O
these	O
data	O
suggest	O
an	O
explanation	O
as	O
to	O
how	O
p53	O
inhibition	O
can	O
result	O
in	O
cardioprotection	O
during	O
drug	O
treatment	O
and	O
,	O
paradoxically	O
,	O
enhanced	O
cardiotoxicity	B-Disease
long	O
after	O
the	O
cessation	O
of	O
drug	O
treatment	O
.	O
Metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
:	O
an	O
uncommon	O
scenario	O
.	O
Metronidazole	B-Chemical
can	O
produce	O
neurological	O
complications	O
although	O
it	O
is	O
not	O
a	O
common	O
scenario	O
.	O
We	O
present	O
a	O
case	O
where	O
a	O
patient	O
developed	O
features	O
of	O
encephalopathy	B-Disease
following	O
prolonged	O
metronidazole	B-Chemical
intake	O
.	O
Magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
brain	O
showed	O
abnormal	O
signal	O
intensity	O
involving	O
both	O
dentate	O
nuclei	O
of	O
cerebellum	O
and	O
splenium	O
of	O
corpus	O
callosum	O
.	O
The	O
diagnosis	O
of	O
metronidazole	B-Chemical
toxicity	B-Disease
was	O
made	O
by	O
the	O
MRI	O
findings	O
and	O
supported	O
clinically	O
.	O
Aconitine	B-Chemical
-	O
induced	O
Ca2	B-Chemical
+	O
overload	O
causes	O
arrhythmia	B-Disease
and	O
triggers	O
apoptosis	O
through	O
p38	O
MAPK	O
signaling	O
pathway	O
in	O
rats	O
.	O
Aconitine	B-Chemical
is	O
a	O
major	O
bioactive	O
diterpenoid	O
alkaloid	O
with	O
high	O
content	O
derived	O
from	O
herbal	O
aconitum	O
plants	O
.	O
Emerging	O
evidence	O
indicates	O
that	O
voltage	O
-	O
dependent	O
Na	B-Chemical
(	O
+	O
)	O
channels	O
have	O
pivotal	O
roles	O
in	O
the	O
cardiotoxicity	B-Disease
of	O
aconitine	B-Chemical
.	O
However	O
,	O
no	O
reports	O
are	O
available	O
on	O
the	O
role	O
of	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
in	O
aconitine	B-Chemical
poisoning	B-Disease
.	O
In	O
this	O
study	O
,	O
we	O
explored	O
the	O
importance	O
of	O
pathological	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
signaling	O
in	O
aconitine	B-Chemical
poisoning	B-Disease
in	O
vitro	O
and	O
in	O
vivo	O
.	O
We	O
found	O
that	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
overload	O
lead	O
to	O
accelerated	O
beating	O
rhythm	O
in	O
adult	O
rat	O
ventricular	O
myocytes	O
and	O
caused	O
arrhythmia	B-Disease
in	O
conscious	O
freely	O
moving	O
rats	O
.	O
To	O
investigate	O
effects	O
of	O
aconitine	B-Chemical
on	O
myocardial	B-Disease
injury	I-Disease
,	O
we	O
performed	O
cytotoxicity	B-Disease
assay	O
in	O
neonatal	O
rat	O
ventricular	O
myocytes	O
(	O
NRVMs	O
)	O
,	O
as	O
well	O
as	O
measured	O
lactate	B-Chemical
dehydrogenase	O
level	O
in	O
the	O
culture	O
medium	O
of	O
NRVMs	O
and	O
activities	O
of	O
serum	O
cardiac	O
enzymes	O
in	O
rats	O
.	O
The	O
results	O
showed	O
that	O
aconitine	B-Chemical
resulted	O
in	O
myocardial	B-Disease
injury	I-Disease
and	O
reduced	O
NRVMs	O
viability	O
dose	O
-	O
dependently	O
.	O
To	O
confirm	O
the	O
pro	O
-	O
apoptotic	O
effects	O
,	O
we	O
performed	O
flow	O
cytometric	O
detection	O
,	O
cardiac	O
histology	O
,	O
transmission	O
electron	O
microscopy	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	B-Chemical
-	O
biotin	B-Chemical
nick	O
end	O
labeling	O
assay	O
.	O
The	O
results	O
showed	O
that	O
aconitine	B-Chemical
stimulated	O
apoptosis	O
time	O
-	O
dependently	O
.	O
The	O
expression	O
analysis	O
of	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
handling	O
proteins	O
demonstrated	O
that	O
aconitine	B-Chemical
promoted	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
overload	O
through	O
the	O
expression	O
regulation	O
of	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
handling	O
proteins	O
.	O
The	O
expression	O
analysis	O
of	O
apoptosis	O
-	O
related	O
proteins	O
revealed	O
that	O
pro	O
-	O
apoptotic	O
protein	O
expression	O
was	O
upregulated	O
,	O
and	O
anti	O
-	O
apoptotic	O
protein	O
BCL	O
-	O
2	O
expression	O
was	O
downregulated	O
.	O
Furthermore	O
,	O
increased	O
phosphorylation	O
of	O
MAPK	O
family	O
members	O
,	O
especially	O
the	O
P	O
-	O
P38	O
/	O
P38	O
ratio	O
was	O
found	O
in	O
cardiac	O
tissues	O
.	O
Hence	O
,	O
our	O
results	O
suggest	O
that	O
aconitine	B-Chemical
significantly	O
aggravates	O
Ca	B-Chemical
(	O
2	O
+	O
)	O
overload	O
and	O
causes	O
arrhythmia	B-Disease
and	O
finally	O
promotes	O
apoptotic	O
development	O
via	O
phosphorylation	O
of	O
P38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O
Chronic	O
treatment	O
with	O
metformin	B-Chemical
suppresses	O
toll	O
-	O
like	O
receptor	O
4	O
signaling	O
and	O
attenuates	O
left	B-Disease
ventricular	I-Disease
dysfunction	I-Disease
following	O
myocardial	B-Disease
infarction	I-Disease
.	O
Acute	O
treatment	O
with	O
metformin	B-Chemical
has	O
a	O
protective	O
effect	O
in	O
myocardial	B-Disease
infarction	I-Disease
by	O
suppression	O
of	O
inflammatory	O
responses	O
due	O
to	O
activation	O
of	O
AMP	B-Chemical
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
chronic	O
pre	O
-	O
treatment	O
with	O
metformin	B-Chemical
on	O
cardiac	B-Disease
dysfunction	I-Disease
and	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
activities	O
following	O
myocardial	B-Disease
infarction	I-Disease
and	O
their	O
relation	O
with	O
AMPK	O
were	O
assessed	O
.	O
Male	O
Wistar	O
rats	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
5	O
groups	O
(	O
n	O
=	O
6	O
)	O
:	O
normal	O
control	O
and	O
groups	O
were	O
injected	O
isoproterenol	B-Chemical
after	O
chronic	O
pre	O
-	O
treatment	O
with	O
0	O
,	O
25	O
,	O
50	O
,	O
or	O
100mg	O
/	O
kg	O
of	O
metformin	B-Chemical
twice	O
daily	O
for	O
14	O
days	O
.	O
Isoproterenol	B-Chemical
(	O
100mg	O
/	O
kg	O
)	O
was	O
injected	O
subcutaneously	O
on	O
the	O
13th	O
and	O
14th	O
days	O
to	O
induce	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
.	O
Isoproterenol	B-Chemical
alone	O
decreased	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
myocardial	O
contractility	O
indexed	O
as	O
LVdp	O
/	O
dtmax	O
and	O
LVdp	O
/	O
dtmin	O
.	O
The	O
left	B-Disease
ventricular	I-Disease
dysfunction	I-Disease
was	O
significantly	O
lower	O
in	O
the	O
groups	O
treated	O
with	O
25	O
and	O
50mg	O
/	O
kg	O
of	O
metformin	B-Chemical
.	O
Metfromin	O
markedly	O
lowered	O
isoproterenol	B-Chemical
-	O
induced	O
elevation	O
in	O
the	O
levels	O
of	O
TLR4	O
mRNA	O
,	O
myeloid	O
differentiation	O
protein	O
88	O
(	O
MyD88	O
)	O
,	O
tumor	B-Disease
necrosis	B-Disease
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
a	O
)	O
,	O
and	O
interleukin	O
6	O
(	O
IL	O
-	O
6	O
)	O
in	O
the	O
heart	O
tissues	O
.	O
Similar	O
changes	O
were	O
also	O
seen	O
in	O
the	O
serum	O
levels	O
of	O
TNF	O
-	O
a	O
and	O
IL	O
-	O
6	O
.	O
However	O
,	O
the	O
lower	O
doses	O
of	O
25	O
and	O
50mg	O
/	O
kg	O
were	O
more	O
effective	O
than	O
100mg	O
/	O
kg	O
.	O
Phosphorylated	O
AMPKa	O
(	O
p	O
-	O
AMPK	O
)	O
in	O
the	O
myocardium	O
was	O
significantly	O
elevated	O
by	O
25mg	O
/	O
kg	O
of	O
metformin	B-Chemical
,	O
slightly	O
by	O
50mg	O
/	O
kg	O
,	O
but	O
not	O
by	O
100mg	O
/	O
kg	O
.	O
Chronic	O
pre	O
-	O
treatment	O
with	O
metformin	B-Chemical
reduces	O
post	O
-	O
myocardial	B-Disease
infarction	I-Disease
cardiac	O
dysfunction	O
and	O
suppresses	O
inflammatory	O
responses	O
,	O
possibly	O
through	O
inhibition	O
of	O
TLR4	O
activities	O
.	O
This	O
mechanism	O
can	O
be	O
considered	O
as	O
a	O
target	O
to	O
protect	O
infarcted	O
myocardium	O
.	O
Unusual	O
complications	O
of	O
antithyroid	O
drug	O
therapy	O
:	O
four	O
case	O
reports	O
and	O
review	O
of	O
literature	O
.	O
Two	O
cases	O
of	O
propylthiouracil	B-Chemical
-	O
associated	O
acute	O
hepatitis	B-Disease
,	O
one	O
case	O
of	O
fatal	O
methimazole	B-Chemical
-	O
associated	O
hepatocellular	B-Disease
necrosis	I-Disease
and	O
one	O
case	O
of	O
propylthiouracil	B-Chemical
-	O
associated	O
lupus	B-Disease
-	I-Disease
like	I-Disease
syndrome	I-Disease
are	O
described	O
.	O
The	O
literature	O
related	O
to	O
antithyroid	O
drug	O
side	O
effects	O
and	O
the	O
mechanisms	O
for	O
their	O
occurrence	O
are	O
reviewed	O
and	O
the	O
efficacy	O
and	O
complications	O
of	O
thyroidectomy	O
and	O
radioiodine	O
compared	O
to	O
those	O
of	O
antithyroid	O
drugs	O
.	O
It	O
is	O
concluded	O
that	O
in	O
most	O
circumstances	O
131I	O
is	O
the	O
therapy	O
of	O
choice	O
for	O
hyperthyroidism	B-Disease
.	O
Neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
induced	O
by	O
combination	O
therapy	O
with	O
tetrabenazine	B-Chemical
and	O
tiapride	B-Chemical
in	O
a	O
Japanese	O
patient	O
with	O
Huntington	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
at	O
the	O
terminal	O
stage	O
of	O
recurrent	O
breast	B-Disease
cancer	I-Disease
.	O
We	O
herein	O
describe	O
the	O
case	O
of	O
an	O
81	O
-	O
year	O
-	O
old	O
Japanese	O
woman	O
with	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
that	O
occurred	O
36	O
days	O
after	O
the	O
initiation	O
of	O
combination	O
therapy	O
with	O
tiapride	B-Chemical
(	O
75	O
mg	O
/	O
day	O
)	O
and	O
tetrabenazine	B-Chemical
(	O
12	O
.	O
5	O
mg	O
/	O
day	O
)	O
for	O
Huntington	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
The	O
patient	O
had	O
been	O
treated	O
with	O
tiapride	B-Chemical
or	O
tetrabenazine	B-Chemical
alone	O
without	O
any	O
adverse	O
effects	O
before	O
the	O
administration	O
of	O
the	O
combination	O
therapy	O
.	O
She	O
also	O
had	O
advanced	O
breast	B-Disease
cancer	I-Disease
when	O
the	O
combination	O
therapy	O
was	O
initiated	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
occurrence	O
of	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
due	O
to	O
combination	O
therapy	O
with	O
tetrabenazine	B-Chemical
and	O
tiapride	B-Chemical
has	O
not	O
been	O
previously	O
reported	O
.	O
Tetrabenazine	B-Chemical
should	O
be	O
administered	O
very	O
carefully	O
in	O
combination	O
with	O
other	O
neuroleptic	B-Chemical
drugs	I-Chemical
,	O
particularly	O
in	O
patients	O
with	O
a	O
worsening	O
general	O
condition	O
.	O
A	O
metoprolol	B-Chemical
-	O
terbinafine	B-Chemical
combination	O
induced	O
bradycardia	B-Disease
.	O
To	O
report	O
a	O
sinus	B-Disease
bradycardia	I-Disease
induced	O
by	O
metoprolol	B-Chemical
and	O
terbinafine	B-Chemical
drug	O
-	O
drug	O
interaction	O
and	O
its	O
management	O
.	O
A	O
63	O
year	O
-	O
old	O
Caucasian	O
man	O
on	O
metoprolol	B-Chemical
200	O
mg	O
/	O
day	O
for	O
stable	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
was	O
prescribed	O
a	O
90	O
-	O
day	O
course	O
of	O
oral	O
terbinafine	B-Chemical
250	O
mg	O
/	O
day	O
for	O
onychomycosis	B-Disease
.	O
On	O
the	O
49th	O
day	O
of	O
terbinafine	B-Chemical
therapy	O
,	O
he	O
was	O
brought	O
to	O
the	O
emergency	O
room	O
for	O
a	O
decrease	O
of	O
his	O
global	O
health	O
status	O
,	O
confusion	B-Disease
and	O
falls	O
.	O
The	O
electrocardiogram	O
revealed	O
a	O
37	O
beats	O
/	O
min	O
sinus	B-Disease
bradycardia	I-Disease
.	O
A	O
score	O
of	O
7	O
on	O
the	O
Naranjo	O
adverse	B-Disease
drug	I-Disease
reaction	I-Disease
probability	O
scale	O
indicates	O
a	O
probable	O
relationship	O
between	O
the	O
patient	O
'	O
s	O
sinus	B-Disease
bradycardia	I-Disease
and	O
the	O
drug	O
interaction	O
between	O
metoprolol	B-Chemical
and	O
terbinafine	B-Chemical
.	O
The	O
heart	O
rate	O
ameliorated	O
first	O
with	O
a	O
decrease	O
in	O
the	O
dose	O
of	O
metoprolol	B-Chemical
.	O
It	O
was	O
subsequently	O
changed	O
to	O
bisoprolol	B-Chemical
and	O
the	O
heart	O
rate	O
remained	O
normal	O
.	O
By	O
inhibiting	O
the	O
cytochrome	O
P450	O
2D6	O
,	O
terbinafine	B-Chemical
had	O
decreased	O
metoprolol	B-Chemical
'	O
s	O
clearance	O
,	O
leading	O
in	O
metoprolol	B-Chemical
accumulation	O
which	O
has	O
resulted	O
in	O
clinically	O
significant	O
sinus	B-Disease
bradycardia	I-Disease
.	O
Optochiasmatic	O
and	O
peripheral	B-Disease
neuropathy	I-Disease
due	O
to	O
ethambutol	B-Chemical
overtreatment	O
.	O
Ethambutol	B-Chemical
is	O
known	O
to	O
cause	O
optic	B-Disease
neuropathy	I-Disease
and	O
,	O
more	O
rarely	O
,	O
axonal	O
polyneuropathy	B-Disease
.	O
We	O
characterize	O
the	O
clinical	O
,	O
neurophysiological	O
,	O
and	O
neuroimaging	O
findings	O
in	O
a	O
72	O
-	O
year	O
-	O
old	O
man	O
who	O
developed	O
visual	B-Disease
loss	I-Disease
and	O
paresthesias	B-Disease
after	O
11	O
weeks	O
of	O
exposure	O
to	O
a	O
supratherapeutic	O
dose	O
of	O
ethambutol	B-Chemical
.	O
This	O
case	O
demonstrates	O
the	O
selective	O
vulnerability	O
of	O
the	O
anterior	O
visual	O
pathways	O
and	O
peripheral	O
nerves	O
to	O
ethambutol	B-Chemical
toxicity	B-Disease
.	O
Testosterone	B-Chemical
ameliorates	O
streptozotocin	B-Chemical
-	O
induced	O
memory	B-Disease
impairment	I-Disease
in	O
male	O
rats	O
.	O
AIM	O
:	O
To	O
study	O
the	O
effects	O
of	O
testosterone	B-Chemical
on	O
streptozotocin	B-Chemical
(	O
STZ	B-Chemical
)	O
-	O
induced	O
memory	B-Disease
impairment	I-Disease
in	O
male	O
rats	O
.	O
METHODS	O
:	O
Adult	O
male	O
Wistar	O
rats	O
were	O
intracerebroventricularly	O
(	O
icv	O
)	O
infused	O
with	O
STZ	B-Chemical
(	O
750	O
ug	O
)	O
on	O
d	O
1	O
and	O
d	O
3	O
,	O
and	O
a	O
passive	O
avoidance	O
task	O
was	O
assessed	O
2	O
weeks	O
after	O
the	O
first	O
injection	O
of	O
STZ	B-Chemical
.	O
Castration	O
surgery	O
was	O
performed	O
in	O
another	O
group	O
of	O
rats	O
,	O
and	O
the	O
passive	O
avoidance	O
task	O
was	O
assessed	O
4	O
weeks	O
after	O
the	O
operation	O
.	O
Testosterone	B-Chemical
(	O
1	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
sc	O
)	O
,	O
the	O
androgen	B-Chemical
receptor	O
antagonist	O
flutamide	B-Chemical
(	O
10	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
ip	O
)	O
,	O
the	O
estrogen	B-Chemical
receptor	O
antagonist	O
tamoxifen	B-Chemical
(	O
1	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
ip	O
)	O
or	O
the	O
aromatase	O
inhibitor	O
letrozole	B-Chemical
(	O
4	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
,	O
ip	O
)	O
were	O
administered	O
for	O
6	O
d	O
after	O
the	O
first	O
injection	O
of	O
STZ	B-Chemical
.	O
RESULTS	O
:	O
STZ	B-Chemical
administration	O
and	O
castration	O
markedly	O
decreased	O
both	O
STL1	O
(	O
the	O
short	O
memory	O
)	O
and	O
STL2	O
(	O
the	O
long	O
memory	O
)	O
in	O
passive	O
avoidance	O
tests	O
.	O
Testosterone	B-Chemical
replacement	O
almost	O
restored	O
the	O
STL1	O
and	O
STL2	O
in	O
castrated	O
rats	O
,	O
and	O
significantly	O
prolonged	O
the	O
STL1	O
and	O
STL2	O
in	O
STZ	B-Chemical
-	O
treated	O
rats	O
.	O
Administration	O
of	O
flutamide	B-Chemical
,	O
letrozole	B-Chemical
or	O
tamoxifen	B-Chemical
significantly	O
impaired	B-Disease
the	I-Disease
memory	I-Disease
in	O
intact	O
rats	O
,	O
and	O
significantly	O
attenuated	O
the	O
testosterone	B-Chemical
replacement	O
in	O
improving	O
STZ	B-Chemical
-	O
and	O
castration	O
-	O
induced	O
memory	B-Disease
impairment	I-Disease
.	O
CONCLUSION	O
:	O
Testosterone	B-Chemical
administration	O
ameliorates	O
STZ	B-Chemical
-	O
and	O
castration	O
-	O
induced	O
memory	B-Disease
impairment	I-Disease
in	O
male	O
Wistar	O
rats	O
.	O
Behavioral	O
and	O
neurochemical	O
studies	O
in	O
mice	O
pretreated	O
with	O
garcinielliptone	B-Chemical
FC	I-Chemical
in	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
.	O
Garcinielliptone	B-Chemical
FC	I-Chemical
(	O
GFC	B-Chemical
)	O
isolated	O
from	O
hexanic	O
fraction	O
seed	O
extract	O
of	O
species	O
Platonia	O
insignis	O
Mart	O
.	O
It	O
is	O
widely	O
used	O
in	O
folk	O
medicine	O
to	O
treat	O
skin	B-Disease
diseases	I-Disease
in	O
both	O
humans	O
and	O
animals	O
as	O
well	O
as	O
the	O
seed	O
decoction	O
has	O
been	O
used	O
to	O
treat	O
diarrheas	B-Disease
and	O
inflammatory	B-Disease
diseases	I-Disease
.	O
However	O
,	O
there	O
is	O
no	O
research	O
on	O
GFC	B-Chemical
effects	O
in	O
the	O
central	O
nervous	O
system	O
of	O
rodents	O
.	O
The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
GFC	B-Chemical
effects	O
at	O
doses	O
of	O
25	O
,	O
50	O
or	O
75	O
mg	O
/	O
kg	O
on	O
seizure	B-Disease
parameters	O
to	O
determine	O
their	O
anticonvulsant	O
activity	O
and	O
its	O
effects	O
on	O
amino	B-Chemical
acid	I-Chemical
(	O
r	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
(	O
GABA	B-Chemical
)	O
,	O
glutamine	B-Chemical
,	O
aspartate	B-Chemical
and	O
glutathione	B-Chemical
)	O
levels	O
as	O
well	O
as	O
on	O
acetylcholinesterase	O
(	O
AChE	O
)	O
activity	O
in	O
mice	O
hippocampus	O
after	O
seizures	B-Disease
.	O
GFC	B-Chemical
produced	O
an	O
increased	O
latency	O
to	O
first	O
seizure	B-Disease
,	O
at	O
doses	O
25mg	O
/	O
kg	O
(	O
20	O
.	O
12	O
+	O
2	O
.	O
20	O
min	O
)	O
,	O
50mg	O
/	O
kg	O
(	O
20	O
.	O
95	O
+	O
2	O
.	O
21	O
min	O
)	O
or	O
75	O
mg	O
/	O
kg	O
(	O
23	O
.	O
43	O
+	O
1	O
.	O
99	O
min	O
)	O
when	O
compared	O
with	O
seized	O
mice	O
.	O
In	O
addition	O
,	O
GABA	B-Chemical
content	O
of	O
mice	O
hippocampus	O
treated	O
with	O
GFC75	O
plus	O
P400	O
showed	O
an	O
increase	O
of	O
46	O
.	O
90	O
%	O
when	O
compared	O
with	O
seized	O
mice	O
.	O
In	O
aspartate	B-Chemical
,	O
glutamine	B-Chemical
and	O
glutamate	B-Chemical
levels	O
detected	O
a	O
decrease	O
of	O
5	O
.	O
21	O
%	O
,	O
13	O
.	O
55	O
%	O
and	O
21	O
.	O
80	O
%	O
,	O
respectively	O
in	O
mice	O
hippocampus	O
treated	O
with	O
GFC75	O
plus	O
P400	O
when	O
compared	O
with	O
seized	O
mice	O
.	O
Hippocampus	O
mice	O
treated	O
with	O
GFC75	O
plus	O
P400	O
showed	O
an	O
increase	O
in	O
AChE	O
activity	O
(	O
63	O
.	O
30	O
%	O
)	O
when	O
compared	O
with	O
seized	O
mice	O
.	O
The	O
results	O
indicate	O
that	O
GFC	B-Chemical
can	O
exert	O
anticonvulsant	O
activity	O
and	O
reduce	O
the	O
frequency	O
of	O
installation	O
of	O
pilocarpine	B-Chemical
-	O
induced	O
status	B-Disease
epilepticus	I-Disease
,	O
as	O
demonstrated	O
by	O
increase	O
in	O
latency	O
to	O
first	O
seizure	B-Disease
and	O
decrease	O
in	O
mortality	O
rate	O
of	O
animals	O
.	O
In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
GFC	B-Chemical
may	O
influence	O
in	O
epileptogenesis	O
and	O
promote	O
anticonvulsant	O
actions	O
in	O
pilocarpine	B-Chemical
model	O
by	O
modulating	O
the	O
GABA	B-Chemical
and	O
glutamate	B-Chemical
contents	O
and	O
of	O
AChE	O
activity	O
in	O
seized	O
mice	O
hippocampus	O
.	O
This	O
compound	O
may	O
be	O
useful	O
to	O
produce	O
neuronal	O
protection	O
and	O
it	O
can	O
be	O
considered	O
as	O
an	O
anticonvulsant	O
agent	O
.	O
Standard	O
operating	O
procedures	O
for	O
antibiotic	O
therapy	O
and	O
the	O
occurrence	O
of	O
acute	B-Disease
kidney	I-Disease
injury	I-Disease
:	O
a	O
prospective	O
,	O
clinical	O
,	O
non	O
-	O
interventional	O
,	O
observational	O
study	O
.	O
INTRODUCTION	O
:	O
Acute	B-Disease
kidney	I-Disease
injury	I-Disease
(	O
AKI	B-Disease
)	O
occurs	O
in	O
7	O
%	O
of	O
hospitalized	O
and	O
66	O
%	O
of	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O
patients	O
.	O
It	O
increases	O
mortality	O
,	O
hospital	O
length	O
of	O
stay	O
,	O
and	O
costs	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
,	O
whether	O
there	O
is	O
an	O
association	O
between	O
adherence	O
to	O
guidelines	O
(	O
standard	O
operating	O
procedures	O
(	O
SOP	O
)	O
)	O
for	O
potentially	O
nephrotoxic	B-Disease
antibiotics	O
and	O
the	O
occurrence	O
of	O
AKI	B-Disease
.	O
METHODS	O
:	O
This	O
study	O
was	O
carried	O
out	O
as	O
a	O
prospective	O
,	O
clinical	O
,	O
non	O
-	O
interventional	O
,	O
observational	O
study	O
.	O
Data	O
collection	O
was	O
performed	O
over	O
a	O
total	O
of	O
170	O
days	O
in	O
three	O
ICUs	O
at	O
Charite	O
-	O
Universitaetsmedizin	O
Berlin	O
.	O
A	O
total	O
of	O
675	O
patients	O
were	O
included	O
;	O
163	O
of	O
these	O
had	O
therapy	O
with	O
vancomycin	B-Chemical
,	O
gentamicin	B-Chemical
,	O
or	O
tobramycin	B-Chemical
;	O
were	O
>	O
18	O
years	O
;	O
and	O
treated	O
in	O
the	O
ICU	O
for	O
>	O
24	O
hours	O
.	O
Patients	O
with	O
an	O
adherence	O
to	O
SOP	O
>	O
70	O
%	O
were	O
classified	O
into	O
the	O
high	O
adherence	O
group	O
(	O
HAG	O
)	O
and	O
patients	O
with	O
an	O
adherence	O
of	O
<	O
70	O
%	O
into	O
the	O
low	O
adherence	O
group	O
(	O
LAG	O
)	O
.	O
AKI	B-Disease
was	O
defined	O
according	O
to	O
RIFLE	O
criteria	O
.	O
Adherence	O
to	O
SOPs	O
was	O
evaluated	O
by	O
retrospective	O
expert	O
audit	O
.	O
Development	O
of	O
AKI	B-Disease
was	O
compared	O
between	O
groups	O
with	O
exact	O
Chi2	O
-	O
test	O
and	O
multivariate	O
logistic	O
regression	O
analysis	O
(	O
two	O
-	O
sided	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
RESULTS	O
:	O
LAG	O
consisted	O
of	O
75	O
patients	O
(	O
46	O
%	O
)	O
versus	O
88	O
HAG	O
patients	O
(	O
54	O
%	O
)	O
.	O
AKI	B-Disease
occurred	O
significantly	O
more	O
often	O
in	O
LAG	O
with	O
36	O
%	O
versus	O
21	O
%	O
in	O
HAG	O
(	O
P	O
=	O
0	O
.	O
035	O
)	O
.	O
Basic	O
characteristics	O
were	O
comparable	O
,	O
except	O
an	O
increased	O
rate	O
of	O
soft	O
tissue	O
infections	B-Disease
in	O
LAG	O
.	O
Multivariate	O
analysis	O
revealed	O
an	O
odds	O
ratio	O
of	O
2	O
.	O
5	O
-	O
fold	O
for	O
LAG	O
to	O
develop	O
AKI	B-Disease
compared	O
with	O
HAG	O
(	O
95	O
%	O
confidence	O
interval	O
1	O
.	O
195	O
to	O
5	O
.	O
124	O
,	O
P	O
=	O
0	O
.	O
039	O
)	O
.	O
CONCLUSION	O
:	O
Low	O
adherence	O
to	O
SOPs	O
for	O
potentially	O
nephrotoxic	B-Disease
antibiotics	O
was	O
associated	O
with	O
a	O
higher	O
occurrence	O
of	O
AKI	B-Disease
.	O
TRIAL	O
REGISTRATION	O
:	O
Current	O
Controlled	O
Trials	O
ISRCTN54598675	O
.	O
Registered	O
17	O
August	O
2007	O
.	O
Rhabdomyolysis	B-Disease
in	O
a	O
hepatitis	B-Disease
C	I-Disease
virus	I-Disease
infected	I-Disease
patient	O
treated	O
with	O
telaprevir	B-Chemical
and	O
simvastatin	B-Chemical
.	O
A	O
46	O
-	O
year	O
old	O
man	O
with	O
a	O
chronic	O
hepatitis	B-Disease
C	I-Disease
virus	I-Disease
infection	I-Disease
received	O
triple	O
therapy	O
with	O
ribavirin	B-Chemical
,	O
pegylated	B-Chemical
interferon	I-Chemical
and	O
telaprevir	B-Chemical
.	O
The	O
patient	O
also	O
received	O
simvastatin	B-Chemical
.	O
One	O
month	O
after	O
starting	O
the	O
antiviral	O
therapy	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
because	O
he	O
developed	O
rhabdomyolysis	B-Disease
.	O
At	O
admission	O
simvastatin	B-Chemical
and	O
all	O
antiviral	O
drugs	O
were	O
discontinued	O
because	O
toxicity	B-Disease
due	O
to	O
a	O
drug	O
-	O
drug	O
interaction	O
was	O
suspected	O
.	O
The	O
creatine	B-Chemical
kinase	O
peaked	O
at	O
62	O
,	O
246	O
IU	O
/	O
L	O
and	O
the	O
patient	O
was	O
treated	O
with	O
intravenous	O
normal	O
saline	O
.	O
The	O
patient	O
'	O
s	O
renal	O
function	O
remained	O
unaffected	O
.	O
Fourteen	O
days	O
after	O
hospitalization	O
,	O
creatine	B-Chemical
kinase	O
level	O
had	O
returned	O
to	O
230	O
IU	O
/	O
L	O
and	O
the	O
patient	O
was	O
discharged	O
.	O
Telaprevir	B-Chemical
was	O
considered	O
the	O
probable	O
causative	O
agent	O
of	O
an	O
interaction	O
with	O
simvastatin	B-Chemical
according	O
to	O
the	O
Drug	O
Interaction	O
Probability	O
Scale	O
.	O
The	O
interaction	O
is	O
due	O
to	O
inhibition	O
of	O
CYP3A4	O
-	O
mediated	O
simvastatin	B-Chemical
clearance	O
.	O
Simvastatin	B-Chemical
plasma	O
concentration	O
increased	O
30	O
times	O
in	O
this	O
patient	O
and	O
statin	B-Chemical
induced	O
muscle	B-Disease
toxicity	I-Disease
is	O
related	O
to	O
the	O
concentration	O
of	O
the	O
statin	B-Chemical
in	O
blood	O
.	O
In	O
conclusion	O
,	O
with	O
this	O
case	O
we	O
illustrate	O
that	O
telaprevir	B-Chemical
as	O
well	O
as	O
statins	B-Chemical
are	O
susceptible	O
to	O
clinical	O
relevant	O
drug	O
-	O
drug	O
interactions	O
.	O
Combination	O
of	O
bortezomib	B-Chemical
,	O
thalidomide	B-Chemical
,	O
and	O
dexamethasone	B-Chemical
(	O
VTD	O
)	O
as	O
a	O
consolidation	O
therapy	O
after	O
autologous	O
stem	O
cell	O
transplantation	O
for	O
symptomatic	O
multiple	B-Disease
myeloma	I-Disease
in	O
Japanese	O
patients	O
.	O
Consolidation	O
therapy	O
for	O
patients	O
with	O
multiple	B-Disease
myeloma	I-Disease
(	O
MM	B-Disease
)	O
has	O
been	O
widely	O
adopted	O
to	O
improve	O
treatment	O
response	O
following	O
autologous	O
stem	O
cell	O
transplantation	O
.	O
In	O
this	O
study	O
,	O
we	O
retrospectively	O
analyzed	O
the	O
safety	O
and	O
efficacy	O
of	O
combination	O
regimen	O
of	O
bortezomib	B-Chemical
,	O
thalidomide	B-Chemical
,	O
and	O
dexamethasone	B-Chemical
(	O
VTD	O
)	O
as	O
consolidation	O
therapy	O
in	O
24	O
Japanese	O
patients	O
with	O
newly	O
diagnosed	O
MM	B-Disease
.	O
VTD	O
consisted	O
of	O
bortezomib	B-Chemical
at	O
a	O
dose	O
of	O
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
dexamethasone	B-Chemical
at	O
a	O
dose	O
of	O
40	O
mg	O
/	O
day	O
on	O
days	O
1	O
,	O
8	O
,	O
15	O
,	O
and	O
22	O
of	O
a	O
35	O
-	O
day	O
cycle	O
,	O
with	O
daily	O
oral	O
thalidomide	B-Chemical
at	O
a	O
dose	O
of	O
100	O
mg	O
/	O
day	O
.	O
Grade	O
3	O
-	O
4	O
neutropenia	B-Disease
and	O
thrombocytopenia	B-Disease
were	O
documented	O
in	O
four	O
and	O
three	O
patients	O
(	O
17	O
and	O
13	O
%	O
)	O
,	O
respectively	O
,	O
but	O
drug	O
dose	O
reduction	O
due	O
to	O
cytopenia	B-Disease
was	O
not	O
required	O
in	O
any	O
case	O
.	O
Peripheral	B-Disease
neuropathy	I-Disease
was	O
common	O
(	O
63	O
%	O
)	O
,	O
but	O
severe	O
grade	O
3	O
-	O
4	O
peripheral	B-Disease
neuropathy	I-Disease
was	O
not	O
observed	O
.	O
Very	O
good	O
partial	O
response	O
or	O
better	O
response	O
(	O
>	O
VGPR	O
)	O
rates	O
before	O
and	O
after	O
consolidation	O
therapy	O
were	O
54	O
and	O
79	O
%	O
,	O
respectively	O
.	O
Patients	O
had	O
a	O
significant	O
probability	O
of	O
improving	O
from	O
<	O
VGPR	O
before	O
consolidation	O
therapy	O
to	O
>	O
VGPR	O
after	O
consolidation	O
therapy	O
(	O
p	O
=	O
0	O
.	O
041	O
)	O
.	O
The	O
VTD	O
regimen	O
may	O
be	O
safe	O
and	O
effective	O
as	O
a	O
consolidation	O
therapy	O
in	O
the	O
treatment	O
of	O
MM	O
in	O
Japanese	O
population	O
.	O
Conversion	O
to	O
sirolimus	B-Chemical
ameliorates	O
cyclosporine	B-Chemical
-	O
induced	O
nephropathy	B-Disease
in	O
the	O
rat	O
:	O
focus	O
on	O
serum	O
,	O
urine	O
,	O
gene	O
,	O
and	O
protein	O
renal	O
expression	O
biomarkers	O
.	O
Protocols	O
of	O
conversion	O
from	O
cyclosporin	B-Chemical
A	I-Chemical
(	O
CsA	B-Chemical
)	O
to	O
sirolimus	B-Chemical
(	O
SRL	B-Chemical
)	O
have	O
been	O
widely	O
used	O
in	O
immunotherapy	O
after	O
transplantation	O
to	O
prevent	O
CsA	B-Chemical
-	O
induced	O
nephropathy	B-Disease
,	O
but	O
the	O
molecular	O
mechanisms	O
underlying	O
these	O
protocols	O
remain	O
nuclear	O
.	O
This	O
study	O
aimed	O
to	O
identify	O
the	O
molecular	O
pathways	O
and	O
putative	O
biomarkers	O
of	O
CsA	B-Chemical
-	O
to	O
-	O
SRL	B-Chemical
conversion	O
in	O
a	O
rat	O
model	O
.	O
Four	O
animal	O
groups	O
(	O
n	O
=	O
6	O
)	O
were	O
tested	O
during	O
9	O
weeks	O
:	O
control	O
,	O
CsA	B-Chemical
,	O
SRL	B-Chemical
,	O
and	O
conversion	O
(	O
CsA	B-Chemical
for	O
3	O
weeks	O
followed	O
by	O
SRL	B-Chemical
for	O
6	O
weeks	O
)	O
.	O
Classical	O
and	O
emergent	O
serum	O
,	O
urinary	O
,	O
and	O
kidney	O
tissue	O
(	O
gene	O
and	O
protein	O
expression	O
)	O
markers	O
were	O
assessed	O
.	O
Renal	B-Disease
lesions	I-Disease
were	O
analyzed	O
in	O
hematoxylin	B-Chemical
and	O
eosin	B-Chemical
,	O
periodic	O
acid	O
-	O
Schiff	O
,	O
and	O
Masson	O
'	O
s	O
trichrome	O
stains	O
.	O
SRL	B-Chemical
-	O
treated	O
rats	O
presented	O
proteinuria	B-Disease
and	O
NGAL	O
(	O
serum	O
and	O
urinary	O
)	O
as	O
the	O
best	O
markers	O
of	O
renal	B-Disease
impairment	I-Disease
.	O
Short	O
CsA	B-Chemical
treatment	O
presented	O
slight	O
or	O
even	O
absent	O
kidney	B-Disease
lesions	I-Disease
and	O
TGF	O
-	O
b	O
,	O
NF	O
-	O
kb	O
,	O
mTOR	O
,	O
PCNA	O
,	O
TP53	O
,	O
KIM	O
-	O
1	O
,	O
and	O
CTGF	O
as	O
relevant	O
gene	O
and	O
protein	O
changes	O
.	O
Prolonged	O
CsA	B-Chemical
exposure	O
aggravated	O
renal	B-Disease
damage	I-Disease
,	O
without	O
clear	O
changes	O
on	O
the	O
traditional	O
markers	O
,	O
but	O
with	O
changes	O
in	O
serums	O
TGF	O
-	O
b	O
and	O
IL	O
-	O
7	O
,	O
TBARs	O
clearance	O
,	O
and	O
kidney	O
TGF	O
-	O
b	O
and	O
mTOR	O
.	O
Conversion	O
to	O
SRL	B-Chemical
prevented	O
CsA	B-Chemical
-	O
induced	O
renal	B-Disease
damage	I-Disease
evolution	O
(	O
absent	O
/	O
mild	O
grade	O
lesions	O
)	O
,	O
while	O
NGAL	O
(	O
serum	O
versus	O
urine	O
)	O
seems	O
to	O
be	O
a	O
feasible	O
biomarker	O
of	O
CsA	B-Chemical
replacement	O
to	O
SRL	B-Chemical
.	O
Kinin	O
B2	O
receptor	O
deletion	O
and	O
blockage	O
ameliorates	O
cisplatin	B-Chemical
-	O
induced	O
acute	B-Disease
renal	I-Disease
injury	I-Disease
.	O
Cisplatin	B-Chemical
treatment	O
has	O
been	O
adopted	O
in	O
some	O
chemotherapies	O
;	O
however	O
,	O
this	O
drug	O
can	O
induce	O
acute	B-Disease
kidney	I-Disease
injury	I-Disease
due	O
its	O
ability	O
to	O
negatively	O
affect	O
renal	O
function	O
,	O
augment	O
serum	O
levels	O
of	O
creatinine	B-Chemical
and	O
urea	B-Chemical
,	O
increase	O
the	O
acute	B-Disease
tubular	I-Disease
necrosis	I-Disease
score	O
and	O
up	O
-	O
regulate	O
cytokines	O
(	O
e	O
.	O
g	O
.	O
,	O
IL	O
-	O
1b	O
and	O
TNF	O
-	O
a	O
)	O
.	O
The	O
kinin	O
B2	O
receptor	O
has	O
been	O
associated	O
with	O
the	O
inflammation	B-Disease
process	O
,	O
as	O
well	O
as	O
the	O
regulation	O
of	O
cytokine	O
expression	O
,	O
and	O
its	O
deletion	O
resulted	O
in	O
an	O
improvement	O
in	O
the	O
diabetic	B-Disease
nephropathy	I-Disease
status	O
.	O
To	O
examine	O
the	O
role	O
of	O
the	O
kinin	O
B2	O
receptor	O
in	O
cisplatin	B-Chemical
-	O
induced	O
acute	B-Disease
kidney	I-Disease
injury	I-Disease
,	O
kinin	O
B2	O
receptor	O
knockout	O
mice	O
were	O
challenged	O
with	O
cisplatin	B-Chemical
.	O
Additionally	O
,	O
WT	O
mice	O
were	O
treated	O
with	O
a	O
B2	O
receptor	O
antagonist	O
after	O
cisplatin	B-Chemical
administration	O
.	O
B2	O
receptor	O
-	O
deficient	O
mice	O
were	O
less	O
sensitive	O
to	O
this	O
drug	O
than	O
the	O
WT	O
mice	O
,	O
as	O
shown	O
by	O
reduced	O
weight	B-Disease
loss	I-Disease
,	O
better	O
preservation	O
of	O
kidney	O
function	O
,	O
down	O
regulation	O
of	O
inflammatory	O
cytokines	O
and	O
less	O
acute	B-Disease
tubular	I-Disease
necrosis	I-Disease
.	O
Moreover	O
,	O
treatment	O
with	O
the	O
kinin	O
B2	O
receptor	O
antagonist	O
effectively	O
reduced	O
the	O
levels	O
of	O
serum	O
creatinine	B-Chemical
and	O
blood	O
urea	B-Chemical
after	O
cisplatin	B-Chemical
administration	O
.	O
Thus	O
,	O
our	O
data	O
suggest	O
that	O
the	O
kinin	O
B2	O
receptor	O
is	O
involved	O
in	O
cisplatin	B-Chemical
-	O
induced	O
acute	B-Disease
kidney	I-Disease
injury	I-Disease
by	O
mediating	O
the	O
necrotic	B-Disease
process	O
and	O
the	O
expression	O
of	O
inflammatory	O
cytokines	O
,	O
thus	O
resulting	O
in	O
declined	O
renal	O
function	O
.	O
These	O
results	O
highlight	O
the	O
kinin	O
B2	O
receptor	O
antagonist	O
treatment	O
in	O
amelioration	O
of	O
nephrotoxicity	B-Disease
induced	O
by	O
cisplatin	B-Chemical
therapy	O
.	O
Safety	O
and	O
efficacy	O
of	O
fluocinolone	B-Chemical
acetonide	I-Chemical
intravitreal	O
implant	O
(	O
0	O
.	O
59	O
mg	O
)	O
in	O
birdshot	B-Disease
retinochoroidopathy	I-Disease
.	O
PURPOSE	O
:	O
To	O
report	O
the	O
treatment	O
outcomes	O
of	O
the	O
fluocinolone	B-Chemical
acetonide	I-Chemical
intravitreal	O
implant	O
(	O
0	O
.	O
59	O
mg	O
)	O
in	O
patients	O
with	O
birdshot	B-Disease
retinochoroidopathy	I-Disease
whose	O
disease	O
is	O
refractory	O
or	O
intolerant	O
to	O
conventional	O
immunomodulatory	O
therapy	O
.	O
METHODS	O
:	O
A	O
retrospective	O
case	O
series	O
involving	O
11	O
birdshot	B-Disease
retinochoroidopathy	I-Disease
patients	O
(	O
11	O
eyes	O
)	O
.	O
Eleven	O
patients	O
(	O
11	O
eyes	O
)	O
underwent	O
surgery	O
for	O
fluocinolone	B-Chemical
acetonide	I-Chemical
implant	O
(	O
0	O
.	O
59	O
mg	O
)	O
.	O
Treatment	O
outcomes	O
of	O
interest	O
were	O
noted	O
at	O
baseline	O
,	O
before	O
fluocinolone	B-Chemical
acetonide	I-Chemical
implant	O
,	O
and	O
then	O
at	O
6	O
months	O
,	O
1	O
year	O
,	O
2	O
years	O
,	O
3	O
years	O
,	O
and	O
beyond	O
3	O
years	O
.	O
Disease	O
activity	O
markers	O
,	O
including	O
signs	O
of	O
ocular	O
inflammation	B-Disease
,	O
evidence	O
of	O
retinal	B-Disease
vasculitis	I-Disease
,	O
Swedish	O
interactive	O
threshold	O
algorithm	O
-	O
short	O
wavelength	O
automated	O
perimetry	O
Humphrey	O
visual	O
field	O
analysis	O
,	O
electroretinographic	O
parameters	O
,	O
and	O
optical	O
coherence	O
tomography	O
were	O
recorded	O
.	O
Data	O
on	O
occurrence	O
of	O
cataract	B-Disease
and	O
raised	B-Disease
intraocular	I-Disease
pressure	I-Disease
were	O
collected	O
in	O
all	O
eyes	O
.	O
RESULTS	O
:	O
Intraocular	O
inflammation	B-Disease
was	O
present	O
in	O
54	O
.	O
5	O
,	O
9	O
.	O
9	O
,	O
11	O
.	O
1	O
,	O
and	O
0	O
%	O
of	O
patients	O
at	O
baseline	O
,	O
6	O
months	O
,	O
1	O
year	O
,	O
2	O
years	O
,	O
3	O
years	O
,	O
and	O
beyond	O
3	O
years	O
after	O
receiving	O
the	O
implant	O
,	O
respectively	O
.	O
Active	O
vasculitis	B-Disease
was	O
noted	O
in	O
36	O
.	O
3	O
%	O
patients	O
at	O
baseline	O
and	O
0	O
%	O
at	O
3	O
years	O
of	O
follow	O
-	O
up	O
.	O
More	O
than	O
20	O
%	O
(	O
47	O
.	O
61	O
-	O
67	O
.	O
2	O
%	O
)	O
reduction	O
in	O
central	O
retinal	O
thickness	O
was	O
noted	O
in	O
all	O
patients	O
with	O
cystoid	B-Disease
macular	I-Disease
edema	I-Disease
at	O
6	O
months	O
,	O
1	O
year	O
,	O
2	O
years	O
,	O
and	O
3	O
years	O
postimplant	O
.	O
At	O
baseline	O
,	O
54	O
.	O
5	O
%	O
patients	O
were	O
on	O
immunomodulatory	O
agents	O
.	O
This	O
percentage	O
decreased	O
to	O
45	O
.	O
45	O
,	O
44	O
.	O
4	O
,	O
and	O
14	O
.	O
28	O
%	O
at	O
1	O
year	O
,	O
2	O
years	O
,	O
and	O
3	O
years	O
postimplant	O
,	O
respectively	O
.	O
Adverse	O
events	O
included	O
increased	B-Disease
intraocular	I-Disease
pressure	I-Disease
(	O
54	O
.	O
5	O
%	O
)	O
and	O
cataract	B-Disease
formation	O
(	O
100	O
%	O
)	O
.	O
CONCLUSION	O
:	O
The	O
data	O
suggest	O
that	O
fluocinolone	B-Chemical
acetonide	I-Chemical
implant	O
(	O
0	O
.	O
59	O
mg	O
)	O
helps	O
to	O
control	O
inflammation	B-Disease
in	O
otherwise	O
treatment	O
-	O
refractory	O
cases	O
of	O
birdshot	B-Disease
retinochoroidopathy	I-Disease
.	O
It	O
is	O
associated	O
with	O
significant	O
side	O
effects	O
of	O
cataract	B-Disease
and	O
ocular	B-Disease
hypertension	I-Disease
requiring	O
treatment	O
.	O
Optimal	O
precurarizing	O
dose	O
of	O
rocuronium	B-Chemical
to	O
decrease	O
fasciculation	B-Disease
and	O
myalgia	B-Disease
following	O
succinylcholine	B-Chemical
administration	O
.	O
BACKGROUND	O
:	O
Succinylcholine	B-Chemical
commonly	O
produces	O
frequent	O
adverse	O
effects	O
,	O
including	O
muscle	B-Disease
fasciculation	I-Disease
and	O
myalgia	B-Disease
.	O
The	O
current	O
study	O
identified	O
the	O
optimal	O
dose	O
of	O
rocuronium	B-Chemical
to	O
prevent	O
succinylcholine	B-Chemical
-	O
induced	O
fasciculation	B-Disease
and	O
myalgia	B-Disease
and	O
evaluated	O
the	O
influence	O
of	O
rocuronium	B-Chemical
on	O
the	O
speed	O
of	O
onset	O
produced	O
by	O
succinylcholine	B-Chemical
.	O
METHODS	O
:	O
This	O
randomized	O
,	O
double	O
-	O
blinded	O
study	O
was	O
conducted	O
in	O
100	O
patients	O
randomly	O
allocated	O
into	O
five	O
groups	O
of	O
20	O
patients	O
each	O
.	O
Patients	O
were	O
randomized	O
to	O
receive	O
0	O
.	O
02	O
,	O
0	O
.	O
03	O
,	O
0	O
.	O
04	O
,	O
0	O
.	O
05	O
and	O
0	O
.	O
06	O
mg	O
/	O
kg	O
rocuronium	B-Chemical
as	O
a	O
precurarizing	O
dose	O
.	O
Neuromuscular	O
monitoring	O
after	O
each	O
precurarizing	O
dose	O
was	O
recorded	O
from	O
the	O
adductor	O
pollicis	O
muscle	O
using	O
acceleromyography	O
with	O
train	O
-	O
of	O
-	O
four	O
stimulation	O
of	O
the	O
ulnar	O
nerve	O
.	O
All	O
patients	O
received	O
succinylcholine	B-Chemical
1	O
.	O
5	O
mg	O
/	O
kg	O
at	O
2	O
minutes	O
after	O
the	O
precurarization	O
,	O
and	O
were	O
assessed	O
the	O
incidence	O
and	O
severity	O
of	O
fasciculations	B-Disease
,	O
while	O
myalgia	B-Disease
was	O
assessed	O
at	O
24	O
hours	O
after	O
surgery	O
.	O
RESULTS	O
:	O
The	O
incidence	O
and	O
severity	O
of	O
visible	O
muscle	B-Disease
fasciculation	I-Disease
was	O
significantly	O
less	O
with	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	B-Chemical
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
Those	O
of	O
myalgia	B-Disease
tend	O
to	O
decrease	O
according	O
to	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	B-Chemical
,	O
but	O
there	O
was	O
no	O
significance	O
(	O
P	O
=	O
0	O
.	O
072	O
)	O
.	O
The	O
onset	O
time	O
of	O
succinylcholine	B-Chemical
was	O
significantly	O
longer	O
with	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	B-Chemical
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
CONCLUSIONS	O
:	O
Precurarization	O
with	O
0	O
.	O
04	O
mg	O
/	O
kg	O
rocuronium	B-Chemical
was	O
the	O
optimal	O
dose	O
considering	O
the	O
reduction	O
in	O
the	O
incidence	O
and	O
severity	O
of	O
fasciculation	B-Disease
and	O
myalgia	B-Disease
with	O
acceptable	O
onset	O
time	O
,	O
and	O
the	O
safe	O
and	O
effective	O
precurarization	O
.	O
Absence	O
of	O
PKC	O
-	O
alpha	O
attenuates	O
lithium	B-Chemical
-	O
induced	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
.	O
Lithium	B-Chemical
,	O
an	O
effective	O
antipsychotic	O
,	O
induces	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
(	O
NDI	B-Disease
)	O
in	O
40	O
%	O
of	O
patients	O
.	O
The	O
decreased	O
capacity	O
to	O
concentrate	O
urine	O
is	O
likely	O
due	O
to	O
lithium	B-Chemical
acutely	O
disrupting	O
the	O
cAMP	B-Chemical
pathway	O
and	O
chronically	O
reducing	O
urea	B-Chemical
transporter	O
(	O
UT	O
-	O
A1	O
)	O
and	O
water	O
channel	O
(	O
AQP2	O
)	O
expression	O
in	O
the	O
inner	O
medulla	O
.	O
Targeting	O
an	O
alternative	O
signaling	O
pathway	O
,	O
such	O
as	O
PKC	O
-	O
mediated	O
signaling	O
,	O
may	O
be	O
an	O
effective	O
method	O
of	O
treating	O
lithium	B-Chemical
-	O
induced	O
polyuria	B-Disease
.	O
PKC	O
-	O
alpha	O
mice	O
(	O
PKCa	O
KO	O
)	O
and	O
strain	O
-	O
matched	O
wild	O
type	O
(	O
WT	O
)	O
controls	O
were	O
treated	O
with	O
lithium	B-Chemical
for	O
0	O
,	O
3	O
or	O
5	O
days	O
.	O
WT	O
mice	O
had	O
increased	O
urine	O
output	O
and	O
lowered	O
urine	O
osmolality	O
after	O
3	O
and	O
5	O
days	O
of	O
treatment	O
whereas	O
PKCa	O
KO	O
mice	O
had	O
no	O
change	O
in	O
urine	O
output	O
or	O
concentration	O
.	O
Western	O
blot	O
analysis	O
revealed	O
that	O
AQP2	O
expression	O
in	O
medullary	O
tissues	O
was	O
lowered	O
after	O
3	O
and	O
5	O
days	O
in	O
WT	O
mice	O
;	O
however	O
,	O
AQP2	O
was	O
unchanged	O
in	O
PKCa	O
KO	O
.	O
Similar	O
results	O
were	O
observed	O
with	O
UT	O
-	O
A1	O
expression	O
.	O
Animals	O
were	O
also	O
treated	O
with	O
lithium	B-Chemical
for	O
6	O
weeks	O
.	O
Lithium	B-Chemical
-	O
treated	O
WT	O
mice	O
had	O
19	O
-	O
fold	O
increased	O
urine	O
output	O
whereas	O
treated	O
PKCa	O
KO	O
animals	O
had	O
a	O
4	O
-	O
fold	O
increase	O
in	O
output	O
.	O
AQP2	O
and	O
UT	O
-	O
A1	O
expression	O
was	O
lowered	O
in	O
6	O
week	O
lithium	B-Chemical
-	O
treated	O
WT	O
animals	O
whereas	O
in	O
treated	O
PKCa	O
KO	O
mice	O
,	O
AQP2	O
was	O
only	O
reduced	O
by	O
2	O
-	O
fold	O
and	O
UT	O
-	O
A1	O
expression	O
was	O
unaffected	O
.	O
Urinary	O
sodium	B-Chemical
,	O
potassium	B-Chemical
and	O
calcium	B-Chemical
were	O
elevated	O
in	O
lithium	B-Chemical
-	O
fed	O
WT	O
but	O
not	O
in	O
lithium	B-Chemical
-	O
fed	O
PKCa	O
KO	O
mice	O
.	O
Our	O
data	O
show	O
that	O
ablation	O
of	O
PKCa	O
preserves	O
AQP2	O
and	O
UT	O
-	O
A1	O
protein	O
expression	O
and	O
localization	O
in	O
lithium	B-Chemical
-	O
induced	O
NDI	B-Disease
,	O
and	O
prevents	O
the	O
development	O
of	O
the	O
severe	O
polyuria	B-Disease
associated	O
with	O
lithium	B-Chemical
therapy	O
.	O
Is	O
Dysguesia	B-Disease
Going	O
to	O
be	O
a	O
Rare	O
or	O
a	O
Common	O
Side	O
-	O
effect	O
of	O
Amlodipine	B-Chemical
?	O
A	O
very	O
rare	O
side	O
-	O
effect	O
of	O
amlodipine	B-Chemical
is	O
dysguesia	B-Disease
.	O
A	O
review	O
of	O
the	O
literature	O
produced	O
only	O
one	O
case	O
.	O
We	O
report	O
a	O
case	O
about	O
a	O
female	O
with	O
essential	O
hypertension	B-Disease
on	O
drug	O
treatment	O
with	O
amlodipine	B-Chemical
developed	O
loss	B-Disease
of	I-Disease
taste	I-Disease
sensation	I-Disease
.	O
Condition	O
moderately	O
improved	O
on	O
stoppage	O
of	O
the	O
drug	O
for	O
25	O
days	O
.	O
We	O
conclude	O
that	O
amlodipine	B-Chemical
can	O
cause	O
dysguesia	B-Disease
.	O
Here	O
,	O
we	O
describe	O
the	O
clinical	O
presentation	O
and	O
review	O
the	O
relevant	O
literature	O
on	O
amlodipine	B-Chemical
and	O
dysguesia	B-Disease
.	O
Rhabdomyolysis	B-Disease
in	O
association	O
with	O
simvastatin	B-Chemical
and	O
dosage	O
increment	O
in	O
clarithromycin	B-Chemical
.	O
Clarithromycin	B-Chemical
is	O
the	O
most	O
documented	O
cytochrome	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
inhibitor	O
to	O
cause	O
an	O
adverse	O
interaction	O
with	O
simvastatin	B-Chemical
.	O
This	O
particular	O
case	O
is	O
of	O
interest	O
as	O
rhabdomyolysis	B-Disease
only	O
occurred	O
after	O
an	O
increase	O
in	O
the	O
dose	O
of	O
clarithromycin	B-Chemical
.	O
The	O
patient	O
developed	O
raised	O
cardiac	O
biomarkers	O
without	O
any	O
obvious	O
cardiac	O
issues	O
,	O
a	O
phenomenon	O
that	O
has	O
been	O
linked	O
to	O
rhabdomyolysis	B-Disease
previously	O
.	O
To	O
date	O
,	O
there	O
has	O
been	O
no	O
reported	O
effect	O
of	O
rhabdomyolysis	B-Disease
on	O
the	O
structure	O
and	O
function	O
of	O
cardiac	O
muscle	O
.	O
Clinicians	O
need	O
to	O
be	O
aware	O
of	O
prescribing	O
concomitant	O
medications	O
that	O
increase	O
the	O
risk	O
of	O
myopathy	B-Disease
or	O
inhibit	O
the	O
CYP3A4	O
enzyme	O
.	O
Our	O
case	O
suggests	O
that	O
troponin	O
elevation	O
could	O
be	O
associated	O
with	O
statin	B-Chemical
induced	O
rhabdomyolysis	B-Disease
,	O
which	O
may	O
warrant	O
further	O
studies	O
.	O
Characterization	O
of	O
a	O
novel	O
BCHE	O
""""	O
silent	O
""""	O
allele	O
:	O
point	O
mutation	O
(	O
p	O
.	O
Val204Asp	O
)	O
causes	O
loss	O
of	O
activity	O
and	O
prolonged	O
apnea	B-Disease
with	O
suxamethonium	B-Chemical
.	O
Butyrylcholinesterase	B-Disease
deficiency	I-Disease
is	O
characterized	O
by	O
prolonged	O
apnea	B-Disease
after	O
the	O
use	O
of	O
muscle	O
relaxants	O
(	O
suxamethonium	B-Chemical
or	O
mivacurium	B-Chemical
)	O
in	O
patients	O
who	O
have	O
mutations	O
in	O
the	O
BCHE	O
gene	O
.	O
Here	O
,	O
we	O
report	O
a	O
case	O
of	O
prolonged	O
neuromuscular	O
block	O
after	O
administration	O
of	O
suxamethonium	B-Chemical
leading	O
to	O
the	O
discovery	O
of	O
a	O
novel	O
BCHE	O
variant	O
(	O
c	O
.	O
695T	O
>	O
A	O
,	O
p	O
.	O
Val204Asp	O
)	O
.	O
Inhibition	O
studies	O
,	O
kinetic	O
analysis	O
and	O
molecular	O
dynamics	O
were	O
undertaken	O
to	O
understand	O
how	O
this	O
mutation	O
disrupts	O
the	O
catalytic	O
triad	O
and	O
determines	O
a	O
""""	O
silent	O
""""	O
phenotype	O
.	O
Low	O
activity	O
of	O
patient	O
plasma	O
butyrylcholinesterase	O
with	O
butyrylthiocholine	B-Chemical
(	O
BTC	B-Chemical
)	O
and	O
benzoylcholine	B-Chemical
,	O
and	O
values	O
of	O
dibucaine	B-Chemical
and	O
fluoride	B-Chemical
numbers	O
fit	O
with	O
heterozygous	O
atypical	O
silent	O
genotype	O
.	O
Electrophoretic	O
analysis	O
of	O
plasma	O
BChE	O
of	O
the	O
proband	O
and	O
his	O
mother	O
showed	O
that	O
patient	O
has	O
a	O
reduced	O
amount	O
of	O
tetrameric	O
enzyme	O
in	O
plasma	O
and	O
that	O
minor	O
fast	O
-	O
moving	O
BChE	O
components	O
:	O
monomer	O
,	O
dimer	O
,	O
and	O
monomer	O
-	O
albumin	O
conjugate	O
are	O
missing	O
.	O
Kinetic	O
analysis	O
showed	O
that	O
the	O
p	O
.	O
Val204Asp	O
/	O
p	O
.	O
Asp70Gly	O
-	O
p	O
.	O
Ala539Thr	O
BChE	O
displays	O
a	O
pure	O
Michaelian	O
behavior	O
with	O
BTC	B-Chemical
as	O
the	O
substrate	O
.	O
Both	O
catalytic	O
parameters	O
Km	O
=	O
265	O
uM	O
for	O
BTC	B-Chemical
,	O
two	O
times	O
higher	O
than	O
that	O
of	O
the	O
atypical	O
enzyme	O
,	O
and	O
a	O
low	O
Vmax	O
are	O
consistent	O
with	O
the	O
absence	O
of	O
activity	O
against	O
suxamethonium	B-Chemical
.	O
Molecular	O
dynamic	O
(	O
MD	O
)	O
simulations	O
showed	O
that	O
the	O
overall	O
effect	O
of	O
the	O
mutation	O
p	O
.	O
Val204Asp	O
is	O
disruption	O
of	O
hydrogen	B-Chemical
bonding	O
between	O
Gln223	O
and	O
Glu441	O
,	O
leading	O
Ser198	O
and	O
His438	O
to	O
move	O
away	O
from	O
each	O
other	O
with	O
subsequent	O
disruption	O
of	O
the	O
catalytic	O
triad	O
functionality	O
regardless	O
of	O
the	O
type	O
of	O
substrate	O
.	O
MD	O
also	O
showed	O
that	O
the	O
enzyme	O
volume	O
is	O
increased	O
,	O
suggesting	O
a	O
pre	O
-	O
denaturation	O
state	O
.	O
This	O
fits	O
with	O
the	O
reduced	O
concentration	O
of	O
p	O
.	O
Ala204Asp	O
/	O
p	O
.	O
Asp70Gly	O
-	O
p	O
.	O
Ala539Thr	O
tetrameric	O
enzyme	O
in	O
the	O
plasma	O
and	O
non	O
-	O
detectable	O
fast	O
moving	O
-	O
bands	O
on	O
electrophoresis	O
gels	O
.	O
Delayed	O
anemia	B-Disease
after	O
treatment	O
with	O
injectable	O
artesunate	B-Chemical
in	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
:	O
a	O
manageable	O
issue	O
.	O
Cases	O
of	O
delayed	O
hemolytic	B-Disease
anemia	I-Disease
have	O
been	O
described	O
after	O
treatment	O
with	O
injectable	O
artesunate	B-Chemical
,	O
the	O
current	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
-	O
recommended	O
first	O
-	O
line	O
drug	O
for	O
the	O
treatment	O
of	O
severe	O
malaria	B-Disease
.	O
A	O
total	O
of	O
350	O
patients	O
(	O
215	O
[	O
61	O
.	O
4	O
%	O
]	O
<	O
5	O
years	O
of	O
age	O
and	O
135	O
[	O
38	O
.	O
6	O
%	O
]	O
>	O
5	O
years	O
of	O
age	O
)	O
were	O
followed	O
-	O
up	O
after	O
treatment	O
with	O
injectable	O
artesunate	B-Chemical
for	O
severe	O
malaria	B-Disease
in	O
hospitals	O
and	O
health	O
centers	O
of	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
.	O
Complete	O
series	O
of	O
hemoglobin	O
(	O
Hb	O
)	O
measurements	O
were	O
available	O
for	O
201	O
patients	O
.	O
A	O
decrease	O
in	O
Hb	O
levels	O
between	O
2	O
and	O
5	O
g	O
/	O
dL	O
was	O
detected	O
in	O
23	O
(	O
11	O
.	O
4	O
%	O
)	O
patients	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O
For	O
five	O
patients	O
,	O
Hb	O
levels	O
decreased	O
below	O
5	O
g	O
/	O
dL	O
during	O
at	O
least	O
one	O
follow	O
-	O
up	O
visit	O
.	O
All	O
cases	O
of	O
delayed	O
anemia	B-Disease
were	O
clinically	O
manageable	O
and	O
resolved	O
within	O
one	O
month	O
.	O
Regulation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
and	O
apoptotic	O
pathways	O
by	O
betaine	B-Chemical
attenuates	O
isoproterenol	B-Chemical
-	O
induced	O
acute	O
myocardial	B-Disease
injury	I-Disease
in	O
rats	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
cardioprotective	O
effects	O
of	O
betaine	B-Chemical
on	O
acute	O
myocardial	B-Disease
ischemia	I-Disease
induced	O
experimentally	O
in	O
rats	O
focusing	O
on	O
regulation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
STAT3	O
)	O
and	O
apoptotic	O
pathways	O
as	O
the	O
potential	O
mechanism	O
underlying	O
the	O
drug	O
effect	O
.	O
Male	O
Sprague	O
Dawley	O
rats	O
were	O
treated	O
with	O
betaine	B-Chemical
(	O
100	O
,	O
200	O
,	O
and	O
400	O
mg	O
/	O
kg	O
)	O
orally	O
for	O
40	O
days	O
.	O
Acute	O
myocardial	B-Disease
ischemic	I-Disease
injury	I-Disease
was	O
induced	O
in	O
rats	O
by	O
subcutaneous	O
injection	O
of	O
isoproterenol	B-Chemical
(	O
85	O
mg	O
/	O
kg	O
)	O
,	O
for	O
two	O
consecutive	O
days	O
.	O
Serum	O
cardiac	O
marker	O
enzyme	O
,	O
histopathological	O
variables	O
and	O
expression	O
of	O
protein	O
levels	O
were	O
analyzed	O
.	O
Oral	O
administration	O
of	O
betaine	B-Chemical
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
significantly	O
reduced	O
the	O
level	O
of	O
cardiac	O
marker	O
enzyme	O
in	O
the	O
serum	O
and	O
prevented	O
left	O
ventricular	B-Disease
remodeling	I-Disease
.	O
Western	O
blot	O
analysis	O
showed	O
that	O
isoproterenol	B-Chemical
-	O
induced	O
phosphorylation	O
of	O
STAT3	O
was	O
maintained	O
or	O
further	O
enhanced	O
by	O
betaine	B-Chemical
treatment	O
in	O
myocardium	O
.	O
Furthermore	O
,	O
betaine	B-Chemical
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
treatment	O
increased	O
the	O
ventricular	O
expression	O
of	O
Bcl	O
-	O
2	O
and	O
reduced	O
the	O
level	O
of	O
Bax	O
,	O
therefore	O
causing	O
a	O
significant	O
increase	O
in	O
the	O
ratio	O
of	O
Bcl	O
-	O
2	O
/	O
Bax	O
.	O
The	O
protective	O
role	O
of	O
betaine	B-Chemical
on	O
myocardial	B-Disease
damage	I-Disease
was	O
further	O
confirmed	O
by	O
histopathological	O
examination	O
.	O
In	O
summary	O
,	O
our	O
results	O
showed	O
that	O
betaine	B-Chemical
pretreatment	O
attenuated	O
isoproterenol	B-Chemical
-	O
induced	O
acute	O
myocardial	B-Disease
ischemia	I-Disease
via	O
the	O
regulation	O
of	O
STAT3	O
and	O
apoptotic	O
pathways	O
.	O
Quetiapine	B-Chemical
-	O
induced	O
neutropenia	B-Disease
in	O
a	O
bipolar	B-Disease
patient	O
with	O
hepatocellular	B-Disease
carcinoma	I-Disease
.	O
OBJECTIVE	O
:	O
Quetiapine	B-Chemical
is	O
a	O
dibenzothiazepine	O
derivative	O
,	O
similar	O
to	O
clozapine	B-Chemical
,	O
which	O
has	O
the	O
highest	O
risk	O
of	O
causing	O
blood	B-Disease
dyscrasias	I-Disease
,	O
especially	O
neutropenia	B-Disease
.	O
There	O
are	O
some	O
case	O
reports	O
about	O
this	O
side	O
effect	O
of	O
quetiapine	B-Chemical
,	O
but	O
possible	O
risk	O
factors	O
are	O
seldom	O
discussed	O
and	O
identified	O
.	O
A	O
case	O
of	O
a	O
patient	O
with	O
hepatocellular	B-Disease
carcinoma	I-Disease
that	O
developed	O
neutropenia	B-Disease
after	O
treatment	O
with	O
quetiapine	B-Chemical
is	O
described	O
here	O
.	O
CASE	O
REPORT	O
:	O
A	O
62	O
-	O
year	O
-	O
old	O
Taiwanese	O
widow	O
with	O
bipolar	B-Disease
disorder	I-Disease
was	O
diagnosed	O
with	O
hepatocellular	B-Disease
carcinoma	I-Disease
at	O
age	O
60	O
.	O
She	O
developed	O
leucopenia	B-Disease
after	O
being	O
treated	O
with	O
quetiapine	B-Chemical
.	O
After	O
quetiapine	B-Chemical
was	O
discontinued	O
,	O
her	O
white	O
blood	O
cell	O
count	O
returned	O
to	O
normal	O
.	O
CONCLUSIONS	O
:	O
Although	O
neutropenia	B-Disease
is	O
not	O
a	O
common	O
side	O
effect	O
of	O
quetiapine	B-Chemical
,	O
physicians	O
should	O
be	O
cautious	O
about	O
its	O
presentation	O
and	O
associated	O
risk	O
factors	O
.	O
Hepatic	B-Disease
dysfunction	I-Disease
may	O
be	O
one	O
of	O
the	O
possible	O
risk	O
factors	O
,	O
and	O
concomitant	O
fever	B-Disease
may	O
be	O
a	O
diagnostic	O
marker	O
for	O
adverse	O
reaction	O
to	O
quetiapine	B-Chemical
.	O
Lateral	O
antebrachial	O
cutaneous	O
neuropathy	B-Disease
after	O
steroid	B-Chemical
injection	O
at	O
lateral	O
epicondyle	O
.	O
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
This	O
report	O
aimed	O
to	O
present	O
a	O
case	O
of	O
lateral	O
antebrachial	O
cutaneous	O
neuropathy	B-Disease
(	O
LACNP	O
)	O
that	O
occurred	O
after	O
a	O
steroid	B-Chemical
injection	O
in	O
the	O
lateral	O
epicondyle	O
to	O
treat	O
lateral	B-Disease
epicondylitis	I-Disease
in	O
a	O
40	O
-	O
year	O
-	O
old	O
woman	O
.	O
MATERIAL	O
AND	O
METHOD	O
:	O
A	O
40	O
-	O
year	O
-	O
old	O
woman	O
presented	O
with	O
decreased	O
sensation	O
and	O
paresthesia	B-Disease
over	O
her	O
right	O
lateral	O
forearm	O
;	O
the	O
paresthesia	B-Disease
had	O
occurred	O
after	O
a	O
steroid	B-Chemical
injection	O
in	O
the	O
right	O
lateral	O
epicondyle	O
3	O
months	O
before	O
.	O
Her	O
sensation	O
of	O
light	O
touch	O
and	O
pain	B-Disease
was	O
diminished	O
over	O
the	O
lateral	O
side	O
of	O
the	O
right	O
forearm	O
and	O
wrist	O
area	O
.	O
RESULTS	O
:	O
The	O
sensory	O
action	O
potential	O
amplitude	O
of	O
the	O
right	O
lateral	O
antebrachial	O
cutaneous	O
nerve	O
(	O
LACN	O
)	O
(	O
6	O
.	O
2	O
uV	O
)	O
was	O
lower	O
than	O
that	O
of	O
the	O
left	O
(	O
13	O
.	O
1	O
uV	O
)	O
.	O
The	O
difference	O
of	O
amplitude	O
between	O
both	O
sides	O
was	O
significant	O
because	O
there	O
was	O
more	O
than	O
a	O
50	O
%	O
reduction	O
.	O
She	O
was	O
diagnosed	O
with	O
right	O
LACNP	O
(	O
mainly	O
axonal	O
involvement	O
)	O
on	O
the	O
basis	O
of	O
the	O
clinical	O
manifestation	O
and	O
the	O
electrodiagnostic	O
findings	O
.	O
Her	O
symptoms	O
improved	O
through	O
physical	O
therapy	O
but	O
persisted	O
to	O
some	O
degree	O
.	O
CONCLUSION	O
:	O
This	O
report	O
describes	O
the	O
case	O
of	O
a	O
woman	O
with	O
LACNP	O
that	O
developed	O
after	O
a	O
steroid	B-Chemical
injection	O
for	O
the	O
treatment	O
of	O
lateral	B-Disease
epicondylitis	I-Disease
.	O
An	O
electrodiagnostic	O
study	O
,	O
including	O
a	O
nerve	O
conduction	O
study	O
of	O
the	O
LACN	O
,	O
was	O
helpful	O
to	O
diagnose	O
right	O
LACNP	O
and	O
to	O
find	O
the	O
passage	O
of	O
the	O
LACN	O
on	O
the	O
lateral	O
epicondyle	O
.	O
Curcumin	B-Chemical
prevents	O
maleate	B-Chemical
-	O
induced	O
nephrotoxicity	B-Disease
:	O
relation	O
to	O
hemodynamic	O
alterations	O
,	O
oxidative	O
stress	O
,	O
mitochondrial	O
oxygen	B-Chemical
consumption	O
and	O
activity	O
of	O
respiratory	O
complex	O
I	O
.	O
The	O
potential	O
protective	O
effect	O
of	O
the	O
dietary	O
antioxidant	O
curcumin	B-Chemical
(	O
120	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
6	O
days	O
)	O
against	O
the	O
renal	B-Disease
injury	I-Disease
induced	O
by	O
maleate	B-Chemical
was	O
evaluated	O
.	O
Tubular	O
proteinuria	B-Disease
and	O
oxidative	O
stress	O
were	O
induced	O
by	O
a	O
single	O
injection	O
of	O
maleate	B-Chemical
(	O
400	O
mg	O
/	O
kg	O
)	O
in	O
rats	O
.	O
Maleate	B-Chemical
-	O
induced	O
renal	B-Disease
injury	I-Disease
included	O
increase	O
in	O
renal	O
vascular	O
resistance	O
and	O
in	O
the	O
urinary	O
excretion	O
of	O
total	O
protein	O
,	O
glucose	B-Chemical
,	O
sodium	B-Chemical
,	O
neutrophil	O
gelatinase	O
-	O
associated	O
lipocalin	O
(	O
NGAL	O
)	O
and	O
N	O
-	O
acetyl	O
b	O
-	O
D	O
-	O
glucosaminidase	O
(	O
NAG	O
)	O
,	O
upregulation	O
of	O
kidney	B-Disease
injury	I-Disease
molecule	O
(	O
KIM	O
)	O
-	O
1	O
,	O
decrease	O
in	O
renal	O
blood	O
flow	O
and	O
claudin	O
-	O
2	O
expression	O
besides	O
of	O
necrosis	B-Disease
and	O
apoptosis	O
of	O
tubular	O
cells	O
on	O
24	O
h	O
.	O
Oxidative	O
stress	O
was	O
determined	O
by	O
measuring	O
the	O
oxidation	O
of	O
lipids	O
and	O
proteins	O
and	O
diminution	O
in	O
renal	O
Nrf2	O
levels	O
.	O
Studies	O
were	O
also	O
conducted	O
in	O
renal	O
epithelial	O
LLC	O
-	O
PK1	O
cells	O
and	O
in	O
mitochondria	O
isolated	O
from	O
kidneys	O
of	O
all	O
the	O
experimental	O
groups	O
.	O
Maleate	B-Chemical
induced	O
cell	O
damage	O
and	O
reactive	O
oxygen	B-Chemical
species	O
(	O
ROS	O
)	O
production	O
in	O
LLC	O
-	O
PK1	O
cells	O
in	O
culture	O
.	O
In	O
addition	O
,	O
maleate	B-Chemical
treatment	O
reduced	O
oxygen	B-Chemical
consumption	O
in	O
ADP	B-Chemical
-	O
stimulated	O
mitochondria	O
and	O
diminished	O
respiratory	O
control	O
index	O
when	O
using	O
malate	B-Chemical
/	O
glutamate	B-Chemical
as	O
substrate	O
.	O
The	O
activities	O
of	O
both	O
complex	O
I	O
and	O
aconitase	O
were	O
also	O
diminished	O
.	O
All	O
the	O
above	O
-	O
described	O
alterations	O
were	O
prevented	O
by	O
curcumin	B-Chemical
.	O
It	O
is	O
concluded	O
that	O
curcumin	B-Chemical
is	O
able	O
to	O
attenuate	O
in	O
vivo	O
maleate	B-Chemical
-	O
induced	O
nephropathy	B-Disease
and	O
in	O
vitro	O
cell	O
damage	O
.	O
The	O
in	O
vivo	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
oxidative	O
stress	O
and	O
preservation	O
of	O
mitochondrial	O
oxygen	B-Chemical
consumption	O
and	O
activity	O
of	O
respiratory	O
complex	O
I	O
,	O
and	O
the	O
in	O
vitro	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
ROS	O
production	O
.	O
Anticonvulsant	O
actions	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
on	O
the	O
lithium	B-Chemical
-	O
pilocarpine	B-Chemical
model	O
of	O
status	B-Disease
epilepticus	I-Disease
in	O
rats	O
.	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
,	O
a	O
noncompetitive	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	B-Chemical
)	O
receptor	O
antagonist	O
,	O
was	O
tested	O
for	O
anticonvulsant	O
effects	O
in	O
rats	O
using	O
two	O
seizure	B-Disease
models	O
,	O
coadministration	O
of	O
lithium	B-Chemical
and	O
pilocarpine	B-Chemical
and	O
administration	O
of	O
a	O
high	O
dose	O
of	O
pilocarpine	B-Chemical
alone	O
.	O
Three	O
major	O
results	O
are	O
reported	O
.	O
First	O
,	O
pretreatment	O
with	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
produced	O
an	O
effective	O
and	O
dose	O
-	O
dependent	O
anticonvulsant	O
action	O
with	O
the	O
lithium	B-Chemical
-	O
pilocarpine	B-Chemical
model	O
but	O
not	O
with	O
rats	O
treated	O
with	O
pilocarpine	B-Chemical
alone	O
,	O
suggesting	O
that	O
different	O
biochemical	O
mechanisms	O
control	O
seizures	B-Disease
in	O
these	O
two	O
models	O
.	O
Second	O
,	O
the	O
anticonvulsant	O
effect	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
in	O
the	O
lithium	B-Chemical
-	O
pilocarpine	B-Chemical
model	O
only	O
occurred	O
after	O
initial	O
periods	O
of	O
seizure	B-Disease
activity	O
.	O
This	O
observation	O
is	O
suggested	O
to	O
be	O
an	O
in	O
vivo	O
demonstration	O
of	O
the	O
conclusion	O
derived	O
from	O
in	O
vitro	O
experiments	O
that	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
binding	O
requires	O
agonist	O
-	O
induced	O
opening	O
of	O
the	O
channel	O
sites	O
of	O
the	O
NMDA	B-Chemical
receptor	O
.	O
Third	O
,	O
although	O
it	O
is	O
relatively	O
easy	O
to	O
block	O
seizures	B-Disease
induced	O
by	O
lithium	B-Chemical
and	O
pilocarpine	B-Chemical
by	O
administration	O
of	O
anticonvulsants	O
prior	O
to	O
pilocarpine	B-Chemical
,	O
it	O
is	O
more	O
difficult	O
to	O
terminate	O
ongoing	O
status	B-Disease
epilepticus	I-Disease
and	O
block	O
the	O
lethality	O
of	O
the	O
seizures	B-Disease
.	O
Administration	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
30	O
or	O
60	O
min	O
after	O
pilocarpine	B-Chemical
,	O
i	O
.	O
e	O
.	O
,	O
during	O
status	B-Disease
epilepticus	I-Disease
,	O
gradually	O
reduced	O
electrical	O
and	O
behavioral	O
seizure	B-Disease
activity	O
and	O
greatly	O
enhanced	O
the	O
survival	O
rate	O
.	O
These	O
results	O
suggest	O
that	O
activation	O
of	O
NMDA	B-Chemical
receptors	O
plays	O
an	O
important	O
role	O
in	O
status	B-Disease
epilepticus	I-Disease
and	O
brain	B-Disease
damage	I-Disease
in	O
the	O
lithium	B-Chemical
-	O
pilocarpine	B-Chemical
model	O
.	O
This	O
was	O
further	O
supported	O
by	O
results	O
showing	O
that	O
nonconvulsive	O
doses	O
of	O
NMDA	B-Chemical
and	O
pilocarpine	B-Chemical
were	O
synergistic	O
,	O
resulting	O
in	O
status	B-Disease
epilepticus	I-Disease
and	O
subsequent	O
mortality	O
.	O
Continuous	O
infusion	O
tobramycin	B-Chemical
combined	O
with	O
carbenicillin	B-Chemical
for	O
infections	B-Disease
in	O
cancer	B-Disease
patients	O
.	O
The	O
cure	O
rate	O
of	O
infections	B-Disease
in	O
cancer	B-Disease
patients	O
is	O
adversely	O
affected	O
by	O
neutropenia	B-Disease
(	O
less	O
than	O
1	O
,	O
000	O
/	O
mm3	O
)	O
.	O
In	O
particular	O
,	O
patients	O
with	O
severe	O
neutropenia	B-Disease
(	O
less	O
than	O
100	O
/	O
mm3	O
)	O
have	O
shown	O
a	O
poor	O
response	O
to	O
antibiotics	O
.	O
To	O
overcome	O
the	O
adverse	O
effects	O
of	O
neutropenia	B-Disease
,	O
tobramycin	B-Chemical
was	O
given	O
by	O
continuous	O
infusion	O
and	O
combined	O
with	O
intermittent	O
carbenicillin	B-Chemical
.	O
Tobramycin	B-Chemical
was	O
given	O
to	O
a	O
total	O
daily	O
dose	O
of	O
300	O
mg	O
/	O
m2	O
and	O
carbenicillin	B-Chemical
was	O
given	O
at	O
a	O
dose	O
of	O
5	O
gm	O
every	O
four	O
hours	O
.	O
There	O
were	O
125	O
infectious	O
episodes	O
in	O
116	O
cancer	B-Disease
patients	O
receiving	O
myelosuppressive	O
chemotherapy	O
.	O
The	O
overall	O
cure	O
rate	O
was	O
70	O
%	O
.	O
Pneumonia	B-Disease
was	O
the	O
most	O
common	O
infection	B-Disease
and	O
61	O
%	O
of	O
59	O
episodes	O
were	O
cured	O
.	O
Gram	O
-	O
negative	O
bacilli	O
were	O
the	O
most	O
common	O
causative	O
organisms	O
and	O
69	O
%	O
of	O
these	O
infections	B-Disease
were	O
cured	O
.	O
The	O
most	O
common	O
pathogen	O
was	O
Klebsiella	O
pneumoniae	B-Disease
and	O
this	O
,	O
together	O
with	O
Escherichia	O
coli	O
and	O
Pseudomonas	O
aeruginosa	O
,	O
accounted	O
for	O
74	O
%	O
of	O
all	O
gram	B-Disease
-	I-Disease
negative	I-Disease
bacillary	I-Disease
infections	I-Disease
.	O
Response	O
was	O
not	O
influenced	O
by	O
the	O
initial	O
neutrophil	O
count	O
,	O
with	O
a	O
62	O
%	O
cure	O
rate	O
for	O
39	O
episodes	O
associated	O
with	O
severe	O
neutropenia	B-Disease
.	O
However	O
,	O
failure	O
of	O
the	O
neutrophil	O
count	O
to	O
increase	O
during	O
therapy	O
adversely	O
affected	O
response	O
.	O
Azotemia	B-Disease
was	O
the	O
major	O
side	O
effect	O
recognized	O
,	O
and	O
it	O
occurred	O
in	O
11	O
%	O
of	O
episodes	O
.	O
Major	O
azotemia	B-Disease
(	O
serum	O
creatinine	B-Chemical
greater	O
than	O
2	O
.	O
5	O
mg	O
/	O
dl	O
or	O
BUN	O
greater	O
than	O
50	O
mg	O
/	O
dl	O
)	O
occurred	O
in	O
only	O
2	O
%	O
.	O
Azotemia	B-Disease
was	O
not	O
related	O
to	O
duration	O
of	O
therapy	O
or	O
serum	O
tobramycin	B-Chemical
concentration	O
.	O
This	O
antibiotic	O
regimen	O
showed	O
both	O
therapeutic	O
efficacy	O
and	O
acceptable	O
renal	B-Disease
toxicity	I-Disease
for	O
these	O
patients	O
.	O
Incidence	O
of	O
solid	O
tumours	B-Disease
among	O
pesticide	O
applicators	O
exposed	O
to	O
the	O
organophosphate	B-Chemical
insecticide	O
diazinon	B-Chemical
in	O
the	O
Agricultural	O
Health	O
Study	O
:	O
an	O
updated	O
analysis	O
.	O
OBJECTIVE	O
:	O
Diazinon	B-Chemical
,	O
a	O
common	O
organophosphate	B-Chemical
insecticide	O
with	O
genotoxic	O
properties	O
,	O
was	O
previously	O
associated	O
with	O
lung	B-Disease
cancer	I-Disease
in	O
the	O
Agricultural	O
Health	O
Study	O
(	O
AHS	O
)	O
cohort	O
,	O
but	O
few	O
other	O
epidemiological	O
studies	O
have	O
examined	O
diazinon	B-Chemical
-	O
associated	O
cancer	B-Disease
risk	O
.	O
We	O
used	O
updated	O
diazinon	B-Chemical
exposure	O
and	O
cancer	B-Disease
incidence	O
information	O
to	O
evaluate	O
solid	O
tumour	B-Disease
risk	O
in	O
the	O
AHS	O
.	O
METHODS	O
:	O
Male	O
pesticide	O
applicators	O
in	O
Iowa	O
and	O
North	O
Carolina	O
reported	O
lifetime	O
diazinon	B-Chemical
use	O
at	O
enrolment	O
(	O
1993	O
-	O
1997	O
)	O
and	O
follow	O
-	O
up	O
(	O
1998	O
-	O
2005	O
)	O
;	O
cancer	B-Disease
incidence	O
was	O
assessed	O
through	O
2010	O
(	O
North	O
Carolina	O
)	O
/	O
2011	O
(	O
Iowa	O
)	O
.	O
Among	O
applicators	O
with	O
usage	O
information	O
sufficient	O
to	O
evaluate	O
exposure	O
-	O
response	O
patterns	O
,	O
we	O
used	O
Poisson	O
regression	O
to	O
estimate	O
adjusted	O
rate	O
ratios	O
(	O
RRs	O
)	O
and	O
95	O
%	O
CI	O
for	O
cancer	B-Disease
sites	O
with	O
>	O
10	O
exposed	O
cases	O
for	O
both	O
lifetime	O
(	O
LT	O
)	O
exposure	O
days	O
and	O
intensity	O
-	O
weighted	O
(	O
IW	O
)	O
lifetime	O
exposure	O
days	O
(	O
accounting	O
for	O
factors	O
impacting	O
exposure	O
)	O
.	O
RESULTS	O
:	O
We	O
observed	O
elevated	O
lung	B-Disease
cancer	I-Disease
risks	O
(	O
N	O
=	O
283	O
)	O
among	O
applicators	O
with	O
the	O
greatest	O
number	O
of	O
LT	O
(	O
RR	O
=	O
1	O
.	O
60	O
;	O
95	O
%	O
CI	O
1	O
.	O
11	O
to	O
2	O
.	O
31	O
;	O
Ptrend	O
=	O
0	O
.	O
02	O
)	O
and	O
IW	O
days	O
of	O
diazinon	B-Chemical
use	O
(	O
RR	O
=	O
1	O
.	O
41	O
;	O
95	O
%	O
CI	O
0	O
.	O
98	O
to	O
2	O
.	O
04	O
;	O
Ptrend	O
=	O
0	O
.	O
08	O
)	O
.	O
Kidney	B-Disease
cancer	I-Disease
(	O
N	O
=	O
94	O
)	O
risks	O
were	O
non	O
-	O
significantly	O
elevated	O
(	O
RRLT	O
days	O
=	O
1	O
.	O
77	O
;	O
95	O
%	O
CI	O
0	O
.	O
90	O
to	O
3	O
.	O
51	O
;	O
Ptrend	O
=	O
0	O
.	O
09	O
;	O
RRIW	O
days	O
1	O
.	O
37	O
;	O
95	O
%	O
CI	O
0	O
.	O
64	O
to	O
2	O
.	O
92	O
;	O
Ptrend	O
=	O
0	O
.	O
50	O
)	O
,	O
as	O
were	O
risks	O
for	O
aggressive	O
prostate	B-Disease
cancer	I-Disease
(	O
N	O
=	O
656	O
)	O
.	O
CONCLUSIONS	O
:	O
Our	O
updated	O
evaluation	O
of	O
diazinon	B-Chemical
provides	O
additional	O
evidence	O
of	O
an	O
association	O
with	O
lung	B-Disease
cancer	I-Disease
risk	O
.	O
Newly	O
identified	O
links	O
to	O
kidney	B-Disease
cancer	I-Disease
and	O
associations	O
with	O
aggressive	O
prostate	B-Disease
cancer	I-Disease
require	O
further	O
evaluation	O
.	O
Associations	O
of	O
Ozone	B-Chemical
and	O
PM2	O
.	O
5	O
Concentrations	O
With	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
Disease	I-Disease
Among	O
Participants	O
in	O
the	O
Agricultural	O
Health	O
Study	O
.	O
OBJECTIVE	O
:	O
This	O
study	O
describes	O
associations	O
of	O
ozone	B-Chemical
and	O
fine	O
particulate	B-Chemical
matter	I-Chemical
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
observed	O
among	O
farmers	O
in	O
North	O
Carolina	O
and	O
Iowa	O
.	O
METHODS	O
:	O
We	O
used	O
logistic	O
regression	O
to	O
determine	O
the	O
associations	O
of	O
these	O
pollutants	O
with	O
self	O
-	O
reported	O
,	O
doctor	O
-	O
diagnosed	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
Daily	O
predicted	O
pollutant	O
concentrations	O
were	O
used	O
to	O
derive	O
surrogates	O
of	O
long	O
-	O
term	O
exposure	O
and	O
link	O
them	O
to	O
study	O
participants	O
'	O
geocoded	O
addresses	O
.	O
RESULTS	O
:	O
We	O
observed	O
positive	O
associations	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
with	O
ozone	B-Chemical
(	O
odds	O
ratio	O
=	O
1	O
.	O
39	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
98	O
to	O
1	O
.	O
98	O
)	O
and	O
fine	O
particulate	B-Chemical
matter	I-Chemical
(	O
odds	O
ratio	O
=	O
1	O
.	O
34	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
93	O
to	O
1	O
.	O
93	O
)	O
in	O
North	O
Carolina	O
but	O
not	O
in	O
Iowa	O
.	O
CONCLUSIONS	O
:	O
The	O
plausibility	O
of	O
an	O
effect	O
of	O
ambient	O
concentrations	O
of	O
these	O
pollutants	O
on	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
risk	O
is	O
supported	O
by	O
experimental	O
data	O
demonstrating	O
damage	O
to	O
dopaminergic	O
neurons	O
at	O
relevant	O
concentrations	O
.	O
Additional	O
studies	O
are	O
needed	O
to	O
address	O
uncertainties	O
related	O
to	O
confounding	O
and	O
to	O
examine	O
temporal	O
aspects	O
of	O
the	O
associations	O
we	O
observed	O
.	O
Low	O
functional	O
programming	O
of	O
renal	O
AT2R	O
mediates	O
the	O
developmental	O
origin	O
of	O
glomerulosclerosis	B-Disease
in	O
adult	O
offspring	O
induced	O
by	O
prenatal	O
caffeine	B-Chemical
exposure	O
.	O
UNASSIGNED	O
:	O
Our	O
previous	O
study	O
has	O
indicated	O
that	O
prenatal	O
caffeine	B-Chemical
exposure	O
(	O
PCE	O
)	O
could	O
induce	O
intrauterine	B-Disease
growth	I-Disease
retardation	I-Disease
(	O
IUGR	B-Disease
)	O
of	O
offspring	O
.	O
Recent	O
research	O
suggested	O
that	O
IUGR	B-Disease
is	O
a	O
risk	O
factor	O
for	O
glomerulosclerosis	B-Disease
.	O
However	O
,	O
whether	O
PCE	O
could	O
induce	O
glomerulosclerosis	B-Disease
and	O
its	O
underlying	O
mechanisms	O
remain	O
unknown	O
.	O
This	O
study	O
aimed	O
to	O
demonstrate	O
the	O
induction	O
to	O
glomerulosclerosis	B-Disease
in	O
adult	O
offspring	O
by	O
PCE	O
and	O
its	O
intrauterine	O
programming	O
mechanisms	O
.	O
A	O
rat	O
model	O
of	O
IUGR	B-Disease
was	O
established	O
by	O
PCE	O
,	O
male	O
fetuses	O
and	O
adult	O
offspring	O
at	O
the	O
age	O
of	O
postnatal	O
week	O
24	O
were	O
euthanized	O
.	O
The	O
results	O
revealed	O
that	O
the	O
adult	O
offspring	O
kidneys	O
in	O
the	O
PCE	O
group	O
exhibited	O
glomerulosclerosis	B-Disease
as	O
well	O
as	O
interstitial	B-Disease
fibrosis	I-Disease
,	O
accompanied	O
by	O
elevated	O
levels	O
of	O
serum	O
creatinine	B-Chemical
and	O
urine	O
protein	O
.	O
Renal	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
type	O
2	O
(	O
AT2R	O
)	O
gene	O
expression	O
in	O
adult	O
offspring	O
was	O
reduced	O
by	O
PCE	O
,	O
whereas	O
the	O
renal	O
angiotensin	B-Chemical
II	I-Chemical
receptor	O
type	O
1a	O
(	O
AT1aR	O
)	O
/	O
AT2R	O
expression	O
ratio	O
was	O
increased	O
.	O
The	O
fetal	O
kidneys	O
in	O
the	O
PCE	O
group	O
displayed	O
an	O
enlarged	O
Bowman	O
'	O
s	O
space	O
and	O
a	O
shrunken	O
glomerular	O
tuft	O
,	O
accompanied	O
by	O
a	O
reduced	O
cortex	O
width	O
and	O
an	O
increase	O
in	O
the	O
nephrogenic	O
zone	O
/	O
cortical	O
zone	O
ratio	O
.	O
Observation	O
by	O
electronic	O
microscope	O
revealed	O
structural	O
damage	O
of	O
podocytes	O
;	O
the	O
reduced	O
expression	O
level	O
of	O
podocyte	O
marker	O
genes	O
,	O
nephrin	O
and	O
podocin	O
,	O
was	O
also	O
detected	O
by	O
q	O
-	O
PCR	O
.	O
Moreover	O
,	O
AT2R	O
gene	O
and	O
protein	O
expressions	O
in	O
fetal	O
kidneys	O
were	O
inhibited	O
by	O
PCE	O
,	O
associated	O
with	O
the	O
repression	O
of	O
the	O
gene	O
expression	O
of	O
glial	O
-	O
cell	O
-	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
GDNF	O
)	O
/	O
tyrosine	B-Chemical
kinase	O
receptor	O
(	O
c	O
-	O
Ret	O
)	O
signaling	O
pathway	O
.	O
These	O
results	O
demonstrated	O
that	O
PCE	O
could	O
induce	O
dysplasia	B-Disease
of	I-Disease
fetal	I-Disease
kidneys	I-Disease
as	O
well	O
as	O
glomerulosclerosis	B-Disease
of	O
adult	O
offspring	O
,	O
and	O
the	O
low	O
functional	O
programming	O
of	O
renal	O
AT2R	O
might	O
mediate	O
the	O
developmental	O
origin	O
of	O
adult	O
glomerulosclerosis	B-Disease
.	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
Butadiene	I-Chemical
,	O
CML	B-Disease
and	O
the	O
t	O
(	O
9	O
:	O
22	O
)	O
translocation	O
:	O
A	O
reality	O
check	O
.	O
UNASSIGNED	O
:	O
Epidemiological	O
studies	O
of	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
butadiene	I-Chemical
have	O
suggest	O
that	O
exposures	O
to	O
humans	O
are	O
associated	O
with	O
chronic	B-Disease
myeloid	I-Disease
leukemia	I-Disease
(	O
CML	B-Disease
)	O
.	O
CML	B-Disease
has	O
a	O
well	O
-	O
documented	O
association	O
with	O
ionizing	O
radiation	O
,	O
but	O
reports	O
of	O
associations	O
with	O
chemical	O
exposures	O
have	O
been	O
questioned	O
.	O
Ionizing	O
radiation	O
is	O
capable	O
of	O
inducing	O
the	O
requisite	O
CML	B-Disease
-	O
associated	O
t	O
(	O
9	O
:	O
22	O
)	O
translocation	O
(	O
Philadelphia	B-Disease
chromosome	I-Disease
)	O
in	O
appropriate	O
cells	O
in	O
vitro	O
but	O
,	O
thus	O
far	O
,	O
chemicals	O
have	O
not	O
shown	O
this	O
capacity	O
.	O
We	O
have	O
proposed	O
that	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
butadiene	I-Chemical
metabolites	O
be	O
so	O
tested	O
as	O
a	O
reality	O
check	O
on	O
the	O
epidemiological	O
reports	O
.	O
In	O
order	O
to	O
conduct	O
reliable	O
testing	O
in	O
this	O
regard	O
,	O
it	O
is	O
essential	O
that	O
a	O
positive	O
control	O
for	O
induction	O
be	O
available	O
.	O
We	O
have	O
used	O
ionizing	O
radiation	O
to	O
develop	O
such	O
a	O
control	O
.	O
Results	O
described	O
here	O
demonstrate	O
that	O
this	O
agent	O
does	O
in	O
fact	O
induce	O
pathogenic	O
t	O
(	O
9	O
:	O
22	O
)	O
translocations	O
in	O
a	O
human	O
myeloid	O
cell	O
line	O
in	O
vitro	O
,	O
but	O
does	O
so	O
at	O
low	O
frequencies	O
.	O
Conditions	O
that	O
will	O
be	O
required	O
for	O
studies	O
of	O
1	B-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
butadiene	I-Chemical
are	O
discussed	O
.	O
Cancer	B-Disease
incidence	O
and	O
metolachlor	B-Chemical
use	O
in	O
the	O
Agricultural	O
Health	O
Study	O
:	O
An	O
update	O
.	O
UNASSIGNED	O
:	O
Metolachlor	B-Chemical
,	O
a	O
widely	O
used	O
herbicide	O
,	O
is	O
classified	O
as	O
a	O
Group	O
C	O
carcinogen	O
by	O
the	O
U	O
.	O
S	O
.	O
Environmental	O
Protection	O
Agency	O
based	O
on	O
increased	O
liver	B-Disease
neoplasms	I-Disease
in	O
female	O
rats	O
.	O
Epidemiologic	O
studies	O
of	O
the	O
health	O
effects	O
of	O
metolachlor	B-Chemical
have	O
been	O
limited	O
.	O
The	O
Agricultural	O
Health	O
Study	O
(	O
AHS	O
)	O
is	O
a	O
prospective	O
cohort	O
study	O
including	O
licensed	O
private	O
and	O
commercial	O
pesticide	O
applicators	O
in	O
Iowa	O
and	O
North	O
Carolina	O
enrolled	O
1993	O
-	O
1997	O
.	O
We	O
evaluated	O
cancer	B-Disease
incidence	O
through	O
2010	O
/	O
2011	O
(	O
NC	O
/	O
IA	O
)	O
for	O
49	O
,	O
616	O
applicators	O
,	O
53	O
%	O
of	O
whom	O
reported	O
ever	O
using	O
metolachlor	B-Chemical
.	O
We	O
used	O
Poisson	O
regression	O
to	O
evaluate	O
relations	O
between	O
two	O
metrics	O
of	O
metolachlor	B-Chemical
use	O
(	O
lifetime	O
days	O
,	O
intensity	O
-	O
weighted	O
lifetime	O
days	O
)	O
and	O
cancer	B-Disease
incidence	O
.	O
We	O
saw	O
no	O
association	O
between	O
metolachlor	B-Chemical
use	O
and	O
incidence	O
of	O
all	O
cancers	B-Disease
combined	O
(	O
n	O
=	O
5	O
,	O
701	O
with	O
a	O
5	O
-	O
year	O
lag	O
)	O
or	O
most	O
site	O
-	O
specific	O
cancers	B-Disease
.	O
For	O
liver	B-Disease
cancer	I-Disease
,	O
in	O
analyses	O
restricted	O
to	O
exposed	O
workers	O
,	O
elevations	O
observed	O
at	O
higher	O
categories	O
of	O
use	O
were	O
not	O
statistically	O
significant	O
.	O
However	O
,	O
trends	O
for	O
both	O
lifetime	O
and	O
intensity	O
-	O
weighted	O
lifetime	O
days	O
of	O
metolachor	B-Chemical
use	O
were	O
positive	O
and	O
statistically	O
significant	O
with	O
an	O
unexposed	O
reference	O
group	O
.	O
A	O
similar	O
pattern	O
was	O
observed	O
for	O
follicular	B-Disease
cell	I-Disease
lymphoma	I-Disease
,	O
but	O
no	O
other	O
lymphoma	B-Disease
subtypes	O
.	O
An	O
earlier	O
suggestion	O
of	O
increased	O
lung	B-Disease
cancer	I-Disease
risk	O
at	O
high	O
levels	O
of	O
metolachlor	B-Chemical
use	O
in	O
this	O
cohort	O
was	O
not	O
confirmed	O
in	O
this	O
update	O
.	O
This	O
suggestion	O
of	O
an	O
association	O
between	O
metolachlor	B-Chemical
and	O
liver	B-Disease
cancer	I-Disease
among	O
pesticide	O
applicators	O
is	O
a	O
novel	O
finding	O
and	O
echoes	O
observation	O
of	O
increased	O
liver	B-Disease
neoplasms	I-Disease
in	O
some	O
animal	O
studies	O
.	O
However	O
,	O
our	O
findings	O
for	O
both	O
liver	B-Disease
cancer	I-Disease
and	O
follicular	O
cell	O
lymphoma	B-Disease
warrant	O
follow	O
-	O
up	O
to	O
better	O
differentiate	O
effects	O
of	O
metolachlor	B-Chemical
use	O
from	O
other	O
factors	O
.	O
Mechanisms	O
Underlying	O
Latent	O
Disease	O
Risk	O
Associated	O
with	O
Early	O
-	O
Life	O
Arsenic	B-Chemical
Exposure	O
:	O
Current	O
Research	O
Trends	O
and	O
Scientific	O
Gaps	O
.	O
BACKGROUND	O
:	O
Millions	O
of	O
individuals	O
worldwide	O
,	O
particularly	O
those	O
living	O
in	O
rural	O
and	O
developing	O
areas	O
,	O
are	O
exposed	O
to	O
harmful	O
levels	O
of	O
inorganic	B-Chemical
arsenic	I-Chemical
(	O
iAs	B-Chemical
)	O
in	O
their	O
drinking	O
water	O
.	O
Inorganic	B-Chemical
As	I-Chemical
exposure	O
during	O
key	O
developmental	O
periods	O
is	O
associated	O
with	O
a	O
variety	O
of	O
adverse	O
health	O
effects	O
including	O
those	O
that	O
are	O
evident	O
in	O
adulthood	O
.	O
There	O
is	O
considerable	O
interest	O
in	O
identifying	O
the	O
molecular	O
mechanisms	O
that	O
relate	O
early	O
-	O
life	O
iAs	B-Chemical
exposure	O
to	O
the	O
development	O
of	O
these	O
latent	O
diseases	O
,	O
particularly	O
in	O
relationship	O
to	O
cancer	B-Disease
.	O
OBJECTIVES	O
:	O
This	O
work	O
summarizes	O
research	O
on	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
the	O
increased	O
risk	O
of	O
cancer	B-Disease
development	O
in	O
adulthood	O
that	O
is	O
associated	O
with	O
early	O
-	O
life	O
iAs	B-Chemical
exposure	O
.	O
DISCUSSION	O
:	O
Epigenetic	O
reprogramming	O
that	O
imparts	O
functional	O
changes	O
in	O
gene	O
expression	O
,	O
the	O
development	O
of	O
cancer	B-Disease
stem	O
cells	O
,	O
and	O
immunomodulation	O
are	O
plausible	O
underlying	O
mechanisms	O
by	O
which	O
early	O
-	O
life	O
iAs	B-Chemical
exposure	O
elicits	O
latent	O
carcinogenic	O
effects	O
.	O
CONCLUSIONS	O
:	O
Evidence	O
is	O
mounting	O
that	O
relates	O
early	O
-	O
life	O
iAs	B-Chemical
exposure	O
and	O
cancer	B-Disease
development	O
later	O
in	O
life	O
.	O
Future	O
research	O
should	O
include	O
animal	O
studies	O
that	O
address	O
mechanistic	O
hypotheses	O
and	O
studies	O
of	O
human	O
populations	O
that	O
integrate	O
early	O
-	O
life	O
exposure	O
,	O
molecular	O
alterations	O
,	O
and	O
latent	O
disease	O
outcomes	O
.	O
Nifedipine	B-Chemical
induced	O
bradycardia	B-Disease
in	O
a	O
patient	O
with	O
autonomic	B-Disease
neuropathy	I-Disease
.	O
An	O
80	O
year	O
old	O
diabetic	B-Disease
male	O
with	O
evidence	O
of	O
peripheral	B-Disease
and	I-Disease
autonomic	I-Disease
neuropathy	I-Disease
was	O
admitted	O
with	O
chest	B-Disease
pain	I-Disease
.	O
He	O
was	O
found	O
to	O
have	O
atrial	B-Disease
flutter	I-Disease
at	O
a	O
ventricular	O
rate	O
of	O
70	O
/	O
min	O
which	O
slowed	O
down	O
to	O
30	O
-	O
40	O
/	O
min	O
when	O
nifedipine	B-Chemical
(	O
60	O
mg	O
)	O
in	O
3	O
divided	O
doses	O
,	O
during	O
which	O
he	O
was	O
paced	O
at	O
a	O
rate	O
of	O
70	O
/	O
min	O
.	O
This	O
is	O
inconsistent	O
with	O
the	O
well	O
-	O
established	O
finding	O
that	O
nifedipine	B-Chemical
induces	O
tachycardia	B-Disease
in	O
normally	O
innervated	O
hearts	O
.	O
However	O
,	O
in	O
hearts	O
deprived	O
of	O
compensatory	O
sympathetic	O
drive	O
,	O
it	O
may	O
lead	O
to	O
bradycardia	B-Disease
.	O
The	O
effect	O
of	O
haloperidol	B-Chemical
in	O
cocaine	B-Chemical
and	O
amphetamine	B-Chemical
intoxication	O
.	O
The	O
effectiveness	O
of	O
haloperidol	B-Chemical
pretreatment	O
in	O
preventing	O
the	O
toxic	O
effects	O
of	O
high	O
doses	O
of	O
amphetamine	B-Chemical
and	O
cocaine	B-Chemical
was	O
studied	O
in	O
rats	O
.	O
In	O
this	O
model	O
,	O
toxic	O
effects	O
were	O
induced	O
by	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.	O
)	O
injection	O
of	O
amphetamine	B-Chemical
75	O
mg	O
/	O
kg	O
(	O
100	O
%	O
death	O
rate	O
)	O
or	O
cocaine	B-Chemical
70	O
mg	O
/	O
kg	O
(	O
82	O
%	O
death	O
rate	O
)	O
.	O
Haloperidol	B-Chemical
failed	O
to	O
prevent	O
amphetamine	B-Chemical
-	O
induced	O
seizures	B-Disease
,	O
but	O
did	O
lower	O
the	O
mortality	O
rate	O
at	O
most	O
doses	O
tested	O
.	O
Haloperidol	B-Chemical
decreased	O
the	O
incidence	O
of	O
cocaine	B-Chemical
-	O
induced	O
seizures	B-Disease
at	O
the	O
two	O
highest	O
doses	O
,	O
but	O
the	O
lowering	O
of	O
the	O
mortality	O
rate	O
did	O
not	O
reach	O
statistical	O
significance	O
at	O
any	O
dose	O
.	O
These	O
data	O
suggest	O
a	O
protective	O
role	O
for	O
the	O
central	O
dopamine	B-Chemical
blocker	O
haloperidol	B-Chemical
against	O
death	O
from	O
high	O
-	O
dose	O
amphetamine	B-Chemical
exposure	O
without	O
reducing	O
the	O
incidence	O
of	O
seizures	B-Disease
.	O
In	O
contrast	O
,	O
haloperidol	B-Chemical
demonstrated	O
an	O
ability	O
to	O
reduce	O
cocaine	B-Chemical
-	O
induced	O
seizures	B-Disease
without	O
significantly	O
reducing	O
mortality	O
.	O
Autoradiographic	O
evidence	O
of	O
estrogen	B-Chemical
binding	O
sites	O
in	O
nuclei	O
of	O
diethylstilbesterol	B-Chemical
induced	O
hamster	O
renal	B-Disease
carcinomas	I-Disease
.	O
Estrogen	B-Chemical
binding	O
sites	O
were	O
demonstrated	O
by	O
autoradiography	O
in	O
one	O
transplantable	O
and	O
five	O
primary	O
diethylstilbesterol	B-Chemical
induced	O
renal	B-Disease
carcinomas	I-Disease
in	O
three	O
hamsters	O
.	O
Radiolabelling	O
,	O
following	O
the	O
in	O
vivo	O
injection	O
of	O
3H	O
-	O
17	O
beta	O
estradiol	B-Chemical
,	O
was	O
increased	O
only	O
over	O
the	O
nuclei	O
of	O
tumor	B-Disease
cells	O
;	O
stereologic	O
analysis	O
revealed	O
a	O
4	O
.	O
5	O
-	O
to	O
6	O
.	O
7	O
-	O
times	O
higher	O
concentration	O
of	O
reduced	O
silver	B-Chemical
grains	O
over	O
nuclei	O
than	O
cytoplasm	O
of	O
these	O
cells	O
.	O
Despite	O
rapid	O
tubular	O
excretion	O
of	O
estradiol	B-Chemical
which	O
peaked	O
in	O
less	O
than	O
1	O
h	O
,	O
the	O
normal	O
cells	O
did	O
not	O
appear	O
to	O
bind	O
the	O
ligand	O
.	O
This	O
is	O
the	O
first	O
published	O
report	O
documenting	O
the	O
preferential	O
in	O
vivo	O
binding	O
of	O
estrogen	B-Chemical
to	O
nuclei	O
of	O
cells	O
in	O
estrogen	B-Chemical
induced	O
hamster	O
renal	B-Disease
carcinomas	I-Disease
.	O
Bradycardia	B-Disease
due	O
to	O
biperiden	B-Chemical
.	O
In	O
a	O
38	O
-	O
year	O
-	O
old	O
male	O
patient	O
suffering	O
from	O
a	O
severe	O
postzosteric	B-Disease
trigeminal	B-Disease
neuralgia	I-Disease
,	O
intravenous	O
application	O
of	O
10	O
mg	O
biperiden	B-Chemical
lactate	I-Chemical
led	O
to	O
a	O
long	O
-	O
lasting	O
paradoxical	O
reaction	O
characterized	O
by	O
considerable	O
bradycardia	B-Disease
,	O
dysarthria	B-Disease
,	O
and	O
dysphagia	B-Disease
.	O
The	O
heart	O
rate	O
was	O
back	O
to	O
normal	O
within	O
12	O
hours	O
upon	O
administration	O
of	O
orciprenaline	B-Chemical
under	O
cardiac	O
monitoring	O
in	O
an	O
intensive	O
care	O
unit	O
.	O
Bradycardia	B-Disease
induced	O
by	O
biperiden	B-Chemical
is	O
attributed	O
to	O
the	O
speed	O
of	O
injection	O
and	O
to	O
a	O
dose	O
-	O
related	O
dual	O
effect	O
of	O
atropine	B-Chemical
-	O
like	O
drugs	O
on	O
muscarine	B-Chemical
receptors	O
.	O
Deliberate	O
hypotension	B-Disease
induced	O
by	O
labetalol	B-Chemical
with	O
halothane	B-Chemical
,	O
enflurane	B-Chemical
or	O
isoflurane	B-Chemical
for	O
middle	O
-	O
ear	O
surgery	O
.	O
The	O
feasibility	O
of	O
using	O
labetalol	B-Chemical
,	O
an	O
alpha	O
-	O
and	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
,	O
as	O
a	O
hypotensive	B-Disease
agent	O
in	O
combination	O
with	O
inhalation	O
anaesthetics	O
(	O
halothane	B-Chemical
,	O
enflurane	B-Chemical
or	O
isoflurane	B-Chemical
)	O
was	O
studied	O
in	O
23	O
adult	O
patients	O
undergoing	O
middle	O
-	O
ear	O
surgery	O
.	O
The	O
mean	O
arterial	O
pressure	O
was	O
decreased	O
from	O
86	O
+	O
/	O
-	O
5	O
(	O
s	O
.	O
e	O
.	O
mean	O
)	O
mmHg	O
to	O
52	O
+	O
/	O
-	O
1	O
mmHg	O
(	O
11	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
6	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
98	O
+	O
/	O
-	O
10	O
min	O
in	O
the	O
halothane	B-Chemical
(	O
H	B-Chemical
)	O
group	O
,	O
from	O
79	O
+	O
/	O
-	O
5	O
to	O
53	O
+	O
/	O
-	O
1	O
mmHg	O
(	O
10	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
7	O
to	O
7	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
129	O
+	O
/	O
-	O
11	O
min	O
in	O
the	O
enflurane	B-Chemical
(	O
E	B-Chemical
)	O
group	O
,	O
and	O
from	O
80	O
+	O
/	O
-	O
4	O
to	O
49	O
+	O
/	O
-	O
1	O
mmHg	O
(	O
10	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
5	O
to	O
6	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
1	O
kPa	O
)	O
for	O
135	O
+	O
/	O
-	O
15	O
min	O
in	O
the	O
isoflurane	B-Chemical
(	O
I	B-Chemical
)	O
group	O
.	O
The	O
mean	O
H	B-Chemical
concentration	O
during	O
hypotension	B-Disease
in	O
the	O
inspiratory	O
gas	O
was	O
0	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
1	O
vol	O
%	O
,	O
the	O
mean	O
E	B-Chemical
concentration	O
1	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
2	O
vol	O
%	O
,	O
and	O
the	O
mean	O
I	B-Chemical
concentration	O
1	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
vol	O
%	O
.	O
In	O
addition	O
,	O
the	O
patients	O
received	O
fentanyl	B-Chemical
and	O
d	B-Chemical
-	I-Chemical
tubocurarine	I-Chemical
.	O
The	O
initial	O
dose	O
of	O
labetalol	B-Chemical
for	O
lowering	O
blood	O
pressure	O
was	O
similar	O
,	O
0	O
.	O
52	O
-	O
0	O
.	O
59	O
mg	O
/	O
kg	O
,	O
in	O
all	O
the	O
groups	O
.	O
During	O
hypotension	B-Disease
,	O
the	O
heart	O
rate	O
was	O
stable	O
without	O
tachy	B-Disease
-	I-Disease
or	I-Disease
bradycardia	I-Disease
.	O
The	O
operating	O
conditions	O
regarding	O
bleeding	B-Disease
were	O
estimated	O
in	O
a	O
double	O
-	O
blind	O
manner	O
,	O
and	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
.	O
During	O
hypotension	B-Disease
,	O
the	O
serum	O
creatinine	B-Chemical
concentration	O
rose	O
significantly	O
in	O
all	O
groups	O
from	O
the	O
values	O
before	O
hypotension	B-Disease
and	O
returned	O
postoperatively	O
to	O
the	O
initial	O
level	O
in	O
the	O
other	O
groups	O
,	O
except	O
the	O
isoflurane	B-Chemical
group	O
.	O
After	O
hypotension	B-Disease
there	O
was	O
no	O
rebound	O
phenomenon	O
in	O
either	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O
These	O
results	O
indicate	O
that	O
labetalol	B-Chemical
induces	O
easily	O
adjustable	O
hypotension	B-Disease
without	O
compensatory	O
tachycardia	B-Disease
and	O
rebound	O
hypertension	B-Disease
.	O
Convulsion	B-Disease
following	O
intravenous	O
fluorescein	B-Chemical
angiography	O
.	O
Tonic	B-Disease
-	I-Disease
clonic	I-Disease
seizures	I-Disease
followed	O
intravenous	O
fluorescein	B-Chemical
injection	O
for	O
fundus	O
angiography	O
in	O
a	O
47	O
-	O
year	O
-	O
old	O
male	O
.	O
Despite	O
precautions	O
this	O
adverse	O
reaction	O
recurred	O
on	O
re	O
-	O
exposure	O
to	O
intravenous	O
fluorescein	B-Chemical
.	O
Pharmacology	O
of	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
(	O
phenytoin	B-Chemical
prodrug	O
)	O
.	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
,	O
the	O
disodium	B-Chemical
phosphate	I-Chemical
ester	I-Chemical
of	O
3	B-Chemical
-	I-Chemical
hydroxymethyl	I-Chemical
-	I-Chemical
5	I-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
diphenylhydantoin	I-Chemical
,	O
is	O
a	O
prodrug	O
of	O
phenytoin	B-Chemical
with	O
advantageous	O
physicochemical	O
properties	O
.	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
is	O
rapidly	O
converted	O
enzymatically	O
to	O
phenytoin	B-Chemical
in	O
vivo	O
.	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
phenytoin	B-Chemical
sodium	I-Chemical
have	O
equivalent	O
anticonvulsant	O
activity	O
against	O
seizures	B-Disease
induced	O
by	O
maximal	O
electroshock	O
(	O
MES	O
)	O
in	O
mice	O
following	O
i	O
.	O
p	O
.	O
,	O
oral	O
,	O
or	O
i	O
.	O
v	O
.	O
administration	O
.	O
The	O
ED50	O
doses	O
were	O
16	O
mg	O
/	O
kg	O
for	O
i	O
.	O
v	O
.	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
8	O
mg	O
/	O
kg	O
for	O
i	O
.	O
v	O
.	O
phenytoin	B-Chemical
sodium	I-Chemical
.	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
phenytoin	B-Chemical
sodium	I-Chemical
have	O
similar	O
antiarrhythmic	O
activity	O
against	O
ouabain	B-Chemical
-	O
induced	O
ventricular	B-Disease
tachycardia	I-Disease
in	O
anesthetized	O
dogs	O
.	O
The	O
total	O
doses	O
of	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
or	O
phenytoin	B-Chemical
sodium	I-Chemical
necessary	O
to	O
convert	O
the	O
arrhythmia	B-Disease
to	O
a	O
normal	O
sinus	O
rhythm	O
were	O
24	O
+	O
/	O
-	O
6	O
and	O
14	O
+	O
/	O
-	O
3	O
mg	O
/	O
kg	O
,	O
respectively	O
.	O
Only	O
phenytoin	B-Chemical
sodium	I-Chemical
displayed	O
in	O
vitro	O
antiarrhythmic	O
activity	O
against	O
strophanthidin	B-Chemical
-	O
induced	O
arrhythmias	B-Disease
in	O
guinea	O
pig	O
right	O
atria	O
.	O
In	O
anesthetized	O
dogs	O
,	O
a	O
high	O
dose	O
of	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
(	O
31	O
mg	O
/	O
kg	O
)	O
was	O
infused	O
over	O
15	O
,	O
20	O
,	O
and	O
30	O
min	O
and	O
the	O
responses	O
were	O
compared	O
to	O
an	O
equimolar	O
dose	O
of	O
phenytoin	B-Chemical
sodium	I-Chemical
(	O
21	O
mg	O
/	O
kg	O
)	O
.	O
The	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
phenytoin	B-Chemical
sodium	I-Chemical
treatments	O
produced	O
similar	O
marked	O
reductions	O
in	O
diastolic	O
blood	O
pressure	O
and	O
contractile	O
force	O
(	O
LVdP	O
/	O
dt	O
)	O
.	O
The	O
maximum	O
effects	O
of	O
each	O
treatment	O
occurred	O
at	O
the	O
time	O
of	O
maximum	O
phenytoin	B-Chemical
sodium	I-Chemical
levels	O
.	O
Acute	O
toxicity	B-Disease
studies	O
of	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
and	O
phenytoin	B-Chemical
sodium	I-Chemical
were	O
carried	O
out	O
in	O
mice	O
,	O
rats	O
,	O
rabbits	O
,	O
and	O
dogs	O
by	O
i	O
.	O
v	O
.	O
,	O
i	O
.	O
m	O
.	O
,	O
and	O
i	O
.	O
p	O
.	O
routes	O
of	O
administration	O
.	O
The	O
systemic	O
toxic	O
signs	O
of	O
both	O
agents	O
were	O
similar	O
and	O
occurred	O
at	O
approximately	O
equivalent	O
doses	O
.	O
Importantly	O
,	O
the	O
local	O
irritation	O
of	O
ACC	B-Chemical
-	I-Chemical
9653	I-Chemical
was	O
markedly	O
less	O
than	O
phenytoin	B-Chemical
sodium	I-Chemical
following	O
i	O
.	O
m	O
.	O
administration	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Tachyphylaxis	O
to	O
systemic	O
but	O
not	O
to	O
airway	O
responses	O
during	O
prolonged	O
therapy	O
with	O
high	O
dose	O
inhaled	O
salbutamol	B-Chemical
in	O
asthmatics	B-Disease
.	O
High	O
doses	O
of	O
inhaled	O
salbutamol	B-Chemical
produce	O
substantial	O
improvements	O
in	O
airway	O
response	O
in	O
patients	O
with	O
asthma	B-Disease
,	O
and	O
are	O
associated	O
with	O
dose	O
-	O
dependent	O
systemic	O
beta	O
-	O
adrenoceptor	O
responses	O
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
tachyphylaxis	O
occurs	O
during	O
prolonged	O
treatment	O
with	O
high	O
dose	O
inhaled	O
salbutamol	B-Chemical
.	O
Twelve	O
asthmatic	B-Disease
patients	O
(	O
FEV1	O
,	O
81	O
+	O
/	O
-	O
4	O
%	O
predicted	O
)	O
,	O
requiring	O
only	O
occasional	O
inhaled	O
beta	O
-	O
agonists	O
as	O
their	O
sole	O
therapy	O
,	O
were	O
given	O
a	O
14	O
-	O
day	O
treatment	O
with	O
high	O
dose	O
inhaled	O
salbutamol	B-Chemical
(	O
HDS	O
)	O
,	O
4	O
,	O
000	O
micrograms	O
daily	O
,	O
low	O
dose	O
inhaled	O
salbutamol	B-Chemical
(	O
LDS	O
)	O
,	O
800	O
micrograms	O
daily	O
,	O
or	O
placebo	O
(	O
PI	O
)	O
by	O
metered	O
-	O
dose	O
inhaler	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
crossover	O
design	O
.	O
During	O
the	O
14	O
-	O
day	O
run	O
-	O
in	O
and	O
during	O
washout	O
periods	O
,	O
inhaled	O
beta	O
-	O
agonists	O
were	O
withheld	O
and	O
ipratropium	B-Chemical
bromide	I-Chemical
was	O
substituted	O
for	O
rescue	O
purposes	O
.	O
At	O
the	O
end	O
of	O
each	O
14	O
-	O
day	O
treatment	O
,	O
a	O
dose	O
-	O
response	O
curve	O
(	O
DRC	O
)	O
was	O
performed	O
,	O
and	O
airway	O
(	O
FEV1	O
,	O
FEF25	O
-	O
75	O
)	O
chronotropic	O
(	O
HR	O
)	O
,	O
tremor	B-Disease
,	O
and	O
metabolic	O
(	O
K	B-Chemical
,	O
Glu	B-Chemical
)	O
responses	O
were	O
measured	O
at	O
each	O
step	O
(	O
from	O
100	O
to	O
4	O
,	O
000	O
micrograms	O
)	O
.	O
Treatment	O
had	O
no	O
significant	O
effect	O
on	O
baseline	O
values	O
.	O
There	O
were	O
dose	O
-	O
dependent	O
increases	O
in	O
FEV1	O
and	O
FEF25	O
-	O
75	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
pretreatment	O
with	O
HDS	O
did	O
not	O
displace	O
the	O
DRC	O
to	O
the	O
right	O
.	O
DRC	O
for	O
HR	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
K	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
Glu	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
were	O
attenuated	O
after	O
treatment	O
with	O
HDS	O
compared	O
with	O
PI	O
.	O
There	O
were	O
also	O
differences	O
between	O
HDS	O
and	O
LDS	O
for	O
HR	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
Glu	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
responses	O
.	O
Frequency	O
and	O
severity	O
of	O
subjective	O
adverse	O
effects	O
were	O
also	O
reduced	O
after	O
HDS	O
:	O
tremor	B-Disease
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
palpitations	B-Disease
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Phenytoin	B-Chemical
induced	O
fatal	O
hepatic	B-Disease
injury	I-Disease
.	O
A	O
61	O
year	O
old	O
female	O
developed	O
fatal	O
hepatic	B-Disease
failure	I-Disease
after	O
phenytoin	B-Chemical
administration	O
.	O
A	O
typical	O
multisystem	O
clinical	O
pattern	O
precedes	O
the	O
manifestations	O
of	O
hepatic	B-Disease
injury	I-Disease
.	O
The	O
hematologic	O
,	O
biochemical	O
and	O
pathologic	O
features	O
indicate	O
a	O
mixed	O
hepatocellular	B-Disease
damage	I-Disease
due	O
to	O
drug	B-Disease
hypersensitivity	I-Disease
.	O
In	O
a	O
patient	O
receiving	O
phenytoin	B-Chemical
who	O
presents	O
a	O
viral	O
-	O
like	O
illness	O
,	O
early	O
recognition	O
and	O
discontinuation	O
of	O
the	O
drug	O
are	O
mandatory	O
.	O
Treatment	O
of	O
lethal	O
pertussis	B-Chemical
vaccine	I-Chemical
reaction	O
with	O
histamine	B-Chemical
H1	O
antagonists	O
.	O
We	O
studied	O
mortality	O
after	O
pertussis	B-Disease
immunization	O
in	O
the	O
mouse	O
.	O
Without	O
treatment	O
,	O
73	O
of	O
92	O
animals	O
(	O
80	O
%	O
)	O
died	O
after	O
injection	O
of	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
on	O
day	O
+	O
7	O
of	O
pertussis	B-Disease
immunization	O
.	O
After	O
pretreatment	O
with	O
3	O
mg	O
of	O
cyproheptadine	B-Chemical
,	O
2	O
mg	O
mianserin	B-Chemical
,	O
or	O
2	O
mg	O
chlorpheniramine	B-Chemical
,	O
only	O
5	O
of	O
105	O
animals	O
(	O
5	O
%	O
)	O
died	O
after	O
receiving	O
BSA	O
on	O
day	O
+	O
7	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
Blockade	O
of	O
histamine	B-Chemical
H1	O
receptors	O
may	O
reduce	O
mortality	O
in	O
pertussis	B-Disease
immunization	O
-	O
induced	O
encephalopathy	B-Disease
in	O
mice	O
.	O
Support	O
for	O
adrenaline	B-Chemical
-	O
hypertension	B-Disease
hypothesis	O
:	O
18	O
hour	O
pressor	O
effect	O
after	O
6	O
hours	O
adrenaline	B-Chemical
infusion	O
.	O
In	O
a	O
double	O
blind	O
,	O
crossover	O
study	O
6	O
h	O
infusions	O
of	O
adrenaline	B-Chemical
(	O
15	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5	O
.	O
458	O
pmol	O
)	O
,	O
noradrenaline	B-Chemical
(	O
30	O
ng	O
/	O
kg	O
/	O
min	O
;	O
1	O
ng	O
=	O
5	O
.	O
911	O
pmol	O
)	O
,	O
and	O
a	O
5	O
%	O
dextrose	B-Chemical
solution	O
(	O
5	O
.	O
4	O
ml	O
/	O
h	O
)	O
,	O
were	O
given	O
to	O
ten	O
healthy	O
volunteers	O
in	O
random	O
order	O
2	O
weeks	O
apart	O
.	O
By	O
means	O
of	O
intra	O
-	O
arterial	O
ambulatory	O
monitoring	O
the	O
haemodynamic	O
effects	O
were	O
followed	O
for	O
18	O
h	O
after	O
the	O
infusions	O
were	O
stopped	O
.	O
Adrenaline	B-Chemical
,	O
but	O
not	O
noradrenaline	B-Chemical
,	O
caused	O
a	O
delayed	O
and	O
protracted	O
pressor	O
effect	O
.	O
Over	O
the	O
total	O
postinfusion	O
period	O
systolic	O
and	O
diastolic	O
arterial	O
pressure	O
were	O
6	O
(	O
SEM	O
2	O
)	O
%	O
and	O
7	O
(	O
2	O
)	O
%	O
,	O
respectively	O
,	O
higher	O
than	O
after	O
dextrose	B-Chemical
infusion	O
(	O
ANOVA	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O
Thus	O
,	O
""""	O
stress	O
""""	O
levels	O
of	O
adrenaline	B-Chemical
(	O
230	O
pg	O
/	O
ml	O
)	O
for	O
6	O
h	O
cause	O
a	O
delayed	O
and	O
protracted	O
pressor	O
effect	O
.	O
These	O
findings	O
are	O
strong	O
support	O
for	O
the	O
adrenaline	B-Chemical
-	O
hypertension	B-Disease
hypothesis	O
in	O
man	O
.	O
Effect	O
of	O
alkylxanthines	B-Chemical
on	O
gentamicin	B-Chemical
-	O
induced	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
in	O
the	O
rat	O
.	O
Adenosine	B-Chemical
antagonists	O
have	O
been	O
previously	O
shown	O
to	O
be	O
of	O
benefit	O
in	O
some	O
ischaemic	B-Disease
and	O
nephrotoxic	B-Disease
models	O
of	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
(	O
ARF	B-Disease
)	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
three	O
alkylxanthines	B-Chemical
with	O
different	O
potencies	O
as	O
adenosine	B-Chemical
antagonists	O
8	B-Chemical
-	I-Chemical
phenyltheophylline	I-Chemical
,	O
theophylline	B-Chemical
and	O
enprofylline	B-Chemical
,	O
were	O
examined	O
in	O
rats	O
developing	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
after	O
4	O
daily	O
injections	O
of	O
gentamicin	B-Chemical
(	O
200	O
mg	O
kg	O
-	O
1	O
)	O
.	O
Renal	O
function	O
was	O
assessed	O
by	O
biochemical	O
(	O
plasma	O
urea	B-Chemical
and	O
creatinine	B-Chemical
)	O
,	O
functional	O
(	O
urine	O
analysis	O
and	O
[	O
3H	O
]	O
inulin	O
and	O
[	O
14C	O
]	O
p	B-Chemical
-	I-Chemical
aminohippuric	I-Chemical
acid	I-Chemical
clearances	O
)	O
and	O
morphological	O
(	O
degree	O
of	O
necrosis	B-Disease
)	O
indices	O
.	O
The	O
various	O
drug	O
treatments	O
produced	O
improvements	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
measurements	O
of	O
renal	O
function	O
.	O
However	O
,	O
any	O
improvement	O
produced	O
by	O
drug	O
treatment	O
was	O
largely	O
a	O
result	O
of	O
a	O
beneficial	O
effect	O
exerted	O
by	O
its	O
vehicle	O
(	O
polyethylene	B-Chemical
glycol	I-Chemical
and	O
NaOH	B-Chemical
)	O
.	O
The	O
lack	O
of	O
any	O
consistent	O
protective	O
effect	O
noted	O
with	O
the	O
alkylxanthines	B-Chemical
tested	O
in	O
the	O
present	O
study	O
indicates	O
that	O
adenosine	B-Chemical
plays	O
little	O
,	O
if	O
any	O
,	O
pathophysiological	O
role	O
in	O
gentamicin	B-Chemical
-	O
induced	O
ARF	B-Disease
.	O
Adverse	O
ocular	O
reactions	O
possibly	O
associated	O
with	O
isotretinoin	B-Chemical
.	O
A	O
total	O
of	O
261	O
adverse	O
ocular	O
reactions	O
occurred	O
in	O
237	O
patients	O
who	O
received	O
isotretinoin	B-Chemical
,	O
a	O
commonly	O
used	O
drug	O
in	O
the	O
treatment	O
of	O
severe	O
cystic	O
acne	B-Disease
.	O
Blepharoconjunctivitis	B-Disease
,	O
subjective	O
complaints	O
of	O
dry	B-Disease
eyes	I-Disease
,	O
blurred	B-Disease
vision	I-Disease
,	O
contact	O
lens	O
intolerance	O
,	O
and	O
photodermatitis	B-Disease
are	O
reversible	O
side	O
effects	O
.	O
More	O
serious	O
ocular	O
adverse	O
reactions	O
include	O
papilledema	B-Disease
,	O
pseudotumor	B-Disease
cerebri	I-Disease
,	O
and	O
white	O
or	O
gray	O
subepithelial	O
corneal	B-Disease
opacities	I-Disease
;	O
all	O
of	O
these	O
are	O
reversible	O
if	O
the	O
drug	O
is	O
discontinued	O
.	O
Reported	O
cases	O
of	O
decreased	O
dark	O
adaptation	O
are	O
under	O
investigation	O
.	O
Isotretinoin	B-Chemical
is	O
contraindicated	O
in	O
pregnancy	O
because	O
of	O
the	O
many	O
reported	O
congenital	B-Disease
abnormalities	I-Disease
after	O
maternal	O
use	O
(	O
including	O
microphthalmos	B-Disease
,	O
orbital	O
hypertelorism	B-Disease
,	O
and	O
optic	B-Disease
nerve	I-Disease
hypoplasia	I-Disease
)	O
.	O
Procaterol	B-Chemical
and	O
terbutaline	B-Chemical
in	O
bronchial	B-Disease
asthma	I-Disease
.	O
A	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
cross	O
-	O
over	O
study	O
.	O
Procaterol	B-Chemical
,	O
a	O
new	O
beta	O
-	O
2	O
adrenoceptor	O
stimulant	O
,	O
was	O
studied	O
in	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
cross	O
-	O
over	O
trial	O
in	O
patients	O
with	O
bronchial	B-Disease
asthma	I-Disease
.	O
Oral	O
procaterol	B-Chemical
50	O
micrograms	O
b	O
.	O
d	O
.	O
,	O
procaterol	B-Chemical
100	O
micrograms	O
b	O
.	O
d	O
.	O
,	O
and	O
terbutaline	B-Chemical
5	O
mg	O
t	O
.	O
i	O
.	O
d	O
.	O
,	O
were	O
compared	O
when	O
given	O
randomly	O
in	O
1	O
-	O
week	O
treatment	O
periods	O
.	O
The	O
best	O
clinical	O
effect	O
was	O
found	O
with	O
terbutaline	B-Chemical
.	O
Both	O
anti	O
-	O
asthmatic	B-Disease
and	O
tremorgenic	B-Disease
effects	O
of	O
procaterol	B-Chemical
were	O
dose	O
-	O
related	O
.	O
Procaterol	B-Chemical
appeared	O
effective	O
in	O
the	O
doses	O
tested	O
,	O
and	O
a	O
twice	O
daily	O
regimen	O
would	O
appear	O
to	O
be	O
suitable	O
with	O
this	O
drug	O
.	O
Subacute	O
effects	O
of	O
propranolol	B-Chemical
and	O
B	O
24	O
/	O
76	O
on	O
isoproterenol	B-Chemical
-	O
induced	O
rat	O
heart	B-Disease
hypertrophy	I-Disease
in	O
correlation	O
with	O
blood	O
pressure	O
.	O
We	O
compared	O
the	O
potential	O
beta	O
-	O
receptor	O
blocker	O
,	O
B	O
24	O
/	O
76	O
i	O
.	O
e	O
.	O
1	O
-	O
(	O
2	O
,	O
4	O
-	O
dichlorophenoxy	O
)	O
-	O
3	O
[	O
2	O
-	O
3	O
,	O
4	O
-	O
dimethoxyphenyl	O
)	O
ethanolamino	O
]	O
-	O
prop	O
an	O
-	O
2	O
-	O
ol	O
,	O
which	O
is	O
characterized	O
by	O
beta	O
1	O
-	O
adrenoceptor	O
blocking	O
and	O
beta	O
2	O
-	O
adrenoceptor	O
stimulating	O
properties	O
with	O
propranolol	B-Chemical
.	O
The	O
studies	O
were	O
performed	O
using	O
an	O
experimental	O
model	O
of	O
isoproterenol	B-Chemical
-	O
induced	O
heart	B-Disease
hypertrophy	I-Disease
in	O
rats	O
.	O
A	O
correlation	O
of	O
the	O
blood	O
pressure	O
was	O
neither	O
found	O
in	O
the	O
development	O
nor	O
in	O
the	O
attempt	O
to	O
suppress	O
the	O
development	O
of	O
heart	B-Disease
hypertrophy	I-Disease
with	O
the	O
two	O
beta	O
-	O
receptor	O
blockers	O
.	O
Both	O
beta	O
-	O
blockers	O
influenced	O
the	O
development	O
of	O
hypertrophy	B-Disease
to	O
a	O
different	O
,	O
but	O
not	O
reproducible	O
extent	O
.	O
It	O
was	O
possible	O
to	O
suppress	O
the	O
increased	O
ornithine	B-Chemical
decarboxylase	O
activity	O
with	O
both	O
beta	O
-	O
blockers	O
in	O
hypertrophied	B-Disease
hearts	I-Disease
,	O
but	O
there	O
was	O
no	O
effect	O
on	O
the	O
heart	O
mass	O
.	O
Neither	O
propranolol	B-Chemical
nor	O
B	O
24	O
/	O
76	O
could	O
stop	O
the	O
changes	O
in	O
the	O
characteristic	O
myosin	O
isoenzyme	O
pattern	O
of	O
the	O
hypertrophied	B-Disease
rat	O
heart	O
.	O
Thus	O
,	O
the	O
investigations	O
did	O
not	O
provide	O
any	O
evidence	O
that	O
the	O
beta	O
-	O
receptor	O
blockers	O
propranolol	B-Chemical
and	O
B	O
24	O
/	O
76	O
have	O
the	O
potency	O
to	O
prevent	O
isoproterenol	B-Chemical
from	O
producing	O
heart	B-Disease
hypertrophy	I-Disease
.	O
Increased	O
anxiogenic	O
effects	O
of	O
caffeine	B-Chemical
in	O
panic	B-Disease
disorders	I-Disease
.	O
The	O
effects	O
of	O
oral	O
administration	O
of	O
caffeine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
on	O
behavioral	O
ratings	O
,	O
somatic	O
symptoms	O
,	O
blood	O
pressure	O
and	O
plasma	O
levels	O
of	O
3	B-Chemical
-	I-Chemical
methoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
hydroxyphenethyleneglycol	I-Chemical
(	O
MHPG	B-Chemical
)	O
and	O
cortisol	B-Chemical
were	O
determined	O
in	O
17	O
healthy	O
subjects	O
and	O
21	O
patients	O
meeting	O
DSM	O
-	O
III	O
criteria	O
for	O
agoraphobia	B-Disease
with	O
panic	B-Disease
attacks	I-Disease
or	O
panic	B-Disease
disorder	I-Disease
.	O
Caffeine	B-Chemical
produced	O
significantly	O
greater	O
increases	O
in	O
subject	O
-	O
rated	O
anxiety	B-Disease
,	O
nervousness	O
,	O
fear	O
,	O
nausea	B-Disease
,	O
palpitations	B-Disease
,	O
restlessness	B-Disease
,	O
and	O
tremors	B-Disease
in	O
the	O
patients	O
compared	O
with	O
healthy	O
subjects	O
.	O
In	O
the	O
patients	O
,	O
but	O
not	O
the	O
healthy	O
subjects	O
,	O
these	O
symptoms	O
were	O
significantly	O
correlated	O
with	O
plasma	O
caffeine	B-Chemical
levels	O
.	O
Seventy	O
-	O
one	O
percent	O
of	O
the	O
patients	O
reported	O
that	O
the	O
behavioral	O
effects	O
of	O
caffeine	B-Chemical
were	O
similar	O
to	O
those	O
experienced	O
during	O
panic	B-Disease
attacks	I-Disease
.	O
Caffeine	B-Chemical
did	O
not	O
alter	O
plasma	O
MHPG	B-Chemical
levels	O
in	O
either	O
the	O
healthy	O
subjects	O
or	O
patients	O
.	O
Caffeine	B-Chemical
increased	O
plasma	O
cortisol	B-Chemical
levels	O
equally	O
in	O
the	O
patient	O
and	O
healthy	O
groups	O
.	O
Because	O
caffeine	B-Chemical
is	O
an	O
adenosine	B-Chemical
receptor	O
antagonist	O
,	O
these	O
results	O
suggest	O
that	O
some	O
panic	B-Disease
disorder	I-Disease
patients	O
may	O
have	O
abnormalities	B-Disease
in	I-Disease
neuronal	I-Disease
systems	I-Disease
involving	O
adenosine	B-Chemical
.	O
Patients	O
with	O
anxiety	B-Disease
disorders	I-Disease
may	O
benefit	O
by	O
avoiding	O
caffeine	B-Chemical
-	O
containing	O
foods	O
and	O
beverages	O
.	O
Comparison	O
of	O
the	O
effect	O
of	O
oxitropium	B-Chemical
bromide	I-Chemical
and	O
of	O
slow	O
-	O
release	O
theophylline	B-Chemical
on	O
nocturnal	O
asthma	B-Disease
.	O
The	O
effects	O
of	O
a	O
new	O
inhaled	O
antimuscarinic	O
drug	O
,	O
oxitropium	B-Chemical
bromide	I-Chemical
,	O
and	O
of	O
a	O
slow	O
-	O
release	O
theophylline	B-Chemical
preparation	O
upon	O
nocturnal	O
asthma	B-Disease
were	O
compared	O
in	O
a	O
placebo	O
-	O
controlled	O
double	O
-	O
blind	O
study	O
.	O
Two	O
samples	O
were	O
studied	O
:	O
12	O
patients	O
received	O
oxitropium	B-Chemical
at	O
600	O
micrograms	O
(	O
6	O
subjects	O
)	O
or	O
at	O
400	O
micrograms	O
t	O
.	O
i	O
.	O
d	O
.	O
(	O
6	O
subjects	O
)	O
whereas	O
11	O
received	O
theophylline	B-Chemical
at	O
300	O
mg	O
b	O
.	O
i	O
.	O
d	O
.	O
Morning	O
dipping	O
,	O
assessed	O
by	O
the	O
fall	O
in	O
peak	O
flow	O
overnight	O
,	O
was	O
significantly	O
reduced	O
in	O
the	O
periods	O
when	O
either	O
active	O
drug	O
was	O
taken	O
,	O
whereas	O
no	O
difference	O
was	O
noticed	O
during	O
the	O
placebo	O
administration	O
.	O
No	O
significant	O
difference	O
was	O
noticed	O
between	O
results	O
obtained	O
with	O
either	O
active	O
drug	O
,	O
as	O
well	O
as	O
with	O
either	O
dosage	O
of	O
oxitropium	B-Chemical
.	O
No	O
subject	O
reported	O
side	O
effects	O
of	O
oxitropium	B-Chemical
,	O
as	O
compared	O
to	O
three	O
subjects	O
reporting	O
nausea	B-Disease
,	O
vomiting	B-Disease
and	O
tremors	B-Disease
after	O
theophylline	B-Chemical
.	O
Oxitropium	B-Chemical
proves	O
to	O
be	O
a	O
valuable	O
alternative	O
to	O
theophylline	B-Chemical
in	O
nocturnal	O
asthma	B-Disease
,	O
since	O
it	O
is	O
equally	O
potent	O
,	O
safer	O
and	O
does	O
not	O
require	O
the	O
titration	O
of	O
dosage	O
.	O
Penicillin	B-Chemical
anaphylaxis	B-Disease
.	O
A	O
case	O
of	O
oral	O
penicillin	B-Chemical
anaphylaxis	B-Disease
is	O
described	O
,	O
and	O
the	O
terminology	O
,	O
occurrence	O
,	O
clinical	O
manifestations	O
,	O
pathogenesis	O
,	O
prevention	O
,	O
and	O
treatment	O
of	O
anaphylaxis	B-Disease
are	O
reviewed	O
.	O
Emergency	O
physicians	O
should	O
be	O
aware	O
of	O
oral	O
penicillin	B-Chemical
anaphylaxis	B-Disease
in	O
order	O
to	O
prevent	O
its	O
occurrence	O
by	O
prescribing	O
the	O
antibiotic	O
judiciously	O
and	O
knowledgeably	O
and	O
to	O
offer	O
optimal	O
medical	O
therapy	O
once	O
this	O
life	O
-	O
threatening	O
reaction	O
has	O
begun	O
.	O
Reversible	O
valproic	B-Chemical
acid	I-Chemical
-	O
induced	O
dementia	B-Disease
:	O
a	O
case	O
report	O
.	O
Reversible	O
valproic	B-Chemical
acid	I-Chemical
-	O
induced	O
dementia	B-Disease
was	O
documented	O
in	O
a	O
21	O
-	O
year	O
-	O
old	O
man	O
with	O
epilepsy	B-Disease
who	O
had	O
a	O
3	O
-	O
year	O
history	O
of	O
insidious	O
progressive	O
decline	O
in	O
global	O
cognitive	O
abilities	O
documented	O
by	O
serial	O
neuropsychological	O
studies	O
.	O
Repeat	O
neuropsychological	O
testing	O
7	O
weeks	O
after	O
discontinuation	O
of	O
the	O
drug	O
revealed	O
dramatic	O
improvement	O
in	O
IQ	O
,	O
memory	O
,	O
naming	O
,	O
and	O
other	O
tasks	O
commensurate	O
with	O
clinical	O
recovery	O
in	O
his	O
intellectual	O
capacity	O
.	O
Possible	O
pathophysiological	O
mechanisms	O
which	O
may	O
have	O
been	O
operative	O
in	O
this	O
case	O
include	O
:	O
a	O
direct	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
toxic	O
effect	O
of	O
valproic	B-Chemical
acid	I-Chemical
;	O
a	O
paradoxical	O
epileptogenic	O
effect	O
secondary	O
to	O
the	O
drug	O
;	O
and	O
an	O
indirect	O
CNS	O
toxic	O
effect	O
mediated	O
through	O
valproic	B-Chemical
acid	I-Chemical
-	O
induced	O
hyperammonemia	B-Disease
.	O
Reversal	O
of	O
scopolamine	B-Chemical
-	O
induced	O
amnesia	B-Disease
of	O
passive	O
avoidance	O
by	O
pre	O
-	O
and	O
post	O
-	O
training	O
naloxone	B-Chemical
.	O
In	O
a	O
series	O
of	O
five	O
experiments	O
,	O
the	O
modulating	O
role	O
of	O
naloxone	B-Chemical
on	O
a	O
scopolamine	B-Chemical
-	O
induced	O
retention	B-Disease
deficit	I-Disease
in	O
a	O
passive	O
avoidance	O
paradigm	O
was	O
investigated	O
in	O
mice	O
.	O
Scopolamine	B-Chemical
,	O
but	O
not	O
methyl	B-Chemical
scopolamine	I-Chemical
(	O
1	O
and	O
3	O
mg	O
/	O
kg	O
)	O
,	O
induced	O
an	O
amnesia	B-Disease
as	O
measured	O
by	O
latency	O
and	O
duration	O
parameters	O
.	O
Naloxone	B-Chemical
(	O
0	O
.	O
3	O
,	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
)	O
injected	O
prior	O
to	O
training	O
attenuated	O
the	O
retention	B-Disease
deficit	I-Disease
with	O
a	O
peak	O
of	O
activity	O
at	O
3	O
mg	O
/	O
kg	O
.	O
The	O
effect	O
of	O
naloxone	B-Chemical
could	O
be	O
antagonized	O
with	O
morphine	B-Chemical
(	O
1	O
,	O
3	O
,	O
and	O
10	O
mg	O
/	O
kg	O
)	O
,	O
demonstrating	O
the	O
opioid	O
specificity	O
of	O
the	O
naloxone	B-Chemical
effect	O
.	O
Post	O
-	O
training	O
administration	O
of	O
naloxone	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
)	O
as	O
a	O
single	O
or	O
as	O
a	O
split	O
dose	O
also	O
attenuated	O
the	O
scopolamine	B-Chemical
-	O
induced	O
amnesia	B-Disease
.	O
Control	O
experiments	O
indicated	O
that	O
neither	O
an	O
increase	O
in	O
pain	B-Disease
sensitivity	O
(	O
pre	O
-	O
training	O
naloxone	B-Chemical
)	O
nor	O
an	O
induced	O
aversive	O
state	O
(	O
post	O
-	O
training	O
naloxone	B-Chemical
)	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
influence	O
of	O
naloxone	B-Chemical
on	O
the	O
scopolamine	B-Chemical
-	O
induced	O
retention	B-Disease
deficit	I-Disease
.	O
These	O
results	O
extend	O
previous	O
findings	O
implicating	O
a	O
cholinergic	O
-	O
opioid	O
interaction	O
in	O
memory	O
processes	O
.	O
A	O
possible	O
mechanism	O
for	O
this	O
interaction	O
involving	O
the	O
septo	O
-	O
hippocampal	O
cholinergic	O
pathway	O
is	O
discussed	O
.	O
Electron	O
microscopic	O
investigations	O
of	O
the	O
cyclophosphamide	B-Chemical
-	O
induced	O
lesions	B-Disease
of	I-Disease
the	I-Disease
urinary	I-Disease
bladder	I-Disease
of	O
the	O
rat	O
and	O
their	O
prevention	O
by	O
mesna	B-Chemical
.	O
Fully	O
developed	O
cyclophosphamide	B-Chemical
-	O
induced	O
cystitis	B-Disease
is	O
characterized	O
by	O
nearly	O
complete	O
detachment	O
of	O
the	O
urothelium	O
,	O
severe	O
submucosal	O
edema	B-Disease
owing	O
to	O
damage	O
to	O
the	O
microvascular	O
bed	O
and	O
focal	O
muscle	O
necroses	B-Disease
.	O
The	O
initial	O
response	O
to	O
the	O
primary	O
attack	O
by	O
the	O
cyclophosphamide	B-Chemical
metabolites	O
seems	O
to	O
be	O
fragmentation	O
of	O
the	O
luminal	B-Chemical
membrane	O
.	O
This	O
damages	O
the	O
cellular	O
barrier	O
against	O
the	O
hypertonic	O
urine	O
.	O
Subsequent	O
breaks	O
in	O
the	O
lateral	O
cell	O
membranes	O
of	O
the	O
superficial	O
cells	O
and	O
in	O
all	O
the	O
plasma	O
membranes	O
of	O
the	O
intermediate	O
and	O
basal	O
cells	O
,	O
intercellular	O
and	O
intracellular	O
edema	B-Disease
and	O
disintegration	O
of	O
the	O
desmosomes	O
and	O
hemidesmosomes	O
lead	O
to	O
progressive	O
degeneration	O
and	O
detachment	O
of	O
the	O
epithelial	O
cells	O
with	O
exposure	O
and	O
splitting	O
of	O
the	O
basal	O
membrane	O
.	O
The	O
morphological	O
changes	O
of	O
the	O
endothelial	O
cells	O
,	O
which	O
become	O
more	O
pronounced	O
in	O
the	O
later	O
stages	O
of	O
the	O
experiment	O
,	O
the	O
involvement	O
of	O
blood	O
vessels	O
regardless	O
of	O
their	O
diameter	O
and	O
the	O
location	O
-	O
dependent	O
extent	O
of	O
the	O
damage	O
indicate	O
a	O
direct	O
type	O
of	O
damage	O
which	O
is	O
preceded	O
by	O
a	O
mediator	O
-	O
induced	O
increase	O
in	O
permeability	O
,	O
the	O
morphological	O
correlate	O
of	O
which	O
is	O
the	O
formation	O
of	O
gaps	O
in	O
the	O
interendothelial	O
cell	O
connections	O
on	O
the	O
venules	O
.	O
These	O
changes	O
can	O
be	O
effectively	O
prevented	O
by	O
mesna	B-Chemical
.	O
The	O
only	O
sign	O
of	O
a	O
possible	O
involvement	O
is	O
the	O
increase	O
in	O
the	O
number	O
of	O
specific	O
granules	O
with	O
a	O
presumed	O
lysosomal	O
function	O
in	O
the	O
superficial	O
cells	O
.	O
Increase	O
in	O
intragastric	O
pressure	O
during	O
suxamethonium	B-Chemical
-	O
induced	O
muscle	B-Disease
fasciculations	I-Disease
in	O
children	O
:	O
inhibition	O
by	O
alfentanil	B-Chemical
.	O
Changes	O
in	O
intragastric	O
pressure	O
after	O
the	O
administration	O
of	O
suxamethonium	B-Chemical
1	O
.	O
5	O
mg	O
kg	O
-	O
1	O
i	O
.	O
v	O
.	O
were	O
studied	O
in	O
32	O
children	O
(	O
mean	O
age	O
6	O
.	O
9	O
yr	O
)	O
pretreated	O
with	O
either	O
physiological	O
saline	O
or	O
alfentanil	B-Chemical
50	O
micrograms	O
kg	O
-	O
1	O
.	O
Anaesthesia	O
was	O
induced	O
with	O
thiopentone	B-Chemical
5	O
mg	O
kg	O
-	O
1	O
.	O
The	O
incidence	O
and	O
intensity	O
of	O
muscle	B-Disease
fasciculations	I-Disease
caused	O
by	O
suxamethonium	B-Chemical
were	O
significantly	O
greater	O
in	O
the	O
control	O
than	O
in	O
the	O
alfentanil	B-Chemical
group	O
.	O
The	O
intragastric	O
pressure	O
during	O
muscle	B-Disease
fasciculations	I-Disease
was	O
significantly	O
higher	O
in	O
the	O
control	O
group	O
(	O
16	O
+	O
/	O
-	O
0	O
.	O
7	O
(	O
SEM	O
)	O
cm	O
H2O	B-Chemical
)	O
than	O
in	O
the	O
alfentanil	B-Chemical
group	O
(	O
7	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
5	O
(	O
SEM	O
)	O
cm	O
H2O	B-Chemical
)	O
.	O
The	O
increase	O
in	O
intragastric	O
pressure	O
was	O
directly	O
related	O
to	O
the	O
intensity	O
of	O
muscle	B-Disease
fasciculations	I-Disease
(	O
regression	O
line	O
:	O
y	O
=	O
0	O
.	O
5	O
+	O
4	O
.	O
78x	O
with	O
r	O
of	O
0	O
.	O
78	O
)	O
.	O
It	O
is	O
concluded	O
that	O
intragastric	O
pressure	O
increases	O
significantly	O
during	O
muscle	B-Disease
fasciculations	I-Disease
caused	O
by	O
suxamethonium	B-Chemical
in	O
healthy	O
children	O
.	O
Alfentanil	B-Chemical
50	O
micrograms	O
kg	O
-	O
1	O
effectively	O
inhibits	O
the	O
incidence	O
and	O
intensity	O
of	O
suxamethonium	B-Chemical
-	O
induced	O
muscle	B-Disease
fasciculations	I-Disease
;	O
moreover	O
,	O
intragastric	O
pressure	O
remains	O
at	O
its	O
control	O
value	O
.	O
Acute	O
insulin	O
treatment	O
normalizes	O
the	O
resistance	O
to	O
the	O
cardiotoxic	B-Disease
effect	O
of	O
isoproterenol	B-Chemical
in	O
streptozotocin	B-Chemical
diabetic	B-Disease
rats	O
.	O
A	O
morphometric	O
study	O
of	O
isoproterenol	B-Chemical
induced	O
myocardial	O
fibrosis	B-Disease
.	O
The	O
acute	O
effect	O
of	O
insulin	O
treatment	O
on	O
the	O
earlier	O
reported	O
protective	O
effect	O
of	O
streptozotocin	B-Chemical
diabetes	B-Disease
against	O
the	O
cardiotoxic	B-Disease
effect	O
of	O
high	O
doses	O
of	O
isoproterenol	B-Chemical
(	O
ISO	B-Chemical
)	O
was	O
investigated	O
in	O
rats	O
.	O
Thirty	O
to	O
135	O
min	O
after	O
the	O
injection	O
of	O
crystalline	O
insulin	O
,	O
ISO	B-Chemical
was	O
given	O
subcutaneously	O
and	O
when	O
ISO	B-Chemical
induced	O
fibrosis	B-Disease
in	O
the	O
myocardium	O
was	O
morphometrically	O
analyzed	O
7	O
days	O
later	O
,	O
a	O
highly	O
significant	O
correlation	O
(	O
r	O
=	O
0	O
.	O
83	O
,	O
2	O
p	O
=	O
0	O
.	O
006	O
)	O
to	O
the	O
slope	O
of	O
the	O
fall	O
in	O
blood	O
glucose	B-Chemical
after	O
insulin	O
treatment	O
appeared	O
.	O
The	O
myocardial	O
content	O
of	O
catecholamines	B-Chemical
was	O
estimated	O
in	O
these	O
8	O
day	O
diabetic	B-Disease
rats	O
.	O
The	O
norepinephrine	B-Chemical
content	O
was	O
significantly	O
increased	O
while	O
epinephrine	B-Chemical
remained	O
unchanged	O
.	O
An	O
enhanced	O
sympathetic	O
nervous	O
system	O
activity	O
with	O
a	O
consequent	O
down	O
regulation	O
of	O
the	O
myocardial	O
beta	O
-	O
adrenergic	O
receptors	O
could	O
,	O
therefore	O
,	O
explain	O
this	O
catecholamine	B-Chemical
resistance	O
.	O
The	O
rapid	O
reversion	O
after	O
insulin	O
treatment	O
excludes	O
the	O
possibility	O
that	O
streptozotocin	B-Chemical
in	O
itself	O
causes	O
the	O
ISO	B-Chemical
resistance	O
and	O
points	O
towards	O
a	O
direct	O
insulin	O
effect	O
on	O
myocardial	O
catecholamine	B-Chemical
sensitivity	O
in	O
diabetic	B-Disease
rats	O
.	O
The	O
phenomenon	O
described	O
might	O
elucidate	O
pathogenetic	O
mechanisms	O
behind	O
toxic	O
myocardial	O
cell	O
degeneration	O
and	O
may	O
possibly	O
have	O
relevance	O
for	O
acute	O
cardiovascular	O
complications	O
in	O
diabetic	B-Disease
patients	O
.	O
Differential	O
effects	O
of	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
on	O
seizures	B-Disease
produced	O
by	O
pilocarpine	B-Chemical
in	O
rats	O
.	O
The	O
muscarinic	O
cholinergic	O
agonist	O
pilocarpine	B-Chemical
induces	O
in	O
rats	O
seizures	B-Disease
and	O
status	B-Disease
epilepticus	I-Disease
followed	O
by	O
widespread	O
damage	O
to	O
the	O
forebrain	O
.	O
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
5	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
sodium	B-Chemical
salicylate	I-Chemical
,	O
phenylbutazone	B-Chemical
,	O
indomethacin	B-Chemical
,	O
ibuprofen	B-Chemical
and	O
mefenamic	B-Chemical
acid	I-Chemical
,	O
on	O
seizures	B-Disease
produced	O
by	O
pilocarpine	B-Chemical
.	O
Pretreatment	O
of	O
rats	O
with	O
sodium	B-Chemical
salicylate	I-Chemical
,	O
ED50	O
103	O
mg	O
/	O
kg	O
(	O
60	O
-	O
174	O
)	O
,	O
and	O
phenylbutazone	B-Chemical
,	O
59	O
mg	O
/	O
kg	O
(	O
50	O
-	O
70	O
)	O
converted	O
the	O
non	O
-	O
convulsant	O
dose	O
of	O
pilocarpine	B-Chemical
,	O
200	O
mg	O
/	O
kg	O
,	O
to	O
a	O
convulsant	O
one	O
.	O
Indomethacin	B-Chemical
,	O
1	O
-	O
10	O
mg	O
/	O
kg	O
,	O
and	O
ibuprofen	B-Chemical
,	O
10	O
-	O
100	O
mg	O
/	O
kg	O
,	O
failed	O
to	O
modulate	O
seizures	B-Disease
produced	O
by	O
pilocarpine	B-Chemical
.	O
Mefenamic	B-Chemical
acid	I-Chemical
,	O
26	O
(	O
22	O
-	O
30	O
)	O
mg	O
/	O
kg	O
,	O
prevented	O
seizures	B-Disease
and	O
protected	O
rats	O
from	O
seizure	B-Disease
-	O
related	O
brain	B-Disease
damage	I-Disease
induced	O
by	O
pilocarpine	B-Chemical
,	O
380	O
mg	O
/	O
kg	O
.	O
These	O
results	O
indicate	O
that	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
differentially	O
modulate	O
the	O
threshold	O
for	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
.	O
Acute	B-Disease
neurologic	I-Disease
dysfunction	I-Disease
after	O
high	O
-	O
dose	O
etoposide	B-Chemical
therapy	O
for	O
malignant	B-Disease
glioma	I-Disease
.	O
Etoposide	B-Chemical
(	O
VP	B-Chemical
-	I-Chemical
16	I-Chemical
-	I-Chemical
213	I-Chemical
)	O
has	O
been	O
used	O
in	O
the	O
treatment	O
of	O
many	O
solid	O
tumors	B-Disease
and	O
hematologic	B-Disease
malignancies	I-Disease
.	O
When	O
used	O
in	O
high	O
doses	O
and	O
in	O
conjunction	O
with	O
autologous	O
bone	O
marrow	O
transplantation	O
,	O
this	O
agent	O
has	O
activity	O
against	O
several	O
treatment	O
-	O
resistant	O
cancers	B-Disease
including	O
malignant	B-Disease
glioma	I-Disease
.	O
In	O
six	O
of	O
eight	O
patients	O
(	O
75	O
%	O
)	O
who	O
we	O
treated	O
for	O
recurrent	O
or	O
resistant	O
glioma	B-Disease
,	O
sudden	O
severe	O
neurologic	B-Disease
deterioration	I-Disease
occurred	O
.	O
This	O
developed	O
a	O
median	O
of	O
9	O
days	O
after	O
initiation	O
of	O
high	O
-	O
dose	O
etoposide	B-Chemical
therapy	O
.	O
Significant	O
clinical	O
manifestations	O
have	O
included	O
confusion	B-Disease
,	O
papilledema	B-Disease
,	O
somnolence	B-Disease
,	O
exacerbation	O
of	O
motor	B-Disease
deficits	I-Disease
,	O
and	O
sharp	O
increase	O
in	O
seizure	B-Disease
activity	O
.	O
These	O
abnormalities	O
resolved	O
rapidly	O
after	O
initiation	O
of	O
high	O
-	O
dose	O
intravenous	O
dexamethasone	B-Chemical
therapy	O
.	O
In	O
all	O
patients	O
,	O
computerized	O
tomographic	O
(	O
CT	O
)	O
brain	O
scans	O
demonstrated	O
stability	O
in	O
tumor	B-Disease
size	O
and	O
peritumor	O
edema	B-Disease
when	O
compared	O
with	O
pretransplant	O
scans	O
.	O
This	O
complication	O
appears	O
to	O
represent	O
a	O
significant	O
new	O
toxicity	B-Disease
of	O
high	O
-	O
dose	O
etoposide	B-Chemical
therapy	O
for	O
malignant	B-Disease
glioma	I-Disease
.	O
Progressive	O
bile	B-Disease
duct	I-Disease
injury	I-Disease
after	O
thiabendazole	B-Chemical
administration	O
.	O
A	O
27	O
-	O
yr	O
-	O
old	O
man	O
developed	O
jaundice	B-Disease
2	O
wk	O
after	O
exposure	O
to	O
thiabendazole	B-Chemical
.	O
Cholestasis	B-Disease
persisted	O
for	O
3	O
yr	O
,	O
at	O
which	O
time	O
a	O
liver	O
transplant	O
was	O
performed	O
.	O
Two	O
liver	O
biopsy	O
specimens	O
and	O
the	O
hepatectomy	O
specimen	O
were	O
remarkable	O
for	O
almost	O
complete	O
disappearance	O
of	O
interlobular	O
bile	O
ducts	O
.	O
Prominent	O
fibrosis	B-Disease
and	O
hepatocellular	O
regeneration	O
were	O
also	O
present	O
;	O
however	O
,	O
the	O
lobular	O
architecture	O
was	O
preserved	O
.	O
This	O
case	O
represents	O
an	O
example	O
of	O
""""	O
idiosyncratic	O
""""	O
drug	B-Disease
-	I-Disease
induced	I-Disease
liver	I-Disease
damage	I-Disease
in	O
which	O
the	O
primary	O
target	O
of	O
injury	O
is	O
the	O
bile	O
duct	O
.	O
An	O
autoimmune	O
pathogenesis	O
of	O
the	O
bile	B-Disease
duct	I-Disease
destruction	I-Disease
is	O
suggested	O
.	O
Differential	O
effects	O
of	O
1	B-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
dihydropyridine	I-Chemical
calcium	B-Chemical
channel	I-Chemical
blockers	I-Chemical
:	O
therapeutic	O
implications	O
.	O
Increasing	O
recognition	O
of	O
the	O
importance	O
of	O
calcium	B-Chemical
in	O
the	O
pathogenesis	O
of	O
cardiovascular	B-Disease
disease	I-Disease
has	O
stimulated	O
research	O
into	O
the	O
use	O
of	O
calcium	B-Chemical
channel	I-Chemical
blocking	I-Chemical
agents	I-Chemical
for	O
treatment	O
of	O
a	O
variety	O
of	O
cardiovascular	B-Disease
diseases	I-Disease
.	O
The	O
favorable	O
efficacy	O
and	O
tolerability	O
profiles	O
of	O
these	O
agents	O
make	O
them	O
attractive	O
therapeutic	O
modalities	O
.	O
Clinical	O
applications	O
of	O
calcium	B-Chemical
channel	I-Chemical
blockers	I-Chemical
parallel	O
their	O
tissue	O
selectivity	O
.	O
In	O
contrast	O
to	O
verapamil	B-Chemical
and	O
diltiazem	B-Chemical
,	O
which	O
are	O
roughly	O
equipotent	O
in	O
their	O
actions	O
on	O
the	O
heart	O
and	O
vascular	O
smooth	O
muscle	O
,	O
the	O
dihydropyridine	B-Chemical
calcium	B-Chemical
channel	I-Chemical
blockers	I-Chemical
are	O
a	O
group	O
of	O
potent	O
peripheral	O
vasodilator	O
agents	O
that	O
exert	O
minimal	O
electrophysiologic	O
effects	O
on	O
cardiac	O
nodal	O
or	O
conduction	O
tissue	O
.	O
As	O
the	O
first	O
dihydropyridine	B-Chemical
available	O
for	O
use	O
in	O
the	O
United	O
States	O
,	O
nifedipine	B-Chemical
controls	O
angina	B-Disease
and	O
hypertension	B-Disease
with	O
minimal	O
depression	O
of	O
cardiac	O
function	O
.	O
Additional	O
members	O
of	O
this	O
group	O
of	O
calcium	B-Chemical
channel	I-Chemical
blockers	I-Chemical
have	O
been	O
studied	O
for	O
a	O
variety	O
of	O
indications	O
for	O
which	O
they	O
may	O
offer	O
advantages	O
over	O
current	O
therapy	O
.	O
Once	O
or	O
twice	O
daily	O
dosage	O
possible	O
with	O
nitrendipine	B-Chemical
and	O
nisoldipine	B-Chemical
offers	O
a	O
convenient	O
administration	O
schedule	O
,	O
which	O
encourages	O
patient	O
compliance	O
in	O
long	O
-	O
term	O
therapy	O
of	O
hypertension	B-Disease
.	O
The	O
coronary	O
vasodilating	O
properties	O
of	O
nisoldipine	B-Chemical
have	O
led	O
to	O
the	O
investigation	O
of	O
this	O
agent	O
for	O
use	O
in	O
angina	B-Disease
.	O
Selectivity	O
for	O
the	O
cerebrovascular	O
bed	O
makes	O
nimodipine	B-Chemical
potentially	O
useful	O
in	O
the	O
treatment	O
of	O
subarachnoid	B-Disease
hemorrhage	I-Disease
,	O
migraine	B-Disease
headache	I-Disease
,	O
dementia	B-Disease
,	O
and	O
stroke	B-Disease
.	O
In	O
general	O
,	O
the	O
dihydropyridine	B-Chemical
calcium	B-Chemical
channel	I-Chemical
blockers	I-Chemical
are	O
usually	O
well	O
tolerated	O
,	O
with	O
headache	B-Disease
,	O
facial	O
flushing	B-Disease
,	O
palpitations	B-Disease
,	O
edema	B-Disease
,	O
nausea	B-Disease
,	O
anorexia	B-Disease
,	O
and	O
dizziness	B-Disease
being	O
the	O
more	O
common	O
adverse	O
effects	O
.	O
The	O
enhancement	O
of	O
aminonucleoside	B-Chemical
nephrosis	B-Disease
by	O
the	O
co	O
-	O
administration	O
of	O
protamine	O
.	O
An	O
experimental	O
model	O
of	O
focal	B-Disease
segmental	I-Disease
glomerular	I-Disease
sclerosis	I-Disease
(	O
FSGS	B-Disease
)	O
was	O
developed	O
in	O
rats	O
by	O
the	O
combined	O
administration	O
of	O
puromycin	B-Chemical
-	I-Chemical
aminonucleoside	I-Chemical
(	O
AMNS	B-Chemical
)	O
and	O
protamine	B-Chemical
sulfate	I-Chemical
(	O
PS	B-Chemical
)	O
.	O
Male	O
Sprague	O
-	O
Dawley	O
rats	O
,	O
uninephrectomized	O
three	O
weeks	O
before	O
,	O
received	O
daily	O
injections	O
of	O
subcutaneous	O
AMNS	B-Chemical
(	O
1	O
mg	O
/	O
100	O
g	O
body	O
wt	O
)	O
and	O
intravenous	O
PS	B-Chemical
(	O
2	O
separated	O
doses	O
of	O
2	O
.	O
5	O
mg	O
/	O
100	O
g	O
body	O
wt	O
)	O
for	O
four	O
days	O
.	O
The	O
series	O
of	O
injections	O
were	O
repeated	O
another	O
three	O
times	O
at	O
10	O
day	O
intervals	O
.	O
The	O
animals	O
were	O
sacrificed	O
on	O
days	O
24	O
,	O
52	O
,	O
and	O
80	O
.	O
They	O
developed	O
nephrotic	B-Disease
syndrome	I-Disease
and	O
finally	O
renal	B-Disease
failure	I-Disease
.	O
The	O
time	O
-	O
course	O
curve	O
of	O
creatinine	B-Chemical
clearance	O
dropped	O
and	O
showed	O
significant	O
difference	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
from	O
that	O
of	O
each	O
control	O
group	O
,	O
such	O
as	O
,	O
AMNS	B-Chemical
alone	O
,	O
PS	B-Chemical
alone	O
or	O
saline	O
injected	O
.	O
Their	O
glomeruli	O
showed	O
changes	O
of	O
progressive	O
FSGS	B-Disease
.	O
The	O
ultrastructural	O
studies	O
in	O
the	O
initial	O
stage	O
revealed	O
significant	O
lack	O
of	O
particles	O
of	O
perfused	O
ruthenium	B-Chemical
red	O
on	O
the	O
lamina	O
rara	O
externa	O
and	O
marked	O
changes	O
in	O
epithelial	O
cell	O
cytoplasm	O
.	O
Therefore	O
,	O
it	O
is	O
suggested	O
that	O
the	O
administration	O
of	O
PS	B-Chemical
enhances	O
the	O
toxicity	B-Disease
of	O
AMNS	B-Chemical
on	O
the	O
glomerulus	O
and	O
readily	O
produces	O
progressive	O
FSGS	B-Disease
in	O
rats	O
resulting	O
in	O
the	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
.	O
Theophylline	B-Chemical
neurotoxicity	B-Disease
in	O
pregnant	O
rats	O
.	O
The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
whether	O
the	O
neurotoxicity	B-Disease
of	O
theophylline	B-Chemical
is	O
altered	O
in	O
advanced	O
pregnancy	O
.	O
Sprague	O
-	O
Dawley	O
rats	O
that	O
were	O
20	O
days	O
pregnant	O
and	O
nonpregnant	O
rats	O
of	O
the	O
same	O
age	O
and	O
strain	O
received	O
infusions	O
of	O
aminophylline	B-Chemical
until	O
onset	O
of	O
maximal	O
seizures	B-Disease
which	O
occurred	O
after	O
28	O
and	O
30	O
minutes	O
respectively	O
.	O
Theophylline	B-Chemical
concentrations	O
at	O
this	O
endpoint	O
in	O
serum	O
(	O
total	O
)	O
and	O
CSF	O
were	O
similar	O
but	O
serum	O
(	O
free	O
)	O
and	O
brain	O
concentrations	O
were	O
slightly	O
different	O
in	O
pregnant	O
rats	O
.	O
Theophylline	B-Chemical
serum	O
protein	O
binding	O
determined	O
by	O
equilibrium	O
dialysis	O
was	O
lower	O
in	O
pregnant	O
rats	O
.	O
Fetal	O
serum	O
concentrations	O
at	O
onset	O
of	O
seizures	B-Disease
in	O
the	O
mother	O
were	O
similar	O
to	O
maternal	O
brain	O
and	O
CSF	O
concentrations	O
and	O
correlated	O
significantly	O
with	O
the	O
former	O
.	O
It	O
is	O
concluded	O
that	O
advanced	O
pregnancy	O
has	O
a	O
negligible	O
effect	O
on	O
the	O
neurotoxic	B-Disease
response	O
to	O
theophylline	B-Chemical
in	O
rats	O
.	O
Hyperkalemia	B-Disease
induced	O
by	O
indomethacin	B-Chemical
and	O
naproxen	B-Chemical
and	O
reversed	O
by	O
fludrocortisone	B-Chemical
.	O
We	O
have	O
described	O
a	O
patient	O
with	O
severe	O
rheumatoid	B-Disease
arthritis	I-Disease
and	O
a	O
history	O
of	O
mefenamic	B-Chemical
acid	I-Chemical
nephropathy	B-Disease
in	O
whom	O
hyperkalemia	B-Disease
and	O
inappropriate	O
hypoaldosteronism	B-Disease
were	O
caused	O
by	O
both	O
indomethacin	B-Chemical
and	O
naproxen	B-Chemical
,	O
without	O
major	O
decline	O
in	O
renal	O
function	O
.	O
It	O
is	O
likely	O
that	O
preexisting	O
renal	B-Disease
disease	I-Disease
predisposed	O
this	O
patient	O
to	O
type	B-Disease
IV	I-Disease
renal	I-Disease
tubular	I-Disease
acidosis	I-Disease
with	O
prostaglandin	B-Chemical
synthetase	O
inhibitors	O
.	O
Because	O
he	O
was	O
unable	O
to	O
discontinue	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
therapy	O
,	O
fludrocortisone	B-Chemical
was	O
added	O
,	O
correcting	O
the	O
hyperkalemia	B-Disease
and	O
allowing	O
indomethacin	B-Chemical
therapy	O
to	O
be	O
continued	O
safely	O
.	O
Hypotension	B-Disease
as	O
a	O
manifestation	O
of	O
cardiotoxicity	B-Disease
in	O
three	O
patients	O
receiving	O
cisplatin	B-Chemical
and	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
.	O
Cardiac	O
symptoms	O
,	O
including	O
hypotension	B-Disease
,	O
developed	O
in	O
three	O
patients	O
with	O
advanced	O
colorectal	B-Disease
carcinoma	I-Disease
while	O
being	O
treated	O
with	O
cisplatin	B-Chemical
(	O
CDDP	B-Chemical
)	O
and	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
.	O
In	O
two	O
patients	O
,	O
hypotension	B-Disease
was	O
associated	O
with	O
severe	O
left	B-Disease
ventricular	I-Disease
dysfunction	I-Disease
.	O
All	O
three	O
patients	O
required	O
therapy	O
discontinuation	O
.	O
Cardiac	O
enzymes	O
remained	O
normal	O
despite	O
transient	O
electrocardiographic	O
(	O
EKG	O
)	O
changes	O
.	O
The	O
presentation	O
and	O
cardiac	O
evaluation	O
(	O
hemodynamic	O
,	O
echocardiographic	O
,	O
and	O
scintigraphic	O
)	O
of	O
these	O
patients	O
suggest	O
new	O
manifestations	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
cardiotoxicity	B-Disease
that	O
may	O
be	O
influenced	O
by	O
CDDP	B-Chemical
.	O
The	O
possible	O
pathophysiologic	O
mechanisms	O
are	O
discussed	O
.	O
Fatal	O
aplastic	B-Disease
anemia	I-Disease
in	O
a	O
patient	O
treated	O
with	O
carbamazepine	B-Chemical
.	O
A	O
case	O
of	O
fatal	O
aplastic	B-Disease
anemia	I-Disease
due	O
to	O
carbamazepine	B-Chemical
treatment	O
in	O
an	O
epileptic	B-Disease
woman	O
is	O
reported	O
.	O
Despite	O
concerns	O
of	O
fatal	O
bone	B-Disease
marrow	I-Disease
toxicity	I-Disease
due	O
to	O
carbamazepine	B-Chemical
,	O
this	O
is	O
only	O
the	O
fourth	O
documented	O
and	O
published	O
report	O
.	O
Carbamazepine	B-Chemical
is	O
a	O
safe	O
drug	O
,	O
but	O
physicians	O
and	O
patients	O
should	O
be	O
aware	O
of	O
the	O
exceedingly	O
rare	O
but	O
potentially	O
fatal	O
side	O
effects	O
,	O
better	O
prevented	O
by	O
clinical	O
than	O
by	O
laboratory	O
monitoring	O
.	O
Participation	O
of	O
a	O
bulbospinal	O
serotonergic	O
pathway	O
in	O
the	O
rat	O
brain	O
in	O
clonidine	B-Chemical
-	O
induced	O
hypotension	B-Disease
and	O
bradycardia	B-Disease
.	O
The	O
effects	O
of	O
microinjection	O
of	O
clonidine	B-Chemical
(	O
1	O
-	O
10	O
micrograms	O
in	O
1	O
microliter	O
)	O
into	O
a	O
region	O
adjacent	O
to	O
the	O
ventrolateral	O
surface	O
of	O
the	O
medulla	O
oblongata	O
on	O
cardiovascular	O
function	O
were	O
assessed	O
in	O
urethane	B-Chemical
-	O
anesthetized	O
rats	O
.	O
Intramedullary	O
administration	O
of	O
clonidine	B-Chemical
,	O
but	O
not	O
saline	O
vehicle	O
,	O
caused	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
both	O
the	O
mean	O
arterial	O
pressure	O
and	O
the	O
heart	O
rate	O
.	O
The	O
clonidine	B-Chemical
-	O
induced	O
hypotension	B-Disease
was	O
antagonized	O
by	O
prior	O
spinal	O
transection	O
,	O
but	O
not	O
bilateral	O
vagotomy	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
clonidine	B-Chemical
-	O
induced	O
bradycardia	B-Disease
was	O
antagonized	O
by	O
prior	O
bilateral	O
vagotomy	O
,	O
but	O
not	O
spinal	O
transection	O
.	O
Furthermore	O
,	O
selective	O
destruction	O
of	O
the	O
spinal	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
nerves	O
,	O
produced	O
by	O
bilateral	O
spinal	O
injection	O
of	O
5	B-Chemical
,	I-Chemical
7	I-Chemical
-	I-Chemical
dihydroxytryptamine	I-Chemical
,	O
reduced	O
the	O
magnitude	O
of	O
the	O
vasodepressor	O
or	O
the	O
bradycardiac	B-Disease
responses	O
to	O
clonidine	B-Chemical
microinjected	O
into	O
the	O
area	O
near	O
the	O
ventrolateral	O
surface	O
of	O
the	O
medulla	O
oblongata	O
in	O
rats	O
.	O
The	O
data	O
indicate	O
that	O
a	O
bulbospinal	O
serotonergic	O
pathway	O
is	O
involved	O
in	O
development	O
of	O
clonidine	B-Chemical
-	O
induced	O
hypotension	B-Disease
and	O
bradycardia	B-Disease
.	O
The	O
induced	O
hypotension	B-Disease
is	O
brought	O
about	O
by	O
a	O
decrease	O
in	O
sympathetic	O
efferent	O
activity	O
,	O
whereas	O
the	O
induced	O
bradycardia	B-Disease
was	O
due	O
to	O
an	O
increase	O
in	O
vagal	O
efferent	O
activity	O
.	O
Hypertension	B-Disease
in	O
neuroblastoma	B-Disease
induced	O
by	O
imipramine	B-Chemical
.	O
Hypertension	B-Disease
is	O
a	O
well	O
-	O
known	O
finding	O
in	O
some	O
patients	O
with	O
neuroblastoma	B-Disease
.	O
However	O
,	O
it	O
has	O
not	O
previously	O
been	O
described	O
in	O
association	O
with	O
the	O
use	O
of	O
Imipramine	B-Chemical
.	O
We	O
report	O
the	O
occurrence	O
of	O
severe	O
hypertension	B-Disease
(	O
blood	O
pressure	O
190	O
/	O
160	O
)	O
in	O
a	O
4	O
-	O
year	O
-	O
old	O
girl	O
with	O
neuroblastoma	B-Disease
who	O
was	O
given	O
Imipramine	B-Chemical
to	O
control	O
a	O
behavior	B-Disease
disorder	I-Disease
.	O
It	O
was	O
determined	O
later	O
that	O
this	O
patient	O
'	O
s	O
tumor	B-Disease
was	O
recurring	O
at	O
the	O
time	O
of	O
her	O
hypertensive	B-Disease
episode	O
.	O
Since	O
she	O
had	O
no	O
blood	O
pressure	O
elevation	O
at	O
initial	O
diagnosis	O
and	O
none	O
following	O
discontinuation	O
of	O
the	O
Imipramine	B-Chemical
(	O
when	O
she	O
was	O
in	O
florid	O
relapse	O
)	O
,	O
we	O
believe	O
that	O
this	O
drug	O
rather	O
than	O
her	O
underlying	O
disease	O
alone	O
caused	O
her	O
hypertension	B-Disease
.	O
The	O
mechanism	O
for	O
this	O
reaction	O
is	O
believed	O
to	O
be	O
increased	O
levels	O
of	O
vasoactive	O
catecholamines	B-Chemical
due	O
to	O
interference	O
of	O
their	O
physiologic	O
inactivation	O
by	O
Imipramine	B-Chemical
.	O
From	O
this	O
experience	O
,	O
we	O
urge	O
extreme	O
caution	O
in	O
the	O
use	O
of	O
tricyclic	O
antidepressants	O
in	O
children	O
with	O
active	O
neuroblastoma	B-Disease
.	O
Rechallenge	O
of	O
patients	O
who	O
developed	O
oral	B-Disease
candidiasis	I-Disease
or	O
hoarseness	B-Disease
with	O
beclomethasone	B-Chemical
dipropionate	I-Chemical
.	O
Of	O
158	O
asthmatic	B-Disease
patients	O
who	O
were	O
placed	O
on	O
inhaled	O
beclomethasone	B-Chemical
,	O
15	O
(	O
9	O
.	O
5	O
%	O
)	O
developed	O
either	O
hoarseness	B-Disease
(	O
8	O
)	O
,	O
oral	O
thrush	B-Disease
(	O
6	O
)	O
,	O
or	O
both	O
(	O
1	O
)	O
.	O
When	O
their	O
adverse	O
reactions	O
subsided	O
,	O
seven	O
of	O
these	O
15	O
patients	O
were	O
rechallenged	O
with	O
inhaled	O
beclomethasone	B-Chemical
.	O
These	O
included	O
five	O
cases	O
who	O
developed	O
hoarseness	B-Disease
and	O
three	O
who	O
developed	O
Candidiasis	B-Disease
.	O
One	O
patient	O
had	O
both	O
.	O
Oral	O
thrush	B-Disease
did	O
not	O
recur	O
,	O
but	O
60	O
%	O
(	O
3	O
/	O
5	O
)	O
of	O
patients	O
with	O
hoarseness	B-Disease
had	O
recurrence	O
.	O
We	O
conclude	O
that	O
patients	O
may	O
be	O
restarted	O
on	O
inhaled	O
beclomethasone	B-Chemical
when	O
clinically	O
indicated	O
;	O
however	O
,	O
because	O
of	O
the	O
high	O
recurrence	O
rate	O
,	O
patients	O
who	O
develop	O
hoarseness	B-Disease
should	O
not	O
be	O
re	O
-	O
challenged	O
.	O
Concomitant	O
use	O
of	O
oral	O
prednisone	B-Chemical
and	O
topical	O
beclomethasone	B-Chemical
may	O
increase	O
the	O
risk	O
of	O
developing	O
hoarseness	B-Disease
or	O
candidiasis	B-Disease
.	O
Cyclophosphamide	B-Chemical
cardiotoxicity	B-Disease
:	O
an	O
analysis	O
of	O
dosing	O
as	O
a	O
risk	O
factor	O
.	O
Patients	O
who	O
undergo	O
bone	O
marrow	O
transplantation	O
are	O
generally	O
immunosuppressed	O
with	O
a	O
dose	O
of	O
cyclophosphamide	B-Chemical
(	O
CYA	B-Chemical
)	O
which	O
is	O
usually	O
calculated	O
based	O
on	O
the	O
patient	O
'	O
s	O
weight	O
.	O
At	O
these	O
high	O
doses	O
of	O
CYA	B-Chemical
,	O
serious	O
cardiotoxicity	B-Disease
may	O
occur	O
,	O
but	O
definitive	O
risk	O
factors	O
for	O
the	O
development	O
of	O
such	O
cardiotoxicity	B-Disease
have	O
not	O
been	O
described	O
.	O
Since	O
chemotherapeutic	O
agent	O
toxicity	B-Disease
generally	O
correlates	O
with	O
dose	O
per	O
body	O
surface	O
area	O
,	O
we	O
retrospectively	O
calculated	O
the	O
dose	O
of	O
CYA	B-Chemical
in	O
patients	O
transplanted	O
at	O
our	O
institution	O
to	O
determine	O
whether	O
the	O
incidence	O
of	O
CYA	B-Chemical
cardiotoxicity	B-Disease
correlated	O
with	O
the	O
dose	O
per	O
body	O
surface	O
area	O
.	O
Eighty	O
patients	O
who	O
were	O
to	O
receive	O
CYA	B-Chemical
50	O
mg	O
/	O
kg	O
/	O
d	O
for	O
four	O
days	O
as	O
preparation	O
for	O
marrow	O
grafting	O
underwent	O
a	O
total	O
of	O
84	O
transplants	O
for	O
aplastic	B-Disease
anemia	I-Disease
,	O
Wiskott	B-Disease
-	I-Disease
Aldrich	I-Disease
syndrome	I-Disease
,	O
or	O
severe	B-Disease
combined	I-Disease
immunodeficiency	I-Disease
syndrome	I-Disease
.	O
Fourteen	O
of	O
84	O
(	O
17	O
%	O
)	O
patients	O
had	O
symptoms	O
and	O
signs	O
consistent	O
with	O
CYA	B-Chemical
cardiotoxicity	B-Disease
within	O
ten	O
days	O
of	O
receiving	O
1	O
to	O
4	O
doses	O
of	O
CYA	B-Chemical
.	O
Six	O
of	O
the	O
14	O
patients	O
died	O
with	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
.	O
The	O
dose	O
of	O
CYA	B-Chemical
per	O
body	O
surface	O
area	O
was	O
calculated	O
for	O
all	O
patients	O
and	O
the	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
based	O
on	O
daily	O
CYA	B-Chemical
dose	O
:	O
Group	O
1	O
,	O
CYA	B-Chemical
less	O
than	O
or	O
equal	O
to	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
;	O
Group	O
2	O
,	O
CYA	B-Chemical
greater	O
than	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
.	O
Cardiotoxicity	B-Disease
that	O
was	O
thought	O
to	O
be	O
related	O
to	O
CYA	B-Chemical
occurred	O
in	O
1	O
/	O
32	O
(	O
3	O
%	O
)	O
of	O
patients	O
in	O
Group	O
1	O
and	O
in	O
13	O
/	O
52	O
(	O
25	O
%	O
)	O
patients	O
in	O
Group	O
2	O
(	O
P	O
less	O
than	O
0	O
.	O
025	O
)	O
.	O
Congestive	B-Disease
heart	I-Disease
failure	I-Disease
caused	O
or	O
contributed	O
to	O
death	O
in	O
0	O
/	O
32	O
patients	O
in	O
Group	O
1	O
v	O
6	O
/	O
52	O
(	O
12	O
%	O
)	O
of	O
patients	O
in	O
Group	O
2	O
(	O
P	O
less	O
than	O
0	O
.	O
25	O
)	O
.	O
There	O
was	O
no	O
difference	O
in	O
the	O
rate	O
of	O
engraftment	O
of	O
evaluable	O
patients	O
in	O
the	O
two	O
groups	O
(	O
P	O
greater	O
than	O
0	O
.	O
5	O
)	O
.	O
We	O
conclude	O
that	O
the	O
CYA	B-Chemical
cardiotoxicity	B-Disease
correlates	O
with	O
CYA	B-Chemical
dosage	O
as	O
calculated	O
by	O
body	O
surface	O
area	O
,	O
and	O
that	O
patients	O
with	O
aplastic	B-Disease
anemia	I-Disease
and	O
immunodeficiencies	B-Disease
can	O
be	O
effectively	O
prepared	O
for	O
bone	O
marrow	O
grafting	O
at	O
a	O
CYA	B-Chemical
dose	O
of	O
1	O
.	O
55	O
g	O
/	O
m2	O
/	O
d	O
for	O
four	O
days	O
with	O
a	O
lower	O
incidence	O
of	O
cardiotoxicity	B-Disease
than	O
patients	O
whose	O
CYA	B-Chemical
dosage	O
is	O
calculated	O
based	O
on	O
weight	O
.	O
This	O
study	O
reaffirms	O
the	O
principle	O
that	O
drug	O
toxicity	B-Disease
correlates	O
with	O
dose	O
per	O
body	O
surface	O
area	O
.	O
Studies	O
of	O
risk	O
factors	O
for	O
aminoglycoside	B-Chemical
nephrotoxicity	B-Disease
.	O
The	O
epidemiology	O
of	O
aminoglycoside	B-Chemical
-	O
induced	O
nephrotoxicity	B-Disease
is	O
not	O
fully	O
understood	O
.	O
Experimental	O
studies	O
in	O
healthy	O
human	O
volunteers	O
indicate	O
aminoglycosides	B-Chemical
cause	O
proximal	O
tubular	O
damage	O
in	O
most	O
patients	O
,	O
but	O
rarely	O
,	O
if	O
ever	O
,	O
cause	O
glomerular	B-Disease
or	I-Disease
tubular	I-Disease
dysfunction	I-Disease
.	O
Clinical	O
trials	O
of	O
aminoglycosides	B-Chemical
in	O
seriously	O
ill	O
patients	O
indicate	O
that	O
the	O
relative	O
risk	O
for	O
developing	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
during	O
therapy	O
ranges	O
from	O
8	O
to	O
10	O
and	O
that	O
the	O
attributable	O
risk	O
is	O
70	O
%	O
to	O
80	O
%	O
.	O
Further	O
analysis	O
of	O
these	O
data	O
suggests	O
that	O
the	O
duration	O
of	O
therapy	O
,	O
plasma	O
aminoglycoside	B-Chemical
levels	O
,	O
liver	B-Disease
disease	I-Disease
,	O
advanced	O
age	O
,	O
high	O
initial	O
estimated	O
creatinine	B-Chemical
clearance	O
and	O
,	O
possibly	O
,	O
female	O
gender	O
all	O
increase	O
the	O
risk	O
for	O
nephrotoxicity	B-Disease
.	O
Other	O
causes	O
of	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
,	O
such	O
as	O
shock	B-Disease
,	O
appear	O
to	O
have	O
an	O
additive	O
effect	O
.	O
Predictive	O
models	O
have	O
been	O
developed	O
from	O
these	O
analyses	O
that	O
should	O
be	O
useful	O
for	O
identifying	O
patients	O
at	O
high	O
risk	O
.	O
These	O
models	O
may	O
also	O
be	O
useful	O
in	O
developing	O
insights	O
into	O
the	O
pathophysiology	O
of	O
aminoglycoside	B-Chemical
-	O
induced	O
nephrotoxicity	B-Disease
.	O
Central	O
action	O
of	O
narcotic	O
analgesics	O
.	O
Part	O
IV	O
.	O
Noradrenergic	O
influences	O
on	O
the	O
activity	O
of	O
analgesics	O
in	O
rats	O
.	O
The	O
effect	O
of	O
clonidine	B-Chemical
,	O
naphazoline	B-Chemical
and	O
xylometazoline	B-Chemical
on	O
analgesia	O
induced	O
by	O
morphine	B-Chemical
,	O
codeine	B-Chemical
,	O
fentanyl	B-Chemical
and	O
pentazocine	B-Chemical
,	O
and	O
on	O
cataleptic	B-Disease
effect	O
of	O
morphine	B-Chemical
,	O
codine	B-Chemical
and	O
fentanyl	B-Chemical
was	O
studied	O
in	O
rats	O
.	O
The	O
biochemical	O
assays	O
on	O
the	O
influence	O
of	O
four	O
analgesics	O
on	O
the	O
brain	O
concentration	O
and	O
turnover	O
of	O
noradrenaline	B-Chemical
(	O
)	O
were	O
also	O
performed	O
.	O
It	O
was	O
found	O
that	O
three	O
drugs	O
stimulating	O
central	O
receptors	O
failed	O
to	O
affect	O
the	O
analgesic	O
ED50	O
of	O
all	O
antinociceptive	O
agents	O
and	O
they	O
enhanced	O
catalepsy	B-Disease
induced	O
by	O
morphine	B-Chemical
and	O
fentanyl	B-Chemical
.	O
Codeine	B-Chemical
catalepsy	B-Disease
was	O
increased	O
by	O
clonidine	B-Chemical
and	O
decreased	O
by	O
naphazoline	B-Chemical
and	O
xylometazoline	B-Chemical
.	O
The	O
brain	O
concentration	O
of	O
was	O
not	O
changed	O
by	O
morphine	B-Chemical
and	O
fentanyl	B-Chemical
,	O
but	O
one	O
of	O
the	O
doses	O
of	O
codeine	B-Chemical
(	O
45	O
mg	O
/	O
kg	O
)	O
slightly	O
enhanced	O
it	O
.	O
Pentazocine	B-Chemical
dose	O
-	O
dependently	O
decreased	O
the	O
brain	O
level	O
of	O
.	O
The	O
rate	O
of	O
turnover	O
was	O
not	O
altered	O
by	O
analgesics	O
except	O
for	O
the	O
higher	O
dose	O
of	O
fentanyl	B-Chemical
(	O
0	O
.	O
2	O
mg	O
/	O
kg	O
)	O
following	O
which	O
the	O
disappearance	O
of	O
from	O
the	O
brain	O
was	O
diminished	O
.	O
The	O
results	O
are	O
discussed	O
in	O
the	O
light	O
of	O
various	O
and	O
non	O
-	O
uniform	O
data	O
from	O
the	O
literature	O
.	O
It	O
is	O
suggested	O
that	O
in	O
rats	O
the	O
brain	O
plays	O
a	O
less	O
important	O
function	O
than	O
the	O
other	O
monoamines	B-Chemical
in	O
the	O
behavioural	O
activity	O
of	O
potent	O
analgesics	O
.	O
Flurothyl	B-Chemical
seizure	B-Disease
thresholds	O
in	O
mice	O
treated	O
neonatally	O
with	O
a	O
single	O
injection	O
of	O
monosodium	B-Chemical
glutamate	I-Chemical
(	O
MSG	B-Chemical
)	O
:	O
evaluation	O
of	O
experimental	O
parameters	O
in	O
flurothyl	B-Chemical
seizure	B-Disease
testing	O
.	O
Monosodium	B-Chemical
glutamate	I-Chemical
(	O
MSG	B-Chemical
)	O
administration	O
to	O
neonatal	O
rodents	O
produces	O
convulsions	B-Disease
and	O
results	O
in	O
numerous	O
biochemical	O
and	O
behavioral	O
deficits	O
.	O
These	O
studies	O
were	O
undertaken	O
to	O
determine	O
if	O
neonatal	O
administration	O
of	O
MSG	B-Chemical
produced	O
permanent	O
alterations	O
in	O
seizure	B-Disease
susceptibility	O
,	O
since	O
previous	O
investigations	O
were	O
inconclusive	O
.	O
A	O
flurothyl	B-Chemical
ether	B-Chemical
seizure	B-Disease
screening	O
technique	O
was	O
used	O
to	O
evaluate	O
seizure	B-Disease
susceptibility	O
in	O
adult	O
mice	O
that	O
received	O
neonatal	O
injections	O
of	O
MSG	B-Chemical
(	O
4	O
mg	O
/	O
g	O
and	O
1	O
mg	O
/	O
g	O
)	O
.	O
MSG	B-Chemical
treatment	O
resulted	O
in	O
significant	O
reductions	O
in	O
whole	O
brain	O
weight	O
but	O
did	O
not	O
alter	O
seizure	B-Disease
threshold	O
.	O
A	O
naloxone	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
)	O
challenge	O
was	O
also	O
ineffective	O
in	O
altering	O
the	O
seizure	B-Disease
thresholds	O
of	O
either	O
control	O
of	O
MSG	B-Chemical
-	O
treated	O
mice	O
.	O
Flurothyl	B-Chemical
ether	B-Chemical
produced	O
hypothermia	B-Disease
which	O
was	O
correlated	O
with	O
the	O
duration	O
of	O
flurothyl	B-Chemical
exposure	O
;	O
however	O
,	O
the	O
relationship	O
of	O
hypothermia	B-Disease
to	O
seizure	B-Disease
induction	O
was	O
unclear	O
.	O
Flurothyl	B-Chemical
seizure	B-Disease
testing	O
proved	O
to	O
be	O
a	O
rapid	O
and	O
reliable	O
technique	O
with	O
which	O
to	O
evaluate	O
seizure	B-Disease
susceptibility	O
.	O
Susceptibility	O
to	O
seizures	B-Disease
produced	O
by	O
pilocarpine	B-Chemical
in	O
rats	O
after	O
microinjection	O
of	O
isoniazid	B-Chemical
or	O
gamma	B-Chemical
-	I-Chemical
vinyl	I-Chemical
-	I-Chemical
GABA	I-Chemical
into	O
the	O
substantia	O
nigra	O
.	O
Pilocarpine	B-Chemical
,	O
given	O
intraperitoneally	O
to	O
rats	O
,	O
reproduces	O
the	O
neuropathological	O
sequelae	O
of	O
temporal	B-Disease
lobe	I-Disease
epilepsy	I-Disease
and	O
provides	O
a	O
relevant	O
animal	O
model	O
for	O
studying	O
mechanisms	O
of	O
buildup	O
of	O
convulsive	B-Disease
activity	O
and	O
pathways	O
operative	O
in	O
the	O
generalization	O
and	O
propagation	O
of	O
seizures	B-Disease
within	O
the	O
forebrain	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
manipulating	O
the	O
activity	O
of	O
the	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
(	O
GABA	B-Chemical
)	O
-	O
mediated	O
synaptic	O
inhibition	O
within	O
the	O
substantia	O
nigra	O
on	O
seizures	B-Disease
produced	O
by	O
pilocarpine	B-Chemical
in	O
rats	O
,	O
were	O
investigated	O
.	O
In	O
animals	O
pretreated	O
with	O
microinjections	O
of	O
isoniazid	B-Chemical
,	O
150	O
micrograms	O
,	O
an	O
inhibitor	O
of	O
activity	O
of	O
the	O
GABA	B-Chemical
-	O
synthesizing	O
enzyme	O
,	O
L	B-Chemical
-	I-Chemical
glutamic	I-Chemical
acid	I-Chemical
decarboxylase	O
,	O
into	O
the	O
substantia	O
nigra	O
pars	O
reticulata	O
(	O
SNR	O
)	O
,	O
bilaterally	O
,	O
non	O
-	O
convulsant	O
doses	O
of	O
pilocarpine	B-Chemical
,	O
100	O
and	O
200	O
mg	O
/	O
kg	O
,	O
resulted	O
in	O
severe	O
motor	O
limbic	O
seizures	B-Disease
and	O
status	B-Disease
epilepticus	I-Disease
.	O
Electroencephalographic	O
and	O
behavioral	O
monitoring	O
revealed	O
a	O
profound	O
reduction	O
of	O
the	O
threshold	O
for	O
pilocarpine	B-Chemical
-	O
induced	O
convulsions	B-Disease
.	O
Morphological	O
analysis	O
of	O
frontal	O
forebrain	O
sections	O
with	O
light	O
microscopy	O
revealed	O
seizure	B-Disease
-	O
related	O
damage	O
to	O
the	O
hippocampal	O
formation	O
,	O
thalamus	O
,	O
amygdala	O
,	O
olfactory	O
cortex	O
,	O
substantia	O
nigra	O
and	O
neocortex	O
,	O
which	O
is	O
typically	O
observed	O
with	O
pilocarpine	B-Chemical
in	O
doses	O
exceeding	O
350	O
mg	O
/	O
kg	O
.	O
Bilateral	O
intrastriatal	O
injections	O
of	O
isoniazid	B-Chemical
did	O
not	O
augment	O
seizures	B-Disease
produced	O
by	O
pilocarpine	B-Chemical
,	O
200	O
mg	O
/	O
kg	O
.	O
Application	O
of	O
an	O
irreversible	O
inhibitor	O
of	O
GABA	B-Chemical
transaminase	O
,	O
gamma	B-Chemical
-	I-Chemical
vinyl	I-Chemical
-	I-Chemical
GABA	I-Chemical
(	O
D	B-Chemical
,	I-Chemical
L	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
amino	I-Chemical
-	I-Chemical
hex	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
enoic	I-Chemical
acid	I-Chemical
)	O
,	O
5	O
micrograms	O
,	O
into	O
the	O
SNR	O
,	O
bilaterally	O
,	O
suppressed	O
the	O
appearance	O
of	O
electrographic	O
and	O
behavioral	O
seizures	B-Disease
produced	O
by	O
pilocarpine	B-Chemical
,	O
380	O
mg	O
/	O
kg	O
.	O
This	O
treatment	O
was	O
also	O
sufficient	O
to	O
protect	O
animals	O
from	O
the	O
occurrence	O
of	O
brain	B-Disease
damage	I-Disease
.	O
Microinjections	O
of	O
gamma	B-Chemical
-	I-Chemical
vinyl	I-Chemical
-	I-Chemical
GABA	I-Chemical
,	O
5	O
micrograms	O
,	O
into	O
the	O
dorsal	O
striatum	O
,	O
bilaterally	O
,	O
failed	O
to	O
prevent	O
the	O
development	O
of	O
convulsions	B-Disease
produced	O
by	O
pilocarpine	B-Chemical
,	O
380	O
mg	O
/	O
kg	O
.	O
The	O
results	O
demonstrate	O
that	O
the	O
threshold	O
for	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
in	O
rats	O
is	O
subjected	O
to	O
the	O
regulation	O
of	O
the	O
GABA	B-Chemical
-	O
mediated	O
synaptic	O
inhibition	O
within	O
the	O
substantia	O
nigra	O
.	O
Human	O
and	O
canine	O
ventricular	O
vasoactive	O
intestinal	O
polypeptide	O
:	O
decrease	O
with	O
heart	B-Disease
failure	I-Disease
.	O
Vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
is	O
a	O
systemic	O
and	O
coronary	O
vasodilator	O
that	O
may	O
have	O
positive	O
inotropic	O
properties	O
.	O
Myocardial	O
levels	O
of	O
VIP	O
were	O
assayed	O
before	O
and	O
after	O
the	O
development	O
of	O
heart	B-Disease
failure	I-Disease
in	O
two	O
canine	O
models	O
.	O
In	O
the	O
first	O
,	O
cobalt	B-Chemical
cardiomyopathy	B-Disease
was	O
induced	O
in	O
eight	O
dogs	O
;	O
VIP	O
(	O
by	O
radioimmunoassay	O
)	O
decreased	O
from	O
35	O
+	O
/	O
-	O
11	O
pg	O
/	O
mg	O
protein	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
to	O
5	O
+	O
/	O
-	O
4	O
pg	O
/	O
mg	O
protein	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
In	O
six	O
dogs	O
with	O
doxorubicin	B-Chemical
-	O
induced	O
heart	B-Disease
failure	I-Disease
,	O
VIP	O
decreased	O
from	O
31	O
+	O
/	O
-	O
7	O
to	O
11	O
+	O
/	O
-	O
4	O
pg	O
/	O
mg	O
protein	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
In	O
addition	O
,	O
VIP	O
content	O
of	O
left	O
ventricular	O
muscle	O
of	O
resected	O
failing	O
hearts	O
in	O
10	O
patients	O
receiving	O
a	O
heart	O
transplant	O
was	O
compared	O
with	O
the	O
papillary	O
muscles	O
in	O
14	O
patients	O
(	O
five	O
with	O
rheumatic	B-Disease
disease	I-Disease
,	O
nine	O
with	O
myxomatous	B-Disease
degeneration	I-Disease
)	O
receiving	O
mitral	O
valve	O
prostheses	O
.	O
The	O
lowest	O
myocardial	O
VIP	O
concentration	O
was	O
found	O
in	O
the	O
hearts	O
of	O
patients	O
with	O
coronary	B-Disease
disease	I-Disease
(	O
one	O
patient	O
receiving	O
a	O
transplant	O
and	O
three	O
receiving	O
mitral	O
prostheses	O
)	O
(	O
6	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
pg	O
/	O
mg	O
protein	O
)	O
.	O
The	O
other	O
patients	O
undergoing	O
transplantation	O
had	O
an	O
average	O
ejection	O
fraction	O
of	O
17	O
%	O
+	O
/	O
-	O
6	O
%	O
and	O
a	O
VIP	O
level	O
of	O
8	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
9	O
pg	O
/	O
mg	O
protein	O
.	O
The	O
hearts	O
without	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
(	O
average	O
ejection	O
fraction	O
of	O
this	O
group	O
62	O
%	O
+	O
/	O
-	O
10	O
%	O
)	O
had	O
a	O
VIP	O
concentration	O
of	O
14	O
.	O
1	O
+	O
/	O
-	O
7	O
.	O
9	O
pg	O
/	O
mg	O
protein	O
,	O
and	O
this	O
was	O
greater	O
than	O
in	O
hearts	O
of	O
the	O
patients	O
with	O
coronary	B-Disease
disease	I-Disease
and	O
the	O
hearts	O
of	O
patients	O
receiving	O
a	O
transplant	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
Myocardial	O
catecholamines	B-Chemical
were	O
also	O
determined	O
in	O
14	O
subjects	O
;	O
a	O
weak	O
correlation	O
(	O
r	O
=	O
0	O
.	O
57	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
between	O
the	O
tissue	O
concentrations	O
of	O
VIP	O
and	O
norepinephrine	B-Chemical
was	O
noted	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Non	O
-	O
invasive	O
detection	O
of	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
by	O
body	O
surface	O
electrocardiographic	O
mapping	O
after	O
dipyridamole	B-Chemical
infusion	O
.	O
Electrocardiographic	O
changes	O
after	O
dipyridamole	B-Chemical
infusion	O
(	O
0	O
.	O
568	O
mg	O
/	O
kg	O
/	O
4	O
min	O
)	O
were	O
studied	O
in	O
41	O
patients	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
and	O
compared	O
with	O
those	O
after	O
submaximal	O
treadmill	O
exercise	O
by	O
use	O
of	O
the	O
body	O
surface	O
mapping	O
technique	O
.	O
Patients	O
were	O
divided	O
into	O
three	O
groups	O
;	O
19	O
patients	O
without	O
myocardial	B-Disease
infarction	I-Disease
(	O
non	O
-	O
MI	B-Disease
group	O
)	O
,	O
14	O
with	O
anterior	B-Disease
infarction	I-Disease
(	O
ANT	B-Disease
-	I-Disease
MI	I-Disease
)	O
and	O
eight	O
with	O
inferior	B-Disease
infarction	I-Disease
(	O
INF	B-Disease
-	I-Disease
MI	I-Disease
)	O
.	O
Eighty	O
-	O
seven	O
unipolar	O
electrocardiograms	O
(	O
ECGs	O
)	O
distributed	O
over	O
the	O
entire	O
thoracic	O
surface	O
were	O
simultaneously	O
recorded	O
.	O
After	O
dipyridamole	B-Chemical
,	O
ischemic	B-Disease
ST	O
-	O
segment	O
depression	B-Disease
(	O
0	O
.	O
05	O
mV	O
or	O
more	O
)	O
was	O
observed	O
in	O
84	O
%	O
of	O
the	O
non	O
-	O
MI	B-Disease
group	O
,	O
29	O
%	O
of	O
the	O
ANT	B-Disease
-	I-Disease
MI	I-Disease
group	O
,	O
63	O
%	O
of	O
the	O
INF	B-Disease
-	I-Disease
MI	I-Disease
group	O
and	O
61	O
%	O
of	O
the	O
total	O
population	O
.	O
Exercise	O
-	O
induced	O
ST	O
depression	B-Disease
was	O
observed	O
in	O
84	O
%	O
of	O
the	O
non	O
-	O
MI	B-Disease
group	O
,	O
43	O
%	O
of	O
the	O
ANT	B-Disease
-	I-Disease
MI	I-Disease
group	O
,	O
38	O
%	O
of	O
the	O
INF	B-Disease
-	I-Disease
MI	I-Disease
group	O
and	O
61	O
%	O
of	O
the	O
total	O
.	O
For	O
individual	O
patients	O
,	O
there	O
were	O
no	O
obvious	O
differences	O
between	O
the	O
body	O
surface	O
distribution	O
of	O
ST	O
depression	B-Disease
in	O
both	O
tests	O
.	O
The	O
increase	O
in	O
pressure	O
rate	O
product	O
after	O
dipyridamole	B-Chemical
was	O
significantly	O
less	O
than	O
that	O
during	O
the	O
treadmill	O
exercise	O
.	O
The	O
data	O
suggest	O
that	O
the	O
dipyridamole	B-Chemical
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
is	O
caused	O
by	O
the	O
inhomogenous	O
distribution	O
of	O
myocardial	O
blood	O
flow	O
.	O
We	O
conclude	O
that	O
the	O
dipyridamole	B-Chemical
ECG	O
test	O
is	O
as	O
useful	O
as	O
the	O
exercise	O
ECG	O
test	O
for	O
the	O
assessment	O
of	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
.	O
Bradycardia	B-Disease
after	O
high	O
-	O
dose	O
intravenous	O
methylprednisolone	B-Chemical
therapy	O
.	O
In	O
5	O
consecutive	O
patients	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
who	O
received	O
intravenous	O
high	O
-	O
dose	O
methylprednisolone	B-Chemical
(	O
MP	B-Chemical
)	O
therapy	O
(	O
1	O
g	O
daily	O
for	O
2	O
or	O
3	O
consecutive	O
days	O
)	O
,	O
a	O
decline	O
in	O
pulse	O
rate	O
was	O
observed	O
,	O
most	O
pronounced	O
on	O
day	O
4	O
.	O
In	O
one	O
of	O
the	O
5	O
patients	O
the	O
bradycardia	B-Disease
was	O
associated	O
with	O
complaints	O
of	O
substernal	O
pressure	O
.	O
Reversal	O
to	O
normal	O
heart	O
rate	O
was	O
found	O
on	O
day	O
7	O
.	O
Electrocardiographic	O
registrations	O
showed	O
sinus	B-Disease
bradycardia	I-Disease
in	O
all	O
cases	O
.	O
No	O
significant	O
changes	O
in	O
plasma	O
concentrations	O
of	O
electrolytes	O
were	O
found	O
.	O
Careful	O
observation	O
of	O
patients	O
receiving	O
high	O
-	O
dose	O
MP	B-Chemical
is	O
recommended	O
.	O
High	O
-	O
dose	O
MP	B-Chemical
may	O
be	O
contraindicated	O
in	O
patients	O
with	O
known	O
heart	B-Disease
disease	I-Disease
.	O
Two	O
cases	O
of	O
downbeat	B-Disease
nystagmus	I-Disease
and	O
oscillopsia	B-Disease
associated	O
with	O
carbamazepine	B-Chemical
.	O
Downbeat	B-Disease
nystagmus	I-Disease
is	O
often	O
associated	O
with	O
structural	O
lesions	O
at	O
the	O
craniocervical	O
junction	O
,	O
but	O
has	O
occasionally	O
been	O
reported	O
as	O
a	O
manifestation	O
of	O
metabolic	O
imbalance	O
or	O
drug	O
intoxication	O
.	O
We	O
recorded	O
the	O
eye	O
movements	O
of	O
two	O
patients	O
with	O
reversible	O
downbeat	B-Disease
nystagmus	I-Disease
related	O
to	O
carbamazepine	B-Chemical
therapy	O
.	O
The	O
nystagmus	B-Disease
of	O
both	O
patients	O
resolved	O
after	O
reduction	O
of	O
the	O
serum	O
carbamazepine	B-Chemical
levels	O
.	O
Neuroradiologic	O
investigations	O
including	O
magnetic	O
resonance	O
imaging	O
scans	O
in	O
both	O
patients	O
showed	O
no	O
evidence	O
of	O
intracranial	O
abnormality	O
.	O
In	O
patients	O
with	O
downbeat	B-Disease
nystagmus	I-Disease
who	O
are	O
taking	O
anticonvulsant	O
medications	O
,	O
consideration	O
should	O
be	O
given	O
to	O
reduction	O
in	O
dose	O
before	O
further	O
investigation	O
is	O
undertaken	O
.	O
Improvement	O
by	O
denopamine	B-Chemical
(	O
TA	B-Chemical
-	I-Chemical
064	I-Chemical
)	O
of	O
pentobarbital	B-Chemical
-	O
induced	O
cardiac	B-Disease
failure	I-Disease
in	O
the	O
dog	O
heart	O
-	O
lung	O
preparation	O
.	O
The	O
efficacy	O
of	O
denopamine	B-Chemical
,	O
an	O
orally	O
active	O
beta	O
1	O
-	O
adrenoceptor	O
agonist	O
,	O
in	O
improving	O
cardiac	B-Disease
failure	I-Disease
was	O
assessed	O
in	O
dog	O
heart	O
-	O
lung	O
preparations	O
.	O
Cardiac	O
functions	O
depressed	O
by	O
pentobarbital	B-Chemical
(	O
118	O
+	O
/	O
-	O
28	O
mg	O
;	O
mean	O
value	O
+	O
/	O
-	O
SD	O
)	O
such	O
that	O
cardiac	O
output	O
and	O
maximum	O
rate	O
of	O
rise	O
of	O
left	O
ventricular	O
pressure	O
(	O
LV	O
dP	O
/	O
dt	O
max	O
)	O
had	O
been	O
reduced	O
by	O
about	O
35	O
%	O
and	O
26	O
%	O
of	O
the	O
respective	O
controls	O
were	O
improved	O
by	O
denopamine	B-Chemical
(	O
10	O
-	O
300	O
micrograms	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
With	O
100	O
micrograms	O
denopamine	B-Chemical
,	O
almost	O
complete	O
restoration	O
of	O
cardiac	O
performance	O
was	O
attained	O
,	O
associated	O
with	O
a	O
slight	O
increase	O
in	O
heart	O
rate	O
.	O
No	O
arrhythmias	B-Disease
were	O
induced	O
by	O
these	O
doses	O
of	O
denopamine	B-Chemical
.	O
The	O
results	O
warrant	O
clinical	O
trials	O
of	O
denopamine	B-Chemical
in	O
the	O
treatment	O
of	O
cardiac	B-Disease
failure	I-Disease
.	O
Clonazepam	B-Chemical
monotherapy	O
for	O
epilepsy	B-Disease
in	O
childhood	O
.	O
Sixty	O
patients	O
(	O
age	O
-	O
range	O
one	O
month	O
to	O
14	O
years	O
)	O
with	O
other	O
types	O
of	O
epilepsy	B-Disease
than	O
infantile	B-Disease
spasms	I-Disease
were	O
treated	O
with	O
clonazepam	B-Chemical
.	O
Disappearance	O
of	O
seizures	B-Disease
and	O
normalization	O
of	O
abnormal	O
EEG	O
with	O
disappearance	O
of	O
seizures	B-Disease
were	O
recognized	O
in	O
77	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O
Seizures	B-Disease
disappeared	O
in	O
71	O
%	O
of	O
the	O
patients	O
with	O
generalized	O
seizures	B-Disease
and	O
89	O
%	O
of	O
partial	O
seizures	B-Disease
.	O
Improvement	O
of	O
abnormal	O
EEG	O
was	O
noticed	O
in	O
76	O
%	O
of	O
diffuse	O
paroxysms	O
and	O
in	O
67	O
%	O
of	O
focal	O
paroxysms	O
.	O
In	O
excellent	O
cases	O
,	O
mean	O
effective	O
dosages	O
were	O
0	O
.	O
086	O
+	O
/	O
-	O
0	O
.	O
021	O
mg	O
/	O
kg	O
/	O
day	O
in	O
infants	O
and	O
0	O
.	O
057	O
+	O
/	O
-	O
0	O
.	O
022	O
mg	O
/	O
kg	O
/	O
day	O
in	O
schoolchildren	O
,	O
this	O
difference	O
was	O
statistically	O
significant	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O
The	O
incidence	O
of	O
side	O
effects	O
such	O
as	O
drowsiness	B-Disease
and	O
ataxia	B-Disease
was	O
only	O
5	O
%	O
.	O
Postmarketing	O
study	O
of	O
timolol	B-Chemical
-	O
hydrochlorothiazide	B-Chemical
antihypertensive	O
therapy	O
.	O
A	O
postmarketing	O
surveillance	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
a	O
fixed	O
-	O
ratio	O
combination	O
containing	O
10	O
mg	O
of	O
timolol	B-Chemical
maleate	I-Chemical
and	O
25	O
mg	O
of	O
hydrochlorothiazide	B-Chemical
,	O
administered	O
twice	O
daily	O
for	O
one	O
month	O
to	O
hypertensive	B-Disease
patients	O
.	O
Data	O
on	O
9	O
,	O
037	O
patients	O
were	O
collected	O
by	O
1	O
,	O
455	O
participating	O
physicians	O
.	O
Mean	O
systolic	O
blood	O
pressure	O
decreased	O
25	O
mmHg	O
and	O
mean	O
diastolic	O
blood	O
pressure	O
declined	O
15	O
mmHg	O
after	O
one	O
month	O
of	O
timolol	B-Chemical
-	O
hydrochlorothiazide	B-Chemical
therapy	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
,	O
both	O
comparisons	O
)	O
.	O
Age	O
,	O
race	O
,	O
and	O
sex	O
appeared	O
to	O
have	O
no	O
influence	O
on	O
the	O
decrease	O
in	O
blood	O
pressure	O
.	O
The	O
antihypertensive	O
effect	O
of	O
the	O
drug	O
was	O
greater	O
in	O
patients	O
with	O
more	O
severe	O
hypertension	B-Disease
.	O
Overall	O
,	O
1	O
,	O
453	O
patients	O
experienced	O
a	O
total	O
of	O
2	O
,	O
658	O
adverse	O
events	O
,	O
the	O
most	O
common	O
being	O
fatigue	B-Disease
,	O
dizziness	B-Disease
,	O
and	O
weakness	B-Disease
.	O
Treatment	O
in	O
590	O
patients	O
was	O
discontinued	O
because	O
of	O
adverse	O
events	O
.	O
Salicylate	B-Chemical
nephropathy	B-Disease
in	O
the	O
Gunn	O
rat	O
:	O
potential	O
role	O
of	O
prostaglandins	B-Chemical
.	O
We	O
examined	O
the	O
potential	O
role	O
of	O
prostaglandins	B-Chemical
in	O
the	O
development	O
of	O
analgesic	O
nephropathy	B-Disease
in	O
the	O
Gunn	O
strain	O
of	O
rat	O
.	O
The	O
homozygous	O
Gunn	O
rats	O
have	O
unconjugated	O
hyperbilirubinemia	B-Disease
due	O
to	O
the	O
absence	O
of	O
glucuronyl	B-Chemical
transferase	O
,	O
leading	O
to	O
marked	O
bilirubin	B-Chemical
deposition	O
in	O
renal	O
medulla	O
and	O
papilla	O
.	O
These	O
rats	O
are	O
also	O
highly	O
susceptible	O
to	O
develop	O
papillary	B-Disease
necrosis	I-Disease
with	O
analgesic	O
administration	O
.	O
We	O
used	O
homozygous	O
(	O
jj	O
)	O
and	O
phenotypically	O
normal	O
heterozygous	O
(	O
jJ	O
)	O
animals	O
.	O
Four	O
groups	O
of	O
rats	O
(	O
n	O
=	O
7	O
)	O
were	O
studied	O
:	O
jj	O
and	O
jJ	O
rats	O
treated	O
either	O
with	O
aspirin	B-Chemical
300	O
mg	O
/	O
kg	O
every	O
other	O
day	O
or	O
sham	O
-	O
treated	O
.	O
After	O
one	O
week	O
,	O
slices	O
of	O
cortex	O
,	O
outer	O
and	O
inner	O
medulla	O
from	O
one	O
kidney	O
were	O
incubated	O
in	O
buffer	O
and	O
prostaglandin	B-Chemical
synthesis	O
was	O
determined	O
by	O
radioimmunoassay	O
.	O
The	O
other	O
kidney	O
was	O
examined	O
histologically	O
.	O
A	O
marked	O
corticomedullary	O
gradient	O
of	O
prostaglandin	B-Chemical
synthesis	O
was	O
observed	O
in	O
all	O
groups	O
.	O
PGE2	B-Chemical
synthesis	O
was	O
significantly	O
higher	O
in	O
outer	O
medulla	O
,	O
but	O
not	O
cortex	O
or	O
inner	O
medulla	O
,	O
of	O
jj	O
(	O
38	O
+	O
/	O
-	O
6	O
ng	O
/	O
mg	O
prot	O
)	O
than	O
jJ	O
rats	O
(	O
15	O
+	O
/	O
-	O
3	O
)	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
Aspirin	B-Chemical
treatment	O
reduced	O
PGE2	B-Chemical
synthesis	O
in	O
all	O
regions	O
,	O
but	O
outer	O
medullary	O
PGE2	B-Chemical
remained	O
higher	O
in	O
jj	O
(	O
18	O
+	O
/	O
-	O
3	O
)	O
than	O
jJ	O
rats	O
(	O
9	O
+	O
/	O
-	O
2	O
)	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
PGF2	B-Chemical
alpha	I-Chemical
was	O
also	O
significantly	O
higher	O
in	O
the	O
outer	O
medulla	O
of	O
jj	O
rats	O
with	O
and	O
without	O
aspirin	B-Chemical
administration	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
The	O
changes	O
in	O
renal	O
prostaglandin	B-Chemical
synthesis	O
were	O
accompanied	O
by	O
evidence	O
of	O
renal	B-Disease
damage	I-Disease
in	O
aspirin	B-Chemical
-	O
treated	O
jj	O
but	O
not	O
jJ	O
rats	O
as	O
evidenced	O
by	O
:	O
increased	O
incidence	O
and	O
severity	O
of	O
hematuria	B-Disease
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
;	O
increased	O
serum	O
creatinine	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
;	O
and	O
increase	O
in	O
outer	O
medullary	O
histopathologic	O
lesions	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
compared	O
to	O
either	O
sham	O
-	O
treated	O
jj	O
or	O
aspirin	B-Chemical
-	O
treated	O
jJ	O
)	O
.	O
These	O
results	O
suggest	O
that	O
enhanced	O
prostaglandin	B-Chemical
synthesis	O
contributes	O
to	O
maintenance	O
of	O
renal	O
function	O
and	O
morphological	O
integrity	O
,	O
and	O
that	O
inhibition	O
of	O
prostaglandin	B-Chemical
synthesis	O
may	O
lead	O
to	O
pathological	B-Disease
renal	I-Disease
medullary	I-Disease
lesions	I-Disease
and	O
deterioration	B-Disease
of	I-Disease
renal	I-Disease
function	I-Disease
.	O
Prophylactic	O
lidocaine	B-Chemical
in	O
the	O
early	O
phase	O
of	O
suspected	O
myocardial	B-Disease
infarction	I-Disease
.	O
Four	O
hundred	O
two	O
patients	O
with	O
suspected	O
myocardial	B-Disease
infarction	I-Disease
seen	O
within	O
6	O
hours	O
of	O
the	O
onset	O
of	O
symptoms	O
entered	O
a	O
double	O
-	O
blind	O
randomized	O
trial	O
of	O
lidocaine	B-Chemical
vs	O
placebo	O
.	O
During	O
the	O
1	O
hour	O
after	O
administration	O
of	O
the	O
drug	O
the	O
incidence	O
of	O
ventricular	B-Disease
fibrillation	I-Disease
or	O
sustained	O
ventricular	B-Disease
tachycardia	I-Disease
among	O
the	O
204	O
patients	O
with	O
acute	O
myocardial	B-Disease
infarction	I-Disease
was	O
low	O
,	O
1	O
.	O
5	O
%	O
.	O
Lidocaine	B-Chemical
,	O
given	O
in	O
a	O
300	O
mg	O
dose	O
intramuscularly	O
followed	O
by	O
100	O
mg	O
intravenously	O
,	O
did	O
not	O
prevent	O
sustained	O
ventricular	B-Disease
tachycardia	I-Disease
,	O
although	O
there	O
was	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
patients	O
with	O
warning	O
arrhythmias	B-Disease
between	O
15	O
and	O
45	O
minutes	O
after	O
the	O
administration	O
of	O
lidocaine	B-Chemical
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
The	O
average	O
plasma	O
lidocaine	B-Chemical
level	O
10	O
minutes	O
after	O
administration	O
for	O
patients	O
without	O
a	O
myocardial	B-Disease
infarction	I-Disease
was	O
significantly	O
higher	O
than	O
that	O
for	O
patients	O
with	O
an	O
acute	O
infarction	B-Disease
.	O
The	O
mean	O
plasma	O
lidocaine	B-Chemical
level	O
of	O
patients	O
on	O
beta	O
-	O
blocking	O
agents	O
was	O
no	O
different	O
from	O
that	O
in	O
patients	O
not	O
on	O
beta	O
blocking	O
agents	O
.	O
During	O
the	O
1	O
-	O
hour	O
study	O
period	O
,	O
the	O
incidence	O
of	O
central	O
nervous	O
system	O
side	O
effects	O
was	O
significantly	O
greater	O
in	O
the	O
lidocaine	B-Chemical
group	O
,	O
hypotension	B-Disease
occurred	O
in	O
11	O
patients	O
,	O
nine	O
of	O
whom	O
had	O
received	O
lidocaine	B-Chemical
,	O
and	O
four	O
patients	O
died	O
from	O
asystole	B-Disease
,	O
three	O
of	O
whom	O
had	O
had	O
lidocaine	B-Chemical
.	O
We	O
cannot	O
advocate	O
the	O
administration	O
of	O
lidocaine	B-Chemical
prophylactically	O
in	O
the	O
early	O
hours	O
of	O
suspected	O
myocardial	B-Disease
infarction	I-Disease
.	O
Evidence	O
for	O
a	O
cholinergic	O
role	O
in	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
.	O
Experiments	O
in	O
mice	O
tested	O
previous	O
evidence	O
that	O
activation	O
of	O
cholinergic	O
systems	O
promotes	O
catalepsy	B-Disease
and	O
that	O
cholinergic	O
mechanisms	O
need	O
to	O
be	O
intact	O
for	O
full	O
expression	O
of	O
neuroleptic	B-Chemical
-	O
induced	O
catalepsy	B-Disease
.	O
Large	O
doses	O
of	O
the	O
cholinomimetic	O
,	O
pilocarpine	B-Chemical
,	O
could	O
induce	O
catalepsy	B-Disease
when	O
peripheral	O
cholinergic	O
receptors	O
were	O
blocked	O
.	O
Low	O
doses	O
of	O
pilocarpine	B-Chemical
caused	O
a	O
pronounced	O
enhancement	O
of	O
the	O
catalepsy	B-Disease
that	O
was	O
induced	O
by	O
the	O
dopaminergic	O
blocker	O
,	O
haloperidol	B-Chemical
.	O
A	O
muscarinic	O
receptor	O
blocker	O
,	O
atropine	B-Chemical
,	O
disrupted	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
.	O
Intracranial	O
injection	O
of	O
an	O
acetylcholine	B-Chemical
-	O
synthesis	O
inhibitor	O
,	O
hemicholinium	B-Chemical
,	O
prevented	O
the	O
catalepsy	B-Disease
that	O
is	O
usually	O
induced	O
by	O
haloperidol	B-Chemical
.	O
These	O
findings	O
suggest	O
the	O
hypothesis	O
that	O
the	O
catalepsy	B-Disease
that	O
is	O
produced	O
by	O
neuroleptics	B-Chemical
such	O
as	O
haloperidol	B-Chemical
is	O
actually	O
mediated	O
by	O
intrinsic	O
central	O
cholinergic	O
systems	O
.	O
Alternatively	O
,	O
activation	O
of	O
central	O
cholinergic	O
systems	O
could	O
promote	O
catalepsy	B-Disease
by	O
suppression	O
of	O
dopaminergic	O
systems	O
.	O
Cardiovascular	B-Disease
dysfunction	I-Disease
and	O
hypersensitivity	B-Disease
to	O
sodium	B-Chemical
pentobarbital	I-Chemical
induced	O
by	O
chronic	O
barium	B-Chemical
chloride	I-Chemical
ingestion	O
.	O
Barium	B-Chemical
-	O
supplemented	O
Long	O
-	O
Evans	O
hooded	O
rats	O
were	O
characterized	O
by	O
a	O
persistent	O
hypertension	B-Disease
that	O
was	O
evident	O
after	O
1	O
month	O
of	O
barium	B-Chemical
(	O
100	O
micrograms	O
/	O
ml	O
mineral	O
fortified	O
water	O
)	O
treatment	O
.	O
Analysis	O
of	O
in	O
vivo	O
myocardial	O
excitability	O
,	O
contractility	O
,	O
and	O
metabolic	O
characteristics	O
at	O
16	O
months	O
revealed	O
other	O
significant	O
barium	B-Chemical
-	O
induced	O
disturbances	B-Disease
within	I-Disease
the	I-Disease
cardiovascular	I-Disease
system	I-Disease
.	O
The	O
most	O
distinctive	O
aspect	O
of	O
the	O
barium	B-Chemical
effect	O
was	O
a	O
demonstrated	O
hypersensitivity	B-Disease
of	O
the	O
cardiovascular	O
system	O
to	O
sodium	B-Chemical
pentobarbital	I-Chemical
.	O
Under	O
barbiturate	B-Chemical
anesthesia	O
,	O
virtually	O
all	O
of	O
the	O
myocardial	O
contractile	O
indices	O
were	O
depressed	O
significantly	O
in	O
barium	B-Chemical
-	O
exposed	O
rats	O
relative	O
to	O
the	O
corresponding	O
control	O
-	O
fed	O
rats	O
.	O
The	O
lack	O
of	O
a	O
similar	O
response	O
to	O
ketamine	B-Chemical
and	O
xylazine	B-Chemical
anesthesia	O
revealed	O
that	O
the	O
cardiovascular	O
actions	O
of	O
sodium	B-Chemical
pentobarbital	I-Chemical
in	O
barium	B-Chemical
-	O
treated	O
rats	O
were	O
linked	O
specifically	O
to	O
this	O
anesthetic	O
,	O
and	O
were	O
not	O
representative	O
of	O
a	O
generalized	O
anesthetic	O
response	O
.	O
Other	O
myocardial	O
pathophysiologic	O
and	O
metabolic	O
changes	O
induced	O
by	O
barium	B-Chemical
were	O
manifest	O
,	O
irrespective	O
of	O
the	O
anesthetic	O
employed	O
.	O
The	O
contractile	O
element	O
shortening	O
velocity	O
of	O
the	O
cardiac	O
muscle	O
fibers	O
was	O
significantly	O
slower	O
in	O
both	O
groups	O
of	O
barium	B-Chemical
-	O
treated	O
rats	O
relative	O
to	O
the	O
control	O
groups	O
,	O
irrespective	O
of	O
the	O
anesthetic	O
regimen	O
.	O
Similarly	O
,	O
significant	O
disturbances	O
in	O
myocardial	O
energy	O
metabolism	O
were	O
detected	O
in	O
the	O
barium	B-Chemical
-	O
exposed	O
rats	O
which	O
were	O
consistent	O
with	O
the	O
reduced	O
contractile	O
element	O
shortening	O
velocity	O
.	O
In	O
addition	O
,	O
the	O
excitability	O
of	O
the	O
cardiac	O
conduction	O
system	O
was	O
depressed	O
preferentially	O
in	O
the	O
atrioventricular	O
nodal	O
region	O
of	O
hearts	O
from	O
barium	B-Chemical
-	O
exposed	O
rats	O
.	O
Overall	O
,	O
the	O
altered	O
cardiac	O
contractility	O
and	O
excitability	O
characteristics	O
,	O
the	O
myocardial	O
metabolic	B-Disease
disturbances	I-Disease
,	O
and	O
the	O
hypersensitivity	B-Disease
of	O
the	O
cardiovascular	O
system	O
to	O
sodium	B-Chemical
pentobarbital	I-Chemical
suggest	O
the	O
existence	O
of	O
a	O
heretofore	O
undescribed	O
cardiomyopathic	B-Disease
disorder	I-Disease
induced	O
by	O
chronic	O
barium	B-Chemical
exposure	O
.	O
These	O
experimental	O
findings	O
represent	O
the	O
first	O
indication	O
that	O
life	O
-	O
long	O
barium	B-Chemical
ingestion	O
may	O
have	O
significant	O
adverse	O
effects	O
on	O
the	O
mammalian	O
cardiovascular	O
system	O
.	O
Propranolol	B-Chemical
antagonism	O
of	O
phenylpropanolamine	B-Chemical
-	O
induced	O
hypertension	B-Disease
.	O
Phenylpropanolamine	B-Chemical
(	O
PPA	B-Chemical
)	O
overdose	B-Disease
can	O
cause	O
severe	O
hypertension	B-Disease
,	O
intracerebral	B-Disease
hemorrhage	I-Disease
,	O
and	O
death	O
.	O
We	O
studied	O
the	O
efficacy	O
and	O
safety	O
of	O
propranolol	B-Chemical
in	O
the	O
treatment	O
of	O
PPA	B-Chemical
-	O
induced	O
hypertension	B-Disease
.	O
Subjects	O
received	O
propranolol	B-Chemical
either	O
by	O
mouth	O
for	O
48	O
hours	O
before	O
PPA	B-Chemical
or	O
as	O
a	O
rapid	O
intravenous	O
infusion	O
after	O
PPA	B-Chemical
.	O
PPA	B-Chemical
,	O
75	O
mg	O
alone	O
,	O
increased	O
blood	O
pressure	O
(	O
31	O
+	O
/	O
-	O
14	O
mm	O
Hg	O
systolic	O
,	O
20	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
diastolic	O
)	O
,	O
and	O
propranolol	B-Chemical
pretreatment	O
antagonized	O
this	O
increase	O
(	O
12	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
systolic	O
,	O
10	O
+	O
/	O
-	O
7	O
mm	O
Hg	O
diastolic	O
)	O
.	O
Intravenous	O
propranolol	B-Chemical
after	O
PPA	B-Chemical
also	O
decreased	O
blood	O
pressure	O
.	O
Left	O
ventricular	O
function	O
(	O
assessed	O
by	O
echocardiography	O
)	O
showed	O
that	O
PPA	B-Chemical
increased	O
the	O
stroke	B-Disease
volume	O
30	O
%	O
(	O
from	O
62	O
.	O
5	O
+	O
/	O
-	O
20	O
.	O
9	O
to	O
80	O
.	O
8	O
+	O
/	O
-	O
22	O
.	O
4	O
ml	O
)	O
,	O
the	O
ejection	O
fraction	O
9	O
%	O
(	O
from	O
64	O
%	O
+	O
/	O
-	O
10	O
%	O
to	O
70	O
%	O
+	O
/	O
-	O
7	O
%	O
)	O
,	O
and	O
cardiac	O
output	O
14	O
%	O
(	O
from	O
3	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
6	O
to	O
4	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
0	O
L	O
/	O
min	O
)	O
.	O
Intravenous	O
propranolol	B-Chemical
reversed	O
these	O
effects	O
.	O
Systemic	O
vascular	O
resistance	O
was	O
increased	O
by	O
PPA	B-Chemical
28	O
%	O
(	O
from	O
1710	O
+	O
/	O
-	O
200	O
to	O
2190	O
+	O
/	O
-	O
700	O
dyne	O
X	O
sec	O
/	O
cm5	O
)	O
and	O
was	O
further	O
increased	O
by	O
propranolol	B-Chemical
22	O
%	O
(	O
to	O
2660	O
+	O
/	O
-	O
1200	O
dyne	O
X	O
sec	O
/	O
cm5	O
)	O
.	O
We	O
conclude	O
that	O
PPA	B-Chemical
increases	O
blood	O
pressure	O
by	O
increasing	O
systemic	O
vascular	O
resistance	O
and	O
cardiac	O
output	O
,	O
and	O
that	O
propranolol	B-Chemical
antagonizes	O
this	O
increase	O
by	O
reversing	O
the	O
effect	O
of	O
PPA	B-Chemical
on	O
cardiac	O
output	O
.	O
That	O
propranolol	B-Chemical
antagonizes	O
the	O
pressor	O
effect	O
of	O
PPA	B-Chemical
is	O
in	O
contrast	O
to	O
the	O
interaction	O
in	O
which	O
propranolol	B-Chemical
enhances	O
the	O
pressor	O
effect	O
of	O
norepinephrine	B-Chemical
.	O
This	O
is	O
probably	O
because	O
PPA	B-Chemical
has	O
less	O
beta	O
2	O
activity	O
than	O
does	O
norepinephrine	B-Chemical
.	O
Mesangial	O
function	O
and	O
glomerular	B-Disease
sclerosis	I-Disease
in	O
rats	O
with	O
aminonucleoside	B-Chemical
nephrosis	B-Disease
.	O
The	O
possible	O
relationship	O
between	O
mesangial	B-Disease
dysfunction	I-Disease
and	O
development	O
of	O
glomerular	B-Disease
sclerosis	I-Disease
was	O
studied	O
in	O
the	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
model	O
.	O
Five	O
male	O
Wistar	O
rats	O
received	O
repeated	O
subcutaneous	O
PAN	B-Chemical
injections	O
;	O
five	O
controls	O
received	O
saline	O
only	O
.	O
After	O
4	O
weeks	O
the	O
PAN	B-Chemical
rats	O
were	O
severely	O
proteinuric	B-Disease
(	O
190	O
+	O
/	O
-	O
80	O
mg	O
/	O
24	O
hr	O
)	O
,	O
and	O
all	O
rats	O
were	O
given	O
colloidal	O
carbon	B-Chemical
(	O
CC	O
)	O
intravenously	O
.	O
At	O
5	O
months	O
glomerular	B-Disease
sclerosis	I-Disease
was	O
found	O
in	O
7	O
.	O
6	O
+	O
/	O
-	O
3	O
.	O
4	O
%	O
of	O
the	O
glomeruli	O
of	O
PAN	B-Chemical
rats	O
;	O
glomeruli	O
of	O
the	O
controls	O
were	O
normal	O
.	O
Glomeruli	O
of	O
PAN	B-Chemical
rats	O
contained	O
significantly	O
more	O
CC	O
than	O
glomeruli	O
of	O
controls	O
.	O
Glomeruli	O
with	O
sclerosis	B-Disease
contained	O
significantly	O
more	O
CC	O
than	O
non	O
-	O
sclerotic	O
glomeruli	O
in	O
the	O
same	O
kidneys	O
.	O
CC	O
was	O
preferentially	O
localized	O
within	O
the	O
sclerotic	O
areas	O
of	O
the	O
affected	O
glomeruli	O
.	O
Since	O
mesangial	O
CC	O
clearance	O
from	O
the	O
mesangium	O
did	O
not	O
change	O
during	O
chronic	O
PAN	B-Chemical
treatment	O
,	O
we	O
conclude	O
that	O
this	O
preferential	O
CC	O
localization	O
within	O
the	O
lesions	O
is	O
caused	O
by	O
an	O
increased	O
CC	O
uptake	O
shortly	O
after	O
injection	O
in	O
apparent	O
vulnerable	O
areas	O
where	O
sclerosis	B-Disease
will	O
develop	O
subsequently	O
.	O
Cluster	O
analysis	O
showed	O
a	O
random	O
distribution	O
of	O
lesions	O
in	O
the	O
PAN	B-Chemical
glomeruli	O
in	O
concordance	O
with	O
the	O
random	O
localization	O
of	O
mesangial	O
areas	O
with	O
dysfunction	O
in	O
this	O
model	O
.	O
Similar	O
to	O
the	O
remnant	O
kidney	O
model	O
in	O
PAN	B-Chemical
nephrosis	B-Disease
the	O
development	O
of	O
glomerular	B-Disease
sclerosis	I-Disease
may	O
be	O
related	O
to	O
""""	O
mesangial	O
overloading	O
.	O
""""	O
Relationship	O
between	O
nicotine	B-Chemical
-	O
induced	O
seizures	B-Disease
and	O
hippocampal	O
nicotinic	O
receptors	O
.	O
A	O
controversy	O
has	O
existed	O
for	O
several	O
years	O
concerning	O
the	O
physiological	O
relevance	O
of	O
the	O
nicotinic	O
receptor	O
measured	O
by	O
alpha	O
-	O
bungarotoxin	O
binding	O
.	O
Using	O
mice	O
derived	O
from	O
a	O
classical	O
F2	O
and	O
backcross	O
genetic	O
design	O
,	O
a	O
relationship	O
between	O
nicotine	B-Chemical
-	O
induced	O
seizures	B-Disease
and	O
alpha	O
-	O
bungarotoxin	O
nicotinic	O
receptor	O
concentration	O
was	O
found	O
.	O
Mice	O
sensitive	O
to	O
the	O
convulsant	O
effects	O
of	O
nicotine	B-Chemical
had	O
greater	O
alpha	O
-	O
bungarotoxin	O
binding	O
in	O
the	O
hippocampus	O
than	O
seizure	B-Disease
insensitive	O
mice	O
.	O
The	O
binding	O
sites	O
from	O
seizure	B-Disease
sensitive	O
and	O
resistant	O
mice	O
were	O
equally	O
affected	O
by	O
treatment	O
with	O
dithiothreitol	B-Chemical
,	O
trypsin	O
or	O
heat	O
.	O
Thus	O
it	O
appears	O
that	O
the	O
difference	O
between	O
seizure	B-Disease
sensitive	O
and	O
insensitive	O
animals	O
may	O
be	O
due	O
to	O
a	O
difference	O
in	O
hippocampal	O
nicotinic	O
receptor	O
concentration	O
as	O
measured	O
with	O
alpha	O
-	O
bungarotoxin	O
binding	O
.	O
The	O
role	O
of	O
p	B-Chemical
-	I-Chemical
aminophenol	I-Chemical
in	O
acetaminophen	B-Chemical
-	O
induced	O
nephrotoxicity	B-Disease
:	O
effect	O
of	O
bis	B-Chemical
(	I-Chemical
p	I-Chemical
-	I-Chemical
nitrophenyl	I-Chemical
)	I-Chemical
phosphate	I-Chemical
on	O
acetaminophen	B-Chemical
and	O
p	B-Chemical
-	I-Chemical
aminophenol	I-Chemical
nephrotoxicity	B-Disease
and	O
metabolism	O
in	O
Fischer	O
344	O
rats	O
.	O
Acetaminophen	B-Chemical
(	O
APAP	B-Chemical
)	O
produces	O
proximal	O
tubular	B-Disease
necrosis	I-Disease
in	O
Fischer	O
344	O
(	O
F344	O
)	O
rats	O
.	O
Recently	O
,	O
p	B-Chemical
-	I-Chemical
aminophenol	I-Chemical
(	O
PAP	B-Chemical
)	O
,	O
a	O
known	O
potent	O
nephrotoxicant	O
,	O
was	O
identified	O
as	O
a	O
metabolite	O
of	O
APAP	B-Chemical
in	O
F344	O
rats	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
PAP	B-Chemical
formation	O
is	O
a	O
requisite	O
step	O
in	O
APAP	B-Chemical
-	O
induced	O
nephrotoxicity	B-Disease
.	O
Therefore	O
,	O
the	O
effect	O
of	O
bis	B-Chemical
(	I-Chemical
p	I-Chemical
-	I-Chemical
nitrophenyl	I-Chemical
)	I-Chemical
phosphate	I-Chemical
(	O
BNPP	B-Chemical
)	O
,	O
an	O
acylamidase	O
inhibitor	O
,	O
on	O
APAP	B-Chemical
and	O
PAP	B-Chemical
nephrotoxicity	B-Disease
and	O
metabolism	O
was	O
determined	O
.	O
BNPP	B-Chemical
(	O
1	O
to	O
8	O
mM	O
)	O
reduced	O
APAP	B-Chemical
deacetylation	O
and	O
covalent	O
binding	O
in	O
F344	O
renal	O
cortical	O
homogenates	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O
Pretreatment	O
of	O
animals	O
with	O
BNPP	B-Chemical
prior	O
to	O
APAP	B-Chemical
or	O
PAP	B-Chemical
administration	O
resulted	O
in	O
marked	O
reduction	O
of	O
APAP	B-Chemical
(	O
900	O
mg	O
/	O
kg	O
)	O
nephrotoxicity	B-Disease
but	O
not	O
PAP	B-Chemical
nephrotoxicity	B-Disease
.	O
This	O
result	O
was	O
not	O
due	O
to	O
altered	O
disposition	O
of	O
either	O
APAP	B-Chemical
or	O
acetylated	O
metabolites	O
in	O
plasma	O
or	O
renal	O
cortical	O
and	O
hepatic	O
tissue	O
.	O
Rather	O
,	O
BNPP	B-Chemical
pretreatment	O
reduced	O
the	O
fraction	O
of	O
APAP	B-Chemical
excreted	O
as	O
PAP	B-Chemical
by	O
64	O
and	O
75	O
%	O
after	O
APAP	B-Chemical
doses	O
of	O
750	O
and	O
900	O
mg	O
/	O
kg	O
.	O
BNPP	B-Chemical
did	O
not	O
alter	O
the	O
excretion	O
of	O
APAP	B-Chemical
or	O
any	O
of	O
its	O
non	O
-	O
deacetylated	O
metabolites	O
nor	O
did	O
BNPP	B-Chemical
alter	O
excretion	O
of	O
PAP	B-Chemical
or	O
its	O
metabolites	O
after	O
PAP	B-Chemical
doses	O
of	O
150	O
and	O
300	O
mg	O
/	O
kg	O
.	O
Therefore	O
,	O
the	O
BNPP	B-Chemical
-	O
induced	O
reduction	O
in	O
APAP	B-Chemical
-	O
induced	O
nephrotoxicity	B-Disease
appears	O
to	O
be	O
due	O
to	O
inhibition	O
of	O
APAP	B-Chemical
deacetylation	O
.	O
It	O
is	O
concluded	O
that	O
PAP	B-Chemical
formation	O
,	O
in	O
vivo	O
,	O
accounts	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
APAP	B-Chemical
-	O
induced	O
renal	B-Disease
tubular	I-Disease
necrosis	I-Disease
.	O
Morphine	B-Chemical
-	O
induced	O
seizures	B-Disease
in	O
newborn	O
infants	O
.	O
Two	O
neonates	O
suffered	O
from	O
generalized	O
seizures	B-Disease
during	O
the	O
course	O
of	O
intravenous	O
morphine	B-Chemical
sulfate	I-Chemical
for	O
post	O
-	O
operative	O
analgesia	O
.	O
They	O
received	O
morphine	B-Chemical
in	O
doses	O
of	O
32	O
micrograms	O
/	O
kg	O
/	O
hr	O
and	O
40	O
micrograms	O
/	O
kg	O
/	O
hr	O
larger	O
than	O
a	O
group	O
of	O
10	O
neonates	O
who	O
received	O
6	O
-	O
24	O
micrograms	O
/	O
kg	O
/	O
hr	O
and	O
had	O
no	O
seizures	B-Disease
.	O
Plasma	O
concentrations	O
of	O
morphine	B-Chemical
in	O
these	O
neonates	O
was	O
excessive	O
(	O
60	O
and	O
90	O
mg	O
/	O
ml	O
)	O
.	O
Other	O
known	O
reasons	O
for	O
seizures	B-Disease
were	O
ruled	O
out	O
and	O
the	O
convulsions	B-Disease
stopped	O
a	O
few	O
hours	O
after	O
cessation	O
of	O
morphine	B-Chemical
and	O
did	O
not	O
reoccur	O
in	O
the	O
subsequent	O
8	O
months	O
.	O
It	O
is	O
suggested	O
that	O
post	O
-	O
operative	O
intravenous	O
morphine	B-Chemical
should	O
not	O
exceed	O
20	O
micrograms	O
/	O
kg	O
/	O
ml	O
in	O
neonates	O
.	O
Indomethacin	B-Chemical
induced	O
hypotension	B-Disease
in	O
sodium	B-Chemical
and	O
volume	O
depleted	O
rats	O
.	O
After	O
a	O
single	O
oral	O
dose	O
of	O
4	O
mg	O
/	O
kg	O
indomethacin	B-Chemical
(	O
IDM	B-Chemical
)	O
to	O
sodium	B-Chemical
and	O
volume	O
depleted	O
rats	O
plasma	O
renin	O
activity	O
(	O
PRA	O
)	O
and	O
systolic	O
blood	O
pressure	O
fell	O
significantly	O
within	O
four	O
hours	O
.	O
In	O
sodium	B-Chemical
repleted	O
animals	O
indomethacin	B-Chemical
did	O
not	O
change	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
although	O
plasma	O
renin	O
activity	O
was	O
decreased	O
.	O
Thus	O
,	O
indomethacin	B-Chemical
by	O
inhibition	O
of	O
prostaglandin	B-Chemical
synthesis	O
may	O
diminish	O
the	O
blood	O
pressure	O
maintaining	O
effect	O
of	O
the	O
stimulated	O
renin	O
-	O
angiotensin	B-Chemical
system	O
in	O
sodium	B-Chemical
and	O
volume	O
depletion	O
.	O
On	O
the	O
antiarrhythmic	O
activity	O
of	O
one	O
N	O
-	O
substituted	O
piperazine	B-Chemical
derivative	O
of	O
trans	B-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
amino	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
tetrahydroanaphthalene	I-Chemical
.	O
The	O
antiarrhythmic	O
activity	O
of	O
the	O
compound	O
N	B-Chemical
-	I-Chemical
(	I-Chemical
trans	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
2	I-Chemical
,	I-Chemical
3	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
tetrahydro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
naphthyl	I-Chemical
)	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
oxo	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
phenyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
methylpropyl	I-Chemical
)	I-Chemical
-	I-Chemical
piperazine	I-Chemical
hydrochloride	I-Chemical
,	O
referred	O
to	O
as	O
P11	B-Chemical
,	O
is	O
studied	O
on	O
anaesthesized	O
cats	O
and	O
Wistar	O
albino	O
rats	O
,	O
as	O
well	O
as	O
on	O
non	O
-	O
anaesthesized	O
rabbits	O
.	O
Four	O
types	O
of	O
experimental	O
arrhythmia	B-Disease
are	O
used	O
-	O
-	O
with	O
BaCl2	B-Chemical
,	O
with	O
chloroform	B-Chemical
-	O
adrenaline	B-Chemical
,	O
with	O
strophantine	B-Chemical
G	I-Chemical
and	O
with	O
aconitine	B-Chemical
.	O
The	O
compound	O
P11	B-Chemical
is	O
introduced	O
in	O
doses	O
of	O
0	O
.	O
25	O
and	O
0	O
.	O
50	O
mg	O
/	O
kg	O
intravenously	O
and	O
10	O
mg	O
/	O
kg	O
orally	O
.	O
The	O
compound	O
manifests	O
antiarrhythmic	O
activity	O
in	O
all	O
models	O
of	O
experimental	O
arrhythmia	B-Disease
used	O
,	O
causing	O
greatest	O
inhibition	O
on	O
the	O
arrhythmia	B-Disease
induced	O
by	O
chloroform	B-Chemical
-	O
adrenaline	B-Chemical
(	O
in	O
90	O
per	O
cent	O
)	O
and	O
with	O
BaCl2	B-Chemical
(	O
in	O
84	O
per	O
cent	O
)	O
.	O
The	O
results	O
obtained	O
are	O
associated	O
with	O
the	O
beta	O
-	O
adrenoblocking	O
and	O
with	O
the	O
membrane	O
-	O
stabilizing	O
action	O
of	O
the	O
compound	O
.	O
Recurrent	O
subarachnoid	B-Disease
hemorrhage	I-Disease
associated	O
with	O
aminocaproic	B-Chemical
acid	I-Chemical
therapy	O
and	O
acute	B-Disease
renal	I-Disease
artery	I-Disease
thrombosis	I-Disease
.	O
Case	O
report	O
.	O
Epsilon	B-Chemical
aminocaproic	I-Chemical
acid	I-Chemical
(	O
EACA	B-Chemical
)	O
has	O
been	O
used	O
to	O
prevent	O
rebleeding	O
in	O
patients	O
with	O
subarachnoid	B-Disease
hemorrhage	I-Disease
(	O
SAH	B-Disease
)	O
.	O
Although	O
this	O
agent	O
does	O
decrease	O
the	O
frequency	O
of	O
rebleeding	O
,	O
several	O
reports	O
have	O
described	O
thrombotic	B-Disease
complications	O
of	O
EACA	B-Chemical
therapy	O
.	O
These	O
complications	O
have	O
included	O
clinical	O
deterioration	O
and	O
intracranial	B-Disease
vascular	I-Disease
thrombosis	I-Disease
in	O
patients	O
with	O
SAH	B-Disease
,	O
arteriolar	O
and	O
capillary	O
fibrin	O
thrombi	B-Disease
in	O
patients	O
with	O
fibrinolytic	O
syndromes	O
treated	O
with	O
EACA	B-Chemical
,	O
or	O
other	O
thromboembolic	B-Disease
phenomena	I-Disease
.	O
Since	O
intravascular	O
fibrin	O
thrombi	B-Disease
are	O
often	O
observed	O
in	O
patients	O
with	O
fibrinolytic	O
disorders	O
,	O
EACA	B-Chemical
should	O
not	O
be	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
fibrin	O
thrombi	B-Disease
in	O
patients	O
with	O
disseminated	B-Disease
intravascular	I-Disease
coagulation	I-Disease
or	O
other	O
""""	O
consumption	B-Disease
coagulopathies	I-Disease
.	O
""""	O
This	O
report	O
describes	O
subtotal	O
infarction	B-Disease
of	O
the	O
kidney	O
due	O
to	O
thrombosis	B-Disease
of	I-Disease
a	I-Disease
normal	I-Disease
renal	I-Disease
artery	I-Disease
.	O
This	O
occlusion	O
occurred	O
after	O
EACA	B-Chemical
therapy	O
in	O
a	O
patient	O
with	O
SAH	B-Disease
and	O
histopathological	O
documentation	O
of	O
recurrent	O
SAH	B-Disease
.	O
The	O
corresponding	O
clinical	O
event	O
was	O
characterized	O
by	O
marked	O
hypertension	B-Disease
and	O
abrupt	O
neurological	O
deterioration	O
.	O
Effect	O
of	O
vincristine	B-Chemical
sulfate	I-Chemical
on	O
Pseudomonas	B-Disease
infections	I-Disease
in	O
monkeys	O
.	O
In	O
rhesus	O
monkeys	O
,	O
intravenous	O
challenge	O
with	O
0	O
.	O
6	O
x	O
10	O
(	O
10	O
)	O
to	O
2	O
.	O
2	O
x	O
10	O
(	O
10	O
)	O
Pseudomonas	O
aeruginosa	O
organisms	O
caused	O
acute	O
illness	O
of	O
4	O
to	O
5	O
days	O
'	O
duration	O
with	O
spontaneous	O
recovery	O
in	O
13	O
of	O
15	O
monkeys	O
;	O
blood	O
cultures	O
became	O
negative	O
3	O
to	O
17	O
days	O
after	O
challenge	O
.	O
Leukocytosis	B-Disease
was	O
observed	O
in	O
all	O
monkeys	O
.	O
Intravenous	O
or	O
intratracheal	O
inoculation	O
of	O
2	O
.	O
0	O
to	O
2	O
.	O
5	O
mg	O
of	O
vincristine	B-Chemical
sulfate	I-Chemical
was	O
followed	O
by	O
leukopenia	B-Disease
in	O
4	O
to	O
5	O
days	O
.	O
Intravenous	O
inoculation	O
of	O
4	O
.	O
2	O
x	O
10	O
(	O
10	O
)	O
to	O
7	O
.	O
8	O
x	O
10	O
(	O
10	O
)	O
pyocin	O
type	O
6	O
Pseudomonas	O
organisms	O
in	O
monkeys	O
given	O
vincristine	B-Chemical
sulfate	I-Chemical
4	O
days	O
previously	O
resulted	O
in	O
fatal	O
infection	B-Disease
in	O
11	O
of	O
14	O
monkeys	O
,	O
whereas	O
none	O
of	O
four	O
receiving	O
Pseudomonas	O
alone	O
died	O
.	O
These	O
studies	O
suggest	O
that	O
an	O
antimetabolite	O
-	O
induced	O
leukopenia	B-Disease
predisposes	O
to	O
severe	O
Pseudomonas	O
sepsis	B-Disease
and	O
that	O
such	O
monkeys	O
may	O
serve	O
as	O
a	O
biological	O
model	O
for	O
study	O
of	O
comparative	O
efficacy	O
of	O
antimicrobial	O
agents	O
.	O
Modification	O
by	O
propranolol	B-Chemical
of	O
cardiovascular	O
effects	O
of	O
induced	O
hypoglycaemia	B-Disease
.	O
The	O
cardiovascular	O
effects	O
of	O
hypoglycaemia	B-Disease
,	O
with	O
and	O
without	O
beta	O
-	O
blockade	O
,	O
were	O
compared	O
in	O
fourteen	O
healthy	O
men	O
.	O
Eight	O
received	O
insulin	O
alone	O
,	O
and	O
eight	O
,	O
including	O
two	O
of	O
the	O
original	O
insulin	O
-	O
only	O
group	O
,	O
were	O
given	O
propranolol	B-Chemical
and	O
insulin	O
.	O
In	O
the	O
insulin	O
-	O
group	O
the	O
period	O
of	O
hypoglycaemia	B-Disease
was	O
associated	O
with	O
an	O
increase	O
in	O
heart	O
-	O
rate	O
and	O
a	O
fall	O
in	O
diastolic	O
blood	O
-	O
pressure	O
.	O
In	O
the	O
propranolol	B-Chemical
-	O
insulin	O
group	O
there	O
was	O
a	O
significant	O
fall	O
in	O
heart	O
-	O
rate	O
in	O
most	O
subjects	O
and	O
an	O
increase	O
in	O
diastolic	O
pressure	O
.	O
Typical	O
S	O
-	O
T	O
/	O
T	O
changes	O
occurred	O
in	O
the	O
insulin	O
-	O
group	O
but	O
in	O
none	O
of	O
the	O
propranolol	B-Chemical
-	O
insulin	O
group	O
.	O
Hypertension	B-Disease
in	O
diabetics	B-Disease
prone	O
to	O
hypoglycaemia	B-Disease
attacks	O
should	O
not	O
be	O
treated	O
with	O
beta	O
-	O
blockers	O
because	O
these	O
drugs	O
may	O
cause	O
a	O
sharp	O
rise	O
in	O
blood	O
-	O
pressure	O
in	O
such	O
patients	O
.	O
Long	O
-	O
term	O
propranolol	B-Chemical
therapy	O
in	O
pregnancy	O
:	O
maternal	O
and	O
fetal	O
outcome	O
.	O
Propranolol	B-Chemical
,	O
a	O
beta	O
-	O
adrenergic	O
blocking	O
agent	O
,	O
has	O
found	O
an	O
important	O
position	O
in	O
the	O
practice	O
of	O
medicine	O
.	O
Its	O
use	O
in	O
pregnancy	O
,	O
however	O
,	O
is	O
an	O
open	O
question	O
as	O
a	O
number	O
of	O
detrimental	O
side	O
effects	O
have	O
been	O
reported	O
in	O
the	O
fetus	O
and	O
neonate	O
.	O
Ten	O
patients	O
and	O
12	O
pregnancies	O
are	O
reported	O
where	O
chronic	O
propranolol	B-Chemical
has	O
been	O
administered	O
.	O
Five	O
patients	O
with	O
serial	O
pregnancies	O
with	O
and	O
without	O
propranolol	B-Chemical
therapy	O
are	O
also	O
examined	O
.	O
Maternal	O
,	O
fetal	O
,	O
and	O
neonatal	O
complications	O
are	O
examined	O
.	O
An	O
attempt	O
is	O
made	O
to	O
differentiate	O
drug	O
-	O
related	O
complications	O
from	O
maternal	O
disease	O
-	O
-	O
related	O
complications	O
.	O
We	O
conclude	O
that	O
previously	O
reported	O
hypoglycemia	B-Disease
,	O
hyperbilirubinemia	B-Disease
,	O
polycythemia	B-Disease
,	O
neonatal	B-Disease
apnea	I-Disease
,	O
and	O
bradycardia	B-Disease
are	O
not	O
invariable	O
and	O
cannot	O
be	O
statistically	O
correlated	O
with	O
chronic	O
propranolol	B-Chemical
therapy	O
.	O
Growth	B-Disease
retardation	I-Disease
,	O
however	O
,	O
appears	O
to	O
be	O
significant	O
in	O
both	O
of	O
our	O
series	O
.	O
Central	O
excitatory	O
actions	O
of	O
flurazepam	B-Chemical
.	O
Toxic	O
actions	O
of	O
flurazepam	B-Chemical
(	O
FZP	B-Chemical
)	O
were	O
studied	O
in	O
cats	O
,	O
mice	O
and	O
rats	O
.	O
High	O
doses	O
caused	O
an	O
apparent	O
central	O
excitation	O
,	O
most	O
clearly	O
seen	O
as	O
clonic	O
convulsions	B-Disease
,	O
superimposed	O
on	O
general	O
depression	B-Disease
.	O
Following	O
a	O
lethal	O
dose	O
,	O
death	O
was	O
always	O
associated	O
with	O
convulsions	B-Disease
.	O
Comparing	O
the	O
relative	O
sensitivity	O
to	O
central	O
depression	B-Disease
and	O
excitation	O
revealed	O
that	O
rats	O
were	O
least	O
likely	O
to	O
have	O
convulsions	B-Disease
at	O
doses	O
that	O
did	O
not	O
first	O
cause	O
loss	B-Disease
of	I-Disease
consciousness	I-Disease
,	O
while	O
cats	O
most	O
clearly	O
showed	O
marked	O
central	O
excitatory	O
actions	O
.	O
Signs	O
of	O
FZP	B-Chemical
toxocity	B-Disease
in	O
cats	O
included	O
excessive	O
salivation	B-Disease
,	O
extreme	O
apprehensive	O
behavior	O
,	O
retching	O
,	O
muscle	B-Disease
tremors	I-Disease
and	O
convulsions	B-Disease
.	O
An	O
interaction	O
between	O
FZP	B-Chemical
and	O
pentylenetetrazol	B-Chemical
(	O
PTZ	B-Chemical
)	O
was	O
shown	O
by	O
pretreating	O
mice	O
with	O
FZP	B-Chemical
before	O
PTZ	B-Chemical
challenge	O
.	O
As	O
a	O
function	O
of	O
dose	O
,	O
FZP	B-Chemical
first	O
protected	O
against	O
convulsions	B-Disease
and	O
death	O
.	O
At	O
higher	O
doses	O
,	O
however	O
,	O
convulsions	B-Disease
again	O
emerged	O
.	O
These	O
doses	O
of	O
FZP	B-Chemical
were	O
lower	O
than	O
those	O
that	O
would	O
alone	O
cause	O
convulsions	B-Disease
.	O
These	O
results	O
may	O
be	O
relevant	O
to	O
the	O
use	O
of	O
FZP	B-Chemical
in	O
clinical	O
situations	O
in	O
which	O
there	O
is	O
increased	O
neural	O
excitability	O
,	O
such	O
as	O
epilepsy	B-Disease
or	O
sedative	O
-	O
hypnotic	O
drug	O
withdrawal	O
.	O
Use	O
of	O
propranolol	B-Chemical
in	O
the	O
treatment	O
of	O
idiopathic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
.	O
Five	O
patients	O
with	O
idiopathic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
who	O
had	O
physiologic	O
and	O
biochemical	O
evidence	O
of	O
severe	O
autonomic	O
dysfunction	O
were	O
included	O
in	O
the	O
study	O
.	O
They	O
all	O
exhibited	O
markedly	O
reduced	O
plasma	O
catecholamines	B-Chemical
and	O
plasma	O
renin	O
activity	O
in	O
both	O
recumbent	O
and	O
upright	O
positions	O
and	O
had	O
marked	O
hypersensitivity	B-Disease
to	O
the	O
pressor	O
effects	O
of	O
infused	O
norepinephrine	B-Chemical
.	O
Treatment	O
with	O
propanolol	B-Chemical
administered	O
intravenously	O
(	O
1	O
-	O
5	O
mg	O
)	O
produced	O
increases	O
in	O
supine	O
and	O
upright	O
blood	O
pressure	O
in	O
4	O
of	O
the	O
5	O
individuals	O
with	O
rises	O
ranging	O
from	O
11	O
/	O
6	O
to	O
22	O
/	O
11	O
mmHg	O
.	O
Chronic	O
oral	O
administration	O
of	O
propranolol	B-Chemical
(	O
40	O
-	O
160	O
mg	O
/	O
day	O
)	O
also	O
elevated	O
the	O
blood	O
pressures	O
of	O
these	O
individuals	O
with	O
increases	O
in	O
the	O
order	O
of	O
20	O
-	O
35	O
/	O
15	O
-	O
25	O
mmg	O
being	O
observed	O
.	O
In	O
1	O
patient	O
,	O
marked	O
hypertension	B-Disease
was	O
induced	O
by	O
propranolol	B-Chemical
and	O
the	O
drug	O
had	O
to	O
be	O
withdrawn	O
.	O
It	O
otherwise	O
was	O
well	O
tolerated	O
and	O
no	O
important	O
side	O
effects	O
were	O
observed	O
.	O
Treatment	O
has	O
been	O
continued	O
in	O
3	O
individuals	O
for	O
6	O
-	O
13	O
months	O
with	O
persistence	O
of	O
the	O
pressor	O
effect	O
,	O
although	O
there	O
appears	O
to	O
have	O
been	O
some	O
decrease	O
in	O
the	O
degree	O
of	O
response	O
with	O
time	O
.	O
Hemodynamic	O
measurements	O
in	O
1	O
of	O
the	O
patients	O
demonstrated	O
an	O
increase	O
in	O
total	O
peripheral	O
resistance	O
and	O
essentially	O
no	O
change	O
in	O
cardiac	O
output	O
following	O
propranolol	B-Chemical
therapy	O
.	O
The	O
studies	O
suggest	O
that	O
propranolol	B-Chemical
is	O
a	O
useful	O
drug	O
in	O
selected	O
patients	O
with	O
severe	O
idiopathic	B-Disease
orthostatic	I-Disease
hypotension	I-Disease
.	O
Total	O
intravenous	O
anesthesia	O
with	O
etomidate	B-Chemical
.	O
III	O
.	O
Some	O
observations	O
in	O
adults	O
.	O
An	O
investigation	O
was	O
undertaken	O
to	O
determine	O
the	O
dosage	O
of	O
etomidate	B-Chemical
required	O
to	O
maintain	O
sleep	O
in	O
adults	O
undergoing	O
surgery	O
under	O
regional	O
local	O
anesthesia	O
.	O
Premedication	O
of	O
diazepam	B-Chemical
10	O
mg	O
and	O
atropine	B-Chemical
0	O
.	O
5	O
mg	O
was	O
given	O
,	O
and	O
sleep	O
was	O
induced	O
and	O
maintained	O
by	O
intermittent	O
intravenous	O
injections	O
of	O
etomidate	B-Chemical
0	O
.	O
1	O
/	O
mg	O
/	O
kg	O
,	O
given	O
whenever	O
the	O
patient	O
would	O
open	O
his	O
eyes	O
on	O
request	O
.	O
A	O
mean	O
overall	O
dose	O
of	O
etomidate	B-Chemical
17	O
.	O
4	O
microgram	O
/	O
kg	O
/	O
min	O
.	O
was	O
required	O
to	O
maintain	O
sleep	O
,	O
but	O
great	O
individual	O
variation	O
occurred	O
,	O
with	O
older	O
patients	O
requiring	O
less	O
drug	O
.	O
The	O
investigation	O
was	O
discontinued	O
after	O
18	O
patients	O
because	O
of	O
the	O
frequency	O
and	O
intensity	O
of	O
side	O
-	O
effects	O
,	O
particularly	O
pain	B-Disease
and	O
myoclonia	B-Disease
,	O
which	O
caused	O
the	O
technique	O
to	O
be	O
abandoned	O
in	O
two	O
cases	O
.	O
It	O
is	O
considered	O
unlikely	O
that	O
etomidate	B-Chemical
will	O
prove	O
to	O
be	O
the	O
hypnotic	O
of	O
choice	O
for	O
a	O
totally	O
intravenous	O
anesthetic	O
technique	O
in	O
adults	O
because	O
of	O
the	O
high	O
incidence	O
of	O
myoclonia	B-Disease
after	O
prolonged	O
administration	O
.	O
In	O
several	O
patients	O
uncontrollable	O
muscle	O
movements	O
persisted	O
for	O
many	O
minutes	O
after	O
complete	O
recovery	O
of	O
consciousness	O
.	O
Evidence	O
for	O
cardiac	O
beta	O
2	O
-	O
adrenoceptors	O
in	O
man	O
.	O
We	O
compared	O
the	O
effects	O
of	O
single	O
doses	O
of	O
50	O
mg	O
atenolol	B-Chemical
(	O
cardioselective	O
)	O
,	O
40	O
mg	O
propranolol	B-Chemical
(	O
nonselective	O
)	O
,	O
and	O
placebo	O
on	O
both	O
exercise	O
-	O
and	O
isoproterenol	B-Chemical
-	O
induced	O
tachycardia	B-Disease
in	O
two	O
experiments	O
involving	O
nine	O
normal	O
subjects	O
.	O
Maximal	O
exercise	O
heart	O
rate	O
was	O
reduced	O
from	O
187	O
+	O
/	O
-	O
4	O
(	O
SEM	O
)	O
after	O
placebo	O
to	O
146	O
+	O
/	O
-	O
7	O
bpm	O
after	O
atenolol	B-Chemical
and	O
138	O
+	O
/	O
-	O
6	O
bpm	O
after	O
propranolol	B-Chemical
,	O
but	O
there	O
were	O
no	O
differences	O
between	O
the	O
drugs	O
.	O
The	O
effects	O
on	O
isoproterenol	B-Chemical
tachycardia	B-Disease
were	O
determined	O
before	O
and	O
after	O
atropine	B-Chemical
(	O
0	O
.	O
04	O
mg	O
/	O
kg	O
IV	O
)	O
.	O
Isoproterenol	B-Chemical
sensitivity	O
was	O
determined	O
as	O
the	O
intravenous	O
dose	O
that	O
increased	O
heart	O
rate	O
by	O
25	O
bpm	O
(	O
CD25	O
)	O
and	O
this	O
was	O
increased	O
from	O
1	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
3	O
micrograms	O
after	O
placebo	O
to	O
38	O
.	O
9	O
+	O
/	O
-	O
8	O
.	O
3	O
micrograms	O
after	O
propranolol	B-Chemical
and	O
8	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
7	O
micrograms	O
after	O
atenolol	B-Chemical
.	O
The	O
difference	O
in	O
the	O
effects	O
of	O
the	O
two	O
was	O
significant	O
.	O
After	O
atropine	B-Chemical
the	O
CD25	O
was	O
unchanged	O
after	O
placebo	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
3	O
micrograms	O
)	O
and	O
atenolol	B-Chemical
(	O
7	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
3	O
micrograms	O
)	O
;	O
it	O
was	O
reduced	O
after	O
propranolol	B-Chemical
(	O
24	O
.	O
8	O
+	O
/	O
-	O
5	O
.	O
0	O
micrograms	O
)	O
,	O
but	O
remained	O
different	O
from	O
atenolol	B-Chemical
.	O
This	O
change	O
with	O
propranolol	B-Chemical
sensitivity	O
was	O
calculated	O
as	O
the	O
apparent	O
Ka	O
,	O
this	O
was	O
unchanged	O
by	O
atropine	B-Chemical
(	O
11	O
.	O
7	O
+	O
/	O
-	O
2	O
.	O
1	O
and	O
10	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
5	O
ml	O
/	O
ng	O
)	O
.	O
These	O
data	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
exercise	O
-	O
induced	O
tachycardia	B-Disease
results	O
largely	O
from	O
beta	O
1	O
-	O
receptor	O
activation	O
that	O
is	O
blocked	O
by	O
both	O
cardioselective	O
and	O
nonselective	O
drugs	O
,	O
whereas	O
isoproterenol	B-Chemical
activates	O
both	O
beta	O
1	O
-	O
and	O
beta	O
2	O
-	O
receptors	O
so	O
that	O
after	O
cardioselective	O
blockade	O
there	O
remains	O
a	O
beta	O
2	O
-	O
component	O
that	O
can	O
be	O
blocked	O
with	O
a	O
nonselective	O
drug	O
.	O
While	O
there	O
appear	O
to	O
be	O
beta	O
2	O
-	O
receptors	O
in	O
the	O
human	O
heart	O
,	O
their	O
physiologic	O
or	O
pathologic	O
roles	O
remain	O
to	O
be	O
defined	O
.	O
Hormones	O
and	O
risk	O
of	O
breast	B-Disease
cancer	I-Disease
.	O
This	O
paper	O
reports	O
the	O
results	O
of	O
a	O
study	O
of	O
50	O
menopausal	O
women	O
receiving	O
hormonal	O
replacement	O
therapy	O
.	O
The	O
majority	O
(	O
29	O
)	O
had	O
surgical	O
menopause	O
;	O
their	O
mean	O
age	O
was	O
45	O
.	O
7	O
years	O
.	O
It	O
was	O
hypothesized	O
that	O
progestins	B-Chemical
could	O
equilibrate	O
the	O
effects	O
of	O
the	O
estrogenic	O
stimulation	O
on	O
the	O
mammary	O
and	O
endometrial	O
target	O
tissues	O
of	O
women	O
on	O
hormonal	O
replacement	O
therapy	O
.	O
The	O
treatment	O
schedule	O
consisted	O
of	O
conjugated	B-Chemical
estrogens	I-Chemical
(	O
Premarin	B-Chemical
)	O
1	O
.	O
25	O
mg	O
/	O
day	O
for	O
21	O
days	O
and	O
Medroxyprogesterone	B-Chemical
acetate	I-Chemical
10	O
mg	O
/	O
day	O
for	O
10	O
days	O
in	O
each	O
month	O
.	O
The	O
mean	O
treatment	O
period	O
was	O
18	O
months	O
.	O
During	O
the	O
follow	O
-	O
up	O
period	O
,	O
attention	O
was	O
paid	O
to	O
breast	O
modifications	O
as	O
evidenced	O
by	O
symptomatology	O
,	O
physical	O
examination	O
,	O
and	O
plate	O
thermography	O
.	O
Mastodynia	B-Disease
was	O
reported	O
by	O
21	O
patients	O
,	O
and	O
physical	O
examination	O
revealed	O
a	O
light	O
increase	O
in	O
breast	O
firmness	O
in	O
12	O
women	O
and	O
a	O
moderate	O
increase	O
in	O
breast	O
nodularity	O
in	O
2	O
women	O
.	O
Themography	O
confirmed	O
the	O
existence	O
of	O
an	O
excessive	O
breast	O
stimulation	O
in	O
1	O
women	O
who	O
complained	O
of	O
moderate	O
mastodynia	B-Disease
and	O
in	O
5	O
of	O
the	O
7	O
women	O
who	O
complained	O
of	O
severe	O
mastodynia	B-Disease
.	O
Normalization	O
was	O
obtained	O
by	O
halving	O
the	O
estrogen	B-Chemical
dose	O
.	O
These	O
results	O
suggest	O
that	O
hormonal	O
replacement	O
therapy	O
can	O
be	O
safely	O
prescribed	O
if	O
the	O
following	O
criteria	O
are	O
satisfied	O
:	O
1	O
)	O
preliminary	O
evaluation	O
of	O
patients	O
from	O
a	O
clinical	O
,	O
metabolic	O
,	O
cytologic	O
,	O
and	O
mammographic	O
perspective	O
;	O
2	O
)	O
cyclic	O
treatment	O
schedule	O
,	O
with	O
a	O
progestative	O
phase	O
of	O
10	O
days	O
;	O
and	O
3	O
)	O
periodic	O
complete	O
follow	O
-	O
up	O
,	O
with	O
accurate	O
thermographic	O
evaluation	O
of	O
the	O
breast	O
target	O
tissues	O
.	O
Early	O
infections	B-Disease
in	O
kidney	O
,	O
heart	O
,	O
and	O
liver	O
transplant	O
recipients	O
on	O
cyclosporine	B-Chemical
.	O
Eighty	O
-	O
one	O
renal	O
,	O
seventeen	O
heart	O
,	O
and	O
twenty	O
-	O
four	O
liver	O
transplant	O
patients	O
were	O
followed	O
for	O
infection	B-Disease
.	O
Seventeen	O
renal	O
patients	O
received	O
azathioprine	B-Chemical
(	O
Aza	B-Chemical
)	O
and	O
prednisone	B-Chemical
as	O
part	O
of	O
a	O
randomized	O
trial	O
of	O
immunosuppression	O
with	O
21	O
cyclosporine	B-Chemical
-	O
and	O
-	O
prednisone	B-Chemical
-	O
treated	O
renal	O
transplant	O
patients	O
.	O
All	O
others	O
received	O
cyclosporine	B-Chemical
and	O
prednisone	B-Chemical
.	O
The	O
randomized	O
Aza	B-Chemical
patients	O
had	O
more	O
overall	O
infections	B-Disease
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
more	O
nonviral	O
infections	B-Disease
(	O
P	O
less	O
than	O
0	O
.	O
02	O
)	O
than	O
the	O
randomized	O
cyclosporine	B-Chemical
patients	O
.	O
Heart	O
and	O
liver	O
patients	O
had	O
more	O
infections	B-Disease
than	O
cyclosporine	B-Chemical
renal	O
patients	O
but	O
fewer	O
infections	B-Disease
than	O
the	O
Aza	B-Chemical
renal	O
patients	O
.	O
There	O
were	O
no	O
infectious	O
deaths	O
in	O
renal	O
transplant	O
patients	O
on	O
cyclosporine	B-Chemical
or	O
Aza	B-Chemical
,	O
but	O
infection	B-Disease
played	O
a	O
major	O
role	O
in	O
3	O
out	O
of	O
6	O
cardiac	O
transplant	O
deaths	O
and	O
in	O
8	O
out	O
of	O
9	O
liver	O
transplant	O
deaths	O
.	O
Renal	O
patients	O
on	O
cyclosporine	B-Chemical
had	O
the	O
fewest	O
bacteremias	B-Disease
.	O
Analysis	O
of	O
site	O
of	O
infection	B-Disease
showed	O
a	O
preponderance	O
of	O
abdominal	B-Disease
infections	I-Disease
in	O
liver	O
patients	O
,	O
intrathoracic	O
infections	B-Disease
in	O
heart	O
patients	O
,	O
and	O
urinary	B-Disease
tract	I-Disease
infections	I-Disease
in	O
renal	O
patients	O
.	O
Pulmonary	O
infections	B-Disease
were	O
less	O
common	O
in	O
cyclosporine	B-Chemical
-	O
treated	O
renal	O
patients	O
than	O
in	O
Aza	B-Chemical
-	O
treated	O
patients	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O
Aza	B-Chemical
patients	O
had	O
significantly	O
more	O
staphylococcal	B-Disease
infections	I-Disease
than	O
all	O
other	O
transplant	O
groups	O
(	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
,	O
and	O
systemic	O
fungal	B-Disease
infections	I-Disease
occurred	O
only	O
in	O
the	O
liver	O
transplant	O
group	O
.	O
Cytomegalovirus	O
(	O
CMV	O
)	O
shedding	O
or	O
serological	O
rises	O
in	O
antibody	O
titer	O
,	O
or	O
both	O
occurred	O
in	O
78	O
%	O
of	O
cyclosporine	B-Chemical
patients	O
and	O
76	O
%	O
of	O
Aza	B-Chemical
patients	O
.	O
Of	O
the	O
cyclosporine	B-Chemical
patients	O
,	O
15	O
%	O
had	O
symptoms	O
related	O
to	O
CMV	B-Disease
infection	I-Disease
.	O
Serological	O
evidence	O
for	O
Epstein	B-Disease
Barr	I-Disease
Virus	I-Disease
infection	I-Disease
was	O
found	O
in	O
20	O
%	O
of	O
65	O
cyclosporine	B-Chemical
patients	O
studied	O
.	O
Three	O
had	O
associated	O
symptoms	O
,	O
and	O
one	O
developed	O
a	O
lymphoma	B-Disease
.	O
Structure	O
-	O
activity	O
and	O
dose	O
-	O
effect	O
relationships	O
of	O
the	O
antagonism	O
of	O
picrotoxin	B-Chemical
-	O
induced	O
seizures	B-Disease
by	O
cholecystokinin	B-Chemical
,	O
fragments	O
and	O
analogues	O
of	O
cholecystokinin	B-Chemical
in	O
mice	O
.	O
Intraperitoneal	O
administration	O
of	O
cholecystokinin	B-Chemical
octapeptide	I-Chemical
sulphate	O
ester	O
(	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
SE	O
)	O
and	O
nonsulphated	O
cholecystokinin	B-Chemical
octapeptide	I-Chemical
(	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
NS	O
)	O
enhanced	O
the	O
latency	O
of	O
seizures	B-Disease
induced	O
by	O
picrotoxin	B-Chemical
in	O
mice	O
.	O
Experiments	O
with	O
N	O
-	O
and	O
C	O
-	O
terminal	O
fragments	O
revealed	O
that	O
the	O
C	O
-	O
terminal	O
tetrapeptide	O
(	O
CCK	O
-	O
5	O
-	O
8	O
)	O
was	O
the	O
active	O
centre	O
of	O
the	O
CCK	O
octapeptide	O
molecule	O
.	O
The	O
analogues	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
SE	O
and	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
NS	O
(	O
dose	O
range	O
0	O
.	O
2	O
-	O
6	O
.	O
4	O
mumol	O
/	O
kg	O
)	O
and	O
caerulein	B-Chemical
dose	O
range	O
0	O
.	O
1	O
-	O
0	O
.	O
8	O
mumol	O
/	O
kg	O
)	O
showed	O
bell	O
-	O
shaped	O
dose	O
-	O
effect	O
curves	O
,	O
with	O
the	O
greatest	O
maximum	O
inhibition	O
for	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
NS	O
.	O
The	O
peptide	O
CCK	O
-	O
5	O
-	O
8	O
had	O
weak	O
anticonvulsant	O
activity	O
in	O
comparison	O
to	O
the	O
octapeptides	O
,	O
3	O
.	O
2	O
mumol	O
/	O
kg	O
and	O
larger	O
doses	O
of	O
the	O
reference	O
drug	O
,	O
diazepam	B-Chemical
,	O
totally	O
prevented	O
picrotoxin	B-Chemical
-	O
induced	O
seizures	B-Disease
and	O
mortality	O
.	O
The	O
maximum	O
effect	O
of	O
the	O
peptides	O
tested	O
was	O
less	O
than	O
that	O
of	O
diazepam	B-Chemical
.	O
Experiments	O
with	O
analogues	O
and	O
derivatives	O
of	O
CCK	O
-	O
5	O
-	O
8	O
demonstrated	O
that	O
the	O
effectiveness	O
of	O
the	O
beta	O
-	O
alanyl	O
derivatives	O
of	O
CCK	O
-	O
5	O
-	O
8	O
were	O
enhanced	O
and	O
that	O
they	O
were	O
equipotent	O
with	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
SE	O
.	O
Of	O
the	O
CCK	O
-	O
2	O
-	O
8	O
analogues	O
,	O
Ser	O
(	O
SO3H	O
)	O
7	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	O
and	O
Thr	O
(	O
SO3H	O
)	O
7	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	O
and	O
Hyp	O
(	O
SO3H	O
)	O
-	O
Ac	O
-	O
CCK	O
-	O
2	O
-	O
8	O
-	O
SE	O
were	O
slightly	O
more	O
active	O
than	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
-	O
SE	O
.	O
Vasopressin	B-Chemical
as	O
a	O
possible	O
contributor	O
to	O
hypertension	B-Disease
.	O
The	O
role	O
of	O
vasopressin	B-Chemical
as	O
a	O
pressor	O
agent	O
to	O
the	O
hypertensive	B-Disease
process	O
was	O
examined	O
.	O
Vasopressin	B-Chemical
plays	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
of	O
DOCA	B-Chemical
-	O
salt	O
hypertension	B-Disease
,	O
since	O
the	O
elevation	O
of	O
blood	O
pressure	O
was	O
not	O
substantial	O
in	O
the	O
rats	O
with	O
lithium	B-Chemical
-	O
treated	O
diabetes	B-Disease
insipidus	I-Disease
after	O
DOCA	B-Chemical
-	O
salt	O
treatment	O
.	O
Administration	O
of	O
DDAVP	B-Chemical
which	O
has	O
antidiuretic	O
action	O
but	O
minimal	O
vasopressor	O
effect	O
failed	O
to	O
increase	O
blood	O
pressure	O
to	O
the	O
levels	O
observed	O
after	O
administration	O
of	O
AVP	O
.	O
Furthermore	O
,	O
the	O
pressor	O
action	O
of	O
vasopressin	B-Chemical
appears	O
to	O
be	O
important	O
in	O
the	O
development	O
of	O
this	O
model	O
of	O
hypertension	B-Disease
,	O
since	O
the	O
enhanced	O
pressor	O
responsiveness	O
to	O
the	O
hormone	O
was	O
observed	O
in	O
the	O
initial	O
stage	O
of	O
hypertension	B-Disease
.	O
Increased	O
secretion	O
of	O
vasopressin	B-Chemical
from	O
neurohypophysis	O
also	O
promotes	O
the	O
function	O
of	O
the	O
hormone	O
as	O
a	O
pathogenetic	O
factor	O
in	O
hypertension	B-Disease
.	O
An	O
unproportional	O
release	O
of	O
vasopressin	B-Chemical
compared	O
to	O
plasma	O
osmolality	O
may	O
be	O
induced	O
by	O
the	O
absence	O
of	O
an	O
adjusting	O
control	O
of	O
angiotensin	B-Chemical
II	O
forming	O
and	O
receptor	O
binding	O
capacity	O
for	O
sodium	B-Chemical
balance	O
in	O
the	O
brain	O
.	O
However	O
,	O
the	O
role	O
of	O
vasopressin	B-Chemical
remains	O
to	O
be	O
determined	O
in	O
human	O
essential	O
hypertension	B-Disease
.	O
Toxic	B-Disease
hepatitis	I-Disease
induced	O
by	O
disulfiram	B-Chemical
in	O
a	O
non	O
-	O
alcoholic	O
.	O
A	O
reversible	O
toxic	B-Disease
liver	I-Disease
damage	I-Disease
was	O
observed	O
in	O
a	O
non	O
-	O
alcoholic	O
woman	O
treated	O
with	O
disulfiram	B-Chemical
.	O
The	O
causative	O
relationship	O
was	O
proven	O
by	O
challenge	O
.	O
Atrial	B-Disease
thrombosis	I-Disease
involving	O
the	O
heart	O
of	O
F	O
-	O
344	O
rats	O
ingesting	O
quinacrine	B-Chemical
hydrochloride	I-Chemical
.	O
Quinacrine	B-Chemical
hydrochloride	I-Chemical
is	O
toxic	O
for	O
the	O
heart	O
of	O
F	O
-	O
344	O
rats	O
.	O
Rats	O
treated	O
with	O
500	O
ppm	O
quinacrine	B-Chemical
hydrochloride	I-Chemical
in	O
the	O
diet	O
all	O
developed	O
a	O
high	O
incidence	O
of	O
left	O
atrial	B-Disease
thrombosis	I-Disease
.	O
The	O
lesion	O
was	O
associated	O
with	O
cardiac	B-Disease
hypertrophy	I-Disease
and	O
dilatation	O
and	O
focal	O
myocardial	B-Disease
degeneration	I-Disease
.	O
Rats	O
died	O
from	O
cardiac	B-Disease
hypertrophy	I-Disease
with	O
severe	O
acute	O
and	O
chronic	O
congestion	O
of	O
the	O
lungs	O
,	O
liver	O
,	O
and	O
other	O
organs	O
.	O
Seventy	O
percent	O
of	O
rats	O
given	O
250	O
ppm	O
quinacrine	B-Chemical
hydrochloride	I-Chemical
and	O
1	O
,	O
000	O
ppm	O
sodium	B-Chemical
nitrite	I-Chemical
simultaneously	O
in	O
the	O
diet	O
had	O
thrombosis	B-Disease
of	O
the	O
atria	O
of	O
the	O
heart	O
,	O
while	O
untreated	O
control	O
rats	O
in	O
this	O
laboratory	O
did	O
not	O
have	O
atrial	B-Disease
thrombosis	I-Disease
.	O
Sodium	B-Chemical
nitrite	I-Chemical
in	O
combination	O
with	O
quinacrine	B-Chemical
hydrochloride	I-Chemical
appeared	O
to	O
have	O
no	O
additional	O
effect	O
.	O
Alternating	B-Disease
sinus	I-Disease
rhythm	I-Disease
and	O
intermittent	O
sinoatrial	B-Disease
block	I-Disease
induced	O
by	O
propranolol	B-Chemical
.	O
Alternating	B-Disease
sinus	I-Disease
rhythm	I-Disease
and	O
intermittent	O
sinoatrial	B-Disease
(	I-Disease
S	I-Disease
-	I-Disease
A	I-Disease
)	I-Disease
block	I-Disease
was	O
observed	O
in	O
a	O
57	O
-	O
year	O
-	O
old	O
woman	O
,	O
under	O
treatment	O
for	O
angina	B-Disease
with	O
80	O
mg	O
propranolol	B-Chemical
daily	O
.	O
The	O
electrocardiogram	O
showed	O
alternation	O
of	O
long	O
and	O
short	O
P	O
-	O
P	O
intervals	O
and	O
occasional	O
pauses	O
.	O
These	O
pauses	O
were	O
always	O
preceded	O
by	O
the	O
short	O
P	O
-	O
P	O
intervals	O
and	O
were	O
usually	O
followed	O
by	O
one	O
or	O
two	O
P	O
-	O
P	O
intervals	O
of	O
0	O
.	O
92	O
-	O
0	O
.	O
95	O
s	O
representing	O
the	O
basic	O
sinus	O
cycle	O
.	O
Following	O
these	O
basic	O
sinus	O
cycles	O
,	O
alternating	B-Disease
rhythm	I-Disease
started	O
with	O
the	O
longer	O
P	O
-	O
P	O
interval	O
.	O
The	O
long	O
P	O
-	O
P	O
intervals	O
ranged	O
between	O
1	O
.	O
04	O
-	O
1	O
.	O
12	O
s	O
and	O
the	O
short	O
P	O
-	O
P	O
intervals	O
between	O
0	O
.	O
80	O
-	O
0	O
.	O
84	O
s	O
,	O
respectively	O
.	O
The	O
duration	O
of	O
the	O
pauses	O
were	O
equal	O
or	O
almost	O
equal	O
to	O
one	O
short	O
plus	O
one	O
long	O
P	O
-	O
P	O
interval	O
or	O
to	O
twice	O
the	O
basic	O
sinus	O
cycle	O
.	O
In	O
one	O
recording	O
a	O
short	O
period	O
of	O
regular	O
sinus	O
rhythm	O
with	O
intermittent	O
2	O
/	O
1	O
S	B-Disease
-	I-Disease
A	I-Disease
block	I-Disease
was	O
observed	O
.	O
This	O
short	O
period	O
of	O
sinus	O
rhythm	O
was	O
interrupted	O
by	O
sudden	O
prolongation	O
of	O
the	O
P	O
-	O
P	O
interval	O
starting	O
the	O
alternative	O
rhythm	O
.	O
There	O
were	O
small	O
changes	O
in	O
the	O
shape	O
of	O
the	O
P	O
waves	O
and	O
P	O
-	O
R	O
intervals	O
.	O
S	O
-	O
A	O
conduction	O
through	O
two	O
pathways	O
,	O
the	O
first	O
with	O
2	O
/	O
1	O
block	O
the	O
second	O
having	O
0	O
.	O
12	O
-	O
0	O
.	O
14	O
s	O
longer	O
conduction	O
time	O
and	O
with	O
occasional	O
2	O
/	O
1	O
block	O
was	O
proposed	O
for	O
the	O
explanation	O
of	O
the	O
alternating	O
P	O
-	O
P	O
interval	O
and	O
other	O
electrocardiographic	O
features	O
seen	O
.	O
Atropine	B-Chemical
1	O
mg	O
given	O
intravenously	O
resulted	O
in	O
shortening	O
of	O
all	O
P	O
-	O
P	O
intervals	O
without	O
changing	O
the	O
rhythm	O
.	O
The	O
abnormal	O
rhythm	O
disappeared	O
with	O
the	O
withdrawal	O
of	O
propranolol	B-Chemical
and	O
when	O
the	O
drug	O
was	O
restarted	O
a	O
2	O
/	O
1	O
S	B-Disease
-	I-Disease
A	I-Disease
block	I-Disease
was	O
seen	O
.	O
This	O
was	O
accepted	O
as	O
evidence	O
for	O
propranolol	B-Chemical
being	O
the	O
cause	O
of	O
this	O
conduction	B-Disease
disorder	I-Disease
.	O
Antitumor	O
effect	O
,	O
cardiotoxicity	B-Disease
,	O
and	O
nephrotoxicity	B-Disease
of	O
doxorubicin	B-Chemical
in	O
the	O
IgM	O
solid	O
immunocytoma	B-Disease
-	O
bearing	O
LOU	O
/	O
M	O
/	O
WSL	O
rat	O
.	O
Antitumor	O
activity	O
,	O
cardiotoxicity	B-Disease
,	O
and	O
nephrotoxicity	B-Disease
induced	O
by	O
doxorubicin	B-Chemical
were	O
studied	O
in	O
LOU	O
/	O
M	O
/	O
WSL	O
inbred	O
rats	O
each	O
bearing	O
a	O
transplantable	O
solid	O
IgM	O
immunocytoma	B-Disease
.	O
Animals	O
with	O
a	O
tumor	B-Disease
(	O
diameter	O
,	O
15	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
3	O
mm	O
)	O
were	O
treated	O
with	O
iv	O
injections	O
of	O
doxorubicin	B-Chemical
on	O
5	O
consecutive	O
days	O
,	O
followed	O
by	O
1	O
weekly	O
injection	O
for	O
7	O
weeks	O
(	O
dose	O
range	O
,	O
0	O
.	O
015	O
-	O
4	O
.	O
0	O
mg	O
/	O
kg	O
body	O
wt	O
)	O
.	O
Tumor	B-Disease
regression	O
was	O
observed	O
with	O
0	O
.	O
5	O
mg	O
doxorubicin	B-Chemical
/	O
kg	O
.	O
Complete	O
disappearance	O
of	O
the	O
tumor	B-Disease
was	O
induced	O
with	O
1	O
.	O
0	O
mg	O
doxorubicin	B-Chemical
/	O
kg	O
.	O
Histologic	O
evidence	O
of	O
cardiotoxicity	B-Disease
scored	O
as	O
grade	O
III	O
was	O
only	O
observed	O
at	O
a	O
dose	O
of	O
1	O
.	O
0	O
mg	O
doxorubicin	B-Chemical
/	O
kg	O
.	O
Light	O
microscopic	O
evidence	O
of	O
renal	B-Disease
damage	I-Disease
was	O
seen	O
above	O
a	O
dose	O
of	O
0	O
.	O
5	O
mg	O
doxorubicin	B-Chemical
/	O
kg	O
,	O
which	O
resulted	O
in	O
albuminuria	B-Disease
and	O
very	O
low	O
serum	O
albumin	O
levels	O
.	O
In	O
the	O
group	O
that	O
received	O
1	O
.	O
0	O
mg	O
doxorubicin	B-Chemical
/	O
kg	O
,	O
the	O
serum	O
albumin	O
level	O
decreased	O
from	O
33	O
.	O
6	O
+	O
/	O
-	O
4	O
.	O
1	O
to	O
1	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
5	O
g	O
/	O
liter	O
.	O
Ascites	B-Disease
and	O
hydrothorax	B-Disease
were	O
observed	O
simultaneously	O
.	O
The	O
same	O
experiments	O
were	O
performed	O
with	O
non	O
-	O
tumor	B-Disease
-	O
bearing	O
rats	O
,	O
in	O
which	O
no	O
major	O
differences	O
were	O
observed	O
.	O
In	O
conclusion	O
,	O
antitumor	O
activity	O
,	O
cardiotoxicity	B-Disease
,	O
and	O
nephrotoxicity	B-Disease
were	O
studied	O
simultaneously	O
in	O
the	O
same	O
LOU	O
/	O
M	O
/	O
WSL	O
rat	O
.	O
Albuminuria	B-Disease
due	O
to	O
renal	B-Disease
damage	I-Disease
led	O
to	O
extremely	O
low	O
serum	O
albumin	O
levels	O
,	O
so	O
ascites	B-Disease
and	O
hydrothorax	B-Disease
were	O
not	O
necessarily	O
a	O
consequence	O
of	O
the	O
observed	O
cardiomyopathy	B-Disease
.	O
Intraoperative	O
bradycardia	B-Disease
and	O
hypotension	B-Disease
associated	O
with	O
timolol	B-Chemical
and	O
pilocarpine	B-Chemical
eye	O
drops	O
.	O
A	O
69	O
-	O
yr	O
-	O
old	O
man	O
,	O
who	O
was	O
concurrently	O
being	O
treated	O
with	O
pilocarpine	B-Chemical
nitrate	I-Chemical
and	O
timolol	B-Chemical
maleate	I-Chemical
eye	O
drops	O
,	O
developed	O
a	O
bradycardia	B-Disease
and	O
became	O
hypotensive	B-Disease
during	O
halothane	B-Chemical
anaesthesia	O
.	O
Both	O
timolol	B-Chemical
and	O
pilocarpine	B-Chemical
were	O
subsequently	O
identified	O
in	O
a	O
24	O
-	O
h	O
collection	O
of	O
urine	O
.	O
Timolol	B-Chemical
(	O
but	O
not	O
pilocarpine	B-Chemical
)	O
was	O
detected	O
in	O
a	O
sample	O
of	O
plasma	O
removed	O
during	O
surgery	O
;	O
the	O
plasma	O
concentration	O
of	O
timolol	B-Chemical
(	O
2	O
.	O
6	O
ng	O
ml	O
-	O
1	O
)	O
was	O
consistent	O
with	O
partial	O
beta	O
-	O
adrenoceptor	O
blockade	O
.	O
It	O
is	O
postulated	O
that	O
this	O
action	O
may	O
have	O
been	O
enhanced	O
during	O
halothane	B-Chemical
anaesthesia	O
with	O
resultant	O
bradycardia	B-Disease
and	O
hypotension	B-Disease
.	O
Pilocarpine	B-Chemical
may	O
have	O
had	O
a	O
contributory	O
effect	O
.	O
Succinylcholine	B-Chemical
apnoea	B-Disease
:	O
attempted	O
reversal	O
with	O
anticholinesterases	O
.	O
Anticholinesterases	O
were	O
administered	O
in	O
an	O
attempt	O
to	O
antagonize	O
prolonged	O
neuromuscular	B-Disease
blockade	I-Disease
following	O
the	O
administration	O
of	O
succinylcholine	B-Chemical
in	O
a	O
patient	O
later	O
found	O
to	O
be	O
homozygous	O
for	O
atypical	O
plasma	O
cholinesterase	O
.	O
Edrophonium	B-Chemical
10	O
mg	O
,	O
given	O
74	O
min	O
after	O
succinylcholine	B-Chemical
,	O
when	O
train	O
-	O
of	O
-	O
four	O
stimulation	O
was	O
characteristic	O
of	O
phase	O
II	O
block	O
,	O
produced	O
partial	O
antagonism	O
which	O
was	O
not	O
sustained	O
.	O
Repeated	O
doses	O
of	O
edrophonium	B-Chemical
to	O
70	O
mg	O
and	O
neostigmine	B-Chemical
to	O
2	O
.	O
5	O
mg	O
did	O
not	O
antagonize	O
or	O
augment	O
the	O
block	O
.	O
Spontaneous	O
respiration	O
recommenced	O
200	O
min	O
after	O
succinylcholine	B-Chemical
administration	O
.	O
It	O
is	O
concluded	O
that	O
anticholinesterases	O
are	O
only	O
partially	O
effective	O
in	O
restoring	O
neuromuscular	O
function	O
in	O
succinylcholine	B-Chemical
apnoea	B-Disease
despite	O
muscle	O
twitch	O
activity	O
typical	O
of	O
phase	O
II	O
block	O
.	O
Effect	O
of	O
doxorubicin	B-Chemical
on	O
[	B-Chemical
omega	I-Chemical
-	I-Chemical
I	I-Chemical
-	I-Chemical
131	I-Chemical
]	I-Chemical
heptadecanoic	I-Chemical
acid	I-Chemical
myocardial	O
scintigraphy	O
and	O
echocardiography	O
in	O
dogs	O
.	O
The	O
effects	O
of	O
serial	O
treatment	O
with	O
doxorubicin	B-Chemical
on	O
dynamic	O
myocardial	O
scintigraphy	O
with	O
[	B-Chemical
omega	I-Chemical
-	I-Chemical
I	I-Chemical
-	I-Chemical
131	I-Chemical
]	I-Chemical
heptadecanoic	I-Chemical
acid	I-Chemical
(	O
I	B-Chemical
-	I-Chemical
131	I-Chemical
HA	I-Chemical
)	O
,	O
and	O
on	O
global	O
left	O
-	O
ventricular	O
function	O
determined	O
echocardiographically	O
,	O
were	O
studied	O
in	O
a	O
group	O
of	O
nine	O
mongrel	O
dogs	O
.	O
Total	O
extractable	O
myocardial	O
lipid	O
was	O
compared	O
postmortem	O
between	O
a	O
group	O
of	O
control	O
dogs	O
and	O
doxorubicin	B-Chemical
-	O
treated	O
dogs	O
.	O
A	O
significant	O
and	O
then	O
progressive	O
fall	O
in	O
global	O
LV	O
function	O
was	O
observed	O
at	O
a	O
cumulative	O
doxorubicin	B-Chemical
dose	O
of	O
4	O
mg	O
/	O
kg	O
.	O
A	O
significant	O
increase	O
in	O
the	O
myocardial	O
t1	O
/	O
2	O
of	O
the	O
I	B-Chemical
-	I-Chemical
131	I-Chemical
HA	I-Chemical
was	O
observed	O
only	O
at	O
a	O
higher	O
cumulative	O
dose	O
,	O
10	O
mg	O
/	O
kg	O
.	O
No	O
significant	O
alteration	O
in	O
total	O
extractable	O
myocardial	O
lipids	O
was	O
observed	O
between	O
control	O
dogs	O
and	O
those	O
treated	O
with	O
doxorubicin	B-Chemical
.	O
Our	O
findings	O
suggest	O
that	O
the	O
changes	O
leading	O
to	O
an	O
alteration	O
of	O
myocardial	O
dynamic	O
imaging	O
with	O
I	B-Chemical
-	I-Chemical
131	I-Chemical
HA	I-Chemical
are	O
not	O
the	O
initiating	O
factor	O
in	O
doxorubicin	B-Chemical
cardiotoxicity	B-Disease
.	O
Hemodynamics	O
and	O
myocardial	O
metabolism	O
under	O
deliberate	O
hypotension	B-Disease
.	O
An	O
experimental	O
study	O
in	O
dogs	O
.	O
Coronary	O
blood	O
flow	O
,	O
cardiac	O
work	O
and	O
metabolism	O
were	O
studied	O
in	O
dogs	O
under	O
sodium	B-Chemical
nitroprusside	I-Chemical
(	O
SNP	B-Chemical
)	O
and	O
trimetaphan	B-Chemical
(	O
TMP	B-Chemical
)	O
deliberate	O
hypotension	B-Disease
(	O
20	O
%	O
and	O
40	O
%	O
mean	O
pressure	O
decrease	O
from	O
baseline	O
)	O
.	O
Regarding	O
the	O
effects	O
of	O
drug	O
-	O
induced	O
hypotension	B-Disease
on	O
coronary	O
blood	O
flow	O
,	O
aortic	O
and	O
coronary	O
sinus	O
metabolic	O
data	O
(	O
pH	O
,	O
pO2	O
,	O
pCO2	O
)	O
we	O
could	O
confirm	O
that	O
nitroprusside	B-Chemical
hypotension	B-Disease
could	O
be	O
safely	O
used	O
to	O
30	O
%	O
mean	O
blood	O
pressure	O
decrease	O
from	O
control	O
,	O
trimetaphan	B-Chemical
hypotension	B-Disease
to	O
20	O
%	O
mean	O
blood	O
pressure	O
decrease	O
.	O
Cardiac	O
work	O
was	O
significantly	O
reduced	O
during	O
SNP	B-Chemical
hypotension	B-Disease
.	O
Myocardial	O
O2	B-Chemical
consumption	O
and	O
O2	B-Chemical
availability	O
were	O
directly	O
dependent	O
on	O
the	O
coronary	O
perfusion	O
.	O
Careful	O
invasive	O
monitoring	O
of	O
the	O
blood	O
pressure	O
,	O
blood	O
gases	O
and	O
of	O
the	O
ECG	O
ST	O
-	O
T	O
segment	O
is	O
mandatory	O
.	O
Evidence	O
for	O
a	O
selective	O
brain	O
noradrenergic	O
involvement	O
in	O
the	O
locomotor	O
stimulant	O
effects	O
of	O
amphetamine	B-Chemical
in	O
the	O
rat	O
.	O
Male	O
rats	O
received	O
the	O
noradrenaline	B-Chemical
neurotoxin	O
DSP4	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
)	O
7	O
days	O
prior	O
to	O
injection	O
of	O
D	B-Chemical
-	I-Chemical
amphetamine	I-Chemical
(	O
10	O
or	O
40	O
mumol	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
.	O
The	O
hyperactivity	B-Disease
induced	O
by	O
D	B-Chemical
-	I-Chemical
amphetamine	I-Chemical
(	O
10	O
mumol	O
/	O
kg	O
)	O
was	O
significantly	O
reduced	O
by	O
DSP4	B-Chemical
pretreatment	O
.	O
However	O
,	O
the	O
increased	O
rearings	O
and	O
the	O
amphetamine	B-Chemical
-	O
induced	O
stereotypies	B-Disease
were	O
not	O
blocked	O
by	O
pretreatment	O
with	O
DSP4	B-Chemical
.	O
The	O
reduction	O
of	O
amphetamine	B-Chemical
hyperactivity	B-Disease
induced	O
by	O
DSP4	B-Chemical
was	O
blocked	O
by	O
pretreatment	O
with	O
the	O
noradrenaline	B-Chemical
-	O
uptake	O
blocking	O
agent	O
,	O
desipramine	B-Chemical
,	O
which	O
prevents	O
the	O
neurotoxic	B-Disease
action	O
of	O
DSP4	B-Chemical
.	O
The	O
present	O
results	O
suggest	O
a	O
selective	O
involvement	O
of	O
central	O
noradrenergic	O
neurones	O
in	O
the	O
locomotor	O
stimulant	O
effect	O
of	O
amphetamine	B-Chemical
in	O
the	O
rat	O
.	O
Accelerated	B-Disease
junctional	I-Disease
rhythms	I-Disease
during	O
oral	O
verapamil	B-Chemical
therapy	O
.	O
This	O
study	O
examined	O
the	O
frequency	O
of	O
atrioventricular	O
(	O
AV	O
)	O
dissociation	O
and	O
accelerated	B-Disease
junctional	I-Disease
rhythms	I-Disease
in	O
59	O
patients	O
receiving	O
oral	O
verapamil	B-Chemical
.	O
Accelerated	B-Disease
junctional	I-Disease
rhythms	I-Disease
and	O
AV	O
dissociation	O
were	O
frequent	O
in	O
patients	O
with	O
supraventricular	B-Disease
tachyarrhythmias	I-Disease
,	O
particularly	O
AV	O
nodal	O
reentry	O
.	O
Verapamil	B-Chemical
administration	O
to	O
these	O
patients	O
led	O
to	O
an	O
asymptomatic	O
increase	O
in	O
activity	O
of	O
these	O
junctional	O
pacemakers	O
.	O
In	O
patients	O
with	O
various	O
chest	B-Disease
pain	I-Disease
syndromes	O
,	O
verapamil	B-Chemical
neither	O
increased	O
the	O
frequency	O
of	O
junctional	O
rhythms	O
nor	O
suppressed	O
their	O
role	O
as	O
escape	O
rhythms	O
under	O
physiologically	O
appropriate	O
circumstances	O
.	O
Interstrain	O
variation	O
in	O
acute	O
toxic	O
response	O
to	O
caffeine	B-Chemical
among	O
inbred	O
mice	O
.	O
Acute	O
toxic	O
dosage	O
-	O
dependent	O
behavioral	O
effects	O
of	O
caffeine	B-Chemical
were	O
compared	O
in	O
adult	O
males	O
from	O
seven	O
inbred	O
mouse	O
strains	O
(	O
A	O
/	O
J	O
,	O
BALB	O
/	O
cJ	O
,	O
CBA	O
/	O
J	O
,	O
C3H	O
/	O
HeJ	O
,	O
C57BL	O
/	O
6J	O
,	O
DBA	O
/	O
2J	O
,	O
SWR	O
/	O
J	O
)	O
.	O
C57BL	O
/	O
6J	O
,	O
chosen	O
as	O
a	O
""""	O
prototypic	O
""""	O
mouse	O
strain	O
,	O
was	O
used	O
to	O
determine	O
behavioral	O
responses	O
to	O
a	O
broad	O
range	O
(	O
5	O
-	O
500	O
mg	O
/	O
kg	O
)	O
of	O
caffeine	B-Chemical
doses	O
.	O
Five	O
phenotypic	O
characteristics	O
-	O
-	O
locomotor	O
activity	O
,	O
righting	O
ability	O
,	O
clonic	B-Disease
seizure	I-Disease
induction	O
,	O
stress	O
-	O
induced	O
lethality	O
,	O
death	O
without	O
external	O
stress	O
-	O
-	O
were	O
scored	O
at	O
various	O
caffeine	B-Chemical
doses	O
in	O
drug	O
-	O
naive	O
animals	O
under	O
empirically	O
optimized	O
,	O
rigidly	O
constant	O
experimental	O
conditions	O
.	O
Mice	O
(	O
n	O
=	O
12	O
for	O
each	O
point	O
)	O
received	O
single	O
IP	O
injections	O
of	O
a	O
fixed	O
volume	O
/	O
g	O
body	O
weight	O
of	O
physiological	O
saline	O
carrier	O
with	O
or	O
without	O
caffeine	B-Chemical
in	O
doses	O
ranging	O
from	O
125	O
-	O
500	O
mg	O
/	O
kg	O
.	O
Loss	O
of	O
righting	O
ability	O
was	O
scored	O
at	O
1	O
,	O
3	O
,	O
5	O
min	O
post	O
dosing	O
and	O
at	O
5	O
min	O
intervals	O
thereafter	O
for	O
20	O
min	O
.	O
In	O
the	O
same	O
animals	O
the	O
occurrence	O
of	O
clonic	B-Disease
seizures	I-Disease
was	O
scored	O
as	O
to	O
time	O
of	O
onset	O
and	O
severity	O
for	O
20	O
min	O
after	O
drug	O
administration	O
.	O
When	O
these	O
proceeded	O
to	O
tonic	B-Disease
seizures	I-Disease
,	O
death	O
occurred	O
in	O
less	O
than	O
20	O
min	O
.	O
Animals	O
surviving	O
for	O
20	O
min	O
were	O
immediately	O
stressed	O
by	O
a	O
swim	O
test	O
in	O
25	O
degrees	O
C	O
water	O
,	O
and	O
death	O
-	O
producing	O
tonic	B-Disease
seizures	I-Disease
were	O
scored	O
for	O
2	O
min	O
.	O
In	O
other	O
animals	O
locomotor	O
activity	O
was	O
measured	O
15	O
or	O
60	O
min	O
after	O
caffeine	B-Chemical
administration	O
.	O
By	O
any	O
single	O
behavioral	O
criterion	O
or	O
a	O
combination	O
of	O
these	O
criteria	O
,	O
marked	O
differences	O
in	O
response	O
to	O
toxic	O
caffeine	B-Chemical
doses	O
were	O
observed	O
between	O
strains	O
.	O
These	O
results	O
indicate	O
that	O
behavioral	O
toxicity	B-Disease
testing	O
of	O
alkylxanthines	B-Chemical
in	O
a	O
single	O
mouse	O
strain	O
may	O
be	O
misleading	O
and	O
suggest	O
that	O
toxic	O
responses	O
of	O
the	O
central	O
nervous	O
system	O
to	O
this	O
class	O
of	O
compounds	O
are	O
genetically	O
influenced	O
in	O
mammals	O
.	O
Treatment	O
of	O
ovarian	B-Disease
cancer	I-Disease
with	O
a	O
combination	O
of	O
cis	B-Chemical
-	I-Chemical
platinum	I-Chemical
,	O
adriamycin	B-Chemical
,	O
cyclophosphamide	B-Chemical
and	O
hexamethylmelamine	B-Chemical
.	O
During	O
the	O
last	O
2	O
1	O
/	O
2	O
years	O
,	O
38	O
patients	O
with	O
ovarian	B-Disease
cancer	I-Disease
were	O
treated	O
with	O
a	O
combination	O
of	O
cisplatinum	B-Chemical
(	O
CPDD	B-Chemical
)	O
,	O
50	O
mg	O
/	O
m2	O
,	O
adriamycin	B-Chemical
,	O
30	O
mg	O
/	O
m2	O
,	O
cyclophosphamide	B-Chemical
,	O
300	O
mg	O
/	O
m2	O
,	O
on	O
day	O
1	O
;	O
and	O
hexamethylmelamine	B-Chemical
(	O
HMM	B-Chemical
)	O
,	O
6	O
mg	O
/	O
kg	O
daily	O
,	O
for	O
14	O
days	O
.	O
Each	O
course	O
was	O
repeated	O
monthly	O
.	O
2	O
patients	O
had	O
stage	O
II	O
,	O
14	O
stage	O
III	O
and	O
22	O
stage	O
IV	O
disease	O
.	O
14	O
of	O
the	O
38	O
patients	O
were	O
previously	O
treated	O
with	O
chemotherapy	O
,	O
1	O
with	O
radiation	O
,	O
6	O
with	O
both	O
chemotherapy	O
and	O
radiation	O
,	O
and	O
17	O
did	O
not	O
have	O
any	O
treatment	O
before	O
CPDD	B-Chemical
combination	O
.	O
31	O
of	O
the	O
38	O
cases	O
(	O
81	O
.	O
5	O
%	O
)	O
demonstrated	O
objective	O
responses	O
lasting	O
for	O
2	O
months	O
or	O
more	O
.	O
These	O
responses	O
were	O
partial	O
in	O
19	O
and	O
complete	O
in	O
12	O
cases	O
.	O
Hematologic	B-Disease
toxicity	I-Disease
was	O
moderate	O
and	O
with	O
reversible	O
anemia	B-Disease
developing	O
in	O
71	O
%	O
of	O
patients	O
.	O
Gastrointestinal	O
side	O
effects	O
from	O
CPDD	B-Chemical
were	O
universal	O
.	O
HMM	B-Chemical
gastrointestinal	B-Disease
toxicity	I-Disease
necessitated	O
discontinuation	O
of	O
the	O
drug	O
in	O
5	O
patients	O
.	O
Severe	O
nephrotoxicity	B-Disease
was	O
observed	O
in	O
2	O
patients	O
but	O
was	O
reversible	O
.	O
There	O
were	O
no	O
drug	O
-	O
related	O
deaths	O
.	O
Nontraumatic	O
dissecting	B-Disease
aneurysm	I-Disease
of	O
the	O
basilar	O
artery	O
.	O
A	O
case	O
of	O
nontraumatic	O
dissecting	B-Disease
aneurysm	I-Disease
of	O
the	O
basilar	O
artery	O
in	O
association	O
with	O
hypertension	B-Disease
,	O
smoke	O
,	O
and	O
oral	B-Chemical
contraceptives	I-Chemical
is	O
reported	O
in	O
a	O
young	O
female	O
patient	O
with	O
a	O
locked	B-Disease
-	I-Disease
in	I-Disease
syndrome	I-Disease
.	O
A	O
method	O
for	O
the	O
measurement	O
of	O
tremor	B-Disease
,	O
and	O
a	O
comparison	O
of	O
the	O
effects	O
of	O
tocolytic	O
beta	O
-	O
mimetics	O
.	O
A	O
method	O
permitting	O
measurement	O
of	O
finger	O
tremor	B-Disease
as	O
a	O
displacement	O
-	O
time	O
curve	O
is	O
described	O
,	O
using	O
a	O
test	O
system	O
with	O
simple	O
amplitude	O
calibration	O
.	O
The	O
coordinates	O
of	O
the	O
inversion	O
points	O
of	O
the	O
displacement	O
-	O
time	O
curves	O
were	O
transferred	O
through	O
graphical	O
input	O
equipment	O
to	O
punched	O
tape	O
.	O
By	O
means	O
of	O
a	O
computer	O
program	O
,	O
periods	O
and	O
amplitudes	O
of	O
tremor	B-Disease
oscillations	O
were	O
calculated	O
and	O
classified	O
.	O
The	O
event	O
frequency	O
for	O
each	O
class	O
of	O
periods	O
and	O
amplitudes	O
was	O
determined	O
.	O
The	O
actions	O
of	O
fenoterol	B-Chemical
-	I-Chemical
hydrobromide	I-Chemical
,	O
ritodrin	B-Chemical
-	I-Chemical
HCl	I-Chemical
and	O
placebo	O
given	O
to	O
10	O
healthy	O
subjects	O
by	O
intravenous	O
infusion	O
in	O
a	O
double	O
-	O
blind	O
crossover	O
study	O
were	O
tested	O
by	O
this	O
method	O
.	O
At	O
therapeutic	O
doses	O
both	O
substances	O
raised	O
the	O
mean	O
tremor	B-Disease
amplitude	O
to	O
about	O
three	O
times	O
the	O
control	O
level	O
.	O
At	O
the	O
same	O
time	O
,	O
the	O
mean	O
period	O
within	O
each	O
class	O
of	O
amplitudes	O
shortened	O
by	O
10	O
-	O
-	O
20	O
ms	O
,	O
whereas	O
the	O
mean	O
periods	O
calculated	O
from	O
all	O
oscillations	O
together	O
did	O
not	O
change	O
significantly	O
.	O
After	O
the	O
end	O
of	O
fenoterol	B-Chemical
-	I-Chemical
hydrobromide	I-Chemical
infusion	O
,	O
tremor	B-Disease
amplitudes	O
decreased	O
significantly	O
faster	O
than	O
those	O
following	O
ritodrin	B-Chemical
-	I-Chemical
HCl	I-Chemical
infusion	O
.	O
Propylthiouracil	B-Chemical
-	O
induced	O
hepatic	B-Disease
damage	I-Disease
.	O
Two	O
cases	O
of	O
propylthiouracil	B-Chemical
-	O
induced	O
liver	B-Disease
damage	I-Disease
have	O
been	O
observed	O
.	O
The	O
first	O
case	O
is	O
of	O
an	O
acute	O
type	O
of	O
damage	O
,	O
proven	O
by	O
rechallenge	O
;	O
the	O
second	O
presents	O
a	O
clinical	O
and	O
histologic	O
picture	O
resembling	O
chronic	B-Disease
active	I-Disease
hepatitis	I-Disease
,	O
with	O
spontaneous	O
remission	O
.	O
Studies	O
on	O
the	O
bradycardia	B-Disease
induced	O
by	O
bepridil	B-Chemical
.	O
Bepridil	B-Chemical
,	O
a	O
novel	O
active	O
compound	O
for	O
prophylactic	O
treatment	O
of	O
anginal	B-Disease
attacks	I-Disease
,	O
induced	O
persistent	O
bradycardia	B-Disease
and	O
a	O
non	O
-	O
specific	O
anti	O
-	O
tachycardial	B-Disease
effect	O
,	O
the	O
mechanisms	O
of	O
which	O
were	O
investigated	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
In	O
vitro	O
perfusion	O
of	O
bepridil	B-Chemical
in	O
the	O
life	O
-	O
support	O
medium	O
for	O
isolated	O
sino	O
-	O
atrial	O
tissue	O
from	O
rabbit	O
heart	O
,	O
caused	O
a	O
reduction	O
in	O
action	O
potential	O
(	O
AP	O
)	O
spike	O
frequency	O
(	O
recorded	O
by	O
KCl	B-Chemical
microelectrodes	O
)	O
starting	O
at	O
doses	O
of	O
5	O
X	O
10	O
(	O
-	O
6	O
)	O
M	O
.	O
This	O
effect	O
was	O
dose	O
-	O
dependent	O
up	O
to	O
concentrations	O
of	O
5	O
X	O
10	O
(	O
-	O
5	O
)	O
M	O
,	O
whereupon	O
blockade	O
of	O
sinus	O
activity	O
set	O
in	O
.	O
Bepridil	B-Chemical
at	O
a	O
dose	O
of	O
5	O
X	O
10	O
(	O
-	O
6	O
)	O
M	O
,	O
induced	O
a	O
concomitant	O
reduction	O
in	O
AP	O
amplitude	O
(	O
falling	O
from	O
71	O
+	O
/	O
-	O
8	O
mV	O
to	O
47	O
+	O
/	O
-	O
6	O
mV	O
)	O
,	O
maximum	O
systolic	O
depolarization	O
velocity	O
(	O
phase	O
0	O
)	O
which	O
fell	O
from	O
1	O
.	O
85	O
+	O
/	O
-	O
0	O
.	O
35	O
V	O
/	O
s	O
to	O
0	O
.	O
84	O
+	O
/	O
-	O
0	O
.	O
28	O
V	O
/	O
s	O
,	O
together	O
with	O
maximum	O
diastolic	O
depolarization	O
velocity	O
(	O
phase	O
4	O
)	O
which	O
fell	O
from	O
38	O
+	O
/	O
-	O
3	O
mV	O
/	O
s	O
to	O
24	O
+	O
/	O
-	O
5	O
mV	O
/	O
s	O
.	O
In	O
vivo	O
injection	O
of	O
bepridil	B-Chemical
at	O
a	O
dose	O
of	O
5	O
mg	O
/	O
kg	O
(	O
i	O
.	O
v	O
.	O
)	O
into	O
6	O
anaesthetized	O
dogs	O
which	O
had	O
undergone	O
ablation	O
of	O
all	O
the	O
extrinsic	O
cardiac	O
afferent	O
nerve	O
supply	O
,	O
together	O
with	O
a	O
bilateral	O
medullo	O
-	O
adrenalectomy	O
,	O
caused	O
a	O
marked	O
reduction	O
in	O
heart	O
rate	O
which	O
fell	O
from	O
98	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
2	O
beats	O
/	O
min	O
to	O
76	O
+	O
/	O
-	O
5	O
.	O
3	O
beats	O
/	O
min	O
sustained	O
for	O
more	O
than	O
45	O
min	O
.	O
It	O
is	O
concluded	O
that	O
bepridil	B-Chemical
reduces	O
heart	O
rate	O
by	O
acting	O
directly	O
on	O
the	O
sinus	O
node	O
.	O
This	O
effect	O
,	O
which	O
results	O
in	O
a	O
flattening	O
of	O
the	O
phase	O
0	O
and	O
phase	O
4	O
slope	O
,	O
together	O
with	O
a	O
longer	O
AP	O
duration	O
,	O
may	O
be	O
due	O
to	O
an	O
increase	O
in	O
the	O
time	O
constants	O
of	O
slow	O
inward	O
ionic	O
currents	O
(	O
already	O
demonstrated	O
elsewhere	O
)	O
,	O
but	O
also	O
to	O
an	O
increased	O
time	O
constant	O
for	O
deactivation	O
of	O
the	O
outward	O
potassium	B-Chemical
current	O
(	O
Ip	O
)	O
.	O
Hepatitis	B-Disease
and	O
renal	B-Disease
tubular	I-Disease
acidosis	I-Disease
after	O
anesthesia	O
with	O
methoxyflurane	B-Chemical
.	O
A	O
69	O
-	O
year	O
-	O
old	O
man	O
operated	O
for	O
acute	B-Disease
cholecystitis	I-Disease
under	O
methoxyflurane	B-Chemical
anesthesia	O
developed	O
postoperatively	O
a	O
hepatic	B-Disease
insufficiency	I-Disease
syndrome	I-Disease
and	O
renal	B-Disease
tubular	I-Disease
acidosis	I-Disease
.	O
Massive	O
bleeding	B-Disease
appeared	O
during	O
surgery	O
which	O
lasted	O
for	O
six	O
hours	O
.	O
Postoperative	O
evolution	O
under	O
supportive	O
therapy	O
was	O
favourable	O
.	O
Complete	O
recovery	O
was	O
confirmed	O
by	O
repeated	O
controls	O
performed	O
over	O
a	O
period	O
of	O
one	O
year	O
after	O
surgery	O
.	O
Pituitary	O
response	O
to	O
luteinizing	O
hormone	O
-	O
releasing	O
hormone	O
during	O
haloperidol	B-Chemical
-	O
induced	O
hyperprolactinemia	B-Disease
.	O
The	O
effects	O
of	O
a	O
6	O
-	O
hour	O
infusion	O
with	O
haloperidol	B-Chemical
on	O
serum	O
prolactin	O
and	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
levels	O
was	O
studied	O
in	O
a	O
group	O
of	O
male	O
subjects	O
.	O
Five	O
hours	O
after	O
starting	O
the	O
infusions	O
,	O
a	O
study	O
of	O
the	O
pituitary	O
responses	O
to	O
LH	O
-	O
releasing	O
hormone	O
(	O
LH	O
-	O
RH	O
)	O
was	O
carried	O
out	O
.	O
Control	O
patients	O
received	O
infusions	O
of	O
0	O
.	O
9	O
%	O
NaCl	B-Chemical
solution	O
.	O
During	O
the	O
course	O
of	O
haloperidol	B-Chemical
infusions	O
,	O
significant	O
hyperprolactinemia	B-Disease
was	O
found	O
,	O
together	O
with	O
an	O
abolished	O
pituitary	O
response	O
to	O
LH	O
-	O
RH	O
,	O
as	O
compared	O
with	O
responses	O
of	O
control	O
subjects	O
.	O
Antirifampicin	O
antibodies	O
in	O
acute	O
rifampicin	B-Chemical
-	O
associated	O
renal	B-Disease
failure	I-Disease
.	O
5	O
patients	O
with	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
(	O
3	O
with	O
thrombopenia	B-Disease
and	O
hemolysis	B-Disease
)	O
induced	O
by	O
the	O
reintroduction	O
of	O
rifampicin	B-Chemical
are	O
described	O
.	O
No	O
correlation	O
was	O
found	O
between	O
the	O
severity	O
of	O
clinical	O
manifestations	O
and	O
the	O
total	O
dose	O
taken	O
by	O
the	O
patients	O
.	O
In	O
all	O
but	O
1	O
patient	O
,	O
antirifampicin	O
antibodies	O
were	O
detected	O
.	O
Antibodies	O
suggested	O
to	O
be	O
of	O
the	O
IgM	O
class	O
were	O
detected	O
in	O
all	O
3	O
patients	O
with	O
hematological	B-Disease
disorders	I-Disease
.	O
The	O
pattern	O
of	O
non	O
-	O
specific	O
acute	B-Disease
tubular	I-Disease
necrosis	I-Disease
found	O
in	O
the	O
2	O
biopsied	O
patients	O
,	O
indistinguishable	O
from	O
that	O
of	O
ischemic	O
origin	O
,	O
raised	O
the	O
possibility	O
of	O
a	O
vascular	O
-	O
mediated	O
damage	O
.	O
In	O
3	O
patients	O
,	O
the	O
possibility	O
of	O
a	O
triggering	O
immunoallergic	O
mechanism	O
is	O
discussed	O
.	O
Cardiovascular	O
effects	O
of	O
hypotension	B-Disease
induced	O
by	O
adenosine	B-Chemical
triphosphate	I-Chemical
and	O
sodium	B-Chemical
nitroprusside	I-Chemical
on	O
dogs	O
with	O
denervated	O
hearts	O
.	O
Adenosine	B-Chemical
triphosphate	I-Chemical
(	O
ATP	B-Chemical
)	O
and	O
sodium	B-Chemical
nitroprusside	I-Chemical
(	O
SNP	B-Chemical
)	O
are	O
administered	O
to	O
patients	O
to	O
induce	O
and	O
control	O
hypotension	B-Disease
during	O
anesthesia	O
.	O
SNP	B-Chemical
is	O
authorized	O
for	O
clinical	O
use	O
in	O
USA	O
and	O
UK	O
,	O
and	O
ATP	B-Chemical
is	O
clinically	O
used	O
in	O
other	O
countries	O
such	O
as	O
Japan	O
.	O
We	O
investigated	O
how	O
these	O
two	O
drugs	O
act	O
on	O
the	O
cardiovascular	O
systems	O
of	O
20	O
dogs	O
whose	O
hearts	O
had	O
been	O
denervated	O
by	O
a	O
procedure	O
we	O
had	O
devised	O
.	O
ATP	B-Chemical
(	O
10	O
dogs	O
)	O
or	O
SNP	B-Chemical
(	O
10	O
dogs	O
)	O
was	O
administered	O
to	O
reduce	O
mean	O
arterial	O
pressure	O
by	O
30	O
%	O
to	O
70	O
%	O
of	O
control	O
.	O
Before	O
,	O
during	O
and	O
after	O
induced	O
hypotension	B-Disease
,	O
we	O
measured	O
major	O
cardiovascular	O
parameters	O
.	O
Hypotension	B-Disease
induced	O
by	O
ATP	B-Chemical
was	O
accompanied	O
by	O
significant	O
decreases	O
in	O
mean	O
pulmonary	O
arterial	O
pressure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
central	O
venous	O
pressure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
total	O
peripheral	O
resistance	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
rate	O
pressure	O
product	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
total	O
body	O
oxygen	B-Chemical
consumption	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
and	O
heart	O
rate	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
;	O
all	O
these	O
variables	O
returned	O
normal	O
within	O
30	O
min	O
after	O
ATP	B-Chemical
was	O
stopped	O
.	O
Cardiac	O
output	O
did	O
not	O
change	O
.	O
During	O
hypotension	B-Disease
produced	O
by	O
SNP	B-Chemical
similar	O
decreases	O
were	O
observed	O
in	O
mean	O
pulmonary	O
arterial	O
pressure	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
central	O
venous	O
pressure	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
total	O
peripheral	O
resistance	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
rate	O
pressure	O
product	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
oxygen	B-Chemical
content	O
difference	O
between	O
arterial	O
and	O
mixed	O
venous	O
blood	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
while	O
heart	O
rate	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
cardiac	O
output	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
were	O
increased	O
.	O
Recoveries	O
of	O
heart	O
rate	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
were	O
not	O
shown	O
within	O
60	O
min	O
after	O
SNP	B-Chemical
had	O
been	O
stopped	O
.	O
Both	O
ATP	B-Chemical
and	O
SNP	B-Chemical
should	O
act	O
on	O
the	O
pacemaker	O
tissue	O
of	O
the	O
heart	O
.	O
Comparative	O
study	O
:	O
Endografine	B-Chemical
(	O
diatrizoate	B-Chemical
)	O
,	O
Vasurix	B-Chemical
polyvidone	I-Chemical
(	O
acetrizoate	B-Chemical
)	O
,	O
Dimer	B-Chemical
-	I-Chemical
X	I-Chemical
(	O
iocarmate	B-Chemical
)	O
and	O
Hexabrix	B-Chemical
(	O
ioxaglate	B-Chemical
)	O
in	O
hysterosalpingography	O
.	O
Side	O
effects	O
of	O
hysterosalpingography	O
with	O
Dimer	B-Chemical
-	I-Chemical
X	I-Chemical
,	O
Hexabrix	B-Chemical
,	O
Vasurix	B-Chemical
polyvidone	I-Chemical
and	O
Endografine	B-Chemical
in	O
142	O
consecutive	O
patients	O
,	O
receiving	O
one	O
of	O
the	O
four	O
tested	O
media	O
were	O
evaluated	O
from	O
replies	O
to	O
postal	O
questionnaires	O
.	O
The	O
Dimer	B-Chemical
-	I-Chemical
X	I-Chemical
group	O
had	O
a	O
higher	O
incidence	O
of	O
nausea	B-Disease
and	O
dizziness	B-Disease
.	O
The	O
Endografine	B-Chemical
group	O
had	O
a	O
higher	O
incidence	O
of	O
abdominal	B-Disease
pain	I-Disease
.	O
These	O
differences	O
occur	O
especially	O
in	O
the	O
age	O
groups	O
under	O
30	O
years	O
.	O
Hexabrix	B-Chemical
and	O
Vasurix	B-Chemical
polyvidone	I-Chemical
are	O
considered	O
the	O
best	O
contrast	B-Chemical
media	I-Chemical
for	O
hysterosalpingography	O
and	O
perhaps	O
because	O
of	O
its	O
low	O
toxicity	B-Disease
Hexabrix	B-Chemical
should	O
be	O
preferred	O
.	O
Post	O
-	O
suxamethonium	B-Chemical
pains	B-Disease
in	O
Nigerian	O
surgical	O
patients	O
.	O
Contrary	O
to	O
an	O
earlier	O
report	O
by	O
Coxon	O
,	O
scoline	B-Chemical
pain	B-Disease
occurs	O
in	O
African	O
negroes	O
.	O
Its	O
incidence	O
was	O
determined	O
in	O
a	O
prospective	O
study	O
involving	O
a	O
total	O
of	O
100	O
Nigerian	O
patients	O
(	O
50	O
out	O
-	O
patients	O
and	O
50	O
in	O
-	O
patients	O
)	O
.	O
About	O
62	O
%	O
of	O
the	O
out	O
-	O
patients	O
developed	O
scoline	B-Chemical
pain	B-Disease
as	O
compared	O
with	O
about	O
26	O
%	O
among	O
the	O
in	O
-	O
patients	O
.	O
The	O
abolition	O
of	O
muscle	O
fasciculations	B-Disease
(	O
by	O
0	O
.	O
075mg	O
/	O
kg	O
dose	O
of	O
Fazadinium	B-Chemical
)	O
did	O
not	O
influence	O
the	O
occurrence	O
of	O
scoline	B-Chemical
pain	B-Disease
.	O
Neither	O
the	O
type	O
of	O
induction	O
agent	O
(	O
Althesin	B-Chemical
or	O
Thiopentone	B-Chemical
)	O
nor	O
the	O
salt	O
preparation	O
of	O
suxamethonium	B-Chemical
used	O
(	O
chloride	B-Chemical
or	O
bromide	B-Chemical
)	O
,	O
affected	O
the	O
incidence	O
of	O
scoline	B-Chemical
pain	B-Disease
.	O
Invasive	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
renal	I-Disease
pelvis	I-Disease
following	O
cyclophosphamide	B-Chemical
therapy	O
for	O
nonmalignant	O
disease	O
.	O
A	O
47	O
-	O
year	O
-	O
old	O
woman	O
with	O
right	O
hydroureteronephrosis	B-Disease
due	O
to	O
ureterovesical	O
junction	O
obstruction	O
had	O
gross	O
hematuria	B-Disease
after	O
being	O
treated	O
for	O
five	O
years	O
wtih	O
cyclophosphamide	B-Chemical
for	O
cerebral	B-Disease
vasculitis	I-Disease
.	O
A	O
right	O
nephroureterectomy	O
was	O
required	O
for	O
control	O
of	O
bleeding	B-Disease
.	O
The	O
pathology	O
specimen	O
contained	O
clinically	O
occult	O
invasive	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
renal	I-Disease
pelvis	I-Disease
.	O
Although	O
the	O
ability	O
of	O
cyclophosphamide	B-Chemical
to	O
cause	O
hemorrhagic	B-Disease
cystitis	I-Disease
and	O
urine	O
cytologic	O
abnormalities	O
indistinguishable	O
from	O
high	O
grade	O
carcinoma	B-Disease
is	O
well	O
known	O
,	O
it	O
is	O
less	O
widely	O
appreciated	O
that	O
it	O
is	O
also	O
associated	O
with	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
urinary	I-Disease
tract	I-Disease
.	O
Twenty	O
carcinomas	B-Disease
of	I-Disease
the	I-Disease
urinary	I-Disease
bladder	I-Disease
and	O
one	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
prostate	I-Disease
have	O
been	O
reported	O
in	O
association	O
with	O
its	O
use	O
.	O
The	O
present	O
case	O
is	O
the	O
first	O
carcinoma	B-Disease
of	I-Disease
the	I-Disease
renal	I-Disease
pelvis	I-Disease
reported	O
in	O
association	O
with	O
cyclophosphamide	B-Chemical
treatment	O
.	O
It	O
is	O
the	O
third	O
urinary	B-Disease
tract	I-Disease
cancer	I-Disease
reported	O
in	O
association	O
with	O
cyclophosphamide	B-Chemical
treatment	O
for	O
nonmalignant	O
disease	O
.	O
The	O
association	O
of	O
the	O
tumor	B-Disease
with	O
preexisting	O
hydroureteronephrosis	B-Disease
suggests	O
that	O
stasis	O
prolonged	O
and	O
intensified	O
exposure	O
of	O
upper	O
urinary	O
tract	O
epithelium	O
to	O
cyclophosphamide	B-Chemical
.	O
Patients	O
who	O
are	O
candidates	O
for	O
long	O
-	O
term	O
cyclophosphamide	B-Chemical
treatment	O
should	O
be	O
routinely	O
evaluated	O
for	O
obstructive	B-Disease
uropathy	I-Disease
.	O
Medial	O
changes	O
in	O
arterial	O
spasm	B-Disease
induced	O
by	O
L	B-Chemical
-	I-Chemical
norepinephrine	I-Chemical
.	O
In	O
normal	O
rats	O
,	O
the	O
media	O
of	O
small	O
arteries	O
(	O
0	O
.	O
4	O
-	O
-	O
0	O
.	O
2	O
mm	O
in	O
diameter	O
)	O
previously	O
was	O
shown	O
to	O
contain	O
intracellular	O
vacuoles	O
,	O
identified	O
ultrastructurally	O
as	O
herniations	O
of	O
one	O
smooth	O
muscle	O
cell	O
into	O
another	O
.	O
The	O
hypothesis	O
that	O
intense	O
vasoconstriction	O
would	O
increase	O
the	O
number	O
of	O
such	O
vacuoles	O
has	O
been	O
tested	O
.	O
In	O
the	O
media	O
of	O
the	O
saphenous	O
artery	O
and	O
its	O
distal	O
branch	O
,	O
vasoconstriction	O
induced	O
by	O
L	B-Chemical
-	I-Chemical
norepinephrine	I-Chemical
produced	O
many	O
cell	O
-	O
to	O
-	O
cell	O
hernias	B-Disease
within	O
15	O
minutes	O
.	O
At	O
1	O
day	O
their	O
number	O
was	O
reduced	O
to	O
about	O
1	O
/	O
10	O
of	O
the	O
original	O
number	O
.	O
By	O
7	O
days	O
the	O
vessel	O
was	O
almost	O
restored	O
to	O
normal	O
.	O
Triple	O
stimulation	O
over	O
1	O
day	O
induced	O
more	O
severe	O
changes	O
in	O
the	O
media	O
.	O
These	O
findings	O
suggest	O
that	O
smooth	O
muscle	O
cells	O
are	O
susceptible	O
to	O
damage	O
in	O
the	O
course	O
of	O
their	O
specific	O
function	O
.	O
The	O
experimental	O
data	O
are	O
discussed	O
in	O
relation	O
to	O
medial	O
changes	O
observed	O
in	O
other	O
instances	O
of	O
arterial	O
spasm	B-Disease
.	O
Endothelial	O
changes	O
that	O
developed	O
in	O
the	O
same	O
experimental	O
model	O
were	O
described	O
in	O
a	O
previous	O
paper	O
.	O
Bilateral	O
retinal	B-Disease
artery	I-Disease
and	I-Disease
choriocapillaris	I-Disease
occlusion	I-Disease
following	O
the	O
injection	O
of	O
long	O
-	O
acting	O
corticosteroid	B-Chemical
suspensions	O
in	O
combination	O
with	O
other	O
drugs	O
:	O
I	O
.	O
Clinical	O
studies	O
.	O
Two	O
well	O
-	O
documented	O
cases	O
of	O
bilateral	O
retinal	B-Disease
artery	I-Disease
and	I-Disease
choriocapillaris	I-Disease
occlusions	I-Disease
with	O
blindness	B-Disease
following	O
head	O
and	O
neck	O
soft	O
-	O
tissue	O
injection	O
with	O
methylprednisolone	B-Chemical
acetate	I-Chemical
in	O
combination	O
with	O
lidocaine	B-Chemical
,	O
epinephrine	B-Chemical
,	O
or	O
penicillin	B-Chemical
are	O
reported	O
.	O
One	O
case	O
had	O
only	O
a	O
unilateral	O
injection	O
.	O
The	O
acute	O
observations	O
included	O
hazy	O
sensorium	O
,	O
superior	O
gaze	O
palsy	B-Disease
,	O
pupillary	B-Disease
abnormalities	I-Disease
,	O
and	O
conjunctival	O
hemorrhages	B-Disease
with	O
edema	B-Disease
.	O
Follow	O
-	O
up	O
changes	O
showed	O
marked	O
visual	B-Disease
loss	I-Disease
,	O
constricted	O
visual	O
fields	O
,	O
optic	O
nerve	O
pallor	O
,	O
vascular	O
attenuation	O
,	O
and	O
chorioretinal	B-Disease
atrophy	I-Disease
.	O
The	O
literature	O
is	O
reviewed	O
,	O
and	O
possible	O
causes	O
are	O
discussed	O
.	O
Abnormalities	O
of	O
the	O
pupil	O
and	O
visual	O
-	O
evoked	O
potential	O
in	O
quinine	B-Chemical
amblyopia	B-Disease
.	O
Total	O
blindness	B-Disease
with	O
a	O
transient	O
tonic	B-Disease
pupillary	I-Disease
response	O
,	O
denervation	O
supersensitivity	O
,	O
and	O
abnormal	O
visual	O
-	O
evoked	O
potentials	O
developed	O
in	O
a	O
54	O
-	O
year	O
-	O
old	O
man	O
after	O
the	O
use	O
of	O
quinine	B-Chemical
sulfate	I-Chemical
for	O
leg	B-Disease
cramps	I-Disease
.	O
He	O
later	O
recovered	O
normal	O
visual	O
acuity	O
.	O
A	O
transient	O
tonic	B-Disease
pupillary	I-Disease
response	O
,	O
denervation	O
supersensitivity	O
,	O
and	O
abnormal	O
visual	O
-	O
evoked	O
potentials	O
in	O
quinine	B-Chemical
toxicity	B-Disease
,	O
to	O
our	O
knowledge	O
,	O
have	O
not	O
been	O
previously	O
reported	O
.	O
Suxamethonium	B-Chemical
-	O
induced	O
jaw	B-Disease
stiffness	I-Disease
and	O
myalgia	B-Disease
associated	O
with	O
atypical	O
cholinesterase	O
:	O
case	O
report	O
.	O
An	O
11	O
-	O
year	O
-	O
old	O
boy	O
was	O
given	O
halothane	B-Chemical
,	O
nitrous	B-Chemical
oxide	I-Chemical
and	O
oxygen	B-Chemical
,	O
pancuronium	B-Chemical
0	O
.	O
4	O
mg	O
and	O
suxamethonium	B-Chemical
100	O
mg	O
for	O
induction	O
of	O
anaesthesia	O
.	O
In	O
response	O
to	O
this	O
a	O
marked	O
jaw	B-Disease
stiffness	I-Disease
occurred	O
which	O
lasted	O
for	O
two	O
minutes	O
and	O
the	O
anaesthesia	O
were	O
terminated	O
.	O
Four	O
hours	O
of	O
apnoea	B-Disease
ensued	O
and	O
he	O
suffered	O
generalized	O
severe	O
myalgia	B-Disease
lasting	O
for	O
one	O
week	O
.	O
He	O
was	O
found	O
to	O
have	O
atypical	O
plasma	O
cholinesterase	O
with	O
a	O
dibucaine	B-Chemical
number	O
of	O
12	O
,	O
indicating	O
homozygocity	O
.	O
This	O
was	O
verified	O
by	O
study	O
of	O
the	O
family	O
.	O
The	O
case	O
shows	O
that	O
prolonged	B-Disease
jaw	I-Disease
rigidity	I-Disease
and	O
myalgia	B-Disease
may	O
occur	O
after	O
suxamethonium	B-Chemical
in	O
patients	O
with	O
atypical	O
cholinesterase	O
despite	O
pretreatment	O
with	O
pancuronium	B-Chemical
.	O
Indomethacin	B-Chemical
-	O
induced	O
hyperkalemia	B-Disease
in	O
three	O
patients	O
with	O
gouty	B-Disease
arthritis	I-Disease
.	O
We	O
describe	O
three	O
patients	O
in	O
whom	O
severe	O
,	O
life	O
-	O
threatening	O
hyperkalemia	B-Disease
and	O
renal	B-Disease
insufficiency	I-Disease
developed	O
after	O
treatment	O
of	O
acute	O
gouty	B-Disease
arthritis	I-Disease
with	O
indomethacin	B-Chemical
.	O
This	O
complication	O
may	O
result	O
from	O
an	O
inhibition	O
of	O
prostaglandin	B-Chemical
synthesis	O
and	O
consequent	O
hyporeninemic	B-Disease
hypoaidosteronism	I-Disease
.	O
Careful	O
attention	O
to	O
renal	O
function	O
and	O
potassium	B-Chemical
balance	O
in	O
patients	O
receiving	O
indomethacin	B-Chemical
or	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
agents	O
,	O
particularly	O
in	O
those	O
patients	O
with	O
diabetes	B-Disease
mellitus	I-Disease
or	O
preexisting	O
renal	B-Disease
disease	I-Disease
,	O
will	O
help	O
prevent	O
this	O
potentially	O
serious	O
complication	O
.	O
Etomidate	B-Chemical
:	O
a	O
foreshortened	O
clinical	O
trial	O
.	O
A	O
clinical	O
evaluation	O
of	O
etomidate	B-Chemical
for	O
outpatient	O
cystoscopy	O
was	O
embarked	O
upon	O
.	O
Unpremedicated	O
patients	O
were	O
given	O
fentanyl	B-Chemical
1	O
microgram	O
/	O
kg	O
followed	O
by	O
etomidate	B-Chemical
0	O
.	O
3	O
mg	O
/	O
kg	O
.	O
Anaesthesia	O
was	O
maintained	O
with	O
intermittent	O
etomidate	B-Chemical
in	O
2	O
-	O
4	O
mg	O
doses	O
.	O
Patients	O
were	O
interviewed	O
personally	O
later	O
the	O
same	O
day	O
,	O
and	O
by	O
questionnaire	O
three	O
to	O
four	O
weeks	O
later	O
.	O
The	O
trial	O
was	O
discontinued	O
after	O
20	O
cases	O
because	O
of	O
an	O
unacceptable	O
incidence	O
of	O
side	O
effects	O
.	O
Venous	O
pain	B-Disease
occurred	O
in	O
68	O
%	O
of	O
patients	O
and	O
50	O
%	O
had	O
redness	O
,	O
pain	B-Disease
or	O
swelling	B-Disease
related	O
to	O
the	O
injection	O
site	O
,	O
in	O
some	O
cases	O
lasting	O
up	O
to	O
three	O
weeks	O
after	O
anaesthesia	O
.	O
Skeletal	O
movements	O
occurred	O
in	O
50	O
%	O
of	O
patients	O
;	O
30	O
%	O
experienced	O
respiratory	B-Disease
upset	I-Disease
,	O
one	O
sufficiently	O
severe	O
to	O
necessitate	O
abandoning	O
the	O
technique	O
.	O
Nausea	B-Disease
and	O
vomiting	B-Disease
occurred	O
in	O
40	O
%	O
and	O
25	O
%	O
had	O
disturbing	O
emergence	O
psychoses	B-Disease
.	O
Levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
are	O
improved	O
by	O
fluoxetine	B-Chemical
.	O
We	O
evaluated	O
the	O
severity	O
of	O
motor	B-Disease
disability	I-Disease
and	O
dyskinesias	B-Disease
in	O
seven	O
levodopa	B-Chemical
-	O
responsive	O
patients	O
with	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
after	O
an	O
acute	O
challenge	O
with	O
the	O
mixed	O
dopamine	B-Chemical
agonist	O
,	O
apomorphine	B-Chemical
,	O
before	O
and	O
after	O
the	O
administration	O
of	O
fluoxetine	B-Chemical
(	O
20	O
mg	O
twice	O
per	O
day	O
)	O
for	O
11	O
+	O
/	O
-	O
1	O
days	O
.	O
After	O
fluoxetine	B-Chemical
treatment	O
,	O
there	O
was	O
a	O
significant	O
47	O
%	O
improvement	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
apomorphine	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
without	O
modification	O
of	O
parkinsonian	B-Disease
motor	B-Disease
disability	I-Disease
.	O
The	O
dyskinesias	B-Disease
were	O
reduced	O
predominantly	O
in	O
the	O
lower	O
limbs	O
during	O
the	O
onset	O
and	O
disappearance	O
of	O
dystonic	B-Disease
dyskinesias	I-Disease
(	O
onset	O
-	O
and	O
end	O
-	O
of	O
-	O
dose	O
dyskinesias	B-Disease
)	O
and	O
in	O
the	O
upper	O
limbs	O
during	O
choreic	B-Disease
mid	I-Disease
-	I-Disease
dose	I-Disease
dyskinesias	I-Disease
.	O
The	O
results	O
suggest	O
that	O
increased	O
brain	O
serotoninergic	O
transmission	O
with	O
fluoxetine	B-Chemical
may	O
reduce	O
levodopa	B-Chemical
-	O
or	O
dopamine	B-Chemical
agonist	O
-	O
induced	O
dyskinesias	B-Disease
without	O
aggravating	O
parkinsonian	B-Disease
motor	B-Disease
disability	I-Disease
.	O
A	O
large	O
population	O
-	O
based	O
follow	O
-	O
up	O
study	O
of	O
trimethoprim	B-Chemical
-	I-Chemical
sulfamethoxazole	I-Chemical
,	O
trimethoprim	B-Chemical
,	O
and	O
cephalexin	B-Chemical
for	O
uncommon	O
serious	O
drug	B-Disease
toxicity	I-Disease
.	O
We	O
conducted	O
a	O
population	O
-	O
based	O
45	O
-	O
day	O
follow	O
-	O
up	O
study	O
of	O
232	O
,	O
390	O
people	O
who	O
were	O
prescribed	O
trimethoprim	B-Chemical
-	I-Chemical
sulfamethoxazole	I-Chemical
(	O
TMP	B-Chemical
-	I-Chemical
SMZ	I-Chemical
)	O
,	O
266	O
,	O
951	O
prescribed	O
trimethoprim	B-Chemical
alone	O
,	O
and	O
196	O
,	O
397	O
prescribed	O
cephalexin	B-Chemical
,	O
to	O
estimate	O
the	O
risk	O
of	O
serious	O
liver	B-Disease
,	I-Disease
blood	I-Disease
,	I-Disease
skin	I-Disease
,	I-Disease
and	I-Disease
renal	I-Disease
disorders	I-Disease
resulting	O
in	O
referral	O
or	O
hospitalization	O
associated	O
with	O
these	O
drugs	O
.	O
The	O
results	O
were	O
based	O
on	O
information	O
recorded	O
on	O
office	O
computers	O
by	O
selected	O
general	O
practitioners	O
in	O
the	O
United	O
Kingdom	O
,	O
together	O
with	O
a	O
review	O
of	O
clinical	O
records	O
.	O
The	O
risk	O
of	O
clinically	O
important	O
idiopathic	O
liver	B-Disease
disease	I-Disease
was	O
similar	O
for	O
persons	O
prescribed	O
TMP	B-Chemical
-	I-Chemical
SMZ	I-Chemical
(	O
5	O
.	O
2	O
/	O
100	O
,	O
000	O
)	O
and	O
those	O
prescribed	O
trimethoprim	B-Chemical
alone	O
(	O
3	O
.	O
8	O
/	O
100	O
,	O
000	O
)	O
.	O
The	O
risk	O
for	O
those	O
prescribed	O
cephalexin	B-Chemical
was	O
somewhat	O
lower	O
(	O
2	O
.	O
0	O
/	O
100	O
,	O
000	O
)	O
.	O
Only	O
five	O
patients	O
experienced	O
blood	O
disorders	O
,	O
one	O
of	O
whom	O
was	O
exposed	O
to	O
TMP	B-Chemical
-	I-Chemical
SMZ	I-Chemical
;	O
of	O
seven	O
with	O
erythema	B-Disease
multiforme	I-Disease
and	O
Stevens	B-Disease
-	I-Disease
Johnson	I-Disease
syndrome	I-Disease
,	O
four	O
were	O
exposed	O
to	O
TMP	B-Chemical
-	I-Chemical
SMZ	I-Chemical
.	O
The	O
one	O
case	O
of	O
toxic	B-Disease
epidermal	I-Disease
necrolysis	I-Disease
occurred	O
in	O
a	O
patient	O
who	O
took	O
cephalexin	B-Chemical
.	O
Finally	O
,	O
only	O
five	O
cases	O
of	O
acute	O
parenchymal	O
renal	B-Disease
disease	I-Disease
occurred	O
,	O
none	O
likely	O
to	O
be	O
caused	O
by	O
a	O
study	O
drug	O
.	O
We	O
conclude	O
that	O
the	O
risk	O
of	O
the	O
serious	O
diseases	O
studied	O
is	O
small	O
for	O
the	O
three	O
agents	O
,	O
and	O
compares	O
reasonably	O
with	O
the	O
risk	O
for	O
many	O
other	O
antibiotics	O
.	O
Clinical	O
safety	O
of	O
lidocaine	B-Chemical
in	O
patients	O
with	O
cocaine	B-Chemical
-	O
associated	O
myocardial	B-Disease
infarction	I-Disease
.	O
STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
safety	O
of	O
lidocaine	B-Chemical
in	O
the	O
setting	O
of	O
cocaine	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
(	O
MI	B-Disease
)	O
.	O
DESIGN	O
:	O
A	O
retrospective	O
,	O
multicenter	O
study	O
.	O
SETTING	O
:	O
Twenty	O
-	O
nine	O
university	O
,	O
university	O
-	O
affiliated	O
,	O
or	O
community	O
hospitals	O
during	O
a	O
6	O
-	O
year	O
period	O
(	O
total	O
of	O
117	O
cumulative	O
hospital	O
-	O
years	O
)	O
.	O
PARTICIPANTS	O
:	O
Patients	O
with	O
cocaine	B-Chemical
-	O
associated	O
MI	B-Disease
who	O
received	O
lidocaine	B-Chemical
in	O
the	O
emergency	O
department	O
.	O
RESULTS	O
:	O
Of	O
29	O
patients	O
who	O
received	O
lidocaine	B-Chemical
in	O
the	O
setting	O
of	O
cocaine	B-Chemical
-	O
associated	O
MI	B-Disease
,	O
no	O
patient	O
died	O
;	O
exhibited	O
bradydysrhythmias	B-Disease
,	O
ventricular	B-Disease
tachycardia	I-Disease
,	O
or	O
ventricular	B-Disease
fibrillation	I-Disease
;	O
or	O
experienced	O
seizures	B-Disease
after	O
administration	O
of	O
lidocaine	B-Chemical
(	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
%	O
to	O
11	O
%	O
)	O
.	O
CONCLUSION	O
:	O
Despite	O
theoretical	O
concerns	O
that	O
lidocaine	B-Chemical
may	O
enhance	O
cocaine	B-Chemical
toxicity	B-Disease
,	O
the	O
use	O
of	O
lidocaine	B-Chemical
in	O
patients	O
with	O
cocaine	B-Chemical
-	O
associated	O
MI	B-Disease
was	O
not	O
associated	O
with	O
significant	O
cardiovascular	B-Disease
or	I-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
toxicity	I-Disease
.	O
Experimental	O
progressive	O
muscular	B-Disease
dystrophy	I-Disease
and	O
its	O
treatment	O
with	O
high	O
doses	O
anabolizing	O
agents	O
.	O
We	O
are	O
still	O
a	O
long	O
way	O
from	O
discovering	O
an	O
unequivocal	O
pathogenetic	O
interpretation	O
of	O
progressive	O
muscular	B-Disease
dystrophy	I-Disease
in	O
man	O
.	O
Noteworthy	O
efforts	O
have	O
been	O
made	O
in	O
the	O
experimental	O
field	O
;	O
a	O
recessive	O
autosomic	O
form	O
found	O
in	O
the	O
mouse	O
seems	O
to	O
bear	O
the	O
closest	O
resemblance	O
to	O
the	O
human	O
form	O
from	O
the	O
genetic	O
point	O
of	O
view	O
.	O
Myopathy	B-Disease
due	O
to	O
lack	O
of	O
vitamin	B-Chemical
E	I-Chemical
and	O
myopathy	B-Disease
induced	O
by	O
certain	O
viruses	O
have	O
much	O
in	O
common	O
anatomically	O
and	O
pathologically	O
with	O
the	O
human	O
form	O
.	O
The	O
authors	O
induced	O
myodystrophy	B-Disease
in	O
the	O
rat	O
by	O
giving	O
it	O
a	O
diet	O
lacking	O
in	O
vitamin	B-Chemical
E	I-Chemical
.	O
The	O
pharmacological	O
characteristics	O
of	O
vitamin	B-Chemical
E	I-Chemical
and	O
the	O
degenerative	O
changes	O
brought	O
about	O
by	O
its	O
deficiency	O
,	O
especially	O
in	O
the	O
muscles	O
,	O
are	O
illustrated	O
.	O
It	O
is	O
thus	O
confirmed	O
that	O
the	O
histological	O
characteristics	O
of	O
myopathic	B-Disease
rat	O
muscle	O
induced	O
experimentally	O
are	O
extraordinarily	O
similar	O
to	O
those	O
of	O
human	O
myopathy	B-Disease
as	O
confirmed	O
during	O
biopsies	O
performed	O
at	O
the	O
Orthopaedic	O
Traumatological	O
Centre	O
,	O
Florence	O
.	O
The	O
encouraging	O
results	O
obtained	O
in	O
various	O
authoratative	O
departments	O
in	O
myopathic	B-Disease
patients	O
by	O
using	O
anabolizing	O
steroids	B-Chemical
have	O
encouraged	O
the	O
authors	O
to	O
investigate	O
the	O
beneficial	O
effects	O
of	O
one	O
anabolizing	O
agent	O
(	O
Dianabol	B-Chemical
,	O
CIBA	B-Chemical
)	O
at	O
high	O
doses	O
in	O
rats	O
rendered	O
myopathic	B-Disease
by	O
a	O
diet	O
deficient	O
in	O
vitamin	B-Chemical
E	I-Chemical
.	O
In	O
this	O
way	O
they	O
obtained	O
appreciable	O
changes	O
in	O
body	O
weight	O
(	O
increased	O
from	O
50	O
to	O
70	O
g	O
after	O
forty	O
days	O
at	O
a	O
dose	O
of	O
5	O
mg	O
per	O
day	O
of	O
anabolizing	O
agent	O
)	O
,	O
but	O
most	O
of	O
all	O
they	O
found	O
histological	O
changes	O
due	O
to	O
""""	O
regenerative	O
""""	O
changes	O
in	O
the	O
muscle	O
tissue	O
,	O
which	O
however	O
maintained	O
its	O
myopathic	B-Disease
characteristics	O
in	O
the	O
control	O
animals	O
that	O
were	O
not	O
treated	O
with	O
the	O
anabolizing	O
agent	O
.	O
The	O
authors	O
conclude	O
by	O
affirming	O
the	O
undoubted	O
efficacy	O
of	O
the	O
anabolizing	O
steroids	B-Chemical
in	O
experimental	O
myopathic	B-Disease
disease	I-Disease
,	O
but	O
they	O
have	O
reservations	O
as	O
to	O
the	O
transfer	O
of	O
the	O
results	O
into	O
the	O
human	O
field	O
,	O
where	O
high	O
dosage	O
cannot	O
be	O
carried	O
out	O
continuously	O
because	O
of	O
the	O
effects	O
of	O
the	O
drug	O
on	O
virility	O
;	O
because	O
the	O
tissue	O
injury	O
too	O
often	O
occurs	O
at	O
an	O
irreversible	O
stage	O
vis	O
-	O
a	O
-	O
vis	O
the	O
""""	O
regeneration	O
""""	O
of	O
the	O
muscle	O
tissue	O
;	O
and	O
finally	O
because	O
the	O
dystrophic	O
injurious	O
agent	O
is	O
certainly	O
not	O
the	O
lack	O
of	O
vitamin	B-Chemical
E	I-Chemical
but	O
something	O
as	O
yet	O
unknown	O
.	O
Paclitaxel	B-Chemical
3	O
-	O
hour	O
infusion	O
given	O
alone	O
and	O
combined	O
with	O
carboplatin	B-Chemical
:	O
preliminary	O
results	O
of	O
dose	O
-	O
escalation	O
trials	O
.	O
Paclitaxel	B-Chemical
(	O
Taxol	B-Chemical
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
by	O
3	O
-	O
hour	O
infusion	O
was	O
combined	O
with	O
carboplatin	B-Chemical
in	O
a	O
phase	O
I	O
/	O
II	O
study	O
directed	O
to	O
patients	O
with	O
non	B-Disease
-	I-Disease
small	I-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
.	O
Carboplatin	B-Chemical
was	O
given	O
at	O
a	O
fixed	O
target	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
of	O
6	O
.	O
0	O
by	O
the	O
Calvert	O
formula	O
,	O
whereas	O
paclitaxel	B-Chemical
was	O
escalated	O
in	O
patient	O
cohorts	O
from	O
150	O
mg	O
/	O
m2	O
(	O
dose	O
level	O
I	O
)	O
to	O
175	O
,	O
200	O
,	O
225	O
,	O
and	O
250	O
mg	O
/	O
m2	O
.	O
The	O
225	O
mg	O
/	O
m2	O
level	O
was	O
expanded	O
for	O
the	O
phase	O
II	O
study	O
since	O
the	O
highest	O
level	O
achieved	O
(	O
250	O
mg	O
/	O
m2	O
)	O
required	O
modification	O
because	O
of	O
nonhematologic	O
toxicities	B-Disease
(	O
arthralgia	B-Disease
and	O
sensory	B-Disease
neuropathy	I-Disease
)	O
.	O
Therapeutic	O
effects	O
were	O
noted	O
at	O
all	O
dose	O
levels	O
,	O
with	O
objective	O
responses	O
in	O
17	O
(	O
two	O
complete	O
and	O
15	O
partial	O
regressions	O
)	O
of	O
41	O
previously	O
untreated	O
patients	O
.	O
Toxicities	B-Disease
were	O
compared	O
with	O
a	O
cohort	O
of	O
patients	O
in	O
a	O
phase	O
I	O
trial	O
of	O
paclitaxel	B-Chemical
alone	O
at	O
identical	O
dose	O
levels	O
.	O
Carboplatin	B-Chemical
did	O
not	O
appear	O
to	O
add	O
to	O
the	O
hematologic	B-Disease
toxicities	I-Disease
observed	O
,	O
and	O
the	O
paclitaxel	B-Chemical
/	O
carboplatin	B-Chemical
combination	O
could	O
be	O
dosed	O
every	O
3	O
weeks	O
.	O
The	O
dose	O
-	O
dependent	O
effect	O
of	O
misoprostol	B-Chemical
on	O
indomethacin	B-Chemical
-	O
induced	O
renal	B-Disease
dysfunction	I-Disease
in	O
well	O
compensated	O
cirrhosis	B-Disease
.	O
Misoprostol	B-Chemical
(	O
200	O
micrograms	O
)	O
has	O
been	O
shown	O
to	O
acutely	O
counteract	O
the	O
indomethacin	B-Chemical
-	O
induced	O
renal	B-Disease
dysfunction	I-Disease
in	O
well	O
compensated	O
cirrhotic	B-Disease
patients	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
the	O
prophylactic	O
value	O
of	O
misoprostol	B-Chemical
was	O
dose	O
-	O
dependent	O
.	O
Parameters	O
of	O
renal	O
hemodynamics	O
and	O
tubular	O
sodium	B-Chemical
and	O
water	O
handling	O
were	O
assessed	O
by	O
clearance	O
techniques	O
in	O
26	O
well	O
compensated	O
cirrhotic	B-Disease
patients	O
before	O
and	O
after	O
an	O
oral	O
combination	O
of	O
50	O
mg	O
of	O
indomethacin	B-Chemical
and	O
various	O
doses	O
of	O
misoprostol	B-Chemical
.	O
The	O
200	O
-	O
micrograms	O
dose	O
was	O
able	O
to	O
totally	O
abolish	O
the	O
deleterious	O
renal	O
effects	O
of	O
indomethacin	B-Chemical
,	O
whereas	O
the	O
800	O
-	O
micrograms	O
dose	O
resulted	O
in	O
significant	O
worsening	O
of	O
renal	O
hemodynamics	O
and	O
sodium	B-Chemical
retention	O
.	O
These	O
changes	O
were	O
maximal	O
in	O
the	O
hour	O
immediately	O
after	O
medications	O
and	O
slowly	O
returned	O
toward	O
base	O
-	O
line	O
levels	O
thereafter	O
.	O
These	O
results	O
suggest	O
that	O
the	O
renal	O
protective	O
effects	O
of	O
misoprostol	B-Chemical
is	O
dose	O
-	O
dependent	O
.	O
However	O
,	O
until	O
this	O
apparent	O
ability	O
of	O
200	O
micrograms	O
of	O
misoprostol	B-Chemical
to	O
prevent	O
the	O
adverse	O
effects	O
of	O
indomethacin	B-Chemical
on	O
renal	O
function	O
is	O
confirmed	O
with	O
chronic	O
frequent	O
dosing	O
,	O
it	O
would	O
be	O
prudent	O
to	O
avoid	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
therapy	O
in	O
patients	O
with	O
cirrhosis	B-Disease
.	O
Increased	O
frequency	O
and	O
severity	O
of	O
angio	B-Disease
-	I-Disease
oedema	I-Disease
related	O
to	O
long	O
-	O
term	O
therapy	O
with	O
angiotensin	B-Chemical
-	I-Chemical
converting	I-Chemical
enzyme	I-Chemical
inhibitor	I-Chemical
in	O
two	O
patients	O
.	O
Adverse	O
reactions	O
to	O
drugs	O
are	O
well	O
recognized	O
as	O
a	O
cause	O
of	O
acute	O
or	O
chronic	O
urticaria	B-Disease
,	O
and	O
angio	B-Disease
-	I-Disease
oedema	I-Disease
.	O
Angiotensin	B-Chemical
-	I-Chemical
converting	I-Chemical
enzyme	I-Chemical
(	I-Chemical
ACE	I-Chemical
)	I-Chemical
inhibitors	I-Chemical
,	O
used	O
to	O
treat	O
hypertension	B-Disease
and	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
,	O
were	O
introduced	O
in	O
Europe	O
in	O
the	O
middle	O
of	O
the	O
eighties	O
,	O
and	O
the	O
use	O
of	O
these	O
drugs	O
has	O
increased	O
progressively	O
.	O
Soon	O
after	O
the	O
introduction	O
of	O
ACE	B-Chemical
inhibitors	I-Chemical
,	O
acute	O
bouts	O
of	O
angio	B-Disease
-	I-Disease
oedema	I-Disease
were	O
reported	O
in	O
association	O
with	O
the	O
use	O
of	O
these	O
drugs	O
.	O
We	O
wish	O
to	O
draw	O
attention	O
to	O
the	O
possibility	O
of	O
adverse	O
reactions	O
to	O
ACE	B-Chemical
inhibitors	I-Chemical
after	O
long	O
-	O
term	O
use	O
and	O
in	O
patients	O
with	O
pre	O
-	O
existing	O
angio	B-Disease
-	I-Disease
oedema	I-Disease
.	O
Myoclonus	B-Disease
associated	O
with	O
lorazepam	B-Chemical
therapy	O
in	O
very	O
-	O
low	O
-	O
birth	O
-	O
weight	O
infants	O
.	O
Lorazepam	B-Chemical
is	O
being	O
used	O
with	O
increasing	O
frequency	O
as	O
a	O
sedative	O
in	O
the	O
newborn	O
and	O
the	O
young	O
infant	O
.	O
Concern	O
has	O
been	O
raised	O
with	O
regard	O
to	O
the	O
safety	O
of	O
lorazepam	B-Chemical
in	O
this	O
age	O
group	O
,	O
especially	O
in	O
very	O
-	O
low	O
-	O
birth	O
-	O
weight	O
(	O
VLBW	O
;	O
<	O
1	O
,	O
500	O
g	O
)	O
infants	O
.	O
Three	O
young	O
infants	O
,	O
all	O
of	O
birth	O
weight	O
<	O
1	O
,	O
500	O
g	O
,	O
experienced	O
myoclonus	B-Disease
following	O
the	O
intravenous	O
administration	O
of	O
lorazepam	B-Chemical
.	O
The	O
potential	O
neurotoxic	B-Disease
effects	O
of	O
the	O
drug	O
(	O
and	O
its	O
vehicle	O
)	O
in	O
this	O
population	O
are	O
discussed	O
.	O
Injectable	O
lorazepam	B-Chemical
should	O
be	O
used	O
with	O
caution	O
in	O
VLBW	O
infants	O
.	O
Transvenous	O
right	O
ventricular	O
pacing	O
during	O
cardiopulmonary	O
resuscitation	O
of	O
pediatric	O
patients	O
with	O
acute	O
cardiomyopathy	B-Disease
.	O
We	O
describe	O
the	O
cardiopulmonary	O
resuscitation	O
efforts	O
on	O
five	O
patients	O
who	O
presented	O
in	O
acute	O
circulatory	B-Disease
failure	I-Disease
from	O
myocardial	B-Disease
dysfunction	I-Disease
.	O
Three	O
patients	O
had	O
acute	O
viral	O
myocarditis	B-Disease
,	O
one	O
had	O
a	O
carbamazepine	B-Chemical
-	O
induced	O
acute	O
eosinophilic	B-Disease
myocarditis	I-Disease
,	O
and	O
one	O
had	O
cardiac	O
hemosiderosis	O
resulting	O
in	O
acute	O
cardiogenic	B-Disease
shock	I-Disease
.	O
All	O
patients	O
were	O
continuously	O
monitored	O
with	O
central	O
venous	O
and	O
arterial	O
catheters	O
in	O
addition	O
to	O
routine	O
noninvasive	O
monitoring	O
.	O
An	O
introducer	O
sheath	O
,	O
a	O
pacemaker	O
,	O
and	O
sterile	O
pacing	O
wires	O
were	O
made	O
readily	O
available	O
for	O
the	O
patients	O
,	O
should	O
the	O
need	O
arise	O
to	O
terminate	O
resistant	O
cardiac	O
dysrhythmias	B-Disease
.	O
All	O
patients	O
developed	O
cardiocirculatory	O
arrest	O
associated	O
with	O
extreme	O
hypotension	B-Disease
and	O
dysrhythmias	B-Disease
within	O
the	O
first	O
48	O
hours	O
of	O
their	O
admission	O
to	O
the	O
pediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
)	O
.	O
Right	O
ventricular	O
pacemaker	O
wires	O
were	O
inserted	O
in	O
all	O
of	O
them	O
during	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	O
)	O
.	O
In	O
four	O
patients	O
,	O
cardiac	O
pacing	O
was	O
used	O
,	O
resulting	O
in	O
a	O
temporary	O
captured	O
rhythm	O
and	O
restoration	O
of	O
their	O
cardiac	O
output	O
.	O
These	O
patients	O
had	O
a	O
second	O
event	O
of	O
cardiac	B-Disease
arrest	I-Disease
,	O
resulting	O
in	O
death	O
,	O
within	O
10	O
to	O
60	O
minutes	O
.	O
In	O
one	O
patient	O
,	O
cardiac	O
pacing	O
was	O
not	O
used	O
,	O
because	O
he	O
converted	O
to	O
normal	O
sinus	O
rhythm	O
by	O
electrical	O
defibrillation	O
within	O
three	O
minutes	O
of	O
initiating	O
CPR	O
.	O
We	O
conclude	O
that	O
cardiac	O
pacing	O
during	O
resuscitative	O
efforts	O
in	O
pediatric	O
patients	O
suffering	O
from	O
acute	O
myocardial	B-Disease
dysfunction	I-Disease
may	O
not	O
have	O
long	O
-	O
term	O
value	O
in	O
and	O
of	O
itself	O
;	O
however	O
,	O
if	O
temporary	O
hemodynamic	O
stability	O
is	O
achieved	O
by	O
this	O
procedure	O
,	O
it	O
may	O
provide	O
additional	O
time	O
needed	O
to	O
institute	O
other	O
therapeutic	O
modalities	O
.	O
Efficacy	O
and	O
safety	O
of	O
granisetron	B-Chemical
,	O
a	O
selective	O
5	B-Chemical
-	I-Chemical
hydroxytryptamine	I-Chemical
-	O
3	O
receptor	O
antagonist	O
,	O
in	O
the	O
prevention	O
of	O
nausea	B-Disease
and	O
vomiting	B-Disease
induced	O
by	O
high	O
-	O
dose	O
cisplatin	B-Chemical
.	O
PURPOSE	O
:	O
To	O
assess	O
the	O
antiemetic	O
effects	O
and	O
safety	O
profile	O
of	O
four	O
different	O
doses	O
of	O
granisetron	B-Chemical
(	O
Kytril	B-Chemical
;	O
SmithKline	O
Beecham	O
Pharmaceuticals	O
,	O
Philadelphia	O
,	O
PA	O
)	O
when	O
administered	O
as	O
a	O
single	O
intravenous	O
(	O
IV	O
)	O
dose	O
for	O
prophylaxis	O
of	O
cisplatin	B-Chemical
-	O
induced	O
nausea	B-Disease
and	O
vomiting	B-Disease
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
One	O
hundred	O
eighty	O
-	O
four	O
chemotherapy	O
-	O
naive	O
patients	O
receiving	O
high	O
-	O
dose	O
cisplatin	B-Chemical
(	O
81	O
to	O
120	O
mg	O
/	O
m2	O
)	O
were	O
randomized	O
to	O
receive	O
one	O
of	O
four	O
granisetron	B-Chemical
doses	O
(	O
5	O
,	O
10	O
,	O
20	O
,	O
or	O
40	O
micrograms	O
/	O
kg	O
)	O
administered	O
before	O
chemotherapy	O
.	O
Patients	O
were	O
observed	O
on	O
an	O
inpatient	O
basis	O
for	O
18	O
to	O
24	O
hours	O
,	O
and	O
vital	O
signs	O
,	O
nausea	B-Disease
,	O
vomiting	B-Disease
,	O
retching	O
,	O
and	O
appetite	O
were	O
assessed	O
.	O
Safety	O
analyses	O
included	O
incidence	O
of	O
adverse	O
experiences	O
and	O
laboratory	O
parameter	O
changes	O
.	O
RESULTS	O
:	O
After	O
granisetron	B-Chemical
doses	O
of	O
5	O
,	O
10	O
,	O
20	O
,	O
and	O
40	O
micrograms	O
/	O
kg	O
,	O
a	O
major	O
response	O
(	O
<	O
or	O
=	O
two	O
vomiting	B-Disease
or	O
retching	O
episodes	O
,	O
and	O
no	O
antiemetic	O
rescue	O
)	O
was	O
recorded	O
in	O
23	O
%	O
,	O
57	O
%	O
,	O
58	O
%	O
,	O
and	O
60	O
%	O
of	O
patients	O
,	O
respectively	O
,	O
and	O
a	O
complete	O
response	O
(	O
no	O
vomiting	B-Disease
or	O
retching	O
,	O
and	O
no	O
antiemetic	O
rescue	O
)	O
in	O
18	O
%	O
,	O
41	O
%	O
,	O
40	O
%	O
,	O
and	O
47	O
%	O
of	O
patients	O
,	O
respectively	O
.	O
There	O
was	O
a	O
statistically	O
longer	O
time	O
to	O
first	O
episode	O
of	O
nausea	B-Disease
(	O
P	O
=	O
.	O
0015	O
)	O
and	O
vomiting	B-Disease
(	O
P	O
=	O
.	O
0001	O
)	O
,	O
and	O
fewer	O
patients	O
were	O
administered	O
additional	O
antiemetic	O
medication	O
in	O
the	O
10	O
-	O
micrograms	O
/	O
kg	O
dosing	O
groups	O
than	O
in	O
the	O
5	O
-	O
micrograms	O
/	O
kg	O
dosing	O
group	O
.	O
As	O
granisetron	B-Chemical
dose	O
increased	O
,	O
appetite	O
return	O
increased	O
(	O
P	O
=	O
.	O
040	O
)	O
.	O
Headache	B-Disease
was	O
the	O
most	O
frequently	O
reported	O
adverse	O
event	O
(	O
20	O
%	O
)	O
.	O
CONCLUSION	O
:	O
A	O
single	O
10	O
-	O
,	O
20	O
-	O
,	O
or	O
40	O
-	O
micrograms	O
/	O
kg	O
dose	O
of	O
granisetron	B-Chemical
was	O
effective	O
in	O
controlling	O
vomiting	B-Disease
in	O
57	O
%	O
to	O
60	O
%	O
of	O
patients	O
who	O
received	O
cisplatin	B-Chemical
at	O
doses	O
greater	O
than	O
81	O
mg	O
/	O
m2	O
and	O
totally	O
prevented	O
vomiting	B-Disease
in	O
40	O
%	O
to	O
47	O
%	O
of	O
patients	O
.	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
efficacy	O
between	O
the	O
10	O
-	O
micrograms	O
/	O
kg	O
dose	O
and	O
the	O
20	O
-	O
and	O
40	O
-	O
micrograms	O
/	O
kg	O
doses	O
.	O
Granisetron	B-Chemical
was	O
well	O
tolerated	O
at	O
all	O
doses	O
.	O
Adverse	O
interaction	O
between	O
clonidine	B-Chemical
and	O
verapamil	B-Chemical
.	O
OBJECTIVE	O
:	O
To	O
report	O
two	O
cases	O
of	O
a	O
possible	O
adverse	O
interaction	O
between	O
clonidine	B-Chemical
and	O
verapamil	B-Chemical
resulting	O
in	O
atrioventricular	B-Disease
(	I-Disease
AV	I-Disease
)	I-Disease
block	I-Disease
in	O
both	O
patients	O
and	O
severe	O
hypotension	B-Disease
in	O
one	O
patient	O
.	O
CASE	O
SUMMARIES	O
:	O
A	O
54	O
-	O
year	O
-	O
old	O
woman	O
with	O
hyperaldosteronism	B-Disease
was	O
treated	O
with	O
verapamil	B-Chemical
480	O
mg	O
/	O
d	O
and	O
spironolactone	B-Chemical
100	O
mg	O
/	O
d	O
.	O
After	O
the	O
addition	O
of	O
a	O
minimal	O
dose	O
of	O
clonidine	B-Chemical
(	O
0	O
.	O
15	O
mg	O
bid	O
)	O
,	O
she	O
developed	O
complete	O
AV	B-Disease
block	I-Disease
and	O
severe	O
hypotension	B-Disease
,	O
which	O
resolved	O
upon	O
cessation	O
of	O
all	O
medications	O
.	O
A	O
65	O
-	O
year	O
-	O
old	O
woman	O
was	O
treated	O
with	O
extended	O
-	O
release	O
verapamil	B-Chemical
240	O
mg	O
/	O
d	O
.	O
After	O
the	O
addition	O
of	O
clonidine	B-Chemical
0	O
.	O
15	O
mg	O
bid	O
she	O
developed	O
complete	O
AV	B-Disease
block	I-Disease
,	O
which	O
resolved	O
after	O
all	O
therapy	O
was	O
stopped	O
.	O
DISCUSSION	O
:	O
An	O
adverse	O
interaction	O
between	O
clonidine	B-Chemical
and	O
verapamil	B-Chemical
has	O
not	O
been	O
reported	O
previously	O
.	O
We	O
describe	O
two	O
such	O
cases	O
and	O
discuss	O
the	O
various	O
mechanisms	O
that	O
might	O
cause	O
such	O
an	O
interaction	O
.	O
Clinicians	O
should	O
be	O
acquainted	O
with	O
this	O
possibly	O
fatal	O
interaction	O
between	O
two	O
commonly	O
used	O
antihypertensive	O
drugs	O
.	O
CONCLUSIONS	O
:	O
Caution	O
is	O
recommended	O
in	O
combining	O
clonidine	B-Chemical
and	O
verapamil	B-Chemical
therapy	O
,	O
even	O
in	O
patients	O
who	O
do	O
not	O
have	O
sinus	O
or	O
AV	O
node	O
dysfunction	O
.	O
The	O
two	O
drugs	O
may	O
act	O
synergistically	O
on	O
both	O
the	O
AV	O
node	O
and	O
the	O
peripheral	O
circulation	O
.	O
Pharmacological	O
studies	O
on	O
a	O
new	O
dihydrothienopyridine	B-Chemical
calcium	I-Chemical
antagonist	O
,	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
d	I-Chemical
.	O
5th	O
communication	O
:	O
anticonvulsant	O
effects	O
in	O
mice	O
.	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
,	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
d	I-Chemical
,	O
but	O
not	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
l	I-Chemical
,	O
L	O
-	O
type	O
calcium	B-Chemical
channel	O
antagonists	O
,	O
showed	O
anticonvulsant	O
effects	O
on	O
the	O
audiogenic	B-Disease
tonic	I-Disease
convulsions	I-Disease
in	O
DBA	O
/	O
2	O
mice	O
;	O
and	O
their	O
ED50	O
values	O
were	O
18	O
.	O
4	O
(	O
12	O
.	O
8	O
-	O
27	O
.	O
1	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
and	O
15	O
.	O
0	O
(	O
10	O
.	O
2	O
-	O
23	O
.	O
7	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
,	O
respectively	O
,	O
while	O
that	O
of	O
flunarizine	B-Chemical
was	O
34	O
.	O
0	O
(	O
26	O
.	O
0	O
-	O
44	O
.	O
8	O
)	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
Although	O
moderate	O
anticonvulsant	O
effects	O
of	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
d	I-Chemical
in	O
higher	O
doses	O
were	O
observed	O
against	O
the	O
clonic	O
convulsions	B-Disease
induced	O
by	O
pentylenetetrazole	B-Chemical
(	O
85	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
or	O
bemegride	B-Chemical
(	O
40	O
mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
,	O
no	O
effects	O
were	O
observed	O
in	O
convulsions	B-Disease
induced	O
by	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
,	O
picrotoxin	B-Chemical
,	O
or	O
electroshock	O
in	O
Slc	O
:	O
ddY	O
mice	O
.	O
S	B-Chemical
-	I-Chemical
312	I-Chemical
-	I-Chemical
d	I-Chemical
may	O
be	O
useful	O
in	O
the	O
therapy	O
of	O
certain	O
types	O
of	O
human	O
epilepsy	B-Disease
.	O
Transmural	O
myocardial	B-Disease
infarction	I-Disease
with	O
sumatriptan	B-Chemical
.	O
For	O
sumatriptan	B-Chemical
,	O
tightness	O
in	O
the	O
chest	O
caused	O
by	O
an	O
unknown	O
mechanism	O
has	O
been	O
reported	O
in	O
3	O
-	O
5	O
%	O
of	O
users	O
.	O
We	O
describe	O
a	O
47	O
-	O
year	O
-	O
old	O
woman	O
with	O
an	O
acute	O
myocardial	B-Disease
infarction	I-Disease
after	O
administration	O
of	O
sumatriptan	B-Chemical
6	O
mg	O
subcutaneously	O
for	O
cluster	B-Disease
headache	I-Disease
.	O
The	O
patient	O
had	O
no	O
history	O
of	O
underlying	O
ischaemic	B-Disease
heart	I-Disease
disease	I-Disease
or	O
Prinzmetal	B-Disease
'	I-Disease
s	I-Disease
angina	I-Disease
.	O
She	O
recovered	O
without	O
complications	O
.	O
Flumazenil	B-Chemical
induces	O
seizures	B-Disease
and	O
death	O
in	O
mixed	O
cocaine	B-Chemical
-	O
diazepam	B-Chemical
intoxications	O
.	O
STUDY	O
HYPOTHESIS	O
:	O
Administration	O
of	O
the	O
benzodiazepine	B-Chemical
antagonist	O
flumazenil	B-Chemical
may	O
unmask	O
seizures	B-Disease
in	O
mixed	O
cocaine	B-Chemical
-	O
benzodiazepine	B-Chemical
intoxication	O
.	O
DESIGN	O
:	O
Male	O
Sprague	O
-	O
Dawley	O
rats	O
received	O
100	O
mg	O
/	O
kg	O
cocaine	B-Chemical
IP	O
alone	O
,	O
5	O
mg	O
/	O
kg	O
diazepam	B-Chemical
alone	O
,	O
or	O
a	O
combination	O
of	O
diazepam	B-Chemical
and	O
cocaine	B-Chemical
.	O
Three	O
minutes	O
later	O
,	O
groups	O
were	O
challenged	O
with	O
vehicle	O
or	O
flumazenil	B-Chemical
5	O
or	O
10	O
mg	O
/	O
kg	O
IP	O
.	O
Animal	O
behavior	O
,	O
seizures	B-Disease
(	O
time	O
to	O
and	O
incidence	O
)	O
,	O
death	O
(	O
time	O
to	O
and	O
incidence	O
)	O
,	O
and	O
cortical	O
EEG	O
tracings	O
were	O
recorded	O
.	O
INTERVENTIONS	O
:	O
Administration	O
of	O
flumazenil	B-Chemical
to	O
animals	O
after	O
they	O
had	O
received	O
a	O
combination	O
dose	O
of	O
cocaine	B-Chemical
and	O
diazepam	B-Chemical
.	O
RESULTS	O
:	O
In	O
group	O
1	O
,	O
animals	O
received	O
cocaine	B-Chemical
followed	O
by	O
vehicle	O
.	O
This	O
resulted	O
in	O
100	O
%	O
developing	O
seizures	B-Disease
and	O
death	O
.	O
Group	O
2	O
received	O
diazepam	B-Chemical
alone	O
followed	O
by	O
vehicle	O
.	O
Animals	O
became	O
somnolent	O
and	O
none	O
died	O
.	O
Group	O
3	O
received	O
diazepam	B-Chemical
followed	O
by	O
5	O
mg	O
/	O
kg	O
flumazenil	B-Chemical
.	O
Animals	O
became	O
somnolent	O
after	O
diazepam	B-Chemical
and	O
then	O
active	O
after	O
flumazenil	B-Chemical
administration	O
.	O
In	O
group	O
4	O
,	O
a	O
combination	O
of	O
cocaine	B-Chemical
and	O
diazepam	B-Chemical
was	O
administered	O
simultaneously	O
.	O
This	O
resulted	O
in	O
no	O
overt	O
or	O
EEG	O
-	O
detectable	O
seizures	B-Disease
and	O
a	O
50	O
%	O
incidence	O
of	O
death	O
.	O
Group	O
5	O
received	O
a	O
similar	O
combination	O
of	O
cocaine	B-Chemical
and	O
diazepam	B-Chemical
,	O
followed	O
later	O
by	O
5	O
mg	O
/	O
kg	O
flumazenil	B-Chemical
.	O
This	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
seizures	B-Disease
,	O
90	O
%	O
(	O
P	O
<	O
.	O
01	O
)	O
,	O
and	O
death	O
,	O
100	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
01	O
)	O
,	O
compared	O
with	O
group	O
4	O
.	O
Group	O
6	O
received	O
cocaine	B-Chemical
and	O
diazepam	B-Chemical
followed	O
by	O
10	O
mg	O
/	O
kg	O
flumazenil	B-Chemical
.	O
This	O
also	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
seizures	B-Disease
,	O
90	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
01	O
)	O
,	O
and	O
death	O
,	O
90	O
%	O
(	O
P	O
<	O
or	O
=	O
.	O
05	O
)	O
,	O
compared	O
with	O
group	O
4	O
.	O
CONCLUSION	O
:	O
Flumazenil	B-Chemical
can	O
unmask	O
seizures	B-Disease
and	O
increase	O
the	O
incidence	O
of	O
death	O
in	O
a	O
model	O
of	O
combined	O
cocaine	B-Chemical
-	O
diazepam	B-Chemical
intoxications	O
.	O
Mechanisms	O
for	O
protective	O
effects	O
of	O
free	O
radical	O
scavengers	O
on	O
gentamicin	B-Chemical
-	O
mediated	O
nephropathy	B-Disease
in	O
rats	O
.	O
Studies	O
were	O
performed	O
to	O
examine	O
the	O
mechanisms	O
for	O
the	O
protective	O
effects	O
of	O
free	O
radical	O
scavengers	O
on	O
gentamicin	B-Chemical
(	O
GM	B-Chemical
)	O
-	O
mediated	O
nephropathy	B-Disease
.	O
Administration	O
of	O
GM	B-Chemical
at	O
40	O
mg	O
/	O
kg	O
sc	O
for	O
13	O
days	O
to	O
rats	O
induced	O
a	O
significant	O
reduction	O
in	O
renal	O
blood	O
flow	O
(	O
RBF	O
)	O
and	O
inulin	O
clearance	O
(	O
CIn	O
)	O
as	O
well	O
as	O
marked	O
tubular	B-Disease
damage	I-Disease
.	O
A	O
significant	O
reduction	O
in	O
urinary	O
guanosine	B-Chemical
3	I-Chemical
'	I-Chemical
,	I-Chemical
5	I-Chemical
'	I-Chemical
-	I-Chemical
cyclic	I-Chemical
monophosphate	I-Chemical
(	O
cGMP	B-Chemical
)	O
excretion	O
and	O
a	O
significant	O
increase	O
in	O
renal	O
cortical	O
renin	O
and	O
endothelin	O
-	O
1	O
contents	O
were	O
also	O
observed	O
in	O
GM	B-Chemical
-	O
mediated	O
nephropathy	B-Disease
.	O
Superoxide	B-Chemical
dismutase	O
(	O
SOD	O
)	O
or	O
dimethylthiourea	B-Chemical
(	O
DMTU	B-Chemical
)	O
significantly	O
lessened	O
the	O
GM	B-Chemical
-	O
induced	O
decrement	O
in	O
CIn	O
.	O
The	O
SOD	O
-	O
induced	O
increase	O
in	O
glomerular	O
filtration	O
rate	O
was	O
associated	O
with	O
a	O
marked	O
improvement	O
in	O
RBF	O
,	O
an	O
increase	O
in	O
urinary	O
cGMP	B-Chemical
excretion	O
,	O
and	O
a	O
decrease	O
in	O
renal	O
renin	O
and	O
endothelin	O
-	O
1	O
content	O
.	O
SOD	O
did	O
not	O
attenuate	O
the	O
tubular	B-Disease
damage	I-Disease
.	O
In	O
contrast	O
,	O
DMTU	B-Chemical
significantly	O
reduced	O
the	O
tubular	B-Disease
damage	I-Disease
and	O
lipid	O
peroxidation	O
,	O
but	O
it	O
did	O
not	O
affect	O
renal	O
hemodynamics	O
and	O
vasoactive	O
substances	O
.	O
Neither	O
SOD	O
nor	O
DMTU	B-Chemical
affected	O
the	O
renal	O
cortical	O
GM	B-Chemical
content	O
in	O
GM	B-Chemical
-	O
treated	O
rats	O
.	O
These	O
results	O
suggest	O
that	O
1	O
)	O
both	O
SOD	O
and	O
DMTU	B-Chemical
have	O
protective	O
effects	O
on	O
GM	B-Chemical
-	O
mediated	O
nephropathy	B-Disease
,	O
2	O
)	O
the	O
mechanisms	O
for	O
the	O
protective	O
effects	O
differ	O
for	O
SOD	O
and	O
DMTU	B-Chemical
,	O
and	O
3	O
)	O
superoxide	B-Chemical
anions	O
play	O
a	O
critical	O
role	O
in	O
GM	B-Chemical
-	O
induced	O
renal	O
vasoconstriction	O
.	O
Cephalothin	B-Chemical
-	O
induced	O
immune	O
hemolytic	B-Disease
anemia	I-Disease
.	O
A	O
patient	O
with	O
renal	B-Disease
disease	I-Disease
developed	O
Coombs	O
-	O
positive	O
hemolytic	B-Disease
anemia	I-Disease
while	O
receiving	O
cephalothin	B-Chemical
therapy	O
.	O
An	O
anti	O
-	O
cephalothin	B-Chemical
IgG	O
antibody	O
was	O
detected	O
in	O
the	O
patient	O
'	O
s	O
serum	O
and	O
in	O
the	O
eluates	O
from	O
her	O
erythrocytes	O
.	O
In	O
addition	O
,	O
nonimmunologic	O
binding	O
of	O
normal	O
and	O
patient	O
'	O
s	O
serum	O
proteins	O
to	O
her	O
own	O
and	O
cephalothin	B-Chemical
-	O
coated	O
normal	O
red	O
cells	O
was	O
demonstrated	O
.	O
Skin	O
tests	O
and	O
in	O
vitro	O
lymphocyte	O
stimulation	O
revealed	O
that	O
the	O
patient	O
was	O
sensitized	O
to	O
cephalothin	B-Chemical
and	O
also	O
to	O
ampicillin	B-Chemical
.	O
Careful	O
investigation	O
of	O
drug	O
-	O
induced	O
hemolytic	B-Disease
anemias	I-Disease
reveals	O
the	O
complexity	O
of	O
the	O
immune	O
mechanisms	O
involved	O
.	O
Assessment	O
of	O
cardiomyocyte	O
DNA	O
synthesis	O
during	O
hypertrophy	B-Disease
in	O
adult	O
mice	O
.	O
The	O
ability	O
of	O
cardiomyocytes	O
to	O
synthesize	O
DNA	O
in	O
response	O
to	O
experimentally	O
induced	O
cardiac	B-Disease
hypertrophy	I-Disease
was	O
assessed	O
in	O
adult	O
mice	O
.	O
Isoproterenol	B-Chemical
delivered	O
by	O
osmotic	O
minipump	O
implantation	O
in	O
adult	O
C3Heb	O
/	O
FeJ	O
mice	O
resulted	O
in	O
a	O
46	O
%	O
increase	O
in	O
heart	O
weight	O
and	O
a	O
19	O
.	O
3	O
%	O
increase	O
in	O
cardiomyocyte	O
area	O
.	O
No	O
DNA	O
synthesis	O
,	O
as	O
assessed	O
by	O
autoradiographic	O
analysis	O
of	O
isolated	O
cardiomyocytes	O
,	O
was	O
observed	O
in	O
control	O
or	O
hypertrophic	B-Disease
hearts	I-Disease
.	O
A	O
survey	O
of	O
15	O
independent	O
inbred	O
strains	O
of	O
mice	O
revealed	O
that	O
ventricular	O
cardiomyocyte	O
nuclear	O
number	O
ranged	O
from	O
3	O
to	O
13	O
%	O
mononucleate	O
,	O
suggesting	O
that	O
cardiomyocyte	O
terminal	O
differentiation	O
is	O
influenced	O
directly	O
or	O
indirectly	O
by	O
genetic	O
background	O
.	O
To	O
determine	O
whether	O
the	O
capacity	O
for	O
reactive	O
DNA	O
synthesis	O
was	O
also	O
subject	O
to	O
genetic	O
regulation	O
,	O
cardiac	B-Disease
hypertrophy	I-Disease
was	O
induced	O
in	O
the	O
strains	O
of	O
mice	O
comprising	O
the	O
extremes	O
of	O
the	O
nuclear	O
number	O
survey	O
.	O
These	O
data	O
indicate	O
that	O
adult	O
mouse	O
atrial	O
and	O
ventricular	O
cardiomyocytes	O
do	O
not	O
synthesize	O
DNA	O
in	O
response	O
to	O
isoproterenol	B-Chemical
-	O
induced	O
cardiac	B-Disease
hypertrophy	I-Disease
.	O
Central	O
cardiovascular	O
effects	O
of	O
AVP	B-Chemical
and	O
ANP	O
in	O
normotensive	O
and	O
spontaneously	O
hypertensive	B-Disease
rats	O
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
influence	O
of	O
central	O
arginine	B-Chemical
vasopressin	I-Chemical
(	O
AVP	B-Chemical
)	O
and	O
of	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	O
)	O
on	O
control	O
of	O
arterial	O
blood	O
pressure	O
(	O
MAP	O
)	O
and	O
heart	O
rate	O
(	O
HR	O
)	O
in	O
normotensive	O
(	O
WKY	O
)	O
and	O
spontaneously	O
hypertensive	B-Disease
(	O
SHR	O
)	O
rats	O
.	O
Three	O
series	O
of	O
experiments	O
were	O
performed	O
on	O
30	O
WKY	O
and	O
30	O
SHR	O
,	O
chronically	O
instrumented	O
with	O
guide	O
tubes	O
in	O
the	O
lateral	O
ventricle	O
(	O
LV	O
)	O
and	O
arterial	O
and	O
venous	O
catheters	O
.	O
MAP	O
and	O
HR	O
were	O
monitored	O
before	O
and	O
after	O
i	O
.	O
v	O
.	O
injections	O
of	O
either	O
vehicle	O
or	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	B-Chemical
and	O
25	O
,	O
125	O
and	O
500	O
ng	O
of	O
ANP	O
.	O
Sensitivity	O
of	O
cardiac	O
component	O
of	O
baroreflex	O
(	O
CCB	O
)	O
,	O
expressed	O
as	O
a	O
slope	O
of	O
the	O
regression	O
line	O
was	O
determined	O
from	O
relationships	O
between	O
systolic	O
arterial	O
pressure	O
(	O
SAP	O
)	O
and	O
HR	O
period	O
(	O
HRp	O
)	O
during	O
phenylephrine	B-Chemical
(	O
Phe	B-Chemical
)	O
-	O
induced	O
hypertension	B-Disease
and	O
sodium	B-Chemical
nitroprusside	I-Chemical
(	O
SN	B-Chemical
)	O
-	O
induced	O
hypotension	B-Disease
.	O
CCB	O
was	O
measured	O
before	O
and	O
after	O
administration	O
of	O
either	O
vehicle	O
,	O
AVP	B-Chemical
,	O
ANP	O
,	O
or	O
both	O
peptides	O
together	O
.	O
Increases	O
of	O
MAP	O
occurred	O
after	O
LV	O
administration	O
of	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	B-Chemical
in	O
WKY	O
and	O
of	O
10	O
and	O
50	O
ng	O
in	O
SHR	O
.	O
ANP	O
did	O
not	O
cause	O
significant	O
changes	O
in	O
MAP	O
in	O
both	O
strains	O
as	O
compared	O
to	O
vehicle	O
,	O
but	O
it	O
abolished	O
AVP	B-Chemical
-	O
induced	O
MAP	O
increase	O
in	O
WKY	O
and	O
SHR	O
.	O
CCB	O
was	O
reduced	O
in	O
WKY	O
and	O
SHR	O
after	O
LV	O
administration	O
of	O
AVP	B-Chemical
during	O
SN	B-Chemical
-	O
induced	O
hypotension	B-Disease
.	O
In	O
SHR	O
but	O
not	O
in	O
WKY	O
administration	O
of	O
ANP	O
,	O
AVP	B-Chemical
and	O
ANP	O
+	O
AVP	B-Chemical
decreased	O
CCB	O
during	O
Phe	B-Chemical
-	O
induced	O
MAP	O
elevation	O
.	O
The	O
results	O
indicate	O
that	O
centrally	O
applied	O
AVP	B-Chemical
and	O
ANP	O
exert	O
differential	O
effects	O
on	O
blood	O
pressure	O
and	O
baroreflex	O
control	O
of	O
heart	O
rate	O
in	O
WKY	O
and	O
SHR	O
and	O
suggest	O
interaction	O
of	O
these	O
two	O
peptides	O
in	O
blood	O
pressure	O
regulation	O
at	O
the	O
level	O
of	O
central	O
nervous	O
system	O
.	O
Cutaneous	O
exposure	O
to	O
warfarin	B-Chemical
-	O
like	O
anticoagulant	O
causing	O
an	O
intracerebral	B-Disease
hemorrhage	I-Disease
:	O
a	O
case	O
report	O
.	O
A	O
case	O
of	O
intercerebral	O
hematoma	B-Disease
due	O
to	O
warfarin	B-Chemical
-	O
induced	O
coagulopathy	B-Disease
is	O
presented	O
.	O
The	O
39	O
-	O
year	O
-	O
old	O
woman	O
had	O
spread	O
a	O
warfarin	B-Chemical
-	O
type	O
rat	O
poison	O
around	O
her	O
house	O
weekly	O
using	O
her	O
bare	O
hands	O
,	O
with	O
no	O
washing	O
post	O
application	O
.	O
Percutaneous	O
absorption	O
of	O
warfarin	B-Chemical
causing	O
coagulopathy	B-Disease
,	O
reported	O
three	O
times	O
in	O
the	O
past	O
,	O
is	O
a	O
significant	O
risk	O
if	O
protective	O
measures	O
,	O
such	O
as	O
gloves	O
,	O
are	O
not	O
used	O
.	O
An	O
adverse	O
drug	O
interaction	O
with	O
piroxicam	B-Chemical
,	O
which	O
she	O
took	O
occasionally	O
,	O
may	O
have	O
exacerbated	O
the	O
coagulopathy	B-Disease
.	O
Pediatric	O
heart	O
transplantation	O
without	O
chronic	O
maintenance	O
steroids	B-Chemical
.	O
From	O
1986	O
to	O
February	O
1993	O
,	O
40	O
children	O
aged	O
2	O
months	O
to	O
18	O
years	O
(	O
average	O
age	O
10	O
.	O
4	O
+	O
/	O
-	O
5	O
.	O
8	O
years	O
)	O
underwent	O
heart	O
transplantation	O
.	O
Indications	O
for	O
transplantation	O
were	O
idiopathic	B-Disease
cardiomyopathy	I-Disease
(	O
52	O
%	O
)	O
,	O
congenital	B-Disease
heart	I-Disease
disease	I-Disease
(	O
35	O
%	O
)	O
with	O
and	O
without	O
prior	O
repair	O
(	O
71	O
%	O
and	O
29	O
%	O
,	O
respectively	O
)	O
,	O
hypertrophic	B-Disease
cardiomyopathy	I-Disease
(	O
5	O
%	O
)	O
,	O
valvular	B-Disease
heart	I-Disease
disease	I-Disease
(	O
3	O
%	O
)	O
,	O
and	O
doxorubicin	B-Chemical
cardiomyopathy	B-Disease
(	O
5	O
%	O
)	O
.	O
Patients	O
were	O
managed	O
with	O
cyclosporine	B-Chemical
and	O
azathioprine	B-Chemical
.	O
No	O
prophylaxis	O
with	O
antilymphocyte	O
globulin	O
was	O
used	O
.	O
Steroids	B-Chemical
were	O
given	O
to	O
39	O
%	O
of	O
patients	O
for	O
refractory	O
rejection	O
,	O
but	O
weaning	O
was	O
always	O
attempted	O
and	O
generally	O
successful	O
(	O
64	O
%	O
)	O
.	O
Five	O
patients	O
(	O
14	O
%	O
)	O
received	O
maintenance	O
steroids	B-Chemical
.	O
Four	O
patients	O
died	O
in	O
the	O
perioperative	O
period	O
and	O
one	O
died	O
4	O
months	O
later	O
.	O
There	O
have	O
been	O
no	O
deaths	O
related	O
to	O
rejection	O
or	O
infection	B-Disease
.	O
Average	O
follow	O
-	O
up	O
was	O
36	O
+	O
/	O
-	O
19	O
months	O
(	O
range	O
1	O
to	O
65	O
months	O
)	O
.	O
Cumulative	O
survival	O
is	O
88	O
%	O
at	O
5	O
years	O
.	O
In	O
patients	O
less	O
than	O
7	O
years	O
of	O
age	O
,	O
rejection	O
was	O
monitored	O
noninvasively	O
.	O
In	O
the	O
first	O
postoperative	O
month	O
,	O
89	O
%	O
of	O
patients	O
were	O
treated	O
for	O
rejection	O
.	O
Freedom	O
from	O
serious	O
infections	B-Disease
was	O
83	O
%	O
at	O
1	O
month	O
and	O
65	O
%	O
at	O
1	O
year	O
.	O
Cytomegalovirus	B-Disease
infections	I-Disease
were	O
treated	O
successfully	O
with	O
ganciclovir	B-Chemical
in	O
11	O
patients	O
.	O
No	O
impairment	O
of	O
growth	O
was	O
observed	O
in	O
children	O
who	O
underwent	O
transplantation	O
compared	O
with	O
a	O
control	O
population	O
.	O
Twenty	O
-	O
one	O
patients	O
(	O
60	O
%	O
)	O
have	O
undergone	O
annual	O
catheterizations	O
and	O
no	O
sign	O
of	O
graft	O
atherosclerosis	B-Disease
has	O
been	O
observed	O
.	O
Seizures	B-Disease
occurred	O
in	O
five	O
patients	O
(	O
14	O
%	O
)	O
and	O
hypertension	B-Disease
was	O
treated	O
in	O
10	O
patients	O
(	O
28	O
%	O
)	O
.	O
No	O
patient	O
was	O
disabled	O
and	O
no	O
lymphoproliferative	B-Disease
disorder	I-Disease
was	O
observed	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Delirium	B-Disease
during	O
fluoxetine	B-Chemical
treatment	O
.	O
A	O
case	O
report	O
.	O
The	O
correlation	O
between	O
high	O
serum	O
tricyclic	O
antidepressant	O
concentrations	O
and	O
central	O
nervous	O
system	O
side	O
effects	O
has	O
been	O
well	O
established	O
.	O
Only	O
a	O
few	O
reports	O
exist	O
,	O
however	O
,	O
on	O
the	O
relationship	O
between	O
the	O
serum	O
concentrations	O
of	O
selective	O
serotonin	B-Chemical
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
and	O
their	O
toxic	O
effects	O
.	O
In	O
some	O
cases	O
,	O
a	O
high	O
serum	O
concentration	O
of	O
citalopram	B-Chemical
(	O
>	O
600	O
nmol	O
/	O
L	O
)	O
in	O
elderly	O
patients	O
has	O
been	O
associated	O
with	O
increased	O
somnolence	B-Disease
and	O
movement	B-Disease
difficulties	I-Disease
.	O
Widespread	O
cognitive	B-Disease
disorders	I-Disease
,	O
such	O
as	O
delirium	B-Disease
,	O
have	O
not	O
been	O
previously	O
linked	O
with	O
high	O
blood	O
levels	O
of	O
SSRIs	O
.	O
In	O
this	O
report	O
,	O
we	O
describe	O
a	O
patient	O
with	O
acute	O
hyperkinetic	B-Disease
delirium	B-Disease
connected	O
with	O
a	O
high	O
serum	O
total	O
fluoxetine	B-Chemical
(	O
fluoxetine	B-Chemical
plus	O
desmethylfluoxetine	B-Chemical
)	O
concentration	O
.	O
Pulmonary	B-Disease
edema	I-Disease
and	O
shock	B-Disease
after	O
high	O
-	O
dose	O
aracytine	B-Chemical
-	I-Chemical
C	I-Chemical
for	O
lymphoma	B-Disease
;	O
possible	O
role	O
of	O
TNF	O
-	O
alpha	O
and	O
PAF	O
.	O
Four	O
out	O
of	O
23	O
consecutive	O
patients	O
treated	O
with	O
high	O
-	O
dose	O
Ara	B-Chemical
-	I-Chemical
C	I-Chemical
for	O
lymphomas	B-Disease
in	O
our	O
institution	O
developed	O
a	O
strikingly	O
similar	O
syndrome	O
during	O
the	O
perfusion	O
.	O
It	O
was	O
characterized	O
by	O
the	O
onset	O
of	O
fever	B-Disease
,	O
diarrhea	B-Disease
,	O
shock	B-Disease
,	O
pulmonary	B-Disease
edema	I-Disease
,	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
,	O
metabolic	B-Disease
acidosis	I-Disease
,	O
weight	B-Disease
gain	I-Disease
and	O
leukocytosis	B-Disease
.	O
Thorough	O
bacteriological	O
screening	O
failed	O
to	O
provide	O
evidence	O
of	O
infection	B-Disease
.	O
Sequential	O
biological	O
assays	O
of	O
IL	O
-	O
1	O
,	O
IL	O
-	O
2	O
,	O
TNF	O
and	O
PAF	O
were	O
performed	O
during	O
Ara	B-Chemical
-	I-Chemical
C	I-Chemical
infusion	O
to	O
ten	O
patients	O
,	O
including	O
the	O
four	O
who	O
developed	O
the	O
syndrome	O
.	O
TNF	O
and	O
PAF	O
activity	O
was	O
found	O
in	O
the	O
serum	O
of	O
respectively	O
two	O
and	O
four	O
of	O
the	O
cases	O
,	O
but	O
not	O
in	O
the	O
six	O
controls	O
.	O
As	O
TNF	O
and	O
PAF	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
septic	O
shock	B-Disease
and	O
adult	B-Disease
respiratory	I-Disease
distress	I-Disease
syndrome	I-Disease
,	O
we	O
hypothesize	O
that	O
high	O
-	O
dose	O
Ara	B-Chemical
-	I-Chemical
C	I-Chemical
may	O
be	O
associated	O
with	O
cytokine	O
release	O
.	O
Protective	O
effect	O
of	O
clentiazem	B-Chemical
against	O
epinephrine	B-Chemical
-	O
induced	O
cardiac	B-Disease
injury	I-Disease
in	O
rats	O
.	O
We	O
investigated	O
the	O
effects	O
of	O
clentiazem	B-Chemical
,	O
a	O
1	B-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
benzothiazepine	I-Chemical
calcium	B-Chemical
antagonist	O
,	O
on	O
epinephrine	B-Chemical
-	O
induced	O
cardiomyopathy	B-Disease
in	O
rats	O
.	O
With	O
2	O
-	O
week	O
chronic	O
epinephrine	B-Chemical
infusion	O
,	O
16	O
of	O
30	O
rats	O
died	O
within	O
4	O
days	O
,	O
and	O
severe	O
ischemic	B-Disease
lesions	I-Disease
and	O
fibrosis	B-Disease
of	O
the	O
left	O
ventricles	O
were	O
observed	O
.	O
In	O
epinephrine	B-Chemical
-	O
treated	O
rats	O
,	O
left	O
atrial	O
and	O
left	O
ventricular	O
papillary	O
muscle	O
contractile	O
responses	O
to	O
isoproterenol	B-Chemical
were	O
reduced	O
,	O
but	O
responses	O
to	O
calcium	B-Chemical
were	O
normal	O
or	O
enhanced	O
compared	O
to	O
controls	O
.	O
Left	O
ventricular	O
alpha	O
and	O
beta	O
adrenoceptor	O
densities	O
were	O
also	O
reduced	O
compared	O
to	O
controls	O
.	O
Treatment	O
with	O
clentiazem	B-Chemical
prevented	O
epinephrine	B-Chemical
-	O
induced	O
death	O
(	O
P	O
<	O
.	O
05	O
)	O
,	O
and	O
attenuated	O
the	O
ventricular	O
ischemic	B-Disease
lesions	I-Disease
and	O
fibrosis	B-Disease
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
Left	O
atrial	O
and	O
left	O
ventricular	O
papillary	O
muscle	O
contractile	O
responses	O
to	O
isoproterenol	B-Chemical
were	O
reduced	O
compared	O
to	O
controls	O
in	O
groups	O
treated	O
with	O
clentiazem	B-Chemical
alone	O
,	O
but	O
combined	O
with	O
epinephrine	B-Chemical
,	O
clentiazem	B-Chemical
restored	O
left	O
atrial	O
responses	O
and	O
enhanced	O
left	O
ventricular	O
papillary	O
responses	O
to	O
isoproterenol	B-Chemical
.	O
On	O
the	O
other	O
hand	O
clentiazem	B-Chemical
did	O
not	O
prevent	O
epinephrine	B-Chemical
-	O
induced	O
down	O
-	O
regulation	O
of	O
alpha	O
and	O
beta	O
adrenoceptors	O
.	O
Interestingly	O
,	O
clentiazem	B-Chemical
,	O
infused	O
alone	O
,	O
resulted	O
in	O
decreased	O
adrenergic	O
receptor	O
densities	O
in	O
the	O
left	O
ventricle	O
.	O
Clentiazem	B-Chemical
also	O
did	O
not	O
prevent	O
the	O
enhanced	O
responses	O
to	O
calcium	B-Chemical
seen	O
in	O
the	O
epinephrine	B-Chemical
-	O
treated	O
animals	O
,	O
although	O
the	O
high	O
dose	O
of	O
clentiazem	B-Chemical
partially	O
attenuated	O
the	O
maximal	O
response	O
to	O
calcium	B-Chemical
compared	O
to	O
epinephrine	B-Chemical
-	O
treated	O
animals	O
.	O
In	O
conclusion	O
,	O
clentiazem	B-Chemical
attenuated	O
epinephrine	B-Chemical
-	O
induced	O
cardiac	B-Disease
injury	I-Disease
,	O
possibly	O
through	O
its	O
effect	O
on	O
the	O
adrenergic	O
pathway	O
.	O
Kaliuretic	O
effect	O
of	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
treatment	O
in	O
parkinsonian	B-Disease
patients	O
.	O
Hypokalemia	B-Disease
,	O
sometimes	O
severe	O
,	O
was	O
observed	O
in	O
some	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
-	O
treated	O
parkinsonian	B-Disease
patients	O
.	O
The	O
influence	O
of	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
on	O
the	O
renal	O
excretion	O
of	O
potassium	B-Chemical
was	O
studied	O
in	O
3	O
patients	O
with	O
hypokalemia	B-Disease
and	O
in	O
5	O
normokalemic	O
patients	O
by	O
determination	O
of	O
renal	O
plasma	O
flow	O
,	O
glomerular	O
filtration	O
rate	O
,	O
plasma	O
concentration	O
of	O
potassium	B-Chemical
and	O
sodium	B-Chemical
as	O
well	O
as	O
urinary	O
excretion	O
of	O
potassium	B-Chemical
,	O
sodium	B-Chemical
and	O
aldosterone	B-Chemical
.	O
L	B-Chemical
-	I-Chemical
Dopa	I-Chemical
intake	O
was	O
found	O
to	O
cause	O
an	O
increased	O
excretion	O
of	O
potassium	B-Chemical
,	O
and	O
sometimes	O
also	O
of	O
sodium	B-Chemical
,	O
in	O
the	O
hypokalemic	O
but	O
not	O
in	O
the	O
normokalemic	O
patients	O
.	O
This	O
effect	O
on	O
the	O
renal	O
function	O
could	O
be	O
prohibited	O
by	O
the	O
administration	O
of	O
a	O
peripheral	O
dopa	O
decarbodylase	O
inhibitor	O
.	O
It	O
is	O
not	O
known	O
why	O
this	O
effect	O
occurred	O
in	O
some	O
individuals	O
but	O
not	O
in	O
others	O
,	O
but	O
our	O
results	O
indicate	O
a	O
correlation	O
between	O
aldosterone	B-Chemical
production	O
and	O
this	O
renal	O
effect	O
of	O
L	B-Chemical
-	I-Chemical
dopa	I-Chemical
.	O
Cocaine	B-Chemical
induced	O
myocardial	B-Disease
ischemia	I-Disease
.	O
We	O
report	O
a	O
case	O
of	O
myocardial	B-Disease
ischemia	I-Disease
induced	O
by	O
cocaine	B-Chemical
.	O
The	O
ischemia	B-Disease
probably	O
induced	O
by	O
coronary	B-Disease
artery	I-Disease
spasm	I-Disease
was	O
reversed	O
by	O
nitroglycerin	B-Chemical
and	O
calcium	B-Chemical
blocking	O
agents	O
.	O
Doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
monitored	O
by	O
ECG	O
in	O
freely	O
moving	O
mice	O
.	O
A	O
new	O
model	O
to	O
test	O
potential	O
protectors	O
.	O
In	O
laboratory	O
animals	O
,	O
histology	O
is	O
most	O
commonly	O
used	O
to	O
study	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
However	O
,	O
for	O
monitoring	O
during	O
treatment	O
,	O
large	O
numbers	O
of	O
animals	O
are	O
needed	O
.	O
Recently	O
we	O
developed	O
a	O
new	O
method	O
to	O
measure	O
ECG	O
values	O
in	O
freely	O
moving	O
mice	O
by	O
telemetry	O
.	O
With	O
this	O
model	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
doxorubicin	B-Chemical
administration	O
on	O
the	O
ECG	O
of	O
freely	O
moving	O
BALB	O
/	O
c	O
mice	O
and	O
the	O
efficacy	O
of	O
ICRF	B-Chemical
-	I-Chemical
187	I-Chemical
as	O
a	O
protective	O
agent	O
.	O
The	O
ST	O
interval	O
significantly	O
widened	O
from	O
15	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
5	O
to	O
56	O
.	O
8	O
+	O
/	O
-	O
11	O
.	O
8	O
ms	O
in	O
week	O
10	O
(	O
7	O
weekly	O
doses	O
of	O
4	O
mg	O
/	O
kg	O
doxorubicin	B-Chemical
given	O
i	O
.	O
v	O
.	O
plus	O
3	O
weeks	O
of	O
observation	O
)	O
.	O
The	O
ECG	O
of	O
the	O
control	O
animals	O
did	O
not	O
change	O
during	O
the	O
entire	O
study	O
.	O
After	O
sacrifice	O
the	O
hearts	O
of	O
doxorubicin	B-Chemical
-	O
treated	O
animals	O
were	O
enlarged	O
and	O
the	O
atria	O
were	O
hypertrophic	B-Disease
.	O
As	O
this	O
schedule	O
exerted	O
more	O
toxicity	B-Disease
than	O
needed	O
to	O
investigate	O
protective	O
agents	O
,	O
the	O
protection	O
of	O
ICRF	B-Chemical
-	I-Chemical
187	I-Chemical
was	O
determined	O
using	O
a	O
dose	O
schedule	O
with	O
lower	O
general	O
toxicity	B-Disease
(	O
6	O
weekly	O
doses	O
of	O
4	O
mg	O
/	O
kg	O
doxorubicin	B-Chemical
given	O
i	O
.	O
v	O
.	O
plus	O
2	O
weeks	O
of	O
observation	O
)	O
.	O
On	O
this	O
schedule	O
,	O
the	O
animals	O
'	O
hearts	O
appeared	O
normal	O
after	O
sacrifice	O
and	O
ICRF	B-Chemical
-	I-Chemical
187	I-Chemical
(	O
50	O
mg	O
/	O
kg	O
given	O
i	O
.	O
p	O
.	O
1	O
h	O
before	O
doxorubicin	B-Chemical
)	O
provided	O
almost	O
full	O
protection	O
.	O
These	O
data	O
were	O
confirmed	O
by	O
histology	O
.	O
The	O
results	O
indicate	O
that	O
this	O
new	O
model	O
is	O
very	O
sensitive	O
and	O
enables	O
monitoring	O
of	O
the	O
development	O
of	O
cardiotoxicity	B-Disease
with	O
time	O
.	O
These	O
findings	O
result	O
in	O
a	O
model	O
that	O
allows	O
the	O
testing	O
of	O
protectors	O
against	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
as	O
demonstrated	O
by	O
the	O
protection	O
provided	O
by	O
ICRF	B-Chemical
-	I-Chemical
187	I-Chemical
.	O
Epinephrine	B-Chemical
dysrhythmogenicity	O
is	O
not	O
enhanced	O
by	O
subtoxic	O
bupivacaine	B-Chemical
in	O
dogs	O
.	O
Since	O
bupivacaine	B-Chemical
and	O
epinephrine	B-Chemical
may	O
both	O
precipitate	O
dysrhythmias	B-Disease
,	O
circulating	O
bupivacaine	B-Chemical
during	O
regional	O
anesthesia	O
could	O
potentiate	O
dysrhythmogenic	O
effects	O
of	O
epinephrine	B-Chemical
.	O
We	O
therefore	O
examined	O
whether	O
bupivacaine	B-Chemical
alters	O
the	O
dysrhythmogenicity	O
of	O
subsequent	O
administration	O
of	O
epinephrine	B-Chemical
in	O
conscious	O
,	O
healthy	O
dogs	O
and	O
in	O
anesthetized	O
dogs	O
with	O
myocardial	B-Disease
infarction	I-Disease
.	O
Forty	O
-	O
one	O
conscious	O
dogs	O
received	O
10	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephrine	B-Chemical
.	O
Seventeen	O
animals	O
responded	O
with	O
ventricular	B-Disease
tachycardia	I-Disease
(	O
VT	B-Disease
)	O
within	O
3	O
min	O
.	O
After	O
3	O
h	O
,	O
these	O
responders	O
randomly	O
received	O
1	O
or	O
2	O
mg	O
/	O
kg	O
bupivacaine	B-Chemical
or	O
saline	O
over	O
5	O
min	O
,	O
followed	O
by	O
10	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephrine	B-Chemical
.	O
In	O
the	O
bupivacaine	B-Chemical
groups	O
,	O
epinephrine	B-Chemical
caused	O
fewer	O
prodysrhythmic	O
effects	O
than	O
without	O
bupivacaine	B-Chemical
.	O
VT	B-Disease
appeared	O
in	O
fewer	O
dogs	O
and	O
at	O
a	O
later	O
time	O
,	O
and	O
there	O
were	O
more	O
sinoatrial	O
beats	O
and	O
less	O
ectopies	O
.	O
Epinephrine	B-Chemical
shortened	O
QT	O
less	O
after	O
bupivacaine	B-Chemical
than	O
in	O
control	O
animals	O
.	O
One	O
day	O
after	O
experimental	O
myocardial	B-Disease
infarction	I-Disease
,	O
six	O
additional	O
halothane	B-Chemical
-	O
anesthetized	O
dogs	O
received	O
4	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephrine	B-Chemical
until	O
VT	B-Disease
appeared	O
.	O
After	O
45	O
min	O
,	O
1	O
mg	O
/	O
kg	O
bupivacaine	B-Chemical
was	O
injected	O
over	O
5	O
min	O
,	O
again	O
followed	O
by	O
4	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
epinephrine	B-Chemical
.	O
In	O
these	O
dogs	O
,	O
the	O
prodysrhythmic	O
response	O
to	O
epinephrine	B-Chemical
was	O
also	O
mitigated	O
by	O
preceding	O
bupivacaine	B-Chemical
.	O
Bupivacaine	B-Chemical
antagonizes	O
epinephrine	B-Chemical
dysrhythmogenicity	O
in	O
conscious	O
dogs	O
susceptible	O
to	O
VT	B-Disease
and	O
in	O
anesthetized	O
dogs	O
with	O
spontaneous	O
postinfarct	O
dysrhythmias	B-Disease
.	O
There	O
is	O
no	O
evidence	O
that	O
systemic	O
subtoxic	O
bupivacaine	B-Chemical
administration	O
enhances	O
the	O
dysrhythmogenicity	O
of	O
subsequent	O
epinephrine	B-Chemical
.	O
Milk	B-Disease
-	I-Disease
alkali	I-Disease
syndrome	I-Disease
induced	O
by	O
1	B-Chemical
,	I-Chemical
25	I-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
2D	I-Chemical
in	O
a	O
patient	O
with	O
hypoparathyroidism	B-Disease
.	O
Milk	B-Disease
-	I-Disease
alkali	I-Disease
syndrome	I-Disease
was	O
first	O
described	O
70	O
years	O
ago	O
in	O
the	O
context	O
of	O
the	O
treatment	O
of	O
peptic	B-Disease
ulcer	I-Disease
disease	I-Disease
with	O
large	O
amounts	O
of	O
calcium	B-Chemical
and	O
alkali	B-Chemical
.	O
Although	O
with	O
current	O
ulcer	B-Disease
therapy	O
(	O
H	O
-	O
2	O
blockers	O
,	O
omeprazole	B-Chemical
,	O
and	O
sucralfate	B-Chemical
)	O
,	O
the	O
frequency	O
of	O
milk	B-Disease
-	I-Disease
alkali	I-Disease
syndrome	I-Disease
has	O
decreased	O
significantly	O
,	O
the	O
classic	O
triad	O
of	O
hypercalcemia	B-Disease
,	O
alkalosis	B-Disease
,	O
and	O
renal	B-Disease
impairment	I-Disease
remains	O
the	O
hallmark	O
of	O
the	O
syndrome	O
.	O
Milk	B-Disease
-	I-Disease
alkali	I-Disease
syndrome	I-Disease
can	O
present	O
serious	O
and	O
occasionally	O
life	O
-	O
threatening	O
illness	O
unless	O
diagnosed	O
and	O
treated	O
appropriately	O
.	O
This	O
article	O
presents	O
a	O
patient	O
with	O
hypoparathyroidism	B-Disease
who	O
was	O
treated	O
with	O
calcium	B-Chemical
carbonate	I-Chemical
and	O
calcitriol	B-Chemical
resulting	O
in	O
two	O
admissions	O
to	O
the	O
hospital	O
for	O
milk	B-Disease
-	I-Disease
alkali	I-Disease
syndrome	I-Disease
.	O
The	O
patient	O
was	O
successfully	O
treated	O
with	O
intravenous	O
pamidronate	B-Chemical
on	O
his	O
first	O
admission	O
and	O
with	O
hydrocortisone	B-Chemical
on	O
the	O
second	O
.	O
This	O
illustrates	O
intravenous	O
pamidronate	B-Chemical
as	O
a	O
valuable	O
therapeutic	O
tool	O
when	O
milk	B-Disease
-	I-Disease
alkali	I-Disease
syndrome	I-Disease
presents	O
as	O
hypercalcemic	B-Disease
emergency	I-Disease
.	O
Famotidine	B-Chemical
-	O
associated	O
delirium	B-Disease
.	O
A	O
series	O
of	O
six	O
cases	O
.	O
Famotidine	B-Chemical
is	O
a	O
histamine	O
H2	O
-	O
receptor	O
antagonist	O
used	O
in	O
inpatient	O
settings	O
for	O
prevention	O
of	O
stress	O
ulcers	B-Disease
and	O
is	O
showing	O
increasing	O
popularity	O
because	O
of	O
its	O
low	O
cost	O
.	O
Although	O
all	O
of	O
the	O
currently	O
available	O
H2	O
-	O
receptor	O
antagonists	O
have	O
shown	O
the	O
propensity	O
to	O
cause	O
delirium	B-Disease
,	O
only	O
two	O
previously	O
reported	O
cases	O
have	O
been	O
associated	O
with	O
famotidine	B-Chemical
.	O
The	O
authors	O
report	O
on	O
six	O
cases	O
of	O
famotidine	B-Chemical
-	O
associated	O
delirium	B-Disease
in	O
hospitalized	O
patients	O
who	O
cleared	O
completely	O
upon	O
removal	O
of	O
famotidine	B-Chemical
.	O
The	O
pharmacokinetics	O
of	O
famotidine	B-Chemical
are	O
reviewed	O
,	O
with	O
no	O
change	O
in	O
its	O
metabolism	O
in	O
the	O
elderly	O
population	O
seen	O
.	O
The	O
implications	O
of	O
using	O
famotidine	B-Chemical
in	O
elderly	O
persons	O
are	O
discussed	O
.	O
Encephalopathy	B-Disease
during	O
amitriptyline	B-Chemical
therapy	O
:	O
are	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
and	O
serotonin	B-Disease
syndrome	I-Disease
spectrum	O
disorders	O
?	O
This	O
report	O
describes	O
a	O
case	O
of	O
encephalopathy	B-Disease
developed	O
in	O
the	O
course	O
of	O
amitriptyline	B-Chemical
therapy	O
,	O
during	O
a	O
remission	O
of	O
unipolar	B-Disease
depression	I-Disease
.	O
This	O
patient	O
could	O
have	O
been	O
diagnosed	O
as	O
having	O
either	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
(	O
NMS	B-Disease
)	O
or	O
serotonin	B-Disease
syndrome	I-Disease
(	O
SS	B-Disease
)	O
.	O
The	O
major	O
determinant	O
of	O
the	O
symptoms	O
may	O
have	O
been	O
dopamine	B-Chemical
/	O
serotonin	B-Chemical
imbalance	O
in	O
the	O
central	O
nervous	O
system	O
.	O
The	O
NMS	B-Disease
-	O
like	O
encephalopathy	B-Disease
that	O
develops	O
in	O
association	O
with	O
the	O
use	O
of	O
antidepressants	O
indicates	O
that	O
NMS	B-Disease
and	O
SS	B-Disease
are	O
spectrum	O
disorders	O
induced	O
by	O
drugs	O
with	O
both	O
antidopaminergic	O
and	O
serotonergic	O
effects	O
.	O
Genetic	O
separation	O
of	O
tumor	B-Disease
growth	O
and	O
hemorrhagic	B-Disease
phenotypes	O
in	O
an	O
estrogen	B-Chemical
-	O
induced	O
tumor	B-Disease
.	O
Chronic	O
administration	O
of	O
estrogen	B-Chemical
to	O
the	O
Fischer	O
344	O
(	O
F344	O
)	O
rat	O
induces	O
growth	O
of	O
large	O
,	O
hemorrhagic	B-Disease
pituitary	B-Disease
tumors	I-Disease
.	O
Ten	O
weeks	O
of	O
diethylstilbestrol	B-Chemical
(	O
DES	B-Chemical
)	O
treatment	O
caused	O
female	O
F344	O
rat	O
pituitaries	O
to	O
grow	O
to	O
an	O
average	O
of	O
109	O
.	O
2	O
+	O
/	O
-	O
6	O
.	O
3	O
mg	O
(	O
mean	O
+	O
/	O
-	O
SE	O
)	O
versus	O
11	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
4	O
mg	O
for	O
untreated	O
rats	O
,	O
and	O
to	O
become	O
highly	O
hemorrhagic	B-Disease
.	O
The	O
same	O
DES	B-Chemical
treatment	O
produced	O
no	O
significant	O
growth	O
(	O
8	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
for	O
treated	O
females	O
versus	O
8	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
1	O
for	O
untreated	O
females	O
)	O
or	O
morphological	O
changes	O
in	O
Brown	O
Norway	O
(	O
BN	O
)	O
rat	O
pituitaries	O
.	O
An	O
F1	O
hybrid	O
of	O
F344	O
and	O
BN	O
exhibited	O
significant	O
pituitary	O
growth	O
after	O
10	O
weeks	O
of	O
DES	B-Chemical
treatment	O
with	O
an	O
average	O
mass	O
of	O
26	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
compared	O
with	O
8	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
9	O
mg	O
for	O
untreated	O
rats	O
.	O
Surprisingly	O
,	O
the	O
F1	O
hybrid	O
tumors	B-Disease
were	O
not	O
hemorrhagic	B-Disease
and	O
had	O
hemoglobin	O
content	O
and	O
outward	O
appearance	O
identical	O
to	O
that	O
of	O
BN	O
.	O
Expression	O
of	O
both	O
growth	O
and	O
morphological	O
changes	O
is	O
due	O
to	O
multiple	O
genes	O
.	O
However	O
,	O
while	O
DES	B-Chemical
-	O
induced	O
pituitary	O
growth	O
exhibited	O
quantitative	O
,	O
additive	O
inheritance	O
,	O
the	O
hemorrhagic	B-Disease
phenotype	O
exhibited	O
recessive	O
,	O
epistatic	O
inheritance	O
.	O
Only	O
5	O
of	O
the	O
160	O
F2	O
pituitaries	O
exhibited	O
the	O
hemorrhagic	B-Disease
phenotype	O
;	O
36	O
of	O
the	O
160	O
F2	O
pituitaries	O
were	O
in	O
the	O
F344	O
range	O
of	O
mass	O
,	O
but	O
31	O
of	O
these	O
were	O
not	O
hemorrhagic	B-Disease
,	O
indicating	O
that	O
the	O
hemorrhagic	B-Disease
phenotype	O
is	O
not	O
merely	O
a	O
consequence	O
of	O
extensive	O
growth	O
.	O
The	O
hemorrhagic	B-Disease
F2	O
pituitaries	O
were	O
all	O
among	O
the	O
most	O
massive	O
,	O
indicating	O
that	O
some	O
of	O
the	O
genes	O
regulate	O
both	O
phenotypes	O
.	O
Increased	O
expression	O
of	O
neuronal	O
nitric	B-Chemical
oxide	I-Chemical
synthase	O
in	O
bladder	O
afferent	O
pathways	O
following	O
chronic	O
bladder	B-Disease
irritation	I-Disease
.	O
Immunocytochemical	O
techniques	O
were	O
used	O
to	O
examine	O
alterations	O
in	O
the	O
expression	O
of	O
neuronal	O
nitric	B-Chemical
oxide	I-Chemical
synthase	O
(	O
NOS	O
)	O
in	O
bladder	O
pathways	O
following	O
acute	O
and	O
chronic	O
irritation	B-Disease
of	I-Disease
the	I-Disease
urinary	I-Disease
tract	I-Disease
of	O
the	O
rat	O
.	O
Chemical	O
cystitis	B-Disease
was	O
induced	O
by	O
cyclophosphamide	B-Chemical
(	O
CYP	B-Chemical
)	O
which	O
is	O
metabolized	O
to	O
acrolein	B-Chemical
,	O
an	O
irritant	O
eliminated	O
in	O
the	O
urine	O
.	O
Injection	O
of	O
CYP	B-Chemical
(	O
n	O
=	O
10	O
,	O
75	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
2	O
hours	O
prior	O
to	O
perfusion	O
(	O
acute	O
treatment	O
)	O
of	O
the	O
animals	O
increased	O
Fos	O
-	O
immunoreactivity	O
(	O
IR	O
)	O
in	O
neurons	O
in	O
the	O
dorsal	O
commissure	O
,	O
dorsal	O
horn	O
,	O
and	O
autonomic	O
regions	O
of	O
spinal	O
segments	O
(	O
L1	O
-	O
L2	O
and	O
L6	O
-	O
S1	O
)	O
which	O
receive	O
afferent	O
inputs	O
from	O
the	O
bladder	O
,	O
urethra	O
,	O
and	O
ureter	O
.	O
Fos	O
-	O
IR	O
in	O
the	O
spinal	O
cord	O
was	O
not	O
changed	O
in	O
rats	O
receiving	O
chronic	O
CYP	B-Chemical
treatment	O
(	O
n	O
=	O
15	O
,	O
75	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
,	O
every	O
3rd	O
day	O
for	O
2	O
weeks	O
)	O
.	O
In	O
control	O
animals	O
and	O
in	O
animals	O
treated	O
acutely	O
with	O
CYP	B-Chemical
,	O
only	O
small	O
numbers	O
of	O
NOS	O
-	O
IR	O
cells	O
(	O
0	O
.	O
5	O
-	O
0	O
.	O
7	O
cell	O
profiles	O
/	O
sections	O
)	O
were	O
detected	O
in	O
the	O
L6	O
-	O
S1	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
.	O
Chronic	O
CYP	B-Chemical
administration	O
significantly	O
(	O
P	O
<	O
or	O
=	O
.	O
002	O
)	O
increased	O
bladder	O
weight	O
by	O
60	O
%	O
and	O
increased	O
(	O
7	O
-	O
to	O
11	O
-	O
fold	O
)	O
the	O
numbers	O
of	O
NOS	O
-	O
immunoreactive	O
(	O
IR	O
)	O
afferent	O
neurons	O
in	O
the	O
L6	O
-	O
S1	O
DRG	O
.	O
A	O
small	O
increase	O
(	O
1	O
.	O
5	O
-	O
fold	O
)	O
also	O
occurred	O
in	O
the	O
L1	O
DRG	O
,	O
but	O
no	O
change	O
was	O
detected	O
in	O
the	O
L2	O
and	O
L5	O
DRG	O
.	O
Bladder	O
afferent	O
cells	O
in	O
the	O
L6	O
-	O
S1	O
DRG	O
labeled	O
by	O
Fluorogold	O
(	O
40	O
microliters	O
)	O
injected	O
into	O
the	O
bladder	O
wall	O
did	O
not	O
exhibit	O
NOS	O
-	O
IR	O
in	O
control	O
animals	O
;	O
however	O
,	O
following	O
chronic	O
CYP	B-Chemical
administration	O
,	O
a	O
significant	O
percentage	O
of	O
bladder	O
afferent	O
neurons	O
were	O
NOS	O
-	O
IR	O
:	O
L6	O
(	O
19	O
.	O
8	O
+	O
/	O
-	O
4	O
.	O
6	O
%	O
)	O
and	O
S1	O
(	O
25	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
9	O
%	O
)	O
.	O
These	O
results	O
indicate	O
that	O
neuronal	O
gene	O
expression	O
in	O
visceral	O
sensory	O
pathways	O
can	O
be	O
upregulated	O
by	O
chemical	O
irritation	O
of	O
afferent	O
receptors	O
in	O
the	O
urinary	O
tract	O
and	O
/	O
or	O
that	O
pathological	O
changes	O
in	O
the	O
urinary	O
tract	O
can	O
initiate	O
chemical	O
signals	O
that	O
alter	O
the	O
chemical	O
properties	O
of	O
visceral	O
afferent	O
neurons	O
.	O
Effects	O
of	O
a	O
new	O
calcium	B-Chemical
antagonist	O
,	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
,	O
on	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
in	O
dogs	O
with	O
partial	O
coronary	B-Disease
stenosis	I-Disease
.	O
Effects	O
of	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
on	O
isoproterenol	B-Chemical
(	O
ISO	B-Chemical
)	O
-	O
induced	O
myocardial	B-Disease
ischemia	I-Disease
were	O
studied	O
in	O
dogs	O
with	O
partial	O
coronary	B-Disease
stenosis	I-Disease
of	O
the	O
left	O
circumflex	O
coronary	O
artery	O
and	O
findings	O
were	O
compared	O
with	O
those	O
for	O
nifedipine	B-Chemical
or	O
diltiazem	B-Chemical
.	O
In	O
the	O
presence	O
of	O
coronary	B-Disease
artery	I-Disease
stenosis	I-Disease
,	O
3	O
-	O
min	O
periods	O
of	O
intracoronary	O
ISO	B-Chemical
infusion	O
(	O
10	O
ng	O
/	O
kg	O
/	O
min	O
)	O
increased	O
heart	O
rate	O
and	O
maximal	O
rate	O
of	O
left	O
ventricular	O
pressure	O
rise	O
,	O
which	O
resulted	O
in	O
a	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
and	O
ST	O
-	O
segment	O
elevation	O
of	O
the	O
epicardial	O
electrocardiogram	O
.	O
After	O
the	O
control	O
ISO	B-Chemical
infusion	O
with	O
stenosis	B-Disease
was	O
performed	O
,	O
equihypotensive	O
doses	O
of	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
(	O
3	O
and	O
10	O
micrograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
)	O
,	O
nifedipine	B-Chemical
(	O
1	O
and	O
3	O
micrograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
9	O
)	O
or	O
diltiazem	B-Chemical
(	O
10	O
and	O
30	O
micrograms	O
/	O
kg	O
/	O
min	O
,	O
n	O
=	O
7	O
)	O
were	O
infused	O
5	O
min	O
before	O
and	O
during	O
the	O
second	O
and	O
third	O
ISO	B-Chemical
infusion	O
.	O
Both	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
and	O
diltiazem	B-Chemical
,	O
but	O
not	O
nifedipine	B-Chemical
,	O
significantly	O
reduced	O
the	O
increase	O
in	O
heart	O
rate	O
induced	O
by	O
ISO	B-Chemical
infusion	O
.	O
In	O
contrast	O
to	O
nifedipine	B-Chemical
,	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
(	O
10	O
micrograms	O
/	O
kg	O
/	O
min	O
)	O
prevented	O
the	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
from	O
32	O
+	O
/	O
-	O
12	O
%	O
to	O
115	O
+	O
/	O
-	O
26	O
%	O
of	O
the	O
control	O
value	O
(	O
P	O
<	O
.	O
01	O
)	O
and	O
ST	O
-	O
segment	O
elevation	O
from	O
5	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
0	O
mV	O
to	O
1	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
3	O
mV	O
(	O
P	O
<	O
.	O
01	O
)	O
at	O
3	O
min	O
after	O
ISO	B-Chemical
infusion	O
with	O
stenosis	B-Disease
.	O
Diltiazem	B-Chemical
(	O
30	O
micrograms	O
/	O
kg	O
/	O
min	O
)	O
also	O
prevented	O
the	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
from	O
34	O
+	O
/	O
-	O
14	O
%	O
to	O
63	O
+	O
/	O
-	O
18	O
%	O
of	O
the	O
control	O
value	O
(	O
P	O
<	O
.	O
05	O
)	O
and	O
ST	O
-	O
segment	O
elevation	O
from	O
4	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
7	O
mV	O
to	O
2	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
7	O
mV	O
(	O
P	O
<	O
.	O
01	O
)	O
at	O
3	O
min	O
after	O
ISO	B-Chemical
infusion	O
with	O
stenosis	B-Disease
.	O
These	O
data	O
show	O
that	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
improves	O
myocardial	B-Disease
ischemia	I-Disease
during	O
ISO	B-Chemical
infusion	O
with	O
stenosis	B-Disease
and	O
suggest	O
that	O
the	O
negative	O
chronotropic	O
property	O
of	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
plays	O
a	O
major	O
role	O
in	O
the	O
beneficial	O
effects	O
of	O
CD	B-Chemical
-	I-Chemical
832	I-Chemical
.	O
The	O
effect	O
of	O
recombinant	O
human	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
I	O
on	O
chronic	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephropathy	B-Disease
in	O
rats	O
.	O
We	O
recently	O
demonstrated	O
that	O
recombinant	O
hGH	O
exacerbates	O
renal	O
functional	O
and	O
structural	O
injury	O
in	O
chronic	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
)	O
nephropathy	B-Disease
,	O
an	O
experimental	O
model	O
of	O
glomerular	B-Disease
disease	I-Disease
.	O
Therefore	O
,	O
we	O
examined	O
whether	O
recombinant	O
human	O
(	O
rh	O
)	O
IGF	O
-	O
I	O
is	O
a	O
safer	O
alternative	O
for	O
the	O
treatment	O
of	O
growth	B-Disease
failure	I-Disease
in	O
rats	O
with	O
chronic	O
PAN	B-Chemical
nephropathy	B-Disease
.	O
The	O
glomerulopathy	B-Disease
was	O
induced	O
by	O
seven	O
serial	O
injections	O
of	O
PAN	B-Chemical
over	O
12	O
wk	O
.	O
Experimental	O
animals	O
(	O
n	O
=	O
6	O
)	O
received	O
rhIGF	O
-	O
I	O
,	O
400	O
micrograms	O
/	O
d	O
,	O
whereas	O
control	O
rats	O
(	O
n	O
=	O
6	O
)	O
received	O
the	O
vehicle	O
.	O
rhIGF	O
-	O
I	O
improved	O
weight	O
gain	O
by	O
14	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
without	O
altering	O
hematocrit	O
or	O
blood	O
pressure	O
in	O
rats	O
with	O
renal	B-Disease
disease	I-Disease
.	O
Urinary	O
protein	O
excretion	O
was	O
unaltered	O
by	O
rhIGF	O
-	O
I	O
treatment	O
in	O
rats	O
with	O
chronic	O
PAN	B-Chemical
nephropathy	B-Disease
.	O
After	O
12	O
wk	O
,	O
the	O
inulin	O
clearance	O
was	O
higher	O
in	O
rhIGF	O
-	O
I	O
-	O
treated	O
rats	O
,	O
0	O
.	O
48	O
+	O
/	O
-	O
0	O
.	O
08	O
versus	O
0	O
.	O
24	O
+	O
/	O
-	O
0	O
.	O
06	O
mL	O
/	O
min	O
/	O
100	O
g	O
of	O
body	O
weight	O
in	O
untreated	O
PAN	B-Chemical
nephropathy	B-Disease
animals	O
,	O
p	O
<	O
0	O
.	O
05	O
.	O
The	O
improvement	O
in	O
GFR	O
was	O
not	O
associated	O
with	O
enhanced	O
glomerular	B-Disease
hypertrophy	I-Disease
or	O
increased	O
segmental	O
glomerulosclerosis	B-Disease
,	O
tubulointerstitial	B-Disease
injury	I-Disease
,	O
or	O
renal	O
cortical	O
malondialdehyde	B-Chemical
content	O
.	O
In	O
rats	O
with	O
PAN	B-Chemical
nephropathy	B-Disease
,	O
administration	O
of	O
rhIGF	O
-	O
I	O
increased	O
IGF	O
-	O
I	O
and	O
GH	O
receptor	O
gene	O
expression	O
,	O
without	O
altering	O
the	O
steady	O
state	O
level	O
of	O
IGF	O
-	O
I	O
receptor	O
mRNA	O
.	O
In	O
normal	O
rats	O
with	O
intact	O
kidneys	O
,	O
rhIGF	O
-	O
I	O
administration	O
(	O
n	O
=	O
4	O
)	O
did	O
not	O
alter	O
weight	O
gain	O
,	O
blood	O
pressure	O
,	O
proteinuria	B-Disease
,	O
GFR	O
,	O
glomerular	O
planar	O
area	O
,	O
renal	O
cortical	O
malondialdehyde	B-Chemical
content	O
,	O
or	O
glomerular	O
or	O
tubulointerstitial	B-Disease
damage	I-Disease
,	O
compared	O
with	O
untreated	O
animals	O
(	O
n	O
=	O
4	O
)	O
.	O
rhIGF	O
-	O
I	O
treatment	O
reduced	O
the	O
steady	O
state	O
renal	O
IGF	O
-	O
I	O
mRNA	O
level	O
but	O
did	O
not	O
modify	O
gene	O
expression	O
of	O
the	O
IGF	O
-	O
I	O
or	O
GH	O
receptors	O
.	O
We	O
conclude	O
that	O
:	O
1	O
)	O
administration	O
of	O
rhIGF	O
-	O
I	O
improves	O
growth	O
and	O
GFR	O
in	O
rats	O
with	O
chronic	O
PAN	B-Chemical
nephropathy	B-Disease
and	O
2	O
)	O
unlike	O
rhGH	O
,	O
long	O
-	O
term	O
use	O
of	O
rhIGF	O
-	O
I	O
does	O
not	O
worsen	O
renal	O
functional	O
and	O
structural	O
injury	O
in	O
this	O
disease	O
model	O
.	O
Nefiracetam	B-Chemical
(	O
DM	B-Chemical
-	I-Chemical
9384	I-Chemical
)	O
reverses	O
apomorphine	B-Chemical
-	O
induced	O
amnesia	B-Disease
of	O
a	O
passive	O
avoidance	O
response	O
:	O
delayed	O
emergence	O
of	O
the	O
memory	O
retention	O
effects	O
.	O
Nefiracetam	B-Chemical
is	O
a	O
novel	O
pyrrolidone	B-Chemical
derivative	O
which	O
attenuates	O
scopolamine	B-Chemical
-	O
induced	O
learning	B-Disease
and	I-Disease
post	I-Disease
-	I-Disease
training	I-Disease
consolidation	I-Disease
deficits	I-Disease
.	O
Given	O
that	O
apomorphine	B-Chemical
inhibits	O
passive	O
avoidance	O
retention	O
when	O
given	O
during	O
training	O
or	O
in	O
a	O
defined	O
10	O
-	O
12h	O
post	O
-	O
training	O
period	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
nefiracetam	B-Chemical
to	O
attenuate	O
amnesia	B-Disease
induced	O
by	O
dopaminergic	O
agonism	O
.	O
A	O
step	O
-	O
down	O
passive	O
avoidance	O
paradigm	O
was	O
employed	O
and	O
nefiracetam	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
)	O
and	O
apomorphine	B-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
were	O
given	O
alone	O
or	O
in	O
combination	O
during	O
training	O
and	O
at	O
the	O
10	O
-	O
12h	O
post	O
-	O
training	O
period	O
of	O
consolidation	O
.	O
Co	O
-	O
administration	O
of	O
nefiracetam	B-Chemical
and	O
apomorphine	B-Chemical
during	O
training	O
or	O
10h	O
thereafter	O
produced	O
no	O
significant	O
anti	O
-	O
amnesic	O
effect	O
.	O
However	O
,	O
administration	O
of	O
nefiracetam	B-Chemical
during	O
training	O
completely	O
reversed	O
the	O
amnesia	B-Disease
induced	O
by	O
apomorphine	B-Chemical
at	O
the	O
10h	O
post	O
-	O
training	O
time	O
and	O
the	O
converse	O
was	O
also	O
true	O
.	O
These	O
effects	O
were	O
not	O
mediated	O
by	O
a	O
dopaminergic	O
mechanism	O
as	O
nefiracetam	B-Chemical
,	O
at	O
millimolar	O
concentrations	O
,	O
failed	O
to	O
displace	O
either	O
[	O
3H	O
]	O
SCH	B-Chemical
23390	I-Chemical
or	O
[	O
3H	O
]	O
spiperone	B-Chemical
binding	O
from	O
D1	O
or	O
D2	O
dopamine	B-Chemical
receptor	O
subtypes	O
,	O
respectively	O
.	O
It	O
is	O
suggested	O
that	O
nefiracetam	B-Chemical
augments	O
molecular	O
processes	O
in	O
the	O
early	O
stages	O
of	O
events	O
which	O
ultimately	O
lead	O
to	O
consolidation	O
of	O
memory	O
.	O
Phenytoin	B-Chemical
encephalopathy	B-Disease
as	O
probable	O
idiosyncratic	O
reaction	O
:	O
case	O
report	O
.	O
A	O
case	O
of	O
phenytoin	B-Chemical
(	O
DPH	B-Chemical
)	O
encephalopathy	B-Disease
with	O
increasing	O
seizures	B-Disease
and	O
EEG	O
and	O
mental	O
changes	O
is	O
described	O
.	O
Despite	O
adequate	O
oral	O
dosage	O
of	O
DPH	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
/	O
daily	O
)	O
the	O
plasma	O
level	O
was	O
very	O
low	O
(	O
2	O
.	O
8	O
microgramg	O
/	O
ml	O
)	O
.	O
The	O
encephalopathy	B-Disease
was	O
probably	O
an	O
idiosyncratic	O
and	O
not	O
toxic	O
or	O
allergic	O
reaction	O
.	O
In	O
fact	O
the	O
concentration	O
of	O
free	O
DPH	B-Chemical
was	O
normal	O
,	O
the	O
patient	O
presented	O
a	O
retarded	O
morbilliform	O
rash	B-Disease
during	O
DPH	B-Chemical
treatment	O
,	O
the	O
protidogram	O
was	O
normal	O
,	O
and	O
an	O
intradermic	O
DPH	B-Chemical
injection	O
had	O
no	O
local	O
effect	O
.	O
The	O
authors	O
conclude	O
that	O
in	O
a	O
patient	O
starting	O
DPH	B-Chemical
treatment	O
an	O
unexpected	O
increase	O
in	O
seizures	B-Disease
,	O
with	O
EEG	O
and	O
mental	O
changes	O
occurring	O
simultaneously	O
,	O
should	O
alert	O
the	O
physician	O
to	O
the	O
possible	O
need	O
for	O
eliminating	O
DPH	B-Chemical
from	O
the	O
therapeutic	O
regimen	O
,	O
even	O
if	O
plasma	O
concentrations	O
are	O
low	O
.	O
Prevention	O
and	O
treatment	O
of	O
endometrial	B-Disease
disease	I-Disease
in	O
climacteric	O
women	O
receiving	O
oestrogen	B-Chemical
therapy	O
.	O
The	O
treatment	O
regimens	O
are	O
described	O
in	O
74	O
patients	O
with	O
endometrial	B-Disease
disease	I-Disease
among	O
850	O
climacteric	O
women	O
receiving	O
oestrogen	B-Chemical
therapy	O
.	O
Cystic	O
hyperplasia	B-Disease
was	O
associated	O
with	O
unopposed	O
oestrogen	B-Chemical
therapy	O
without	O
progestagen	B-Chemical
.	O
Two	O
courses	O
of	O
21	O
days	O
of	O
5	O
mg	O
norethisterone	B-Chemical
daily	O
caused	O
reversion	O
to	O
normal	O
in	O
all	O
57	O
cases	O
of	O
cystic	O
hyperplasia	B-Disease
and	O
6	O
of	O
the	O
8	O
cases	O
of	O
atypical	O
hyperplasia	B-Disease
.	O
4	O
cases	O
of	O
endometrial	B-Disease
carcinoma	I-Disease
referred	O
from	O
elsewhere	O
demonstrated	O
the	O
problems	O
of	O
inappropriate	O
and	O
unsupervised	O
unopposed	O
oestrogen	B-Chemical
therapy	O
and	O
the	O
difficulty	O
in	O
distinguishing	O
severe	O
hyperplasia	B-Disease
from	O
malignancy	B-Disease
.	O
Cyclical	O
low	O
-	O
dose	O
oestrogen	B-Chemical
therapy	O
with	O
7	O
-	O
-	O
13	O
days	O
of	O
progestagen	B-Chemical
does	O
not	O
seem	O
to	O
increase	O
the	O
risk	O
of	O
endometrial	B-Disease
hyperplasia	I-Disease
or	O
carcinoma	B-Disease
.	O
Effects	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
.	O
The	O
effect	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
was	O
studied	O
in	O
male	O
rats	O
.	O
Ninety	O
-	O
three	O
rats	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
.	O
The	O
exercise	O
-	O
isoproterenol	B-Chemical
(	O
E	O
-	O
1	O
)	O
and	O
exercise	O
control	O
(	O
EC	O
)	O
groups	O
exercised	O
daily	O
for	O
thirty	O
days	O
on	O
a	O
treadmill	O
at	O
1	O
mph	O
,	O
2	O
%	O
grade	O
while	O
animals	O
of	O
the	O
sedentary	O
-	O
isoproterenol	B-Chemical
(	O
S	O
-	O
I	O
)	O
group	O
remained	O
sedentary	O
.	O
Eight	O
animals	O
were	O
assigned	O
to	O
the	O
sedentary	O
control	O
(	O
SC	O
)	O
group	O
which	O
remained	O
sedentary	O
throughout	O
the	O
experimental	O
period	O
.	O
Forty	O
-	O
eight	O
hours	O
after	O
the	O
final	O
exercise	O
period	O
,	O
S	O
-	O
I	O
and	O
E	O
-	O
I	O
animals	O
received	O
a	O
single	O
subcutaneous	O
injection	O
of	O
isoproterenol	B-Chemical
(	O
250	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
.	O
Animals	O
of	O
the	O
S	O
-	O
I	O
group	O
exhibited	O
significantly	O
(	O
Pp	O
less	O
than	O
0	O
.	O
05	O
)	O
greater	O
mortality	O
from	O
the	O
effects	O
of	O
isoproterenol	B-Chemical
than	O
animals	O
of	O
the	O
E	O
-	O
I	O
group	O
.	O
Serum	O
CPK	O
activity	O
for	O
E	O
-	O
I	O
animals	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
greater	O
than	O
for	O
animals	O
in	O
the	O
S	O
-	O
I	O
and	O
EC	O
groups	O
twenty	O
hours	O
following	O
isoproterenol	B-Chemical
injection	O
.	O
No	O
statistically	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
two	O
isoproterenol	B-Chemical
treated	O
groups	O
for	O
severity	O
of	O
the	O
induced	O
lesions	O
,	O
changes	O
in	O
heart	O
weight	O
,	O
or	O
heart	O
weight	O
to	O
body	O
weight	O
ratios	O
.	O
The	O
results	O
indicated	O
that	O
exercise	O
reduced	O
the	O
mortality	O
associated	O
with	O
the	O
effects	O
of	O
large	O
dosages	O
of	O
isoproterenol	B-Chemical
but	O
had	O
little	O
on	O
the	O
severity	O
of	O
the	O
infarction	B-Disease
.	O
Human	O
corticotropin	B-Chemical
-	O
releasing	O
hormone	O
and	O
thyrotropin	B-Chemical
-	O
releasing	O
hormone	O
modulate	O
the	O
hypercapnic	B-Disease
ventilatory	O
response	O
in	O
humans	O
.	O
Human	O
corticotropin	B-Chemical
-	O
releasing	O
hormone	O
(	O
hCRH	O
)	O
and	O
thyrotropin	B-Chemical
-	O
releasing	O
hormone	O
(	O
TRH	O
)	O
are	O
known	O
to	O
stimulate	O
ventilation	O
after	O
i	O
.	O
v	O
.	O
administration	O
in	O
humans	O
.	O
In	O
a	O
placebo	O
-	O
controlled	O
,	O
single	O
-	O
blind	O
study	O
we	O
aimed	O
to	O
clarify	O
if	O
both	O
peptides	O
act	O
by	O
altering	O
central	O
chemosensitivity	O
.	O
Two	O
subsequent	O
CO2	B-Chemical
-	O
rebreathing	O
tests	O
were	O
performed	O
in	O
healthy	O
young	O
volunteers	O
.	O
During	O
the	O
first	O
test	O
0	O
.	O
9	O
%	O
NaCl	B-Chemical
was	O
given	O
i	O
.	O
v	O
.	O
;	O
during	O
the	O
second	O
test	O
200	O
micrograms	O
of	O
hCRH	O
(	O
n	O
=	O
12	O
)	O
or	O
400	O
micrograms	O
of	O
TRH	O
(	O
n	O
=	O
6	O
)	O
was	O
administered	O
i	O
.	O
v	O
.	O
Nine	O
subjects	O
received	O
0	O
.	O
9	O
%	O
NaCl	B-Chemical
i	O
.	O
v	O
.	O
during	O
both	O
rebreathing	O
manoeuvres	O
.	O
The	O
CO2	B-Chemical
-	O
response	O
curves	O
for	O
the	O
two	O
tests	O
were	O
compared	O
within	O
the	O
same	O
subject	O
.	O
In	O
the	O
hCRH	O
group	O
a	O
marked	O
parallel	O
shift	O
of	O
the	O
CO2	B-Chemical
-	O
response	O
curve	O
to	O
the	O
left	O
was	O
observed	O
after	O
hCRH	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
The	O
same	O
effect	O
occurred	O
following	O
TRH	O
but	O
was	O
less	O
striking	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O
hCRH	O
and	O
TRH	O
caused	O
a	O
reduction	O
in	O
the	O
CO2	B-Chemical
threshold	O
.	O
The	O
CO2	B-Chemical
-	O
response	O
curves	O
in	O
the	O
control	O
group	O
were	O
nearly	O
identical	O
.	O
The	O
results	O
indicate	O
an	O
additive	O
effect	O
of	O
both	O
releasing	O
hormones	O
on	O
the	O
hypercapnic	B-Disease
ventilatory	O
response	O
in	O
humans	O
,	O
presumably	O
independent	O
of	O
central	O
chemosensitivity	O
.	O
Lamivudine	B-Chemical
is	O
effective	O
in	O
suppressing	O
hepatitis	B-Disease
B	I-Disease
virus	O
DNA	O
in	O
Chinese	O
hepatitis	B-Chemical
B	I-Chemical
surface	I-Chemical
antigen	I-Chemical
carriers	O
:	O
a	O
placebo	O
-	O
controlled	O
trial	O
.	O
Lamivudine	B-Chemical
is	O
a	O
novel	O
2	B-Chemical
'	I-Chemical
,	I-Chemical
3	I-Chemical
'	I-Chemical
-	I-Chemical
dideoxy	I-Chemical
cytosine	I-Chemical
analogue	O
that	O
has	O
potent	O
inhibitory	O
effects	O
on	O
hepatitis	B-Disease
B	I-Disease
virus	O
replication	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
We	O
performed	O
a	O
single	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
to	O
assess	O
its	O
effectiveness	O
and	O
safety	O
in	O
Chinese	O
hepatitis	B-Chemical
B	I-Chemical
surface	I-Chemical
antigen	I-Chemical
(	O
HBsAg	B-Chemical
)	O
carriers	O
.	O
Forty	O
-	O
two	O
Chinese	O
HBsAg	B-Chemical
carriers	O
were	O
randomized	O
to	O
receive	O
placebo	O
(	O
6	O
patients	O
)	O
or	O
lamivudine	B-Chemical
orally	O
in	O
dosages	O
of	O
25	O
mg	O
,	O
100	O
mg	O
,	O
or	O
300	O
mg	O
daily	O
(	O
12	O
patients	O
for	O
each	O
dosage	O
)	O
.	O
The	O
drug	O
was	O
given	O
for	O
4	O
weeks	O
.	O
The	O
patients	O
were	O
closely	O
monitored	O
clinically	O
,	O
biochemically	O
,	O
and	O
serologically	O
up	O
to	O
4	O
weeks	O
after	O
drug	O
treatment	O
.	O
All	O
36	O
patients	O
receiving	O
lamivudine	B-Chemical
had	O
a	O
decrease	O
in	O
hepatitis	B-Disease
B	I-Disease
virus	O
(	O
HBV	O
)	O
DNA	O
values	O
of	O
>	O
90	O
%	O
(	O
P	O
<	O
.	O
001	O
compared	O
with	O
placebo	O
)	O
.	O
Although	O
25	O
mg	O
of	O
lamivudine	B-Chemical
was	O
slightly	O
less	O
effective	O
than	O
100	O
mg	O
(	O
P	O
=	O
.	O
011	O
)	O
and	O
300	O
mg	O
(	O
P	O
=	O
.	O
005	O
)	O
,	O
it	O
still	O
induced	O
94	O
%	O
suppression	O
of	O
HBV	O
DNA	O
after	O
the	O
fourth	O
week	O
of	O
therapy	O
.	O
HBV	O
DNA	O
values	O
returned	O
to	O
pretreatment	O
levels	O
within	O
4	O
weeks	O
of	O
cessation	O
of	O
therapy	O
.	O
There	O
was	O
no	O
change	O
in	O
the	O
hepatitis	B-Disease
B	I-Disease
e	O
antigen	O
status	O
or	O
in	O
aminotransferase	O
levels	O
.	O
No	O
serious	O
adverse	O
events	O
were	O
observed	O
.	O
In	O
conclusion	O
,	O
a	O
4	O
-	O
week	O
course	O
of	O
lamivudine	B-Chemical
was	O
safe	O
and	O
effective	O
in	O
suppression	O
of	O
HBV	O
DNA	O
in	O
Chinese	O
HBsAg	B-Chemical
carriers	O
.	O
The	O
suppression	O
was	O
>	O
90	O
%	O
but	O
reversible	O
.	O
Studies	O
with	O
long	O
-	O
term	O
lamivudine	B-Chemical
administration	O
should	O
be	O
performed	O
to	O
determine	O
if	O
prolonged	O
suppression	O
of	O
HBV	O
DNA	O
can	O
be	O
achieved	O
.	O
Population	O
-	O
based	O
study	O
of	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
associated	O
with	O
various	O
oral	B-Chemical
contraceptives	I-Chemical
.	O
BACKGROUND	O
:	O
Four	O
studies	O
published	O
since	O
December	O
,	O
1995	O
,	O
reported	O
that	O
the	O
incidence	O
of	O
venous	B-Disease
thromboembolism	I-Disease
(	O
VTE	B-Disease
)	O
was	O
higher	O
in	O
women	O
who	O
used	O
oral	B-Chemical
contraceptives	I-Chemical
(	O
OCs	B-Chemical
)	O
containing	O
the	O
third	O
-	O
generation	O
progestagens	B-Chemical
gestodene	B-Chemical
or	O
desogestrel	B-Chemical
than	O
in	O
users	O
of	O
OCs	B-Chemical
containing	O
second	O
-	O
generation	O
progestagens	B-Chemical
.	O
However	O
,	O
confounding	O
and	O
bias	O
in	O
the	O
design	O
of	O
these	O
studies	O
may	O
have	O
affected	O
the	O
findings	O
.	O
The	O
aim	O
of	O
our	O
study	O
was	O
to	O
re	O
-	O
examine	O
the	O
association	O
between	O
risk	O
of	O
VTE	B-Disease
and	O
OC	B-Chemical
use	O
with	O
a	O
different	O
study	O
design	O
and	O
analysis	O
to	O
avoid	O
some	O
of	O
the	O
bias	O
and	O
confounding	O
of	O
the	O
earlier	O
studies	O
.	O
METHODS	O
:	O
We	O
used	O
computer	O
records	O
of	O
patients	O
from	O
143	O
general	O
practices	O
in	O
the	O
UK	O
.	O
The	O
study	O
was	O
based	O
on	O
the	O
medical	O
records	O
of	O
about	O
540	O
,	O
000	O
women	O
born	O
between	O
1941	O
and	O
1981	O
.	O
All	O
women	O
who	O
had	O
a	O
recorded	O
diagnosis	O
of	O
deep	B-Disease
-	I-Disease
vein	I-Disease
thrombosis	I-Disease
,	O
venous	B-Disease
thrombosis	I-Disease
not	O
otherwise	O
specified	O
,	O
or	O
pulmonary	O
embolus	O
during	O
the	O
study	O
period	O
,	O
and	O
who	O
had	O
been	O
treated	O
with	O
an	O
anticoagulant	O
were	O
identified	O
as	O
potential	O
cases	O
of	O
VTE	B-Disease
.	O
We	O
did	O
a	O
cohort	O
analysis	O
to	O
estimate	O
and	O
compare	O
incidence	O
of	O
VTE	B-Disease
in	O
users	O
of	O
the	O
main	O
OC	B-Chemical
preparations	O
,	O
and	O
a	O
nested	O
case	O
-	O
control	O
study	O
to	O
calculate	O
the	O
odds	O
ratios	O
of	O
VTE	B-Disease
associated	O
with	O
use	O
of	O
different	O
types	O
of	O
OC	B-Chemical
,	O
after	O
adjustment	O
for	O
potential	O
confounding	O
factors	O
.	O
In	O
the	O
case	O
-	O
control	O
study	O
,	O
we	O
matched	O
cases	O
to	O
controls	O
by	O
exact	O
year	O
of	O
birth	O
,	O
practice	O
,	O
and	O
current	O
use	O
of	O
OCs	B-Chemical
.	O
We	O
used	O
a	O
multiple	O
logistic	O
regression	O
model	O
that	O
included	O
body	O
-	O
mass	O
index	O
,	O
number	O
of	O
cycles	O
,	O
change	O
in	O
type	O
of	O
OC	B-Chemical
prescribed	O
within	O
3	O
months	O
of	O
the	O
event	O
,	O
previous	O
pregnancy	O
,	O
and	O
concurrent	O
disease	O
.	O
FINDINGS	O
:	O
85	O
women	O
met	O
the	O
inclusion	O
criteria	O
for	O
VTE	B-Disease
,	O
two	O
of	O
whom	O
were	O
users	O
of	O
progestagen	B-Chemical
-	O
only	O
OCs	B-Chemical
.	O
Of	O
the	O
83	O
cases	O
of	O
VTE	B-Disease
associated	O
with	O
use	O
of	O
combined	O
OCs	B-Chemical
,	O
43	O
were	O
recorded	O
as	O
deep	B-Disease
-	I-Disease
vein	I-Disease
thrombosis	I-Disease
,	O
35	O
as	O
pulmonary	O
thrombosis	B-Disease
,	O
and	O
five	O
as	O
venous	B-Disease
thrombosis	I-Disease
not	O
otherwise	O
specified	O
.	O
The	O
crude	O
rate	O
of	O
VTE	B-Disease
per	O
10	O
,	O
000	O
woman	O
-	O
years	O
was	O
4	O
.	O
10	O
in	O
current	O
users	O
of	O
any	O
OC	B-Chemical
,	O
3	O
.	O
10	O
in	O
users	O
of	O
second	O
-	O
generation	O
OCs	B-Chemical
,	O
and	O
4	O
.	O
96	O
in	O
users	O
of	O
third	O
-	O
generation	O
preparations	O
.	O
After	O
adjustment	O
for	O
age	O
,	O
the	O
rate	O
ratio	O
of	O
VTE	B-Disease
in	O
users	O
of	O
third	O
-	O
generation	O
relative	O
to	O
second	O
-	O
generation	O
OCs	B-Chemical
was	O
1	O
.	O
68	O
(	O
95	O
%	O
CI	O
1	O
.	O
04	O
-	O
2	O
.	O
75	O
)	O
.	O
Logistic	O
regression	O
showed	O
no	O
significant	O
difference	O
in	O
the	O
risk	O
of	O
VTE	B-Disease
between	O
users	O
of	O
third	O
-	O
generation	O
and	O
second	O
-	O
generation	O
OCs	B-Chemical
.	O
Among	O
users	O
of	O
third	O
-	O
generation	O
progestagens	B-Chemical
,	O
the	O
risk	O
of	O
VTE	B-Disease
was	O
higher	O
in	O
users	O
of	O
desogestrel	B-Chemical
with	O
20	O
g	O
ethinyloestradiol	B-Chemical
than	O
in	O
users	O
of	O
gestodene	B-Chemical
or	O
desogestrel	B-Chemical
with	O
30	O
g	O
ethinyloestradiol	B-Chemical
.	O
With	O
all	O
second	O
-	O
generation	O
OCs	B-Chemical
as	O
the	O
reference	O
,	O
the	O
odds	O
ratios	O
for	O
VTE	B-Disease
were	O
3	O
.	O
49	O
(	O
1	O
.	O
21	O
-	O
10	O
.	O
12	O
)	O
for	O
desogestrel	B-Chemical
plus	O
20	O
g	O
ethinyloestradiol	B-Chemical
and	O
1	O
.	O
18	O
(	O
0	O
.	O
66	O
-	O
2	O
.	O
17	O
)	O
for	O
the	O
other	O
third	O
-	O
generation	O
progestagens	B-Chemical
.	O
INTERPRETATION	O
:	O
The	O
previously	O
reported	O
increase	O
in	O
odds	O
ratio	O
associated	O
with	O
third	O
-	O
generation	O
OCs	B-Chemical
when	O
compared	O
with	O
second	O
-	O
generation	O
products	O
is	O
likely	O
to	O
have	O
been	O
the	O
result	O
of	O
residual	O
confounding	O
by	O
age	O
.	O
The	O
increased	O
odds	O
ratio	O
associated	O
with	O
products	O
containing	O
20	O
micrograms	O
ethinyloestradiol	B-Chemical
and	O
desogestrel	B-Chemical
compared	O
with	O
the	O
30	O
micrograms	O
product	O
is	O
biologically	O
implausible	O
,	O
and	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
preferential	O
prescribing	O
and	O
,	O
thus	O
,	O
confounding	O
.	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
augments	O
pilocarpine	B-Chemical
-	O
induced	O
electrographic	O
seizure	B-Disease
but	O
protects	O
against	O
brain	B-Disease
damage	I-Disease
in	O
rats	O
.	O
1	O
.	O
The	O
authors	O
examined	O
the	O
anticonvulsant	O
effects	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
on	O
the	O
pilocarpine	B-Chemical
-	O
induced	O
seizure	B-Disease
model	O
.	O
Intraperitoneal	O
injection	O
of	O
pilocarpine	B-Chemical
(	O
400	O
mg	O
/	O
kg	O
)	O
induced	O
tonic	B-Disease
and	I-Disease
clonic	I-Disease
seizure	I-Disease
.	O
Scopolamine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
and	O
pentobarbital	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
)	O
prevented	O
development	O
of	O
pilocarpine	B-Chemical
-	O
induced	O
behavioral	O
seizure	B-Disease
but	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
did	O
not	O
.	O
2	O
.	O
An	O
electrical	O
seizure	B-Disease
measured	O
with	O
hippocampal	O
EEG	O
appeared	O
in	O
the	O
pilocarpine	B-Chemical
-	O
treated	O
group	O
.	O
Scopolamine	B-Chemical
and	O
pentobarbital	B-Chemical
blocked	O
the	O
pilocarpine	B-Chemical
-	O
induced	O
electrographic	O
seizure	B-Disease
,	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
treatment	O
augmented	O
the	O
electrographic	O
seizure	B-Disease
induced	O
by	O
pilocarpine	B-Chemical
.	O
3	O
.	O
Brain	B-Disease
damage	I-Disease
was	O
assessed	O
by	O
examining	O
the	O
hippocampus	O
microscopically	O
.	O
Pilocarpine	B-Chemical
produced	O
neuronal	B-Disease
death	I-Disease
in	O
the	O
hippocampus	O
,	O
which	O
showed	O
pyknotic	O
changes	O
.	O
Pentobarbital	B-Chemical
,	O
scopolamine	B-Chemical
and	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
protected	O
the	O
brain	B-Disease
damage	I-Disease
by	O
pilocarpine	B-Chemical
,	O
though	O
in	O
the	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
-	O
treated	O
group	O
,	O
the	O
pyramidal	O
cells	O
of	O
hippocampus	O
appeared	O
darker	O
than	O
normal	O
.	O
In	O
all	O
treatments	O
,	O
granule	O
cells	O
of	O
the	O
dentate	O
gyrus	O
were	O
not	O
affected	O
.	O
4	O
.	O
These	O
results	O
indicate	O
that	O
status	B-Disease
epilepticus	I-Disease
induced	O
by	O
pilocarpine	B-Chemical
is	O
initiated	O
by	O
cholinergic	O
overstimulation	O
and	O
propagated	O
by	O
glutamatergic	O
transmission	O
,	O
the	O
elevation	O
of	O
which	O
may	O
cause	O
brain	B-Disease
damage	I-Disease
through	O
an	O
excitatory	O
NMDA	B-Chemical
receptor	O
-	O
mediated	O
mechanism	O
.	O
Paclitaxel	B-Chemical
,	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
,	O
and	O
folinic	B-Chemical
acid	I-Chemical
in	O
metastatic	O
breast	B-Disease
cancer	I-Disease
:	O
BRE	O
-	O
26	O
,	O
a	O
phase	O
II	O
trial	O
.	O
5	B-Chemical
-	I-Chemical
Fluorouracil	I-Chemical
plus	O
folinic	B-Chemical
acid	I-Chemical
and	O
paclitaxel	B-Chemical
(	O
Taxol	B-Chemical
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
are	O
effective	O
salvage	O
therapies	O
for	O
metastatic	O
breast	B-Disease
cancer	I-Disease
patients	O
.	O
Paclitaxel	B-Chemical
and	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
have	O
additive	O
cytotoxicity	B-Disease
in	O
MCF	O
-	O
7	O
cell	O
lines	O
.	O
We	O
performed	O
a	O
phase	O
II	O
trial	O
of	O
paclitaxel	B-Chemical
175	O
mg	O
/	O
m2	O
over	O
3	O
hours	O
on	O
day	O
I	O
followed	O
by	O
folinic	B-Chemical
acid	I-Chemical
300	O
mg	O
over	O
1	O
hour	O
before	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
350	O
mg	O
/	O
m2	O
on	O
days	O
1	O
to	O
3	O
every	O
28	O
days	O
(	O
TFL	O
)	O
in	O
women	O
with	O
metastatic	O
breast	B-Disease
cancer	I-Disease
.	O
Analysis	O
is	O
reported	O
on	O
37	O
patients	O
with	O
a	O
minimum	O
of	O
6	O
months	O
follow	O
-	O
up	O
who	O
received	O
a	O
total	O
of	O
192	O
cycles	O
of	O
TFL	O
:	O
nine	O
cycles	O
(	O
5	O
%	O
)	O
were	O
associated	O
with	O
grade	O
3	O
/	O
4	O
neutropenia	B-Disease
requiring	O
hospitalization	O
;	O
seven	O
(	O
4	O
%	O
)	O
cycles	O
in	O
two	O
patients	O
required	O
granulocyte	B-Chemical
colony	I-Chemical
-	I-Chemical
stimulating	I-Chemical
factor	I-Chemical
due	O
to	O
neutropenia	B-Disease
;	O
no	O
patient	O
required	O
platelet	O
transfusions	O
.	O
Grade	O
3	O
/	O
4	O
nonhematologic	O
toxicities	B-Disease
were	O
uncommon	O
.	O
Among	O
the	O
34	O
patients	O
evaluable	O
for	O
response	O
,	O
there	O
were	O
three	O
complete	O
responses	O
(	O
9	O
%	O
)	O
and	O
18	O
partial	O
responses	O
(	O
53	O
%	O
)	O
for	O
an	O
overall	O
response	O
rate	O
of	O
62	O
%	O
.	O
Of	O
the	O
19	O
evaluable	O
patients	O
with	O
prior	O
doxorubicin	B-Chemical
exposure	O
,	O
11	O
(	O
58	O
%	O
)	O
responded	O
compared	O
with	O
nine	O
of	O
15	O
(	O
60	O
%	O
)	O
without	O
prior	O
doxorubicin	B-Chemical
.	O
Plasma	O
paclitaxel	B-Chemical
concentrations	O
were	O
measured	O
at	O
the	O
completion	O
of	O
paclitaxel	B-Chemical
infusion	O
and	O
at	O
24	O
hours	O
in	O
19	O
patients	O
.	O
TFL	O
is	O
an	O
active	O
,	O
well	O
-	O
tolerated	O
regimen	O
in	O
metastatic	O
breast	B-Disease
cancer	I-Disease
.	O
Efficacy	O
and	O
proarrhythmia	B-Disease
with	O
the	O
use	O
of	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalol	I-Chemical
for	O
sustained	O
ventricular	B-Disease
tachyarrhythmias	I-Disease
.	O
This	O
study	O
prospectively	O
evaluated	O
the	O
clinical	O
efficacy	O
,	O
the	O
incidence	O
of	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
,	O
and	O
the	O
presumable	O
risk	O
factors	O
for	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
in	O
patients	O
treated	O
with	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalol	I-Chemical
for	O
sustained	O
ventricular	B-Disease
tachyarrhythmias	I-Disease
.	O
Eighty	O
-	O
one	O
consecutive	O
patients	O
(	O
54	O
with	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
,	O
and	O
20	O
with	O
dilated	B-Disease
cardiomyopathy	I-Disease
)	O
with	O
inducible	O
sustained	O
ventricular	B-Disease
tachycardia	I-Disease
or	O
ventricular	B-Disease
fibrillation	I-Disease
received	O
oral	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalol	I-Chemical
to	O
prevent	O
induction	O
of	O
the	O
ventricular	B-Disease
tachyarrhythmia	I-Disease
.	O
During	O
oral	O
loading	O
with	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalol	I-Chemical
,	O
continuous	O
electrocardiographic	O
(	O
ECG	O
)	O
monitoring	O
was	O
performed	O
.	O
Those	O
patients	O
in	O
whom	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalol	I-Chemical
prevented	O
induction	O
of	O
ventricular	B-Disease
tachycardia	I-Disease
or	O
ventricular	B-Disease
fibrillation	I-Disease
were	O
discharged	O
with	O
the	O
drug	O
and	O
followed	O
up	O
on	O
an	O
outpatient	O
basis	O
for	O
21	O
+	O
/	O
-	O
18	O
months	O
.	O
Induction	O
of	O
the	O
ventricular	B-Disease
tachyarrhythmia	I-Disease
was	O
prevented	O
by	O
oral	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalol	I-Chemical
in	O
35	O
(	O
43	O
%	O
)	O
patients	O
;	O
the	O
ventricular	B-Disease
tachyarrhythmia	I-Disease
remained	O
inducible	O
in	O
40	O
(	O
49	O
%	O
)	O
patients	O
;	O
and	O
two	O
(	O
2	O
.	O
5	O
%	O
)	O
patients	O
did	O
not	O
tolerate	O
even	O
40	O
mg	O
of	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalol	I-Chemical
once	O
daily	O
.	O
Four	O
(	O
5	O
%	O
)	O
patients	O
had	O
from	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
during	O
the	O
initial	O
oral	O
treatment	O
with	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalol	I-Chemical
.	O
Neither	O
ECG	O
[	O
sinus	O
-	O
cycle	O
length	O
(	O
SCL	O
)	O
,	O
QT	O
or	O
QTc	O
interval	O
,	O
or	O
U	O
wave	O
]	O
nor	O
clinical	O
parameters	O
identified	O
patients	O
at	O
risk	O
for	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
.	O
However	O
,	O
the	O
oral	O
dose	O
of	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalol	I-Chemical
was	O
significantly	O
lower	O
in	O
patients	O
with	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
(	O
200	O
+	O
/	O
-	O
46	O
vs	O
.	O
328	O
+	O
/	O
-	O
53	O
mg	O
/	O
day	O
;	O
p	O
=	O
0	O
.	O
0017	O
)	O
.	O
Risk	O
factors	O
associated	O
with	O
the	O
development	O
of	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
were	O
the	O
appearance	O
of	O
an	O
U	O
wave	O
(	O
p	O
=	O
0	O
.	O
049	O
)	O
,	O
female	O
gender	O
(	O
p	O
=	O
0	O
.	O
015	O
)	O
,	O
and	O
significant	O
dose	O
-	O
corrected	O
changes	O
of	O
SCL	O
,	O
QT	O
interval	O
,	O
and	O
QTc	O
interval	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
During	O
follow	O
-	O
up	O
,	O
seven	O
(	O
20	O
%	O
)	O
patients	O
had	O
a	O
nonfatal	O
ventricular	B-Disease
tachycardia	I-Disease
recurrence	O
,	O
and	O
two	O
(	O
6	O
%	O
)	O
patients	O
died	O
suddenly	O
.	O
One	O
female	O
patient	O
with	O
stable	O
cardiac	B-Disease
disease	I-Disease
had	O
recurrent	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
after	O
2	O
years	O
of	O
successful	O
treatment	O
with	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalol	I-Chemical
.	O
Torsades	B-Disease
de	I-Disease
pointes	I-Disease
occurred	O
early	O
during	O
treatment	O
even	O
with	O
low	O
doses	O
of	O
oral	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalol	I-Chemical
.	O
Pronounced	O
changes	O
in	O
the	O
surface	O
ECG	O
(	O
cycle	O
length	O
,	O
QT	O
,	O
and	O
QTc	O
)	O
in	O
relation	O
to	O
the	O
dose	O
of	O
oral	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalol	I-Chemical
might	O
identify	O
a	O
subgroup	O
of	O
patients	O
with	O
an	O
increased	O
risk	O
for	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
.	O
Other	O
ECG	O
parameters	O
before	O
the	O
application	O
of	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalol	I-Chemical
did	O
not	O
identify	O
patients	O
at	O
increased	O
risk	O
for	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
.	O
Recurrence	O
rates	O
of	O
ventricular	B-Disease
tachyarrhythmias	I-Disease
are	O
high	O
despite	O
complete	O
suppression	O
of	O
the	O
arrhythmia	B-Disease
during	O
programmed	O
stimulation	O
.	O
Therefore	O
programmed	O
electrical	O
stimulation	O
in	O
the	O
case	O
of	O
d	B-Chemical
,	I-Chemical
l	I-Chemical
-	I-Chemical
sotalol	I-Chemical
seems	O
to	O
be	O
of	O
limited	O
prognostic	O
value	O
.	O
Chronic	O
hyperprolactinemia	B-Disease
and	O
changes	O
in	O
dopamine	B-Chemical
neurons	O
.	O
The	O
tuberoinfundibular	O
dopaminergic	O
(	O
TIDA	O
)	O
system	O
is	O
known	O
to	O
inhibit	O
prolactin	O
(	O
PRL	O
)	O
secretion	O
.	O
In	O
young	O
animals	O
this	O
system	O
responds	O
to	O
acute	O
elevations	O
in	O
serum	O
PRL	O
by	O
increasing	O
its	O
activity	O
.	O
However	O
,	O
this	O
responsiveness	O
is	O
lost	O
in	O
aging	O
rats	O
with	O
chronically	O
high	O
serum	O
PRL	O
levels	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
induce	O
hyperprolactinemia	B-Disease
in	O
rats	O
for	O
extended	O
periods	O
of	O
time	O
and	O
examine	O
its	O
effects	O
on	O
dopaminergic	O
systems	O
in	O
the	O
brain	O
.	O
Hyperprolactinemia	B-Disease
was	O
induced	O
by	O
treatment	O
with	O
haloperidol	B-Chemical
,	O
a	O
dopamine	B-Chemical
receptor	O
antagonist	O
,	O
and	O
Palkovits	O
'	O
microdissection	O
technique	O
in	O
combination	O
with	O
high	O
-	O
performance	O
liquid	O
chromatography	O
was	O
used	O
to	O
measure	O
neurotransmitter	O
concentrations	O
in	O
several	O
areas	O
of	O
the	O
brain	O
.	O
After	O
6	O
months	O
of	O
hyperprolactinemia	B-Disease
,	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
concentrations	O
in	O
the	O
median	O
eminence	O
(	O
ME	O
)	O
increased	O
by	O
84	O
%	O
over	O
the	O
control	O
group	O
.	O
Nine	O
months	O
of	O
hyperprolactinemia	B-Disease
produced	O
a	O
50	O
%	O
increase	O
in	O
DA	B-Chemical
concentrations	O
in	O
the	O
ME	O
over	O
the	O
control	O
group	O
.	O
However	O
,	O
DA	B-Chemical
response	O
was	O
lost	O
if	O
a	O
9	O
-	O
month	O
long	O
haloperidol	B-Chemical
-	O
induced	O
hyperprolactinemia	B-Disease
was	O
followed	O
by	O
a	O
1	O
1	O
/	O
2	O
month	O
-	O
long	O
extremely	O
high	O
increase	O
in	O
serum	O
PRL	O
levels	O
produced	O
by	O
implantation	O
of	O
MMQ	O
cells	O
under	O
the	O
kidney	O
capsule	O
.	O
There	O
was	O
no	O
change	O
in	O
the	O
levels	O
of	O
DA	B-Chemical
,	O
norepinephrine	B-Chemical
(	O
NE	B-Chemical
)	O
,	O
serotonin	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
,	O
or	O
their	O
metabolites	O
in	O
the	O
arcuate	O
nucleus	O
(	O
AN	O
)	O
,	O
medial	O
preoptic	O
area	O
(	O
MPA	O
)	O
,	O
caudate	O
putamen	O
(	O
CP	O
)	O
,	O
substantia	O
nigra	O
(	O
SN	O
)	O
,	O
and	O
zona	O
incerta	O
(	O
ZI	O
)	O
,	O
except	O
for	O
a	O
decrease	O
in	O
5	B-Chemical
-	I-Chemical
hydroxyindoleacetic	I-Chemical
acid	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
HIAA	I-Chemical
)	O
in	O
the	O
AN	O
after	O
6	O
-	O
months	O
of	O
hyperprolactinemia	B-Disease
and	O
an	O
increase	O
in	O
DA	B-Chemical
concentrations	O
in	O
the	O
AN	O
after	O
9	O
-	O
months	O
of	O
hyperprolactinemia	B-Disease
.	O
These	O
results	O
demonstrate	O
that	O
hyperprolactinemia	B-Disease
specifically	O
affects	O
TIDA	O
neurons	O
and	O
these	O
effects	O
vary	O
,	O
depending	O
on	O
the	O
duration	O
and	O
intensity	O
of	O
hyperprolactinemia	B-Disease
.	O
The	O
age	O
-	O
related	O
decrease	O
in	O
hypothalamic	O
dopamine	B-Chemical
function	O
may	O
be	O
associated	O
with	O
increases	O
in	O
PRL	O
secretion	O
.	O
Treatment	O
-	O
related	O
disseminated	O
necrotizing	O
leukoencephalopathy	B-Disease
with	O
characteristic	O
contrast	O
enhancement	O
of	O
the	O
white	O
matter	O
.	O
This	O
report	O
describes	O
unique	O
contrast	O
enhancement	O
of	O
the	O
white	O
matter	O
on	O
T1	O
-	O
weighted	O
magnetic	O
resonance	O
images	O
of	O
two	O
patients	O
with	O
disseminated	O
necrotizing	O
leukoencephalopathy	B-Disease
,	O
which	O
developed	O
from	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
treated	O
with	O
high	O
-	O
dose	O
methotrexate	B-Chemical
.	O
In	O
both	O
patients	O
,	O
the	O
enhancement	O
was	O
more	O
pronounced	O
near	O
the	O
base	O
of	O
the	O
brain	O
than	O
at	O
the	O
vertex	O
.	O
Necropsy	O
of	O
the	O
first	O
case	O
revealed	O
loss	B-Disease
of	I-Disease
myelination	I-Disease
and	O
necrosis	B-Disease
of	O
the	O
white	O
matter	O
.	O
Possible	O
mechanisms	O
causing	O
such	O
a	O
leukoencephalopathy	B-Disease
are	O
discussed	O
.	O
Thrombotic	B-Disease
complications	O
in	O
acute	B-Disease
promyelocytic	I-Disease
leukemia	I-Disease
during	O
all	B-Chemical
-	I-Chemical
trans	I-Chemical
-	I-Chemical
retinoic	I-Chemical
acid	I-Chemical
therapy	O
.	O
A	O
case	O
of	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
,	O
due	O
to	O
occlusion	B-Disease
of	I-Disease
renal	I-Disease
vessels	I-Disease
in	O
a	O
patient	O
with	O
acute	B-Disease
promyelocytic	I-Disease
leukemia	I-Disease
(	O
APL	B-Disease
)	O
treated	O
with	O
all	B-Chemical
-	I-Chemical
trans	I-Chemical
-	I-Chemical
retinoic	I-Chemical
acid	I-Chemical
(	O
ATRA	B-Chemical
)	O
and	O
tranexamic	B-Chemical
acid	I-Chemical
has	O
been	O
described	O
recently	O
.	O
We	O
report	O
a	O
case	O
of	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
in	O
an	O
APL	B-Disease
patient	O
treated	O
with	O
ATRA	B-Chemical
alone	O
.	O
This	O
case	O
further	O
supports	O
the	O
concern	O
about	O
thromboembolic	B-Disease
complications	O
associated	O
with	O
ATRA	B-Chemical
therapy	O
in	O
APL	B-Disease
patients	O
.	O
The	O
patients	O
,	O
a	O
43	O
-	O
year	O
-	O
old	O
man	O
,	O
presented	O
all	O
the	O
signs	O
and	O
symptoms	O
of	O
APL	B-Disease
and	O
was	O
included	O
in	O
a	O
treatment	O
protocol	O
with	O
ATRA	B-Chemical
.	O
After	O
10	O
days	O
of	O
treatment	O
,	O
he	O
developed	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
that	O
was	O
completely	O
reversible	O
after	O
complete	O
remission	O
of	O
APL	B-Disease
was	O
achieved	O
and	O
therapy	O
discontinued	O
.	O
We	O
conclude	O
that	O
ATRA	B-Chemical
is	O
a	O
valid	O
therapeutic	O
choice	O
for	O
patients	O
with	O
APL	B-Disease
,	O
although	O
the	O
procoagulant	O
tendency	O
is	O
not	O
completely	O
corrected	O
.	O
Thrombotic	B-Disease
events	O
,	O
however	O
,	O
could	O
be	O
avoided	O
by	O
using	O
low	O
-	O
dose	O
heparin	B-Chemical
.	O
Pupillary	O
changes	O
associated	O
with	O
the	O
development	O
of	O
stimulant	O
-	O
induced	O
mania	B-Disease
:	O
a	O
case	O
report	O
.	O
A	O
30	O
-	O
year	O
-	O
old	O
cocaine	B-Chemical
-	O
dependent	O
man	O
who	O
was	O
a	O
subject	O
in	O
a	O
study	O
evaluating	O
the	O
anticraving	O
efficacy	O
of	O
the	O
stimulant	O
medication	O
diethylpropion	B-Chemical
(	O
DEP	B-Chemical
)	O
became	O
manic	B-Disease
during	O
his	O
second	O
week	O
on	O
the	O
study	O
drug	O
.	O
Pupillometric	O
changes	O
while	O
on	O
DEP	B-Chemical
,	O
especially	O
changes	O
in	O
the	O
total	O
power	O
of	O
pupillary	B-Disease
oscillation	I-Disease
,	O
were	O
dramatically	O
different	O
than	O
those	O
observed	O
in	O
the	O
eight	O
other	O
study	O
subjects	O
who	O
did	O
not	O
become	O
manic	B-Disease
.	O
The	O
large	O
changes	O
in	O
total	O
power	O
of	O
pupillary	B-Disease
oscillation	I-Disease
occurred	O
a	O
few	O
days	O
before	O
the	O
patient	O
became	O
fully	O
manic	B-Disease
.	O
Such	O
medication	O
-	O
associated	O
changes	O
in	O
the	O
total	O
power	O
of	O
pupillary	B-Disease
oscillation	I-Disease
might	O
be	O
of	O
utility	O
in	O
identifying	O
persons	O
at	O
risk	O
for	O
manic	B-Disease
-	O
like	O
adverse	O
effects	O
during	O
the	O
medical	O
use	O
of	O
psychomotor	O
stimulants	O
or	O
sympathomimetic	O
agents	O
.	O
Fetal	O
risks	O
due	O
to	O
warfarin	B-Chemical
therapy	O
during	O
pregnancy	O
.	O
Two	O
mothers	O
with	O
heart	O
valve	O
prosthesis	O
were	O
treated	O
with	O
warfarin	B-Chemical
during	O
pregnancy	O
.	O
In	O
the	O
first	O
case	O
a	O
caesarean	O
section	O
was	O
done	O
one	O
week	O
after	O
replacement	O
of	O
warfarin	B-Chemical
with	O
heparin	B-Chemical
.	O
The	O
baby	O
died	O
of	O
cerebral	B-Disease
and	I-Disease
pulmonary	I-Disease
hemorrhage	I-Disease
.	O
The	O
second	O
mother	O
had	O
a	O
male	O
infant	O
by	O
caesarean	O
section	O
.	O
The	O
baby	O
showed	O
warfarin	B-Chemical
-	O
induced	O
embryopathy	B-Disease
with	O
nasal	B-Disease
hypoplasia	I-Disease
and	O
stippled	B-Disease
epiphyses	I-Disease
(	O
chondrodysplasia	B-Disease
punctata	I-Disease
)	O
.	O
Nasal	B-Disease
hypoplasia	I-Disease
with	O
or	O
without	O
stippled	B-Disease
epiphyses	I-Disease
has	O
now	O
been	O
reported	O
in	O
11	O
infants	O
born	O
to	O
mothers	O
treated	O
with	O
warfarin	B-Chemical
during	O
the	O
first	O
trimester	O
,	O
and	O
a	O
causal	O
association	O
is	O
probable	O
.	O
In	O
view	O
of	O
the	O
risks	O
to	O
both	O
mother	O
and	O
fetus	O
in	O
women	O
with	O
prosthetic	O
cardiac	O
valves	O
it	O
is	O
recommended	O
that	O
therapeutic	O
abortion	O
be	O
advised	O
as	O
the	O
first	O
alternative	O
.	O
The	O
negative	O
mucosal	O
potential	O
:	O
separating	O
central	O
and	O
peripheral	O
effects	O
of	O
NSAIDs	O
in	O
man	O
.	O
OBJECTIVE	O
:	O
We	O
wanted	O
to	O
test	O
whether	O
assessment	O
of	O
both	O
a	O
central	O
pain	B-Disease
-	O
related	O
signal	O
(	O
chemo	O
-	O
somatosensory	O
evoked	O
potential	O
,	O
CSSEP	O
)	O
and	O
a	O
concomitantly	O
recorded	O
peripheral	O
signal	O
(	O
negative	O
mucosal	O
potential	O
,	O
NMP	O
)	O
allows	O
for	O
separation	O
of	O
central	O
and	O
peripheral	O
effects	O
of	O
NSAIDs	O
.	O
For	O
this	O
purpose	O
,	O
experimental	O
conditions	O
were	O
created	O
in	O
which	O
NSAIDs	O
had	O
previously	O
been	O
observed	O
to	O
produce	O
effects	O
on	O
phasic	O
and	O
tonic	O
pain	B-Disease
by	O
either	O
central	O
or	O
peripheral	O
mechanisms	O
.	O
METHODS	O
:	O
According	O
to	O
a	O
double	O
-	O
blind	O
,	O
randomised	O
,	O
controlled	O
,	O
threefold	O
cross	O
-	O
over	O
design	O
,	O
18	O
healthy	O
subjects	O
(	O
11	O
males	O
,	O
7	O
females	O
;	O
mean	O
age	O
26	O
years	O
)	O
received	O
either	O
placebo	O
,	O
400	O
mg	O
ibuprofen	B-Chemical
,	O
or	O
800	O
mg	O
ibuprofen	B-Chemical
.	O
Phasic	O
pain	B-Disease
was	O
applied	O
by	O
means	O
of	O
short	O
pulses	O
of	O
CO2	B-Chemical
to	O
the	O
nasal	O
mucosa	O
(	O
stimulus	O
duration	O
500	O
ms	O
,	O
interval	O
approximately	O
60	O
s	O
)	O
,	O
and	O
tonic	O
pain	B-Disease
was	O
induced	O
in	O
the	O
nasal	O
cavity	O
by	O
means	O
of	O
dry	O
air	O
of	O
controlled	O
temperature	O
,	O
humidity	O
and	O
flow	O
rate	O
(	O
22	O
degrees	O
C	O
,	O
0	O
%	O
relative	O
humidity	O
,	O
145	O
ml	O
.	O
s	O
-	O
1	O
)	O
.	O
Both	O
CSSEPs	O
as	O
central	O
and	O
NMPs	O
as	O
peripheral	O
correlates	O
of	O
pain	B-Disease
were	O
obtained	O
in	O
response	O
to	O
the	O
CO2	B-Chemical
stimuli	O
.	O
Additionally	O
,	O
the	O
subjects	O
rated	O
the	O
intensity	O
of	O
both	O
phasic	O
and	O
tonic	O
pain	B-Disease
by	O
means	O
of	O
visual	O
analogue	O
scales	O
.	O
RESULTS	O
:	O
As	O
described	O
earlier	O
,	O
administration	O
of	O
ibuprofen	B-Chemical
was	O
followed	O
by	O
a	O
decrease	O
in	O
tonic	O
pain	B-Disease
but	O
-	O
relative	O
to	O
placebo	O
-	O
an	O
increase	O
in	O
correlates	O
of	O
phasic	O
pain	B-Disease
,	O
indicating	O
a	O
specific	O
effect	O
of	O
ibuprofen	B-Chemical
on	O
the	O
interaction	O
between	O
the	O
pain	B-Disease
stimuli	O
under	O
these	O
special	O
experimental	O
conditions	O
.	O
Based	O
on	O
the	O
similar	O
behaviour	O
of	O
CSSEP	O
and	O
NMP	O
,	O
it	O
was	O
concluded	O
that	O
the	O
pharmacological	O
process	O
underlying	O
this	O
phenomenon	O
was	O
localised	O
in	O
the	O
periphery	O
.	O
By	O
means	O
of	O
the	O
simultaneous	O
recording	O
of	O
interrelated	O
peripheral	O
and	O
central	O
electrophysiologic	O
correlates	O
of	O
nociception	O
,	O
it	O
was	O
possible	O
to	O
separate	O
central	O
and	O
peripheral	O
effects	O
of	O
an	O
NSAID	O
.	O
The	O
major	O
advantage	O
of	O
this	O
pain	B-Disease
model	O
is	O
the	O
possibility	O
of	O
obtaining	O
peripheral	O
pain	B-Disease
-	O
related	O
activity	O
directly	O
using	O
a	O
non	O
-	O
invasive	O
technique	O
in	O
humans	O
.	O
Effect	O
of	O
D	B-Chemical
-	I-Chemical
Glucarates	I-Chemical
on	O
basic	O
antibiotic	O
-	O
induced	O
renal	B-Disease
damage	I-Disease
in	O
rats	O
.	O
Dehydrated	B-Disease
rats	O
regularly	O
develop	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
following	O
single	O
injection	O
of	O
aminoglycoside	B-Chemical
antibiotics	O
combined	O
with	O
dextran	O
or	O
of	O
antibiotics	O
only	O
.	O
Oral	O
administration	O
of	O
2	B-Chemical
,	I-Chemical
5	I-Chemical
-	I-Chemical
di	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
glucaro	I-Chemical
-	I-Chemical
1	I-Chemical
,	I-Chemical
4	I-Chemical
-	I-Chemical
6	I-Chemical
,	I-Chemical
3	I-Chemical
-	I-Chemical
dilactone	I-Chemical
protected	O
rats	O
against	O
renal	B-Disease
failure	I-Disease
induced	O
by	O
kanamycin	B-Chemical
-	O
dextran	O
.	O
The	O
protective	O
effect	O
was	O
prevalent	O
among	O
D	B-Chemical
-	I-Chemical
glucarates	I-Chemical
,	O
and	O
also	O
to	O
other	O
saccharic	B-Chemical
acid	I-Chemical
,	O
hexauronic	B-Chemical
acids	I-Chemical
and	O
hexaaldonic	B-Chemical
acids	I-Chemical
,	O
although	O
to	O
a	O
lesser	O
degree	O
,	O
but	O
not	O
to	O
a	O
hexaaldose	O
,	O
sugar	B-Chemical
alcohols	I-Chemical
,	O
substances	O
inthe	O
TCA	B-Chemical
cycle	O
and	O
other	O
acidic	O
compounds	O
.	O
D	B-Chemical
-	I-Chemical
Glucarates	I-Chemical
were	O
effective	O
against	O
renal	B-Disease
damage	I-Disease
induced	O
by	O
peptide	O
antibiotics	O
as	O
well	O
as	O
various	O
aminoglycoside	B-Chemical
antibitocis	O
.	O
Dose	O
-	O
responses	O
were	O
observed	O
in	O
the	O
protective	O
effect	O
of	O
D	B-Chemical
-	I-Chemical
Glucarates	I-Chemical
.	O
With	O
a	O
D	B-Chemical
-	I-Chemical
glucarate	I-Chemical
of	O
a	O
fixed	O
size	O
of	O
dose	O
,	O
approximately	O
the	O
same	O
degree	O
of	O
protection	O
was	O
obtained	O
against	O
renal	B-Disease
damages	I-Disease
induced	O
by	O
different	O
basic	O
antibiotics	O
despite	O
large	O
disparities	O
in	O
administration	O
doses	O
of	O
different	O
antibiotics	O
.	O
D	B-Chemical
-	I-Chemical
Glucarates	I-Chemical
had	O
the	O
ability	O
to	O
prevent	O
renal	B-Disease
damage	I-Disease
but	O
not	O
to	O
cure	O
it	O
.	O
Rats	O
excreted	O
acidic	O
urine	O
when	O
they	O
were	O
spared	O
from	O
renal	B-Disease
lesions	I-Disease
by	O
monosaccharides	B-Chemical
.	O
The	O
reduction	O
effect	O
of	O
D	B-Chemical
-	I-Chemical
glucarates	I-Chemical
against	O
nephrotoxicity	B-Disease
of	O
basic	O
antibiotics	O
was	O
discussed	O
.	O
Acute	O
severe	O
depression	B-Disease
following	O
peri	O
-	O
operative	O
ondansetron	B-Chemical
.	O
A	O
41	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
strong	O
history	O
of	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
presented	O
for	O
abdominal	O
hysterectomy	O
3	O
months	O
after	O
a	O
previous	O
anaesthetic	O
where	O
ondansetron	B-Chemical
prophylaxis	O
had	O
been	O
used	O
.	O
She	O
had	O
developed	O
a	O
severe	O
acute	O
major	B-Disease
depression	I-Disease
disorder	I-Disease
almost	O
immediately	O
thereafter	O
,	O
possibly	O
related	O
to	O
the	O
use	O
of	O
a	O
serotonin	B-Chemical
antagonist	O
.	O
Nine	O
years	O
before	O
she	O
had	O
experienced	O
a	O
self	O
-	O
limited	O
puerperal	O
depressive	B-Disease
episode	I-Disease
.	O
Anaesthesia	O
with	O
a	O
propofol	B-Chemical
infusion	O
and	O
avoidance	O
of	O
serotonin	B-Chemical
antagonists	O
provided	O
a	O
nausea	B-Disease
-	O
free	O
postoperative	O
course	O
without	O
exacerbation	O
of	O
the	O
depression	B-Disease
disorder	I-Disease
.	O
Hypertensive	B-Disease
response	O
during	O
dobutamine	B-Chemical
stress	O
echocardiography	O
.	O
Among	O
3	O
,	O
129	O
dobutamine	B-Chemical
stress	O
echocardiographic	O
studies	O
,	O
a	O
hypertensive	B-Disease
response	O
,	O
defined	O
as	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
>	O
or	O
=	O
220	O
mm	O
Hg	O
and	O
/	O
or	O
diastolic	O
BP	O
>	O
or	O
=	O
110	O
mm	O
Hg	O
,	O
occurred	O
in	O
30	O
patients	O
(	O
1	O
%	O
)	O
.	O
Patients	O
with	O
this	O
response	O
more	O
often	O
had	O
a	O
history	O
of	O
hypertension	B-Disease
and	O
had	O
higher	O
resting	O
systolic	O
and	O
diastolic	O
BP	O
before	O
dobutamine	B-Chemical
infusion	O
.	O
Continuously	O
nebulized	O
albuterol	B-Chemical
in	O
severe	O
exacerbations	O
of	O
asthma	B-Disease
in	O
adults	O
:	O
a	O
case	O
-	O
controlled	O
study	O
.	O
A	O
retrospective	O
,	O
case	O
-	O
controlled	O
analysis	O
comparing	O
patients	O
admitted	O
to	O
a	O
medical	O
intensive	O
care	O
unit	O
with	O
severe	O
exacerbations	O
of	O
asthma	B-Disease
who	O
received	O
continuously	O
nebulized	O
albuterol	B-Chemical
(	O
CNA	O
)	O
versus	O
intermittent	O
albuterol	B-Chemical
(	O
INA	O
)	O
treatments	O
is	O
reported	O
.	O
Forty	O
matched	O
pairs	O
of	O
patients	O
with	O
asthma	B-Disease
are	O
compared	O
.	O
CNA	O
was	O
administered	O
for	O
a	O
mean	O
of	O
11	O
+	O
/	O
-	O
10	O
hr	O
.	O
The	O
incidence	O
of	O
cardiac	B-Disease
dysrhythmias	I-Disease
was	O
similar	O
between	O
groups	O
.	O
Symptomatic	O
hypokalemia	B-Disease
did	O
not	O
occur	O
.	O
CNA	O
patients	O
had	O
higher	O
heart	O
rates	O
during	O
treatment	O
,	O
which	O
may	O
reflect	O
severity	O
of	O
illness	O
.	O
The	O
incidence	O
of	O
intubation	O
was	O
similar	O
.	O
We	O
conclude	O
that	O
CNA	O
and	O
INA	O
demonstrated	O
similar	O
profiles	O
with	O
regard	O
to	O
safety	O
,	O
morbidity	O
,	O
and	O
mortality	O
.	O
Paraplegia	B-Disease
following	O
intrathecal	O
methotrexate	B-Chemical
:	O
report	O
of	O
a	O
case	O
and	O
review	O
of	O
the	O
literature	O
.	O
A	O
patient	O
who	O
developed	O
paraplegia	B-Disease
following	O
the	O
intrathecal	O
instillation	O
of	O
methotrexate	B-Chemical
is	O
discribed	O
.	O
The	O
ten	O
previously	O
reported	O
cases	O
of	O
this	O
unusual	O
complication	O
are	O
reviewed	O
.	O
The	O
following	O
factors	O
appear	O
to	O
predispose	O
to	O
the	O
development	O
of	O
this	O
complication	O
:	O
abnormal	O
cerebrospinal	O
dynamics	O
related	O
to	O
the	O
presence	O
of	O
central	B-Disease
nervous	I-Disease
system	I-Disease
leukemia	I-Disease
,	O
and	O
epidural	O
cerebrospinal	O
leakage	O
;	O
elevated	O
cerebrospinal	O
fluid	O
methothexate	B-Chemical
concentration	O
related	O
to	O
abnormal	O
cerebrospinal	O
fluid	O
dynamics	O
and	O
to	O
inappropriately	O
high	O
methotrexate	B-Chemical
doses	O
based	O
on	O
body	O
surface	O
area	O
calculations	O
in	O
older	O
children	O
and	O
adults	O
;	O
the	O
presence	O
of	O
neurotoxic	B-Disease
preservatives	O
in	O
commercially	O
available	O
methotrexate	B-Chemical
preparations	O
and	O
diluents	O
;	O
and	O
the	O
use	O
of	O
methotrexate	B-Chemical
diluents	O
of	O
unphysiologic	O
pH	O
,	O
ionic	O
content	O
and	O
osmolarity	O
.	O
The	O
role	O
of	O
methotrexate	B-Chemical
contaminants	O
,	O
local	O
folate	B-Disease
deficiency	I-Disease
,	O
and	O
cranial	O
irradiation	O
in	O
the	O
pathogenesis	O
of	O
intrathecal	O
methotrexate	B-Chemical
toxicity	B-Disease
is	O
unclear	O
.	O
The	O
incidence	O
of	O
neurotoxicity	B-Disease
may	O
be	O
reduced	O
by	O
employing	O
lower	O
doses	O
of	O
methotrexate	B-Chemical
in	O
the	O
presence	O
of	O
central	B-Disease
nervous	I-Disease
system	I-Disease
leukemia	I-Disease
,	O
in	O
older	O
children	O
and	O
adults	O
,	O
and	O
in	O
the	O
presence	O
of	O
epidural	O
leakage	O
.	O
Only	O
preservative	O
-	O
free	O
methotrexate	B-Chemical
in	O
Elliott	O
'	O
s	O
B	O
Solution	O
at	O
a	O
concentration	O
of	O
not	O
more	O
than	O
1	O
mg	O
/	O
ml	O
should	O
be	O
used	O
for	O
intrathecal	O
administration	O
.	O
Periodic	O
monitoring	O
of	O
cerebruspinal	O
fluid	O
methotrexate	B-Chemical
levels	O
may	O
be	O
predictive	O
of	O
the	O
development	O
of	O
serious	O
neurotoxicity	B-Disease
.	O
Hyperosmolar	B-Disease
nonketotic	I-Disease
coma	I-Disease
precipitated	O
by	O
lithium	B-Chemical
-	O
induced	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
.	O
A	O
45	O
-	O
year	O
-	O
old	O
man	O
,	O
with	O
a	O
10	O
-	O
year	O
history	O
of	O
manic	B-Disease
depression	I-Disease
treated	O
with	O
lithium	B-Chemical
,	O
was	O
admitted	O
with	O
hyperosmolar	B-Disease
,	I-Disease
nonketotic	I-Disease
coma	I-Disease
.	O
He	O
gave	O
a	O
five	O
-	O
year	O
history	O
of	O
polyuria	B-Disease
and	O
polydipsia	B-Disease
,	O
during	O
which	O
time	O
urinalysis	O
had	O
been	O
negative	O
for	O
glucose	B-Chemical
.	O
After	O
recovery	O
from	O
hyperglycaemia	B-Disease
,	O
he	O
remained	O
polyuric	B-Disease
despite	O
normal	O
blood	O
glucose	B-Chemical
concentrations	O
;	O
water	O
deprivation	O
testing	O
indicated	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
,	O
likely	O
to	O
be	O
lithium	B-Chemical
-	O
induced	O
.	O
We	O
hypothesize	O
that	O
when	O
this	O
man	O
developed	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
,	O
chronic	O
polyuria	B-Disease
due	O
to	O
nephrogenic	B-Disease
diabetes	I-Disease
insipidus	I-Disease
was	O
sufficient	O
to	O
precipitate	O
hyperosmolar	O
dehydration	B-Disease
.	O
Effects	O
of	O
the	O
intracoronary	O
infusion	O
of	O
cocaine	B-Chemical
on	O
left	O
ventricular	O
systolic	O
and	O
diastolic	O
function	O
in	O
humans	O
.	O
BACKGROUND	O
:	O
In	O
dogs	O
,	O
a	O
large	O
amount	O
of	O
intravenous	O
cocaine	B-Chemical
causes	O
a	O
profound	O
deterioration	B-Disease
of	I-Disease
left	I-Disease
ventricular	I-Disease
(	I-Disease
LV	I-Disease
)	I-Disease
systolic	I-Disease
function	I-Disease
and	O
an	O
increase	O
in	O
LV	O
end	O
-	O
diastolic	O
pressure	O
.	O
This	O
study	O
was	O
done	O
to	O
assess	O
the	O
influence	O
of	O
a	O
high	O
intracoronary	O
cocaine	B-Chemical
concentration	O
on	O
LV	O
systolic	O
and	O
diastolic	O
function	O
in	O
humans	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
In	O
20	O
patients	O
(	O
14	O
men	O
and	O
6	O
women	O
aged	O
39	O
to	O
72	O
years	O
)	O
referred	O
for	O
cardiac	O
catheterization	O
for	O
the	O
evaluation	O
of	O
chest	B-Disease
pain	I-Disease
,	O
we	O
measured	O
heart	O
rate	O
,	O
systemic	O
arterial	O
pressure	O
,	O
LV	O
pressure	O
and	O
its	O
first	O
derivative	O
(	O
dP	O
/	O
dt	O
)	O
,	O
and	O
LV	O
volumes	O
and	O
ejection	O
fraction	O
before	O
and	O
during	O
the	O
final	O
2	O
to	O
3	O
minutes	O
of	O
a	O
15	O
-	O
minute	O
intracoronary	O
infusion	O
of	O
saline	O
(	O
n	O
=	O
10	O
,	O
control	O
subjects	O
)	O
or	O
cocaine	B-Chemical
hydrochloride	I-Chemical
1	O
mg	O
/	O
min	O
(	O
n	O
=	O
10	O
)	O
.	O
No	O
variable	O
changed	O
with	O
saline	O
.	O
With	O
cocaine	B-Chemical
,	O
the	O
drug	O
concentration	O
in	O
blood	O
obtained	O
from	O
the	O
coronary	O
sinus	O
was	O
3	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
4	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
mg	O
/	O
L	O
,	O
similar	O
in	O
magnitude	O
to	O
the	O
blood	O
cocaine	B-Chemical
concentration	O
reported	O
in	O
abusers	O
dying	O
of	O
cocaine	B-Chemical
intoxication	O
.	O
Cocaine	B-Chemical
induced	O
no	O
significant	O
change	O
in	O
heart	O
rate	O
,	O
LV	O
dP	O
/	O
dt	O
(	O
positive	O
or	O
negative	O
)	O
,	O
or	O
LV	O
end	O
-	O
diastolic	O
volume	O
,	O
but	O
it	O
caused	O
an	O
increase	O
in	O
systolic	O
and	O
mean	O
arterial	O
pressures	O
,	O
LV	O
end	O
-	O
diastolic	O
pressure	O
,	O
and	O
LV	O
end	O
-	O
systolic	O
volume	O
,	O
as	O
well	O
as	O
a	O
decrease	O
in	O
LV	O
ejection	O
fraction	O
.	O
CONCLUSIONS	O
:	O
In	O
humans	O
,	O
the	O
intracoronary	O
infusion	O
of	O
cocaine	B-Chemical
sufficient	O
in	O
amount	O
to	O
achieve	O
a	O
high	O
drug	O
concentration	O
in	O
coronary	O
sinus	O
blood	O
causes	O
a	O
deterioration	B-Disease
of	I-Disease
LV	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
performance	I-Disease
.	O
Ascending	O
dose	O
tolerance	O
study	O
of	O
intramuscular	O
carbetocin	B-Chemical
administered	O
after	O
normal	O
vaginal	O
birth	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
carbetocin	B-Chemical
(	O
a	O
long	O
-	O
acting	O
synthetic	O
analogue	O
of	O
oxytocin	B-Chemical
)	O
,	O
when	O
administered	O
immediately	O
after	O
vaginal	O
delivery	O
at	O
term	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Carbetocin	B-Chemical
was	O
given	O
as	O
an	O
intramuscular	O
injection	O
immediately	O
after	O
the	O
birth	O
of	O
the	O
infant	O
in	O
45	O
healthy	O
women	O
with	O
normal	O
singleton	O
pregnancies	O
who	O
delivered	O
vaginally	O
at	O
term	O
.	O
Dosage	O
groups	O
of	O
15	O
,	O
30	O
,	O
50	O
,	O
75	O
,	O
100	O
,	O
125	O
,	O
150	O
,	O
175	O
or	O
200	O
microg	O
carbetocin	B-Chemical
were	O
assigned	O
to	O
blocks	O
of	O
three	O
women	O
according	O
to	O
the	O
continual	O
reassessment	O
method	O
(	O
CRM	O
)	O
.	O
RESULTS	O
:	O
All	O
dosage	O
groups	O
consisted	O
of	O
three	O
women	O
,	O
except	O
those	O
with	O
100	O
microg	O
(	O
n	O
=	O
6	O
)	O
and	O
200	O
microg	O
(	O
n	O
=	O
18	O
)	O
.	O
Recorded	O
were	O
dose	O
-	O
limiting	O
adverse	O
events	O
:	O
hyper	B-Disease
-	I-Disease
or	I-Disease
hypotension	I-Disease
(	O
three	O
)	O
,	O
severe	O
abdominal	B-Disease
pain	I-Disease
(	O
0	O
)	O
,	O
vomiting	B-Disease
(	O
0	O
)	O
and	O
retained	B-Disease
placenta	I-Disease
(	O
four	O
)	O
.	O
Serious	O
adverse	O
events	O
occurred	O
in	O
seven	O
women	O
:	O
six	O
cases	O
with	O
blood	B-Disease
loss	I-Disease
>	O
or	O
=	O
1000	O
ml	O
,	O
four	O
cases	O
of	O
manual	O
placenta	O
removal	O
,	O
five	O
cases	O
of	O
additional	O
oxytocics	O
administration	O
and	O
five	O
cases	O
of	O
blood	O
transfusion	O
.	O
Maximum	O
blood	B-Disease
loss	I-Disease
was	O
greatest	O
at	O
the	O
upper	O
and	O
lower	O
dose	O
levels	O
,	O
and	O
lowest	O
in	O
the	O
70	O
-	O
125	O
microg	O
dose	O
range	O
.	O
Four	O
out	O
of	O
six	O
cases	O
with	O
blood	B-Disease
loss	I-Disease
>	O
or	O
=	O
1000	O
ml	O
occurred	O
in	O
the	O
200	O
microg	O
group	O
.	O
The	O
majority	O
of	O
additional	O
administration	O
of	O
oxytocics	O
(	O
4	O
/	O
5	O
)	O
and	O
blood	O
transfusion	O
(	O
3	O
/	O
5	O
)	O
occurred	O
in	O
the	O
dose	O
groups	O
of	O
200	O
microg	O
.	O
All	O
retained	O
placentae	O
were	O
found	O
in	O
the	O
group	O
of	O
200	O
microg	O
.	O
CONCLUSION	O
:	O
The	O
MTD	O
was	O
calculated	O
to	O
be	O
at	O
200	O
microg	O
carbetocin	B-Chemical
.	O
Heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
,	O
paradoxical	O
thromboembolism	B-Disease
,	O
and	O
other	O
side	O
effects	O
of	O
heparin	B-Chemical
therapy	O
.	O
Although	O
several	O
new	O
anticoagulant	O
drugs	O
are	O
in	O
development	O
,	O
heparin	B-Chemical
remains	O
the	O
drug	O
of	O
choice	O
for	O
most	O
anticoagulation	O
needs	O
.	O
The	O
clinical	O
effects	O
of	O
heparin	B-Chemical
are	O
meritorious	O
,	O
but	O
side	O
effects	O
do	O
exist	O
.	O
Important	O
untoward	O
effects	O
of	O
heparin	B-Chemical
therapy	O
including	O
heparin	B-Chemical
-	O
induced	O
thrombocytopenia	B-Disease
,	O
heparin	B-Chemical
-	O
associated	O
osteoporosis	B-Disease
,	O
eosinophilia	B-Disease
,	O
skin	B-Disease
reactions	I-Disease
,	O
allergic	B-Disease
reactions	I-Disease
other	O
than	O
thrombocytopenia	B-Disease
and	O
alopecia	B-Disease
will	O
be	O
discussed	O
in	O
this	O
article	O
.	O
Nonopaque	O
crystal	O
deposition	O
causing	O
ureteric	B-Disease
obstruction	I-Disease
in	O
patients	O
with	O
HIV	O
undergoing	O
indinavir	B-Chemical
therapy	O
.	O
OBJECTIVE	O
:	O
We	O
describe	O
the	O
unique	O
CT	O
features	O
of	O
ureteric	B-Disease
calculi	I-Disease
in	O
six	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
patients	O
receiving	O
indinavir	B-Chemical
,	O
the	O
most	O
commonly	O
used	O
HIV	O
protease	O
inhibitor	O
,	O
which	O
is	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
urolithiasis	B-Disease
.	O
CONCLUSION	O
:	O
Ureteric	B-Disease
obstruction	I-Disease
caused	O
by	O
precipitated	O
indinavir	B-Chemical
crystals	O
may	O
be	O
difficult	O
to	O
diagnose	O
with	O
unenhanced	O
CT	O
.	O
The	O
calculi	O
are	O
not	O
opaque	O
,	O
and	O
secondary	O
signs	O
of	O
obstruction	O
may	O
be	O
absent	O
or	O
minimal	O
and	O
should	O
be	O
sought	O
carefully	O
.	O
Images	O
may	O
need	O
to	O
be	O
obtained	O
using	O
i	O
.	O
v	O
.	O
contrast	O
material	O
to	O
enable	O
diagnosis	O
of	O
ureteric	B-Disease
stones	I-Disease
or	I-Disease
obstruction	I-Disease
in	O
patients	O
with	O
HIV	B-Disease
infection	I-Disease
who	O
receive	O
indinavir	B-Chemical
therapy	O
.	O
Ischemic	B-Disease
colitis	I-Disease
and	O
sumatriptan	B-Chemical
use	O
.	O
Sumatriptan	B-Chemical
succinate	I-Chemical
,	O
a	O
serotonin	B-Chemical
-	O
1	O
(	O
5	B-Chemical
-	I-Chemical
hydroxytryptamine	I-Chemical
-	O
1	O
)	O
receptor	O
agonist	O
,	O
is	O
an	O
antimigraine	O
drug	O
that	O
is	O
reported	O
to	O
act	O
by	O
selectively	O
constricting	O
intracranial	O
arteries	O
.	O
Recently	O
,	O
vasopressor	O
responses	O
that	O
are	O
distinct	O
from	O
the	O
cranial	O
circulation	O
have	O
been	O
demonstrated	O
to	O
occur	O
in	O
the	O
systemic	O
,	O
pulmonary	O
,	O
and	O
coronary	O
circulations	O
.	O
Cases	O
have	O
been	O
published	O
of	O
coronary	B-Disease
vasospasm	I-Disease
,	O
myocardial	B-Disease
ischemia	I-Disease
,	O
and	O
myocardial	B-Disease
infarction	I-Disease
occurring	O
after	O
sumatriptan	B-Chemical
use	O
.	O
We	O
report	O
on	O
the	O
development	O
of	O
8	O
serious	O
cases	O
of	O
ischemic	B-Disease
colitis	I-Disease
in	O
patients	O
with	O
migraine	B-Disease
treated	O
with	O
sumatriptan	B-Chemical
.	O
Pallidotomy	O
with	O
the	O
gamma	O
knife	O
:	O
a	O
positive	O
experience	O
.	O
51	O
patients	O
with	O
medically	O
refractory	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
underwent	O
stereotactic	O
posteromedial	O
pallidotomy	O
between	O
August	O
1993	O
and	O
February	O
1997	O
for	O
treatment	O
of	O
bradykinesia	B-Disease
,	O
rigidity	B-Disease
,	O
and	O
L	B-Chemical
-	I-Chemical
DOPA	I-Chemical
-	O
induced	O
dyskinesias	B-Disease
.	O
In	O
29	O
patients	O
,	O
the	O
pallidotomies	O
were	O
performed	O
with	O
the	O
Leksell	O
Gamma	O
Knife	O
and	O
in	O
22	O
they	O
were	O
performed	O
with	O
the	O
standard	O
radiofrequency	O
(	O
RF	O
)	O
method	O
.	O
Clinical	O
assessment	O
as	O
well	O
as	O
blinded	O
ratings	O
of	O
Unified	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
Disease	I-Disease
Rating	O
Scale	O
(	O
UPDRS	O
)	O
scores	O
were	O
carried	O
out	O
pre	O
-	O
and	O
postoperatively	O
.	O
Mean	O
follow	O
-	O
up	O
time	O
is	O
20	O
.	O
6	O
months	O
(	O
range	O
6	O
-	O
48	O
)	O
and	O
all	O
except	O
4	O
patients	O
have	O
been	O
followed	O
more	O
than	O
one	O
year	O
.	O
85	O
percent	O
of	O
patients	O
with	O
dyskinesias	B-Disease
were	O
relieved	O
of	O
symptoms	O
,	O
regardless	O
of	O
whether	O
the	O
pallidotomies	O
were	O
performed	O
with	O
the	O
Gamma	O
Knife	O
or	O
radiofrequency	O
methods	O
.	O
About	O
2	O
/	O
3	O
of	O
the	O
patients	O
in	O
both	O
Gamma	O
Knife	O
and	O
radiofrequency	O
groups	O
showed	O
improvements	O
in	O
bradykinesia	B-Disease
and	O
rigidity	B-Disease
,	O
although	O
when	O
considered	O
as	O
a	O
group	O
neither	O
the	O
Gamma	O
Knife	O
nor	O
the	O
radiofrequency	O
group	O
showed	O
statistically	O
significant	O
improvements	O
in	O
UPDRS	O
scores	O
.	O
One	O
patient	O
in	O
the	O
Gamma	O
Knife	O
group	O
(	O
3	O
.	O
4	O
%	O
)	O
developed	O
a	O
homonymous	B-Disease
hemianopsia	I-Disease
9	O
months	O
following	O
treatment	O
and	O
5	O
patients	O
(	O
27	O
.	O
7	O
%	O
)	O
in	O
the	O
radiofrequency	O
group	O
became	O
transiently	O
confused	O
postoperatively	O
.	O
No	O
other	O
complications	O
were	O
seen	O
.	O
Gamma	O
Knife	O
pallidotomy	O
is	O
as	O
effective	O
as	O
radiofrequency	O
pallidotomy	O
in	O
controlling	O
certain	O
of	O
the	O
symptoms	O
of	O
Parkinson	B-Disease
'	I-Disease
s	I-Disease
disease	I-Disease
.	O
It	O
may	O
be	O
the	O
only	O
practical	O
technique	O
available	O
in	O
certain	O
patients	O
,	O
such	O
as	O
those	O
who	O
take	O
anticoagulants	O
,	O
have	O
bleeding	B-Disease
diatheses	O
or	O
serious	O
systemic	O
medical	O
illnesses	O
.	O
It	O
is	O
a	O
viable	O
option	O
for	O
other	O
patients	O
as	O
well	O
.	O
Centrally	O
mediated	O
cardiovascular	O
effects	O
of	O
intracisternal	O
application	O
of	O
carbachol	B-Chemical
in	O
anesthetized	O
rats	O
.	O
The	O
pressor	O
response	O
to	O
the	O
intracisternal	O
(	O
i	O
.	O
c	O
.	O
)	O
injection	O
of	O
carbachol	B-Chemical
(	O
1	O
mug	O
)	O
in	O
anesthetized	O
rats	O
was	O
analyzed	O
.	O
This	O
response	O
was	O
significantly	O
reduced	O
by	O
the	O
intravenous	O
(	O
i	O
.	O
v	O
.	O
)	O
injection	O
of	O
guanethidine	B-Chemical
(	O
5	O
mg	O
)	O
,	O
hexamethonium	B-Chemical
(	O
10	O
mg	O
)	O
or	O
phentolamine	B-Chemical
(	O
5	O
mg	O
)	O
,	O
and	O
conversely	O
,	O
potentiated	O
by	O
i	O
.	O
v	O
.	O
desmethylimipramine	B-Chemical
(	O
0	O
.	O
3	O
mg	O
)	O
,	O
while	O
propranolol	B-Chemical
(	O
0	O
.	O
5	O
mg	O
)	O
i	O
.	O
v	O
.	O
selectively	O
inhibited	O
the	O
enlargement	B-Disease
of	I-Disease
pulse	I-Disease
pressure	I-Disease
and	O
the	O
tachycardia	B-Disease
following	O
i	O
.	O
c	O
.	O
carbachol	B-Chemical
(	O
1	O
mug	O
)	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
pressor	O
response	O
to	O
i	O
.	O
c	O
.	O
carbachol	B-Chemical
(	O
1	O
mug	O
)	O
was	O
almost	O
completely	O
blocked	O
by	O
i	O
.	O
c	O
.	O
atropine	B-Chemical
(	O
3	O
mug	O
)	O
or	O
hexamethonium	B-Chemical
(	O
500	O
mug	O
)	O
,	O
and	O
significantly	O
reduced	O
by	O
i	O
.	O
c	O
.	O
chlorpromazine	B-Chemical
(	O
50	O
mug	O
)	O
but	O
significantly	O
potentiated	O
by	O
i	O
.	O
c	O
.	O
desmethylimipramine	B-Chemical
(	O
30	O
mug	O
)	O
.	O
The	O
pressor	O
response	O
to	O
i	O
.	O
c	O
.	O
carbachol	B-Chemical
(	O
1	O
mug	O
)	O
remained	O
unchanged	O
after	O
sectioning	O
of	O
the	O
bilateral	O
cervical	O
vagal	O
nerves	O
but	O
disappeared	O
after	O
sectioning	O
of	O
the	O
spinal	O
cord	O
(	O
C7	O
-	O
C8	O
)	O
.	O
From	O
the	O
above	O
result	O
it	O
is	O
suggested	O
that	O
the	O
pressor	O
response	O
to	O
i	O
.	O
c	O
.	O
carbachol	B-Chemical
ortral	O
and	O
peripheral	O
adrenergic	O
mechanisms	O
,	O
and	O
that	O
the	O
sympathetic	O
trunk	O
is	O
the	O
main	O
pathway	O
.	O
Neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
and	O
methylphenidate	B-Chemical
.	O
A	O
1	O
-	O
year	O
-	O
old	O
female	O
presented	O
with	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
probably	O
caused	O
by	O
methylphenidate	B-Chemical
.	O
She	O
had	O
defects	O
in	O
the	O
supratentorial	O
brain	O
including	O
the	O
basal	O
ganglia	O
and	O
the	O
striatum	O
(	O
multicystic	B-Disease
encephalomalacia	I-Disease
)	O
due	O
to	O
severe	O
perinatal	O
hypoxic	B-Disease
-	I-Disease
ischemic	I-Disease
encephalopathy	I-Disease
,	O
which	O
was	O
considered	O
to	O
be	O
a	O
possible	O
predisposing	O
factor	O
causing	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
.	O
A	O
dopaminergic	O
blockade	O
mechanism	O
generally	O
is	O
accepted	O
as	O
the	O
pathogenesis	O
of	O
this	O
syndrome	O
.	O
However	O
,	O
methylphenidate	B-Chemical
is	O
a	O
dopamine	B-Chemical
agonist	O
via	O
the	O
inhibition	O
of	O
uptake	O
of	O
dopamine	B-Chemical
,	O
and	O
therefore	O
dopaminergic	O
systems	O
in	O
the	O
brainstem	O
(	O
mainly	O
the	O
midbrain	O
)	O
and	O
the	O
spinal	O
cord	O
were	O
unlikely	O
to	O
participate	O
in	O
the	O
onset	O
of	O
this	O
syndrome	O
.	O
A	O
relative	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
-	O
ergic	O
deficiency	O
might	O
occur	O
because	O
diazepam	B-Chemical
,	O
a	O
gamma	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
-	O
mimetic	O
agent	O
,	O
was	O
strikingly	O
effective	O
.	O
This	O
is	O
the	O
first	O
reported	O
patient	O
with	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
probably	O
caused	O
by	O
methylphenidate	B-Chemical
.	O
Differential	O
effects	O
of	O
17alpha	B-Chemical
-	I-Chemical
ethinylestradiol	I-Chemical
on	O
the	O
neutral	O
and	O
acidic	O
pathways	O
of	O
bile	B-Chemical
salt	I-Chemical
synthesis	O
in	O
the	O
rat	O
.	O
Effects	O
of	O
17alpha	B-Chemical
-	I-Chemical
ethinylestradiol	I-Chemical
(	O
EE	B-Chemical
)	O
on	O
the	O
neutral	O
and	O
acidic	O
biosynthetic	O
pathways	O
of	O
bile	B-Chemical
salt	I-Chemical
(	O
BS	B-Chemical
)	O
synthesis	O
were	O
evaluated	O
in	O
rats	O
with	O
an	O
intact	O
enterohepatic	O
circulation	O
and	O
in	O
rats	O
with	O
long	O
-	O
term	O
bile	O
diversion	O
to	O
induce	O
BS	B-Chemical
synthesis	O
.	O
For	O
this	O
purpose	O
,	O
bile	B-Chemical
salt	I-Chemical
pool	O
composition	O
,	O
synthesis	O
of	O
individual	O
BS	B-Chemical
in	O
vivo	O
,	O
hepatic	O
activities	O
,	O
and	O
expression	O
levels	O
of	O
cholesterol	B-Chemical
7alpha	O
-	O
hydroxylase	O
(	O
CYP7A	O
)	O
,	O
and	O
sterol	B-Chemical
27	O
-	O
hydroxylase	O
(	O
CYP27	O
)	O
,	O
as	O
well	O
as	O
of	O
other	O
enzymes	O
involved	O
in	O
BS	B-Chemical
synthesis	O
,	O
were	O
analyzed	O
in	O
rats	O
treated	O
with	O
EE	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
,	O
3	O
days	O
)	O
or	O
its	O
vehicle	O
.	O
BS	B-Chemical
pool	O
size	O
was	O
decreased	O
by	O
27	O
%	O
but	O
total	O
BS	B-Chemical
synthesis	O
was	O
not	O
affected	O
by	O
EE	B-Chemical
in	O
intact	O
rats	O
.	O
Synthesis	O
of	O
cholate	B-Chemical
was	O
reduced	O
by	O
68	O
%	O
in	O
EE	B-Chemical
-	O
treated	O
rats	O
,	O
while	O
that	O
of	O
chenodeoxycholate	B-Chemical
was	O
increased	O
by	O
60	O
%	O
.	O
The	O
recently	O
identified	O
Delta22	O
-	O
isomer	O
of	O
beta	O
-	O
muricholate	O
contributed	O
for	O
5	O
.	O
4	O
%	O
and	O
18	O
.	O
3	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
to	O
the	O
pool	O
in	O
control	O
and	O
EE	B-Chemical
-	O
treated	O
rats	O
,	O
respectively	O
,	O
but	O
could	O
not	O
be	O
detected	O
in	O
bile	O
after	O
exhaustion	O
of	O
the	O
pool	O
.	O
A	O
clear	O
reduction	O
of	O
BS	B-Chemical
synthesis	O
was	O
found	O
in	O
bile	O
-	O
diverted	O
rats	O
treated	O
with	O
EE	B-Chemical
,	O
yet	O
biliary	O
BS	B-Chemical
composition	O
was	O
only	O
minimally	O
affected	O
.	O
Activity	O
of	O
CYP7A	O
was	O
decreased	O
by	O
EE	B-Chemical
in	O
both	O
intact	O
and	O
bile	O
-	O
diverted	O
rats	O
,	O
whereas	O
the	O
activity	O
of	O
the	O
CYP27	O
was	O
not	O
affected	O
.	O
Hepatic	O
mRNA	O
levels	O
of	O
CYP7A	O
were	O
significantly	O
reduced	O
by	O
EE	B-Chemical
in	O
bile	O
-	O
diverted	O
rats	O
only	O
;	O
CYP27	O
mRNA	O
levels	O
were	O
not	O
affected	O
by	O
EE	B-Chemical
.	O
In	O
addition	O
,	O
mRNA	O
levels	O
of	O
sterol	B-Chemical
12alpha	O
-	O
hydroxylase	O
and	O
lithocholate	O
6beta	O
-	O
hydroxylase	O
were	O
increased	O
by	O
bile	O
diversion	O
and	O
suppressed	O
by	O
EE	B-Chemical
.	O
This	O
study	O
shows	O
that	O
17alpha	B-Chemical
-	I-Chemical
ethinylestradiol	I-Chemical
(	O
EE	B-Chemical
)	O
-	O
induced	O
intrahepatic	B-Disease
cholestasis	I-Disease
in	O
rats	O
is	O
associated	O
with	O
selective	O
inhibition	O
of	O
the	O
neutral	O
pathway	O
of	O
bile	B-Chemical
salt	I-Chemical
(	O
BS	B-Chemical
)	O
synthesis	O
.	O
Simultaneous	O
impairment	O
of	O
other	O
enzymes	O
in	O
the	O
BS	B-Chemical
biosynthetic	O
pathways	O
may	O
contribute	O
to	O
overall	O
effects	O
of	O
EE	B-Chemical
on	O
BS	B-Chemical
synthesis	O
.	O
Glibenclamide	B-Chemical
-	O
sensitive	O
hypotension	B-Disease
produced	O
by	O
helodermin	B-Chemical
assessed	O
in	O
the	O
rat	O
.	O
The	O
effects	O
of	O
helodermin	B-Chemical
,	O
a	O
basic	O
35	O
-	O
amino	B-Chemical
acid	I-Chemical
peptide	O
isolated	O
from	O
the	O
venom	O
of	O
a	O
lizard	O
salivary	O
gland	O
,	O
on	O
arterial	O
blood	O
pressure	O
and	O
heart	O
rate	O
were	O
examined	O
in	O
the	O
rat	O
,	O
focusing	O
on	O
the	O
possibility	O
that	O
activation	O
of	O
ATP	B-Chemical
sensitive	O
K	B-Chemical
+	O
(	O
K	B-Chemical
(	O
ATP	B-Chemical
)	O
)	O
channels	O
is	O
involved	O
in	O
the	O
responses	O
.	O
The	O
results	O
were	O
also	O
compared	O
with	O
those	O
of	O
vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
.	O
Helodermin	B-Chemical
produced	O
hypotension	B-Disease
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
approximately	O
similar	O
potency	O
and	O
duration	O
to	O
VIP	O
.	O
Hypotension	B-Disease
induced	O
by	O
both	O
peptides	O
was	O
significantly	O
attenuated	O
by	O
glibenclamide	B-Chemical
,	O
which	O
abolished	O
a	O
levcromakalim	B-Chemical
-	O
produced	O
decrease	O
in	O
arterial	O
blood	O
pressure	O
.	O
Oxyhemoglobin	O
did	O
not	O
affect	O
helodermin	B-Chemical
-	O
induced	O
hypotension	B-Disease
,	O
whereas	O
it	O
shortened	O
the	O
duration	O
of	O
acetylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
-	O
produced	O
hypotension	B-Disease
.	O
These	O
findings	O
suggest	O
that	O
helodermin	B-Chemical
-	O
produced	O
hypotension	B-Disease
is	O
partly	O
attributable	O
to	O
the	O
activation	O
of	O
glibenclamide	B-Chemical
-	O
sensitive	O
K	B-Chemical
+	O
channels	O
(	O
K	B-Chemical
(	O
ATP	B-Chemical
)	O
channels	O
)	O
,	O
which	O
presumably	O
exist	O
on	O
arterial	O
smooth	O
muscle	O
cells	O
.	O
EDRF	O
(	O
endothelium	O
-	O
derived	O
relaxing	O
factor	O
)	O
/	O
nitric	B-Chemical
oxide	I-Chemical
does	O
not	O
seem	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
peptide	O
-	O
produced	O
hypotension	B-Disease
.	O
Long	O
-	O
term	O
efficacy	O
and	O
adverse	O
event	O
of	O
nifedipine	B-Chemical
sustained	O
-	O
release	O
tablets	O
for	O
cyclosporin	B-Chemical
A	I-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
patients	O
with	O
psoriasis	B-Disease
.	O
Thirteen	O
psoriatic	B-Disease
patients	O
with	O
hypertension	B-Disease
during	O
the	O
course	O
of	O
cyclosporin	B-Chemical
A	I-Chemical
therapy	O
were	O
treated	O
for	O
25	O
months	O
with	O
a	O
calcium	B-Chemical
channel	O
blocker	O
,	O
sustained	O
-	O
release	O
nifedipine	B-Chemical
,	O
to	O
study	O
the	O
clinical	O
antihypertensive	O
effects	O
and	O
adverse	O
events	O
during	O
treatment	O
with	O
both	O
drugs	O
.	O
Seven	O
of	O
the	O
13	O
patients	O
had	O
exhibited	O
a	O
subclinical	O
hypertensive	B-Disease
state	O
before	O
cyclosporin	B-Chemical
A	I-Chemical
therapy	O
.	O
Both	O
systolic	O
and	O
diastolic	O
blood	O
pressures	O
of	O
these	O
13	O
patients	O
were	O
decreased	O
significantly	O
after	O
4	O
weeks	O
of	O
nifedipine	B-Chemical
therapy	O
,	O
and	O
blood	O
pressure	O
was	O
maintained	O
within	O
the	O
normal	O
range	O
thereafter	O
for	O
25	O
months	O
.	O
The	O
adverse	O
events	O
during	O
combined	O
therapy	O
with	O
cyclosporin	B-Chemical
A	I-Chemical
and	O
nifedipine	B-Chemical
included	O
an	O
increase	O
in	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
levels	O
in	O
9	O
of	O
the	O
13	O
patients	O
and	O
development	O
of	O
gingival	B-Disease
hyperplasia	I-Disease
in	O
2	O
of	O
the	O
13	O
patients	O
.	O
Our	O
findings	O
indicate	O
that	O
sustained	O
-	O
release	O
nifedipine	B-Chemical
is	O
useful	O
for	O
hypertensive	B-Disease
psoriatic	B-Disease
patients	O
under	O
long	O
-	O
term	O
treatment	O
with	O
cyclosporin	B-Chemical
A	I-Chemical
,	O
but	O
that	O
these	O
patients	O
should	O
be	O
monitored	O
for	O
gingival	B-Disease
hyperplasia	I-Disease
.	O
